PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Castoria, G; Giovannelli, P; Lombardi, M; De Rosa, C; Giraldi, T; de Falco, A; Barone, MV; Abbondanza, C; Migliaccio, A; Auricchio, F				Castoria, G.; Giovannelli, P.; Lombardi, M.; De Rosa, C.; Giraldi, T.; de Falco, A.; Barone, M. V.; Abbondanza, C.; Migliaccio, A.; Auricchio, F.			Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells	ONCOGENE			English	Article						estradiol receptor; tyrosine phosphorylation; Src; nuclear export; cell cycle; breast cancer	HUMAN ESTROGEN-RECEPTOR; FORKHEAD TRANSCRIPTION FACTORS; DNA-SYNTHESIS; PROGESTERONE-RECEPTOR; PROTEIN-KINASE; MCF-7 CELLS; IN-VITRO; ACTIVATION; ALPHA; BINDING	We report that in breast cancer cells, tyrosine phosphorylation of the estradiol receptor alpha (ERalpha) by Src regulates cytoplasmic localization of the receptor and DNA synthesis. Inhibition of Src or use of a peptide mimicking the ERalpha p-Tyr537 sequence abolishes ERalpha tyrosine phosphorylation and traps the receptor in nuclei of estradiol-treated MCF-7 cells. An ERalpha mutant carrying a mutation of Tyr537 to phenylalanine (ER537F) persistently localizes in nuclei of various cell types. In contrast with ERalpha wt, ER537F does not associate with Ran and its interaction with Crm1 is insensitive to estradiol. Thus, independently of estradiol, ER537F is retained in nuclei, where it entangles FKHR-driving cell cycle arrest. Chromatin immunoprecipitation analysis reveals that overexpression of ER537F in breast cancer cells enhances FKHR interaction with cyclin D1 promoter. This mutant also counteracts cell transformation by the activated forms of Src or PI3-K. In conclusion, in addition to regulating receptor localization, ERalpha phosphorylation by Src is required for hormone responsiveness of DNA synthesis in breast cancer cells.	[Castoria, G.; Giovannelli, P.; Lombardi, M.; De Rosa, C.; Giraldi, T.; de Falco, A.; Abbondanza, C.; Migliaccio, A.; Auricchio, F.] Univ Naples 2, Dept Gen Pathol, I-80138 Naples, Italy; [Barone, M. V.] ELFID, Naples, Italy	Universita della Campania Vanvitelli	Migliaccio, A (corresponding author), Univ Naples 2, Dept Gen Pathol, Via L De Crecchio 7, I-80138 Naples, Italy.	antimo.migliaccio@unina2.it	Castoria, Gabriella/I-3349-2019; Migliaccio, Antimo/AAB-3376-2019; Giovannelli, Pia/J-7931-2019	Castoria, Gabriella/0000-0002-0576-4494; BARONE, Maria Vittoria/0000-0001-6190-4917; Giovannelli, Pia/0000-0002-2488-917X; Migliaccio, Antimo/0000-0002-4197-2055; ABBONDANZA, Ciro/0000-0001-5346-4835	Italian Association for Cancer Research (A.I.R.C.) [IG 5389]; A.I.R.C.	Italian Association for Cancer Research (A.I.R.C.)(Fondazione AIRC per la ricerca sul cancro); A.I.R.C.(Fondazione AIRC per la ricerca sul cancro)	This work was funded by the Italian Association for Cancer Research (A.I.R.C.; Grant No. IG 5389). PG is supported by a fellowship from A.I.R.C.	Abbondanza C, 2012, J CELL PHYSIOL, V227, P964, DOI 10.1002/jcp.22803; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Arnold SF, 1997, BIOCHEM BIOPH RES CO, V235, P336, DOI 10.1006/bbrc.1997.6779; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARNOLD SF, 1995, J BIOL CHEM, V270, P30205; AURICCHIO F, 1981, BIOCHEM J, V198, P699, DOI 10.1042/bj1980699; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Blake Richard A., 2000, AMERICA, V181, P20; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Castoria G, 2004, MOL CELL BIOL, V24, P7643, DOI 10.1128/MCB.24.17.7643-7653.2004; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; Castoria G, 1996, INT J CANCER, V65, P574, DOI 10.1002/(SICI)1097-0215(19960301)65:5<574::AID-IJC4>3.0.CO;2-#; Castoria G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017218; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Erenburg I, 1997, MOL ENDOCRINOL, V11, P2004, DOI 10.1210/me.11.13.2004; Haendeler J, 2003, MOL CELL BIOL, V23, P4598, DOI 10.1128/MCB.23.13.4598-4610.2003; He X, 2010, ONCOGENE, V29, P2238, DOI 10.1038/onc.2009.513; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Kaspar JW, 2010, J BIOL CHEM, V285, P153, DOI 10.1074/jbc.M109.040022; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Lee H, 2000, MOL ENDOCRINOL, V14, P1882, DOI 10.1210/me.14.11.1882; Levin ER, 2011, MOL ENDOCRINOL, V25, P377, DOI 10.1210/me.2010-0284; Lombardi M, 2008, J CELL BIOL, V182, P327, DOI 10.1083/jcb.200712125; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MIGLIACCIO A, 1992, INT J CANCER, V51, P733, DOI 10.1002/ijc.2910510512; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Morelli C, 2010, MOL CELL BIOL, V30, P857, DOI 10.1128/MCB.00824-09; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossi M, 2011, J BIOL CHEM, V286, P8507, DOI 10.1074/jbc.M110.179523; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Varricchio L, 2007, MOL CANCER RES, V5, P1213, DOI 10.1158/1541-7786.MCR-07-0150; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427	55	51	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4868	4877		10.1038/onc.2011.642	http://dx.doi.org/10.1038/onc.2011.642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266855				2022-12-28	WOS:000311210700007
J	Sadagopan, S; Veettil, MV; Chakraborty, S; Sharma-Walia, N; Paudel, N; Bottero, V; Chandran, B				Sadagopan, S.; Veettil, M. V.; Chakraborty, S.; Sharma-Walia, N.; Paudel, N.; Bottero, V.; Chandran, B.			Angiogenin functionally interacts with p53 and regulates p53-mediated apoptosis and cell survival	ONCOGENE			English	Article						angiogenin; p53; KSHV; cancer; anti-apoptosis; p53 ubiquitination	ENDOTHELIAL-CELLS; SERUM-LEVELS; EXPRESSION; PROTEIN; GROWTH; PHOSPHORYLATION; PROLIFERATION; REQUIREMENT; INDUCTION; PROMOTES	Angiogenin, a 14-kDa multifunctional pro-angiogenic growth factor, is upregulated in several types of cancers. Anti-angiogenin monoclonal antibodies used as antagonists inhibited the establishment, progression and metastasis of human cancer cells in athymic mice (Olson et al., 1994). Silencing angiogenin and inhibition of angiogenin's nuclear translocation blocked cell survival and induced cell death in B-lymphoma and endothelial cells latently infected with Kaposi sarcoma-associated herpesvirus (Sadagopan et al., 2009), suggesting that actively proliferating cancer cells could be inducing angiogenin for inhibiting apoptotic pathways. However, the mechanism of cell survival and apoptosis regulation by angiogenin and their functional significance in cancer is not known. We demonstrate that angiogenin interacts with p53 and colocalizes in the nucleus. Silencing endogenous angiogenin induced p53 promoter activation and p53 target gene (p53, p21 and Bax) expression, downregulated anti-apoptotic Bcl-2 gene expression and increased p53-mediated cell death. In contrast, angiogenin expression blocked pro-apoptotic Bax and p21 expression, induced Bcl-2 and blocked cell death. Angiogenin also co-immunoprecipitated with p53 regulator protein Mdm2. Angiogenin expression resulted in the inhibition of p53 phosphorylation, increased p53-Mdm2 interaction, and consequently increased ubiquitination of p53. Taken together, these studies demonstrate that angiogenin promotes the inhibition of p53 function to mediate anti-apoptosis and cell survival. Our results reveal for the first time a novel p53 interacting function of angiogenin in anti-apoptosis and survival of cancer cells and suggest that targeting angiogenin could be an effective therapy for several cancers. Oncogene (2012) 31, 4835-4847; doi:10.1038/onc.2011.648; published online 23 January 2012	[Sadagopan, S.; Veettil, M. V.; Chakraborty, S.; Sharma-Walia, N.; Paudel, N.; Bottero, V.; Chandran, B.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Microbiol & Immunol, HM Bligh Canc Res Labs, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Chandran, B (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Microbiol & Immunol, HM Bligh Canc Res Labs, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	bala.chandran@rosalindfranklin.edu	Chakraborty, Sayan/AAC-5622-2019	Chakraborty, Sayan/0000-0002-5591-8164	Public Health Service [AI 091767]; RFUMS-HM Bligh Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA075911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI091767] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); RFUMS-HM Bligh Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported in part by Public Health Service grants, AI 091767 and the RFUMS-HM Bligh Cancer Research Fund to BC. We thank Dr AP Rapoport (University of Maryland) for providing p53 constructs. We thank Dr B Vogelstein (Johns Hopkins University) for the p53<SUP>+/+</SUP> and p53 <SUP>/</SUP> HCT116 cell lines. We thank Keith Philibert for critically reading the manuscript and Bob Dickinson for FACS analysis at the RFUMS core facility.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barton DPJ, 1997, CLIN CANCER RES, V3, P1579; Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Chopra V, 1997, J CANCER RES CLIN, V123, P167, DOI 10.1007/BF01214669; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Foulkes WD, 2007, NEW ENGL J MED, V357, P2539, DOI 10.1056/NEJMp0707422; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; Kishimoto K, 2005, ONCOGENE, V24, P445, DOI 10.1038/sj.onc.1208223; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; LI DC, 1994, J PATHOL, V172, P171, DOI 10.1002/path.1711720203; Liu SM, 2001, BIOCHEM BIOPH RES CO, V287, P305, DOI 10.1006/bbrc.2001.5568; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Montero S, 1998, CLIN CANCER RES, V4, P2161; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; OLSON KA, 1994, CANCER RES, V54, P4576; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sadagopan S, 2011, J VIROL, V85, P2666, DOI 10.1128/JVI.01532-10; Sadagopan S, 2009, J VIROL, V83, P3342, DOI 10.1128/JVI.02052-08; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Shimoyama S, 1996, CANCER RES, V56, P2703; Tsuji T, 2005, CANCER RES, V65, P1352, DOI 10.1158/0008-5472.CAN-04-2058; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Xu ZP, 2003, BIOCHEMISTRY-US, V42, P121, DOI 10.1021/bi020465x; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	40	43	47	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4835	4847		10.1038/onc.2011.648	http://dx.doi.org/10.1038/onc.2011.648			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266868	Green Accepted			2022-12-28	WOS:000311210700004
J	Sekine, Y; Ikeda, O; Mizushima, A; Ueno, Y; Muromoto, R; Yoshimura, A; Kanakura, Y; Oritani, K; Matsuda, T				Sekine, Y.; Ikeda, O.; Mizushima, A.; Ueno, Y.; Muromoto, R.; Yoshimura, A.; Kanakura, Y.; Oritani, K.; Matsuda, T.			STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis	ONCOGENE			English	Article						chronic myeloid leukemia; BCR-ABL; signal-transducing adaptor protein-2; chemokine; tumorigenesis	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; KINASE DOMAIN MUTATIONS; TRANSDUCING ADAPTER PROTEIN-2; TYROSINE KINASE; CHEMOTACTIC RESPONSE; IMATINIB THERAPY; INHIBITOR STI571; CELL-SURVIVAL; RESISTANCE	In chronic myeloid leukemia (CML), the BCR-ABL fusion oncoprotein activates multiple pathways involved in cell survival, growth promotion and disease progression. In this report, we show that the signal-transducing adaptor protein-2 (STAP-2) is involved in BCR-ABL activity. We demonstrate that STAP-2 bound to BCR-ABL, and BCR and ABL proteins, depending on the STAP-2 Src homology 2-like domain. BCR-ABL phosphorylates STAP-2 Tyr250 and the phosphorylated STAP-2 in turn upregulated BCR-ABL phosphorylation, leading to enhanced activation of downstream signaling molecules including ERK (extracellular-signal-regulated kinase), STAT5 (signal transducer and activator of transcription 5), BCL-xL (B-cell lymphoma-extra large) and BCL-2(B-cell lymphoma 2). In addition, STAP-2 interacts with BCR-ABL to alter chemokine receptor expression leading to downregulation of CXCR4 and upregulation of CCR7. The interaction between STAP-2 and BCR-ABL plays a crucial role in conferring a growth advantage and resistance to imatinib, a BCR-ABL inhibitor, as well as tumor progression. Notably, mice injected with BCRABL/STAP-2-expressing Ba/F3 cells developed lymph node enlargement and hepatosplenomegaly. Moreover, suppression of STAP-2 in K562 CML cells resulted in no tumor formation in mice. Our results demonstrate a critical contribution of STAP-2 in BCR-ABL activity, and suggest that STAP-2 might be an important candidate for drug development for patients with CML. Furthermore, the expression of STAP-2 provides useful information for estimating the characteristics of individual CML clones. Oncogene (2012) 31, 4384-4396; doi:10.1038/onc.2011.604; published online 9 January 2012	[Matsuda, T.] Hokkaido Univ, Dept Immunol, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan; [Kanakura, Y.; Oritani, K.] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka, Japan	Hokkaido University; Keio University; Osaka University	Matsuda, T (corresponding author), Hokkaido Univ, Dept Immunol, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Muromoto, Ryuta/E-4203-2012; Sekine, Yuichi/S-8813-2019; Yoshimura, Akihiko/K-5515-2013; Matsuda, Tadashi/A-3835-2012	Muromoto, Ryuta/0000-0002-7474-493X; Sekine, Yuichi/0000-0002-2861-603X; Matsuda, Tadashi/0000-0002-3089-3757	Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [21591202] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported in part by the Grant-in-Aid for scientific research from Ministry of Education, Culture, Sports, Science and Technology of Japan.	Brehme M, 2009, P NATL ACAD SCI USA, V106, P7414, DOI 10.1073/pnas.0900653106; Bruennert D, 2009, LEUKEMIA, V23, P983, DOI 10.1038/leu.2008.337; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang YC, 2009, ONCOGENE, V28, P4105, DOI 10.1038/onc.2009.260; Chu S, 2007, CANCER RES, V67, P7045, DOI 10.1158/0008-5472.CAN-06-4312; Corbin AS, 2003, BLOOD, V101, P4611, DOI 10.1182/blood-2002-12-3659; Cortes J, 2007, BLOOD, V110, P4005, DOI 10.1182/blood-2007-03-080838; Crossman LC, 2005, BLOOD, V106, P1133, DOI 10.1182/blood-2005-02-0694; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Gambacorti-Passerini C, 2003, CLIN CANCER RES, V9, P625; Gambacorti-Passerini CB, 2003, LANCET ONCOL, V4, P75, DOI 10.1016/S1470-2045(03)00979-3; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hochhaus A, 2004, LEUKEMIA, V18, P1321, DOI 10.1038/sj.leu.2403426; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Ikeda O, 2011, CANCER SCI, V102, P756, DOI 10.1111/j.1349-7006.2010.01842.x; Jin LH, 2008, MOL CANCER THER, V7, P48, DOI 10.1158/1535-7163.MCT-07-0042; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Lowenberg B, 2003, NEW ENGL J MED, V349, P1399, DOI 10.1056/NEJMp038130; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mburu YK, 2006, IMMUNOL RES, V36, P61, DOI 10.1385/IR:36:1:61; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 1996, ONCOGENE, V12, P839; Sekine Y, 2006, J IMMUNOL, V176, P380, DOI 10.4049/jimmunol.176.1.380; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2007, J IMMUNOL, V179, P2397, DOI 10.4049/jimmunol.179.4.2397; Sekine Y, 2007, BIOCHEM BIOPH RES CO, V356, P517, DOI 10.1016/j.bbrc.2007.03.031; Sekine Y, 2009, J IMMUNOL, V183, P7966, DOI 10.4049/jimmunol.0902096; Sekine Y, 2009, BIOCHEM BIOPH RES CO, V384, P187, DOI 10.1016/j.bbrc.2009.04.109; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Tokunaga M, 2010, J BIOL CHEM, V285, P31774, DOI 10.1074/jbc.M110.118653; Toyofuku T, 2004, NAT CELL BIOL, V6, P1204, DOI 10.1038/ncb1193; Wang L, 2008, CLIN PHARMACOL THER, V83, P258, DOI 10.1038/sj.clpt.6100268; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yamamoto T, 2003, BIOCHEM BIOPH RES CO, V306, P767, DOI 10.1016/S0006-291X(03)01042-8	50	16	16	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4384	4396		10.1038/onc.2011.604	http://dx.doi.org/10.1038/onc.2011.604			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22231445	Green Submitted			2022-12-28	WOS:000309591300005
J	Rogers, AEJ; Le, JP; Sather, S; Pernu, BM; Graham, DK; Pierce, AM; Keating, AK				Rogers, A. E. J.; Le, J. P.; Sather, S.; Pernu, B. M.; Graham, D. K.; Pierce, A. M.; Keating, A. K.			Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology	ONCOGENE			English	Article						MerTK; receptor tyrosine kinase; glioblastoma multiforme; migration; focal adhesion kinase; morphology	ACUTE LYMPHOBLASTIC-LEUKEMIA; THERAPEUTIC TARGET; ADJUVANT TEMOZOLOMIDE; APOPTOTIC CELLS; TUMOR-GROWTH; AXL; CANCER; RADIOTHERAPY; METASTASIS; SURVIVAL	Glioblastoma multiforme (GBM) is an aggressive brain tumor, fatal within 1 year from diagnosis in most patients despite intensive multimodality therapy. The migratory and microscopically invasive nature of GBM as well as its resistance to chemotherapy renders conventional therapies inadequate in its treatment. Although Mer receptor tyrosine kinase (RTK) inhibition has been shown to decrease the long-term survival and improve the chemosensitivity of GBM in vitro, its role in malignant cellular migration has not been previously evaluated. In this study, we report for the first time a role for Mer RTK in brain tumor migration and show that Mer inhibition profoundly impedes GBM migration and alters cellular morphology. Our data demonstrate that Mer RTK inhibition results in altered signaling through focal adhesion kinase (FAK) and RhoA GTPase and a transformation of cytoskeletal organization, suggesting both molecular and structural mechanisms for the abrogation of migration. We also describe a novel and translational method of Mer RTK inhibition using a newly developed monoclonal antibody, providing proof of principle for future evaluation of Mer-targeted translational therapies in the treatment of GBM. Previous findings implicating Mer signaling in glioblastoma survival and chemotherapy resistance coupled with our discovery of the role of Mer RTK in GBM cellular migration support the development of novel Mer-targeted therapies for this devastating disease. Oncogene (2012) 31, 4171-4181; doi:10.1038/onc.2011.588; published online 19 December 2011	[Rogers, A. E. J.; Le, J. P.; Sather, S.; Pernu, B. M.; Graham, D. K.; Pierce, A. M.; Keating, A. K.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO 80045 USA; [Rogers, A. E. J.; Graham, D. K.; Keating, A. K.] Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado	Keating, AK (corresponding author), Univ Colorado, Sch Med, Dept Pediat, MS 8302,12800 E 19th Ave,Rm P18-4105, Aurora, CO 80045 USA.	amy.keating@ucdenver.edu			NIH [R01 1CA137078, K12 HD068372]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD068372] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA082086, R01CA137078, P30CA046934] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Rachel Linger, PhD for her expertise and insight into this project. We thank Jennifer Schlegel for production of the Mer add-back vector, the Advanced Light Microscopy Core Facility at the University of Colorado School of Medicine for their technical support in microscopy, and the University of Colorado Cancer Center Tissue Culture Core for their technical support in monoclonal antibody development. DKG is supported by NIH R01 1CA137078. AKK is generously supported by the St Baldrick's Foundation and the NIH K12 HD068372Child Health Research Career Development Award.	Chung H, 2011, J BIOL CHEM, V286, P13438, DOI 10.1074/jbc.M110.166751; Donson AM, 1999, J NEUROSURG, V90, P533, DOI 10.3171/jns.1999.90.3.0533; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goldberg L, 2006, CANCER RES, V66, P11709, DOI 10.1158/0008-5472.CAN-06-1878; Graham DK, 2006, CLIN CANCER RES, V12, P2662, DOI 10.1158/1078-0432.CCR-05-2208; HOCHBERG FH, 1980, NEUROLOGY, V30, P907, DOI 10.1212/WNL.30.9.907; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RMA, 2009, BLOOD, V114, P2678, DOI 10.1182/blood-2009-03-209247; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rochlitz C, 1999, LEUKEMIA, V13, P1352, DOI 10.1038/sj.leu.2401484; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schwock J, 2010, EXPERT OPIN THER TAR, V14, P77, DOI 10.1517/14728220903460340; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Souhami L, 2004, INT J RADIAT ONCOL, V60, P853, DOI 10.1016/j.ijrobp.2004.04.011; Steinle M, 2011, RADIOTHER ONCOL, V101, P122, DOI 10.1016/j.radonc.2011.05.069; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Wu CW, 2002, ANTICANCER RES, V22, P1071; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632	27	49	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4171	4181		10.1038/onc.2011.588	http://dx.doi.org/10.1038/onc.2011.588			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22179835	Green Accepted			2022-12-28	WOS:000308975800001
J	Roth, L; Agemy, L; Kotamraju, VR; Braun, G; Teesalu, T; Sugahara, KN; Hamzah, J; Ruoslahti, E				Roth, L.; Agemy, L.; Kotamraju, V. R.; Braun, G.; Teesalu, T.; Sugahara, K. N.; Hamzah, J.; Ruoslahti, E.			Transtumoral targeting enabled by a novel neuropilin-binding peptide	ONCOGENE			English	Article						tumor homing; tumor penetration; breast cancer; nanoparticles	ENDOTHELIAL GROWTH-FACTOR; HOMING PEPTIDE; TUMOR-CELLS; SEMAPHORIN-III; RECEPTOR; NANOPARTICLES; CANCER; PERMEABILITY; DRUGS; VEGF	We have recently described a class of peptides that improve drug delivery by increasing penetration of drugs into solid tumors. These peptides contain a C-terminal Cend Rule (CendR) sequence motif (R/K)XX(R/K), which is responsible for cell internalization and tissue-penetration activity. Tumor-specific CendR peptides contain both a tumor-homing motif and a cryptic CendR motif that is proteolytically unmasked in tumor tissue. A previously described cyclic tumor-homing peptide, LyP-1 (sequence: CGNKRTRGC), contains a CendR element and is capable of tissue penetration. We use here the truncated form of LyP-1, in which the CendR motif is exposed (CGNKRTR; tLyP-1), and show that both LyP-1 and tLyP-1 internalize into cells through the neuropilin-1-dependent CendR internalization pathway. Moreover, we show that neuropilin-2 also binds tLyP-1 and that this binding equally activates the CendR pathway. Fluorescein-labeled tLyP-1 peptide and tLyP-1-conjugated nanoparticles show robust and selective homing to tumors, penetrating from the blood vessels into the tumor parenchyma. The truncated peptide is more potent in this regard than the parent peptide LyP-1. tLyP-1 furthermore improves extravasation of a co-injected nanoparticle into the tumor tissue. These properties make tLyP-1 a promising tool for targeted delivery of therapeutic and diagnostic agents to breast cancers and perhaps other types of tumors. Oncogene (2012) 31, 3754-3763; doi:10.1038/onc.2011.537; published online 19 December 2011	[Roth, L.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Hamzah, J.; Ruoslahti, E.] Univ Calif Santa Barbara, Sanford Burnham Med Res Inst, Vasc Mapping Lab, Ctr Nanomed, Santa Barbara, CA 93106 USA; [Roth, L.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Sugahara, K. N.; Hamzah, J.; Ruoslahti, E.] La Jolla Canc Res Fdn, Canc Res Ctr, Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [Braun, G.] Univ Calif Santa Barbara, Inst Collaborat Biotechnol, Santa Barbara, CA 93106 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Santa Barbara; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Santa Barbara	Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Sanford Burnham Med Res Inst, Vasc Mapping Lab, Ctr Nanomed, UCSB Campus,Biol 2 Bldg,Room 3119, Santa Barbara, CA 93106 USA.	ruoslahti@sanfordburnham.org	hamzah, juliana/G-3114-2013; Teesalu, Tambet/J-1802-2015; Braun, Gary/A-4913-2009	Braun, Gary/0000-0002-6301-0228; Roth, Lise/0000-0001-7555-2916	USAMRAA for the Department of Defense [W81XWH-09-1-0698, W81XWH-08-1-0727]; Susan G Komen for the Cure post-doctoral fellowship [KG091411]; Santa Barbara Cancer Center; Cancer Center Support Grant from the NCI [CA30199]; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	USAMRAA for the Department of Defense; Susan G Komen for the Cure post-doctoral fellowship(Susan G. Komen Breast Cancer Foundation); Santa Barbara Cancer Center; Cancer Center Support Grant from the NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Eva Engvall for comments on the manuscript. This work was supported by grant number W81XWH-09-1-0698 and W81XWH-08-1-0727 from the USAMRAA for the Department of Defense (ER). LR was supported by Susan G Komen for the Cure post-doctoral fellowship (KG091411) and GB by a fellowship from the Santa Barbara Cancer Center. ER was supported in part by CA30199 the Cancer Center Support Grant from the NCI.	Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Agemy L, 2010, BLOOD, V116, P2847, DOI 10.1182/blood-2010-03-274258; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Becker PM, 2005, CIRC RES, V96, P1257, DOI 10.1161/01.RES.0000171756.13554.49; Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Dallas NA, 2008, CLIN CANCER RES, V14, P8052, DOI 10.1158/1078-0432.CCR-08-1520; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Greish K, 2007, J DRUG TARGET, V15, P457, DOI 10.1080/10611860701539584; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hamzah J, 2011, P NATL ACAD SCI USA, V108, P7154, DOI 10.1073/pnas.1104540108; Haspel N, 2011, BIOCHEMISTRY-US, V50, P1755, DOI 10.1021/bi101662j; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jain R, 1999, IEEE MULTIMEDIA, V6, P1, DOI 10.1109/MMUL.1999.809225; Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Laakkonen P, 2004, P NATL ACAD SCI USA, V101, P9381, DOI 10.1073/pnas.0403317101; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Mamluk Roni, 2005, Angiogenesis, V8, P217, DOI 10.1007/s10456-005-9009-6; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Park JH, 2009, SMALL, V5, P694, DOI 10.1002/smll.200801789; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 2002, DRUG DISCOV TODAY, V7, P1138, DOI 10.1016/S1359-6446(02)02501-1; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Thorek DLJ, 2006, ANN BIOMED ENG, V34, P23, DOI 10.1007/s10439-005-9002-7; Uchida M, 2011, ACS NANO, V5, P2493, DOI 10.1021/nn102863y; von Maltzahn G, 2008, BIOCONJUGATE CHEM, V19, P1570, DOI 10.1021/bc800077y	39	175	191	8	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	33					3754	3763		10.1038/onc.2011.537	http://dx.doi.org/10.1038/onc.2011.537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22179825				2022-12-28	WOS:000307924900002
J	Brennan, DJ; O'Connor, DP; Laursen, H; McGee, SF; McCarthy, S; Zagozdzon, R; Rexhepaj, E; Culhane, AC; Martin, FM; Duffy, MJ; Landberg, G; Ryden, L; Hewitt, SM; Kuhar, MJ; Bernards, R; Millikan, RC; Crown, JP; Jirstrom, K; Gallagher, WM				Brennan, D. J.; O'Connor, D. P.; Laursen, H.; McGee, S. F.; McCarthy, S.; Zagozdzon, R.; Rexhepaj, E.; Culhane, A. C.; Martin, F. M.; Duffy, M. J.; Landberg, G.; Ryden, L.; Hewitt, S. M.; Kuhar, M. J.; Bernards, R.; Millikan, R. C.; Crown, J. P.; Jirstrom, K.; Gallagher, W. M.			The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER alpha, and is an independent prognostic factor in node-negative breast cancer	ONCOGENE			English	Article						cocaine- and amphetamine-regulated transcript; breast cancer; prognosis; estrogen receptor	NERVE GROWTH-FACTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CART PEPTIDES; PHOSPHORYLATION; TAMOXIFEN; PROTEIN; TRIAL; SERINE-118; THERAPY	Personalized medicine requires the identification of unambiguous prognostic and predictive biomarkers to inform therapeutic decisions. Within this context, the management of lymph node-negative breast cancer is the subject of much debate with particular emphasis on the requirement for adjuvant chemotherapy. The identification of prognostic and predictive biomarkers in this group of patients is crucial. Here, we demonstrate by tissue microarray and automated image analysis that the cocaine- and amphetamine-regulated transcript (CART) is expressed in primary and metastatic breast cancer and is an independent poor prognostic factor in estrogen receptor (ER)-positive, lymph node-negative tumors in two separate breast cancer cohorts (n = 690; P = 0.002, 0.013). We also show that CART increases the transcriptional activity of ER alpha in a ligand-independent manner via the mitogen-activated protein kinase pathway and that CART stimulates an autocrine/paracrine loop within tumor cells to amplify the CART signal. Additionally, we demonstrate that CART expression in ER-positive breast cancer cell lines protects against tamoxifen-mediated cell death and that high CART expression predicts disease outcome in tamoxifen-treated patients in vivo in three independent breast cancer cohorts. We believe that CART profiling will help facilitate stratification of lymph node-negative breast cancer patients into high- and low-risk categories and allow for the personalization of therapy. Oncogene (2012) 31, 3483-3494; doi:10.1038/onc.2011.519; published online 5 December 2011	[Brennan, D. J.; O'Connor, D. P.; Laursen, H.; McGee, S. F.; McCarthy, S.; Zagozdzon, R.; Rexhepaj, E.; Martin, F. M.; Gallagher, W. M.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland; [Culhane, A. C.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biost & Computat Biol, Boston, MA 02115 USA; [Duffy, M. J.] Univ Coll Dublin, UCD Sch Med & Med Sci, UCD Conway Inst, Dublin 2, Ireland; [Duffy, M. J.] St Vincents Univ Hosp, Dept Pathol & Lab Med, Dublin 4, Ireland; [Landberg, G.] Lund Univ, Skane Univ Hosp, Ctr Mol Pathol, Dept Lab Med, Malmo, Sweden; [Hewitt, S. M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Kuhar, M. J.] Emory Univ, Yerkes Natl Primate Res Ctr, Div Neurosci, Atlanta, GA 30322 USA; [Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Millikan, R. C.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Crown, J. P.] St Vincents Univ Hosp, Dublin 4, Ireland; [Ryden, L.] Lund Univ, Div Surg, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden; [Jirstrom, K.] Lund Univ, Skane Univ Hosp, Div Pathol, Dept Clin Sci, Lund, Sweden	University College Dublin; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; University College Dublin; University College Dublin; Saint Vincent's University Hospital; Lund University; Skane University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University; Netherlands Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University College Dublin; Saint Vincent's University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital	Gallagher, WM (corresponding author), Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	william.gallagher@ucd.ie	Zagozdzon, Radoslaw/K-2141-2012; Crown, John/AAL-3367-2020; Zagozdzon, Radoslaw/AAC-4298-2019; Duffy, Michael/J-5610-2019; Culhane, Aedin/AAG-8490-2019; McCarthy, Sarah/HCI-8963-2022	Zagozdzon, Radoslaw/0000-0002-7957-2372; Duffy, Michael/0000-0002-9259-6619; Culhane, Aedin/0000-0002-1395-9734; Hewitt, Stephen/0000-0001-8283-1788; Brennan, Donal/0000-0002-6747-3342; Bernards, Rene/0000-0001-8677-3423; O'Connor, Darran/0000-0002-8835-1547; Gallagher, William/0000-0002-4307-5999	Program for Third Level Institutions; Health Research Board of Ireland; Enterprise Ireland; Science Foundation Ireland [08/SRC/B1410]; European Community [224865];  [RR00165]; NATIONAL CANCER INSTITUTE [P50CA058223, ZICBC010923] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010732] Funding Source: NIH RePORTER	Program for Third Level Institutions; Health Research Board of Ireland; Enterprise Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); European Community(European Commission); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The UCD Conway Institute is funded by the Program for Third Level Institutions, as administered by the Higher Education Authority of Ireland. Funding is acknowledged from the Health Research Board of Ireland, Enterprise Ireland and the Science Foundation Ireland Strategic Research Cluster award to Molecular Therapeutics for Cancer Ireland (08/SRC/B1410). The work of Dr R Zagozdzon has been supported by a Marie Curie International Reintegration Grant no. 224865 within the 7th European Community Framework Program. Dr MJ Kuhar is funded by RR00165.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Arora S, 2006, NEUROPEPTIDES, V40, P375, DOI 10.1016/j.npep.2006.07.001; Bech P, 2008, J CLIN ENDOCR METAB, V93, P1246, DOI 10.1210/jc.2007-1946; Borgquist S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2146; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Brennan DJ, 2006, CLIN CANCER RES, V12, P6421, DOI 10.1158/1078-0432.CCR-06-0480; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Cardoso F, 2008, J CLIN ONCOL, V26, P729, DOI 10.1200/JCO.2007.14.3222; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; Cheng JW, 2007, ENDOCRINOLOGY, V148, P4634, DOI 10.1210/en.2007-0148; Clarke M, 1998, LANCET, V351, P1451; Dolle L, 2004, CURR CANCER DRUG TAR, V4, P463, DOI 10.2174/1568009043332853; Dominguez G, 2004, MOL BRAIN RES, V126, P22, DOI 10.1016/j.molbrainres.2004.02.027; Dominguez G, 2006, PEPTIDES, V27, P1913, DOI 10.1016/j.peptides.2006.01.025; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Epping MT, 2007, P NATL ACAD SCI USA, V104, P17777, DOI 10.1073/pnas.0702518104; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Jia J, 2008, NEUROPEPTIDES, V42, P653, DOI 10.1016/j.npep.2008.05.006; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keegan BP, 2006, BREAST CANCER RES TR, V95, P265, DOI 10.1007/s10549-005-9024-8; Koylu EO, 1997, J NEUROENDOCRINOL, V9, P823, DOI 10.1046/j.1365-2826.1997.00651.x; Koylu EO, 2006, PEPTIDES, V27, P1956, DOI 10.1016/j.peptides.2006.03.032; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lakatos A, 2005, NEUROSCI LETT, V384, P198, DOI 10.1016/j.neulet.2005.04.072; Mantzoros CS, 1999, INT J CANCER, V80, P523, DOI 10.1002/(SICI)1097-0215(19990209)80:4<523::AID-IJC7>3.3.CO;2-3; O'Brien SL, 2007, INT J CANCER, V120, P1434, DOI 10.1002/ijc.22413; Rogge G, 2008, NAT REV NEUROSCI, V9, P747, DOI 10.1038/nrn2493; Ruscica M, 2007, PEPTIDES, V28, P426, DOI 10.1016/j.peptides.2006.08.045; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; Sen A, 2008, MOL ENDOCRINOL, V22, P2655, DOI 10.1210/me.2008-0077; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; TAYLOR AH, 1990, CANCER RES, V50, P7882; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078; Zoubir M, 2008, ANN ONCOL, V19, P1402, DOI 10.1093/annonc/mdn151; Zujewski JA, 2008, FUTURE ONCOL, V4, P603, DOI 10.2217/14796694.4.5.603; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	43	7	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3483	3494		10.1038/onc.2011.519	http://dx.doi.org/10.1038/onc.2011.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22139072	Green Accepted, Green Submitted			2022-12-28	WOS:000306844100001
J	Leushacke, M; Barker, N				Leushacke, M.; Barker, N.			Lgr5 and Lgr6 as markers to study adult stem cell roles in self-renewal and cancer	ONCOGENE			English	Review						Lgr5; Lgr6; adult stem cell; epithelial renewal; cancer	PROTEIN-COUPLED RECEPTORS; MOUSE SMALL INTESTINE; HAIR FOLLICLE; BETA-CATENIN; EPITHELIAL-CELLS; EXPRESSION; ORIGIN; DIFFERENTIATION; IDENTIFICATION; ACTIVATION	The extended longevity of many mammals imposes the need for an effective tissue renewal capacity within the vital organs to maintain optimal function. Resident adult stem cells are instrumental in delivering this renewal capacity by virtue of their characteristic ability to maintain themselves long-term as a population (self-renewal), whilst also supplying all functional cell-lineages of the respective tissue (multipotency). The homeostatic activity of these adult stem cell reservoirs is tailored to meet the specific renewal requirements of individual tissues through a combination of intrinsic genetic programming and local cues delivered from the surrounding environment (the niche). Considerable phenotypic diversity therefore exists between adult stem cell populations in different organs, making it a considerable challenge to identify broadly applicable markers that facilitate their identification and characterization. However, the 7-transmembrane receptor, Lgr5 has recently gained prominence as a marker of Wnt-regulated adult stem cell populations in the hair-follicle, intestine and stomach. A closely-related protein, Lgr6 marks adult stem cells responsible for fueling the renewal of the sebaceous gland and skin. The discovery of these markers has already greatly improved our understanding of stem cell biology in these rapidly renewing tissues and has major implications for the identification and isolation of human adult stem cell populations for exploitation of their regenerative medicine potential in the clinic. Oncogene (2012) 31, 3009-3022; doi: 10.1038/onc.2011.479; published online 17 October 2011	[Leushacke, M.; Barker, N.] A STAR Inst Med Biol, Singapore 138648, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Barker, N (corresponding author), A STAR Inst Med Biol, 8A Biomed Grove,06-06 Immunos, Singapore 138648, Singapore.	nicholas.barker@imb.a-star.edu.sg	Barker, Nick/AAS-2774-2020; Barker, Nick/AAE-9833-2021; Barker, Nick/A-5535-2011	Barker, Nick/0000-0003-3566-4475; 				Barker N, 2007, GASTROENTEROLOGY, V7, P656; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; Bjerknes M, 2002, AM J PHYSIOL-GASTR L, V283, pG767, DOI 10.1152/ajpgi.00415.2001; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bonfanti P, 2010, NATURE, V466, P978, DOI 10.1038/nature09269; Breault DT, 2008, P NATL ACAD SCI USA, V105, P10420, DOI 10.1073/pnas.0804800105; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Dignass AU, 2001, EUR J GASTROEN HEPAT, V13, P763, DOI 10.1097/00042737-200107000-00002; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Fuller MT, 2007, SCIENCE, V316, P402, DOI 10.1126/science.1140861; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; Green H, 2008, BIOESSAYS, V30, P897, DOI 10.1002/bies.20797; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Lin SA, 2011, J GASTROENTEROL, V46, P1039, DOI 10.1007/s00535-011-0424-8; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Mazerbourg S, 2004, MOL ENDOCRINOL, V18, P2241, DOI 10.1210/me.2004-0133; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Mustata RC, 2011, EMBO REP, V12, P558, DOI 10.1038/embor.2011.52; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Offerhaus GJA, 1999, HEPATO-GASTROENTEROL, V46, P667; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Park WS, 1999, CANCER RES, V59, P4257; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; POTTEN CS, 1974, CELL TISSUE KINET, V7, P271, DOI 10.1111/j.1365-2184.1974.tb00907.x; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Preston SL, 2003, CANCER RES, V63, P3819; Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schepers AG, 2011, EMBO J, V30, P1104, DOI 10.1038/emboj.2011.26; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Snippert HJ, 2011, EMBO REP, V12, P113, DOI 10.1038/embor.2010.216; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Takahashi H, 2011, ANN SURG ONCOL, V18, P1166, DOI 10.1245/s10434-010-1373-9; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Tomita H, 2007, CANCER RES, V67, P4079, DOI 10.1158/0008-5472.CAN-06-4025; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Van Schoore G, 2005, HISTOCHEM CELL BIOL, V124, P35, DOI 10.1007/s00418-005-0002-3; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Walker F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022733; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zeki SS, 2011, NAT REV GASTRO HEPAT, V8, P90, DOI 10.1038/nrgastro.2010.211; Zhang YV, 2009, CELL STEM CELL, V5, P267, DOI 10.1016/j.stem.2009.06.004; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	104	86	93	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3009	3022		10.1038/onc.2011.479	http://dx.doi.org/10.1038/onc.2011.479			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002312				2022-12-28	WOS:000305705900001
J	Sasaki, Y; Kamei, D; Ishikawa, Y; Ishii, T; Uematsu, S; Akira, S; Murakami, M; Hara, S				Sasaki, Y.; Kamei, D.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Murakami, M.; Hara, S.			Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis	ONCOGENE			English	Article						mPGES-1; colon cancer; prostaglandin E-2; macrophage	HYPERPLASTIC GASTRIC TUMORS; CANCER; MICE; EXPRESSION; CYCLOOXYGENASE-2; AZOXYMETHANE; INFLAMMATION; PHYSIOLOGY; ROFECOXIB; DELETION	Accumulating evidence indicates that cyclooxygenase (COX)-2-derived prostaglandin (PG) E-2 is involved in the development of various tumors, including colorectal cancer. However, the precise contribution of microsomal PGE synthase (mPGES)-1, a terminal enzyme that acts downstream of COX-2 in the PGE(2)-biosynthetic pathway, to multiple processes of tumor development is not yet fully understood. Here, we show the pro-tumorigenic role of mPGES-1 in chemical carcinogen-induced colon carcinogenesis and intrasplenic tumor transplantation models. Genetic deletion of mPGES-1 significantly reduced both the total number and size of colorectal polyps at 18 weeks after azoxymethane administration with reduced nuclear translocation of beta-catenin, altered expression profiles of chemokines/cytokines and increased production of anti-tumorigenic PGs, prostaglandin D-2 and prostacyclin in tumor tissues. At an early stage (6 weeks), mPGES-1 deficiency significantly reduced the number of aberrant crypt foci, while its transgenic overexpression increased the number. Furthermore, the growth of intrasplenically transplanted tumor cells was suppressed in mPGES-1 knockout (KO) mice. Co-culture of tumor cells with bone marrow-derived macrophages (BM-M Phi s) isolated from wild-type (WT) mice resulted in the induction of mPGES-1 in BM-M Phi s and increased the growth of tumor cells in vitro, whereas mPGES-1-null BM-M Phi s failed to facilitate tumor growth. The adoptive transfer of WT BM-M Phi s into mPGES-1 KO mice restored the growth of transplanted tumor cells, indicating that mPGES-1 in M Phi s is important for the growth of adjacent tumor cells. Taken together, our findings suggest that the inhibition of mPGES-1 is an alternative therapeutic target for colorectal and possibly other cancers.	[Hara, S.] Showa Univ, Sch Pharm, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; [Kamei, D.] Showa Univ, Sch Pharm, Dept Res & Dev Innovat Med Needs, Tokyo 1428555, Japan; [Ishikawa, Y.; Ishii, T.] Toho Univ, Sch Med, Dept Pathol, Tokyo, Japan; [Uematsu, S.; Akira, S.] Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Osaka, Japan; [Murakami, M.] Tokyo Metropolitan Inst Med Sci, Lipid Metab Project, Tokyo 113, Japan	Showa University; Showa University; Toho University; Osaka University; Tokyo Metropolitan Institute of Medical Science	Hara, S (corresponding author), Showa Univ, Sch Pharm, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	haras@pharm.showa-u.ac.jp	Akira, Shizuo/C-3134-2009		Ministry of Education, Sports, Science, Culture and Technology of Japan; Japan Society for the Promotion of Science for Young Scientists; PRESTO from the Japan Science and Technology Agency; Grants-in-Aid for Scientific Research [21689015, 22116005] Funding Source: KAKEN	Ministry of Education, Sports, Science, Culture and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); PRESTO from the Japan Science and Technology Agency; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by Grants-in-Aid for Scientific Research; by a Private University High Technology Research Center Project matching-fund subsidy from the Ministry of Education, Sports, Science, Culture and Technology of Japan; and by a Showa University Special Grant-in-Aid for Innovative Collaborative Research Projects. D Kamei was supported by Research Fellowships from the Japan Society for the Promotion of Science for Young Scientists. M Murakami was supported by PRESTO from the Japan Science and Technology Agency.	Ban JO, 2010, CHEM-BIOL INTERACT, V188, P75, DOI 10.1016/j.cbi.2010.06.001; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Boulet L, 2004, J BIOL CHEM, V279, P23229, DOI 10.1074/jbc.M400443200; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Casos K, 2011, MICROVASC RES, V81, P261, DOI 10.1016/j.mvr.2011.01.006; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cathcart MC, 2010, BBA-REV CANCER, V1805, P153, DOI 10.1016/j.bbcan.2010.01.006; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Golijanin D, 2004, CLIN CANCER RES, V10, P1024, DOI 10.1158/1078-0432.CCR-1032-3; Guda K, 2004, ONCOGENE, V23, P3813, DOI 10.1038/sj.onc.1207489; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Hara S, 2010, BIOCHIMIE, V92, P651, DOI 10.1016/j.biochi.2010.02.007; Hembruff Stacey L, 2009, Cancer Ther, V7, P254; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kamata H, 2010, BIOMED PHARMACOTHER, V64, P409, DOI 10.1016/j.biopha.2010.01.017; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2004, J BIOL CHEM, V279, P33684, DOI 10.1074/jbc.M400199200; Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Keith RL, 2004, CANCER RES, V64, P5897, DOI 10.1158/0008-5472.CAN-04-1070; Lavergne E, 2004, J IMMUNOL, V173, P3755, DOI 10.4049/jimmunol.173.6.3755; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; Mansure JJ, 2009, CANCER BIOL THER, V8, P1; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Nakanishi M, 2008, CANCER RES, V68, P3251, DOI 10.1158/0008-5472.CAN-07-6100; Nakanishi M, 2011, CANCER PREV RES, V4, P1198, DOI 10.1158/1940-6207.CAPR-11-0188; Nakatani Y, 2007, J HEALTH SCI, V53, P251, DOI 10.1248/jhs.53.251; Nambiar PR, 2003, INT J ONCOL, V22, P145; Ohtsuki M, 2006, J BIOL CHEM, V281, P36420, DOI 10.1074/jbc.M607975200; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima M, 2005, CANCER RES, V65, P9147, DOI 10.1158/0008-5472.CAN-05-1936; Park JM, 2007, CANCER RES, V67, P881, DOI 10.1158/0008-5472.CAN-05-3767; Qian XS, 2011, J BIOL CHEM, V286, P2111, DOI 10.1074/jbc.M110.154971; Robinson SC, 2003, CANCER RES, V63, P8360; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Singh B, 2007, J SURG RES, V140, P220, DOI 10.1016/j.jss.2007.01.039; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Thompson EA, 2007, MOL CELLS, V24, P167; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809	47	48	50	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	24					2943	2952		10.1038/onc.2011.472	http://dx.doi.org/10.1038/onc.2011.472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	21986945				2022-12-28	WOS:000305388400004
J	Mei, YP; Liao, JP; Shen, J; Yu, L; Liu, BL; Liu, L; Li, RY; Ji, L; Dorsey, SG; Jiang, ZR; Katz, RL; Wang, JY; Jiang, F				Mei, Y-P; Liao, J-P; Shen, J.; Yu, L.; Liu, B-L; Liu, L.; Li, R-Y; Ji, L.; Dorsey, S. G.; Jiang, Z-R; Katz, R. L.; Wang, J-Y; Jiang, F.			Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis	ONCOGENE			English	Article						small nucleolar RNA; tumorigenesis; biomarkers; apoptosis; p53	NONCODING RNAS; CANCER; P53; ACTIVATION; EXPRESSION; MICRORNAS; APOPTOSIS; CLUSTER; ARRAY	Non-small cell lung cancer (NSCLC) is the leading cause of cancer death, reflecting the need for better understanding the oncogenesis, and developing new diagnostic and therapeutic targets for the malignancy. Emerging evidence suggests that small nucleolar RNAs (snoRNAs) have malfunctioning roles in tumorigenesis. Our recent study demonstrated that small nucleolar RNA 42 (SNORA42) was overexpressed in lung tumors. Here, we investigate the role of SNORA42 in tumorigenesis of NSCLC. We simultaneously assess genomic dosages and expression levels of SNORA42 and its host gene, KIAA0907, in 10 NSCLC cell lines and a human bronchial epithelial cell line. We then determine in vitro functional significance of SNORA42 in lung cancer cell lines through gain- and loss-of-function analyses. We also inoculate cancer cells with SNORA42-siRNA into mice through either tail vein or subcutaneous injection. We finally evaluate expression level of SNORA42 on frozen surgically resected lung tumor tissues of 64 patients with stage I NSCLC by using quantitative reverse transcriptase PCR assay. Genomic amplification and associated high expression of SNORA42 rather than KIAA0907 are frequently observed in lung cancer cells, suggesting that SNORA42 overexpression is activated by its genomic amplification. SNORA42 knockdown in NSCLC cells inhibits in vitro and in vivo tumorigenicity, whereas enforced SNORA42 expression in bronchial epitheliums increases cell growth and colony formation. Such pleiotropy of SNORA42 suppression could be achieved at least partially through increased apoptosis of NSCLC cells in a p53-dependent manner. SNORA42 expression in lung tumor tissue specimens is inversely correlated with survival of NSCLC patients. Therefore, SNORA42 activation could have an oncogenic role in lung tumorigenesis and provide potential diagnostic and therapeutic targets for the malignancy. Oncogene (2012) 31, 2794-2804; doi: 10.1038/onc.2011.449; published online 10 October 2011	[Mei, Y-P; Liao, J-P; Shen, J.; Yu, L.; Jiang, Z-R; Jiang, F.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Liu, B-L] Univ Colorado Denver, Sch Med, Dept Pathol, Aurora, CO USA; [Liu, L.; Li, R-Y; Wang, J-Y] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Ji, L.] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; [Dorsey, S. G.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA; [Katz, R. L.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center	Jiang, F (corresponding author), Univ Maryland, Sch Med, Dept Pathol, 10 S Pine St,MSTF 7th Floor, Baltimore, MD 21201 USA.	fjiang@som.umaryland.edu	liao, Jipei/B-2758-2017	liao, Jipei/0000-0001-5073-2275; Liu, Bolin/0000-0003-0150-8650	National Cancer Institute (NCI) [CA-135382, CA-137742, CA-133956]; NCI-The Early Detection Research Network; American Cancer Society; Maryland Stem Cell Research Fund; NIH; Flight Attendant Medical Research Institute [1 P30 NR011396]; Wendy Will Case Cancer Award; NATIONAL CANCER INSTITUTE [R03CA133956, R03CA137742, R01CA161837, R21CA135382] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [P30NR011396] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI-The Early Detection Research Network; American Cancer Society(American Cancer Society); Maryland Stem Cell Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Flight Attendant Medical Research Institute; Wendy Will Case Cancer Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This work was supported in part by the National Cancer Institute (NCI) Grants CA-135382, CA-137742 and CA-133956, the Wendy Will Case Cancer Award, Associate Member Award from the NCI-The Early Detection Research Network, the American Cancer Society Research Scholar Grant, an exploratory research grant from the Maryland Stem Cell Research Fund, the NIH-K12-Multidisciplinary Clinical Research Career Development Program, and an clinical innovator award from the Flight Attendant Medical Research Institute to FJ and 1 P30 NR011396 to SGD.	Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Chang LS, 2002, BIOCHEM BIOPH RES CO, V299, P196, DOI 10.1016/S0006-291X(02)02623-2; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4; Donsante A, 2007, SCIENCE, V317, P477, DOI 10.1126/science.1142658; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiang F, 2010, CANCER PREV RES, V3, P1571, DOI 10.1158/1940-6207.CAPR-10-0128; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Li RY, 2006, LAB INVEST, V86, P619, DOI 10.1038/labinvest.3700408; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Malstrom SE, 2004, TOXICOL APPL PHARM, V200, P219, DOI 10.1016/j.taap.2004.04.021; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Pena JTG, 2009, NAT METHODS, V6, P139, DOI [10.1038/NMETH.1294, 10.1038/nmeth.1294]; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; PRESS MF, 1990, PROG CLIN BIOL RES, V354, P209; Testa JR, 1997, CANCER GENET CYTOGEN, V95, P20, DOI 10.1016/S0165-4608(96)00337-8; Turner AMW, 2010, BIOTECHNIQUES, V48, pIX, DOI 10.2144/000113442; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; Wang XW, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp864; Winnard PT, 2006, NEOPLASIA, V8, P796, DOI 10.1593/neo.06304; Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200	37	182	194	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2794	2804		10.1038/onc.2011.449	http://dx.doi.org/10.1038/onc.2011.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21986946	hybrid, Green Accepted			2022-12-28	WOS:000304769000009
J	Ali, AY; Abedini, MR; Tsang, BK				Ali, A. Y.; Abedini, M. R.; Tsang, B. K.			The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation	ONCOGENE			English	Article						cisplatin resistance; apoptosis; ovarian cancer; PPM1D; Chk1; p53	DNA-DAMAGE-RESPONSE; CANCER-CELLS; WIP1 PHOSPHATASE; TUMOR-SUPPRESSOR; 7-HYDROXYSTAUROSPORINE UCN-01; P53-INDUCED PHOSPHATASE; P53-DEFICIENT CELLS; INHIBITORY PROTEIN; CHK1; PHOSPHORYLATION	Cisplatin (CDDP: cis-diamminedichloroplatinum) resistance is a major hurdle in the treatment of human ovarian cancer (OVCA). A better understanding of the mechanisms of CDDP resistance can greatly improve therapeutic outcome for patients. A determinant of CDDP sensitivity in OVCA, p53, is activated by checkpoint kinase 1 (Chk1) in response to DNA damage. Although the oncogenic phosphatase protein phosphatase magnesium-dependent 1 (PPM1D) can deactivate both p53 and Chk1 through site-specific dephosphorylation, whether PPM1D has a role in CDDP resistance is unknown. Here, using pair-matched wild-type p53 CDDP-sensitive (OV2008) and -resistant (C13*) cells, and p53-compromised CDDP-resistant cells (A2780cp, OCC-1, OVCAR-3 and SKOV3), we have demonstrated (i) the existence of site-specific differences in phospho-Ser-Chk1 content between sensitive and resistant cells in response to CDDP; (ii) PPM1D, but not phosphoinositide-3-kinase-related kinase (ataxia telangiectasia and Rad3 related protein (ATR)), is important in the regulation of CDDP-induced Chk1 activation and OVCA cell chemosensitivity; (iii) PPM1D downregulation sensitizes resistant cells to CDDP primarily by activating Chk1 and p53. Our findings establish for the first time that PPM1D confers CDDP resistance in OVCA cells through attenuating CDDP-induced, Chk1-mediated, p53-dependent apoptosis. These findings extend the current knowledge on the molecular and cellular basis of cisplatin resistance and offer the rationale for PPMID as a potential target for treatment of chemoresistant OVCA. Oncogene (2012) 31, 2175-2186; doi:10.1038/onc.2011.399; published online 19 September 2011	[Tsang, B. K.] Univ Ottawa, Ottawa Hosp Res Inst, Dept Obstet & Gynaecol, Chron Dis Program, Ottawa, ON K1Y 4E9, Canada; [Ali, A. Y.; Abedini, M. R.; Tsang, B. K.] Univ Ottawa, Dept Cellular Med, Ottawa, ON K1Y 4E9, Canada; [Ali, A. Y.; Abedini, M. R.; Tsang, B. K.] Univ Ottawa, Dept Mol Med, Ottawa, ON K1Y 4E9, Canada; [Abedini, M. R.] Birjand Univ Med Sci, Dept Physiol & Pharmacol, Birjand, Iran; [Tsang, B. K.] Univ Ottawa, Dept Obstet & Gynaecol, Ottawa, ON K1Y 4E9, Canada; [Tsang, B. K.] Seoul Natl Univ, Coll Agr & Life Sci, Dept Agr Biotechnol, World Class Univ WCU Biomodulat Major, Seoul, South Korea	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; Seoul National University (SNU)	Tsang, BK (corresponding author), Univ Ottawa, Ottawa Hosp Res Inst, Dept Obstet & Gynaecol, Chron Dis Program, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca	Darmian, Faezeh Vahedi/AAF-7755-2019; amiri, omolbanin/G-4425-2017	amiri, omolbanin/0000-0002-3815-5716; Tsang, Benjamin K./0000-0003-1213-3946	Canadian Institutes of Health Research [MOP-15691]; World Class University (WCU) through the National Research Foundation of Korea [R31-10056]; Ministry of Education, Science and Technology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); World Class University (WCU) through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from the Canadian Institutes of Health Research (MOP-15691), the World Class University (WCU) program (R31-10056) through the National Research Foundation of Korea, funded by the Ministry of Education, Science and Technology.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Canadian Cancer Society, 2009, CAN CANC STAT; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; Carrassa L, 2004, CELL CYCLE, V3, P1177; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Choi J, 2000, GENOMICS, V64, P298, DOI 10.1006/geno.2000.6134; Chuman Y, 2008, PROTEIN PEPTIDE LETT, V15, P938, DOI 10.2174/092986608785849236; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JEKUNEN AP, 1994, CANCER RES, V54, P2680; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jurvansuu J, 2007, J MOL BIOL, V372, P397, DOI 10.1016/j.jmb.2007.06.077; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu XB, 2005, CELL CYCLE, V4, P1060; Lu XB, 2004, CELL CYCLE, V3, P1363, DOI 10.4161/cc.3.11.1241; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; MISTRY P, 1992, CANCER RES, V52, P6188; Ouyang GL, 2009, CELL BIOL INT, V33, P1237, DOI 10.1016/j.cellbi.2009.08.011; Pan Y, 2009, CANCER BIOL THER, V8, P1559, DOI 10.4161/cbt.8.16.8955; Perego P, 2003, INT J CANCER, V105, P617, DOI 10.1002/ijc.11140; Perego P, 1996, CANCER RES, V56, P556; Playle LC, 2002, BRIT J CANCER, V87, P352, DOI 10.1038/sj.bjc.6600492; Qu YH, 2005, MOL BIOL CELL, V16, P1684; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rong JJ, 2010, CANCER LETT, V296, P55, DOI 10.1016/j.canlet.2010.03.016; Sasaki H, 2000, CANCER RES, V60, P5659; Shao RG, 1997, CANCER RES, V57, P4029; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Wagner JM, 2009, MOL PHARMACOL, V76, P208, DOI 10.1124/mol.109.055178; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yang X, 2008, BRIT J CANCER, V98, P803, DOI 10.1038/sj.bjc.6604223; Yang XK, 2006, CANCER RES, V66, P3126, DOI 10.1158/0008-5472.CAN-05-0425; Yazlovitskaya EM, 2003, ANTICANCER RES, V23, P2275; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhang XN, 2009, CANCER RES, V69, P7960, DOI 10.1158/0008-5472.CAN-09-0634; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	55	52	54	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2175	2186		10.1038/onc.2011.399	http://dx.doi.org/10.1038/onc.2011.399			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927021				2022-12-28	WOS:000303415900006
J	Zhang, Y; Cheng, Y; Ren, X; Zhang, L; Yap, KL; Wu, H; Patel, R; Liu, D; Qin, ZH; Shih, IM; Yang, JM				Zhang, Y.; Cheng, Y.; Ren, X.; Zhang, L.; Yap, K. L.; Wu, H.; Patel, R.; Liu, D.; Qin, Z-H; Shih, I-M; Yang, J-M			NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response	ONCOGENE			English	Article						NAC1; autophagy; apoptosis; HMGB1; cisplatin; ovarian cancer	EMBRYONIC STEM-CELLS; HMGB1 RELEASE; REGULATES AUTOPHAGY; MEDIATED AUTOPHAGY; PROTEIN NAC-1; TUMOR-CELLS; RESISTANCE; CARCINOMA; APOPTOSIS; PLURIPOTENCY	Nucleus accumbens-1 (NAC1), a nuclear factor belonging to the BTB/POZ gene family, is known to have important roles in proliferation and growth of tumor cells and in chemotherapy resistance. Yet, the mechanisms underlying how NAC1 contributes to drug resistance remain largely unclear. We report here that autophagy was involved in NAC1-mediated resistance to cisplatin, a commonly used chemotherapeutic drug in the treatment of ovarian cancer. We found that treatment with cisplatin caused an activation of autophagy in ovarian cancer cell lines, A2780, OVCAR3 and SKOV3. We further demonstrated that knockdown of NAC1 by RNA interference or inactivation of NAC1 by inducing the expression of a NAC1 deletion mutant that contains only the BTB/POZ domain significantly inhibited the cisplatin-induced autophagy, resulting in increased cisplatin cytotoxicity. Moreover, inhibition of autophagy and sensitization to cisplatin by NAC1 knockdown or inactivation were accompanied by induction of apoptosis. To confirm that the sensitizing effect of NAC1 inhibition on the cytotoxicity of cisplatin was attributed to suppression of autophagy, we assessed the effects of the autophagy inhibitors 3-methyladenosine and chloroquine, and small interfering RNAs (siRNAs) targeting beclin 1 or Atg5 on the cytotoxicity of cisplatin. Treatment with 3-methyladenosine, chloroquine or beclin 1 and Atg5-targeted siRNA also enhanced the sensitivity of SKOV3, A2780 and OVCAR3 cells to cisplatin, indicating that suppression of autophagy indeed renders tumor cells more sensitive to cisplatin. Regulation of autophagy by NAC1 was mediated by the high-mobility group box 1 (HMGB1), as the functional status of NAC1 was associated with the expression, translocation and release of HMGB1. The results of our study not only revealed a new mechanism determining cisplatin sensitivity but also identified NAC1 as a novel regulator of autophagy. Thus, the NAC1-mediated autophagy may be exploited as a new target for enhancing the efficacy of cisplatin against ovarian cancer and other types of malignancies. Oncogene (2012) 31, 1055-1064; doi:10.1038/onc.2011.290; published online 11 July 2011	[Zhang, Y.; Cheng, Y.; Ren, X.; Liu, D.; Yang, J-M] Penn State Univ, Dept Pharmacol, Penn State Hershey Canc Inst, Coll Med, Hershey, PA 17033 USA; [Zhang, Y.; Cheng, Y.; Ren, X.; Liu, D.; Yang, J-M] Penn State Univ Hosp, Milton S Hershey Med Ctr, Hershey, PA 17033 USA; [Zhang, Y.; Zhang, L.; Qin, Z-H; Yang, J-M] Soochow Univ, Sch Pharm, Dept Pharmacol, Suzhou, Jiangsu, Peoples R China; [Yap, K. L.; Shih, I-M] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA; [Yap, K. L.; Shih, I-M] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD USA; [Yap, K. L.; Shih, I-M] Johns Hopkins Univ, Sch Med, Dept Obstet Gynecol, Baltimore, MD USA; [Wu, H.; Patel, R.] Univ Med & Dent New Jersey, Dept Pathol, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Soochow University - China; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Yang, JM (corresponding author), Penn State Univ, Dept Pharmacol, Penn State Hershey Canc Inst, Coll Med, CH74,500 Univ Dr,POB 850, Hershey, PA 17033 USA.	shihie@yahoo.com; juy16@psu.edu	sdsd, shihieih/ABE-6190-2020	Yap, Kai Lee/0000-0003-4496-5464	US Public Health Service [R01CA135038, RO1CA103937]; Penn State College of Medicine; NATIONAL CANCER INSTITUTE [R01CA135038, R01CA103937] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Penn State College of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the US Public Health Service (R01CA135038 and RO1CA103937) and the Penn State College of Medicine	Borst P, 2008, CELL CYCLE, V7, P1353, DOI 10.4161/cc.7.10.5930; Cheng Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009715; Davidson B, 2007, HUM PATHOL, V38, P1030, DOI 10.1016/j.humpath.2006.12.009; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; Fanzani A, 2011, TOXICOL APPL PHARM, V250, P312, DOI 10.1016/j.taap.2010.11.003; Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; Jinawath N, 2009, ONCOGENE, V28, P1941, DOI 10.1038/onc.2009.37; Kaushal GP, 2008, AUTOPHAGY, V4, P710, DOI 10.4161/auto.6309; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Liu D., 2009, MED ONCOL, V28, P105; Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Muller FJ, 2008, NATURE, V455, P401, DOI 10.1038/nature07213; Nagatani G, 2001, CANCER RES, V61, P1592; Nakayama K, 2007, CANCER RES, V67, P8058, DOI 10.1158/0008-5472.CAN-07-1357; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Sharma A, 2009, DNA CELL BIOL, V28, P311, DOI 10.1089/dna.2009.0851; Sun Y, 2010, CANCER LETT, V294, P204, DOI 10.1016/j.canlet.2010.02.001; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143; Thorburn J, 2009, AUTOPHAGY, V5, P247, DOI 10.4161/auto.5.2.7552; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang J, 2007, CANCER RES, V67, P11933, DOI 10.1158/0008-5472.CAN-07-5185; Wei M, 2003, J BIOL CHEM, V278, P1769, DOI 10.1074/jbc.M210562200; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872; Yeasmin S, 2008, CLIN CANCER RES, V14, P1686, DOI 10.1158/1078-0432.CCR-07-4085	32	88	93	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1055	1064		10.1038/onc.2011.290	http://dx.doi.org/10.1038/onc.2011.290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21743489	Green Accepted			2022-12-28	WOS:000300709700011
J	Luker, KE; Lewin, SA; Mihalko, LA; Schmidt, BT; Winkler, JS; Coggins, NL; Thomas, DG; Luker, GD				Luker, K. E.; Lewin, S. A.; Mihalko, L. A.; Schmidt, B. T.; Winkler, J. S.; Coggins, N. L.; Thomas, D. G.; Luker, G. D.			Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells	ONCOGENE			English	Article						chemokines; luciferase; bioluminescence; breast cancer; chemokine receptor	CHEMOKINE RECEPTOR CXCR4; IN-VIVO; ENDOTHELIAL-CELLS; DENDRITIC CELLS; PROSTATE-CANCER; EXPRESSION; MIGRATION; LUCIFERASE; FACTOR-1-ALPHA; INVOLVEMENT	Chemokine CXCL12 and receptor CXCR4 control multiple steps in primary tumor growth and metastasis in breast cancer and more than 20 other human malignancies. Mechanisms that regulate availability of CXCL12 in tumor microenvironments will substantially impact cancer progression and ongoing efforts to target the CXCL12-CXCR4 pathway for cancer chemotherapy. We used dual luciferase imaging to investigate CXCR7-dependent scavenging of CXCL12 in breast tumors in vivo and quantify effects of CXCR7 on tumor growth and metastasis of a separate population of CXCR4+ breast cancer cells. In a mouse xenograft model of human breast cancer, in vivo imaging showed that malignant cells expressing CXCR7 reduced bioluminescent CXCL12 secreted in the primary tumor microenvironment. Capitalizing on sensitive detection of bioluminescent CXCL12, we also demonstrated that CXCR7+ cells reduced amounts of chemokine released from orthotopic tumors into the circulation. Immunofluorescence staining of human primary breast cancers showed expression of CXCR4 and CXCR7 on malignant cells in approximate to 30% of cases. In most cases, CXCR4 and CXCR7 predominantly were expressed on separate populations of malignant cells in a tumor. We modeled these cases of human breast cancer by co-implanting tumor xenografts with CXCR4+ breast cancer cells, human mammary fibroblasts secreting CXCL12, and CXCR7+ or control breast cancer cells. Bioluminescence imaging showed that CXCR7+ breast cancer cells enhanced proliferation of CXCR4+ breast cancer cells in orthotopic tumors and spontaneous metastases. Treatment with a small-molecule inhibitor of CXCR7 chemokine limited the growth of CXCR4+ breast cancer cells in tumors that also contained malignant CXCR7+ cells. These studies establish a new in vivo imaging method to quantify chemokine scavenging by CXCR7 in the tumor microenvironment and identify that CXCR7+ cells promote growth and metastasis of CXCR4+ breast cancer cells.	[Luker, K. E.; Lewin, S. A.; Mihalko, L. A.; Schmidt, B. T.; Winkler, J. S.; Coggins, N. L.; Luker, G. D.] Univ Michigan, Sch Med, Ctr Mol Imaging, Dept Radiol, Ann Arbor, MI 48109 USA; [Thomas, D. G.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; [Luker, G. D.] Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Luker, GD (corresponding author), Univ Michigan, Sch Med, Ctr Mol Imaging, Dept Radiol, 109 Zina Pitcher Pl,A526 BSRB, Ann Arbor, MI 48109 USA.	gluker@umich.edu		Schmidt, Bradley/0000-0002-4011-4630; luker, gary/0000-0001-6832-2581	NIH [R01CA136553, R01CA136829, P50CA093990, R24CA083099]; Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE [R01CA136829, R24CA083099, R01CA136553, P50CA093990] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fashion Footwear Association of New York (FFANY)/QVC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research was supported by NIH grantsR01CA136553, R01CA136829, P50CA093990 and R24CA083099. Support also was provided by Fashion Footwear Association of New York (FFANY)/QVC presents Shoes on Sale. We thank ChemoCentryx for small-molecule inhibitors of CXCR7 and antibody 11G8.	Akashi T, 2008, CANCER SCI, V99, P539, DOI 10.1111/j.1349-7006.2007.00712.x; Albright CF, 2005, MOL CANCER THER, V4, P751, DOI 10.1158/1535-7163.MCT-05-0006; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Sanchez-Alcaniz JA, 2011, NEURON, V69, P77, DOI 10.1016/j.neuron.2010.12.006; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Busillo JM, 2007, BBA-BIOMEMBRANES, V1768, P952, DOI 10.1016/j.bbamem.2006.11.002; Chu QYD, 2010, J SURG RES, V159, P689, DOI 10.1016/j.jss.2008.09.020; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Hattermann K, 2010, CANCER RES, V70, P3299, DOI 10.1158/0008-5472.CAN-09-3642; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Konoplev S, 2011, CANCER-AM CANCER SOC, V117, P4689, DOI 10.1002/cncr.26113; Lee BC, 2004, MOL CANCER RES, V2, P327; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Luker GD, 2003, NAT MED, V9, P969, DOI 10.1038/nm894; Luker KE, 2010, ONCOGENE, V29, P4599, DOI 10.1038/onc.2010.212; Luker KE, 2009, BIOTECHNIQUES, V47, P625, DOI 10.2144/000113126; Luker KE, 2009, FASEB J, V23, P823, DOI 10.1096/fj.08-116749; Meng H, 2011, CLIN CANCER RES, V17, P2426, DOI 10.1158/1078-0432.CCR-10-2385; Miao Z, 2007, P NATL ACAD SCI USA, V104, P15735, DOI 10.1073/pnas.0610444104; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Naumann U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009175; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Song JW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005756; Takano S, 2010, J ONCOL, V2010, DOI 10.1155/2010/351908; Tannous BA, 2005, MOL THER, V11, P435, DOI 10.1016/j.ymthe.2004.10.016; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Torisawa YS, 2010, INTEGR BIOL-UK, V2, P680, DOI 10.1039/c0ib00041h; Wang JH, 2008, J BIOL CHEM, V283, P4283, DOI 10.1074/jbc.M707465200; Wang YL, 2011, NEURON, V69, P61, DOI 10.1016/j.neuron.2010.12.005; Wurdinger T, 2008, NAT METHODS, V5, P171, DOI 10.1038/NMETH.1177; Zabel BA, 2009, J IMMUNOL, V183, P3204, DOI 10.4049/jimmunol.0900269; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339	38	148	154	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4750	4758		10.1038/onc.2011.633	http://dx.doi.org/10.1038/onc.2011.633			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266857	Green Accepted			2022-12-28	WOS:000311033000003
J	Byles, V; Zhu, L; Lovaas, JD; Chmilewski, LK; Wang, J; Faller, DV; Dai, Y				Byles, V.; Zhu, L.; Lovaas, J. D.; Chmilewski, L. K.; Wang, J.; Faller, D. V.; Dai, Y.			SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis	ONCOGENE			English	Article						SIRT1; EMT; prostate cancer; migration; metastasis; E-cadherin	E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; MESENCHYMAL TRANSITION; BREAST-CANCER; CALORIE RESTRICTION; POOR-PROGNOSIS; CARCINOMA; PROGRESSION; SIRTUINS; FAMILY	The epithelial-to-mesenchymal transition (EMT) is a crucial program for the invasion and metastasis of epithelial tumors that involves loss of cell-cell adhesion and increased cell mobility; however, mechanisms underlying this transition are not fully elucidated. Here, we propose a novel mechanism through which the nicotinamide adenine dinucleotide-dependent histone deacetylase SIRT1 regulates EMT in prostate cancer cells through cooperation with the EMT inducing transcription factor ZEB1. We found that forced expression of SIRT1 in non-transformed PZ-HPV-7 prostate epithelial cells disrupts the epithelial morphology concomitant with decreased expression of the epithelial marker, E-cadherin, and increased expression of mesenchymal markers. In contrast, silencing SIRT1 in metastatic prostate tumor cells restores cell-cell adhesion and induces a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. We also found that SIRT1 has a physiologically relevant role in endogenous EMT induced by EGF signaling in prostate cancer cells. We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1. Specifically, we show that SIRT1 silencing reduces expression of ZEB1 and that SIRT1 is recruited to the E-cadherin proximal promoter by ZEB1 to deacetylate histone H3 and to reduce binding of RNA polymerase II, ultimately suppressing E-cadherin transcription. We thus identify a necessary role for ZEB1 in SIRT1-mediated EMT. Finally, we show that reduction of SIRT1 decreases prostate cancer cell migration in vitro and metastasis in vivo in immunodeficient mice, which is largely independent of any general effects of SIRT1 on prostate cancer growth and survival. We therefore identify SIRT1 as a positive regulator of EMT and metastatic growth of prostate cancer cells and our findings implicate overexpressed SIRT1 as a potential therapeutic target to reverse EMT and to prevent prostate cancer progression.	[Dai, Y.] Boston Univ, Sch Med, Ctr Canc, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Dai, Y (corresponding author), Boston Univ, Sch Med, Ctr Canc, 72 E Concord St,L913, Boston, MA 02118 USA.	yandai@bu.edu		Dai, Yan/0000-0002-6894-6930	National Cancer Institute [1R21CA141036, CA101992]; Clinical and Translational Science Institute award of NIH [UL1RR025771]; Karin Grunebaum Cancer Research Foundation; American Cancer Society [IRG-72-001-27-IRG]; Department of Medicine Pilot Project Grant Award; NATIONAL CANCER INSTITUTE [R01CA101992, R21CA129046, R21CA141036] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025771] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Clinical and Translational Science Institute award of NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Karin Grunebaum Cancer Research Foundation; American Cancer Society(American Cancer Society); Department of Medicine Pilot Project Grant Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr F Picard (Laval University, Canada), Dr Michael Korn (USCF, CA), Dr M Ott (UCSF, CA) for providing plasmid constructs. We greatly thank the technical support in tumor cell s.c. injection from Dr Zhijun Luo (Boston University School of Medicine). We thank Lora Forman for the technical assistant (Boston University) and Christine Chiao (Boston University) for the proofreading of this manuscript. This work was supported by grants from the National Cancer Institute (1R21CA141036) (YD), the Clinical and Translational Science Institute award of NIH (UL1RR025771) (YD), the National Cancer Institute (CA101992) (DVF), the Karin Grunebaum Cancer Research Foundation (YD and DVF), the American Cancer Society (IRG-72-001-27-IRG) (YD), and the Department of Medicine Pilot Project Grant Award (YD).	Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Dai Y, 2008, TRANSLATIONAL ONCOGE, V3, P137; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dai Y, 2007, MOL ENDOCRINOL, V21, P1807, DOI 10.1210/me.2006-0467; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Ellis AL, 2010, J VIROL, V84, P6139, DOI 10.1128/JVI.02706-09; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Kim EJ, 2008, BMB REP, V41, P751, DOI 10.5483/BMBRep.2008.41.11.751; Kwon HS, 2008, TRENDS BIOCHEM SCI, V33, P517, DOI 10.1016/j.tibs.2008.08.001; Lacher MD, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-91; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Michael E, 2001, CURR PROTOC CELL BIO, P1921; Mimeault M, 2006, CARCINOGENESIS, V27, P1, DOI 10.1093/carcin/bgi229; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107; Richmond PJM, 1997, CANCER RES, V57, P3189; ROSS JS, 1994, MODERN PATHOL, V7, P835; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972; Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470; UMBAS R, 1992, CANCER RES, V52, P5104; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wallerand H, 2010, UROL ONCOL-SEMIN ORI, V28, P473, DOI 10.1016/j.urolonc.2008.12.018; Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079; Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388	47	231	247	4	42	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4619	4629		10.1038/onc.2011.612	http://dx.doi.org/10.1038/onc.2011.612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22249256	Green Accepted			2022-12-28	WOS:000310528200005
J	Rius, M; Lyko, F				Rius, M.; Lyko, F.			Epigenetic cancer therapy: rationales, targets and drugs	ONCOGENE			English	Review						DNA methylation; chromatin; DNA methyltransferase inhibitors; histone deacetylase inhibitors; metabolic activation; stem cells	DNA METHYLTRANSFERASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; B-CELL LYMPHOMAS; MYELODYSPLASTIC SYNDROME; NUCLEOSIDE ANALOGS; IN-VIVO; CYTOSINE-ARABINOSIDE; SOMATIC MUTATIONS; GENE EZH2	The fundamental role of altered epigenetic modification patterns in tumorigenesis establishes epigenetic regulatory enzymes as important targets for cancer therapy. Over the past few years, several drugs with an epigenetic activity have received approval for the treatment of cancer patients, which has led to a detailed characterization of their modes of action. The results showed that both established drug classes, the histone deacetylase (HDAC) inhibitors and the DNA methyltransferase inhibitors, show substantial limitations in their epigenetic specificity. HDAC inhibitors are highly specific drugs, but the enzymes have a broad substrate specificity and deacetylate numerous proteins that are not associated with epigenetic regulation. Similarly, the induction of global DNA demethylation by non-specific inhibition of DNA methyltransferases shows pleiotropic effects on epigenetic regulation with no apparent tumor-specificity. Second-generation azanucleoside drugs have integrated the knowledge about the cellular uptake and metabolization pathways, but do not show any increased specificity for cancer epigenotypes. As such, the traditional rationale of epigenetic cancer therapy appears to be in need of refinement, as we move from the global inhibition of epigenetic modifications toward the identification and targeting of tumor-specific epigenetic programs. Recent studies have identified epigenetic mechanisms that promote self-renewal and developmental plasticity in cancer cells. Druggable somatic mutations in the corresponding epigenetic regulators are beginning to be identified and should facilitate the development of epigenetic therapy approaches with improved tumor specificity. Oncogene (2012) 31, 4257-4265; doi:10.1038/onc.2011.601; published online 19 December 2011	[Rius, M.; Lyko, F.] German Canc Res Ctr, Div Epigenet, DKFZ ZMBH Alliance, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Lyko, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	f.lyko@dkfz.de			Clavis Pharma; Deutsche Forschungsgemeinschaft [RI 2121/1-1]; Deutsche Krebshilfe [109773]	Clavis Pharma; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	Maria Rius declares no conflict of interest. Frank Lyko received a commercial research grant from Clavis Pharma.; We thank Bodo Bruckner for critically reading the manuscript. This work is supported by grants from the Deutsche Forschungsgemeinschaft (RI 2121/1-1) and Deutsche Krebshilfe (grant number 109773).	Aiden AP, 2010, CELL STEM CELL, V6, P591, DOI 10.1016/j.stem.2010.03.016; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bhatla D, 2009, BRIT J HAEMATOL, V144, P388, DOI 10.1111/j.1365-2141.2008.07461.x; Bocker MT, 2011, BLOOD, V117, pE182, DOI 10.1182/blood-2011-01-331926; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Brueckner B, 2010, MOL CANCER THER, V9, P1256, DOI 10.1158/1535-7163.MCT-09-1202; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Choi SH, 2007, BRIT J HAEMATOL, V138, P616, DOI 10.1111/j.1365-2141.2007.06707.x; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172; Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048; Cole SPC, 2006, TRENDS PHARMACOL SCI, V27, P438, DOI 10.1016/j.tips.2006.06.008; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Damaraju VL, 2009, NUCLEOS NUCLEOT NUCL, V28, P450, DOI 10.1080/15257770903044499; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547; FLASSHOVE M, 1994, LEUKEMIA, V8, P780; Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hagemann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017388; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001; Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631; Huang Y, 2004, CANCER RES, V64, P4294, DOI 10.1158/0008-5472.CAN-03-3884; Huber-Ruano I, 2009, CURR DRUG METAB, V10, P347, DOI 10.2174/138920009788499030; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kroep JR, 2002, MOL CANCER THER, V1, P371; Kuck D, 2010, BIOORGAN MED CHEM, V18, P822, DOI 10.1016/j.bmc.2009.11.050; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; LI LH, 1970, CANCER RES, V30, P2760; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Lizardi PM, 2010, ONCOGENE, V29, P5772, DOI 10.1038/onc.2010.372; Maring JG, 2010, EUR J CLIN PHARMACOL, V66, P611, DOI 10.1007/s00228-010-0799-0; Medina-Franco JL, 2011, MOL DIVERS, V15, P293, DOI 10.1007/s11030-010-9262-5; Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Parmar S, 2011, PHARMACOGENOMICS, V12, P503, DOI [10.2217/PGS.10.200, 10.2217/pgs.10.200]; Pastor-Anglada M, 2005, VIRUS RES, V107, P151, DOI 10.1016/j.virusres.2004.11.005; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038; Rius M, 2010, DRUG METAB DISPOS, V38, P1054, DOI 10.1124/dmd.110.032664; Rius M, 2009, MOL CANCER THER, V8, P225, DOI 10.1158/1535-7163.MCT-08-0743; Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576; STEGMANN APA, 1995, LEUKEMIA, V9, P1032; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Van Rompay AR, 2001, MOL PHARMACOL, V59, P1181, DOI 10.1124/mol.59.5.1181; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Weber B, 2010, ONCOGENE, V29, P5775, DOI 10.1038/onc.2010.227; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251	80	112	117	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4257	4265		10.1038/onc.2011.601	http://dx.doi.org/10.1038/onc.2011.601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179827	Bronze			2022-12-28	WOS:000309520200001
J	Hon, WC; Berndt, A; Williams, RL				Hon, W-C; Berndt, A.; Williams, R. L.			Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases	ONCOGENE			English	Article						PIK3CA mutations; p110 alpha; lipid binding; crystal structure; inhibitor; growth factor signalling	KINASE-C-ALPHA; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3'-KINASE; PIK3CA MUTATIONS; CANCER; DOMAIN; PATHWAY; PI3K; PI3K-ALPHA; P110-ALPHA	Somatic missense mutations in PIK3CA, which encodes the p110 alpha catalytic subunit of phosphoinositide 3-kinases, occur frequently in human cancers. Activating mutations spread across multiple domains, some of which are located at inhibitory contact sites formed with the regulatory subunit p85 alpha. PIK3R1, which encodes p85 alpha, also has activating somatic mutations. We find a strong correlation between lipid kinase and lipid-binding activities for both wild-type (WT) and a representative set of oncogenic mutant complexes of p110 alpha/p85 alpha. Lipid binding involves both electrostatic and hydrophobic interactions. Activation caused by a phosphorylated receptor tyrosine kinase (RTK) peptide binding to the p85 alpha N-terminal SH2 domain (nSH2) induces lipid binding. This depends on the polybasic activation loop as well as a conserved hydrophobic motif in the C-terminal region of the kinase domain. The hotspot E545K mutant largely mimics the activated WT p110 alpha. It shows the highest basal activity and lipid binding, and is not significantly activated by an RTK phosphopeptide. Both the hotspot H1047R mutant and rare mutations (C420R, M1043I, H1047L, G1049R and p85 alpha-N564D) also show increased basal kinase activities and lipid binding. However, their activities are further enhanced by an RTK phosphopeptide to levels markedly exceeding that of activated WT p110 alpha. Phosphopeptide binding to p110 beta/p85 alpha and p110 delta/p85 alpha complexes also induces their lipid binding. We present a crystal structure of WT p110 alpha complexed with the p85 alpha inter-SH2 domain and the inhibitor PIK-108. Additional to the ATP-binding pocket, an unexpected, second PIK-108 binding site is observed in the kinase C-lobe. We show a global conformational change in p110 alpha consistent with allosteric regulation of the kinase domain by nSH2. These findings broaden our understanding of the differential biological outputs exhibited by distinct types of mutations regarding growth factor dependence, and suggest a two-tier classification scheme relating p110 alpha and p85 alpha mutations with signalling potential. Oncogene (2012) 31, 3655-3666; doi:10.1038/onc.2011.532; published online 28 November 2011	[Hon, W-C; Berndt, A.; Williams, R. L.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England	MRC Laboratory Molecular Biology	Williams, RL (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 0QH, England.	rlw@mrc-lmb.cam.ac.uk		Williams, Roger/0000-0001-7754-4207	Medical Research Council, UK; MRC [MC_U105184308] Funding Source: UKRI; Medical Research Council [MC_U105184308] Funding Source: researchfish	Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to Kevan Shokat and co-workers (UCSF, USA), including Beth Apsel, Benjamin Houseman, Eli Zunder, Morri Feldman and Zachary Knight, for their generous gift of PI3K inhibitors, which were crucial for crystallization screening. We thank the beamline scientists and members of the staff at the ESRF beamlines ID14-1, ID14-2, ID14-4, ID23-1, ID23-2, and ID29 (Grenoble, France) and Diamond Light Source beamlines I02 and I03 (UK). We also thank past and present members of the Williams's group, particularly Simon Miller, for assistance with remote crystal data collection, Olga Perisic for providing baculovirus of mouse p110 beta, Alexey Murzin for his structural insight of the WIF motif conformation, Andrew Leslie and Nicolas Soler for providing scripts to create Figure 4d. This work was supported by the Medical Research Council, UK.	Adams JR, 2011, CANCER RES, V71, P2706, DOI 10.1158/0008-5472.CAN-10-0738; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Berndt A, 2010, NAT CHEM BIOL, V6, P117, DOI [10.1038/nchembio.293, 10.1038/NCHEMBIO.293]; Burke JE, 2011, STRUCTURE, V19, P1127, DOI 10.1016/j.str.2011.06.003; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Carson JD, 2008, BIOCHEM J, V409, P519, DOI 10.1042/BJ20070681; Chakrabarty A, 2010, ONCOGENE, V29, P5193, DOI 10.1038/onc.2010.257; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337; Drees BE, 2003, COMB CHEM HIGH T SCR, V6, P321; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gills JJ, 2009, CURR ONCOL REP, V11, P102, DOI 10.1007/s11912-009-0016-4; Gonzalez B, 2004, MOL CELL, V15, P689, DOI 10.1016/j.molcel.2004.08.004; Guerrero-Valero M, 2009, P NATL ACAD SCI USA, V106, P6603, DOI 10.1073/pnas.0813099106; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Mandelker D, 2009, P NATL ACAD SCI USA, V106, P16996, DOI 10.1073/pnas.0908444106; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Miller S, 2010, SCIENCE, V327, P1638, DOI 10.1126/science.1184429; Narayan K, 2006, METHODS, V39, P122, DOI 10.1016/j.ymeth.2006.05.006; Oda K, 2008, CANCER RES, V68, P8127, DOI 10.1158/0008-5472.CAN-08-0755; Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82_2010_43; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Stahelin RV, 2003, J BIOL CHEM, V278, P12452, DOI 10.1074/jbc.M212864200; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Wu HY, 2009, P NATL ACAD SCI USA, V106, P20258, DOI 10.1073/pnas.0902369106; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhang HJ, 2008, BREAST CANCER RES TR, V112, P217, DOI 10.1007/s10549-007-9847-6; Zhang XX, 2011, MOL CELL, V41, P567, DOI 10.1016/j.molcel.2011.01.026; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	51	73	75	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	32					3655	3666		10.1038/onc.2011.532	http://dx.doi.org/10.1038/onc.2011.532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22120714	Green Accepted			2022-12-28	WOS:000307653800001
J	Santoro, R; Marani, M; Blandino, G; Muti, P; Strano, S				Santoro, R.; Marani, M.; Blandino, G.; Muti, P.; Strano, S.			Melatonin triggers p53(Ser) phosphorylation and prevents DNA damage accumulation	ONCOGENE			English	Article						melatonin; p53; cancer; prevention; DNA; repair	BREAST-CANCER; P53 STABILITY; PML; RISK; APOPTOSIS; PROSTATE; PROTEIN; LIGHT; PREMENOPAUSAL; GAMMA-H2AX	Several epidemiological studies have shown that high levels of melatonin, an indolic hormone secreted mainly by the pineal gland, reduce the risks of developing cancer, thus suggesting that melatonin triggers the activation of tumor-suppressor pathways that lead to the prevention of malignant transformation. This paper illustrates that melatonin induces phosphorylation of p53 at Ser-15 inhibiting cell proliferation and preventing DNA damage accumulation of both normal and transformed cells. This activity requires p53 and promyelocytic leukemia (PML) expression and efficient phosphorylation of p53 at Ser-15 residue. Melatonin-induced p53 phosphorylation at Ser-15 residue does not require ataxia telangiectasia-mutated activity, whereas it is severely impaired upon chemical inhibition of p38 mitogen-activated protein kinase activity. By and large, these findings imply that the activation of the p53 tumor-suppressor pathway is a critical mediator of melatonin and its anticancer effects. Therefore, it provides molecular insights into increasing observational evidence for the role that melatonin has in cancer prevention.	[Santoro, R.; Marani, M.; Strano, S.] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Dept Mol Med, I-00144 Rome, Italy; [Blandino, G.] Italian Natl Canc Inst Regina Elena, Dept Mol Med, Translat Oncogenom Unit ROC, I-00144 Rome, Italy; [Muti, P.] Italian Natl Canc Inst Regina Elena, Sci Director Off, I-00144 Rome, Italy		Strano, S (corresponding author), Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Dept Mol Med, Via Elio Chianesi 53, I-00144 Rome, Italy.	strano@ifo.it	Strano, Sabrina/K-9654-2016; Muti, Paola/AAD-9108-2020; Santoro, Raffaela/B-1152-2013; Blandino, Giovanni/B-1137-2013; strano, sabrina/B-6743-2013	Santoro, Raffaela/0000-0003-3218-2358; Blandino, Giovanni/0000-0002-6970-2241; strano, sabrina/0000-0002-6341-4230; Marani, Marina/0000-0003-1585-3586	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero della Salute; Fondazione Veronesi; FIRB; New Idea Award; Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Fondazione Veronesi(Fondazione Umberto Veronesi); FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); New Idea Award; Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Dr E O'Neill and Dr Y Shiloh for gift of reagents and cell lines. Moreover, we also thank T Merlino for kindly revising the English text. This study was supported by Associazione Italiana Ricerca sul Cancro (AIRC, to SS and GB), Ministero della Salute (GB and PM), Fondazione Veronesi (GB), FIRB (GB), New Idea Award (SS) and Fondazione Italiana Ricerca sul Cancro (FIRC, fellowship to RS).	Alpert M, 2009, MED HYPOTHESES, V73, P324, DOI 10.1016/j.mehy.2009.02.027; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chiu SJ, 2008, TOXICOL LETT, V179, P63, DOI 10.1016/j.toxlet.2008.04.004; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Flynn-Evans EE, 2009, CANCER CAUSE CONTROL, V20, P1753, DOI 10.1007/s10552-009-9405-0; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Ji CX, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-50; KANE MA, 1994, MELANOMA RES, V4, P59, DOI 10.1097/00008390-199402000-00009; Kim CH, 2010, KOREAN J PHYSIOL PHA, V14, P365, DOI 10.4196/kjpp.2010.14.6.365; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Kliukiene J, 2001, BRIT J CANCER, V84, P397, DOI 10.1054/bjoc.2000.1617; Kloog I, 2009, CHRONOBIOL INT, V26, P108, DOI 10.1080/07420520802694020; Kloog I, 2008, CHRONOBIOL INT, V25, P65, DOI 10.1080/07420520801921572; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lipton J, 2009, NEUROLOGY, V73, P323, DOI 10.1212/WNL.0b013e3181af78a5; Lukas J, 2009, NATURE, V458, P581, DOI 10.1038/458581a; Markantonis SL, 2008, J CLIN PHARMACOL, V48, P240, DOI 10.1177/0091270007311112; Mediavilla MD, 1999, LIFE SCI, V65, P415, DOI 10.1016/S0024-3205(99)00262-3; Nur-E-Kamal A, 2003, J BIOL CHEM, V278, P12475, DOI 10.1074/jbc.M212915200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Roy D, 2001, ENDOCRINOLOGY, V142, P4711, DOI 10.1210/en.142.11.4711; Sainz RM, 2005, PROSTATE, V63, P29, DOI 10.1002/pros.20155; Schernhammer ES, 2008, JNCI-J NATL CANCER I, V100, P898, DOI 10.1093/jnci/djn171; Schernhammer ES, 2010, CANCER EPIDEM BIOMAR, V19, P729, DOI 10.1158/1055-9965.EPI-09-1229; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Sliwinski T, 2007, MUTAT RES-GEN TOX EN, V634, P220, DOI 10.1016/j.mrgentox.2007.07.013; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VAKKURI O, 1985, LIFE SCI, V37, P489, DOI 10.1016/0024-3205(85)90412-6; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Xi SC, 2000, J PINEAL RES, V29, P172, DOI 10.1034/j.1600-079X.2000.d01-64.x; Xian ZH, 2005, WORLD J GASTROENTERO, V11, P4102, DOI 10.3748/wjg.v11.i26.4102	43	63	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	24					2931	2942		10.1038/onc.2011.469	http://dx.doi.org/10.1038/onc.2011.469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22002314	Green Published			2022-12-28	WOS:000305388400003
J	Brazzatti, JA; Klingler-Hoffmann, M; Haylock-Jacobs, S; Harata-Lee, Y; Niu, M; Higgins, MD; Kochetkova, M; Hoffmann, P; McColl, SR				Brazzatti, J. A.; Klingler-Hoffmann, M.; Haylock-Jacobs, S.; Harata-Lee, Y.; Niu, M.; Higgins, M. D.; Kochetkova, M.; Hoffmann, P.; McColl, S. R.			Differential roles for the p101 and p84 regulatory subunits of PI3K gamma in tumor growth and metastasis	ONCOGENE			English	Article						phosphoinositide 3-kinase gamma; p101; p84/p87(PIKAP); breast cancer; apoptosis	G-BETA-GAMMA; I PHOSPHOINOSITIDE 3-KINASE; BREAST-CANCER METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ONCOGENIC TRANSFORMATION; GENETIC ALTERATIONS; EPITHELIAL-CELLS; PI 3-KINASE; CLASS IPI3K	Phosphoinositide 3-kinase gamma (PI3K gamma) consists of a catalytic subunit p110 gamma, which forms mutually exclusive dimers with one of the regulatory subunits called p101 and p84/p87(PIKAP). Recently, PI3K gamma emerged as being a potential oncogene because overexpression of the catalytic subunit p110 gamma or the regulatory subunit p101 leads to oncogenic cellular transformation and malignancy. However, the contribution of the individual subunits to tumor growth and metastasis and the mechanisms involved are not understood. We therefore individually knocked down the PI3K gamma subunits (p84, p101 and p110 gamma) in MDA-MB-231 cells, which reduced in vitro migration of the cell lines. Knockdown of p110 gamma or p101 inhibited apoptosis, Akt phosphorylation and lung colonization in SCID mice. Similarly, the knockdown of p110 gamma and p101 in murine epithelial carcinoma 4T1.2 cells inhibited primary tumor growth and spontaneous metastasis, as well as lung colonization. In contrast, knockdown of p84 in MDA-MB-231 cells enhanced Akt phosphorylation and lung colonization. These findings are the first to implicate differential functions of the two PI3K gamma regulatory subunits in the process of oncogenesis, and indicate that loss of p101 is sufficient to reduce in vivo tumor growth and metastasis to the same extent as that of p110 gamma. Oncogene (2012) 31, 2350-2361; doi:10.1038/onc.2011.414; published online 26 September 2011	[Brazzatti, J. A.; Klingler-Hoffmann, M.; Haylock-Jacobs, S.; Harata-Lee, Y.; Niu, M.; Higgins, M. D.; Kochetkova, M.; Hoffmann, P.; McColl, S. R.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Adelaide	McColl, SR (corresponding author), Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	shaun.mccoll@adelaide.edu.au	Hoffmann, Peter/U-5996-2017; Kochetkova, Marina/ABE-9538-2021; Klingler-Hoffmann, Manuela/D-1934-2018	Hoffmann, Peter/0000-0001-8493-2208; Brazzatti, Julie/0000-0002-4015-9679; Klingler-Hoffmann, Manuela/0000-0003-2165-7813; Kochetkova, Marina/0000-0002-0599-7378	National Health and Medical Research Council of Australia	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	We thank Mark Bunting for assistance with animal experiments, John Brazzatti for assistance with statistical analysis and Francisco Olmo for assistance with apoptosis experiments. The work was supported by grants from the National Health and Medical Research Council of Australia.	Akekawatchai C, 2005, J BIOL CHEM, V280, P39701, DOI 10.1074/jbc.M509829200; Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Barber DF, 2005, NAT MED, V11, P933, DOI 10.1038/nm1291; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Bohnacker T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000259; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bretland AJ, 2001, CELL PROLIFERAT, V34, P199, DOI 10.1046/j.1365-2184.2001.00198.x; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ching TT, 1999, J BIOL CHEM, V274, P8611, DOI 10.1074/jbc.274.13.8611; Costa C, 2007, P NATL ACAD SCI USA, V104, P14354, DOI 10.1073/pnas.0703175104; David M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009741; Deane JA, 2004, ANNU REV IMMUNOL, V22, P563, DOI 10.1146/annurev.immunol.22.012703.104721; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Edling CE, 2010, CLIN CANCER RES, V16, P4928, DOI 10.1158/1078-0432.CCR-10-1210; El Haibi CP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-85; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Goldberg GS, 2001, CANCER RES, V61, P1334; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Holland JD, 2006, CANCER RES, V66, P4117, DOI 10.1158/0008-5472.CAN-05-1631; Johnson C, 2007, ONCOGENE, V26, P7049, DOI 10.1038/sj.onc.1210504; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kim JH, 2011, J CELL PHYSIOL, V226, P2881, DOI 10.1002/jcp.22631; Knobbe CB, 2003, BRAIN PATHOL, V13, P507; Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Orme MH, 2006, NAT CELL BIOL, V8, P1298, DOI 10.1038/ncb1493; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; PONS S, 1995, MOL CELL BIOL, V15, P4453; Procko E, 2005, BIOESSAYS, V27, P153, DOI 10.1002/bies.20157; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Rodrigues DH, 2010, J NEUROIMMUNOL, V222, P90, DOI 10.1016/j.jneuroim.2010.02.016; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Suire S, 2006, NAT CELL BIOL, V8, P1303, DOI 10.1038/ncb1494; Tang MKS, 2010, NEOPLASIA, V12, P128, DOI 10.1593/neo.91438; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wang LH, 2004, MT SINAI J MED, V71, P361; Williams SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-250; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Yamada M, 2004, BIOCHEM J, V378, P649, DOI 10.1042/BJ20031398; YU G, 1995, J BIOL CHEM, V270, P4792, DOI 10.1074/jbc.270.9.4792; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhao M, 2008, BREAST CANCER RES TR, V110, P211, DOI 10.1007/s10549-007-9712-7; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	69	42	43	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2350	2361		10.1038/onc.2011.414	http://dx.doi.org/10.1038/onc.2011.414			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21996737				2022-12-28	WOS:000303610800009
J	Chang, CY; Lin, SC; Su, WH; Ho, CM; Jou, YS				Chang, C-Y; Lin, S-C; Su, W-H; Ho, C-M; Jou, Y-S			Somatic LMCD1 mutations promoted cell migration and tumor metastasis in hepatocellular carcinoma	ONCOGENE			English	Article						somatic mutations; LMCD1; LIM domain; metastasis; hepatocellular carcinoma	FOCAL ADHESION PROTEIN; BREAST-CANCER CELLS; LIM DOMAIN GENE; LOCALIZATION; GROWTH; ACTIN; ONCOGENES; TES; HYPERMETHYLATION; IDENTIFICATION	Common genetic alteration in cancer genomes is implicated for embracing an aberrant cancer gene participated in tumor progression. In this study, we identified a somatic mutated LIM and cysteine-rich domains-1 (LMCD1) as a putative metastatic oncogene in human hepatocellular carcinoma (HCC) using integrated genomic approaches. In addition to revealing genomic amplification and gene upregulation, we identified recurrent E135K (3/48 cases) mutations in HCC tissues and K237R mutation in the PLC/PRF/5 HCC cell line. Expression of mutant LMCD1 E135K or K237R reduced the stress fiber assembly, increased cortical actin accumulation and induced lamellipodial extension. Consistently, these mutations enhanced cell migration and showed activation of the Rac1-signaling pathway. Inhibition of the LMCD1/Rac1 pathway by an LMCD1 short-hairpin RNA (shLMCD1) or the Rac1 inhibitor NSC23766 suppressed the mutation-mediated lamellipodial protrusion and cell migration. In PLC/PRF/5 cells with endogenous K237R mutation, cell migration was enhanced by estrogen-induced LMCD1 expression but reversed by shLMCD1 treatment. Moreover, overexpression of LMCD1 E135K mutation significantly promoted systemic lung metastasis in a murine tail vein injection model. Together, our results suggest that LMCD1 mutations are potential oncogenic events in HCC metastasis to promote cell migration through the Rac1-signaling pathway. Oncogene (2012) 31, 2640-2652; doi:10.1038/onc.2011.440; published online 26 September 2011	[Chang, C-Y; Lin, S-C; Jou, Y-S] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chang, C-Y; Jou, Y-S] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Su, W-H] Chang Gung Univ, Chang Gung Mol Med Res Ctr, Grad Inst Biomed Sci, Dept Biomed Sci, Tao Yuan, Taiwan; [Ho, C-M] Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu, Taiwan; [Ho, C-M; Jou, Y-S] Acad Sinica, Bioinformat Program, Taiwan Int Grad Program, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Chang Gung Memorial Hospital; Chang Gung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Jou, YS (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	jou@ibms.sinica.edu.tw	Jou, Yuh-Shan/O-5921-2018	Jou, Yuh-Shan/0000-0001-5090-3732; Su, Wen-Hui/0000-0003-1037-4615	National Science Council, Taiwan [NSC98-3112-B-001-004, NSC98-3112-B-001-031, NSC99-3112-B-001-019]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr Pei-Jer Chen and Dr Ding-Shinn Chen at School of Medicine, National Taiwan University, for helpful discussions and advice on the work. We also thank the core facilities from National Research Program for Genomic Medicine, National Science Council, Taiwan, including the National Genotyping Center, for their service in SNP genotyping and the National RNAi Core facility for providing shRNAs. Financial Support: This work was funded by the National Research Program for Genomic Medicine of the National Science Council, Taiwan, through grant numbers NSC98-3112-B-001-004, NSC98-3112-B-001-031 and NSC99-3112-B-001-019.	Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Barrientos T, 2007, J BIOL CHEM, V282, P8393, DOI 10.1074/jbc.M607549200; Bespalova IN, 2000, GENOMICS, V63, P69, DOI 10.1006/geno.1999.6049; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHALLEN C, 1992, J HEPATOL, V14, P342, DOI 10.1016/0168-8278(92)90181-N; Chen CF, 2010, HEPATOLOGY, V52, P1690, DOI 10.1002/hep.23847; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Dudek P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001859; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Griffith E, 2005, CELL MOTIL CYTOSKEL, V60, P140, DOI 10.1002/cm.20052; Grise F, 2009, BBA-REV CANCER, V1795, P137, DOI 10.1016/j.bbcan.2008.12.003; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Harvell DME, 2006, ENDOCRINOLOGY, V147, P700, DOI 10.1210/en.2005-0617; Imbeaud S, 2010, SEMIN LIVER DIS, V30, P75, DOI 10.1055/s-0030-1247134; Jagadeeswaran R, 2008, CANCER RES, V68, P132, DOI 10.1158/0008-5472.CAN-07-1998; Jou YS, 2004, CANCER RES, V64, P3030, DOI 10.1158/0008-5472.CAN-03-2320; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; KANAI T, 1987, CANCER, V60, P810, DOI 10.1002/1097-0142(19870815)60:4<810::AID-CNCR2820600417>3.0.CO;2-1; Kang SM, 2000, CANCER RES, V60, P5296; Khurana T, 2002, PROTOPLASMA, V219, P1, DOI 10.1007/s007090200000; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Liu CY, 2009, J PATHOL, V219, P222, DOI 10.1002/path.2589; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Murata H, 2004, LAB INVEST, V84, P1050, DOI 10.1038/labinvest.3700118; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Rath N, 2005, MOL CELL BIOL, V25, P8864, DOI 10.1128/MCB.25.20.8864-8873.2005; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wang G, 2001, GENE CHROMOSOME CANC, V31, P221, DOI 10.1002/gcc.1138; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; Yoshida T, 2010, CANCER INFORM, V9, P147; Zheng Q, 2007, BIOL CELL, V99, P489, DOI 10.1042/BC20060126	48	31	31	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	21					2640	2652		10.1038/onc.2011.440	http://dx.doi.org/10.1038/onc.2011.440			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21996735				2022-12-28	WOS:000304523500004
J	Zhang, H; Wong, CCL; Wei, H; Gilkes, DM; Korangath, P; Chaturvedi, P; Schito, L; Chen, J; Krishnamachary, B; Winnard, PT; Raman, V; Zhen, L; Mitzner, WA; Sukumar, S; Semenza, GL				Zhang, H.; Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Korangath, P.; Chaturvedi, P.; Schito, L.; Chen, J.; Krishnamachary, B.; Winnard, P. T., Jr.; Raman, V.; Zhen, L.; Mitzner, W. A.; Sukumar, S.; Semenza, G. L.			HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs	ONCOGENE			English	Article						breast cancer; metastasis; hypoxia	INDUCIBLE FACTOR-I; LYSYL OXIDASE; FACTOR-1-ALPHA; OVEREXPRESSION; PROGNOSIS; PREDICTS; BIOLOGY; SERIES; GENES	Most cases of breast cancer (BrCa) mortality are due to vascular metastasis. BrCa cells must intravasate through endothelial cells (ECs) to enter a blood vessel in the primary tumor and then adhere to ECs and extravasate at the metastatic site. In this study we demonstrate that inhibition of hypoxia-inducible factor (HIF) activity in BrCa cells by RNA interference or digoxin treatment inhibits primary tumor growth and also inhibits the metastasis of BrCa cells to the lungs by blocking the expression of angiopoietin-like 4 (ANGPTL4) and L1 cell adhesion molecule (L1CAM). ANGPTL4 is a secreted factor that inhibits EC-EC interaction, whereas L1CAM increases the adherence of BrCa cells to ECs. Interference with HIF, ANGPTL4 or L1CAM expression inhibits vascular metastasis of BrCa cells to the lungs. Oncogene (2012) 31, 1757-1770; doi: 10.1038/onc.2011.365; published online 22 August 2011	[Zhang, H.; Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Chaturvedi, P.; Schito, L.; Chen, J.; Semenza, G. L.] Johns Hopkins Univ, Vasc Program, Inst Cell Engn, Sch Med, Baltimore, MD 21205 USA; [Zhang, H.; Korangath, P.; Sukumar, S.; Semenza, G. L.] Johns Hopkins Univ, Dept Oncol, Sch Med, Baltimore, MD 21205 USA; [Wong, C. C. L.; Wei, H.; Gilkes, D. M.; Chaturvedi, P.; Chen, J.; Semenza, G. L.] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Sch Med, Baltimore, MD 21205 USA; [Krishnamachary, B.; Winnard, P. T., Jr.; Raman, V.] Johns Hopkins Univ, Dept Radiol, Sch Med, Baltimore, MD 21205 USA; [Zhang, H.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Schito, L.] Univ Roma La Sapienza, Rome, Italy; [Zhen, L.; Mitzner, W. A.] Johns Hopkins Univ, Div Physiol, Sch Publ Hlth, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Pediat, Sch Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Med, Sch Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Radiat Oncol, Sch Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Dept Biol Chem, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Sapienza University Rome; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Vasc Program, Inst Cell Engn, Sch Med, 733 N Broadway,Suite 671, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu	Gilkes, Daniele M/AAI-8133-2020; Zhang, Huafeng/A-7188-2012; Wong, Carmen Chak Lui/C-4660-2009	Gilkes, Daniele M/0000-0003-3984-9338; Korangath, Preethi/0000-0002-6623-493X; Wong, Carmen Chak Lui/0000-0001-5866-4705; Chen, Jasper/0000-0001-6070-5940	Emerald Foundation; National Institutes of Health [U54-CA143868]; Johns Hopkins Institute for Cell Engineering; Postdoctoral Training Program in Nanotechnology for Cancer Medicine [T32-CA130840]; NATIONAL CANCER INSTITUTE [T32CA130840, U54CA143868] Funding Source: NIH RePORTER	Emerald Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Johns Hopkins Institute for Cell Engineering; Postdoctoral Training Program in Nanotechnology for Cancer Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Karen Padgett of Novus Biologicals for generous gifts of antibodies against HIF-1 alpha, HIF-2 alpha and L1CAM. This work was supported by the Emerald Foundation, the National Institutes of Health (U54-CA143868) and the Johns Hopkins Institute for Cell Engineering. DMG was supported by the Postdoctoral Training Program in Nanotechnology for Cancer Medicine (T32-CA130840). GLS is the C Michael Armstrong Professor at Johns Hopkins University School of Medicine.	Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Chintala S, 2010, CANCER CHEMOTH PHARM, V66, P899, DOI 10.1007/s00280-009-1238-8; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Generali D, 2006, CLIN CANCER RES, V12, P4562, DOI 10.1158/1078-0432.CCR-05-2690; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P7972, DOI 10.1158/1078-0432.CCR-04-1068; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Issa Y, 2009, J MOL MED, V87, P99, DOI 10.1007/s00109-008-0410-7; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Kronblad A, 2006, INT J CANCER, V118, P2609, DOI 10.1002/ijc.21676; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Liotta LA, 2000, CANC MED, P121; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Melillo G, 2007, CANCER METAST REV, V26, P341, DOI 10.1007/s10555-007-9059-x; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nishi H, 2004, ENDOCRINOLOGY, V145, P4113, DOI 10.1210/en.2003-1639; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Schindl M, 2002, CLIN CANCER RES, V8, P1831; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Tafani M, 2010, CANCER SCI, V101, P1014, DOI 10.1111/j.1349-7006.2010.01493.x; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Trastour C, 2007, INT J CANCER, V120, P1451, DOI 10.1002/ijc.22436; Ueno M, 2011, AM J PHYSIOL-LUNG C, V300, pL740, DOI 10.1152/ajplung.00146.2010; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Verheul HMW, 2008, CLIN CANCER RES, V14, P3589, DOI 10.1158/1078-0432.CCR-07-4306; Vleugel MM, 2005, J CLIN PATHOL, V58, P172, DOI 10.1136/jcp.2004.019885; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yamamoto Y, 2008, BREAST CANCER RES TR, V110, P465, DOI 10.1007/s10549-007-9742-1; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	43	243	254	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1757	1770		10.1038/onc.2011.365	http://dx.doi.org/10.1038/onc.2011.365			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860410	Green Accepted			2022-12-28	WOS:000302785200002
J	Zhang, J; Zhu, F; Li, X; Dong, Z; Xu, Y; Peng, C; Li, S; Cho, YY; Yao, K; Zykova, TA; Bode, AM; Dong, Z				Zhang, J.; Zhu, F.; Li, X.; Dong, Z.; Xu, Y.; Peng, C.; Li, S.; Cho, Y-Y; Yao, K.; Zykova, T. A.; Bode, A. M.; Dong, Z.			Rack1 protects N-terminal phosphorylated c-Jun from Fbw7-mediated degradation	ONCOGENE			English	Article						cell transformation; Rack1; c-Jun; phosphorylation; degradation	UBIQUITIN LIGASE; JNK; RAS; AP-1; RECOGNITION; ACTIVATION; RECEPTOR; TARGETS	The c-Jun transcription factor is a highly unstable oncoprotein. Several ubiquitin ligases mediate c-Jun degradation. However, c-Jun can be stabilized once it is phosphorylated at the N-terminus by c-Jun N-terminal kinases (JNKs) or other protein kinases. This phosphorylation decreases c-Jun ubiquitination and degradation. The underlying mechanism for this phenomenon is still unknown. Here, we show that receptor for activated C-kinase 1 (Rack1) can bind with c-Jun and ubiquitin ligase Fbw7 to form a complex. When c-Jun is phosphorylated at the N-terminus, c-Jun is released from the complex and cannot be ubiquitinated by Fbw7, which leads to increased stabilization and accumulation of c-Jun. These results reveal that Rack1 has a very important role in tumorigenesis by maintaining the stability of c-Jun that has been phosphorylated at its N-terminus by JNKs or other kinases. Oncogene (2012) 31, 1835-1844; doi: 10.1038/onc.2011.369; published online 22 August 2011	[Zhang, J.; Zhu, F.; Li, X.; Xu, Y.; Peng, C.; Li, S.; Cho, Y-Y; Yao, K.; Zykova, T. A.; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Dept Cellular & Mol Biol, 801 16th Ave NE, Austin, MN 55912 USA; [Li, X.; Dong, Z.] Zhengzhou Univ, Basic Med Sch, Zhengzhou, Peoples R China; [Cho, Y-Y] Catholic Univ Korea, Coll Pharm, Gyeonggi Do, South Korea	University of Minnesota System; Zhengzhou University; Catholic University of Korea	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, Dept Cellular & Mol Biol, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	Cho, Yong-Yeon/AAD-4263-2020; ZHU, Feng/G-3567-2010; ZHU, Feng/C-1303-2010; zhang, jinhui/GXF-6528-2022	Zhu, Feng/0000-0003-1172-0102; Cho, Yong-Yeon/0000-0003-1107-2651	The Hormel Foundation; National Institutes of Health [CA077646, CA111536, CA120388, ES016548, R37 CA081064]; NATIONAL CANCER INSTITUTE [R01CA111536, R37CA081064, R01CA120388, R01CA077646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	The Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Wang Luhai and Dr Ronai Ze'ev for providing the HA-FL-Rack1, HA-WD1-4-Rack1 and HA-WD5-7-Rack1 vectors and Dr Wei Wenyi for providing the Flag-wt-c-Jun, Flag-Delta JNK-c-Jun, Flag-AF-c-Jun and Flag-AF-Delta JNK-c-Jun plasmids. We also thank Dr Bohmann Dirk for providing the c-Jun<SUP>Ala</SUP> and c-Jun<SUP>Asp</SUP> mutant c-Jun plasmids. This study was supported by The Hormel Foundation and National Institutes of Health grants CA077646, CA111536, CA120388, ES016548 and R37 CA081064.	Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Cao XX, 2010, BREAST CANCER RES TR, V123, P375, DOI 10.1007/s10549-009-0657-x; Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120; Cho YY, 2009, CANCER RES, V69, P272, DOI 10.1158/0008-5472.CAN-08-3125; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Dong Z, 1994, EARLY DETECTION CANC, P123; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Egidy G, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-34; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nagashio R, 2010, LUNG CANCER, V69, P54, DOI 10.1016/j.lungcan.2009.09.015; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Thornton C, 2004, J BIOL CHEM, V279, P31357, DOI 10.1074/jbc.M402316200; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wang Z, 2008, MOL CELL PROTEOMICS, V7, P1639, DOI 10.1074/mcp.M700520-MCP200; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	36	18	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1835	1844		10.1038/onc.2011.369	http://dx.doi.org/10.1038/onc.2011.369			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860413				2022-12-28	WOS:000302785200009
J	Gurzov, EN; Barthson, J; Marhfour, I; Ortis, F; Naamane, N; Igoillo-Esteve, M; Gysemans, C; Mathieu, C; Kitajima, S; Marchetti, P; Orntoft, TF; Bakiri, L; Wagner, EF; Eizirik, DL				Gurzov, E. N.; Barthson, J.; Marhfour, I.; Ortis, F.; Naamane, N.; Igoillo-Esteve, M.; Gysemans, C.; Mathieu, C.; Kitajima, S.; Marchetti, P.; Orntoft, T. F.; Bakiri, L.; Wagner, E. F.; Eizirik, D. L.			Pancreatic beta-cells activate a JunB/ATF3-dependent survival pathway during inflammation	ONCOGENE			English	Article						type 1 diabetes; pancreatic beta cells; JunB; ATF3; apoptosis	ENDOPLASMIC-RETICULUM STRESS; ADAPTIVE-RESPONSE GENE; ER STRESS; APOPTOSIS; JUNB; ATF3; EXPRESSION; DEATH; CYTOKINES; MICE	Destruction of insulin-producing pancreatic beta-cells by local autoimmune inflammation is a hallmark of type 1 diabetes. Histochemical analysis of pancreases from non-obese diabetic mice indicated activation of the transcription factor JunB/AP-1 (activator protein-1) after autoimmune infiltration of the islets. In vitro studies demonstrated that the cytokines tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma induce JunB expression as a protective mechanism against apoptosis in both human and rodent beta-cells. The gene network affected was studied by microarray analysis showing that JunB regulates nearly 20% of the cytokine-modified beta-cell genes, including the transcription factor ATF3. Direct transcriptional induction of ATF3 by JunB is a key event for beta-cell survival after TNF-alpha + IFN-gamma treatment. Moreover, pharmacological upregulation of JunB/ATF3 via increased cAMP protected rodent primary beta-cells and human islet cells against pro-inflammatory mediators. These results were confirmed in genetically modified islets derived from Ubi-JunB transgenic mice. Our findings identify ATF3 as a novel downstream target of JunB in the survival mechanism of beta-cells under inflammatory stress. Oncogene (2012) 31, 1723-1732; doi:10.1038/onc.2011.353; published online 15 August 2011	[Gurzov, E. N.; Barthson, J.; Marhfour, I.; Ortis, F.; Naamane, N.; Igoillo-Esteve, M.; Eizirik, D. L.] Univ Libre Bruxelles, Expt Med Lab, B-1070 Brussels, Belgium; [Gysemans, C.; Mathieu, C.] Katholieke Univ Leuven, Fac Med, Lab Expt Med Endocrinol LEGENDO, Louvain, Belgium; [Kitajima, S.] Tokyo Med & Dent Univ, Med Res Inst, Sch Biomed Sci, Dept Biochem Genet, Tokyo, Japan; [Kitajima, S.] Tokyo Med & Dent Univ, Sch Biomed Sci, Lab Genome Struct & Regulat, Tokyo, Japan; [Marchetti, P.] Univ Pisa, Osped Cisanello, Metab Unit, Dept Endocrinol & Metab, Pisa, Italy; [Orntoft, T. F.] CMO Aros Appl Biotechnol AS, Aarhus, Denmark; [Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus, Denmark; [Bakiri, L.; Wagner, E. F.] Banco Bilbao Vizcaya Argentaria BBVA Fdn, Canc Cell Biol Programme, CNIO, Madrid, Spain	Universite Libre de Bruxelles; KU Leuven; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Pisa; Aarhus University; Centro Nacional de Investigaciones Oncologicas (CNIO)	Gurzov, EN (corresponding author), Univ Libre Bruxelles, Expt Med Lab, Route Lennik 808,CP-618, B-1070 Brussels, Belgium.	egurzov@ulb.ac.be; deizirik@ulb.ac.be	Bakiri, Latifa/N-5780-2014; mathieu, chantal/ABD-5505-2021; Bakiri, Latifa/AAP-1674-2020; Ortis, Fernanda/M-7190-2019; Ortis, Fernanda/K-7917-2014; Marchetti, Piero/J-7439-2013	mathieu, chantal/0000-0002-4055-5233; Marchetti, Piero/0000-0003-4907-0635; Wagner, Erwin F/0000-0001-7872-0196; gysemans, conny/0000-0003-3559-6089; Ortis, Fernanda/0000-0002-9551-2839; Igoillo-Esteve, Mariana/0000-0002-3264-7912; bakiri, latifa/0000-0002-6300-2420; Gurzov, Esteban/0000-0003-4642-0273	Communaute Francaise de Belgique-Actions de Recherche Concertees (ARC); Fonds National de la Recherche Scientifique (FNRS) Belgium; Belgium Program on Interuniversity Poles of Attraction [IUAP P6/40]; Juvenile Diabetes Research Foundation International (JDRFI) [17-2009-106]; European Union (European Community); EMBO; FWO Vlaanderen	Communaute Francaise de Belgique-Actions de Recherche Concertees (ARC); Fonds National de la Recherche Scientifique (FNRS) Belgium(Fonds de la Recherche Scientifique - FNRS); Belgium Program on Interuniversity Poles of Attraction; Juvenile Diabetes Research Foundation International (JDRFI)(Juvenile Diabetes Research Foundation); European Union (European Community)(European Commission); EMBO(European Molecular Biology Organization (EMBO)); FWO Vlaanderen(FWO)	We thank MA Neef, G Vandenbroeck, M Urbain, R Makhnas, AE Musuaya and S Mertens of the Laboratory of Experimental Medicine (Universite Libre de Bruxelles, Brussels, Belgium) for excellent technical support, and Drs L Marselli and L Ladriere for help with human islet preparations. This work was supported by grants from the Communaute Francaise de Belgique-Actions de Recherche Concertees (ARC), Fonds National de la Recherche Scientifique (FNRS) Belgium, the Belgium Program on Interuniversity Poles of Attraction initiated by the Belgium State (IUAP P6/40), the Juvenile Diabetes Research Foundation International (JDRFI Grant 17-2009-106) and the European Union (project Naimit, in the Framework Programme 7 of the European Community). ENG was supported by an EMBO long-term fellowship. CG and CM were supported by a postdoctoral and senior clinical scholarship from the FWO Vlaanderen, respectively.	Allagnat F, 2011, CELL DEATH DIFFER, V18, P328, DOI 10.1038/cdd.2010.105; Borchers AT, 2010, AUTOIMMUN REV, V9, pA355, DOI 10.1016/j.autrev.2009.12.003; Bosi E, 2010, J CLIN ENDOCR METAB, V95, P2607, DOI 10.1210/jc.2009-2741; Cardozo AK, 2005, DIABETES, V54, P452, DOI 10.2337/diabetes.54.2.452; Carrington EM, 2009, DIABETES, V58, P2316, DOI 10.2337/db08-1602; Colli ML, 2010, HUM MOL GENET, V19, P135, DOI 10.1093/hmg/ddp474; Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062; Cunha DA, 2009, DIABETES, V58, P2851, DOI 10.2337/db09-0685; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eizirik DL, 2009, NAT REV ENDOCRINOL, V5, P219, DOI 10.1038/nrendo.2009.21; Eizirik DL, 2001, DIABETOLOGIA, V44, P2115, DOI 10.1007/s001250100021; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gurzov EN, 2009, CELL DEATH DIFFER, V16, P1539, DOI 10.1038/cdd.2009.99; Gurzov EN, 2010, J BIOL CHEM, V285, P19910, DOI 10.1074/jbc.M110.122374; Gurzov EN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003030; Heimberg H, 2001, DIABETES, V50, P2219, DOI 10.2337/diabetes.50.10.2219; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Kutlu B, 2003, DIABETES, V52, P2701, DOI 10.2337/diabetes.52.11.2701; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Maida A, 2008, ENDOCRINOLOGY, V149, P5670, DOI 10.1210/en.2008-0336; Matsuoka T, 2010, DIABETES, V59, P1709, DOI 10.2337/db08-0693; Meixner A, 2008, NAT CELL BIOL, V10, P1003, DOI 10.1038/ncb1761; Moore F, 2011, J BIOL CHEM, V286, P929, DOI 10.1074/jbc.M110.162131; Moore F, 2009, DIABETES, V58, P1283, DOI 10.2337/db08-1510; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; Pflegerl P, 2009, P NATL ACAD SCI USA, V106, P20423, DOI 10.1073/pnas.0910371106; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Salameh A, 2010, J BIOL CHEM, V285, P23094, DOI 10.1074/jbc.M109.087221; Schmidt D, 2007, EMBO J, V26, P710, DOI 10.1038/sj.emboj.7601539; Schorpp M, 1996, NUCLEIC ACIDS RES, V24, P1787, DOI 10.1093/nar/24.9.1787; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zmuda EJ, 2010, DIABETOLOGIA, V53, P1438, DOI 10.1007/s00125-010-1696-x; Zmuda EJ, 2010, MOL ENDOCRINOL, V24, P1423, DOI 10.1210/me.2009-0463	40	32	32	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1723	1732		10.1038/onc.2011.353	http://dx.doi.org/10.1038/onc.2011.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841823				2022-12-28	WOS:000302231400010
J	Acunzo, M; Visone, R; Romano, G; Veronese, A; Lovat, F; Palmieri, D; Bottoni, A; Garofalo, M; Gasparini, P; Condorelli, G; Chiariello, M; Croce, CM				Acunzo, M.; Visone, R.; Romano, G.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Condorelli, G.; Chiariello, M.; Croce, C. M.			miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222	ONCOGENE			English	Article						MET; miR-130a; NSCLC; TRAIL	CELL LUNG-CANCER; SIGNALING PATHWAY; OVARIAN-CANCER; RESISTANCE; APOPTOSIS	Non-small cell lung cancer (NSCLC) accounts for similar to 80% of all lung cancers. Although some advances in lung cancer therapy have been made, patient survival is still quite poor. Two microRNAs, miR-221 and miR-222, upregulated by the MET proto-oncogene, have been already described to enhance cell survival and to induce TNF-related apoptosis-inducing ligand (TRAIL) resistance in NSCLC cell lines, through the downregulation of p27(kip1), PTEN and TIMP3. Here, we further investigated this pathway and showed that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in NSCLC cells through the c-Jun-mediated downregulation of miR-221 and miR-222. Moreover, we found that miR-130a reduced migratory capacity of NSCLC. A better understanding of MET-miR-221 and 222 axis regulation in drug resistance is the key in developing new strategies in NSCLC therapy. Oncogene (2012) 31, 634-642; doi:10.1038/onc.2011.260; published online 27 June 2011	[Acunzo, M.; Visone, R.; Veronese, A.; Lovat, F.; Palmieri, D.; Bottoni, A.; Garofalo, M.; Gasparini, P.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Romano, G.] Fdn IRCCS SDN, Naples, Italy; [Palmieri, D.; Condorelli, G.] Univ Naples Federico II, Fac Biotechnol Sci, Consiglio Nazl Ric, Dept Cellular & Mol Biol & Pathol,Ist Endocrinol, Naples, Italy; [Chiariello, M.] Consiglio Nazl Ric IFC CNR, ITT, Siena, Italy; [Chiariello, M.] Consiglio Nazl Ric IFC CNR, Ist Fisiol Clin, Siena, Italy	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Croce, CM (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	carlo.croce@osumc.edu	Chiariello, Mario/O-3642-2014; Condorelli, Gerolama/AAC-3472-2022; Veronese, Angelo/I-4292-2019; Acunzo, Mario/ABE-1739-2020; Young, Richard A/F-6495-2012; Gasparini, Pierluigi/ABA-2811-2021; visone, rosa/K-7910-2016	Chiariello, Mario/0000-0001-8434-5177; Condorelli, Gerolama/0000-0003-0177-8829; Young, Richard A/0000-0001-8855-8647; Gasparini, Pierluigi/0000-0001-8311-8845; Veronese, Angelo/0000-0002-1451-1392; VISONE, Rosa/0000-0002-4993-0220; Acunzo, Mario/0000-0002-3942-9061; Palmieri, Dario/0000-0002-0797-4268	NCI; Associazione Italiana Ricerca sul Cancro, AIRC; NATIONAL CANCER INSTITUTE [P01CA129242, U01CA152758] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Associazione Italiana Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NCI grants to (CMC) and Associazione Italiana Ricerca sul Cancro, AIRC grant to GC. We thank Veronica Balatti, Giampiero di Leva, Claudia Piovan, Hansjuerg Alder and Paolo Fadda for the helpful discussions about this manuscript.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Cecchi F, 2010, EUR J CANCER, V46, P1260, DOI 10.1016/j.ejca.2010.02.028; Cimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fan S, 2004, MOL CELL BIOL, V21, P4968; Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018; Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Ramalingam S, 1998, J CLIN ONCOL, V16, P651, DOI 10.1200/JCO.1998.16.2.651; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Segarra J, 2006, J BIOL CHEM, V281, P4771, DOI 10.1074/jbc.M508298200; Socinski MA, 2007, CHEST, V132, p277S, DOI 10.1378/chest.07-1381; Song H, 2006, NEUROSCI RES, V56, P29, DOI 10.1016/j.neures.2006.04.019; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; Tulasne D, 2008, CELL DEATH DIFFER, V15, P427, DOI 10.1038/sj.cdd.4402229; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488	24	160	174	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					634	642		10.1038/onc.2011.260	http://dx.doi.org/10.1038/onc.2011.260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706050	Green Accepted			2022-12-28	WOS:000300221800009
J	Niu, X; Zhang, T; Liao, L; Zhou, L; Lindner, DJ; Zhou, M; Rini, B; Yan, Q; Yang, H				Niu, X.; Zhang, T.; Liao, L.; Zhou, L.; Lindner, D. J.; Zhou, M.; Rini, B.; Yan, Q.; Yang, H.			The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C	ONCOGENE			English	Article						von Hippel-Lindau; hypoxia-inducible factor; JARID1C/KDM5C/SMCX; trimethyl H3K4; gene expression	HYPOXIA-INDUCIBLE-FACTOR; RENAL-CELL CARCINOMA; HIF-ALPHA; INHIBITION; STABILIZATION; INACTIVATION; METHYLATION; ACTIVATION; COMPONENT; REVEALS	In clear-cell renal cell carcinoma (ccRCC), inactivation of the tumor suppressor von Hippel-Lindau (VHL) occurs in the majority of the tumors and is causal for the pathogenesis of ccRCC. Recently, a large-scale genomic sequencing study of ccRCC tumors revealed that enzymes that regulate histone H3 lysine 4 trimethylation (H3K4Me3), such as JARID1C/KDM5C/SMCX and MLL2, were mutated in ccRCC tumors, suggesting that H3K4Me3 might have an important role in regulating gene expression and tumorigenesis. In this study we report that in VHL-deficient ccRCC cells, the overall H3K4Me3 levels were significantly lower than that of VHL+/+ counterparts. Furthermore, this was hypoxia-inducible factor (HIF) dependent, as depletion of HIF subunits by small hairpin RNA in VHL-deficient ccRCC cells restored H3K4Me3 levels. In addition, we demonstrated that only loss of JARID1C, not JARID1A or JARID1B, abolished the difference of H3K4Me3 levels between VHL-/- and VHL+/+ cells, and JARID1C displayed HIF-dependent expression pattern. JARID1C in VHL-/- cells was responsible for the suppression of HIF-responsive genes insulin-like growth factor-binding protein 3 (IGFBP3), DNAJC12, COL6A1, growth and differentiation factor 15 (GDF15) and density-enhanced phosphatase 1. Consistent with these findings, the H3K4Me3 levels at the promoters of IGFBP3, DNAJC12, COL6A1 and GDF15 were lower in VHL-/- cells than in VHL+/+ cells, and the differences disappeared after JARID1C depletion. Although HIF2 alpha is an oncogene in ccRCC, some of its targets might have tumor suppressive activity. Consistent with this, knockdown of JARID1C in 786-O VHL-/- ccRCC cells significantly enhanced tumor growth in a xenograft model, suggesting that JARID1C is tumor suppressive and its mutations are tumor promoting in ccRCC. Thus, VHL inactivation decreases H3K4Me3 levels through JARID1C, which alters gene expression and suppresses tumor growth. Oncogene (2012) 31, 776-786; doi:10.1038/onc.2011.266; published online 4 July 2011	[Niu, X.; Zhang, T.; Liao, L.; Zhou, L.; Yang, H.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; [Lindner, D. J.; Rini, B.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA; [Zhou, M.] Cleveland Clin, Dept Pathol, Cleveland, OH 44195 USA; [Yan, Q.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Yale University	Yang, H (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Canc Biol, NB-40,9500 Euclid Ave, Cleveland, OH 44195 USA.	yangh2@ccf.org	Zhou, Liang/F-7201-2014; Lindner, Daniel/ABB-5440-2020; Zhou, Liang/N-8220-2013; Yan, Qin/E-8893-2012	Yan, Qin/0000-0003-4077-453X	American Cancer Society; Cleveland Clinic; V scholar Award; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Cleveland Clinic; V scholar Award; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The 786-O and RCC4 cell lines were kind gifts from Dr William Kaelin Jr. This work was supported by American Cancer Society Pilot Award (to HY) and the seed fund from Cleveland Clinic to HY. QY is a Breast Cancer Alliance Young Investigator who was also supported by V scholar Award. We thank Dr Donal Luse for his critical reading of the manuscript.	Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Cheung I, 2010, P NATL ACAD SCI USA, V107, P8824, DOI 10.1073/pnas.1001702107; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Isaacs JS, 2004, J BIOL CHEM, V279, P16128, DOI 10.1074/jbc.M313342200; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Li N, 2008, P NATL ACAD SCI USA, V105, P17055, DOI 10.1073/pnas.0807765105; Linehan WM, 2004, CLIN CANCER RES, V10, p6282S, DOI 10.1158/1078-0432.CCR-050013; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mersman DP, 2009, GENE DEV, V23, P951, DOI 10.1101/gad.1769209; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Nakamura E, 2006, AM J PATHOL, V168, P574, DOI 10.2353/ajpath.2006.050867; Negrotto S, 2011, CANCER RES, V71, P1431, DOI 10.1158/0008-5472.CAN-10-2422; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Rini BI, 2005, BJU INT, V96, P286, DOI 10.1111/j.1464-410X.2005.05616.x; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Schraml P, 2009, MODERN PATHOL, V22, P31, DOI 10.1038/modpathol.2008.132; Semenza G.L., 2007, SCI STKE, V2007, pcm8; Semenza GL, 1997, KIDNEY INT, V51, P553, DOI 10.1038/ki.1997.77; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Wellmann S, 2008, BIOCHEM BIOPH RES CO, V372, P892, DOI 10.1016/j.bbrc.2008.05.150; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhou X, 2010, CANCER RES, V70, P4214, DOI 10.1158/0008-5472.CAN-09-2942; Zimmer M, 2004, MOL CANCER RES, V2, P89	46	106	108	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					776	786		10.1038/onc.2011.266	http://dx.doi.org/10.1038/onc.2011.266			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725364	Green Accepted			2022-12-28	WOS:000300222100010
J	Zhu, G; Wang, Y; Huang, B; Liang, J; Ding, Y; Xu, A; Wu, W				Zhu, G.; Wang, Y.; Huang, B.; Liang, J.; Ding, Y.; Xu, A.; Wu, W.			A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells	ONCOGENE			English	Article						colon cancer; beta-catenin; PAK1; Rac1; phosphorylation	WNT SIGNALING PATHWAY; COLORECTAL-CANCER; PHOSPHORYLATION; PAK; EXPRESSION; KINASES; RAC1; LOCALIZATION; PROGRESSION; INHIBITION	P21-activated kinase 1 (PAK1) is associated with colon cancer progression and metastasis, whereas the molecular mechanism remains elusive. Here, we show that down-regulation of PAK1 in colon cancer cells reduces total beta-catenin level, as well as cell proliferation. Mechanistically, PAK1 directly phosphorylates beta-catenin proteins at Ser675 site and this leads to more stable and transcriptional active beta-catenin. Corroborating these results, PAK1 is required for full Wnt signaling, and superactivation of beta-catenin is achieved by simultaneous knockdown of adenomatous polyposis coli protein and activation of PAK1. Moreover, we show that Rac1 functions upstream of PAK1 in colon cancer cells and contributes to beta-catenin phosphorylation and accumulation. We conclude that a Rac1/PAK1 cascade controls beta-catenin S675 phosphorylation and full activation in colon cancer cells. Supporting this conclusion, overexpression of PAK1 is observed in 70% of colon cancer samples and is correlated with massive beta-catenin accumulation. Oncogene (2012) 31, 1001-1012; doi:10.1038/onc.2011.294; published online 8 August 2011	[Zhu, G.; Wang, Y.; Huang, B.; Liang, J.; Ding, Y.; Wu, W.] Tsinghua Univ, Prot Sci Lab, Minist Educ, Sch Life Sci, Beijing 100084, Peoples R China; [Xu, A.] Beijing Friendship Hosp, Beijing, Peoples R China	Tsinghua University; Capital Medical University	Wu, W (corresponding author), Tsinghua Univ, Prot Sci Lab, Minist Educ, Sch Life Sci, Qinghuayuan 1, Beijing 100084, Peoples R China.	wwu@mail.tsinghua.edu.cn			National Natural Science Foundation of China [30730048, 30921004]; Major Science Programs of China [2006CB943402, 2011CB943803]; Tsinghua University [2010THZ0]; Bayer Healthcare	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Science Programs of China; Tsinghua University; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals)	We thank Drs Ye-Guang Chen, Jonathan Chernoff, Raymond Habas, Alan Hall, Tianhui Hu, Edward Leof, Chaojun Li, Randy Moon, Christof Niehrs, Roel Nusse and Thomas Rudel for reagents. This work was supported by grants to WW from the National Natural Science Foundation of China (No. 30730048, 30921004), the Major Science Programs of China (2006CB943402, 2011CB943803), Tsinghua University Initiative Scientific Research Program (2010THZ0) and Bayer Healthcare.	Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Arias-Romero LE, 2008, BIOL CELL, V100, P97, DOI 10.1042/BC20070109; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bikkavilli RK, 2008, J CELL SCI, V121, P234, DOI 10.1242/jcs.021964; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; He H, 2008, BBA-MOL CELL RES, V1783, P1943, DOI 10.1016/j.bbamcr.2008.04.016; Hendriksen J, 2008, J CELL SCI, V121, P1793, DOI 10.1242/jcs.025536; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jacobs T, 2007, J NEUROSCI, V27, P8604, DOI 10.1523/JNEUROSCI.0765-07.2007; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lee SH, 2007, CANCER RES, V67, P11045, DOI 10.1158/0008-5472.CAN-07-0986; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lu ZM, 2004, CELL CYCLE, V3, P571; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Nheu T, 2004, CELL CYCLE, V3, P71; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Rennefahrt UEE, 2007, J BIOL CHEM, V282, P15667, DOI 10.1074/jbc.M700253200; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Segditsas S, 2008, EXP MOL PATHOL, V85, P201, DOI 10.1016/j.yexmp.2008.09.006; Sun J, 2009, ONCOGENE, V28, P3132, DOI 10.1038/onc.2009.167; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Valentini AM, 2003, CURR PHARM DESIGN, V9, P1932, DOI 10.2174/1381612033454216; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang Y, 2010, J BIOL CHEM, V285, P10890, DOI 10.1074/jbc.M109.058347; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wells CM, 2010, BIOCHEM J, V425, P465, DOI 10.1042/BJ20091173; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001	54	153	159	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					1001	1012		10.1038/onc.2011.294	http://dx.doi.org/10.1038/onc.2011.294			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21822311				2022-12-28	WOS:000300709700006
J	Bergamaschi, A; Katzenellenbogen, BS				Bergamaschi, A.; Katzenellenbogen, B. S.			Tamoxifen downregulation of miR-451 increases 14-3-3 zeta and promotes breast cancer cell survival and endocrine resistance	ONCOGENE			English	Article						breast cancer; tamoxifen; endocrine resistance; 14-3-3 zeta; miR-451; tumor suppressor	ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; MICRORNAS; DETERMINANTS; RALOXIFENE; MECHANISM; THERAPY; KINASE; GROWTH; RISK	Many estrogen receptor (ER)-positive breast cancers respond well initially to endocrine therapies, but often develop resistance during treatment with selective ER modulators (SERMs) such as tamoxifen. We have reported that the 14-3-3 family member and conserved protein, 14-3-3 zeta, is upregulated by tamoxifen and that high expression correlated with an early time to disease recurrence. However, the mechanism by which tamoxifen upregulates 14-3-3 zeta and may promote the development of endocrine resistance is not known. Our findings herein reveal that the tamoxifen upregulation of 14-3-3 zeta results from its ability to rapidly downregulate microRNA (miR)-451 that specifically targets 14-3-3 zeta. The levels of 14-3-3 zeta and miR-451 were inversely correlated, with 14-3-3 zeta being elevated and miR-451 being at a greatly reduced level in tamoxifen-resistant breast cancer cells. Of note, downregulation of miR-451 was selectively elicited by tamoxifen but not by other SERMs, such as raloxifene or ICI182,780 (Fulvestrant). Increasing the level of miR-451 by overexpression, which decreased 14-3-3 zeta, suppressed cell proliferation and colony formation, markedly reduced activation of HER2, EGFR and MAPK signaling, increased apoptosis, and, importantly, restored the growth-inhibitory effectiveness of SERMs in endocrine-resistant cells. Opposite effects were elicited by miR-451 knockdown. Thus, we identify tamoxifen downregulation of miR-451, and consequent elevation of the key survival factor 14-3-3 zeta, as a mechanistic basis of tamoxifen-associated development of endocrine resistance. These findings suggest that therapeutic approaches to increase expression of this tumor suppressor-like miR should be considered to downregulate 14-3-3 zeta and enhance the effectiveness of endocrine therapies. Furthermore, the selective ability of the SERM tamoxifen but not raloxifene to regulate miR-451 and 14-3-3 zeta may assist in understanding differences in their activities, as seen in the STAR (Study of Tamoxifen and Raloxifene) breast cancer prevention trial and in other clinical trials. Oncogene (2012) 31, 39-47; doi: 10.1038/onc.2011.223; published online 13 June 2011	[Katzenellenbogen, B. S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Coll Med Urbana Champaign, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@uiuc.edu	Bergamaschi, Anna/D-2022-2009	Bergamaschi, Anna/0000-0001-8709-1766	Breast Cancer Research Foundation; NIH [P01AG024387, P50 AT006268]; Department of Defense [W81XWH-09-1-0398]; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG024387] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by grants from the Breast Cancer Research Foundation (BSK) and the NIH (P01AG024387 and P50 AT006268, BSK), and a Postdoctoral Fellowship from the Department of Defense (W81XWH-09-1-0398, AB). We thank Dr Nancy Weigel, Baylor College of Medicine, for providing lysine-coated adenovirus.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bergamaschi A, 2009, P AM ASS CANC RES AN, V2, P2854; Chang EC, 2008, MOL ENDOCRINOL, V22, P1032, DOI 10.1210/me.2007-0356; Costa RH, 2005, NAT CELL BIOL, V7, P108, DOI 10.1038/ncb0205-108; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dore LC, 2008, P NATL ACAD SCI USA, V105, P3333, DOI 10.1073/pnas.0712312105; Dunn B K, 2001, Breast J, V7, P144, DOI 10.1046/j.1524-4741.2001.007003144.x; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Harfe BD, 2005, CURR OPIN GENET DEV, V15, P410, DOI 10.1016/j.gde.2005.06.012; Herman ME, 1996, J STEROID BIOCHEM, V59, P121, DOI 10.1016/S0960-0760(96)00114-8; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Lowery AJ, 2008, CLIN CANCER RES, V14, P360, DOI 10.1158/1078-0432.CCR-07-0992; Masaki S, 2007, BIOCHEM BIOPH RES CO, V364, P509, DOI 10.1016/j.bbrc.2007.10.077; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Oksvold MP, 2004, FEBS LETT, V569, P207, DOI 10.1016/j.febslet.2004.05.068; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Patrick DM, 2010, GENE DEV, V24, P1614, DOI 10.1101/gad.1942810; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Shan G, 2008, NAT BIOTECHNOL, V26, P933, DOI 10.1038/nbt.1481; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; Vogel VG, 2010, CANCER PREV RES, V3, P696, DOI 10.1158/1940-6207.CAPR-10-0076; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88; Williams AE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-172; Yang JS, 2010, P NATL ACAD SCI USA, V107, P15163, DOI 10.1073/pnas.1006432107; Yu DN, 2010, GENE DEV, V24, P1620, DOI 10.1101/gad.1942110	42	153	167	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					39	47		10.1038/onc.2011.223	http://dx.doi.org/10.1038/onc.2011.223			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666713	Green Accepted			2022-12-28	WOS:000299176200004
J	Wang, X; Venugopal, C; Manoranjan, B; McFarlane, N; O'Farrell, E; Nolte, S; Gunnarsson, T; Hollenberg, R; Kwiecien, J; Northcott, P; Taylor, MD; Hawkins, C; Singh, SK				Wang, X.; Venugopal, C.; Manoranjan, B.; McFarlane, N.; O'Farrell, E.; Nolte, S.; Gunnarsson, T.; Hollenberg, R.; Kwiecien, J.; Northcott, P.; Taylor, M. D.; Hawkins, C.; Singh, S. K.			Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells	ONCOGENE			English	Article						Bmi1; sonic hedgehog; medulloblastoma; brain tumor-initiating cells; CD133; chromatin immunoprecipitation	STEM-LIKE CELLS; BETA-CATENIN STATUS; MOUSE MODEL; SELF-RENEWAL; CHILDHOOD MEDULLOBLASTOMA; GENETIC PROFILES; N-MYC; PATHWAY; CANCER; GROWTH	Bmi1 is a key stem cell regulatory gene implicated in the pathogenesis of many aggressive cancers, including medulloblastoma. Overexpression of Bmi1 promotes cell proliferation and is required for hedgehog (Hh) pathway-driven tumorigenesis. This study aimed to determine if Sonic hedgehog (Shh) modulates the key stem cell regulatory gene Bmi1 in childhood medulloblastoma brain tumor-initiating cells (BTICs). Although current literature suggests that there is a correlation between Shh pathway genes and Bmi1 expression, it is unclear whether there is indeed a direct regulatory mechanism. To address whether Shh induces expression of Bmi1, stem cell-enriched populations from medulloblastoma cell lines and primary samples were treated with Shh ligand and KAAD-cyclopamine (Shh antagonist). Our data indicate that Bmi1 expression positively correlates with increasing Shh ligand concentrations. Chromatin immunoprecipitation reveals that Gli1 preferentially binds to the Bmi1 promoter, and Bmi1 transcript levels are increased and decreased by Gli1 overexpression and down-regulation, respectively. Knockdown experiments of Bmi1 in vitro and in vivo demonstrate that Hh signaling not only drives Bmi1 expression, but a feedback mechanism exists wherein downstream effectors of Bmi1 may, in turn, activate Hh pathway genes. These findings implicate Bmi1 and Hh as mutually indispensable pathways in medulloblastoma BTIC maintenance. Recent molecular characterization of medulloblastoma also reveals that Bmi1 is overexpressed across all subgroups of medulloblastoma, particularly in the most aggressive subtypes. Lastly, despite recent identification of BTIC markers, the molecular characterization of these cell populations remains unclear. In this work, we propose that the BTIC marker CD133 may segregate a cell population with a Hh-receptor phenotype, thus demonstrating a cell-cell interaction between the CD133+ Hh receptor cells and the CD133- Hh-secreting cells. Oncogene (2012) 31, 187-199; doi:10.1038/onc.2011.232; published online 20 June 2011	[Wang, X.; Venugopal, C.; Manoranjan, B.; McFarlane, N.; O'Farrell, E.; Nolte, S.; Singh, S. K.] McMaster Univ, McMaster Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Singh, S. K.] McMaster Univ, Dept Surg, Stem Cell & Canc Res Inst, Hamilton, ON L8N 3Z5, Canada; [Kwiecien, J.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Northcott, P.; Taylor, M. D.] Hosp Sick Children, Dept Surg, Toronto, ON M5G 1X8, Canada; [Northcott, P.; Taylor, M. D.; Hawkins, C.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; [Northcott, P.; Taylor, M. D.; Hawkins, C.] Univ Toronto, Toronto, ON, Canada; [Hawkins, C.] Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; [Singh, S. K.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Singh, S. K.] McMaster Univ, Fac Hlth Sci, Dept Neurosci, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; McMaster University	Singh, SK (corresponding author), McMaster Univ, Dept Surg, Stem Cell & Canc Res Inst, MDCL 5027,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ssingh@mcmaster.ca	Wang, Xin/U-7221-2017; Northcott, Paul A/N-4022-2018; Hawkins, Cynthia/M-2571-2019; Singh, Sheila K/W-2799-2018; Wang, Xin/O-8779-2019; Gunnarsson, Thorsteinn/AAA-1238-2019	Wang, Xin/0000-0001-6292-3087; Northcott, Paul A/0000-0002-1220-5252; Singh, Sheila K/0000-0003-1272-5300; Wang, Xin/0000-0001-6292-3087; Wang, Xin/0000-0001-8783-4080; Taylor, Michael/0000-0001-7009-3466; Gunnarsson, Thorsteinn/0000-0001-6657-4187	Department of Surgery at McMaster University; Ontario Institute for Cancer Research (OICR); JP Bickell Foundation; Stem Cell Network	Department of Surgery at McMaster University; Ontario Institute for Cancer Research (OICR); JP Bickell Foundation; Stem Cell Network	We are very grateful to Atsushi Iwama for kind provision of Bmi1 shRNA lentiviral construct. We thank Merry Wang for artistic illustrations. This work was supported by funds from the Department of Surgery at McMaster University, the Ontario Institute for Cancer Research (OICR) and the JP Bickell Foundation. XW held a training award from the Stem Cell Network.	Altaba ARI, 2002, NAT REV NEUROSCI, V3, P24; Annabi B, 2008, MOL CANCER RES, V6, P907, DOI 10.1158/1541-7786.MCR-07-2184; Annabi B, 2010, MOL CARCINOGEN, V49, P710, DOI 10.1002/mc.20645; Ayrault O, 2010, CANCER RES, V70, P5618, DOI 10.1158/0008-5472.CAN-09-3740; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Chen RH, 2010, CANCER CELL, V17, P362, DOI 10.1016/j.ccr.2009.12.049; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Ellison DW, 2010, ACTA NEUROPATHOL, V120, P305, DOI 10.1007/s00401-010-0726-6; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fattet S, 2009, J PATHOL, V218, P86, DOI 10.1002/path.2514; Flora A, 2009, SCIENCE, V326, P1424, DOI 10.1126/science.1181453; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Gilbertson RJ, 2004, LANCET ONCOL, V5, P209, DOI 10.1016/S1470-2045(04)01424-X; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Johnson R, 2009, CURR ONCOL REP, V11, P68, DOI 10.1007/s11912-009-0011-9; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee EY, 2010, P NATL ACAD SCI USA, V107, P9736, DOI 10.1073/pnas.1004602107; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; McCord AM, 2009, CLIN CANCER RES, V15, P5145, DOI 10.1158/1078-0432.CCR-09-0263; Michael LE, 2008, NEOPLASIA, V10, P1343, DOI 10.1593/neo.81078; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pallini R, 2010, CANCER, V117, P162; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pistollato F, 2010, STEM CELLS, V28, P1918, DOI 10.1002/stem.518; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Read TA, 2009, CANCER CELL, V15, P135, DOI 10.1016/j.ccr.2008.12.016; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Subkhankulova T, 2010, MOL CELL NEUROSCI, V45, P151, DOI 10.1016/j.mcn.2010.06.006; Sutter R, 2010, ONCOGENE, V29, P1845, DOI 10.1038/onc.2009.472; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Thon N, 2010, MOL CELL NEUROSCI, V43, P51, DOI 10.1016/j.mcn.2008.07.022; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wiederschain D, 2007, MOL CELL BIOL, V27, P4968, DOI 10.1128/MCB.02244-06; Yan XW, 2011, P NATL ACAD SCI USA, V108, P1591, DOI 10.1073/pnas.1018696108; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yu CC, 2010, CHILD NERV SYST, V26, P897, DOI 10.1007/s00381-010-1087-0; Zakrzewska M, 2011, CHILD NERV SYST, V27, P79, DOI 10.1007/s00381-010-1260-5	69	92	96	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					187	199		10.1038/onc.2011.232	http://dx.doi.org/10.1038/onc.2011.232			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685941				2022-12-28	WOS:000299307400005
J	Bock, FJ; Peintner, L; Tanzer, M; Manzl, C; Villunger, A				Bock, F. J.; Peintner, L.; Tanzer, M.; Manzl, C.; Villunger, A.			P53-induced protein with a death domain (PIDD): master of puppets?	ONCOGENE			English	Review						PIDD; Caspase-2; RAIDD; p53; NF kappa B	NF-KAPPA-B; DNA-DAMAGE RESPONSE; GENOTOXIC STRESS; CASPASE-2 ACTIVATION; TUMOR SUPPRESSION; INDUCED APOPTOSIS; FEEDBACK LOOP; P53; CANCER; ATM	P53-induced protein with a death domain (PIDD) has been described as primary p53 target gene, induced upon DNA damage. More than 10 years after its discovery, its physiological role in the DNA damage response remains enigmatic, as it seems to be able to execute life-death decisions in vitro, yet genetic ablation in mice failed to reveal an obvious phenotype. Nonetheless, evidence is accumulating that it contributes to the fine-tuning of the DNA-damage response by orchestrating critical processes such as caspase activation or nuclear factor kappa B translocation and can also exert additional nuclear functions, for example, the modulation of translesion synthesis. In this review, we aim to integrate these observations and propose possible unexplored functions of PIDD.	[Bock, F. J.; Peintner, L.; Tanzer, M.; Manzl, C.; Villunger, A.] Innsbruck Med Univ, Bioctr, Div Dev Immunol, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Villunger, A (corresponding author), Innsbruck Med Univ, Bioctr, Div Dev Immunol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Andreas.Villunger@i-med.ac.at		Peintner, Lukas/0000-0002-0445-1445; Bock, Florian/0000-0002-1133-1767	Austrian Science Fund (FWF) [Y212-B12, SFB021]; EU-FP6 RTN 'Apoptrain'; Tyrolean Science Fund (TWF); 'Krebshilfe-Tirol'	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); EU-FP6 RTN 'Apoptrain'; Tyrolean Science Fund (TWF); 'Krebshilfe-Tirol'	This review is dedicated to the late Jurg Tschopp, who spearheaded research on PIDD, a great scientist, colleague and mentor. Research on PIDD in our laboratory is supported by grants from the Austrian Science Fund (FWF; Y212-B12 and SFB021), EU-FP6 RTN 'Apoptrain', the Tyrolean Science Fund (TWF) and the 'Krebshilfe-Tirol'.	Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Bradley G, 2007, BRIT J CANCER, V96, P1425, DOI 10.1038/sj.bjc.6603745; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Grosjean-Raillard J, 2009, ONCOGENE, V28, P1099, DOI 10.1038/onc.2008.457; Hasegawa H, 2011, LEUKEMIA, V25, P575, DOI 10.1038/leu.2010.315; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Heinen CD, 2002, CANCER BIOL THER, V1, P477, DOI 10.4161/cbt.1.5.160; Heinz LX, 2012, CELL DEATH DIFFER, V19, P722, DOI 10.1038/cdd.2011.147; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Huang L, 2011, BIOCHEM BIOPH RES CO, V407, P86, DOI 10.1016/j.bbrc.2011.02.114; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jin HS, 2009, CANCER RES, V69, P1782, DOI 10.1158/0008-5472.CAN-08-2256; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kerley-Hamilton JS, 2005, ONCOGENE, V24, P6090, DOI 10.1038/sj.onc.1208755; Kim IR, 2009, APOPTOSIS, V14, P1039, DOI 10.1007/s10495-009-0375-1; Krumschnabel G, 2009, CELL DEATH DIFFER, V16, P195, DOI 10.1038/cdd.2008.170; Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Logette E, 2011, CELL DEATH DIFFER, V18, P1036, DOI 10.1038/cdd.2011.19; Mabb AM, 2006, NAT CELL BIOL, V8, P986, DOI 10.1038/ncb1458; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Niizuma K, 2008, P NATL ACAD SCI USA, V105, P16368, DOI 10.1073/pnas.0806222105; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Olsson M, 2009, ONCOGENE, V28, P1949, DOI 10.1038/onc.2009.36; Pick R, 2006, BIOCHEM BIOPH RES CO, V349, P1329, DOI 10.1016/j.bbrc.2006.08.176; Pop C, 2009, J BIOL CHEM, V284, P21777, DOI 10.1074/jbc.R800084200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Rosenblum JS, 1999, P NATL ACAD SCI USA, V96, P11370, DOI 10.1073/pnas.96.20.11370; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Sohn D, 2011, CELL DEATH DIFFER, V18, P1664, DOI 10.1038/cdd.2011.34; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2011, CELL DEATH DIFFER, V18, P506, DOI 10.1038/cdd.2010.124; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10	53	21	21	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4733	4739		10.1038/onc.2011.639	http://dx.doi.org/10.1038/onc.2011.639			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266869	Green Accepted			2022-12-28	WOS:000311033000001
J	Tomas, G; Tarabichi, M; Gacquer, D; Hebrant, A; Dom, G; Dumont, JE; Keutgen, X; Fahey, TJ; Maenhaut, C; Detours, V				Tomas, G.; Tarabichi, M.; Gacquer, D.; Hebrant, A.; Dom, G.; Dumont, J. E.; Keutgen, X.; Fahey, T. J., III; Maenhaut, C.; Detours, V.			A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic	ONCOGENE			English	Article						gene expression; differentiation; proliferation; cancer; thyroid	FOLLICULAR VARIANT; PAPILLARY; CARCINOMA; PROFILES; TRANSFORMATION; PHENOTYPE; LEUKEMIA	Differentiation is central to development, while dedifferentiation is central to cancer progression. Hence, a quantitative assessment of differentiation would be most useful. We propose an unbiased method to derive organ-specific differentiation indices from gene expression data and demonstrate its usefulness in thyroid cancer diagnosis. We derived a list of thyroid-specific genes by selecting automatically those genes that are expressed at higher level in the thyroid than in any other organ in a normal tissue's genome-wide gene expression compendium. The thyroid index of a tissue was defined as the median expression of these thyroid-specific genes in that tissue. As expected, the thyroid index was inversely correlated with meta-PCNA, a proliferation metagene, across a wide range of thyroid tumors. By contrast, the two indices were positively correlated in a time course of thyroid-stimulating hormone (TSH) activation of primary thyrocytes. Thus, the thyroid index captures biological information not integrated by proliferation rates. The differential diagnostic of follicular thyroid adenomas and follicular thyroid carcinoma is a notorious challenge for pathologists. The thyroid index discriminated them as accurately as did machine-learning classifiers trained on the genome-wide cancer data. Hence, although it was established exclusively from normal tissue data, the thyroid index integrates the relevant diagnostic information contained in tumoral transcriptomes. Similar results were obtained for the classification of the follicular vs classical variants of papillary thyroid cancers, that is, tumors dedifferentiating along a different route. The automated procedures demonstrated in the thyroid are applicable to other organs. Oncogene (2012) 31, 4490-4498; doi: 10.1038/onc.2011.626; published online 23 January 2012	[Tomas, G.; Tarabichi, M.; Gacquer, D.; Hebrant, A.; Dom, G.; Dumont, J. E.; Maenhaut, C.; Detours, V.] Univ Libre Bruxelles, IRIBHM, B-1070 Brussels, Belgium; [Keutgen, X.; Fahey, T. J., III] Weill Cornell Med Coll, Div Endocrine Surg, Dept Surg, New York, NY USA	Universite Libre de Bruxelles; Cornell University	Detours, V (corresponding author), Univ Libre Bruxelles, Inst Interdisciplinary Res IRIBHM, 808 Route Lennik, B-1070 Brussels, Belgium.	vdetours@ulb.ac.be	Keutgen, Xavier/H-9323-2018; Tarabichi, Maxime/ABA-9246-2020	Keutgen, Xavier/0000-0002-4627-3560; Tarabichi, Maxime/0000-0002-1635-2348	Wallonie-Bruxelles International grant [7450/AMG/VDL/IN, WBI/doh/2009/21649]; FRIA fellowship from FNRS; Brussels-Capital IRSIB project ICT-impulse	Wallonie-Bruxelles International grant; FRIA fellowship from FNRS(Fonds de la Recherche Scientifique - FNRS); Brussels-Capital IRSIB project ICT-impulse	This research was partially funded by the Brussels-Capital IRSIB project ICT-impulse 2006, In Silico Wet Lab. GT is supported by the Wallonie-Bruxelles International grant (7450/AMG/VDL/IN, WBI/doh/2009/21649). MT is supported by a FRIA fellowship from FNRS.	Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Baloch ZW, 2001, DIAGN CYTOPATHOL, V25, P231, DOI 10.1002/dc.2044; Clary KM, 2005, ACTA CYTOL, V49, P378, DOI 10.1159/000326169; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Delys L, 2007, ONCOGENE, V26, P7894, DOI 10.1038/sj.onc.1210588; Detours V, 2007, BRIT J CANCER, V97, P818, DOI 10.1038/sj.bjc.6603938; Finley DJ, 2004, ANN SURG, V240, P425, DOI 10.1097/01.sla.0000137128.64978.bc; Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hegedus L, 2004, NEW ENGL J MED, V351, P1764, DOI 10.1056/NEJMcp031436; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jongeneel CV, 2005, GENOME RES, V15, P1007, DOI 10.1101/gr.4041005; Kebebew E, 2005, CANCER-AM CANCER SOC, V103, P1330, DOI 10.1002/cncr.20936; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Lang BHH, 2006, WORLD J SURG, V30, P752, DOI 10.1007/s00268-005-0356-7; Lin HW, 2010, LARYNGOSCOPE, V120, pS163, DOI 10.1002/lary.21627; Lubitz CC, 2005, SURGERY, V138, P1042, DOI 10.1016/j.surg.2005.09.009; Mills KI, 2009, BLOOD, V114, P1063, DOI 10.1182/blood-2008-10-187203; Moreno JC, 2008, NEW ENGL J MED, V358, P1811, DOI 10.1056/NEJMoa0706819; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Novershtern N, 2011, CELL, V144, P296, DOI 10.1016/j.cell.2011.01.004; R Development Core Team, R LANG ENV STAT COMP; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Ruschhaupt M, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1078; Singh B, 2005, SURGERY, V138, P1048; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Taminau J, 2011, BIOINFORMATICS; van Staveren WCG, 2006, P NATL ACAD SCI USA, V103, P413, DOI 10.1073/pnas.0507354102; Venet D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002240; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; ZURZOLO C, 1991, J CELL SCI, V98, P65	37	63	64	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4490	4498		10.1038/onc.2011.626	http://dx.doi.org/10.1038/onc.2011.626			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266856				2022-12-28	WOS:000309704500007
J	Pippa, R; Espinosa, L; Gundem, G; Garcia-Escudero, R; Dominguez, A; Orlando, S; Gallastegui, E; Saiz, C; Besson, A; Pujol, MJ; Lopez-Bigas, N; Paramio, JM; Bigas, A; Bachs, O				Pippa, R.; Espinosa, L.; Gundem, G.; Garcia-Escudero, R.; Dominguez, A.; Orlando, S.; Gallastegui, E.; Saiz, C.; Besson, A.; Pujol, M. J.; Lopez-Bigas, N.; Paramio, J. M.; Bigas, A.; Bachs, O.			p27(Kip1) represses transcription by direct interaction with p130/E2F4 at the promoters of target genes	ONCOGENE			English	Article						p27; p130; E2F4; transcription	CELL-CYCLE KINASES; CDK INHIBITOR P27; MICE LACKING; EXPRESSION; CANCER; MIGRATION; PROTEINS; DIFFERENTIATION; LEUKEMIA; PHOSPHORYLATION	The cyclin-cdk (cyclin-dependent kinase) inhibitor p27(Kip1) (p27) has a crucial negative role on cell cycle progression. In addition to its classical role as a cyclin-cdk inhibitor, it also performs cyclin-cdk-independent functions as the regulation of cytoskeleton rearrangements and cell motility. p27 deficiency has been associated with tumor aggressiveness and poor clinical outcome, although the mechanisms underlying this participation still remain elusive. We report here a new cellular function of p27 as a transcriptional regulator in association with p130/E2F4 complexes that could be relevant for tumorigenesis. We observed that p27 associates with specific promoters of genes involved in important cellular functions as processing and splicing of RNA, mitochondrial organization and respiration, translation and cell cycle. On these promoters p27 co-localizes with p130, E2F4 and co-repressors as histone deacetylases (HDACs) and mSIN3A. p27 co-immunoprecipitates with these proteins and by affinity chromatography, we demonstrated a direct interaction of p27 with p130 and E2F4 through its carboxyl-half. We have also shown that p130 recruits p27 on the promoters, and there p27 is needed for the subsequent recruitment of HDACs and mSIN3A. Expression microarrays and luciferase assays revealed that p27 behaves as transcriptional repressor of these p27-target genes (p27-TGs). Finally, in human tumors, we established a correlation with overexpression of p27-TGs and poor survival. Thus, this new function of p27 as a transcriptional repressor could have a role in the major aggressiveness of tumors with low levels of p27. Oncogene (2012) 31, 4207-4220; doi:10.1038/onc.2011.582; published online 19 December 2011	[Espinosa, L.; Bigas, A.] Hosp Mar, Inst Municipal Invest Med, Barcelona, Spain; [Gundem, G.; Lopez-Bigas, N.] Univ Pompeu Fabra, Catalan Inst Res & Adv Studies ICREA, Dept Expt & Hlth Sci, Res Unit Biomed Informat, Barcelona, Spain; [Garcia-Escudero, R.; Saiz, C.] CIEMAT, Div Biomed, Mol Oncol Unit, E-28040 Madrid, Spain; [Besson, A.] Canc Res Ctr Toulouse, INSERM, UMR1037, Toulouse, France; [Pippa, R.; Dominguez, A.; Orlando, S.; Gallastegui, E.; Pujol, M. J.; Bachs, O.] Univ Barcelona, IDIBAPS, Dept Cell Biol Immunol & Neurosci, E-08036 Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; ICREA; Pompeu Fabra University; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Fac Med, Dept Cell Biol Immunol & Neurosci, Casanova 143, E-08036 Barcelona, Spain.	obachs@ub.edu	Paramio, Jesus M/M-8482-2014; Lopez-Bigas, Nuria/F-6193-2011; Espinosa, Lluis/ABA-4564-2020; Garcia-Escudero, Ramon/A-2735-2012; Besson, Arnaud/J-6254-2014; Orlando, Serena/AAA-7963-2019; Gasull, Martina/J-4076-2019; Bigas, Anna/A-7457-2014; Pippa, Raffaella/J-4566-2012	Paramio, Jesus M/0000-0001-7520-3177; Lopez-Bigas, Nuria/0000-0003-4925-8988; Espinosa, Lluis/0000-0002-2897-4099; Garcia-Escudero, Ramon/0000-0001-5640-6542; Besson, Arnaud/0000-0002-9599-3943; Pippa, Raffaella/0000-0002-1028-6511; Bigas, Anna/0000-0003-4801-6899; Saiz Ladera, Cristina/0000-0001-8094-5992	Ministerio de Ciencia y Tecnologia of Spain [SAF2006-05212, SAF2009-07769, SAF2009-06954]; Fondo de Investigacion Sanitaria [PI070778]; Instituto de Salud Carlos III (RETICS) [RD06/0020/0010, RD06/0020/0029, RD06/0020/0098]; Comunidad Autonoma de Madrid (Oncocycle Program) [S2006/BIO-0232]; Generalitat de Catalunya [SGR 09-1382]; AGAUR of the Catalonian Government; Association pour la recherche sur le Cancer; Ligue Nationale Contre le Cancer; Institue National du Cancer; ICREA Funding Source: Custom	Ministerio de Ciencia y Tecnologia of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Instituto de Salud Carlos III (RETICS)(Instituto de Salud Carlos III); Comunidad Autonoma de Madrid (Oncocycle Program); Generalitat de Catalunya(Generalitat de Catalunya); AGAUR of the Catalonian Government(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Association pour la recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institue National du Cancer; ICREA(ICREA)	We thank Dr Anxo Vidal for p27<SUP>Delta 51</SUP>- MEF cells; Dr Antonio Giordano for p130 pGEX plasmids; Dr Xavier Mayol for GST-E2F4 vector; and Dr Alan Cassady for the pGL2b plasmid. This work was supported by the Ministerio de Ciencia y Tecnologia of Spain (grants SAF2006-05212 and SAF2009-07769 to OB and SAF2009-06954 to NL-B; the Fondo de Investigacion Sanitaria (grant PI070778 to LE), the Instituto de Salud Carlos III (RETICS RD06/0020/0010 to OB, RD06/0020/0029 to JP and RD06/0020/0098 to A. Bigas), the Comunidad Autonoma de Madrid (Oncocycle Program grant S2006/BIO-0232 to JP) and the Generalitat de Catalunya (grant SGR 09-1382 to OB). GG is supported by a fellowship from AGAUR of the Catalonian Government. AB is supported by grants from the Association pour la recherche sur le Cancer, Ligue Nationale Contre le Cancer and Institue National du Cancer.	Acosta JC, 2008, MOL CELL BIOL, V28, P7286, DOI 10.1128/MCB.00752-08; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Blanco E, 2006, PLOS COMPUT BIOL, V2, P403, DOI 10.1371/journal.pcbi.0020049; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Carter BZ, 2006, CELL CYCLE, V5, P2223, DOI 10.4161/cc.5.19.3255; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Flicek P, 2008, NUCLEIC ACIDS RES, V36, pD707, DOI 10.1093/nar/gkm988; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Gundem G, 2010, NAT METHODS, V7, P92, DOI 10.1038/nmeth0210-92; Gutierrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Huszar D, 2009, CANCER METAST REV, V28, P197, DOI 10.1007/s10555-009-9185-8; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jones MH, 2004, LANCET, V363, P775, DOI 10.1016/S0140-6736(04)15693-6; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2007, CURR OPIN GENET DEV, V17, P60, DOI 10.1016/j.gde.2006.12.008; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Munoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccaluga PP, 2007, J CLIN INVEST, V117, P823, DOI 10.1172/JCI26833; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Saijo T, 2006, LUNG CANCER, V54, P217, DOI 10.1016/j.lungcan.2006.06.018; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Sicinski P, 2007, GENE DEV, V21, P1703, DOI 10.1101/gad.1583207; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Soeiro I, 2006, MOL CELL BIOL, V26, P6170, DOI 10.1128/MCB.02182-05; Vera J, 2007, PROTEOMICS, V7, P578, DOI 10.1002/pmic.200600458; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Yeh N, 2007, MOL CELL BIOL, V27, P5161, DOI 10.1128/MCB.02431-06	58	54	54	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4207	4220		10.1038/onc.2011.582	http://dx.doi.org/10.1038/onc.2011.582			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22179826				2022-12-28	WOS:000308975800004
J	Church, DN; Phillips, BR; Stuckey, DJ; Barnes, DJ; Buffa, FM; Manek, S; Clarke, K; Harris, AL; Carter, EJ; Hassan, AB				Church, D. N.; Phillips, B. R.; Stuckey, D. J.; Barnes, D. J.; Buffa, F. M.; Manek, S.; Clarke, K.; Harris, A. L.; Carter, E. J.; Hassan, A. B.			Igf2 ligand dependency of Pten(+/-) developmental and tumour phenotypes in the mouse	ONCOGENE			English	Article						PTEN; IGF2; Cowden syndrome; imprinting; placenta; mammary gland	GROWTH-FACTOR-II; INSULIN-RECEPTOR SUBSTRATE-1; BREAST-CANCER; INTESTINAL ADENOMA; COLORECTAL-CANCER; HETEROZYGOUS MICE; MURINE PLACENTA; GLYCOGEN CELLS; H19 GENE; PTEN	The tumour suppressor PTEN is a key negative regulator of the PI3K-Akt pathway, and is frequently either reduced or lost in human tumours. Murine genetic studies have confirmed that reduction of Pten promotes tumourigenesis in multiple organs, and demonstrated dependency of tumour development on the activation of downstream components such as Akt. Insulin-like growth factors (IGFs) act via IGF1R to activate the PI3K-Akt pathway, and are commonly upregulated in cancer. A context-dependent interplay between IGFs and PTEN exists in normal tissue and tumours; increased IGF2 ligand supply induces Pten expression creating an autoregulatory negative feedback loop, whereas complete loss of PTEN may either cooperate with IGF overexpression in tumour promotion, or result in desensitisation to IGF ligand. However, it remains unknown whether neoplasia associated with Pten loss is dependent on upstream IGF ligand supply in vivo. We evaluated this by generation of Pten(+/-) mice with differing allelic dosage of Igf2, an imprinted gene encoding the potent embryonic and tumour growth factor Igf2. We show that biallelic Igf2 supply potentiates a previously unreported Pten(+/-) placental phenotype and results in strain-dependent cardiac hyperplasia and neonatal lethality. Importantly, we also show that the effects of Pten loss in vivo are modified by Igf2 supply, as lack of Igf2 results in extended survival and delayed tumour development while biallelic supply is associated with reduced lifespan and accelerated neoplasia in females. Furthermore, we demonstrate that reduction of PTEN protein to heterozygote levels in human MCF7 cells is associated with increased proliferation in response to IGF2, and does not result in desensitisation to IGF2 signalling. These data indicate that the effects of Pten loss at heterozygote levels commonly observed in human tumours are modified by Igf2 ligand, and emphasise the importance of the evaluation of upstream pathways in tumours with Pten loss. Oncogene (2012) 31, 3635-3646; doi:10.1038/onc.2011.526; published online 28 November 2011	[Church, D. N.; Barnes, D. J.; Carter, E. J.; Hassan, A. B.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Phillips, B. R.; Manek, S.] John Radcliffe Hosp, Dept Histopathol, Oxford OX3 9DU, England; [Stuckey, D. J.; Clarke, K.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3RE, England; [Buffa, F. M.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX1 3RE, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Hassan, AB (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	bass.hassan@path.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Buffa, Francesca/D-2574-2013	Harris, Adrian L/0000-0003-1376-8409; Buffa, Francesca/0000-0003-0409-406X; Carter, Emma/0000-0002-0825-2793; Church, David/0000-0002-4617-962X; stuckey, daniel/0000-0001-8888-627X; Hassan, Andrew/0000-0002-2517-6681; Barnes, David/0000-0002-7937-2004	Cancer Research UK (CRUK) Clinical Research Training Fellowship (DC); CRUK Programme Grant [C429]; British Heart Foundation [PS/02/002/14893, RG/07/004/22659] Funding Source: researchfish; National Institute for Health Research [CL-2010-13-007] Funding Source: researchfish	Cancer Research UK (CRUK) Clinical Research Training Fellowship (DC); CRUK Programme Grant; British Heart Foundation(British Heart Foundation); National Institute for Health Research(National Institute for Health Research (NIHR))	Igf2 knockout mice were a kind gift from Argiris Efstratidiadis, H19/ICR knockout mice from Shirley Tilghman and Pten knockout mice from Ramon Parsons. PTEN shRNA sequences were generously provided by Nick Leslie. We also thank Richard Stillion (histology), Miguel Constancia, Ionel Sandovici, Elisabeth Robertson, Yoichi Sekita and Shuomo Bhattacharya for their helpful discussions. This work was funded by a Cancer Research UK (CRUK) Clinical Research Training Fellowship (DC) and CRUK Programme Grant C429 (ABH).	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Burns JL, 2001, DEVELOPMENT, V128, P3819; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Carter AM, 2006, PLACENTA, V27, P278, DOI 10.1016/j.placenta.2005.01.014; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Coan PM, 2006, DEV DYNAM, V235, P3280, DOI 10.1002/dvdy.20981; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Cui HM, 2002, CANCER RES, V62, P6442; Cully M, 2004, P NATL ACAD SCI USA, V101, P15358, DOI 10.1073/pnas.0406613101; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Esquiliano DR, 2009, PLACENTA, V30, P693, DOI 10.1016/j.placenta.2009.05.004; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Frank D, 2002, P NATL ACAD SCI USA, V99, P7490, DOI 10.1073/pnas.122039999; Gabory A, 2009, DEVELOPMENT, V136, P3413, DOI 10.1242/dev.036061; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Harper J, 2006, CANCER RES, V66, P1940, DOI 10.1158/0008-5472.CAN-05-2036; Hassan AB, 2000, CANCER RES, V60, P1070; Lackey J, 2007, ONCOGENE, V26, P7132, DOI 10.1038/sj.onc.1210520; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Li P, 2011, DEVELOPMENT, V138, P1795, DOI 10.1242/dev.054338; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lopez MF, 1996, ENDOCRINOLOGY, V137, P2100, DOI 10.1210/en.137.5.2100; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reardon W, 2001, J MED GENET, V38, P820, DOI 10.1136/jmg.38.12.820; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; SINGER C, 1995, CANCER RES, V55, P2448; Soroceanu L, 2007, P NATL ACAD SCI USA, V104, P3466, DOI 10.1073/pnas.0611271104; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; van Roozendaal CEP, 1998, FEBS LETT, V437, P107, DOI 10.1016/S0014-5793(98)01211-3; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang H, 2010, P NATL ACAD SCI USA, V107, P5142, DOI 10.1073/pnas.0912524107; Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105	51	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3635	3646		10.1038/onc.2011.526	http://dx.doi.org/10.1038/onc.2011.526			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120709	Green Published, hybrid			2022-12-28	WOS:000307245600006
J	Lee, SO; Andey, T; Jin, UH; Kim, K; Sachdeva, M; Safe, S				Lee, S-O; Andey, T.; Jin, U-H; Kim, K.; Sachdeva, M.; Safe, S.			The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53	ONCOGENE			English	Article						TR3; Nur77; NR4A1; mTORC1; c-DIMs; lung cancer	INDUCED B-ALPHA; NUR77; ACTIVATION; APOPTOSIS; PROTECTOR; PATHWAY; TARGET; GENES; NR4A2; BCL-2	The orphan nuclear receptor TR3 (NR41A and Nur77) is overexpressed in most lung cancer patients and is a negative prognostic factor for patient survival. The function of TR3 was investigated in non-small-cell lung cancer A549 and H460 cells, and knockdown of TR3 by RNA interference (siTR3) inhibited cancer cell growth and induced apoptosis. The prosurvival activity of TR3 was due, in part, to formation of a p300/TR3/specificity protein 1 complex bound to GC-rich promoter regions of survivin and other Sp-regulated genes (mechanism 1). However, in p53 wild-type A549 and H460 cells, siTR3 inhibited the mTORC1 pathway, and this was due to activation of p53 and induction of the p53-responsive gene sestrin 2, which subsequently activated the mTORC1 inhibitor AMP-activated protein kinase alpha (AMPK alpha) (mechanism 2). This demonstrates that the pro-oncogenic activity of TR3 in lung cancer cells was due to inhibition of p53 and activation of mTORC1. 1,1-Bis(3'-indolyl)-1-(p-hydroxyphenyl) methane (DIM-C-pPhOH) is a recently discovered inhibitor of TR3, which mimics the effects of siTR3. DIM-C-pPhOH inhibited growth and induced apoptosis in lung cancer cells and lung tumors in murine orthotopic and metastatic models, and this was accompanied by decreased expression of survivin and inhibition of mTORC1 signaling, demonstrating that inactivators of TR3 represent a novel class of mTORC1 inhibitors. Oncogene (2012) 31, 3265-3276; doi:10.1038/onc.2011.504; published online 14 November 2011	[Safe, S.] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; [Lee, S-O; Jin, U-H; Kim, K.; Safe, S.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Andey, T.; Sachdeva, M.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut, Tallahassee, FL 32307 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; State University System of Florida; Florida A&M University	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, Vet Res Bldg 410, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu		Sachdeva, Mandip/0000-0001-9192-8143; Kim, Kyounghyun/0000-0002-7240-2768; Lee, Syng-Ook/0000-0002-8958-8634	National Institutes of Health [R01-CA124998]; Texas AM AgriLife; NATIONAL CANCER INSTITUTE [R01CA124998] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003020] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas AM AgriLife; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by National Institutes of Health (R01-CA124998) and the Texas A&M AgriLife.	Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bras A, 2000, CELL DEATH DIFFER, V7, P262, DOI 10.1038/sj.cdd.4400653; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Chen LL, 2011, GUT, V60, P534, DOI 10.1136/gut.2010.224071; Chen LL, 2009, HEPATOLOGY, V50, P122, DOI 10.1002/hep.22933; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Cho SD, 2010, MOL PHARMACOL, V77, P396, DOI 10.1124/mol.109.061143; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Lee SO, 2009, MOL CANCER RES, V7, P1169, DOI 10.1158/1541-7786.MCR-08-0473; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li QX, 2006, HISTOL HISTOPATHOL, V21, P533, DOI 10.14670/HH-21.533; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; MARUYAMA K, 1995, CANCER LETT, V96, P117, DOI 10.1016/0304-3835(95)03921-I; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; McKenna NJ, 2009, MOL ENDOCRINOL, V23, P740, DOI 10.1210/me.2009-0135; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Pearen MA, 2010, MOL ENDOCRINOL, V24, P1891, DOI 10.1210/me.2010-0015; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Wu H, 2011, FASEB J, V25, P192, DOI 10.1096/fj.10-166462; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhang XK, 2007, EXPERT OPIN THER TAR, V11, P69, DOI 10.1517/14728222.11.1.69; Zhao BX, 2006, EMBO J, V25, P5703, DOI 10.1038/sj.emboj.7601435	35	83	85	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3265	3276		10.1038/onc.2011.504	http://dx.doi.org/10.1038/onc.2011.504			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22081070	Green Accepted, Bronze			2022-12-28	WOS:000306113400006
J	Pelletier, J; Dayan, F; Durivault, J; Ilc, K; Pecou, E; Pouyssegur, J; Mazure, NM				Pelletier, J.; Dayan, F.; Durivault, J.; Ilc, K.; Pecou, E.; Pouyssegur, J.; Mazure, N. M.			The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis	ONCOGENE			English	Article						FIH; HIF-1; hypoxia; p53; tumor growth	HYPOXIA-INDUCIBLE FACTOR; PAS DOMAIN PROTEIN-1; RENAL-CELL CARCINOMA; TRANSCRIPTIONAL ACTIVITY; FACTOR-I; TRANSACTIVATION DOMAIN; FIH; EXPRESSION; HIF-1-ALPHA; PATHWAY	We showed previously that factor-inhibiting hypoxia-inducible factor HIF (FIH) monitors the expression of a spectrum of genes that are dictated by the cell's partial oxygen pressure. This action is mediated by the C-TAD, one of two transactivation domains (TADs) of the hypoxia-inducible factor. Here, we questioned: (1) the function of FIH as a HIF-1 modulator of gene expression in the context of a physiological oxygen gradient occurring in three-dimensional cultures and in tumors and (2) the role of FIH as a modulator of the growth of human tumor cells. We first showed that the expression pattern of HIF target genes that depend on the C-TAD, such as carbonic anhydrase IX, was spacially displaced to more oxygenated areas when FIH was silenced, whereas overexpression of FIH restricted this pattern to more hypoxic areas. Second, we showed that silencing fih severely reduced in vitro cell proliferation and in vivo tumor growth of LS174 colon adenocarcinoma and A375 melanoma cells. Finally, silencing of fih significantly increased both the total and phosphorylated forms of the tumor suppressor p53, leading to an increase in its direct target, the cell cycle inhibitor p21. Moreover, p53-deficient or mutant cells were totally insensitive to FIH expression. Thus, FIH activity is essential for tumor growth through the suppression of the p53-p21 axis, the major barrier that prevents cancer progression.	[Mazure, N. M.] Univ Nice Sophia Antipolis, CNRS, Inst Dev Biol & Canc Res, Ctr Antoine Lacassagne,UMR 6543, F-06189 Nice, France; [Dayan, F.; Pecou, E.] Univ Nice Sophia Antipolis, CNRS, Lab JA Dieudonne, UMR 6632, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Mazure, NM (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Dev Biol & Canc Res, Ctr Antoine Lacassagne,UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.	Nathalie.Mazure@unice.fr	pelletier, joffrey/K-8930-2014	pelletier, joffrey/0000-0001-9174-044X; Durivault, Jerome/0000-0002-8228-2915; Pecou Gambaudo, Elisabeth/0000-0002-1108-7282	Ligue Nationale Contre le Cancer (equipe labellisee); Association pour la Recherche contre le Cancer; Institut National du Cancer; Agence Nationale pour la Recherche; METOXIA (EU); Centre A Lacassagne; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; University of Nice	Ligue Nationale Contre le Cancer (equipe labellisee)(Ligue nationale contre le cancer); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale pour la Recherche(French National Research Agency (ANR)); METOXIA (EU)(European Commission); Centre A Lacassagne; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Nice	The laboratory is funded by the Ligue Nationale Contre le Cancer (equipe labellisee), the Association pour la Recherche contre le Cancer, the Institut National du Cancer, the Agence Nationale pour la Recherche, METOXIA (EU program FP7), the Centre A Lacassagne, the Centre National de la Recherche Scientifique, the Institut National de la Sante et de la Recherche Medicale and the University of Nice (http://www.unice.fr/isdbc/). We thank Dr Corinne Bertolotto and Dr Frederic Bost for their helpful advices. We also thank Dr M Christiane Brahimi-Horn for critical reading and editorial correction.	Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501; Chiche J, 2009, CANCER RES, V69, P358, DOI 10.1158/0008-5472.CAN-08-2470; Cockman ME, 2006, P NATL ACAD SCI USA, V103, P14767, DOI 10.1073/pnas.0606877103; Cockman ME, 2009, ANN NY ACAD SCI, V1177, P9, DOI 10.1111/j.1749-6632.2009.05042.x; Dayan F, 2006, CANCER RES, V66, P3688, DOI 10.1158/0008-5472.CAN-05-4564; Dayan F, 2008, CANCER MICROENVIRON, V1, P53, DOI 10.1007/s12307-008-0006-3; Dayan F, 2009, J THEOR BIOL, V259, P304, DOI 10.1016/j.jtbi.2009.03.009; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaluz S, 2008, BLOOD, V111, P5258, DOI 10.1182/blood-2008-02-140079; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kroeze SGC, 2010, EUR J CANCER, V46, P3375, DOI 10.1016/j.ejca.2010.07.018; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Lisy K, 2008, CELL DEATH DIFFER, V15, P642, DOI 10.1038/sj.cdd.4402315; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Newbold RF, 2002, MUTAGENESIS, V17, P539, DOI 10.1093/mutage/17.6.539; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Sakamoto T, 2009, J BIOL CHEM, V284, P30350, DOI 10.1074/jbc.M109.019216; Schodel J, 2010, KIDNEY INT, V78, P857, DOI 10.1038/ki.2010.284; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian YM, 2011, J BIOL CHEM, V286, P13041, DOI 10.1074/jbc.M110.211110; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yan JL, 2007, P NATL ACAD SCI USA, V104, P1841, DOI 10.1073/pnas.0605562104; Zhang N, 2010, CELL METAB, V11, P364, DOI 10.1016/j.cmet.2010.03.001	40	29	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2989	3001		10.1038/onc.2011.471	http://dx.doi.org/10.1038/onc.2011.471			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22002313				2022-12-28	WOS:000305388400008
J	Hsu, CH; Peng, KL; Jhang, HC; Lin, CH; Wu, SY; Chiang, CM; Lee, SC; Yu, WCY; Juan, LJ				Hsu, C-H; Peng, K-L; Jhang, H-C; Lin, C-H; Wu, S-Y; Chiang, C-M; Lee, S-C; Yu, W. C. Y.; Juan, L-J			The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription	ONCOGENE			English	Article						HMT; chromatin; HPV; E6; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; PROTEIN ARGININE METHYLATION; P53 ACTIVITY; NONHISTONE PROTEINS; LYSINE METHYLATION; HIGH-RISK; ACETYLATION; DEGRADATION; PRMT1; UBIQUITINATION	Expression of viral proteins causes important epigenetic changes leading to abnormal cell growth. Whether viral proteins directly target histone methyltransferases (HMTs), a key family enzyme for epigenetic regulation, and modulate their enzymatic activities remains elusive. Here we show that the E6 proteins of both low-risk and high-risk human papillomavirus (HPV) interact with three coactivator HMTs, CARM1, PRMT1 and SET7, and downregulate their enzymatic activities in vitro and in HPV-transformed HeLa cells. Furthermore, these three HMTs are required for E6 to attenuate p53 transactivation function. Mechanistically, E6 hampers CARM1- and PRMT1-catalyzed histone methylation at p53-responsive promoters, and suppresses the binding of p53 to chromatinized DNA independently of E6-mediated p53 degradation. p53 pre-methylated at lysine-372 (p53K372 monomethylation) by SET7 protects p53 from E6-induced degradation. Consistently, E6 downregulates p53K372 mono-methylation and thus reduces p53 protein stability. As a result of the E6-mediated inhibition of HMT activity, expression of p53 downstream genes is suppressed. Together, our results not only reveal a clever approach for the virus to interfere with p53 function, but also demonstrate the modulation of HMT activity as a novel mechanism of epigenetic regulation by a viral oncoprotein. Oncogene (2012) 31, 2335-2349; doi:10.1038/onc.2011.415; published online 3 October 2011	[Hsu, C-H; Peng, K-L; Jhang, H-C; Lin, C-H; Juan, L-J] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Peng, K-L; Juan, L-J] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Lin, C-H; Lee, S-C; Juan, L-J] Natl Taiwan Univ, Inst Mol Med, Coll Med, Taipei 10764, Taiwan; [Lin, C-H] Natl Hlth Res Inst, Inst Canc Res, Zhunan Town, Miaoli County, Taiwan; [Wu, S-Y; Chiang, C-M] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Wu, S-Y; Chiang, C-M] Univ Texas SW Med Ctr Dallas, Dept Biochem, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Yu, W. C. Y.] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan Town, Miaoli County, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Taiwan University; National Health Research Institutes - Taiwan; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Health Research Institutes - Taiwan	Juan, LJ (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sec 2, Taipei 115, Taiwan.	ljjuan@gate.sinica.edu.tw	Juan, Li-Jung/H-6631-2015; Hsu, Chih-Hung/AEM-8298-2022; Yu, C.Y./E-3666-2010	Hsu, Chih-Hung/0000-0001-8071-0122; 	Academia Sinica; NRPGM/DOH; NHRI; National Institutes of Health [CA103867, CA124760]; NATIONAL CANCER INSTITUTE [R01CA124760, R01CA103867] Funding Source: NIH RePORTER	Academia Sinica(Academia Sinica - Taiwan); NRPGM/DOH; NHRI(National Health Research Institutes - Taiwan); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs WH Lee and Y Zhang for valuable suggestions; WH Lee for critical reading of the manuscript; MR Stallcup for providing pSG5HA, pSG5HA-CARM1, pSG5HA-CARM1 E267Q, pSG5HA-PRMT1 and pSG5HA-PRMT1 E153Q; D Reinberg for pcDNA3.1-SET7 and SET7H297A; G Trave for p513-16E66C/6S F47R; SY Shieh for p21-Luc and pcDNA3.1-p53; and CW Wu for partial funding support. We also thank the GRC Peptide Synthesis Core for providing the p53 peptide. This research was primarily supported by grants from Academia Sinica and NRPGM/DOH to L-JJ, and partly from NHRI to L-JJ, as well as Grants CA103867 and CA124760 from the National Institutes of Health to C-MC.	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805; Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen YC, 2004, CANCER-AM CANCER SOC, V101, P1428, DOI 10.1002/cncr.20538; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Ganguly N, 2009, J BIOSCIENCES, V34, P113, DOI 10.1007/s12038-009-0013-7; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Howley Peter M, 2006, Trans Am Clin Climatol Assoc, V117, P113; Howley PM, 2009, VIROLOGY, V384, P256, DOI 10.1016/j.virol.2008.12.006; Howley PM., 2006, T AM CLIN CLIMAT ASS, V117, P126; Hsu CH, 2004, EMBO J, V23, P2269, DOI 10.1038/sj.emboj.7600239; Hu D, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2008.03.064; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kruse JP, 2008, CELL, V133, DOI 10.1016/j.cell.2008.05.020; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Lacey CJN, 2006, VACCINE, V24, P35, DOI 10.1016/j.vaccine.2006.06.015; Lee DY, 2007, MOL ENDOCRINOL, V21, P1381, DOI 10.1210/me.2006-0389; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Massimi P, 2008, ONCOGENE, V27, P1800, DOI 10.1038/sj.onc.1210810; McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Mujtaba S, 2008, NAT CELL BIOL, V10, P1114, DOI 10.1038/ncb1772; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Pal S, 2007, J CELL PHYSIOL, V213, P306, DOI 10.1002/jcp.21180; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2010, APMIS, V118, P471, DOI 10.1111/j.1600-0463.2010.02618.x; Pradhan S, 2009, EPIGENETICS, V4, P282; Reeves M, 2006, J VIROL, V80, P9998, DOI 10.1128/JVI.01297-06; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shukla A, 2009, CELL MOL LIFE SCI, V66, P1419, DOI 10.1007/s00018-008-8605-1; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Wolf SS, 2009, CELL MOL LIFE SCI, V66, P2109, DOI 10.1007/s00018-009-0010-x; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yu ZB, 2009, MOL CELL BIOL, V29, P2982, DOI 10.1128/MCB.00042-09; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	63	57	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2335	2349		10.1038/onc.2011.415	http://dx.doi.org/10.1038/onc.2011.415			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21963854	Green Published, hybrid			2022-12-28	WOS:000303610800008
J	Geraldo, MV; Yamashita, AS; Kimura, ET				Geraldo, M. V.; Yamashita, A. S.; Kimura, E. T.			MicroRNA miR-146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer	ONCOGENE			English	Article						microRNA; TGF-beta; papillary thyroid carcinoma	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; PCCL3 CELLS; ACTIVIN-A; THYROTROPIN; ONCOGENE; DIFFERENTIATION; METASTASIS	MicroRNAs (miRNA) are small non-coding RNAs involved in post-transcriptional gene regulation that have crucial roles in several types of tumors, including papillary thyroid carcinoma (PTC). miR-146b-5p is overexpressed in PTCs and is regarded as a relevant diagnostic marker for this type of cancer. A computational search revealed that miR-146b-5p putatively binds to the 3' untranslated region (UTR) of SMAD4, an important member of the transforming growth factor beta (TGF-beta) signaling pathway. The TGF-beta pathway is a negative regulator of thyroid follicular cell growth, and the mechanism by which thyroid cancer cells evade its inhibitory signal remains unclear. We questioned whether the modulation of the TGF-beta pathway by miR-146b-5p can contribute to thyroid tumorigenesis. Luciferase reporter assay confirmed the direct binding of miR-146b-5p on the SMAD4 3'UTR. Specific inhibition of miR-146b-5p with a locked nucleic acid-modified anti-miR-146b oligonucleotide significantly increased SMAD4 levels in the human papillary carcinoma cell lines, TPC-1 and BCPAP. Moreover, suppression of miR-146b-5p increased the cellular response to the TGF-beta anti-proliferative signal, significantly decreasing the proliferation rate. The overexpression of miR-146b-5p in normal rat follicular PCCL3 cells decreased SMAD4 levels and disrupted TGF-beta signal transduction. MiR-146b-5p overexpression in PCCL3 cells also significantly increased cell proliferation in the absence of thyroid-stimulating hormone and conferred resistance to TGF-beta-mediated cell-cycle arrest. Additionally, the activation of thyroid most common oncogenes RET/PTC3 and BRAF in PCCL3 cells upregulated miR-146b-5p expression. Our results confirm the oncogenic role of miR-146b-5p in thyroid follicular cells and contribute to knowledge regarding the modulation of TGF-beta signal transduction by miRNAs in PTCs. Oncogene (2012) 31, 1910-1922; doi:10.1038/onc.2011.381; published online 29 August 2011	[Geraldo, M. V.; Yamashita, A. S.; Kimura, E. T.] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo, Brazil	Universidade de Sao Paulo	Kimura, ET (corresponding author), Univ Sao Paulo, Dept Cell & Dev Biol, Inst Biomed Sci, Av Prof Lineu Prestes 1524,Room 414, BR-05508000 So Paulo, Brazil.	etkimura@usp.br	Yamashita, Alex Shimura/B-3772-2013; Geraldo, Murilo V/C-6427-2016; Kimura, Edna/D-7334-2012; Geraldo, Murilo V/F-7211-2013	Kimura, Edna/0000-0001-8403-4459; Geraldo, Murilo V/0000-0002-9418-6103	Fundaco de Amparo A Pesquisa do Estado de So Paulo (FAPESP); Conselho Nacional de Desenvolvimento CientUfico e Tecnoloegico (CNPq)	Fundaco de Amparo A Pesquisa do Estado de So Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento CientUfico e Tecnoloegico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF))	We thank Dr Konstantin D Taganov for donation of pcDNA3.1-miR-146b plasmid, Dr Joan MassaguO for donation of p3TP-Lux plasmid, Dr Nancy Carrasco for donation of anti-NIS antibody, Dr Massimo Santoro for BCPAP, and Dr James A Fagin for PCCL3, PCCL3-rtTA, PTC3-5, TPC-1, and ARO cell lines used in this study. This work was supported by Fundaco de Amparo A Pesquisa do Estado de So Paulo (FAPESP) and Conselho Nacional de Desenvolvimento CientUfico e Tecnoloegico (CNPq).	Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Cahill S, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-70; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cerutti JM, 2003, J ENDOCRINOL INVEST, V26, P516, DOI 10.1007/BF03345213; Chou CK, 2010, THYROID, V20, P489, DOI 10.1089/thy.2009.0027; Costamagna E, 2004, J BIOL CHEM, V279, P3439, DOI 10.1074/jbc.M307138200; D'Inzeo S, 2010, J MOL ENDOCRINOL, V45, P229, DOI 10.1677/JME-10-0044; Dykxhoorn DM, 2010, CANCER RES, V70, P6401, DOI 10.1158/0008-5472.CAN-10-1346; Ellenrieder V, 2008, ANTICANCER RES, V28, P1531; Ermak G, 2003, ANAL BIOCHEM, V318, P152, DOI 10.1016/S0003-2697(03)00166-0; FABIEN N, 1994, CANCER, V73, P2206, DOI 10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Franzen A, 1999, ENDOCRINOLOGY, V140, P4300, DOI 10.1210/en.140.9.4300; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Garcia-Jimenez C, 2007, ARQ BRAS ENDOCRINOL, V51, P654, DOI 10.1590/S0004-27302007000500003; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; JHIANG SM, 1992, ONCOGENE, V7, P1331; Kawaguchi A, 1997, THYROID, V7, P789, DOI 10.1089/thy.1997.7.789; Kimura ET, 2003, CANCER RES, V63, P1454; Kimura ET, 1999, THYROID, V9, P119, DOI 10.1089/thy.1999.9.119; Lazzereschi D, 2005, ONCOGENE, V24, P5344, DOI 10.1038/sj.onc.1208603; Ricarte JCM, 2009, TRANSL ONCOL, V2, P236, DOI 10.1593/tlo.09151; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsuo SE, 2010, ARQ BRAS ENDOCRINOL, V54, P406, DOI 10.1590/S0004-27302010000400010; Matsuo SE, 2006, J ENDOCRINOL, V190, P141, DOI 10.1677/joe.1.06713; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Nicolussi A, 2003, MOL CELL ENDOCRINOL, V207, P1, DOI 10.1016/S0303-7207(03)00238-7; Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696; Nikiforova MN, 2009, ENDOCR PATHOL, V20, P85, DOI 10.1007/s12022-009-9069-z; Pacifico F, 2010, J CLIN ENDOCR METAB, V95, P1421, DOI 10.1210/jc.2009-1128; Paire A, 1997, J BIOL CHEM, V272, P18245, DOI 10.1074/jbc.272.29.18245; Pallante P, 2010, ENDOCR-RELAT CANCER, V17, pF91, DOI 10.1677/ERC-09-0217; Palona I, 2006, ENDOCRINOLOGY, V147, P5699, DOI 10.1210/en.2006-0400; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; TATON M, 1993, MOL CELL ENDOCRINOL, V95, P13, DOI 10.1016/0303-7207(93)90024-E; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037; Yang G, 2010, INT J BIOL SCI, V6, P1; Zhong H, 2010, INT J HEMATOL, V92, P129, DOI 10.1007/s12185-010-0626-5	53	154	156	0	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1910	1922		10.1038/onc.2011.381	http://dx.doi.org/10.1038/onc.2011.381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874046				2022-12-28	WOS:000302809900004
J	Mauviel, A; Nallet-Staub, F; Varelas, X				Mauviel, A.; Nallet-Staub, F.; Varelas, X.			Integrating developmental signals: a Hippo in the (path) way	ONCOGENE			English	Review						Hippo signaling; TGF-beta signaling; Wnt signaling; TAZ; YAP; growth control	YES-ASSOCIATED PROTEIN; TGF-BETA RECEPTOR; TUMOR-SUPPRESSOR PATHWAY; STEM-CELL PROLIFERATION; ORGAN SIZE CONTROL; TRANSCRIPTIONAL COACTIVATOR; PROMOTER HYPERMETHYLATION; NUCLEAR-LOCALIZATION; DOWN-REGULATION; WW DOMAINS	The Hippo pathway, a signaling cascade that controls cell cycle progression, apoptosis and cell differentiation, has emerged as a fundamental regulator of many physiological and pathological processes. Recent studies have revealed a complex network of interactions directing Hippo pathway activity, and have connected this pathway with other key signaling pathways. Such crosstalk has uncovered novel roles for Hippo signaling, including regulation of TGF beta/SMAD and WNT/beta-catenin pathways. This review highlights some of the recent findings in the Hippo field with an emphasis on how the Hippo pathway is integrated with other pathways to mediate diverse processes. Oncogene (2012) 31, 1743-1756; doi: 10.1038/onc.2011.363; published online 29 August 2011	[Mauviel, A.] Inst Curie, CNRS, INSERM, U1021,Univ Ctr,UMR3347, F-91400 Orsay, France; [Mauviel, A.; Nallet-Staub, F.] Inst Curie, Ctr Rech, F-91405 Orsay, France; [Mauviel, A.; Nallet-Staub, F.] Univ Paris 11, Orsay, France; [Varelas, X.] Boston Univ, Dept Biochem, Sch Med, Boston, MA 02118 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Universite Paris Saclay; Boston University	Mauviel, A (corresponding author), Inst Curie, CNRS, INSERM, U1021,Univ Ctr,UMR3347, Bldg 110, F-91400 Orsay, France.	alain.mauviel@curie.fr; xvarelas@bu.edu	MAUVIEL, Alain/F-6251-2013; Varelas, Xaralabos/ABB-9141-2020; han, jing/A-2527-2015	Mauviel, Alain/0000-0002-0438-2793; Varelas, Xaralabos/0000-0002-2882-4541	Karin Grunebaum Cancer Foundation; Donation Henriette et Emile Goutiere, Institut National du Cancer (INCa) [PLBIO-2008]; INSERM; CNRS; Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE); Universite Paris XI; Ligue Nationale Contre le Cancer	Karin Grunebaum Cancer Foundation; Donation Henriette et Emile Goutiere, Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE); Universite Paris XI; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	Supported by the Karin Grunebaum Cancer Foundation (to X. V.), and Donation Henriette et Emile Goutiere, Institut National du Cancer (INCa, PLBIO-2008), INSERM, CNRS, Ligue Nationale Contre le Cancer (Equipe Labellisee LIGUE), Universite Paris XI (to A. M.). F. N-S. the recipient of a Ligue Nationale Contre le Cancer doctoral studentship.	Affolter M, 2007, NAT REV GENET, V8, P663, DOI 10.1038/nrg2166; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Baena-Lopez LA, 2008, P NATL ACAD SCI USA, V105, P9645, DOI 10.1073/pnas.0803747105; Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Arnold SJ, 2009, NAT REV MOL CELL BIO, V10, P91, DOI 10.1038/nrm2618; Attisano L, 2004, CANCER METAST REV, V23, P53, DOI 10.1023/A:1025811012690; Aylon Y, 2010, GENE DEV, V24, P2420, DOI 10.1101/gad.1954410; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Bulgakova NA, 2009, J CELL SCI, V122, P2587, DOI 10.1242/jcs.023648; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2011, ONCOGENE, V30, P600, DOI 10.1038/onc.2010.438; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Corbit KC, 2008, NAT CELL BIOL, V10, P70, DOI 10.1038/ncb1670; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Dai FY, 2010, METHODS MOL BIOL, V647, P125, DOI 10.1007/978-1-60761-738-9_7; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Di Palma T, 2009, EXP CELL RES, V315, P162, DOI 10.1016/j.yexcr.2008.10.016; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Duning K, 2010, J BIOL CHEM, V285, P33584, DOI 10.1074/jbc.C110.146381; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Habbig S, 2011, J CELL BIOL, V193, P633, DOI 10.1083/jcb.201009069; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heallen T, 2011, SCIENCE, V332, P458, DOI 10.1126/science.1199010; Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; Hossain Z, 2007, P NATL ACAD SCI USA, V104, P1631, DOI 10.1073/pnas.0605266104; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Islas S, 2002, EXP CELL RES, V274, P138, DOI 10.1006/excr.2001.5457; Jang SW, 2007, J BIOL CHEM, V282, P30836, DOI 10.1074/jbc.M704542200; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Jiang Z, 2006, NEUROSCI RES, V56, P450, DOI 10.1016/j.neures.2006.09.006; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Karpowicz P, 2010, DEVELOPMENT, V137, P4135, DOI 10.1242/dev.060483; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009616; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Lian I, 2010, GENE DEV, V24, P1106, DOI 10.1101/gad.1903310; Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107; Liu CY, 2011, J BIOL CHEM, V286, P5558, DOI 10.1074/jbc.M110.194019; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Makita R, 2008, AM J PHYSIOL-RENAL, V294, pF542, DOI 10.1152/ajprenal.00201.2007; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Meignin C, 2007, CURR BIOL, V17, P1871, DOI 10.1016/j.cub.2007.09.062; Miller BW, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.72; Morin-Kensicki EM, 2006, MOL CELL BIOL, V26, P77, DOI 10.1128/MCB.26.1.77-87.2006; Murakami M, 2006, BIOCHEM BIOPH RES CO, V339, P533, DOI 10.1016/j.bbrc.2005.10.214; Murakami M, 2005, P NATL ACAD SCI USA, V102, P18034, DOI 10.1073/pnas.0509109102; Nicolas FJ, 2004, J CELL SCI, V117, P4113, DOI 10.1242/jcs.01289; Nishioka N, 2009, DEV CELL, V16, P398, DOI 10.1016/j.devcel.2009.02.003; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Oh H, 2011, DEV CELL, V20, P109, DOI 10.1016/j.devcel.2010.12.002; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Polesello C, 2007, CURR BIOL, V17, P1864, DOI 10.1016/j.cub.2007.09.049; Reddy BVVG, 2010, DEVELOPMENT, V137, P2397, DOI 10.1242/dev.050013; Remue E, 2010, FEBS LETT, V584, P4175, DOI 10.1016/j.febslet.2010.09.020; Ren FF, 2010, P NATL ACAD SCI USA, V107, P21064, DOI 10.1073/pnas.1012759107; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Sansom OJ, 2005, ONCOGENE, V24, P8205, DOI 10.1038/sj.onc.1208956; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Seidel C, 2007, MOL CARCINOGEN, V46, P865, DOI 10.1002/mc.20317; Shaw RL, 2010, DEVELOPMENT, V137, P4147, DOI 10.1242/dev.052506; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Staley BK, 2010, CURR BIOL, V20, P1580, DOI 10.1016/j.cub.2010.07.041; Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Sudol M, 2011, GENES CANC, V1, P1115; Takahashi Y, 2005, CLIN CANCER RES, V11, P1380, DOI 10.1158/1078-0432.CCR-04-1773; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tian Y, 2007, MOL CELL BIOL, V27, P6383, DOI 10.1128/MCB.00254-07; Tyler DM, 2007, DEV BIOL, V305, P187, DOI 10.1016/j.ydbio.2007.02.004; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Varelas X, 2010, DEV CELL, V18, P579, DOI 10.1016/j.devcel.2010.03.007; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vigneron AM, 2010, GENE DEV, V24, P2430, DOI 10.1101/gad.1954310; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Webb C, 2011, BIOCHEMISTRY-US, V50, P3300, DOI 10.1021/bi2001888; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yim H, 2011, J AM SOC NEPHROL, V22, P832, DOI 10.1681/ASN.2010090992; Yu JZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001761; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Yuan ZQ, 2010, J BIOL CHEM, V285, P3815, DOI 10.1074/jbc.M109.059675; Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	146	87	91	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1743	1756		10.1038/onc.2011.363	http://dx.doi.org/10.1038/onc.2011.363			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21874053				2022-12-28	WOS:000302785200001
J	Tho, LM; Libertini, S; Rampling, R; Sansom, O; Gillespie, DA				Tho, L. M.; Libertini, S.; Rampling, R.; Sansom, O.; Gillespie, D. A.			Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis	ONCOGENE			English	Article						checkpoints; carcinogenesis; DNA damage; genome stability; apoptosis; senescence	ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE; STEM-CELLS; TUMOR-FORMATION; HAIR FOLLICLE; CANCER; CHECKPOINT; EPIDERMIS; MICE; ATR	Chk1 is a key regulator of DNA damage checkpoint responses and genome stability in eukaryotes. To better understand how checkpoint proficiency relates to cancer development, we investigated the effects of genetic ablation of Chk1 in the mouse skin on tumors induced by chemical carcinogens. We found that homozygous deletion of Chk1 immediately before carcinogen exposure strongly suppressed benign tumor (papilloma) formation, and that the few, small lesions that formed in the ablated skin always retained Chk1 expression. Remarkably, Chk1 deletion rapidly triggered spontaneous cell proliferation, gamma-H2AX staining and apoptosis within the hair follicle, a principal site of origin for carcinogen-induced tumors. At later times, the ablated skin was progressively repopulated by non-recombined Chk1-expressing cells and ultimately normal sensitivity to tumor induction was restored when carcinogen treatment was delayed. In marked contrast, papillomas formed normally in Chk1 hemizygous skin but showed an increased propensity to progress to carcinoma. Thus, complete loss of Chk1 is incompatible with epithelial tumorigenesis, whereas partial loss of function (haploinsufficiency) fosters benign malignant tumor progression. Oncogene (2012) 31, 1366-1375; doi:10.1038/onc.2011.326; published online 1 August 2011	[Tho, L. M.; Libertini, S.; Sansom, O.; Gillespie, D. A.] Univ Glasgow, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Tho, L. M.; Rampling, R.; Sansom, O.; Gillespie, D. A.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; University of Glasgow	Gillespie, DA (corresponding author), Univ Glasgow, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Tho, Lye Mun/A-1232-2011; Tho, Lye Mun/X-1745-2019; Gillespie, David/R-4771-2019; Libertini, Silvana/A-3531-2011	Gillespie, David/0000-0002-6338-0544; Libertini, Silvana/0000-0003-2633-1564; Sansom, Owen J./0000-0001-9540-3010	Cancer Research UK (CR-UK); Marie Curie EU; Royal College of Radiologists; CRUK: Royal College of Radiologists; Marie Curie fellowship; Cancer Research UK [12481] Funding Source: researchfish	Cancer Research UK (CR-UK)(Cancer Research UK); Marie Curie EU(European Commission); Royal College of Radiologists; CRUK: Royal College of Radiologists; Marie Curie fellowship(European Commission); Cancer Research UK(Cancer Research UK)	We thank Cancer Research UK (CR-UK), Marie Curie EU and the Royal College of Radiologists for financial support, Drs S Elledge, J Rosen and M Lam for the kind gift of reagents, as well as Dr G Inman for constructive comments on the manuscript. LMT was the recipient of a joint CRUK: Royal College of Radiologists fellowship and SL was the recipient of a Marie Curie fellowship.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Ashwell S, 2008, EXPERT OPIN INV DRUG, V17, P1331, DOI [10.1517/13543784.17.9.1331, 10.1517/13543784.17.9.1331 ]; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Greenow KR, 2009, ONCOGENE, V28, P1443, DOI 10.1038/onc.2008.482; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Kangsamaksin T, 2007, MOL CARCINOGEN, V46, P579, DOI 10.1002/mc.20355; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Liu QH, 2000, GENE DEV, V14, P1448; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Mulherkar R, 2003, ONCOGENE, V22, P1936, DOI 10.1038/sj.onc.1206229; Niida H, 2010, EMBO J, V29, P3558, DOI 10.1038/emboj.2010.218; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Toledo LI, 2008, GENE DEV, V22, P297, DOI 10.1101/gad.452308; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104	26	31	33	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1366	1375		10.1038/onc.2011.326	http://dx.doi.org/10.1038/onc.2011.326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804609				2022-12-28	WOS:000301780000004
J	Quintavalle, C; Garofalo, M; Zanca, C; Romano, G; Iaboni, M; De Caro, MD; Martinez-Montero, JC; Incoronato, M; Nuovo, G; Croce, CM; Condorelli, G				Quintavalle, C.; Garofalo, M.; Zanca, C.; Romano, G.; Iaboni, M.; De Caro, M. del Basso; Martinez-Montero, J. C.; Incoronato, M.; Nuovo, G.; Croce, C. M.; Condorelli, G.			miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTP mu	ONCOGENE			English	Article						Glioma; microRNA; tumorigenesis; apoptosis	GLIOMA-CELL MIGRATION; MICRORNA SIGNATURES; TRAIL RESISTANCE; INVASION; RECEPTOR; CANCER; GENE	Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, survival of patients remains poor. In order to identify microRNAs (miRs) involved in glioma tumorigenesis, we evaluated, by a miRarray, differential expression of miRs in the tumorigenic glioma LN-18, LN-229 and U87MG cells compared with the non-tumorigenic T98G cells. Among different miRs we focused our attention on miR-221 and -222. We demonstrated the presence of a binding site for these two miRs in the 30 untranslated region of the protein tyrosine phosphatase l (PTP mu). Previous studies indicated that PTPl suppresses cell migration and is downregulated in glioblastoma. Significantly, we found that miR-221 and -222 overexpression induced a downregulation of PTPl as analyzed by both western blot and real-time PCR. Furthermore, miR-222 and -221 induced an increase in cell migration and growth in soft agar in glioma cells. Interestingly, the re-expression of PTPl gene was able to revert the miR-222 and -221 effects on cell migration. Furthermore, we found an inverse correlation between miR-221 and -222 and PTPl in human glioma cancer samples. In conclusion, our results suggest that miR-221 and -222 regulate glioma tumorigenesis at least in part through the control of PTPl protein expression. Oncogene (2012) 31, 858-868; doi: 10.1038/onc.2011.280;published online 11 July 2011	[Condorelli, G.] Univ Naples Federico II, Fac Sci Biotecnol, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, NA, Italy; [Garofalo, M.; Nuovo, G.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Human Canc Genet Program, Columbus, OH 43210 USA; [Romano, G.; Incoronato, M.] Fdn IRCCS SDN, Naples, Italy; [De Caro, M. del Basso] Sez Anat Patol & Fitopatol, Dipartimento Sci Biomorfol & Funzionali, Bologna, Italy; [Martinez-Montero, J. C.] Hosp Univ Gregorio Maranon, Inst Oftalm, Madrid, Spain; [Condorelli, G.] CNR, IEOS, I-80125 Naples, Italy	University of Naples Federico II; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); General University Gregorio Maranon Hospital; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR)	Condorelli, G (corresponding author), Univ Naples Federico II, Fac Sci Biotecnol, Dipartimento Biol & Patol Cellulare & Mol, Ed 19 A,2 Floor,Via Pansini 5, I-80131 Naples, NA, Italy.	gecondor@unina.it	Incoronato, Mariarosaria/K-8727-2016; Incoronato, Mariarosaria/AAA-7541-2021; Condorelli, Gerolama/AAC-3472-2022; Quintavalle, Cristina/AHH-9379-2022; Young, Richard A/F-6495-2012	Incoronato, Mariarosaria/0000-0001-7019-0581; Incoronato, Mariarosaria/0000-0001-7019-0581; Condorelli, Gerolama/0000-0003-0177-8829; Young, Richard A/0000-0001-8855-8647; Del Basso De Caro, Marialaura/0000-0002-5055-5050	Associazione Italiana Ricerca sul Cancro, AIRC [10620]; MERIT [RBNE08E8CZ_002]; Federazione Italiana Ricerca sul Cancro (FIRC); American-Italian Cancer Foundation; NATIONAL CANCER INSTITUTE [P30CA016058, P01CA129242] Funding Source: NIH RePORTER	Associazione Italiana Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro); MERIT; Federazione Italiana Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro); American-Italian Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by funds from Associazione Italiana Ricerca sul Cancro, AIRC to GC ( Grant n. ro 10620) and MERIT (RBNE08E8CZ_002) to GC. CQ is supported by a Federazione Italiana Ricerca sul Cancro (FIRC) Post-Doctoral Research Fellowship. CZ is supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship.	BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Burgoyne AM, 2009, NEURO-ONCOLOGY, V11, P767, DOI 10.1215/15228517-2009-019; Burgoyne AM, 2009, CANCER RES, V69, P6960, DOI 10.1158/0008-5472.CAN-09-0863; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cerchia L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007971; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Demuth T, 2004, J NEURO-ONCOL, V70, P217, DOI 10.1007/s11060-004-2751-6; DERIDDER LI, 1987, ACTA NEUROPATHOL, V72, P207, DOI 10.1007/BF00691091; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garofalo M, 2008, ONCOGENE, V27, P3845, DOI 10.1038/onc.2008.6; Garofalo M, 2010, CELL DEATH DIFFER, V17, P200, DOI 10.1038/cdd.2009.105; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Incoronato M, 2010, CANCER RES, V70, P3638, DOI 10.1158/0008-5472.CAN-09-3341; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Liang YX, 2002, J BIOL CHEM, V277, P20087, DOI 10.1074/jbc.M201766200; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Nuovo GJ, 2009, BIOTECHNIQUES, V46, P115, DOI 10.2144/000113068; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Purow B, 2009, NAT REV NEUROL, V5, P419, DOI 10.1038/nrneurol.2009.96; Sredni ST, 2010, CHILD NERV SYST, V26, P279, DOI 10.1007/s00381-009-1028-y; Tran B, 2010, J CLIN NEUROSCI, V17, P417, DOI 10.1016/j.jocn.2009.09.004; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037	29	145	151	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					858	868		10.1038/onc.2011.280	http://dx.doi.org/10.1038/onc.2011.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743492	Green Accepted			2022-12-28	WOS:000300615800005
J	Dou, L; Zheng, D; Li, J; Li, Y; Gao, L; Wang, L; Yu, L				Dou, L.; Zheng, D.; Li, J.; Li, Y.; Gao, L.; Wang, L.; Yu, L.			Methylation-mediated repression of microRNA-143 enhances MLL-AF4 oncogene expression	ONCOGENE			English	Article						miR-143; MLL-AF4; methylation; leukemia	ACUTE MYELOID-LEUKEMIA; COLORECTAL-CANCER; MIR-143; PROGNOSIS; AND-145; GENE; TUMORIGENESIS; TRANSCRIPTION; DIAGNOSIS; PROFILES	Fusion proteins containing the amino terminus of mixed lineage leukemia (MLL) are common in acute lymphoblastic leukemia (ALL) due to translocations. The MLL-AF4 fusion protein is generated by the translocation t(4;11)(q21;q23), and t(4;11)-positive ALL patients (MLL-AF4 ALL), have a notoriously poorer prognosis compared with patients with other MLL-associated leukemias. The detailed role of this fusion protein in leukemogenesis is not well understood. MicroRNAs (miRNAs) targeting the AF4 3' untranslated regions may modulate MLL-AF4 fusion protein levels, raising the question of whether regulation of these miRNAs are involved in the progression of MLL-AF4 ALL. In this study, we show that miR-143 was identified as a regulator of MLL-AF4 expression in MLL-AF4 ALL samples. Restoration of miR-143 in MLL-AF4-positive RS4;11 and MV4-11 cells induced apoptosis, negatively contributing to leukemia cell growth by reducing MLL-AF4 fusion protein levels. Furthermore, miR-143 was epigenetically repressed by promoter hypermethylation in MLL-AF4-positive primary blasts and cell lines, but not in normal bone marrow cells and MLL-AF4-negative primary blasts, which was directly associated with expression of the MLL-AF4 oncogene. This is the first study to show that miR-143 functions as a tumor suppressor in MLL-AF4 B-cell ALL. These data reveal the therapeutic promise of upregulating miR-143 expression for MLL-AF4 B-cell ALL. Oncogene (2012) 31, 507-517; doi: 10.1038/onc.2011.248; published online 27 June 2011	[Dou, L.; Li, J.; Li, Y.; Gao, L.; Wang, L.; Yu, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China; [Zheng, D.] Chinese PLA 309th Hosp, Dept Hepatobiliary Surg, Organ Transplant Ctr, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital	Yu, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Fuxing Rd 28th, Beijing 100853, Peoples R China.	daughter126@126.com; chunhuiliyu@yahoo.com		Yu, Li/0000-0001-6872-2665	National Natural Science Foundation of China [30800482, 30971297, 90919044]; Medical Capital Development Fund [2007-2040]; Beijing Natural Science Foundation of China [7102147]; National 973 Project of China [2005CB522400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Capital Development Fund; Beijing Natural Science Foundation of China(Beijing Natural Science Foundation); National 973 Project of China(National Basic Research Program of China)	We are grateful to Professor Xiaofei Zheng for miRNA-expressing plasmids. We thank Wei Wang, Yi Ding, Yuanyuan Xu, Nan Wang, Chengwang Xu, Meng Li, Xufeng Luo, Huiyuan Kang, Xinrong Wang and Xiaoning Gao for excellent technical assistance. This work was supported by the National Natural Science Foundation of China (Nos. 30800482, 30971297 and 90919044), Medical Capital Development Fund (2007-2040), the Beijing Natural Science Foundation of China (No. 7102147) and the National 973 Project of China (No. 2005CB522400).	Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88; Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x; Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019; Bittner S, 2010, ANN NEUROL, V68, P58, DOI 10.1002/ana.22010; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Erfurth FE, 2008, P NATL ACAD SCI USA, V105, P7517, DOI 10.1073/pnas.0800090105; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018; Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689; Lin TC, 2011, LEUKEMIA, V25, P32, DOI 10.1038/leu.2010.222; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Lowenberg B, 2008, NEW ENGL J MED, V358, P1960, DOI 10.1056/NEJMe0802379; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Luty AA, 2010, ANN NEUROL, V68, P639, DOI 10.1002/ana.22274; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Meyer B, 2011, NUCLEIC ACIDS RES, V39, P1526, DOI 10.1093/nar/gkq931; RONCHI AE, 1995, J BIOL CHEM, V270, P21934, DOI 10.1074/jbc.270.37.21934; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Thomas M, 2005, BLOOD, V106, P3559, DOI 10.1182/blood-2005-03-1283; Walker BA, 2011, BLOOD, V117, P553, DOI 10.1182/blood-2010-04-279539; Wang CJ, 2009, DIS MARKERS, V26, P27, DOI [10.3233/DMA-2009-0601, 10.1155/2009/921907]; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	32	44	54	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					507	517		10.1038/onc.2011.248	http://dx.doi.org/10.1038/onc.2011.248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706045				2022-12-28	WOS:000300219300009
J	Xu, PZ; Chen, ML; Jeon, SM; Peng, XD; Hay, N				Xu, P-Z; Chen, M-L; Jeon, S-M; Peng, X-D; Hay, N.			The effect Akt2 deletion on tumor development in Pten(+/-) mice	ONCOGENE			English	Article						Akt2; Pten; tumor development; hyperinsulinemia	INSULIN-RESISTANCE; PROSTATE-CANCER; CELL-MIGRATION; IN-VIVO; PTEN; DEFICIENCY; BREAST; SUPPRESSION; NEOPLASIA; GROWTH	The serine/threonine kinase Akt is frequently activated in human cancers and is considered an attractive therapeutic target. However, the relative contributions of the different Akt isoforms to tumorigenesis, and the effect of their deficiencies on cancer development are not well understood. We had previously shown that Akt1 deficiency is sufficient to markedly reduce the incidence of tumors in Pten(+/-) mice. Particularly, Akt1 deficiency inhibits endometrial carcinoma and prostate neoplasia in Pten(+/-) mice. Here, we analyzed the effect of Akt2 deficiency on the incidence of tumors in Pten(+/-) mice. Relative to Akt1, Akt2 deficiency had little-to-no effect on the incidence of prostate neoplasia, endometrial carcinoma, intestinal polyps and adrenal lesions in Pten(+/-) mice. However, Akt2 deficiency significantly decreased the incidence of thyroid tumors in Pten(+/-), which correlates with the relatively high level of Akt2 expression in the thyroid. Thus, unlike Akt1 deletion, Akt2 deletion is not sufficient to markedly inhibit tumorigenesis in Pten(+/-) mice in most tested tissues. The relatively small effect of Akt2 deletion on the inhibition of tumorigenesis in Pten(+/-) mice could be explained, in part, by an insufficient decrease in total Akt activity, due to the relatively lower Akt2 versus Akt1 expression, and relatively high blood insulin levels in Pten(+/-) Akt2(-/-) mice. The relatively high blood insulin levels in Pten(+/-) Akt2(-/-) mice may elevate the activity of Akt1, and possibly Akt3, thus, limiting the reduction of total Akt activity and preventing this activity from dropping to a threshold level required to inhibit tumorigenesis. Oncogene (2012) 31, 518-526; doi: 10.1038/onc.2011.243; published online 11 July 2011	[Xu, P-Z; Chen, M-L; Jeon, S-M; Peng, X-D; Hay, N.] Univ Illinois, Dept Biochem & Mol Genet, Coll Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hay, N (corresponding author), Univ Illinois, Dept Biochem & Mol Genet MC 669, Coll Med, 900 S Ashland Ave, Chicago, IL 60607 USA.	nhay@uic.edu	Jeon, Sang-Min/I-7917-2018; Peng, Xiao-ding/B-2478-2012	Jeon, Sang-Min/0000-0002-0132-925X; Peng, Xiao-ding/0000-0002-9214-0136	NIH [CA090764, AG016927, AG025953]; NATIONAL CANCER INSTITUTE [R01CA090764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025953, R01AG016927] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000733] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs(US Department of Veterans Affairs)	These studies were supported by NIH grants, CA090764, AG016927 and AG025953 to NH.	Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chen WS, 2009, MOL CELL BIOL, V29, P3151, DOI 10.1128/MCB.01792-08; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chin YR, 2010, MOL CELL, V38, P333, DOI 10.1016/j.molcel.2010.02.031; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Gallagher EJ, 2010, CURR DIABETES REP, V10, P93, DOI 10.1007/s11892-010-0101-y; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; Li YW, 2009, BIOORG MED CHEM LETT, V19, P834, DOI 10.1016/j.bmcl.2008.12.017; Lindsley CW, 2010, CURR TOP MED CHEM, V10, P458, DOI 10.2174/156802610790980602; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Muller M, 2000, Prostate Cancer Prostatic Dis, V3, pS32, DOI 10.1038/sj.pcan.4500457; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Parsons Ramon, 2003, Methods Mol Biol, V222, P147; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ringel MD, 2001, CANCER RES, V61, P6105; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Stambolic V, 2000, CANCER RES, V60, P3605; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tashiro H, 1997, CANCER RES, V57, P3935; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299	31	26	27	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					518	526		10.1038/onc.2011.243	http://dx.doi.org/10.1038/onc.2011.243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21743498	hybrid, Green Published			2022-12-28	WOS:000300219300010
J	Rohlin, A; Engwall, Y; Fritzell, K; Goransson, K; Bergsten, A; Einbeigi, Z; Nilbert, M; Karlsson, P; Bjork, J; Nordling, M				Rohlin, A.; Engwall, Y.; Fritzell, K.; Goransson, K.; Bergsten, A.; Einbeigi, Z.; Nilbert, M.; Karlsson, P.; Bjork, J.; Nordling, M.			Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis	ONCOGENE			English	Article						familial adenomatous ployposis; APC; mutation; promoter; Q-PCR	GERM-LINE MUTATIONS; CLINICAL CHARACTERIZATION; TRUNCATING MUTATIONS; COLORECTAL-CANCER; BETA-CATENIN; COLI GENE; HYPERMETHYLATION; EXPRESSION; METHYLATION; REGION	Familial adenomatous polyposis (FAP) is caused by germline mutations in the adenomatous polyposis coli (APC) gene. Two promoters, 1A and 1B, have been recognized in APC, and 1B is thought to have a minor role in the regulation of the gene. We have identified a novel deletion encompassing half of this promoter in the largest family (Family 1) of the Swedish Polyposis Registry. The mutation leads to an imbalance in allele-specific expression of APC, and transcription from promoter 1B was highly impaired in both normal colorectal mucosa and blood from mutation carriers. To establish the significance of promoter 1B in normal colorectal mucosa (from controls), expression levels of specific transcripts from each of the promoters, 1A and 1B, were examined, and the expression from 1B was significantly higher compared with 1A. Significant amounts of transcripts generated from promoter 1B were also determined in a panel of 20 various normal tissues examined. In FAP-related tumors, the APC germline mutation is proposed to dictate the second hit. Mutations leaving two or three out of seven 20-amino-acid repeats in the central domain of APC intact seem to be required for tumorigenesis. We examined adenomas from mutation carriers in Family 1 for second hits in the entire gene without any findings, however, loss of the residual expression of the deleterious allele was observed. Three major conclusions of significant importance in relation to the function of APC can be drawn from this study; (i) germline inactivation of promoter 1B is disease causing in FAP; (ii) expression of transcripts from promoter 1B is generated at considerable higher levels compared with 1A, demonstrating a hitherto unknown importance of 1B; (iii) adenoma formation in FAP, caused by impaired function of promoter 1B, does not require homozygous inactivation of APC allowing for alternative genetic models as basis for adenoma formation. Oncogene (2011) 30, 4977-4989; doi:10.1038/onc.2011.201; published online 6 June 2011	[Rohlin, A.; Engwall, Y.; Bergsten, A.; Nordling, M.] Univ Gothenburg, Dept Clin Genet, Inst Biomed, Sahlgrens Univ Hosp,Sahlgrenska Acad, SE-41345 Gothenburg, Sweden; [Fritzell, K.; Goransson, K.; Bjork, J.] Karolinska Univ Hosp, Karolinska Inst, Dept Gastroenterol & Hepatol, Swedish Polyposis Registry, Stockholm, Sweden; [Einbeigi, Z.; Karlsson, P.] Univ Gothenburg, Dept Oncol, Sahlgrenska Acad, Sahlgrens Univ Hosp, SE-41345 Gothenburg, Sweden; [Nilbert, M.] Lund Univ, Dept Oncol, Lund, Sweden; [Nilbert, M.] Univ Copenhagen, Hvidovre Hosp, Clin Res Ctr, DK-2650 Hvidovre, Denmark	Sahlgrenska University Hospital; University of Gothenburg; Karolinska Institutet; Karolinska University Hospital; Sahlgrenska University Hospital; University of Gothenburg; Lund University; University of Copenhagen	Nordling, M (corresponding author), Univ Gothenburg, Dept Clin Genet, Inst Biomed, Sahlgrens Univ Hosp,Sahlgrenska Acad, Medicinargatan 3B, SE-41345 Gothenburg, Sweden.	margareta.nordling@gu.se		Fritzell, Kaisa/0000-0002-3554-074X; Nilbert, Mef/0000-0003-2717-1937	Swedish Cancer Society [ID CAN 2008/792]; Swedish state under the LUA/ALF agreement concerning research and education of doctors [76310]; Health and Medical Care Committee of the Region Vastra Gotaland [96750]; Laboratory division, Sahlgrenska University Hospital; Nilsson-Ehle Foundation; Assar Gabrielsson Foundation; Wilhelm and Martina Lundgren Research Foundation; Sahlgrenska University Hospital Foundation	Swedish Cancer Society(Swedish Cancer Society); Swedish state under the LUA/ALF agreement concerning research and education of doctors; Health and Medical Care Committee of the Region Vastra Gotaland; Laboratory division, Sahlgrenska University Hospital; Nilsson-Ehle Foundation; Assar Gabrielsson Foundation; Wilhelm and Martina Lundgren Research Foundation; Sahlgrenska University Hospital Foundation	The authors are grateful to the patients who participated in the study. This study was supported by grants from the Swedish Cancer Society (ID CAN 2008/792), the Swedish state under the LUA/ALF agreement concerning research and education of doctors, (ID no. 76310), the Health and Medical Care Committee of the Region Vastra Gotaland, (ID no. 96750), Project grant from the Laboratory division, Sahlgrenska University Hospital, the Nilsson-Ehle Foundation, the Assar Gabrielsson Foundation, the Wilhelm and Martina Lundgren Research Foundation and the Sahlgrenska University Hospital Foundation.	Amos-Landgraf JM, 2007, P NATL ACAD SCI USA, V104, P4036, DOI 10.1073/pnas.0611690104; Andreutti-Zaugg C, 1999, Hum Mutat, V13, P170, DOI 10.1002/(SICI)1098-1004(1999)13:2<170::AID-HUMU13>3.0.CO;2-4; BISGAARD ML, 1994, HUM MUTAT, V3, P121, DOI 10.1002/humu.1380030206; Blaker H, 2003, AM J CLIN PATHOL, V120, P418, DOI 10.1309/4E4WG3AYGJNCD11P; Castellsague E, 2010, GASTROENTEROLOGY, V139, P439, DOI 10.1053/j.gastro.2010.04.047; Charames GS, 2008, HUM GENET, V124, P535, DOI 10.1007/s00439-008-0579-4; Cowie S, 2004, HUM MUTAT, V24, P261, DOI 10.1002/humu.20078; De Rosa M, 2007, GENE, V395, P8, DOI 10.1016/j.gene.2006.10.027; Dobbie Z, 1996, J MED GENET, V33, P274, DOI 10.1136/jmg.33.4.274; Esteller M, 2000, CANCER RES, V60, P4366; Fiering S, 1999, METHOD ENZYMOL, V306, P42; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; GAYTHER SA, 1994, HUM MOL GENET, V3, P53, DOI 10.1093/hmg/3.1.53; Gismondi V, 1997, HUM MUTAT, V9, P370, DOI 10.1002/(SICI)1098-1004(1997)9:4<370::AID-HUMU14>3.3.CO;2-Z; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Hosoya K, 2009, CANCER LETT, V285, P182, DOI 10.1016/j.canlet.2009.05.016; Joensuu EI, 2008, CANCER RES, V68, P4597, DOI 10.1158/0008-5472.CAN-07-6645; JOHANNESSON T, 1991, HEREDITAS, V115, P295; Judson H, 2006, J PATHOL, V210, P344, DOI 10.1002/path.2044; Kanter-Smoler G, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-10; Kaufmann A, 2009, J MOL DIAGN, V11, P131, DOI 10.2353/jmoldx.2009.080129; Kawaji H, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r40; Kohoutova M, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9028; LAMBERTZ S, 1993, HUM GENET, V90, P650; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Moisio AL, 2002, GUT, V50, P845, DOI 10.1136/gut.50.6.845; Mutoh M, 2006, JPN J CLIN ONCOL, V36, P166, DOI 10.1093/jjco/hyi233; Nilbert M, 2000, SCAND J GASTROENTERO, V35, P1200; Palin K, 2006, NAT PROTOC, V1, P368, DOI 10.1038/nprot.2006.56; Phelps RA, 2009, CELL CYCLE, V8, P2549, DOI 10.4161/cc.8.16.9278; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Renkonen ET, 2005, J CLIN ONCOL, V23, P5651, DOI 10.1200/JCO.2005.14.712; Ripa R, 2002, EUR J HUM GENET, V10, P631, DOI 10.1038/sj.ejhg.5200853; Romero-Gimenez J, 2008, INT J CANCER, V122, P1422, DOI 10.1002/ijc.23247; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Segditsas S, 2008, EXP MOL PATHOL, V85, P201, DOI 10.1016/j.yexmp.2008.09.006; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; Stenson PD, 2009, GENOME MED, V1, DOI 10.1186/gm13; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704; Venesio T, 2003, LAB INVEST, V83, P1859, DOI 10.1097/01.LAB.0000106722.37873.8D; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799	45	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	50					4977	4989		10.1038/onc.2011.201	http://dx.doi.org/10.1038/onc.2011.201			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21643010	Green Published, hybrid			2022-12-28	WOS:000298346500006
J	Alitalo, A; Detmar, M				Alitalo, A.; Detmar, M.			Interaction of tumor cells and lymphatic vessels in cancer progression	ONCOGENE			English	Review						lymphangiogenesis; metastasis; lymph node; VEGF-C; VEGF; therapy	ENDOTHELIAL-GROWTH-FACTOR; FACTOR-C; BREAST-CANCER; VEGF-C; IN-VIVO; MACROPHAGE RECRUITMENT; FACTOR RECEPTOR-3; NODE METASTASIS; INDUCED LYMPHANGIOGENESIS; THERAPEUTIC IMPLICATIONS	Metastatic spread of cancer through the lymphatic system affects hundreds of thousands of patients yearly. Growth of new lymphatic vessels, lymphangiogenesis, is activated in cancer and inflammation, but is largely inactive in normal physiology, and therefore offers therapeutic potential. Key mediators of lymphangiogenesis have been identified in developmental studies. During embryonic development, lymphatic endothelial cells derive from the blood vascular endothelium and differentiate under the guidance of lymphatic-specific regulators, such as the prospero homeobox 1 transcription factor. Vascular endothelial growth factor-C (VEGF-C) and VEGF receptor 3 signaling are essential for the further development of lymphatic vessels and therefore they provide a promising target for inhibition of tumor lymphangiogenesis. Lymphangiogenesis is important for the progression of solid tumors as shown for melanoma and breast cancer. Tumor cells may use chemokine gradients as guidance cues and enter lymphatic vessels through intercellular openings between endothelial cell junctions or, possibly, by inducing larger discontinuities in the endothelial cell layer. Tumor-draining sentinel lymph nodes show enhanced lymphangiogenesis even before cancer metastasis and they may function as a permissive 'lymphovascular niche' for the survival of metastatic cells. Although our current knowledge indicates that the development of anti-lymphangiogenic therapies may be beneficial for the treatment of cancer patients, several open questions remain with regard to the frequency, mechanisms and biological importance of lymphatic metastases.	[Alitalo, A.; Detmar, M.] Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Detmar, M (corresponding author), Swiss Fed Inst Technol, Swiss Fed Inst Technol, Inst Pharmaceut Sci, Wolfgang Pauli Str 10,HCI H303, CH-8093 Zurich, Switzerland.	michael.detmar@pharma.ethz.ch			Swiss National Science Foundation [3100A0108207, 31003A-130627]; Commission of the European Communities [LSHCCT2005518178]; Advanced European Research Council; Oncosuisse; Krebsliga Zurich	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Commission of the European Communities(European Commission); Advanced European Research Council(European Research Council (ERC)); Oncosuisse; Krebsliga Zurich	Work in the authors' lab is supported by the Swiss National Science Foundation (grant numbers 3100A0108207and 31003A-130627); Commission of the European Communities (grant number LSHCCT2005518178); Advanced European Research Council (grant LYVICAM); and Oncosuisse and Krebsliga Zurich (to MD).	Anisimov A, 2009, CIRC RES, V104, P1302, DOI 10.1161/CIRCRESAHA.109.197830; Azzali G, 2007, AM J PATHOL, V170, P334, DOI 10.2353/ajpath.2007.060447; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Bertozzi CC, 2010, ARTERIOSCL THROM VAS, V30, P2368, DOI 10.1161/ATVBAHA.110.217281; Bertozzi CC, 2010, BLOOD, V116, P661, DOI 10.1182/blood-2010-02-270876; Bos FL, 2011, CIRC RES, V109, P486, DOI 10.1161/CIRCRESAHA.111.250738; Burton JB, 2008, CANCER RES, V68, P7828, DOI 10.1158/0008-5472.CAN-08-1488; Cady B, 2007, ANN SURG ONCOL, V14, P1790, DOI 10.1245/s10434-006-9234-2; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; Carreira CM, 2001, CANCER RES, V61, P8079; Catalano O, 2010, AM J ROENTGENOL, V194, P735, DOI 10.2214/AJR.09.2422; Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029; Chang LK, 2004, P NATL ACAD SCI USA, V101, P11658, DOI 10.1073/pnas.0404272101; Chen L, 2010, J CELL BIOL, V189, P417, DOI 10.1083/jcb.200912037; Cho CH, 2007, CIRC RES, V100, pE47, DOI 10.1161/01.RES.0000259564.92792.93; Christiansen A, 2011, GENES CANC; Cueni LN, 2010, BLOOD, V116, P4376, DOI 10.1182/blood-2010-04-278564; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Dadiani M, 2006, CANCER RES, V66, P8037, DOI 10.1158/0008-5472.CAN-06-0728; Dadras SS, 2005, MODERN PATHOL, V18, P1232, DOI 10.1038/modpathol.3800410; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832; Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014; Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x; Galvagni F, 2010, CIRC RES, V106, P1839, DOI 10.1161/CIRCRESAHA.109.206326; Garcia M, 2007, GLOBAL CANC FACTS FI; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gordon EJ, 2010, DEVELOPMENT, V137, P3899, DOI 10.1242/dev.050021; Haiko P, 2008, MOL CELL BIOL, V28, P4843, DOI 10.1128/MCB.02214-07; Halin C, 2007, BLOOD, V110, P3158, DOI 10.1182/blood-2007-01-066811; Harris NC, 2011, FASEB J, V25, P2615, DOI 10.1096/fj.10-179788; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896; Hirakawa S, 2007, BLOOD, V109, P1010, DOI 10.1182/blood-2006-05-021758; Hirakawa S, 2009, CANCER SCI, V100, P983, DOI 10.1111/j.1349-7006.2009.01142.x; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Jackson DG, 2009, IMMUNOL REV, V230, P216, DOI 10.1111/j.1600-065X.2009.00803.x; Kabashima K, 2007, AM J PATHOL, V171, P1249, DOI 10.2353/ajpath.2007.070225; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kajiya K, 2005, EMBO J, V24, P2885, DOI 10.1038/sj.emboj.7600763; Kang J, 2010, BLOOD, V116, P140, DOI 10.1182/blood-2009-11-252270; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Karpanen T, 2001, CANCER RES, V61, P1786; Kerjaschki D, 2011, J CLIN INVEST, V121, P2000, DOI 10.1172/JCI44751; Kim KE, 2009, AM J PATHOL, V175, P1733, DOI 10.2353/ajpath.2009.090133; Kim M, 2010, CANCER RES, V70, P10411, DOI 10.1158/0008-5472.CAN-10-2591; Krag DN, 2010, LANCET ONCOL, V11, P927, DOI 10.1016/S1470-2045(10)70207-2; Kunstfeld R, 2004, BLOOD, V104, P1048, DOI 10.1182/blood-2003-08-2964; Kyzas PA, 2005, J PATHOL, V206, P170, DOI 10.1002/path.1776; Laakkonen P, 2007, CANCER RES, V67, P593, DOI 10.1158/0008-5472.CAN-06-3567; Leong SPL, 2011, J SURG ONCOL, V103, P607, DOI 10.1002/jso.21841; Leong SPL, 2011, J SURG ONCOL, V103, P518, DOI 10.1002/jso.21815; Leppanen VM, 2011, BLOOD, V117, P1507, DOI 10.1182/blood-2010-08-301549; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Louis-Sylvestre C, 2004, J CLIN ONCOL, V22, P97, DOI 10.1200/JCO.2004.12.108; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marino D, 2011, J VASC RES, V48, P236, DOI 10.1159/000320620; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; Moehrle M, 2004, DERMATOL SURG, V30, P1319, DOI 10.1111/j.1524-4725.2004.30376.x; Moussai D, 2011, J INVEST DERMATOL, V131, P229, DOI 10.1038/jid.2010.266; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mumprecht V, 2010, CANCER RES, V70, P8842, DOI 10.1158/0008-5472.CAN-10-0896; Murakami M, 2008, ARTERIOSCL THROM VAS, V28, P658, DOI 10.1161/ATVBAHA.107.150433; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Nilsson I, 2010, EMBO J, V29, P1377, DOI 10.1038/emboj.2010.30; Norrmen C, 2009, J CELL BIOL, V185, P439, DOI 10.1083/jcb.200901104; Oliver G, 2008, ANN NY ACAD SCI, V1131, P75, DOI 10.1196/annals.1413.006; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Pflicke H, 2009, J EXP MED, V206, P2925, DOI 10.1084/jem.20091739; Proulx ST, 2010, CANCER RES, V70, P7053, DOI 10.1158/0008-5472.CAN-10-0271; Qian CN, 2006, CANCER RES, V66, P10365, DOI 10.1158/0008-5472.CAN-06-2977; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rinderknecht M, 2009, LYMPHANGIOGENESIS CA; Rinderknecht M, 2008, J CELL PHYSIOL, V216, P347, DOI 10.1002/jcp.21494; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843; Ruddell A, 2008, NEOPLASIA, V10, P706, DOI 10.1593/neo.08342; Saaristo A, 2006, AM J PATHOL, V169, P1080, DOI 10.2353/ajpath.2006.051251; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Schledzewski K, 2006, J PATHOL, V209, P67, DOI 10.1002/path.1942; Schoppmann SF, 2002, AM J PATHOL, V161, P947, DOI 10.1016/S0002-9440(10)64255-1; Shaul ME, 2010, DIABETES, V59, P1171, DOI 10.2337/db09-1402; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Sung HK, 2006, BIOCHEM BIOPH RES CO, V345, P545, DOI 10.1016/j.bbrc.2006.04.121; Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083; Tammela T, 2011, NAT CELL BIOL, V13, P1202, DOI 10.1038/ncb2331; Tammela T, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001699; Thiele W, 2006, J BIOTECHNOL, V124, P224, DOI 10.1016/j.jbiotec.2006.01.007; van Akkooi ACJ, 2006, ANN ONCOL, V17, P1578, DOI 10.1093/annonc/mdl176; Van den Eynden GG, 2007, CANCER LETT, V256, P279, DOI 10.1016/j.canlet.2007.07.005; Van der Auwera I, 2005, CLIN CANCER RES, V11, P7637, DOI 10.1158/1078-0432.CCR-05-1142; van der Schaft DWJ, 2007, CANCER LETT, V254, P128, DOI 10.1016/j.canlet.2007.03.001; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Viehl CT, 2011, J SURG ONCOL, V103, P531, DOI 10.1002/jso.21693; Wick N, 2008, AM J PATHOL, V173, P1202, DOI 10.2353/ajpath.2008.080101; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Wirzenius M, 2007, J EXP MED, V204, P1431, DOI 10.1084/jem.20062642; Wong SY, 2005, CANCER RES, V65, P9789, DOI 10.1158/0008-5472.CAN-05-0901; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Yang H, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-36; Yoshimatsu Y, 2011, J CELL SCI, V124, P2753, DOI 10.1242/jcs.083998; Yuan L, 2002, DEVELOPMENT, V129, P4797; Zhang LQ, 2010, CELL RES, V20, P1319, DOI 10.1038/cr.2010.116; Zheng W, 2011, BLOOD, V118, P1154, DOI 10.1182/blood-2010-11-317800	114	253	268	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4499	4508		10.1038/onc.2011.602	http://dx.doi.org/10.1038/onc.2011.602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22179834				2022-12-28	WOS:000309982100001
J	Bonavia, R; Inda, MM; Vandenberg, S; Cheng, SY; Nagane, M; Hadwiger, P; Tan, P; Sah, DWY; Cavenee, WK; Furnari, FB				Bonavia, R.; Inda, M. M.; Vandenberg, S.; Cheng, S-Y; Nagane, M.; Hadwiger, P.; Tan, P.; Sah, D. W. Y.; Cavenee, W. K.; Furnari, F. B.			EGFRvIII promotes glioma angiogenesis and growth through the NF-kappa B, interleukin-8 pathway	ONCOGENE			English	Article						glioblastoma; EGFR; Delta EGFR; angiogenesis; NF-kappa B; IL-8	SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR AP-1; FACTOR RECEPTOR COMMON; BREAST-CANCER CELLS; IN-VITRO; TYROSINE PHOSPHORYLATION; GLIOBLASTOMA-MULTIFORME; TUMOR-GROWTH; BRAIN-TUMOR; STEM-CELL	Sustaining a high growth rate requires tumors to exploit resources in their microenvironment. One example of this is the extensive angiogenesis that is a typical feature of high-grade gliomas. Here, we show that expression of the constitutively active mutant epidermal growth factor receptor, Delta EGFR (EGFRvIII, EGFR*, de2-7EGFR) is associated with significantly higher expression levels of the pro-angiogenic factor interleukin (IL)-8 in human glioma specimens and glioma stem cells. Furthermore, the ectopic expression of Delta EGFR in different glioma cell lines caused up to 60-fold increases in the secretion of IL-8. Xenografts of these cells exhibit increased neovascularization, which is not elicited by cells overexpressing wildtype (wt) EGFR or DEGFR with an additional kinase domain mutation. Analysis of the regulation of IL-8 by site-directed mutagenesis of its promoter showed that DEGFR regulates its expression through the transcription factors nuclear factor (NF)-kappa B, activator protein 1 (AP-1) and CCAAT/enhancer binding protein (C/EBP). Glioma cells overexpressing Delta EGFR showed constitutive activation and DNA binding of NF-kappa B, overexpression of c-Jun and activation of its upstream kinase c-Jun N-terminal kinase (JNK) and overexpression of C/EBP beta. Selective pharmacological or genetic targeting of the NF-kappa B or AP-1 pathways efficiently blocked promoter activity and secretion of IL-8. Moreover, RNA interference-mediated knock-down of either IL-8 or the NF-kappa B subunit p65, in Delta EGFR-expressing cells attenuated their ability to form tumors and to induce angiogenesis when injected subcutaneously into nude mice. On the contrary, the overexpression of IL-8 in glioma cells lacking Delta EGFR potently enhanced their tumorigenicity and produced highly vascularized tumors, suggesting the importance of this cytokine and its transcription regulators in promoting glioma angiogenesis and tumor growth. Oncogene (2012) 31, 4054-4066; doi: 10.1038/onc.2011.563; published online 5 December 2011	[Bonavia, R.; Inda, M. M.; Cavenee, W. K.; Furnari, F. B.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Bonavia, R.; Vandenberg, S.] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; [Vandenberg, S.; Cavenee, W. K.; Furnari, F. B.] Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; [Cheng, S-Y] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Nagane, M.] Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo, Japan; [Hadwiger, P.; Tan, P.] Alnylam Europe AG, Kulmbach, Germany; [Sah, D. W. Y.] Alnylam Pharmaceut Inc, Cambridge, MA USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyorin University	Furnari, FB (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	ffurnari@ucsd.edu		Furnari, Frank/0000-0003-1909-4361	Goldhirsh Foundation; NIH [P01-CA95616, RO1CA130966]; Pennsylvania Department of Health; Innovative Research Scholar Award of the Hillman Foundation; Gobierno de Navarra, Spain; American Brain Tumor Association in Honor of Walter Terlik; Federazione Italiana Ricerca Cancro; NATIONAL CANCER INSTITUTE [P01CA095616, R01CA130966] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22591618] Funding Source: KAKEN	Goldhirsh Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; Innovative Research Scholar Award of the Hillman Foundation; Gobierno de Navarra, Spain; American Brain Tumor Association in Honor of Walter Terlik; Federazione Italiana Ricerca Cancro(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Donna Harclerode and Donald Pizzo for technical assistance with immunostaining and Dr Cameron Brennan for providing the GBM tumorspheres. This work was supported by an award from the Goldhirsh Foundation (to FBF), and NIH Grant P01-CA95616 (to WKC, FBF), as well as NIH RO1CA130966, a grant with Pennsylvania Department of Health and an Innovative Research Scholar Award of the Hillman Foundation (to SYC). WKC is a fellow of the National Foundation for Cancer Research. MM Inda thanks the Gobierno de Navarra, Spain, and the American Brain Tumor Association in Honor of Walter Terlik for the fellowships received. R Bonavia was supported by a fellowship from Federazione Italiana Ricerca Cancro.	Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; BROWN PH, 1993, ONCOGENE, V8, P877; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Le Page C, 2005, PROSTATE, V65, P306, DOI 10.1002/pros.20291; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Magnus N, 2010, BLOOD, V116, P815, DOI 10.1182/blood-2009-10-250639; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Norden AD, 2008, LANCET NEUROL, V7, P1152, DOI 10.1016/S1474-4422(08)70260-6; Petit AMV, 1997, AM J PATHOL, V151, P1523; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Shinojima N, 2003, CANCER RES, V63, P6962; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yao C, 2007, INT J CANCER, V121, P1949, DOI 10.1002/ijc.22930; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	57	125	127	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4054	4066		10.1038/onc.2011.563	http://dx.doi.org/10.1038/onc.2011.563			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22139077	Green Accepted			2022-12-28	WOS:000308688800006
J	Kawada, M; Seno, H; Kanda, K; Nakanishi, Y; Akitake, R; Komekado, H; Kawada, K; Sakai, Y; Mizoguchi, E; Chiba, T				Kawada, M.; Seno, H.; Kanda, K.; Nakanishi, Y.; Akitake, R.; Komekado, H.; Kawada, K.; Sakai, Y.; Mizoguchi, E.; Chiba, T.			Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer	ONCOGENE			English	Article						chitinase; tumor; microenvironment; chemokine; MAPK	COLONIC EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; SERUM YKL-40; TUMOR ANGIOGENESIS; BACTERIAL ADHESION; PROTEIN; CHEMOKINES; INFLAMMATION; CLASSIFICATION; GLYCOPROTEIN	Chitinase 3-like 1 (CHI3L1), one of the mammalian members of the chitinase family, is expressed in several types of human cancer, and elevated serum level of CHI3L1 is suggested to be a biomarker of poor prognosis in advanced cancer patients. However, the overall biological function of CHI3L1 in human cancers still remains unknown. Studies were performed to characterize the role of CHI3L1 in cancer pathophysiology utilizing human colorectal cancer samples and human cell lines. Plasma protein and tissue mRNA expression levels of CHI3L1 in colorectal cancer were strongly upregulated. Immunohistochemical analysis showed that CHI3L1 was expressed in cancer cells, and CHI3L1 expression had a significant association with the number of infiltrated macrophages and microvessel density (MVD). By utilizing transwell migration and tube-formation assays, overexpression of CHI3L1 in SW480 cells (human colon cancer cells) enhanced the migration of THP-1 cells (human macrophage cells) and HUVECs (human endothelial cells), and the tube formation of HUVECs. The knockdown of CHI3L1 by RNA interference or the neutralization of CHI3L1 by anti-CHI3L1 antibody displayed strong suppression of CHI3L1-induced migration and tube formation. Cell proliferation assay showed that CHI3L1 overexpression significantly enhanced the proliferation of SW480 cells. Enzyme-linked immunosorbent assay (ELISA) analysis showed that CHI3L1 increased the secretion of inflammatory chemokines, IL-8 and monocyte chemoattractant protein-1 (MCP-1), from SW480 cells through mitogen-activated protein kinase (MAPK) signaling pathway. Both neutralization of IL-8 or MCP-1 and inhibition or knockdown of MAPK in SW480 cells significantly inhibited CHI3L1-induced migration and tube formation. In a xenograft mouse model, overexpression of CHI3L1 in HCT116 cells (human colon cancer cells) enhanced the tumor growth as well as macrophage infiltration and MVD. In conclusion, CHI3L1 expressed in colon cancer cells promotes cancer cell proliferation, macrophage recruitment and angiogenesis. Thus, the inhibition of CHI3L1 activity may be a novel therapeutic strategy for human colorectal cancer. Oncogene (2012) 31, 3111-3123; doi:10.1038/onc.2011.498; published online 7 November 2011	[Kawada, M.; Seno, H.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin, Kyoto 6068507, Japan; [Kawada, M.] Japan Soc Promot Sci JSPS, Tokyo, Japan; [Kawada, K.; Sakai, Y.] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan; [Mizoguchi, E.] Harvard Univ, Sch Med, Dept Med, Gastrointestinal Unit, Boston, MA USA; [Mizoguchi, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA	Kyoto University; Japan Society for the Promotion of Science; Kyoto University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kawada, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawahara Cho, Shogoin, Kyoto 6068507, Japan.	kawadam@kuhp.kyoto-u.ac.jp; seno@kuhp.kyoto-u.ac.jp		Seno, Hiroshi/0000-0002-8509-8128	Japan Society for the Promotion of Science (JSPS) [20790493, 21-40033, 23590937, 21229009]; Ministry of Health, Labor and Welfare, Japan; National Institutes of Health in USA [R01DK80070]; Research Foundation of Translational Research Center, Kyoto University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK080070] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23590937, 21229009] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); National Institutes of Health in USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Foundation of Translational Research Center, Kyoto University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (20790493, 21-40033, 23590937, 21229009), and Health and Labor Science Research Grants for Research on Intractable Diseases, and Research on Hepatitis from the Ministry of Health, Labor and Welfare, Japan, and Research Foundation of Translational Research Center, Kyoto University and by a research grant (R01DK80070) from the National Institutes of Health in USA.	Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Chen CC, 2011, AM J PATHOL, V179, P1494, DOI 10.1016/j.ajpath.2011.05.038; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Eurich K, 2009, WORLD J GASTROENTERO, V15, P5249, DOI 10.3748/wjg.15.5249; Guo XY, 2008, J BIOL CHEM, V283, P19864, DOI 10.1074/jbc.M800798200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herrera-Estrella A, 1999, EXS, V87, P171; Johansen JS, 2006, CANCER EPIDEM BIOMAR, V15, P194, DOI 10.1158/1055-9965.EPI-05-0011; Johansen JS, 2006, DAN MED BULL, V53, P172; Kawada K, 2009, MOL CELL BIOL, V29, P4508, DOI 10.1128/MCB.00015-09; Kawada M, 2008, LAB INVEST, V88, P883, DOI 10.1038/labinvest.2008.47; Kawada Mayumi, 2007, Keio Journal of Medicine, V56, P21, DOI 10.2302/kjm.56.21; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mizoguchi E, 2006, GASTROENTEROLOGY, V130, P398, DOI 10.1053/j.gastro.2005.12.007; Ono M, 2008, CANCER SCI, V99, P1501, DOI 10.1111/j.1349-7006.2008.00853.x; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286	34	126	132	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	26					3111	3123		10.1038/onc.2011.498	http://dx.doi.org/10.1038/onc.2011.498			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22056877	Green Submitted, Green Accepted			2022-12-28	WOS:000305934400001
J	Wang, L; Wang, J				Wang, L.; Wang, J.			MicroRNA-mediated breast cancer metastasis: from primary site to distant organs	ONCOGENE			English	Review						miRNA; breast cancer; metastasis; EMT/MET; stemness	EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; REGULATORY FEEDBACK LOOP; FACTOR-KAPPA-B; STEM-CELLS; MIR-200 FAMILY; GENE-EXPRESSION; SELF-RENEWAL; E-CADHERIN; REPRESSORS ZEB1	The recent upsurge of interest in microRNA (miRNA) is partly attributed to the discovery of the novel roles of miRNAs in many physiological and pathological processes, including tumor development. Research on breast cancer metastasis has also focused on the concept of miRNA, which can act either as promoters or as suppressors of metastases. This review will focus on a series of recent studies that demonstrate the involvement of miRNAs in breast cancer metastasis and will briefly describe various pathways of miRNA-regulated metastasis. Finally, future prospects will be discussed for the potential role of miRNAs as predictive markers and therapeutic agents for patients with breast cancer metastases. Oncogene (2012) 31, 2499-2511; doi:10.1038/onc.2011.444; published online 3 October 2011	[Wang, L.; Wang, J.] Gen Hosp Guangzhou Mil Command, Dept Med Res, Guangzhou 510010, Guangdong, Peoples R China; [Wang, L.] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Guangdong, Peoples R China	Southern Theater Command General Hospital; South China University of Technology	Wang, J (corresponding author), Gen Hosp Guangzhou Mil Command, Dept Med Res, Liuhua Rd, Guangzhou 510010, Guangdong, Peoples R China.	jiew@tom.com	Xie, Huangming/B-2260-2012	Wang, Li/0000-0001-8321-102X				Adams BD, 2009, MOL ENDOCRINOL, V23, P1215, DOI 10.1210/me.2009-0062; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Berezikov E, 2006, NAT GENET, V38, pS2, DOI 10.1038/ng1794; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cabodi S, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2563; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Cicek M, 2005, CANCER RES, V65, P3586, DOI 10.1158/0008-5472.CAN-04-3139; Connolly EC, 2010, MOL CANCER RES, V8, P691, DOI 10.1158/1541-7786.MCR-09-0465; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102; Divijendra S, 2009, CANCER RES, V69, P5639, DOI 10.1158/0008-5472.CAN-09-0898; Du J, 2009, CELL RES, V19, P487, DOI 10.1038/cr.2009.34; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; FIDLER IJ, 1975, CANCER RES, V35, P218; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Forstemann K, 2007, CELL, V130, P287, DOI 10.1016/j.cell.2007.05.056; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Hedley BD, 2009, ADV CANCER RES, V102, P67, DOI 10.1016/S0065-230X(09)02003-X; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933; Hoser M, 2007, J NEUROSCI, V27, P5495, DOI 10.1523/JNEUROSCI.1384-07.2007; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang TH, 2009, J BIOL CHEM, V284, P18515, DOI 10.1074/jbc.M109.006676; Hurst DR, 2008, J BIOL CHEM, V283, P7438, DOI 10.1074/jbc.M709446200; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Jin ZG, 2007, CURR BIOL, V17, P539, DOI 10.1016/j.cub.2007.01.050; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Khraiwesh B, 2010, CELL, V140, P111, DOI 10.1016/j.cell.2009.12.023; Kim DH, 2008, P NATL ACAD SCI USA, V105, P16230, DOI 10.1073/pnas.0808830105; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li SW, 2009, MOL ENDOCRINOL, V23, P901, DOI 10.1210/me.2008-0368; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372; Lin SL, 2008, RNA, V14, P417, DOI 10.1261/rna.874808; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Pawelek JM, 2008, NAT REV CANCER, V8, P377, DOI 10.1038/nrc2371; Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sempere LF, 2010, CLIN CANCER RES, V16, P4246, DOI 10.1158/1078-0432.CCR-10-1152; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862; Spizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117; Stark A, 2007, NATURE, V450, P219, DOI 10.1038/nature06340; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Vaidya KS, 2008, J BIOL CHEM, V283, P28354, DOI 10.1074/jbc.M710068200; Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410; Valastyan S, 2009, GENE DEV, V23, P2592, DOI 10.1101/gad.1832709; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; WAGHORNE C, 1988, CANCER RES, V48, P6109; Wang K, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-12; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Xu D, 2011, J CELL BIOL, V193, P409, DOI 10.1083/jcb.201010100; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	138	76	81	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2499	2511		10.1038/onc.2011.444	http://dx.doi.org/10.1038/onc.2011.444			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21963843				2022-12-28	WOS:000304191800001
J	Walia, V; Yu, Y; Cao, D; Sun, M; McLean, JR; Hollier, BG; Cheng, J; Mani, SA; Rao, K; Premkumar, L; Elble, RC				Walia, V.; Yu, Y.; Cao, D.; Sun, M.; McLean, J. R.; Hollier, B. G.; Cheng, J.; Mani, S. A.; Rao, K.; Premkumar, L.; Elble, R. C.			Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis	ONCOGENE			English	Article						hCLCA2; epithelial-to-mesenchymal transition; differentiation; breast; metastasis; chloride	TUMOR PROGRESSION; CANCER CELLS; E-CADHERIN; IN-VITRO; ION CHANNELS; CLAUDIN-LOW; EXPRESSION; GENE; PH; TRANSFORMATION	Transition between epithelial and mesenchymal states is a feature of both normal development and tumor progression. We report that expression of chloride channel accessory protein hCLCA2 is a characteristic of epithelial differentiation in the immortalized MCF10A and HMLE models, while induction of epithelial-to-mesenchymal transition by cell dilution, TGF beta or mesenchymal transcription factors sharply reduces hCLCA2 levels. Attenuation of hCLCA2 expression by lentiviral small hairpin RNA caused cell overgrowth and focus formation, enhanced migration and invasion, and increased mammosphere formation in methylcellulose. These changes were accompanied by downregulation of E-cadherin and upregulation of mesenchymal markers such as vimentin and fibronectin. Moreover, hCLCA2 expression is greatly downregulated in breast cancer cells with a mesenchymal or claudin-low profile. These observations suggest that loss of hCLCA2 may promote metastasis. We find that higher-than-median expression of hCLCA2 is associated with a one-third lower rate of metastasis over an 18-year period among breast cancer patients compared with lower-than- median (n = 344, unfiltered for subtype). Thus, hCLCA2 is required for epithelial differentiation, and its loss during tumor progression contributes to metastasis. Overexpression of hCLCA2 has been reported to inhibit cell proliferation and is accompanied by increases in chloride current at the plasma membrane and reduced intracellular pH (pHi). We found that knockdown cells have sharply reduced chloride current and higher pHi, both characteristics of tumor cells. These results suggest a mechanism for the effects on differentiation. Loss of hCLCA2 may allow escape from pHi homeostatic mechanisms, permitting the higher intracellular and lower extracellular pH that are characteristic of aggressive tumor cells. Oncogene (2012) 31, 2237-2246; doi:10.1038/onc.2011.392; published online 12 September 2011	[Walia, V.; Cao, D.; Premkumar, L.; Elble, R. C.] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA; [Walia, V.; Yu, Y.; Cheng, J.; Rao, K.; Elble, R. C.] So Illinois Univ, Sch Med, Simmons Canc Inst, Springfield, IL 62794 USA; [Sun, M.] Univ Chicago, Comm Genet Genom & Syst Biol GGSB, Chicago, IL 60637 USA; [McLean, J. R.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37212 USA; [Hollier, B. G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Mani, S. A.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; University of Chicago; Vanderbilt University; Queensland University of Technology (QUT); University of Texas System; UTMD Anderson Cancer Center	Elble, RC (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, POB 19629, Springfield, IL 62794 USA.	relble2@siumed.edu	Mani, Sendurai A./A-7244-2009; Cao, Deshou/G-8697-2014	Mani, Sendurai A./0000-0002-5918-4276; 	NIH [1R15CA151094-01, DK065742, DA028017]; Excellence in Academic Medicine [56252, 56253]; NATIONAL CANCER INSTITUTE [R15CA151094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065742, R56DK065742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA028017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Excellence in Academic Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the following grants: NIH grant 1R15CA151094-01 and Excellence in Academic Medicine grants 56252 and 56253 to RCE; and NIH grants DK065742 and DA028017 to LP.	Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; Beckley JR, 2004, J BIOL CHEM, V279, P41634, DOI 10.1074/jbc.M408334200; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Cheng JM, 2006, INT J CANCER, V118, P2957, DOI 10.1002/ijc.21739; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; D'Assoro AB, 2010, INT J ONCOL, V37, P1167, DOI 10.3892/ijo_00000768; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Elble RC, 2006, J BIOL CHEM, V281, P29448, DOI 10.1074/jbc.M605919200; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Enerback C, 2002, CANCER RES, V62, P43; Furlong IJ, 1997, J CELL SCI, V110, P653; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; Gruber AD, 1999, CANCER RES, V59, P5488; Hajra KM, 2002, CANCER RES, V62, P1613; Hamann M, 2009, J PHYSIOL-LONDON, V587, P2255, DOI 10.1113/jphysiol.2009.170159; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; HESKETH TR, 1985, NATURE, V313, P481, DOI 10.1038/313481a0; Hsu YM, 2007, CANCER RES, V67, P11064, DOI 10.1158/0008-5472.CAN-07-2443; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Kogan-Sakin I, 2011, CELL DEATH DIFFER, V18, P271, DOI 10.1038/cdd.2010.94; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Li XR, 2004, ONCOGENE, V23, P1474, DOI 10.1038/sj.onc.1207249; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Malo ME, 2007, J BIOL CHEM, V282, P6292, DOI 10.1074/jbc.M611073200; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marshall A, 2009, CELL TISSUE RES, V335, P383, DOI 10.1007/s00441-008-0719-0; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rao K, 2003, CANCER LETT, V201, P79, DOI 10.1016/S0304-3835(03)00423-3; Rao K, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-15; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sontheimer H, 2008, EXP BIOL MED, V233, P779, DOI 10.3181/0711-MR-308; Tanaka H, 2006, INT J CANCER, V118, P1680, DOI 10.1002/ijc.21559; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Walia V, 2010, STEM CELLS DEV, V19, P1175, DOI 10.1089/scd.2009.0430; Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	57	52	52	3	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2237	2246		10.1038/onc.2011.392	http://dx.doi.org/10.1038/onc.2011.392			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21909135	Green Accepted			2022-12-28	WOS:000303415900011
J	Liu, XF; Xiang, L; Zhang, Y; Becker, KG; Bera, TK; Pastan, I				Liu, X-F; Xiang, L.; Zhang, Y.; Becker, K. G.; Bera, T. K.; Pastan, I.			CAPC negatively regulates NF-kappa B activation and suppresses tumor growth and metastasis	ONCOGENE			English	Article						CAPC; tumor growth; NF-kappa B; cytokines	BREAST-CANCER CELLS; COLORECTAL-CANCER; CYSTATIN SN; INFLAMMATION; PROTEIN; PATHWAY; GENES	CAPC, also known as LRRC26, is expressed in normal prostate and salivary gland. We developed a mAb to CAPC and used it to characterize the protein and study its function. CAPC protein was detected in normal prostate and salivary gland, in several human breast cancer cell lines and in the prostate cancer cell line LNCaP. Knockdown of CAPC by siRNA in LNCaP cells enhanced anchorage-independent growth in soft agar. Conversely, overexpression of CAPC in MDA-231 breast cancer cells and A431 epidermoid cancer cells inhibited growth in soft agar and tumorigenesis in nude mice, and suppressed the metastasis of MDA-231 cells to the lung. Overexpression of CAPC downregulated NF-kappa B activity and its target genes, including GM-CSF (CSF2), CXCL1, IL8 and LTB1. It also suppressed genes encoding the serine protease mesotrypsin (PRSS3) and cystatin SN (CST1). CAPC expressing tumors showed a decrease in the number of proliferating cells and a large increase in ECM. The role of CAPC in the suppression of tumor growth and metastasis may be through its alteration of the tumor microenvironment. Oncogene (2012) 31, 1673-1682; doi:10.1038/onc.2011.355; published online 8 August 2011	[Liu, X-F; Xiang, L.; Bera, T. K.; Pastan, I.] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhang, Y.; Becker, K. G.] NIA, Gene Express & Genom Unit, Res Resources Branch, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Room 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Becker, Kevin/0000-0002-6794-6656	NIH, National Cancer Institute, Center for Cancer Research; National Institute on Aging; NATIONAL CANCER INSTITUTE [ZIABC010298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZICAG000616] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The CAPC antibody was provided by BD BioSciences Pharmingen as an outcome of Antibody Co-development Collaboration between the NCI and BD BioSciences. We thank William H Wood III (National Institute on Aging) and the Confocal Core Facility members (Center for Cancer Research, NIH) for technical assistance. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and in part by the National Institute on Aging.	American Cancer Society, 2009, CANC FACTS FIG 2009; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Chatterjee Sabarni K, 2005, Future Oncol, V1, P37, DOI 10.1517/14796694.1.1.37; Choi EH, 2009, CLIN CHIM ACTA, V406, P45, DOI 10.1016/j.cca.2009.05.008; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Egland KA, 2006, P NATL ACAD SCI USA, V103, P5929, DOI 10.1073/pnas.0601296103; Egland KA, 2003, P NATL ACAD SCI USA, V100, P1099, DOI 10.1073/pnas.0337425100; Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784; Hockla A, 2010, BREAST CANCER RES TR, V124, P27, DOI 10.1007/s10549-009-0699-0; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Lee M, 2004, CHEM SOC REV, V33, P401, DOI 10.1039/b209224g; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Loza MJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001035; Nam JS, 2006, CANCER RES, V66, P7176, DOI 10.1158/0008-5472.CAN-06-0825; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699; Yan JS, 2010, NATURE, V466, P513, DOI 10.1038/nature09162; Yoneda K, 2009, INT J ONCOL, V35, P33, DOI 10.3892/ijo_00000310	27	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1673	1682		10.1038/onc.2011.355	http://dx.doi.org/10.1038/onc.2011.355			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21822313	Green Accepted			2022-12-28	WOS:000302231400006
J	Liu, Y; Mayo, MW; Nagji, AS; Smith, PW; Ramsey, CS; Li, D; Jones, DR				Liu, Y.; Mayo, M. W.; Nagji, A. S.; Smith, P. W.; Ramsey, C. S.; Li, D.; Jones, D. R.			Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1	ONCOGENE			English	Article						DNMT-1; phosphorylation; RelA/p65; TNF; transcription	NF-KAPPA-B; CELL LUNG-CANCER; BREAST-CANCER; INDUCED APOPTOSIS; METHYLTRANSFERASE RECRUITMENT; DNA METHYLTRANSFERASES; TARGET PROMOTERS; DOWN-REGULATION; EXPRESSION; ACTIVATION	The majority of patients with lung cancer present with metastatic disease. Chronic inflammation and subsequent activation of nuclear factor-kappa B (NF-kappa B) have been associated with the development of cancers. The RelA/p65 subunit of NF-kappa B is typically associated with transcriptional activation. In this report we show that RelA/p65 can function as an active transcriptional repressor through enhanced methylation of the BRMS1 (breast cancer metastasis suppressor 1) metastasis suppressor gene promoter via direct recruitment of DNMT-1 (DNA (cytosine-5)-methyltransferase 1) to chromatin in response to tumor necrosis factor (TNF). TNF-mediated phosphorylation of S276 on RelA/p65 is required for RelA/p65-DNMT-1 interactions, chromatin loading of DNMT-1 and subsequent BRMS1 promoter methylation and transcriptional repression. The ability of RelA/p65 to function as an active transcriptional repressor is promoter specific, as the NF-kappa B-regulated gene cIAP2 (cellular inhibitor of apoptosis 2) is transcriptionally activated whereas BRMS1 is repressed under identical conditions. Small-molecule inhibition of either of the minimal interacting domains between RelA/p65-DNMT-1 and RelA/p65-BRMS1 promoter abrogates BRMS1 methylation and its transcriptional repression. The ability of RelA/p65 to directly recruit DNMT-1 to chromatin, resulting in promoter-specific methylation and transcriptional repression of tumor metastasis suppressor gene BRMS1, highlights a new mechanism through which NF-kappa B can regulate metastatic disease, and offers a potential target for newer-generation epigenetic oncopharmaceuticals. Oncogene (2012) 31, 1143-1154; doi:10.1038/onc.2011.308; published online 18 July 2011	[Liu, Y.; Nagji, A. S.; Smith, P. W.; Jones, D. R.] Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; [Mayo, M. W.; Ramsey, C. S.; Li, D.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Jones, DR (corresponding author), Univ Virginia, Dept Surg, Box 800679, Charlottesville, VA 22908 USA.	djones@virginia.edu	Smith, Philip/P-7736-2019	Smith, Philip/0000-0003-3441-1062; Jones, David/0000-0002-3318-0146	 [R01 CA136705];  [R01 CA104397];  [R01 CA132580]; NATIONAL CANCER INSTITUTE [R01CA136705, R01CA104397, R01CA132580] Funding Source: NIH RePORTER	; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01 CA136705 (to DRJ), R01 CA104397 (to MWM) and R01 CA132580 (to MWM). In addition, this project was supported in part by a gift provided to the University of Virginia by Philip Morris USA. The review and approval process was overseen by an independent National External Advisory Board without any affiliation with the University, Philip Morris USA or any other tobacco company.	Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Ceribelli M, 2008, MOL CELL BIOL, V28, P2047, DOI 10.1128/MCB.01861-07; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Denlinger Chadrick E, 2004, Semin Thorac Cardiovasc Surg, V16, P28, DOI 10.1053/j.semtcvs.2003.12.004; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hodge DR, 2005, CANCER RES, V65, P6255, DOI 10.1158/0008-5472.CAN-04-4482; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06; Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; Nagji AS, 2010, J PATHOL, V221, P229, DOI 10.1002/path.2707; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208; Romano A, 2010, MOL CELL ENDOCRINOL, V314, P90, DOI 10.1016/j.mce.2009.08.008; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Smith PW, 2009, CANCER LETT, V276, P196, DOI 10.1016/j.canlet.2008.11.024; Snyder M, 2010, J BIOL CHEM, V285, P23639, DOI 10.1074/jbc.M110.101063; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Takada Y, 2005, ONCOGENE, V24, P6957, DOI 10.1038/sj.onc.1208845; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102; Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	57	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1143	1154		10.1038/onc.2011.308	http://dx.doi.org/10.1038/onc.2011.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765477	Green Accepted			2022-12-28	WOS:000300945900007
J	Arpaia, E; Blaser, H; Quintela-Fandino, M; Duncan, G; Leong, HS; Ablack, A; Nambiar, SC; Lind, EF; Silvester, J; Fleming, CK; Rufini, A; Tusche, MW; Brustle, A; Ohashi, PS; Lewis, JD; Mak, TW				Arpaia, E.; Blaser, H.; Quintela-Fandino, M.; Duncan, G.; Leong, H. S.; Ablack, A.; Nambiar, S. C.; Lind, E. F.; Silvester, J.; Fleming, C. K.; Rufini, A.; Tusche, M. W.; Bruestle, A.; Ohashi, P. S.; Lewis, J. D.; Mak, T. W.			The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk	ONCOGENE			English	Article						Rho-GTPase; caveolin-1; alpha5-integrin; Src; cancer; intravital microscopy	CELL-MIGRATION; IN-VIVO; PROSTATE-CANCER; ACTIN CYTOSKELETON; SIGNALING PATHWAY; TUMOR PROGRESSION; INTEGRIN ALPHA-5; CARCINOMA-CELLS; MELANOMA-CELLS; KINASE	Proteins containing a caveolin-binding domain (CBD), such as the Rho-GTPases, can interact with caveolin-1 (Cav1) through its caveolin scaffold domain. Rho-GTPases are important regulators of p130(Cas), which is crucial for both normal cell migration and Src kinase-mediated metastasis of cancer cells. However, although Rho-GTPases (particularly RhoC) and Cav1 have been linked to cancer progression and metastasis, the underlying molecular mechanisms are largely unknown. To investigate the function of Cav1-Rho-GTPase interaction in metastasis, we disrupted Cav1-Rho-GTPase binding in melanoma and mammary epithelial tumor cells by overexpressing CBD, and examined the loss-of-function of RhoC in metastatic cancer cells. Cancer cells overexpressing CBD or lacking RhoC had reduced p130(Cas) phosphorylation and Rac1 activation, resulting in an inhibition of migration and invasion in vitro. The activity of Src and the activation of its downstream targets FAK, Pyk2, Ras and extracellular signal-regulated kinase (Erk) 1/2 were also impaired. A reduction in alpha 5-integrin expression, which is required for binding to fibronectin and thus cell migration and survival, was observed in CBD-expressing cells and cells lacking RhoC. As a result of these defects, CBD-expressing melanoma cells had a reduced ability to metastasize in recipient mice, and impaired extravasation and survival in secondary sites in chicken embryos. Our data indicate that interaction between Cav1 and Rho-GTPases (most likely RhoC but not RhoA) promotes metastasis by stimulating alpha 5-integrin expression and regulating the Src-dependent activation of p130(Cas)/Rac1, FAK/Pyk2 and Ras/Erk1/2 signaling cascades. Oncogene (2012) 31, 884-896; doi: 10.1038/onc.2011.288; published online 18 July 2011	[Arpaia, E.; Blaser, H.; Quintela-Fandino, M.; Duncan, G.; Lind, E. F.; Silvester, J.; Fleming, C. K.; Rufini, A.; Tusche, M. W.; Bruestle, A.; Ohashi, P. S.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; [Arpaia, E.; Ohashi, P. S.; Mak, T. W.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Arpaia, E.; Ohashi, P. S.; Mak, T. W.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Quintela-Fandino, M.] Spain Spanish Natl Canc Ctr CNIO, Clin Invest Unit, Breast Canc Grp, Madrid, Spain; [Leong, H. S.; Ablack, A.; Nambiar, S. C.; Lewis, J. D.] London Reg Canc Program, Translat Prostate Canc Res Grp, London, England; [Rufini, A.] Univ Leicester, Lab Apoptosis Canc, MRC, Toxicol Unit, Lancaster, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Leicester	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2M9, Canada.	tmak@uhnresearch.ca		quintela-fandino, miguel/0000-0003-1648-1964; Silvester, Jennifer/0000-0001-6087-4066; Leong, Hon/0000-0001-7801-1402; Ohashi, Pamela S./0000-0003-2915-9317; Lind, Evan/0000-0001-7026-2012	Canadian Institutes of Health Research [179815]; National Cancer Institute of Canada/Terry Fox Foundation [18176]; Canadian Breast Cancer Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada/Terry Fox Foundation; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS))	We thank Dr Marc Pellegrini for helpful discussions and Dr Mary Saunders for insightful scientific editing. This work was supported by Grant # 179815 from the Canadian Institutes of Health Research to TWM, and Grant # 18176 from the National Cancer Institute of Canada/Terry Fox Foundation to JDL. HSL is funded by a Canadian Breast Cancer Foundation Post-Doctoral fellowship.	Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Campbell L, 2008, BRIT J CANCER, V98, P931, DOI 10.1038/sj.bjc.6604243; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cokakli M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-65; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Fecchi K, 2012, INT J CANCER, V130, P1273, DOI 10.1002/ijc.26092; Felicetti F, 2009, INT J CANCER, V125, P1514, DOI 10.1002/ijc.24451; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Goetz JG, 2008, J CELL BIOL, V180, P1261, DOI 10.1083/jcb.200709019; Grande-Garcia A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kidera Yasuhiro, 2010, J Exp Clin Cancer Res, V29, P127, DOI 10.1186/1756-9966-29-127; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Lewis JD, 2006, NAT MED, V12, P354, DOI 10.1038/nm1368; Li LK, 2001, CANCER RES, V61, P4386; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lim ST, 2010, J BIOL CHEM, V285, P1743, DOI 10.1074/jbc.M109.064212; Lin M, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-21; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Meenderink LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013412; Mierke CT, 2011, J CELL SCI, V124, P369, DOI 10.1242/jcs.071985; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; NATALI PG, 1995, BRIT J CANCER, V71, P1243, DOI 10.1038/bjc.1995.240; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Sharma A, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-50; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Williams TM, 2005, J BIOL CHEM, V280, P25134, DOI 10.1074/jbc.M501186200; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Wu L, 2008, ONCOGENE, V27, P1439, DOI 10.1038/sj.onc.1210770; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zijlstra A, 2002, CANCER RES, V62, P7083; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	68	85	88	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					884	896		10.1038/onc.2011.288	http://dx.doi.org/10.1038/onc.2011.288			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21765460	Green Published, hybrid			2022-12-28	WOS:000300615800007
J	Jiang, J; Zhang, Y; Chuai, S; Wang, Z; Zheng, D; Xu, F; Zhang, Y; Li, C; Liang, Y; Chen, Z				Jiang, J.; Zhang, Y.; Chuai, S.; Wang, Z.; Zheng, D.; Xu, F.; Zhang, Y.; Li, C.; Liang, Y.; Chen, Z.			Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype	ONCOGENE			English	Article						gastric cancer; cancer stem cells; CD90; ERBB2; trastuzumab (herceptin)	MAMMARY STEM/PROGENITOR CELLS; BREAST-CANCER; INITIATING CELLS; PROSPECTIVE IDENTIFICATION; GASTROINTESTINAL-TRACT; EXPRESSION PATTERNS; GENE AMPLIFICATION; PROGENITOR CELLS; LIVER-CANCER; POPULATION	Identification and characterization of cancer stem cells (CSCs) in gastric cancer are difficult owing to the lack of specific markers and consensus methods. In this study, we show that cells with the CD90 surface marker in gastric tumors could be enriched under non-adherent, serum-free and sphere-forming conditions. These CD90(+) cells possess a higher ability to initiate tumor in vivo and could re-establish the cellular hierarchy of tumors from single-cell implantation, demonstrating their self-renewal properties. Interestingly, higher proportion of CD90(+) cells correlates with higher in vivo tumorigenicity of gastric primary tumor models. In addition, it was found that ERBB2 was overexpressed in about 25% of the gastric primary tumor models, which correlates with the higher level of CD90 expression in these tumors. Trastuzumab (humanized anti-ERBB2 antibody) treatment of high-tumorigenic gastric primary tumor models could reduce the CD90(+) population in tumor mass and suppress tumor growth when combined with traditional chemotherapy. Moreover, tumorigenicity of tumor cells could also be suppressed when trastuzumab treatment starts at the same time as cell implantation. Therefore, we have identified a CSC population in gastric primary tumors characterized by their CD90 phenotype. The finding that trastuzumab targets the CSC population in gastric tumors suggests that ERBB2 signaling has a role in maintaining CSC populations, thus contributing to carcinogenesis and tumor invasion. In conclusion, the results from this study provide new insights into the gastric tumorigenic process and offer potential implications for the development of anticancer drugs as well as therapeutic treatment of gastric cancers. Oncogene (2012) 31, 671-682; doi:10.1038/onc.2011.282; published online 11 July 2011	[Jiang, J.; Zhang, Y.; Chuai, S.; Wang, Z.; Zheng, D.; Xu, F.; Zhang, Y.; Li, C.; Liang, Y.; Chen, Z.] China Novartis Inst Biomed Res, Shanghai, Peoples R China	Novartis	Chen, Z (corresponding author), Novartis Inst Biomed Res, Lab Anim Sci, Bldg 8,Lane 898,Halei Rd,Zhangjiang Hitech Pk,Pud, Shanghai 201203, Peoples R China.	zhi-1.chen@novartis.com			Novartis Education Office	Novartis Education Office	Dr Jiang has been funded by a fellowship from the Novartis Education Office. Other authors declare no conflict of interest.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Araki H, 2007, BLOOD, V109, P3570, DOI 10.1182/blood-2006-07-035287; BERNSTEIN ID, 1980, SCIENCE, V207, P68, DOI 10.1126/science.6965328; Beuzeboc P, 1999, B CANCER, V86, P544; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bowles MJ, 2001, BRIT MED J, V323, P1413, DOI 10.1136/bmj.323.7326.1413; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; CHEN W, 2007, CANCER BIOL THER, V6, P763; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dan YY, 2006, P NATL ACAD SCI USA, V103, P9912, DOI 10.1073/pnas.0603824103; Dennis JE, 2007, STEM CELLS, V25, P2575, DOI 10.1634/stemcells.2007-0204; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fukuda K, 2009, INT J ONCOL, V34, P1201, DOI 10.3892/ijo_00000248; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; HAACKSORENSEN M, 2007, SCAND J CLIN LAB INV, V12, P1; Herrera MB, 2006, STEM CELLS, V24, P2840, DOI 10.1634/stemcells.2006-0114; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Lazaro CA, 2003, HEPATOLOGY, V38, P1095, DOI 10.1053/jhep.2003.50448; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Marx AH, 2009, HUM PATHOL, V40, P769, DOI 10.1016/j.humpath.2008.11.014; Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064; Nakamura Y, 2006, BRIT J DERMATOL, V154, P1062, DOI 10.1111/j.1365-2133.2006.07209.x; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oikonomou D, 2007, J CANCER RES CLIN, V133, P951, DOI 10.1007/s00432-007-0238-5; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Paik S, 2008, NEW ENGL J MED, V358, P1409, DOI 10.1056/NEJMc0801440; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Qiang L, 2009, CANCER LETT, V279, P13, DOI 10.1016/j.canlet.2009.01.016; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rege TA, 2006, FASEB J, V20, P1045, DOI 10.1096/fj.05-5460rev; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Riley L, 2010, AACR 2010 M; Ruangpratheep Chetana, 2005, J Med Assoc Thai, V88 Suppl 3, pS281; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; SEEGER RC, 1982, J IMMUNOL, V128, P983; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Spisek R, 2007, J EXP MED, V204, P831, DOI 10.1084/jem.20062387; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takaishi S, 2008, J CLIN ONCOL, V26, P2876, DOI 10.1200/JCO.2007.15.2603; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Wang KH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-288; Wang Q, 2009, ANTICANCER RES, V29, P1233; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yano T, 2006, ONCOL REP, V15, P65; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737; Zou GM, 2008, J CELL PHYSIOL, V217, P598, DOI 10.1002/jcp.21541	72	89	96	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					671	682		10.1038/onc.2011.282	http://dx.doi.org/10.1038/onc.2011.282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21743497				2022-12-28	WOS:000300222100001
J	Ma, W; Lin, Y; Xuan, W; Iversen, PL; Smith, LJ; Benchimol, S				Ma, W.; Lin, Y.; Xuan, W.; Iversen, P. L.; Smith, L. J.; Benchimol, S.			Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs	ONCOGENE			English	Article						p53 tumor suppressor protein; morpholino antisense oligomers; chemosensitivity	LI-FRAUMENI-SYNDROME; WILD-TYPE P53; MUTANT P53; MONOCLONAL-ANTIBODIES; PENETRATING PEPTIDES; ANTICANCER AGENTS; BREAST-CANCER; APOPTOSIS; ISOFORMS; DOMAIN	The p53 tumor suppressor gene encodes a transcription factor that is commonly mutated in cancer. Tumors arise when premalignant cells are unable to undergo p53-dependent apoptosis, cell cycle arrest or DNA repair. The p53-signaling pathway affects not only tumor development, but also the response of tumors to chemotherapeutic drugs. In this study, we use cell penetrating peptide conjugates of phosphorodiamidate morpholino oligomers (PPMOs) to inhibit p53 expression. We examine the functional properties of endogenous p53 isoforms that are produced upon PPMO-mediated inhibition of p53 translation and splicing, and report that loss of N-terminal or C-terminal sequences interferes with the transcriptional activity of p53. Importantly, we report that PPMO-mediated inhibition of p53 expression sensitizes human cancer cells with wild-type p53 to chemotherapeutic drugs. Oncogene (2012) 31, 1024-1033; doi:10.1038/onc.2011.300; published online 18 July 2011	[Ma, W.; Lin, Y.; Xuan, W.; Benchimol, S.] York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; [Iversen, P. L.] AVI BioPharma Inc, Corvallis, OR USA; [Smith, L. J.] Eleos Inc, Omaha, NE USA	York University - Canada	Benchimol, S (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	benchimo@yorku.ca	Iversen, Patrick L/D-8854-2019; Iversen, Patrick L./L-5454-2019	Iversen, Patrick L/0000-0003-0106-9790; Iversen, Patrick L./0000-0003-0106-9790; Benchimol, Samuel/0000-0003-3433-890X	Eleos Inc; Canada Research Chair	Eleos Inc; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by a grant from Eleos Inc to SB. SB is supported by a Canada Research Chair.	Abes R, 2008, J PEPT SCI, V14, P455, DOI 10.1002/psc.979; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fei PW, 2002, CANCER RES, V62, P7316; Flaman JM, 1996, ONCOGENE, V12, P813; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harms KL, 2006, CELL DEATH DIFFER, V13, P890, DOI 10.1038/sj.cdd.4401904; HORIKAWA I, 1995, HUM MOL GENET, V4, P313, DOI 10.1093/hmg/4.2.313; Iversen PL, 2001, CURR OPIN MOL THER, V3, P235; Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030; Koonin EV, 2005, CELL CYCLE, V4, P686, DOI 10.4161/cc.4.5.1691; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Nelson MH, 2005, BIOCONJUGATE CHEM, V16, P959, DOI 10.1021/bc0501045; OConnor PM, 1997, CANCER RES, V57, P4285; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; WANG C, 1989, LEUKEMIA, V3, P699; Wu RP, 2007, NUCLEIC ACIDS RES, V35, P5182, DOI 10.1093/nar/gkm478; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	41	11	11	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					1024	1033		10.1038/onc.2011.300	http://dx.doi.org/10.1038/onc.2011.300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765469				2022-12-28	WOS:000300709700008
J	Angus, L; Moleirinho, S; Herron, L; Sinha, A; Zhang, X; Niestrata, M; Dholakia, K; Prystowsky, MB; Harvey, KF; Reynolds, PA; Gunn-Moore, FJ				Angus, L.; Moleirinho, S.; Herron, L.; Sinha, A.; Zhang, X.; Niestrata, M.; Dholakia, K.; Prystowsky, M. B.; Harvey, K. F.; Reynolds, P. A.; Gunn-Moore, F. J.			Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP	ONCOGENE			English	Article						Willin/FRMD6; Expanded; Hippo pathway; ezrin; merlin	ORGAN SIZE CONTROL; CELL CONTACT INHIBITION; TUMOR-SUPPRESSOR; DROSOPHILA; GROWTH; PROLIFERATION; PROTEIN; APOPTOSIS; REGULATOR; UPSTREAM	The Salvador/Warts/Hippo (Hippo) signaling pathway defines a novel signaling cascade regulating cell contact inhibition, organ size control, cell growth, proliferation, apoptosis and cancer development in mammals. The Drosophila melanogaster protein Expanded acts in the Hippo signaling pathway to control organ size. Previously, willin/FRMD6 has been proposed as the human orthologue of Expanded. Willin lacks C-terminal sequences that are present in Expanded and, to date, little is known about the functional role of willin in mammalian cells. When willin is expressed in D. melanogaster epithelial tissues, it has the same subcellular localization as Expanded, but cannot rescue growth defects associated with expanded deficiency. However, we show that ectopic willin expression causes an increase in phosphorylation of the core Hippo signaling pathway components MST1/2, LATS1 and YAP, an effect that can be antagonized by ezrin. In MCF10A cells, loss of willin expression displays epithelial-to-mesenchymal transition features and willin overexpression antagonizes YAP activity via the N-terminal FERM domain of willin. Therefore, in mammalian cells willin influences Hippo signaling activity by activating the core Hippo pathway kinase cassette. Oncogene (2012) 31, 238-250; doi:10.1038/onc.2011.224; published online 13 June 2011	[Angus, L.; Moleirinho, S.; Herron, L.; Gunn-Moore, F. J.] Univ St Andrews, Sch Biol, St Andrews KY16 9TF, Fife, Scotland; [Moleirinho, S.; Niestrata, M.; Reynolds, P. A.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland; [Sinha, A.; Zhang, X.; Harvey, K. F.] Peter MacCallum Canc Ctr, Cell Growth & Proliferat Lab, Melbourne, Vic, Australia; [Sinha, A.; Zhang, X.; Harvey, K. F.] Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; [Dholakia, K.] Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9TF, Fife, Scotland; [Prystowsky, M. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA	University of St Andrews; University of St Andrews; Peter Maccallum Cancer Center; University of Melbourne; University of St Andrews; Yeshiva University; Albert Einstein College of Medicine	Gunn-Moore, FJ (corresponding author), Univ St Andrews, Sch Biol, Med & Biol Sci Bldg, St Andrews KY16 9TF, Fife, Scotland.	fjg1@st-and.ac.uk	Herron, Lissa/C-7780-2013; Harvey, Kieran/AAD-5268-2022	Gunn-Moore, Francis James/0000-0003-3422-3387; Harvey, Kieran/0000-0001-7845-369X; Herron, Lissa/0000-0001-9961-4421; Dholakia, Kishan/0000-0001-6534-9009; Reynolds, Paul/0000-0001-8738-1245	BBSRC; EPSRC; Scottish University Life Science Alliance; International Human Frontier Science Program Organization; National Health and Medical Research Council of Australia; Melbourne International Research Scholarship; Fee Remission Scholarship	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Scottish University Life Science Alliance; International Human Frontier Science Program Organization(Human Frontier Science Program); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Melbourne International Research Scholarship; Fee Remission Scholarship	We thank P Burke for embryo injections and N Chang for technical assistance. We also thank the BBSRC and EPSRC for funding to LA; Scottish University Life Science Alliance for funding to SM. KFH holds Career Development Awards from the International Human Frontier Science Program Organization and the National Health and Medical Research Council of Australia and a Project Grant from the National Health and Medical Research Council of Australia. AS holds Melbourne International Research and Fee Remission Scholarships.	Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Bennett FC, 2006, CURR BIOL, V16, P2101, DOI 10.1016/j.cub.2006.09.045; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Grusche FA, 2010, CURR BIOL, V20, pR574, DOI 10.1016/j.cub.2010.05.023; Gunn-Moore FJ, 2005, FEBS LETT, V579, P5089, DOI 10.1016/j.febslet.2005.07.097; Haase D, 2007, ONCOGENE, V26, P4464, DOI 10.1038/sj.onc.1210225; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Mao YP, 2011, DEVELOPMENT, V138, P947, DOI 10.1242/dev.057166; Milton CC, 2010, DEVELOPMENT, V137, P735, DOI 10.1242/dev.042309; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Silva E, 2006, CURR BIOL, V16, P2081, DOI 10.1016/j.cub.2006.09.004; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Tyler DM, 2007, DEV BIOL, V305, P187, DOI 10.1016/j.ydbio.2007.02.004; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	35	76	78	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					238	250		10.1038/onc.2011.224	http://dx.doi.org/10.1038/onc.2011.224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666719	Green Submitted			2022-12-28	WOS:000299307400009
J	Spassov, DS; Wong, CH; Harris, G; McDonough, S; Phojanakong, P; Wang, D; Hann, B; Bazarov, AV; Yaswen, P; Khanafshar, E; Moasser, MM				Spassov, D. S.; Wong, C. H.; Harris, G.; McDonough, S.; Phojanakong, P.; Wang, D.; Hann, B.; Bazarov, A. V.; Yaswen, P.; Khanafshar, E.; Moasser, M. M.			A tumor-suppressing function in the epithelial adhesion protein Trask	ONCOGENE			English	Article						Trask; CDCP1; SIMA135; 3p21.3; metastasis	DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; SUBSTRATE TRASK; LUNG METASTASIS; FAK INHIBITOR; CANCER-CELLS; KINASE; EXPRESSION; CDCP1; ADENOCARCINOMA	Trask/CDCP1 is a transmembrane glycoprotein widely expressed in epithelial tissues whose functions are just beginning to be understood, but include a role as an anti-adhesive effector of Src kinases. Early studies looking at RNA transcript levels seemed to suggest overexpression in some cancers, but immunostaining studies are now providing more accurate analyses of its expression. In an immuno-histochemical survey of human cancer specimens, we find that Trask expression is retained, reduced or sometimes lost in some tumors compared with their normal epithelial tissue counterparts. A survey of human cancer cell lines also show a similar wide variation in the expression of Trask, including some cell types with the loss of Trask expression, and additional cell types that have lost the physiological detachment-induced phosphorylation of Trask. Three experimental models were established to interrogate the role of Trask in tumor progression, including two gain-of-function models with tet-inducible expression of Trask in tumor cells lacking Trask expression, and one loss-of-function model to suppress Trask expression in tumor cells with abundant Trask expression. The induction of Trask expression and phosphorylation in MCF-7 cells and in 3T3v-src cells was associated with a reduction in tumor metastases while the shRNA-induced knockdown of Trask in L3.6pl cancer cells was associated with increased tumor metastases. The results from these three models are consistent with a tumor-suppressing role for Trask. These data identify Trask as one of several potential candidates for functionally relevant tumor suppressors on the 3p21.3 region of the genome frequently lost in human cancers. Oncogene (2012) 31, 419-431; doi: 10.1038/onc.2011.246; published online 27 June 2011	[Spassov, D. S.; Wong, C. H.; Harris, G.; McDonough, S.; Moasser, M. M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Spassov, D. S.; Wong, C. H.; Phojanakong, P.; Wang, D.; Hann, B.; Moasser, M. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Bazarov, A. V.; Yaswen, P.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; [Khanafshar, E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Dept Med, UCSF Box 1387,2340 Sutter St,Rm N-144, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu	Spassov, Danislav S/GQA-4368-2022	Spassov, Danislav S/0000-0002-6680-877X	National Institutes of Health [CA113952]; Susan G Komen for the Cure; California Breast Cancer Research Program Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE [R01CA113952] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); California Breast Cancer Research Program Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Institutes of Health CA113952 (MMM). DS is funded by a Susan G Komen for the Cure Postdoctoral Fellowship. CHW is funded by a California Breast Cancer Research Program Postdoctoral Fellowship. We wish to thank Michael McManus and the UCSF Sandler Lentiviral RNAi core facility. We acknowledge the use of core facilities of the UCSF Helen Diller Family Comprehensive Cancer Center, including the Preclinical Therapeutics Core, the immunohistochemistry core and the mouse pathology core.	Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Chen JS, 2010, CLIN EXP METASTAS, V27, P71, DOI 10.1007/s10585-010-9306-3; Conze T, 2003, ANN NY ACAD SCI, V996, P222, DOI 10.1111/j.1749-6632.2003.tb03249.x; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; Hanada M, 2005, CLIN EXP METASTAS, V22, P485, DOI 10.1007/s10585-005-3733-6; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Ikeda JI, 2006, J PATHOL, V210, P75, DOI 10.1002/path.2026; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Mamat S, 2010, ONCOL REP, V23, P1221, DOI 10.3892/or_00000753; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Perry SE, 2007, FEBS LETT, V581, P1137, DOI 10.1016/j.febslet.2007.02.025; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Ramsay AG, 2007, CANCER METAST REV, V26, P567, DOI 10.1007/s10555-007-9078-7; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Spassov DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019154; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Spassov DS, 2009, AM J PATHOL, V174, P1756, DOI 10.2353/ajpath.2009.080890; Spiegelberg BD, 2007, CURR OPIN GENET DEV, V17, P40, DOI 10.1016/j.gde.2006.12.002; Srinivasan Divya Mani, 2005, Curr Opin Investig Drugs, V6, P1246; Sun HH, 2010, CANCER BIOL THER, V10, P38, DOI 10.4161/cbt.10.1.11993; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Trimmer C, 2010, CANCER RES, V70, P7489, DOI 10.1158/0008-5472.CAN-10-0900; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Walsh C, 2010, CANCER BIOL THER, V9, P778, DOI 10.4161/cbt.9.10.11433; Wistuba II, 2000, CANCER RES, V60, P1949; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533	41	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					419	431		10.1038/onc.2011.246	http://dx.doi.org/10.1038/onc.2011.246			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706059	Green Submitted, Green Accepted			2022-12-28	WOS:000300219300002
J	Zhang, K; Wong, P; Zhang, L; Jacobs, B; Borden, EC; Aster, JC; Bedogni, B				Zhang, K.; Wong, P.; Zhang, L.; Jacobs, B.; Borden, E. C.; Aster, J. C.; Bedogni, B.			A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth	ONCOGENE			English	Article						NIC: Notch1 intracellular domain; Notch1-TM: transmembrane Notch1; NRG1: neuregulin1; ERBB: erythroblastic leukemia viral oncogene homolog or EGF (epidermal growth factor) family of transmembrane receptor tyrosine kinases; p27KIP1: CDKN1B: cyclin-dependent kinase inhibitor 1B	GENE-EXPRESSION PROFILES; STEM-CELLS; NOTCH; INHIBITION; PHOSPHORYLATION; DIFFERENTIATION; PROGRESSION; ACTIVATION; APOPTOSIS; PROLIFERATION	The Notch pathway is an evolutionary conserved signaling cascade that has an essential role in melanoblast and melanocyte stem cell homeostasis. Notch signaling is emerging as a key player in melanoma, the most deadly form of skin cancer. In melanoma, Notch1 is inappropriately reactivated and contributes to melanoma tumorigenicity. Here, we propose a novel mechanism by which Notch1 promotes the disease. We found that Notch1 directly regulates the transcription of neuregulin1 (NRG1) by binding to its promoter region. NRG1 is the ligand for ERBB3 and 4, members of the epidermal growth factor family of receptors that are involved in the genesis and progression of a number of cancers. Notch1 and NRG1 expression are associated in melanoma and inhibition of NRG1 signaling leads to melanoma cell growth inhibition and tumor growth delay. Mechanistically, these effects are associated with the inhibition of the PI3Kinase/Akt signaling pathway and with the accumulation of p27Kip1. On the other end, addition of recombinant NRG1 can partially restore melanoma cell growth that is inhibited by Notch1 ablation. Taken together, our findings underline a new, previously undescribed autocrine signaling loop between Notch1 and NRG1 that controls melanoma growth and provide experimental evidence that the targeting of Notch and ERBB signaling may represent a novel potential therapeutic approach in melanoma.	[Zhang, K.; Wong, P.; Zhang, L.; Bedogni, B.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Jacobs, B.; Borden, E. C.] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Aster, J. C.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Aster, J. C.] Harvard Univ, Sch Med, Boston, MA USA	Case Western Reserve University; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bedogni, B (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Wood Bldg,Room W420,10900 Euclid Ave, Cleveland, OH 44106 USA.	barbara.bedogni@case.edu			American Cancer Society [ACS-IRG-91-022, ACS-RSG-11-139-01-DDC]; National Institute of Health [P30CA147877]; NATIONAL CANCER INSTITUTE [P30CA147877] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Grant # ACS-IRG-91-022 and Grant # ACS-RSG-11-139-01-DDC from the American Cancer Society and by start up funds awarded by the National Institute of Health (award number: P30CA147877: New Faculty Recruitment to Enhance Melanoma Research). We thank Drs Scott Welford and David Samols for critical discussion; Dr Marianne Broome Powell for making available many of the melanoma cell lines used in this work.	Altekruse SFKC, 1975, SEER CANC STAT REV; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balint K, 2005, J CLIN INVEST, V115, P3166, DOI 10.1172/JCI25001; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Birchmeier C, 2009, EXP CELL RES, V315, P611, DOI 10.1016/j.yexcr.2008.10.035; Brabletz S, 2009, J PATHOL, V217, P307, DOI 10.1002/path.2475; Buac K, 2009, PIGM CELL MELANOMA R, V22, P773, DOI 10.1111/j.1755-148X.2009.00616.x; Calvo M, 2011, GLIA, V59, P554, DOI 10.1002/glia.21124; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Dong YY, 2010, CANCER RES, V70, P5465, DOI 10.1158/0008-5472.CAN-10-0173; Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fukazawa R, 2003, J MOL CELL CARDIOL, V35, P1473, DOI 10.1016/j.yjmcc.2003.09.012; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Gilbert CA, 2010, CANCER RES, V70, P6870, DOI 10.1158/0008-5472.CAN-10-1378; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hardy KM, 2010, CANCER RES, V70, P10340, DOI 10.1158/0008-5472.CAN-10-0705; Herzog C, 2007, SEER AYA MONOGRAPH, P53; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Ieguchi K, 2010, J BIOL CHEM, V285, P31388, DOI 10.1074/jbc.M110.113878; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Johansson P, 2007, PIGM CELL RES, V20, P216, DOI 10.1111/j.1600-0749.2007.00375.x; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Osawa M, 2008, J INVEST DERMATOL, V128, P2571, DOI 10.1038/jid.2008.289; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Pahlman S, 2004, SEMIN CANCER BIOL, V14, P365, DOI 10.1016/j.semcancer.2004.04.016; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pancewicz J, 2010, P NATL ACAD SCI USA, V107, P16619, DOI 10.1073/pnas.1010722107; Pinnix CC, 2009, CANCER RES, V69, P5312, DOI 10.1158/0008-5472.CAN-08-3767; Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rasul S, 2009, BRIT J CANCER, V100, P1879, DOI 10.1038/sj.bjc.6605034; Razorenova O V, 2005, Mol Biol (Mosk), V39, P286; Reschke M, 2008, CLIN CANCER RES, V14, P5188, DOI 10.1158/1078-0432.CCR-08-0186; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Sjolund J, 2008, J CLIN INVEST, V118, P217, DOI 10.1172/JCI32086; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tworkoski K, 2011, MOL CANC RES; Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8; Woodhoo A, 2009, NAT NEUROSCI, V12, P839, DOI 10.1038/nn.2323; Zhou K, 2010, ANN HEMATOL, V89, P749, DOI 10.1007/s00277-010-0923-3	53	39	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4609	4618		10.1038/onc.2011.606	http://dx.doi.org/10.1038/onc.2011.606			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22249266	Green Accepted			2022-12-28	WOS:000310528200004
J	Casar, B; He, Y; Iconomou, M; Hooper, JD; Quigley, JP; Deryugina, EI				Casar, B.; He, Y.; Iconomou, M.; Hooper, J. D.; Quigley, J. P.; Deryugina, E. I.			Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells	ONCOGENE			English	Article						CDCP1; plasmin; cleavage; colonization; apoptosis; signaling	DOMAIN-CONTAINING PROTEIN-1; PROTEASE-ACTIVATED RECEPTORS; CUB-DOMAIN; TYROSINE PHOSPHORYLATION; PKC-DELTA; SRC; CARCINOMA; MIGRATION; ADHESION; PLASMIN	The CUB domain-containing protein-1 (CDCP1) is a transmembrane molecule that has recently been implicated in cancer progression. In this study we have established a novel mechanism for initiation of CDCP1-mediated signaling in vivo and demonstrated that specific 135 -> 70-kDa processing of cell-surface CDCP1 by extracellular serine proteases is a prerequisite for CDCP1-dependent survival of cancer cells during metastasis. The in vivo cleavage of CDCP1 triggers a survival program involving recruitment of Src and PKC delta, Src-mediated phosphorylation of cell-surface-retained 70-kDa CDCP1, activation of Akt and suppression of PARP1-induced apoptosis. We demonstrate in vivo that phosphorylated Src, PKC delta and Akt all constitute activated elements of a CDCP1-signaling axis during tissue colonization of tumor cells. Preventing in vivo cleavage of CDCP1 with unique anti-CDCP1 antibodies, serine protease inhibitors or genetic modulation of the cleavage site in the CDCP1 molecule completely abrogated survival signaling associated with the 70-kDa CDCP1, and induced PARP1 cleavage and PARP1-mediated apoptosis, ultimately resulting in substantial inhibition of tissue colonization by tumor cells. The lack of CDCP1 cleavage in the lung tissue of plasminogen-knockout mice along with a coordinated reduction in tumor cell survival in a lung retention model, and importantly rescue of both by in vivo supplied plasmin, indicated that plasmin is the crucial serine pr otease executing in vivo cleavage of cell-surface CDCP1 during early stages of lung colonization. Together, our findings indicate that in vivo blocking of CDCP1 cleavage upstream from CDCP1-induced pro-survival signaling provides a potential mechanism for therapeutic intervention into metastatic disease. Oncogene ( 2012) 31, 3924-3938; doi:10.1038/onc.2011.555; published online 19 December 2011	[Casar, B.; Quigley, J. P.; Deryugina, E. I.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [He, Y.; Iconomou, M.; Hooper, J. D.] Mater Med Res Inst, Brisbane, Qld, Australia	Scripps Research Institute; Mater Research	Deryugina, EI (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,SP3030-3120, La Jolla, CA 92037 USA.	deryugin@scripps.edu	CASAR, BERTA/M-2291-2014; Hooper, John/C-1481-2016	CASAR, BERTA/0000-0002-3058-5631; Hooper, John/0000-0003-1054-8486; HE, Yaowu/0000-0002-7828-263X	NATIONAL CANCER INSTITUTE [R01CA129484, R01CA105412] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 129484, R01 CA129484, R01 CA105412, R01 CA 105412] Funding Source: Medline; NCRR NIH HHS [UL1 RR025774, RR 025774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851; Gray K, 2008, FEBS LETT, V582, P907, DOI 10.1016/j.febslet.2008.02.026; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Landis RC, 2001, ANN THORAC SURG, V72, P2169, DOI 10.1016/S0003-4975(01)02821-1; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Schmidt A, 2005, J BIOL CHEM, V280, P34441, DOI 10.1074/jbc.M501903200; Shi XL, 2004, MOL CANCER RES, V2, P395; Spassov DS, 2011, CELL CYCLE, V10, P1225, DOI 10.4161/cc.10.8.15343; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Wortmann A, 2011, J BIOL CHEM; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	30	51	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3924	3938		10.1038/onc.2011.555	http://dx.doi.org/10.1038/onc.2011.555			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22179830	Green Accepted			2022-12-28	WOS:000308342800002
J	Neeb, A; Wallbaum, S; Novac, N; Dukovic-Schulze, S; Scholl, I; Schreiber, C; Schlag, P; Moll, J; Stein, U; Sleeman, JP				Neeb, A.; Wallbaum, S.; Novac, N.; Dukovic-Schulze, S.; Scholl, I.; Schreiber, C.; Schlag, P.; Moll, J.; Stein, U.; Sleeman, J. P.			The immediate early gene Ier2 promotes tumor cell motility and metastasis, and predicts poor survival of colorectal cancer patients	ONCOGENE			English	Article						Ier2; Pip92; ETR101; metastasis; motility; invasion	SIGNALING PATHWAYS; T-LYMPHOCYTE; PC12 CELLS; EXPRESSION; GROWTH; PIP92; PROTEIN; IDENTIFICATION; TRANSCRIPTION; DIFFERENTIATION	Here, we report unbiased screens for genes expressed in metastatic tumor cells that are associated with cell motility. These screens identified Ier2, an immediate early gene of unknown function, as potentially having a role in tumor cell motility and metastasis. Knockdown of Ier2 in 3T3 fibroblasts inhibited their motility upon relief of contact inhibition in monolayer wounding assays. Furthermore, ectopic Ier2 expression promoted the motility and invasiveness of poorly metastatic 1AS pancreatic tumor cells in vitro. Relief of contact inhibition was associated with translocation of the Ier2 protein from the cytoplasm to the nucleus in both 3T3 fibroblasts and 1AS tumor cells. Importantly, ectopic Ier2 expression in 1AS cells stimulated metastasis formation when cells were implanted into experimental animals. Furthermore, we found elevated Ier2 expression in a wide variety of human tumor types. This correlated with poor metastasis-free and overall survival in patients with colorectal adenocarcinomas. Together, these data reveal Ier2 as a new player in the regulation of tumor progression and metastasis, and suggest that Ier2 may be useful prognostically and therapeutically in the management of cancer. Oncogene (2012) 31, 3796-3806; doi: 10.1038/onc.2011.535; published online 28 November 2011	[Sleeman, J. P.] Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, D-68167 Mannheim, Germany; [Neeb, A.; Wallbaum, S.; Novac, N.; Dukovic-Schulze, S.; Scholl, I.; Schreiber, C.; Moll, J.; Sleeman, J. P.] Karlsruhe Inst Technol, Inst Genet & Toxikol, Karlsruhe, Germany; [Schlag, P.] Charite Comprehens Canc Ctr, Berlin, Germany; [Stein, U.] Charite, Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, D-13353 Berlin, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sleeman, JP (corresponding author), Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, TRIDOMUS Gebaude Haus C,Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	sleeman@medma.uni-heidelberg.de	Sleeman, Jonathan P/H-2515-2013; Dukowic-Schulze, Stefanie/AAC-8685-2019	Sleeman, Jonathan P/0000-0003-1718-7687; Dukowic-Schulze, Stefanie/0000-0003-2675-1075; Stein, Ulrike/0000-0001-7006-282X; Neeb, Antje/0000-0002-6516-2938	BMBF NGFN2 CancerNet Programme; European Union [LSHC-CT-2004-503224, HEALTH-F2-2008-201662]	BMBF NGFN2 CancerNet Programme(Federal Ministry of Education & Research (BMBF)); European Union(European Commission)	We are very grateful to Norma Howells, Selma Huber and Manuela Sauer for their assistance with the animal experiments, to Anja Steffen for expert technical support and to Wilko Thiele for critical reading of this manuscript. The contribution of Franziska Arlt and Markus Niederstrasser is also gratefully acknowledged. This work was supported by grants to JPS and US from the BMBF NGFN2 CancerNet Programme and to JPS from the European Union (FP6 STREP project BRECOSM, contract no. LSHC-CT-2004-503224 and FP7 Collaborative Project TuMIC, contract no. HEALTH-F2-2008-201662).	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Bradley LM, 2003, CURR OPIN IMMUNOL, V15, P343, DOI 10.1016/S0952-7915(03)00043-8; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; Chen L, 2003, J GEN VIROL, V84, P3203, DOI 10.1099/vir.0.19283-0; Chiou CC, 2001, GUT, V48, P598, DOI 10.1136/gut.48.5.598; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Chung KC, 2000, J NEUROCHEM, V75, P9, DOI 10.1046/j.1471-4159.2000.0750009.x; COLECLOUGH C, 1990, P NATL ACAD SCI USA, V87, P1753, DOI 10.1073/pnas.87.5.1753; Eschelbach A, 1998, ANN NY ACAD SCI, V865, P181, DOI 10.1111/j.1749-6632.1998.tb11177.x; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Gutmann DH, 2002, CANCER RES, V62, P2085; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; Hippo Y, 2002, CANCER RES, V62, P233; Hofmann M, 1998, J CELL SCI, V111, P1673; Hong SK, 2009, P NATL ACAD SCI USA, V106, P2230, DOI 10.1073/pnas.0812880106; Keeton AB, 2002, J BIOL CHEM, V277, P48565, DOI 10.1074/jbc.M207837200; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Li W, 2004, MOL BIOL CELL, V15, P294, DOI 10.1091/mbc.e03-05-0352; Mengwasser J, 2004, ONCOGENE, V23, P7430, DOI 10.1038/sj.onc.1207987; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Nestl A, 2001, CANCER RES, V61, P1569; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Schneider A, 2004, J CEREBR BLOOD F MET, V24, P224, DOI 10.1097/01.WCB.0000104960.26014.7A; SCOTT JL, 1994, J CELL BIOCHEM, V54, P135, DOI 10.1002/jcb.240540202; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; Skotheim RI, 2005, CANCER RES, V65, P5588, DOI 10.1158/0008-5472.CAN-05-0153; Sleeman JP, 2011, INT J CANCER, V128, P2511, DOI 10.1002/ijc.26027; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Takaya T, 2009, BIOSCI BIOTECH BIOCH, V73, P1653, DOI 10.1271/bbb.90162; Wallbaum S, 2009, BIOTECHNIQUES, V46, P433, DOI 10.2144/000113121; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	37	29	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3796	3806		10.1038/onc.2011.535	http://dx.doi.org/10.1038/onc.2011.535			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120713				2022-12-28	WOS:000307924900006
J	Gallagher, EJ; Fierz, Y; Vijayakumar, A; Haddad, N; Yakar, S; LeRoith, D				Gallagher, E. J.; Fierz, Y.; Vijayakumar, A.; Haddad, N.; Yakar, S.; LeRoith, D.			Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia	ONCOGENE			English	Article						insulin resistance; diabetes; breast cancer; PI3K inhibitor	BREAST-CANCER; CELL-PROLIFERATION; GLUCOSE-UPTAKE; IGF-I; TRASTUZUMAB; PROGRESSION; CARCINOMA; ISOFORM; PATHWAY; KINASE	Women with type 2 diabetes mellitus (T2DM) are at a greater risk of developing and dying from breast cancer than women without T2DM. Insulin resistance and hyperinsulinemia underlie the pathogenesis of T2DM. In the MKR mouse model of insulin resistance, we have previously shown increased activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in association with accelerated mammary tumor growth. In this study, we demonstrate that inhibiting PI3K with the oral pan-class I PI3K inhibitor, NVP-BKM120 reduced the growth of Met-1 and MCNeuA mammary tumor orthografts in the MKR mouse. NVP-BKM120 treatment decreased phosphorylation of Akt and S6 ribosomal protein (S6rp); no change in Erk1/2 phosphorylation was seen. Hyperglycemia, hypertriglyceridemia and greater hyperinsulinemia developed in the MKR mice treated with NVP-BKM120. We previously reported reduced tumor growth using intraperitoneal rapamycin in the MKR mouse, with the development of hyperglycemia and hypertriglyceridemia. Therefore, we examined whether the oral PI3K/mTOR inhibitor NVP-BEZ235 augmented the tumor suppressing effects of PI3K inhibition. We also investigated the effect of targeted PI3K/mTOR inhibition on PI3K/Akt/mTOR and Erk1/2 signaling, and the potential effects on glycemia. NVP-BEZ235 suppressed the growth of Met-1 and MCNeuA tumor orthografts, and decreased Akt and S6rp phosphorylation, despite increased Erk1/2 phosphorylation in Met-1 orthografts of MKR mice. Less marked hyperglycemia and hyperinsulinemia developed with NVP-BEZ235 than NVP-BKM120. Overall, the results of this study demonstrated that inhibiting PI3K/Akt/mTOR signaling with the oral agents NVP-BKM120 and NVP-BEZ235 decreased mammary tumor growth in the hyperinsulinemic MKR mouse. Inhibiting PI3K alone led to more severe metabolic derangement than inhibiting both PI3K and mTOR. Therefore, PI3K may be an important target for the treatment of breast cancer in women with insulin resistance. Monitoring for hyperglycemia and dyslipidemia should be considered when using these agents in humans, given the metabolic changes detected in this study. Oncogene (2012) 31, 3213-3222; doi:10.1038/onc.2011.495; published online 31 October 2011	[Gallagher, E. J.; Fierz, Y.; Vijayakumar, A.; Haddad, N.; Yakar, S.; LeRoith, D.] Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	LeRoith, D (corresponding author), Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA.	Derek.LeRoith@mssm.edu			American Diabetes Association; National Cancer Institute [R01-5R01-CA128799]; Swiss National Science Foundation [PBBSB-120851, PBBSB3-120851]; Novartis Foundation; Roche Research Foundation; Oncosuisse Foundation; NATIONAL CANCER INSTITUTE [R01CA128799] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis); Roche Research Foundation; Oncosuisse Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DLR received a mentor award from the American Diabetes Association. This work was funded by National Cancer Institute grant R01-5R01-CA128799. YF received grants from the Swiss National Science Foundation [PBBSB-120851 and PBBSB3-120851] and the Novartis Foundation, the Roche Research Foundation and the Oncosuisse Foundation. NVP-BKM120 and NVP-BEZ235 were supplied by Novartis Pharma (Basel, Switzerland) free of charge.	Agnoli C, 2010, NUTR METAB CARDIOVAS, V20, P41, DOI 10.1016/j.numecd.2009.02.006; Arpino G, 2007, JNCI-J NATL CANCER I, V99, P694, DOI 10.1093/jnci/djk151; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Campbell MJ, 2002, IN VITRO CELL DEV-AN, V38, P326; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Fierz Y, 2010, ENDOCR-RELAT CANCER, V17, P941, DOI 10.1677/ERC-10-0091; Foukas LC, 2010, P NATL ACAD SCI USA, V107, P11381, DOI 10.1073/pnas.0906461107; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Liu LZ, 2006, MOL BIOL CELL, V17, P2322, DOI 10.1091/mbc.E05-10-0969; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Patterson RE, 2010, BREAST CANCER RES TR, V122, P859, DOI 10.1007/s10549-010-0732-3; Peairs KS, 2011, J CLIN ONCOL, V29, P40, DOI 10.1200/JCO.2009.27.3011; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Sopasakis VR, 2010, CELL METAB, V11, P220, DOI 10.1016/j.cmet.2010.02.002; Tan SX, 2010, BIOCHEM J, V432, P191, DOI 10.1042/BJ20100750; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Wells V, 2007, ONCOGENE, V26, P7709, DOI 10.1038/sj.onc.1210580	26	57	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3213	3222		10.1038/onc.2011.495	http://dx.doi.org/10.1038/onc.2011.495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22037215	Green Accepted			2022-12-28	WOS:000306113400001
J	Zaynagetdinov, R; Stathopoulos, GT; Sherrill, TP; Cheng, DS; McLoed, AG; Ausborn, JA; Polosukhin, VV; Connelly, L; Zhou, W; Fingleton, B; Peebles, RS; Prince, LS; Yull, FE; Blackwell, TS				Zaynagetdinov, R.; Stathopoulos, G. T.; Sherrill, T. P.; Cheng, D-S; McLoed, A. G.; Ausborn, J. A.; Polosukhin, V. V.; Connelly, L.; Zhou, W.; Fingleton, B.; Peebles, R. S.; Prince, L. S.; Yull, F. E.; Blackwell, T. S.			Epithelial nuclear factor-kappa B signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes	ONCOGENE			English	Article						mouse; lung; cancer; Treg; inflammation; NF-kappa B	OBSTRUCTIVE PULMONARY-DISEASE; ANTI-CD25 MONOCLONAL-ANTIBODY; FUNCTIONAL INACTIVATION; CHRONIC INFLAMMATION; SMOKING-CESSATION; CUTTING EDGE; CANCER; CELLS; COPD; DEPLETION	The mechanisms by which chronic inflammatory lung diseases, particularly chronic obstructive pulmonary disease, confer enhanced risk for lung cancer are not well-defined. To investigate whether nuclear factor (NF)-kappa B, a key mediator of immune and inflammatory responses, provides an interface between persistent lung inflammation and carcinogenesis, we utilized tetracycline-inducible transgenic mice expressing constitutively active I kappa B kinase beta in airway epithelium (IKTA (IKK beta trans-activated) mice). Intraperitoneal injection of ethyl carbamate (urethane), or 3-methylcholanthrene (MCA) and butylated hydroxytoluene (BHT) was used to induce lung tumorigenesis. Doxycycline-treated IKTA mice developed chronic airway inflammation and markedly increased numbers of lung tumors in response to urethane, even when transgene expression (and therefore epithelial NF-kappa B activation) was begun after exposure to carcinogen. Studies using a separate tumor initiator/promoter model (MCA+BHT) indicated that NF-kappa B functions as an independent tumor promoter. Enhanced tumor formation in IKTA mice was preceded by increased proliferation and reduced apoptosis of alveolar epithelium, resulting in increased formation of premalignant lesions. Investigation of inflammatory cells in lungs of IKTA mice revealed a substantial increase in macrophages and lymphocytes, including functional CD4+/CD25+/FoxP3+ regulatory T lymphocytes (Tregs). Importantly, Treg depletion using repetitive injections of anti-CD25 antibodies limited excessive tumor formation in IKTA mice. At 6 weeks following urethane injection, antibody-mediated Treg depletion in IKTA mice reduced the number of premalignant lesions in the lungs in association with an increase in CD8 lymphocytes. Thus, persistent NF-kappa B signaling in airway epithelium facilitates carcinogenesis by sculpting the immune/inflammatory environment in the lungs. Oncogene (2012) 31, 3164-3176; doi:10.1038/onc.2011.480; published online 17 October 2011	[Blackwell, T. S.] Vanderbilt Univ, Sch Med, Ctr Lung Res, Dept Med,Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [McLoed, A. G.; Ausborn, J. A.; Connelly, L.; Fingleton, B.; Yull, F. E.; Blackwell, T. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Prince, L. S.; Blackwell, T. S.] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Peebles, R. S.; Blackwell, T. S.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; [Prince, L. S.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Blackwell, TS (corresponding author), Vanderbilt Univ, Sch Med, Ctr Lung Res, Dept Med,Div Allergy Pulm & Crit Care Med, 1161 21st Ave S,T-1218 MCN, Nashville, TN 37232 USA.	timothy.blackwell@vanderbilt.edu	Connelly, Linda/GVS-4612-2022; Stathopoulos, Georgios/D-6576-2013; Stathopoulos, Georgios/AAE-6884-2020	Stathopoulos, Georgios/0000-0002-9215-6461; 	Department of Veterans Affairs; Vanderbilt Cancer Center; National Institutes of Health [5T32HL094296-03, CA113734]; NATIONAL CANCER INSTITUTE [T32CA009592, R01CA113734] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086324, T32HL094296, R01HL097195] Funding Source: NIH RePORTER	Department of Veterans Affairs(US Department of Veterans Affairs); Vanderbilt Cancer Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Department of Veterans Affairs (TSB), Vanderbilt Cancer Center Support Grant 2010 (TSB), National Institutes of Health Grants (no.5T32HL094296-03, RZ and CA113734, FEY).	Alberg AJ, 2007, CHEST, V132, p29S, DOI 10.1378/chest.07-1347; Banerjee DK, 2006, BLOOD, V108, P2655, DOI 10.1182/blood-2006-03-011353; Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008; Barnes Peter J, 2008, Proc Am Thorac Soc, V5, P857, DOI 10.1513/pats.200807-069TH; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Bauer AK, 2005, J NATL CANCER I, V97, P1778, DOI 10.1093/jnci/dji403; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515, DOI 10.1165/ajrcmb.25.4.4515; Brody Jerome S, 2006, Proc Am Thorac Soc, V3, P535, DOI 10.1513/pats.200603-089MS; Cheng DS, 2007, J IMMUNOL, V178, P6504, DOI 10.4049/jimmunol.178.10.6504; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Degl'Innocenti E, 2008, CANCER RES, V68, P292, DOI 10.1158/0008-5472.CAN-07-2429; Gamble E, 2007, EUR RESPIR J, V30, P467, DOI 10.1183/09031936.00013006; Granville CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005061; Hashimoto K, 2005, J IMMUNOL, V174, P525, DOI 10.4049/jimmunol.174.1.525; Houghton AM, 2008, NAT MED, V14, P1023, DOI 10.1038/nm1008-1023; Kohm AP, 2006, J IMMUNOL, V176, P3301, DOI 10.4049/jimmunol.176.6.3301; Lane N, 2010, CLIN SCI, V119, P75, DOI 10.1042/CS20100033; Lapperre TS, 2006, THORAX, V61, P115, DOI 10.1136/thx.2005.040519; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Malkinson AM, 2000, CHEST, V117, p228S, DOI 10.1378/chest.117.5_suppl_1.228S; Malkinson AM, 1997, CANCER RES, V57, P2832; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Miller YE, 2005, AM J RESP CELL MOL, V33, P216, DOI 10.1165/rcmb.2005-0158OE; Moghaddam SJ, 2009, AM J RESP CELL MOL, V40, P443, DOI 10.1165/rcmb.2008-0198OC; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Nummer D, 2007, J NATL CANCER I, V99, P1188, DOI 10.1093/jnci/djm064; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pasparakis M, 2009, NAT REV IMMUNOL, V9, P778, DOI 10.1038/nri2655; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Plumb J, 2009, EUR RESPIR J, V34, P89, DOI 10.1183/09031936.00100708; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Schneider T, 2011, J THORAC ONCOL, V6, P432, DOI 10.1097/JTO.0b013e31820b80ca; Schottenfeld D, 2006, CA-CANCER J CLIN, V56, P69, DOI 10.3322/canjclin.56.2.69; Setiady YY, 2010, EUR J IMMUNOL, V40, P780, DOI 10.1002/eji.200939613; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503, DOI 10.7326/0003-4819-105-4-503; Smale ST, 2010, CELL, V140, P833, DOI 10.1016/j.cell.2010.01.037; Smyth LJC, 2007, CHEST, V132, P156, DOI 10.1378/chest.07-0083; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Stephens LA, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Thiberville L, 2009, EUR RESPIR J, V33, P974, DOI 10.1183/09031936.00083708; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; Wilke CM, 2010, INT J CANCER, V127, P748, DOI 10.1002/ijc.25464; Willemse BWM, 2005, EUR RESPIR J, V26, P835, DOI 10.1183/09031936.05.00108904; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208; Yull FE, 2003, J HISTOCHEM CYTOCHEM, V51, P741, DOI 10.1177/002215540305100605; Zelenay S, 2006, J IMMUNOL, V177, P2036, DOI 10.4049/jimmunol.177.4.2036-a	54	40	42	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	26					3164	3176		10.1038/onc.2011.480	http://dx.doi.org/10.1038/onc.2011.480			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22002309	Green Accepted			2022-12-28	WOS:000305934400005
J	Russell, P; Hennessy, BT; Li, J; Carey, MS; Bast, RC; Freeman, T; Venkitaraman, AR				Russell, P.; Hennessy, B. T.; Li, J.; Carey, M. S.; Bast, R. C.; Freeman, T.; Venkitaraman, A. R.			Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest	ONCOGENE			English	Article						mitotic checkpoint; cyclin G1; anti-mitotic drugs; cancer therapy	SPINDLE-ASSEMBLY CHECKPOINT; CELL-CYCLE; ANTIMITOTIC DRUGS; CANCER-CELLS; DNA-DAMAGE; TARGET; PROTEIN; P53; MICROTUBULES; BRCA2	Anti-mitotic chemotherapeutic agents such as taxanes activate the spindle assembly checkpoint (SAC) to arrest anaphase onset, but taxane-exposed cells eventually undergo slippage to exit mitosis. The therapeutic efficacy of taxanes depends on whether slippage after SAC arrest culminates in continued cell survival, or in death by apoptosis. However, the mechanisms that determine these outcomes remain unclear. Here, we identify a novel role for cyclin G1 (CCNG1), an atypical cyclin. Increased CCNG1 expression accompanies paclitaxel-induced, SAC-mediated mitotic arrest, independent of p53 integrity or signaling through the SAC component, BUBR1. CCNG1 overexpression promotes cell survival after paclitaxel exposure. Conversely, CCNG1 depletion by RNA interference delays slippage and enhances paclitaxel-induced apoptosis. Consistent with these observations, CCNG1 amplification is associated with significantly shorter post-surgical survival in patients with ovarian cancer who have received adjuvant chemotherapy with taxanes and platinum compounds. Collectively, our findings implicate CCNG1 in regulating slippage and the outcome of taxane-induced mitotic arrest, with potential implications for cancer therapy. Oncogene (2012) 31, 2450-2460; doi: 10.1038/onc.2011.431; published online 7 November 2011	[Russell, P.; Venkitaraman, A. R.] Univ Cambridge, Med Res Council Canc Cell Unit, Dept Oncol, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England; [Hennessy, B. T.; Li, J.; Carey, M. S.; Bast, R. C.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Freeman, T.] Roslin Inst, Roslin, Midlothian, Scotland	University of Cambridge; University of Texas System; UTMD Anderson Cancer Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Venkitaraman, AR (corresponding author), Univ Cambridge, Med Res Council Canc Cell Unit, Dept Oncol, Hutchison MRC Res Ctr, Hills Rd, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Hennessy, Bryan/0000-0002-7871-6477	UK Medical Research Council; MRC [G1001521, G0600332, MC_U105359877, G0700651] Funding Source: UKRI; Medical Research Council [G0700651, MC_U105359877, G1001521, G0600332] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The experiments described in this paper were conceived and performed by PR and ARV, with the exception of the results in Figure 6, which were the work of BTH, JL, MSC and RCB. TF provided advice and assistance for microarray hybridization and analysis. This work was supported in ARV's laboratory by the UK Medical Research Council.	Abkevich V, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/386870; Bates S, 1996, ONCOGENE, V13, P1103; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6; Huang HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015724; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Markman M, 2008, DRUGS, V68, P771, DOI 10.2165/00003495-200868060-00004; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michalakis J, 2005, CANCER CHEMOTH PHARM, V56, P615, DOI 10.1007/s00280-005-1002-7; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sena G, 1999, CYTOMETRY, V37, P113, DOI 10.1002/(SICI)1097-0320(19991001)37:2<113::AID-CYTO4>3.0.CO;2-M; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; TAMURA K, 1993, ONCOGENE, V8, P2113; van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011	31	30	32	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2450	2460		10.1038/onc.2011.431	http://dx.doi.org/10.1038/onc.2011.431			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	22056875	hybrid, Green Published			2022-12-28	WOS:000303985300007
J	Wen, S; So, Y; Singh, K; Slingerland, JM; Resnick, MB; Zhang, S; Ruiz, V; Moss, SF				Wen, S.; So, Y.; Singh, K.; Slingerland, J. M.; Resnick, M. B.; Zhang, S.; Ruiz, V.; Moss, S. F.			Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer	ONCOGENE			English	Article						gastric cancer; Helicobacter pylori; cell cycle regulation; cyclin-dependent kinase inhibitor	KINASE INHIBITOR P27(KIP1); EPITHELIAL-CELLS; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; ACTIVATION; RISK; ERADICATION; PHENOTYPE; CARCINOMA	The cyclin-dependent kinase (CDK) inhibitor p27 has an important role in cell cycle regulation. Reduced expression of p27 is commonly associated with poor prognosis in many malignancies, including gastric cancer. Cytoplasmic p27 mislocalization may be an additional indicator of high-grade tumors and poor prognosis in cancer. As chronic infection by Helicobacter pylori is the most important risk factor for gastric cancer development, we evaluated the effects of H. pylori on p27 expression and localization in gastric cancer cells. Co-culture of gastric cells with H. pylori induced cytoplasmic p27 expression and reduced nuclear p27 expression in vitro. Cytoplasmic p27 expression was associated with and dependent upon phosphorylation of p27 at T157 and T198: wild-type p27 accumulated in the cytoplasm, but non-phosphorylatable mutants affecting T157 or T198 were nuclear in H. pylori-infected cells. These post-translational p27 changes were secondary to activation of cellular phosphoinositide-3 kinase (PI3K) and AKT signaling pathways, and dependent upon a functional H. pylori cag pathogenicity island. We investigated the clinical significance of cytoplasmic p27 mislocalization in 164 cases of resected gastric cancer in tissue microarrays. In 97 cases (59%), cytoplasmic p27 mislocalization was observed, and this was associated with increased mortality in multivariate analysis. These results show that H. pylori infection induces AKT/PI3K-mediated phosphorylation of p27 at T157 and T198 to cause cytoplasmic p27 mislocalization in gastric cancer, and that p27 mislocalization is an adverse prognostic feature in gastric cancer. This is the first demonstration of the translocation of a specific bacterial virulence factor that post-translationally regulates a host cell CDK inhibitor. This is of particular significance, because p27 has both tumor-suppressive and oncogenic activities, depending upon its subcellular localization. Cytoplasmic mislocalization of p27 induced by H. pylori may be an important mechanistic link between H. pylori infection and gastric carcinogenesis. Oncogene (2012) 31, 1771-1780; doi: 10.1038/onc.2011.362; published online 15 August 2011	[Wen, S.; So, Y.; Zhang, S.; Ruiz, V.; Moss, S. F.] Brown Univ, Dept Med, Div Gastroenterol, Rhode Isl Hosp, Providence, RI 02903 USA; [Wen, S.; So, Y.; Singh, K.; Resnick, M. B.; Zhang, S.; Ruiz, V.; Moss, S. F.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02903 USA; [Singh, K.; Resnick, M. B.] Brown Univ, Dept Pathol, Rhode Isl Hosp, Providence, RI 02903 USA; [Slingerland, J. M.] Univ Miami, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, Miami, FL USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Miami	Moss, SF (corresponding author), Brown Univ, Dept Med, Div Gastroenterol, Rhode Isl Hosp, 593 Eddy St,APC 414, Providence, RI 02903 USA.	Steven_Moss@Brown.edu	wen, sicheng/E-7676-2012; Resnick, Murray/U-2986-2019	Ruiz, Victoria/0000-0002-0121-4727; Singh, Kamaljeet/0000-0002-2506-5703	US Public Health Service [NIH R01CA111533, NIH P20RR17695]; NATIONAL CANCER INSTITUTE [R01CA111533] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017695] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We appreciate the help of Virginia Hovanesian for technical assistance with confocal microscopy, and Leila Noble and Rose Tavares for immunohistochemistry. The study was funded by US Public Health Service Grants NIH R01CA111533 (to SFM) and NIH P20RR17695 (to MBR).	Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Duncan TJ, 2010, INT J GYNECOL PATHOL, V29, P8, DOI 10.1097/PGP.0b013e3181b64ec3; Eguchi H, 2004, GUT, V53, P797, DOI 10.1136/gut.2003.032144; Feakins RM, 2000, CANCER, V89, P1684, DOI 10.1002/1097-0142(20001015)89:8<1684::AID-CNCR6>3.0.CO;2-6; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fock KM, 2008, J GASTROEN HEPATOL, V23, P351, DOI 10.1111/j.1440-1746.2008.05314.x; Forman D, 2006, BEST PRACT RES CL GA, V20, P633, DOI 10.1016/j.bpg.2006.04.008; Fuccio L, 2009, ANN INTERN MED, V151, P121, DOI 10.7326/0003-4819-151-2-200907210-00009; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Hidaka T, 2009, ANTICANCER RES, V29, P597; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Jubelin G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004855; Kajihara R, 2010, BIOCHEM BIOPH RES CO, V401, P350, DOI 10.1016/j.bbrc.2010.09.051; Kim SS, 2006, MODERN PATHOL, V19, P49, DOI 10.1038/modpathol.3800476; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kuzushita N, 2005, GASTROENTEROLOGY, V129, P1544, DOI 10.1053/j.gastro.2005.07.056; Larrea MD, 2008, MOL CELL BIOL, V28, P6462, DOI 10.1128/MCB.02300-07; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu H, 2009, GASTROENTEROLOGY, V137, P1367, DOI 10.1053/j.gastro.2009.07.041; Mimuro H, 2007, CELL HOST MICROBE, V2, P250, DOI 10.1016/j.chom.2007.09.005; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Resnick MB, 2005, HUM PATHOL, V36, P886, DOI 10.1016/j.humpath.2005.05.019; Saito Y, 2010, J EXP MED, V207, P2157, DOI 10.1084/jem.20100602; Schiappacassi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017673; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Shirin H, 2000, INFECT IMMUN, V68, P5321, DOI 10.1128/IAI.68.9.5321-5328.2000; Shirin H, 1999, CANCER RES, V59, P2277; Tabassam FH, 2009, CELL MICROBIOL, V11, P70, DOI 10.1111/j.1462-5822.2008.01237.x; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	43	22	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1771	1780		10.1038/onc.2011.362	http://dx.doi.org/10.1038/onc.2011.362			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21841827	Green Accepted			2022-12-28	WOS:000302785200003
J	Ammoun, S; Schmid, MC; Zhou, L; Ristic, N; Ercolano, E; Hilton, DA; Perks, CM; Hanemann, CO				Ammoun, S.; Schmid, M. C.; Zhou, L.; Ristic, N.; Ercolano, E.; Hilton, D. A.; Perks, C. M.; Hanemann, C. O.			Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival	ONCOGENE			English	Article						human schwannoma; IGFBP-1; PTEN/AKT; Src/FAK; proliferation; adhesion	CELL-PROLIFERATION; SIGNALING PATHWAY; BREAST-CANCER; KINASE; PTEN; ACTIVATION; INTEGRIN; MERLIN; PHOSPHORYLATION; AKT	Merlin is a tumour suppressor involved in the development of a variety of tumours including mesotheliomas. Neurofibromatosis type 2 (NF2), a dominantly inherited tumour disease, is also caused by loss of merlin. NF2 patients suffer from multiple genetically well-defined tumours, schwannomas are most frequent among those. Using our in vitro model for human schwannoma, we found that schwannoma cells display enhanced proliferation because of the overexpression/activation of platelet-derived growth factor receptor and ErbB2/3, increased cell-matrix adhesion because of the overexpression of integrins, and decreased apoptosis. Mechanisms underlying schwannomas basal proliferation and cell-matrix adhesion are not understood. Here, we investigated insulin-like growth factor-binding protein-1 (IGFBP-1), which is expressed and released from central nervous system tumours and strongly overexpressed in schwannoma at the mRNA level. IGFBP-1 acts via beta 1-integrin and focal-adhesion-kinase (FAK), which are strongly overexpressed and basally activated in schwannoma. Using short hairpin RNA knockdown, small inhibitors and recombinant IGFBP-1, we demonstrate that schwannoma cells, in contrast to Schwann cells, release IGFBP-1 that activates the Src/FAK pathway, via integrin beta 1, potentiating schwannoma's proliferation and cell-matrix adhesion. We show that FAK localizes to the nucleus and Src triggers IGFBP-1 production. Further, we observed downregulation of the tumour-suppressor phosphatase and tensin homolog in schwannoma cells leading to increased activity of antiapoptotic AKT. Thus, IGFBP-1/integrin beta 1/Src/FAK pathway has a crucial role in merlin-related tumourigenesis and therefore represents an important therapeutic target in the treatment of merlin-deficient tumours. Oncogene (2012) 31, 1710-1722; doi:10.1038/onc.2011.357; published online 5 September 2011	[Ammoun, S.; Schmid, M. C.; Zhou, L.; Ristic, N.; Ercolano, E.; Hanemann, C. O.] Peninsula Coll Med & Dent, Plymouth PL6 8BU, Devon, England; [Hilton, D. A.] Derriford Hosp, Dept Histopathol, Plymouth PL6 8DH, Devon, England; [Perks, C. M.] Univ Bristol, Dept Clin Sci N Bristol, IGFs & Metab Endocrinol, Bristol, Avon, England	University of Plymouth; Derriford Hospital; University of Bristol	Hanemann, CO (corresponding author), Peninsula Coll Med & Dent, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.	oliver.hanemann@pms.ac.uk	Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Perks, Claire/0000-0003-1562-891X	CTF; Northcott Devon Medical Foundation; Peninsula College of Medicine and Dentistry, Plymouth, UK; Action Medical Research [1792] Funding Source: researchfish	CTF; Northcott Devon Medical Foundation; Peninsula College of Medicine and Dentistry, Plymouth, UK; Action Medical Research	This work was supported by the CTF, Northcott Devon Medical Foundation and by Peninsula College of Medicine and Dentistry, Plymouth, UK. Pfizer supplied inhibitor.	Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2010, NEURO-ONCOLOGY, V12, P834, DOI 10.1093/neuonc/noq012; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P1379, DOI 10.1093/carcin/bgm052; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Chaves J, 2011, ANTI-CANCER DRUG, V22, P206, DOI 10.1097/CAD.0b013e32834258a1; Feron M, 2009, AM J PATHOL, V174, P1459, DOI 10.2353/ajpath.2009.080460; Flaiz C, 2007, J NEUROPATH EXP NEUR, V66, P608, DOI 10.1097/nen.0b013e318093e555; Fraenzer JT, 2003, INT J ONCOL, V23, P1493; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Houshmandi SS, 2009, MOL CELL BIOL, V29, P1472, DOI 10.1128/MCB.01392-08; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1991, P NATL ACAD SCI USA, V88, P7481, DOI 10.1073/pnas.88.17.7481; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lin CH, 2003, J NEUROSCI, V23, P1574; Liu WJ, 2008, ANTICANCER RES, V28, P3613; McClatchey AI, 2009, TRENDS CELL BIOL, V19, P198, DOI 10.1016/j.tcb.2009.02.006; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Nagashima T, 2008, ENDOCRINOLOGY, V149, P1227, DOI 10.1210/en.2007-1217; Okada T, 2007, TRENDS CELL BIOL, V17, P222, DOI 10.1016/j.tcb.2007.03.006; Park CH, 2008, BRAIN RES, V1234, P148, DOI 10.1016/j.brainres.2008.07.082; Perks CM, 2007, ONCOGENE, V26, P5966, DOI 10.1038/sj.onc.1210397; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Rosenbaum C, 2000, NEUROBIOL DIS, V7, P483, DOI 10.1006/nbdi.2000.0307; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Utermark T, 2005, BRAIN PATHOL, V15, P17; Utermark T, 2003, BRAIN PATHOL, V13, P352; Wheatcroft SB, 2009, TRENDS ENDOCRIN MET, V20, P153, DOI 10.1016/j.tem.2009.01.002; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; Zhang H, 2006, CLIN CANCER RES, V12, P6323, DOI 10.1158/1078-0432.CCR-06-1707; Zumkeller W, 2001, J CLIN PATHOL-MOL PA, V54, P227, DOI 10.1136/mp.54.4.227	46	38	39	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1710	1722		10.1038/onc.2011.357	http://dx.doi.org/10.1038/onc.2011.357			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21892205				2022-12-28	WOS:000302231400009
J	de Lange, J; Ly, LV; Lodder, K; Verlaan-de Vries, M; Teunisse, AFAS; Jager, MJ; Jochemsen, AG				de Lange, J.; Ly, L. V.; Lodder, K.; Verlaan-de Vries, M.; Teunisse, A. F. A. S.; Jager, M. J.; Jochemsen, A. G.			Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma	ONCOGENE			English	Article						uveal melanoma; p53; Nutlin-3; RITA; topotecan; hypoxia	INDUCIBLE FACTOR 1-ALPHA; CHRONIC LYMPHOCYTIC-LEUKEMIA; DOWN-REGULATION; CANCER-CELLS; IN-VIVO; APOPTOSIS; MDM2; HYPOXIA; ATM; RITA	The prognosis of patients with uveal melanoma is poor. Because of the limited efficacy of current treatments, new therapeutic strategies need to be developed. Because p53 mutations are uncommon in uveal melanoma, reactivation of p53 may be used to achieve tumor regression. We investigated the use of combination therapies for intraocular melanoma, based on the p53 activators Nutlin-3 and reactivation of p53 and induction of tumor cell apoptosis (RITA) and the topoisomerase I inhibitor Topotecan. Nutlin-3 treatment induced p53-dependent growth inhibition in human uveal melanoma cell lines. The sensitivity to Nutlin-3 of the investigated cell lines did not correlate with basal Hdm2 or Hdmx levels. Nutlin-3 synergized with RITA and Topotecan to induce apoptosis in uveal melanoma cell lines and short-term cultures. Drug synergy correlated with enhanced induction of p53-Ser46 phosphorylation, which was attenuated by ATM inhibition. Nutlin-3 and Topotecan also significantly delayed tumor growth in vivo in a murine B16F10 model for ocular melanoma. Combination treatment appeared to inhibit tumor growth slightly more efficient than either drug alone. Nutlin-3, RITA and Topotecan lead to comparable p53 activation and growth inhibition under normoxia and hypoxia. Treatment with Nutlin-3 or RITA had no effect on HIF-1 alpha induction by hypoxia, whereas the combination of these two drugs did inhibit hypoxia-induced HIF-1 alpha. Also Topotecan, alone or in combination with Nutlin-3, reduced HIF-1 alpha protein levels, suggesting that a certain level of DNA damage response is required for p53-mediated downregulation of HIF-1 alpha. In conclusion, combination treatments based on small-molecule-induced p53 activation may have clinical potential for uveal melanoma. Oncogene (2012) 31, 1105-1116; doi:10.1038/onc.2011.309; published online 18 July 2011	[de Lange, J.; Lodder, K.; Verlaan-de Vries, M.; Teunisse, A. F. A. S.; Jochemsen, A. G.] Leiden Univ, Dept Mol Cell Biol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Ly, L. V.; Jager, M. J.] Leiden Univ, Dept Ophthalmol, Med Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Dept Mol Cell Biol, Med Ctr, POB 9600, NL-2300 RC Leiden, Netherlands.	A.G.Jochemsen@lumc.nl	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; de Lange, Job/0000-0002-9002-8829	Netherlands Organization for Scientific Research NWO [017.003.059]; EC [503576]	Netherlands Organization for Scientific Research NWO(Netherlands Organization for Scientific Research (NWO)); EC(European CommissionEuropean Commission Joint Research Centre)	We thank Dr PA van der Velden and M Versluis for the primer sets to detect the expression of the HIF target genes and the early cultures of primary uveal melanoma cells, Dr A Vertegaal for the antibodies detecting HIF-1 alpha and HIF-2 alpha proteins, Prof BR Ksander for providing the Mel cell lines, Dr G Selivanova for providing RITA and Dr A Levine for providing anti-Mdm2 antibody. This study was supported by grants from the Netherlands Organization for Scientific Research NWO (Mozaiek Grant 017.003.059) and by EC FP6 funding (contract 503576).	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Augsburger JJ, 2009, AM J OPHTHALMOL, V148, P119, DOI 10.1016/j.ajo.2009.01.023; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Chou T.-C., 2007, COMPUSYN SOFTWARE DR; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Coll-Mulet L, 2006, BLOOD, V107, P4109, DOI 10.1182/blood-2005-08-3273; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208; Enge M, 2009, CANCER CELL, V15, P171, DOI 10.1016/j.ccr.2009.01.019; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Kaluzova M, 2004, MOL CELL BIOL, V24, P5757, DOI 10.1128/MCB.24.13.5757-5766.2004; Kivela Tero, 2006, International Ophthalmology Clinics, V46, P133, DOI 10.1097/01.iio.0000195861.71558.13; Kodama M, 2010, MOL CELL BIOL, V30, P1620, DOI 10.1128/MCB.00810-09; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; Krajewski M, 2005, NAT MED, V11, P1135, DOI 10.1038/nm1105-1135; Lam S, 2010, ONCOGENE, V29, P2415, DOI 10.1038/onc.2009.522; LaRusch GA, 2007, CANCER RES, V67, P450, DOI 10.1158/0008-5472.CAN-06-2710; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee YM, 2009, CARCINOGENESIS, V30, P1768, DOI 10.1093/carcin/bgp196; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Ly LV, 2010, J IMMUNOL, V185, P3481, DOI 10.4049/jimmunol.0903479; Moeller BJ, 2005, CANCER CELL, V8, P99, DOI 10.1016/j.ccr.2005.06.016; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Ravi R, 2000, GENE DEV, V14, P34; Rinaldo C, 2009, CANCER RES, V69, P6241, DOI 10.1158/0008-5472.CAN-09-0337; Saha MN, 2010, MOL CANCER THER, V9, P3041, DOI 10.1158/1535-7163.MCT-10-0471; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Tomicic MT, 2010, J PHARMACOL EXP THER, V332, P316, DOI 10.1124/jpet.109.159962; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; Yang J, 2009, MOL CELL BIOL, V29, P2243, DOI 10.1128/MCB.00959-08	37	46	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1105	1116		10.1038/onc.2011.309	http://dx.doi.org/10.1038/onc.2011.309			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765463				2022-12-28	WOS:000300945900004
J	Kais, Z; Chiba, N; Ishioka, C; Parvin, JD				Kais, Z.; Chiba, N.; Ishioka, C.; Parvin, J. D.			Functional differences among BRCA1 missense mutations in the control of centrosome duplication	ONCOGENE			English	Article						BRCA1; breast cancer; centrosomes; RING domain	POLYMERASE-II HOLOENZYME; UBIQUITIN-LIGASE; TRANSCRIPTIONAL ACTIVATION; CANCER SUSCEPTIBILITY; CELL-CYCLE; BREAST; IDENTIFICATION; AMPLIFICATION; INTERACT; BINDING	We analyzed the effects of 14 different missense mutations in the RING domain of BRCA1 on the function of the protein in the control of centrosome number in tissue culture cells. Whereas 2 of the 14 BRCA1 variant proteins were neutral in the centrosome duplication assay, missense mutations of zinc-coordinating residues (C24R, C27A, C39Y, H41F, C44F and C47G) and mutations encoding BRCA1 variants M18T and I42V resulted in BRCA1 proteins that caused centrosome amplification. BRCA1 variant proteins I21V, I31M, L52F and D67Y had an intermediate effect on centrosome duplication. In addition, one of the variants, L52F, caused a peculiar phenotype with amplified centrosomes but the centrioles remained paired. By comparison, other BRCA1 variants that caused centrosome amplification had clustering of supernumerary centrosomes with unpaired centrioles. This surprising phenotype suggests that the BRCA1 protein regulates two functions in the control of centrosome duplication: regulation of centrosome number and regulation of centriole pairing. The L52F is unusual as it is defective in only one of these processes. This study analyzes the function of BRCA1 missense mutations in the control of centrosome duplication, a critical step in the maintenance of genetic stability of mammary epithelial cells, and indicates a new function of BRCA1 in the control of centriole pairing. Oncogene (2012) 31, 799-804; doi:10.1038/onc.2011.271; published online 4 July 2011	[Kais, Z.; Parvin, J. D.] Ohio State Univ, Ctr Comprehens Canc, Dept Biomed Informat, Columbus, OH 43210 USA; [Chiba, N.] Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Immunol, Sendai, Miyagi 980, Japan; [Ishioka, C.] Tohoku Univ, Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 980, Japan	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Tohoku University; Tohoku University	Parvin, JD (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Biomed Informat, 904 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	Jeffrey.Parvin@osumc.edu	Parvin, Jeffrey D/C-8955-2009	Ishioka, Chikashi/0000-0002-3023-1227	NIH [CA111480]; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA111480] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant CA111480 (JDP).	Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chiba N, 2002, CANCER RES, V62, P4222; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Easton DF, 2007, AM J HUM GENET, V81, P873, DOI 10.1086/521032; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kais Z, 2008, CANCER BIOL THER, V7, P1540, DOI 10.4161/cbt.7.10.7053; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Morris JR, 2006, HUM MOL GENET, V15, P599, DOI 10.1093/hmg/ddi476; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Ransburgh DJR, 2010, CANCER RES, V70, P988, DOI 10.1158/0008-5472.CAN-09-2850; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sankaran S, 2007, CANCER BIOL THER, V6, P1853, DOI 10.4161/cbt.6.12.5164; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sinilnikova OM, 2006, FAM CANCER, V5, P15, DOI 10.1007/s10689-005-2571-7; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Vega A, 2001, Hum Mutat, V17, P520, DOI 10.1002/humu.1136; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	26	39	39	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					799	804		10.1038/onc.2011.271	http://dx.doi.org/10.1038/onc.2011.271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725363	Green Accepted			2022-12-28	WOS:000300222100012
J	Regan, JL; Kendrick, H; Magnay, FA; Vafaizadeh, V; Groner, B; Smalley, MJ				Regan, J. L.; Kendrick, H.; Magnay, F-A; Vafaizadeh, V.; Groner, B.; Smalley, M. J.			c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer	ONCOGENE			English	Article						Brca1; c-Kit; mammary; progenitor	PROTEIN-TYROSINE KINASE; FUNCTIONAL MAMMARY-GLAND; ESTROGEN-RECEPTOR-ALPHA; 2 SPLICE FORMS; STEM-CELLS; SIGNAL-TRANSDUCTION; LINEAGE-COMMITMENT; BRCA1; ACTIVATION; MOUSE	BRCA1 mutation-associated breast cancer originates in oestrogen receptor-alpha-negative (ER-) progenitors in the mammary luminal epithelium. These cells also express high levels of the Kit gene and a recent study demonstrated a correlation between Brca1 loss and Kit over-expression in the mammary epithelium. However, the functional significance of c-Kit expression in the mammary gland is unknown. To address this, c-Kit(-) and c-Kit(+) mammary epithelial subsets were isolated by flow cytometry, characterised for expression of lineage-specific cell markers and functionally analysed by in vitro colony forming and in vivo transplantation assays. The results confirm that the majority of luminal ER- progenitors are c-Kit(+), but also that most stem cells and the differentiated cell populations are c-Kit(-). A subset of c-Kit(+) cells with high proliferative potential was found in the luminal ER+ population, however, suggesting the existence of a distinct luminal ER+ progenitor cell type. Analysis of mouse Brca1 mammary tumours demonstrated that they expressed Kit and its downstream effector Lyn at levels comparable to the most strongly c-Kit(+) luminal ER- progenitors. Consistent with c-Kit being a progenitor cell marker, in vitro threedimensional differentiation of c-Kit(+) cells resulted in a loss of c-Kit expression, whereas c-Kit over-expression prevented normal differentiation in vivo. Furthermore, c-Kit was a functional marker of proliferative potential, as c-Kit inhibition by short hairpin knockdown prevented normal epithelial growth and caused cells to undergo apoptosis. Therefore, c-Kit defines distinct progenitor populations in the mammary epithelium and is critical for mammary progenitor survival and proliferation. Importantly, c-Kit is only the second mammary epithelial stem/progenitor marker to be shown to have a functional role in the mammary epithelium and the first marker to be shown to be required for progenitor cell function. The c-Kit signalling network has potential as a target for therapy and/or prevention in BRCA1-associated breast cancer. Oncogene (2012) 31, 869-883; doi:10.1038/onc.2011.289; published online 18 July 2011	[Regan, J. L.; Kendrick, H.; Magnay, F-A; Smalley, M. J.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Vafaizadeh, V.; Groner, B.] Georg Speyer Haus, Inst Biomed Res, Frankfurt, Germany	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Octapharma	Smalley, MJ (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	matthew.smalley@icr.ac.uk	Regan, Joseph/K-4188-2019; Smalley, Matthew J/M-7000-2015	Regan, Joseph/0000-0001-9987-7942; Smalley, Matthew J/0000-0001-9540-1146; Vafaizadeh, Vida/0000-0002-0875-6246	Breakthrough Breast Cancer; NHS	Breakthrough Breast Cancer; NHS	We thank Eric So for the c-Kit cDNA, Fredrik Wallberg for help with flow cytometry analysis and Jorge Reis-Filho and Arno Gauthier for assistance with assessment of Lyn staining on mouse tumours. This work was funded by Breakthrough Breast Cancer. We acknowledge NHS funding to the NIHR Biomedical Research Centre. This work was funded by Breakthrough Breast Cancer. We acknowledge NHS funding to the NIHR Biomedical Research Centre.	Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Arendt LM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2819; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Barton J, 2006, J CLIN ONCOL, V24, P10716; Baxter LL, 2004, PIGM CELL RES, V17, P215, DOI 10.1111/j.1600-0749.2004.00147.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Britt KL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2245; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Chew HK, 2006, J CLIN ONCOL S18, V24, P10529; Chin H, 1998, BLOOD, V91, P3734; Clarke RB, 1997, CANCER RES, V57, P4987; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Driessen RL, 2003, EXP HEMATOL, V31, P1284, DOI 10.1016/j.exphem.2003.08.015; Fernandez-Gonzalez R, 2009, INTEGR BIOL, V1, P80, DOI 10.1039/b816933k; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Gommerman JL, 2000, BLOOD, V96, P3734, DOI 10.1182/blood.V96.12.3734.h8003734_3734_3742; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Haley BB, 2007, J CLIN ONCOL, V25; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036; Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591; Kent D, 2008, CLIN CANCER RES, V14, P1926, DOI 10.1158/1078-0432.CCR-07-5134; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lilla JN, 2010, DEV BIOL, V337, P124, DOI 10.1016/j.ydbio.2009.10.021; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Molyneux G, 2007, CELL MOL LIFE SCI, V64, P3248, DOI 10.1007/s00018-007-7391-5; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pathan NI, 1996, J BIOL CHEM, V271, P27517, DOI 10.1074/jbc.271.44.27517; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shivakrupa R, 2005, CELL SIGNAL, V17, P103, DOI 10.1016/j.cellsig.2004.06.004; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Smalley MJ, 2010, METHODS MOL BIOL, V633, P139, DOI 10.1007/978-1-59745-019-5_11; Smart CE, 2011, ONCOGENE, V30, P1597, DOI 10.1038/onc.2010.538; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Sun JM, 2008, J BIOL CHEM, V283, P27444, DOI 10.1074/jbc.M709703200; Taddei I, 2008, NAT CELL BIOL, V10, P716, DOI 10.1038/ncb1734; Vafaizadeh V, 2010, STEM CELLS, V28, P928, DOI 10.1002/stem.407; Vidarsson H, 2002, FEBS LETT, V532, P247, DOI 10.1016/S0014-5793(02)03684-0; Voytyuk O, 2003, J BIOL CHEM, V278, P9159, DOI 10.1074/jbc.M211726200; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; WATERHOUSE DM, 2008, J CLIN ONCOL S, V26; Westbury CB, 2009, J PATHOL, V219, P131, DOI 10.1002/path.2581; Young SM, 2007, CELL SIGNAL, V19, P2572, DOI 10.1016/j.cellsig.2007.08.004; Yu M, 2006, J BIOL CHEM, V281, P28615, DOI 10.1074/jbc.M603742200	56	76	77	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					869	883		10.1038/onc.2011.289	http://dx.doi.org/10.1038/onc.2011.289			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21765473				2022-12-28	WOS:000300615800006
J	Luo, Y; Zheng, C; Zhang, J; Lu, D; Zhuang, J; Xing, S; Feng, J; Yang, D; Yan, X				Luo, Y.; Zheng, C.; Zhang, J.; Lu, D.; Zhuang, J.; Xing, S.; Feng, J.; Yang, D.; Yan, X.			Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration	ONCOGENE			English	Article						cell migration; CD146; ERM proteins; RhoA; RhoGDI1	PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; ANTI-CD146 MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; INHIBITS ANGIOGENESIS; ADHESION MOLECULE; RHO-FAMILY; EXPRESSION; EZRIN/RADIXIN/MOESIN; ACTIVATION; MUC18	Tumor cell migration is a well-orchestrated multistep process that drives cancer development and metastasis. Previous data indicated that CD146 expression correlates with malignant progression and metastatic potential of human melanoma cells. However, the exact molecular mechanism of how CD146 promotes melanoma cell migration still remains poorly understood. Here, we report that CD146 physically interacts with actin-linking ezrin-radixin-moesin (ERM) proteins and recruits ERM proteins to cell protrusions, promoting the formation and elongation of microvilli. Moreover, CD146-promoted melanoma cell migration is linked to RhoA activation and ERM phosphorylation. CD146 recruits Rho guanine nucleotide dissociation inhibitory factors 1 (RhoGDI1) through ERM proteins and thus sequesters RhoGDI1 from RhoA, which leads to upregulated RhoA activity and increased melanoma cell motility. CD146-activated RhoA also promotes further ERM phosphorylation and activation through Rho-phosphatidylinositol-4-phosphate-5-kinase-phosphatidylinositol 4,5-biphosphate pathway, which reinforces CD146/ERM association. Thus, our results provide a mechanistic basis to understand the role of CD146 in regulating human melanoma cell motility. Oncogene (2012) 31, 306-321; doi:10.1038/onc.2011.244; published online 4 July 2011	[Luo, Y.; Zheng, C.; Zhang, J.; Lu, D.; Zhuang, J.; Xing, S.; Feng, J.; Yang, D.; Yan, X.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; [Luo, Y.; Zheng, C.; Zhang, J.; Lu, D.; Zhuang, J.; Xing, S.; Feng, J.; Yang, D.; Yan, X.] Chinese Acad Sci, Inst Biophys, Chinese Acad Sci Univ Tokyo Joint Lab Struct Viro, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS	Yan, X (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	yanxy@ibp.ac.cn	Zheng, Chaogu/P-2753-2019; Lu, Di/D-9836-2018	Zheng, Chaogu/0000-0002-5048-4520; Lu, Di/0000-0002-4083-1656; Luo, Yongting/0000-0001-7834-8742	National 863 Grant [2006AA02A245]; National Basic Research Program of China (973 Program) [2009CB521704, 2011CB933503]; National Important Science and Technology Specific Projects [2008ZX10004-005, 2008ZX10002-017, 2009ZX09102-247]; National Natural Science Foundation of China [91029732]; Chinese Academy of Sciences [KSCX2-YW-R-121, KSCX2-YW-R-173, KSCX2-YW-M15]	National 863 Grant; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Important Science and Technology Specific Projects; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr J Johnson for providing the CD146-transfected Mel-888<SUP>CD146</SUP> cells and CD146 gene contained in pUC-CD146 plasmids. This work is partly supported by grants from the National 863 Grant (2006AA02A245), the National Basic Research Program of China (973 Program) (2009CB521704, 2011CB933503), the National Important Science and Technology Specific Projects (2008ZX10004-005, 2008ZX10002-017, 2009ZX09102-247), the National Natural Science Foundation of China (91029732) and the Knowledge Innovation Program of the Chinese Academy of Sciences (KSCX2-YW-R-121, KSCX2-YW-R-173, KSCX2-YW-M15).	Aldovini D, 2006, INT J CANCER, V119, P1920, DOI 10.1002/ijc.22082; Lacalle RA, 2007, J CELL BIOL, V179, P1539, DOI 10.1083/jcb.200705044; Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Bani MR, 1996, CANCER RES, V56, P3075; Barreiro O, 2004, FRONT BIOSCI-LANDMRK, V9, P1849, DOI 10.2741/1285; Barrero-Villar M, 2008, J IMMUNOL, V181, P6882, DOI 10.4049/jimmunol.181.10.6882; Bartolome RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561; Bidlingmaier S, 2009, CANCER RES, V69, P1570, DOI 10.1158/0008-5472.CAN-08-1363; Boureux A, 2007, MOL BIOL EVOL, V24, P203, DOI 10.1093/molbev/msl145; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Bretscher A, 1997, J CELL SCI, V110, P3011; Bu PC, 2006, MOL CANCER THER, V5, P2872, DOI 10.1158/1535-7163.MCT-06-0260; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Gervais L, 2008, DEVELOPMENT, V135, P3829, DOI 10.1242/dev.029009; Guezguez B, 2006, FEBS LETT, V580, P3649, DOI 10.1016/j.febslet.2006.05.048; Hebert M, 2008, J IMMUNOL, V181, P5963, DOI 10.4049/jimmunol.181.9.5963; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Johnson JP, 1997, INT J CANCER, V73, P769; JOHNSON JP, 1993, MELANOMA RES, V3, P337, DOI 10.1097/00008390-199310000-00006; Kristiansen G, 2003, ANAL CELL PATHOL, V25, P77, DOI 10.1155/2003/574829; Lee JH, 2004, J CELL BIOL, V167, P327, DOI 10.1083/jcb.200403091; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Masiero L, 1999, J CELL SCI, V112, P3205; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; McClatchey AI, 2009, TRENDS CELL BIOL, V19, P198, DOI 10.1016/j.tcb.2009.02.006; Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200; Niggli V, 2008, INT J BIOCHEM CELL B, V40, P344, DOI 10.1016/j.biocel.2007.02.012; Oleksy A, 2006, J BIOL CHEM, V281, P32891, DOI 10.1074/jbc.M606220200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Ouhtit A, 2009, BBA-REV CANCER, V1795, P130, DOI 10.1016/j.bbcan.2009.01.002; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ridley AJ, 2006, TRENDS CELL BIOL, V16, P522, DOI 10.1016/j.tcb.2006.08.006; Saci A, 2005, MOL CELL, V17, P205, DOI 10.1016/j.molcel.2004.12.012; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, CANCER RES, V54, P2514; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Wu GJ, 2004, GENE, V327, P201, DOI 10.1016/j.gene.2003.11.018; Wu GJ, 2001, GENE, V279, P17, DOI 10.1016/S0378-1119(01)00736-3; Xie SH, 1997, CANCER RES, V57, P2295; Yan XY, 2003, BLOOD, V102, P184, DOI 10.1182/blood-2002-04-1004; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Zheng CG, 2009, INT J BIOCHEM CELL B, V41, P2163, DOI 10.1016/j.biocel.2009.03.014	55	105	124	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					306	321		10.1038/onc.2011.244	http://dx.doi.org/10.1038/onc.2011.244			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21725352				2022-12-28	WOS:000299542100004
J	Fatima, S; Lee, NP; Tsang, FH; Kolligs, FT; Ng, IOL; Poon, RTP; Fan, ST; Luk, JM				Fatima, S.; Lee, N. P.; Tsang, F. H.; Kolligs, F. T.; Ng, I. O. L.; Poon, R. T. P.; Fan, S. T.; Luk, J. M.			Dickkopf 4 (DKK4) acts on Wnt/beta-catenin pathway by influencing beta-catenin in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; Wnt/beta-catenin signalling; DKK4; tumourigenesis	FREQUENT EPIGENETIC INACTIVATION; LIVER-CANCER; PROGNOSTIC-SIGNIFICANCE; NEGATIVE REGULATOR; FAMILY GENES; TUMOR-GROWTH; COLON-CANCER; EXPRESSION; ANTAGONIST; PHOSPHORYLATION	Deregulation of Wnt/beta-catenin pathway is a hallmark of major gastrointestinal cancers including hepatocellular carcinoma (HCC). The oncogenic role of beta-catenin is well defined but reasons for its accumulation in HCC remain unclear. Dickkopf 4 (DKK4) acts as a negative regulator of Wnt/beta-catenin pathway but its functional role in liver carcinogenesis has not been studied. We investigated the role of DKK4 in beta-catenin regulation in HCC. Reduced expression of DKK4 was found in 47% (38/81) of HCC, as measured by quantitative real time PCR. Ectopic expression of DKK4 in two HCC cell lines, PLC/PRF/5 (PLC) and MHCC97L (97L), attenuated beta-catenin responsive luciferase activity, and decreased both beta-catenin and cyclin D1 protein levels. To study the effect of DKK4 on cell growth and tumourigenicity, two stable HCC cell lines were established from PLC and 97L cells. Functional assays demonstrated that overexpression of DKK4 hampered cell proliferation, reduced colony formation and retarded cell migration. When DKK4-expressing 97L stable cells were used to induce tumour xenografts in nude mice (n = 8), reduction in tumour sizes was observed (P = 0.027). Furthermore, immunohistochemical studies showed that decreased expression of DKK4 was associated with beta-catenin accumulation in HCC tissues. Additionally, inhibition of the proteasome using specific inhibitor in DKK4-expressing 97L stable cells masked the effect of beta-catenin. Our findings suggest a potential tumour suppressive role of DKK4 as well as that of an important regulator of HCC. Oncogene (2012) 31, 4233-4244; doi:10.1038/onc.2011.580; published online 16 January 2012	[Luk, J. M.] pRED China, Roche R& Ctr, Dept Oncol, Shanghai 201203, Peoples R China; [Fatima, S.; Lee, N. P.; Tsang, F. H.; Poon, R. T. P.; Fan, S. T.; Luk, J. M.] Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China; [Kolligs, F. T.] Univ Munich, Klinikum Grosshadern, Dept Med 2, D-8000 Munich, Germany; [Ng, I. O. L.] Univ Hong Kong, Dept Pathol, Pokfulam, Hong Kong, Peoples R China; [Luk, J. M.] Natl Univ Singapore, Dept Pharmacol, Singapore 117548, Singapore; [Luk, J. M.] Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; [Luk, J. M.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; [Luk, J. M.] Canc Sci Inst, Singapore, Singapore	University of Hong Kong; University of Munich; University of Hong Kong; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Luk, JM (corresponding author), pRED China, Roche R& Ctr, Dept Oncol, 720 Cai Lun Rd, Shanghai 201203, Peoples R China.	dr.johnluk@gmail.com	Luk, John/A-4085-2008	Luk, John/0000-0002-6323-7940; Ng, Irene Oi-lin/0000-0001-7532-2029				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Apte U, 2008, HEPATOLOGY, V47, P288, DOI 10.1002/hep.21973; Baehs S, 2009, CANCER LETT, V276, P152, DOI 10.1016/j.canlet.2008.11.003; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chen TC, 1998, CANCER LETT, V134, P23, DOI 10.1016/S0304-3835(98)00238-9; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding Z, 2009, WORLD J GASTROENTERO, V15, P2595, DOI 10.3748/wjg.15.2595; Fatima S, 2011, WORLD J CLIN ONCOL, V2, P311, DOI 10.5306/wjco.v2.i8.311; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Gonzalez FJ, 2006, HEPATOLOGY, V43, P650, DOI 10.1002/hep.21154; Hao K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-389; Hirata H, 2011, CANCER-AM CANCER SOC, V117, P1649, DOI 10.1002/cncr.25666; Hirata H, 2009, CLIN CANCER RES, V15, P5678, DOI 10.1158/1078-0432.CCR-09-0558; Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008-5472.CAN-09-0541; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kemp W, 2005, J GASTROEN HEPATOL, V20, P873, DOI 10.1111/j.1440-1746.2005.03844.x; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913; Lee NP, 2010, INT J CANCER, V127, P968, DOI 10.1002/ijc.25100; Lee NP, 2009, J PROTEOME RES, V8, P1293, DOI 10.1021/pr800637z; Lee NPY, 2008, PROTEOMICS, V8, P2136, DOI 10.1002/pmic.200700590; Lee NPY, 2006, FEBS LETT, V580, P923, DOI 10.1016/j.febslet.2006.01.019; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Liao CH, 2011, HEPATOLOGY; Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036; Liu LX, 2009, HEPATOLOGY, V50, P1453, DOI 10.1002/hep.23143; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WJ, 2011, INT J CANCER, V129, P1806, DOI 10.1002/ijc.25857; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Matsui A, 2009, CANCER SCI, V100, P1923, DOI 10.1111/j.1349-7006.2009.01272.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakamura T, 2008, J CELL MOL MED, V12, P391, DOI 10.1111/j.1582-4934.2007.00201.x; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pendas-Franco N, 2008, ONCOGENE, V27, P4467, DOI 10.1038/onc.2008.88; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750; Takagi H, 2008, J GASTROENTEROL, V43, P378, DOI 10.1007/s00535-008-2170-0; Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tung EKK, 2011, LIVER INT, V31, P1494, DOI 10.1111/j.1478-3231.2011.02597.x; Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194; Wiesman KC, 2010, J CELL COMMUN SIGNAL, V4, P91, DOI 10.1007/s12079-010-0087-x; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wu YY, 2010, J BIOL CHEM, V285, P34621, DOI 10.1074/jbc.M110.148791; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yang B, 2010, WORLD J GASTROENTERO, V16, P755, DOI 10.3748/wjg.v16.i6.755; Yi X, 2008, MOL CELL PROTEOMICS, V7, P315, DOI 10.1074/mcp.M700116-MCP200; Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020; Yuan BZ, 1998, CANCER RES, V58, P2196; Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhang K, 2010, INT J ONCOL, V37, P1495, DOI 10.3892/ijo_00000802; Zhang LH, 2003, J CANCER RES CLIN, V129, P279, DOI 10.1007/s00432-002-0407-5	70	38	41	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4233	4244		10.1038/onc.2011.580	http://dx.doi.org/10.1038/onc.2011.580			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22249261				2022-12-28	WOS:000308975800006
J	Lee, JJ; Drakaki, A; Iliopoulos, D; Struhl, K				Lee, J-J; Drakaki, A.; Iliopoulos, D.; Struhl, K.			MiR-27b targets PPAR gamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells	ONCOGENE			English	Article						miR-27b; PPAR gamma; NHE1; NF-kappa beta; inflammation; neuroblastomas	ACTIVATED-RECEPTOR-GAMMA; BREAST-CANCER; TERMINAL DIFFERENTIATION; KAPPA-B; EXPRESSION; ROSIGLITAZONE; MICRORNAS; AGONISTS; TRANSFORMATION; PROLIFERATION	The peroxisome proliferators-activated receptor (PPAR)gamma pathway is involved in cancer, but it appears to have both tumor suppressor and oncogenic functions. In neuroblastoma cells, miR-27b targets the 30 untranslated region of PPAR gamma and inhibits its mRNA and protein expression. miR-27b overexpression or PPAR gamma inhibition blocks cell growth in vitro and tumor growth in mouse xenografts. PPAR gamma activates expression of the pH regulator NHE1, which is associated with tumor progression. Lastly, miR-27b through PPAR gamma regulates nuclear factor-kappa B activity and transcription of inflammatory target genes. Thus, in neuroblastoma, miR-27b functions as a tumor suppressor by inhibiting the tumor-promoting function of PPAR gamma, which triggers an increased inflammatory response. In contrast, in breast cancer cells, PPAR gamma inhibits NHE1 expression and the inflammatory response, and it functions as a tumor suppressor. We suggest that the ability of PPAR gamma to promote or suppress tumor formation is linked to cell type-specific differences in regulation of NHE1 and other target genes. Oncogene (2012) 31, 3818-3825; doi: 10.1038/onc.2011.543; published online 28 November 2011	[Lee, J-J; Iliopoulos, D.; Struhl, K.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Drakaki, A.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; [Iliopoulos, D.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	kevin@hms.harvard.edu	Iliopoulos, Dimitrios/AAE-9106-2019		Dana Farber Cancer Institute; National Institutes of Health [CA 107486]; NATIONAL CANCER INSTITUTE [R01CA107486] Funding Source: NIH RePORTER	Dana Farber Cancer Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by start-up funds to DI from the Dana Farber Cancer Institute and by a research grant to KS from the National Institutes of Health (CA 107486).	Abe A, 2002, EUR J PHARMACOL, V436, P7, DOI 10.1016/S0014-2999(01)01577-1; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161; Cellai I, 2006, BRIT J CANCER, V95, P879, DOI 10.1038/sj.bjc.6603344; Cellai I, 2010, BRIT J CANCER, V102, P685, DOI 10.1038/sj.bjc.6605506; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Han S, 2007, ANTI-CANCER DRUG, V18, P237, DOI 10.1097/CAD.0b013e328011e67d; Han SW, 2001, CLIN CANCER RES, V7, P98; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jennewein C, 2010, J BIOL CHEM, V285, P11846, DOI 10.1074/jbc.M109.066399; Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Kim SY, 2010, BIOCHEM BIOPH RES CO, V392, P323, DOI 10.1016/j.bbrc.2010.01.012; Kumar AP, 2009, CANCER RES, V69, P8636, DOI 10.1158/0008-5472.CAN-09-0219; Lecomte J, 2008, BREAST CANCER RES TR, V112, P437, DOI 10.1007/s10549-007-9886-z; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Morosetti R, 2004, INT J ONCOL, V25, P493; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nwankwo JO, 2001, PROSTAG LEUKOTR ESS, V64, P241, DOI 10.1054/plef.2001.0266; OBER SS, 1987, P NATL ACAD SCI USA, V84, P2766, DOI 10.1073/pnas.84.9.2766; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SICZKOWSKI M, 1994, AM J PHYSIOL, V267, pC745, DOI 10.1152/ajpcell.1994.267.3.C745; SOULE HD, 1990, CANCER RES, V50, P6075; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403; Venkatachalam G, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S3-S5; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005	44	117	121	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3818	3825		10.1038/onc.2011.543	http://dx.doi.org/10.1038/onc.2011.543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120719	Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000307924900008
J	Kidoya, H; Kunii, N; Naito, H; Muramatsu, F; Okamoto, Y; Nakayama, T; Takakura, N				Kidoya, H.; Kunii, N.; Naito, H.; Muramatsu, F.; Okamoto, Y.; Nakayama, T.; Takakura, N.			The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy	ONCOGENE			English	Article						tumor angiogenesis; immune therapy; vascular normalization; vascular maturation; apelin/APJ	KILLER T-CELLS; V-ALPHA-14 NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; IN-VIVO; ENDOTHELIAL-CELLS; ANGIOGENIC FACTOR; BLOOD-VESSELS; APJ RECEPTOR; CANCER; ACTIVATION	Immature and unstable tumor vasculature provides an aberrant tumor microenvironment and leads to resistance of tumors to conventional therapy. Hence, normalization of tumor vessels has been reported to improve the effect of immuno-, chemo- and radiation therapy. However, the humoral factors, which can effectively induce maturation of tumor vasculature, have not been elucidated. In this study, we found that the novel peptide apelin and its receptor APJ can induce the morphological and functional maturation of blood vessels in tumors. This apelin-induced tumor vascular maturation enhances the efficacy of cancer dendritic cell-based immunotherapy and significantly suppresses tumor growth by promoting the infiltration of invariant natural killer T cells into the central region of the tumor and thereby robustly inducing apoptosis of tumor cells. Additionally, we showed APJ expression to be enhanced in the tumor endothelium in comparison with normal-state endothelial cells. These findings provide a new target for tumor vascular-specific maturation, which is expected to improve the efficacy of conventional cancer therapies. Oncogene (2012) 31, 3254-3264; doi:10.1038/onc.2011.489; published online 31 October 2011	[Kidoya, H.; Naito, H.; Muramatsu, F.; Takakura, N.] Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, Suita, Osaka 5650871, Japan; [Kunii, N.; Okamoto, Y.] Chiba Univ, Grad Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Chiba, Japan; [Kunii, N.; Nakayama, T.] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan	Osaka University; Chiba University; Chiba University	Takakura, N (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	ntakaku@biken.osaka-u.ac.jp	Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007; Naito, Hisamichi/0000-0002-0750-1743	Japan Society for the Promotion of Science (JSPS) and Research [KAKENHI 21890124]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; YASUDA Medical Foundation	Japan Society for the Promotion of Science (JSPS) and Research; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); YASUDA Medical Foundation	We thank Ms C Takeshita, Ms K Fukuhara and Ms N Fujimoto for technical assistance. Financial support: This work was supported by Grant-in-Aid for Research Activity Start-up (KAKENHI 21890124) from the Japan Society for the Promotion of Science (JSPS) and Research; a grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; and the YASUDA Medical Foundation.	Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452; Dai TY, 2006, EUR J PHARMACOL, V553, P222, DOI 10.1016/j.ejphar.2006.09.034; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Dings RPM, 2011, CLIN CANCER RES, V17, P3134, DOI 10.1158/1078-0432.CCR-10-2443; Eyries M, 2008, CIRC RES, V103, P432, DOI 10.1161/CIRCRESAHA.108.179333; Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Gerber HP, 2005, CANCER RES, V65, P671; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635; Kalin RE, 2007, DEV BIOL, V305, P599, DOI 10.1016/j.ydbio.2007.03.004; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kawano T, 1999, CANCER RES, V59, P5102; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kidoya H, 2008, EMBO J, V27, P522, DOI 10.1038/sj.emboj.7601982; Kidoya H, 2010, BLOOD, V115, P3166, DOI 10.1182/blood-2009-07-232306; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kunii N, 2009, CANCER SCI, V100, P1092, DOI 10.1111/j.1349-7006.2009.01135.x; Lago F, 2007, CYTOKINE GROWTH F R, V18, P313, DOI 10.1016/j.cytogfr.2007.04.007; Lambrecht NWG, 2006, PHYSIOL GENOMICS, V25, P153, DOI 10.1152/physiolgenomics.00271.2005; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Motohashi S, 2009, J IMMUNOL, V182, P2492, DOI 10.4049/jimmunol.0800126; Nieda M, 2001, BLOOD, V97, P2067, DOI 10.1182/blood.V97.7.2067; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Seino K, 2005, SPRINGER SEMIN IMMUN, V27, P65, DOI 10.1007/s00281-004-0194-y; Shin T, 2001, INT J CANCER, V91, P523, DOI 10.1002/1097-0215(20010215)91:4<523::AID-IJC1087>3.0.CO;2-L; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Smyth MJ, 2002, BLOOD, V99, P1259, DOI 10.1182/blood.V99.4.1259; Sorli SC, 2007, ONCOGENE, V26, P7692, DOI 10.1038/sj.onc.1210573; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Willett CG, 2006, SEMIN ONCOL, V33, pS35, DOI 10.1053/j.seminoncol.2006.08.007; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004; Yamada Y, 2006, J EXP MED, V203, P1055, DOI 10.1084/jem.20050373	52	56	66	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3254	3264		10.1038/onc.2011.489	http://dx.doi.org/10.1038/onc.2011.489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22037214	Bronze			2022-12-28	WOS:000306113400005
J	Yu, D; Zhan, XH; Zhao, XF; Williams, MS; Carey, GB; Smith, E; Scott, D; Zhu, J; Guo, Y; Cherukuri, S; Civin, CI; Zhan, X				Yu, D.; Zhan, X. H.; Zhao, X. F.; Williams, M. S.; Carey, G. B.; Smith, E.; Scott, D.; Zhu, J.; Guo, Y.; Cherukuri, S.; Civin, C. I.; Zhan, X.			Mice deficient in MIM expression are predisposed to lymphomagenesis	ONCOGENE			English	Article						MIM; I-BAR; chemokine; B cells; lymphoma	MISSING-IN-METASTASIS; SUPPRESSOR 1 MTSS1; B-CELL LYMPHOMA; TUMOR-SUPPRESSOR; STRUCTURAL BASIS; DOWN-REGULATION; BLADDER-CANCER; SONIC HEDGEHOG; ACTIN; GENE	Missing in metastasis (MIM) is a member of newly emerged inverse Bin-Amphiphysin-Rvs (BAR) domain protein family and a putative metastasis suppressor. Although reduced MIM expression has been associated with bladder, breast and gastric cancers, evidence for the role of MIM in tumor progression remains scarce and controversial. Herein we characterized a MIM knockout mouse strain and observed that MIM-deficient mice often developed enlarged spleens. Autopsy and histological analysis revealed that nearly 78% of MIM(-/-) mice developed tumors with features similar to diffuse large B lymphoma during a period from 1 to 2 years. MIM(-/-) mice also exhibited abnormal distribution of B cells in lymphoid organs with decrease in the spleen but increase in the bone marrow and the peripheral blood. Furthermore, the bone marrow of MIM(-/-) mice contained a higher percentage of pre-B2 cells but fewer immature B-cells than wild-type mice. In response to CXCL13, a B-cell chemokine released from splenic stromal cells, MIM-deficient B-cells did not undergo chemotaxis or morphological changes in response to the chemokine and also did not internalize CXCR5, the receptor of CXCL13. Microarray analyses demonstrated that MIM is the only member of the I-BAR domain family that was highly expressed in human B cells. However, low or absent MIM expression was common in either primary B-cell malignancies or established B-cell acute lymphocytic leukemia or lymphomas. Thus, our data demonstrate for the first time an important role for MIM in B-cell development and suggest that predisposition of MIM-null mice to lymphomagenesis may involve aberrant interactions between B lineage cells and the lymphoid microenvironment. Oncogene (2012) 31, 3561-3568; doi:10.1038/onc.2011.509; published online 14 November 2011	[Yu, D.; Zhan, X. H.; Williams, M. S.; Carey, G. B.; Smith, E.; Zhan, X.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA; [Zhao, X. F.; Zhan, X.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Williams, M. S.; Carey, G. B.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; [Scott, D.] Univ Hlth Sci, Res Dept Med Uniformed Serv, Bethesda, MD USA; [Zhu, J.] Nantong Univ, Affiliated Hosp, Dept Gen Surg, Nantong, Peoples R China; [Guo, Y.; Cherukuri, S.; Civin, C. I.] Univ Maryland, Sch Med, Dept Pediat & Physiol, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA; [Zhan, X.] Univ Maryland, Sch Med, Marlene Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Nantong University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Zhan, X (corresponding author), Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, 800 W Baltimore St, Baltimore, MD 21201 USA.	xzhan@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA113809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070823] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA113809-05] Funding Source: Medline; NIAID NIH HHS [R01 AI070823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509; Bodenstine TM, 2008, CANCER MICROENVIRON, V1, P1, DOI 10.1007/s12307-008-0001-8; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Frost A, 2009, CELL, V137, P191, DOI 10.1016/j.cell.2009.04.010; Gallop JL, 2005, BIOCHEM SOC SYMP, V72, P223, DOI 10.1042/bss0720223; Gribben JG, 2010, CURR OPIN ONCOL, V22, P424, DOI 10.1097/CCO.0b013e32833d5938; Karnoub Antoine E, 2006, Breast Dis, V26, P75; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Lindemann RK, 2008, CANCER RES, V68, P961, DOI 10.1158/0008-5472.CAN-07-5500; Lipp M, 2004, NAT IMMUNOL, V5, P12, DOI 10.1038/ni0104-12; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Liu W, 2011, DEVELOPMENT, V138, P2035, DOI 10.1242/dev.058800; Loberg RD, 2005, INT J ONCOL, V26, P1699; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; Martensson IL, 2010, FEBS LETT, V584, P2572, DOI 10.1016/j.febslet.2010.04.057; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Middendorp S, 2009, BLOOD, V114, P2280, DOI 10.1182/blood-2009-03-208215; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Nowee ME, 2007, J PATHOL, V213, P46, DOI 10.1002/path.2217; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Quinones GA, 2010, CELL CYCLE, V9, P2522, DOI 10.4161/cc.9.13.12123; Rolink Antonius G, 2004, Methods Mol Biol, V271, P271; Saarikangas J, 2011, J CELL SCI, V124, P1245, DOI 10.1242/jcs.082610; Scita G, 2008, TRENDS CELL BIOL, V18, P52, DOI 10.1016/j.tcb.2007.12.002; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Su Y, 2008, J IMMUNOL, V181, P1153, DOI 10.4049/jimmunol.181.2.1153; Wang D, 2011, J GASTROINTEST SURG, V15, P1205, DOI 10.1007/s11605-011-1546-2; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Xia S, 2010, DEVELOPMENT, V137, P1075, DOI 10.1242/dev.049437; Yu D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020845; Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370	44	26	27	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3561	3568		10.1038/onc.2011.509	http://dx.doi.org/10.1038/onc.2011.509			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22081072	Green Accepted			2022-12-28	WOS:000306844100008
J	Chen, PH; Chang, H; Chang, JT; Lin, P				Chen, P-H; Chang, H.; Chang, J. T.; Lin, P.			Aryl hydrocarbon receptor in association with RelA modulates IL-6 expression in non-smoking lung cancer	ONCOGENE			English	Article						AhR; NF kappa B; IL-6; non-smokers; lung adeno carcinoma	NF-KAPPA-B; NEVER-SMOKERS; CONSTITUTIVE ACTIVATION; PROSTATE-CANCER; AH RECEPTOR; IN-VIVO; CELLS; OVEREXPRESSION; INTERLEUKIN-6; RISK	Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is activated by cigarette smoke. Previously, we demonstrated that AhR is overexpressed in lung adenocarcinomas (ADs). In this study we observed that AhR expression is significantly correlated with nuclear RelA (a nuclear factor-kappa B (NF kappa B) subunit) and cytosolic interleukin-6 (IL-6) in 200 non-small cell lung cancer patients, especially among never smokers. Overexpression of AhR increased IL-6 expression in H1355 cells and immortalized human bronchial epithelial cells BEAS-2B. As NF kappa B inhibitor and knockdown RelA expression greatly reduced constitutive AhR-induced IL-6 expression, we hypothesized that AhR expression, in the absence of exogenous ligand, is able to modulate NF kappa B activity and subsequently upregulate IL-6 expression, thus promoting the development of lung AD. Specifically, AhR overexpression significantly increased NF kappa B activity, whereas interference with AhR expression significantly reduced NF kappa B activity and IL-6 expression in H1355 cells. We demonstrated that AhR associates with RelA in the cytosol and nucleus of human lung cells. Furthermore, AhR overexpression enhanced nuclear localization of AhR and RelA, and increased the association of AhR-RelA with the NF kappa B response element of the IL-6 promoter. However, p50 was not involved. Our results indicate that AhR, without exposure to a ligand, associates with RelA, which then positively modulates NF kappa B activity and then upregulates IL-6 expression in human lung cells. Thus we have identified a new mechanism for lung tumorigenesis in non-smokers. Oncogene (2012) 31, 2555-2565; doi:10.1038/onc.2011.438; published online 26 September 2011	[Chen, P-H; Chang, J. T.; Lin, P.] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Chen, P-H; Chang, J. T.; Lin, P.] Chung Shan Med Univ, Inst Med & Mol Toxicol, Taichung, Taiwan; [Chen, P-H; Lin, P.] Natl Hlth Res Inst, Div Environm Hlth & Occupat Med, Zhunan 350, Miaoli County, Taiwan; [Chang, H.] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Chang, H.] China Med Univ, Sch Med, Taichung, Taiwan; [Chang, J. T.] Chung Shan Med Univ Hosp, Dept Med Oncol & Chest Med, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; National Health Research Institutes - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital	Chang, JT (corresponding author), Chung Shan Med Univ, Inst Med, 110,Sect 1,Jianguo N Rd, Taichung, Taiwan.	jinghuat@csmu.edu.tw; pplin@nhri.org.tw	Lin, Pinpin/B-2668-2010; Lin, PinPin/A-2006-2019; Chang, Jinghua/AAV-5620-2021	Lin, Pinpin/0000-0001-5459-907X; Lin, PinPin/0000-0001-5459-907X; 	National Health Research Institutes [99A1-EOPP02-014]; National Science Council of Taiwan [NSC 97-2320-B-040-016, NSC 97-2314-B-400-010]	National Health Research Institutes(National Health Research Institutes, Japan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the National Health Research Institutes (99A1-EOPP02-014) and the National Science Council (NSC 97-2320-B-040-016 and NSC 97-2314-B-400-010) of Taiwan.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ando M, 2003, INT J CANCER, V105, P249, DOI 10.1002/ijc.11043; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046; Bryant A, 2007, CHEST, V132, P185, DOI 10.1378/chest.07-0442; Camacho IA, 2005, J IMMUNOL, V175, P90, DOI 10.4049/jimmunol.175.1.90; Carolan BJ, 2008, J IMMUNOL, V181, P5760, DOI 10.4049/jimmunol.181.8.5760; Chang JHT, 2007, CLIN CANCER RES, V13, P38, DOI 10.1158/1078-0432.CCR-06-1166; Chang LW, 2007, CARCINOGENESIS, V28, P1606, DOI 10.1093/carcin/bgm013; Chen CL, 2004, JAMA-J AM MED ASSOC, V292, P2984, DOI 10.1001/jama.292.24.2984; Chen JY, 2005, CARCINOGENESIS, V26, P1035, DOI 10.1093/carcin/bgi052; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen YC, 2004, CANCER-AM CANCER SOC, V101, P1428, DOI 10.1002/cncr.20538; Dalwadi H, 2005, CLIN CANCER RES, V11, P7674, DOI 10.1158/1078-0432.CCR-05-1205; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dietrich C, 2010, CARCINOGENESIS, V31, P1319, DOI 10.1093/carcin/bgq028; Dijsselbloem N, 2004, BIOCHEM PHARMACOL, V68, P1171, DOI 10.1016/j.bcp.2004.05.036; DiNatale BC, 2010, J BIOL CHEM, V285, P24388, DOI 10.1074/jbc.M110.118570; Fukuda I, 2007, BIOCHEM BIOPH RES CO, V359, P822, DOI 10.1016/j.bbrc.2007.05.199; Gao Shu-geng, 2007, Zhonghua Yi Xue Za Zhi, V87, P1701; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Ishida M, 2010, CARCINOGENESIS, V31, P287, DOI 10.1093/carcin/bgp222; Izawa H, 2008, BIOSCI BIOTECH BIOCH, V72, P1235, DOI 10.1271/bbb.70705; Jensen Brenda A, 2003, Environ Health, V2, P16, DOI 10.1186/1476-069X-2-16; Kasai A, 2006, CANCER RES, V66, P7143, DOI 10.1158/0008-5472.CAN-05-4541; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Liaw YP, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-22; Lin PH, 2007, TOXICOL LETT, V172, P146, DOI 10.1016/j.toxlet.2007.06.003; Lin PP, 2003, TOXICOL PATHOL, V31, P22, DOI 10.1080/01926230309746; Lu F, 2008, CANCER PREV RES, V1, P135, DOI 10.1158/1940-6207.CAPR-08-0037; Matsumoto Y, 2007, ENVIRON SCI TECHNOL, V41, P3775, DOI 10.1021/es062793g; Mukai M, 2007, TOXICOL SCI, V95, P172, DOI 10.1093/toxsci/kfl126; Oesch-Bartlomowicz B, 2005, P NATL ACAD SCI USA, V102, P9218, DOI 10.1073/pnas.0503488102; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Peng TL, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-27; Pollenz RS, 2002, CHEM-BIOL INTERACT, V141, P41, DOI 10.1016/S0009-2797(02)00065-0; Puga A, 2000, BIOCHEM PHARMACOL, V59, P997, DOI 10.1016/S0006-2952(99)00406-2; Scagliotti GV, 2009, CURR OPIN ONCOL, V21, P99, DOI 10.1097/CCO.0b013e328321049e; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Shimba S, 2002, J BIOCHEM, V132, P795, DOI 10.1093/oxfordjournals.jbchem.a003289; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Su JM, 2009, ANTICANCER RES, V29, P509; Subramanian J, 2007, J THORAC ONCOL, V2, P827, DOI 10.1097/JTO.0b013e318145af79; Tan XL, 2009, CLIN CANCER RES, V15, P7562, DOI 10.1158/1078-0432.CCR-09-1694; Thun MJ, 2008, PLOS MED, V5, P1357, DOI 10.1371/journal.pmed.0050185; Tian YA, 2009, BIOCHEM PHARMACOL, V77, P670, DOI 10.1016/j.bcp.2008.10.023; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Tse LA, 2009, AM J EPIDEMIOL, V169, P533, DOI 10.1093/aje/kwn385; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; Wang CK, 2009, INT J CANCER, V125, P807, DOI 10.1002/ijc.24348; Wang XR, 2009, CANCER CAUSE CONTROL, V20, P757, DOI 10.1007/s10552-008-9289-4; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Yu ITS, 2006, CANCER RES, V66, P4961, DOI 10.1158/0008-5472.CAN-05-2932; Zerbini LF, 2003, CANCER RES, V63, P2206	57	41	44	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2555	2565		10.1038/onc.2011.438	http://dx.doi.org/10.1038/onc.2011.438			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996739				2022-12-28	WOS:000304191800006
J	Ward, PS; Cross, JR; Lu, C; Weigert, O; Abel-Wahab, O; Levine, RL; Weinstock, DM; Sharp, KA; Thompson, CB				Ward, P. S.; Cross, J. R.; Lu, C.; Weigert, O.; Abel-Wahab, O.; Levine, R. L.; Weinstock, D. M.; Sharp, K. A.; Thompson, C. B.			Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production	ONCOGENE			English	Article						IDH1; IDH2; 2-hydroxyglutarate; oncometabolite; NADPH	ACUTE MYELOID-LEUKEMIA; HIGH-GRADE GLIOMAS; ISOCITRATE; MECHANISM; DISEASE	Mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) or its mitochondrial homolog IDH2 can lead to R(-)-2-hydroxyglutarate (2HG) production. To date, mutations in three active site arginine residues, IDH1 R132, IDH2 R172 and IDH2 R140, have been shown to result in the neomorphic production of 2HG. Here we report on three additional 2HG-producing IDH1 mutations: IDH1 R100, which is affected in adult glioma, IDH1 G97, which is mutated in colon cancer cell lines and pediatric glioblastoma, and IDH1 Y139. All these new mutants stereospecifically produced 2HG's (R) enantiomer. In contrast, we find that the IDH1 SNPs V71I and V178I, as well as a number of other single-sample reports of IDH non-synonymous mutation, did not elevate cellular 2HG levels in cells and retained the wild-type ability for isocitrate-dependent NADPH production. Finally, we report the existence of additional rare, but recurring mutations found in lymphoma and thyroid cancer, which while failing to elevate 2HG nonetheless displayed loss of function, indicating a possible tumorigenic mechanism for a non-2HG-producing subset of IDH mutations in some malignancies. These data broaden our understanding of how IDH mutations may contribute to cancer through either neomorphic R(-)-2HG production or reduced wildtype enzymatic activity, and highlight the potential value of metabolite screening in identifying IDH-mutated tumors associated with elevated oncometabolite levels. Oncogene (2012) 31, 2491-2498; doi: 10.1038/onc.2011.416; published online 26 September 2011	[Ward, P. S.; Cross, J. R.; Lu, C.; Thompson, C. B.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Ward, P. S.; Lu, C.] Univ Penn, Abramson Canc Ctr, Dept Canc Biol, Philadelphia, PA 19104 USA; [Weigert, O.; Weinstock, D. M.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Abel-Wahab, O.; Levine, R. L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Abel-Wahab, O.; Levine, R. L.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10065 USA; [Sharp, K. A.] Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Pennsylvania	Thompson, CB (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Room M110, New York, NY 10065 USA.	thompsonc@mskcc.org	levine, ross/AAE-7658-2019; Lu, Chao/E-8047-2012; Ward, Patrick/H-2361-2014	Ward, Patrick/0000-0001-6437-8174; Abdel-Wahab, Omar/0000-0002-3907-6171; Lu, Chao/0000-0003-0982-8122; Cross, Justin/0000-0002-6356-057X	NCI; NIH; HHMI; Stand Up To Cancer Innovative Research Grant; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA092660, R01CA105463] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HHMI(Howard Hughes Medical Institute); Stand Up To Cancer Innovative Research Grant; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by grants from the NCI and NIH. RL Levine is a HHMI Early Career Award Recipient and Geoffrey Beene Junior Faculty Chair at MSKCC. DM Weinstock is supported by a Stand Up To Cancer Innovative Research Grant and American Cancer Society Research Scholar Grant.	Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Bleeker FE, 2009, HUM MUTAT, V30, P7, DOI 10.1002/humu.20937; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DeLano W., 2006, PYMOL MOL GRAPHICS S; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Hemerly JP, 2010, EUR J ENDOCRINOL, V163, P747, DOI 10.1530/EJE-10-0473; Ho PA, 2010, LEUKEMIA, V24, P909, DOI 10.1038/leu.2010.56; Jin GL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016812; KAMERLING JP, 1981, J CHROMATOGR, V222, P276, DOI 10.1016/S0378-4347(00)81061-0; Kranendijk M, 2010, SCIENCE, V330, P336, DOI 10.1126/science.1192632; Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Paugh BS, 2010, J CLIN ONCOL, V28, P3061, DOI 10.1200/JCO.2009.26.7252; Pusch S, 2011, NEUROPATH APPL NEURO, V37, P428, DOI 10.1111/j.1365-2990.2010.01127.x; Rakheja D, 2011, PEDIATR BLOOD CANCER, V56, P379, DOI 10.1002/pbc.22697; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zou Y, 2010, BIOCHEM BIOPH RES CO, V402, P378, DOI 10.1016/j.bbrc.2010.10.038	27	144	150	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	19					2491	2498		10.1038/onc.2011.416	http://dx.doi.org/10.1038/onc.2011.416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996744	Green Accepted			2022-12-28	WOS:000303985300011
J	Arwert, EN; Mentink, RA; Driskell, RR; Hoste, E; Goldie, SJ; Quist, S; Watt, FM				Arwert, E. N.; Mentink, R. A.; Driskell, R. R.; Hoste, E.; Goldie, S. J.; Quist, S.; Watt, F. M.			Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation	ONCOGENE			English	Article						epidermis; MEK1; IL-1 alpha; CD26; dipeptidyl peptidase-4; Sitagliptin	DIPEPTIDYL-PEPTIDASE-IV; ENZYME-ACTIVITY; EPIDERMAL-CELLS; STEM-CELLS; KERATINOCYTES; INHIBITION; DIFFERENTIATION; PROLIFERATION; GLYCOSYLATION; SITAGLIPTIN	We have previously described InvEE transgenic mice in which non-dividing, differentiating epidermal cells express oncogenically activated MAPK kinase 1 (MEK1). Skin wounding triggers tumour formation in InvEE mice via a mechanism that involves epidermal release of IL-1 alpha and attraction of a pro-tumorigenic inflammatory infiltrate. To look for potential effects on the underlying connective tissue, we screened InvEE and wild-type epidermis for differential expression of cytokines and immune modulators. We identified a single protein, CD26 (dipeptidyl peptidase-4). CD26 serum levels were not increased in InvEE mice. In contrast, CD26 was upregulated in keratinocytes expressing mutant MEK1 and in the epithelial compartment of InvEE tumours, where it accumulated at cell-cell borders. CD26 expression was increased in dermal fibroblasts following skin wounding but was downregulated in tumour stroma. CD26 activity was stimulated by calcium-induced intercellular adhesion in keratinocytes, suggesting that the upregulation of CD26 in InvEE epidermis is due to expansion of the differentiated cell layers. IL-1 alpha treatment of dermal fibroblasts stimulated CD26 activity, and therefore epidermal IL-1 alpha release may contribute to the upregulation of CD26 expression in wounded dermis. Pharmacological blockade of CD26, via Sitagliptin, reduced growth of InvEE tumours, while combined inhibition of IL-1 alpha and CD26 delayed tumour onset and reduced tumour incidence. Our results demonstrate that inappropriate activation of MEK1 in the epidermis leads to changes in dermal fibroblasts that, like the skin inflammatory infiltrate, contribute to tumour formation. Oncogene (2012) 31, 992-1000; doi:10.1038/onc.2011.298; published online 18 July 2011	[Arwert, E. N.; Mentink, R. A.; Hoste, E.; Goldie, S. J.; Quist, S.; Watt, F. M.] Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Cambridge CB2 0RE, Cambs, England; [Driskell, R. R.; Watt, F. M.] Wellcome Trust Ctr Stem Cell Res, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Watt, FM (corresponding author), Li Ka Shing Ctr, Canc Res UK Cambridge Res Inst, Robinson Way, Cambridge CB2 0RE, Cambs, England.	Fiona.watt@cancer.org.uk	Quist, Sven R/G-2052-2013; Hoste, Esther/M-9926-2014; Hoste, Esther/AAG-2218-2020; Watt, Fiona/AHB-0226-2022; Quist, Sven R/C-9102-2017	Quist, Sven R/0000-0002-9548-7813; Hoste, Esther/0000-0002-3181-431X; Hoste, Esther/0000-0002-3181-431X; Watt, Fiona/0000-0001-9151-5154; Quist, Sven R/0000-0002-9548-7813; Driskell, Ryan/0000-0001-7673-2564; Arwert, Esther/0000-0001-7475-9704; Mentink, Remco/0000-0003-1005-7767	Cancer Research UK; Dutch Cancer Society; Wellcome Trust; MRC; European Union; Hutchison Whampoa; Cambridge University; Medical Research Council [G0701336, G1100073] Funding Source: researchfish; MRC [G0701336, G1100073] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Dutch Cancer Society(KWF Kankerbestrijding); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Hutchison Whampoa; Cambridge University(University of Cambridge); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Donna Michelle Smith for performing SG chromatography. We acknowledge support from Cancer Research UK, the Dutch Cancer Society (to RM), the Wellcome Trust, the MRC, the European Union, Hutchison Whampoa and Cambridge University.	Aertgeerts K, 2004, PROTEIN SCI, V13, P145, DOI 10.1110/ps.03352504; Ansorge S, 2009, CLIN CHEM LAB MED, V47, P253, DOI 10.1515/CCLM.2009.063; Arwert EN, 2010, P NATL ACAD SCI USA, V107, P19903, DOI 10.1073/pnas.1007404107; Cordero OJ, 2009, CANCER IMMUNOL IMMUN, V58, P1725, DOI 10.1007/s00262-009-0728-1; Deacon CF, 2007, EXPERT OPIN INV DRUG, V16, P533, DOI 10.1517/13543784.16.4.533; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Fan H, 1997, EUR J BIOCHEM, V246, P243, DOI 10.1111/j.1432-1033.1997.00243.x; Hobbs RM, 2004, J INVEST DERMATOL, V123, P503, DOI 10.1111/j.0022-202X.2004.23225.x; Iwata S, 1999, J EXP MED, V190, P301, DOI 10.1084/jem.190.3.301; Jackson EK, 2008, HYPERTENSION, V51, P1637, DOI 10.1161/HYPERTENSIONAHA.108.112532; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817; Karlsson L, 1999, DEVELOPMENT, V126, P2611; Kim D, 2005, J MED CHEM, V48, P141, DOI 10.1021/jm0493156; KOHL A, 1991, AGENTS ACTIONS, V32, P125, DOI 10.1007/BF01983337; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380; Lindsay JR, 2005, DIABETIC MED, V22, P654, DOI 10.1111/j.1464-5491.2005.01461.x; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Nemoto E, 1999, INFECT IMMUN, V67, P6225; Novelli M, 1996, BRIT J DERMATOL, V134, P1052, DOI 10.1046/j.1365-2133.1996.d01-900.x; Ohnuma K, 2008, TRENDS IMMUNOL, V29, P295, DOI 10.1016/j.it.2008.02.010; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Pereira DA, 2003, BRAZ J MED BIOL RES, V36, P567, DOI 10.1590/S0100-879X2003000500003; Reinhold D, 1998, FEBS LETT, V428, P100, DOI 10.1016/S0014-5793(98)00502-X; Romero MR, 1999, EXP DERMATOL, V8, P53, DOI 10.1111/j.1600-0625.1999.tb00348.x; Ta NN, 2010, ATHEROSCLEROSIS, V213, P429, DOI 10.1016/j.atherosclerosis.2010.08.064; Takasawa W, 2010, BIOCHEM BIOPH RES CO, V401, P7, DOI 10.1016/j.bbrc.2010.08.112; VIVIER I, 1991, J IMMUNOL, V147, P447; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Willheim M, 1997, J ALLERGY CLIN IMMUN, V100, P348, DOI 10.1016/S0091-6749(97)70248-3	31	32	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					992	1000		10.1038/onc.2011.298	http://dx.doi.org/10.1038/onc.2011.298			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765471				2022-12-28	WOS:000300709700005
J	Gamble, LD; Kees, UR; Tweddle, DA; Lunec, J				Gamble, L. D.; Kees, U. R.; Tweddle, D. A.; Lunec, J.			MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63	ONCOGENE			English	Article						MYCN; neuroblastoma; MDM2-p53 antagonists; apoptosis; growth inhibition	DIRECT TRANSCRIPTIONAL TARGET; P53 GENE-MUTATIONS; N-MYC; P53-DEPENDENT APOPTOSIS; IN-VIVO; P53/MDM2/P14(ARF) PATHWAY; G(1) ARREST; DNA-DAMAGE; CELL-DEATH; AMPLIFICATION	MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN has contradictory roles in promoting cell growth and sensitizing cells to apoptosis. We have recently shown that p53 is a direct transcriptional target of MYCN in neuroblastoma and that p53-mediated apoptosis may be an important mechanism of MYCN-induced apoptosis. Although p53 mutations are rare in neuroblastoma at diagnosis, the p53/MDM2/p14(ARF) pathway is often inactivated through MDM2 amplification or p14(ARF) inactivation. We hypothesized that reactivation of p53 by inhibition of its negative regulator MDM2, using the MDM2-p53 antagonists Nutlin-3 and MI-63, will result in p53-mediated growth arrest and apoptosis especially in MYCN-amplified cells. Using the SHEP Tet21N MYCN-regulatable system, MYCN(-) cells were more resistant to both Nutlin-3 and MI-63 mediated growth inhibition and apoptosis compared with MYCN(+) cells and siRNA-mediated knockdown of MYCN in four MYCN-amplified cell lines resulted in decreased p53 expression and activation, as well as decreased levels of apoptosis following treatment with MDM2-p53 antagonists. In a panel of 18 neuroblastoma cell lines treated with Nutlin-3 and MI-63, the subset amplified for MYCN had a significantly lower mean GI(50) value (50% growth inhibition) and increased caspase 3/7 activity compared with the non-MYCN-amplified group of cell lines, but p53 mutant cell lines were resistant to the antagonists regardless of MYCN status. We conclude that amplification or overexpression of MYCN sensitizes neuroblastoma cell lines with wild-type p53 to MDM2-p53 antagonists and that these compounds may therefore be particularly effective in treating high-risk MYCN-amplified disease. Oncogene (2012) 31, 752-763; doi:10.1038/onc.2011.270; published online 4 July 2011	[Lunec, J.] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Kees, U. R.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia	Newcastle University - UK; Telethon Kids Institute; University of Western Australia	Lunec, J (corresponding author), Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Canc Ctr, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	John.Lunec@newcastle.ac.uk		Gamble, Laura D./0000-0001-8496-9705; Lunec, John/0000-0002-1878-8583	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank the following for cell lines: Sue Cohn (NBLW and NBLS), Linda Harris (SJNB1), Penny Lovat (SHSY5Y, SHEP and IMR32), John Maris (NB69), Patrick Reynolds (SKNRA, SMSKCNR, LAN5, LAN6 and CHLA136), Manfred Schwab (LS and SHEP Tet21N), Rogier Versteeg (NGP), Barbara Spengler (SKNBe2C), Micro Ponzoni (GIMEN), Ursula Kees (PER108), Maria Lastowska (TR14), Clinton Stewart (NB1691) and Jean Benard (SKNAS, IGRN91). We are grateful to Mike Cole (Newcastle Cancer Centre, Newcastle University) for his statistical advice and to Cancer Research UK for funding this work. This study is supported by Cancer Research UK.	Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Amente S, 2007, FEBS LETT, V581, P821, DOI 10.1016/j.febslet.2007.01.062; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Bell E, 2006, CELL CYCLE, V5, P2639, DOI 10.4161/cc.5.22.3443; Canner JA, 2009, BRIT J CANCER, V101, P774, DOI 10.1038/sj.bjc.6605199; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Carr-Wilkinson J, 2010, CLIN CANCER RES, V16, P1108, DOI 10.1158/1078-0432.CCR-09-1865; Chen LD, 2010, CANCER RES, V70, P1377, DOI 10.1158/0008-5472.CAN-09-2598; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Cohn SL, 2004, EUR J CANCER, V40, P2639, DOI 10.1016/j.ejca.2004.07.025; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; CORVI R, 1995, ONCOGENE, V10, P1081; Demidenko ZN, 2010, P NATL ACAD SCI USA, V107, P9660, DOI 10.1073/pnas.1002298107; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; Fulda S, 2000, MED PEDIATR ONCOL, V35, P582, DOI 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Korotchkina LG, 2010, AGING-US, V2, P344, DOI 10.18632/aging.100160; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Michalak E, 2005, BIOCHEM BIOPH RES CO, V331, P786, DOI 10.1016/j.bbrc.2005.03.183; Muller CR, 2007, INT J CANCER, V121, P199, DOI 10.1002/ijc.22643; Petroni M, 2011, MOL CANCER RES, V9, P67, DOI 10.1158/1541-7786.MCR-10-0227; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Slack A, 2005, CELL CYCLE, V4, P857, DOI 10.4161/cc.4.7.1790; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Van Maerken T, 2011, MOL CANCER THER, V10, P983, DOI 10.1158/1535-7163.MCT-10-1090; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; van Noesel MM, 2003, CANCER LETT, V197, P165, DOI 10.1016/S0304-3835(03)00101-0; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VOGAN K, 1993, CANCER RES, V53, P5269; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					752	763		10.1038/onc.2011.270	http://dx.doi.org/10.1038/onc.2011.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725357	Green Accepted, Bronze			2022-12-28	WOS:000300222100008
J	Law, EWL; Cheung, AKL; Kashuba, VI; Pavlova, TV; Zabarovsky, ER; Lung, HL; Cheng, Y; Chua, D; Kwong, DLW; Tsao, SW; Sasaki, T; Stanbridge, EJ; Lung, ML				Law, E. W. L.; Cheung, A. K. L.; Kashuba, V. I.; Pavlova, T. V.; Zabarovsky, E. R.; Lung, H. L.; Cheng, Y.; Chua, D.; Kwong, D. Lai-wan; Tsao, S. W.; Sasaki, T.; Stanbridge, E. J.; Lung, M. L.			Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma	ONCOGENE			English	Article						anti-angiogenic; fibulin-2; nasopharyngeal carcinoma; tumor suppressor; VEGF; methylation	EXTRACELLULAR-MATRIX PROTEIN; CHROMOSOME 3P21.3; COPY NUMBER; EXPRESSION; BREAST; CANCER; IDENTIFICATION; PROGRESSION; METASTASIS; ESOPHAGEAL	Fibulin-2 (FBLN2) has been identified as a candidate tumor-suppressor gene in nasopharyngeal carcinoma (NPC). Originally identified through a chromosome 3 NotI genomic microarray screen, it shows frequent deletion or methylation in NPC. FBLN2 is located on chromosome 3p25.1 and is associated with tumor development through its important interactions with the extracellular matrix (ECM) proteins. FBLN2 encodes two isoforms. The short isoform (FBLN2S) is expressed abundantly in normal tissues, but is dramatically downregulated in NPC, while the long isoform (FBLN2L) is either not detectable or is expressed only at low levels in both normal and tumor tissues. Reintroduction of this FBLN2S inhibited cell proliferation, migration, invasion and angiogenesis in vitro. Furthermore, in vivo studies in nude mice show its expression is associated with tumor and angiogenesis suppression. FBLN2-associated angiogenesis occurs via concomitant downregulation of vascular endothelial growth factor and matrix metalloproteinase 2. This study provides compelling evidence that FBLN2S has an important tumor-suppressive and anti-angiogenic role in NPC. Oncogene (2012) 31, 728-738; doi:10.1038/onc.2011.272; published online 11 July 2011	[Law, E. W. L.; Cheung, A. K. L.; Lung, H. L.; Cheng, Y.; Chua, D.; Kwong, D. Lai-wan; Lung, M. L.] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Law, E. W. L.; Cheung, A. K. L.; Lung, H. L.; Cheng, Y.; Chua, D.; Kwong, D. Lai-wan; Lung, M. L.] Univ Hong Kong, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China; [Kashuba, V. I.; Pavlova, T. V.; Zabarovsky, E. R.] Karolinska Inst, Dept Clin Sci & Educ, Dept Microbiol Tumor & Cell Biol, Sodersjukhuset, Stockholm, Sweden; [Zabarovsky, E. R.] Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Struct & Funct Genom, Moscow, Russia; [Chua, D.] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Happy Valley, Hong Kong, Peoples R China; [Tsao, S. W.] Univ Hong Kong, Dept Anat, Pokfulam, Hong Kong, Peoples R China; [Sasaki, T.] Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr Mol Med, Dept Expt Med 1, D-91054 Erlangen, Germany; [Stanbridge, E. J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of Hong Kong; University of Hong Kong; Karolinska Institutet; Sodersjukhuset Hospital; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Hong Kong; University of Erlangen Nuremberg; University of California System; University of California Irvine	Lung, ML (corresponding author), Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China.	mlilung@hku.hk	Cheung, Arthur Kwok Leung/H-8940-2013; Zabarovsky, Eugene R/A-6645-2010; Kashuba, Vladimir I/N-3732-2017; Kashuba, Vladimir/AAO-7742-2020; Cheng, Yue/E-9853-2010; Lung, Maria Li/C-4495-2009	Kashuba, Vladimir I/0000-0001-9416-8282; Cheng, Yue/0000-0002-2472-1879; Cheung, Arthur Kwok Leung/0000-0001-5446-2209; Pavlova, Tatiana/0000-0002-2857-5696; Lung, Maria Li/0000-0003-2559-3626	University Grants Council [AoE/M-06/08]; Swedish Cancer Society; Swedish Research Council; Swedish Institute; Karolinska Institute	University Grants Council; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Institute; Karolinska Institute(Karolinska Institutet)	This work was supported by University Grants Council Area of Excellence grant AoE/M-06/08 to MLL and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute, and Karolinska Institute to ERZ.	Chattopadhyay I, 2010, MUTAT RES-GEN TOX EN, V696, P130, DOI 10.1016/j.mrgentox.2010.01.001; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheung AKL, 2008, CANCER RES, V68, P8137, DOI 10.1158/0008-5472.CAN-08-0904; Cheung AKL, 2009, P NATL ACAD SCI USA, V106, P14478, DOI 10.1073/pnas.0900198106; de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6; Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752; Fassler R, 1996, EXP CELL RES, V222, P111, DOI 10.1006/excr.1996.0014; Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001; Grassel S, 1999, EUR J BIOCHEM, V263, P471, DOI 10.1046/j.1432-1327.1999.00523.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li JF, 2002, P NATL ACAD SCI USA, V99, P10724, DOI 10.1073/pnas.132271699; Libra M, 2009, INT J ONCOL, V34, P897, DOI 10.3892/ijo_00000215; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Lung HL, 2010, INT J CANCER, V127, P304, DOI 10.1002/ijc.25047; MCDONNELL S, 1990, CANCER METAST REV, V9, P305; Mutirangura A, 1997, BRIT J CANCER, V76, P770, DOI 10.1038/bjc.1997.460; Nakao M, 2011, ONCOL REP, V25, P1603, DOI 10.3892/or.2011.1246; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PFAFF M, 1995, EXP CELL RES, V219, P87, DOI 10.1006/excr.1995.1208; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Senchenko VN, 2004, ONCOGENE, V23, P5719, DOI 10.1038/sj.onc.1207760; Strom A, 2006, CARDIOVASC RES, V69, P755, DOI 10.1016/j.cardiores.2005.12.001; Tsuda T, 2001, DEV DYNAM, V222, P89, DOI 10.1002/dvdy.1172; Wu Y, 2010, J THROMB HAEMOST, V8, P185, DOI 10.1111/j.1538-7836.2009.03662.x; Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232; Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007; ZHANG HY, 1995, DEV BIOL, V167, P18, DOI 10.1006/dbio.1995.1003	32	72	75	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					728	738		10.1038/onc.2011.272	http://dx.doi.org/10.1038/onc.2011.272			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21743496				2022-12-28	WOS:000300222100006
J	Thomas, M; Lange-Grunweller, K; Weirauch, U; Gutsch, D; Aigner, A; Grunweller, A; Hartmann, RK				Thomas, M.; Lange-Gruenweller, K.; Weirauch, U.; Gutsch, D.; Aigner, A.; Gruenweller, A.; Hartmann, R. K.			The proto-oncogene Pim-1 is a target of miR-33a	ONCOGENE			English	Article						Pim-1; microRNA; miR-33a; proliferation; RNAi; siRNA	PROSTATE-CANCER CELLS; C-MYC; PROTEIN-KINASE; MICRORNAS; PHOSPHORYLATION; GENES; RNA; AKT; APOPTOSIS; GROWTH	The constitutively active serine/threonine kinase Pim-1 is upregulated in different cancer types, mainly based on the action of several interleukines and growth factors at the transcriptional level. So far, a regulation of oncogenic Pim-1 by microRNAs (miRNAs) has not been reported. Here, we newly establish miR-33a as a miRNA with potential tumor suppressor activity, acting through inhibition of Pim-1. A screen for miRNA expression in K562 lymphoma, LS174T colon carcinoma and several other cell lines revealed generally low endogenous miR33a levels relative to other miRNAs. Transfection of K562 and LS174T cells with a miR-33a mimic reduced Pim-1 levels substantially. In contrast, the cell-cycle regulator cyclin-dependent kinase 6 predicted to be a conserved miR-33a target, was not downregulated by the miR-33a mimic. Seed mutagenesis of the Pim-1 30-untranslated region in a luciferase reporter construct and in a Pim-1 cDNA expressed in Pim-1-deficient Skov-3 cells demonstrated specific and direct downregulation of Pim-1 by the miR-33a mimic. The persistence of this effect was comparable to that of a small interfering RNA-mediated knockdown of Pim-1, resulting in decelerated cell proliferation. In conclusion, we demonstrate the potential of miR-33a to act as a tumor suppressor miRNA, which suggests miR-33a replacement therapy through delivery of miR mimics as a novel therapeutic strategy. Oncogene (2012) 31, 918-928; doi: 10.1038/onc.2011.278; published online 11 July 2011	[Gruenweller, A.] Univ Marburg, Inst Pharmaceut Chem, Fac Pharm, AG Hartmann, D-35037 Marburg, Germany; [Weirauch, U.; Gutsch, D.; Aigner, A.] Univ Marburg, Inst Pharmacol, Fac Med, D-35037 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Grunweller, A (corresponding author), Univ Marburg, Inst Pharmaceut Chem, Fac Pharm, AG Hartmann, Marbacher Weg 6, D-35037 Marburg, Germany.	arnold.gruenweller@staff.uni-marburg.de; roland.hartmann@staff.uni-marburg.de	Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256	Fritz Thyssen Stiftung [10.06.1.186]; Deutsche Krebshilfe [109260, 106992]; DFG Forschergruppe Nanohale [AI 24/6-1]	Fritz Thyssen Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); DFG Forschergruppe Nanohale(German Research Foundation (DFG))	We thank Robert Prinz, Dorothee Hartmann, Dennis Streng, Meike Thomas and Heide Marika Genau for technical support. This study was supported by the Fritz Thyssen Stiftung (reference no. 10.06.1.186 to AG and RKH), the Deutsche Krebshilfe (reference no. 109260 to AG, RKH and AA, and reference no. 106992 to AA) and DFG Forschergruppe Nanohale (AI 24/6-1).	Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Bachmann M, 2004, J BIOL CHEM, V279, P48319, DOI 10.1074/jbc.M404440200; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Brault L, 2010, HAEMATOL-HEMATOL J, V95, P1004, DOI 10.3324/haematol.2009.017079; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Crowell JA, 2007, MOL CANCER THER, V6, P2139, DOI 10.1158/1535-7163.MCT-07-0120; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Grunweller A, 2003, NUCLEIC ACIDS RES, V31, P3185, DOI 10.1093/nar/gkg409; Herrera-Merchan A, 2010, CELL CYCLE, V9, P3277, DOI 10.4161/cc.9.16.12598; Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Martelli AM, 2007, CURR MED CHEM, V14, P2009; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; Muraski JA, 2007, NAT MED, V13, P1467, DOI 10.1038/nm1671; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang HW, 2009, NAT STRUCT MOL BIOL, V16, P1148, DOI 10.1038/nsmb.1673; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Xia ZP, 2009, J MED CHEM, V52, P74, DOI 10.1021/jm800937p; Xie Y, 2006, ONCOGENE, V25, P70, DOI 10.1038/sj.onc.1209058; Yang ZZ, 2004, BIOCHEM SOC T, V32, P350, DOI 10.1042/BST0320350; Zhang T, 2010, J SURG ONCOL, V101, P513, DOI 10.1002/jso.21524; ZHANG W, 1993, CANCER RES, V53, P4772; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	58	99	102	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					918	928		10.1038/onc.2011.278	http://dx.doi.org/10.1038/onc.2011.278			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743487				2022-12-28	WOS:000300615800010
J	Verhaegen, M; Checinska, A; Riblett, MB; Wang, S; Soengas, MS				Verhaegen, M.; Checinska, A.; Riblett, M. B.; Wang, S.; Soengas, M. S.			E2F1-dependent oncogenic addiction of melanoma cells to MDM2	ONCOGENE			English	Article						melanoma; senescence; oncogene dependency; MDM-2 inhibitors	TUMOR-SUPPRESSOR; P53 ACTIVATION; E3 LIGASE; APOPTOSIS; PROTEIN; DEGRADATION; INHIBITOR; EXPRESSION; UBIQUITINATION; INACTIVATION	One of the defining features of aggressive melanomas is their complexity. Hundreds of mutations and an ever increasing list of changes in the transcriptome and proteome distinguish normal from malignant melanocytic cells. Yet, despite this altered genetic background, a long-known attribute of melanomas is a relatively low rate of mutations in the p53 gene. However, it is unclear whether p53 is maintained in melanoma cells because it is required for their survival, or because it is functionally disabled. More pressing from a translational perspective, is to define whether there is a tumor cell-selective wiring of p53 that offers a window for therapeutic intervention. Here, we provide genetic and pharmacological evidence demonstrating that p53 represents a liability to melanoma cells, which they thwart by assuming an oncogenic dependency on the E3 ligase murine double minute-2 (MDM2). Specifically, we used a combination of RNA interference and two structurally independent small molecule inhibitors of the p53-MDM2 interaction to assess the relative requirement of both proteins for the viability of normal melanocytes and a broad panel of melanoma cell lines. We demonstrated in vitro and in vivo that MDM2 is selectively required to blunt latent pro-senescence signals in melanoma cells. Notably, the outcome of MDM2 inactivation depends not only on the mutational status of p53, but also on its ability to signal to the transcription factor E2F1. These data support MDM2 as a drug target in melanoma cells, and identify E2F1 as a biomarker to consider when stratifying putative candidates for clinical studies of p53-MDM2 inhibitors. Oncogene (2012) 31, 828-841; doi: 10.1038/onc.2011.277; published online 11 July 2011	[Checinska, A.; Soengas, M. S.] Spanish Natl Canc Res Ctr, Melanoma Lab, Mol Pathol Programme, CNIO, Madrid 28049, Spain; [Verhaegen, M.; Riblett, M. B.] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI USA; [Verhaegen, M.; Riblett, M. B.; Wang, S.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI USA; [Wang, S.] Univ Michigan, Dept Internal Med & Pharmacol, Ann Arbor, MI 48109 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Soengas, MS (corresponding author), Spanish Natl Canc Res Ctr, Melanoma Lab, Mol Pathol Programme, CNIO, Melchor Fernandez Almagro 3, Madrid 28049, Spain.	msoengas@cnio.es	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Wang, Shaomeng/0000-0002-8782-6950	NIH [R01CA107237]; Spanish Ministry of Science and Innovation [SAF2008-01950]; Spanish Association Against Cancer (AECC); Dermatology Foundation;  [R01CA121279]; NATIONAL CANCER INSTITUTE [R01CA121279, R01CA107237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Association Against Cancer (AECC); Dermatology Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Joshua A Bauer, J Chadwick Brenner and Thomas E Carey for shRNA constructs against p53 and MDM2, Andrzej Dlugosz for support and Mikhail Nikiforov for helpful suggestions at early stages of this study. MSS was supported by R01CA107237 from the NIH, SAF2008-01950 from the Spanish Ministry of Science and Innovation, and a development grant from the Spanish Association Against Cancer (AECC). SW was funded by R01CA121279 and MV is the recipient of a Career Development Award from the Dermatology Foundation.	Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P27, DOI 10.1111/j.1755-148X.2007.00433.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hoek KS, 2007, PIGM CELL RES, V20, P466, DOI 10.1111/j.1600-0749.2007.00412.x; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang BY, 2009, MOL CANCER RES, V7, P1497, DOI 10.1158/1541-7786.MCR-09-0144; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kass EM, 2009, CELL CYCLE, V8, P430, DOI 10.4161/cc.8.3.7624; Korotchkina LG, 2009, CELL CYCLE, V8, P3777, DOI 10.4161/cc.8.22.10121; Kumamoto K, 2008, CANCER RES, V68, P3193, DOI 10.1158/0008-5472.CAN-07-2780; Long JT, 2010, BLOOD, V116, P71, DOI 10.1182/blood-2010-01-261628; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moran DM, 2010, MOL CANCER THER, V9, P895, DOI 10.1158/1535-7163.MCT-09-1220; Murga M, 2009, NAT GENET, V41, P891, DOI 10.1038/ng.420; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shen H, 2008, CANCER RES, V68, P8260, DOI 10.1158/0008-5472.CAN-08-1901; Smalley KSM, 2007, CANCER RES, V67, P209, DOI 10.1158/0008-5472.CAN-06-1538; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Terzian T, 2010, PIGM CELL MELANOMA R, V23, P781, DOI 10.1111/j.1755-148X.2010.00773.x; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Verma R, 2010, BIOCHEM PHARMACOL, V79, P565, DOI 10.1016/j.bcp.2009.09.020; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	50	23	24	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					828	841		10.1038/onc.2011.277	http://dx.doi.org/10.1038/onc.2011.277			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743494	Green Accepted, Green Submitted			2022-12-28	WOS:000300615800003
J	Wang, Y; Lazo, JS				Wang, Y.; Lazo, J. S.			Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion	ONCOGENE			English	Article						PRL-2; lung cancer; cell invasion; ERK	PROTEIN-TYROSINE-PHOSPHATASE; PANCREATIC-CANCER CELLS; REGENERATING LIVER-3; COLORECTAL-CANCER; BREAST-CANCER; LUNG-CANCER; EXPRESSION; PROMOTES; MOTILITY; PROGNOSIS	The phosphatase of regenerating liver (PRL) family, comprising PRL-1, PRL-2 and PRL-3, is a group of prenylated phosphatases that are candidate cancer biomarkers and therapeutic targets. Although several studies have documented that altered expression of PRL-1 or PRL-3 can influence cell proliferation, migration and invasion, there is a dearth of knowledge about the biological functions of PRL-2. Thus, in the current study we have evaluated the role of PRL-2 in cell migration and invasion in human cancer cells. We found that four human lung cancer cells, including A549 cells, overexpress PRL-2 when compared with normal lung cells. PRL-2 knockdown by RNA interference markedly inhibited cell migration and invasion, and this inhibition can be restored by overexpressing the short interference RNA (siRNA)resistant vector HA-PRL-2m. PRL-2 suppression by siRNA decreased p130Cas and vinculin expression, and decreased extracellular signal-regulated kinase (ERK) phosphorylation, while increasing the phosphorylation of ezrin on tyrosine 146. We found no significant changes in total p53, Akt and c-Src expression levels or their phosphorylation status, suggesting that PRL-2 knockdown could inhibit tumor cell migration and invasion through a Src-independent p130Cas signaling pathway. Ectopic expression of wild-type PRL-2, a catalytic inactive C101S mutant and a C-terminal CAAX deletion revealed a requirement for both the PRL-2 catalytic functionality and prenylation site. Expression of wild-type but not mutant forms of PRL-2 caused ERK phosphorylation and nuclear translocation. These results support a model in which PRL-2 promotes cell migration and invasion through an ERK-dependent signaling pathway. Oncogene (2012) 31, 818-827; doi: 10.1038/onc.2011.281; published online 18 July 2011	[Wang, Y.; Lazo, J. S.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Virginia, Dept Pharmacol, POB 800793, Charlottesville, VA 22908 USA.	lazo@virginia.edu			National Institutes of Health National Cancer Institute [CA78039]; Fiske Drug Discovery Fund; NATIONAL CANCER INSTITUTE [P01CA078039] Funding Source: NIH RePORTER	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fiske Drug Discovery Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the National Institutes of Health National Cancer Institute (CA78039) and the Fiske Drug Discovery Fund.	Achiwa H, 2007, CANCER RES, V67, P643, DOI 10.1158/0008-5472.CAN-06-2436; Basak S, 2008, MOL CELL, V30, P303, DOI 10.1016/j.molcel.2008.04.002; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116; Forte E, 2008, BBA-MOL CELL RES, V1783, P334, DOI 10.1016/j.bbamcr.2007.11.004; Guo K, 2004, CANCER BIOL THER, V3, P945, DOI 10.4161/cbt.3.10.1111; Han HY, 2002, CANCER RES, V62, P2890; Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041; Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485; Kim W, 2004, J BIOL CHEM, V279, P8333, DOI 10.1074/jbc.M312026200; Li ZR, 2007, SURG TODAY, V37, P646, DOI 10.1007/s00595-006-3437-9; Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200; Luo Y, 2009, BIOCHEMISTRY-US, V48, P1838, DOI 10.1021/bi8020789; Min SH, 2009, ONCOGENE, V28, P545, DOI 10.1038/onc.2008.409; Ming J, 2009, PATHOLOGY, V41, P118, DOI 10.1080/00313020802579268; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Peng LR, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-110; Peng LR, 2004, J CANCER RES CLIN, V130, P521, DOI 10.1007/s00432-004-0563-x; Radke I, 2006, BRIT J CANCER, V95, P347, DOI 10.1038/sj.bjc.6603261; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248; Stephens B, 2008, MOL CANCER THER, V7, P202, DOI 10.1158/1535-7163.MCT-07-0542; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang J, 2002, J BIOL CHEM, V277, P46659, DOI 10.1074/jbc.M206407200; Wang L, 2006, ANN ONCOL, V17, P1517, DOI 10.1093/annonc/mdl159; Wang Q, 2002, CANCER LETT, V175, P63, DOI 10.1016/S0304-3835(01)00703-0; Wang Y, 2007, INT J COLORECTAL DIS, V22, P1179, DOI 10.1007/s00384-007-0303-1; Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7; Yagi T, 2003, BLOOD, V102, P1849, DOI 10.1182/blood-2003-02-0578; Zamir E, 2001, J CELL SCI, V114, P3583; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zeng Q, 2003, CANCER RES, V63, P2716	34	29	31	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					818	827		10.1038/onc.2011.281	http://dx.doi.org/10.1038/onc.2011.281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21765462	Green Accepted			2022-12-28	WOS:000300615800002
J	Bruno, RD; Boulanger, CA; Smith, GH				Bruno, R. D.; Boulanger, C. A.; Smith, G. H.			Notch-induced mammary tumorigenesis does not involve the lobule-limited epithelial progenitor	ONCOGENE			English	Article						lobular progenitor; PI-MEC; Int3; Notch4; mammary development	TUMOR VIRUS; PROGESTERONE-RECEPTOR; CELLS; STEM; DIFFERENTIATION; EXPRESSION; INT-3; GENE	The mouse mammary epithelial cell hierarchy contains both multipotent stem cell as well as lineage-limited duct and lobular progenitor cell functions. The latter-also termed parity-identified mammary epithelial cells (PI-MECs)-are marked by beta-galactosidase (beta Gal) expression following pregnancy and involution in whey acidic protein promoter (WAP)-Cre/Rosa26-flox-stop-flox-lacZ (WC/R26) mice, and are the targets of tumorigenic transformation in mouse mammary tumor virus-erbB2 transgenic mice. In this study, we demonstrate that an epithelial population distinct from PI-MECs is transformed during WAP-Int3 tumorigenesis. As expected, WAP-Int3/WC/R26 triple-transgenic mice failed to undergo secretory alveolar development, failed to lactate and developed mammary tumors. Following pregnancy and involution, beta Gal+ mammary epithelial cells were found in the normal mammary tissue, but the resulting mammary tumors were all beta Gal-. WAP-Int3/WC/R26 mammary glands contained ample estrogen receptor alpha (ER alpha)+ MECs, but only rare (<1%) progesterone receptor (PR)+ and RANKL+ cells. In addition, dissociated MECs from WAP-Int3/WC/R26 glands failed to regenerate a mammary tree upon transplantation into a cleared fat-pad of a nu/nu recipient mouse. However, when mixed with normal MECs, PI-MECs from WAP-Int3/WC/R26 mice contributed progeny to the resulting functional outgrowth. The WAP-Int3/WC/R26-derived PI-MECs displayed all of the properties of fully functional lobular progenitors including giving rise to ER alpha+, PR+, smooth muscle actin+ and RANKL+ epithelial progeny. These results demonstrate that WAP-Int3 has no oncogenic effect upon PI-MECs and that the expansion of functional lobular progenitors is required for secretory alveolar development and lactation. Furthermore, lobular progenitor function is ultimately controlled by signals within its microenvironment. Oncogene (2012) 31, 60-67; doi: 10.1038/onc.2011.215; published online 13 June 2011	[Smith, G. H.] NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Smith, GH (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 1112B, Bethesda, MD 20892 USA.	smithg@mail.nih.gov		Bruno, Robert/0000-0003-3329-9478	NCI's Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010021] Funding Source: NIH RePORTER	NCI's Center for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The NCI's Center for Cancer Research Intramural Research Program funded this work.	Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; Booth BW, 2008, P NATL ACAD SCI USA, V105, P14891, DOI 10.1073/pnas.0803214105; Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Boulanger CA, 2007, P NATL ACAD SCI USA, V104, P3871, DOI 10.1073/pnas.0611637104; Brisken C, 1998, P NATL ACAD SCI USA, V95, P5076, DOI 10.1073/pnas.95.9.5076; Bruno RD, 2011, STEM CELL REV REP, V7, P238, DOI 10.1007/s12015-010-9191-9; Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Mukherjee A, 2010, FASEB J, V24, P4408, DOI 10.1096/fj.10-157982; Raafat A, 2009, ONCOGENE, V28, P219, DOI 10.1038/onc.2008.379; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323	23	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					60	67		10.1038/onc.2011.215	http://dx.doi.org/10.1038/onc.2011.215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666720	Green Accepted			2022-12-28	WOS:000299176200006
J	Colas, E; Muinelo-Romay, L; Alonso-Alconada, L; Llaurado, M; Monge, M; Barbazan, J; Gonzalez, M; Schoumacher, M; Pedrola, N; Ertekin, T; Devis, L; Ruiz, A; Castellvi, J; Doll, A; Gil-Moreno, A; Vazquez-Levin, M; Lapyckyj, L; Lopez-Lopez, R; Robine, S; Friederich, E; Castro, M; Reventos, J; Vignjevic, D; Abal, M				Colas, E.; Muinelo-Romay, L.; Alonso-Alconada, L.; Llaurado, M.; Monge, M.; Barbazan, J.; Gonzalez, M.; Schoumacher, M.; Pedrola, N.; Ertekin, T.; Devis, L.; Ruiz, A.; Castellvi, J.; Doll, A.; Gil-Moreno, A.; Vazquez-Levin, M.; Lapyckyj, L.; Lopez-Lopez, R.; Robine, S.; Friederich, E.; Castro, M.; Reventos, J.; Vignjevic, D.; Abal, M.			ETV5 cooperates with LPP as a sensor of extracellular signals and promotes EMT in endometrial carcinomas	ONCOGENE			English	Article						ETV5; EMT; LPP; carcinoma invasion; endometrial cancer	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR; MYOMETRIAL INFILTRATION; CELL-ADHESION; UP-REGULATION; CANCER; FIBROBLASTS; PROGRESSION; EXPRESSION; INITIATION	Endometrial carcinoma (EC) is the most frequent among infiltrating tumors of the female genital tract, with myometrial invasion representing an increase in the rate of recurrences and a decrease in survival. We have previously described ETV5 transcription factor associated with myometrial infiltration in human ECs. In this work, we further investigated ETV5 orchestrating downstream effects to confer the tumor the invasive capabilities needed to disseminate in the early stages of EC dissemination. Molecular profiling evidenced ETV5 having a direct role on epithelial-to-mesenchymal transition (EMT). In particular, ETV5 modulated Zeb1 expression and E-Cadherin repression leading to a complete reorganization of cell-cell and cell-substrate contacts. ETV5-promoted EMT resulted in the acquisition of migratory and invasive capabilities in endometrial cell lines. Furthermore, we identified the lipoma-preferred partner protein as a regulatory partner of ETV5, acting as a sensor for extracellular signals promoting tumor invasion. All together, we propose ETV5-transcriptional regulation of the EMT process through a crosstalk with the tumor surrounding microenvironment, as a principal event initiating EC invasion.	[Muinelo-Romay, L.; Alonso-Alconada, L.; Barbazan, J.; Lopez-Lopez, R.; Abal, M.] Complexo Hosp Univ Santiago SERGAS, Dept Med Oncol, Translat Lab, Santiago De Compostela 15706, Spain; [Colas, E.; Llaurado, M.; Monge, M.; Gonzalez, M.; Pedrola, N.; Ertekin, T.; Devis, L.; Ruiz, A.; Doll, A.; Reventos, J.; Abal, M.] Vall dHebron Univ Hosp, Res Inst, Biomed Res Unit, Barcelona, Spain; [Schoumacher, M.; Robine, S.; Vignjevic, D.] Inst Curie, CNRS, UMR 144, F-75231 Paris, France; [Castellvi, J.] Vall dHebron Univ Hosp, Dept Gynecol Oncol, Barcelona, Spain; [Gil-Moreno, A.] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Vazquez-Levin, M.; Lapyckyj, L.] Consejo Nacl Invest Cient & Tecn, Natl Res Council Argentina, Inst Biol & Med Expt, RA-1033 Buenos Aires, DF, Argentina; [Friederich, E.] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg; [Castro, M.] Univ Santiago de Compostela, Dept Pharmacol, BioFarma Res Grp, Santiago De Compostela, Spain; [Colas, E.; Gil-Moreno, A.; Reventos, J.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Complexo Hospitalario Universitario de Santiago de Compostela; Hospital Universitari Vall d'Hebron; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Luxembourg; Universidade de Santiago de Compostela; Autonomous University of Barcelona	Abal, M (corresponding author), Complexo Hosp Univ Santiago SERGAS, Dept Med Oncol, Translat Lab, Trav Choupana S-N, Santiago De Compostela 15706, Spain.	miguel.abal.posada@sergas.es	Gil-Moreno, Antonio/C-1122-2016; Monge, Marta/I-3667-2015; Castellvi, Josep/C-5092-2014; vignjevic, Danijela Matic/R-5160-2019; Vignjevic, Danijela/L-9721-2017; Doll, Andreas/I-1449-2012; Barbazán, Jorge/AAM-3263-2020; Castro, Marián/K-5747-2014; Jauregui, Laura Devis/ABH-5740-2020	Gil-Moreno, Antonio/0000-0003-1106-5590; Monge, Marta/0000-0002-9839-4903; Castellvi, Josep/0000-0001-5745-9996; vignjevic, Danijela Matic/0000-0003-4250-703X; Barbazán, Jorge/0000-0002-7165-8497; Castro, Marián/0000-0002-4732-1966; Lopez Lopez, Rafael/0000-0003-1315-655X; Doll, Andreas/0000-0001-8965-8682; Devis-Jauregui, Laura/0000-0003-3736-3983; Abal Posada, Miguel/0000-0003-3533-7781	Spanish Ministry of Science and Innovation [SAF 2005-06771, SAF 2008-03996]; Spanish Ministry of Health [RTICC RD06/0020/0058, CP08/00142, PI08/0797]; European Commission Program Fondo Europeo de Desarrollo Regional (FEDER); Catalan Institute of Health [DURSI 2005SGR00553]; Fundacio La Marato de TV3 [050431]; ACCIO [RDITSCON07-1-0001]; AECC; National Programme of Biotecnology [FIT-010000-2007-26]; Basque Government (Spain); Spanish Ministry of Education and Science	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); European Commission Program Fondo Europeo de Desarrollo Regional (FEDER); Catalan Institute of Health; Fundacio La Marato de TV3; ACCIO; AECC; National Programme of Biotecnology; Basque Government (Spain)(Basque Government); Spanish Ministry of Education and Science(Spanish Government)	This work was supported by the Spanish Ministry of Science and Innovation (SAF 2005-06771; SAF 2008-03996), Spanish Ministry of Health (RTICC RD06/0020/0058; CP08/00142, PI08/0797), European Commission Program Fondo Europeo de Desarrollo Regional (FEDER), Catalan Institute of Health (DURSI 2005SGR00553), Fundacio La Marato de TV3 (grant 050431), ACCIO (RDITSCON07-1-0001), AECC (Grupos Estables de Investigacion 2011) and National Programme of Biotecnology (FIT-010000-2007-26). LAA and JB are recipients of fellowships from the Basque Government (Spain) and the Spanish Ministry of Education and Science, respectively.	Abal M, 2007, CLIN TRANSL ONCOL, V9, P272, DOI 10.1007/s12094-007-0054-z; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chacon MR, 2011, CELL ADHES MIGR, V5, P52, DOI 10.4161/cam.5.1.13681; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Eo J, 2008, J ENDOCRINOL, V198, P281, DOI 10.1677/JOE-08-0142; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Guo BQ, 2006, MOL CELL BIOL, V26, P4529, DOI 10.1128/MCB.01667-05; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hurt EM, 2008, MOL CELL BIOCHEM, V318, P89, DOI 10.1007/s11010-008-9860-z; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Llaurado M, 2012, INT J CANCER, V130, P1532, DOI 10.1002/ijc.26148; Monge M, 2007, CANCER RES, V67, P6753, DOI 10.1158/0008-5472.CAN-06-4487; Monge M, 2009, J PROTEOME RES, V8, P4676, DOI 10.1021/pr900390t; Monge M, 2009, CARCINOGENESIS, V30, P1288, DOI 10.1093/carcin/bgp119; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Muinelo-Romay L, 2011, MOL CANCER THER, V10, P1357, DOI 10.1158/1535-7163.MCT-10-1019; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Petit MMR, 2003, J BIOL CHEM, V278, P2157, DOI 10.1074/jbc.M206106200; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Planaguma J, 2005, J PATHOL, V207, P422, DOI 10.1002/path.1853; Prat J, 2004, HUM PATHOL, V35, P649, DOI 10.1016/j.humpath.2004.02.007; Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sivridis E, 2001, ANTICANCER RES, V21, P4383; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Swart GWM, 2005, CANCER METAST REV, V24, P223, DOI 10.1007/s10555-005-1573-0; Tavora B, 2010, EMBO MOL MED, V2, P516, DOI 10.1002/emmm.201000106; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2004, NAT MED, V10, P777, DOI 10.1038/nm0804-777; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tsukamoto H, 2007, CLIN EXP METASTAS, V24, P423, DOI 10.1007/s10585-007-9079-5; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	43	33	34	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4778	4788		10.1038/onc.2011.632	http://dx.doi.org/10.1038/onc.2011.632			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266854	Green Published			2022-12-28	WOS:000311033000006
J	Petrelli, A; Perra, A; Schernhuber, K; Cargnelutti, M; Salvi, A; Migliore, C; Ghiso, E; Benetti, A; Barlati, S; Ledda-Columbano, GM; Portolani, N; De Petro, G; Columbano, A; Giordano, S				Petrelli, A.; Perra, A.; Schernhuber, K.; Cargnelutti, M.; Salvi, A.; Migliore, C.; Ghiso, E.; Benetti, A.; Barlati, S.; Ledda-Columbano, G. M.; Portolani, N.; De Petro, G.; Columbano, A.; Giordano, S.			Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression	ONCOGENE			English	Article						miRNA; HCC; animal model; PLK1; hepatocarcinogenesis	HUMAN HEPATOCELLULAR-CARCINOMA; MICRORNA EXPRESSION PROFILES; AGGRESSIVE LIVER-CANCER; POLO-LIKE KINASES; GENE-EXPRESSION; CELLS; IDENTIFICATION; MODEL; CARCINOGENESIS; MICROARRAY	MicroRNAs (miRNAs) have an important role in a wide range of physiological and pathological processes, and their dysregulation has been reported to affect the development and progression of cancers, including hepatocellular carcinoma (HCC). However, in the plethora of dysregulated miRNAs, it is largely unknown which of them have a causative role in the hepatocarcinogenic process. In the present study, we first aimed to determine changes in the expression profile of miRNAs in human HCCs and to compare them with liver tumors generated in a rat model of chemically induced HCC. We found that members of the miR-100 family (miR-100, miR-99a) were downregulated in human HCCs; a similar downregulation was also observed in rat HCCs. Their reduction was paralleled by an increased expression of polo like kinase 1 (PLK1), a target of these miRNAs. The introduction of miR-100 in HCC cells impaired their growth ability and their capability to form colonies in soft agar. Next, we aimed at investigating, in the same animal model, if dysregulation of miR-100 and PLK1 is an early or late event along the multistep process of hepatocarcinogenesis. The obtained results showed that miR-100 downregulation (i) is already evident in very early preneoplastic lesions generated 9 weeks after carcinogenic treatment; (ii) is also observed in adenomas and early HCCs; and (iii) is not simply a marker of proliferating hepatocytes. To our knowledge, this is the first work unveiling the role of a miRNA family along HCC progression. Oncogene (2012) 31, 4517-4526; doi:10.1038/onc.2011.631; published online 16 January 2012	[Petrelli, A.; Schernhuber, K.; Cargnelutti, M.; Migliore, C.; Ghiso, E.; Giordano, S.] Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, Turin, Italy; [Perra, A.; Ledda-Columbano, G. M.; Columbano, A.] Univ Cagliari, Dept Toxicol, Unit Oncol & Mol Pathol, Cagliari, Italy; [Salvi, A.; Barlati, S.; De Petro, G.] Univ Brescia, Sch Med, Div Biol & Genet, Dept Biomed Sci & Biotechnol, Brescia, Italy; [Benetti, A.] Univ Brescia, Sch Med, Dept Pathol, Brescia, Italy; [Portolani, N.] Univ Brescia, Sch Med, Surg Clin, Dept Med & Surg Sci, Brescia, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Cagliari; University of Brescia; University of Brescia; University of Brescia	Petrelli, A (corresponding author), Inst Canc Res & Treatment, Div Mol Oncol, SP 142km 3-9, I-10060 Candiolo, TO, Italy.	annalisa.petrelli@ircc.it; columbano@unica.it; silvia.giordano@unito.it	Columbano, Amedeo/C-7463-2011; Salvi, Alessandro/AAB-7896-2019; De Petro, Giuseppina/C-2719-2011; Giordano, Silvia/J-9858-2018	Columbano, Amedeo/0000-0002-6956-9030; Salvi, Alessandro/0000-0001-6993-1565; De Petro, Giuseppina/0000-0001-9306-0851; Giordano, Silvia/0000-0003-1854-1086; Migliore, Cristina/0000-0003-3722-2814	Associazione Italiana per la Ricerca sul Cancro (AIRC); Regione Piemonte; MIUR	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Regione Piemonte(Regione Piemonte); MIUR(Ministry of Education, Universities and Research (MIUR))	We thank L Tamagnone, S Corso, MM Angioni and our colleagues for helpful discussions; C Manca for the preparation of rat samples and C Isella for statistical analysis; L Palmas for technical assistance. Work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC grants to SG, AC), Regione Piemonte (grant to SG) and MIUR (grants to SG, AC, GMLC, GDP).	Andersen JB, 2010, HEPATOLOGY, V51, P1401, DOI 10.1002/hep.23488; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; De Petro G, 1998, CANCER RES, V58, P2234; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; ENOMOTO K, 1982, CANCER RES, V42, P2330; Fu LM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-3; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Imbeaud S, 2010, SEMIN LIVER DIS, V30, P75, DOI 10.1055/s-0030-1247134; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Leite KR, 2009, UROL ONCOL, V29, P265; Liu W, 2009, CHINESE MED J-PEKING, V122, P2405, DOI 10.3760/cma.j.issn.0366-6999.2009.20.002; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Oneyama C, 2011, ONCOGENE, V30, P3489, DOI 10.1038/onc.2011.63; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pellegrino R, 2010, HEPATOLOGY, V51, P857, DOI 10.1002/hep.23467; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SOLT DB, 1977, AM J PATHOL, V88, P595; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Tarantino C, 2010, FASEB J, V24, P3255, DOI 10.1096/fj.09-152207; Thorgeirsson SS, 2011, J HEPATOL, V55, P486, DOI 10.1016/j.jhep.2011.01.042; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666	33	63	66	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	42					4517	4526		10.1038/onc.2011.631	http://dx.doi.org/10.1038/onc.2011.631			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22249248	Green Submitted			2022-12-28	WOS:000309982100003
J	Yoshida, Y; Ninomiya, K; Hamada, H; Noda, M				Yoshida, Y.; Ninomiya, K.; Hamada, H.; Noda, M.			Involvement of the SKP2-p27(KIP1) pathway in suppression of cancer cell proliferation by RECK	ONCOGENE			English	Article						RECK; cell cycle; extracellular matrix; SKP2; p27; collagen	GENE-EXPRESSION SIGNATURE; REGULATOR RECK; IN-VIVO; PROTEIN; SKP2; INHIBITOR; P27; METALLOPROTEINASE; CLASSIFICATION; ACCUMULATION	The membrane-anchored matrix metalloproteinase-regulator RECK is often downregulated in cancers; in some cases, a significant correlation between the level of residual RECK in resected tumors and patient survival has been noted. Furthermore, restoration of RECK expression in certain cancer-derived cell lines results in reduced tumorigenicity. Here we report that acute RECK expression in colon carcinoma cells results in cell cycle-arrest accompanied by downregulation of a ubiquitin ligase component, S-phase kinase-associated protein 2 (SKP2), and upregulation of its substrate, p27(KIP1). Our data indicate that RECK-induced growth suppression is at least partially dependent on p27, and that RECK and type I collagen share similar effects on the SKP2-p27 pathway. Importantly, in patients with lung, colorectal and bladder cancers, the RECK/SKP2 ratio is high in normal tissues and lower in the cancer tissues. These findings reveal a novel molecular pathway linking cell-cycle progression to RECK downregulation, extracellular matrix degradation and SKP2 upregulation, and suggest that treatment regimens that induce RECK expression could be promising cancer therapies. Oncogene (2012) 31, 4128-4138; doi:10.1038/onc.2011.570; published online 12 December 2011	[Yoshida, Y.; Ninomiya, K.; Noda, M.] Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; [Yoshida, Y.; Ninomiya, K.; Noda, M.] Kyoto Univ, Global COE Program, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; [Hamada, H.] Tokyo Univ Pharm & Life Sci, Dept Life Sci, Lab Oncol, Tokyo, Japan	Kyoto University; Kyoto University; Tokyo University of Pharmacy & Life Sciences	Noda, M (corresponding author), Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	mnoda@virus.kyoto-u.ac.jp			JSPS; MEXT	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Chiaki Takahashi for the RECK cDNA, Mako Yamamoto for R1B2-6 cells, Hitoshi Kitayama and Tomoko Matsuzaki for discussions, David Alexander for critical reading of the manuscript, Hai-Ou Gu and Aiko Nishimoto for technical assistance and Aki Miyazaki for secretarial assistance. This work was supported by JSPS Grant-in-Aid for Creative Scientific Research and MEXT Grant-in-Aid on Priority Areas.	Bond M, 2008, CARDIOVASC RES, V80, P290, DOI 10.1093/cvr/cvn188; Caswell PT, 2009, NAT REV MOL CELL BIO, V10, P843, DOI 10.1038/nrm2799; Chandana EPS, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-84; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Freshney R.I., 1987, CULTURE ANIMAL CELLS, P117; Fu Y, 2007, J CELL BIOCHEM, V102, P704, DOI 10.1002/jcb.21323; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hatta M, 2009, CELL SIGNAL, V21, P1885, DOI 10.1016/j.cellsig.2009.08.005; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kondo S, 2007, J CELL SCI, V120, P849, DOI 10.1242/jcs.03388; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23; Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Murai R, 2010, ONCOTARGET, V1, P252; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Omura A, 2009, J BIOL CHEM, V284, P3461, DOI 10.1074/jbc.M806212200; Prifti E, 2008, BIOINFORMATICS, V24, P2636, DOI 10.1093/bioinformatics/btn492; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Yoshida Y, 1997, BIOCHEM BIOPH RES CO, V230, P426, DOI 10.1006/bbrc.1996.5975; Zhang H, 2003, HEPATOLOGY, V38, P305, DOI 10.1053/jhep.2003.50345; Zhu L, 2010, CELL RES, V20, P605, DOI 10.1038/cr.2010.71	40	26	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4128	4138		10.1038/onc.2011.570	http://dx.doi.org/10.1038/onc.2011.570			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158033				2022-12-28	WOS:000308688900005
J	Anastas, JN; Biechele, TL; Robitaille, M; Muster, J; Allison, KH; Angers, S; Moon, RT				Anastas, J. N.; Biechele, T. L.; Robitaille, M.; Muster, J.; Allison, K. H.; Angers, S.; Moon, R. T.			A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression	ONCOGENE			English	Article						SCRIB; NOS1AP; VANGL1; migration; PCP	NITRIC-OXIDE SYNTHASE; NEURAL-TUBE DEFECTS; EXTENSION MOVEMENTS; E-CADHERIN; LOCALIZATION; INTERACTS; ADHESION; PATHWAY; CAPON; DEGRADATION	By analyzing public data sets of gene expression in human breast cancers we observed that increased levels of transcripts encoding the planar cell polarity (PCP) proteins SCRIB and VANGL1 correlate with increased risk of patient relapse. Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays. To investigate SCRIB-associated proteins that might participate in the responses of breast cancer cells to altered levels of SCRIB, we used mass spectrometry and confocal microscopy. These studies reveal that SCRIB is present in at least two unique protein complexes: (1) a complex of SCRIB, ARHGEF, GIT and PAK (p21-activated kinase), and (2) a complex of SCRIB, NOS1AP and VANGL. Focusing on NOS1AP, we observed that NOS1AP colocalizes with both SCRIB and VANGL1 along cellular protrusions in metastatic breast cancer cells, but does not colocalize with either SCRIB or VANGL1 at cell junctions in normal breast cells. We investigated the effects of shRNA-mediated knockdown of NOS1AP and SCRIB in vitro, and found that reducing NOS1AP and SCRIB slows breast cancer cell migration and prevents the establishment of leading-trailing polarity. We also find that reduction of NOS1AP enhances anchorage-independent growth. Collectively these data point to the relevance of NOS1AP and SCRIB protein complexes in breast cancer. Oncogene (2012) 31, 3696-3708; doi:10.1038/onc.2011.528; published online 19 December 2011	[Anastas, J. N.; Biechele, T. L.; Muster, J.; Moon, R. T.] Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA; [Anastas, J. N.] Univ Washington, Sch Med, Mol & Cellular Biol Grad Program, Seattle, WA 98109 USA; [Biechele, T. L.; Muster, J.; Moon, R. T.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98109 USA; [Biechele, T. L.; Muster, J.; Moon, R. T.] Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98109 USA; [Robitaille, M.; Angers, S.] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada; [Robitaille, M.; Angers, S.] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Allison, K. H.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Toronto; University of Toronto; University of Washington; University of Washington Seattle	Moon, RT (corresponding author), Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Campus Box 358056,815 Mercer St,Room S524, Seattle, WA 98109 USA.	rtmoon@uw.edu	Moon, Randall T/B-1743-2014; Robitaille, Melanie/ABA-5861-2020; Angers, Stephane/E-1432-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Robitaille, Melanie/0000-0001-9354-5162; Angers, Stephane/0000-0001-7241-9044; Moon, Randall/0000-0002-9352-1408; Muster, Jeanot/0000-0002-1972-6851	US Department of Defense Breast Cancer Research Award [W81XWH-070100367]; Canadian Breast Cancer Foundation-Ontario Region	US Department of Defense Breast Cancer Research Award; Canadian Breast Cancer Foundation-Ontario Region	Funding for this research was provided by the US Department of Defense Breast Cancer Research Award (Grant W81XWH-070100367). RTM is an investigator of the Howard Hughes Medical Institute. MR holds a postdoctoral fellowship from the Canadian Breast Cancer Foundation-Ontario Region. Special thanks to Allison Adams for providing the GFP viruses, and Ron Steifert and the Lynn and Mike Garvey Imaging Center for their assistance.	Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Carrel D, 2009, J NEUROSCI, V29, P8248, DOI 10.1523/JNEUROSCI.5287-08.2009; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Courbard JR, 2009, DEV BIOL, V333, P67, DOI 10.1016/j.ydbio.2009.06.024; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Ivanov AI, 2010, AM J PATHOL, V176, P134, DOI 10.2353/ajpath.2010.090220; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Metais JY, 2005, FEBS LETT, V579, P3725, DOI 10.1016/j.febslet.2005.05.062; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Moreau MM, 2010, J NEUROSCI, V30, P9738, DOI 10.1523/JNEUROSCI.6007-09.2010; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Petit MMR, 2005, FEBS LETT, V579, P5061, DOI 10.1016/j.febslet.2005.08.012; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Richier L, 2010, J NEUROSCI, V30, P4796, DOI 10.1523/JNEUROSCI.3726-09.2010; Vervenne HBVK, 2008, DEV BIOL, V320, P267, DOI 10.1016/j.ydbio.2008.05.529; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	34	84	84	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3696	3708		10.1038/onc.2011.528	http://dx.doi.org/10.1038/onc.2011.528			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22179838	Green Published, hybrid			2022-12-28	WOS:000307653800004
J	Huang, Z; Cheng, Y; Chiu, PM; Cheung, FMF; Nicholls, JM; Kwong, DLW; Lee, AWM; Zabarovsky, ER; Stanbridge, EJ; Lung, HL; Lung, ML				Huang, Z.; Cheng, Y.; Chiu, P. M.; Cheung, F. M. F.; Nicholls, J. M.; Kwong, D. L-W; Lee, A. W. M.; Zabarovsky, E. R.; Stanbridge, E. J.; Lung, H. L.; Lung, M. L.			Tumor suppressor Alpha B-crystallin (CRYAB) associates with the cadherin/catenin adherens junction and impairs NPC progression-associated properties	ONCOGENE			English	Article						Alpha B-crystallin; nasopharyngeal carcinoma; E-cadherin; beta-catenin	EPSTEIN-BARR-VIRUS; NASOPHARYNGEAL EPITHELIAL-CELLS; LYMPH-NODE METASTASIS; DOWN-REGULATION; MESENCHYMAL TRANSITIONS; MOLECULAR-MECHANISMS; DECREASED EXPRESSION; GENE-EXPRESSION; BETA-CATENIN; CARCINOMA	Alpha B-crystallin (CRYAB) maps within the nasopharyngeal carcinoma (NPC) tumor-suppressive critical region 11q22-23 and its downregulation is significantly associated with the progression of NPC. However, little is known about the functional impact of CRYAB on NPC progression. In this study we evaluated the NPC tumor-suppressive and progression-associated functions of CRYAB. Activation of CRYAB suppressed NPC tumor formation in nude mice. Overexpression of CRYAB affected NPC progression-associated phenotypes such as loss of cell adhesion, invasion, interaction with the tumor microenvironment, invasive protrusion formation in three dimensional Matrigel culture, as well as expression of epithelial-mesenchymal transition-associated markers. CRYAB mediates this ability to suppress cancer progression by inhibition of E-cadherin cytoplasmic internalization and maintenance of beta-catenin in the membrane that subsequently reduces the levels of expression of critical downstream targets such as cyclin-D1 and c-myc. Both ectopically expressed and recombinant CRYAB proteins were associated with endogenous E-cadherin and beta-catenin, and, thus, the cadherin/catenin adherens junction. The CRYAB alpha-crystallin core domain is responsible for the interaction of CRYAB with both E-cadherin and beta-catenin. Taken together, these results indicate that CRYAB functions to suppress NPC progression by associating with the cadherin/catenin adherens junction and modulating the beta-catenin function. Oncogene (2012) 31, 3709-3720; doi:10.1038/onc.2011.529; published online 12 December 2011	[Huang, Z.; Cheng, Y.; Chiu, P. M.; Kwong, D. L-W; Lung, H. L.; Lung, M. L.] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Cheung, F. M. F.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Pathol, Hong Kong, Peoples R China; [Nicholls, J. M.] Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China; [Lee, A. W. M.] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Hong Kong, Peoples R China; [Huang, Z.; Cheng, Y.; Chiu, P. M.; Kwong, D. L-W; Lung, H. L.; Lung, M. L.] Univ Hong Kong, Ctr Canc Res, Hong Kong, Peoples R China; Karolinska Inst, Dept Microbiol,Tumor & Cell Biol, Stockholm, Sweden; [Zabarovsky, E. R.] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden; [Zabarovsky, E. R.] Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Struct & Funct Genom, Moscow, Russia; [Stanbridge, E. J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; University of Hong Kong; Karolinska Institutet; Karolinska Institutet; Sodersjukhuset Hospital; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of California System; University of California Irvine	Lung, HL (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room L2-23,2-F Lab Block,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	hllung2@hku.hk; mlilung@hku.hk	Lung, Maria Li/C-4495-2009; Nicholls, John Malcolm/C-4375-2009; /E-9853-2010	Lung, Maria Li/0000-0003-2559-3626; Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-2472-1879	Research Grants Council; University Grants Council of Hong Kong Special Administrative Region, People's Republic of China [AoE/M-06/08]; University of Hong Kong Seed Funding Programme for Basic Research; Swedish Cancer Society; Swedish Research Council; Swedish Institute; Karolinska Institute	Research Grants Council(Hong Kong Research Grants Council); University Grants Council of Hong Kong Special Administrative Region, People's Republic of China; University of Hong Kong Seed Funding Programme for Basic Research(University of Hong Kong); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Institute; Karolinska Institute(Karolinska Institutet)	We thank Patrick Vicart for the pcDNA3-CRYAB construct. We acknowledge the funding support from the Research Grants Council grants, and the University Grants Council of Hong Kong Special Administrative Region, People's Republic of China, for AoE/M-06/08 to MLL; The University of Hong Kong Seed Funding Programme for Basic Research to HLL; and the Swedish Cancer Society, the Swedish Research Council, the Swedish Institute and Karolinska Institute to ERZ. We acknowledge the Area of Excellence Hong Kong NPC Research Tissue Bank for the NPC specimens and tissue blocks.	Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Chetty R, 2008, ADV ANAT PATHOL, V15, P234, DOI 10.1097/PAP.0b013e31817bf566; Cheung AKL, 2009, P NATL ACAD SCI USA, V106, P14478, DOI 10.1073/pnas.0900198106; Cheung ST, 1999, INT J CANCER, V83, P121, DOI 10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Ghosh JG, 2007, INT J BIOCHEM CELL B, V39, P1804, DOI 10.1016/j.biocel.2007.04.027; Ghosh JG, 2007, BIOCHEMISTRY-US, V46, P6308, DOI 10.1021/bi700149h; Green KJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000125; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hui ABY, 1996, CANCER RES, V56, P3225; Kong QL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000940; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Leung ACC, 2008, INT J CANCER, V122, P587, DOI 10.1002/ijc.23144; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin JC, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-105; Lo AKF, 2003, LAB INVEST, V83, P697, DOI 10.1097/01.LAB.0000067480.44925.10; Lo KW, 2000, CANCER RES, V60, P3348; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2008, INT J CANCER, V122, P1288, DOI 10.1002/ijc.23259; Lung HL, 2006, CANCER RES, V66, P9385, DOI 10.1158/0008-5472.CAN-06-0590; Lung HL, 2010, INT J CANCER, V127, P304, DOI 10.1002/ijc.25047; Maddala R, 2005, EXP CELL RES, V306, P203, DOI 10.1016/j.yexcr.2005.01.026; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Ohto-Fujita E, 2007, CELL STRESS CHAPERON, V12, P163, DOI 10.1379/CSC-255.1; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Simon S, 2007, J BIOL CHEM, V282, P34276, DOI 10.1074/jbc.M703267200; Solares CA, 2010, OTOLARYNG HEAD NECK, V142, pS15, DOI 10.1016/j.otohns.2009.12.001; Stronach EA, 2003, CANCER RES, V63, P8648; Takashi M, 1998, UROL RES, V26, P395, DOI 10.1007/s002400050075; Thedieck C, 2008, J MOL BIOL, V378, P145, DOI 10.1016/j.jmb.2008.02.008; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thomson S, 2011, CLIN EXP METASTAS, V28, P137, DOI 10.1007/s10585-010-9367-3; Wong VCL, 2011, BRIT J CANCER, V104, P841, DOI 10.1038/bjc.2011.25; Wong VCL, 2012, INT J CANCER, V130, P83, DOI 10.1002/ijc.25970; Zhang JJ, 2010, CELL CYCLE, V9, P4848, DOI 10.4161/cc.9.24.14136; ZHANG SH, 1983, INT J CANCER, V31, P587, DOI 10.1002/ijc.2910310509; Zheng Z, 1999, HUM PATHOL, V30, P458, DOI 10.1016/S0046-8177(99)90123-5	43	48	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	32					3709	3720		10.1038/onc.2011.529	http://dx.doi.org/10.1038/onc.2011.529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22158051				2022-12-28	WOS:000307653800005
J	Macia, A; Gallel, P; Vaquero, M; Gou-Fabregas, M; Santacana, M; Maliszewska, A; Robledo, M; Gardiner, JR; Basson, MA; Matias-Guiu, X; Encinas, M				Macia, A.; Gallel, P.; Vaquero, M.; Gou-Fabregas, M.; Santacana, M.; Maliszewska, A.; Robledo, M.; Gardiner, J. R.; Basson, M. A.; Matias-Guiu, X.; Encinas, M.			Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma	ONCOGENE			English	Article						sprouty; medullary thyroid carcinoma; mouse models	RET PROTOONCOGENE; CELLULAR SENESCENCE; KINASE INHIBITOR; GDNF FAMILY; C-CELL; EXPRESSION; GROWTH; MICE; MORPHOGENESIS; PROTEINS	Medullary thyroid carcinoma (MTC) is a malignancy derived from the calcitonin-producing C-cells of the thyroid gland. Oncogenic mutations of the Ret protooncogene are found in all heritable forms of MTC and roughly one half of the sporadic cases. However, several lines of evidence argue for the existence of additional genetic lesions necessary for the development of MTC. Sprouty (Spry) family of genes is composed of four members in mammals (Spry1-4). Some Spry family members have been proposed as candidate tumor-suppressor genes in a variety of cancerous pathologies. In this work, we show that targeted deletion of Spry1 causes C-cell hyperplasia, a precancerous lesion preceding MTC, in young adult mice. Expression of Spry1 restrains proliferation of the MTC-derived cell line, TT. Finally, we found that the Spry1 promoter is frequently methylated in MTC and that Spry1 expression is consequently decreased. These findings identify Spry1 as a candidate tumor- suppressor gene in MTC. Oncogene (2012) 31, 3961-3972; doi:10.1038/onc.2011.556; published online 12 December 2011	[Macia, A.; Vaquero, M.; Gou-Fabregas, M.; Encinas, M.] Univ Lleida, Inst Recerca Biomed Lleida, Dept Expt Med, Lleida, Spain; [Gallel, P.; Santacana, M.; Matias-Guiu, X.] Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet, Lleida, Spain; [Maliszewska, A.; Robledo, M.] Spanish Natl Canc Res Ctr CNIO, Hereditary Endocrine Canc Grp, Madrid, Spain; [Maliszewska, A.; Robledo, M.] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain; [Gardiner, J. R.; Basson, M. A.] Kings Coll London, Dept Craniofacial Dev, London WC2R 2LS, England	Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Institut de Recerca Biomedica - IRB Lleida; Universitat de Lleida; Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of London; King's College London	Encinas, M (corresponding author), Hosp Arnau Vilanova, Lab Invest UdL HUAV, Dept Med Expt, Rovira Roure 80, Lleida 25198, Spain.	mario.encinas@mex.udl.cat	Armengol, Anna Macià/V-2631-2017; Basson, M. Albert/C-5565-2009; Gou-Fabregas, Myriam/K-1899-2016; Robledo, Mercedes/O-2230-2013; matias-guiu, xavier/C-3039-2009; Encinas, Mario/B-5600-2009	Armengol, Anna Macià/0000-0001-6038-178X; Gou-Fabregas, Myriam/0000-0002-5329-7640; Robledo, Mercedes/0000-0001-6256-5902; matias-guiu, xavier/0000-0002-7201-6605; Encinas, Mario/0000-0003-3509-7431; Basson, M. Albert/0000-0001-9834-7528; Santacana, Maria/0000-0003-1975-2598; Vaquero Susagna, Marta/0000-0002-3856-6769	Ministerio de Educacion y Ciencia [BFU2007-67619, BFU2010-17628]; Fundacio La Marato de TV3; Suport als Grups de Recerca from Generalitat de Catalunya [2009 SGR 740]; programa de intensificacion de la investigacion, Instituto Carlos III; Fondo de Investigaciones Sanitarias [PI080883]; Fundacion Mutua Madrilena [AP2775/2008]; Medical Research Council [G0601104]; Tumor Banc Platform of RTICC [RD09/0076/00059]; Universitat de Lleida; Fundacio Alicia Cuello de Merigo;  [2009SGR794];  [RD06/0020/1034]; MRC [G0601104] Funding Source: UKRI	Ministerio de Educacion y Ciencia(Spanish Government); Fundacio La Marato de TV3; Suport als Grups de Recerca from Generalitat de Catalunya; programa de intensificacion de la investigacion, Instituto Carlos III; Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Tumor Banc Platform of RTICC; Universitat de Lleida; Fundacio Alicia Cuello de Merigo; ; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to Esteban J Rozen for his initial contribution to the development of this work. We also thank Ana Velasco and Carme Guerris for technical assistance. This work was supported by grants from Ministerio de Educacion y Ciencia (BFU2007-67619 and BFU2010-17628) and Fundacio La Marato de TV3, and funding from Suport als Grups de Recerca (2009 SGR 740) from Generalitat de Catalunya to ME; grants 2009SGR794,RD06/0020/1034 and programa de intensificacion de la investigacion, Instituto Carlos III to XM-G; grants from Fondo de Investigaciones Sanitarias (PI080883) and Fundacion Mutua Madrilena (AP2775/2008) to MR; and from the Medical Research Council (G0601104) to MAB Tumor samples were obtained with the support of Xarxa catalana de Bancs de Tumors, the Tumor Banc Platform of RTICC and RD09/0076/00059. AM is supported by a predoctoral fellowship from Universitat de Lleida and was supported by a fellowship from a Fundacio Alicia Cuello de Merigo. MV was recipient of a 'beca d'introduccio a la recerca fellowship from Universitat de Lleida.	Acton DS, 2000, ONCOGENE, V19, P3121, DOI 10.1038/sj.onc.1203648; Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Akeno-Stuart N, 2007, CANCER RES, V67, P6956, DOI 10.1158/0008-5472.CAN-06-4605; Aranda S, 2008, MOL CELL BIOL, V28, P5899, DOI 10.1128/MCB.00394-08; Asai N, 2006, PATHOL INT, V56, P164, DOI 10.1111/j.1440-1827.2006.01942.x; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Basson MA, 2006, DEV BIOL, V299, P466, DOI 10.1016/j.ydbio.2006.08.051; Basson MA, 2005, DEV CELL, V8, P229, DOI 10.1016/j.devcel.2004.12.004; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Cerrato A, 2009, J MOL ENDOCRINOL, V43, P143, DOI 10.1677/JME-09-0024; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Darimipourain M, 2011, PROSTATE CANCER P D, V14, P279, DOI 10.1038/pcan.2011.33; Edwin F, 2009, MOL PHARMACOL, V76, P679, DOI 10.1124/mol.109.055848; Encinas M, 2008, CELL DEATH DIFFER, V15, P1510, DOI 10.1038/cdd.2008.76; Eritja N, 2010, AM J PATHOL, V176, P2722, DOI 10.2353/ajpath.2010.090974; Fagman H, 2010, MOL CELL ENDOCRINOL, V323, P35, DOI 10.1016/j.mce.2009.12.008; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; Fritzsche S, 2006, ENDOCR-RELAT CANCER, V13, P839, DOI 10.1677/erc.1.01190; Gagel RF, 2003, WILLIAMS TXB ENDOCRI, P1717; Gallel P, 2008, HUM PATHOL, V39, P994, DOI 10.1016/j.humpath.2007.11.015; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Ishida M, 2007, CANCER SCI, V98, P815, DOI 10.1111/j.1349-7006.2007.00457.x; Kawai K, 2000, CANCER RES, V60, P5254; Kwabi-Addo B, 2004, CANCER RES, V64, P4728, DOI 10.1158/0008-5472.CAN-03-3759; Kwabi-Addo B, 2009, EPIGENETICS, V4, P54, DOI 10.4161/epi.4.1.7400; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Llobet D, 2008, ONCOGENE, V27, P2513, DOI 10.1038/sj.onc.1210924; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Matias-Guiu X, 2004, PATHOLOGY GENETICS T, V8, P86; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; Michos O, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000809; Plaza-Menacho I, 2006, TRENDS GENET, V22, P627, DOI 10.1016/j.tig.2006.09.005; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Reynolds L, 2001, ONCOGENE, V20, P3986, DOI 10.1038/sj.onc.1204434; Rozen EJ, 2009, J AM SOC NEPHROL, V20, P255, DOI 10.1681/ASN.2008030267; Santarpia L, 2009, J INTERN MED, V266, P99, DOI 10.1111/j.1365-2796.2009.02112.x; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Velasco A, 2011, HUM PATHOL, V42, P185, DOI 10.1016/j.humpath.2010.08.001; Yaguchi Y, 2009, DEV DYNAM, V238, P2058, DOI 10.1002/dvdy.22013; Ye L, 2008, J CLIN ENDOCR METAB, V93, P4367, DOI 10.1210/jc.2008-0912; Yin L, 2007, INT J CANCER, V121, P292, DOI 10.1002/ijc.22378; Zaremba A, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-192; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	55	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	35					3961	3972		10.1038/onc.2011.556	http://dx.doi.org/10.1038/onc.2011.556			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22158037	Bronze, Green Accepted			2022-12-28	WOS:000308342800005
J	Palermo, R; Checquolo, S; Giovenco, A; Grazioli, P; Kumar, V; Campese, AF; Giorgi, A; Napolitano, M; Canettieri, G; Ferrara, G; Schinina, ME; Maroder, M; Frati, L; Gulino, A; Vacca, A; Screpanti, I				Palermo, R.; Checquolo, S.; Giovenco, A.; Grazioli, P.; Kumar, V.; Campese, A. F.; Giorgi, A.; Napolitano, M.; Canettieri, G.; Ferrara, G.; Schinina, M. E.; Maroder, M.; Frati, L.; Gulino, A.; Vacca, A.; Screpanti, I.			Acetylation controls Notch3 stability and function in T-cell leukemia	ONCOGENE			English	Article						leukemia; Notch3; T-ALL; acetylation	HISTONE DEACETYLASE INHIBITORS; NF-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-TCR; HDAC INHIBITORS; TRANSGENIC MICE; DNA-DAMAGE; EXPRESSION; TARGET; CANCER	Post-translational modifications of Notch3 and their functional role with respect to Notch3 overexpression in T-cell leukemia are still poorly understood. We identify here a specific novel property of Notch3 that is acetylated and deacetylated at lysines 1692 and 1731 by p300 and HDAC1, respectively, a balance impaired by HDAC inhibitors (HDACi) that favor hyperacetylation. By using HDACi and a non-acetylatable Notch3 mutant carrying K/R1692-1731 mutations in the intracellular domain, we show that Notch3 acetylation primes ubiquitination and proteasomal-mediated degradation of the protein. As a consequence, Notch3 protein expression and its transcriptional activity are decreased both in vitro and in vivo in Notch3 transgenic (tg) mice, thus impairing downstream signaling upon target genes. Consistently, Notch3-induced T-cell proliferation is inhibited by HDACi, whereas it is enhanced by the non-acetylatable Notch3-K/R1692-1731 mutant. Finally, HDACi-induced Notch3 hyperacetylation prevents in vivo growth of T-cell leukemia/lymphoma in Notch3 tg mice. Together, our findings suggest a novel level of Notch signaling control in which Notch3 acetylation/deacetylation process represents a key regulatory switch, thus representing a suitable druggable target for Notch3-sustained T-cell acute lymphoblastic leukemia therapy. Oncogene (2012) 31, 3807-3817; doi: 10.1038/onc.2011.533; published online 28 November 2011	[Palermo, R.; Giovenco, A.; Vacca, A.] Sapienza Univ, Dept Expt Med, I-00161 Rome, Italy; [Checquolo, S.; Maroder, M.] Sapienza Univ, Dept Biotechnol & Med Surg Sci, Latina, Italy; [Grazioli, P.; Kumar, V.; Campese, A. F.; Napolitano, M.; Canettieri, G.; Ferrara, G.; Frati, L.; Gulino, A.; Screpanti, I.] Sapienza Univ, Dept Mol Med, I-00161 Rome, Italy; [Giorgi, A.; Schinina, M. E.] Sapienza Univ, Dept Biochem Sci, I-00161 Rome, Italy; [Napolitano, M.] IRCCS OASI, Troina, Italy; [Frati, L.; Gulino, A.] Neuromed Inst, Pozzilli, Italy; [Screpanti, I.] Sapienza Univ, Inst Pasteur, Cenci Bolognetti Fdn, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; IRCCS Neuromed; Fondazione Cenci Bolognetti; Sapienza University Rome	Vacca, A (corresponding author), Sapienza Univ, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.	alessandra.vacca@uniroma1.it; isabella.screpanti@uniroma1.it	Campese, Antonio/A-9783-2015; Frati, Luigi/ABI-7437-2020; Palermo, Rocco/I-5140-2016	Palermo, Rocco/0000-0003-0134-9370; VACCA, Alessandra/0000-0002-0006-5379; CHECQUOLO, Saula/0000-0001-5109-8392; CAMPESE, Antonio Francesco/0000-0002-8535-6609; CANETTIERI, Gianluca/0000-0001-6694-2613	Italian Association for Cancer Research (AIRC); Italian Ministry of University and Research (MIUR); Italian Ministry of Health; European Union [FP7-MC-ITN 215761]; Eleonora Lorillard Spencer Cenci Foundation; Fondazione Roma	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health(Ministry of Health, Italy); European Union(European Commission); Eleonora Lorillard Spencer Cenci Foundation; Fondazione Roma(Fondazione RomaEuropean Commission)	We are grateful to Dr Sonia Coni for experimental support. This work was supported by the Italian Association for Cancer Research (AIRC), the Italian Ministry of University and Research (MIUR), PRIN and FIRB Programs, the Italian Ministry of Health, the European Union (NotchIT ITN Project; FP7-MC-ITN 215761), Eleonora Lorillard Spencer Cenci Foundation and the Fondazione Roma (fellowship to RP).	Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Anastasi E, 2003, J IMMUNOL, V171, P4504, DOI 10.4049/jimmunol.171.9.4504; Barbarulo A, 2011, J IMMUNOL, V186, P6199, DOI 10.4049/jimmunol.1002136; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446; Clappier E, 2010, LEUKEMIA, V24, P2023, DOI 10.1038/leu.2010.205; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Galbiati L, 2005, CELL CYCLE, V4, P930, DOI 10.4161/cc.4.7.1784; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917; Hernandez-Hernandez A, 2006, EMBO J, V25, P3264, DOI 10.1038/sj.emboj.7601228; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kim MY, 2007, MOL CELL BIOL, V27, P6506, DOI 10.1128/MCB.01515-06; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Mateo F, 2009, ONCOGENE, V28, P2654, DOI 10.1038/onc.2009.127; Mercurio C, 2010, PHARMACOL RES, V62, P18, DOI 10.1016/j.phrs.2010.02.010; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Piekarz RL, 2007, CANCER J, V13, P30, DOI 10.1097/PPO.0b013e31803c73cc; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Screpanti I, 2003, TRENDS MOL MED, V9, P30, DOI 10.1016/S1471-4914(02)00003-5; Stockhausen MT, 2005, BRIT J CANCER, V92, P751, DOI 10.1038/sj.bjc.6602309; Talora C, 2006, BLOOD, V107, P3313, DOI 10.1182/blood-2005-07-2823; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tsapis M, 2007, INT J BIOCHEM CELL B, V39, P1500, DOI 10.1016/j.biocel.2007.03.009; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Zhang B, 2010, CANCER CELL, V17, P427, DOI 10.1016/j.ccr.2010.03.011	41	44	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3807	3817		10.1038/onc.2011.533	http://dx.doi.org/10.1038/onc.2011.533			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120716				2022-12-28	WOS:000307924900007
J	Zhang, S; Shan, C; Kong, G; Du, Y; Ye, L; Zhang, X				Zhang, S.; Shan, C.; Kong, G.; Du, Y.; Ye, L.; Zhang, X.			MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappa B-inducing kinase (NIK)	ONCOGENE			English	Article						microRNA-520e; DNA methylation; hepatocellular carcinoma; cell proliferation; NF-kappa B-inducing kinase	HUMAN HEPATOCELLULAR-CARCINOMA; FREQUENT EPIGENETIC INACTIVATION; HUMAN CANCER-CELLS; CONSTITUTIVE ACTIVATION; P38 MAPK; EXPRESSION; PROLIFERATION; BIOGENESIS; TUMORS; FAMILY	MicroRNAs (miRNAs) are small, non-coding RNAs that can act as oncogenes or tumor suppressor genes in human cancer. Emerging evidence indicates that deregulation of miRNAs contributes to the hepatocarcinogenesis. In the present study, we demonstrated that the levels of miR-520e were dramatically decreased in examined hepatoma cell lines and clinical hepatocellular carcinoma (HCC) tissues. Moreover, we found that DNA hypermethylation in the upstream region of miR-520e resulted in the downregulation of miR-520e. Next, we demonstrated that introduction of miR-520e dramatically suppressed the growth of hepatoma cells in vitro and in vivo, whereas silencing the expression of miR-520e by anti-miR-520e resulted in a promoted cell proliferation, suggesting that miR-520e may be a novel tumor suppressor. Further studies revealed that NF-kappa B-inducing kinase (NIK) was one of the direct target genes of miR-520e, as miR-520e directly bound to the 3'untranslated region of NIK, which reduced the expression of NIK at the levels of mRNA and protein. Moreover, silencing of NIK was able to inhibit the growth of hepatoma cells, similar to the effect of miR-520e overexpression on growth of hepatoma cells. Meanwhile, the knockdown of NIK expression reversed the enhanced proliferation mediated by anti-miR-520e. In addition, miR-520e significantly decreased the phosphorylation of ERK1/2 (p-ERK1/2) and depressed the transcriptional activity and nuclear translocation of nuclear factor kappa B (NF-kappa B) (p65). These results suggest that miR-520e suppresses the growth of hepatoma cells by targeting NIK involving the NIK/p-ERK1/2/NF-kappa B signaling pathway. Finally, we showed that the intratumoral injection with miR-520e was able to directly repress the growth of hepatoma cells in the nude mice. Thus, our finding provides new insight into the mechanism of hepatocarcinogenesis, indicating a therapeutic potential of miR-520e in the treatment of HCC. Oncogene (2012) 31, 3607-3620; doi:10.1038/onc.2011.523; published online 21 November 2011	[Zhang, S.; Shan, C.; Kong, G.; Du, Y.; Zhang, X.] Nankai Univ, Key Lab Mol Microbiol & Technol, Dept Canc Res, Minist Educ,Inst Mol Biol,Coll Life Sci, Tianjin 300071, Peoples R China; [Ye, L.] Nankai Univ, Coll Life Sci, Dept Biochem, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Zhang, X (corresponding author), Nankai Univ, Key Lab Mol Microbiol & Technol, Dept Canc Res, Minist Educ,Inst Mol Biol,Coll Life Sci, 94 Weijin Rd, Tianjin 300071, Peoples R China.	yelihong@nankai.edu.cn; zhangxd@nankai.edu.cn	Kong, Guangyao/L-2162-2013; Shan, changliang/L-9029-2016		National Basic Research Program of China (973 Program) [2009CB521702]; National Natural Science Foundation of China [81071624]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Basic Research Program of China (973 Program, No. 2009CB521702) and National Natural Science Foundation of China (No. 81071624).	Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457; Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen KH, 2007, BIOCHEM PHARMACOL, V73, P215, DOI 10.1016/j.bcp.2006.09.018; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cui W, 2010, CANCER BIOL THER, V10, P232; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Gessi M, 2011, NEUROPATH APPL NEURO, V37, P406, DOI 10.1111/j.1365-2990.2010.01151.x; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Ji JF, 2009, CANCER BIOL THER, V8, P1683, DOI 10.4161/cbt.8.18.8898; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Li MH, 2009, CANCER CELL, V16, P533, DOI 10.1016/j.ccr.2009.10.025; Li Q, 2010, J GASTROEN HEPATOL, V25, P164, DOI 10.1111/j.1440-1746.2009.05971.x; Li S, 2009, HEPATOLOGY, V49, P1194, DOI 10.1002/hep.22757; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lyle R, 2000, NAT GENET, V25, P19, DOI 10.1038/75546; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Nishina T, 2009, BIOCHEM BIOPH RES CO, V388, P96, DOI 10.1016/j.bbrc.2009.07.125; Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Shan CL, 2010, CELL RES, V20, P563, DOI 10.1038/cr.2010.49; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x; Ying SY, 2005, BIOCHEM BIOPH RES CO, V326, P515, DOI 10.1016/j.bbrc.2004.10.215	45	100	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	31					3607	3620		10.1038/onc.2011.523	http://dx.doi.org/10.1038/onc.2011.523			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22105365				2022-12-28	WOS:000307245600004
J	Piskunov, A; Rochette-Egly, C				Piskunov, A.; Rochette-Egly, C.			A retinoic acid receptor RAR alpha pool present in membrane lipid rafts forms complexes with G protein alpha Q to activate p38MAPK	ONCOGENE			English	Article						retinoic acid; RAR; p38MAPK; G alpha Q; lipid rafts	BREAST-CANCER; F9 CELLS; SIGNAL-TRANSDUCTION; NONGENOMIC ACTIONS; ESTROGEN-RECEPTOR; TARGET GENES; IN-VIVO; PHOSPHORYLATION; DIFFERENTIATION; PATHWAY	Retinoic acid (RA) regulates several gene programs by nuclear RA receptors (RARs) that are ligand-dependent transcriptional transregulators. The basic mechanism for switching on transcription of cognate-target genes involves RAR binding at specific response elements and a network of interactions with coregulatory protein complexes. In addition to these classical genomic effects, we recently demonstrated that RA also induces the rapid activation of the p38MAPK/MSK1 pathway, with characteristic downstream consequences on the phosphorylation of RARs and the expression of their target genes. Here, we aimed at deciphering the underlying mechanism of the rapid nongenomic effects of RA. We highlighted a novel paradigm in which a fraction of the cellular RAR alpha pool is present in membrane lipid rafts, where it forms complexes with G protein alpha Q (G alpha q) in response to RA. This rapid RA-induced formation of RAR alpha/G alpha q complexes in lipid rafts is required for the activation of p38MAPK that occurs in response to RA. Accordingly, in RA-resistant cancer cells, characterized by the absence of p38MAPK activation, RAR alpha present in membrane lipid rafts does not associate with Gaq, pointing out the essential contribution of RAR alpha/G alpha q complexes in RA signaling. Oncogene (2012) 31, 3333-3345; doi: 10.1038/onc.2011.499; published online 7 November 2011	[Rochette-Egly, C.] Univ Strasbourg, Dept Funct Genom & Canc, INSERM, U964,IGBMC, F-67404 Illkirch Graffenstaden, Bas Rhin, France; Univ Strasbourg, CNRS, UMR7104, F-67404 Illkirch Graffenstaden, Bas Rhin, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Univ Strasbourg, Dept Funct Genom & Canc, INSERM, U964,IGBMC, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, Bas Rhin, France.	cegly@igbmc.fr	Piskunov, Aleksandr/H-9871-2014	Piskunov, Aleksandr/0000-0001-5552-5419	CNRS; INSERM; Agence Nationale pour la Recherche [ANR-05-BLAN-0390-02, ANR-09-BLAN-0297-01]; Association pour la Recherche sur le Cancer [ARC-07-1-3169]; Fondation pour la Recherche Medicale [DEQ20090515423]; Institut National du Cancer [INCa-PL09-194, PL07-96099]; Fondation pour la Recherche Medicale; Lady TATA Memorial Trust	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Lady TATA Memorial Trust	We are grateful to the members of the cell culture facilities for their help and to all the members of the team for their helpful discussions and suggestions. Special thanks to Nathalie Bruck for GTPases analysis and to Regis Lutzing for generating the RAR gamma WT MEF rescue line. This work was supported by funds from CNRS, INSERM, the Agence Nationale pour la Recherche (ANR-05-BLAN-0390-02 and ANR-09-BLAN-0297-01), the Association pour la Recherche sur le Cancer (ARC-07-1-3169), the Fondation pour la Recherche Medicale (DEQ20090515423) and the Institut National du Cancer (INCa-PL09-194 and PL07-96099). AP was supported by the Fondation pour la Recherche Medicale and by the Lady TATA Memorial Trust.	Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bour G, 2005, P NATL ACAD SCI USA, V102, P16608, DOI 10.1073/pnas.0505556102; Bruck N, 2009, EMBO J, V28, P34, DOI 10.1038/emboj.2008.256; Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com; Clagett-Dame M, 2011, NUTRIENTS, V3, P385, DOI 10.3390/nu3040385; de Laurentiis Angela, 2007, Open Biochem J, V1, P12, DOI 10.2174/1874091X00701010012; Dey N, 2007, MOL CELL BIOL, V27, P4179, DOI 10.1128/MCB.01352-06; Duong V, 2011, BBA-MOL BASIS DIS, V1812, P1023, DOI 10.1016/j.bbadis.2010.10.007; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; Gianni M, 2006, EMBO J, V25, P739, DOI 10.1038/sj.emboj.7600981; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Huhtakangas JA, 2004, MOL ENDOCRINOL, V18, P2660, DOI 10.1210/me.2004-0116; Lai L, 2008, J PINEAL RES, V45, P476, DOI 10.1111/j.1600-079X.2008.00620.x; Laudet V., 2001, NUCL RECEPTOR FACTSB; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Luoma JI, 2008, MOL CELL ENDOCRINOL, V290, P8, DOI 10.1016/j.mce.2008.04.005; Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020; Masia S, 2007, MOL ENDOCRINOL, V21, P2391, DOI 10.1210/me.2007-0062; Matthews L, 2008, MOL ENDOCRINOL, V22, P1320, DOI 10.1210/me.2007-0154; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Mizuno N, 2009, NEUROSIGNALS, V17, P42, DOI 10.1159/000186689; Norman AW, 2001, STEROIDS, V66, P147, DOI 10.1016/S0039-128X(00)00165-3; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Ordonez-Moran P, 2008, J CELL BIOL, V183, P697, DOI 10.1083/jcb.200803020; Ostrom Rennolds S., 2006, V332, P181; Pan J, 2005, J NEUROCHEM, V93, P571, DOI 10.1111/j.1471-4159.2005.03106.x; Park SS, 2005, HISTOPATHOLOGY, V47, P625, DOI 10.1111/j.1365-2559.2005.02303.x; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Piskunov A., 2011, MSKS; Qiu J, 2003, J NEUROSCI, V23, P9529; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; Rochette-Egly Cecile, 2009, Nucl Recept Signal, V7, pe005, DOI 10.1621/nrs.07005; Samarut E, 2011, MOL CELL ENDOCRINOL; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Staubach S, 2011, EXPERT REV PROTEOMIC, V8, P263, DOI [10.1586/EPR.11.2, 10.1586/epr.11.2]; Stuermer CAO, 2011, J NEUROCHEM, V116, P708, DOI 10.1111/j.1471-4159.2010.07007.x; Sugawara Y, 2007, CELL SIGNAL, V19, P1301, DOI 10.1016/j.cellsig.2007.01.012; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Vasudevan N, 2008, FRONT NEUROENDOCRIN, V29, P238, DOI 10.1016/j.yfrne.2007.08.003; Waugh Mark G., 2009, V462, P403, DOI 10.1007/978-1-60327-115-8_26; White CD, 2008, MOL ENDOCRINOL, V22, P2520, DOI 10.1210/me.2008-0122; Yao Y, 2009, CELL RES, V19, P497, DOI 10.1038/cr.2009.27; Zanotto A, 2008, TOXICOL IN VITRO, V22, P1205, DOI 10.1016/j.tiv.2008.04.001	53	65	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	28					3333	3345		10.1038/onc.2011.499	http://dx.doi.org/10.1038/onc.2011.499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22056876				2022-12-28	WOS:000306367600003
J	Ding, Y; Ding, J; Wu, K; Wen, W; Liu, C; Yan, HX; Chen, C; Wang, S; Tang, H; Gao, CK; Guo, LN; Cao, D; Li, Z; Feng, GS; Wang, HY; Xu, ZF				Ding, Y.; Ding, J.; Wu, K.; Wen, W.; Liu, C.; Yan, H-X; Chen, C.; Wang, S.; Tang, H.; Gao, C-K; Guo, L-N; Cao, D.; Li, Z.; Feng, G-S; Wang, H-Y; Xu, Z-F			Cross-talk between endothelial cells and tumor via delta-like ligand4/Notch/PTEN signaling inhibits lung cancer growth	ONCOGENE			English	Article						lung cancer; vascular endothelial cells; delta-like ligand 4; Notch; PTEN	UP-REGULATION; THERAPEUTIC IMPLICATIONS; NOTCH; ANGIOGENESIS; DLL4; ACTIVATION; PATHWAY; PTEN; PROLIFERATION; EXPRESSION	Lung cancer is a leading cause of cancer death in many countries. Notch signaling has been demonstrated to frequently participate in the process of lung carcinogenesis. Delta-like ligand 4 (Dll4) is a vascular-specific ligand of Notch, and has a critical role in the angiogenesis of numerous cancers. However, the role of Dll4 in the crosstalk between endothelial cells (ECs) and tumor cells remains obscure. Herein, our study revealed that Dll4-expressing ECs (EC-Dll4) significantly suppressed the proliferation of neighboring non-small cell lung cancer (NSCLC) cells and attenuated the growth of NSCLC xenograft in nude mice. On the contrary, silencing endothelial Dll4 by its specific interference RNA reversed these effects of Dll4 on NSCLC cell proliferation and tumor formation. Furthermore, activation of Notch1, but not Notch2 or Notch3, was enhanced in NSCLC cells cultured with EC-Dll4, as well as in xenografts induced by a mixture of NSCLC cells and EC-Dll4. Interference of Notch1 significantly attenuated Dll4-mediated suppression of NSCLC cell proliferations, indicating that Dll4/Notch1 signaling negatively modulates the NSCLC growth. Moreover, PTEN expression in NSCLC cells was increased by EC-Dll4 or rhDll4 (recombinant human-Dll4 protein), and the induction was impaired by Notch1 interference suggesting that Dll4 could upregulate PTEN expression by Notch1. Taken together, we conclude that the cross-talk between ECs and NSCLC cells by Dll4/Notch1/PTEN signaling pathway inhibits the growth of NSCLC. Oncogene (2012) 31, 2899-2906; doi:10.1038/onc.2011.467; published online 17 October 2011	[Ding, Y.; Wang, S.; Tang, H.; Gao, C-K; Xu, Z-F] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Thorac & Cardiovasc Surg, Shanghai 200003, Peoples R China; [Ding, J.; Wu, K.; Wen, W.; Liu, C.; Yan, H-X; Chen, C.; Guo, L-N; Cao, D.; Li, Z.; Wang, H-Y] Second Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China; [Feng, G-S] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Feng, G-S] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Naval Medical University; Naval Medical University; University of California System; University of California San Diego; University of California System; University of California San Diego	Xu, ZF (corresponding author), Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Thorac & Cardiovasc Surg, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	hywangk@vip.sina.com; xu_zhi_fei@yahoo.com.cn	ding, jin/GVT-5062-2022		National Natural Science Foundation of China [30972965, 31071236, 30800576]; Shanghai Pujiang program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Pujiang program(Shanghai Pujiang Program)	This work was supported by grants from the National Natural Science Foundation of China (30972965, 31071236 and 30800576) and the Shanghai Pujiang program.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Collins BJ, 2004, SEMIN CANCER BIOL, V14, P357, DOI 10.1016/j.semcancer.2004.04.015; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; Detterbeck FC, 2009, CHEST, V136, P260, DOI 10.1378/chest.08-0978; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fortini ME, 2009, DEV CELL, V16, P633, DOI 10.1016/j.devcel.2009.03.010; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; Hofmann JJ, 2007, GENE EXPR PATTERNS, V7, P461, DOI 10.1016/j.modgep.2006.11.002; Indraccolo S, 2009, CANCER RES, V69, P1314, DOI 10.1158/0008-5472.CAN-08-2791; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kunnimalaiyaan M, 2005, AM J PHYSIOL-GASTR L, V289, pG636, DOI 10.1152/ajpgi.00146.2005; Kunnimalaiyaan M, 2007, ONCOLOGIST, V12, P535, DOI 10.1634/theoncologist.12-5-535; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104; Mailhos C, 2001, DIFFERENTIATION, V69, P135, DOI 10.1046/j.1432-0436.2001.690207.x; Meurette O, 2009, CANCER RES, V69, P5015, DOI 10.1158/0008-5472.CAN-08-3478; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Nor JE, 2001, CANCER RES, V61, P2183; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015; Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood-2006-12-063933; Segarra M, 2008, BLOOD, V112, P1904, DOI 10.1182/blood-2007-11-126045; Wen W, 2010, CANCER RES, V70, P2010, DOI 10.1158/0008-5472.CAN-08-4910; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000; Winer E, 2009, J CLIN ONCOL, V27, P812, DOI 10.1200/JCO.2008.21.2134; Yan MH, 2007, CLIN CANCER RES, V13, P7243, DOI 10.1158/1078-0432.CCR-07-1393; Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751; Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004	37	37	40	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2899	2906		10.1038/onc.2011.467	http://dx.doi.org/10.1038/onc.2011.467			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22002304				2022-12-28	WOS:000305277900009
J	Pichierri, P; Nicolai, S; Cignolo, L; Bignami, M; Franchitto, A				Pichierri, P.; Nicolai, S.; Cignolo, L.; Bignami, M.; Franchitto, A.			The RAD9-RAD1-HUS1 (9.1.1) complex interacts with WRN and is crucial to regulate its response to replication fork stalling	ONCOGENE			English	Article						RecQ helicases; replication checkpoint; genome instability; Werner syndrome	WERNER-SYNDROME PROTEIN; DNA-POLYMERASE-BETA; GENOMIC INSTABILITY; HELICASE ACTIVITY; CHK1 ACTIVATION; COMMON PATHWAY; MRE11 COMPLEX; MOUSE HUS1; CELL-CYCLE; S-PHASE	The WRN protein belongs to the RecQ family of DNA helicases and is implicated in replication fork restart, but how its function is regulated remains unknown. We show that WRN interacts with the 9.1.1 complex, one of the central factors of the replication checkpoint. This interaction is mediated by the binding of the RAD1 subunit to the N-terminal region of WRN and is instrumental for WRN relocalization in nuclear foci and its phosphorylation in response to replication arrest. We also find that ATR-dependent WRN phosphorylation depends on TopBP1, which is recruited by the 9.1.1 complex in response to replication arrest. Finally, we provide evidence for a cooperation between WRN and 9.1.1 complex in preventing accumulation of DNA breakage and maintaining genome integrity at naturally occurring replication fork stalling sites. Taken together, our data unveil a novel functional interplay between WRN helicase and the replication checkpoint, contributing to shed light into the molecular mechanism underlying the response to replication fork arrest. Oncogene (2012) 31, 2809-2823; doi:10.1038/onc.2011.468; published online 17 October 2011	[Pichierri, P.] Ist Super Sanita, Sect Expt & Computat Carcinogenesis, Dept Environm & Primary Prevent, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Pichierri, P (corresponding author), Ist Super Sanita, Sect Expt & Computat Carcinogenesis, Dept Environm & Primary Prevent, Viale Regina Elena 299, I-00161 Rome, Italy.	pietro.pichierri@iss.it	Pichierri, Pietro/AAA-5476-2021; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Franchitto, Annapaola/0000-0003-4232-4727	Fondazione Telethon [GGP04094]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG9294, IG4400]	Fondazione Telethon(Fondazione TelethonEuropean Commission); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Drs L Comai and M Lalle for providing recombinant proteins and Drs D Toniolo and M Rocchi for providing BACs for FISH analysis. This work was supported by Fondazione Telethon to PP (Grant no. GGP04094) and, in part, by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) to PP (Grant no. IG9294) and AF (Grant no. IG4400).	Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Cheng WH, 2007, EXP GERONTOL, V42, P871, DOI 10.1016/j.exger.2007.04.011; Cheng WH, 2004, J BIOL CHEM, V279, P21169, DOI 10.1074/jbc.M312770200; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Dore AS, 2009, MOL CELL, V34, P735, DOI 10.1016/j.molcel.2009.04.027; Franchitto A, 2004, CELL CYCLE, V3, P1331, DOI 10.4161/cc.3.10.1185; Franchitto A, 2008, J CELL BIOL, V183, P241, DOI 10.1083/jcb.200803173; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; Guan X, 2007, NUCLEIC ACIDS RES, V35, P2463, DOI 10.1093/nar/gkm075; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Machwe A, 2006, BIOCHEMISTRY-US, V45, P13939, DOI 10.1021/bi0615487; Martin GM, 2000, NATURE, V408, P263, DOI 10.1038/35041705; Mordes DA, 2008, GENE DEV, V22, P1478, DOI 10.1101/gad.1666208; Muftuoglu M, 2008, HUM GENET, V124, P369, DOI 10.1007/s00439-008-0562-0; Muftuoglu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001918; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088; Pichierri P, 2004, EMBO J, V23, P3154, DOI 10.1038/sj.emboj.7600277; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; Pichierri Pietro, 2007, Ital J Biochem, V56, P130; Pirzio LM, 2008, J CELL BIOL, V180, P305, DOI 10.1083/jcb.200705126; Rodriguez-Lopez AM, 2003, MECH AGEING DEV, V124, P167, DOI 10.1016/S0047-6374(02)00131-8; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sidorova JM, 2008, DNA REPAIR, V7, P1776, DOI 10.1016/j.dnarep.2008.07.017; Toueille M, 2004, NUCLEIC ACIDS RES, V32, P3316, DOI 10.1093/nar/gkh652; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; Weiss RS, 2000, GENE DEV, V14, P1886; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Xu M, 2009, J BIOL CHEM, V284, P20457, DOI 10.1074/jbc.C109.022384; Zhu M, 2007, MOL BIOL CELL, V18, P1044, DOI 10.1091/mbc.E06-10-0957; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	48	18	20	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2809	2823		10.1038/onc.2011.468	http://dx.doi.org/10.1038/onc.2011.468			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22002307	Green Accepted			2022-12-28	WOS:000305277900002
J	Rao, VH; Kandel, A; Lynch, D; Pena, Z; Marwaha, N; Deng, C; Watson, P; Hansen, LA				Rao, V. H.; Kandel, A.; Lynch, D.; Pena, Z.; Marwaha, N.; Deng, C.; Watson, P.; Hansen, L. A.			A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion	ONCOGENE			English	Article						HER2; ADAM12; head and neck cancer; oral cancer; migration; invasion	GROWTH-FACTOR-RECEPTOR; HUMAN-BREAST-CANCER; GENE-EXPRESSION; PROTEIN EXPRESSION; FAMILY-MEMBERS; CARCINOMA; OVEREXPRESSION; AMPLIFICATION; ERBB2; EGFR	Increased activation of epidermal growth factor receptor (EGFR) family members such as HER2/Erbb2 can result in more aggressive disease, resistance to chemotherapy and reduced survival of head and neck squamous cell carcinoma (HNSCC) patients. In order to identify mechanisms through which these receptor tyrosine kinases accelerate tumor progression, the regulation of metalloprotease expression by EGFR family members was investigated in 11 squamous cell carcinoma (SCC) cell lines. HER2 expression was significantly correlated with ADAM12 (A Disintegrin And Metalloprotease 12) expression in these cell lines and was co-expressed in human head and neck cancers. Inhibition of HER2 or EGFR decreased ADAM12 transcripts whereas HER2 transfection upregulated ADAM12 expression. To understand the molecular mechanisms underlying HER2 regulation of ADAM12, we investigated the signaling pathways directing ADAM12 production in SCC cells. Inhibition of phosphatidyl inositol-3-kinase or mammalian target of rapamycin decreased ADAM12 transcripts in HER2-expressing SCC cells, whereas transfection with AKT increased ADAM12 mRNA. Experiments utilizing ADAM12 transfection or siRNA targeting of ADAM12 revealed that the protease increased both the migration and invasiveness of oral SCC cells. Surprisingly, ADAM12 also increased HER2 message, protein levels and activity through an Ets1-dependent mechanism. Collectively, these results reveal a novel positive activation loop between ADAM12 and HER2 that may contribute to HNSCC progression. Oncogene (2012) 31, 2888-2898; doi:10.1038/onc.2011.460; published online 10 October 2011	[Rao, V. H.; Kandel, A.; Lynch, D.; Pena, Z.; Marwaha, N.; Hansen, L. A.] Creighton Univ, Sch Med, Dept Biomed Sci, Omaha, NE 68178 USA; [Deng, C.] Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA; [Watson, P.] Creighton Univ, Sch Med, Dept Prevent Hlth, Omaha, NE 68178 USA	Creighton University; Creighton University; Creighton University	Hansen, LA (corresponding author), Creighton Univ, Sch Med, Dept Biomed Sci, 2500 Calif Plaza,Criss 2,Room 431, Omaha, NE 68178 USA.	LHansen@creighton.edu			NIH; Nebraska Cancer and Smoking-Related Diseases Research Program; Dobleman Institute for Head and Neck Cancer Research; National Institutes of Health [1RO1ES015585]; State of Nebraska [LB595]; Dobleman Head and Neck Cancer Institute; National Center for Research Resources, National Institutes of Health [1CO6RR17417-01, G20RR024001]; NATIONAL CENTER FOR RESEARCH RESOURCES [G20RR024001, C06RR017417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015585] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Cancer and Smoking-Related Diseases Research Program; Dobleman Institute for Head and Neck Cancer Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); State of Nebraska; Dobleman Head and Neck Cancer Institute; National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Dr Hansen's work has been funded by the NIH, the Nebraska Cancer and Smoking-Related Diseases Research Program and the Dobleman Institute for Head and Neck Cancer Research. The other authors declare no conflict of interest.; The cell lines used in this study were gifts from Drs Greg Oakley (University of Nebraska, Lincoln) and Thomas Carey (University of Michigan). We also thank Drs U. Wewer and C. Frohlich (University of Copenhagen, Denmark) for the gifts of ADAM12 plasmids. This research was supported by the National Institutes of Health (1RO1ES015585), the State of Nebraska LB595 and The Dobleman Head and Neck Cancer Institute. This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant Numbers 1CO6RR17417-01 and G20RR024001 from the National Center for Research Resources, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.	Akervall J, 2004, ACTA OTO-LARYNGOL, V124, P851, DOI 10.1080/00016480410017323; Ang KK, 2002, CANCER RES, V62, P7350; Arora S, 2005, CLIN CANCER RES, V11, P2272, DOI 10.1158/1078-0432.CCR-04-0572; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Brunner K, 2010, ANAL QUANT CYTOL, V32, P78; Carl-McGrath S, 2005, INT J ONCOL, V26, P17; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chin D, 2006, EXPERT REV ANTICANC, V6, P1111, DOI 10.1586/14737140.6.7.1111; Coutant A, 2005, J HEPATOL, V43, P1038; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404; Ettl T, 2008, HISTOPATHOLOGY, V53, P567, DOI 10.1111/j.1365-2559.2008.03159.x; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; GRENMAN R, 1991, CANCER, V67, P2741, DOI 10.1002/1097-0142(19910601)67:11<2741::AID-CNCR2820671105>3.0.CO;2-S; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Hudson LG, 2009, FUTURE ONCOL, V5, P323, DOI 10.2217/FON.09.10; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Jacobsen J, 2009, CURR PHARM DESIGN, V15, P2300, DOI 10.2174/138161209788682389; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Kong A, 2006, CANCER RES, V66, P2834, DOI 10.1158/0008-5472.CAN-05-2994; Kornberg LJ, 2005, LARYNGOSCOPE, V115, P690, DOI 10.1097/01.mlg.0000161333.67977.93; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lendeckel U, 2005, J CANCER RES CLIN, V131, P41, DOI 10.1007/s00432-004-0619-y; Liu F, 2001, EUR J BIOCHEM, V268, P3501, DOI 10.1046/j.1432-1327.2001.02254.x; Madson JG, 2006, AM J PATHOL, V169, P1402, DOI 10.2353/ajpath.2006.060082; Madson JG, 2009, AM J PATHOL, V174, P2357, DOI 10.2353/ajpath.2009.080638; Markowski J, 2009, J PHYSIOL PHARMACOL, V60, P57; Mino N, 2009, J SURG ONCOL, V100, P267, DOI 10.1002/jso.21313; Moon C, 2010, EXP BIOL MED, V235, P907, DOI 10.1258/ebm.2009.009181; O-Charoenrat P, 2000, INT J CANCER, V86, P307, DOI 10.1002/(SICI)1097-0215(20000501)86:3<307::AID-IJC2>3.0.CO;2-I; Ou CC, 2008, CARCINOGENESIS, V29, P299, DOI 10.1093/carcin/bgm263; Pande P, 1999, J PATHOL, V189, P40, DOI 10.1002/(SICI)1096-9896(199909)189:1<40::AID-PATH405>3.0.CO;2-#; Pande P, 2001, CANCER DETECT PREV, V25, P496; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Ragin CCR, 2007, J DENT RES, V86, P104, DOI 10.1177/154405910708600202; Rocks N, 2006, BRIT J CANCER, V94, P724, DOI 10.1038/sj.bjc.6602990; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Rohatgi N, 2005, ORAL ONCOL, V41, P806, DOI 10.1016/j.oraloncology.2005.04.010; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Sato-Kuwabara Y, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-6; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Squire JA, 2002, HEAD NECK-J SCI SPEC, V24, P874, DOI 10.1002/hed.10122; Thodeti CK, 2005, EXP CELL RES, V309, P438, DOI 10.1016/j.yexcr.2005.06.020; Worsham MJ, 1999, J CLIN PATHOL-MOL PA, V52, P42, DOI 10.1136/mp.52.1.42; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294	52	37	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2888	2898		10.1038/onc.2011.460	http://dx.doi.org/10.1038/onc.2011.460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986939	Green Accepted			2022-12-28	WOS:000305277900008
J	Neal, CL; Xu, J; Li, P; Mori, S; Yang, J; Neal, NN; Zhou, X; Wyszomierski, SL; Yu, D				Neal, C. L.; Xu, J.; Li, P.; Mori, S.; Yang, J.; Neal, N. N.; Zhou, X.; Wyszomierski, S. L.; Yu, D.			Overexpression of 14-3-3 zeta in cancer cells activates PI3K via binding the p85 regulatory subunit	ONCOGENE			English	Article						14-3-3 zeta; breast cancer; PI3K; Akt	BREAST-CANCER; CAMP-PKA; 14-3-3-PROTEINS; INHIBITION; PROTEINS; SURVIVAL; GROWTH; PHOSPHORYLATION; ISOFORMS; RECEPTOR	The ubiquitously expressed 14-3-3 proteins regulate many pathways involved in transformation. Previously, we found that 14-3-3 zeta overexpression increased Akt phosphorylation in human mammary epithelial cells. Here, we investigated the clinical relevance and molecular mechanism of 14-3-3 zeta-overexpression-mediated Akt phosphorylation, and its potential impact on breast cancer progression. We found that 14-3-3 zeta overexpression was significantly (P = 0.005) associated with increased Akt phosphorylation in human breast tumors. Additionally, 14-3-3 zeta overexpression combined with strong Akt phosphorylation was significantly (P = 0.01) associated with increased cancer recurrence in patients. In contrast, knockdown of 14-3-3 zeta expression by small interfering RNA in cancer cell lines and tumor xenografts reduced Akt phosphorylation. Furthermore, 14-3-3 zeta enhanced Akt phosphorylation through activation of phosphoinositide 3-kinase (PI3K). Mechanistically, 14-3-3 zeta bound to the p85 regulatory subunit of PI3K and increased PI3K translocation to the cell membrane. A single 14-3-3-binding motif encompassing serine 83 on p85 is largely responsible for 14-3-3 zeta-mediated p85 binding and PI3K/Akt activation. Mutation of serine 83 to alanine on p85 inhibited 14-3-3 zeta binding to the p85 subunit of PI3K, reduced PI3K membrane localization and activation, impeded anchorage-independent growth and enhanced stress-induced apoptosis. These findings revealed a novel mechanism by which 14-3-3 zeta overexpression activates PI3K, a key node in the mitogenic signaling network known to promote malignancies in many cell types. Oncogene (2012) 31, 897-906; doi: 10.1038/onc.2011.284; published online 11 July 2011	[Neal, C. L.; Xu, J.; Li, P.; Mori, S.; Yang, J.; Neal, N. N.; Zhou, X.; Wyszomierski, S. L.; Yu, D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Xu, J.; Yang, J.; Yu, D.] Univ Texas Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Yu, D (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Bolvard,Box 108, Houston, TX 77030 USA.	dyu@mdanderson.org		Xu, Jia/0000-0003-0254-6261; Yu, Dihua/0000-0001-6231-9381	NIH [P30-CA 16672, RO1-CA112567, PO1-CA099031]; Department of Defense (DOD) [BC050006, W81XWH-08-1-0712]; Susan G Komen Breast Cancer Foundation [KG091020]; NATIONAL CANCER INSTITUTE [R01CA112567, P01CA099031, P30CA016672] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (DOD)(United States Department of Defense); Susan G Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NIH P30-CA 16672 ( MDACC); RO1-CA112567, PO1-CA099031 project 4, Department of Defense (DOD) Center of Excellence (BC050006) subproject, DOD Synergistic Award W81XWH-08-1-0712 and Susan G Komen Breast Cancer Foundation Promise Grant KG091020 ( D Yu). Dr Dihua Yu is the Hubert L and Olive Stringer Distinguished Chair in Basic Science, MDACC. We thank Dr Lewis Cantley for providing p85 knockout MEFs. We also thank X Du, K Matias, T Chen, J Hannay, S Zhang and S Rehman for reagents, suggestions and manuscript reading.	AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Barboric M, 2005, EMBO J, V24, P4291, DOI 10.1038/sj.emboj.7600883; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Brachmann SA, 2005, MOL CELL BIOL, V25, P2593, DOI 10.1128/MCB.25.7.2593-2606.2005; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cosentino C, 2007, ONCOGENE, V26, P2095, DOI 10.1038/sj.onc.1210027; Craparo A, 1997, J BIOL CHEM, V272, P11663; Danes CG, 2008, CANCER RES, V68, P1760, DOI 10.1158/0008-5472.CAN-07-3177; De Gregorio G, 2007, ONCOGENE, V26, P2039, DOI 10.1038/sj.onc.1210011; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kim SJ, 2005, FEBS LETT, V579, P534, DOI 10.1016/j.febslet.2004.12.024; Lonic A, 2008, MOL CELL BIOL, V28, P3372, DOI 10.1128/MCB.01837-07; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Munday AD, 2000, BLOOD, V96, P577; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; Oksvold MP, 2004, FEBS LETT, V569, P207, DOI 10.1016/j.febslet.2004.05.068; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Tan M, 1997, CANCER RES, V57, P1199; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	32	67	68	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					897	906		10.1038/onc.2011.284	http://dx.doi.org/10.1038/onc.2011.284			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743495	Green Accepted			2022-12-28	WOS:000300615800008
J	Xu, J; Wang, B; Xu, Y; Sun, L; Tian, W; Shukla, D; Barod, R; Grillari, J; Grillari-Voglauer, R; Maxwell, PH; Esteban, MA				Xu, J.; Wang, B.; Xu, Y.; Sun, L.; Tian, W.; Shukla, D.; Barod, R.; Grillari, J.; Grillari-Voglauer, R.; Maxwell, P. H.; Esteban, M. A.			Epigenetic regulation of HIF-1 alpha in renal cancer cells involves HIF-1 alpha/2 alpha binding to a reverse hypoxia-response element	ONCOGENE			English	Article						von Hippel-Lindau tumor suppressor gene; hypoxia-inducible factor; renal cancer; epigenetics; histone modifications	TUMOR-SUPPRESSOR PROTEIN; INDUCIBLE FACTOR-I; HISTONE DEMETHYLASES; C-MYC; EXPRESSION; VHL; HIF; CARCINOMA; ALPHA; GENE	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene underlies the majority of sporadic clear cell renal cell carcinomas (CCRCCs) and is also responsible for the hereditary VHL cancer syndrome. VHL loss of function results in constitutive stabilization of hypoxia-inducible factors (HIF-1 alpha and HIF-2 alpha) due to insufficient proteolysis in the presence of oxygen. This activates multiple genes relevant to tumorigenesis, allowing cells to acquire further mutations and undergo malignant transformation. However, the specific role of each HIF-alpha subunit in CCRCC tumorigenesis is not yet well understood. The current paradigm supports that in the first stages of CCRCC formation the stabilization of HIF-1 alpha is dominant and this limits proliferation, but later on HIF-2 alpha increases and this induces a more aggressive cell behavior. Understanding how this transition happens is highly relevant, as it may provide novel ways to treat these cancers. Here, we show that VHL inactivation in CCRCC cells results in HIF-1 alpha/2 alpha-dependent down-regulation of HIF-1 alpha mRNA through direct binding of either subunit to a reverse hypoxia-response element in the HIF-1 alpha proximal promoter. This binding activates a series of repressive histone modification marks including histone 3 lysine 27 trimethylation (H3K27me3) to make the changes stable, and if overturned reduces CCRCC cell proliferation due to excessive HIF-1 alpha expression level. Our findings thus help understand how HIF-alpha subunits influence each other and also reinforce the idea that epigenetic mechanisms are a key step of CCRCC progression. Oncogene (2012) 31, 1065-1072; doi:10.1038/onc.2011.305; published online 15 August 2011	[Xu, J.; Wang, B.; Xu, Y.; Sun, L.; Tian, W.; Esteban, M. A.] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, S China Inst Stem Cell Biol & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China; [Shukla, D.; Barod, R.; Maxwell, P. H.] UCL, Rayne Inst, Ctr Cell Signaling & Mol Genet, London, England; [Grillari, J.; Grillari-Voglauer, R.] Univ Nat Resources & Life Sci, Dept Biotechnol Aging & Immortalizat Res, Vienna, Austria	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; University of London; King's College London; University College London; University of Natural Resources & Life Sciences, Vienna	Esteban, MA (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Stem Cell & Canc Biol Grp,Key Lab Regenerat Biol, S China Inst Stem Cell Biol & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China.	estebanb@gibh.org	Grillari, Johannes/B-2967-2011; Maxwell, Patrick H/C-5557-2008	Grillari, Johannes/0000-0001-5474-6332; Maxwell, Patrick H/0000-0002-0338-2679; Tian, Weihua/0000-0003-2357-3947; Xu, Yan/0000-0001-5653-291X	Guangzhou Institutes of Biomedicine and Health; Chinese Academy of Sciences [KSCX2-YW-R-244]; National Institute for Health Research [NF-SI-0507-10315] Funding Source: researchfish	Guangzhou Institutes of Biomedicine and Health; Chinese Academy of Sciences(Chinese Academy of Sciences); National Institute for Health Research(National Institute for Health Research (NIHR))	This work was supported by start-up funding from the Guangzhou Institutes of Biomedicine and Health and the Chinese Academy of Sciences Grant KSCX2-YW-R-244 to MAE. We thank Dr Duanqing Pei for his constant support.	Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Christophersen NS, 2010, J EXP MED, V207, P2287, DOI 10.1084/jem.20101438; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dayan F, 2006, CANCER RES, V66, P3688, DOI 10.1158/0008-5472.CAN-05-4564; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Jeong CH, 2007, J BIOL CHEM, V282, P13672, DOI 10.1074/jbc.M700534200; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koslowski M, 2011, ONCOGENE, V30, P876, DOI 10.1038/onc.2010.481; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Lee KJ, 2010, BBA-MOL CELL RES, V1803, P608, DOI 10.1016/j.bbamcr.2010.01.004; Lin Q, 2011, MOL CANC RES, DOI 10.115811541-7786. MCR-11-0053; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 2002, CANCER RES, V62, P1158; Menrad H, 2010, HEPATOLOGY, V51, P2183, DOI 10.1002/hep.23597; Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Xu JY, 2010, J AM SOC NEPHROL, V21, P2041, DOI 10.1681/ASN.2010040345; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930	39	27	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1065	1072		10.1038/onc.2011.305	http://dx.doi.org/10.1038/onc.2011.305			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21841824				2022-12-28	WOS:000300709700012
J	Cao, X; Geradts, J; Dewhirst, MW; Lo, HW				Cao, X.; Geradts, J.; Dewhirst, M. W.; Lo, H-W			Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells	ONCOGENE			English	Article						GLI1; tGLI1; breast cancer; angiogenesis; migration and invasion; VEGF	GROWTH-FACTOR RECEPTOR; SONIC-HEDGEHOG; STEM-CELLS; HUMAN GLIOMA; MAMMALIAN HEPARANASE; DOWN-REGULATION; SELF-RENEWAL; TUMOR-GROWTH; FLOOR PLATE; PATHWAY	The Hedgehog signaling pathway is one of the most dysregulated pathways in human cancers. The glioma-associated oncogene homolog 1 (GLI1) transcription factor is the terminal effector of the Hedgehog pathway, frequently activated in human breast cancer and an emerging target of breast cancer therapy. While somatic mutations in the human GLI1 gene have never been reported in any cell or tumor type, we recently uncovered the existence of a novel alternatively spliced, truncated GLI1 (tGLI1) that has an in-frame deletion of 41 codons spanning the entire exon 3 and part of exon 4 of the GLI1 gene. Using glioblastoma models, we showed that tGLI1 has gained the ability to promote glioblastoma migration and invasion via its gain-of-function transcriptional activity. However, the pathological impact of tGLI1 on breast cancer remains undefined. Here, we report that tGLI1 is frequently expressed in human breast cancer cell lines and primary specimens we have examined to date, but is undetectable in normal breast tissues. We found for the first time that tGLI1, but not GLI1, binds to and enhances the human vascular endothelial growth factor-A (VEGF-A) gene promoter, leading to its upregulation. Consequently, tGLI1-expressing MDA-MB-231 breast cancer cells secret higher levels of VEGF-A and contain a higher propensity, than the isogenic cells with control vector and GLI1, to stimulate in vitro angiogenesis of human vascular endothelial cells. We further showed that tGLI1 has gained the ability to enhance the motility and invasiveness of breast cancer cells in a proliferation-independent manner and that this functional gain is associated with increased expression of migration/invasion-associated genes, CD24, MMP-2 and MMP-9. tGLI1 has also acquired the property to facilitate anchorage-independent growth of breast cancer cells. Collectively, our results define tGLI1 as a gain-of-function GLI1 transcription factor and a novel mediator of the behavior of clinically more aggressive breast cancer. Oncogene (2012) 31, 104-115; doi: 10.1038/onc.2011.219; published online 13 June 2011	[Cao, X.; Lo, H-W] Duke Univ, Sch Med, Dept Surg, Div Surg Sci, Durham, NC 27710 USA; [Geradts, J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA; [Dewhirst, M. W.] Duke Univ, Sch Med, Dept Radiat Oncol, Durham, NC 27710 USA; [Geradts, J.; Dewhirst, M. W.; Lo, H-W] Duke Canc Inst, Durham, NC USA; [Lo, H-W] Duke Univ, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Lo, HW (corresponding author), Duke Univ, Sch Med, Dept Surg, Div Surg Sci, Box 3156,433A MSRB I,103 Res Dr, Durham, NC 27710 USA.	huiwen.lo@duke.edu	Dewhirst, Mark/Q-1302-2019	Dewhirst, Mark/0000-0003-3459-6546; Lo, Hui-Wen/0000-0002-0681-7914	NIH [K01-CA118423]; DOD [W81XWH-07-1-0390]; Pediatric Brain Tumor Foundation; Beez Foundation; Intramural Division of Surgical Sciences Dani P. Bolognesi; NATIONAL CANCER INSTITUTE [K01CA118423] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); Pediatric Brain Tumor Foundation; Beez Foundation; Intramural Division of Surgical Sciences Dani P. Bolognesi; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH grant K01-CA118423, DOD grant W81XWH-07-1-0390, the Pediatric Brain Tumor Foundation and the Beez Foundation and the Intramural Division of Surgical Sciences Dani P. Bolognesi, PhD Award (to H-WL).	Ahmad A, 2010, BREAST CANCER RES TR, V122, P337, DOI 10.1007/s10549-009-0572-1; Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Cao XY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-26; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dasari VR, 2010, AGING-US, V2, P791, DOI 10.18632/aging.100217; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Gondi CS, 2004, NEURON GLIA BIOL, V1, P165, DOI 10.1017/S1740925X04000237; Kameda C, 2009, ANTICANCER RES, V29, P871; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI [10.2217/fon.09.145, 10.2217/FON.09.145]; Keysar SB, 2010, MOL CANCER THER, V9, P2450, DOI 10.1158/1535-7163.MCT-10-0530; Kim HJ, 2007, CANCER LETT, V258, P98, DOI 10.1016/j.canlet.2007.08.025; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3; Lee JH, 2009, ONCOL REP, V22, P1149, DOI 10.3892/or_00000548; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2008, MOL CANCER RES, V6, P843, DOI 10.1158/1541-7786.MCR-07-2105; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; Nagase T, 2008, ANGIOGENESIS, V11, P71, DOI 10.1007/s10456-008-9105-5; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Runz S, 2008, BIOCHEM BIOPH RES CO, V365, P35, DOI 10.1016/j.bbrc.2007.10.139; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schmidt M, 2008, ANTICANCER RES, V28, P1719; Shimokawa T, 2008, J BIOL CHEM, V283, P14345, DOI 10.1074/jbc.M800299200; ten Haaf A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-298; Timoshenko AV, 2006, BRIT J CANCER, V94, P1154, DOI 10.1038/sj.bjc.6603067; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Zhu H, 2010, CANCER LETT, V294, P101, DOI 10.1016/j.canlet.2010.01.028; Zhu H, 2010, CURR GENOMICS, V11, P238, DOI 10.2174/138920210791233108	52	91	96	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					104	115		10.1038/onc.2011.219	http://dx.doi.org/10.1038/onc.2011.219			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666711	Green Accepted			2022-12-28	WOS:000299176200010
J	Hunter, JE; Willmore, E; Irving, JAE; Hostomsky, Z; Veuger, SJ; Durkacz, BW				Hunter, J. E.; Willmore, E.; Irving, J. A. E.; Hostomsky, Z.; Veuger, S. J.; Durkacz, B. W.			NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699	ONCOGENE			English	Article						PARP-1; NF-kappa B; radio-sensitization; AG-014699; PAR	CHRONIC LYMPHOCYTIC-LEUKEMIA; ADP-RIBOSE POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE-1; IONIZING-RADIATION; TRANSCRIPTION FACTORS; DNA-DAMAGE; BINDING-ACTIVITY; CANCER THERAPY; CELL-LINES; ACTIVATION	The stress-inducible transcription factor, nuclear factor (NF)-kappa B induces genes involved in proliferation and apoptosis. Aberrant NF-kappa B activity is common in cancer and contributes to therapeutic-resistance. Poly(ADPribose) polymerase-1 (PARP-1) is activated during DNA strand break repair and is a known transcriptional co-regulator. Here, we investigated the role of PARP-1 function during NF-kappa B activation using p65 small interfering RNA (siRNA), PARP siRNA or the potent PARP-1 inhibitor, AG-014699. Survival and apoptosis assays showed that NF-kappa B p65(-/-) cells were more sensitive to ionizing radiation (IR) than p65(+/+) cells. Co-incubation with p65 siRNA, PARP siRNA or AG-014699 radio-sensitized p65(+/+), but not p65(-/-) cells, demonstrating that PARP-1 mediates its effects on survival via NF-kappa B. Single-strand break (SSB) repair kinetics, and the effect SSB repair inhibition by AG-014699 were similar in p65(+/+) and p65(-/-) cells. As preventing SSB repair did not radio-sensitize p65(-/-) cells, we conclude that radio-sensitization by AG-014699 is due to downstream inhibition of NF-kappa B activation, and independent of SSB repair inhibition. PARP-1 catalytic activity was essential for IR-induced p65 DNA binding and NF-kappa B-dependent gene transcription, whereas for tumor necrosis factor (TNF)-alpha-treated cells, PARP-1 protein alone was sufficient. We hypothesize that this stimulus-dependent differential is mediated via stimulation of the poly(ADP-ribose) polymer, which was induced following IR, not TNF-alpha. Targeting DNA damage-activated NF-kappa B using AG-014699 may therefore overcome toxicity observed with classical NF-kappa B inhibitors without compromising other vital inflammatory functions. These data highlight the potential of PARP-1 inhibitors to overcome NF-kappa B-mediated therapeutic resistance and widens the spectrum of cancers in which these agents may be utilized. Oncogene (2012) 31, 251-264; doi:10.1038/onc.2011.229; published online 27 June 2011	[Hunter, J. E.; Willmore, E.; Irving, J. A. E.; Veuger, S. J.; Durkacz, B. W.] Newcastle Univ, No Inst Canc Res, Newcastle Canc Ctr, Tyneside, England; [Hostomsky, Z.] Pfizer GRD, La Jolla, CA USA	Newcastle University - UK; Pfizer	Veuger, SJ (corresponding author), Newcastle Univ, Newcastle Canc Ctr, No Inst Canc Res, Sch Med, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	s.j.veuger@ncl.ac.uk	Hostomsky, Zdenek/G-3513-2011; Willmore, Elaine/B-4350-2009	Willmore, Elaine/0000-0002-4762-094X	Pfizer [AG-014699]; Cancer Research UK [C7369/A8048]	Pfizer(Pfizer); Cancer Research UK(Cancer Research UK)	We gratefully acknowledge Pfizer for the supply of AG-014699. This work was supported by Cancer Research UK, grant number C7369/A8048.	ALTHAUS FR, 1994, MOL CELL BIOCHEM, V138, P53, DOI 10.1007/BF00928443; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Daniel RA, 2009, CLIN CANCER RES, V15, P1241, DOI 10.1158/1078-0432.CCR-08-1095; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; Drew Y, 2009, DRUG RESIST UPDATE, V12, P153, DOI 10.1016/j.drup.2009.10.001; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Ghosh G., 1999, GENE THER MOL BIOL, V4, P75; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Hassa PO, 2005, J BIOL CHEM, V280, P40450, DOI 10.1074/jbc.M507553200; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hewamana S, 2008, BLOOD, V111, P4681, DOI 10.1182/blood-2007-11-125278; Hewamana S, 2009, J CLIN ONCOL, V27, P763, DOI 10.1200/JCO.2008.19.1114; Hewamana S, 2008, CLIN CANCER RES, V14, P8102, DOI 10.1158/1078-0432.CCR-08-1673; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; Kanzawa T, 2003, J BIOMED BIOTECHNOL, P25; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Mulligan EA, 2010, BLOOD, V116, P1477; OGOREK B, 1985, MUTAT RES, V146, P63, DOI 10.1016/0167-8817(85)90056-2; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Plummer ER, 2005, CLIN CANCER RES, V11, P3402, DOI 10.1158/1078-0432.CCR-04-2353; Plummer R, 2005, J CLIN ONCOL, V23, p208S; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; SAHIJDAK WM, 1994, RADIAT RES, V138, pS47, DOI 10.2307/3578760; Shaw H, 2006, J CLIN ONCOL, V24, p127S; SLAMA JT, 1995, J MED CHEM, V38, P389, DOI 10.1021/jm00002a021; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tschaharganeh D, 2007, PATHOL ONCOL RES, V13, P84, DOI 10.1007/BF02893482; Turco MC, 2004, LEUKEMIA, V18, P11, DOI 10.1038/sj.leu.2403171; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; Veuger SJ, 2009, ONCOGENE, V28, P832, DOI 10.1038/onc.2008.439; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Zaremba T, 2009, BRIT J CANCER, V101, P256, DOI 10.1038/sj.bjc.6605166	57	27	30	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					251	264		10.1038/onc.2011.229	http://dx.doi.org/10.1038/onc.2011.229			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21706052	Green Accepted			2022-12-28	WOS:000299307400010
J	Mathiasen, DP; Egebjerg, C; Andersen, SH; Rafn, B; Puustinen, P; Khanna, A; Daugaard, M; Valo, E; Tuomela, S; Bottzauw, T; Nielsen, CF; Willumsen, BM; Hautaniemi, S; Lahesmaa, R; Westermarck, J; Jaattela, M; Kallunki, T				Mathiasen, D. P.; Egebjerg, C.; Andersen, S. H.; Rafn, B.; Puustinen, P.; Khanna, A.; Daugaard, M.; Valo, E.; Tuomela, S.; Bottzauw, T.; Nielsen, C. F.; Willumsen, B. M.; Hautaniemi, S.; Lahesmaa, R.; Westermarck, J.; Jaattela, M.; Kallunki, T.			Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation	ONCOGENE			English	Article						JNK knockout; CIP2A; ATF3; c-Myc; Ras transformation	PROTEIN-KINASE ACTIVATION; TRANSCRIPTION FACTOR; HA-RAS; NH2-TERMINAL KINASE; GENE-EXPRESSION; RESPONSE GENE; GROWTH; PHOSPHORYLATION; ATF3; JNK	Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Ras-mediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation. Oncogene (2012) 31, 390-401; doi:10.1038/onc.2011.230; published online 27 June 2011	[Mathiasen, D. P.; Egebjerg, C.; Andersen, S. H.; Rafn, B.; Puustinen, P.; Daugaard, M.; Bottzauw, T.; Nielsen, C. F.; Jaattela, M.; Kallunki, T.] Danish Canc Soc, Inst Canc Biol, Apoptosis Dept, DK-2100 Copenhagen, Denmark; [Mathiasen, D. P.; Egebjerg, C.; Andersen, S. H.; Rafn, B.; Puustinen, P.; Daugaard, M.; Bottzauw, T.; Nielsen, C. F.; Jaattela, M.; Kallunki, T.] Danish Canc Soc, Inst Canc Biol, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark; [Khanna, A.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Valo, E.; Hautaniemi, S.] Univ Helsinki, Inst Biomed, Computat Syst Biol Lab, Helsinki, Finland; [Valo, E.; Hautaniemi, S.] Univ Helsinki, Genome Scale Biol Res Program, Helsinki, Finland; [Tuomela, S.; Lahesmaa, R.; Westermarck, J.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Tuomela, S.; Lahesmaa, R.; Westermarck, J.] Abo Akad Univ, Turku, Finland; [Willumsen, B. M.] Univ Copenhagen, Dept Biol, Copenhagen, Denmark; [Westermarck, J.] Univ Turku, Dept Pathol, Turku, Finland	Danish Cancer Society; Danish Cancer Society; Tampere University; University of Helsinki; University of Helsinki; University of Turku; Abo Akademi University; University of Copenhagen; University of Turku	Kallunki, T (corresponding author), Danish Canc Soc, Inst Canc Biol, Apoptosis Dept, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	tk@cancer.dk	Jäättelä, Marja/AAT-7932-2021; Hautaniemi, Sampsa/CAG-0362-2022; Nielsen, Christian Friberg/HHN-0347-2022; Westermarck, Jukka/AAL-6464-2020; Hautaniemi, Sampsa/A-3122-2009; Willumsen, Berthe M/H-1903-2012; Daugaard, Mads/Y-6483-2018	Jäättelä, Marja/0000-0001-5950-7111; Hautaniemi, Sampsa/0000-0002-7749-2694; Westermarck, Jukka/0000-0001-7478-3018; Hautaniemi, Sampsa/0000-0002-7749-2694; Willumsen, Berthe M/0000-0002-2277-6999; Nielsen, Christian Friberg/0000-0002-2886-317X; Valo, Erkka/0000-0003-0672-554X; Kallunki, Tuula/0000-0002-8571-383X; Daugaard, Mads/0000-0001-8383-055X	Danish Cancer Society; Danish Medical Research Council; Ellen and Aage Fausboll Helsefond; Danish National Research Foundation; Danish Cancer Research Foundation; Novo Nordisk Foundation; Academy of Finland; Pirkanmaa Hospital District; Finnish Cancer Society; Finnish Cancer Organizations; Finnish Microarray and Sequencing Centre at Turku Centre for Biotechnology; Cancer Foundation Finland sr [110134, 120139] Funding Source: researchfish	Danish Cancer Society(Danish Cancer Society); Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ellen and Aage Fausboll Helsefond; Danish National Research Foundation(Danmarks Grundforskningsfond); Danish Cancer Research Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Academy of Finland(Academy of Finland); Pirkanmaa Hospital District; Finnish Cancer Society; Finnish Cancer Organizations; Finnish Microarray and Sequencing Centre at Turku Centre for Biotechnology; Cancer Foundation Finland sr	This work was supported by the Danish Cancer Society (TK, MJ), the Danish Medical Research Council (TK), Ellen and Aage Fausboll Helsefond (TK), the Danish National Research Foundation (MJ), Danish Cancer Research Foundation (CE), the Novo Nordisk Foundation (CE), the Academy of Finland (JW, RL, SH), Competetive Research Funding of the Pirkanmaa Hospital District (JW, AK), the Finnish Cancer Society (JW, SH) and the Finnish Cancer Organizations (RL) and the Finnish Microarray and Sequencing Centre at Turku Centre for Biotechnology. We additionally thank Dr G Nolan for the pB-puro and pB-hygro constructs, Dr H Land for the c-Myc pB-puro construct, Dr S Kitajima for the ATF3 reporter constructs and Dr T Hai for the ATF3 construct. We are thankful for KG Henriksen and P Rammer for excellent assistance and LB Larsen and L Jorgensen for the in vivo tumorigenicity assay.	Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Berger AJ, 2003, CANCER RES, V63, P8103; Bhoumik A, 2004, CANCER RES, V64, P8222, DOI 10.1158/0008-5472.CAN-04-0714; Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bost F, 1999, MOL CELL BIOL, V19, P1938; BRUNET A, 1994, ONCOGENE, V9, P3379; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chen NY, 2001, CANCER RES, V61, P3908; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dietrich N, 2004, CELL DEATH DIFFER, V11, P301, DOI 10.1038/sj.cdd.4401353; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hubbard TJP, 2009, NUCLEIC ACIDS RES, V37, pD690, DOI 10.1093/nar/gkn828; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Kemp CJ, 2005, SEMIN CANCER BIOL, V15, P460, DOI 10.1016/j.semcancer.2005.06.003; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Mei Y, 2008, NEUROSCIENCE, V151, P771, DOI 10.1016/j.neuroscience.2007.10.057; Nielsen C, 2007, CANCER RES, V67, P178, DOI 10.1158/0008-5472.CAN-06-2801; Nielsen KH, 2001, ONCOGENE, V20, P2091, DOI 10.1038/sj.onc.1204306; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Ovaska K, 2010, GENOME MED, V2, DOI 10.1186/gm186; Pearn L, 2007, BLOOD, V109, P4461, DOI 10.1182/blood-2006-09-047217; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Schimanski CC, 2010, INT J COLORECTAL DIS, V25, P181, DOI 10.1007/s00384-009-0843-7; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sharma A, 2010, J BIOL CHEM, V285, P15724, DOI 10.1074/jbc.M109.100016; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Wang A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-268; Yao DC, 2010, DIABETES, V59, P249, DOI 10.2337/db09-0801; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	65	34	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					390	401		10.1038/onc.2011.230	http://dx.doi.org/10.1038/onc.2011.230			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21706057				2022-12-28	WOS:000299542100011
J	Zheng, YS; Zhang, H; Zhang, XJ; Feng, DD; Luo, XQ; Zeng, CW; Lin, KY; Zhou, H; Qu, LH; Zhang, P; Chen, YQ				Zheng, Y-S; Zhang, H.; Zhang, X-J; Feng, D-D; Luo, X-Q; Zeng, C-W; Lin, K-Y; Zhou, H.; Qu, L-H; Zhang, P.; Chen, Y-Q			MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia	ONCOGENE			English	Article						microRNA; acute myeloblastic leukemia; granulocyte/monocyte differentiation; RBSP3-pRB-E2F1 pathway	RETINOBLASTOMA PROTEIN PATHWAY; FREQUENT ALTERATIONS; BINDING PROTEIN; CANCER; MICRORNAS; CYCLE; E2F1; KARYOTYPE; APOPTOSIS; PATTERNS	Acute myeloblastic leukemia (AML) is characterized by the accumulation of abnormal myeloblasts (mainly granulocyte or monocyte precursors) in the bone marrow and blood. Though great progress has been made for improvement in clinical treatment during the past decades, only minority with AML achieve long-term survival. Therefore, further understanding mechanisms of leukemogenesis and exploring novel therapeutic strategies are still crucial for improving disease outcome. MicroRNA-100 (miR-100), a small non-coding RNA molecule, has been reported as a frequent event aberrantly expressed in patients with AML; however, the molecular basis for this phenotype and the statuses of its downstream targets have not yet been elucidated. In the present study, we found that the expression level of miR-100 in vivo was related to the stage of the maturation block underlying the subtypes of myeloid leukemia. In vitro experiments further demonstrated that miR-100 was required to promote the cell proliferation of promyelocytic blasts and arrest them differentiated to granulocyte/monocyte lineages. Significantly, we identified RBSP3, a phosphatase-like tumor suppressor, as a bona fide target of miR-100 and validated that RBSP3 was involved in cell differentiation and survival in AML. Moreover, we revealed a new pathway that miR-100 regulates G1/S transition and S-phase entry and blocks the terminal differentiation by targeting RBSP3, which partly in turn modulates the cell cycle effectors pRB/E2F1 in AML. These events promoted cell proliferation and blocked granulocyte/monocyte differentiation. Our data highlight an important role of miR-100 in the molecular etiology of AML, and implicate the potential application of miR-100 in cancer therapy. Oncogene (2012) 31, 80-92; doi: 10.1038/onc.2011.208; published online 6 June 2011	[Chen, Y-Q] Sun Yat Sen Univ, Minist Educ, Biotechnol Res Ctr, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China; [Zheng, Y-S] Hainan Univ, Dept Biotechnol, Hainan, Peoples R China; [Luo, X-Q] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, P.] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing, Peoples R China; [Zhang, P.] Third Mil Med Univ, Southwest Hosp, SW Canc Ctr, Chongqing, Peoples R China	Sun Yat Sen University; Hainan University; Sun Yat Sen University; Army Medical University; Army Medical University	Chen, YQ (corresponding author), Sun Yat Sen Univ, Minist Educ, Biotechnol Res Ctr, Key Lab Gene Engn,State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.	lsscyq@mail.sysu.edu.cn	Lin, Kangyu/I-8050-2016; Zhang, Hua/AAF-3999-2020; Zeng, Chengwu/AAA-8920-2019; Zhang, Hua/AAA-2164-2022	Lin, Kangyu/0000-0003-0140-2557; Zhang, Hua/0000-0001-9731-2737; Zhang, Xingju/0000-0003-0717-2510; Zhou, Hui/0000-0001-9157-3792; Zeng, Chengwu/0000-0002-1333-3918	National Science and Technology Department [2011CBA01105, 2011CB811301, 2009ZX09103-641]; National Natural Science Foundation of China [30872784, 81070440]; Fundamental Research Funds for the Central Universities	National Science and Technology Department; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank the following investigators and hospitals that provided samples for the analysis: Dr Hai-Xia Guo at the Second Affiliated Hospital of Sun Yat-sen University; Li-Bing Huang at the First Affiliated Hospital of Sun Yat-sen University; This work was supported by National Science and Technology Department (2011CBA01105, 2011CB811301 and 2009ZX09103-641) and the funds from National Natural Science Foundation of China (No 30872784 and 81070440), as well as supported by 'the Fundamental Research Funds for the Central Universities'. We thank Nature Publishing Group Language Editing, LLC for editing the text of the manuscript.	Anedchenko EA, 2008, MOL BIOL+, V42, P859, DOI 10.1134/S0026893308060058; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bousquet M, 2008, J EXP MED, V205, P2499, DOI 10.1084/jem.20080285; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Estey E, 2007, J CLIN ONCOL, V25, P1908, DOI 10.1200/JCO.2006.10.2731; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Farag SS, 2005, J CLIN ONCOL, V23, P482, DOI 10.1200/JCO.2005.06.090; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Ghosh A, 2010, CANCER SCI, V101, P1511, DOI 10.1111/j.1349-7006.2010.01551.x; Guo XB, 2010, BIOCHEM BIOPH RES CO, V398, P1, DOI 10.1016/j.bbrc.2010.05.082; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831; Ji Y, 2004, CANCER RES, V64, P370, DOI 10.1158/0008-5472.CAN-03-3029; Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863; Jongen-Lavrencic M, 2008, BLOOD, V111, P5078, DOI 10.1182/blood-2008-01-133355; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Kashuba VI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005231; Lee KH, 2009, ONCOGENE, V28, P3360, DOI 10.1038/onc.2009.192; Leite KR, 2009, UROL ONCOL, V29, P265; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin RJ, 2010, MOL CARCINOGEN, V49, P719, DOI 10.1002/mc.20647; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Pigazzi M, 2009, CANCER RES, V69, P2471, DOI 10.1158/0008-5472.CAN-08-3404; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rosa A, 2007, P NATL ACAD SCI USA, V104, P19849, DOI 10.1073/pnas.0706963104; Senchenko VN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-75; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Sinha S, 2008, CANCER SCI, V99, P1984, DOI 10.1111/j.1349-7006.2008.00952.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang JR, 2009, EUR J CELL BIOL, V88, P103, DOI 10.1016/j.ejcb.2008.05.003; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826	48	94	107	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					80	92		10.1038/onc.2011.208	http://dx.doi.org/10.1038/onc.2011.208			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643017	Green Published, hybrid			2022-12-28	WOS:000299176200008
J	Fenouille, N; Puissant, A; Tichet, M; Zimniak, G; Abbe, P; Mallavialle, A; Rocchi, S; Ortonne, JP; Deckert, M; Ballotti, R; Tartare-Deckert, S				Fenouille, N.; Puissant, A.; Tichet, M.; Zimniak, G.; Abbe, P.; Mallavialle, A.; Rocchi, S.; Ortonne, J-P; Deckert, M.; Ballotti, R.; Tartare-Deckert, S.			SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival	ONCOGENE			English	Article						melanoma; p53; signaling; tumor biology	INTEGRIN-LINKED KINASE; TUMOR-SUPPRESSOR P53; MALIGNANT-MELANOMA; THERAPEUTIC TARGET; CYSTEINE SPARC; UP-REGULATION; CANCER CELLS; E-CADHERIN; APOPTOSIS; EXPRESSION	Aberrant expression of Secreted Protein Acidic and Rich in Cysteine (SPARC)/osteonectin has been associated with an invasive tumor cell phenotype and poor outcome in human melanomas. Although it is known that SPARC controls melanoma tumorigenesis, the precise role of SPARC in melanoma cell survival is still unclear. Here, we show that SPARC has a cell-autonomous survival activity, which requires Akt-dependent regulation of p53. Suppression of SPARC by RNA interference in several human melanoma cells and xenografted A375 tumors triggers apoptotic cell death through the mitochondrial intrinsic pathway and activation of caspase-3. Cell death induced by depletion of SPARC is dependent on p53 and induction of Bax, and results in the generation of ROS. Stabilization of p53 in SPARC-depleted cells is associated with a decrease in Akt-mediated activating phosphorylation of MDM2. Inhibition of Akt signaling pathway is important for the observed changes as overexpression of constitutively active Akt protects cells against apoptosis induced by SPARC depletion. Conversely, increased expression of SPARC stimulates Akt and MDM2 phosphorylation, thus facilitating p53 degradation. Finally, we show that overexpression of SPARC renders cells more resistant to the p53-mediated cytotoxic effects of the DNA-damaging drug actinomycin-D. Our study indicates that SPARC functions through activation of Akt and MDM2 to limit p53 levels and that acquired expression of SPARC during melanoma development would confer survival advantages through suppression of p53-dependent apoptotic pathways. Oncogene (2011) 30, 4887-4900; doi: 10.1038/onc.2011.198; published online 20 June 2011	[Fenouille, N.; Tichet, M.; Zimniak, G.; Abbe, P.; Rocchi, S.; Ortonne, J-P; Ballotti, R.; Tartare-Deckert, S.] INSERM, Ctr Mediterraneene Med Mole C3M, U895, F-06204 Nice 3, France; [Fenouille, N.; Puissant, A.; Tichet, M.; Zimniak, G.; Abbe, P.; Mallavialle, A.; Rocchi, S.; Ortonne, J-P; Deckert, M.; Ballotti, R.; Tartare-Deckert, S.] Univ Nice Sophia Antipolis, Fac Med, Inst Signalisat & Pathol IFR50, Nice, France; [Mallavialle, A.; Deckert, M.] INSERM, U576, F-06204 Nice 3, France; [Rocchi, S.; Ballotti, R.; Tartare-Deckert, S.] Hop Archet, CHU Nice, Dept Dermatol, Nice, France; [Deckert, M.] Hop Archet, CHU Nice, Dept Clin Hematol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice	Tartare-Deckert, S (corresponding author), INSERM, Ctr Mediterraneene Med Mole C3M, U895, Equipe 1,151 Route St Antoine Ginestiere,BP 23194, F-06204 Nice 3, France.	tartare@unice.fr	PUISSANT, ALEXANDRE/O-9575-2016; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/T-3566-2019; Deckert, Marcel/M-4998-2016; Fenouille, Nina/AAI-1027-2021; BALLOTTI, Robert/F-8825-2013; Puissant, Alexandre/AAF-3875-2021; Rocchi, Stephane/O-4152-2016	PUISSANT, ALEXANDRE/0000-0002-3997-9282; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X; Puissant, Alexandre/0000-0002-3997-9282; Rocchi, Stephane/0000-0002-0943-1304; mallavialle, aude/0000-0002-9380-6788; Tichet, Melanie/0000-0001-7128-4061; BALLOTTI, Robert/0000-0002-7322-4908	INSERM (Institut National de la Santeet de la Recherche Medicale); ARC (Association pour la Recherche sur le Cancer) [1136]	INSERM (Institut National de la Santeet de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer)	This work was supported in part by INSERM (Institut National de la Santeet de la Recherche Medicale) and grant 1136 from ARC (Association pour la Recherche sur le Cancer). S Tartare-Deckert is a recipient of a Contrat d'Interface Clinique, Service de Dermatologie, CHU de Nice.	ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Arnold SA, 2009, J CELL COMMUN SIGNAL, V3, P255, DOI 10.1007/s12079-009-0072-4; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bailet O, 2009, CANCER RES, V69, P2748, DOI 10.1158/0008-5472.CAN-08-2690; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Chang W, 2010, J BIOL CHEM, V285, P8196, DOI 10.1074/jbc.M109.025684; Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503; De S, 2003, J BIOL CHEM, V278, P39044, DOI 10.1074/jbc.M304494200; Fenouille N, 2011, PIGM CELL MELANOMA R, V24, P219, DOI 10.1111/j.1755-148X.2010.00790.x; Fenouille N, 2010, CANCER RES, V70, P9659, DOI 10.1158/0008-5472.CAN-10-2034; Fukunaga-Kalabis M, 2008, CANCER MICROENVIRON, V1, P93, DOI 10.1007/s12307-008-0009-0; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Horie K, 2010, CANCER SCI, V101, P913, DOI 10.1111/j.1349-7006.2009.01476.x; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Khwaja FW, 2006, ONCOGENE, V25, P7650, DOI 10.1038/sj.onc.1209969; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; MIYASHITA T, 1995, CELL, V80, P293; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Nie J, 2008, STEM CELLS, V26, P2735, DOI 10.1634/stemcells.2008-0212; Nie J, 2009, J CELL COMMUN SIGNAL, V3, P247, DOI 10.1007/s12079-009-0064-4; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Portela M, 2010, DEV CELL, V19, P562, DOI 10.1016/j.devcel.2010.09.004; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008-5472.CAN-08-1327; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Shi Q, 2007, ONCOGENE, V26, P4084, DOI 10.1038/sj.onc.1210181; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Smalley KSM, 2007, CANCER RES, V67, P209, DOI 10.1158/0008-5472.CAN-06-1538; Smit DJ, 2007, INT J CANCER, V121, P2653, DOI 10.1002/ijc.23039; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Sturm RA, 2002, CANCER RES, V62, P226; Tang MJ, 2007, J BIOL CHEM, V282, P34457, DOI 10.1074/jbc.M704459200; Tuveson DA, 2003, CANCER CELL, V4, P95, DOI 10.1016/S1535-6108(03)00189-2; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weaver MS, 2008, J BIOL CHEM, V283, P22826, DOI 10.1074/jbc.M706563200; WEISS J, 1993, INT J CANCER, V54, P693, DOI 10.1002/ijc.2910540427; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	53	49	49	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	49					4887	4900		10.1038/onc.2011.198	http://dx.doi.org/10.1038/onc.2011.198			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21685937				2022-12-28	WOS:000298346400005
J	Li, B; Antonyak, MA; Zhang, J; Cerione, RA				Li, B.; Antonyak, M. A.; Zhang, J.; Cerione, R. A.			RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells	ONCOGENE			English	Article						microvesicles; oncosomes; RhoA; ROCK; LIMK; tissue transglutaminase	LIM-KINASE; PROSTATE-CANCER; TISSUE TRANSGLUTAMINASE; IN-VIVO; ROCK; METASTASIS; EXOSOMES; PHOSPHORYLATION; MEDIATORS; INVASION	Vesicular structures called microvesicles (MVs) that are shed from the surfaces of cancer cells are capable of transferring oncogenic cargo to recipient cancer cells, as well as to normal cells, sending mitogenic signals that greatly enhance tumor growth. Because MVs are stable in the circulation, they also may have a key role in secondary colonization and metastasis. Thus, understanding how MVs are generated could have important consequences for interfering with cancer progression. Here we report that the small GTPase RhoA triggers a specific signaling pathway essential for MV biogenesis in various human cancer cells. Inhibiting the activity of different proteins comprising this pathway blocks MV biogenesis in the donor cancer cells and prevents oncogenic transformation in cell culture as well as tumor growth in mice. Although RhoA has often been implicated in human cancer, these findings now highlight a previously unappreciated role for this GTPase in malignant transformation, and demonstrate that blocking MV biogenesis may offer novel approaches for interfering with malignant transformation.	[Li, B.; Antonyak, M. A.; Zhang, J.; Cerione, R. A.] Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; [Li, B.; Cerione, R. A.] Cornell Univ, Baker Lab, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu	Li, Bo/O-7127-2019; Li, Bo/M-2192-2013; Li, Bo/Y-2835-2019; Li, Bo/M-2192-2013	Li, Bo/0000-0002-7979-8339; Li, Bo/0000-0002-7979-8339; Li, Bo/0000-0001-8256-5045	NIH; Komen Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458, R01GM040654] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Cindy Westmiller for her secretarial assistance and the NIH and the Komen Foundation for funding.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Antonyak MA, 2011, P NATL ACAD SCI USA, V108, P4852, DOI 10.1073/pnas.1017667108; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Catellana D, 2009, CANCER RES, V69, P785; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Davila M, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-40; Di Vizio D, 2009, CANCER RES, V69, P5601, DOI 10.1158/0008-5472.CAN-08-3860; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Hao S., 2006, Experimental Oncology, V28, P126; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Jung T, 2009, NEOPLASIA, V11, P1093, DOI 10.1593/neo.09822; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Keller S, 2006, IMMUNOL LETT, V107, P102, DOI 10.1016/j.imlet.2006.09.005; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Li B, 2010, P NATL ACAD SCI USA, V107, P1408, DOI 10.1073/pnas.0907907107; Loirand G, 2006, CIRC RES, V98, P322, DOI 10.1161/01.RES.0000201960.04223.3c; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9; Micuda S, 2010, CURR CANCER DRUG TAR, V10, P127, DOI 10.2174/156800910791054202; Muralidharan-Chari V, 2009, CURR BIOL, V19, P1875, DOI 10.1016/j.cub.2009.09.059; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Petrache I, 2003, FASEB J, V17, P407, DOI 10.1096/fj.02-0672com; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Teis D, 2009, CELL, V137, DOI 10.1016/j.cell.2009.03.027; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048	35	214	216	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4740	4749		10.1038/onc.2011.636	http://dx.doi.org/10.1038/onc.2011.636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266864	Green Accepted			2022-12-28	WOS:000311033000002
J	Thaler, S; Schmidt, M; Schad, A; Sleeman, JP				Thaler, S.; Schmidt, M.; Schad, A.; Sleeman, J. P.			RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development	ONCOGENE			English	Article						RASSF1A; estrogen receptor alpha; senescence; breast cancer inhibition	ONCOGENE-INDUCED SENESCENCE; C-MYC; ACTIVATION; BCL-2; DNA; CELLS; MICE; TRANSFORMATION; PROLIFERATION; METHYLATION	The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ER alpha) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ER alpha levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive genes Bcl-2 and c-Myc that cooperatively contribute to the immortalization and transformation of breast epithelial cells. This downregulation was associated with induction of cell-cycle arrest and senescence that constitute early barriers to cancer initiation and progression. Knockdown of ER alpha showed that downregulation of ER alpha suffices to increase senescence and inhibit expression of Bcl-2, c-Myc and Id1. However, enforced expression of ER alpha only partially rescued RASSF1A-mediated growth inhibition and senescence, suggesting that suppression of ER alpha expression and activity is not the only mechanism by which RASSF1A inhibits growth and survival of breast cancer cells. Ectopic expression of Bcl-2, c-Myc and Id1 had little or no effect on RASSF1A-mediated growth arrest, indicating that RASSF1A acts dominantly over these oncogenes. Mechanistically, RASSF1A was found to suppress ER alpha expression through Akt1. It also transiently inhibited ER alpha-induced Ras-MAPK activity after exposure of cells to E2. Together, our data show that RASSF1A acts as a tumor suppressor in ER alpha+ mammary epithelial cells, in part through inhibiting ER alpha expression and activity. These findings suggest that RASSF1A has a key role in suppressing the transformation of human breast epithelial cells and ER alpha+ breast cancer initiation.	[Thaler, S.] Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, D-68167 Mannheim, Germany; [Schmidt, M.] Johannes Gutenberg Univ Mainz, Dept Obstet & Gynecol, Mainz, Germany; [Schad, A.] Johannes Gutenberg Univ Mainz, Dept Pathol, D-6500 Mainz, Germany; [Sleeman, J. P.] Kernforschungszentrum Karlsruhe GmbH, Inst Genet & Toxikol, D-7500 Karlsruhe, Germany	Ruprecht Karls University Heidelberg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology	Thaler, S (corresponding author), Heidelberg Univ, Univ Med Mannheim, Ctr Biomed & Med Technol Mannheim CBTM, Med Fac Mannheim, TRIDOMUS Gebaude Haus C,Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	Sonja.Thaler@medma.uni-heidelberg.de	Schmidt, Marcus/H-3383-2013; Thaler, Sonja/AAC-4784-2020; Sleeman, Jonathan P/H-2515-2013	Schmidt, Marcus/0000-0003-1365-2414; Sleeman, Jonathan P/0000-0003-1718-7687	Deutsche Forschungsgemeinschaft [TH1523/1-2]; MAIFOR	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); MAIFOR	We are grateful to Selma Huber and workers in the KIT rodent facility and Gitta Flaig for excellent technical assistance. We thank Robert Weinberg for kindly providing pBabe-neo; William Hahn for providing pBabe-Neo-Myr-Flag-AKT1 and pWZL Blast myc and Jean Zhao for pWZL Neo Myr Flag AKT3. pMIG Bcl-2 was created in the laboratory of Stanley Korsmeyer and was kindly provided from Dana Farber Cancer Institute. This study was supported by Deutsche Forschungsgemeinschaft grant TH1523/1-2 to ST and MAIFOR (ST and MS).	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Blanco-Aparicio C, 2007, CARCINOGENESIS, V28, P584, DOI 10.1093/carcin/bgl190; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chen L, 2009, CANCER LETT, V278, P210, DOI 10.1016/j.canlet.2009.01.008; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clarke RB, 1997, CANCER RES, V57, P4987; Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DUBIK D, 1992, ONCOGENE, V7, P1587; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kondo N, 2008, CANCER RES, V68, P5004, DOI 10.1158/0008-5472.CAN-08-0180; Lawson JS, 1999, LANCET, V354, P1787, DOI 10.1016/S0140-6736(99)04936-3; Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390; Li TH, 2006, AM J PATHOL, V168, P1998, DOI 10.2353/ajpath.2006.051089; Lin CQ, 2000, CANCER RES, V60, P1332; Magro G, 2000, HISTOPATHOLOGY, V36, P515, DOI 10.1046/j.1365-2559.2000.00907.x; Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Planas-Silva MD, 2007, EXP MOL PATHOL, V82, P85, DOI 10.1016/j.yexmp.2006.09.001; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810; Shoker BS, 2000, J CLIN PATHOL, V53, P778, DOI 10.1136/jcp.53.10.778; Shoker BS, 1999, J PATHOL, V188, P237; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Sunami E, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2098; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Thaler S, 2009, CANCER RES, V69, P1748, DOI 10.1158/0008-5472.CAN-08-1377; Urlinger S, 2000, P NATL ACAD SCI USA, V97, P7963, DOI 10.1073/pnas.130192197; Yang QF, 1999, PATHOL INT, V49, P775, DOI 10.1046/j.1440-1827.1999.00942.x; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	53	16	17	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	47					4912	4922		10.1038/onc.2011.658	http://dx.doi.org/10.1038/onc.2011.658			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266866				2022-12-28	WOS:000311430200003
J	Cutrupi, S; Reineri, S; Panetto, A; Grosso, E; Caizzi, L; Ricci, L; Friard, O; Agati, S; Scatolini, M; Chiorino, G; Lykkesfeldt, AE; De Bortoli, M				Cutrupi, S.; Reineri, S.; Panetto, A.; Grosso, E.; Caizzi, L.; Ricci, L.; Friard, O.; Agati, S.; Scatolini, M.; Chiorino, G.; Lykkesfeldt, A. E.; De Bortoli, M.			Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						Tab2; tamoxifen resistance; estrogen receptor; breast cancer	ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; ANTIESTROGEN RESISTANCE; N-COR; KINASE; GROWTH; TAK1; PHOSPHORYLATION; METAANALYSIS; ACTIVATION	Pharmacological resistance is a serious threat to the clinical success of hormone therapy for breast cancer. The antiproliferative response to antagonistic drugs such as tamoxifen (Tam) critically depends on the recruitment of NCoR/SMRT corepressors to estrogen receptor alpha (ER alpha) bound to estrogen target genes. Under certain circumstances, as demonstrated in the case of interleukin-1 beta (IL-1 beta) treatment, the protein Tab2 interacts with ER alpha/NCoR and causes dismissal of NCoR from these genes, leading to loss of the antiproliferative response. In Tam-resistant (TamR) ER-positive breast cancer cells, we observed that Tab2 presents a shift in mobility on sodium dodecyl sulfate-PAGE (SDS-PAGE) similar to that seen in MCF7 wt upon stimulation with IL-1 beta, suggesting constitutive activation. Accordingly, TamR treatment with Tab2-specific short interfering RNA, restored the antiproliferative response to Tam in these cells. As Tab2 is known to directly interact with the N-terminal domain of ER alpha , we synthesized a peptide composed of a 14-aa motif of this domain, which effectively competes with ER alpha/Tab2 interaction in pull-down and co-immunoprecipitation experiments, fused to the carrier TAT peptide to allow internalization. Treatment of TamR cells with this peptide resulted in partial recovery of the antiproliferative response to Tam, suggesting a strategy to revert pharmacological resistance in breast cancer. Silencing of Tab2 in TamR cells by siRNA caused modulation of a gene set related to the control of cell cycle and extensively connected to BRCA1 in a functional network. These genes were able to discern two groups of patients, from a published data set of Tam-treated breast cancer profiles, with significantly different disease-free survival. Altogether, our data implicate Tab2 as a mediator of resistance to endocrine therapy and as a potential new target to reverse pharmacological resistance and potentiate antiestrogen action. Oncogene (2012) 31, 4353-4361; doi:10.1038/onc.2011.627; published online 16 January 2012	[Cutrupi, S.; Reineri, S.; Panetto, A.; Grosso, E.; Caizzi, L.; Ricci, L.; Friard, O.; De Bortoli, M.] Univ Turin, Ctr Mol Syst Biol, I-10060 Turin, Italy; [Cutrupi, S.] Univ Turin, Dept Human & Anim Biol, I-10060 Turin, Italy; [Reineri, S.; Caizzi, L.; Agati, S.; De Bortoli, M.] Univ Turin, Dept Oncol Sci, I-10060 Turin, Italy; [Panetto, A.; Ricci, L.] Bioind Pk Silvano Fumero, Turin, Italy; [Grosso, E.; Scatolini, M.; Chiorino, G.] Fdn Edo & Elvo Tempia Valenta, Lab Canc Genom, Biella, Italy; [Lykkesfeldt, A. E.] Danish Canc Soc, Inst Canc Biol, Dept Breast Canc Res, Copenhagen, Denmark	University of Turin; University of Turin; University of Turin; Danish Cancer Society	De Bortoli, M (corresponding author), Univ Turin, Ctr Mol Syst Biol, C-O IRCC SP142,Km 3-95, I-10060 Turin, Italy.	michele.debortoli@unito.it	De Bortoli, Michele/B-5418-2013; Scatolini, Maria/ABA-7311-2020; cutrupi, santina/AAC-4479-2022; Chiorino, Giovanna/K-5037-2016; Caizzi, Livia/AAO-2725-2021; Friard, Olivier/ABG-2435-2021	De Bortoli, Michele/0000-0002-6666-9052; Chiorino, Giovanna/0000-0002-9502-6400; Friard, Olivier/0000-0002-0374-9872; CUTRUPI, SANTINA/0000-0002-2358-5852; Caizzi, Livia/0000-0001-9723-6893	PRIN [2008PC9CFW_002]; Associazione Italiana per la Ricerca sul Cancro [IG9397]; public grant 'ERSF -DOCUP (Misura 3.4)' - hitechplat project; Associazione Sviluppo Piemonte (Turin); Compagnia di San Paolo (Turin) grant; UICC travel fellowship	PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); public grant 'ERSF -DOCUP (Misura 3.4)' - hitechplat project; Associazione Sviluppo Piemonte (Turin); Compagnia di San Paolo (Turin) grant(Compagnia di San Paolo); UICC travel fellowship	This work was supported by grants from PRIN (2008PC9CFW_002) and from the Associazione Italiana per la Ricerca sul Cancro (Grant number IG9397), and in part by the public grant 'ERSF -DOCUP 2000-2006 (Misura 3.4)' - hitechplat project. LR is a CRT Fondazione Lagrange (Turin) fellow. AP was supported in part by the Associazione Sviluppo Piemonte (Turin). EG was a CRT Fondazione Lagrange (Turin) fellow and was supported in part by a Compagnia di San Paolo (Turin) grant and by a UICC travel fellowship.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Broglie P, 2010, J BIOL CHEM, V285, P2333, DOI 10.1074/jbc.M109.090522; Carroll JS, 2003, CANCER RES, V63, P4322; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946; Hackshaw A, 2011, J CLIN ONCOL, V29, P1657, DOI 10.1200/JCO.2010.32.2933; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Hughes-Davies L, 2009, BRIT J CANCER, V101, P875, DOI 10.1038/sj.bjc.6605231; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee YH, 2001, GENE DEV, V25, P176; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; Madsen MW, 1997, CANCER RES, V57, P585; Mendoza H, 2008, BIOCHEM J, V409, P711, DOI 10.1042/BJ20071149; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Ochsner SA, 2009, CANCER RES, V69, P23, DOI 10.1158/0008-5472.CAN-08-3492; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Patel LN, 2007, PHARM RES, V24, P1977, DOI 10.1007/s11095-007-9303-7; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Shin MS, 2009, BBA-MOL CELL RES, V1793, P1156, DOI 10.1016/j.bbamcr.2009.04.005; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Yue W, 2007, J STEROID BIOCHEM, V106, P102, DOI 10.1016/j.jsbmb.2007.05.008; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	40	19	19	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4353	4361		10.1038/onc.2011.627	http://dx.doi.org/10.1038/onc.2011.627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249258	Green Published			2022-12-28	WOS:000309591300002
J	Dart, DA; Brooke, GN; Sita-Lumsden, A; Waxman, J; Bevan, CL				Dart, D. A.; Brooke, G. N.; Sita-Lumsden, A.; Waxman, J.; Bevan, C. L.			Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens	ONCOGENE			English	Article						prohibitin; androgen receptor; prostate; androgens; castrate-resistant prostate cancer; corepressor	TRANSCRIPTIONAL REPRESSION; CANCER CELLS; NUCLEUS; PROTEIN; RAT; SUPERFAMILY; RECRUITMENT; SUPPRESSION; PROGRESSION; SENESCENCE	Prostate cancers (PCs), initially responsive to anti-androgen therapies, often advance to a hormone-refractory 'castrate-resistant' PC (CRPC) stage. However, the androgen receptor (AR) pathway remains active and key for cell growth and gene expression within tumours, even in the apparent absence of hormone. Proposed mechanisms to explain progression, including AR amplification/mutation, are insufficient to completely explain CRPC and possible roles of AR cofactors such as prohibitin (PHB) are poorly understood. We investigated whether PHB loss could sensitise PC cells and tumours to adrenal gland-derived androgens, which persist even after androgen ablation, hence contribute to development of CRPC. Using a pair of PC cell lines, inducibly expressing ectopic cDNA or RNAi for PHB, responses to different androgens and hormone concentrations were studied both in vitro and in vivo. PHB was found at the promoters of several genes, both AR and non-AR-regulated, and knockdown increased histone acetylation at these promoters. Further, PHB knockdown increased the rate of AR ligand-induced chromatin binding, and binding rate and occupancy of AR upon the PSA promoter. This resulted in increased cell growth and AR activity in response to all androgens, including promoting a response to the weaker adrenal androgens previously absent at physiological concentrations. In vivo this had functional consequences such that PHB knockdown resulted in androstenedione being sufficient to promote tumour growth, under conditions mimicking those in patients undergoing androgen ablation therapy. We conclude that reduction in PHB levels is sufficient to lower the threshold of AR activity in vitro and in vivo; this may be via a general increase in histone acetylation that could potentially affect signalling by other transcription factors. PHB loss may provide a mechanism for progression to CRPC by sensitising PC cells to 'castrate' conditions-that is, low levels of testicular androgens in the continued presence of weak adrenal and dietary androgens.	[Dart, D. A.; Brooke, G. N.; Sita-Lumsden, A.; Bevan, C. L.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Androgen Signalling Lab, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England	Imperial College London; Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Androgen Signalling Lab, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Brooke, Greg/ABF-4859-2020; Bevan, Charlotte/T-7769-2019; Brooke, Greg/C-9426-2013; Bevan, Charlotte L/K-2276-2012	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Hammersmith Hospital; Medical Research Council of the UK; Cancer Research UK; Prostate Cancer Charity; Medical Research Council [G0700915] Funding Source: researchfish; Prostate Cancer UK [PG10-25] Funding Source: researchfish; MRC [G0700915] Funding Source: UKRI	Hammersmith Hospital; Medical Research Council of the UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Prostate Cancer Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Prostate Cancer UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to members of the Androgen Signalling Laboratory for advice and technical help, to Ana Costa Pereira for the kind gift of TAP1 primers and interferon, and to Malcolm Parker for advice and critical reading of the manuscript. This work was supported by grants from the Hammersmith Hospital Special Trustees, the Medical Research Council of the UK, Cancer Research UK and The Prostate Cancer Charity.	Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; Brinkmann AO, 2001, MOL CELL ENDOCRINOL, V179, P105, DOI 10.1016/S0303-7207(01)00466-X; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Chen F, 2004, J STEROID BIOCHEM, V91, P247, DOI 10.1016/j.jsbmb.2004.04.009; Choi D, 2008, ONCOGENE, V27, P1716, DOI 10.1038/sj.onc.1210806; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Dai Y, 2008, CARCINOGENESIS, V29, P1725, DOI 10.1093/carcin/bgn117; Dart DA, 2009, ENDOCR-RELAT CANCER, V16, P1157, DOI 10.1677/ERC-09-0028; DELATORRE B, 1976, ACTA ENDOCRINOL-COP, V81, P170, DOI 10.1530/acta.0.0810170; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEEK CM, 1989, J STEROID BIOCHEM, V32, P573, DOI 10.1016/0022-4731(89)90392-0; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; He B, 2008, MOL ENDOCRINOL, V22, P344, DOI 10.1210/me.2007-0400; Isaacs JT, 2004, NAT MED, V10, P26, DOI 10.1038/nm0104-26; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Joshi B, 2007, BIOCHEM J, V401, P155, DOI 10.1042/BJ20060364; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kokontis JM, 1999, VITAM HORM, V55, P219; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Min W, 1996, J IMMUNOL, V156, P3174; Mullins LJ, 2009, J BIOL CHEM, V284, P3925, DOI 10.1074/jbc.M805081200; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Pignatelli D, 2006, J ENDOCRINOL, V191, P301, DOI 10.1677/joe.1.06972; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Rastogi S, 2006, MOL CELL BIOL, V26, P4161, DOI 10.1128/MCB.02142-05; Shi SL, 2009, J CELL BIOCHEM, V108, P926, DOI 10.1002/jcb.22324; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; VANWEERDEN WM, 1992, LIFE SCI, V50, P857, DOI 10.1016/0024-3205(92)90204-3; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Zhang LQ, 2003, CANCER RES, V63, P4552	38	16	18	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	43					4588	4598		10.1038/onc.2011.591	http://dx.doi.org/10.1038/onc.2011.591			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22179832	Green Submitted, Green Accepted			2022-12-28	WOS:000310528200002
J	Huang, W; Fridman, Y; Bonfil, RD; Ustach, CV; Conley-LaComb, MK; Wiesner, C; Saliganan, A; Cher, ML; Kim, HRC				Huang, W.; Fridman, Y.; Bonfil, R. D.; Ustach, C. V.; Conley-LaComb, M. K.; Wiesner, C.; Saliganan, A.; Cher, M. L.; Kim, H-R C.			A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth	ONCOGENE			English	Article						prostate cancer; bone responses; osteoclastic differentiation; PDGF-D	PROSTATE-CANCER; PLASMINOGEN-ACTIVATOR; PDGF-D; BONE; RANKL; METALLOPROTEINASE; THERAPY	Although increasing evidence suggests a critical role for platelet-derived growth factor (PDGF) receptor beta (beta-PDGFR) signaling in prostate cancer (PCa) progression, the precise roles of beta-PDGFR and PDGF isoform-specific cell signaling have not been delineated. Recently, we identified the PDGF-D isoform as a ligand for beta-PDGFR in PCa and showed that PDGF-D is activated by serine protease-mediated proteolytic removal of the CUB domain in a two-step process, yielding first a hemidimer (HD) and then a growth factor domain dimer. Herein, we demonstrate that the expression of PDGF-D in human PCa LNCaP cells leads to enhanced bone tumor growth and bone responses in immunodeficient mice. Histopathological analyses of bone tumors generated by PDGF-D-expressing LNCaP cells (LNCaP-PDGF-D) revealed osteolytic and osteoblastic responses similar to those observed in human PCa bone metastases. Importantly, we discovered a novel function of PDGF-D in the regulation of osteoclast differentiation, independent of the RANKL/RANK signaling axis. Although both PDGF-B and -D were able to activate beta-PDGFR, only PDGF-D was able to induce osteoclastic differentiation in vitro, and upregulate the expression and nuclear translocation of nuclear factor of activated T cells 1, a master transcription factor for osteoclastogenesis. Taken together, these results reveal a new function of PDGF-D as a regulator of osteoclastic differentiation, an activity critical for the establishment of skeletal metastatic deposit in PCa patients.	[Huang, W.; Fridman, Y.; Bonfil, R. D.; Ustach, C. V.; Conley-LaComb, M. K.; Cher, M. L.; Kim, H-R C.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; [Bonfil, R. D.; Wiesner, C.; Saliganan, A.; Cher, M. L.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Urol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	hrckim@med.wayne.edu	Huang, Wei/O-2346-2013	Bonfil, R. Daniel/0000-0002-1605-8317	NIH/NCI [CA64139, CA123362, R01CA137280]; Ruth L. Kirschstein National Research Service Award [T32-CA009531]; NATIONAL CANCER INSTITUTE [T32CA009531, R01CA137280, R01CA123362, R01CA064139, R29CA064139] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI RO1 grants CA64139 and CA123362 (to H-RCK), R01CA137280 (to MLC) as well as the Ruth L. Kirschstein National Research Service Award T32-CA009531 (to MKC-L). We thank Dr. C-J Kim for his help with IHC analysis.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140; Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381; Bonfil RD, 2007, AM J PATHOL, V170, P2100, DOI 10.2353/ajpath.2007.060720; Breccia M, 2009, LEUKEMIA RES, V33, P871, DOI 10.1016/j.leukres.2009.01.040; Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044; Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Ehnman M, 2009, ONCOGENE, V28, P534, DOI 10.1038/onc.2008.410; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Godwin SL, 1997, J BIOL CHEM, V272, P11307; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9-3-271; Himeno M, 2002, J BONE MINER RES, V17, P1297, DOI 10.1359/jbmr.2002.17.7.1297; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078-0432.CCR-07-1269; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Ng SSW, 2004, CLIN CANCER RES, V10, P4192, DOI 10.1158/1078-0432.CCR-03-0700; Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742-4658.2005.04989.x; Robbins JR, 1999, DEV BIOL, V212, P255, DOI 10.1006/dbio.1999.9373; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; Ustach CV, 2004, CANCER RES, V64, P1722, DOI 10.1158/0008-5472.CAN-03-3047; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; van der Poel HG, 2004, EUR UROL, V45, P1, DOI 10.1016/j.eururo.2003.08.011; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	37	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4527	4535		10.1038/onc.2011.573	http://dx.doi.org/10.1038/onc.2011.573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22158043	Green Published, hybrid			2022-12-28	WOS:000309982100004
J	Pareja, F; Ferraro, DA; Rubin, C; Cohen-Dvashi, H; Zhang, F; Aulmann, S; Ben-Chetrit, N; Pines, G; Navon, R; Crosetto, N; Kostler, W; Carvalho, S; Lavi, S; Schmitt, F; Dikic, I; Yakhini, Z; Sinn, P; Mills, GB; Yarden, Y				Pareja, F.; Ferraro, D. A.; Rubin, C.; Cohen-Dvashi, H.; Zhang, F.; Aulmann, S.; Ben-Chetrit, N.; Pines, G.; Navon, R.; Crosetto, N.; Koestler, W.; Carvalho, S.; Lavi, S.; Schmitt, F.; Dikic, I.; Yakhini, Z.; Sinn, P.; Mills, G. B.; Yarden, Y.			Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression	ONCOGENE			English	Article						gene amplification; deubiquitination; endocytosis; growth factor	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; UBIQUITIN RECOGNITION; BINDING DOMAINS; BREAST-CANCER; ENDOCYTOSIS; DEGRADATION; PROTEIN; AMSH; MONOUBIQUITINATION	Once stimulated, the epidermal growth factor receptor (EGFR) undergoes self-phosphorylation, which, on the one hand, instigates signaling cascades, and on the other hand, recruits CBL ubiquitin ligases, which mark EGFRs for degradation. Using RNA interference screens, we identified a deubiquitinating enzyme, Cezanne-1, that opposes receptor degradation and enhances EGFR signaling. These functions require the catalytic-and ubiquitin-binding domains of Cezanne-1, and they involve physical interactions and transphosphorylation of Cezanne-1 by EGFR. In line with the ability of Cezanne-1 to augment EGF-induced growth and migration signals, the enzyme is overexpressed in breast cancer. Congruently, the corresponding gene is amplified in approximately one third of mammary tumors, and high transcript levels predict an aggressive disease course. In conclusion, deubiquitination by Cezanne-1 curtails degradation of growth factor receptors, thereby promotes oncogenic growth signals.	[Pareja, F.; Ferraro, D. A.; Rubin, C.; Cohen-Dvashi, H.; Ben-Chetrit, N.; Pines, G.; Koestler, W.; Carvalho, S.; Lavi, S.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Zhang, F.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Aulmann, S.; Sinn, P.] Heidelberg Univ, Inst Pathol, D-6900 Heidelberg, Germany; [Navon, R.; Yakhini, Z.] Agilent Labs, Tel Aviv, Israel; [Crosetto, N.; Dikic, I.] Goethe Univ Frankfurt, Frankfurt Inst Mol Life Sci, Frankfurt, Germany; [Crosetto, N.; Dikic, I.] Goethe Univ Frankfurt, Inst Biochem 2, Frankfurt, Germany; [Carvalho, S.; Schmitt, F.] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal; [Carvalho, S.; Schmitt, F.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Yakhini, Z.] Technion Israel Inst Technol, Dept Comp Sci, IL-32000 Haifa, Israel	Weizmann Institute of Science; University of Texas System; UTMD Anderson Cancer Center; Ruprecht Karls University Heidelberg; Agilent Technologies; Goethe University Frankfurt; Goethe University Frankfurt; Universidade do Porto; Universidade do Porto; Technion Israel Institute of Technology	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Max & Lillian Candiotty Bldg,Room 312,Herzl St 1, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Sinn, Hans-Peter/C-5661-2008; Dikic, Ivan/O-4650-2015; Schmitt, Fernando/A-5270-2008; Pines, Gur/X-7501-2019; YARDEN, YOSEF/K-1467-2012	Sinn, Hans-Peter/0000-0003-2836-6699; Dikic, Ivan/0000-0001-8156-9511; Schmitt, Fernando/0000-0002-3711-8681; Pines, Gur/0000-0002-1757-6722; Schmitt, Fernando/0000-0003-1006-6946; Yakhini, Zohar/0000-0002-0420-5412	National Cancer Institute [5R37CA072981, CCSG, P30 CA16672]; European Commission; German-Israeli Project Cooperation; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE [R37CA072981, P50CA098258, R01CA123219, P01CA099031, P30CA016672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Commission(European CommissionEuropean Commission Joint Research Centre); German-Israeli Project Cooperation; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Tissue Bank of the National Center for Tumor Diseases, Heidelberg University Hospital (Heidelberg, Germany). Our research is supported by grants from the National Cancer Institute (5R37CA072981, CCSG and P30 CA16672), the European Commission, the German-Israeli Project Cooperation, the Israel Cancer Research Fund, the Dr Miriam and Sheldon G Adelson Medical Research Foundation and the MD Moross Institute for Cancer Research. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.	Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Courjal F, 1997, CANCER RES, V57, P4368; Crosetto N, 2008, J BIOL CHEM, V283, P35173, DOI 10.1074/jbc.M803219200; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Duex JE, 2009, MOL BIOL CELL, V20, P1833, DOI 10.1091/mbc.E08-08-0880; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Frosi Y, 2010, J CELL BIOL, V189, P557, DOI 10.1083/jcb.201002032; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hawthorn L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-460; Hou QS, 2008, CANCER RES, V68, P4623, DOI 10.1158/0008-5472.CAN-07-5870; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Ma YM, 2007, J BIOL CHEM, V282, P9805, DOI 10.1074/jbc.M611635200; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakamura M, 2006, GENES CELLS, V11, P593, DOI 10.1111/j.1365-2443.2006.00963.x; Orsetti B, 2006, BRIT J CANCER, V95, P1439, DOI 10.1038/sj.bjc.6603433; Palmieri D, 2006, BREAST CANCER RES TR, V100, P127, DOI 10.1007/s10549-006-9244-6; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622	40	64	72	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4599	4608		10.1038/onc.2011.587	http://dx.doi.org/10.1038/onc.2011.587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22179831	Bronze, Green Accepted			2022-12-28	WOS:000310528200003
J	Zarnegar, MA; Rothenberg, EV				Zarnegar, M. A.; Rothenberg, E. V.			Ikaros represses and activates PU.1 cell-type-specifically through the multifunctional Sfpi1 URE and a myeloid specific enhancer	ONCOGENE			English	Article						cis-regulatory element; hematopoiesis; chromatin immune precipitation; context dependent regulation; RNA polymerase II	TRANSCRIPTION FACTOR PU.1; EXPRESSION; LINEAGE; GENE; COMMITMENT; FATE; DIFFERENTIATION; HEMATOPOIESIS; PROGENITORS; REDUCTION	Generation of myeloid and lymphoid cells from progenitors involves dynamic changes in transcription factor expression and use, and disruption of hematopoietic transcription factor function and expression can contribute to leukemic transformation. PU.1 and Ikaros are pivotal factors whose expression and utilization are dynamically altered during hematopoietic development. Here, we demonstrate that expression of PU.1, encoded by the Sfpi1 gene, is divergently regulated by Ikaros in distinct cell type-specific contexts. Chromatin immune precipitation analysis and functional perturbations revealed that Ikaros can directly repress or activate Sfpi1 transcription via different PU.1 cis-elements, with PU.1 and Ikaros collaborating at myeloid-specific elements but not at other elements. Our results thus shed light on how PU.1 and Ikaros can act as lineage competency factors to facilitate both myeloid and lymphoid developmental programs.	[Zarnegar, M. A.; Rothenberg, E. V.] CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Rothenberg, EV (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	evroth@its.caltech.edu		Rothenberg, Ellen/0000-0002-3901-347X	NIH [R01 CA90233]; LA Garfinkle Memorial Laboratory Fund; Al Sherman Foundation; AB Ruddock Professorship; NATIONAL CANCER INSTITUTE [R01CA090233] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LA Garfinkle Memorial Laboratory Fund; Al Sherman Foundation; AB Ruddock Professorship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grant R01 CA90233, the LA Garfinkle Memorial Laboratory Fund, the Al Sherman Foundation and the AB Ruddock Professorship to EVR.	Anderson MK, 1999, DEVELOPMENT, V126, P3131; Back J, 2005, EXP HEMATOL, V33, P395, DOI 10.1016/j.exphem.2004.12.010; Carotta S, 2010, IMMUNITY, V32, P628, DOI 10.1016/j.immuni.2010.05.005; CHEN HM, 1995, ONCOGENE, V11, P1549; Chou ST, 2009, BLOOD, V114, P983, DOI 10.1182/blood-2009-03-207944; DeKoter RP, 2002, IMMUNITY, V16, P297, DOI 10.1016/S1074-7613(02)00269-8; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; Dijon M, 2008, BLOOD, V111, P1138, DOI 10.1182/blood-2007-07-098202; Ebralidze AK, 2008, GENE DEV, V22, P2085, DOI 10.1101/gad.1654808; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, CURR OPIN IMMUNOL, V9, P222, DOI 10.1016/S0952-7915(97)80139-2; Hoogenkamp M, 2007, MOL CELL BIOL, V27, P7425, DOI 10.1128/MCB.00905-07; Houston IB, 2007, EXP HEMATOL, V35, P1056, DOI 10.1016/j.exphem.2007.04.005; Iwasaki H, 2007, ONCOGENE, V26, P6687, DOI 10.1038/sj.onc.1210754; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Laiosa CV, 2006, ANNU REV IMMUNOL, V24, P705, DOI 10.1146/annurev.immunol.24.021605.090742; Leddin M, 2011, BLOOD, V117, P2827, DOI 10.1182/blood-2010-08-302976; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Ng SYM, 2009, IMMUNITY, V30, P493, DOI 10.1016/j.immuni.2009.01.014; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Reynaud D, 2008, NAT IMMUNOL, V9, P927, DOI 10.1038/ni.1626; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Spooner CJ, 2009, IMMUNITY, V31, P576, DOI 10.1016/j.immuni.2009.07.011; Stehling-Sun S, 2009, NAT IMMUNOL, V10, P289, DOI 10.1038/ni.1694; Swiers G, 2006, DEV BIOL, V294, P525, DOI 10.1016/j.ydbio.2006.02.051; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Yagi T, 2002, BLOOD, V99, P1350, DOI 10.1182/blood.V99.4.1350; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314; Zarnegar MA, 2010, MOL CELL BIOL, V30, P4922, DOI 10.1128/MCB.00354-10	32	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	43					4647	4654		10.1038/onc.2011.597	http://dx.doi.org/10.1038/onc.2011.597			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22231443	Green Accepted			2022-12-28	WOS:000310528200008
J	Goidts, V; Bageritz, J; Puccio, L; Nakata, S; Zapatka, M; Barbus, S; Toedt, G; Campos, B; Korshunov, A; Momma, S; Van Schaftingen, E; Reifenberger, G; Herold-Mende, C; Lichter, P; Radlwimmer, B				Goidts, V.; Bageritz, J.; Puccio, L.; Nakata, S.; Zapatka, M.; Barbus, S.; Toedt, G.; Campos, B.; Korshunov, A.; Momma, S.; Van Schaftingen, E.; Reifenberger, G.; Herold-Mende, C.; Lichter, P.; Radlwimmer, B.			RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival	ONCOGENE			English	Article						loss-of-function screen; apoptosis; glioblastoma; cancer stem-like cells; glycolysis	HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-GROWTH; HUMAN BRAIN; EXPRESSION; GLIOBLASTOMA; GENE; 6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE; METABOLISM; ACTIVATION; DIFFERENTIATION	The concept of cancer stem-like cells (CSCs) has gained considerable attention in various solid tumors including glioblastoma, the most common primary brain tumor. This sub-population of tumor cells has been intensively investigated and their role in therapy resistance as well as tumor recurrence has been demonstrated. In that respect, development of therapeutic strategies that target CSCs (and possibly also the tumor bulk) appears a promising approach in patients suffering from primary brain tumors. In the present study, we utilized RNA interference (RNAi) to screen the complete human kinome and phosphatome (682 and 180 targets, respectively) in order to identify genes and pathways relevant for the survival of brain CSCs and thereby potential therapeutical targets for glioblastoma. We report of 46 putative candidates including known survival-related kinases and phosphatases. Interestingly, a number of genes identified are involved in metabolism, especially glycolysis, such as PDK1 and PKM2 and, most prominently PFKFB4. In vitro studies confirmed an essential role of PFKFB4 in the maintenance of brain CSCs. Furthermore, high PFKFB4 expression was associated with shorter survival of primary glioblastoma patients. Our findings support the importance of the glycolytic pathway in the maintenance of malignant glioma cells and brain CSCs and imply tumor metabolism as a promising therapeutic target in glioblastoma. Oncogene (2012) 31, 3235-3243; doi:10.1038/onc.2011.490; published online 7 November 2011	[Goidts, V.; Bageritz, J.; Puccio, L.; Nakata, S.; Zapatka, M.; Barbus, S.; Toedt, G.; Lichter, P.; Radlwimmer, B.] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; [Goidts, V.] Univ Heidelberg, Childrens Hosp, Dept Pediat Oncol Hematol & Immunol, D-6900 Heidelberg, Germany; [Campos, B.; Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Korshunov, A.] Univ Heidelberg, Dept Neuropathol, Heidelberg, Germany; [Korshunov, A.] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, D-69120 Heidelberg, Germany; [Momma, S.] Goethe Univ Frankfurt, Sch Med, Edinger Inst, Frankfurt, Germany; [Van Schaftingen, E.] Catholic Univ Louvain, de Duve Inst, Lab Physiol Chem, B-1200 Brussels, Belgium; [Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Universite Catholique Louvain; Heinrich Heine University Dusseldorf	Goidts, V (corresponding author), German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	v.goidts@dkfz.de	Zapatka, Marc/G-9896-2013; Reifenberger, Guido/AAE-3599-2019; Van+Schaftingen, Emile/AAF-5532-2020; Radlwimmer, Bernhard F/I-3229-2013	Zapatka, Marc/0000-0001-8287-5967; Radlwimmer, Bernhard F/0000-0002-4553-7800; Korshunov, Andrey/0000-0002-5257-3623; Van Schaftingen, Emile/0000-0002-6199-7647; Bageritz, Josephine/0000-0002-9531-0452	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network (NGFNplus) [01GS0883, 01GS0884]; Alexander von Humboldt foundation; Medical Faculty of Heidelberg; Grants-in-Aid for Scientific Research [23791491] Funding Source: KAKEN	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network (NGFNplus)(Federal Ministry of Education & Research (BMBF)); Alexander von Humboldt foundation(Alexander von Humboldt Foundation); Medical Faculty of Heidelberg; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr S Pfister and D Haag for their helpful comments. We thank Mrs V Lang and G Iren for their technical help. We thank Dr J Chesney for kindly providing 3PO. This work was supported by the German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network (NGFNplus; 01GS0883, 01GS0884), a stipend from the Alexander von Humboldt foundation (to SN) and by the grant 'Young Investigator Fellowship' of the Medical Faculty of Heidelberg (to VG).	Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61; Atsumi T, 2002, CANCER RES, V62, P5881; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Ernst A, 2009, CLIN CANCER RES, V15, P6541, DOI 10.1158/1078-0432.CCR-09-0695; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Floridi A, 1989, J Neurosurg Sci, V33, P55; Giroux V, 2006, FASEB J, V20, P1982, DOI 10.1096/fj.06-6239com; Gomez M, 2005, FEBS LETT, V579, P357, DOI 10.1016/j.febslet.2004.11.096; Gomez-Brouchet A, 2007, MOL PHARMACOL, V72, P341, DOI 10.1124/mol.106.033738; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kessler R, 2001, MOL BRAIN RES, V87, P190, DOI 10.1016/S0169-328X(01)00014-6; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Park CY, 2009, MOL THER, V17, P219, DOI 10.1038/mt.2008.254; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; SAKATA J, 1991, J BIOL CHEM, V266, P15764; Singh SK, 2003, CANCER RES, V63, P5821; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Toedt G, 2011, INT J CANCER, V128, P1095, DOI 10.1002/ijc.25448; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; ZIMMERMAN DW, 1993, CAN J EXP PSYCHOL, V47, P523, DOI 10.1037/h0078850	42	101	108	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3235	3243		10.1038/onc.2011.490	http://dx.doi.org/10.1038/onc.2011.490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22056879				2022-12-28	WOS:000306113400003
J	Diaz-Rodriguez, E; Garcia-Lavandeira, M; Perez-Romero, S; Senra, A; Canibano, C; Palmero, I; Borrello, MG; Dieguez, C; Alvarez, CV				Diaz-Rodriguez, E.; Garcia-Lavandeira, M.; Perez-Romero, S.; Senra, A.; Canibano, C.; Palmero, I.; Borrello, M. G.; Dieguez, C.; Alvarez, C. V.			Direct promoter induction of p19Arf by Pit-1 explains the dependence receptor RET/Pit-1/p53-induced apoptosis in the pituitary somatotroph cells	ONCOGENE			English	Article						dependence receptor; apoptosis; p19Arf; p53; Pit-1; OIA	ARF TUMOR-SUPPRESSOR; REGULATES P53-DEPENDENT APOPTOSIS; RET-GENE-EXPRESSION; NONCODING RNA; CYCLE ARREST; P53 PATHWAY; DAP KINASE; RB+/-MICE; GROWTH; SENESCENCE	Somatotrophs produce growth hormone (GH) and are the most abundant secretory cells of the pituitary. Somatotrophs express the transcription factor Pit-1 and the dependence receptor RET, its co-receptor GFRa1 and ligand GDNF. Pit-1 is a transcription factor essential for somatotroph proliferation and differentiation and for GH expression. GDNF represses excess Pit-1 expression preventing excess GH. In the absence of GDNF, RET behaves as a dependence receptor, becomes intracellularly processed and induces strong Pit-1 expression leading to p53 accumulation and apoptosis. How accumulation of Pit-1 leads to p53 expression is unknown. We have unveiled the relationship of Pit-1 with the p19Arf gene. There is a parallel correlation of RET processing, Pit-1 increase and ARF protein and mRNA expression. Interfering the pathway with RET, Pit-1 or p19Arf siRNA blocked apoptosis. We have found a Pit-1 DNA-binding element within the ARF promoter. Pit-1 directly regulates the CDKN2A locus and binds to the p19Arft promoter inducing p19Arf gene expression. The Pit-1-binding element is conserved in rodents and humans. RET/Pit-1 induces p19Arf/p53 and apoptosis not only in a somatotroph cell line but also in primary cultures of pituitary somatotrophs, where ARF siRNA interference also blocks p53 and apoptosis. Analyses of the somatotrophs in whole pituitaries supported the above findings. Thus Pit-1, a differentiation factor, activates the oncogene-induced apoptosis (OIA) pathway as oncogenes exerting a tight control in somatotrophs to prevent the disease due to excess of GH (insulin-resistance, metabolic disease, acromegaly). Oncogene (2012) 31, 2824-2835; doi:10.1038/onc.2011.458; published online 24 October 2011	[Diaz-Rodriguez, E.; Garcia-Lavandeira, M.; Perez-Romero, S.; Senra, A.; Canibano, C.; Dieguez, C.; Alvarez, C. V.] Univ Santiago de Compostela, CIMUS, IDIS Neoplasia & Endocrine Differentiat, Dept Physiol,Sch Med, Santiago De Compostela, Spain; [Palmero, I.] Alberto Sols CSIC UAM, Inst Invest Biomed, Madrid, Spain; [Borrello, M. G.] IRCCS Ist Nazl Tumori Fdn, Dept Expt Oncol, Operat Unit Mol Mech Canc Growth & Progress, Milan, Italy	Universidade de Santiago de Compostela; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Fondazione IRCCS Istituto Nazionale Tumori Milan	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Dept Physiol, Sch Med, IDIS CIMUS, Santiago De Compostela 15782, Spain.	clara.alvarez@usc.es	Lavandeira, Montserrat García/R-4708-2019; Palmero, Ignacio/B-4346-2013; Borrello, Maria Grazia/C-3161-2017; Alvarez, Clara V/AAN-4173-2020	Lavandeira, Montserrat García/0000-0001-9208-2418; Borrello, Maria Grazia/0000-0002-6854-2848; Perez, Sihara/0000-0003-1744-0208; dieguez, carlos/0000-0002-0919-4337; Alvarez, Clara V/0000-0003-1500-4058	Xunta de Galicia-MICINN-FEDER [06PXIB208107PR, 09CSA011208PR, BFU2007-60571, BFU2010-16652]; European Community (Fondo Social Europeo)	Xunta de Galicia-MICINN-FEDER; European Community (Fondo Social Europeo)	We thank Susana Bravo and Maria Garcia-Rendueles for helpful methodological advice. This project has been supported by grants Xunta de Galicia-MICINN-FEDER, 06PXIB208107PR, 09CSA011208PR, BFU2007-60571 and BFU2010-16652 to CVA. E D-R has been an Anxeles Alvarino fellow and M G-L is a Lucas Labrada fellow (Xunta de Galicia). These programs are co-financed by the European Community (Fondo Social Europeo). The text has been reviewed by G Lockhart, a professional editor of biomedical English.	Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Bravo SB, 2010, ANAL BIOCHEM, V400, P219, DOI 10.1016/j.ab.2010.01.034; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105; Chesnokova V, 2008, RES PERSPECT END INT, P83, DOI 10.1007/978-3-540-73855-8_8; Chesnokova V, 2007, CANCER RES, V67, P10564, DOI 10.1158/0008-5472.CAN-07-0974; Clayton PE, 2011, NAT REV ENDOCRINOL, V7, P11, DOI 10.1038/nrendo.2010.171; Colao A, 2010, FRONT HORM RES, V38, P94, DOI 10.1159/000318499; Coya R, 1999, J NEUROENDOCRINOL, V11, P351; Cunnington MS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000899; Davis SW, 2010, MOL CELL ENDOCRINOL, V323, P4, DOI 10.1016/j.mce.2009.12.012; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; del Arroyo AG, 2007, CELL CYCLE, V6, P2697; Evan GI, 2009, CURR OPIN GENET DEV, V19, P25, DOI 10.1016/j.gde.2008.11.009; Garcia A, 2001, MOL ENDOCRINOL, V15, P1484, DOI 10.1210/me.15.9.1484; Garcia-Lavandeira M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004815; Garcia-Lavandeira M, 2010, FRONT HORM RES, V38, P127, DOI 10.1159/000318502; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002; Japon MA, 2002, J CLIN ENDOCR METAB, V87, P1879, DOI 10.1210/jc.87.4.1879; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P1117, DOI 10.1177/42.8.8027530; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Khutornenko AA, 2010, P NATL ACAD SCI USA, V107, P12828, DOI 10.1073/pnas.0910885107; Kirsch M, 2009, GENE CHROMOSOME CANC, V48, P143, DOI 10.1002/gcc.20621; Kovi RC, 2010, CELL DEATH DIFFER, V17, P513, DOI 10.1038/cdd.2009.140; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Nikoletopoulou V, 2010, NATURE, V467, P59, DOI 10.1038/nature09336; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pasmant E, 2007, CANCER RES, V67, P3963, DOI 10.1158/0008-5472.CAN-06-2004; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Serrano M, 2010, CELL CYCLE, V9, P4256, DOI 10.4161/cc.9.21.13785; Solloso A, 2008, J CELL PHYSIOL, V215, P140, DOI 10.1002/jcp.21295; Taneja P, 2010, CANCER RES, V70, P9084, DOI 10.1158/0008-5472.CAN-10-0159; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; van Beek AP, 2010, J CLIN ENDOCR METAB, V95, P3664, DOI 10.1210/jc.2009-2506; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152; Ward RD, 2006, MOL ENDOCRINOL, V20, P1378, DOI 10.1210/me.2005-0409; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou ZX, 2005, CANCER RES, V65, P787; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	62	19	20	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2824	2835		10.1038/onc.2011.458	http://dx.doi.org/10.1038/onc.2011.458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22020338				2022-12-28	WOS:000305277900003
J	Heinke, J; Kerber, M; Rahner, S; Mnich, L; Lassmann, S; Helbing, T; Werner, M; Patterson, C; Bode, C; Moser, M				Heinke, J.; Kerber, M.; Rahner, S.; Mnich, L.; Lassmann, S.; Helbing, T.; Werner, M.; Patterson, C.; Bode, C.; Moser, M.			Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior	ONCOGENE			English	Article						BMPER; BMPs; MMPs; tumor progression; tumor angiogenesis	BREAST-CANCER CELLS; MATRIX METALLOPROTEINASES; EXTRACELLULAR REGULATION; ID1 EXPRESSION; DIRECT BINDING; METASTASIS; GROWTH; ANGIOGENESIS; ANTAGONIST; PROSTATE	Bone morphogenetic proteins (BMPs) are growth factors that exert important functions in cell proliferation, migration and differentiation. Till date, multiple human tumors have been reported to display a dysregulation of several members of the BMP pathway that is associated with enhanced malignant tumor growth and metastasis. BMPER (BMP endothelial cell precursor-derived regulator) is a direct BMP modulator that is necessary for BMPs to exert their full-range signaling activity. Moreover, BMPER is expressed by endothelial cells and their progenitors, and has pro-angiogenic features in these cells. Here, we describe the expression of BMPER in human specimens of lung, colon and cervix carcinomas and cell lines derived from such carcinomas. In contrast to healthy tissues, BMPER is highly expressed upon malignant deterioration. Functionally, loss of BMPER in the lung tumor cell line A549 impairs proliferation, migration, invasion as well as tumor cell-induced endothelial cell sprout formation. In contrast, stimulation of A549 cells with exogenous BMPER had no further effect. We found that the BMPER effect may be transduced by regulation of the BMP target transcription factor inhibitor of DNA binding 1 (Id1) and matrix metalloproteinases (MMPs) 9 and 2. These facilitators of cell migration are down-regulated when BMPER is absent. To prove the relevance of our in vitro results in vivo, we generated Lewis lung carcinoma cells with impaired BMPER expression and implanted them into the lungs of C57BL/6 mice. In this model, the absence of BMPER resulted in severely reduced tumor growth and tumor angiogenesis. Taken together, these data unequivocally demonstrate that the BMP modulator BMPER is highly expressed in malignant tumors and tumor growth is dependent on the presence of BMPER.	[Heinke, J.; Kerber, M.; Rahner, S.; Mnich, L.; Helbing, T.; Bode, C.; Moser, M.] Univ Freiburg, Dept Med 3, D-79106 Freiburg, Germany; [Lassmann, S.; Werner, M.] Univ Freiburg, Univ Med Ctr, Inst Pathol, D-79106 Freiburg, Germany; [Patterson, C.] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA	University of Freiburg; University of Freiburg; University of North Carolina; University of North Carolina Chapel Hill	Moser, M (corresponding author), Univ Freiburg, Dept Med 3, Hugstetter Str 55, D-79106 Freiburg, Germany.	Martin.Moser@uniklinik-freiburg.de		Esser, Jennifer/0000-0002-8494-2016	German Research Foundation (DFG) [SFB-TR23 (A1), Mo973/5-1, Mo973/6-1, SFB850, SFB850 TP C5, TP Z1]; LandesStiftung Baden-Wurttemberg; Mushett Family Foundation (Chester, NJ, USA); Robert-Bosch-Stiftung; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061656] Funding Source: NIH RePORTER	German Research Foundation (DFG)(German Research Foundation (DFG)); LandesStiftung Baden-Wurttemberg; Mushett Family Foundation (Chester, NJ, USA); Robert-Bosch-Stiftung; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Bianca Engert, Anja Schopflin and Ute Wering for excellent technical assistance. Work in MM's laboratory is supported by German Research Foundation (DFG) SFB-TR23 (A1), DFG Mo973/5-1 and DFG Mo973/6-1. Work in the laboratory of SL and MW is supported by the German Research Foundation/DFG (SFB850 TP C5, TP Z1), the LandesStiftung Baden-Wurttemberg and the Mushett Family Foundation (Chester, NJ, USA) and the Robert-Bosch-Stiftung.	Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273; Arihiro K, 2001, PATHOL INT, V51, P100, DOI 10.1046/j.1440-1827.2001.01164.x; Bailey JM, 2007, J CELL BIOCHEM, V102, P829, DOI 10.1002/jcb.21509; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Blish KR, 2008, MOL BIOL CELL, V19, P457, DOI 10.1091/mbc.E07-05-0433; Brunkow ME, 2001, AM J HUM GENET, V68, P577, DOI 10.1086/318811; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Conley CA, 2000, DEVELOPMENT, V127, P3947; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; Doki Y, 1999, BRIT J CANCER, V79, P1121, DOI 10.1038/sj.bjc.6690178; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gautschi O, 2008, CANCER RES, V68, P2250, DOI 10.1158/0008-5472.CAN-07-6403; Gordon KJ, 2009, CARCINOGENESIS, V30, P238, DOI 10.1093/carcin/bgn274; Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinke J, 2008, CIRC RES, V103, P804, DOI 10.1161/CIRCRESAHA.108.178434; Heinke J, 2007, CARDIOVASC RES, V76, P390, DOI 10.1016/j.cardiores.2007.08.003; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; Ikeya M, 2006, DEVELOPMENT, V133, P4463, DOI 10.1242/dev.02647; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064; Klose A, 2011, NEOPLASIA, V13, P276, DOI 10.1593/neo.101540; Krause C, 2010, J BIOL CHEM, V285, P41614, DOI 10.1074/jbc.M110.153890; Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Laurikkala J, 2003, DEV BIOL, V264, P91, DOI 10.1016/j.ydbio.2003.08.011; Lin KY, 2007, CANCER RES, V67, P1832, DOI 10.1158/0008-5472.CAN-06-3014; Ling MT, 2005, CARCINOGENESIS, V26, P1668, DOI 10.1093/carcin/bgi128; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Maegdefrau U, 2009, J PATHOL, V218, P520, DOI 10.1002/path.2563; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Moll F, 2006, FASEB J, V20, P240, DOI 10.1096/fj.05-4126com; Moser M, 2005, THROMB HAEMOSTASIS, V94, P713, DOI 10.1160/TH05-05-0312; Moser M, 2003, MOL CELL BIOL, V23, P5664, DOI 10.1128/MCB.23.16.5664-5679.2003; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; Orlichenko LS, 2008, CLIN EXP METASTAS, V25, P593, DOI 10.1007/s10585-008-9143-9; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pouliot F, 2002, J ENDOCRINOL, V172, P187, DOI 10.1677/joe.0.1720187; Raida M, 2005, INT J ONCOL, V26, P1465; Rentzsch F, 2006, DEVELOPMENT, V133, P801, DOI 10.1242/dev.02250; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Rothhammer T, 2005, CANCER RES, V65, P448; Rothhammer T, 2008, EUR J CANCER, V44, P2526, DOI 10.1016/j.ejca.2008.07.029; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Serpe M, 2008, DEV CELL, V14, P940, DOI 10.1016/j.devcel.2008.03.023; Sheu BC, 2009, FRONT BIOSCI-LANDMRK, V14, P1571, DOI 10.2741/3325; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Soda H, 1998, ANTI-CANCER DRUG, V9, P327, DOI 10.1097/00001813-199804000-00006; Stabile H, 2007, BLOOD, V109, P1834, DOI 10.1182/blood-2006-06-032276; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Umulis D, 2009, DEVELOPMENT, V136, P3715, DOI 10.1242/dev.031534; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Weiss KR, 2006, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01.blo.0000229333.98781.56; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Wu JB, 2011, CANCER GENE THER, V18, P20, DOI 10.1038/cgt.2010.55; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075; Yang SX, 2005, CANCER RES, V65, P5769, DOI 10.1158/0008-5472.CAN-05-0289; Yu XY, 2008, DEV DYNAM, V237, P3613, DOI 10.1002/dvdy.21769; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	70	25	25	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	24					2919	2930		10.1038/onc.2011.473	http://dx.doi.org/10.1038/onc.2011.473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22020334	Green Published, Green Accepted			2022-12-28	WOS:000305388400002
J	Cao, L; Shao, M; Schilder, J; Guise, T; Mohammad, KS; Matei, D				Cao, L.; Shao, M.; Schilder, J.; Guise, T.; Mohammad, K. S.; Matei, D.			Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer	ONCOGENE			English	Article						TG2; TGF-beta; ovarian cancer; cancer stem cells; epithelial to mesenchymal transition; metastasis	GROWTH-FACTOR-BETA; METASTATIC BREAST-CANCER; E-CADHERIN; SANDWICH DOMAIN; GENE-EXPRESSION; UP-REGULATION; KAPPA-B; CARCINOMA; ACTIVATION; PATHWAY	Tissue transglutaminase (TG2), an enzyme involved in cell proliferation, differentiation and apoptosis is over-expressed in ovarian carcinomas, where it modulates epithelial-to-mesenchymal transition (EMT) and promotes metastasis. Its regulation in ovarian cancer (OC) remains unexplored. Here, we show that transforming growth factor (TGF)-beta, a cytokine involved in tumor dissemination is abundantly secreted in the OC microenvironment and induces TG2 expression and enzymatic activity. This is mediated at transcriptional level by SMADs and by TGF-beta-activated kinase 1-mediated activation of the nuclear factor-kappa B complex. TGF-beta-stimulated OC cells aggregate as spheroids, which enable peritoneal dissemination. We show that TGF-beta-induced TG2 regulates EMT, formation of spheroids and OC metastasis. TG2 knock-down in OC cells decreases the number of cells harboring a cancer stem cell phenotype (CD44+ /CD117+). Furthermore, CD44+ /CD117+ cells isolated from human ovarian tumors express high levels of TG2. In summary, TGF-beta-induced TG2 enhances ovarian tumor metastasis by inducing EMT and a cancer stem cell phenotype. Oncogene (2012) 31, 2521-2534; doi:10.1038/onc.2011.429; published online 3 October 2011	[Cao, L.; Shao, M.; Guise, T.; Mohammad, K. S.; Matei, D.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA; [Cao, L.; Matei, D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Schilder, J.; Matei, D.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN USA; [Schilder, J.; Guise, T.; Mohammad, K. S.; Matei, D.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA; [Matei, D.] Indiana Univ Sch Med, VA Roudebush Hosp, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Matei, D (corresponding author), Indiana Univ, Dept Med, Simon Canc Ctr, 535 Barnhill Dr,RT 473, Indianapolis, IN 46202 USA.	dmatei@iupui.edu	Mohammad, Khalid/AAE-9569-2022; Mohammad, Khalid/AFE-4205-2022	Matei, Daniela/0000-0003-2169-5035	US Department of Veterans Affairs; American Cancer Society; NATIONAL CANCER INSTITUTE [U01CA143057] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs J Tucholski, H Nakshatri, Y Xu, A Belkin and R Bigsby for reagents and Dr A Belkin for useful discussion. This work was supported by the US Department of Veterans Affairs through a VA Merit Award and by the American Cancer Society through a Research Scholar grant to DM.	Abendstein B, 2000, CYTOKINE, V12, P1115, DOI 10.1006/cyto.1999.0632; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Baldwin RL, 2003, CANCER RES, V63, P1413; Bartlett JM, 1997, EUR J CANCER, V33, P2397, DOI 10.1016/S0959-8049(97)00304-3; Bristow RE, 1999, CANCER, V85, P658, DOI 10.1002/(SICI)1097-0142(19990201)85:3<658::AID-CNCR16>3.0.CO;2-M; Cao LY, 2008, CARCINOGENESIS, V29, P1893, DOI 10.1093/carcin/bgn158; Cardillo MR, 1997, J EXP CLIN CANC RES, V16, P49; Chen T, 2001, CANCER RES, V61, P4679; Chou CY, 2011, J BIOL CHEM, V286, P27825, DOI 10.1074/jbc.M111.226340; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dowdy SC, 2003, J BIOL CHEM, V278, P44377, DOI 10.1074/jbc.M307202200; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Gillan L, 2002, CANCER RES, V62, P5358; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Hocevar BA, 2005, J BIOL CHEM, V280, P25920, DOI 10.1074/jbc.M501150200; Hu W, 2000, ANTICANCER RES, V20, P729; Hurteau JA, 2001, GYNECOL ONCOL, V83, P292, DOI 10.1006/gyno.2001.6376; KOPP A, 1995, CANCER RES, V55, P4512; Lopez-Rovira T, 2000, J BIOL CHEM, V275, P28937, DOI 10.1074/jbc.M909923199; Lynch MA, 1998, CANCER RES, V58, P4227; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mann AP, 2006, CANCER RES, V66, P8788, DOI 10.1158/0008-5472.CAN-06-1457; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Moreno-Bueno G, 2006, CANCER RES, V66, P9543, DOI 10.1158/0008-5472.CAN-06-0479; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nilsson E, 2001, MOL CELL ENDOCRINOL, V182, P145, DOI 10.1016/S0303-7207(01)00584-6; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PINCUS JH, 1968, ARCH BIOCHEM BIOPHYS, V126, P44, DOI 10.1016/0003-9861(68)90557-2; Qiao B, 2005, J BIOL CHEM, V280, P17562, DOI 10.1074/jbc.M500646200; Rodriguez GC, 2001, GYNECOL ONCOL, V80, P245, DOI 10.1006/gyno.2000.6042; Satpathy M, 2009, J BIOL CHEM, V284, P15390, DOI 10.1074/jbc.M808331200; Satpathy N, 2007, CANCER RES, V67, P7194, DOI 10.1158/0008-5472.CAN-07-0307; Shao MH, 2009, CANCER RES, V69, P9192, DOI 10.1158/0008-5472.CAN-09-1257; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wakahara K, 2004, J CELL BIOCHEM, V93, P437, DOI 10.1002/jcb.20160; Yamada SD, 1999, GYNECOL ONCOL, V75, P72, DOI 10.1006/gyno.1999.5535; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	55	148	158	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2521	2534		10.1038/onc.2011.429	http://dx.doi.org/10.1038/onc.2011.429			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21963846				2022-12-28	WOS:000304191800003
J	Noetzel, E; Rose, M; Bornemann, J; Gajewski, M; Knuchel, R; Dahl, E				Noetzel, E.; Rose, M.; Bornemann, J.; Gajewski, M.; Knuechel, R.; Dahl, E.			Nuclear transport receptor karyopherin-alpha 2 promotes malignant breast cancer phenotypes in vitro	ONCOGENE			English	Article						KPNA2; colony spreading; migration; adhesion; human breast cancer	GENE-EXPRESSION DATA; NF-KAPPA-B; CELL-MIGRATION; IMPORTIN-ALPHA; PROGNOSTIC MARKER; OVARIAN-CANCER; TUMOR; CARCINOMA; P53; OVEREXPRESSION	Tumorigenesis and tumor progression are associated with dysfunction of the nuclear transport machinery at the level of import and export receptors (karyopherins). Recent studies have shown that the nuclear import factor karyopherin-alpha 2 (KPNA2) is a novel prognostic marker for poor prognosis in human breast cancer. Based on the well-defined hallmarks of cancer progression, we performed a detailed in vitro characterization of the phenotypic effects caused by KPNA2 overexpression and KPNA2 silencing in benign and malignant human breast cells. KPNA2 overexpression clearly increased proliferation of MCF7 tumor cells and further led to a reduction of cell-matrix adhesion in benign MCF10A cells, whereas cell migration was significantly increased (P<0.0001) in both tumor models. Remarkably, these individual effects of KPNA2 overexpression on proliferation, cell-matrix adhesion and migration resulted in an increased colony spreading of benign MCF10A breast cells and malignant MCF7 tumor cells (P<0.001), which is a hallmark of cancer progression. Conversely, RNA interference-mediated KPNA2 silencing caused a complete inhibition of MCF7 tumor cell proliferation and migration (P<0.0001). In addition, in these experiments apoptosis was increased (P<0.05) and formation of tumor cell colonies was reduced (P<0.01). Thus, KPNA2 overexpression provoked increased aggressiveness of malignant MCF7 breast tumor cells and induced a shift in benign MCF10A breast cells toward a malignant breast cancer phenotype. In conclusion, we demonstrate for the first time in experimental tumor models that forced KPNA2 expression drives malignant features relevant for breast cancer progression, while its silencing is required for the remission of those progressive phenotypes. This study gives clear evidence that KPNA2 acts as a novel oncogenic factor in human breast cancer, in vitro. Oncogene (2012) 31, 2101-2114; doi: 10.1038/onc.2011.403; published online 12 September 2011	[Noetzel, E.; Rose, M.; Gajewski, M.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany; [Bornemann, J.] Rhein Westfal TH Aachen, Fac Med, Electron Microscop Facil, Aachen, Germany	RWTH Aachen University; RWTH Aachen University	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Noetzel-Reiss, Erik/GYV-0999-2022	Noetzel-Reiss, Erik/0000-0003-3163-6848	Mediacal Faculty of the RWTH Aachen (START)	Mediacal Faculty of the RWTH Aachen (START)	The excellent technical assistance of Sonja von Serenyi is thankfully acknowledged. This work was supported by a grant from the Mediacal Faculty of the RWTH Aachen (START program 'Tumor marker and their function' Project 1: Inflammation and Cancer).	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Brunet Anne, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P43; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cunningham MD, 2003, BIOCHEM BIOPH RES CO, V300, P403, DOI 10.1016/S0006-291X(02)02863-2; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Dankof A, 2007, VIRCHOWS ARCH, V451, P877, DOI 10.1007/s00428-007-0513-5; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Flamini G, 1996, EUR J CANCER, V32A, P802, DOI 10.1016/0959-8049(95)00625-7; Gluz O, 2008, INT J CANCER, V123, P1433, DOI 10.1002/ijc.23628; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Klein A, 2007, INT J CANCER, V121, P683, DOI 10.1002/ijc.22630; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mayhew TM, 2009, ANN ANAT, V191, P153, DOI 10.1016/j.aanat.2008.11.001; Mortezavi A, 2011, CLIN CANCER RES, V17, P1111, DOI 10.1158/1078-0432.CCR-10-0081; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Runnebaum IB, 1996, GYNECOL ONCOL, V61, P266, DOI 10.1006/gyno.1996.0137; Sakai M, 2010, ANTICANCER RES, V30, P851; Sandrock K, 2010, TRAFFIC, V11, P198, DOI 10.1111/j.1600-0854.2009.01015.x; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stuart-Harris R, 2008, BREAST, V17, P323, DOI 10.1016/j.breast.2008.02.002; Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669; Wang CI, 2011, INT J CANCER, V128, P2364, DOI 10.1002/ijc.25568	44	62	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2101	2114		10.1038/onc.2011.403	http://dx.doi.org/10.1038/onc.2011.403			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909132				2022-12-28	WOS:000303008600010
J	Moore, AE; Young, LE; Dixon, DA				Moore, A. E.; Young, L. E.; Dixon, D. A.			A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation	ONCOGENE			English	Article						COX-2; post-transcriptional regulation; microRNA; SNP; polymorphism	GENETIC POLYMORPHISMS; CANCER; RISK; EXPRESSION; ASSOCIATION; CELLS	Elevated expression of the prostaglandin synthase cyclooxygenase-2 (COX-2) is commonly observed in many chronic inflammatory diseases and cancer. However, the mechanisms allowing for pathogenic COX-2 overexpression are largely unknown. The gene for COX-2 (PTGS2) carries a common single-nucleotide polymorphism (SNP) at position 8473 (T8473C), in exon 10 that is associated with diseases in which COX-2 overexpression is a contributing factor. We demonstrate that the T8473C SNP resides within a region that targets COX-2 mRNA for degradation through microRNA-mediated regulation. miR-542-3p was identified to bind transcripts derived from the 8473T allele and promote mRNA decay. By contrast, the presence of the variant 8473C allele interfered with miR-542-3p binding, allowing for mRNA stabilization, and this effect was rescued using a mutated miR-542-3p at the respective 8473 site. Colon cancer cells and tissue displayed COX-2 mRNA levels that were dependent on T8473C allele dosage, and allele-specific expression of COX-2 was observed to be a contributing factor promoting COX-2 overexpression. These findings provide a novel molecular explanation underlying disease susceptibility associated with COX-2 T8473C SNP, and identify it as a potential marker for identifying cancer patients best served through selective COX-2 inhibition. Oncogene (2012) 31, 1592-1598; doi:10.1038/onc.2011.349; published online 8 August 2011	[Dixon, D. A.] Univ S Carolina, Dept Biol Sci, Jones PSC, Columbia, SC 29208 USA; Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Dixon, DA (corresponding author), Univ S Carolina, Dept Biol Sci, Jones PSC, 712 Main St,Room 614, Columbia, SC 29208 USA.	ddixon@biol.sc.edu			National Institutes of Health [R01CA134609]; American Cancer Society [RSG-06-122-01-CNE]; NATIONAL CANCER INSTITUTE [R01CA134609] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (R01CA134609) and American Cancer Society (RSG-06-122-01-CNE).	Abdelmohsen K, 2008, P NATL ACAD SCI USA, V105, P20297, DOI 10.1073/pnas.0809376106; Ali IU, 2005, BRIT J CANCER, V93, P953, DOI 10.1038/sj.bjc.6602806; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Birkenkamp-Demtroder K, 2005, GUT, V54, P374, DOI 10.1136/gut.2003.036848; Campa D, 2004, CARCINOGENESIS, V25, P229, DOI 10.1093/carcin/bgh008; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dimberg J, 1999, GUT, V45, P730, DOI 10.1136/gut.45.5.730; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Ferguson HR, 2008, CANCER EPIDEM BIOMAR, V17, P727, DOI 10.1158/1055-9965.EPI-07-2570; Gong ZH, 2009, INT J COLORECTAL DIS, V24, P647, DOI 10.1007/s00384-009-0656-8; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Langsenlehner U, 2006, CLIN CANCER RES, V12, P1392, DOI 10.1158/1078-0432.CCR-05-2055; Menter DG, 2010, CLIN CANCER RES, V16, P1384, DOI 10.1158/1078-0432.CCR-09-0788; Nasir Aejaz, 2004, Clin Colorectal Cancer, V3, P243, DOI 10.3816/CCC.2004.n.005; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Ozhan G, 2010, PANCREAS, V39, P371, DOI 10.1097/MPA.0b013e3181bae9ca; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Sanduja S, 2009, AGING-US, V1, P803, DOI 10.18632/aging.100086; Shen J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1629; Siezen CLE, 2005, CARCINOGENESIS, V26, P449, DOI 10.1093/carcin/bgh336; Vogel U, 2008, MUTAT RES-FUND MOL M, V639, P89, DOI 10.1016/j.mrfmmm.2007.11.004; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Young LE, 2010, CURR COLORECT CANC R, V6, P60, DOI 10.1007/s11888-010-0044-3; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010	27	39	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1592	1598		10.1038/onc.2011.349	http://dx.doi.org/10.1038/onc.2011.349			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21822307	Green Accepted			2022-12-28	WOS:000302132000011
J	Singh, P; Wedeken, L; Waters, LC; Carr, MD; Klempnauer, KH				Singh, P.; Wedeken, L.; Waters, L. C.; Carr, M. D.; Klempnauer, K-H			Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation	ONCOGENE			English	Article						Pdcd4; c-myb; translation; RNA binding	PROTEIN PDCD4; EUKARYOTIC TRANSLATION; STRUCTURAL BASIS; GENE-EXPRESSION; C/EBP-BETA; V-MYB; TRANSFORMATION; INITIATION; CELLS; MA-3	Pdcd4 is a novel tumor suppressor protein that functions in the nucleus and the cytoplasm, and appears to be involved in the regulation of transcription and translation. In the cytoplasm, Pdcd4 has been implicated in the suppression of translation of mRNAs containing structured 5'-untranslated regions; however, the mechanisms that recruit Pdcd4 to specific target mRNAs and the identities of these mRNAs are mostly unknown. In this study, we have identified c-myb mRNA as the first natural translational target mRNA of Pdcd4. We have found that translational suppression of c-myb mRNA by Pdcd4 is dependent on sequences located within the c-myb-coding region. Furthermore, we have found that the N-terminal domain of Pdcd4 has an important role in targeting Pdcd4 to c-myb RNA by mediating preferential RNA binding to the Pdcd4-responsive region of c-myb mRNA. Overall, our work demonstrates for the first time that Pdcd4 is directly involved in translational suppression of a natural mRNA and provides the first evidence for a key role of the RNA-binding domain in targeting Pdcd4 to a specific mRNA. Oncogene (2011) 30, 4864-4873; doi:10.1038/onc.2011.202; published online 6 June 2011	[Singh, P.; Wedeken, L.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany; [Waters, L. C.; Carr, M. D.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Munster; University of Leicester	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Singh, Priyanka/N-1372-2018; Singh, Priyanka/GRF-6098-2022	Singh, Priyanka/0000-0003-0841-1544; Singh, Priyanka/0000-0002-5928-6280; Wedeken, Lena/0000-0003-1061-9459; Carr, Mark/0000-0002-3939-0996	Deutsche Krebshilfe [10-1716]; Wilhelm-Sander-Stiftung [2004.088.1]; Wellcome Trust; Graduate School of Chemistry (GSC-MS) at the University of Munster	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm-Sander-Stiftung; Wellcome Trust(Wellcome TrustEuropean Commission); Graduate School of Chemistry (GSC-MS) at the University of Munster	We thank M Hentze and D Ostareck for providing plasmids. This work was supported by the Deutsche Krebshilfe (10-1716), the Wilhelm-Sander-Stiftung (2004.088.1) and the Wellcome Trust. PS and LW were supported by the Graduate School of Chemistry (GSC-MS) at the University of Munster.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hogan DJ, 2008, PLOS BIOL, V6, P2297, DOI 10.1371/journal.pbio.0060255; Lancaster AM, 2006, RNA, V12, P894, DOI 10.1261/rna.2342306; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Plachetka A, 2008, MOL CELL BIOL, V28, P2102, DOI 10.1128/MCB.01943-07; Prechtel AT, 2006, J BIOL CHEM, V281, P10912, DOI 10.1074/jbc.M510306200; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Singh P, 2009, ONCOGENE, V28, P3758, DOI 10.1038/onc.2009.239; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Suzuki C, 2008, P NATL ACAD SCI USA, V105, P3274, DOI 10.1073/pnas.0712235105; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Waters LC, 2011, J BIOL CHEM, V286, P17270, DOI 10.1074/jbc.M110.166157; Wedeken Lena, 2010, Genes Cancer, V1, P293, DOI 10.1177/1947601910364227; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang YY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010618	43	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4864	4873		10.1038/onc.2011.202	http://dx.doi.org/10.1038/onc.2011.202			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21643008				2022-12-28	WOS:000298346400003
J	Mitra, A; Menezes, ME; Pannell, LK; Mulekar, MS; Honkanen, RE; Shevde, LA; Samant, RS				Mitra, A.; Menezes, M. E.; Pannell, L. K.; Mulekar, M. S.; Honkanen, R. E.; Shevde, L. A.; Samant, R. S.			DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3 beta to downregulate beta-catenin transcription target, osteopontin	ONCOGENE			English	Article						DNAJB6; cancer; SPP1; OPN; GSK3 beta; PP2A	PROTEIN PHOSPHATASE 2A; MRJ CO-CHAPERONE; METASTATIC MELANOMA; TUMOR-SUPPRESSOR; BREAST-CANCER; J-DOMAIN; T-CELLS; EXPRESSION; PROGRESSION; WNT	Elevated levels of the oncoprotein, osteopontin (OPN), are associated with poor outcome of several types of cancers including melanoma. We have previously reported an important involvement of DNAJB6, a member of heat-shock protein 40 (HSP40) family, in negatively impacting tumor growth. The current study was prompted by our observations reported here which revealed a reciprocal relationship between DNAJB6 and OPN in melanoma specimens. The 'J domain' is the most conserved domain of HSP40 family of proteins. Hence, we assessed the functional role of the J domain in activities of DNAJB6. We report that the J domain of DNAJB6 is involved in mediating OPN suppression. Deletion of the J domain renders DNAJB6 incapable of impeding malignancy and suppressing OPN. Our mechanistic investigations reveal that DNAJB6 binds HSPA8 (heat-shock cognate protein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3 beta (GSK3 beta) at Ser 9 by recruiting protein phosphatase, PP2A. This dephosphorylation activates GSK3 beta, leading to degradation of beta-catenin and subsequent loss of TCF/LEF (T cell factor1/lymphoid enhancer factor1) activity. Deletion of the J domain abrogates assembly of this multiprotein complex and renders GSK3 beta inactive, thus, stabilizing beta-catenin, a transcription coactivator for OPN expression. Our in-vitro and in-vivo functional analyses show that silencing OPN expression in the background of deletion of the J domain renders the resultant tumor cells less malignant despite the presence of stabilized beta-catenin. Thus, we have uncovered a new mechanism for regulation of GSK3 beta activity leading to inhibition of Wnt/beta-catenin signaling. Oncogene (2012) 31, 4472-4483; doi: 10.1038/onc.2011.623; published online 23 January 2012	[Mitra, A.; Menezes, M. E.; Pannell, L. K.; Shevde, L. A.; Samant, R. S.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA; [Mulekar, M. S.] Univ S Alabama, Dept Math & Stat, Mobile, AL 36604 USA; [Honkanen, R. E.] Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36604 USA	University of South Alabama; University of South Alabama; University of South Alabama	Samant, RS (corresponding author), Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, 1660 Spring Hill Ave, Mobile, AL 36604 USA.	rsamant@usouthal.edu		Samant, Rajeev/0000-0001-5681-4976	USPHS [CA140472, CA138850]; Mayer Mitchell Award for Excellence in Cancer Research; NATIONAL CANCER INSTITUTE [R01CA140472, R01CA138850, R01CA060750] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); Mayer Mitchell Award for Excellence in Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by USPHS grants CA140472 (RSS) and CA138850 (LAS). RSS is the recipient of the Mayer Mitchell Award for Excellence in Cancer Research and acknowledges the support. We thank Dr Randall Moon (HHMI University of Washington) for providing the TOP-Flash reporter.	Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Buback F, 2009, EXP DERMATOL, V18, P750, DOI 10.1111/j.1600-0625.2009.00926.x; Chakraborty G, 2006, CURR MOL MED, V6, P819, DOI 10.2174/156652406779010803; Chiodoni C, 2010, CANCER METAST REV, V29, P295, DOI 10.1007/s10555-010-9221-8; Chuang JZ, 2002, J BIOL CHEM, V277, P19831, DOI 10.1074/jbc.M109613200; Clark DW, 2008, CURR CANCER DRUG TAR, V8, P421, DOI 10.2174/156800908785133196; Dai YS, 2005, MOL CELL BIOL, V25, P9936, DOI 10.1128/MCB.25.22.9936-9948.2005; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Denhardt D, 2005, J INVEST DERMATOL, V124, pXVI, DOI 10.1111/j.0022-202X.2005.23708.x; Dey S, 2009, MOL CELL BIOCHEM, V322, P137, DOI 10.1007/s11010-008-9950-y; Dhennin-Duthille I, 2011, J BIOL CHEM, V286, P5034, DOI 10.1074/jbc.M110.155903; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani MK, 2006, CYTOKINE GROWTH F R, V17, P463, DOI 10.1016/j.cytogfr.2006.09.010; Fan CY, 2003, CELL STRESS CHAPERON, V8, P309, DOI 10.1379/1466-1268(2003)008<0309:MFROHF>2.0.CO;2; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Greillier L, 2008, MOL DIAGN THER, V12, P375, DOI 10.2165/1250444-200812060-00004; Hennessy F, 2005, PROTEIN SCI, V14, P1697, DOI 10.1110/ps.051406805; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Howe LR, 2003, CANCER RES, V63, P1906; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kurzik-Dumke U, 2008, INT J MOL MED, V21, P19; Kurzik-Dumke U, 2007, CELL SIGNAL, V19, P1973, DOI 10.1016/j.cellsig.2007.05.008; Kushiro K, 2011, CLIN EXP METASTAS, V28, P877, DOI 10.1007/s10585-011-9418-4; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; Lin Kimberly, 2010, Genes Cancer, V1, P409; Lopez-Bergami P, 2008, PHOTOCHEM PHOTOBIOL, V84, P289, DOI 10.1111/j.1751-1097.2007.00254.x; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Martin MJ, 2009, CANCER CELL, V15, P163, DOI 10.1016/j.ccr.2009.02.006; Menezes ME, 2012, INT J CANCER, V130, P1477, DOI 10.1002/ijc.26449; Metge BJ, 2010, ONCOLOGY-BASEL, V78, P75, DOI 10.1159/000292363; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Mitra A, 2010, J BIOL CHEM, V285, P24686, DOI 10.1074/jbc.M109.094847; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874; Moore SR, 2008, CLIN CANCER RES, V14, P2927, DOI 10.1158/1078-0432.CCR-07-4068; O'Connell MP, 2009, PIGM CELL MELANOMA R, V22, P724, DOI 10.1111/j.1755-148X.2009.00627.x; Ohtsuka K, 2000, CELL STRESS CHAPERON, V5, P98, DOI 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pecina-Slaus N, 2007, J CUTAN PATHOL, V34, P239, DOI 10.1111/j.1600-0560.2006.00601.x; PolanowskaGrabowska R, 1997, BLOOD, V90, P1516, DOI 10.1182/blood.V90.4.1516.1516_1516_1526; Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6; Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rodolfo M, 2004, CANCER LETT, V214, P133, DOI 10.1016/j.canlet.2004.06.049; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sablina AA, 2007, CELL ADHES MIGR, V1, P140, DOI 10.4161/cam.1.3.4986; Saika S, 2007, LAB INVEST, V87, P130, DOI 10.1038/labinvest.3700508; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shevde LA, 2010, CURR MOL MED, V10, P71, DOI 10.2174/156652410791065381; Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2; Shih IM, 2009, FUTURE ONCOL, V5, P1641, DOI [10.2217/fon.09.126, 10.2217/FON.09.126]; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Vos MJ, 2008, BIOCHEMISTRY-US, V47, P7001, DOI 10.1021/bi800639z; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang HZ, 2011, CYTOKINE, V53, P130, DOI 10.1016/j.cyto.2010.10.009; Watson ED, 2007, DEVELOPMENT, V134, P1809, DOI 10.1242/dev.02843; Watson ED, 2009, DEV DYNAM, V238, P2564, DOI 10.1002/dvdy.22088; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Whalen KA, 2005, J VIROL, V79, P9982, DOI 10.1128/JVI.79.15.9982-9990.2005; Yeatman TJ, 2003, CLIN EXP METASTAS, V20, P85, DOI 10.1023/A:1022502805474; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698; Zhang YF, 2008, BIOCHEM J, V413, P239, DOI 10.1042/BJ20071510; Zhou BHP, 2005, CELL CYCLE, V4, P772, DOI 10.4161/cc.4.6.1744; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x; Zuidervaart W, 2007, MELANOMA RES, V17, P380, DOI 10.1097/CMR.0b013e3282f1d302	75	41	41	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4472	4483		10.1038/onc.2011.623	http://dx.doi.org/10.1038/onc.2011.623			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266849	Green Accepted			2022-12-28	WOS:000309704500005
J	Keklikoglou, I; Koerner, C; Schmidt, C; Zhang, JD; Heckmann, D; Shavinskaya, A; Allgayer, H; Guckel, B; Fehm, T; Schneeweiss, A; Sahin, O; Wiemann, S; Tschulena, U				Keklikoglou, I.; Koerner, C.; Schmidt, C.; Zhang, J. D.; Heckmann, D.; Shavinskaya, A.; Allgayer, H.; Gueckel, B.; Fehm, T.; Schneeweiss, A.; Sahin, Oe; Wiemann, S.; Tschulena, U.			MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappa B and TGF-beta signaling pathways	ONCOGENE			English	Article						NF-kappaB; TGF-beta; miR-373; miR-520c; breast cancer; ER-negative	EMBRYONIC STEM-CELLS; GROWTH-FACTOR; BONE METASTASIS; UP-REGULATION; INVASION; EXPRESSION; ACTIVATION; MICRORNAS; PROLIFERATION; ANGIOGENESIS	MicroRNAs (miRNAs) as modulators of gene expression have been described to display both tumor-promoting and tumor-suppressive functions. Although their role has been studied in different tumor types, little is known about how they regulate nuclear factor kappa B (NF-kappa B) signaling in breast cancer. Here, we performed an unbiased whole genome miRNA (miRome) screen to identify novel modulators of NF-kappa B pathway in breast cancer. The screen identified 13 miRNA families whose members induced consistent effects on NF-kappa B activity. Among those, the miR-520/373 family inhibited NF-kappa B signaling through direct targeting of RELA and thus strongly reduced expression and secretion of the pro-inflammatory cytokines interleukin (IL)-6 and IL-8. With a combination of in vitro and in vivo approaches, we propose a metastasis-suppressive role of miR-520/373 family. miR-520c and miR-373 abrogated both in vitro cell invasion and in vivo intravasation of highly invasive MDA-MB-231 cells. However, knockdown of RELA did not affect their metastatic ability. mRNA profiling of MDA-MB-231 cells on overexpression of miR-520/373 members revealed a strong downregulation of transforming growth factor-beta (TGF-beta) signaling. Mechanistically, the metastasis-suppressive role of miR-520/373 can be attributed to direct suppression of TGFBR2, as the silencing of TGFBR2 phenocopied the effects of miR-520/373 overexpression on suppression of Smad-dependent expression of the metastasis-promoting genes parathyroid hormone-related protein, plasminogen activator inhibitor-1 and angiopoietin-like 4 as well as tumor cell invasion, in vitro and in vivo. A negative correlation between miR-520c and TGFBR2 expression was observed in estrogen receptor negative (ER-) breast cancer patients but not in the ER positive (ER+) subtype. Remarkably, decreased expression of miR-520c correlated with lymph node metastasis specifically in ER- tumors. Taken together, our findings reveal that miR-520/373 family has a tumor-suppressive role in ER- breast cancer by acting as a link between the NF-kappa B and TGF-beta pathways and may thus contribute to the interplay of tumor progression, metastasis and inflammation. Oncogene (2012) 31, 4150-4163; doi:10.1038/onc.2011.571; published online 12 December 2011	[Keklikoglou, I.; Koerner, C.; Schmidt, C.; Zhang, J. D.; Sahin, Oe; Wiemann, S.; Tschulena, U.] German Canc Res Ctr, Div Mol Genome Anal, D-69120 Heidelberg, Germany; [Heckmann, D.; Shavinskaya, A.; Allgayer, H.] German Canc Res Ctr, Clin Cooperat Unit Mol Oncol Solid Tumors, D-69120 Heidelberg, Germany; [Gueckel, B.; Fehm, T.] Univ Tubingen, Womens Hosp, Dept Gynecol & Obstet, Tubingen, Germany; [Schneeweiss, A.] Univ Heidelberg Hosp, Dept Gynecol & Obstet, Natl Ctr Tumor Dis, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Keklikoglou, I (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	i.keklikoglou@dkfz-heidelberg.de; s.wiemann@dkfz-heidelberg.de	Schneeweiss, Andreas/HHS-4098-2022; Wiemann, Stefan/E-4424-2013; Sahin, Özgür/F-4403-2014	Wiemann, Stefan/0000-0003-4683-3174; Sahin, Özgür/0000-0002-8033-7089; Keklikoglou, Ioanna/0000-0003-1219-6912; Schmidt, Christian/0000-0002-9605-5959; Koerner, Cindy/0000-0003-1150-9462; Fehm, Tanja/0000-0002-4926-0108	National Genome Research Network of the German Federal Ministry of Education and Research (BMBF) [01GS0816, 01GS0864]; DKFZ International PhD Program	National Genome Research Network of the German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); DKFZ International PhD Program	We thank Dr Wolfgang Koestler for critical reading of the paper and discussion. We also thank Professor Dr George Mosialos for kindly providing us with the 3xKBL vector, Jennifer Lee for providing us with the pcDNA3.1-TGFBR2 vector, Johanna Sonntag, Dr Frank Goetschel and Dr Ulrike Korf for providing us with antibodies. We thank Serafeim Perdikis for data analysis and Aoife Ward, Angelika Worner, Ute Ernst, Heike Wilhelm, Ewald Munstermann for excellent technical assistance. This work was supported by the National Genome Research Network (Contracts No. 01GS0816 and 01GS0864) of the German Federal Ministry of Education and Research (BMBF). CK and JDZ were supported by the DKFZ International PhD Program.	Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Biswas DK, 2003, CANCER RES, V63, P290; Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078-0432.CCR-0320-03; Camp JT, 2011, MOL CANCER RES, V9, P3, DOI 10.1158/1541-7786.MCR-10-0372; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen YP, 2010, ADV APPL MATH MECH, V2, P56, DOI 10.4208/aamm.09-m0931; Cheng N, 2005, ONCOGENE, V24, P5053, DOI 10.1038/sj.onc.1208685; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Ganapathy V, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-122; Gu S, 2009, NAT STRUCT MOL BIOL, V16, P144, DOI 10.1038/nsmb.1552; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang S, 2000, CANCER RES, V60, P5334; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Katsuno Y, 2008, ONCOGENE, V27, P6322, DOI 10.1038/onc.2008.232; Laurent LC, 2008, J CELL MOL MED, V12, P2181, DOI 10.1111/j.1582-4934.2008.00513.x; Lee KH, 2009, EXP CELL RES, V315, P2529, DOI 10.1016/j.yexcr.2009.06.001; Leek RD, 1996, CANCER RES, V56, P4625; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu ZX, 2011, EMBO J, V30, P57, DOI 10.1038/emboj.2010.296; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ren JQ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-20; Schultz Nikolaus, 2011, Silence, V2, P3, DOI 10.1186/1758-907X-2-3; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sorlie Therese, 2007, Methods Mol Biol, V360, P91; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; van der Horst EH, 2004, BIOTECHNIQUES, V37, P940, DOI 10.2144/04376ST02; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Walter M, 2009, ONCOGENE, V28, P2745, DOI 10.1038/onc.2009.130; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu N., 2011, FEBS J; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhou ZG, 2007, CELL SIGNAL, V19, P1238, DOI 10.1016/j.cellsig.2006.12.013; Zijlstra A, 2002, CANCER RES, V62, P7083	58	214	223	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	37					4150	4163		10.1038/onc.2011.571	http://dx.doi.org/10.1038/onc.2011.571			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158050	hybrid			2022-12-28	WOS:000308688900007
J	Liu, W; Lindberg, J; Sui, G; Luo, J; Egevad, L; Li, T; Xie, C; Wan, M; Kim, ST; Wang, Z; Turner, AR; Zhang, Z; Feng, J; Yan, Y; Sun, J; Bova, GS; Ewing, CM; Yan, G; Gielzak, M; Cramer, SD; Vessella, RL; Zheng, SL; Gronberg, H; Isaacs, WB; Xu, J				Liu, W.; Lindberg, J.; Sui, G.; Luo, J.; Egevad, L.; Li, T.; Xie, C.; Wan, M.; Kim, S-T; Wang, Z.; Turner, A. R.; Zhang, Z.; Feng, J.; Yan, Y.; Sun, J.; Bova, G. S.; Ewing, C. M.; Yan, G.; Gielzak, M.; Cramer, S. D.; Vessella, R. L.; Zheng, S. L.; Gronberg, H.; Isaacs, W. B.; Xu, J.			Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer	ONCOGENE			English	Article						CHD1; homozygous deletion; prostate cancer	COPY NUMBER ANALYSIS; HUMAN LUNG-CANCER; ANDROGEN RECEPTOR; RNAI TECHNOLOGY; STEM-CELLS; CHROMATIN; GENE; EXPRESSION; MUTATIONS; PATHWAY	A clearer definition of the molecular determinants that drive the development and progression of prostate cancer (PCa) is urgently needed. Efforts to map recurrent somatic deletions in the tumor genome, especially homozygous deletions (HODs), have provided important positional information in the search for cancer-causing genes. Analyzing HODs in the tumors of 244 patients from two independent cohorts and 22 PCa xenografts using high-resolution single-nucleotide polymorphism arrays, herein we report the identification of CHD1, a chromatin remodeler, as one of the most frequently homozygously deleted genes in PCa, second only to PTEN in this regard. The HODs observed in CHD1, including deletions affecting only internal exons of CHD1, were found to completely extinguish the expression of mRNA of this gene in PCa xenografts. Loss of this chromatin remodeler in clinical specimens is significantly associated with an increased number of additional chromosomal deletions, both hemi- and homozygous, especially on 2q, 5q and 6q. Together with the deletions observed in HEK293 cells stably transfected with CHD1 small hairpin RNA, these data suggest a causal relationship. Downregulation of Chd1 in mouse prostate epithelial cells caused dramatic morphological changes indicative of increased invasiveness, but did not result in transformation. Indicating a new role of CHD1, these findings collectively suggest that distinct CHD1 associated alterations of genomic structure evolve during and are required for the development of PCa. Oncogene (2012) 31, 3939-3948; doi:10.1038/onc.2011.554; published online 5 December 2011	[Luo, J.; Ewing, C. M.; Yan, G.; Gielzak, M.; Isaacs, W. B.] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21287 USA; [Liu, W.; Li, T.; Xie, C.; Kim, S-T; Wang, Z.; Turner, A. R.; Zhang, Z.; Feng, J.; Sun, J.; Zheng, S. L.; Xu, J.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Canc Genom, Winston Salem, NC 27157 USA; [Liu, W.; Li, T.; Xie, C.; Kim, S-T; Wang, Z.; Turner, A. R.; Zhang, Z.; Feng, J.; Sun, J.; Zheng, S. L.; Xu, J.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom & Personalized Med Res, Winston Salem, NC USA; [Lindberg, J.; Gronberg, H.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Sui, G.; Wan, M.; Cramer, S. D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Egevad, L.] Karolinska Univ Hosp, Dept Pathol & Cytol, Stockholm, Sweden; [Yan, Y.; Xu, J.] Van Andel Res Inst, Ctr Genet Epidemiol & Prevent, Grand Rapids, MI USA; [Bova, G. S.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Vessella, R. L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA	Johns Hopkins University; Johns Hopkins Medicine; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Karolinska Institutet; Wake Forest University; Wake Forest Baptist Medical Center; Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Johns Hopkins University; Johns Hopkins Medicine; University of Washington; University of Washington Seattle	Isaacs, WB (corresponding author), Johns Hopkins Med Inst, Brady Urol Inst, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@jhmi.edu; jxu@wfubmc.edu	Kim, Seong-Tae/E-4474-2017; Lindberg, Johan/F-4104-2011; LI, TAO/AAL-5932-2020	Kim, Seong-Tae/0000-0001-7436-1405; LI, TAO/0000-0001-7343-9688; Lindberg, Johan/0000-0003-3610-6774; Egevad, Lars/0000-0001-8531-222X; Bova, George/0000-0003-1639-3104	National Institutes of Health [CA135008, CA133066, CA119069, CA131338, 133009]; NATIONAL CANCER INSTITUTE [R01CA131338, R01CA129418, R01CA133009, R01CA133066, R01CA112517, R01CA135008, R01CA119069] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The study is partially supported by the National Institutes of Health Grants CA135008 and CA133066 (to W Liu and WB Isaacs), CA119069 (to J Xu), CA131338 and 133009 (to SL Zheng and WB Isaacs). We thank Tamara Adams for editing the manuscript. The support of William T Gerrard, Mario Duhon, Jennifer and John Chalsty and P Kevin Jaffe (to WBI) is gratefully acknowledged.	Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Avvakumov N, 2011, MOL CELL, V41, P502, DOI 10.1016/j.molcel.2011.02.013; Barclay WW, 2008, STEM CELLS, V26, P600, DOI 10.1634/stemcells.2007-0309; Barclay WW, 2005, PROSTATE, V63, P291, DOI 10.1002/pros.20193; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Cengiz B, 2007, ORAL ONCOL, V43, P241, DOI 10.1016/j.oraloncology.2006.03.004; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Deng Z, 2009, ONCOGENE, V28, P3746, DOI 10.1038/onc.2009.231; Deng ZY, 2007, MOL CELL BIOL, V27, P3780, DOI 10.1128/MCB.01761-06; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding Z, 2011, NATURE, V466, P869; Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Konev AY, 2007, SCIENCE, V317, P1087, DOI 10.1126/science.1145339; Liu W, 2007, CLIN CANCER RES, V13, P5028, DOI 10.1158/1078-0432.CCR-07-0300; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Lu YJ, 2010, GENE CHROMOSOME CANC, V49, P412, DOI 10.1002/gcc.20752; McDaniel IE, 2008, GENETICS, V178, P583, DOI 10.1534/genetics.107.079038; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Nancarrow DJ, 2008, CANCER RES, V68, P4163, DOI 10.1158/0008-5472.CAN-07-6710; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010; Sims RJ, 2009, NATURE, V460, P802, DOI 10.1038/460802a; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; STOKES DG, 1995, MOL CELL BIOL, V15, P2745; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sui G, 2005, METH MOL B, V309, P205; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166; Yin D, 2009, MOL CANCER RES, V7, P665, DOI 10.1158/1541-7786.MCR-08-0270	41	69	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3939	3948		10.1038/onc.2011.554	http://dx.doi.org/10.1038/onc.2011.554			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22139082	Green Accepted			2022-12-28	WOS:000308342800003
J	Lindzen, M; Carvalho, S; Starr, A; Ben-Chetrit, N; Pradeep, CR; Koestler, WJ; Rabinkov, A; Lavi, S; Bacus, SS; Yarden, Y				Lindzen, M.; Carvalho, S.; Starr, A.; Ben-Chetrit, N.; Pradeep, C-R; Koestler, W. J.; Rabinkov, A.; Lavi, S.; Bacus, S. S.; Yarden, Y.			A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis	ONCOGENE			English	Article						cancer therapy; EGF; growth factor; tyrosine kinase; signal transduction	CORRESPONDING PRIMARY TUMORS; FACTOR RECEPTOR; IN-VIVO; BREAST-CANCER; LUNG-CANCER; SIGNALING NETWORK; FAMILY-MEMBERS; FACTOR-ALPHA; CELL-LINES; CARCINOMA	Epidermal growth factor (EGF)-like growth factors control tumor progression as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies targeting the cognate receptors, such as EGFR/ErbB-1 and the co-receptor HER2/ErbB-2, are widely used to treat cancer patients, but agents that target the EGF-like growth factors are not available. To circumvent the existence of 11 distinct ErbB ligands, we constructed a soluble fusion protein (hereinafter: TRAP-Fc) comprising truncated extracellular domains of EGFR/ErbB-1 and ErbB-4. The recombinant TRAP-Fc retained high-affinity ligand binding to EGF-like growth factors and partially inhibited growth of a variety of cultured tumor cells. Consistently, TRAP-Fc displayed an inhibitory effect in xenograft models of human cancer, as well as synergy with chemotherapy. Additionally, TRAP-Fc inhibited invasive growth of mammary tumor cells and reduced their metastatic seeding in the lungs of animals. Taken together, the activities displayed by TRAP-Fc reinforce critical roles of EGF-like growth factors in tumor progression, and they warrant further tests of TRAP-Fc in preclinical models. Oncogene (2012) 31, 3505-3515; doi:10.1038/onc.2011.518; published online 21 November 2011	[Lindzen, M.; Carvalho, S.; Ben-Chetrit, N.; Pradeep, C-R; Koestler, W. J.; Lavi, S.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Starr, A.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Pulm Dis, IL-69978 Tel Aviv, Israel; [Rabinkov, A.] Weizmann Inst Sci, Dept Biol Serv, IL-76100 Rehovot, Israel; [Bacus, S. S.] Quintiles, Westmont, IL USA	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Weizmann Institute of Science; IQVIA	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	YARDEN, YOSEF/K-1467-2012	Starr, Alexander/0000-0002-9329-3740	National Cancer Institute [CA072981]; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the help of the Israel Structural Proteomics Center. Our lab is supported by the National Cancer Institute (CA072981), the Israel Cancer Research Fund and Dr Miriam and Sheldon G Adelson Medical Research Foundation. WJK received a fellowship for PhD track for specialist medical doctors from the Linda and Michael Jacobs Charitable Trust. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.	ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; Adams TE, 2009, GROWTH FACTORS, V27, P141, DOI 10.1080/08977190902843565; Atlas E, 2003, MOL CANCER RES, V1, P165; Barozzi C, 2002, CANCER-AM CANCER SOC, V94, P647, DOI 10.1002/cncr.10278; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Bianchi S, 2006, J CELL PHYSIOL, V206, P702, DOI 10.1002/jcp.20535; Bijman MNA, 2009, ANTI-CANCER DRUG, V20, P450, DOI 10.1097/CAD.0b013e32832afc24; Britten CD, 2004, MOL CANCER THER, V3, P1335; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; De Jong KP, 1998, HEPATOLOGY, V28, P971, DOI 10.1002/hep.510280411; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; Freeman DJ, 2009, MOL CANCER THER, V8, P1536, DOI 10.1158/1535-7163.MCT-08-0978; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Hsieh SY, 2011, HEPATOLOGY, V53, P504, DOI 10.1002/hep.24083; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Karamouzis MV, 2007, INT J BIOCHEM CELL B, V39, P851, DOI 10.1016/j.biocel.2006.11.017; Krane IM, 1996, ONCOGENE, V12, P1781; Lindzen M, 2010, P NATL ACAD SCI USA, V107, P12559, DOI 10.1073/pnas.1006218107; Mackenzie RP, 2009, EXPERT REV ANTICANC, V9, P1473, DOI [10.1586/era.09.109, 10.1586/ERA.09.109]; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Sanui A, 2010, ANTICANCER RES, V30, P3143; Sarup J, 2008, MOL CANCER THER, V7, P3223, DOI 10.1158/1535-7163.MCT-07-2151; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Sun MH, 2009, CLIN CANCER RES, V15, P4829, DOI 10.1158/1078-0432.CCR-08-2921; Thogersen VB, 2001, CANCER RES, V61, P6227; Tsujioka H, 2011, CURR OPIN OBSTET GYN, V23, P24, DOI 10.1097/GCO.0b013e3283409c91; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; Weiner Louis M., 2006, Human Antibodies, V15, P103; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	40	25	27	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3505	3515		10.1038/onc.2011.518	http://dx.doi.org/10.1038/onc.2011.518			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105361	Green Accepted			2022-12-28	WOS:000306844100003
J	Shrestha, Y; Schafer, EJ; Boehm, JS; Thomas, SR; He, F; Du, J; Wang, S; Barretina, J; Weir, BA; Zhao, JJ; Polyak, K; Golub, TR; Beroukhim, R; Hahn, WC				Shrestha, Y.; Schafer, E. J.; Boehm, J. S.; Thomas, S. R.; He, F.; Du, J.; Wang, S.; Barretina, J.; Weir, B. A.; Zhao, J. J.; Polyak, K.; Golub, T. R.; Beroukhim, R.; Hahn, W. C.			PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling	ONCOGENE			English	Article						PAK1; transformation; MAPK; MET; merlin	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; ANTITUMOR-ACTIVITY; OVARIAN-CARCINOMA; TYROSINE KINASE; PROTEIN-KINASE; EGF RECEPTOR; IN-VIVO; PATHWAY; CELLS	Activating mutations in the RAS family or BRAF frequently occur in many types of human cancers but are rarely detected in breast tumors. However, activation of the RAS-RAF-MEK-ERK MAPK pathway is commonly observed in human breast cancers, suggesting that other genetic alterations lead to activation of this signaling pathway. To identify breast cancer oncogenes that activate the MAPK pathway, we screened a library of human kinases for their ability to induce anchorage-independent growth in a derivative of immortalized human mammary epithelial cells (HMLE). We identified p21-activated kinase 1 (PAK1) as a kinase that permitted HMLE cells to form anchorage-independent colonies. PAK1 is amplified in several human cancer types, including 30-33% of breast tumor samples and cancer cell lines. The kinase activity of PAK1 is necessary for PAK1-induced transformation. Moreover, we show that PAK1 simultaneously activates MAPK and MET signaling; the latter via inhibition of merlin. Disruption of these activities inhibits PAK1-driven anchorage-independent growth. These observations establish PAK1 amplification as an alternative mechanism for MAPK activation in human breast cancer and credential PAK1 as a breast cancer oncogene that coordinately regulates multiple signaling pathways, the cooperation of which leads to malignant transformation. Oncogene (2012) 31, 3397-3408; doi:10.1038/onc.2011.515; published online 21 November 2011	[Shrestha, Y.; Schafer, E. J.; Thomas, S. R.; Barretina, J.; Weir, B. A.; Polyak, K.; Beroukhim, R.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Shrestha, Y.; Schafer, E. J.; Boehm, J. S.; Thomas, S. R.; He, F.; Du, J.; Barretina, J.; Weir, B. A.; Golub, T. R.; Beroukhim, R.; Hahn, W. C.] Broad Inst Harvard & MIT, Cambridge, MA USA; [He, F.; Du, J.; Golub, T. R.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA; [Wang, S.] Dana Farber Harvard Canc Ctr, Cytogenet Core Facil, Boston, MA USA; [Barretina, J.; Polyak, K.; Golub, T. R.; Hahn, W. C.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA; [Zhao, J. J.; Beroukhim, R.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA; [Polyak, K.; Beroukhim, R.; Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Polyak, K.; Beroukhim, R.; Hahn, W. C.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 1538, Boston, MA 02215 USA.	William_Hahn@dfci.harvard.edu	Barretina, Jordi/A-7192-2013	Barretina, Jordi/0000-0002-3478-4080; Boehm, Jesse/0000-0002-6795-6336	Department of Defense [W81XWH-08-1-0767]; US National Cancer Institute [R33 CA128625, R01 CA130988]; Cancer Center Support Grant [NIH 5 P30 CA06516]; NATIONAL CANCER INSTITUTE [R33CA128625, R01CA130988, P30CA006516, RC2CA148268] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Nicole A Spardy, Christine L Nguyen and Yaara C Zwang for critical reading of the manuscript. We also thank the Dana-Farber/Harvard Cancer Center Cytogenetics Core for their assistance with fluorescence in situ hybridization studies. This work was supported in part by a Department of Defense Breast Cancer Research Program Pre-doctoral Fellowship (W81XWH-08-1-0767, YS), grants from the US National Cancer Institute (R33 CA128625 and R01 CA130988, WCH) and a Cancer Center Support Grant no. NIH 5 P30 CA06516 (Cytogenetics Core).	Appledorn DM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-13; Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; Bostner J, 2007, ONCOGENE, V26, P6997, DOI 10.1038/sj.onc.1210506; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Chattopadhyay I, 2010, MUTAT RES-GEN TOX EN, V696, P130, DOI 10.1016/j.mrgentox.2010.01.001; Christensen JG, 2003, CANCER RES, V63, P7345; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du JY, 2009, NAT BIOTECHNOL, V27, P77, DOI 10.1038/nbt.1513; Dummler B, 2009, CANCER METAST REV, V28, P51, DOI 10.1007/s10555-008-9168-1; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Freihoff D, 1999, BRIT J CANCER, V79, P754, DOI 10.1038/sj.bjc.6690121; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kim DH, 2006, ONCOL REP, V16, P1053; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Knoll JH, 2005, CURR PROTOC HUM GENE; Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681; Lau KS, 2009, MOL CELLS, V28, P315, DOI 10.1007/s10059-009-0143-7; McClatchey AI, 2007, ANNU REV PATHOL-MECH, V2, P191, DOI 10.1146/annurev.pathol.2.010506.091940; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miron A, 2010, CANCER RES, V70, P5674, DOI 10.1158/0008-5472.CAN-08-2660; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Scheid MP, 2001, J MAMMARY GLAND BIOL, V6, P83, DOI 10.1023/A:1009520616247; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Tu HF, 2011, ORAL ONCOL, V47, P211, DOI 10.1016/j.oraloncology.2011.01.003; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weinman EJ, 2006, ANNU REV PHYSIOL, V68, P491, DOI 10.1146/annurev.physiol.68.040104.131050; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200	60	108	115	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	29					3397	3408		10.1038/onc.2011.515	http://dx.doi.org/10.1038/onc.2011.515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22105362	Green Submitted, Green Accepted			2022-12-28	WOS:000306566400001
J	Shola, DTN; Wang, H; Wahdan-Alaswad, R; Danielpour, D				Shola, D. T. N.; Wang, H.; Wahdan-Alaswad, R.; Danielpour, D.			Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8	ONCOGENE			English	Article						Hic-5; BMP; Smad1; Smad; apoptosis; prostate	BONE MORPHOGENETIC PROTEINS; ANDROGEN RECEPTOR; OXIDATIVE STRESS; METASTATIC PROSTATE; UP-REGULATION; LIM PROTEIN; EXPRESSION; IDENTIFICATION; GROWTH; DEATH	Hydrogen peroxide-inducible clone-5 (Hic-5, or androgen receptor-associated protein 55) is a transforming growth factor-beta-inducible LIM protein whose deregulation is implicated in the progression of prostate cancer. Here, we report that Hic-5 binds to Smads 1, 5 and 8, and represses bone morphogenetic protein (BMP) signaling responses. Myc-Hic-5 but not Myc-paxillin was specifically immunoprecipitated with anti-FLAG IgG1 from lysates of HEK293 co-transfected with either Myc-Hic-5 or Myc-paxillin and FLAG-tagged Smads 1, 5 or 8. We showed that such interactions require the LIM3 domain of Hic-5 and the MH2 domain of those Smads. Anti-Hic-5 antibody specifically pulled down endogenous Smad1 in both the PC3 human prostate cell line and primary cultures of rat prostate fibroblasts, supporting that Hic-5 binds to Smad1 at the endogenous level. Bacterially expressed glutathione S-transferase (GST)-Smads 1, 5 or 8, but not GST alone, pulled down in vitro transcribed and translated Hic-5, implicating that Hic-5 binds directly to Smads 1, 5 and 8. Significantly, using Hic-5 small hairpin RNA silencing and overexpression systems, we show that Hic-5 (at both the endogenous and exogenous levels) represses the ability of BMP4 to induce expression of the inhibitor of differentiation-1 (Id1; a downstream target gene of BMP), activate the Id1 gene promoter and induce apoptosis in human and rat prostate epithelial cells. Moreover, silencing of Hic-5 in PC3 cells as well as in the WPMY-1 human prostate stroma cell line greatly enhances the levels of endogenous phospho-Smad1/5/8. Finally, we provide fluorescent microscopic imaging to support that Smad1 and Hic-5 mutually interact also at the level of their nuclear export mechanisms. Collectively, these results provide the first evidence for a physical and mutual functional interaction between Hic-5 and the BMP signaling pathway. Oncogene (2012) 31, 2480-2490; doi: 10.1038/onc.2011.422; published online 26 September 2011	[Danielpour, D.] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Case Comprehens Canc Ctr Res Labs, Cleveland, OH 44106 USA; [Shola, D. T. N.] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; [Wang, H.; Wahdan-Alaswad, R.; Danielpour, D.] Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; [Danielpour, D.] Univ Hosp Cleveland, Dept Urol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Danielpour, D (corresponding author), Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Case Comprehens Canc Ctr Res Labs, Wolstein Res Bldg,Room 3-532V,2103 Cornell Rd, Cleveland, OH 44106 USA.	dxd49@case.edu	Shola, Dorjee/AAE-1443-2019; Wahdan-alaswad, Reema/AAA-5604-2021	Shola, Dorjee/0000-0001-7236-5912; 	NIH [R01CA102074, R01CA134878]; Case Comprehensive Cancer Center [5T32CA059366-15, P30CA43703]; National Research Service [1F31CA142311]; NATIONAL CANCER INSTITUTE [R01CA102074, F31CA142311, P30CA043703, R01CA134878, T32CA059366] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Case Comprehensive Cancer Center; National Research Service; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH Grants R01CA102074 and R01CA134878 (D Danielpour), a pre-doctoral fellowship (R Wahdan-Alaswad) from Case Comprehensive Cancer Center's Research Oncology Training Grant 5T32CA059366-15 and National Research Service Award Individual Fellowship Application 1F31CA142311, and the Case Comprehensive Cancer Center P30CA43703 (for the Cytometry Core facility).	Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273; Barnes J, 1995, WORLD J UROL, V13, P337; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bobinac D, 2005, CROAT MED J, V46, P389; Chipuk JE, 2002, J BIOL CHEM, V277, P26412, DOI 10.1074/jbc.M201244200; Corey E, 2007, J UROLOGY, V178, P750, DOI 10.1016/j.juro.2007.06.007; Csiszar A, 2008, AM J PHYSIOL-HEART C, V295, pH569, DOI 10.1152/ajpheart.00180.2008; Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052; Dabiri G, 2008, J INVEST DERMATOL, V128, P2518, DOI 10.1038/jid.2008.90; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Gambaro K, 2006, CELL DEATH DIFFER, V13, P1075, DOI 10.1038/sj.cdd.4401799; Gao ZL, 2007, EXP CELL RES, V313, P4000, DOI 10.1016/j.yexcr.2007.05.023; Gao ZL, 2005, FEBS LETT, V579, P5651, DOI 10.1016/j.febslet.2005.08.086; Ghogomu SM, 2006, J BIOL CHEM, V281, P1755, DOI 10.1074/jbc.M505869200; Heitzer MD, 2007, STEROIDS, V72, P218, DOI 10.1016/j.steroids.2006.11.010; Heitzer MD, 2006, MOL ENDOCRINOL, V20, P56, DOI 10.1210/me.2005-0065; Hornigold N, 2010, KIDNEY INT, V77, P329, DOI 10.1038/ki.2009.417; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hsu MY, 2005, CANCER METAST REV, V24, P251, DOI 10.1007/s10555-005-1575-y; Katagiri T, 2002, GENES CELLS, V7, P949, DOI 10.1046/j.1365-2443.2002.00573.x; Li X, 2011, ONCOGENE, V30, P167, DOI 10.1038/onc.2010.400; Li Z. L, 2006, ZHONGHUA NAN KE XUE, V12, P132; Li Ze-Liang, 2006, Zhonghua Nan Ke Xue, V12, P126; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Miyazono K, 2010, J BIOCHEM, V147, P35, DOI 10.1093/jb/mvp148; Miyoshi Y, 2003, PROSTATE, V56, P280, DOI 10.1002/pros.10262; Mori K, 2009, MOL BIOL CELL, V20, P218, DOI 10.1091/mbc.E08-04-0428; Przybyszewski WM, 2009, POSTEP HIG MED DOSW, V63, P340; Rahman MM, 2003, P NATL ACAD SCI USA, V100, P5124, DOI 10.1073/pnas.0530097100; SCHIMENTI KJ, 1992, CYTOMETRY, V13, P48, DOI 10.1002/cyto.990130109; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; Song K, 2003, CANCER RES, V63, P4358; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Thomas SM, 1999, J CELL SCI, V112, P181; Trousse F, 2001, J NEUROSCI, V21, P1292; Tumbarello DA, 2007, J CELL PHYSIOL, V211, P736, DOI 10.1002/jcp.20991; Wahdan-Alaswad RS, 2010, CANCER RES, V70, P9106, DOI 10.1158/0008-5472.CAN-10-1119; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Wong WT, 2010, CIRC RES, V107, P984, DOI 10.1161/CIRCRESAHA.110.222794; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Ye L, 2007, J UROLOGY, V178, P1086, DOI 10.1016/j.juro.2007.05.003; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817	48	17	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2480	2490		10.1038/onc.2011.422	http://dx.doi.org/10.1038/onc.2011.422			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996749	Green Accepted			2022-12-28	WOS:000303985300010
J	Spivey, KA; Chung, I; Banyard, J; Adini, I; Feldman, HA; Zetter, BR				Spivey, K. A.; Chung, I.; Banyard, J.; Adini, I.; Feldman, H. A.; Zetter, B. R.			A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis	ONCOGENE			English	Article						collagen; metastasis; adhesion; anchorage-independence	XIII COLLAGEN; TRANSMEMBRANE PROTEINS; CLAC BINDS; EXPRESSION; CADHERIN; ASSOCIATION; PROMOTES; GROWTH; ATTACHMENT; XVII/BP180	Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer that has been used as a tissue and fluid biomarker for non-small cell lung cancer and prostate cancer. To determine whether collagen XXIII facilitates cancer cell metastasis in vivo and to establish a function for collagen XXIII in cancer progression, collagen XXIII knockdown cells were examined for alterations in in vivo metastasis as well as in vitro cell adhesion. In experimental and spontaneous xenograft models of metastasis, H460 cells expressing collagen XXIII shRNA formed fewer lung metastases than control cells. Loss of collagen XXIII in H460 cells also impaired cell adhesion, anchorage-independent growth and cell seeding to the lung, but did not affect cell proliferation. Corroborating a role for collagen XXIII in cell adhesion, overexpression of collagen XXIII in H1299 cells, which do not express endogenous collagen XXIII, enhanced cell adhesion. Consequent reduction in OB-cadherin, alpha-catenin, gamma-catenin, beta-catenin, vimentin and galectin-3 protein expression was also observed in response to loss of collagen XXIII. This study suggests a potential role for collagen XXIII in mediating metastasis by facilitating cell-cell and cell-matrix adhesion as well as anchorage-independent cell growth. Oncogene (2012) 31, 2362-2372; doi:10.1038/onc.2011.406; published online 3 October 2011	[Spivey, K. A.; Chung, I.; Banyard, J.; Adini, I.; Zetter, B. R.] Childrens Hosp, Karp Family Res Labs, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA; [Feldman, H. A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Zetter, BR (corresponding author), Childrens Hosp, Karp Family Res Labs, Dept Surg, Vasc Biol Program, Room 11-125,1 Blackfan Circle, Boston, MA 02115 USA.	Bruce.Zetter@childrens.harvard.edu	Chung, Ivy/C-3804-2012; Feldman, Henry/M-2302-2013		NCI NIH HHS [R01 CA037393, R37 CA037393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200; Banyard J, 2007, CLIN CANCER RES, V13, P2634, DOI 10.1158/1078-0432.CCR-06-2163; Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Di Benedetto A, 2010, J CELL SCI, V123, P2640, DOI 10.1242/jcs.067777; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; Forsell C, 2010, NEUROBIOL AGING, V31, P409, DOI 10.1016/j.neurobiolaging.2008.04.009; Franzke CW, 2009, J BIOL CHEM, V284, P23386, DOI 10.1074/jbc.M109.034090; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2004, J BIOL CHEM, V279, P24521, DOI 10.1074/jbc.M308835200; Franzke CW, 2003, MATRIX BIOL, V22, P299, DOI 10.1016/S0945-053X(03)00051-9; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Glinsky VV, 2003, CANCER RES, V63, P3805; Gordon MK, 2005, INVEST OPHTH VIS SCI, V46; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kakuyama H, 2005, BIOCHEMISTRY-US, V44, P15602, DOI 10.1021/bi051263e; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Kvist AP, 2001, AM J PATHOL, V159, P1581, DOI 10.1016/S0002-9440(10)62542-4; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; NOMURA Y, 1989, CANCER RES, V49, P5288; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Orr F W, 2001, Surg Oncol Clin N Am, V10, P357; Osada Y, 2005, J BIOL CHEM, V280, P8596, DOI 10.1074/jbc.M413340200; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; Pishvaian MJ, 1999, CANCER RES, V59, P947; Roman J, 2010, AM J RESP CELL MOL, V43, P684, DOI 10.1165/rcmb.2009-0375OC; Schmidmaier R, 2008, CURR MED CHEM, V15, P978, DOI 10.2174/092986708784049667; SIMONNEAU L, 1995, CELL ADHES COMMUN, V3, P115, DOI 10.3109/15419069509081281; Soderberg L, 2005, FEBS J, V272, P2231, DOI 10.1111/j.1742-4658.2005.04647.x; Spivey KA, 2010, CANCER EPIDEM BIOMAR, V19, P1362, DOI 10.1158/1055-9965.EPI-09-1095; Takenaka K, 2000, INT J ONCOL, V17, P1187; Tomita K, 2000, CANCER RES, V60, P3650; Tong Y, 2010, NEUROGENETICS, V11, P41, DOI 10.1007/s10048-009-0201-5; Torimura T, 1999, J HEPATOL, V31, P734, DOI 10.1016/S0168-8278(99)80355-9; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Vaisanen T, 2005, J PATHOL, V207, P324, DOI 10.1002/path.1836; Veit G, 2007, J BIOL CHEM, V282, P27424, DOI 10.1074/jbc.M703425200; Veit G, 2011, J BIOL CHEM, V286, P27804, DOI 10.1074/jbc.M111.220046; Wewer UM, 1997, AM J PATHOL, V151, P1191; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; WS Rasband, 2010, IMAGEJ, P1997	50	25	27	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2362	2372		10.1038/onc.2011.406	http://dx.doi.org/10.1038/onc.2011.406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21963851	Green Accepted			2022-12-28	WOS:000303610800010
J	Duran-Prado, M; Gahete, MD; Hergueta-Redondo, M; Martinez-Fuentes, AJ; Cordoba-Chacon, J; Palacios, J; Gracia-Navarro, F; Moreno-Bueno, G; Malagon, MM; Luque, RM; Castano, JP				Duran-Prado, M.; Gahete, M. D.; Hergueta-Redondo, M.; Martinez-Fuentes, A. J.; Cordoba-Chacon, J.; Palacios, J.; Gracia-Navarro, F.; Moreno-Bueno, G.; Malagon, M. M.; Luque, R. M.; Castano, J. P.			The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells	ONCOGENE			English	Article						somatostatin receptors; sst5TMD4; sst2; breast cancer; poor prognosis	PROTEIN MAP KINASE; SUBTYPE 2; PATHWAY; ACTIVATION; ANALOG; PHOSPHORYLATION; GROWTH; AKT; INHIBITION; EXPRESSION	Somatostatin receptors (sst1-5) are present in different types of tumors, where they inhibit key cellular processes such as proliferation and invasion. Although ssts are densely expressed in breast cancer, especially sst2, their role and therapeutic potential remain uncertain. Recently, we identified a new truncated sst5 variant, sst5TMD4, which is related to the abnormal response of certain pituitary tumors to treatment with somatostatin analogs. Here, we investigated the possible role of sst5TMD4 in breast cancer. This study revealed that sst5TMD4 is absent in normal mammary gland, but is abundant in a subset of poorly differentiated human breast tumors, where its expression correlated to that of sst2. Moreover, in the MCF-7 breast cancer model cell, sst5TMD4 expression increased malignancy features such as invasion and proliferation abilities (both in cell cultures and nude mice). This was likely mediated by sst5TMD4-induced increase in phosphorylated extracellular signal-regulated kinases 1 and 2 and p-Akt levels, and cyclin D3 and Arp2/3 complex expression, which also led to mesenchymal-like phenotype. Interestingly, sst5TMD4 interacts physically with sst2 and thereby alters its signaling, enabling disruption of sst2 inhibitory feedback and providing a plausible basis for our findings. These results suggest that sst5TMD4 could be involved in the pathophysiology of certain types of breast tumors. Oncogene (2012) 31, 2049-2061; doi: 10.1038/onc.2011.389; published online 19 September 2011	[Duran-Prado, M.; Gahete, M. D.; Martinez-Fuentes, A. J.; Cordoba-Chacon, J.; Gracia-Navarro, F.; Malagon, M. M.; Luque, R. M.; Castano, J. P.] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Reina Sofia Univ Hosp, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba 14014, Spain; [Duran-Prado, M.; Gahete, M. D.; Martinez-Fuentes, A. J.; Cordoba-Chacon, J.; Gracia-Navarro, F.; Malagon, M. M.; Luque, R. M.; Castano, J. P.] CIBER Fisiopatol Obesidad & Nutr CIBERobn, Cordoba, Spain; [Hergueta-Redondo, M.; Moreno-Bueno, G.] UAM, Inst Invest Biomed Alberto Sols, CSIC UAM, IdiPAZ Inst Invest Sanitaria La Paz,Dept Bioquim, Madrid, Spain; [Hergueta-Redondo, M.; Moreno-Bueno, G.] Fdn MD Anderson Int, Madrid, Spain; [Palacios, J.] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, Serv Anat Patol, Seville, Spain	Universidad de Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital	Castano, JP (corresponding author), Univ Cordoba, Dept Cell Biol Physiol & Immunol, Edificio Severo Ochoa,Planta 3,Campus Rabanales, Cordoba 14014, Spain.	justo@uco.es	Malagon, Maria M/L-5386-2014; Gahete, Manuel D./C-4969-2009; Romo, José A./J-3024-2012; Moreno-Bueno, Gema/K-9354-2016; Cordoba-Chacon, Jose/AAH-5753-2019; Castaño, Justo P/A-7124-2010; Palacios, Jose/AAV-3765-2020; duran-prado, mario/M-6545-2014; Martinez-Fuentes, Antonio J/F-8198-2016; Raul, Luque Huertas/M-6948-2018	Malagon, Maria M/0000-0002-2419-2727; Gahete, Manuel D./0000-0002-4578-2179; Romo, José A./0000-0003-2907-580X; Moreno-Bueno, Gema/0000-0002-5030-6687; Cordoba-Chacon, Jose/0000-0001-8787-2706; Castaño, Justo P/0000-0002-3145-7287; duran-prado, mario/0000-0001-9652-5765; Gracia Navarro, Francisco/0000-0003-2128-4228; Luque, Raul M./0000-0002-7585-1913	IPSEN;  [BIO-0139];  [CTS-01705];  [CTS-5051];  [BFU2004-03883];  [BFU2007-60180/BFI];  [BFU2008-01136-BFI];  [BFU2010-19300];  [FPU-AP20052473];  [FI06-00804];  [SAF2007-63075];  [SAF2007-63075/FMM07];  [SAF2010-201075];  [CD07/00246];  [RYC-2007-00186]	IPSEN(Ipsen); ; ; ; ; ; ; ; ; ; ; ; ; ; 	This work was supported by BIO-0139, CTS-01705, CTS-5051, BFU2004-03883, BFU2007-60180/BFI, BFU2008-01136-BFI, BFU2010-19300, FPU-AP20052473, FI06-00804, SAF2007-63075, SAF2007-63075/FMM07, SAF2010-201075, CD07/00246, RYC-2007-00186 and IPSEN. Ciber is an initiative of the Instituto de Salud Carlos III.	Ben-Shlomo A, 2010, TRENDS ENDOCRIN MET, V21, P123, DOI 10.1016/j.tem.2009.12.003; Benali N, 2000, P NATL ACAD SCI USA, V97, P9180, DOI 10.1073/pnas.130196697; Charland S, 2001, ENDOCRINOLOGY, V142, P121, DOI 10.1210/en.142.1.121; Cordoba-Chacon J, 2010, CELL MOL LIFE SCI, V67, P1147, DOI 10.1007/s00018-009-0240-y; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Duran-Prado M, 2007, ENDOCRINOLOGY, V148, P411, DOI 10.1210/en.2006-0920; Duran-Prado M, 2010, J CLIN ENDOCR METAB, V95, P2497, DOI 10.1210/jc.2009-2247; Duran-Prado M, 2009, J CLIN ENDOCR METAB, V94, P2634, DOI 10.1210/jc.2008-2564; Eralp Y, 2008, ANN ONCOL, V19, P669, DOI 10.1093/annonc/mdm522; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; He Y, 2009, ACTA PHARMACOL SIN, V30, P1053, DOI 10.1038/aps.2009.59; Hubina E, 2006, EUR J ENDOCRINOL, V155, P371, DOI 10.1530/eje.1.02213; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kahan Z, 1999, INT J CANCER, V82, P592, DOI 10.1002/(SICI)1097-0215(19990812)82:4<592::AID-IJC20>3.0.CO;2-0; Keri G, 1996, P NATL ACAD SCI USA, V93, P12513, DOI 10.1073/pnas.93.22.12513; Lee JF, 2006, HISTOCHEM CELL BIOL, V126, P297, DOI 10.1007/s00418-006-0143-z; Leu FP, 2008, MOL CANCER RES, V6, P1029, DOI 10.1158/1541-7786.MCR-07-2073; Liu W, 2007, FRONT BIOSCI-LANDMRK, V12, P4011, DOI 10.2741/2367; Moller LN, 2003, BBA-BIOMEMBRANES, V1616, P1, DOI 10.1016/S0005-2736(03)00235-9; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Nakanishi O, 2007, J BIOCHEM, V141, P319, DOI 10.1093/jb/mvm034; Orlando C, 2004, ENDOCR-RELAT CANCER, V11, P323, DOI 10.1677/erc.0.0110323; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; PREVOST G, 1993, EUR J CANCER, V29A, P1589, DOI 10.1016/0959-8049(93)90300-5; Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Schulz S, 1998, CLIN CANCER RES, V4, P2047; SETYONOHAN B, 1987, CANCER RES, V47, P1566; Sun LC, 2007, CANCER LETT, V246, P157, DOI 10.1016/j.canlet.2006.02.016; Umemura S, 2007, CANCER SCI, V98, P1889, DOI 10.1111/j.1349-7006.2007.00622.x; VANEIJCK CHJ, 1994, LANCET, V343, P640, DOI 10.1016/S0140-6736(94)92637-9; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Watt HL, 2008, MOL CELL ENDOCRINOL, V286, P251, DOI 10.1016/j.mce.2008.01.006; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	41	57	57	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2049	2061		10.1038/onc.2011.389	http://dx.doi.org/10.1038/onc.2011.389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21927030				2022-12-28	WOS:000303008600006
J	Hauser, S; Ulrich, T; Wurster, S; Schmitt, K; Reichert, N; Gaubatz, S				Hauser, S.; Ulrich, T.; Wurster, S.; Schmitt, K.; Reichert, N.; Gaubatz, S.			Loss of LIN9, a member of the DREAM complex, cooperates with SV40 large T antigen to induce genomic instability and anchorage-independent growth	ONCOGENE			English	Article						DREAM complex; senescence; genomic instability; mitosis	SPINDLE-ASSEMBLY CHECKPOINT; PRB-RELATED PROTEINS; B-MYB; MEDIATED TRANSFORMATION; G(2)/M GENES; IN-VIVO; SIMIAN-VIRUS-40; EXPRESSION; ANEUPLOIDY; P107	The DREAM complex is an important regulator of mitotic gene expression during the cell cycle. Here we report that inactivation of LIN9, a subunit of DREAM, results in premature senescence, which can be overcome by the SV40 large T (LT) antigen. Together with the observation that p16(INK4a) and p21(Waf1) are upregulated upon loss of LIN9, these results indicate that senescence is triggered by the pRB and p53 tumor suppressor pathways. We also find that LIN9-null cells that escape senescence are chromosomally instable because of compromised mitotic fidelity. SV40 LT-expressing cells that adapt to the loss of LIN9 can grow anchorage-independently in soft agar, a hallmark of oncogenic transformation. Taken together, these results suggest an important role of mitotic gene regulation in the maintenance of genomic stability and tumor suppression. Oncogene (2012) 31, 1859-1868; doi: 10.1038/onc.2011.364; published online 22 August 2011	[Hauser, S.; Ulrich, T.; Wurster, S.; Schmitt, K.; Reichert, N.; Gaubatz, S.] Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Bavaria, Germany	University of Wurzburg	Gaubatz, S (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Bavaria, Germany.	stefan.gaubatz@biozentrum.uni-wuerzburg.de		Wurster, Sebastian/0000-0002-7784-7256; Gaubatz, Stefan/0000-0001-8751-4191	DFG [575/6-1, TR17-B1]	DFG(German Research Foundation (DFG))	We thank all members of the laboratory for their suggestions and critical reading of the manuscript. We also thank Michael Schmid and Claus Steinlein for their advice and help with karyotype analysis. This work was supported by grants from the DFG (575/6-1 and TR17-B1) to SG.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Chao HHA, 2000, MOL CELL BIOL, V20, P7624, DOI 10.1128/MCB.20.20.7624-7633.2000; Cimini D, 2005, TRENDS CELL BIOL, V15, P442, DOI 10.1016/j.tcb.2005.06.008; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Knight AS, 2009, ONCOGENE, V28, P1737, DOI 10.1038/onc.2009.22; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Maehara K, 2010, MOL CELL BIOL, V30, P2090, DOI 10.1128/MCB.01318-09; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Osterloh L, 2007, EMBO J, V26, P144, DOI 10.1038/sj.emboj.7601478; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Pilkinton M, 2007, J BIOL CHEM, V282, P168, DOI 10.1074/jbc.M609924200; Reichert N, 2010, MOL CELL BIOL, V30, P2896, DOI 10.1128/MCB.00028-10; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Song J, 2010, ONCOGENE, V29, P1976, DOI 10.1038/onc.2009.485; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Ye XF, 2007, MOL CELL BIOL, V27, P2452, DOI 10.1128/MCB.01592-06; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800	28	13	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1859	1868		10.1038/onc.2011.364	http://dx.doi.org/10.1038/onc.2011.364			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860417				2022-12-28	WOS:000302785200011
J	Kurasawa, Y; Kozaki, K; Pimkhaokham, A; Muramatsu, T; Ono, H; Ishihara, T; Uzawa, N; Imoto, I; Amagasa, T; Inazawa, J				Kurasawa, Y.; Kozaki, K.; Pimkhaokham, A.; Muramatsu, T.; Ono, H.; Ishihara, T.; Uzawa, N.; Imoto, I.; Amagasa, T.; Inazawa, J.			Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells	ONCOGENE			English	Article						EMT; DNA hypermethylation; WNT7A; WNT10A; oral squamous cell carcinoma	MIR-200 FAMILY; E-CADHERIN; TRANSITION; METHYLATION; ZEB1; ASSOCIATION; STATISTICS; EXPRESSION; GENES	The epithelial-mesenchymal transition (EMT) has a crucial role in normal and disease processes including tumor progression. In this study, we first classified epithelial-like and mesenchymal-like oral squamous cell carcinoma (OSCC) cell lines based on expression profiles of typical EMT-related genes using a panel of 18 OSCC cell lines. Then, we performed methylation-based and expression-based analyses of components of the Wnt signaling pathway, and identified WNT7A and WNT10A as genes silenced by mesenchymal-specific DNA hypermethylation in OSCCs. A significant association was revealed between some clinicopathological findings and the DNA methylation status of WNT7A (normal vs tumor, P = 0.007; T1-2 vs T3-4, P = 0.040; I-III vs IV, P = 0.016) and WNT10A (N0-N1 vs N2-N3, P = 0.046) in the advanced stages of OSCC. Moreover, we found that E-cadherin expression in cancer cells may be positively regulated by WNT7A, whose expression is negatively regulated by mesenchymal-specific DNA hypermethylation or ZEB1 in mesenchymal-like OSCC cells. Our findings indicate that epithelial-specific gene silencing through mesenchymal-specific DNA hypermethylation may stabilize the phenotypic plasticity of cancer cells during EMT/MET. Oncogene (2012) 31, 1963-1974; doi:10.1038/onc.2011.373; published online 29 August 2011	[Kurasawa, Y.; Kozaki, K.; Pimkhaokham, A.; Muramatsu, T.; Ono, H.; Ishihara, T.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Kurasawa, Y.; Kozaki, K.; Pimkhaokham, A.; Muramatsu, T.; Ono, H.; Ishihara, T.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Sch Biomed Sci, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Kurasawa, Y.; Uzawa, N.; Amagasa, T.] Tokyo Med & Dent Univ, Dept Maxillofacial Surg, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Kozaki, K.; Inazawa, J.] Tokyo Med & Dent Univ, Dept Genome Med, Hard Tissue Genome Res Ctr, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Pimkhaokham, A.] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Bangkok, Thailand; [Inazawa, J.] Tokyo Med & Dent Univ, Program Int Res, Ctr Mol Sci Tooth & Bone Dis, GCOE, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Chulalongkorn University; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Yushima Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Pimkhaokham, Atiphan/AAQ-4177-2021; Imoto, Issei/AAD-5799-2020; imoto, Issei/D-8065-2012; Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X; Pimkhaokham, Atiphan/0000-0002-0170-243X	Ministry of Education, Culture, Sports, Science and Technology, Japan; Ministry of Health, Labour and Welfare, Japan; Core Research for Evolutional Science and Technology of the Japan Science and Technology Corporation; New Energy and Industrial Technology Development Organization; Grants-in-Aid for Scientific Research [23390077, 22134002] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Core Research for Evolutional Science and Technology of the Japan Science and Technology Corporation(Core Research for Evolutional Science and Technology (CREST)); New Energy and Industrial Technology Development Organization(New Energy and Industrial Technology Development Organization (NEDO)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ayako Takahashi and Rumi Mori for technical assistance. This study was supported in part by Grant-in-Aid for Scientific Research (A), (B) and (C), and Scientific Research on Priority Areas and Innovative Areas, and the Global Center of Excellence Program for International Research Center for Molecular Science in Tooth and Bone Diseases from the Ministry of Education, Culture, Sports, Science and Technology, Japan; a Health and Labour Sciences Research Grant by the Ministry of Health, Labour and Welfare, Japan; a grant from Core Research for Evolutional Science and Technology of the Japan Science and Technology Corporation; and a grant from the New Energy and Industrial Technology Development Organization.	Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; McNeill H, 2010, NAT REV MOL CELL BIO, V11, P404, DOI 10.1038/nrm2902; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nomura K, 2005, CANC STAT JAPAN 2005, P36; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Sato N, 2003, CANCER RES, V63, P3735; Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Suzuki E, 2007, ONCOGENE, V26, P7921, DOI 10.1038/sj.onc.1210589; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	30	8	8	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1963	1974		10.1038/onc.2011.373	http://dx.doi.org/10.1038/onc.2011.373			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874048				2022-12-28	WOS:000302809900008
J	Taniguchi, H; Jacinto, FV; Villanueva, A; Fernandez, AF; Yamamoto, H; Carmona, FJ; Puertas, S; Marquez, VE; Shinomura, Y; Imai, K; Esteller, M				Taniguchi, H.; Jacinto, F. V.; Villanueva, A.; Fernandez, A. F.; Yamamoto, H.; Carmona, F. J.; Puertas, S.; Marquez, V. E.; Shinomura, Y.; Imai, K.; Esteller, M.			Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer	ONCOGENE			English	Article						epigenetics; histone methyltransferase; EZH2; KLF2	TRANSCRIPTION FACTORS; CELL-GROWTH; POLYCOMB; REPRESSION; PROGRESSION; EXPRESSION; COMPLEX; TARGET	The Kruppel-like factor (KLF) proteins are multitasked transcriptional regulators with an expanding tumor suppressor function. KLF2 is one of the prominent members of the family because of its diminished expression in malignancies and its growth-inhibitory, pro-apoptotic and anti-angiogenic roles. In this study, we show that epigenetic silencing of KLF2 occurs in cancer cells through direct transcriptional repression mediated by the Polycomb group protein Enhancer of Zeste Homolog 2 (EZH2). Binding of EZH2 to the 5'-end of KLF2 is also associated with a gain of trimethylated lysine 27 histone H3 and a depletion of phosphorylated serine 2 of RNA polymerase. Upon depletion of EZH2 by RNA interference, short hairpin RNA or use of the small molecule 3-Deazaneplanocin A, the expression of KLF2 was restored. The transfection of KLF2 in cells with EZH2-associated silencing showed a significant anti-tumoral effect, both in culture and in xenografted nude mice. In this last setting, KLF2 transfection was also associated with decreased dissemination and lower mortality rate. In EZH2-depleted cells, which characteristically have lower tumorigenicity, the induction of KLF2 depletion 'rescued' partially the oncogenic phenotype, suggesting that KLF2 repression has an important role in EZH2 oncogenesis. Most importantly, the translation of the described results to human primary samples demonstrated that patients with prostate or breast tumors with low levels of KLF2 and high expression of EZH2 had a shorter overall survival. Oncogene (2012) 31, 1988-1994; doi:10.1038/onc.2011.387; published online 5 September 2011	[Taniguchi, H.; Jacinto, F. V.; Fernandez, A. F.; Carmona, F. J.; Esteller, M.] Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain; [Taniguchi, H.; Yamamoto, H.; Shinomura, Y.] Sapporo Med Univ, Sch Med, Dept Internal Med 1, Sapporo, Hokkaido, Japan; [Taniguchi, H.] Sapporo Med Univ, Sch Med, Tumor Med Examinat & Treatment Ctr, Sapporo, Hokkaido, Japan; [Jacinto, F. V.] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Villanueva, A.; Puertas, S.] Bellvitge Biomed Res Inst IDIBELL, ICO, Barcelona, Spain; [Marquez, V. E.] NCI, Biol Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21701 USA; [Imai, K.] Univ Tokyo, Inst Med Sci, Tokyo, Japan; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Sapporo Medical University; Sapporo Medical University; Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via LHosp 199-203, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Marquez, Victor/AAP-3549-2021; Esteller, Manel/L-5956-2014; Taniguchi, Hiroaki/AGB-3012-2022; Fernandez, Agustin F./N-7302-2014	Esteller, Manel/0000-0003-4490-6093; Taniguchi, Hiroaki/0000-0003-0494-5290; Fernandez, Agustin F./0000-0002-3792-4085; Carmona Sanz, F Javier/0000-0001-7904-8493	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; NIH, National Cancer Institute and Center for Cancer Research;  [SAF2007-00027-65134];  [Consolider CSD2006-49]; ICREA Funding Source: Custom	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; NIH, National Cancer Institute and Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; ICREA(ICREA)	We thank O Dominguez for help with the microarray procedures and analysis, F Setien for technical assistance and Miki Kojiya for the flow cytometry analysis. This work was supported by Grants SAF2007-00027-65134, Consolider CSD2006-49, and Lilly Foundation and Dr Josef Steiner Cancer Research Foundation to ME, and the Intramural Research Program of the NIH, National Cancer Institute and Center for Cancer Research to VEM. HT is supported by the Uehara Memorial Foundation and Pancreas Research Foundation of Japan. ME is an ICREA Research Professor.	Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Bhattacharya R, 2005, J BIOL CHEM, V280, P28848, DOI 10.1074/jbc.C500200200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; Bureau C, 2009, CURR GENOMICS, V10, P353, DOI 10.2174/138920209788921010; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Duhagon MA, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-324; Fernandez-Zapico ME, 2011, BIOCHEM J, V435, P529, DOI 10.1042/BJ20100773; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kannan-Thulasiraman P, 2010, J BIOL CHEM, V285, P19106, DOI 10.1074/jbc.M109.099770; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Pasini D, 2004, CELL CYCLE, V3, P396; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang F, 2005, ONCOGENE, V24, P3875, DOI 10.1038/sj.onc.1208546; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zhao CT, 2005, DEV GROWTH DIFFER, V47, P201	26	80	86	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1988	1994		10.1038/onc.2011.387	http://dx.doi.org/10.1038/onc.2011.387			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21892211	Green Published, hybrid			2022-12-28	WOS:000302809900010
J	Mannava, S; Omilian, AR; Wawrzyniak, JA; Fink, EE; Zhuang, D; Miecznikowski, JC; Marshall, JR; Soengas, MS; Sears, RC; Morrison, CD; Nikiforov, MA				Mannava, S.; Omilian, A. R.; Wawrzyniak, J. A.; Fink, E. E.; Zhuang, D.; Miecznikowski, J. C.; Marshall, J. R.; Soengas, M. S.; Sears, R. C.; Morrison, C. D.; Nikiforov, M. A.			PP2A-B56 alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells	ONCOGENE			English	Article						senescence; PP2A; melanoma; C-MYC	C-MYC PROTEIN; BRAF MUTATIONS; PATHWAYS; PHOSPHORYLATION; PROLIFERATION; CIP2A; PP2A; IDENTIFICATION; SUPPRESSION; METABOLISM	Oncoprotein C-MYC is overexpressed in human metastatic melanomas and melanoma-derived cells where it is required for the suppression of oncogene-induced senescence (OIS). The genetic events that maintain high levels of C-MYC in melanoma cells and their role in OIS are unknown. Here we report that C-MYC in cells from several randomly chosen melanoma lines was upregulated at the protein level, and largely because of the increased protein stability. Of all known regulators of C-MYC stability, levels of B56 alpha subunit of the PP2A tumor suppressor complex were substantially suppressed in all human melanoma cells compared with normal melanocytes. Accordingly, immunohistochemical analysis revealed that the lowest and the highest amounts of PP2A-B56 alpha were predominantly detected in metastatic melanoma tissues and in primary melanomas from patients with good clinical outcome, respectively. Importantly, PP2A-B56 alpha overexpression suppressed C-MYC in melanoma cells and induced OIS, whereas depletion of PP2A-B56 alpha in normal human melanocytes upregulated C-MYC protein levels and suppressed BRAF(V600E)- and, less efficiently, NRAS(Q61R)-induced senescence. Our data reveal a mechanism of C-MYC overexpression in melanoma cells and identify a functional role for PP2A-B56 alpha in OIS of melanocytic cells. Oncogene (2012) 31, 1484-1492; doi:10.1038/onc.2011.339; published online 8 August 2011	[Mannava, S.; Wawrzyniak, J. A.; Fink, E. E.; Zhuang, D.; Nikiforov, M. A.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Omilian, A. R.; Morrison, C. D.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Miecznikowski, J. C.] Roswell Pk Canc Inst, Dept Biostat, Buffalo, NY 14263 USA; [Marshall, J. R.] Roswell Pk Canc Inst, Dept Canc Prevent & Populat Sci, Buffalo, NY 14263 USA; [Soengas, M. S.] Spanish Natl Canc Res Ctr, Mol Pathol Programme, Madrid, Spain; [Sears, R. C.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Centro Nacional de Investigaciones Oncologicas (CNIO); Oregon Health & Science University	Nikiforov, MA (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, BLSC L3-317,Elm & Carlton Str, Buffalo, NY 14263 USA.	Mikhail.nikiforov@roswellpark.org	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Fink, Emily/0000-0003-2738-5732	NIH [R01 CA120244, ACS RSG-10-121-01, 5P30CA016056-34]; NATIONAL CANCER INSTITUTE [R01CA120244, P30CA016056, R01CA100855, R01CA129040] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Catherine Burkhart (Cleveland Biolabs) and Dr Shoshanna Zucker (Roswell Park Cancer Institute) for critical reading of the manuscript, Ms Carina Fung (University of Sydney) for the experimental help. This work was supported by the NIH R01 CA120244 and ACS RSG-10-121-01 grants to MAN. The work of JCM was supported in part by the NIH 5P30CA016056-34 grant.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bansal R, 2010, CELL CYCLE, V9, P2782, DOI 10.4161/cc.9.14.12251; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Eilers M, 1999, MOL CELLS, V9, P1; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Haferkamp S, 2009, AGING-US, V1, P542, DOI 10.18632/aging.100051; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Newson R, 2006, STATA J, V2, P45; Nikiforov MA, 2003, J BIOL CHEM, V278, P11094, DOI 10.1074/jbc.M212298200; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Smalley KSM, 2005, SEMIN CANCER BIOL, V15, P451, DOI 10.1016/j.semcancer.2005.06.002; Vaarala MH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-136; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258	47	28	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1484	1492		10.1038/onc.2011.339	http://dx.doi.org/10.1038/onc.2011.339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21822300	Green Accepted			2022-12-28	WOS:000302132000002
J	Wang, F; Chan, CH; Chen, K; Guan, X; Lin, HK; Tong, Q				Wang, F.; Chan, C-H; Chen, K.; Guan, X.; Lin, H-K; Tong, Q.			Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation	ONCOGENE			English	Article						sirtuin; E3 ubiquitin ligase; Forkhead transcription factor; ubiquitination; acetylation; proteasomal degradation	TRANSCRIPTION FACTOR AFX; FORKHEAD TRANSCRIPTION; OXIDATIVE-STRESS; LIFE-SPAN; PROMOTES TUMORIGENESIS; NUCLEAR TRANSLOCATION; CELL-SURVIVAL; E3 LIGASE; CANCER; PHOSPHORYLATION	Sirtuin deacetylases and FOXO (Forkhead box, class O) transcription factors have important roles in many biological pathways, including cancer development. SIRT1 and SIRT2 deacetylate FOXO factors to regulate FOXO function. Because acetylation and ubiquitination both modify the epsilon-amino group of lysine residues, we investigated whether FOXO3 deacetylation by SIRT1 or SIRT2 facilitates FOXO3 ubiquitination and subsequent proteasomal degradation. We found that SIRT1 and SIRT2 promote FOXO3 poly-ubiquitination and degradation. Proteasome-inhibitor treatment prevented sirtuin-induced FOXO3 degradation, indicating that this process is proteasome dependent. In addition, we demonstrated that E3 ubiquitin ligase subunit Skp2 binds preferentially to deacetylated FOXO3. Overexpression of Skp2 caused poly-ubiquitination of FOXO3 and degradation, whereas knockdown of Skp2 increased the amount of FOXO3 protein. We also present evidence that SCF-Skp2 ubiquitinates FOXO3 directly in vitro. Furthermore, mutating four known acetylated lysine residues (K242, K259, K290 and K569) of FOXO3 into arginines to mimic deacetylated FOXO3 resulted in enhanced Skp2 binding but with inhibition of FOXO3 ubiquitination; this suggests that some or all of these four lysine residues are likely the sites for ubiquitination. In the livers of mice deficient in SIRT1, we detected increased expression of FOXO3, indicating SIRT1 regulates FOXO3 protein levels in vivo. Furthermore, we found that the elevation of SIRT1 and Skp2 expression in malignant PC3 and DU145 prostate cells is responsible for the downregulation of FOXO3 protein levels in these cells. Taken together, our data support the notion that deacetylation of FOXO3 by SIRT1 or SIRT2 facilitates Skp2-mediated FOXO3 poly-ubiquitination and proteasomal degradation. Oncogene (2012) 31, 1546-1557; doi:10.1038/onc.2011.347; published online 15 August 2011	[Wang, F.; Chen, K.; Guan, X.; Tong, Q.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; [Chan, C-H; Lin, H-K] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Tong, Q (corresponding author), Baylor Coll Med, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.	qtong@bcm.tmc.edu	高, 雨莉/HGU-8187-2022		Ellison Medical Foundation/American Federation for Aging Research; US Department of Agriculture [6250-51000-055]; NIH [DK075978]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075978] Funding Source: NIH RePORTER	Ellison Medical Foundation/American Federation for Aging Research(Lawrence Ellison Foundation); US Department of Agriculture(United States Department of Agriculture (USDA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Xinhua Feng for providing HA-ubiquitin expression plasmid and Dr Jianping Jin for providing HeLa cells stably transfected with His-Biotin-Ubiquitin. We thank Dr Steven I Reed for providing pcDNA-hSkp1, pcDNA-Cul1, pcDNA-Roc1 constructs, and Dr Anne Brunet for providing pECE-FOXO3-M2 wild-type and K242R, K259R, K290R, K569R individual mutants and 4KR mutants, Dr Tony Kouzarides for providing pcDNA-SIRT1, Dr Junjie Chen for providing pcDNA-SIRT1-H363Y plasmid and Dr Boudewijn MT Burgering for providing 6X DBE-Luc construct. We thank Dr Frederic Alt for providing SIRT1 knockout mice. FW was supported by the Ellison Medical Foundation/American Federation for Aging Research senior postdoctoral fellowship. This work was also supported by the US Department of Agriculture grant (6250-51000-055) and NIH (DK075978) to QT.	Arden KC, 2008, ONCOGENE, V27, P2345, DOI 10.1038/onc.2008.27; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Fukuoka M, 2003, INT J MOL MED, V12, P503; Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kaeberlein M, 2005, PLOS GENET, V1, P614, DOI 10.1371/journal.pgen.0010069; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kojima K, 2008, BIOCHEM BIOPH RES CO, V373, P423, DOI 10.1016/j.bbrc.2008.06.045; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lamming DW, 2005, SCIENCE, V309, P1861, DOI 10.1126/science.1113611; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Perrot V, 2005, MOL ENDOCRINOL, V19, P2283, DOI 10.1210/me.2004-0292; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ravid T, 2007, NAT CELL BIOL, V9, P422, DOI 10.1038/ncb1558; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Schwer B, 2008, CELL METAB, V7, P104, DOI 10.1016/j.cmet.2007.11.006; Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sun Y, 2006, NEOPLASIA, V8, P645, DOI 10.1593/neo.06376; Sung JY, 2010, CANCER SCI, V101, P1738, DOI 10.1111/j.1349-7006.2010.01573.x; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Verdin E, 2007, MOL CELL, V28, P354, DOI 10.1016/j.molcel.2007.10.013; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang F, 2009, MOL BIOL CELL, V20, P801, DOI 10.1091/mbc.E08-06-0647; Wang JD, 2010, J BIOL CHEM, V285, P11458, DOI 10.1074/jbc.M109.087585; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	66	141	146	0	35	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1546	1557		10.1038/onc.2011.347	http://dx.doi.org/10.1038/onc.2011.347			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21841822				2022-12-28	WOS:000302132000007
J	Indovina, P; Giorgi, F; Rizzo, V; Khadang, B; Schenone, S; Di Marzo, D; Forte, IM; Tomei, V; Mattioli, E; D'Urso, V; Grilli, B; Botta, M; Giordano, A; Pentimalli, F				Indovina, P.; Giorgi, F.; Rizzo, V.; Khadang, B.; Schenone, S.; Di Marzo, D.; Forte, I. M.; Tomei, V.; Mattioli, E.; D'Urso, V.; Grilli, B.; Botta, M.; Giordano, A.; Pentimalli, F.			New pyrazolo[3,4-d] pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization	ONCOGENE			English	Article						SRC inhibitors; meso thelioma; apoptosis; p27; AKT; cyclin D1	CANCER CELLS; CYCLE INHIBITORS; MICE LACKING; KINASE; EXPRESSION; P27(KIP1); OVEREXPRESSION; HYPERPLASIA; ACTIVATION; MIGRATION	Malignant mesothelioma (MM) is a highly aggressive tumor of the serous membranes for which there is currently no effective curative modality. Recent data suggest that hyperactivation of the tyrosine kinase SRC has a key role in MM development and therefore this kinase represents an important molecular target for MM therapy. We tested new pyrazolo[3,4-d] pyrimidine SRC inhibitors on a panel of MM cell lines expressing the active form of SRC. These SRC inhibitors exerted a significant proapoptotic effect on MM cells without affecting the normal mesothelial cell line MET-5A, supporting a possible use of these SRC inhibitors for a safe treatment of MM. We also showed that SRC inhibitor-induced apoptosis occurred concomitantly with an increase in the nuclear stability of the cyclin-dependent kinase inhibitor p27. This finding is remarkable considering that loss of nuclear p27 expression is a well-established adverse prognostic factor in MM, and p27 nuclear localization is crucial for its tumor-suppressive function. Consistently, SRC inhibition seems to promote the increase in p27 nuclear level also by inactivating the AKT kinase and downregulating cyclin D1, which would otherwise delay p27 nuclear import and provoke its cytoplasmic accumulation. To determine whether p27 stabilization has a direct role in apoptosis induced by SRC inhibition, we stably silenced the CDKN1B gene, encoding p27, in MSTO-211H and REN mesothelioma cells by transduction with lentiviral vectors expressing short hairpin RNAs against the CDKN1B transcript. Strikingly, p27 silencing was able to suppress the apoptosis induced by these SRC inhibitors in both MM cell lines, suggesting that p27 has a crucial proapoptotic role in MM cells treated with SRC inhibitors. Our findings reveal a new mechanism, dependent on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in MM cells and provide a new rationale for the use of SRC inhibitors in MM therapy. Oncogene (2012) 31, 929-938; doi: 10.1038/onc.2011.286; published online 25 July 2011	[Di Marzo, D.; Forte, I. M.; D'Urso, V.; Giordano, A.; Pentimalli, F.] Pascale Fdn, INT CROM, Natl Canc Inst, Canc Res Ctr, Mercogliano, Italy; [Indovina, P.; Giorgi, F.; Rizzo, V.; Khadang, B.; Forte, I. M.; Tomei, V.; Mattioli, E.; Giordano, A.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Indovina, P.; Tomei, V.; Grilli, B.; Giordano, A.] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Schenone, S.] Univ Genoa, Dept Pharmaceut Sci, Genoa, Italy; [D'Urso, V.] Univ Sassari, Dept Biomed Sci, Natl Inst Biostruct & Biosyst, Div Biochem & Biophys, I-07100 Sassari, Italy; [Botta, M.] Univ Siena, Dept Pharmaceut & Appl Chem, I-53100 Siena, Italy	IRCCS Fondazione Pascale; University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Genoa; University of Sassari; University of Siena	Pentimalli, F (corresponding author), Pascale Fdn, INT CROM, Natl Canc Inst, Canc Res Ctr, Via Ammiraglio Bianco, I-83013 Avellino, Italy.	francesca.pentimalli@gmail.com	Mattioli, Eliseo/AAC-5018-2022; Pentimalli, Francesca/K-4936-2014; Forte, Iris Maria/K-7588-2016; Giordano, Antonio/F-1927-2010	Mattioli, Eliseo/0000-0002-2456-7867; Pentimalli, Francesca/0000-0003-4740-6801; Forte, Iris Maria/0000-0001-9490-5844; Giordano, Antonio/0000-0002-5959-016X; Indovina, Paola/0000-0001-8416-435X; Grilli, Bruna/0000-0003-3698-9503	Human Health Foundation; Sbarro Health Research Organization	Human Health Foundation; Sbarro Health Research Organization	We thank Giuseppe Viglietto for providing lentiviral vectors and Giovanni Gaudino for providing REN cells. PI, FG and VR are the recipients of Human Health Foundation fellowships. FP is also Adjunct Assistant Professor at Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA. This work was funded by Sbarro Health Research Organization (http://www.shro.org) and Human Health Foundation (http://www.hhfonlus.org).	Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Baldi A, 2004, THORAX, V59, P428, DOI 10.1136/thx.2003.008912; Beer TW, 2001, HISTOPATHOLOGY, V38, P535, DOI 10.1046/j.1365-2559.2001.01136.x; Bertino P, 2008, CLIN CANCER RES, V14, P541, DOI 10.1158/1078-0432.CCR-07-1388; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bongiovanni M, 2001, CANCER-AM CANCER SOC, V92, P1245, DOI 10.1002/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Carraro F, 2006, J MED CHEM, V49, P1549, DOI 10.1021/jm050603r; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chiappetta G, 2007, ENDOCR-RELAT CANCER, V14, P405, DOI 10.1677/ERC-06-0030; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Faraonio R, 2006, ANTIOXID REDOX SIGN, V8, P365, DOI 10.1089/ars.2006.8.365; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Katayose Y, 1997, CANCER RES, V57, P5441; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kudo Y, 2000, CLIN CANCER RES, V6, P916; Lee AY, 2007, CANCER-AM CANCER SOC, V109, P1454, DOI 10.1002/cncr.22552; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masuda A, 2001, AM J PATHOL, V158, P87, DOI 10.1016/S0002-9440(10)63947-8; Menges Craig W, 2010, Genes Cancer, V1, P493; Mezquita B, 2010, J CELL BIOCHEM, V110, P732, DOI 10.1002/jcb.22584; Mikami I, 2010, ONCOL REP, V24, P1677, DOI 10.3892/or_00001033; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Schenone S, 2004, BIOORG MED CHEM LETT, V14, P2511, DOI 10.1016/j.bmcl.2004.03.013; Schenone S, 2010, EXPERT OPIN INV DRUG, V19, P931, DOI 10.1517/13543784.2010.499898; Schenone S, 2008, EUR J MED CHEM, V43, P2665, DOI 10.1016/j.ejmech.2008.01.034; Schweppe RE, 2009, J CLIN ENDOCR METAB, V94, P2199, DOI 10.1210/jc.2008-2511; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spreafico A, 2008, FASEB J, V22, P1560, DOI 10.1096/fj.07-9873com; Tsao AS, 2007, MOL CANCER THER, V6, P1962, DOI 10.1158/1535-7163.MCT-07-0052; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang Z, 2005, CELL DEATH DIFFER, V12, P98, DOI 10.1038/sj.cdd.4401515; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yamaguchi H, 2008, J BIOL CHEM, V283, P19112, DOI 10.1074/jbc.M709882200; Yang H, 2006, ONCOGENE, V25, P4585, DOI 10.1038/sj.onc.1209481; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	50	36	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					929	938		10.1038/onc.2011.286	http://dx.doi.org/10.1038/onc.2011.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21785466				2022-12-28	WOS:000300615800011
J	Badgwell, DB; Lu, Z; Le, K; Gao, F; Yang, M; Suh, GK; Bao, JJ; Das, P; Andreeff, M; Chen, W; Yu, Y; Ahmed, AA; Liao, WSL; Bast, RC				Badgwell, D. B.; Lu, Z.; Le, K.; Gao, F.; Yang, M.; Suh, G. K.; Bao, J-J; Das, P.; Andreeff, M.; Chen, W.; Yu, Y.; Ahmed, A. A.; Liao, W. S-L; Bast, R. C., Jr.			The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways	ONCOGENE			English	Article						tumor-suppressor gene ARHI; migration suppression; Stat3; RhoA GTPase; cytoskeleton	EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RHO-GTPASES; G-PROTEIN; BREAST; ACTIVATION; FAK; LOCALIZATION; FIBROBLASTS	Ovarian cancers migrate and metastasize over the surface of the peritoneal cavity. Consequently, dysregulation of mechanisms that limit cell migration may be particularly important in the pathogenesis of the disease. ARHI is an imprinted tumor-suppressor gene that is downregulated in >60% of ovarian cancers, and its loss is associated with decreased progression-free survival. ARHI encodes a 26-kDa GTPase with homology to Ras. In contrast to Ras, ARHI inhibits cell growth, but whether it also regulates cell motility has not been studied previously. Here we report that re-expression of ARHI decreases the motility of IL-6-and epidermal growth factor (EGF)-stimulated SKOv3 and Hey ovarian cancer cells, inhibiting both chemotaxis and haptotaxis. ARHI binds to and sequesters Stat3 in the cytoplasm, preventing its translocation to the nucleus and localization in focal adhesion complexes. Stat3 siRNA or the JAK2 inhibitor AG490 produced similar inhibition of motility. However, the combination of ARHI expression with Stat3 knockdown or inhibition produced greatest inhibition in ovarian cancer cell migration, consistent with Stat3-dependent and Stat3-independent mechanisms. Consistent with two distinct signaling pathways, knockdown of Stat3 selectively inhibited IL-6-stimulated migration, whereas knockdown of focal adhesion kinase (FAK) preferentially inhibited EGF-stimulated migration. In EGF-stimulated ovarian cancer cells, re-expression of ARHI inhibited FAK(Y397) and Src(Y416) phosphorylation, disrupted focal adhesions, and blocked FAK-mediated RhoA signaling, resulting in decreased levels of GTP-RhoA. Re-expression of ARHI also disrupted the formation of actin stress fibers in a FAK- and RhoA-dependent manner. Thus, ARHI has a critical and previously uncharacterized role in the regulation of ovarian cancer cell migration, exerting inhibitory effects on two distinct signaling pathways. Oncogene (2012) 31, 68-79; doi: 10.1038/onc.2011.213; published online 6 June 2011	[Badgwell, D. B.; Lu, Z.; Le, K.; Gao, F.; Yang, M.; Suh, G. K.; Bao, J-J; Das, P.; Chen, W.; Yu, Y.; Ahmed, A. A.; Liao, W. S-L; Bast, R. C., Jr.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Andreeff, M.] Univ Texas MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Box 355, Houston, TX 77030 USA.	rbast@mdanderson.org	Lu, Zhen/E-5221-2015; Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI from the National Institutes of Health [P01 CA064602, 1RO1 CA135354-01]; MD Anderson SPORE in Ovarian Cancer [5P50 CA83639]; CCSG shared resources [CA 5 P30 CA016672]; Ovarian Cancer Research Fund; Cancer Research UK Clinician Scientist fellowship; MD Anderson Cancer Center CCSG NCI [P30 CA16672]; MRC [G0902418] Funding Source: UKRI; Medical Research Council [G0902418] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P01CA064602, P30CA016672, P50CA083639, R01CA135354, T32CA009666] Funding Source: NIH RePORTER	NCI from the National Institutes of Health; MD Anderson SPORE in Ovarian Cancer; CCSG shared resources; Ovarian Cancer Research Fund; Cancer Research UK Clinician Scientist fellowship(Cancer Research UK); MD Anderson Cancer Center CCSG NCI; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants NCI P01 CA064602 and 1RO1 CA135354-01 from the National Institutes of Health. We also acknowledge the support of the MD Anderson SPORE in Ovarian Cancer 5P50 CA83639 and the CCSG shared resources funded, in part, by CA 5 P30 CA016672. Support was also provided by the Ovarian Cancer Research Fund through a Program Project Award. DBB was supported by an Excellence Award from the Ovarian Cancer Research Fund. AAA was supported by a Cancer Research UK Clinician Scientist fellowship. We thank Jodie Polan for excellent technical support with confocal microscopy and Jared Burks from the Flow Cytometry and Cell Imaging core laboratory for the live-cell time-lapse microscopy partially supported by the MD Anderson Cancer Center CCSG NCI P30 CA16672.	Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bongard M, 2005, VISUAL GUIDE; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Colomiere M, 2009, INT J BIOCHEM CELL B, V41, P1034, DOI 10.1016/j.biocel.2008.09.018; Debidda M, 2005, J BIOL CHEM, V280, P17275, DOI 10.1074/jbc.M413187200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323; Ferreira T, 2011, IMAGEJ USER GUIDE, P144; Forcet C, 2005, HUM MOL GENET, V14, P1283, DOI 10.1093/hmg/ddi139; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Jang ACC, 2007, J MAMMARY GLAND BIOL, V12, P103, DOI 10.1007/s10911-007-9042-8; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kakinuma N, 2008, J CELL BIOL, V181, P537, DOI 10.1083/jcb.200707022; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kurokawa K, 2005, BIOCHEM SOC T, V33, P631, DOI 10.1042/BST0330631; LIDOR YJ, 1993, EXP CELL RES, V207, P332, DOI 10.1006/excr.1993.1200; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; LIOTTA LA, 1987, ANTI-CANCER DRUG DES, V2, P195; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; MARTINEZ-MAZA O, 1991, In Vivo (Attiki), V5, P583; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130; Okamura H, 2005, INT REV CYTOL, V242, P1; Orr F W, 2001, Surg Oncol Clin N Am, V10, P357; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db; Rosen DG, 2004, CLIN CANCER RES, V10, P6559, DOI 10.1158/1078-0432.CCR-04-0698; RUSTIN GJS, 1993, ANN ONCOL, V4, P71; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vij N, 2008, MOL VIS, V14, P1020; Yamashita S, 2002, DEV CELL, V2, P363, DOI 10.1016/S1534-5807(02)00126-0; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Yu YH, 2006, METHOD ENZYMOL, V407, P455, DOI 10.1016/S0076-6879(05)07037-0; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	52	68	74	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					68	79		10.1038/onc.2011.213	http://dx.doi.org/10.1038/onc.2011.213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643014	Green Accepted			2022-12-28	WOS:000299176200007
J	Coombs, GS; Schmitt, AA; Canning, CA; Alok, A; Low, ICC; Banerjee, N; Kaur, S; Utomo, V; Jones, CM; Pervaiz, S; Toone, EJ; Virshup, DM				Coombs, G. S.; Schmitt, A. A.; Canning, C. A.; Alok, A.; Low, I. C. C.; Banerjee, N.; Kaur, S.; Utomo, V.; Jones, C. M.; Pervaiz, S.; Toone, E. J.; Virshup, D. M.			Modulation of Wnt/beta-catenin signaling and proliferation by a ferrous iron chelator with therapeutic efficacy in genetically engineered mouse models of cancer	ONCOGENE			English	Article						Wnt/beta-catenin; iron; iron chelator; drug therapy; mouse models of cancer	CONNECTIVITY MAP; BINDING; WNT; EXPRESSION; DISEASE; INHIBITION; ANALOGS; PROTEIN; TUMORS; CELLS	Using a screen for Wnt/beta-catenin inhibitors, a family of 8-hydroxyquinolone derivatives with in vivo anti-cancer properties was identified. Analysis of microarray data for the lead compound N-((8-hydroxy-7-quinolinyl) (4-methylphenyl)methyl)benzamide (HQBA) using the Connectivity Map database suggested that it is an iron chelator that mimics the hypoxic response. HQBA chelates Fe(2+) with a dissociation constant of similar to 10(-19) M, with much weaker binding to Fe(3+) and other transition metals. HQBA inhibited proliferation of multiple cell lines in culture, and blocked the progression of established spontaneous cancers in two distinct genetically engineered mouse models of mammary cancer, MMTV-Wnt1 and MMTV-PyMT mice, without overt toxicity. HQBA may inhibit an iron-dependent factor that regulates cell-type-specific beta-catenin-driven transcription. It inhibits cancer cell proliferation independently of its effect on beta-catenin signaling, as it works equally well in MMTV-PyMT tumors and diverse beta-catenin-independent cell lines. HQBA is a promising specific intracellular Fe(2+) chelator with activity against spontaneous mouse mammary cancers. Oncogene (2012) 31, 213-225; doi:10.1038/onc.2011.228; published online 13 June 2011	[Coombs, G. S.; Alok, A.; Kaur, S.; Utomo, V.; Virshup, D. M.] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Canning, C. A.; Jones, C. M.] ASTAR, Inst Med Biol, Singapore, Singapore; [Schmitt, A. A.; Toone, E. J.] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Low, I. C. C.; Pervaiz, S.; Virshup, D. M.] Natl Univ Singapore, Dept Physiol, Singapore 117548, Singapore; [Banerjee, N.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Virshup, D. M.] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore; [Virshup, D. M.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27706 USA	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Duke University; National University of Singapore; Utah System of Higher Education; University of Utah; National University of Singapore; Duke University	Virshup, DM (corresponding author), Duke NUS Grad Med Sch Singapore, Program Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.	david.virshup@duke-nus.edu.sg	Low, Ivan Cherh Chiet/O-1649-2013; Virshup, David M/C-1449-2009; Pervaiz, Shazib/C-4188-2015	Virshup, David M/0000-0001-6976-850X; Kaur, Simran/0000-0003-1510-928X; Low, Ivan Cherh Chiet/0000-0003-2735-395X; Coombs, Gary/0000-0002-0711-185X	Duke-NUS; Singapore Translational Research (STaR); Agency for Science, Technology and Research, Singapore; Ministry of Health, Singapore; NIH [T32-GM007105-37]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007105] Funding Source: NIH RePORTER	Duke-NUS; Singapore Translational Research (STaR); Agency for Science, Technology and Research, Singapore(Agency for Science Technology & Research (A*STAR)); Ministry of Health, Singapore(Ministry of Health-Singapore); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Chuck Perou and Philipp Kaldis for assistance with the MMTV-Wnt1 and MMTV-PyMT mice, and Elizabeth Leibold for helpful discussions. The compound library was provided by the Huntsman Cancer Institute Drug Screening Resource at the University of Utah. This research was supported by the Duke-NUS Signature Research Program and the Singapore Translational Research (STaR) Investigator Award (to DMV) funded by the Agency for Science, Technology and Research, Singapore, and the Ministry of Health, Singapore. CAC and CMJ were funded by A*STAR, Singapore. AAS acknowledges support from the Duke Pharmacological Sciences Training Program, NIH T32-GM007105-37.	BERGERON RJ, 1993, BLOOD, V81, P2166; Bergeron RJ, 1999, J MED CHEM, V42, P95, DOI 10.1021/jm980340j; Brookes MJ, 2008, ONCOGENE, V27, P966, DOI 10.1038/sj.onc.1210711; Canning CA, 2007, DEV BIOL, V305, P276, DOI 10.1016/j.ydbio.2007.02.009; Coombs GS, 2008, CURR DRUG TARGETS, V9, P513, DOI 10.2174/138945008784911796; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; DiTusa CA, 2001, BIOCHEMISTRY-US, V40, P5338, DOI 10.1021/bi001731e; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Henderson WR, 2010, P NATL ACAD SCI USA, V107, P14309, DOI 10.1073/pnas.1001520107; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hodges YK, 2004, BIOCHEM BIOPH RES CO, V315, P595, DOI 10.1016/j.bbrc.2004.01.101; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jansson PJ, 2010, J INORG BIOCHEM, V104, P1224, DOI 10.1016/j.jinorgbio.2010.07.012; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; McCulloch MWB, 2009, J NAT PROD, V72, P1651, DOI 10.1021/np900336f; McCulloch MWB, 2009, BIOORGAN MED CHEM, V17, P2189, DOI 10.1016/j.bmc.2008.10.077; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Pang H, 2004, J BIOL CHEM, V279, P1491, DOI 10.1074/jbc.M310022200; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Rai K, 2010, CELL, V142, P930, DOI 10.1016/j.cell.2010.08.030; Richardson DR, 2009, BBA-GEN SUBJECTS, V1790, P702, DOI 10.1016/j.bbagen.2008.04.003; Rutherford JC, 2004, EUKARYOT CELL, V3, P1, DOI 10.1128/EC.3.1.1-13.2004; Sheftel A, 2010, TRENDS ENDOCRIN MET, V21, P302, DOI 10.1016/j.tem.2009.12.006; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Teo JL, 2010, ADV DRUG DELIVER REV, V62, P1149, DOI 10.1016/j.addr.2010.09.012; Tian JQ, 2010, CANCER LETT, V298, P231, DOI 10.1016/j.canlet.2010.07.010; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255	33	54	62	4	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	2					213	225		10.1038/onc.2011.228	http://dx.doi.org/10.1038/onc.2011.228			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666721	hybrid, Green Published			2022-12-28	WOS:000299307400007
J	Zaric, J; Joseph, JM; Tercier, S; Sengstag, T; Ponsonnet, L; Delorenzi, M; Ruegg, C				Zaric, J.; Joseph, J-M; Tercier, S.; Sengstag, T.; Ponsonnet, L.; Delorenzi, M.; Rueegg, C.			Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells	ONCOGENE			English	Article						COX-2; Wnt signaling; metastasis; colorectal cancer; tumor suppressor	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTEGRIN-MEDIATED ADHESION; GUANYLATE KINASE; SCAFFOLDING MOLECULE; TISSUE POLARITY; BETA-CATENIN; PDZ DOMAIN; PREVENTION; CELECOXIB; GROWTH	Cyclooxyganase-2 (COX-2), a rate-limiting enzyme in the prostaglandin synthesis pathway, is overexpressed in many cancers and contributes to cancer progression through tumor cell-autonomous and paracrine effects. Regular use of non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors (COXIBs) reduces the risk of cancer development and progression, in particular of the colon. The COXIB celecoxib is approved for adjunct therapy in patients with Familial adenomatous polyposis at high risk for colorectal cancer (CRC) formation. Long-term use of COXIBs, however, is associated with potentially severe cardiovascular complications, which hampers their broader use as preventive anticancer agents. In an effort to better understand the tumor-suppressive mechanisms of COXIBs, we identified MAGUK with Inverted domain structure-1 (MAGI1), a scaffolding protein implicated in the stabilization of adherens junctions, as a gene upregulated by COXIB in CRC cells and acting as tumor suppressor. Overexpression of MAGI1 in CRC cell lines SW480 and HCT116 induced an epithelial-like morphology; stabilized E-cadherin and beta-catenin localization at cell-cell junctions; enhanced actin stress fiber and focal adhesion formation; increased cell adhesion to matrix proteins and suppressed Wnt signaling, anchorage-independent growth, migration and invasion in vitro. Conversely, MAGI1 silencing decreased E-cadherin and beta-catenin localization at cell-cell junctions; disrupted actin stress fiber and focal adhesion formation; and enhanced Wnt signaling, anchorage-independent growth, migration and invasion in vitro. MAGI1 overexpression suppressed SW480 and HCT116 subcutaneous primary tumor growth, attenuated primary tumor growth and spontaneous lung metastasis in an orthotopic model of CRC, and decreased the number and size of metastatic nodules in an experimental model of lung metastasis. Collectively, these results identify MAG1 as a COXIB-induced inhibitor of the Wnt/beta-catenin signaling pathway, with tumor-suppressive and anti-metastatic activity in experimental colon cancer. Oncogene (2012) 31, 48-59; doi: 10.1038/onc.2011.218; published online 13 June 2011	[Zaric, J.; Ponsonnet, L.; Rueegg, C.] Univ Fribourg UNIFR, Dept Med, Fac Sci, CH-1700 Fribourg, Switzerland; [Zaric, J.; Ponsonnet, L.; Rueegg, C.] Univ Lausanne UNIL, Univ Med Ctr CHUV, Multidisciplinary Oncol Ctr CePO, Div Expt Oncol, Lausanne, Switzerland; [Zaric, J.; Delorenzi, M.; Rueegg, C.] Ecole Polytech Fed Lausanne EPFL, Swiss Inst Expt Canc Res ISREC, Natl Ctr Competence Res NCCR, Lausanne, Switzerland; [Joseph, J-M; Tercier, S.] Univ Lausanne UNIL, Univ Med Ctr CHUV, Dept Pediat Surg, Lausanne, Switzerland; [Sengstag, T.; Delorenzi, M.] Swiss Inst Bioinformat SIB, Lausanne, Switzerland	University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; University of Lausanne; Swiss Institute of Bioinformatics	Ruegg, C (corresponding author), Univ Fribourg UNIFR, Dept Med, Fac Sci, 1 Rue Albert Gockel, CH-1700 Fribourg, Switzerland.	curzio.ruegg@unifr.ch			Medic Foundation; National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation); European Union [HEALTH-F2-2008-201662]; Swiss Cancer League [OCS 020020-02-2007]	Medic Foundation; National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation); European Union(European Commission); Swiss Cancer League	We thank Drs M Aguet, Y Hata, L Naldini, A Follenzi and R Iggo for sharing reagents; F Derouet and D Uldry for invaluable technical assistance; N Rives for proof reading the paper and Pfizer for providing celecoxib. This work was supported by grants from the Medic Foundation, the National Center for Competence in Research (NCCR, Molecular Oncology, a research instrument of the Swiss National Science Foundation), the European Union under the auspices of the FP7 collaborative project TuMIC (contract number HEALTH-F2-2008-201662) and by the Swiss Cancer League (OCS 020020-02-2007).	Abassi YA, 2009, CHEM BIOL, V16, P712, DOI 10.1016/j.chembiol.2009.05.011; Araki Y, 2003, CANCER RES, V63, P728; Bertagnolli MM, 2009, CANCER PREV RES, V2, P310, DOI 10.1158/1940-6207.CAPR-08-0206; Bieler G, 2007, ONCOGENE, V26, P5722, DOI 10.1038/sj.onc.1210354; Buchanan FG, 2006, CANCER CELL, V9, P6, DOI 10.1016/j.ccr.2005.12.029; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253; Chastre E, 2009, FASEB J, V23, P916, DOI 10.1096/fj.08-106344; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Futaki N, 1997, INFLAMM RES, V46, P496, DOI 10.1007/s000110050232; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Howe LR, 1999, CANCER RES, V59, P1572; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Jacoby RF, 2000, CANCER RES, V60, P5040; Jones MK, 1999, NAT MED, V5, P1418; Kawajiri A, 2000, BIOCHEM BIOPH RES CO, V273, P712, DOI 10.1006/bbrc.2000.3002; Koch A, 2004, J PATHOL, V204, P546, DOI 10.1002/path.1662; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Monnier Y, 2008, CANCER RES, V68, P7323, DOI 10.1158/0008-5472.CAN-08-0841; Noda M, 2002, J GASTROENTEROL, V37, P896, DOI 10.1007/s005350200151; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Shao JY, 2003, CANCER RES, V63, P5218; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stolfi C, 2008, BIOCHEM PHARMACOL, V75, P668, DOI 10.1016/j.bcp.2007.09.020; Swamy MV, 2006, CANCER RES, V66, P7370, DOI 10.1158/0008-5472.CAN-05-4619; Taylor J, 1998, GENETICS, V150, P199; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tuynman JB, 2008, CANCER RES, V68, P1213, DOI 10.1158/0008-5472.CAN-07-5172; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Cespedes MV, 2007, AM J PATHOL, V170, P1077, DOI 10.2353/ajpath.2007.060773; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2004, CELL CYCLE, V3, P1512, DOI 10.4161/cc.3.12.1288; Wolff T, 1998, DEVELOPMENT, V125, P1149; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Zaric J, 2005, J BIOL CHEM, V280, P1077, DOI 10.1074/jbc.M410006200	51	45	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					48	59		10.1038/onc.2011.218	http://dx.doi.org/10.1038/onc.2011.218			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666716	Green Published, Green Submitted			2022-12-28	WOS:000299176200005
J	Dudgeon, C; Peng, R; Wang, P; Sebastiani, A; Yu, J; Zhang, L				Dudgeon, C.; Peng, R.; Wang, P.; Sebastiani, A.; Yu, J.; Zhang, L.			Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3 beta and NF-kappa B to suppress tumor cell growth	ONCOGENE			English	Article						sorafenib; PUMA; apoptosis; NF-kappa B; GSK3 beta; colon cancer	MULTIKINASE INHIBITOR; DOWN-REGULATION; RAF/MEK/ERK PATHWAY; MEDIATED APOPTOSIS; ANTITUMOR-ACTIVITY; CANCER-THERAPY; UP-REGULATION; PHASE-II; KINASE; COMBINATION	Aberrant Ras/Raf/MEK/ERK signaling is one of the most prevalent oncogenic alterations and confers survival advantage to tumor cells. Inhibition of this pathway can effectively suppress tumor cell growth. For example, sorafenib, a multi-kinase inhibitor targeting c-Raf and other oncogenic kinases, has been used clinically for treating advanced liver and kidney tumors, and also has shown efficacy against other malignancies. However, how inhibition of oncogenic signaling by sorafenib and other drugs suppresses tumor cell growth remains unclear. In this study, we found that sorafenib kills cancer cells by activating PUMA (p53-upregulated modulator of apoptosis), a p53 target and a BH3-only Bcl-2 family protein. Sorafenib treatment induces PUMA in a variety of cancer cells irrespective of their p53 status. Surprisingly, the induction of PUMA by sorafenib is mediated by I kappa B-independent activation of nuclear factor (NF)-kappa B, which directly binds to the PUMA promoter to activate its transcription. NF-kappa B activation by sorafenib requires glycogen synthase kinase 3 beta activation, subsequent to ERK inhibition. Deficiency in PUMA abrogates sorafenib-induced apoptosis and caspase activation, and renders sorafenib resistance in colony formation and xenograft tumor assays. Furthermore, the chemosensitization effect of sorafenib is dependent on PUMA, and involves concurrent PUMA induction through different pathways. BH3 mimetics potentiate the anti-cancer effects of sorafenib, and restore sorafenib sensitivity in resistant cells. Together, these results demonstrate a key role of PUMA-dependent apoptosis in therapeutic inhibition of Ras/Raf/MEK/ERK signaling. They provide a rationale for manipulating the apoptotic machinery to improve sensitivity and overcome resistance to the therapies that target oncogenic kinase signaling.	[Zhang, L.] Univ Pittsburgh, Hillman Canc Ctr, Dept Pharmacol & Chem Biol, UPCI Res Pavil, Pittsburgh, PA 15213 USA; [Yu, J.] Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Pharmacol & Chem Biol, UPCI Res Pavil, Room 2-42A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Dudgeon, Crissy/0000-0001-9010-2569	NIH [CA106348, CA121105]; American Cancer Society [RSG-07-156-01-CNE, RGS-10-124-01-CCE]; Flight Attendant Medical Research Institute, NIH [CA129829]; NIH National Research Service [F32CA139882]; China Scholarship Council; NATIONAL CANCER INSTITUTE [R01CA121105, F32CA139882, R01CA106348, R01CA129829] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Flight Attendant Medical Research Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Monica E Buchanan, Brian Leibowitz, Mathew F Brown and other lab members for critical reading and helpful discussion, and Drs Jennifer R Grandis and Jing Hu for help with analyses of STAT1, STAT3, eIF4E and GSK3 beta. This work is supported by NIH grants CA106348 and CA121105 and American Cancer Society grant RSG-07-156-01-CNE (LZ); Flight Attendant Medical Research Institute, NIH grant CA129829 and American Cancer Society grant RGS-10-124-01-CCE (JY); NIH National Research Service Award postdoctoral fellowship grant F32CA139882 (CD); and China Scholarship Council (RP). LZ is a scholar of the V Foundation for Cancer Research.	Augustine CK, 2010, MOL CANCER THER, V9, P2090, DOI 10.1158/1535-7163.MCT-10-0073; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786; Clark JW, 2005, CLIN CANCER RES, V11, P5472, DOI 10.1158/1078-0432.CCR-04-2658; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Dudgeon C, 2010, MOL CANCER THER, V9, P2893, DOI 10.1158/1535-7163.MCT-10-0635; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Gomez-Benito M, 2005, MOL PHARMACOL, V67, P1991, DOI 10.1124/mol.104.007021; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Hikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836; Hong DS, 2009, CLIN CANCER RES, V15, P7061, DOI 10.1158/1078-0432.CCR-09-1241; Huang SB, 2010, MOL CANCER THER, V9, P742, DOI 10.1158/1535-7163.MCT-09-1004; Kim C, 2010, INVEST NEW DRUGS; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475; Lind JSW, 2010, CLIN CANCER RES, V16, P3078, DOI 10.1158/1078-0432.CCR-09-3033; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309; Martinelli E, 2010, CLIN CANCER RES, V16, P4990, DOI 10.1158/1078-0432.CCR-10-0923; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Molhoek KR, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-39; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Plastaras JP, 2007, CANCER RES, V67, P9443, DOI 10.1158/0008-5472.CAN-07-1473; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sun Q, 2009, ONCOGENE, V28, P2348, DOI 10.1038/onc.2009.108; Sun WJ, 2010, J CLIN ONCOL, V28, P2947, DOI 10.1200/JCO.2009.27.7988; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267; Zhang G, 2008, CLIN CANCER RES, V14, P5385, DOI 10.1158/1078-0432.CCR-08-0469; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002; Zhang W, 2008, LEUKEMIA, V22, P808, DOI 10.1038/sj.leu.2405098	51	57	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4848	4858		10.1038/onc.2011.644	http://dx.doi.org/10.1038/onc.2011.644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22286758	Green Accepted, Bronze			2022-12-28	WOS:000311210700005
J	Russo, A; O'Bryan, JP				Russo, A.; O'Bryan, J. P.			Intersectin 1 is required for neuroblastoma tumorigenesis	ONCOGENE			English	Article						scaffold protein; SH3 domains; EH domains; endocytosis; transformation; oncogenesis	PHOSPHOINOSITIDE 3-KINASE; ACTIVATING MUTATIONS; ALK KINASE; EXPRESSION; ENDOCYTOSIS; CELLS; GENE; RECEPTOR; GROWTH; PROTEINS	Intersectin 1 (ITSN1) is a scaffold protein that regulates diverse cellular pathways, including endocytosis and several signal transduction pathways, including phosphatidylinositol 3-kinase, Class II beta (PI3K-C2 beta). ITSN1's transforming potential in vitro suggests that this scaffold protein may be involved in human tumorigenesis. Herein, we demonstrate that ITSN1 is expressed in primary human neuroblastoma tumors and tumor cell lines and is necessary for their in vitro and in vivo tumorigenic properties. Silencing ITSN1 significantly inhibits the anchorage independent growth of tumor cells in vitro and tumor formation in xenograft assays independent of MYCN status. Overexpression of the ITSN1 target, PI3K-C2 beta, rescues the soft agar growth of ITSN1-silenced cells demonstrating the importance of the ITSN1-PI3K-C2 beta pathway in neuroblastoma tumorigenesis. These findings represent the first demonstration that the ITSN1-PI3K-C2 beta pathway has a requisite role in human cancer, specifically neuroblastomas.	[O'Bryan, J. P.] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	O'Bryan, JP (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 4091 COMRB,835 S Wolcott,E403 M-C 868, Chicago, IL 60612 USA.	obryanj@uic.edu		O'Bryan, John/0000-0001-5386-1080	National Institutes of Health [HL090651]; Department of Defense [PR080428]; Foundation Jerome Lejeune; St Baldrick's Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090651] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Foundation Jerome Lejeune; St Baldrick's Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Naohiko Ikegaki and Bernard Weissman for providing various neuroblastoma cell lines, and Drs Michael Hogarty and Wendy London and the Children's Oncology Group ANBL00B1 Neuroblastoma Biology Studies for providing the primary neuroblastoma tumor samples for analysis. We also thank Dr Ikegaki for providing advice on the xenograft assay, Dr Javed Khan for his helpful discussions regarding the Oncogenomics database, and members of the O'Bryan lab for comments on the manuscript. These studies were supported by grants to JPO from the National Institutes of Health (HL090651), Department of Defense (PR080428), the Foundation Jerome Lejeune, and the St Baldrick's Foundation.	Adams A, 2000, J BIOL CHEM, V275, P27414; Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; Arcaro A, 2002, EMBO J, V21, P5097, DOI 10.1093/emboj/cdf512; Arcaro A, 2000, MOL CELL BIOL, V20, P3817, DOI 10.1128/MCB.20.11.3817-3830.2000; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670; Boller D, 2008, CLIN CANCER RES, V14, P1172, DOI 10.1158/1078-0432.CCR-07-0737; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Das M, 2007, MOL CELL BIOL, V27, P7906, DOI 10.1128/MCB.01369-07; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Izbicka Elzbieta, 2005, Curr Opin Investig Drugs, V6, P1200; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Koutros S, 2010, CANCER RES, V70, P2389, DOI 10.1158/0008-5472.CAN-09-3575; Ma YJ, 2011, J NEUROSCI RES, V89, P1079, DOI 10.1002/jnr.22616; Ma YJ, 2010, BRAIN RES, V1351, P222, DOI 10.1016/j.brainres.2010.05.028; Malacombe M, 2006, EMBO J, V25, P3494, DOI 10.1038/sj.emboj.7601247; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Marras E, 2001, INT J ONCOL, V19, P395; Martin NP, 2006, MOL PHARMACOL, V70, P1643, DOI 10.1124/mol.106.028274; Mohney RP, 2003, J BIOL CHEM, V278, P47038, DOI 10.1074/jbc.M303895200; Momboisse F, 2010, CELL MOL NEUROBIOL, V30, P1327, DOI 10.1007/s10571-010-9580-2; O'Bryan JP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3152re10; Predescu SA, 2007, J BIOL CHEM, V282, P17166, DOI 10.1074/jbc.M608996200; Qian ZJ, 2002, P NATL ACAD SCI USA, V99, P14925, DOI 10.1073/pnas.222491799; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Yu Y, 2008, HUM MOL GENET, V17, P3281, DOI 10.1093/hmg/ddn224	43	28	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	46					4828	4834		10.1038/onc.2011.643	http://dx.doi.org/10.1038/onc.2011.643			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266851	Green Accepted			2022-12-28	WOS:000311210700003
J	Bai, H; Inoue, J; Kawano, T; Inazawa, J				Bai, H.; Inoue, J.; Kawano, T.; Inazawa, J.			A transcriptional variant of the LC3A gene is involved in autophagy and frequently inactivated in human cancers	ONCOGENE			English	Article						autophagy; microtubule-associated protein; human cancers; DNA methylation; ESCC	PROGNOSTIC RELEVANCE; LIGHT; TUMORIGENESIS; BECLIN-1; DEFICIENT; PATTERNS; PROTEIN; MAP1A; P62	Microtubule-associated protein 1 light chain 3 has an important role in autophagy. The human LC3 gene family has five members, LC3A (variant-1: v1 and -2: v2), LC3B, LC3B2 and LC3C. Although a form of LC3B modified by phosphatidylethanolamine (form-II) is localized in autophagosomes, it is not clear whether other LC3 proteins also function in autophagy. Here, we examined the association between autophagy and human LC3 proteins during starvation- or p53-induced autophagy in Saos-2 cells. In an analysis of the intracellular distribution of each LC3 protein fused with GFP, GFP-LC3Av1 was frequently localized in autophagosomes with a punctate pattern, similar to GFP-LC3B. Further, endogenous LC3Av1 generated form-II and mostly localized in LC3B-positive autophagosomes during the induced autophagy. Interestingly, LC3Av1, not LC3B, was frequently inactivated at the transcriptional level in various human cancer cell lines (111/244 cell lines, 45.5%) and its inactivation was due to aberrant DNA methylation in esophageal squamous cell carcinoma (ESCC) cell lines and primary tumors. Restoration of LC3Av1 expression in KYSE170 cells, an LC3Av1-inactivated ESCC cell line, showed the inhibition of tumor growth in vivo. These results suggest that LC3Av1, not only LC3B, functions in autophagy and further, LC3Av1 may be crucial in carcinogenesis. Oncogene (2012) 31, 4397-4408; doi: 10.1038/onc.2011.613; published online 16 January 2012	[Inazawa, J.] Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Bai, H.; Inoue, J.; Inazawa, J.] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Tokyo 1138510, Japan; [Kawano, T.] Tokyo Med & Dent Univ, Dept Surg, Grad Sch, Tokyo 1138510, Japan; [Bai, H.; Inazawa, J.] Tokyo Med & Dent Univ, Global Ctr, Excellence Program Frontier Res Mol Destruct & Re, Tokyo 1138510, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp			Japanese Ministry of Education Core Research for Evolutional Science and Technology of Japan Science and Technology (JST) Corporation; New Energy and Industrial Technology Development Organization (NEDO); Grants-in-Aid for Scientific Research [22134002] Funding Source: KAKEN	Japanese Ministry of Education Core Research for Evolutional Science and Technology of Japan Science and Technology (JST) Corporation; New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ayako Takahashi and Rumi Mori for technical assistance. This work is supported by Grant-in-Aid for Scientific Research on Priority Areas and Innovative Areas, young scientists (B) and a Global Center of Excellence (GCOE) Program from the Japanese Ministry of Education Core Research for Evolutional Science and Technology of Japan Science and Technology (JST) Corporation, and New Energy and Industrial Technology Development Organization (NEDO).	Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Cann GM, 2008, DEV DYNAM, V237, P187, DOI 10.1002/dvdy.21392; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Faller EM, 2009, MOL CELL NEUROSCI, V41, P85, DOI 10.1016/j.mcn.2009.02.001; Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500; Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Inoue J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007099; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; MANN SS, 1994, J BIOL CHEM, V269, P11492; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Shvets E, 2008, J CELL SCI, V121, P2685, DOI 10.1242/jcs.026005; Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947; Sivridis E, 2010, AUTOPHAGY, V6, P830, DOI 10.4161/auto.6.6.12588; Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726; Wu JX, 2006, BIOCHEM BIOPH RES CO, V339, P437, DOI 10.1016/j.bbrc.2005.10.211; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	38	57	61	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4397	4408		10.1038/onc.2011.613	http://dx.doi.org/10.1038/onc.2011.613			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249245				2022-12-28	WOS:000309591300006
J	Li, X; Lu, Y; Liang, K; Hsu, JM; Albarracin, C; Mills, GB; Hung, MC; Fan, Z				Li, X.; Lu, Y.; Liang, K.; Hsu, J-M; Albarracin, C.; Mills, G. B.; Hung, M-C; Fan, Z.			Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR	ONCOGENE			English	Article						EGFR; Brk; Cbl; Src; breast cancer	EPIDERMAL-GROWTH-FACTOR; BREAST-TUMOR KINASE; MAMMARY EPITHELIAL-CELLS; PROTEIN-TYROSINE KINASE; FACTOR RECEPTOR; THERAPEUTIC TARGET; CANCER CELLS; DOWN-REGULATION; BRK; EXPRESSION	Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer. Here, we report a novel regulatory mechanism of EGFR signaling that may explain the low response rates. We found that breast tumor kinase (Brk)/protein-tyrosine kinase 6 (PTK6), a nonreceptor protein-tyrosine kinase highly expressed in most human breast tumors, interacted with EGFR and sustained ligand-induced EGFR signaling. We demonstrate that Brk inhibits ligand-induced EGFR degradation through uncoupling activated EGFR from casitas B-lineage lymphoma-mediated EGFR ubiquitination. In addition, upon activation by EGFR, Brk directly phosphorylated Y845 in the EGFR kinase domain, thereby further potentiating EGFR kinase activity. Experimental elevation of Brk conferred resistance of breast cancer cells to cetuximab (an EGFR-blocking antibody)-induced inhibition of cell signaling and proliferation, whereas knockdown of Brk sensitized the cells to cetuximab by inducing apoptosis. Our findings reveal a previously unknown role of Brk in EGFR-targeted therapy. Oncogene (2012) 31, 4372-4383; doi:10.1038/onc.2011.608; published online 9 January 2012	[Li, X.; Lu, Y.; Liang, K.; Fan, Z.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hsu, J-M; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Albarracin, C.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.	zfan@mdanderson.org	Hsu, Jung-Mao/AAC-9527-2019; Hsu, Jung-Mao/AAP-8045-2020; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	US Congressionally Directed Medical Research Programs of the Department of Defense [W81XWH-06-1-0544, W81XWH-07-1-0526]; Breast Cancer Research Foundation; National Institutes of Health [5R01CA129036]; MD Anderson's NIH Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA129036] Funding Source: NIH RePORTER	US Congressionally Directed Medical Research Programs of the Department of Defense; Breast Cancer Research Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson's NIH Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Mark R Crompton (University of London) for providing the Brk DNA constructs, Dr Steven P Ethier (Karmanos Cancer Institute) for the SUM series of cell lines and Stephanie Deming (Department of Scientific Publications, MD Anderson Cancer Center) for editing the manuscript. This work was supported in part by grants from the US Congressionally Directed Medical Research Programs of the Department of Defense (W81XWH-06-1-0544 and W81XWH-07-1-0526), the Breast Cancer Research Foundation and the National Institutes of Health (5R01CA129036) and MD Anderson's NIH Cancer Center Support Grant (CA016672).	Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Born M, 2005, J PATHOL, V205, P592, DOI 10.1002/path.1720; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; Eck SM, 2009, MOL CANCER RES, V7, P1033, DOI 10.1158/1541-7786.MCR-09-0015; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Harvey AJ, 2004, ANTI-CANCER DRUG, V15, P107, DOI 10.1097/01.cad.0000113339.62364.b5; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Irie HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011729; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kang SA, 2010, J BIOL CHEM, V285, P26013, DOI 10.1074/jbc.M109.088971; LEE ST, 1993, ONCOGENE, V8, P3403; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Li XQ, 2008, MOL CANCER THER, V7, P1207, DOI 10.1158/1535-7163.MCT-07-2187; Liu L, 2006, ONCOGENE, V25, P4904, DOI 10.1038/sj.onc.1209501; Llor X, 1999, CLIN CANCER RES, V5, P1767; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015823; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Normanno N, 2005, FRONT BIOSCI-LANDMRK, V10, P2611, DOI 10.2741/1725; Ostrander JH, 2007, CANCER RES, V67, P4199, DOI 10.1158/0008-5472.CAN-06-3409; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Qiu HQ, 2005, ONCOGENE, V24, P5656, DOI 10.1038/sj.onc.1208721; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; SAINSBURY JRC, 1985, LANCET, V1, P364; Sartor CI, 1997, CANCER RES, V57, P978; Serfas MS, 2003, ONCOL RES, V13, P409; Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Weaver AM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1794; Xiang B, 2008, P NATL ACAD SCI USA, V105, P12463, DOI 10.1073/pnas.0805009105; Yamaoka T, 2011, AM J PHYSIOL-GASTR L, V301, pG368, DOI 10.1152/ajpgi.00327.2010; Zhang P, 2005, J BIOL CHEM, V280, P1982, DOI 10.1074/jbc.M412038200	44	37	37	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4372	4383		10.1038/onc.2011.608	http://dx.doi.org/10.1038/onc.2011.608			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22231447	Green Accepted			2022-12-28	WOS:000309591300004
J	Niemela, M; Kauko, O; Sihto, H; Mpindi, JP; Nicorici, D; Pernila, P; Kallioniemi, OP; Joensuu, H; Hautaniemi, S; Westermarck, J				Niemela, M.; Kauko, O.; Sihto, H.; Mpindi, J-P; Nicorici, D.; Pernila, P.; Kallioniemi, O-P; Joensuu, H.; Hautaniemi, S.; Westermarck, J.			CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes	ONCOGENE			English	Article						KIAA1524; breast cancer; gene expression profile; PLAUR; SERPINE2; PP2A B-subunit	C-MYC; EXPRESSION SIGNATURE; PP2A COMPLEXES; IDENTIFICATION; AMPLIFICATION; METAANALYSIS; CARCINOMA; APOPTOSIS; VARIANCE	Protein phosphatase 2A (PP2A) is a critical human tumor-suppressor complex. A recently characterized PP2A inhibitor protein, namely cancerous inhibitor of PP2A (CIP2A), has been found to be overexpressed at a high frequency in most of the human cancer types. However, our understanding of gene expression programs regulated by CIP2A is almost absent. Moreover, clinical relevance of the CIP2A-regulated transcriptome has not been addressed thus far. Here, we report a high-confidence transcriptional signature regulated by CIP2A. Bioinformatic pathway analysis of the CIP2A signature revealed that CIP2A regulates several MYC-dependent and MYC-independent gene programs. With regard to MYC-independent signaling, JNK2 expression and transwell migration were inhibited by CIP2A depletion, whereas MYC depletion did not affect either of these phenotypes. Instead, depletion of either CIP2A or MYC inhibited cancer cell colony growth with statistically indistinguishable efficiency. Moreover, CIP2A depletion was shown to regulate the expression of several established MYC target genes, out of which most were MYC-repressed genes. CIP2A small-interfering RNA-elicited inhibition of colony growth or activation of MYC-repressed genes was reversed at large by concomitant PP2A inhibition. Finally, the CIP2A signature was shown to cluster with basal-type and human epidermal growth factor receptor (HER) 2-positive (HER2+) breast cancer signatures. Accordingly, CIP2A protein expression was significantly associated with basal-like (P = 0.0014) and HER2+ (P<0.0001) breast cancers. CIP2A expression also associated with MYC gene amplification (P<0.001). Taken together, identification of CIP2A-driven transcriptional signature, and especially novel MYC-independent signaling programs regulated by CIP2A, provides important resource for understanding CIP2A's role as a clinically relevant human oncoprotein. With regard to MYC, these results both validate CIP2A's role in regulating MYC-mediated gene expression and provide a plausible novel explanation for the high MYC activity in basal-like and HER2+ breast cancers. Oncogene (2012) 31, 4266-4278; doi:10.1038/onc.2011.599; published online 16 January 2012	[Westermarck, J.] Univ Turku, Ctr Biotechnol, Dept Pathol, FIN-20520 Turku, Finland; [Niemela, M.; Kauko, O.; Westermarck, J.] Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Niemela, M.; Kauko, O.; Westermarck, J.] Abo Akad Univ, Turku, Finland; [Niemela, M.; Kauko, O.] Turku Grad Sch Biomed Sci, Turku, Finland; [Niemela, M.] Univ Turku, Dept Med Biochem & Genet, FIN-20520 Turku, Finland; [Sihto, H.; Pernila, P.; Joensuu, H.] Univ Helsinki, Lab Mol Oncol, Biomedicum, Helsinki, Finland; [Mpindi, J-P; Nicorici, D.; Kallioniemi, O-P; Westermarck, J.] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Hautaniemi, S.] Univ Helsinki, Res Programs Unit, Helsinki, Finland; [Hautaniemi, S.] Univ Helsinki, Inst Biomed Biochem & Dev Biol, Helsinki, Finland	University of Turku; University of Turku; Abo Akademi University; University of Turku; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Westermarck, J (corresponding author), Univ Turku, Ctr Biotechnol, Dept Pathol, Tykistokatu 6A, FIN-20520 Turku, Finland.	jukwes@utu.fi	Hautaniemi, Sampsa/CAG-0362-2022; Westermarck, Jukka/AAL-6464-2020; Sihto, Harri J/B-3432-2015; Kallioniemi, Olli P/H-5111-2011; Hautaniemi, Sampsa/A-3122-2009	Hautaniemi, Sampsa/0000-0002-7749-2694; Westermarck, Jukka/0000-0001-7478-3018; Sihto, Harri J/0000-0001-5265-5509; Kallioniemi, Olli P/0000-0002-3231-0332; Hautaniemi, Sampsa/0000-0002-7749-2694; Nicorici, Daniel/0000-0002-0278-8263; Joensuu, Heikki/0000-0003-0281-2507	Academy of Finland [125826, 1131449, 8217676]; Sigrid Juselius Foundation; Cancer Society of Finland; Helsinki University Central Hospital [TYH2009304]; Foundation of Finnish Cancer Institute; Cancer Foundation Finland sr [120139, 110071, 120084, 110134] Funding Source: researchfish	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Society of Finland; Helsinki University Central Hospital; Foundation of Finnish Cancer Institute; Cancer Foundation Finland sr	We thank Taina Kalevo-Mattila for expert technical assistance. Melissa R Junttila is acknowledged for PP2A assay data and Minna-Maija Lintunen for performing the FISH hybridizations. Panu Jaakkola is acknowledged for B-subunit siRNAs. The Finnish DNA Microarray centre is acknowledged for the microarray and qRT-PCR analysis. This study was supported by grants from the Academy of Finland (grant no. 125826, 1131449 and 8217676), Sigrid Juselius Foundation, the Cancer Society of Finland, Helsinki University Central Hospital Research Funds (TYH2009304) and the Foundation of Finnish Cancer Institute.	Alles MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004710; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Ben-Israel H, 2008, J VIROL, V82, P9381, DOI 10.1128/JVI.00791-08; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cappellen D, 2007, EMBO REP, V8, P70, DOI 10.1038/sj.embor.7400849; Chandriani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006693; Chen KF, 2010, ONCOGENE, V29, P6257, DOI 10.1038/onc.2010.357; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Choi YA, 2011, FEBS LETT, V585, P755, DOI 10.1016/j.febslet.2011.01.018; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dong QZ, 2011, ANN SURG ONCOL, V18, P857, DOI 10.1245/s10434-010-1313-8; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Ioannidis JPA, 2009, NAT GENET, V41, P149, DOI 10.1038/ng.295; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Joensuu H, 2003, CLIN CANCER RES, V9, P923; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Katz J, 2010, CANCER BIOL THER, V10, P694, DOI 10.4161/cbt.10.7.12895; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin SM, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1075; Mannava S, 2011, ONCOGENE, DOI [10.1038/onc.2011.339, DOI 10.1038/0NC.2011.339]; Mathiasen DP, 2011, ONCOGENE, DOI [10.1038/onc.2011.230, DOI 10.1038/0NC.2011.230]; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Qu W, 2010, MED ONCOL; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855; Sihto H, 2008, CLIN CANCER RES, V14, P4103, DOI 10.1158/1078-0432.CCR-07-5003; Vaarala MH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-136; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	43	60	60	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4266	4278		10.1038/onc.2011.599	http://dx.doi.org/10.1038/onc.2011.599			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22249265				2022-12-28	WOS:000309520200002
J	Ferrero, GO; Velazquez, FN; Caputto, BL				Ferrero, G. O.; Velazquez, F. N.; Caputto, B. L.			The kinase c-Src and the phosphatase TC45 coordinately regulate c-Fos tyrosine phosphorylation and c-Fos phospholipid synthesis activation capacity	ONCOGENE			English	Article						cytoplasmic c-Fos; phospholipid synthesis regulation; c-Fos-tyr phosphorylation; c-Src; TC45 phosphatase	GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATOR; SIGNALING PATHWAY; INSULIN-RECEPTOR; PC12 CELLS; PROTEIN; LIGHT; TCPTP; NUCLEUS; RETINA	Our previous work showed that in T98G cells, a human glioblastoma multiforme-derived cell line, the association of c-Fos to the endoplasmic reticulum (ER) and consequently, the capacity of c-Fos to activate phospholipid synthesis, is regulated by the phosphorylation state of tyrosine (tyr) residues # 10 and # 30 of c-Fos. The small amount of c-Fos present in quiescent cells is tyrphosphorylated, is dissociated from the ER membranes and does not activate phospholipid synthesis. However, on induction of the cell to re-enter growth, c-Fos expression is rapidly induced, it is found dephosphorylated, associated to ER membranes and activating phospholipid synthesis (Portal et al., 2007). Herein, using in vivo and in vitro experimental strategies, we show that the kinase c-Src is capable of phosphorylating tyr residues of c-Fos whereas the phosphatase TC45 T-cell protein-tyr phosphatase (TC-PTP) dephosphorylates them, thus enabling c-Fos/ER association and activation of phospholipid synthesis. Results also suggest that the regulation of the phosphorylation/dephosphorylation cycle of c-Fos occurs at the TC-PTP level: induction of cells to re-enter growth promotes the translocation of TC45 from a nuclear to a cytoplasmic location concomitant with its activation. Activated TC45 in its turn promotes dephosphorylation of pre-formed c-Fos, enabling cells to rapidly activate phospholipid synthesis to respond to its growth demands. Oncogene (2012) 31, 3381-3391; doi: 10.1038/onc.2011.510; published online 21 November 2011	[Ferrero, G. O.; Velazquez, F. N.; Caputto, B. L.] Univ Nacl Cordoba, CIQUIBIC, CONICET, Dept Quim Biol,Fac Ciencias Quim, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, CIQUIBIC, CONICET, Dept Quim Biol,Fac Ciencias Quim, Ciudad Univ, RA-5000 Cordoba, Argentina.	bcaputto@fcq.unc.edu.ar			ANPCyT; CONICET; Ministerio de Ciencia, Tecnologi a e Innovacio n Productiva de Argentina; SECyT-Universidad Nacional de Cordoba, Argentina; JS McDonnell Foundation	ANPCyT(ANPCyT); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Ministerio de Ciencia, Tecnologi a e Innovacio n Productiva de Argentina; SECyT-Universidad Nacional de Cordoba, Argentina(Secretaria de Ciencia y Tecnologia (SECYT)); JS McDonnell Foundation	We thank HJF Maccioni for helpful discussions and H Carbonneau (Pardue University, West Lafayette, IN, USA) for providing pET-TC45a. pCG-TC45 and pCG-D182A were kind gifts from T Tiganis (Cold Spring Harbor Laboratory, New York, NY, USA) and pET-c-Src from MA Seelinger (University of California, Berkeley, CA, USA). Excellent technical assistance from Susana Deza and Gabriela Schachner is acknowledged. This work was supported by grants from the ANPCyT and CONICET, Ministerio de Ciencia, Tecnologi a e Innovacio n Productiva de Argentina, SECyT-Universidad Nacional de Cordoba, Argentina and the JS McDonnell Foundation. BLC is a career member and GOF and FV are fellows of CONICET.	ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Borioli GA, 2001, BIOCHEM BIOPH RES CO, V280, P9, DOI 10.1006/bbrc.2000.4081; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Caputto BL, 2000, NEUROCHEM RES, V25, P153, DOI 10.1023/A:1007508020173; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; COOPER JA, 1984, J BIOL CHEM, V259, P7835; Crespo PM, 2008, J BIOL CHEM, V283, P31163, DOI 10.1074/jbc.M709257200; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Galic S, 2003, MOL CELL BIOL, V23, P2096, DOI 10.1128/MCB.23.6.2096-2108.2003; Gil GA, 2004, MOL BIOL CELL, V15, P1881, DOI 10.1091/mbc.e03-09-0705; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; Hu X, 2007, CHEM BIOL, V14, P764, DOI 10.1016/j.chembiol.2007.05.010; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Klingler-Hoffmann M, 2001, J BIOL CHEM, V276, P46313, DOI 10.1074/jbc.M106571200; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Meng TC, 2004, J BIOL CHEM, V279, P37716, DOI 10.1074/jbc.M404606200; Morgan James J., 1995, Trends in Neurosciences, V18, P66, DOI 10.1016/0166-2236(95)93874-W; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; Portal MM, 2007, ONCOGENE, V26, P3551, DOI 10.1038/sj.onc.1210137; Sambrook J, 2001, MOL CLONING LAB MANU; Silvestre DC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009544; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Tiganis T, 1999, J BIOL CHEM, V274, P27768, DOI 10.1074/jbc.274.39.27768; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tiganis T, 2002, IUBMB LIFE, V53, P3, DOI 10.1080/15216540210811; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x	39	14	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3381	3391		10.1038/onc.2011.510	http://dx.doi.org/10.1038/onc.2011.510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22105363				2022-12-28	WOS:000306367600007
J	Sulzmaier, FJ; Valmiki, MKG; Nelson, DA; Caliva, MJ; Geerts, D; Matter, ML; White, EP; Ramos, JW				Sulzmaier, F. J.; Valmiki, M. K. G.; Nelson, D. A.; Caliva, M. J.; Geerts, D.; Matter, M. L.; White, E. P.; Ramos, J. W.			PEA-15 potentiates H-Ras-mediated epithelial cell transformation through phospholipase D	ONCOGENE			English	Article						PEA-15; PLD; cell cycle; H-Ras; cell transformation	PHOSPHATIDIC-ACID; CYCLIN D1/CDK4; CANCER-CELLS; PROTEIN; EXPRESSION; KINASE; SIGNAL; ACTIVATION; APOPTOSIS; RECEPTOR	The small GTPase H-Ras is a proto-oncogene that activates a variety of different pathways including the extracellular-signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway. H-Ras is mutated in many human malignancies, and these mutations cause the protein to be constitutively active. Phosphoprotein enriched in astrocytes, 15 kDa (PEA-15) blocks ERK-dependent gene transcription and inhibits proliferation by sequestering ERK in the cytoplasm. We therefore investigated whether PEA-15 influences H-Ras-mediated transformation. We found that PEA-15 does not block H-Ras-activated proliferation when H-Ras is constitutively active. We show instead that in H-Ras-transformed mouse kidney epithelial cells, co-expression of PEA-15 resulted in enhanced soft agar colony growth and increased tumor growth in vivo. Overexpression of both H-Ras and PEA-15 resulted in accelerated G1/S cell cycle transition and increased activation of the ERK signaling pathway. PEA-15 mediated these effects through activation of its binding partner phospholipase D1 (PLD1). Inhibition of PLD1 or interference with PEA-15/PLD1 binding blocked PEA-15's ability to increase ERK activation. Our findings reveal a novel mechanism by which PEA-15 positively regulates Ras/ERK signaling and increases the proliferation of H-Ras-transformed epithelial cells through enhanced PLD1 expression and activation. Thus, our work provides a surprising mechanism by which PEA-15 augments H-Ras-driven transformation. These data reveal that PEA-15 not only suppresses ERK signaling and tumorigenesis but also alternatively enhances tumorigenesis in the context of active Ras. Oncogene (2012) 31, 3547-3560; doi:10.1038/onc.2011.514; published online 21 November 2011	[Sulzmaier, F. J.; Valmiki, M. K. G.; Caliva, M. J.; Ramos, J. W.] Univ Hawaii Manoa, Univ Hawaii Canc Ctr, Canc Biol Program, Honolulu, HI 96813 USA; [Sulzmaier, F. J.; Valmiki, M. K. G.; Ramos, J. W.] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI USA; [Nelson, D. A.; White, E. P.] Inst Canc Res, New Brunswick, NJ USA; [Caliva, M. J.; Matter, M. L.] Univ Hawaii Manoa, John A Burns Sch Med, Dept Cell & Mol Biol, Honolulu, HI USA; [Geerts, D.] Sophia Childrens Univ Hosp, Dept Pediat Oncol Hematol, Rotterdam, Netherlands	Cancer Research Center of Hawaii; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Hawaii Manoa; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	Ramos, JW (corresponding author), Univ Hawaii Manoa, Univ Hawaii Canc Ctr, Canc Biol Program, Biosciences Bldg,Room 241C,651 Halo St, Honolulu, HI 96813 USA.	jramos@cc.hawaii.edu	Matter, Michelle/GSN-9703-2022; Ramos, Joe/G-4074-2010; White, Eileen/ABD-6745-2021; Gudur Valmiki, Mohana/H-2391-2017; Geerts, Dirk/K-8260-2015	Ramos, Joe/0000-0002-9708-2115; White, Eileen/0000-0003-2961-3065; Gudur Valmiki, Mohana/0000-0002-7313-9092; Geerts, Dirk/0000-0002-6386-8187; Matter, Michelle/0000-0002-5988-9663	National Institutes of Health National Cancer Institute [R01CA93849]; National Institute of General Medicine [R01GM088266]; Victoria S and Bradley Geist Foundation; NIH National Center for Reasearch Resources [RR016453]; National Institutes of Health [R37CA53370]; NATIONAL CANCER INSTITUTE [P30CA071789, R37CA053370, R01CA093849] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088266] Funding Source: NIH RePORTER	National Institutes of Health National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Victoria S and Bradley Geist Foundation; NIH National Center for Reasearch Resources; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Maarit Tiirikainen and the University of Hawaii Cancer Center Genomics Shared Resource laboratory for their assistance with the mRNA expression analysis. We also thank Anna Knapinska, Shirley Young-Robbins and Marci Takemoto for their excellent technical assistance. This work was supported by the National Institutes of Health National Cancer Institute (R01CA93849 to JWR) and National Institute of General Medicine (R01GM088266 to JWR) and the Victoria S and Bradley Geist Foundation (to JWR). MLM was supported by NIH National Center for Reasearch Resources Grant RR016453. DAN and EPW were supported by a grant from the National Institutes of Health (R37CA53370 to EPW).	Barrett T, 2009, NUCLEIC ACIDS RES, V37, pD885, DOI 10.1093/nar/gkn764; Bartholomeusz C, 2008, CANCER RES, V68, P9302, DOI 10.1158/0008-5472.CAN-08-2592; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cordova-Alarcon E, 2005, ARCH MED RES, V36, P311, DOI 10.1016/j.arcmed.2005.04.001; Degenhardt K, 2006, CLIN CANCER RES, V12, P5298, DOI 10.1158/1078-0432.CCR-06-0439; Donaldson JG, 2009, BBA-MOL CELL BIOL L, V1791, P845, DOI 10.1016/j.bbalip.2009.05.011; Doti N, 2010, MOL BIOSYST, V6, P2039, DOI 10.1039/c005272h; Dunn KL, 2005, BIOCHEM CELL BIOL, V83, P1, DOI 10.1139/O04-121; Ferro E, 2010, CELL SIGNAL, V22, P1804, DOI 10.1016/j.cellsig.2010.05.010; Formisano P, 2005, ONCOGENE, V24, P7012, DOI 10.1038/sj.onc.1208871; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Haling JR, 2010, MOL BIOL CELL, V21, P664, DOI 10.1091/mbc.E09-08-0659; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Joseph T, 2002, ONCOGENE, V21, P3651, DOI 10.1038/sj.onc.1205380; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LOVEC H, 1994, ONCOGENE, V9, P323; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Pastorino S, 2010, FASEB J, V24, P2818, DOI 10.1096/fj.09-144295; Radig K, 1998, PATHOL RES PRACT, V194, P157, DOI 10.1016/S0344-0338(98)80016-2; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Renganathan H, 2005, BIOCHEM J, V390, P729, DOI 10.1042/BJ20050378; Revet I, 2008, EXP CELL RES, V314, P707, DOI 10.1016/j.yexcr.2007.12.008; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Sathyan KM, 2007, MODERN PATHOL, V20, P1141, DOI 10.1038/modpathol.3800948; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Uchida H, 1999, ANTICANCER RES, V19, P671; Uchida N, 1997, J CANCER RES CLIN, V123, P280, DOI 10.1007/s004320050060; Vaidyanathan H, 2007, P NATL ACAD SCI USA, V104, P19837, DOI 10.1073/pnas.0704514104; Viparelli F, 2008, J BIOL CHEM, V283, P21769, DOI 10.1074/jbc.M803771200; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Whitehurst AW, 2004, J BIOL CHEM, V279, P12840, DOI 10.1074/jbc.M310031200; Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3; Zeng X, 2010, ONCOGENE, V29, P5103, DOI 10.1038/onc.2010.253; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	50	26	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3547	3560		10.1038/onc.2011.514	http://dx.doi.org/10.1038/onc.2011.514			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105357	Green Accepted			2022-12-28	WOS:000306844100007
J	Garcia, CB; Shaffer, CM; Alfaro, MP; Smith, AL; Sun, J; Zhao, Z; Young, PP; VanSaun, MN; Eid, JE				Garcia, C. B.; Shaffer, C. M.; Alfaro, M. P.; Smith, A. L.; Sun, J.; Zhao, Z.; Young, P. P.; VanSaun, M. N.; Eid, J. E.			Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2	ONCOGENE			English	Article						cancer; differentiation; gene expression	GENE-EXPRESSION; DIFFERENTIATION; POLYCOMB; GROWTH; ADULT; PROTEINS; NEUROGENESIS; PROGENITORS; ACTIVATION; INHIBITORS	Cell identity is determined by its gene expression programs. The ability of a cell to change its identity and produce cell types outside its lineage is achieved by the activity of transcription controllers capable of reprogramming differentiation gene networks. The synovial sarcoma (SS)-associated protein, SYT-SSX2, reprograms myogenic progenitors and human bone marrow-derived mesenchymal stem cells (BMMSCs) by dictating their commitment to a pro-neural lineage. It fulfills this function by directly targeting an extensive array of neural-specific genes as well as genes of developmental pathway mediators. Concomitantly, the ability of both myoblasts and BMMSCs to differentiate into their normal myogenic and adipogenic lineages was compromised. SS is believed to arise in mesenchymal stem cells where formation of the t(X/18) translocation product, SYT-SSX, constitutes the primary event in the cancer. SYT-SSX is therefore believed to initiate tumorigenesis in its target stem cell. The data presented here allow a glimpse at the initial events that likely occur when SYT-SSX2 is first expressed, and its dominant function in subverting the nuclear program of the stem cell, leading to its aberrant differentiation, as a first step toward transformation. In addition, we identified the fibroblast growth factor receptor gene, Fgfr2, as one occupied and upregulated by SYT-SSX2. Knockdown of FGFR2 in both BMMSCs and SS cells abrogated their growth and attenuated their neural phenotype. These results support the notion that the SYT-SSX2 nuclear function and differentiation effects are conserved throughout sarcoma development and are required for its maintenance beyond the initial phase. They also provide the stem cell regulator, FGFR2, as a promising candidate target for future SS therapy. Oncogene (2012) 31, 2323-2334; doi:10.1038/onc.2011.418; published online 26 September 2011	[Garcia, C. B.; Smith, A. L.; Zhao, Z.; VanSaun, M. N.; Eid, J. E.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Shaffer, C. M.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN 37232 USA; [Alfaro, M. P.; Young, P. P.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Sun, J.; Zhao, Z.] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37232 USA; [Young, P. P.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Eid, JE (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 740 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	josiane.eid@vanderbilt.edu		Garcia, Christina/0000-0001-7892-0120	Alex's Lemonade Stand Foundation; Sarcoma Foundation of America; NCRR of the NIH [P40RR017447]; NATIONAL CANCER INSTITUTE [T32CA009592, P30CA068485] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR017447] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation; Sarcoma Foundation of America; NCRR of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funding was provided by the Alex's Lemonade Stand Foundation (Innovation Award) and the Sarcoma Foundation of America. Microarrays were performed at the Vanderbilt Functional Genomics Shared Resource core supported by the VICC (P30 CA68485), the VDCC (P30 DK58404) and the Vanderbilt Vision Center (P30 EY08126). Some of the materials used in this work were provided by the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White through a grant from NCRR of the NIH (grant no. P40RR017447). We thank BV Mary and H Trinity for assistance; T Ito and M Ladanyi for SYO-1 cells and A Sandelin and S Wilhite for technical support.	Alfaro MP, 2008, P NATL ACAD SCI USA, V105, P18366, DOI 10.1073/pnas.0803437105; Asp P, 2011, P NATL ACAD SCI USA, V108, pE149, DOI 10.1073/pnas.1102223108; Barco R, 2007, MOL BIOL CELL, V18, P4003, DOI 10.1091/mbc.E07-05-0496; Barco R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005060; Chadashvili T, 2006, J COMP NEUROL, V498, P1, DOI 10.1002/cne.21009; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Ever L, 2005, CURR OPIN NEUROBIOL, V15, P29, DOI 10.1016/j.conb.2005.01.005; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Gurdon JB, 2008, SCIENCE, V322, P1811, DOI 10.1126/science.1160810; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Huang W, 2007, FRONT BIOSCI-LANDMRK, V12, P3068, DOI 10.2741/2296; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; Ishibe T, 2008, CLIN ORTHOP RELAT R, V466, P2147, DOI 10.1007/s11999-008-0343-z; Katoh M, 2008, INT J ONCOL, V33, P233, DOI 10.3892/ijo_00000001; Katoh Y, 2009, INT J MOL MED, V23, P307, DOI 10.3892/ijmm_00000132; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Maric D, 2007, J NEUROSCI, V27, P1836, DOI 10.1523/JNEUROSCI.5141-06.2007; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Mateos-Langerak J, 2008, ADV GENET, V61, P45, DOI 10.1016/S0065-2660(07)00002-8; Miraoui H, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3146re9; Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018-008-8429-z; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Pardo OE, 2009, CANCER RES, V69, P8645, DOI 10.1158/0008-5472.CAN-09-1576; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Pruitt KD, 2007, NUCLEIC ACIDS RES, V35, pD61, DOI 10.1093/nar/gkl842; Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Villegas SN, 2010, J CELL BIOCHEM, V110, P10, DOI 10.1002/jcb.22536; Watanabe Y, 2004, GENE DEV, V18, P889, DOI 10.1101/gad.1179004; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	42	50	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2323	2334		10.1038/onc.2011.418	http://dx.doi.org/10.1038/onc.2011.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21996728	Green Accepted			2022-12-28	WOS:000303610800007
J	Yue, P; Zhang, X; Paladino, D; Sengupta, B; Ahmad, S; Holloway, RW; Ingersoll, SB; Turkson, J				Yue, P.; Zhang, X.; Paladino, D.; Sengupta, B.; Ahmad, S.; Holloway, R. W.; Ingersoll, S. B.; Turkson, J.			Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells	ONCOGENE			English	Article						cisplatin-resistance; ovarian cancer; EGF receptor; Stat3; Jaks; cancer aggressiveness	GROWTH-FACTOR RECEPTOR; MESENCHYMAL TRANSITION; CONSTITUTIVE ACTIVATION; CONFERS RESISTANCE; PLATINUM COMPLEXES; MATRIX DEGRADATION; TUMOR PROGRESSION; INDUCED APOPTOSIS; DRUG-RESISTANCE; CARCINOMA CELLS	We present evidence that the cisplatin-resistant human ovarian cancer lines, A2780S/CP1 (S/CP1), A2780S/CP3 (S/CP3) and A2780S/CP5 (S/CP5), derived by subjecting the sensitive A2780S ovarian cancer line to multiple rounds of cisplatin treatments followed by recovery and are resistant to 1, 3 and 5 mu M cisplatin, respectively, have increased colony-forming ability and altered morphology that is consistent with enhanced motility, migration and invasiveness in vitro. The malignant phenotype progresses with increasing resistance and is associated with hyperactive epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (Erk)1/2 and janus kinases (Jaks), aberrant signal transducer and activator of transcription (Stat) 3 activation promoted by EGFR and Jaks, and epithelial-mesenchymal transition (EMT) in vitro. Survivin and FLIP anti-apoptotic factors, vascular endothelial growth factor (VEGF) and matrix metalloproteinase activities are also elevated in the resistant cells. Accordingly, the ectopic expression of constitutively-active Stat3C in the sensitive A2780S cells diminished cisplatin sensitivity. The inhibition of EGFR or Stat3 activity repressed Survivin, VEGF and Vimentin expression and the colony-forming potential, viability, motility and migration of the resistant cells, and sensitized them to cisplatin. Analysis of human ovarian cancer patients' tumor tissues shows aberrantly-active EGFR and Stat3 that in certain cases correlate with Vimentin over-expression. Intra-peritoneal mouse xenograft studies revealed, compared with the sensitive A2780S line that had low tumor incidence restricted to the ovary, a high tumor incidence for the resistant S/CP3 and S/CP5 lines that formed tumor nodules at several locations on the small intestine and colon, and which responded poorly to cisplatin, but were sensitive to concurrent treatment with cisplatin and EGFR or Stat3 inhibitor. Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer. Oncogene (2012) 31, 2309-2322; doi:10.1038/onc.2011.409; published online 12 September 2011	[Yue, P.; Zhang, X.; Paladino, D.; Sengupta, B.; Turkson, J.] Univ Cent Florida, Coll Med, Barnett Sch Biomed Sci, Orlando, FL 32816 USA; [Ahmad, S.; Holloway, R. W.; Ingersoll, S. B.] Florida Hosp Canc Inst, Florida Hosp Gynecol Oncol, Orlando, FL USA	State University System of Florida; University of Central Florida; Adventist Health Services; AdventHealth	Turkson, J (corresponding author), Univ Hawaii Manoa, Univ Hawaii Canc Ctr, Canc Biol Program, Biomed Sci Bldg,Suite 222J,651 ILALO St, Honolulu, HI 96813 USA.	jturkson@cc.hawaii.edu	zhang, xiaolei/D-7698-2012; Yue, Peibin/J-9836-2015	Zhang, Xiaolei/0000-0003-2395-2453	National Cancer Institute [CA106439, CA128865]; Florida Hospital-UCF; State of Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE [R01CA106439, R01CA128865, P30CA071789] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Florida Hospital-UCF; State of Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all colleagues and members of our laboratory for the stimulating discussions and the University of Central Florida Confocal Microscopy and the Transgenic Animal facilities for their assistance. This work was supported by the National Cancer Institute Grants CA106439 and CA128865 (to JT) and the Florida Hospital-UCF-Gala Endowed Program for Oncologic Research Award (JT and RWH) and the State of Florida Bankhead-Coley Cancer Research Program (SBI, RWH and SA).	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Arany I, 2004, AM J PHYSIOL-RENAL, V287, pF543, DOI 10.1152/ajprenal.00112.2004; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabec V, 2005, DRUG RESIST UPDATE, V8, P131, DOI 10.1016/j.drup.2005.04.006; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chan JK, 2005, CANCER RES, V65, P3243, DOI 10.1158/0008-5472.CAN-03-3013; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Desai B, 2008, J BIOL CHEM, V283, P13856, DOI 10.1074/jbc.M709401200; Duan Z, 2006, CANCER RES, V12, P5056; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fajac A, 1996, INT J CANCER, V68, P67, DOI 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3; Gallagher WM, 1997, ONCOGENE, V14, P185; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Ikuta K, 2005, ONCOL REP, V13, P1229; Kassouf W, 2005, CANCER RES, V65, P10524, DOI 10.1158/0008-5472.CAN-05-1536; Kelland LR, 1999, J INORG BIOCHEM, V77, P111, DOI 10.1016/S0162-0134(99)00141-5; Kim YK, 2005, J APPL TOXICOL, V25, P374, DOI 10.1002/jat.1081; Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234; Matsuo M, 2007, CANCER LETT, V251, P288, DOI 10.1016/j.canlet.2006.11.027; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Richardson A, 2005, DRUG RESIST UPDATE, V8, P311, DOI 10.1016/j.drup.2005.09.001; Selvendiran K, 2008, CELL CYCLE, V7, P81, DOI 10.4161/cc.7.1.5103; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Shao H, 2003, CANCER RES, V63, P3923; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Siddiquee KAZ, 2007, ACS CHEM BIOL, V2, P787, DOI 10.1021/cb7001973; Song H, 2004, INT J ONCOL, V24, P1017; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Villedieu M, 2006, GYNECOL ONCOL, V101, P507, DOI 10.1016/j.ygyno.2005.11.017; Wang GD, 2004, ONCOL REP, V12, P955; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	49	103	108	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2309	2322		10.1038/onc.2011.409	http://dx.doi.org/10.1038/onc.2011.409			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21909139	Green Accepted			2022-12-28	WOS:000303610800006
J	Fernandez, A; Squatrito, M; Northcott, P; Awan, A; Holland, EC; Taylor, MD; Nahle, Z; Kenney, AM				Fernandez-L, A.; Squatrito, M.; Northcott, P.; Awan, A.; Holland, E. C.; Taylor, M. D.; Nahle, Z.; Kenney, A. M.			Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation	ONCOGENE			English	Article						medulloblastoma; sonic hedgehog; cerebellum; YAP; IGF; DNA damage	CELL-CYCLE PROGRESSION; SONIC HEDGEHOG; CHECKPOINT ACTIVATION; NEURONAL SURVIVAL; DNA-DAMAGE; N-MYC; GROWTH; PROLIFERATION; PATHWAY; INHIBITION	Radiation therapy remains the standard of care for many cancers, including the malignant pediatric brain tumor medulloblastoma. Radiation leads to long-term side effects, whereas radioresistance contributes to tumor recurrence. Radio-resistant medulloblastoma cells occupy the perivascular niche. They express Yes-associated protein (YAP), a Sonic hedgehog (Shh) target markedly elevated in Shh-driven medulloblastomas. Here we report that YAP accelerates tumor growth and confers radioresistance, promoting ongoing proliferation after radiation. YAP activity enables cells to enter mitosis with un-repaired DNA through driving insulin-like growth factor 2 (IGF2) expression and Akt activation, resulting in ATM/Chk2 inactivation and abrogation of cell cycle checkpoints. Our results establish a central role for YAP in counteracting radiation-based therapies and driving genomic instability, and indicate the YAP/IGF2/Akt axis as a therapeutic target in medulloblastoma. Oncogene (2012) 31, 1923-1937; doi:10.1038/onc.2011.379; published online 29 August 2011	[Awan, A.; Nahle, Z.; Kenney, A. M.] Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37232 USA; [Awan, A.; Nahle, Z.; Kenney, A. M.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Fernandez-L, A.; Squatrito, M.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Northcott, P.; Taylor, M. D.] Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Arthur & Sonia Labatt Brain Tumor Res Ctr,Div Neu, Toronto, ON M5G 1X8, Canada	Vanderbilt University; Vanderbilt University; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kenney, AM (corresponding author), Vanderbilt Univ, Dept Neurosurg, T-4224 MCN, Nashville, TN 37232 USA.	anna.kenney@vanderbilt.edu	Squatrito, Massimo/F-4149-2016; Northcott, Paul A/N-4022-2018	Squatrito, Massimo/0000-0002-4593-3790; Northcott, Paul A/0000-0002-1220-5252; Awan, Aashir/0000-0002-8726-2921; Taylor, Michael/0000-0001-7009-3466	Spanish Ministry of Education; Charles H Revson Foundation; Childhood Brain Tumor Foundation; Alex's Lemonade Stand Foundation; National Brain Tumor Society; James S McDonnell Foundation; NIH [NINDS R01NS061070]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	Spanish Ministry of Education(Spanish Government); Charles H Revson Foundation; Childhood Brain Tumor Foundation; Alex's Lemonade Stand Foundation; National Brain Tumor Society; James S McDonnell Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Martine Roussel and her group at St Jude Children's Research Hospital for training and advice on MBC culture and intracranial implantation. AF-L received support from the Spanish Ministry of Education, the Charles H Revson Foundation and the Childhood Brain Tumor Foundation. This work was supported by grants to AMK from the Alex's Lemonade Stand Foundation, National Brain Tumor Society, James S McDonnell Foundation and the NIH (NINDS R01NS061070).	Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Bhatia B, 2011, ONCOGENE, V30, P410, DOI 10.1038/onc.2010.454; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chrysis DC, 2001, CLIN ENDOCRINOL, V54, P253, DOI 10.1046/j.1365-2265.2001.01198.x; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; Eberhart CG, 2008, CANCER CELL, V14, P105, DOI 10.1016/j.ccr.2008.07.011; Fernandez A, 2010, CELL CYCLE, V9, P2292, DOI 10.4161/cc.9.12.11919; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Frappart PO, 2009, P NATL ACAD SCI USA, V106, P1880, DOI 10.1073/pnas.0806882106; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hirose Y, 2005, CANCER RES, V65, P4861, DOI 10.1158/0008-5472.CAN-04-2633; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Leonard JM, 2008, J CELL BIOL, V183, P385, DOI 10.1083/jcb.200804042; Mueller S, 2009, NEUROTHERAPEUTICS, V6, P570, DOI 10.1016/j.nurt.2009.04.006; Nahle Z, 2008, J BIOL CHEM, V283, P14317, DOI 10.1074/jbc.M706478200; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Tanori M, 2008, CARCINOGENESIS, V29, P1911, DOI 10.1093/carcin/bgn174; Tanori M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-53; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Xu NH, 2010, J CELL BIOL, V190, P297, DOI 10.1083/jcb.201003004; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	52	116	119	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1923	1937		10.1038/onc.2011.379	http://dx.doi.org/10.1038/onc.2011.379			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874045	Green Accepted			2022-12-28	WOS:000302809900005
J	Guedj, M; Marisa, L; de Reynies, A; Orsetti, B; Schiappa, R; Bibeau, F; MacGrogan, G; Lerebours, F; Finetti, P; Longy, M; Bertheau, P; Bertrand, F; Bonnet, F; Martin, AL; Feugeas, JP; Bieche, I; Lehmann-Che, J; Lidereau, R; Birnbaum, D; Bertucci, F; de The, H; Theillet, C				Guedj, M.; Marisa, L.; de Reynies, A.; Orsetti, B.; Schiappa, R.; Bibeau, F.; MacGrogan, G.; Lerebours, F.; Finetti, P.; Longy, M.; Bertheau, P.; Bertrand, F.; Bonnet, F.; Martin, A. L.; Feugeas, J. P.; Bieche, I.; Lehmann-Che, J.; Lidereau, R.; Birnbaum, D.; Bertucci, F.; de The, H.; Theillet, C.			A refined molecular taxonomy of breast cancer	ONCOGENE			English	Article						breast cancer; molecular classification; taxonomy; transcriptome; CGH-array, outcome	ANDROGEN RECEPTOR; SUBTYPES; TUMORS; METASTASIS; PROGENITORS; PREDICTORS; GRADE	The current histoclinical breast cancer classification is simple but imprecise. Several molecular classifications of breast cancers based on expression profiling have been proposed as alternatives. However, their reliability and clinical utility have been repeatedly questioned, notably because most of them were derived from relatively small initial patient populations. We analyzed the transcriptomes of 537 breast tumors using three unsupervised classification methods. A core subset of 355 tumors was assigned to six clusters by all three methods. These six subgroups overlapped with previously defined molecular classes of breast cancer, but also showed important differences, notably the absence of an ERBB2 subgroup and the division of the large luminal ER+ group into four subgroups, two of them being highly proliferative. Of the six subgroups, four were ER+/PR+/AR+, one was ER-PR-/AR+ and one was triple negative (AR-/ER-/PR-). ERBB2-amplified tumors were split between the ER-/PR-/AR+ subgroup and the highly proliferative ER+ LumC subgroup. Importantly, each of these six molecular subgroups showed specific copy-number alterations. Gene expression changes were correlated to specific signaling pathways. Each of these six subgroups showed very significant differences in tumor grade, metastatic sites, relapse-free survival or response to chemotherapy. All these findings were validated on large external datasets including more than 3000 tumors. Our data thus indicate that these six molecular subgroups represent well-defined clinico-biological entities of breast cancer. Their identification should facilitate the detection of novel prognostic factors or therapeutical targets in breast cancer. Oncogene (2012) 31, 1196-1206; doi:10.1038/onc.2011.301; published online 25 July 2011	[Theillet, C.] CRLC Val dAurelle Paul Lamarque, Inst Rech Canc Montpellier, INSERM, U896, F-34298 Montpellier 5, France; [Guedj, M.; Marisa, L.; de Reynies, A.; Schiappa, R.] Ligue Natl Canc, Cartes Identite Tumeurs Program, Paris, France; [Bibeau, F.] CRLC Val dAurelle Paul Lamarque, Dept Pathol, F-34298 Montpellier 5, France; [MacGrogan, G.; Longy, M.; Bonnet, F.] Univ Bordeaux 2, EA 3669, F-33076 Bordeaux, France; [MacGrogan, G.; Longy, M.; Bonnet, F.] Inst Bergonie, Dept Pathol, Bordeaux, France; [Lerebours, F.; Bertrand, F.; Bieche, I.; Lidereau, R.] Inst Curie Hop Ctr Rene Huguenin, Oncogenet Lab, INSERM, U735, St Cloud, France; [Finetti, P.; Birnbaum, D.; Bertucci, F.] Inst J Paoli I Calmettes, Dept Mol Oncol, CRCM, Ctr Rech Canc Marseille, F-13009 Marseille, France; [Bertheau, P.] Univ Paris, Hop St Louis, APHP, Dept Pathol, F-75252 Paris, France; [Martin, A. L.] Federat Natl Ctr Lutte Canc, Paris, France; [Feugeas, J. P.; Lehmann-Che, J.; de The, H.] Hop St Louis, APHP, Dept Biochem, Paris, France; [Feugeas, J. P.; Lehmann-Che, J.; de The, H.] CNRS, INSERM, UMR 944 7212, Paris, France; [Feugeas, J. P.; Lehmann-Che, J.; de The, H.] Univ Paris 07, Univ Hematol Inst, Paris, France; [Theillet, C.] Univ Montpellier 1, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Theillet, C (corresponding author), CRLC Val dAurelle Paul Lamarque, Inst Rech Canc Montpellier, INSERM, U896, F-34298 Montpellier 5, France.	charles.theillet@inserm.fr	SCHIAPPA, Renaud/K-8192-2019; Feillet, Francois/A-3648-2017; de Reyniès, Aurélien/Q-8640-2017; Bièche, Ivan/O-7399-2017; Theillet, Charles/O-7634-2018; Finetti, Pascal/O-8669-2017	Feillet, Francois/0000-0002-8717-469X; de Reyniès, Aurélien/0000-0002-1328-5290; Bièche, Ivan/0000-0002-2430-5429; Theillet, Charles/0000-0001-5555-2759; MacGrogan, Gaetan/0000-0002-3483-9758; SCHIAPPA, Renaud/0000-0001-5104-9507; Finetti, Pascal/0000-0002-2674-3123; Lehmann-Che, jacqueline/0000-0001-6685-3354	Ligue Nationale Contre le Cancer	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the Carte d'Identite des Tumeurs Program from the Ligue Nationale Contre le Cancer. We thank Pr Jacqueline Godet and Dr Jacqueline Metral for their constant support during the course of this work. The expertize of the personnel serving the RNA extraction and qualification (Saint-Louis Hospital, Paris), Affymetrix expression array (IGBMC, Strasbourg), CIT database and array-CGH (IRCM, Montpellier) CIT platforms is gratefully acknowledged. We further thank Dr Stan du Manoir for critical reading of the manuscript, Vessela N Kristensen and Peter Van Loo for making their data available to us.	Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Bertucci F, 2008, ONCOGENE, V27, P5359, DOI 10.1038/onc.2008.158; Bertucci F, 2006, OMICS, V10, P429, DOI 10.1089/omi.2006.10.429; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; ISOLA JJ, 1993, J PATHOL, V170, P31, DOI 10.1002/path.1711700106; Jonsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596; Kapp AV, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-231; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Naderi A, 2008, NEOPLASIA, V10, P542, DOI 10.1593/neo.08274; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; van 't Veer LJ, 2003, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; Weigelt B, 2010, LANCET ONCOL, V11, P339, DOI 10.1016/S1470-2045(10)70008-5; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	35	184	193	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1196	1206		10.1038/onc.2011.301	http://dx.doi.org/10.1038/onc.2011.301			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21785460	Green Submitted, hybrid, Green Published			2022-12-28	WOS:000300945900013
J	Helman, E; Naxerova, K; Kohane, IS				Helman, E.; Naxerova, K.; Kohane, I. S.			DNA hypermethylation in lung cancer is targeted at differentiation-associated genes	ONCOGENE			English	Article						Hypermethylation; development; non-small cell lung cancer; gene expression	TUMOR-SUPPRESSOR GENE; CPG-ISLAND METHYLATION; EMBRYONIC STEM-CELLS; EARLY EVENT; GENOME; MARKERS; GERM; HYPOMETHYLATION; CARDIOMYOCYTES; RETINOBLASTOMA	Aberrant DNA hypermethylation of tumor suppressor genes is thought to be an early event in tumorigenesis. Many studies have reported the methylation status of individual genes with known involvement in cancer, but an unbiased assessment of the biological function of the collective of hypermethylated genes has not been conducted so far. Based on the observation that a variety of human cancers recapitulate developmental gene expression patterns ( that is activate genes normally expressed in early development and suppress late developmental genes), we hypothesized that the silencing of differentiation-associated genes in cancer could be attributed in part to DNA hypermethylation. To this end, we investigated the developmental expression patterns of genes with hypermethylated CpG islands in primary human lung carcinomas and lung cancer cell lines. We found that DNA hypermethylation primarily affects genes that are expressed in late stages of murine lung development. Gene ontology characterization of these genes shows that they are almost exclusively involved in morphogenetic differentiation processes. Our results indicate that DNA hypermethylation in cancer functions as a selective silencing mechanism of genes that are required for the maintenance of a differentiated state. The process of cellular de-differentiation that is evident on both the microscopic and transcriptional level in cancer might at least partly be mediated by these epigenetic events. Our observations provide a mechanistic explanation for induction of differentiation upon treatment with DNA methyltransferase inhibitors. Oncogene (2012) 31, 1181-1188; doi:10.1038/onc.2011.307; published online 1 August 2011	[Kohane, I. S.] Childrens Hosp, Informat Program, Harvard Mit Div Hlth Sci & Technol, Boston, MA 02115 USA; [Naxerova, K.] Harvard Univ, Sch Med, Boston, MA USA; [Naxerova, K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Kohane, IS (corresponding author), Childrens Hosp, Informat Program, Harvard Mit Div Hlth Sci & Technol, 300 Longwood Ave,Enders 6L, Boston, MA 02115 USA.	Isaac_Kohane@hms.harvard.edu	Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160; Naxerova, Kamila/0000-0001-7744-5110				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Armstrong L, 2006, STEM CELLS, V24, P805, DOI 10.1634/stemcells.2005-0350; Banerjee S, 2010, EXP CELL RES, V316, P172, DOI 10.1016/j.yexcr.2009.08.011; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 2001, CANCER RES, V61, P3225; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hayslip J, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-44; Heller G, 2010, CANCER METAST REV, V29, P95, DOI 10.1007/s10555-010-9203-x; HERMAN JG, 1995, CANCER RES, V55, P4525; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; Kho AT, 2004, GENE DEV, V18, P629, DOI 10.1101/gad.1182504; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Liu HY, 2006, PLOS MED, V3, P1090, DOI 10.1371/journal.pmed.0030232; Marchevsky AM, 2004, J MOL DIAGN, V6, P28, DOI 10.1016/S1525-1578(10)60488-6; McLaren A, 2000, MOL CELL ENDOCRINOL, V163, P3, DOI 10.1016/S0303-7207(99)00234-8; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7; Naxerova K, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-7-r108; Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Pfeifer GP, 2009, SEMIN CANCER BIOL, V19, P181, DOI 10.1016/j.semcancer.2009.02.008; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; SAKAI T, 1991, AM J HUM GENET, V48, P880; Sasaki H, 2008, NAT REV GENET, V9, P129, DOI 10.1038/nrg2295; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Yoon BS, 2006, DIFFERENTIATION, V74, P149, DOI 10.1111/j.1432-0436.2006.00063.x	49	19	19	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1181	1188		10.1038/onc.2011.307	http://dx.doi.org/10.1038/onc.2011.307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21804601				2022-12-28	WOS:000300945900011
J	Leis, O; Eguiara, A; Lopez-Arribillaga, E; Alberdi, MJ; Hernandez-Garcia, S; Elorriaga, K; Pandiella, A; Rezola, R; Martin, AG				Leis, O.; Eguiara, A.; Lopez-Arribillaga, E.; Alberdi, M. J.; Hernandez-Garcia, S.; Elorriaga, K.; Pandiella, A.; Rezola, R.; Martin, A. G.			Sox2 expression in breast tumours and activation in breast cancer stem cells	ONCOGENE			English	Article						Sox2; breast cancer; cancer stem cell; mammosphere	IN-VITRO PROPAGATION; SIDE POPULATION; SELF-RENEWAL; MOUSE; IDENTIFICATION; FIBROBLASTS; GENERATION; RESISTANCE; INDUCTION; PATHWAY	The cancer stem cell (CSC) model does not imply that tumours are generated from transformed tissue stem cells. The target of transformation could be a tissue stem cell, a progenitor cell, or a differentiated cell that acquires self-renewal ability. The observation that induced pluripotency reprogramming and cancer are related has lead to the speculation that CSCs may arise through a reprogramming-like mechanism. Expression of pluripotency genes (Oct4, Nanog and Sox2) was tested in breast tumours by immunohistochemistry and it was found that Sox2 is expressed in early stage breast tumours. However, expression of Oct4 or Nanog was not found. Mammosphere formation in culture was used to reveal stem cell properties, where expression of Sox2, but not Oct4 or Nanog, was induced. Over-expression of Sox2 increased mammosphere formation, effect dependent on continuous Sox2 expression; furthermore, Sox2 knockdown prevented mammosphere formation and delayed tumour formation in xenograft tumour initiation models. Induction of Sox2 expression was achieved through activation of the distal enhancer of Sox2 promoter upon sphere formation, the same element that controls Sox2 transcription in pluripotent stem cells. These findings suggest that reactivation of Sox2 represents an early step in breast tumour initiation, explaining tumour heterogeneity by placing the tumour-initiating event in any cell along the axis of mammary differentiation.Oncogene (2012) 31, 1354-1365; doi:10.1038/onc.2011.338; published online 8 August 2011	[Leis, O.; Eguiara, A.; Lopez-Arribillaga, E.; Martin, A. G.] Fdn Inbiomed, Regulat Cell Growth Lab, San Sebastian 20009, Gipuzkoa, Spain; [Alberdi, M. J.; Elorriaga, K.; Rezola, R.] Onkologikoa, Dept Pathol, San Sebastian, Spain; [Hernandez-Garcia, S.; Pandiella, A.] Inst Biol Mol & Celular Canc, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC)	Martin, AG (corresponding author), Fdn Inbiomed, Regulat Cell Growth Lab, Paseo Mikeletegi 61, San Sebastian 20009, Gipuzkoa, Spain.	agmartin@inbiomed.org	Pandiella, Atanasio/O-5180-2014	Pandiella, Atanasio/0000-0002-4704-8971; Lopez-Arribillaga, Erika/0000-0002-9451-6635	Obra Social Kutxa; Fundacion Medica Mutua Madrilena; Gobierno Vasco [PI2010-25]; Instituto de Salud Carlos III Accion Estrategica en Salud [PI2010-01035]	Obra Social Kutxa; Fundacion Medica Mutua Madrilena(Instituto de Salud Carlos III); Gobierno Vasco(Basque Government); Instituto de Salud Carlos III Accion Estrategica en Salud	The Regulation of Cell Growth Laboratory is supported by grants from Obra Social Kutxa, Fundacion Medica Mutua Madrilena, Gobierno Vasco (Saiotek program and Consejeria de Educacion PI2010-25) and Instituto de Salud Carlos III Accion Estrategica en Salud (PI2010-01035). We thank Izaskun Beloqui, Andres Pavon and Maria Diaz for technical support. We thank the Flow Cytometry Unit at Inbiomed for extensive aid in flow cytometric analysis of fresh tumour cells. We thank our colleagues at Inbiomed for helpful discussion. We thank Dr R Sanchez-Pernaute and Dr L Vellon for critical reading of the manuscript.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Akala OO, 2008, NATURE, V453, P228, DOI 10.1038/nature06869; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ambady S, 2010, INT J DEV BIOL, V54, P1743, DOI 10.1387/ijdb.103192sa; Ao A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018810; Callagy G, 2003, DIAGN MOL PATHOL, V12, P27, DOI 10.1097/00019606-200303000-00004; Cantz T, 2008, STEM CELLS, V26, P692, DOI 10.1634/stemcells.2007-0657; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cirenajwis H, 2010, ANTI-CANCER DRUG, V21, P897, DOI 10.1097/CAD.0b013e32833f2f77; Comtesse N, 2005, P NATL ACAD SCI USA, V102, P9601, DOI 10.1073/pnas.0500404102; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Engelmann K, 2008, CANCER RES, V68, P2419, DOI 10.1158/0008-5472.CAN-07-2249; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Ghods AJ, 2007, STEM CELLS, V25, P1645, DOI 10.1634/stemcells.2006-0624; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Katoh M, 2011, CURR PHARM BIOTECHNO, V12, P160, DOI 10.2174/138920111794295710; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; Kim JB, 2009, NATURE, V461, P649, DOI 10.1038/nature08436; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li XL, 2004, INT J ONCOL, V24, P257; Liu M, 2010, CANCER RES, V70, P10464, DOI 10.1158/0008-5472.CAN-10-0732; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyagi S, 2006, J BIOL CHEM, V281, P13374, DOI 10.1074/jbc.M512669200; Miyagi S, 2004, MOL CELL BIOL, V24, P4207, DOI 10.1128/MCB.24.10.4207-4220.2004; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270; Papapetrou EP, 2009, P NATL ACAD SCI USA, V106, P12759, DOI 10.1073/pnas.0904825106; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Rodriguez-Pinilla SM, 2007, MODERN PATHOL, V20, P474, DOI 10.1038/modpathol.3800760; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480; Sholl LM, 2010, AM J SURG PATHOL, V34, P1193, DOI 10.1097/PAS.0b013e3181e5e024; Simoes BM, 2011, BREAST CANCER RES TR, V129, P23, DOI 10.1007/s10549-010-1169-4; Suo GL, 2005, BIOCHEM BIOPH RES CO, V337, P1047, DOI 10.1016/j.bbrc.2005.09.157; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Yamanaka S, 2008, CELL PROLIFERAT, V41, P51, DOI 10.1111/j.1365-2184.2008.00493.x; Zappone MV, 2000, DEVELOPMENT, V127, P2367; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x; Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y	62	383	395	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1354	1365		10.1038/onc.2011.338	http://dx.doi.org/10.1038/onc.2011.338			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822303				2022-12-28	WOS:000301780000003
J	Molina, JR; Agarwal, NK; Morales, FC; Hayashi, Y; Aldape, KD; Cote, G; Georgescu, MM				Molina, J. R.; Agarwal, N. K.; Morales, F. C.; Hayashi, Y.; Aldape, K. D.; Cote, G.; Georgescu, M-M			PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma	ONCOGENE			English	Article						glioblastoma; PTEN; NHERF1; PHLPP; Akt	MEMBRANE ASSOCIATION; BREAST-CANCER; PDZ DOMAIN; PROTEIN; BINDING; GROWTH; AKT; PHOSPHATASE; RECEPTOR; CELLS	The phosphatidylinositol-3-OH kinase (PI3K)-Akt pathway is activated in cancer by genetic or epigenetic events and efforts are under way to develop targeted therapies. phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor is the major brake of the pathway and a common target for inactivation in glioblastoma, one of the most aggressive and therapy-resistant cancers. To achieve potent inhibition of the PI3K-Akt pathway in glioblastoma, we need to understand its mechanism of activation by investigating the interplay between its regulators. We show here that PTEN modulates the PI3K-Akt pathway in glioblastoma within a tumor suppressor network that includes Na+/H+ exchanger regulatory factor 1 (NHERF1) and pleckstrin-homology domain leucine-rich repeat protein phosphatases 1 (PHLPP1). The NHERF1 adaptor, previously characterized by our group as a PTEN ligand and regulator, shows also PTEN-independent Akt-modulating effects that led us to identify the PHLPP1/PHLPP2 Akt phosphatases as NHERF1 ligands. NHERF1 interacts via its PDZ domains with PHLPP1/PHLPP2 and scaffolds heterotrimeric complexes with PTEN. Functionally, PHLPP1 requires NHERF1 for membrane localization and growth-suppressive effects. PHLPP1 loss boosts Akt phosphorylation only in PTEN-negative cells and cooperates with PTEN loss for tumor growth. In a panel of low-grade and high-grade glioma patient samples, we show for the first time a significant disruption of all three members of the PTEN-NHERF1-PHLPP1 tumor suppressor network in high-grade tumors, correlating with Akt activation and patient's abysmal survival. We thus propose a PTEN-NHERF1-PHLPP PI3K-Akt pathway inhibitory network that relies on molecular interactions and can undergo parallel synergistic hits in glioblastoma. Oncogene (2012) 31, 1264-1274; doi:10.1038/onc.2011.324; published online 1 August 2011	[Molina, J. R.; Agarwal, N. K.; Morales, F. C.; Hayashi, Y.; Georgescu, M-M] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Aldape, K. D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Cote, G.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Georgescu, MM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 6767 Bertner Ave, Houston, TX 77030 USA.	mgeorges@mdanderson.org	Georgescu, Maria-Magdalena/AAJ-6359-2020		 [NCI-CA107201];  [NCI-CA16672]; NATIONAL CANCER INSTITUTE [R01CA107201, P30CA016672] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank NCI-CA107201 and the corresponding ARRA supplement (M-M. Georgescu), and NCI-CA16672 that partially supported the DNA sequencing and animal breeding.	Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031; Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271; Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126; Morales FC, 2007, MOL CELL BIOL, V27, P2527, DOI 10.1128/MCB.01372-06; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Shimizu K, 1999, FEBS LETT, V458, P363, DOI 10.1016/S0014-5793(99)01190-4; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204	40	132	134	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1264	1274		10.1038/onc.2011.324	http://dx.doi.org/10.1038/onc.2011.324			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804599	Green Accepted			2022-12-28	WOS:000301344600006
J	Orr, B; Riddick, ACP; Stewart, GD; Anderson, RA; Franco, OE; Hayward, SW; Thomson, AA				Orr, B.; Riddick, A. C. P.; Stewart, G. D.; Anderson, R. A.; Franco, O. E.; Hayward, S. W.; Thomson, A. A.			Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate	ONCOGENE			English	Article						prostate; stromal/epithelial interactions; cancer-associated fibroblasts; cancer microenvironment; Tag profiling	GENE-EXPRESSION; BREAST-CANCER; TUMOR MICROENVIRONMENT; REACTIVE STROMA; GROWTH-FACTOR; CELLS; CARCINOGENESIS; PROGRESSION; MESENCHYME; BETA	The stromal microenvironment has key roles in prostate development and cancer, and cancer-associated fibroblasts (CAFs) stimulate tumourigenesis via several mechanisms including the expression of pro-tumourigenic factors. Mesenchyme (embryonic stroma) controls prostate organogenesis, and in some circumstances can re-differentiate prostate tumours. We have applied next-generation Tag profiling to fetal human prostate, normal human prostate fibroblasts (NPFs) and CAFs to identify molecules expressed in prostatic stroma. Comparison of gene expression profiles of a patient-matched pair of NPFs vs CAFs identified 671 transcripts that were enriched in CAFs and 356 transcripts whose levels were decreased, relative to NPFs. Gene ontology analysis revealed that CAF-enriched transcripts were associated with prostate morphogenesis and CAF-depleted transcripts were associated with cell cycle. We selected mRNAs to follow-up by comparison of our data sets with published prostate cancer fibroblast microarray profiles as well as by focusing on transcripts encoding secreted and peripheral membrane proteins, as well as mesenchymal transcripts identified in a previous study from our group. We confirmed differential transcript expression between CAFs and NPFs using QrtPCR, and defined protein localization using immunohistochemistry in fetal prostate, adult prostate and prostate cancer. We demonstrated that ASPN, CAV1, CFH, CTSK, DCN, FBLN1, FHL1, FN, NKTR, OGN, PARVA, S100A6, SPARC, STC1 and ZEB1 proteins showed specific and varied expression patterns in fetal human prostate and in prostate cancer. Colocalization studies suggested that some stromally expressed molecules were also expressed in subsets of tumour epithelia, indicating that they may be novel markers of EMT. Additionally, two molecules (ASPN and STC1) marked overlapping and distinct subregions of stroma associated with tumour epithelia and may represent new CAF markers. Oncogene (2012) 31, 1130-1142; doi:10.1038/onc.2011.312; published online 1 August 2011	[Orr, B.; Thomson, A. A.] Queens Med Res Inst, Med Res Council Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland; [Riddick, A. C. P.; Stewart, G. D.] Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland; [Anderson, R. A.] Univ Edinburgh, Reprod & Dev Sci Sect, Queens Med Res Inst, Edinburgh, Midlothian, Scotland; [Franco, O. E.; Hayward, S. W.] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA; [Franco, O. E.; Hayward, S. W.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA	University of Edinburgh; University of Edinburgh; University of Edinburgh; Vanderbilt University; Vanderbilt University	Thomson, AA (corresponding author), Queens Med Res Inst, Med Res Council Human Reprod Sci Unit, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	a.thomson@hrsu.mrc.ac.uk	Thomson, Axel/A-7893-2013	Stewart, Grant D./0000-0003-3188-9140; Hayward, Simon/0000-0002-6059-6550	MRC WBSe [1276.00.003.00004.01]; NCI [CA126505]; MRC; Prostate Cancer Charity; Medical Research Council [G1002033, MC_U127684421, G1100357, G1002118] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U54CA126505] Funding Source: NIH RePORTER; MRC [G1002033, MC_U127684421, G1002118, G1100357] Funding Source: UKRI	MRC WBSe(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Prostate Cancer Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We would like to thank Ted Pinner for help with the figure preparation, Donald Dunbar for Bio-informatic advice and Sheila Macpherson for help with colocalization. This work was funded by the MRC WBSe 1276.00.003.00004.01 to AAT and NCI CA126505 to SWH. The MRC Human Reproductive Sciences Unit closed on 31 March 2011. AAT was supported by the MRC and The Prostate Cancer Charity.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; Ayala G, 2003, CLIN CANCER RES, V9, P4792; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franco OE, 2011, CANCER RES, V71, P1272, DOI 10.1158/0008-5472.CAN-10-3142; Gregg JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-165; HAYASHI N, 1991, CANCER RES, V51, P4924; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; Hayward SW, 2001, CANCER RES, V61, P8135; Joensuu K, 2008, CANCER LETT, V265, P76, DOI 10.1016/j.canlet.2008.02.022; Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kiskowski MA, 2011, CANCER RES, V71, P3459, DOI 10.1158/0008-5472.CAN-10-2999; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Lesniak W, 2009, BIOCHEM BIOPH RES CO, V390, P1087, DOI 10.1016/j.bbrc.2009.10.150; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Madar S, 2009, CARCINOGENESIS, V30, P20, DOI 10.1093/carcin/bgn232; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pascal LE, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-317; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Pritchard C, 2009, CANCER RES, V69, P1739, DOI 10.1158/0008-5472.CAN-07-6817; Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302; Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; Stolovitzky GA, 2005, P NATL ACAD SCI USA, V102, P1402, DOI 10.1073/pnas.0406555102; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Thalmann GN, 2010, EUR UROL, V58, P162, DOI 10.1016/j.eururo.2009.08.026; Thomson AA, 1999, DEVELOPMENT, V126, P3693; TIMMS BG, 1995, MICROSC RES TECHNIQ, V30, P319, DOI 10.1002/jemt.1070300407; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Vanpoucke G, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r213; Watson JEV, 2004, PROSTATE, V61, P192, DOI 10.1002/pros.20100; Whitaker HC, 2010, PROSTATE, V70, P333, DOI 10.1002/pros.21059; Witkiewicz AK, 2009, CELL CYCLE, V8, P1654, DOI 10.4161/cc.8.11.8544; Yanagisawa N, 2007, HUM PATHOL, V38, P1611, DOI 10.1016/j.humpath.2007.04.008; Zhao HJ, 2007, J CELL PHYSIOL, V210, P111, DOI 10.1002/jcp.20828	42	83	85	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1130	1142		10.1038/onc.2011.312	http://dx.doi.org/10.1038/onc.2011.312			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21804603	Green Published, hybrid			2022-12-28	WOS:000300945900006
J	Takai, A; Marusawa, H; Minaki, Y; Watanabe, T; Nakase, H; Kinoshita, K; Tsujimoto, G; Chiba, T				Takai, A.; Marusawa, H.; Minaki, Y.; Watanabe, T.; Nakase, H.; Kinoshita, K.; Tsujimoto, G.; Chiba, T.			Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation	ONCOGENE			English	Article						AID; colitis-associated cancer; colonic inflammation; IL-10(-/-) mouse	HELICOBACTER-PYLORI INFECTION; ULCERATIVE-COLITIS; BOWEL-DISEASE; INTERLEUKIN-10-DEFICIENT MICE; DNA DEMETHYLATION; COLORECTAL-CANCER; HUMAN HEPATOCYTES; LAMINA PROPRIA; P53 MUTATIONS; CELLS	Inflammatory bowel disease (IBD) is an important etiologic factor in the development of colorectal cancer. However, the mechanism underlying carcinogenesis through chronic inflammation is still unknown. Activation-induced cytidine deaminase (AID) is induced by the inflammation and involved in various human carcinogenesis via its mutagenic activity. In the current study, we investigated whether the inflammation/AID axis plays an integral role in the development of colitis-associated cancers. Inflammation in the cecum was more severe than that in other colonic regions, and endogenous AID expression was enhanced most prominently in the inflamed cecal mucosa of interleukin (IL)-10(-/-) mice. Blockade of tumor necrosis factor (TNF)-alpha and IL-12 significantly suppressed AID expression. Although proinflammatory cytokine expression was comparable between IL-10(-/-) AID(+/+) and IL-10(-/-) AID(-/-) mice, sequencing analyses revealed a significantly lower incidence of somatic mutations in Trp53 gene in the colonic mucosa of IL-10(-/-) AID(-/-) than IL-10(-/-) AID(+/+) mice. Colon cancers spontaneously developed in the cecum in 6 of 22 (27.2%) IL-10(-/-) AID(+/+) mice. In contrast, none of the IL-10(-/-) AID(-/-) mice developed cancers except only one case of neoplasia in the distal colon. These findings suggest that the proinflammatory cytokine-induced aberrant production of AID links colonic inflammation to an enhanced genetic susceptibility to oncogenic mutagenesis. Targeting AID could be a novel strategy to prevent colitis-associated colon carcinogenesis irrespective of ongoing colonic inflammation. Oncogene (2012) 31, 1733-1742; doi:10.1038/onc.2011.352; published online 15 August 2011	[Marusawa, H.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; [Kinoshita, K.] Shiga Med Ctr Res Inst, Moriyama, Japan; [Tsujimoto, G.] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Marusawa, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	maru@kuhp.kyoto-u.ac.jp	Watanabe, Tomohiro/ABA-4712-2021; Nakase, Hiroshi/AAZ-4425-2020	Marusawa, Hiroyuki/0000-0002-4286-2712	Ministry of Education, Culture, Sports, Science; Ministry of Health, Labor, and Welfare, Japan; Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research [21229009, 23390196] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Keiichiro Suzuki and Dr Tasuku Honjo for critical reading of this manuscript, and Dr Masamichi Muramatsu for providing information of siRNA for AID. This work was supported by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science; a grant-in-aid for Scientific Research from the Ministry of Health, Labor, and Welfare, Japan; and a research grant of the Princess Takamatsu Cancer Research Fund.	Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Chiba T, 2006, J GASTROENTEROL, V41, P1, DOI 10.1007/s00535-005-1743-4; Chiba T, 2009, J MOL MED-JMM, V87, P1023, DOI 10.1007/s00109-009-0527-3; Davidson NJ, 1996, J EXP MED, V184, P241, DOI 10.1084/jem.184.1.241; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Endo Y, 2008, GASTROENTEROLOGY, V135, P889, DOI 10.1053/j.gastro.2008.06.091; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Holzmann K, 1998, INT J CANCER, V76, P1; Hussain SP, 2000, CANCER RES, V60, P3333; Ikeda K, 2007, ANN INTERN MED, V146, P649, DOI 10.7326/0003-4819-146-9-200705010-00008; Inoue S, 2009, CLIN EXP IMMUNOL, V156, P172, DOI 10.1111/j.1365-2249.2008.03872.x; KERN SE, 1994, GASTROENTEROLOGY, V107, P420, DOI 10.1016/0016-5085(94)90167-8; Komori J, 2008, HEPATOLOGY, V47, P888, DOI 10.1002/hep.22125; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lashner BA, 1999, AM J GASTROENTEROL, V94, P456, DOI 10.1016/S0002-9270(98)00758-8; Leedham SJ, 2009, GASTROENTEROLOGY, V136, P542, DOI 10.1053/j.gastro.2008.10.086; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu RK, 2006, AM J PATHOL, V168, P757, DOI 10.2353/ajpath.2006.050907; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Morisawa T, 2008, INT J CANCER, V123, P2735, DOI 10.1002/ijc.23853; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakatani T, 2004, J BIOL CHEM, V279, P16356, DOI 10.1074/jbc.M311740200; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; REDSTON MS, 1995, GASTROENTEROLOGY, V108, P383, DOI 10.1016/0016-5085(95)90064-0; Sturlan S, 2001, CARCINOGENESIS, V22, P665, DOI 10.1093/carcin/22.4.665; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Takai A, 2009, ONCOGENE, V28, P469, DOI 10.1038/onc.2008.415; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Watanabe T, 2006, IMMUNITY, V25, P473, DOI 10.1016/j.immuni.2006.06.018; YIN J, 1993, GASTROENTEROLOGY, V104, P1633, DOI 10.1016/0016-5085(93)90639-T	44	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1733	1742		10.1038/onc.2011.352	http://dx.doi.org/10.1038/onc.2011.352			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841819	Green Published			2022-12-28	WOS:000302231400011
J	Fleisig, HB; Wong, JMY				Fleisig, H. B.; Wong, J. M. Y.			Telomerase promotes efficient cell cycle kinetics and confers growth advantage to telomerase-negative transformed human cells	ONCOGENE			English	Article						telomerase; cell cycle; growth kinetics	CANCER-CELLS; DNA-DAMAGE; IONIZING-RADIATION; CATALYTIC SUBUNIT; IN-VIVO; HUMAN-FIBROBLASTS; ENZYME-ACTIVITY; MAINTENANCE; EXPRESSION; RECOMBINATION	Constitutive telomerase activity maintains telomere length and confers immortal phenotypes to human cancers. The prevalence of telomerase, rather than a homologous recombination-based mechanism, in telomere length maintenance suggests that telomerase also has auxiliary roles in tumorigenesis. Here, we investigate growth advantages provided by the telomerase enzyme in oncogene-transformed human cells that do not require telomerase activity for telomere length control. Our data suggest that in oncogene-transformed cells, telomerase activity accelerates cell growth kinetics in a cell cycle phase-specific manner and promotes anchorage-independent growth. Coculture experiments demonstrated that this growth advantage conferred by telomerase activity is not due to increased cellular cross-talk. Growth advantages provided by telomerase required all functional aspects of the enzyme. Dissociation-of-activity-in-telomerase mutants and other functionally defective versions of telomerase were unable to promote oncogene-transformed cell growth, suggesting that canonical telomerase activities may be involved. We conclude that telomerase provides advantages to oncogene-transformed human cells, thereby supporting the development of telomerase-based anticancer chemotherapies targeting these growth-promoting effects. Oncogene (2012) 31, 954-965; doi:10.1038/onc.2011.292; published online 11 July 2011	[Fleisig, H. B.; Wong, J. M. Y.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Wong, JMY (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada.	judy.wong@ubc.ca	Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143	Canadian Cancer Society Research Institute [019250]; Faculty of Pharmaceutical Sciences, UBC; Canada Research Chairs; Michael Smith Foundation for Health Research	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Faculty of Pharmaceutical Sciences, UBC; Canada Research Chairs(Canada Research ChairsCGIAR); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	We thank Kathleen Collins and William Hahn for generously sharing reagents, Andy Johnson of the Biomedical Research Center at UBC for assistance with FACS analysis and Shirley Yeung, Raina Tamakawa, Naresh Thumati and Xi-Lei Zeng for technical help. Financial supported for this work was received from the Canadian Cancer Society Research Institute (operating grant no. 019250) and Research Reinvestment funds of the Faculty of Pharmaceutical Sciences, UBC. JMYW is supported by the Canada Research Chairs and the Michael Smith Foundation for Health Research Career Development programs.	Armbruster BN, 2004, MOL CELL BIOL, V24, P3552, DOI 10.1128/MCB.24.8.3552-3561.2004; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Chang S, 2002, P NATL ACAD SCI USA, V99, P12520, DOI 10.1073/pnas.212514699; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2003, HISTOL HISTOPATHOL, V18, P541, DOI 10.14670/HH-18.541; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Dong CK, 2005, CRIT REV ONCOL HEMAT, V54, P85, DOI 10.1016/j.critrevonc.2004.12.005; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; Fakhoury J, 2010, J CELL SCI, V123, P1693, DOI 10.1242/jcs.063636; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; Horbinski C, 2010, AM J PATHOL, V177, P1044, DOI 10.2353/ajpath.2010.091270; Huard S, 2004, NUCLEIC ACIDS RES, V32, P2171, DOI 10.1093/nar/gkh546; HURLIN PJ, 1987, CANCER RES, V47, P5752; Janknecht R, 2004, FEBS LETT, V564, P9, DOI 10.1016/S0014-5793(04)00356-4; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee SR, 2003, J BIOL CHEM, V278, P52531, DOI 10.1074/jbc.M311359200; Lindvall C, 2003, CANCER RES, V63, P1743; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nagaprashantha LD, 2011, INT J CANCER, V128, P743, DOI 10.1002/ijc.25725; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; O'Hayer KM, 2006, METHOD ENZYMOL, V407, P637, DOI 10.1016/S0076-6879(05)07050-3; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Oulton R, 2004, MOL BIOL CELL, V15, P3244, DOI 10.1091/mbc.E04-03-0178; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Tamakawa RA, 2010, CANCER RES, V70, P8684, DOI 10.1158/0008-5472.CAN-10-2227; Tokutake Y, 1998, BIOCHEM BIOPH RES CO, V247, P765, DOI 10.1006/bbrc.1998.8876; Verdun RE, 2006, CELL, V127, P709, DOI 10.1016/j.cell.2006.09.034; Verdun RE, 2005, MOL CELL, V20, P551, DOI 10.1016/j.molcel.2005.09.024; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Wong JMY, 2006, GENE DEV, V20, P2848, DOI 10.1101/gad.1476206; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232	52	12	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					954	965		10.1038/onc.2011.292	http://dx.doi.org/10.1038/onc.2011.292			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21743490				2022-12-28	WOS:000300709700002
J	Chou, CH; Teng, CM; Tzen, KY; Chang, YC; Chen, JH; Cheng, JCH				Chou, C. H.; Teng, C-M; Tzen, K-Y; Chang, Y-C; Chen, J-H; Cheng, J. C-H			MMP-9 from sublethally irradiated tumor promotes Lewis lung carcinoma cell invasiveness and pulmonary metastasis	ONCOGENE			English	Article						MMP-9; radiation; Lewis lung carcinoma; invasiveness; metastasis	ENDOTHELIAL GROWTH-FACTOR; MARROW-DERIVED CELLS; MATRIX METALLOPROTEINASES; ANGIOGENESIS; MATRIX-METALLOPROTEINASE-9; CANCER; MICE; ANGIOSTATIN; EXPRESSION; CARCINOGENESIS	Matrix metalloproteinases (MMPs) associate with tumor progression and metastasis. We sought to investigate the role of MMP-9 from sublethally irradiated tumor in accelerated pulmonary metastasis of Lewis lung carcinoma (LLC-LM) and the corresponding anti-metastasis strategies in C57BL/6 mice. We used Matrigel-coated Boyden chamber assays and chicken chorioallantoic membrane assays to evaluate the invasion capability of irradiated LLC-LM cells (7.5 Gy), reverse transcription-polymerase chain reaction and the western blot assay to investigate the expression of MMPs by irradiated cells, and small interfering RNA duplexes to inhibit MMP-9 expression. LLC-LM cells differing in MMP-2 or -9 expression were subcutaneously injected into right thighs and the resulting tumors were irradiated (10 Gy x 5) to induce pulmonary metastasis. Radiation significantly enhanced MMP-9 at both the transcriptional and translational levels. MMP-9 siRNA significantly inhibited in vitro radiation-enhanced invasiveness. The number of radiation-accelerated pulmonary metastases was significantly reduced by MMP-9 knockdown and MMP-2/9 knockdown. Reverse transcription-polymerase chain reaction of LLC-LM cells in the blood and lung tissue revealed MMP-9 involvement in radiation-enhanced intravasation. Either higher-dose irradiation (30 Gy x 2) or pretreatment with prototypical MMP-9 inhibitor, zoledronic acid, significantly reduced the number of pulmonary metastases. The viability of irradiated tumor was seen on both positron emission tomography and magnetic resonance imaging, and tumor/serum MMP-9 levels suggested the association of local control of primary tumor and inhibition of time-dependent MMP-9 activities. Our results demonstrate that MMP-9 is crucially involved in radiation-enhanced LLC-LM cell invasiveness in vitro and in pulmonary metastasis from inadequately irradiated primary tumor in vivo. Oncogene (2012) 31, 458-468; doi: 10.1038/onc.2011.240; published online 27 June 2011	[Chou, C. H.; Cheng, J. C-H] Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, Taipei 100, Taiwan; [Chou, C. H.; Cheng, J. C-H] Natl Taiwan Univ, Grad Inst Oncol, Coll Med, Taipei 10764, Taiwan; [Teng, C-M] Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei, Taiwan; [Tzen, K-Y] Natl Taiwan Univ Hosp, Dept Nucl Med, Taipei 100, Taiwan; [Tzen, K-Y] Natl Taiwan Univ, Mol Imaging Ctr, Taipei 10764, Taiwan; [Chang, Y-C] Natl Taiwan Univ Hosp, Dept Med Imaging, Taipei 100, Taiwan; [Chen, J-H; Cheng, J. C-H] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Coll Elect Engn & Comp Sci, Taipei 10764, Taiwan; [Cheng, J. C-H] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University	Cheng, JCH (corresponding author), Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	jasoncheng@ntu.edu.tw		TZEN, KAI-YUAN/0000-0002-5657-8579; TENG, CHE-MING/0000-0002-9719-7334; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220; CHANG, YEUN-CHUNG/0000-0001-9984-5713	National Science Council, Execute Yuan, Taiwan, ROC [NSC97-2314-B-002-113-MY3, NSC98-2627-B-002-017, NSC99-2627-B-002-008]; National Taiwan University Hospital [NTUH 98S1128]	National Science Council, Execute Yuan, Taiwan, ROC(Ministry of Science and Technology, Taiwan); National Taiwan University Hospital(National Taiwan University)	This work was supported by the National Science Council, Execute Yuan, Taiwan, ROC (Grant numbers NSC97-2314-B-002-113-MY3, NSC98-2627-B-002-017 and NSC99-2627-B-002-008), and the National Taiwan University Hospital (Grant number NTUH 98S1128). We appreciate the contribution of the Molecular Imaging Center, National Taiwan University, in providing the technical support of the dedicated small animal PET/CT scanner for imaging. We also thank Mr Samuel C Leu for his help with the PET/CT scans and image analysis.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Ahn GO, 2009, CELL CYCLE, V8, P970, DOI 10.4161/cc.8.7.8075; Basile DP, 2004, AM J PHYSIOL-RENAL, V286, pF893, DOI 10.1152/ajprenal.00328.2003; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bode W, 2003, BIOL CHEM, V384, P863, DOI 10.1515/BC.2003.097; Camphausen K, 2001, CANCER RES, V61, P2207; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen XW, 2005, INT J CANCER, V116, P52, DOI 10.1002/ijc.20997; Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Hartford AC, 2000, CANCER RES, V60, P2128; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huang SY, 2002, J NATL CANCER I, V94, P1134; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Leeman MF, 2003, J PATHOL, V201, P528, DOI 10.1002/path.1466; Martin FM, 1999, BIOORG MED CHEM LETT, V9, P2887, DOI 10.1016/S0960-894X(99)00494-1; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Osinsky SP, 2005, EXP ONCOL, V27, P202; Owen JL, 2003, J IMMUNOL, V171, P4340, DOI 10.4049/jimmunol.171.8.4340; Pozzi A, 2002, ONCOGENE, V21, P272, DOI 10.1038/sj.onc.1205045; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Thwin MM, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2810; Tofts PS, 1999, J MAGN RESON IMAGING, V10, P223, DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S; TOFTS PS, 1991, MAGNET RESON MED, V17, P357, DOI 10.1002/mrm.1910170208; Vihinen P, 2005, CURR CANCER DRUG TAR, V5, P203, DOI 10.2174/1568009053765799; Zhang Q, 2006, J BIOL CHEM, V281, P18145, DOI 10.1074/jbc.M512566200	29	42	45	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					458	468		10.1038/onc.2011.240	http://dx.doi.org/10.1038/onc.2011.240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706046				2022-12-28	WOS:000300219300005
J	Wade, M; Li, YC; Matani, AS; Braun, SMG; Milanesi, F; Rodewald, LW; Wahl, GM				Wade, M.; Li, Y. C.; Matani, A. S.; Braun, S. M. G.; Milanesi, F.; Rodewald, L. W.; Wahl, G. M.			Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells	ONCOGENE			English	Article						Mdm2; ligase; p53; RING; ubiquitin; Nutlin	DNA-DAMAGE; P53 ACTIVATION; IN-VIVO; ALLOSTERIC ACTIVATION; RING; DEGRADATION; DOMAIN; CANCER; HDM2; ATM	Mdm2 is the major negative regulator of p53 tumor-suppressor activity. This oncoprotein is overexpressed in many human tumors that retain the wild-type p53 allele. As such, targeted inhibition of Mdm2 is being considered as a therapeutic anticancer strategy. The N-terminal hydrophobic pocket of Mdm2 binds to p53 and thereby inhibits the transcription of p53 target genes. Additionally, the C-terminus of Mdm2 contains a RING domain with intrinsic ubiquitin E3 ligase activity. By recruiting E2 ubiquitin-conjugating enzyme(s), Mdm2 acts as a molecular scaffold to facilitate p53 ubiquitination and proteasome-dependent degradation. Mdmx (Mdm4), an Mdm2 homolog, also has a RING domain and hetero-oligomerizes with Mdm2 to stimulate its E3 ligase activity. Recent studies have shown that C-terminal residues adjacent to the RING domain of both Mdm2 and Mdmx contribute to Mdm2 E3 ligase activity. However, the molecular mechanisms mediating this process remain unclear, and the biological consequences of inhibiting Mdm2/Mdmx co-operation or blocking Mdm2 ligase function are relatively unexplored. This study presents biochemical and cell biological data that further elucidate the mechanisms by which Mdm2 and Mdmx co-operate to regulate p53 level and activity. We use chemical and genetic approaches to demonstrate that functional inhibition of Mdm2 ubiquitin ligase activity is insufficient for p53 activation. This unexpected result suggests that concomitant treatment with Mdm2/Mdmx antagonists may be needed to achieve therapeutic benefit.	[Wade, M.; Li, Y. C.; Matani, A. S.; Braun, S. M. G.; Rodewald, L. W.; Wahl, G. M.] Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; [Wade, M.; Milanesi, F.] IIT SEMM, Ctr Genom Sci, I-20139 Milan, Italy; [Matani, A. S.] Univ Calif San Diego, Div Biol Sci, San Diego, CA 92103 USA	Salk Institute; Istituto Italiano di Tecnologia - IIT; University of California System; University of California San Diego	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mark.wade@iit.it; wahl@salk.edu	Wade, Mark/B-6719-2009	Wade, Mark/0000-0002-2688-5965; Braun, Simon/0000-0003-2622-9914; Wade, Mark/0000-0002-8355-9680	National Institutes of Health [CA61449]; sanofi-aventis; NATIONAL CANCER INSTITUTE [R01CA061449, P30CA014195] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); sanofi-aventis(Sanofi-Aventis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by a National Institutes of Health R01 Grant CA61449 and a Discovery Research Grant from sanofi-aventis awarded to GMW. We thank all members of the Wahl lab for input on various aspects of this project, Dimitris Xirodimas (Dundee University) for advice on the ubiquitylation assays and Masha Poyurovsky (Columbia University) for productive discussions. We also thank Rachel Klevit and Chris Pierini (University of Washington) for their comments and insight into ubiquitylation during this project.	Aranda-Anzaldo A, 2007, MECH AGEING DEV, V128, P293, DOI 10.1016/j.mad.2007.01.001; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Das R, 2009, MOL CELL, V34, P674, DOI 10.1016/j.molcel.2009.05.010; Dastidar SG, 2011, CELL CYCLE, V10, P82, DOI 10.4161/cc.10.1.14345; De Clercq S, 2010, MOL CELL BIOL, V30, P5394, DOI 10.1128/MCB.00330-10; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Joseph TL, 2010, CELL CYCLE, V9, P1167, DOI 10.4161/cc.9.6.11067; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kitagaki J, 2008, MOL CANCER THER, V7, P2445, DOI 10.1158/1535-7163.MCT-08-0063; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; Maetens M, 2007, BLOOD, V109, P2630, DOI 10.1182/blood-2006-03-013656; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Popowicz GM, 2008, CELL CYCLE, V7, P2441, DOI 10.4161/cc.6365; Poyurovsky MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Wade M, 2008, CELL CYCLE, V7, P1973, DOI 10.4161/cc.7.13.6072; Wade M, 2009, MOL CANCER RES, V7, P1, DOI 10.1158/1541-7786.MCR-08-0423; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; Weissman A M, 2008, Ernst Schering Found Symp Proc, P171; Wong ET, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni145; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zuckerman V, 2009, J BIOL CHEM, V284, P4031, DOI 10.1074/jbc.M809211200	46	19	19	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4789	4797		10.1038/onc.2011.625	http://dx.doi.org/10.1038/onc.2011.625			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266850	Green Accepted			2022-12-28	WOS:000311033000007
J	Munro, S; Carr, SM; La Thangue, NB				Munro, S.; Carr, S. M.; La Thangue, N. B.			Diversity within the pRb pathway: is there a code of conduct?	ONCOGENE			English	Review						pRb; E2F-1; phosphorylation; acetylation; methylation	RETINOBLASTOMA TUMOR-SUPPRESSOR; CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; CELL-CYCLE; LYSINE METHYLATION; KERATINOCYTE DIFFERENTIATION; E2F1-INDUCED APOPTOSIS; HISTONE METHYLATION; DOCKING SITE; PROTEIN PRB	The failure of cell proliferation to be properly regulated is a hallmark of tumourigenesis. The retinoblastoma protein (pRb) pathway represents a key component in the regulation of the cell cycle and tumour suppression. Recent findings have revealed new levels of complexity reflecting a repertoire of post-translational modifications that occur on pRb together with its key effector E2F-1. Here we provide an overview of the modifications and consider the possibility of a 'code' that endows pRb with the ability to function in diverse physiological settings. Oncogene (2012) 31, 4343-4352; doi: 10.1038/onc.2011.603; published online 16 January 2012	[Munro, S.; Carr, S. M.; La Thangue, N. B.] Univ Oxford, Canc Biol Lab, Dept Oncol, Div Med Sci, Oxford OX3 7DQ, England	University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Canc Biol Lab, Dept Oncol, Div Med Sci, Old Rd Campus Res Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.	nick.lathangue@clinpharm.ox.ac.uk			CRUK; MRC; LRF; EU; AICR; MRC [G1000807] Funding Source: UKRI; Medical Research Council [G1000807] Funding Source: researchfish	CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); LRF; EU(European Commission); AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from CRUK, MRC, LRF, EU and AICR.	Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Bonasio R, 2010, SEMIN CELL DEV BIOL, V21, P221, DOI 10.1016/j.semcdb.2009.09.010; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Carr SM, 2011, EMBO J, V30, P317, DOI 10.1038/emboj.2010.311; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Delston RB, 2011, ONCOGENE, V30, P588, DOI 10.1038/onc.2010.442; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Fang YJ, 2011, CANCER LETT, V306, P10, DOI 10.1016/j.canlet.2011.02.019; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Gorges LL, 2008, AM J PHYSIOL-CELL PH, V295, pC1151, DOI 10.1152/ajpcell.00300.2008; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Hirschi A, 2010, NAT STRUCT MOL BIOL, V17, P1051, DOI 10.1038/nsmb.1868; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Ivanova IA, 2009, ONCOGENE, V28, P52, DOI 10.1038/onc.2008.354; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Khidr L, 2006, ONCOGENE, V25, P5210, DOI 10.1038/sj.onc.1209612; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Lents NH, 2006, CELL CYCLE, V5, P1699, DOI 10.4161/cc.5.15.3126; Lin WC, 2001, GENE DEV, V15, P1833; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Longworth MS, 2010, CHROMOSOMA, V119, P1, DOI 10.1007/s00412-009-0238-0; Lowe ED, 2002, BIOCHEMISTRY-US, V41, P15625, DOI 10.1021/bi0268910; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Min JR, 2007, NAT STRUCT MOL BIOL, V14, P1229, DOI 10.1038/nsmb1340; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pickard A, 2010, J CELL SCI, V123, P3718, DOI 10.1242/jcs.068924; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612; Sahin F, 2010, INT J BIOL SCI, V6, P382; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sherr CJ, 2000, CANCER RES, V60, P3689; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Wang B, 2004, J BIOL CHEM, V279, P54140, DOI 10.1074/jbc.M410493200; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Yeste-Velasco M, 2009, NEUROCHEM INT, V54, P99, DOI 10.1016/j.neuint.2008.10.004; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	94	70	73	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4343	4352		10.1038/onc.2011.603	http://dx.doi.org/10.1038/onc.2011.603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249267				2022-12-28	WOS:000309591300001
J	Ratner, ES; Keane, FK; Lindner, R; Tassi, RA; Paranjape, T; Glasgow, M; Nallur, S; Deng, Y; Lu, L; Steele, L; Sand, S; Muller, RU; Bignotti, E; Bellone, S; Boeke, M; Yao, X; Pecorelli, S; Ravaggi, A; Katsaros, D; Zelterman, D; Cristea, MC; Yu, H; Rutherford, TJ; Weitzel, JN; Neuhausen, SL; Schwartz, PE; Slack, FJ; Santin, AD; Weidhaas, JB				Ratner, E. S.; Keane, F. K.; Lindner, R.; Tassi, R. A.; Paranjape, T.; Glasgow, M.; Nallur, S.; Deng, Y.; Lu, L.; Steele, L.; Sand, S.; Muller, R-U; Bignotti, E.; Bellone, S.; Boeke, M.; Yao, X.; Pecorelli, S.; Ravaggi, A.; Katsaros, D.; Zelterman, D.; Cristea, M. C.; Yu, H.; Rutherford, T. J.; Weitzel, J. N.; Neuhausen, S. L.; Schwartz, P. E.; Slack, F. J.; Santin, A. D.; Weidhaas, J. B.			A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer	ONCOGENE			English	Article						platinum resistance; KRAS variant; ovarian cancer; outcome	LET-7 MICRORNA-BINDING; 3'-UNTRANSLATED REGION; EXPRESSION; CARBOPLATIN; PACLITAXEL; SURVIVAL; MODELS; MARKER; SITE	Germline variants in the 30 untranslated region (3'UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3'UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS variant-positive EOC patients. As this variant seems to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival. EOC patients with complete clinical data were genotyped for the KRAS variant and analyzed for outcome (n = 536), response to neoadjuvant chemotherapy (n = 25) and platinum resistance (n = 306). Outcome was separately analyzed for women with known BRCA mutations (n = 79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were used to confirm altered sensitivity to chemotherapy associated with the KRAS variant. Finally, the KRAS variant was directly targeted through small-interfering RNA/miRNA oligonucleotides in cell lines and survival was measured. Postmenopausal EOC patients with the KRAS variant were significantly more likely to die of ovarian cancer by multivariate analysis (hazard ratio 1.67, 95% confidence interval: 1.09-2.57, P = 0.019, n = 279). Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio 3.18, confidence interval: 1.31-7.72, P = 0.0106, n = 291). In addition, direct targeting of the KRAS variant led to a significant reduction in EOC cell growth and survival in vitro. These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this study supports the hypothesis that these tumors have continued dependence on such 3'UTR lesions, and that direct targeting may be a viable future treatment approach.	[Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [Ratner, E. S.; Bellone, S.; Rutherford, T. J.; Schwartz, P. E.; Santin, A. D.] Yale Univ, Dept Gynecol Oncol, New Haven, CT 06520 USA; [Lindner, R.] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany; [Tassi, R. A.; Bignotti, E.; Pecorelli, S.; Ravaggi, A.] Univ Brescia, Div Gynecol Oncol, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Deng, Y.; Lu, L.; Yao, X.; Zelterman, D.; Yu, H.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Steele, L.; Neuhausen, S. L.] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA; [Sand, S.; Weitzel, J. N.] City Hope Natl Med Ctr, Div Clin Canc Genet, Duarte, CA USA; [Muller, R-U] Univ Cologne, Dept Med, Div Renal, D-50931 Cologne, Germany; [Muller, R-U] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Katsaros, D.] Univ Turin, Dept Gynecol Oncol, Turin, Italy; [Cristea, M. C.] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA; [Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Ruprecht Karls University Heidelberg; University of Brescia; Yale University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; University of Cologne; University of Cologne; University of Turin; City of Hope; Yale University	Weidhaas, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu	Müller, Roman-Ulrich/AAK-3493-2021; Ravaggi, Antonella/K-5585-2016	Müller, Roman-Ulrich/0000-0001-6910-0745; Ravaggi, Antonella/0000-0003-4661-9979; Bellone, Stefania/0000-0001-5909-5292; Sand, Sharon/0000-0002-9390-5583; Weidhaas, Joanne/0000-0002-5096-3281; Slack, Frank/0000-0001-8263-0409; Zelterman, Daniel/0000-0003-0711-8688	Women's Reproductive Health Research (WRHR) Career Development Program grant [5K12HD047018-08]; Mary Kay Foundation; NCI [CA131301-01A1, RC4CA153828]; K08 grant [CA124484]; Morris and Horowitz Families Endowed Professorship; NIH [R01CA74415]; Markel Foundation; Shannon Family Foundation; Segesta family; Office of the Director, National Institutes of Health;  [R01CA122728]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD047018] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA122728, R01CA131301, K08CA124484, R01CA074415, RC4CA153828, R01CA157749] Funding Source: NIH RePORTER	Women's Reproductive Health Research (WRHR) Career Development Program grant; Mary Kay Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); K08 grant; Morris and Horowitz Families Endowed Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Markel Foundation; Shannon Family Foundation; Segesta family; Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank JL and his group for supplying the cell line-associated chemosensitivity data. We appreciate Greg Wilhoite for performing the TaqMan assay and Josef Herzog for processing samples for the City of Hope. We also appreciate Discovery to Cure at Yale University for samples and Jeff Boyd for supplying the BG1 cell line for targeting studies. ER was supported by a Women's Reproductive Health Research (WRHR) Career Development Program grant (5K12HD047018-08). FS and JW were supported by a Mary Kay Foundation Grant, and an R01 from the NCI (CA131301-01A1). JW also was supported by a K08 grant (CA124484). AS was supported by R01CA122728. SLN is partially supported by the Morris and Horowitz Families Endowed Professorship and NIH R01CA74415. JNW and SS are supported by RC4CA153828 from the National Cancer Institute and the Office of the Director, National Institutes of Health, and also by funding from the Markel Foundation. We also appreciate support from the Shannon Family Foundation, the Segesta family and donations made in memory of Jennifer Casey.	ACS, 2010, CANC FACTS FIG 2010, P1; Chen KX, 2008, CARCINOGENESIS, V29, P1306, DOI 10.1093/carcin/bgn116; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099; COX DR, 1972, J R STAT SOC B, V34, P187; Cox DR., 1970, ANAL BINARY DATA; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Graziano F, 2010, PHARMACOGENOMICS J, V10, P458, DOI 10.1038/tpj.2010.9; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Herzog TJ, 2006, NAT CLIN PRACT ONCOL, V3, P604, DOI 10.1038/ncponc0637; Hollestelle A, 2011, BREAST CANCER RES TR, V128, P79, DOI 10.1007/s10549-010-1080-z; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lu L, 2011, GYNECOL ONCOL, V122, P366, DOI 10.1016/j.ygyno.2011.04.033; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mezzanzanica D, 2010, INT J BIOCHEM CELL B, V42, P1262, DOI 10.1016/j.biocel.2009.12.017; Paranjape T, 2011, LANCET ONCOL, V12, P377, DOI 10.1016/S1470-2045(11)70044-4; Parmar MKB, 2003, LANCET, V361, P2099; Peters D, 2005, MOL CANCER THER, V4, P1605, DOI 10.1158/1535-7163.MCT-04-0311; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Pharoah PDP, 2011, CLIN CANCER RES, V17, P3742, DOI 10.1158/1078-0432.CCR-10-3405; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Salzman DW, 2011, NAT MED, V17, P934, DOI 10.1038/nm0811-934; Sasaki H, 2011, J THORAC ONCOL, V6, P15, DOI 10.1097/JTO.0b013e31820594f0; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; van Jaarsveld MTM, 2010, INT J BIOCHEM CELL B, V42, P1282, DOI 10.1016/j.biocel.2010.01.014; Youn CK, 2004, CANCER RES, V64, P4849, DOI 10.1158/0008-5472.CAN-04-0348; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105	33	55	56	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4559	4566		10.1038/onc.2011.539	http://dx.doi.org/10.1038/onc.2011.539			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22139083	Green Accepted, Green Submitted			2022-12-28	WOS:000309982100007
J	Rusiniak, ME; Kunnev, D; Freeland, A; Cady, GK; Pruitt, SC				Rusiniak, M. E.; Kunnev, D.; Freeland, A.; Cady, G. K.; Pruitt, S. C.			Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma	ONCOGENE			English	Article						DNA replication; licensing factor; dormant origins; lymphoblastic lymphoma; Mcm2	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTORS; HUMAN-CELLS; REPLICATIVE STRESS; T-ALL; MUTATIONS; ORIGINS; CANCER; NOTCH1; CYCLE	Mini-chromosome maintenance (Mcm) proteins are part of the replication- licensing complex that is loaded onto chromatin during the G1-phase of the cell cycle and required for initiation of DNA replication in the subsequent S-phase. Mcm proteins are typically loaded in excess of the number of locations that are used during S-phase. Nonetheless, partial depletion of Mcm proteins leads to cancers and stem cell deficiencies. Mcm2 deficient mice, on a 129Sv genetic background, display a high rate of thymic lymphoblastic lymphoma. Here array comparative genomic hybridization is used to characterize the genetic damage accruing in these tumors. The predominant events are deletions averaging less than 0.5 Mbp, considerably shorter than observed in prior studies using alternative mouse lymphoma models or human tumors. Such deletions facilitate identification of specific genes and pathways responsible for the tumors. Mutations in many genes that have been implicated in human lymphomas are recapitulated in this mouse model. These features, and the fact that the mutation underlying the accelerated genetic damage does not target a specific gene or pathway a priori, are valuable features of this mouse model for identification of tumor suppressor genes. Genes affected in all tumors include Pten, Tcfe2a, Mbd3 and Setd1b. Notch1 and additional genes are affected in subsets of tumors. The high frequency of relatively short deletions is consistent with elevated recombination between nearby stalled replication forks in Mcm2-deficient mice. Oncogene (2012) 31, 4034-4044; doi:10.1038/onc.2011.566; published online 12 December 2011	[Rusiniak, M. E.; Kunnev, D.; Freeland, A.; Cady, G. K.; Pruitt, S. C.] Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Pruitt, SC (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton St, Buffalo, NY 14263 USA.	steven.pruitt@roswellpark.org			NIH-NCI; Ellison Medical Foundation; NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE [R01CA130995] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ellison Medical Foundation(Lawrence Ellison Foundation); NYSTEM; NCI-CCS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the NIH-NCI, the Ellison Medical Foundation and NYSTEM to SCP. Cost of animal maintenance and flow cytometry was supported in part by an NCI-CCS grant to RPCI.	Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; Aftab S, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-226; Bai T, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-7; Blow JJ, 2011, TRENDS BIOCHEM SCI, V36, P405, DOI 10.1016/j.tibs.2011.05.002; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Brackertz M, 2002, J BIOL CHEM, V277, P40958, DOI 10.1074/jbc.M207467200; Buckler JL, 2008, IMMUNOL REV, V224, P239, DOI 10.1111/j.1600-065X.2008.00650.x; Chuang CH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001110; Collins-Underwood JR, 2010, LEUKEMIA, V24, P1676, DOI 10.1038/leu.2010.177; De Keersmaecker K, 2010, NAT MED, V16, P1321, DOI 10.1038/nm.2246; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Ge XQ, 2010, J CELL BIOL, V191, P1285, DOI 10.1083/jcb.201007074; Hess JL, 2004, CRIT REV EUKAR GENE, V14, P235, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.10; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; Jeannet R, 2010, BLOOD, V116, P5443, DOI 10.1182/blood-2010-05-286658; Katzav S, 2009, INT J BIOCHEM CELL B, V41, P1245, DOI 10.1016/j.biocel.2008.11.006; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Kuiper RP, 2007, LEUKEMIA, V21, P1258, DOI 10.1038/sj.leu.2404691; Kunnev D, 2010, ONCOGENE, V29, P3630, DOI 10.1038/onc.2010.125; LeBrun DP, 2003, FRONT BIOSCI, V8, pS206, DOI 10.2741/1030; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Meyer C, 2009, LEUKEMIA, V23, P1490, DOI 10.1038/leu.2009.33; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nishiyama A, 2009, CELL STEM CELL, V5, P420, DOI 10.1016/j.stem.2009.07.012; Orr SJ, 2010, ONCOGENE, V29, P3803, DOI 10.1038/onc.2010.138; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pruitt SC, 2007, STEM CELLS, V25, P3121, DOI 10.1634/stemcells.2007-0483; Ramirez J, 2009, EPIGENETICS-US, V4, P532, DOI 10.4161/epi.4.8.10108; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; Remke M, 2009, BLOOD, V114, P1053, DOI 10.1182/blood-2008-10-186536; Santos J, 2010, CANCER GENET CYTOGEN, V197, P60, DOI 10.1016/j.cancergencyto.2009.10.010; Shima N, 2007, NAT GENET, V39, P93, DOI 10.1038/ng1936; Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Williams RT, 2008, COLD SH Q B, V73, P461, DOI 10.1101/sqb.2008.73.039; Yang Q, 2008, J IMMUNOL, V181, P5885, DOI 10.4049/jimmunol.181.9.5885; Zani VJ, 1996, BLOOD, V87, P3124, DOI 10.1182/blood.V87.8.3124.bloodjournal8783124	38	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4034	4044		10.1038/onc.2011.566	http://dx.doi.org/10.1038/onc.2011.566			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158038	Green Accepted			2022-12-28	WOS:000308688800004
J	Dittmann, LM; Danner, A; Gronych, J; Wolter, M; Stuhler, K; Grzendowski, M; Becker, N; Bageritz, J; Goidts, V; Toedt, G; Felsberg, J; Sabel, MC; Barbus, S; Reifenberger, G; Lichter, P; Tews, B				Dittmann, L. M.; Danner, A.; Gronych, J.; Wolter, M.; Stuehler, K.; Grzendowski, M.; Becker, N.; Bageritz, J.; Goidts, V.; Toedt, G.; Felsberg, J.; Sabel, M. C.; Barbus, S.; Reifenberger, G.; Lichter, P.; Tews, B.			Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro	ONCOGENE			English	Article						chemosensitivity; oligodendroglioma; peroxiredoxin 1; promoter methylation; radiosensitivity; temozolomide	GENE-EXPRESSION; PEROXIREDOXIN-II; OXIDATIVE STRESS; CANCER-CELLS; MGMT GENE; 1P; TEMOZOLOMIDE; GRADE; CHEMOTHERAPY; IDENTIFICATION	Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and linked to radio- and chemotherapy response as well as longer survival. The molecular mechanisms underlying this clinically important association are as yet unknown. Here, we studied the peroxiredoxin 1 (PRDX1) gene at 1p34.1 for promoter methylation and expression in primary gliomas and investigated its role in radio- and chemosensitivity of glioma cells in vitro. In total, we screened primary glioma tissues from 93 patients for methylation of the 50-CpG island of PRDX1 by sodium bisulfite sequencing. PRDX1 mRNA and protein expression levels were determined in subsets of the tumours by quantitative PCR and western blot analysis, respectively. PRDX1 hypermethylation and reduced expression were frequently detected in oligodendroglial tumours and secondary glioblastomas, but not in primary glioblastomas. In oligodendroglial tumours, both PRDX1 hypermethylation and reduced mRNA expression were significantly associated with 1p/19q-deletion. Stable knockdown of PRDX1 by lentiviral transduction of short-hairpin (sh) RNA constructs significantly increased apoptosis and reduced cell viability of Hs683 glioma cells exposed to ionizing irradiation or temozolomide in vitro. Taken together, our findings indicate that epigenetic silencing of PRDX1 is frequent in 1p/19q-deleted oligodendroglial tumours and likely contributes to radio- and chemosensitivity of these tumours. Oncogene (2012) 31, 3409-3418; doi:10.1038/onc.2011.513; published online 12 December 2011	[Dittmann, L. M.; Danner, A.; Gronych, J.; Becker, N.; Bageritz, J.; Goidts, V.; Toedt, G.; Barbus, S.; Lichter, P.] German Canc Res Ctr, Div Mol Genet, D-6900 Heidelberg, Germany; [Wolter, M.; Felsberg, J.; Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Stuehler, K.; Grzendowski, M.] Ruhr Univ Bochum, Med Proteom Ctr, Bochum, Germany; [Stuehler, K.] Univ Dusseldorf, Biol Med Forschungszentrum, Mol Prote Lab, D-40225 Dusseldorf, Germany; [Sabel, M. C.] Univ Dusseldorf, Dept Neurosurg, D-40225 Dusseldorf, Germany; [Tews, B.] Univ Zurich, Brain Res Inst, Zurich, Switzerland	Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Heine University Dusseldorf; Ruhr University Bochum; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Zurich	Lichter, P (corresponding author), German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Baden Wuerttemb, Germany.	m.macleod@dkfz.de	Gronych, Jan/G-9954-2013; Reifenberger, Guido/AAE-3599-2019	Bageritz, Josephine/0000-0002-9531-0452	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network NGFN2 [01GS0460, 01GS0462]; NGFN<SUP>plus</SUP> [01GS0883, 01GS0884, 01GS08186]; Ministry for Innovation, Science, Research and Technology (MIWFT) of Nordrhein Westfalen; Helmholtz international graduate school for cancer research	German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network NGFN2(Federal Ministry of Education & Research (BMBF)); NGFN<SUP>plus</SUP>; Ministry for Innovation, Science, Research and Technology (MIWFT) of Nordrhein Westfalen; Helmholtz international graduate school for cancer research	The study was supported by the German Federal Ministry of Education and Research (BMBF) within the National Genome Research Network NGFN2 (01GS0460 to PL, 01GS0462 to GR), NGFN<SUP>plus</SUP> (01GS0883 to PL, 01GS0884 to GR and MW, 01GS08186 to KS) and the Ministry for Innovation, Science, Research and Technology (MIWFT) of Nordrhein Westfalen (MG). JG and JB were supported by scholarships from the Helmholtz international graduate school for cancer research.	Bae JY, 2007, J CELL BIOCHEM, V101, P1038, DOI 10.1002/jcb.21241; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Brada M, 2003, ANN ONCOL, V14, P1715, DOI 10.1093/annonc/mdg371; Branle F, 2002, CANCER-AM CANCER SOC, V95, P641, DOI 10.1002/cncr.10710; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Camby I, 2000, BRAIN PATHOL, V10, P569; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Felsberg J, 2010, ACTA NEUROPATHOL, V119, P501, DOI 10.1007/s00401-010-0647-4; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Grzenclowski M, 2010, NEURO-ONCOLOGY, V12, P243, DOI 10.1093/neuonc/nop025; Grzendowski M, 2009, PROTEOMICS, V9, P4985, DOI 10.1002/pmic.200800902; Hattori Fumiyuki, 2007, V44, P357; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x; Hubstenberger A, 2008, EXP CELL RES, V314, P2870, DOI 10.1016/j.yexcr.2008.06.017; Immenschuh S, 2005, ANTIOXID REDOX SIGN, V7, P768, DOI 10.1089/ars.2005.7.768; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; Kouwenhoven MCM, 2006, EUR J CANCER, V42, P2499, DOI 10.1016/j.ejca.2006.05.021; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mates JM, 2008, ARCH TOXICOL, V82, P273, DOI 10.1007/s00204-008-0304-z; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohgaki H, 2009, CANCER SCI, V100, P2235, DOI 10.1111/j.1349-7006.2009.01308.x; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; Riemenschneider MJ, 2009, CURR OPIN NEUROL, V22, P619, DOI 10.1097/WCO.0b013e32833245b0; Tews B, 2007, ONCOGENE, V26, P5010, DOI 10.1038/sj.onc.1210297; Tews B, 2006, INT J CANCER, V119, P792, DOI 10.1002/ijc.21901; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; van den Bent MJ, 2006, ANN ONCOL, V17, pX186, DOI 10.1093/annonc/mdl258; van den Bent MJ, 2005, LANCET, V366, P985, DOI 10.1016/S0140-6736(05)67070-5; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang TL, 2005, CANCER RES, V65, P10338, DOI 10.1158/0008-5472.CAN-04-4614; Weller M, 2010, NAT REV NEUROL, V6, P39, DOI 10.1038/nrneurol.2009.197; Wick W, 2009, J CLIN ONCOL, V27, P5874, DOI 10.1200/JCO.2009.23.6497; Zhang B, 2008, BIOCHEM PHARMACOL, V75, P660, DOI 10.1016/j.bcp.2007.09.016	42	34	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3409	3418		10.1038/onc.2011.513	http://dx.doi.org/10.1038/onc.2011.513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22158042				2022-12-28	WOS:000306566400002
J	Lin, TY; Cheng, YC; Yang, HC; Lin, WC; Wang, CC; Lai, PL; Shieh, SY				Lin, T-Y; Cheng, Y-C; Yang, H-C; Lin, W-C; Wang, C-C; Lai, P-L; Shieh, S-Y			Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis	ONCOGENE			English	Article						BTG3; ERK; JMJD3/KDM6B; cellular senescence	DEMETHYLASE JMJD3 CONTRIBUTES; ONCOGENE-INDUCED SENESCENCE; DNA-DAMAGE RESPONSE; INK4A-ARF LOCUS; FAMILY; PROTEINS; BARRIER; STRESS; TARGET; RB	The B-cell translocation gene 3 (BTG3) is a member of the antiproliferative BTG gene family and a downstream target of p53. BTG3 also binds and inhibits E2F1. Although it connects functionally two major growth-regulatory pathways, the physiological role of BTG3 remains largely uncharacterized. Here, we present evidence that loss of BTG3 in normal cells induced cellular senescence, which was correlated with enhanced ERK-AP1 signaling and elevated expression of the histone H3K27me3 demethylase JMJD3/KDM6B, leading to acute induction of p16(INK4a). Importantly, we also found that BTG3 expression is specifically downregulated in prostate cancer, thus providing a physiological link with human cancers. Our data suggest that BTG3 may have a fail-safe role against tumorigenic progression. Oncogene (2012) 31, 3287-3297; doi:10.1038/onc.2011.491; published online 24 October 2011	[Lin, T-Y; Cheng, Y-C; Yang, H-C; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Cheng, Y-C] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Lin, W-C; Wang, C-C; Lai, P-L] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Taiwan University; National Taiwan University Hospital	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	National Science Council of Taiwan; Academia Sinica	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	This work was supported by grants from the National Science Council of Taiwan and Academia Sinica to S-Y Shieh.	Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Rahmani Z, 2006, J CELL SCI, V119, P646, DOI 10.1242/jcs.02778; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Yoneda M, 2009, CANCER SCI, V100, P225, DOI 10.1111/j.1349-7006.2008.01030.x; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699	26	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3287	3297		10.1038/onc.2011.491	http://dx.doi.org/10.1038/onc.2011.491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22020331				2022-12-28	WOS:000306113400008
J	Papadimitriou, E; Vasilaki, E; Vorvis, C; Iliopoulos, D; Moustakas, A; Kardassis, D; Stournaras, C				Papadimitriou, E.; Vasilaki, E.; Vorvis, C.; Iliopoulos, D.; Moustakas, A.; Kardassis, D.; Stournaras, C.			Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-beta and miR-24: role in epithelial-to-mesenchymal transition	ONCOGENE			English	Article						TGF-beta; Net1A; RhoA; EMT; miR-24	EXCHANGE FACTOR NET1; SMAD PROTEINS; ADHERENS JUNCTIONS; TUMOR-SUPPRESSOR; FAMILY; DYNAMICS; DOWNSTREAM; MECHANISMS; PLASTICITY; RECEPTORS	In the present study we analyzed the regulation of the two isoforms of the RhoA-specific guanine nucleotide exchange factor Net1 by transforming growth factor-beta (TGF-beta) in keratinocytes. We report that short-term TGF-beta treatment selectively induced Net1 isoform2 (Net1A) but not Net1 isoform1. This led to upregulation of cytoplasmic Net1A protein levels that were necessary for TGF-beta-mediated RhoA activation. Smad signaling and the MAPK/ERK kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway were involved in Net1A upregulation by TGF-beta. Interestingly, long-term TGF-beta treatment resulted in Net1 mRNA downregulation and Net1A protein degradation by the proteasome. Furthermore, we identified the microRNA miR-24 as a novel post-transcriptional regulator of Net1A expression. Silencing of Net1A resulted in disruption of E-cadherin-and zonula occludens-1 (ZO-1)-mediated junctions, as well as expression of the transcriptional repressor of E-cadherin, Slug and the mesenchymal markers N-cadherin, plasminogen activator inhibitor-1 (PAI-1) and fibronectin, indicating that late TGF-beta-induced downregulation of Net1A is involved in epithelial-to-mesenchymal transition (EMT). Finally, miR-24 was found to be implicated in the regulation of the EMT program in response to TGF-beta and was shown to be directly involved in the TGF-beta-induced breast cancer cell invasiveness through Net1A regulation. Our results emphasize the importance of Net1 isoform2 in the short-and long-term TGF-beta-mediated regulation of EMT. Oncogene (2012) 31, 2862-2875; doi:10.1038/onc.2011.457; published online 10 October 2011	[Papadimitriou, E.; Vasilaki, E.; Kardassis, D.; Stournaras, C.] Univ Crete, Dept Biochem, Sch Med, Iraklion 71003, Crete, Greece; [Vorvis, C.; Iliopoulos, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; [Vorvis, C.; Iliopoulos, D.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA; [Vasilaki, E.; Moustakas, A.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden; [Moustakas, A.] Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Uppsala, Sweden	University of Crete; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research; Uppsala University; Uppsala University	Stournaras, C (corresponding author), Univ Crete, Dept Biochem, Sch Med, POB 2208, Iraklion 71003, Crete, Greece.	cstourn@med.uoc.gr	Vasilaki, Eleftheria/AAY-6392-2020; Iliopoulos, Dimitrios/AAE-9106-2019		PENED program of the Greek Secretariat for Research and Technology [PENED03-688]	PENED program of the Greek Secretariat for Research and Technology	This work was supported by the PENED program of the Greek Secretariat for Research and Technology (Grant no. PENED03-688). We thank Dr EA Papakonstanti for valuable comments.	Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; Carr HS, 2009, J BIOL CHEM, V284, P24269, DOI 10.1074/jbc.M109.029439; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Garcia-Mata R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Inoue Y, 2008, CANCER SCI, V99, P2107, DOI 10.1111/j.1349-7006.2008.00925.x; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kardassis D, 2009, FEBS J, V276, P2947, DOI 10.1111/j.1742-4658.2009.07031.x; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lee J, 2010, J BIOL CHEM, V285, P26618, DOI 10.1074/jbc.M109.073155; Lin SC, 2011, ORAL ONCOL, V46, P204; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2008, FEBS LETT, V582, P2051, DOI 10.1016/j.febslet.2008.03.027; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Nakaya Y, 2008, NAT CELL BIOL, V10, P765, DOI 10.1038/ncb1739; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Piek E, 1999, J CELL SCI, V112, P4557; Qin HJ, 2005, J BIOL CHEM, V280, P7603, DOI 10.1074/jbc.M412141200; Qin WM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009429; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schmidt A, 2002, J BIOL CHEM, V277, P14581, DOI 10.1074/jbc.M111108200; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Sun FY, 2009, BIOCHEM BIOPH RES CO, V380, P660, DOI 10.1016/j.bbrc.2009.01.161; Sun Q, 2008, NUCLEIC ACIDS RES, V36, P2690, DOI 10.1093/nar/gkn032; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Vardouli L, 2008, FEBS J, V275, P4074, DOI 10.1111/j.1742-4658.2008.06549.x; Vasilaki E, 2010, FASEB J, V24, P891, DOI 10.1096/fj.09-134742; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang Q, 2008, BLOOD, V111, P588, DOI 10.1182/blood-2007-05-092718; Xie L, 2011, CLIN BIOCHEM, V44, P216, DOI 10.1016/j.clinbiochem.2010.11.002; Zaidi SK, 2009, CANCER RES, V69, P8249, DOI 10.1158/0008-5472.CAN-09-1567; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	44	78	80	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2862	2875		10.1038/onc.2011.457	http://dx.doi.org/10.1038/onc.2011.457			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986943				2022-12-28	WOS:000305277900006
J	Zhang, X; Chen, X; Lin, J; Lwin, T; Wright, G; Moscinski, LC; Dalton, WS; Seto, E; Wright, K; Sotomayor, E; Tao, J				Zhang, X.; Chen, X.; Lin, J.; Lwin, T.; Wright, G.; Moscinski, L. C.; Dalton, W. S.; Seto, E.; Wright, K.; Sotomayor, E.; Tao, J.			Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas	ONCOGENE			English	Article						Myc; miR15a/miR-16-1; lymphoma	C-MYC; HISTONE DEACETYLASE; MICRORNA EXPRESSION; BURKITT-LYMPHOMA; DOWN-REGULATION; LUNG-CANCER; MIR-15A; OVEREXPRESSION; MALIGNANCIES; ACTIVATION	Our recent study demonstrated miR-15a/16-1 down-regulation in mantle cell lymphoma (MCL). Here, we investigated mechanisms of miR-15a/16-1 transcriptional repression and its epigenetic regulation by c-Myc and histone deacetylase (HDAC) in MCL. c-Myc expression was detected in MCL cell lines and in the primary MCL samples, and pri-miR-15a/16-1 mRNAs were significantly upregulated in Mino and Jeko-1 cells with c-Myc knockdown by small interfering RNAs (siRNAs). Our co-immunoprecipitation analysis showed that c-Myc interacted with HDAC3. Moreover, using chromatin immunoprecipitation, we demonstrated that both c-Myc and HDAC3 co-localized to the two promoters of the miR-15a/16-1 cluster gene, DLEU2, and inhibition of HDAC3 increased histone acetylation of the DLEU2 promoters. Luciferase reporter assay confirmed the dependence of Myc-mediated DLEU2 transcriptional repression on HDAC3. Treatment with the pan-HDAC inhibitor, suberoylanilide hydroxamic acid and HDAC3 siRNA resulted in increased miR-15a/16-1 expression. The regulatory mechanism of miR-15a/16-1 was further demonstrated in Burkitt lymphoma and Myc over-expressing cell lines. These findings highlight the role of HDAC3 in Myc-induced miR-15a/16-1 changes and reveal novel mechanisms for c-Myc-driven microRNA suppression and malignant transformation in aggressive B-cell malignancies.	[Zhang, X.; Chen, X.; Lin, J.; Lwin, T.; Wright, G.; Moscinski, L. C.; Dalton, W. S.; Seto, E.; Wright, K.; Sotomayor, E.; Tao, J.] Univ S Florida, Dept Malignant Hematol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol & Expt Therapeut Program, Tampa, FL 33613 USA; [Zhang, X.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Tianjin Medical University	Tao, J (corresponding author), Univ S Florida, Dept Malignant Hematol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol & Expt Therapeut Program, MCC LAB 2071,12902 Magnolia Dr, Tampa, FL 33613 USA.	Jianguo.Tao@moffitt.org	Wright, George W/M-1660-2017		National Cancer Institutes [R01 CA137123]; Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA137123, R01CA134807] Funding Source: NIH RePORTER	National Cancer Institutes(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the Tissue Procurement, Molecular Core Laboratory and Flow Cytometry Core Facilities at H Lee Moffitt Cancer Center for providing specimens and molecular analysis. We thank Rasa Hamilton for editorial assistance. This work was supported by grants from the National Cancer Institutes (R01 CA137123, to JT), Maher Fund (to JT) and Moffitt Cancer Center Foundation (to JT).	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Davidson-Moncada J, 2010, ANN NY ACAD SCI, V1183, P183, DOI 10.1111/j.1749-6632.2009.05121.x; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Han L, 2007, CANCER BIOL THER, V6, P1284; Hartmann E, 2008, J CLIN ONCOL, V26, P4966, DOI 10.1200/JCO.2007.12.0410; Hernandez L, 1999, LEUKEMIA, V13, P2087, DOI 10.1038/sj.leu.2401599; Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552; Lee EM, 2009, INT J MOL MED, V24, P45, DOI 10.3892/ijmm_00000204; Lerner M, 2009, EXP CELL RES, V315, P2941, DOI 10.1016/j.yexcr.2009.07.001; Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Robertus JL, 2010, BRIT J HAEMATOL, V149, P896, DOI 10.1111/j.1365-2141.2010.08111.x; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Sotillo E, 2011, ONCOGENE, V30, P2587, DOI 10.1038/onc.2010.634; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147	29	128	132	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					3002	3008		10.1038/onc.2011.470	http://dx.doi.org/10.1038/onc.2011.470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22002311	Green Accepted			2022-12-28	WOS:000305388400009
J	Feng, H; Liu, KW; Guo, P; Zhang, P; Cheng, T; McNiven, MA; Johnson, GR; Hu, B; Cheng, SY				Feng, H.; Liu, K. W.; Guo, P.; Zhang, P.; Cheng, T.; McNiven, M. A.; Johnson, G. R.; Hu, B.; Cheng, S. Y.			Dynamin 2 mediates PDGFR alpha-SHP-2-promoted glioblastoma growth and invasion	ONCOGENE			English	Article						Dyn2; PDGFR alpha; SHP-2; Src; glioma tumor growth; invasion	TYROSINE-PHOSPHATASE SHP-2; CELL-MIGRATION; MALIGNANT GLIOMAS; ACTIVATION; SRC; PHOSPHORYLATION; FAMILY; CYTOSKELETON; PROTEINS; BINDING	Dynamin 2 (Dyn2), a large GTPase, is involved in receptor tyrosine kinase (RTK)-promoted cell migration. However, the molecular mechanisms by which Dyn2 regulates RTK-induced cell migration have not been established. Recently, we reported that tyrosine-protein phosphatase non-receptor type 11 (SHP-2) and phosphatidylinositol 3-kinase (PI3K) mediate platelet-derived growth factor receptor-alpha (PDGFR alpha)-promoted glioma tumor growth and invasion. Here, we show that Dyn2 is an effector downstream of the PDGFR alpha-PI3K/SHP-2 signaling in glioma cells. Depletion of endogenous Dyn2 by short hairpin RNAs (shRNAs) inhibited PDGFR alpha-stimulated phosphorylation of Akt, Erk1/2, Rac1 and Cdc42 activities, glioma cell migration and survival in vitro and tumor growth and invasion in the brains of mice. Dyn2 binds to SHP-2 and PI3K and colocalizes with PDGFR alpha at the invasive fronts in PDGF-A-stimulated glioma cells. Inhibition of SHP-2 by siRNA knockdown abrogated Dyn2 association with activated PDGFR alpha and PDGFR alpha activation of Rac1 and Cdc42, and glioma cell migration, thereby establishing a link between SHP-2 interaction with Dyn2 and the PDGFR alpha signaling. Furthermore, a dominant-negative SHP-2 C459S mutant inhibited PDGF-A-stimulated glioma cell migration, phosphorylation of Dyn2 and concomitantly blocked PDGFR alpha-induced Src activation. Inhibition of Src by Src inhibitors attenuated PDGF-A-stimulated phosphorylation of Akt and Dyn2 and glioma cell migration. Additionally, mutations of binding sites to PI3K, SHP-2 or Src of PDGFR alpha impaired PDGFR alpha-stimulated phosphorylation of Akt and Dyn2, and Dyn2 association with activated PDGFR alpha. Taken together, this study identifies Dyn2 as an effector that mediates PDGFR alpha-SHP-2-induced glioma tumor growth and invasion, suggesting that targeting the PDGFR alpha-SHP-2-Dyn2 pathway may be beneficial to patients with malignant glioblastomas. Oncogene (2012) 31, 2691-2702; doi:10.1038/onc.2011.436; published online 26 September 2011	[Hu, B.] Univ Pittsburgh, Dept Med, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Feng, H.; Liu, K. W.; Guo, P.; Cheng, S. Y.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Guo, P.] Childrens Hosp, Div Pediat Gen & Thorac Surg, Pittsburgh, PA 15213 USA; [Zhang, P.; Cheng, T.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; [Cheng, T.] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin, Peoples R China; [Cheng, T.] Chinese Acad Med Sci, Blood Dis Hosp, Ctr Stem Cell Med, Tianjin, Peoples R China; [Cheng, T.] Peking Union Med Coll, Tianjin, Peoples R China; [McNiven, M. A.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [McNiven, M. A.] Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN USA; [Johnson, G. R.] US FDA, Chem Lab, Div Therapeut Prot, Bethesda, MD 20014 USA; [Johnson, G. R.] US FDA, Ctr Drug Evaluat & Res, Bethesda, MD 20014 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Mayo Clinic; Mayo Clinic; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Hu, B (corresponding author), Univ Pittsburgh, Dept Med, Inst Canc, Hillman Canc Ctr, Suite 2-26,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	hub@upmc.edu; chengs@upmc.edu	Zhang, Peng/B-6898-2014; Feng, Haizhong/E-5795-2017; Liu, Kun-Wei/A-9370-2013	Zhang, Peng/0000-0001-5574-0899; Feng, Haizhong/0000-0003-3552-6865; 	ACS (RSG) [CSM-107144]; NIH [CA130966]; Pennsylvania Department of Health; Hillman Foundation; James S McDonnell Foundation; NATIONAL CANCER INSTITUTE [R01CA130966, R01CA104125] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER	ACS (RSG)(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; Hillman Foundation; James S McDonnell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Y Zhou and E Van Meir for providing glioma cell lines and Dr H Damke and L Vance for proofreading of this manuscript. This work was supported in part by a grant from ACS (RSG CSM-107144), grants from NIH (CA130966), a grant with the Pennsylvania Department of Health, and Innovative Research Scholar Awards of the Hillman Foundation to SY Cheng and B Hu, and a James S McDonnell Foundation Researching Award in Brain Cancer to B Hu.	Baldassarre M, 2003, MOL BIOL CELL, V14, P1074, DOI 10.1091/mbc.E02-05-0308; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Calzolari F, 2010, BRAIN PATHOL, V20, P527, DOI 10.1111/j.1750-3639.2009.00335.x; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cao H, 2010, MOL CELL BIOL, V30, P781, DOI 10.1128/MCB.00330-09; Carver KC, 2010, J BIOL CHEM, V285, P8003, DOI 10.1074/jbc.M109.066480; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Coyne CB, 2007, EMBO J, V26, P4016, DOI 10.1038/sj.emboj.7601831; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Haberler C, 2006, J NEURO-ONCOL, V76, P105, DOI 10.1007/s11060-005-4570-9; Imanishi Y, 2007, CANCER RES, V67, P4254; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Joshi S, 2010, MOL CANCER THER, V9, P1995, DOI 10.1158/1535-7163.MCT-10-0161; Kawada K, 2009, MOL CELL BIOL, V29, P4508, DOI 10.1128/MCB.00015-09; Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586; Kruchten AE, 2006, J CELL SCI, V119, P1683, DOI 10.1242/jcs.02963; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Liu KW, 2011, J CLIN INVEST, V121, P905, DOI 10.1172/JCI43690; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mitola S, 2006, CIRC RES, V98, P45, DOI 10.1161/01.RES.0000199355.32422.7b; Navis AC, 2010, ACTA NEUROPATHOL, V119, P157, DOI 10.1007/s00401-009-0614-0; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Weller SG, 2010, P NATL ACAD SCI USA, V107, P5863, DOI 10.1073/pnas.0915123107; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	42	58	58	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2691	2702		10.1038/onc.2011.436	http://dx.doi.org/10.1038/onc.2011.436			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21996738	Green Accepted, Green Submitted			2022-12-28	WOS:000304523500008
J	Wang, J; Anderson, PD; Luo, W; Gius, D; Roh, M; Abdulkadir, SA				Wang, J.; Anderson, P. D.; Luo, W.; Gius, D.; Roh, M.; Abdulkadir, S. A.			Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells	ONCOGENE			English	Article						Pim1 kinase; MYC; gene expression; Erk; tumorigenicity	C-MYC; TUMOR-GROWTH; MICE; PHOSPHORYLATION; INHIBITION; CARCINOMA; APOPTOSIS; PROTEIN	PIM1 kinase and MYC are commonly co-expressed in human prostate cancer and synergize to induce rapidly progressing prostate cancer in mouse models. Deficiency of the Pim kinase genes is well tolerated in vivo, suggesting that PIM1 inhibition might offer an attractive therapeutic modality for prostate cancer, particularly for MYC-expressing tumors. Here we examine the molecular consequences of Pim1 and MYC overexpression in the prostate as well as the effects of depleting Pim1 in prostate carcinoma cells with high levels of MYC. Overexpression of Pim1 in the mouse prostate induces several pro-tumorigenic genetic programs including cell cycle genes and Myc regulated genes before the induction of any discernible pathology. Pim1 depletion by RNA interference in mouse and human prostate cancer cells decreased cellular proliferation, survival, Erk signaling and tumorigenicity even when MYC levels were not significantly altered. These results indicate that PIM1 may be necessary to maintain tumorigenicity, and further support efforts aimed at developing PIM1 inhibitors for prostate cancer therapy. Oncogene (2012) 31, 1794-1803; doi: 10.1038/onc.2011.371; published online 22 August 2011	[Anderson, P. D.; Roh, M.; Abdulkadir, S. A.] Vanderbilt Univ, Dept Pathol, Med Ctr, Nashville, TN 37232 USA; [Wang, J.; Gius, D.; Abdulkadir, S. A.] Vanderbilt Univ, Dept Canc Biol, Med Ctr, Nashville, TN 37232 USA; [Luo, W.] Vanderbilt Univ, Dept Cell & Dev Biol, Med Ctr, Nashville, TN 37232 USA; [Gius, D.] Vanderbilt Univ, Dept Pediat, Med Ctr, Nashville, TN 37232 USA; [Gius, D.] Vanderbilt Univ, Dept Radiat Oncol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Dept Pathol, Med Ctr, B33321A MCN, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu			NCI [RO1CA123484, R01CA152601]; DOD [BC093803]; NATIONAL CANCER INSTITUTE [R01CA123484, R01CA152601] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert Matusik, Simon Hayward, Vito Quaranta, Xiuping Yu and Fritz Parl for helpful discussions. Micrographs were taken from Cell Imaging Core at Vanderbilt University Medical Center. This work was supported by Grant RO1CA123484 from the NCI to SAA. while DG is supported by R01CA152601 from the NCI and BC093803 from the DOD.	Abdulkadir SA, 2000, HUM PATHOL, V31, P443, DOI 10.1053/hp.2000.6547; Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Berns A, 1999, CANCER RES, V59, p1773S; Burton GR, 2004, GENE, V329, P167, DOI 10.1016/j.gene.2003.12.012; Chen J, 2009, AM J PATHOL, V175, P400, DOI 10.2353/ajpath.2009.080972; Chen LS, 2009, BLOOD, V114, P4150, DOI 10.1182/blood-2009-03-212852; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Grundler R, 2009, J EXP MED, V206, P1957, DOI 10.1084/jem.20082074; Gu JJ, 2009, ONCOGENE, V28, P4261, DOI 10.1038/onc.2009.276; Hu XF, 2009, J CLIN INVEST, V119, P362, DOI 10.1172/JCI33216; Jager J, 2010, DIABETES, V59, P61, DOI 10.2337/db09-0470; Kim J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-248; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leiblich A, 2007, PROSTATE, V67, P1761, DOI 10.1002/pros.20654; Magnuson NS, 2010, FUTURE ONCOL, V6, P1461, DOI 10.2217/FON.10.106; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Mumenthaler SM, 2009, MOL CANCER THER, V8, P2882, DOI 10.1158/1535-7163.MCT-09-0293; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Roh M, 2003, CANCER RES, V63, P8079; Shah N, 2008, EUR J CANCER, V44, P2144, DOI 10.1016/j.ejca.2008.06.044; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang J, 2010, ONCOGENE, V29, P2477, DOI 10.1038/onc.2010.10; Zhang Y, 2008, ONCOGENE, V27, P4809, DOI 10.1038/onc.2008.123; Zippo A, 2007, NAT CELL BIOL, V9, P932, DOI 10.1038/ncb1618	31	54	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1794	1803		10.1038/onc.2011.371	http://dx.doi.org/10.1038/onc.2011.371			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860423	Green Accepted			2022-12-28	WOS:000302785200005
J	Tognon, CE; Martin, MJ; Moradian, A; Trigo, G; Rotblat, B; Cheng, SWG; Pollard, M; Uy, E; Chow, C; Carboni, JM; Gottardis, MM; Pollak, M; Morin, GB; Sorensen, PHB				Tognon, C. E.; Martin, M. J.; Moradian, A.; Trigo, G.; Rotblat, B.; Cheng, S-W G.; Pollard, M.; Uy, E.; Chow, C.; Carboni, J. M.; Gottardis, M. M.; Pollak, M.; Morin, G. B.; Sorensen, P. H. B.			A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation	ONCOGENE			English	Article						ETV6-NTRK3; insulin-like growth factor 1 receptor (IGF1R); insulin receptor substrate 1 (IRS1); BMS-536924; chimeric tyrosine kinase	FACTOR-I RECEPTOR; PROTEIN-TYROSINE KINASE; GENE FUSION; CONGENITAL FIBROSARCOMA; MESOBLASTIC NEPHROMA; INSULIN; CELLS; SUBSTRATE-1; CARCINOMA; DOMAINS	ETV6-NTRK3 (EN), a chimeric tyrosine kinase generated by t(12; 15) translocations, is a dominantly acting oncoprotein in diverse tumor types. We previously showed that insulin-like growth factor 1 receptor (IGF1R) is essential for EN-mediated oncogenesis and that insulin receptor substrate 1 (IRS1) is constitutively tyrosine phosphorylated and bound by EN in transformed cells. Given that IRS1 is also an adapter for IGF1R, we hypothesized that IRS1 might localize EN to IGF1R at the membrane to activate phosphatidylinositol 3-kinase (PI3K)-Akt, which is critical for EN oncogenesis. In this study, we examined EN/IRS1/IGF1R complexes in detail. We find that both IRS1 and kinase active IGF1R are required for EN transformation, that tyrosine phosphorylated IRS1 is present in high molecular weight complexes with EN and IGF1R, and that EN colocalizes with IGF1R at the plasma membrane. Both IGF1R kinase activity and an intact cytoplasmic Y950 residue, the IRS1-docking site of IGF1R, are required, confirming the importance of the IGF1R/IRS1 interaction for EN oncogenesis. The dual specificity IGF1R and insulin receptor (INSR) inhibitor, BMS-536924, blocks EN transformation activity, cell survival and its interaction with IRS proteins, and induces a striking shift of EN proteins to smaller sized molecular complexes. We conclude that a tripartite complex of EN, IRS1 and IGF1R localizes EN to the membrane and that this is essential for EN-mediated transformation. These findings provide an explanation for the observed IGF1R dependency of EN transformation. Blocking IGF1R kinase activity may, therefore, provide a tractable therapeutic strategy for the many tumor types driven by the EN oncoprotein. Oncogene (2012) 31, 1334-1340; doi: 10.1038/onc.2011.323; published online 1 August 2011	[Tognon, C. E.; Martin, M. J.; Trigo, G.; Rotblat, B.; Pollard, M.; Uy, E.; Chow, C.; Sorensen, P. H. B.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Moradian, A.; Cheng, S-W G.; Morin, G. B.] BC Canc Res Ctr, Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada; [Carboni, J. M.; Gottardis, M. M.] Bristol Myers Squibb Co, Oncol Drug Discovery, Princeton, NJ USA; [Pollak, M.] McGill Univ, Jewish Gen Hosp, SMBD, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Morin, G. B.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; Bristol-Myers Squibb; Lady Davis Institute; McGill University; University of British Columbia	Sorensen, PHB (corresponding author), BC Canc Res Ctr, Dept Mol Oncol, 675 W10th Ave, Vancouver, BC V5Z 1L3, Canada.	psor@interchange.ubc.ca	Morin, Gregg B/E-9123-2012; Pollak, Michael/G-9094-2011; Rotblat, Barak/H-5970-2019	Morin, Gregg B/0000-0001-8949-4374; Pollak, Michael/0000-0003-3047-0604; Rotblat, Barak/0000-0003-2985-7115; , Matthew/0000-0002-8948-961X	ReThink Breast Cancer Career Development Award; Canadian Institutes of Health Research (CIHR); British Columbia Cancer Foundation	ReThink Breast Cancer Career Development Award; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); British Columbia Cancer Foundation	This work was supported by the following grants: a ReThink Breast Cancer Career Development Award to CET, a Canadian Institutes of Health Research (CIHR) Graduate Studentship to MJM, a CIHR grant to PHBS, and funds from the British Columbia Cancer Foundation through donations to PHBS from Team Finn and other generous riders in the Ride to Conquer Cancer. We thank Adrian Wan and Darren Saunders for assistance with the BiFC cloning.	Argani P, 2000, MODERN PATHOL, V13, P29, DOI 10.1038/modpathol.3880006; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Forghieri F, 2011, EUR J HAEMATOL, V86, P352, DOI 10.1111/j.1600-0609.2011.01576.x; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kazakov DV, 2010, AM J SURG PATHOL, V34, P1226, DOI 10.1097/PAS.0b013e3181e4f49d; Kerppola TK, 2009, CHEM SOC REV, V38, P2876, DOI 10.1039/b909638h; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Lannon CL, 2004, J BIOL CHEM, V279, P6225, DOI 10.1074/jbc.M307388200; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; Morrison KB, 2002, ONCOGENE, V21, P5684, DOI 10.1038/sj.onc.1205669; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Sun HZ, 2004, ENDOCRINOLOGY, V145, P5332, DOI 10.1210/en.2004-0668; Tognon C, 2001, CANCER RES, V61, P8909; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 2004, MOL CELL BIOL, V24, P4636, DOI 10.1128/MCB.24.11.4636-4650.2004; Tognon CE, 2011, CANCER RES, V71, P1060, DOI 10.1158/0008-5472.CAN-10-3096; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wittman M, 2005, J MED CHEM, V48, P5639, DOI 10.1021/jm050392q	23	15	16	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1334	1340		10.1038/onc.2011.323	http://dx.doi.org/10.1038/onc.2011.323			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804605				2022-12-28	WOS:000301344600012
J	Spiegel, S; Milstien, S; Grant, S				Spiegel, S.; Milstien, S.; Grant, S.			Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy	ONCOGENE			English	Review						histone deacetylase; histone deacetylase inhibitor; apoptosis; sphingosine-1-phosphate; cancer	NF-KAPPA-B; HUMAN LEUKEMIA-CELLS; SUBEROYLANILIDE HYDROXAMIC ACID; SYNERGISTICALLY INDUCES APOPTOSIS; DNA-DAMAGE; MULTIPLE-MYELOMA; HDAC INHIBITORS; MEDIATED PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; REVERSIBLE ACETYLATION	The class-I histone deacetylases (HDACs) HDAC1 and HDAC2 belong to a family of 11 zinc-dependent human HDACs and are overexpressed in many cancers. Inhibitors of these HDACs now in clinical trials show activity against several types of cancers. This review is focused on recent advances in both clinical and preclinical efforts to understand the basis for the actions of HDACis, with emphasis on implications for rational combinations with conventional or other targeted agents. We will address new perspectives on the molecular mechanisms by which HDACs act and how these actions relate to cancer. We will also review new evidence showing that HDACs are direct intracellular targets of the potent sphingolipid mediator S1P, the first identified endogenous nuclear regulator of these enzymes, linking sphingolipid metabolism in the nucleus to remodeling of chromatin and epigenetic regulation of gene expression. Understanding how endogenous molecules regulate HDAC activity in vivo may facilitate the search for safer and more effective anticancer drugs capable of interfering with HDAC functions in a highly specific manner. Oncogene (2012) 31, 537-551; doi:10.1038/onc.2011.267; published online 4 July 2011	[Spiegel, S.; Milstien, S.] Virginia Commonwealth Univ, Sch Med Richmond, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Grant, S.] Virginia Commonwealth Univ, Sch Med Richmond, Dept Med, Richmond, VA 23298 USA; [Spiegel, S.; Grant, S.] Virginia Commonwealth Univ, Sch Med Richmond, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu			Leukemia and Lymphoma Society of America [6181-10]; V Foundation; Multiple Myeloma Research Foundation;  [R01CA61774];  [R37GM043880];  [R01AI50094];  [1U19AI077435];  [RO1CA93738-05];  [CA100866];  [1P50CA142509];  [RC2CA148431];  [1P50CA130805];  [1R21CA137823]; NATIONAL CANCER INSTITUTE [RC2CA148431, R01CA093738, R01CA061774, P50CA142509, R01CA100866, P50CA130805, R21CA137823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094, U19AI077435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); V Foundation; Multiple Myeloma Research Foundation; ; ; ; ; ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We apologize to authors whose work has not been cited here owing to space limitations. This work was supported by R01CA61774 (SS) R37GM043880 (SS), R01AI50094 (SS), 1U19AI077435 (SS),), R01AI50094 (SS), 1U19AI077435 (SS), RO1CA93738-05 (SG), CA100866 (SG), 1P50CA142509 (SG), RC2CA148431 (SG), 1P50CA130805 (SG), 1R21CA137823, the Leukemia and Lymphoma Society of America 6181-10 (SG), the V Foundation and the Multiple Myeloma Research Foundation (SG).	Albi E, 2008, BIOCHEM J, V410, P381, DOI 10.1042/BJ20070758; Almenara J, 2002, LEUKEMIA, V16, P1331, DOI 10.1038/sj.leu.2402535; Badros A, 2009, CLIN CANCER RES, V15, P5250, DOI 10.1158/1078-0432.CCR-08-2850; Bali P, 2004, CLIN CANCER RES, V10, P4991, DOI 10.1158/1078-0432.CCR-04-0210; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Calao M, 2008, TRENDS BIOCHEM SCI, V33, P339, DOI 10.1016/j.tibs.2008.04.015; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Cerchietti LC, 2011, J CLIN INVE IN PRESS; Chang HH, 2009, ORAL ONCOL, V45, P610, DOI 10.1016/j.oraloncology.2008.08.011; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Chen S, 2009, MOL CELL BIOL, V29, P6149, DOI 10.1128/MCB.01481-08; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Dai CL, 2008, CANCER RES, V68, P7905, DOI 10.1158/0008-5472.CAN-08-0499; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Dai Y, 2008, CLIN CANCER RES, V14, P549, DOI 10.1158/1078-0432.CCR-07-1934; Dai Y, 2010, BRIT J HAEMATOL, V151, P70, DOI 10.1111/j.1365-2141.2010.08319.x; Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fiskus W, 2006, CLIN CANCER RES, V12, P5869, DOI 10.1158/1078-0432.CCR-06-0980; Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Gillespie S, 2006, APOPTOSIS, V11, P2251, DOI 10.1007/s10495-006-0283-6; Gloghini A, 2009, BRIT J HAEMATOL, V147, P515, DOI 10.1111/j.1365-2141.2009.07887.x; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619; Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Kachhap SK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011208; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kawada J, 2009, J BIOL CHEM, V284, P17102, DOI 10.1074/jbc.M809090200; Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107; Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lagger S, 2010, EMBO J, V29, P3992, DOI 10.1038/emboj.2010.264; Lahm A, 2007, P NATL ACAD SCI USA, V104, P17335, DOI 10.1073/pnas.0706487104; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011; Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309; Mandawat A, 2010, BLOOD, V116, P5306, DOI 10.1182/blood-2010-05-284414; Marchion DC, 2004, J CELL BIOCHEM, V92, P223, DOI 10.1002/jcb.20045; Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Miyake K, 2008, PANCREAS, V36, pE1, DOI 10.1097/MPA.0b013e31815f2c2a; Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001; Oehme I, 2009, EXPERT OPIN INV DRUG, V18, P1605, DOI 10.1517/14728220903241658; Osada H, 2004, INT J CANCER, V112, P26, DOI 10.1002/ijc.20395; Ozdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Park MA, 2010, CANCER RES, V70, P6313, DOI 10.1158/0008-5472.CAN-10-0999; Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540; Rahmani M, 2003, CANCER RES, V63, P8420; Rahmani M, 2005, CANCER RES, V65, P2422, DOI 10.1158/0008-5472.CAN-04-2440; Ray S, 2008, NUCLEIC ACIDS RES, V36, P4510, DOI 10.1093/nar/gkn419; Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106; Ropero S, 2006, NAT GENET, V38, P566, DOI 10.1038/ng1773; Rosato RR, 2008, MOL CANCER THER, V7, P3285, DOI 10.1158/1535-7163.MCT-08-0385; Rosato RR, 2010, J BIOL CHEM, V285, P10064, DOI 10.1074/jbc.M109.095208; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Rosato RR, 2003, CANCER RES, V63, P3637; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sakuma T, 2006, INT J ONCOL, V29, P117; Sankala HM, 2007, CANCER RES, V67, P10466, DOI 10.1158/0008-5472.CAN-07-2090; Schuler S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-80; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; Simboeck E, 2010, J BIOL CHEM, V285, P41062, DOI 10.1074/jbc.M110.184481; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113; Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Walker T, 2009, MOL PHARMACOL, V76, P342, DOI 10.1124/mol.109.056523; Walkinshaw DR, 2008, J CELL BIOCHEM, V104, P1541, DOI 10.1002/jcb.21746; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wooten-Blanks LG, 2007, FASEB J, V21, P3386, DOI 10.1096/fj.07-8621com; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Yu CR, 2003, CANCER RES, V63, P2118; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zupkovitz G, 2010, MOL CELL BIOL, V30, P1171, DOI 10.1128/MCB.01500-09	123	102	109	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					537	551		10.1038/onc.2011.267	http://dx.doi.org/10.1038/onc.2011.267			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725353	Green Accepted			2022-12-28	WOS:000300221800001
J	Vasseur, S; Afzal, S; Tomasini, R; Guillaumond, F; Tardivel-Lacombe, J; Mak, TW; Iovanna, JL				Vasseur, S.; Afzal, S.; Tomasini, R.; Guillaumond, F.; Tardivel-Lacombe, J.; Mak, T. W.; Iovanna, J. L.			Consequences of DJ-1 upregulation following p53 loss and cell transformation	ONCOGENE			English	Article						DJ-1; p53; transformation; Akt; ROS	DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; ANTIOXIDANT FUNCTION; PROTEIN; APOPTOSIS; PATHWAY; IDENTIFICATION; INHIBITION; EXPRESSION; ONCOGENE	p53 is a tumor suppressor that responds to various stress signals by initiating cell-cycle arrest, senescence and apoptosis. Mutations of the p53 gene are found in over 50% of human tumors, highlighting the importance of p53 in tumor suppression. Numerous studies have reported on the interactions between p53, IGF-1-AKT and mTOR pathways as potentially explaining some of the tumor suppressive activities of p53. To further understand the basis of these interactions, we analyzed the involvement of DJ-1, an oncogene known to drive AKT-mediated cell survival, in the p53-AKT axis. In this study, we show that DJ-1 and p53 are tightly 'linked': p53 prevents the accumulation of DJ-1 protein, whereas loss of p53 leads to stabilization and enhancement of DJ-1 expression. Interestingly, this increase in DJ-1 level is only observed when p53 loss is accompanied by transformation of cells. Moreover, DJ-1 seems to be required for the enhanced activation of AKT observed in p53-deficient cells. Such observation confers a new property to DJ-1 associated to transforming-process to its oncogenic ability to drive AKT activation. We also show that DJ-1 is necessary for p53 activation following oxidative stress, suggesting the existence of a finely regulated loop between these two proteins in transformed cells. Finally, we demonstrate that in the absence of p53, DJ-1 is stabilized by ROS accumulation, and surprisingly seems to be required for this high intracellular ROS production. These data offer new insights into the regulation of DJ-1 and suggest that DJ-1 is a target of p53. Importantly, our study highlights that during transformation, DJ-1 is having a key role in the p53-regulated AKT pathway and p53-driven oxidative-stress response. Oncogene (2012) 31, 664-670; doi:10.1038/onc.2011.268; published online 4 July 2011	[Vasseur, S.; Afzal, S.; Mak, T. W.] Univ Hlth Network, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON M5G 2C1, Canada; [Vasseur, S.; Tomasini, R.; Guillaumond, F.; Tardivel-Lacombe, J.; Iovanna, J. L.] Inst Natl Sante & Rech Med, U624, F-13288 Marseille 9, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Institut National de la Sante et de la Recherche Medicale (Inserm)	Mak, TW (corresponding author), Univ Hlth Network, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON M5G 2C1, Canada.	tmak@uhnresearch.ca; juan.iovanna@inserm.fr	Guillaumond, Fabienne/E-8265-2017; Iovanna, Juan/M-9805-2017; tomasini, richard/F-1130-2017; vasseur, sophie/O-9803-2017	Guillaumond, Fabienne/0000-0001-7456-7315; Iovanna, Juan/0000-0003-1822-2237; tomasini, richard/0000-0003-0869-0811; vasseur, sophie/0000-0002-2339-8854	Institute National de la Sante et de la Recherche Medicale France; Fondation Sante, Sport et developpement durable; Canadian Institute of Health Research; 'Ligue Contre le Cancer', France; 'Institut National du Cancer (INCa)', France	Institute National de la Sante et de la Recherche Medicale France; Fondation Sante, Sport et developpement durable; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); 'Ligue Contre le Cancer', France; 'Institut National du Cancer (INCa)', France(Institut National du Cancer (INCA) France)	We thank P Spoto and K Sari for technical assistance. S Vasseur, R Tomasini, and J Tardivel-Lacombe were supported by Institute National de la Sante et de la Recherche Medicale France. F Guillaumond was supported by the 'Fondation Sante, Sport et developpement durable'. S Vasseur and S Afzal were supported by the Canadian Institute of Health Research. This work was also supported by grants from the 'Ligue Contre le Cancer', France and the 'Institut National du Cancer (INCa)', France.	Aleyasin H, 2010, P NATL ACAD SCI USA, V107, P3186, DOI 10.1073/pnas.0914876107; Cano CE, 2009, CANCER RES, V69, P219, DOI 10.1158/0008-5472.CAN-08-2320; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Fan J, 2008, FEBS LETT, V582, P1151, DOI 10.1016/j.febslet.2008.03.003; Feng ZH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001057; Giaime E, 2010, CELL DEATH DIFFER, V17, P158, DOI 10.1038/cdd.2009.116; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guzman JN, 2010, NATURE, V468, P696, DOI 10.1038/nature09536; Hao LY, 2010, P NATL ACAD SCI USA, V107, P9747, DOI 10.1073/pnas.0911175107; Hinkle DA, 2011, NEUROPATHOLOGY, V31, P29, DOI 10.1111/j.1440-1789.2010.01124.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kahle PJ, 2009, FREE RADICAL BIO MED, V47, P1354, DOI 10.1016/j.freeradbiomed.2009.08.003; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Marcondes AM, 2010, BLOOD, V115, P1993, DOI 10.1182/blood-2009-08-236992; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Nister M, 2005, ONCOGENE, V24, P3563, DOI 10.1038/sj.onc.1208354; Rahman-Roblick R, 2008, ONCOGENE, V27, P4854, DOI 10.1038/onc.2008.124; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Shenkman M, 2007, BIOCHEM J, V404, P509, DOI 10.1042/BJ20061854; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vasseur S, 2009, P NATL ACAD SCI USA, V106, P1111, DOI 10.1073/pnas.0812745106; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Waak J, 2009, J BIOL CHEM, V284, P14245, DOI 10.1074/jbc.M806902200; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; Zhan H, 2010, J BIOL CHEM, V285, P29662, DOI 10.1074/jbc.M110.125138	28	37	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					664	670		10.1038/onc.2011.268	http://dx.doi.org/10.1038/onc.2011.268			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725356				2022-12-28	WOS:000300221800012
J	Lee, MH; Na, H; Kim, EJ; Lee, HW; Lee, MO				Lee, M-H; Na, H.; Kim, E-J; Lee, H-W; Lee, M-O			Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1	ONCOGENE			English	Article						MTA1; p53; PARP-1; poly(ADP-ribose)ylation	DNA-DAMAGE RESPONSE; HEPATOCELLULAR-CARCINOMA; COVALENT POLY(ADP-RIBOSYL)ATION; UNMETHYLATED STATE; POLYMERASE PARP; EXPRESSION; BINDING; PROTEIN; METASTASIS; APOPTOSIS	The metastasis-associated protein 1 (MTA1) is overexpressed in various human cancers and is closely connected with aggressive phenotypes; however, little is known about the transcriptional regulation of the MTA1 gene. This study identified the MTA1 gene as a target of p53-mediated transrepression. The MTA1 promoter contains two putative p53 response elements (p53REs), which were repressed by the p53-inducing drug 5-fluorouracil (5-FU). Notably, 5-FU treatment decreased MTA1 expression only in p53 wild-type cells. p53 and histone deacetylases 1/2 were recruited, and acetylation of H3K9 was decreased on the promoter region including the p53REs after 5-FU treatment. Proteomics analysis of the p53 repressor complex, which was pulled down by the MTA1 promoter, revealed that the poly(ADP-ribose) polymerase 1 (PARP-1) was part of the complex. Interestingly, p53 was poly(ADP-ribose)ylated by PARP-1, and the p53-mediated transrepression of the MTA1 gene required poly(ADP-ribose)ylation of p53. In summary, we report a novel function for poly(ADP-ribose)ylation of p53 in the gene-specific regulation of the transcriptional mode of p53 on the promoter of MTA1. Oncogene (2012) 31, 5099-5107; doi:10.1038/onc.2012.2; published online 30 January 2012	[Lee, M-H; Na, H.; Kim, E-J; Lee, M-O] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Lee, M-H; Na, H.; Lee, M-O] Seoul Natl Univ, BioMAX Inst, Seoul 151742, South Korea; [Lee, H-W] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 120749, South Korea; [Lee, H-W] Yonsei Univ, Lab Anim Res Ctr, Seoul 120749, South Korea	Seoul National University (SNU); Seoul National University (SNU); Yonsei University; Yonsei University	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.	molee@snu.ac.kr	Na, Hyelin/K-7303-2016	Na, Hyelin/0000-0002-9118-5084	NRF [2009-0080757]; SRC/ERC [R11-2007-107-01001-0]	NRF; SRC/ERC(European Research Council (ERC))	This work was supported by grants from the NRF (2009-0080757), and the SRC/ERC (R11-2007-107-01001-0).	Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kai L, 2011, PROSTATE, V71, P268, DOI 10.1002/pros.21240; Kanai M, 2007, NAT CELL BIOL, V9, P1175, DOI 10.1038/ncb1638; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kumari SR, 1998, CANCER RES, V58, P5075; Lewis BC, 2005, MOL CELL BIOL, V25, P1228, DOI 10.1128/MCB.25.4.1228-1237.2005; Li DQ, 2010, J BIOL CHEM, V285, P19802, DOI 10.1074/jbc.M109.085258; Li DQ, 2010, J BIOL CHEM, V285, P10044, DOI 10.1074/jbc.M109.079095; Li DQ, 2009, J BIOL CHEM, V284, P34545, DOI 10.1074/jbc.M109.056499; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Mehrotra P, 2011, J BIOL CHEM, V286, P1767, DOI 10.1074/jbc.M110.157768; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Moon HE, 2006, ONCOL REP, V16, P929; Morton JP, 2008, AM J PATHOL, V172, P1081, DOI 10.2353/ajpath.2008.070778; Na TY, 2009, HEPATOLOGY, V49, P1122, DOI 10.1002/hep.22740; O'Shaughnessy J, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1007; Petty RD, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-434; Porta C, 2005, ONCOGENE, V24, P605, DOI 10.1038/sj.onc.1208204; Qian HL, 2005, CLIN EXP METASTAS, V22, P653, DOI 10.1007/s10585-006-9005-2; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Sung YH, 2010, CANCER RES, V70, P10454, DOI 10.1158/0008-5472.CAN-10-0031; Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wang B, 2009, P NATL ACAD SCI USA, V106, P14373, DOI 10.1073/pnas.0903284106; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zampieri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004717; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517	44	38	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5099	5107		10.1038/onc.2012.2	http://dx.doi.org/10.1038/onc.2012.2			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286760				2022-12-28	WOS:000312000900006
J	Kudo, K; Gavin, E; Das, S; Amable, L; Shevde, LA; Reed, E				Kudo, K.; Gavin, E.; Das, S.; Amable, L.; Shevde, L. A.; Reed, E.			Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair	ONCOGENE			English	Article						Gli1; ERCC1; XPD; XRCC1; cisplatin; ovarian cancer	MESSENGER-RNA LEVELS; NUCLEOTIDE EXCISION-REPAIR; HEDGEHOG PATHWAY; GENE-EXPRESSION; CANCER-CELLS; RESISTANCE; SURVIVAL; TRANSCRIPTION; EXPOSURE; TISSUES	The transcription of ERCC1 and other nucleotide excision repair (NER) genes is strongly influenced by c-jun. C-jun is transcriptionally regulated by Gli proteins of the Hedgehog pathway. We therefore studied the possible relationships between Gli1, c-jun, and the upregulation of ERCC1, XPD and XRCC1 in cisplatin-resistant human ovarian cancer cells. We studied the paired human ovarian cancer cell lines A2780 and A2780-CP70. We used a shRNA construct that specifically degrades Gli1 message. Genes we assessed for mRNA and/or protein levels included: c-jun, ERCC1, XPD, XRCC1, Gli1, Gli2, SHH, IHH, GAPDH and a-tubulin. Platinum-DNA adduct repair was assessed by atomic absorbance spectrometry with Zeeman background correction. Use of the anti-Gli1 shRNA in cisplatin-resistant cells resulted in a block of the cell's ability to upregulate genes in response to cisplatin treatment, including: c-jun, ERCC1, XPD and XRCC1. This block in upregulation of c-jun was concurrent with a change in the phosphorylation pattern of the c-jun protein, shifting that pattern from a Ser63/73 dominant pattern, to a Thr91/93 dominant pattern. A2780-CP70 cells were treated at their cisplatin IC50, and DNA repair was assessed after pretreatment with anti-Gli1 shRNA or scrambled shRNA control. Control cells repaired 78% of platinum-DNA adducts at 12 h, compared with 33% repair in cells pretreated with anti-Gli1 shRNA resulting in a 2.4-fold difference. Pretreatment of A2780-CP70 cells with anti-Gli1 shRNA resulted in supra-additive cell killing with cisplatin; shifting the cisplatin IC50 (half maximal inhibitory concentration) from 30 mu M to 5 mu M. Pretreatment of these cells with cyclopamine did not shift the cisplatin IC50. We conclude that the transcriptional protein Gli1 is important in the upregulation of these three DNA repair genes in human ovarian cancer cells, and that Gli1 strongly influences platinum-DNA adduct repair, and cellular sensitivity to cisplatin. This Gli1 role has c-jun as an intermediate in the pathway. In all, inhibition of Gli1 by a specific shRNA inhibits the upregulation of c-jun Ser63/73, and also inhibits the upregulation of three genes essential to NER (ERCC1, XPD) and base excision repair (XRCC1).	[Kudo, K.; Gavin, E.; Das, S.; Amable, L.; Shevde, L. A.; Reed, E.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA	University of South Alabama	Reed, E (corresponding author), Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.	eddiereed@usouthal.edu			Mitchell Cancer Institute, University of South Alabama, Mobile	Mitchell Cancer Institute, University of South Alabama, Mobile	This work was supported by funds from two endowments at the Mitchell Cancer Institute, University of South Alabama, Mobile: the Abraham Mitchell endowment, and the Point Clear Charities endowment.	Altaha R, 2004, INT J MOL MED, V14, P959; Bellmunt J, 2007, ANN ONCOL, V18, P522, DOI 10.1093/annonc/mdl435; Bhattacharya R, 2008, CLIN CANCER RES, V14, P7659, DOI 10.1158/1078-0432.CCR-08-1414; Bonovich M, 2002, CANCER GENE THER, V9, P62, DOI 10.1038/sj/cgt/7700409; Chang HH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-6; Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915; DABHOLKAR M, 1993, MUTAT RES, V293, P151, DOI 10.1016/0921-8777(93)90066-P; Dabholkar M, 2000, BIOCHEM PHARMACOL, V60, P1611, DOI 10.1016/S0006-2952(00)00448-2; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Dabholkar MD, 1996, MOL CARCINOGEN, V17, P1, DOI 10.1002/(SICI)1098-2744(199609)17:1<1::AID-MC1>3.0.CO;2-M; DABHOLKAR MD, 1995, CANCER RES, V55, P1261; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Desouza LA, 2011, ENDOCRINOLOGY, V152, P1989, DOI 10.1210/en.2010-1396; Kim MK, 2008, CLIN CANCER RES, V14, P4225, DOI 10.1158/1078-0432.CCR-07-4848; Kriyak TC, 2011, GYNECOL ONCOL, V122, P121, DOI 10.1016/j.ygyno.2011.03.027; Laner-Plamberger S, 2009, ONCOGENE, V28, P1639, DOI 10.1038/onc.2009.10; Li Q, 1999, CELL MOL LIFE SCI, V55, P456, DOI 10.1007/s000180050302; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; Li QD, 1999, BIOCHEM PHARMACOL, V57, P347, DOI 10.1016/S0006-2952(98)00291-3; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Mimnaugh EG, 2000, BIOCHEM PHARMACOL, V60, P1343, DOI 10.1016/S0006-2952(00)00455-X; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Raivich G, 2008, J NEUROCHEM, V107, P898, DOI 10.1111/j.1471-4159.2008.05684.x; Reed E, 2003, CLIN CANCER RES, V9, P5299; Reed E, 2005, CLIN CANCER RES, V11, P6100, DOI 10.1158/1078-0432.CCR-05-1083; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; REED E, 1988, ATOM SPECTROSC, V9, P93; Reed E, 1998, CYTOTECHNOLOGY, V27, P187, DOI 10.1023/A:1008016922425; Reed E, 2008, CANC PRINCIPLES PRAC, P419; REED E, 2006, CANC CHEMOTHERAPY BI, P332; Reed E, 2006, NEW ENGL J MED, V355, P1054, DOI 10.1056/NEJMe068162; Reed E, 2010, CLIN CANCER RES, V16, P4511, DOI 10.1158/1078-0432.CCR-10-0528; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Sugahara F, 2011, DEVELOPMENT, V138, P1217, DOI 10.1242/dev.059360; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Von Hoff DD, 2009, CANCER CELL, V16, P7, DOI 10.1016/j.ccr.2009.06.011; Wei J, 2008, BRIT J CANCER, V98, P1398, DOI 10.1038/sj.bjc.6604317; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Xu HL, 1998, PLANT J, V13, P823, DOI 10.1046/j.1365-313X.1998.00081.x; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689; Zhong XS, 2000, INT J ONCOL, V17, P375	48	48	52	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4718	4724		10.1038/onc.2011.610	http://dx.doi.org/10.1038/onc.2011.610			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266871				2022-12-28	WOS:000310724400007
J	Lago, CU; Nowinski, SM; Rundhaug, JE; Pfeiffer, ME; Kiguchi, K; Hirasaka, K; Yang, X; Abramson, EM; Bratton, SB; Rho, O; Colavitti, R; Kenaston, MA; Nikawa, T; Trempus, C; DiGiovanni, J; Fischer, SM; Mills, EM				Lago, C. U.; Nowinski, S. M.; Rundhaug, J. E.; Pfeiffer, M. E.; Kiguchi, K.; Hirasaka, K.; Yang, X.; Abramson, E. M.; Bratton, S. B.; Rho, O.; Colavitti, R.; Kenaston, M. A.; Nikawa, T.; Trempus, C.; DiGiovanni, J.; Fischer, S. M.; Mills, E. M.			Mitochondrial respiratory uncoupling promotes keratinocyte differentiation and blocks skin carcinogenesis	ONCOGENE			English	Article						mitochondria; uncoupling proteins; skin; carcinogenesis; differentiation	STEM-CELLS; HAIR FOLLICLE; SKELETAL-MUSCLE; CANCER; EXPRESSION; MUTATIONS; METABOLISM; ACTIVATION; INDUCTION; CARCINOMA	Decreased mitochondrial oxidative metabolism is a hallmark bioenergetic characteristic of malignancy that may have an adaptive role in carcinogenesis. By stimulating proton leak, mitochondrial uncoupling proteins (UCP1-3) increase mitochondrial respiration and may thereby oppose cancer development. To test this idea, we generated a mouse model that expresses an epidermal-targeted keratin-5-UCP3 (K5-UCP3) transgene and exhibits significantly increased cutaneous mitochondrial respiration compared with wild type (FVB/N). Remarkably, we observed that mitochondrial uncoupling drove keratinocyte/epidermal differentiation both in vitro and in vivo. This increase in epidermal differentiation corresponded to the loss of markers of the quiescent bulge stem cell population, and an increase in epidermal turnover measured using a bromodeoxyuridine (BrdU)-based transit assay. Interestingly, these changes in K5-UCP3 skin were associated with a nearly complete resistance to chemically-mediated multistage skin carcinogenesis. These data suggest that targeting mitochondrial respiration is a promising novel avenue for cancer prevention and treatment.	[Lago, C. U.; Abramson, E. M.; Bratton, S. B.; Mills, E. M.] Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Lago, C. U.] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA; [Rundhaug, J. E.; Fischer, S. M.] Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX USA; [Yang, X.] Fudan Univ, Shanghai 200433, Peoples R China; [Colavitti, R.] Stanford Univ, Div Radiat & Canc Biol, Stanford, CA 94305 USA; [Nikawa, T.] Univ Tokushima, Inst Hlth Biosci, Dept Nutr Physiol, Tokushima 770, Japan; [Trempus, C.] NIEHS, Matrix Biol Grp, Lab Resp Biol, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Austin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Texas System; UTMD Anderson Cancer Center; Fudan University; Stanford University; Tokushima University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Mills, EM (corresponding author), Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	ted_mills@mail.utexas.edu	Hirasaka, Katsuya/AAJ-7371-2021; Hirasaka, Katsuya/J-5283-2019; Rundhaug, Joyce E/E-9114-2011	Hirasaka, Katsuya/0000-0003-2645-8450; Rundhaug, Joyce E/0000-0002-2481-6317; Nowinski, Sara/0000-0002-4744-6101; Bratton, Shawn/0000-0003-2895-5020	National Institutes of Health [DK089224, T32ES07247]; Grants-in-Aid for Scientific Research [24700753] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [R01CA129521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK089224, R56DK089224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007247] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	EMM was supported by the National Institutes of Health grant # DK089224. SMN was supported by the National Institutes of Health Toxicology Training grant T32ES07247.	Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Derdak Z, 2006, CARCINOGENESIS, V27, P956, DOI 10.1093/carcin/bgi335; Derdak Z, 2008, CANCER RES, V68, P2813, DOI 10.1158/0008-5472.CAN-08-0053; Faurschou A, 2007, EXP DERMATOL, V16, P485, DOI 10.1111/j.1600-0625.2007.00551.x; Gates AC, 2007, CELL METAB, V6, P497, DOI 10.1016/j.cmet.2007.10.010; Guigal N, 2002, J BIOL CHEM, V277, P47407, DOI 10.1074/jbc.M208048200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; MacAskill AF, 2010, EUR J NEUROSCI, V32, P231, DOI 10.1111/j.1460-9568.2010.07345.x; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mills EM, 2002, J BIOL CHEM, V277, P27385, DOI 10.1074/jbc.M111860200; Mori S, 2008, J INVEST DERMATOL, V128, P1894, DOI 10.1038/jid.2008.20; Morris RJ, 2000, CANCER RES, V60, P226; NICHOLLS DG, 1984, BIOCHEM SOC T, V12, P388, DOI 10.1042/bst0120388; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Oakes SA, 2007, P NATL ACAD SCI USA, V104, P15171, DOI 10.1073/pnas.0707798104; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.0.CO;2-3; Sayeed A, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.30; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shakya A, 2009, NAT CELL BIOL, V11, P320, DOI 10.1038/ncb1840; Tamiji S, 2005, J INVEST DERMATOL, V125, P647, DOI 10.1111/j.0022-202X.2005.23885.x; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu WY, 2004, METH MOL B, V289, P79; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	42	13	13	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4725	4731		10.1038/onc.2011.630	http://dx.doi.org/10.1038/onc.2011.630			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266853	Green Accepted			2022-12-28	WOS:000310724400008
J	Zeller, C; Dai, W; Steele, NL; Siddiq, A; Walley, AJ; Wilhelm-Benartzi, CSM; Rizzo, S; van der Zee, A; Plumb, JA; Brown, R				Zeller, C.; Dai, W.; Steele, N. L.; Siddiq, A.; Walley, A. J.; Wilhelm-Benartzi, C. S. M.; Rizzo, S.; van der Zee, A.; Plumb, J. A.; Brown, R.			Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling	ONCOGENE			English	Article						drug resistance; cisplatin; DNA methylation; ovarian cancer; DNMTi; HDACi	HISTONE DEACETYLASE INHIBITION; DRUG-RESISTANCE; CPG ISLANDS; MISMATCH REPAIR; CELL-LINES; GENES; CHEMOTHERAPY; DEMETHYLATION; PROMOTER; STEM	Multiple DNA methylation changes in the cancer methylome are associated with the acquisition of drug resistance; however it remains uncertain how many represent critical DNA methylation drivers of chemoresistance. Using isogenic, cisplatin-sensitive/resistant ovarian cancer cell lines and inducing resensitizaton with demethylating agents, we aimed to identify consistent methylation and expression changes associated with chemoresistance. Using genome-wide DNA methylation profiling across 27 578 CpG sites, we identified loci at 4092 genes becoming hypermethylated in chemoresistant A2780/cp70 compared with the parental-sensitive A2780 cell line. Hypermethylation at gene promoter regions is often associated with transcriptional silencing; however, expression of only 245 of these hypermethylated genes becomes downregulated in A2780/cp70 as measured by microarray expression profiling. Treatment of A2780/cp70 with the demethylating agent 2-deoxy-5'-azacytidine induces resensitization to cisplatin and re-expression of 41 of the downregulated genes. A total of 13/41 genes were consistently hypermethylated in further independent cisplatin-resistant A2780 cell derivatives. CpG sites at 9 of the 13 genes (ARHGDIB, ARMCX2, COL1A, FLNA, FLNC, MEST, MLH1, NTS and PSMB9) acquired methylation in ovarian tumours at relapse following chemotherapy or chemoresistant cell lines derived at the time of patient relapse. Furthermore, 5/13 genes (ARMCX2, COL1A1, MDK, MEST and MLH1) acquired methylation in drug-resistant ovarian cancer-sustaining (side population) cells. MLH1 has a direct role in conferring cisplatin sensitivity when reintroduced into cells in vitro. This combined genomics approach has identified further potential key drivers of chemoresistance whose expression is silenced by DNA methylation that should be further evaluated as clinical biomarkers of drug resistance. Oncogene (2012) 31, 4567-4576; doi:10.1038/onc.2011.611; published online 16 January 2012	[Zeller, C.; Dai, W.; Wilhelm-Benartzi, C. S. M.; Brown, R.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London W12 0NN, England; [Steele, N. L.] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Siddiq, A.; Walley, A. J.] Hammersmith Hosp, Sch Publ Hlth, Dept Genom Common Dis, London, England; [Rizzo, S.; Brown, R.] Inst Canc Res, Med Sect, Sutton, Surrey, England; [van der Zee, A.] Univ Groningen, Dept Obstet & Gynecol, Univ Med Ctr Groningen, Groningen, Netherlands; [Plumb, J. A.] Univ Glasgow, Inst Canc Sci, Canc Res UK Beatson Labs, Glasgow, Lanark, Scotland	Imperial College London; Beatson Oncology Centre; Imperial College London; University of London; Institute of Cancer Research - UK; University of Groningen; Beatson Institute; University of Glasgow	Brown, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, Hammersmith Campus,IRDB 4th Floor, London W12 0NN, England.	b.brown@imperial.ac.uk	Walley, Andrew J/D-2573-2009; Dai, Wei/T-8889-2019	Walley, Andrew J/0000-0001-7707-7549; Dai, Wei/0000-0002-5558-0685; Brown, Robert/0000-0001-7960-5755; Siddiq, Afshan/0000-0002-9110-1434; Wilhelm-Benartzi, Charlotte/0000-0003-4927-6158	Cancer Research UK [C536/A6689]; Imperial Experimental Cancer Medicine Centre; Imperial Biomedical Research Centre; Ovarian Cancer Action; Cancer Research UK [13086] Funding Source: researchfish; Ovarian Cancer Action [OCA3] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Imperial Experimental Cancer Medicine Centre; Imperial Biomedical Research Centre; Ovarian Cancer Action(Ovarian Cancer Action); Cancer Research UK(Cancer Research UK); Ovarian Cancer Action(Ovarian Cancer Action)	We thank Lisa McMillan for her valuable contribution to the initial analysis of the Affymetrix expression data. We also thank Nahal Masrour for preparation of samples and Kerra Pearce for running the Infinium HumanMethylation450 BeadChips at the UCL Genomics Center, London. This work was supported by a Cancer Research UK (CZ, WD and RB) grant (C536/A6689), Imperial Experimental Cancer Medicine Centre, Imperial Biomedical Research Centre and Ovarian Cancer Action (SR and CSMWB).	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Anthoney DA, 1996, CANCER RES, V56, P1374; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Broxterman HJ, 2009, DRUG RESIST UPDATE, V12, P114, DOI 10.1016/j.drup.2009.07.001; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427; Dai W, 2011, CLIN CANCER RES, V17, P4052, DOI 10.1158/1078-0432.CCR-10-3021; Dai W, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-337; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eckstein N, 2009, CANCER RES, V69, P2996, DOI 10.1158/0008-5472.CAN-08-3153; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jung H, 2011, BIOCHEM J, V436, P263, DOI 10.1042/BJ20101512; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; LANGDON SP, 1988, CANCER RES, V48, P6166; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183; Nakanishi H, 2004, ONCOL REP, V12, P1273; O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298; Ozols Robert F, 2004, J Natl Compr Canc Netw, V2 Suppl 2, pS60; Papouli E, 2004, CANCER RES, V64, P3391, DOI 10.1158/0008-5472.CAN-04-0513; Pedersen IS, 2002, HUM MOL GENET, V11, P1449, DOI 10.1093/hmg/11.12.1449; Peng CJ, 2011, INT J GYNECOL CANCER, V21, P280, DOI 10.1097/IGC.0b013e31820aaadb; Plumb JA, 2000, CANCER RES, V60, P6039; Rajasekhar Vinagolu K, 2008, Stem Cells, V26, P292; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Smith CA, 2005, DEV DYNAM, V233, P188, DOI 10.1002/dvdy.20309; Steele N, 2009, BRIT J CANCER, V100, P758, DOI 10.1038/sj.bjc.6604932; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yoshioka K, 2006, MOL CELL, V22, P501, DOI 10.1016/j.molcel.2006.04.023	50	188	193	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	42					4567	4576		10.1038/onc.2011.611	http://dx.doi.org/10.1038/onc.2011.611			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22249249	Green Submitted			2022-12-28	WOS:000309982100008
J	Zheng, B; Liang, L; Huang, S; Zha, R; Liu, L; Jia, D; Tian, Q; Wang, Q; Wang, C; Long, Z; Zhou, Y; Cao, X; Du, C; Shi, Y; He, X				Zheng, B.; Liang, L.; Huang, S.; Zha, R.; Liu, L.; Jia, D.; Tian, Q.; Wang, Q.; Wang, C.; Long, Z.; Zhou, Y.; Cao, X.; Du, C.; Shi, Y.; He, X.			MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers	ONCOGENE			English	Article						gastric cancer; metastasis; microRNA-409; radixin	PANCREATIC-CANCER; IDENTIFICATION; SPECIFICITY; EXPRESSION; CARCINOMA; MIGRATION; PROTEINS; MIR-31; GENES	Emerging evidence has shown that aberrantly expressed microRNAs (miRNAs) are highly associated with tumour development and progression. However, little is known about the potential role of miRNAs in gastric cancer (GC) metastasis. In this study, miR-409-3p was found to be downregulated frequently in human GCs, and its expression was significantly associated with tumor-node-metastasis (TNM) stage and lymph node metastasis. Enforced expression of miR-409 in GC cells significantly reduced their migration and invasion in vitro and their capacity to develop distal pulmonary metastases and peritoneal dissemination in vivo. Moreover, we found that miR-409 exerted its function predominantly through the mature miR-409-3p, but not miR-409-5p. Microarray and bioinformatics analysis identified the pro-metastatic gene radixin (RDX) as a potential miR-409-3p target. Further studies confirmed that miR-409-3p suppressed the expression of RDX by directly binding to its 3'-untranslated region. Silencing of RDX by small interfering RNAs phenocopied the effects of miR-409 overexpression, whereas restoration of RDX in miR-409-overexpressed GC cells reversed the suppressive effects of miR-409. Taken together, these results demonstrate that miR-409 suppresses GC cell invasion and metastasis by directly targeting RDX and that patients with downregulated miR-409-3p are prone to lymph node metastasis.	[Zheng, B.; Wang, Q.; Wang, C.; Long, Z.; Zhou, Y.; Cao, X.; Du, C.; Shi, Y.; He, X.] Fudan Univ, Shanghai Canc Ctr, Dept Gastr Canc & Soft Tissue Sarcomas, Shanghai 200032, Peoples R China; [Zheng, B.; Wang, Q.; Wang, C.; Long, Z.; Zhou, Y.; Cao, X.; Du, C.; Shi, Y.; He, X.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Liang, L.; Huang, S.; Zha, R.; Liu, L.; Jia, D.; Tian, Q.; He, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200030, Peoples R China	Fudan University; Fudan University; Shanghai Jiao Tong University	Shi, Y (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gastr Canc & Soft Tissue Sarcomas, Shanghai 200032, Peoples R China.	yingqiangshi@126.com; xhhe@shsci.org	Huang, Shenglin/N-9472-2018; Jia, Deshui/U-9732-2019; He, Xianghuo/I-1497-2014; liang, linhui/AAW-4176-2021	Huang, Shenglin/0000-0003-1279-0794; He, Xianghuo/0000-0001-8872-668X; Guo, Weijie/0000-0001-7167-9899				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Arpin M, 2011, CELL ADHES MIGR, V5, P199, DOI 10.4161/cam.5.2.15081; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cappetta A, 2012, CRIT REV ONCOL HEMAT, V81, P38, DOI 10.1016/j.critrevonc.2010.12.006; Chen ZL, 2011, J BIOL CHEM, V286, P10725, DOI 10.1074/jbc.M110.165654; Cui YZ, 2009, INT J CANCER, V124, P1614, DOI 10.1002/ijc.24163; Deng JY, 2010, J SURG RES, V161, P47, DOI 10.1016/j.jss.2008.12.019; Ding J, 2010, NAT CELL BIOL, V12, P390, DOI 10.1038/ncb2039; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hoeflich KP, 2004, INT J BIOCHEM CELL B, V36, P2131, DOI 10.1016/j.biocel.2003.11.018; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kanaan Z, 2010, GENET TEST MOL BIOMA, V14, P347, DOI 10.1089/gtmb.2009.0197; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li XH, 2011, J CELL MOL MED, V15, P1887, DOI 10.1111/j.1582-4934.2010.01194.x; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu GQ, 2005, J BIOL CHEM, V280, P39042, DOI 10.1074/jbc.M504341200; Ming OY, 2011, BIOCHIMIE, V93, P954, DOI 10.1016/j.biochi.2011.01.017; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Takei Y, 2011, CANCER RES, V71, P1442, DOI 10.1158/0008-5472.CAN-10-2530; Tie J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000879; Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Wang JB, 2010, CANCER LETT, V297, P137, DOI 10.1016/j.canlet.2010.07.018; Wu WKK, 2010, ONCOGENE, V29, P5761, DOI 10.1038/onc.2010.352; Yu HF, 2011, FRONT BIOSCI-LANDMRK, V16, P1536, DOI 10.2741/3803	40	102	110	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4509	4516		10.1038/onc.2011.581	http://dx.doi.org/10.1038/onc.2011.581			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22179828				2022-12-28	WOS:000309982100002
J	Martin, L; Rainey, M; Santocanale, C; Gardner, LB				Martin, L.; Rainey, M.; Santocanale, C.; Gardner, L. B.			Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation	ONCOGENE			English	Article						hypoxia; ATR; cdc6; DNA replication; APC/C-Cdh1	MINICHROMOSOME MAINTENANCE PROTEINS; INHIBITS REPLICON INITIATION; CELL-CYCLE; S-PHASE; PREREPLICATION COMPLEXES; CDC25A PHOSPHATASE; DAMAGE RESPONSE; INDUCED ARREST; CHECKPOINT; PHOSPHORYLATION	Many severely hypoxic cells fail to initiate DNA replication, but the mechanism underlying this observation is unknown. Specifically, although the ataxia-telangiectasia-rad3 related (ATR) kinase has been shown to be activated in hypoxic cells, several studies have not been able to document down-stream consequences of ATR activation in these cells. By clearly defining the DNA replication initiation checkpoint in hypoxic cells, we now demonstrate that ATR is responsible for activating this checkpoint. We show that the hypoxic activation of ATR leads to the phosphorylation-dependent degradation of the cdc25a phosphatase. Downregulation of cdc25a protein by ATR in hypoxic cells decreases CDK2 phosphorylation and activity, which results in the degradation of cdc6 by APC/C-Cdh1. These events do not occur in hypoxic cells when ATR is depleted, and the initiation of DNA replication is maintained. We therefore present a novel mechanism of cdc6 regulation in which ATR can have a central role in inhibiting the initiation of DNA replication by the regulation of cdc6 by APC/C-Cdh1. This model provides insight into the biology and therapy of hypoxic tumors. Oncogene (2012) 31, 4076-4084; doi: 10.1038/onc.2011.585; published online 19 December 2011	[Gardner, L. B.] NYU, Sch Med, NYU Canc Inst, Div Hematol & Med Oncol,Dept Pharmacol, New York, NY 10016 USA; [Martin, L.; Gardner, L. B.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Rainey, M.; Santocanale, C.] NUI Galway, Ctr Chromosome Biol, Galway, Ireland	New York University; New York University; Ollscoil na Gaillimhe-University of Galway	Gardner, LB (corresponding author), NYU, Sch Med, NYU Canc Inst, Div Hematol & Med Oncol,Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.	Lawrence.gardner@nyumc.org		Santocanale, Corrado/0000-0003-1337-5656; Gardner, Lawrence/0000-0003-0191-0172; Rainey, Michael/0000-0001-9777-873X	Feldstein Foundation;  [DK08164]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081641] Funding Source: NIH RePORTER	Feldstein Foundation; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We appreciate the kind gifts of reagents from John Dillfey and Stephen Elledge. Luca Busino, Michele Pagano, Vincenzo D'Angiolella provided reagents and helpful advice. This work was supported in part by DK08164 and the Feldstein Foundation. LBG is the Saul J Farber Assistant Professor of Medicine.	Benmaamar R, 2005, CELL CYCLE, V4, P1230, DOI 10.4161/cc.4.9.2048; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Brown EJ, 2000, GENE DEV, V14, P397; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; de Oliveira PEQ, 2009, CELL CYCLE, V8, P3157; Gardner LB, 2008, CELL CYCLE, V7, P1916, DOI 10.4161/cc.7.13.6203; Gardner LB, 2003, MOL CELL BIOL, V23, P9032, DOI 10.1128/MCB.23.24.9032-9045.2003; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Green SL, 2001, MOL CELL BIOL, V21, P1196, DOI 10.1128/MCB.21.4.1196-1206.2001; Green SL, 1998, CANCER J SCI AM, V4, P218; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Hammer S, 2007, CELL CYCLE, V6, P1919, DOI 10.4161/cc.6.15.4515; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2004, CANCER RES, V64, P6556, DOI 10.1158/0008-5472.CAN-04-1520; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Heffernan TP, 2007, J BIOL CHEM, V282, P9458, DOI 10.1074/jbc.M611292200; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; KAUFMANN WK, 1980, BIOCHIM BIOPHYS ACTA, V608, P191, DOI 10.1016/0005-2787(80)90147-1; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Martin L, 2010, J BIOL CHEM, V285, P31944, DOI 10.1074/jbc.M110.153148; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Olcina M, 2010, CLIN CANCER RES, V16, P5624, DOI 10.1158/1078-0432.CCR-10-0286; Olive PL, 2002, RADIAT RES, V158, P159, DOI 10.1667/0033-7587(2002)158[0159:TROOIS]2.0.CO;2; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Sivaprasad U, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-8; Sotillo E, 2009, J BIOL CHEM, V284, P14126, DOI 10.1074/jbc.M900687200; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; VAUPEL P, 1991, CANCER RES, V51, P3316; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	47	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4076	4084		10.1038/onc.2011.585	http://dx.doi.org/10.1038/onc.2011.585			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22179839	Green Accepted			2022-12-28	WOS:000308688800008
J	Balli, D; Ren, X; Chou, FS; Cross, E; Zhang, Y; Kalinichenko, VV; Kalin, TV				Balli, D.; Ren, X.; Chou, F-S; Cross, E.; Zhang, Y.; Kalinichenko, V. V.; Kalin, T. V.			Foxm1 transcription factor is required for macrophage migration during lung inflammation and tumor formation	ONCOGENE			English	Article						Forkhead transcription factor FoxM1; transgenic mice; macrophages; lung cancer; monocyte migration; tumor microenvironment	BUTYLATED HYDROXYTOLUENE; EPITHELIAL-CELLS; CIGARETTE-SMOKE; CANCER; MICE; FORKHEAD; EXPRESSION; PROGRESSION; ROLES; TUMORIGENESIS	Macrophages have a key role in tumor-associated pulmonary inflammation that supports the proliferation of tumor cells and promotes lung tumor growth. Although increased numbers of tumor-associated macrophages are linked to poor prognosis in lung cancer patients, little is known regarding the transcriptional mechanisms controlling recruitment of macrophages during lung tumorigenesis. Forkhead Box m1 (Foxm1) transcription factor is induced in multiple cell types within tumor lesions and its increased expression is associated with poor prognosis in patients with lung adenocarcinomas. To determine the role of Foxm1 in recruitment of tumor-associated macrophages, a mouse line with macrophage-specific Foxm1 deletion was generated (macFoxm1(-/-)). Lung tumorigenesis was induced using a 3-methylcholanthrene/butylated hydroxytoluene (BHT; 3,5-di-t-butyl-4-hydroxytoluene) tumor initiation/promotion protocol. Ablation of Foxm1 in macrophages reduced the number and size of lung tumors in macFoxm1(-/-) mice. Decreased tumorigenesis was associated with diminished proliferation of tumor cells and decreased recruitment of macrophages during the early stages of tumor formation. The expression levels of the pro-inflammatory genes iNOS, Cox-2, interleukin-1b (IL-1b) and IL-6, as well as the migration-related genes macrophage inflammatory protein-1 (MIP-1 alpha), MIP-2 and MMP-12, were decreased in macrophages isolated from macFoxm1(-/-) mice. Migration of Foxm1-deficient macrophages was reduced in vitro. The chemokine receptors responsible for monocyte recruitment to the lung, CX(3)CR1 and CXCR4, were decreased in Foxm1-deficient monocytes. In co-transfection experiments, Foxm1 directly bound to and transcriptionally activated the CX(3)CR1 promoter. Adoptive transfer of wild-type monocytes to macFoxm1(-/-) mice restored BHT-induced pulmonary inflammation to the levels observed in control mice. Expression of Foxm1 in macrophages is required for pulmonary inflammation, recruitment of macrophages into tumor sites and lung tumor growth. Oncogene (2012) 31, 3875-3888; doi:10.1038/onc.2011.549; published online 5 December 2011	[Balli, D.; Ren, X.; Cross, E.; Zhang, Y.; Kalinichenko, V. V.; Kalin, T. V.] Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Chou, F-S] Cincinnati Childrens Hosp, Div Expt Hematol & Canc Biol, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, Perinatal Inst, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	Tatiana.kalin@cchmc.org	Ren, Xiaomeng/U-1751-2019	Chou, Fu-Sheng/0000-0002-5770-0580	American Cancer Society, Ohio Division; Concern Foundation [84794]; Department of Defense [PC080478]; NIH [R01 CA142724, R01 HL84151]; NATIONAL CANCER INSTITUTE [R01CA142724] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084151] Funding Source: NIH RePORTER	American Cancer Society, Ohio Division(American Cancer Society); Concern Foundation; Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We dedicate this work to the memory of Dr Robert H Costa, a pioneer in the discovery and characterization of Forkhead transcription factors. We thank Dr Jeff Whitsett, Dr Sheila Bell and Dr Craig Bolte for critical reading of the manuscript, and Shirin Akhter, Jon Snyder and Alyssa Sproles for technical assistance. This work was supported by a Research Grant from the American Cancer Society, Ohio Division (TVK); a Grant from Concern Foundation 84794 (TVK); Department of Defense Award PC080478 (TVK); and NIH Grants R01 CA142724 (TVK) and R01 HL84151 (VVK).	ADAMSON IYR, 1977, LAB INVEST, V36, P26; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Arenberg DA, 2000, CANCER IMMUNOL IMMUN, V49, P63, DOI 10.1007/s002620050603; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balli D, 2011, CANCER RES, V71, P40, DOI 10.1158/0008-5472.CAN-10-2004; Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511; Bauer AK, 2001, TOXICOLOGY, V169, P1, DOI 10.1016/S0300-483X(01)00475-9; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Blaine SA, 2005, CARCINOGENESIS, V26, P209, DOI 10.1093/carcin/bgh302; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Ernst PB, 2000, ANNU REV MICROBIOL, V54, P615, DOI 10.1146/annurev.micro.54.1.615; Faux SP, 2009, BIOMARKERS, V14, P90, DOI 10.1080/13547500902965047; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Heist RS, 2006, CLIN CANCER RES, V12, P5448, DOI 10.1158/1078-0432.CCR-06-0262; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalin TV, 2008, P NATL ACAD SCI USA, V105, P19330, DOI 10.1073/pnas.0806748105; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kanwar JR, 2009, CURR MED CHEM, V16, P2373, DOI 10.2174/092986709788682155; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Malkinson AM, 1997, CANCER RES, V57, P2832; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MARINO AA, 1972, P SOC EXP BIOL MED, V140, P122, DOI 10.3181/00379727-140-36407; Meyer AM, 2006, AM J PHYSIOL-LUNG C, V290, pL1260, DOI 10.1152/ajplung.00182.2005; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nenan S, 2005, MEM I OSWALDO CRUZ, V100, P167, DOI 10.1590/S0074-02762005000900028; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Ren XM, 2010, MOL CELL BIOL, V30, P5381, DOI 10.1128/MCB.00876-10; Sanchez-Martin L, 2011, BLOOD, V117, P88, DOI 10.1182/blood-2009-12-258186; Srivastava M, 2005, J IMMUNOL, V175, P1884, DOI 10.4049/jimmunol.175.3.1884; THOMPSON JA, 1987, DRUG METAB DISPOS, V15, P833; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006609; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Westcott DJ, 2009, J EXP MED, V206, P3143, DOI 10.1084/jem.20091333; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhang JL, 2010, INT J CLIN EXP MED, V3, P233; Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154	48	55	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3875	3888		10.1038/onc.2011.549	http://dx.doi.org/10.1038/onc.2011.549			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139074	Green Accepted, Bronze			2022-12-28	WOS:000307925000005
J	Gillibert-Duplantier, J; Duthey, B; Sisirak, V; Salaun, D; Gargi, T; Tredan, O; Finetti, P; Bertucci, F; Birnbaum, D; Bendriss-Vermare, N; Badache, A				Gillibert-Duplantier, J.; Duthey, B.; Sisirak, V.; Salaun, D.; Gargi, T.; Tredan, O.; Finetti, P.; Bertucci, F.; Birnbaum, D.; Bendriss-Vermare, N.; Badache, A.			Gene expression profiling identifies sST2 as an effector of ErbB2-driven breast carcinoma cell motility, associated with metastasis	ONCOGENE			English	Article						ErbB2/Her2; cell migration; transcriptome; ST2/IL1RL1; metastasis	SOLUBLE ST2 PROTEIN; ERBB SIGNALING NETWORK; ACTIVATED RECEPTOR-2; ACUTE EXACERBATION; RESPONSIVE GENE; IL-1 RECEPTOR; CANCER CELLS; INVASION; INDUCTION; MIGRATION	Overexpression of the ErbB2 receptor tyrosine kinase in breast cancer contributes to tumor development and is associated with poor prognosis. However, the mechanism by which ErbB2 might contribute to metastasis is not well defined. To identify genes that mediate ErbB2-driven cell motility, we performed differential gene expression analysis of ErbB2-expressing migrating breast cancer cells vs mutant ErbB2-expressing non-migrating cells. Among the genes that were specifically induced in migrating cells were known transcriptional targets of ErbB2, such as matrix metalloproteinases, and novel ErbB2 targets. Contribution of selected candidate genes to ErbB2-driven cell motility was tested by small interfering RNA targeting. Knockdown of the soluble form of ST2 (sST2), also called interleukin-1 receptor-like 1, one of the most robustly induced genes, decreased ErbB2-induced cell motility in two different cell lines. In response to ErbB2 activation, sST2 protein expression and secretion were increased. Moreover, recombinant sST2 associated with the plasma membrane and sST2-blocking antibodies reduced ErbB2-induced motility. Interestingly, cells from metastatic breast tumors secreted higher levels of sST2 than primary tumor cells. Finally, sST2 was found at high levels in the serum of metastatic breast cancer patients. Our data suggest that sST2 contributes to breast cancer cell motility and that sST2 secretion is associated with metastasis. Oncogene (2012) 31, 3516-3524; doi:10.1038/onc.2011.525; published online 21 November 2011	[Gillibert-Duplantier, J.; Duthey, B.; Salaun, D.; Finetti, P.; Bertucci, F.; Birnbaum, D.; Badache, A.] Ctr Rech Cancerol Marseille, Inserm U891, Marseille, France; [Gillibert-Duplantier, J.; Duthey, B.; Salaun, D.; Finetti, P.; Bertucci, F.; Birnbaum, D.; Badache, A.] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Gillibert-Duplantier, J.; Duthey, B.; Salaun, D.; Bertucci, F.; Birnbaum, D.; Badache, A.] Aix Marseille Univ, Marseille, France; [Sisirak, V.; Bendriss-Vermare, N.] Ctr Rech Cancerol Lyon, Inserm UMR1052, CNRS UMR5286, Lyon, France; [Sisirak, V.; Tredan, O.; Bendriss-Vermare, N.] Ctr Leon Berard, F-69373 Lyon, France; [Sisirak, V.; Bendriss-Vermare, N.] Univ Lyon 1, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Badache, A (corresponding author), Ctr Rech Cancerol Marseille, Inserm U891, Marseille, France.	ali.badache@inserm.fr	Tredan, Olivier/N-9794-2017; Sisirak, Vanja/GRJ-7805-2022; Sisirak, Vanja/L-7304-2019; Badache, Ali/Q-6098-2017; Sisirak, Vanja/O-9393-2016; Bendriss-Vermare, Nathalie/M-9197-2018; Finetti, Pascal/O-8669-2017	Tredan, Olivier/0000-0001-5881-9383; Sisirak, Vanja/0000-0003-3070-6533; Badache, Ali/0000-0001-7710-2505; Sisirak, Vanja/0000-0003-3070-6533; Bendriss-Vermare, Nathalie/0000-0002-8771-3585; Finetti, Pascal/0000-0002-2674-3123	Fondation de France; Association pour la Recherche contre le Cancer; Inserm Avenir Program; Ligue Nationale Contre le Cancer-Label Ligue; INCa [PL-969-017]; Association pour la Recherche sur le Cancer	Fondation de France(Fondation de France); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Inserm Avenir Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue Nationale Contre le Cancer-Label Ligue; INCa(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank R Marone and N Hynes for support in the preliminary phase of the project, M Lopez and A Goncalves for helpful discussions, and E Tabone and G Clapisson for providing clinical data. This work was supported by Fondation de France, Association pour la Recherche contre le Cancer and Inserm Avenir Program (AB), Ligue Nationale Contre le Cancer-Label Ligue (DB), INCa grant PL-969-017 "Met-Escape" (NB-V) and fellowships from Fondation de France (JG-D and BD) and Association pour la Recherche sur le Cancer (VS).	Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Brunner M, 2004, INTENS CARE MED, V30, P1468, DOI 10.1007/s00134-004-2184-x; Caruso R, 2006, AM J PATHOL, V169, P268, DOI 10.2353/ajpath.2006.050841; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dufour A, 2008, J CELL PHYSIOL, V217, P643, DOI 10.1002/jcp.21535; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fabre S, 2002, J BIOL CHEM, V277, P27006, DOI 10.1074/jbc.M203228200; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; Grossmann KS, 2009, P NATL ACAD SCI USA, V106, P16704, DOI 10.1073/pnas.0904336106; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Hijazi MM, 2000, INT J ONCOL, V17, P629; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jarry A, 2007, BIOCHEM BIOPH RES CO, V364, P689, DOI 10.1016/j.bbrc.2007.10.073; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mazumdar A, 2001, CANCER RES, V61, P400; Meisel C, 2001, J IMMUNOL, V166, P3143, DOI 10.4049/jimmunol.166.5.3143; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277, DOI 10.1164/ajrccm.164.2.2008120; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; Sanada S, 2007, J CLIN INVEST, V117, P1538, DOI 10.1172/JCI30634; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Su S, 2009, ONCOGENE, V28, P3047, DOI 10.1038/onc.2009.163; Tajima S, 2003, CHEST, V124, P1206, DOI 10.1378/chest.124.4.1206; Tominaga S, 1999, BIOCHEM BIOPH RES CO, V264, P14, DOI 10.1006/bbrc.1999.1469; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107	47	29	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3516	3524		10.1038/onc.2011.525	http://dx.doi.org/10.1038/onc.2011.525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105364	Bronze			2022-12-28	WOS:000306844100004
J	Canino, C; Mori, F; Cambria, A; Diamantini, A; Germoni, S; Alessandrini, G; Borsellino, G; Galati, R; Battistini, L; Blandino, R; Facciolo, F; Citro, G; Strano, S; Muti, P; Blandino, G; Cioce, M				Canino, C.; Mori, F.; Cambria, A.; Diamantini, A.; Germoni, S.; Alessandrini, G.; Borsellino, G.; Galati, R.; Battistini, L.; Blandino, R.; Facciolo, F.; Citro, G.; Strano, S.; Muti, P.; Blandino, G.; Cioce, M.			SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells	ONCOGENE			English	Article						EMT; chemoresistance; SASP; mesothelioma	MALIGNANT PLEURAL MESOTHELIOMA; CANCER STEM-CELLS; AUTOCRINE GROWTH-FACTOR; IN-VITRO; BREAST-CANCER; MESENCHYMAL TRANSITION; TUBERCULOUS PLEURISY; CELLULAR SENESCENCE; SIGNAL TRANSDUCER; EXPRESSION	Here we show that pemetrexed-treated mesothelioma cells undergo accelerated senescence. This is characterized by the secretion of proinflammatory and mitogenic cytokines, reminiscent of an SASP (senescence-associated secretory phenotype). Conditioned media from senescent MPM (malignant pleural mesothelioma) cells trigger the emergence of EMT (epithelial-to-mesenchymal)-like, clonogenic and chemoresistant cell subpopulations, expressing high levels of ALDH (aldehyde dehydrogenase) activity (ALDH(bright) cells). We show by fluorescence-activated cell sorting of purified ALDH(bright) and ALDH(low) cells, that both cell-autonomous and cell-non-autonomous mechanisms converge to maintain the SASP-induced, EMT-like cell subpopulations. Chemoresistant ALDH(bright) cells exist within primary MPM specimens and enrichment for ALDH(bright) cells correlates with an earlier tumor onset into NOD/SCID mice. We show that RAS(v12) expression induces SASP-like changes in untransformed human mesothelial cells, and that p53 ablation increases the effect of RASv12 expression. We identify STAT3 activation as a crucial event downstream to SASP signaling. In fact, small hairpin RNA-mediated ablation of STAT3 deeply attenuates the induction of EMT genes and the increase of ALDH(bright) cells induced by SASP-cytokines. This strongly affects the chemoresistance of MPM cells in vitro and leads to anticancer effects in vivo. Oncogene (2012) 31, 3148-3163; doi:10.1038/onc.2011.485; published online 24 October 2011	[Canino, C.; Blandino, G.; Cioce, M.] Italian Natl Canc Inst Regina Elena, Translat Oncogenom Unit, Rome, Italy; [Mori, F.; Galati, R.; Strano, S.] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Rome, Italy; [Cambria, A.; Blandino, R.] S Vincenzo Hosp, Taormina, Italy; [Diamantini, A.; Borsellino, G.; Battistini, L.] IRCCS Santa Lucia Fdn, Neuroimmunol Unit, Rome, Italy; [Germoni, S.; Citro, G.] Italian Natl Canc Inst Regina Elena, SAFU Dept, Rome, Italy; [Alessandrini, G.; Facciolo, F.] Italian Natl Canc Inst, Unit Thorac Surg, Rome, Italy; [Muti, P.] Italian Natl Canc Inst Regina Elena, Sci Directors Off, Rome, Italy	IRCCS Santa Lucia	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Translat Oncogen Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	blandino@ifo.it; mcioce@ifo.it	Cioce, Mario/R-9734-2017; Galati, Rossella/ABH-6437-2020; Muti, Paola/AAD-9108-2020; Galati, Rossella Maria/H-8867-2017; Blandino, Giovanni/B-1137-2013; Strano, Sabrina/K-9654-2016; Battistini, Luca/D-6920-2014; Battistini, luca/ABE-1882-2021; strano, sabrina/B-6743-2013; Borsellino, Giovanna/K-3074-2016	Cioce, Mario/0000-0001-8129-6664; Galati, Rossella/0000-0003-2646-8384; Galati, Rossella Maria/0000-0003-2646-8384; Blandino, Giovanni/0000-0002-6970-2241; Battistini, Luca/0000-0002-6488-4891; strano, sabrina/0000-0002-6341-4230; Borsellino, Giovanna/0000-0002-4227-6481; Alessandrini, Gabriele/0000-0002-4380-7627; Facciolo, Francesco/0000-0002-7137-8946	INAIL (Italian Workers' Compensation Authority)	INAIL (Italian Workers' Compensation Authority)	We thank Ms Tania Merlino (Regina Elena Cancer Institute, Rome) for revising and proofreading the manuscript and Dr Frank Sinicrope (Rochester, MN) for the ShSTAT3 vectors available at ADDGENE (UK). We acknowledge INAIL (Italian Workers' Compensation Authority) for grant support to GB.	Achcar RDD, 2007, ARCH PATHOL LAB MED, V131, P1350; Adhikari AS, 2011, FRONT BIOSCI-LANDMRK, V16, P1927, DOI 10.2741/3831; Albonici L, 2009, INT J IMMUNOPATH PH, V22, P389, DOI 10.1177/039463200902200216; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Casarsa C, 2011, CANCER LETT, V302, P136, DOI 10.1016/j.canlet.2011.01.009; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Cioce M, 2010, CELL CYCLE, V9, P2878, DOI 10.4161/cc.9.14.12371; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Fujino S, 1996, AM J RESP CELL MOL, V14, P508, DOI 10.1165/ajrcmb.14.6.8652179; Galffy G, 1999, CANCER RES, V59, P367; Hazarika M, 2005, CLIN CANCER RES, V11, P982; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396; Huang C, 2011, INT J ONCOL, V38, P1637, DOI 10.3892/ijo.2011.1000; Kim C, 2011, YONSEI MED J, V52, P51, DOI 10.3349/ymj.2011.52.1.51; KRYCZEK I, 2011, INT J CANC; Kubo T, 2011, CLIN CANCER RES, V17, P4965, DOI 10.1158/1078-0432.CCR-10-3040; Laberge RM, 2011, CANC MICROENVIRON; Li Q, 2007, CLIN CANCER RES, V13, P5918, DOI 10.1158/1078-0432.CCR-07-0501; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; METCALF RA, 1992, CANCER RES, V52, P2610; Mor O, 1997, AM J RESP CELL MOL, V16, P9, DOI 10.1165/ajrcmb.16.1.8998073; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Oka M, 2010, EXP DERMATOL, V19, pE50, DOI 10.1111/j.1600-0625.2009.00972.x; Park JS, 2003, SCAND J IMMUNOL, V57, P463, DOI 10.1046/j.1365-3083.2003.01201.x; Pompeo E, 2009, ANN THORAC SURG, V88, P426, DOI 10.1016/j.athoracsur.2009.04.038; Rodier F, 2005, INT J BIOCHEM CELL B, V37, P977, DOI 10.1016/j.biocel.2004.10.012; Ruco LP, 1996, J PATHOL, V179, P266; Scarpa S, 2002, ONCOL REP, V9, P205; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schramm A, 2010, EUR J CARDIO-THORAC, V37, P566, DOI 10.1016/j.ejcts.2009.08.027; Sidi R, 2011, EUR J CANCER, V47, P326, DOI 10.1016/j.ejca.2010.09.044; Sivertsen S, 2006, LUNG CANCER, V54, P309, DOI 10.1016/j.lungcan.2006.08.010; Suzuki Y, 2010, INT J CANCER, V127, P1948, DOI 10.1002/ijc.25197; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108; Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22	49	119	123	3	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3148	3163		10.1038/onc.2011.485	http://dx.doi.org/10.1038/onc.2011.485			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22020330	Green Published			2022-12-28	WOS:000305934400004
J	Horiguchi, K; Sakamoto, K; Koinuma, D; Semba, K; Inoue, A; Inoue, S; Fujii, H; Yamaguchi, A; Miyazawa, K; Miyazono, K; Saitoh, M				Horiguchi, K.; Sakamoto, K.; Koinuma, D.; Semba, K.; Inoue, A.; Inoue, S.; Fujii, H.; Yamaguchi, A.; Miyazawa, K.; Miyazono, K.; Saitoh, M.			TGF-beta drives epithelial-mesenchymal transition through delta EF1-mediated downregulation of ESRP	ONCOGENE			English	Article						alternative splicing; delta EF1; EMT; TGF-beta; ESRP; breast cancer	GROWTH-FACTOR-BETA; BREAST-CANCER; CELL-LINES; METASTASIS; NETWORKS; PROGRESSION; EXPRESSION; RECEPTORS; INDUCTION; INSIGHTS	Epithelial-mesenchymal transition (EMT) is a crucial event in wound healing, tissue repair and cancer progression in adult tissues. We have recently shown that transforming growth factor (TGF)-beta-induced EMT involves isoform switching of fibroblast growth factor receptors by alternative splicing. We performed a microarray-based analysis at single exon level to elucidate changes in splicing variants generated during TGF-beta-induced EMT, and found that TGF-beta induces broad alteration of splicing patterns by downregulating epithelial splicing regulatory proteins (ESRPs). This was achieved by TGF-beta-mediated upregulation of delta EF1 family proteins, delta EF1 and SIP1. delta EF1 and SIP1 each remarkably repressed ESRP2 transcription through binding to the ESRP2 promoter in NMuMG cells. Silencing of both delta EF1 and SIP1, but not either alone, abolished the TGF-beta-induced ESRP repression. The expression profiles of ESRPs were inversely related to those of delta EF1 and SIP in human breast cancer cell lines and primary tumor specimens. Further, overexpression of ESRPs in TGF-beta-treated cells resulted in restoration of the epithelial splicing profiles as well as attenuation of certain phenotypes of EMT. Therefore, delta EF1 family proteins repress the expression of ESRPs to regulate alternative splicing during TGF-beta-induced EMT and the progression of breast cancers. Oncogene (2012) 31, 3190-3201; doi:10.1038/onc.2011.493; published online 31 October 2011	[Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; [Sakamoto, K.; Yamaguchi, A.] Tokyo Med & Dent Univ, Sect Oral Pathol, Grad Sch Med & Dent Sci, Tokyo, Japan; [Semba, K.] Waseda Univ, Dept Life Sci & Med Biosci, Tokyo, Japan; [Inoue, A.; Inoue, S.; Fujii, H.] Univ Yamanashi, Dept Surg 1, Interdisciplinary Grad Sch Med & Engn, Tamaho, Yamanashi, Japan; [Miyazawa, K.; Saitoh, M.] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Biochem, Tamaho, Yamanashi, Japan	University of Tokyo; Tokyo Medical & Dental University (TMDU); Waseda University; University of Yamanashi; University of Yamanashi	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp; msaitoh-ind@umin.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; Koinuma, Daizo/Y-8716-2018	Koinuma, Daizo/0000-0001-5611-2122	University of Yamanashi from Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science; Waseda University from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research [22249061, 22112002, 09J05735, 22390052, 11F01113] Funding Source: KAKEN	University of Yamanashi from Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Waseda University from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs T Shirakihara, S Ehata, M Morikawa and C Iwata for their helpful discussions. This work was supported by KAKENHI (Grants-in-Aid for Scientific Research) and Cooperative Program for Graduate Student Education between University of Yamanashi and Waseda University from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms) from the Japan Society for the Promotion of Science.	Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Chaffer CL, 2007, DIFFERENTIATION, V75, P831, DOI 10.1111/j.1432-0436.2007.00210.x; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Coumoul Xavier, 2003, Birth Defects Research, V69, P286, DOI 10.1002/bdrc.10025; Dutertre M, 2010, CANCER RES, V70, P896, DOI 10.1158/0008-5472.CAN-09-2703; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Lee B, 2008, BIOINFORMATICS, V24, P1026, DOI 10.1093/bioinformatics/btn068; Licatalosi DD, 2010, NAT REV GENET, V11, P75, DOI 10.1038/nrg2673; Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Rasche A, 2010, BIOINFORMATICS, V26, P84, DOI 10.1093/bioinformatics/btp626; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Yamaguchi N, 2008, BIOCHEM BIOPH RES CO, V365, P711, DOI 10.1016/j.bbrc.2007.11.064; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	33	157	160	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3190	3201		10.1038/onc.2011.493	http://dx.doi.org/10.1038/onc.2011.493			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22037216	hybrid, Green Published			2022-12-28	WOS:000305934400007
J	Caino, MC; Lopez-Haber, C; Kim, J; Mochly-Rosen, D; Kazanietz, MG				Caino, M. C.; Lopez-Haber, C.; Kim, J.; Mochly-Rosen, D.; Kazanietz, M. G.			Proteins kinase C epsilon is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes	ONCOGENE			English	Article						PKC epsilon; non-small cell lung carcinoma; tumorigenesis; cell survival; apoptotic genes	CANCER CELLS; PKC-EPSILON; INHIBITORS; DEATH; OVEREXPRESSION; ACTIVATION; RECEPTOR; DELTA; SENESCENCE; MUTATIONS	Protein kinase C (PKC)epsilon, a member of the novel PKC family, has key roles in mitogenesis and survival in normal and cancer cells. PKC epsilon is frequently overexpressed in epithelial cancers, particularly in lung cancer. Using a short-hairpin RNA approach, here we established that PKCe is required for non-small cell lung carcinoma (NSCLC) growth in vitro as well as tumor growth when inoculated into athymic mice. Moreover, sustained delivery of a PKC epsilon-selective inhibitor peptide, epsilon V1-2, reduced xenograft growth in mice. Both RNA interference depletion and pharmacological inhibition of PKCe caused a marked elevation in the number of apoptotic cells in NSCLC tumors. PKC epsilon-depleted NSCLC cells show elevated expression of pro-apoptotic proteins of the Bcl2 family, caspase recruitment domain-containing proteins and tumor necrosis factor ligands/receptor superfamily members. Moreover, a Gene Set Enrichment Analysis revealed that a vast majority of the genes changed in PKC epsilon-depleted cells were also deregulated in human NSCLC. Our results strongly suggest that PKC epsilon is required for NSCLC cell survival and maintenance of NSCLC tumor growth. Therefore, PKC epsilon may represent an attractive therapeutic target for NSCLC. Oncogene (2012) 31, 2593-2600; doi:10.1038/onc.2011.428; published online 26 September 2011	[Caino, M. C.; Lopez-Haber, C.; Kazanietz, M. G.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Kim, J.] Stanford Sch Med, Stanford Comprehens Canc Ctr, Stanford, CA USA; [Mochly-Rosen, D.] Stanford Sch Med, Dept Chem & Syst Biol, Stanford, CA USA	University of Pennsylvania; Stanford University; Stanford University	Kazanietz, MG (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 1256 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	marcelog@upenn.edu		Kim, Jeewon/0000-0002-1063-0239; Caino, M. Cecilia/0000-0001-8294-8070; Mochly-Rosen, Daria/0000-0002-6691-8733; Lopez Haber, Cynthia/0000-0001-9106-543X	NCI NIH HHS [R01 CA074197] Funding Source: Medline; NHLBI NIH HHS [R01 HL052141] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074197] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052141] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; BARR LF, 1991, CANCER RES, V51, P5514; Barry OP, 2001, CURR PHARM DESIGN, V7, P1725, DOI 10.2174/1381612013397041; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Begley R, 2004, BIOCHEM BIOPH RES CO, V318, P949, DOI 10.1016/j.bbrc.2004.04.121; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Budas GR, 2007, BIOCHEM SOC T, V35, P1021, DOI 10.1042/BST0351021; Caino MC, 2011, J BIOL CHEM, V286, P11254, DOI 10.1074/jbc.M110.194332; Caino MC, 2009, APOPTOSIS, V14, P392, DOI 10.1007/s10495-009-0316-z; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Felber M, 2007, PATHOL ONCOL RES, V13, P295, DOI 10.1007/BF02940308; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; HAN EKH, 1995, CARCINOGENESIS, V16, P2423, DOI 10.1093/carcin/16.10.2423; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; Inagaki K, 2005, CIRCULATION, V111, P44, DOI 10.1161/01.CIR.0000151614.22282.F1; Jansen AP, 2001, CANCER RES, V61, P808; Koyanagi T, 2007, J MOL CELL CARDIOL, V43, P517, DOI 10.1016/j.yjmcc.2007.06.003; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lu DM, 2006, J BIOL CHEM, V281, P22799, DOI 10.1074/jbc.M603390200; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; MATYAS GR, 1989, CELL SIGNAL, V1, P395, DOI 10.1016/0898-6568(89)90058-2; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Okhrimenko H, 2005, CANCER RES, V65, P7301, DOI 10.1158/0008-5472.CAN-05-1064; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Perletti GP, 1996, ONCOGENE, V12, P847; PREISS J, 1986, J BIOL CHEM, V261, P8597; RUSCH V, 1993, CANCER RES, V53, P2379; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Serova M, 2006, SEMIN ONCOL, V33, P466, DOI 10.1053/j.seminoncol.2006.04.009; Slupsky JR, 2007, AM J PATHOL, V170, P745, DOI 10.2353/ajpath.2007.060557; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134	47	32	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	20					2593	2600		10.1038/onc.2011.428	http://dx.doi.org/10.1038/onc.2011.428			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996750	Green Accepted			2022-12-28	WOS:000304191800009
J	Ramachandran, I; Thavathiru, E; Ramalingam, S; Natarajan, G; Mills, WK; Benbrook, DM; Zuna, R; Lightfoot, S; Reis, A; Anant, S; Queimado, L				Ramachandran, I.; Thavathiru, E.; Ramalingam, S.; Natarajan, G.; Mills, W. K.; Benbrook, D. M.; Zuna, R.; Lightfoot, S.; Reis, A.; Anant, S.; Queimado, L.			Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo	ONCOGENE			English	Article						Wnt inhibitory factor 1 (WIF1); Wnt; beta-catenin; cervical cancer; hypermethylation; apoptosis	EPIGENETIC INACTIVATION; SIGNAL-TRANSDUCTION; PROGNOSTIC VALUE; POOR-PROGNOSIS; BETA-CATENIN; E-CADHERIN; EXPRESSION; CD44; P53; PATHWAY	activation of Wingless-type (Wnt)beta-catenin signaling is widespread in human cervical cancer. However, the underlying mechanisms of Wnt activation and the therapeutic potential of Wnt inhibition remain largely unknown. Here, we demonstrate that the Wnt inhibitory factor 1 (WIF1), a secreted Wnt antagonist, is downregulated in all human primary cervical tumors and cell lines analyzed. Our data reveal that WIF1 downregulation occurs due to promoter hypermethylation and is an early event in cervical oncogenesis. WIF1 re-expression upon 5-aza-2'-deoxycytidine treatment or WIF1 gene transfer induces significant apoptosis and G(2)/M arrest, and inhibits cervical cancer cell proliferation in vitro. Consistent with this, treatment of established mice tumor xenografts with peritumoral WIF1 gene transfer results in a significant inhibition of cancer growth and invasion. WIF1 treatment causes a significant decrease in intracellular WNT1 and TCF-4 proteins revealing novel Wnt-regulatory mechanisms. Thus, WIF1 causes a major cellular re-distribution of beta-catenin and a significant inhibition of the Wnt/beta-catenin pathway in tumor cells, as documented by a remarkable reversion in the expression of Wnt/beta-catenin transcriptional target genes (E-cadherin, c-Myc, cyclin D1, CD44 and VEGF). Consequently, multiple critical events in tumor progression and metastasis such as cell proliferation, angiogenesis and invasion were inhibited by WIF1. In addition, WIF1 modulated the expression of specific anti-apoptotic and apoptotic proteins, thereby inducing significant apoptosis in vivo. Our findings demonstrate for the first time that WIF1 downregulation by epigenetic gene silencing is an important mechanism of Wnt activation in cervical oncogenesis. Of major clinical relevance, we show that peritumoral WIF1 gene transfer reduces not only cancer growth but also invasion in well-established tumors. Therefore, our data provide novel mechanistic insights into the role of WIF1 in cervical cancer progression, and the important preclinical validation of WIF1 as a potent drug target in cervical cancer treatment. Oncogene (2012) 31, 2725-2737; doi: 10.1038/onc.2011.455; published online 17 October 2011	[Ramachandran, I.; Thavathiru, E.; Mills, W. K.; Queimado, L.] Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, Oklahoma City, OK 73104 USA; [Ramalingam, S.; Natarajan, G.; Anant, S.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; [Benbrook, D. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Obstet & Gynecol, Oklahoma City, OK 73104 USA; [Benbrook, D. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; [Benbrook, D. M.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; [Reis, A.] Univ Oklahoma, Hlth Sci Ctr, Dept Dermatol, Oklahoma City, OK 73104 USA; [Anant, S.; Queimado, L.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; [Queimado, L.] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Queimado, L (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Otorhinolaryngol, 975 NE 10th St,BRC 1272, Oklahoma City, OK 73104 USA.	lurdes-queimado@ouhsc.edu	Anant, Shrikant/AAF-8020-2020; Queimado, Lurdes/L-7465-2013; Queimado, Lurdes/AAY-2545-2021; Ramalingam, Satish/H-1577-2018	Queimado, Lurdes/0000-0002-1106-4873; Queimado, Lurdes/0000-0002-1106-4873; Ramalingam, Satish/0000-0002-3076-279X	Oklahoma Center for the Advancement of Science and Technology [HR08-018]	Oklahoma Center for the Advancement of Science and Technology	We sincerely thank Dr Eric W Howard for kindly providing the pCI-blast vector. We are grateful to Dr Sripathi M Sureban and Dr Dharmalingam Subramaniam for their technical advice and graphic assistance. We also thank Mrs Geraldine A Chissoe and Mr Randal May (Advanced Immunohistochemistry and Morphology Core, OUHSC) for their technical assistance. We appreciate the helpful discussions of Dr Ileng Kumaran Ramachandran (CSHL) and Dr Sivakumar Ramadoss (UCLA). This work was supported by the Oklahoma Center for the Advancement of Science and Technology (LQ) (HR08-018). LQ holds a Presbyterian Health Foundation Endowed Chair in Otorhinolaryngology.	ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ahn WS, 2004, INT J GYNECOL CANCER, V14, P322, DOI 10.1111/j.1048-891x.2004.014217.x; Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Bae DS, 2001, GYNECOL ONCOL, V81, P341, DOI 10.1006/gyno.2001.6196; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Branca M, 2006, EUR J GYNAECOL ONCOL, V27, P215; Byun T, 2005, J CLIN PATHOL, V58, P515, DOI 10.1136/jcp.2004.018598; Chung MT, 2009, GYNECOL ONCOL, V112, P301, DOI 10.1016/j.ygyno.2008.10.004; DeLisser HM, 1997, AM J PATHOL, V151, P671; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Gherghe CM, 2011, FASEB J, V25, P1836, DOI 10.1096/fj.10-172981; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Horn LC, 2006, GYNECOL ONCOL, V103, P906, DOI 10.1016/j.ygyno.2006.05.046; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Johnson CL, 2002, MOL CANCER THER, V1, P861; Jones M, 2000, J BIOL CHEM, V275, P7964, DOI 10.1074/jbc.275.11.7964; KAINZ C, 1995, EUR J CANCER, V31A, P1706, DOI 10.1016/0959-8049(95)00353-K; Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175; Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim J, 2007, J THORAC CARDIOV SUR, V133, P733, DOI 10.1016/j.jtcvs.2006.09.053; Koskimaa HM, 2010, CANCER EPIDEM BIOMAR, V19, P2003, DOI 10.1158/1055-9965.EPI-09-0781; Laux H, 2004, LAB INVEST, V84, P1372, DOI 10.1038/labinvest.3700158; Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913; Li J, 2008, ONCOGENE, V27, P6194, DOI 10.1038/onc.2008.297; Lin YC, 2007, HUM GENE THER, V18, P379, DOI 10.1089/hum.2006.005; Linderholm BK, 2001, CANCER RES, V61, P2256; Lu Shi, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P78; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mathur SP, 2005, GYNECOL ONCOL, V98, P467, DOI 10.1016/j.ygyno.2005.05.003; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Orian-Rousseau V, 2010, EUR J CANCER, V46, P1271, DOI 10.1016/j.ejca.2010.02.024; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Perez-Plasencia Carlos, 2008, Int Arch Med, V1, P10, DOI 10.1186/1755-7682-1-10; Phoophitphong T, 2007, J OBSTET GYNAECOL RE, V33, P840, DOI 10.1111/j.1447-0756.2007.00666.x; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Queimado L, 2008, ARCH OTOLARYNGOL, V134, P94, DOI 10.1001/archotol.134.1.94; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298; Silva-Filho AL, 2006, INT J GYNECOL CANCER, V16, P757, DOI 10.1111/j.1525-1438.2006.00362.x; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Speiser P, 1997, INT J CANCER, V74, P185, DOI 10.1002/(SICI)1097-0215(19970422)74:2<185::AID-IJC8>3.0.CO;2-V; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Uren A, 2005, CANCER RES, V65, P6199, DOI 10.1158/0008-5472.CAN-05-0455; Vijayalakshmi N, 2002, EUR J GYNAECOL ONCOL, V23, P135; Wang H, 2008, ONCOGENE, V27, P1905, DOI 10.1038/sj.onc.1210823; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Wright M, 1999, BIOCHEM BIOPH RES CO, V263, P384, DOI 10.1006/bbrc.1999.1344; Yee DS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-162; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584	60	108	119	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2725	2737		10.1038/onc.2011.455	http://dx.doi.org/10.1038/onc.2011.455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	22002305				2022-12-28	WOS:000304769000003
J	Yang, MH; Lin, BR; Chang, CH; Chen, ST; Lin, SK; Kuo, MYP; Jeng, YM; Kuo, ML; Chang, CC				Yang, M-H; Lin, B-R; Chang, C-H; Chen, S-T; Lin, S-K; Kuo, M. Y-P; Jeng, Y-M; Kuo, M-L; Chang, C-C			Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling	ONCOGENE			English	Article						connective tissue growth factor; microRNA-504; forkhead box P1; oral squamous cell carcinoma; invasion	TUMOR-SUPPRESSOR; FACTOR CTGF; CCN FAMILY; CANCER CELLS; GENE FAMILY; LUNG; METASTASIS; EXPRESSION; MOTILITY; OVEREXPRESSION	Connective tissue growth factor (CTGF) is a multifunctional secreted protein, and it has been shown either to promote or suppress tumor progression among different kinds of cancers. Here, we investigated the role of CTGF in oral squamous cell carcinoma (OSCC) invasion and metastasis. In five OSCC cell lines, endogenous CTGF negatively correlated with invasiveness. Exogenous CTGF protein or forced expression of CTGF gene in the oral cancer cell line SAS significantly decreased their invasive and migratory abilities. MicroRNA (miRNA) microarray analysis was performed in CTGF-overexpressed SAS cells (SAS/CTGF-M3) versus control cells to investigate the mechanism of CTGF-mediated inhibition of OSCC invasion. Among the miRNAs regulated by CTGF, miR-504 and miR-346 were the top two miRNAs downregulated in CTGF transfectants, and the result was confirmed by quantitative reverse transcriptase-PCR. Ectopic miR-504 increased migration and invasion in SAS/CTGF-M3, however, miR-346 did not have such impact on migration/invasion. Furthermore, we identified FOXP1, a member of forkhead transcription factors, as a target gene that takes part in the miR-504-induced cellular invasion. Knockdown of FOXP1 increased invasiveness in SAS/CTGF-M3, confirming the signal axis of CTGF/miR-504/FOXP1 in OSCC. Animal experiments showed that SAS/CTGF-M3-formed orthotopic tumors were associated with a lesser invasive phenotype than control cells. Expression of miR-504 in SAS/CTGF-M3 increased lymph node metastasis, and co-expression of FOXP1 in miR-504-transfected SAS/CTGF-M3 alleviated miR-504-induced metastasis. In OSCC samples, high CTGF was associated with a lower clinical stage and a better outcome. A reverse correlation between CTGF and miR-504, miR-504 and FOXP1, and a positive correlation between CTGF and FOXP1 were shown. Our study discovers a novel signal pathway involving the regulation of miRNA machinery by a secreted cytokine, which will be beneficial for developing therapeutic strategy against advanced OSCC. Oncogene (2012) 31, 2401-2411; doi: 10.1038/onc.2011.423; published online 19 September 2011	[Chang, C-H; Chang, C-C] Natl Taiwan Univ, Sch Dent, Grad Inst Oral Biol, Taipei 100, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Yang, M-H] Taipei Vet Gen Hosp, Dept Med, Div Hematol Oncol, Taipei, Taiwan; [Lin, B-R] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, Yun Lin Branch, Taipei 10016, Taiwan; [Lin, S-K; Kuo, M. Y-P] Natl Taiwan Univ, Sch Dent, Grad Inst Clin Dent, Taipei 100, Taiwan; [Jeng, Y-M] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; [Kuo, M-L] Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 100, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Chang, CC (corresponding author), Natl Taiwan Univ, Sch Dent, Grad Inst Oral Biol, Taipei 100, Taiwan.	ccclrc@gmail.com	Yang, Muh-Hwa/AAE-4691-2020	KUO, MIN-LIANG/0000-0002-7139-0144; LIN, BEEN-REN/0000-0001-8354-1758; JENG, YUNG-MING/0000-0002-3878-4491; Chen, Szu-Ta/0000-0002-9715-1221; LIN, SZE-KWAN/0000-0002-7969-0280; CHANG, CHIA-HSUIN/0000-0003-0024-6177	National Science Council, Taiwan [NSC-97-2314-B-002-031-MY2, NSC-98-2320-B-002-003, NSC-99-2314-B-010-007-MY3]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from National Science Council, Taiwan NSC-97-2314-B-002-031-MY2, NSC-98-2320-B-002-003 (to CCC) and NSC-99-2314-B-010-007-MY3 (to MHY).	Abreu JG, 2002, NAT CELL BIOL, V4, P599, DOI 10.1038/ncb826; Banham AH, 2001, CANCER RES, V61, P8820; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; Chan CS, 2005, PLOS COMPUT BIOL, V1, P564, DOI 10.1371/journal.pcbi.0010069; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chuang JY, 2011, INT IMMUNOPHARMACOL, V11, P948, DOI 10.1016/j.intimp.2011.02.008; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jerjes W, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-9; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kademani D, 2007, MAYO CLIN PROC, V82, P878, DOI 10.4065/82.7.878; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Katoh M, 2004, INT J ONCOL, V25, P1495; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin BR, 2005, GASTROENTEROLOGY, V128, P9, DOI 10.1053/j.gastro.2004.10.007; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Moritani NH, 2003, CANCER LETT, V192, P205, DOI 10.1016/S0304-3835(02)00718-8; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pan LH, 2002, NEUROL RES, V24, P677, DOI 10.1179/016164102101200573; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Shimo T, 2008, ANTICANCER RES, V28, P2343; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wutzl A, 2007, J ORAL MAXIL SURG, V65, P255, DOI 10.1016/j.joms.2006.09.007; Xue ZH, 2010, J IMMUNOL, V184, P3697, DOI 10.4049/jimmunol.0903316; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	41	67	69	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2401	2411		10.1038/onc.2011.423	http://dx.doi.org/10.1038/onc.2011.423			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21927029	Green Submitted			2022-12-28	WOS:000303985300003
J	Zagorodna, O; Martin, SM; Rutkowski, DT; Kuwana, T; Spitz, DR; Knudson, CM				Zagorodna, O.; Martin, S. M.; Rutkowski, D. T.; Kuwana, T.; Spitz, D. R.; Knudson, C. M.			2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines	ONCOGENE			English	Article						2-deoxyglucose (2DG); apoptosis; Bcl-2; Bax; BH3 mimetics; oncogenesis	MOUSE B-CELL; MITOCHONDRIAL APOPTOSIS; BH3-ONLY PROTEINS; BH3 DOMAINS; IN-VITRO; 2-DEOXY-D-GLUCOSE; STRESS; BAX; METABOLISM; ACTIVATION	Targeting altered cancer cell metabolism with the glycolysis inhibitor, 2-deoxyglucose (2DG), is a viable therapeutic strategy, but the effects of 2DG on lymphoma cells and the mechanism of action are unknown. Five T-cell lymphoma lines and two B-cell lymphoma lines were shown to be highly sensitive to 2DG. Examination of the cell death pathway demonstrated pro-apoptotic protein Bax 'activation' and caspase cleavage in 2DG-treated cells. However, Q-VD-OPh, a potent inhibitor of caspase activity provided minimal protection from death. In contrast, overexpressing the anti-apoptotic protein Bcl-2 dramatically enhanced the survival of 2DG-treated cells that was negated by a Bcl-2 antagonist. BH3-only members, Bim and Bmf, were upregulated by 2DG, and shRNAs targeting Bim protected from 2DG toxicity demonstrating that Bim is a critical mediator of 2DG toxicity. 2DG also induced GADD153/CHOP expression, a marker of endoplasmic reticulum (ER) stress and a known activator of Bim. Mannose, a reagent known to alleviate ER stress, transiently protected from 2DG-induced cell death. Examination of the effects of 2DG on energy metabolism showed a drop in ATP levels by 30 min that was not affected by either Bcl-2 or mannose. These results demonstrate that ER stress appears to be rate limiting in 2DG-induced cell death in lymphoma cells, and this cell killing is regulated by the Bcl-2 family of proteins. Bcl-2 inhibition combined with 2DG may be an effective therapeutic strategy for lymphoma. Oncogene (2012) 31, 2738-2749; doi: 10.1038/onc.2011.454; published online 10 October 2011	[Zagorodna, O.; Martin, S. M.; Kuwana, T.; Knudson, C. M.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; [Zagorodna, O.; Spitz, D. R.; Knudson, C. M.] Univ Iowa, Free Radical & Radiat Biol Program, Dept Radiat Oncol, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Rutkowski, D. T.] Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Knudson, CM (corresponding author), Univ Iowa, Dept Pathol, 200 Hawkins Dr,1171 ML, Iowa City, IA 52242 USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466; Spitz, Douglas/0000-0002-1254-8765; Rutkowski, Thomas/0000-0001-6586-4449	 [CA104695];  [CA133114];  [DK084058];  [GM086389.]; NATIONAL CANCER INSTITUTE [R01CA104695, R01CA133114, P50CA097274, T32CA078586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK084058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086389] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by RO1 no. CA104695, RO1 no. CA133114, R01 no. DK084058, and R01 no. GM086389. We thank Dr Chris van de Wetering for assistance in generating lymphoma cell lines, Dr Siegfried Janz and Dr SS Han for B-cell neoplasms, Dr Agshin Taghiyev and Dr Van Tompkins for their advice and assistance with TCL transduction experiments, Dr Craig Kuder and Dr Ray Hohl for antibodies and assistance with ER-stress markers, Heather Tyra for assistance with RT-PCR, Han Du for advice with the Bcl-2 IP experiments, Rebecca Glover and Jacob Wolf for their technical advice on western blotting and Dr Craig Thompson (The Sloan-Kettering Cancer Center) for Bax/Bak double-knockout cells.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; CRANE RK, 1954, J BIOL CHEM, V210, P597; Dasmahapatra G, 2009, CANCER BIOL THER, V8, P808, DOI 10.4161/cbt.8.9.8131; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; El Mjiyad N, 2011, ONCOGENE, V30, P253, DOI 10.1038/onc.2010.466; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han SS, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-22; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kang MH, 2007, BLOOD, V110, P2057, DOI 10.1182/blood-2007-03-080325; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Raden D, 2005, IEE P SYST BIOL, V152, P285, DOI 10.1049/ip-syb:20050048; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374; Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759; Shoemaker AR, 2006, CANCER RES, V66, P8731, DOI 10.1158/0008-5472.CAN-06-0367; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Smaili SS, 2003, BRAZ J MED BIOL RES, V36, P183, DOI 10.1590/S0100-879X2003000200004; TOWER DB, 1958, J NEUROCHEM, V3, P185, DOI 10.1111/j.1471-4159.1958.tb12625.x; van de Wetering CI, 2007, CANCER RES, V67, P8081, DOI 10.1158/0008-5472.CAN-07-1666; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Zhang XD, 2006, ANTICANCER RES, V26, P3561	43	45	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2738	2749		10.1038/onc.2011.454	http://dx.doi.org/10.1038/onc.2011.454			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21986940	Green Accepted			2022-12-28	WOS:000304769000004
J	Chow, C; Wong, N; Pagano, M; Lun, SWM; Nakayama, KI; Nakayama, K; Lo, KW				Chow, C.; Wong, N.; Pagano, M.; Lun, S. W-M; Nakayama, K-I; Nakayama, K.; Lo, K-W			Regulation of APC/C-Cdc20 activity by RASSF1A-APC/C-Cdc20 circuitry	ONCOGENE			English	Article						RASSF1A; APC/C-Cdc20; Aurora; ubiquitination; mitotic checkpoint	TUMOR-SUPPRESSOR RASSF1A; ANAPHASE-PROMOTING COMPLEX/CYCLOSOME; UBIQUITIN-MEDIATED DEGRADATION; SPINDLE ASSEMBLY CHECKPOINT; KINASE AURORA-A; CYCLIN-A; CELL-CYCLE; PSEUDOSUBSTRATE INHIBITOR; MITOTIC CHECKPOINT; D-BOX	RASSF1A is a key tumor-suppressor gene that is often inactivated in a wide variety of solid tumors. Studies have illustrated that RASSF1A plays vital roles in the regulation of cell-cycle progression and functions as a guardian of mitosis. Nevertheless, the precise mechanism of RASSF1A-dependent regulation of mitosis remains largely unclear. APC/C-Cdc20 is the master switch and regulator of mitosis. The activity of APC/C-Cdc20 is tightly controlled by phosphorylation and specific inhibitors to ensure the sequential ubiquitination of downstream targets. Here, we report on the novel finding of a regulated circuitry that controls the timely expression and hence activity of APC/C-Cdc20 during mitosis. Our study showed that RASSF1A and APC/C-Cdc20 form a molecular relay that regulates the APC/C-Cdc20 activity at early mitosis. We found that RASSF1A inhibits APC/C-Cdc20 function through its D-box motifs. Paradoxically, RASSF1A was also demonstrated to be ubiquitinated by APC/C-Cdc20 in vitro and degraded at prometaphase despite of active spindle checkpoint presence. The first two unique D-boxes at the N-terminal of RASSF1A served as specific degron recognized by APC/C-Cdc20. Importantly, we found that Aurora A and Aurora B directly phosphorylate RASSF1A, a critical step by which RASSF1A switches from being an inhibitor to a substrate of APC/C-Cdc20 during the course of mitotic progression. As a result of RASSF1A degradation, APC/C-Cdc20 can then partially activate the ubiquitination of Cyclin A in the presence of spindle checkpoint. This circuitry is essential for the timely degradation of Cyclin A. To conclude, our results propose a new model for RASSF1A-APC/C-Cdc20 interaction in ensuring the sequential progression of mitosis. Oncogene (2012) 31, 1975-1987; doi:10.1038/onc.2011.372; published online 29 August 2011	[Chow, C.; Wong, N.; Lun, S. W-M; Lo, K-W] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Shatin, Hong Kong, Peoples R China; [Wong, N.; Lo, K-W] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Pagano, M.] NYU, Sch Med, Dept Pathol, Inst Canc, New York, NY USA; [Nakayama, K-I] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan; [Nakayama, K.] Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res, Dept Dev Genet,Aoba Ku, Sendai, Miyagi 980, Japan	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; New York University; Kyushu University; Tohoku University	Lo, KW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Shatin, Hong Kong, Peoples R China.	kwlo@cuhk.edu.hk		pagano, michele/0000-0003-3210-2442	Michael and Betty Kadoorie Cancer Genetics Research Program II (MBKCGRPII); Li Ka Shing Institute of Health Science; Hong Kong Research Grant Council [440606]; NATIONAL CANCER INSTITUTE [R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Michael and Betty Kadoorie Cancer Genetics Research Program II (MBKCGRPII); Li Ka Shing Institute of Health Science; Hong Kong Research Grant Council(Hong Kong Research Grants Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Michael and Betty Kadoorie Cancer Genetics Research Program II (MBKCGRPII), Li Ka Shing Institute of Health Science and Hong Kong Research Grant Council (440606).	Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Braunstein I, 2007, P NATL ACAD SCI USA, V104, P4870, DOI 10.1073/pnas.0700523104; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Enquist-Newman M, 2008, MOL CELL, V30, P437, DOI 10.1016/j.molcel.2008.04.004; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Heron NM, 2006, BIOORG MED CHEM LETT, V16, P1320, DOI 10.1016/j.bmcl.2005.11.053; Izawa D, 2011, NAT CELL BIOL, V13, P223, DOI 10.1038/ncb2165; Jiang LY, 2011, J BIOL CHEM, V286, P6971, DOI 10.1074/jbc.M110.186494; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Liu L, 2008, ONCOGENE, V27, P6175, DOI 10.1038/onc.2008.220; Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Mortlock A, 2005, CURR TOP MED CHEM, V5, P805, DOI 10.2174/1568026054637719; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Song MS, 2008, ONCOGENE, V27, P3176, DOI 10.1038/sj.onc.1210971; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Song SJ, 2009, CANCER RES, V69, P8540, DOI 10.1158/0008-5472.CAN-09-1554; van Zon W, 2010, BIOCHEM SOC T, V38, P72, DOI 10.1042/BST0380072; Wang X, 2008, ONCOGENE, V27, P4456, DOI 10.1038/onc.2008.87; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027; Woodbury EL, 2007, NAT CELL BIOL, V9, P106, DOI 10.1038/ncb1523; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	37	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1975	1987		10.1038/onc.2011.372	http://dx.doi.org/10.1038/onc.2011.372			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874044	hybrid, Green Published			2022-12-28	WOS:000302809900009
J	Eppinga, RD; Krueger, EW; Weller, SG; Zhang, L; Cao, H; McNiven, MA				Eppinga, R. D.; Krueger, E. W.; Weller, S. G.; Zhang, L.; Cao, H.; McNiven, M. A.			Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma	ONCOGENE			English	Article						dynamin 2 (Dyn2); pancreatic ductal adenocarcinoma (PDAC); cell migration; invasion; metastasis; Src	ACTIN-BINDING PROTEIN; FOCAL ADHESION; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; SRC; ENDOCYTOSIS; CANCER; CYTOSKELETON; ACTIVATION; INHIBITORS	Pancreatic ductal tumors invade local parenchyma and metastasize to distant organs. Src-mediated tyrosine kinase signaling pathways promote pancreatic ductal adenocarcinoma (PDAC) metastasis, though the molecular mechanisms supporting this invasive process are poorly understood and represent important and novel therapeutic targets. The large GTPase Dynamin 2 (Dyn2), a Src-kinase substrate, regulates membrane-cytoskeletal dynamics although it is yet to be defined if it contributes to tumor cell migration and invasion. Therefore, the goal of this study was to test if Dyn2 is upregulated in human pancreatic tumors and to define its role in cell migration and metastatic invasion using in vitro assays and nude mouse models. Histological analysis showed that 81% of 85 patients had elevated Dyn2 in PDAC. To test if Dyn2 overexpression alters metastatic properties of human pancreatic tumor cells, stable clones of BxPC-3 cells overexpressing either wild-type Dyn2 or a phosphorylation-deficient mutant Dyn2Y(231/597) F known to attenuate Dyn2 function, were generated and analyzed. Importantly, tumor cells overexpressing Dyn2 protruded lamellipodia at twice the rate, migrated faster (180%) and farther (2.5-fold greater distance) on glass and through transwell chambers (2-3-fold more cells through the filter) compared with cells expressing Dyn2Y(231/597) F or vector alone. Further, depletion of Dyn2 and dynamin inhibitors Myristyl trimethyl ammonium bromides and Dynasore significantly reduced cell migration, wound healing and invasion in transwell assays compared with controls. To test the metastatic potential conferred by increased Dyn2 expression, the BxPC-3 cell lines were implanted orthotopically into the pancreas of nude mice. Cells expressing Dyn2-green fluorescent protein exhibited a threefold increase in large distal tumors compared with cells expressing Dyn2Y(231/597) F or vector alone. Finally, histological analysis revealed that Dyn2 is upregulated in 60% of human metastatic pancreatic tumors. These findings are the first to implicate dynamin in any neoplastic condition and to directly demonstrate a role for this mechanoenzyme in invasive cell migration. Oncogene (2012) 31, 1228-1241; doi:10.1038/onc.2011.329; published online 15 August 2011	[Eppinga, R. D.; Krueger, E. W.; Weller, S. G.; Cao, H.; McNiven, M. A.] Mayo Clin, Dept Biochem & Mol Biol, Ctr Digest Dis, Rochester, MN 55905 USA; [Zhang, L.] Mayo Clin, Dept Lab Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Ctr Digest Dis, 200 1st St SW,Guggenheim 1637, Rochester, MN 55905 USA.	mcniven.mark@mayo.edu			National Institutes of Health NCI [R01-CA104125, T32-DK007198]; Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK) [P30DK084567]; Mayo Clinic SPORE in Pancreatic Cancer [P50 CA 102701]; Lustgarten Foundation for Pancreatic Cancer Research; Fraternal Order of the Eagles; NATIONAL CANCER INSTITUTE [R01CA104125, P50CA102701, P20CA102701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK084567, T32DK007198] Funding Source: NIH RePORTER	National Institutes of Health NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Mayo Clinic SPORE in Pancreatic Cancer; Lustgarten Foundation for Pancreatic Cancer Research; Fraternal Order of the Eagles; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful for support from the National Institutes of Health NCI R01-CA104125 (MAM), T32-DK007198 (RDE), the Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK P30DK084567), the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA 102701), the Lustgarten Foundation for Pancreatic Cancer Research and the Fraternal Order of the Eagles.	Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alves F, 2001, PANCREAS, V23, P227, DOI 10.1097/00006676-200110000-00002; Bloomston M, 2006, DIGEST SURG, V23, P74, DOI 10.1159/000093497; Bouvet M, 2000, CLIN EXP METASTAS, V18, P213, DOI 10.1023/A:1006767405609; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cao H, 2010, MOL CELL BIOL, V30, P781, DOI 10.1128/MCB.00330-09; Chao WT, 2009, FEBS LETT, V583, P1337, DOI 10.1016/j.febslet.2009.03.037; Dancer J, 2007, ONCOL REP, V18, P151; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; Hakam A, 2003, DIGEST DIS SCI, V48, P1972, DOI 10.1023/A:1026122421369; Hansen CG, 2009, J CELL SCI, V122, P1713, DOI 10.1242/jcs.033951; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Hasegawa K, 2006, CLIN CANCER RES, V12, P6170, DOI 10.1158/1078-0432.CCR-06-0992; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hill TA, 2004, BIOORG MED CHEM LETT, V14, P3275, DOI 10.1016/j.bmcl.2004.03.096; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Itoh T, 2005, DEV CELL, V9, P791, DOI 10.1016/j.devcel.2005.11.005; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Joshi S, 2010, MOL CANCER THER, V9, P1995, DOI 10.1158/1535-7163.MCT-10-0161; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim DJ, 2006, J BIOL CHEM, V281, P617, DOI 10.1074/jbc.M504450200; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kim Y, 2005, J NEUROSCI, V25, P9515, DOI 10.1523/JNEUROSCI.1643-05.2005; Kruchten AE, 2006, J CELL SCI, V119, P1683, DOI 10.1242/jcs.02963; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mihaljevic AL, 2010, LANGENBECK ARCH SURG, V395, P295, DOI 10.1007/s00423-010-0622-5; Mooren OL, 2009, J BIOL CHEM, V284, P23995, DOI 10.1074/jbc.M109.024398; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Muders MH, 2006, CANCER RES, V66, P10264, DOI 10.1158/0008-5472.CAN-06-2321; Newton AJ, 2006, P NATL ACAD SCI USA, V103, P17955, DOI 10.1073/pnas.0606212103; Nieto J, 2008, ONCOLOGIST, V13, P562, DOI 10.1634/theoncologist.2007-0181; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Quan A, 2007, MOL PHARMACOL, V72, P1425, DOI 10.1124/mol.107.034207; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Thybusch-Bernhardt A, 2001, Int J Surg Investig, V2, P393; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang Y, 2011, MOL BIOL CELL, V22, P1529, DOI 10.1091/mbc.E10-09-0785; Weller SG, 2010, P NATL ACAD SCI USA, V107, P5863, DOI 10.1073/pnas.0915123107; Wu M, 2010, NAT CELL BIOL, V12, P902, DOI 10.1038/ncb2094; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yoo JY, 2005, BIOCHEM BIOPH RES CO, V328, P424, DOI 10.1016/j.bbrc.2004.12.179	63	45	45	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1228	1241		10.1038/onc.2011.329	http://dx.doi.org/10.1038/onc.2011.329			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21841817	Green Accepted			2022-12-28	WOS:000301344600003
J	Sayan, AE; Stanford, R; Vickery, R; Grigorenko, E; Diesch, J; Kulbicki, K; Edwards, R; Pal, R; Greaves, P; Jariel-Encontre, I; Piechaczyk, M; Kriajevska, M; Mellon, JK; Dhillon, AS; Tulchinsky, E				Sayan, A. E.; Stanford, R.; Vickery, R.; Grigorenko, E.; Diesch, J.; Kulbicki, K.; Edwards, R.; Pal, R.; Greaves, P.; Jariel-Encontre, I.; Piechaczyk, M.; Kriajevska, M.; Mellon, J. K.; Dhillon, A. S.; Tulchinsky, E.			Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL	ONCOGENE			English	Article						Fos-related antigen-1; cell motility; bladder cancer	BREAST-CANCER; PROTEASOMAL DEGRADATION; CARCINOMA-CELLS; FAMILY-MEMBERS; C-MET; EXPRESSION; AP-1; RAS; TARGET; GENE	Fos-related antigen 1 (Fra-1) is a Fos family member overexpressed in several types of human cancers. Here, we report that Fra-1 is highly expressed in the muscle-invasive form of the carcinoma of the bladder (80%) and to a lesser extent in superficial bladder cancer (42%). We demonstrate that in this type of cancer Fra-1 is regulated via a C-terminal instability signal and C-terminal phosphorylation. We show that manipulation of Fra-1 expression levels in bladder cancer cell lines affects cell morphology, motility and proliferation. The gene coding for AXL tyrosine kinase is directly upregulated by Fra-1 in bladder cancer and in other cell lines. Importantly, our data demonstrate that AXL mediates the effect of Fra-1 on tumour cell motility but not on cell proliferation. We suggest that AXL may represent an attractive therapeutic target in cancers expressing high Fra-1 levels. Oncogene (2012) 31, 1493-1503; doi:10.1038/onc.2011.336; published online 8 August 2011	[Sayan, A. E.; Stanford, R.; Vickery, R.; Kulbicki, K.; Pal, R.; Kriajevska, M.; Mellon, J. K.; Tulchinsky, E.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Sayan, A. E.] Univ Southampton, Sch Med, Cancer Sci Div, Southampton, Hants, England; [Grigorenko, E.] Life Technol Inc, Woburn, MA USA; [Diesch, J.; Dhillon, A. S.] Univ Melbourne, Dept Biochem & Mol Biol, Inst Bio21, Melbourne, Vic, Australia; [Edwards, R.; Greaves, P.] MRC, Toxicol Unit, Leicester, Leics, England; [Jariel-Encontre, I.; Piechaczyk, M.] Univ Montpellier 1 & 2, CNRS, Inst Genet Mol Montpellier, Montpellier, France	University of Leicester; University of Southampton; Thermo Fisher Scientific; University of Melbourne; University of Leicester; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Dhillon, AS (corresponding author), Peter MacCallum Canc Ctr, Growth & Differentiat Program, Div Res, St Andrews Pl E Melbourne, Melbourne, Vic 3002, Australia.	Amardeep.Dhillon@petermac.org; et32@le.ac.uk	Tulchinsky, Eugene/ABD-7070-2021; SAYAN, A. EMRE/H-7330-2012; Diesch, Jeannine/J-8558-2017; PIECHACZYK, Marc/E-7896-2013	SAYAN, A. EMRE/0000-0002-5291-1485; Diesch, Jeannine/0000-0002-4667-3468; PIECHACZYK, Marc/0000-0003-1367-2597; Stanford, Richard/0000-0002-0189-7468; Dhillon, Amardeep/0000-0002-6065-663X	Association for International Cancer Research [07-0083]; National Health and Medical Research Council of Australia; French Ligue Nationale contre le Cancer	Association for International Cancer Research; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); French Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was supported by the Association for International Cancer Research grant 07-0083 (to ET) and by a grant from the National Health and Medical Research Council of Australia (to AD). MP is supported by an 'Equipe Labelisee' grant from the French Ligue Nationale contre le Cancer	Andersen H, 2005, MOL CELL BIOL, V25, P9138, DOI 10.1128/MCB.25.20.9138-9150.2005; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chiappetta G, 2000, CLIN CANCER RES, V6, P4300; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Debinski W, 2005, MOL CANCER RES, V3, P237; Dixon James M, 2009, Biotechniques, V46, pii, DOI 10.2144/000112746; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Heiring C, 2004, J BIOL CHEM, V279, P6952, DOI 10.1074/jbc.M311750200; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hu CY, 2001, CLIN CANCER RES, V7, P2213; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Knowles MA, 2008, INT J CLIN ONCOL, V13, P287, DOI 10.1007/s10147-008-0812-0; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McHugh LA, 2009, INT J ONCOL, V34, P1155, DOI 10.3892/ijo_00000244; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mitra AP, 2009, ANNU REV PATHOL-MECH, V4, P251, DOI 10.1146/annurev.pathol.4.110807.092230; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Ozanne BW, 2006, CURR OPIN GENET DEV, V16, P65, DOI 10.1016/j.gde.2005.12.012; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Sainaghi PP, 2005, J CELL PHYSIOL, V204, P36, DOI 10.1002/jcp.20265; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Yeh CY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-139; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Zhang WH, 2005, AM J CLIN PATHOL, V124, P11, DOI 10.1309/T1H2Y2CHWY7PD2BN; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	45	68	70	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1493	1503		10.1038/onc.2011.336	http://dx.doi.org/10.1038/onc.2011.336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21822309				2022-12-28	WOS:000302132000003
J	Bangert, A; Cristofanon, S; Eckhardt, I; Abhari, BA; Kolodziej, S; Hacker, S; Vellanki, SHK; Lausen, J; Debatin, KM; Fulda, S				Bangert, A.; Cristofanon, S.; Eckhardt, I.; Abhari, B. A.; Kolodziej, S.; Haecker, S.; Vellanki, S. H. K.; Lausen, J.; Debatin, K-M; Fulda, S.			Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP	ONCOGENE			English	Article						apoptosis; TRAIL; glioblastoma; HDACI; cFLIP	NF-KAPPA-B; LYMPHOCYTIC-LEUKEMIA CELLS; DRUG-INDUCED APOPTOSIS; HDAC INHIBITORS; MALIGNANT GLIOMA; CANCER-CELLS; DEATH; FLIP; ACTIVATION; EXPRESSION	Glioblastoma is the most common primary brain tumor with a very poor prognosis, calling for novel treatment strategies. Here, we provide first evidence that histone deacetylase inhibitors (HDACI) prime glioblastoma cells for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) -induced apoptosis at least in part by c-myc-mediated downregulation of cellular FLICE-inhibitory protein (cFLIP). Pretreatment with distinct HDACI (MS275, suberoylanilide hydroxamic acid, valproic acid) significantly enhances TRAIL-induced apoptosis in several glioblastoma cell lines. Monitoring a panel of apoptosis-regulatory proteins revealed that MS275 reduces the expression of cFLIP(L) and cFLIP(S). This leads to decreased recruitment of cFLIP(L) and cFLIP(S) and increased activation of caspase-8 to the TRAIL death-inducing signaling complex, resulting in enhanced cleavage of caspase-8, -9 and -3 and caspase-dependent apoptosis. Also, MS275 promotes TRAIL-triggered processing of Bid, activation of Bax, loss of mitochondrial membrane potential and release of cytochrome c. MS275-mediated downregulation of cFLIP occurs at the mRNA level independent of proteasome-or caspase-mediated degradation, and is preceded by upregulation of nuclear levels of c-myc, a transcriptional repressor of cFLIP. Notably, MS275 causes increased binding of c-myc to the cFLIP promoter and reduces cFLIP promoter activity. Indeed, knockdown of c-myc partially rescues cFLIP(L) from MS275-inferred downregulation and significantly decreases TRAIL-and MS275-induced apoptosis. Also, overexpression of cFLIP(L) or cFLIP(S) significantly reduces MS275- and TRAIL-induced apoptosis. Importantly, MS275 sensitizes primary cultured glioblastoma cells towards TRAIL and cooperates with TRAIL to reduce long-term clonogenic survival of glioblastoma cells and to suppress glioblastoma growth in vivo underscoring the clinical relevance of this approach. Thus, these findings demonstrate that HDACI represent a promising strategy to prime glioblastoma for TRAIL-induced apoptosis by targeting cFLIP.	[Cristofanon, S.; Eckhardt, I.; Abhari, B. A.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Bangert, A.; Haecker, S.; Vellanki, S. H. K.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, Ulm, Germany; [Kolodziej, S.; Lausen, J.] Inst Biomed Res, Frankfurt, Germany	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Else Kroner-Fresenius-Stiftung; European Community (ApopTrain, APO-SYS);  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Else Kroner-Fresenius-Stiftung; European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); 	We thank O Micheau (Dijon, France) and M Leverkus (Mannheim, Germany) for providing cFLIP vectors. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, Else Kroner-Fresenius-Stiftung, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF).	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Aguilera DG, 2009, J NEURO-ONCOL, V93, P303, DOI 10.1007/s11060-008-9788-x; Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carlisi D, 2009, EUR J CANCER, V45, P2425, DOI 10.1016/j.ejca.2009.06.024; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Eyupoglu LY, 2006, MOL CANCER THER, V5, P1248, DOI 10.1158/1535-7163.MCT-05-0533; Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2008, CURR CANCER DRUG TAR, V8, P132, DOI 10.2174/156800908783769355; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Guo F, 2004, CANCER RES, V64, P2580, DOI 10.1158/0008-5472.CAN-03-2629; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hernandez A, 2001, SURGERY, V130, P265, DOI 10.1067/msy.2001.115897; Inoue S, 2009, MOL CANCER THER, V8, P3088, DOI 10.1158/1535-7163.MCT-09-0451; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim EH, 2005, ONCOGENE, V24, P6877, DOI 10.1038/sj.onc.1208851; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuijlen JMA, 2010, NEUROPATH APPL NEURO, V36, P168, DOI 10.1111/j.1365-2990.2010.01069.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MICHEAU O, 2006, APOPTOSIS CANC THERA, P120; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitchell KO, 2000, CANCER RES, V60, P6318; Nieminen AI, 2007, EMBO J, V26, P1055, DOI 10.1038/sj.emboj.7601551; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Salon C, 2006, CELL DEATH DIFFER, V13, P260, DOI 10.1038/sj.cdd.4401739; Sanchez-Perez T, 2010, CELL DEATH DIFFER, V17, P883, DOI 10.1038/cdd.2009.176; Simonini MV, 2006, P NATL ACAD SCI USA, V103, P1587, DOI 10.1073/pnas.0510341103; Singh TR, 2005, ONCOGENE, V24, P4609, DOI 10.1038/sj.onc.1208585; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vervoorts J, 2006, J BIOL CHEM, V281, P34725, DOI 10.1074/jbc.R600017200; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Watanabe K, 2005, CELL DEATH DIFFER, V12, P10, DOI 10.1038/sj.cdd.4401507; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153	48	61	63	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4677	4688		10.1038/onc.2011.614	http://dx.doi.org/10.1038/onc.2011.614			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266862				2022-12-28	WOS:000310724400003
J	Fassl, A; Tagscherer, KE; Richter, J; Diaz, MB; Llaguno, SRA; Campos, B; Kopitz, J; Herold-Mende, C; Herzig, S; Schmidt, MHH; Parada, LF; Wiestler, OD; Roth, W				Fassl, A.; Tagscherer, K. E.; Richter, J.; Diaz, M. Berriel; Llaguno, S. R. Alcantara; Campos, B.; Kopitz, J.; Herold-Mende, C.; Herzig, S.; Schmidt, M. H. H.; Parada, L. F.; Wiestler, O. D.; Roth, W.			Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1	ONCOGENE			English	Article						glioblastoma; apoptosis; Notch1; Mcl-1; EGFR	GROWTH-FACTOR RECEPTOR; NEURAL STEM-CELLS; MALIGNANT GLIOMA; BRAIN-TUMORS; EXPRESSION; PATHWAY; ACTIVATION; ORIGIN; BCL-2; P53	The Notch1-mediated signaling pathway has a central role in the maintenance of neural stem cells and contributes to growth and progression of glioblastomas, the most frequent malignant brain tumors in adults. Here, we demonstrate that the Notch1 receptor promotes survival of glioblastoma cells by regulation of the anti-apoptotic Mcl-1 protein. Notch1-dependent regulation of Mcl-1 occurs cell type dependent at a transcriptional or post-translational level and is mediated by the induction of epidermal growth factor receptor (EGFR). Inhibition of the Notch1 pathway overcomes apoptosis resistance and sensitizes glioblastoma cells to apoptosis induced by ionizing radiation, the death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) or the Bcl-2/Bcl-XL inhibitor ABT-737. In conclusion, targeting Notch1 might represent a promising novel strategy in the treatment of glioblastomas.	[Diaz, M. Berriel; Herzig, S.] Univ Heidelberg, Ctr Mol Biol, DKFZ, Joint Div Mol Metab Control, D-6900 Heidelberg, Germany; [Diaz, M. Berriel; Herzig, S.] Univ Heidelberg Hosp, Heidelberg, Germany; [Llaguno, S. R. Alcantara; Parada, L. F.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA; [Campos, B.; Herold-Mende, C.] Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany; [Kopitz, J.; Roth, W.] Univ Heidelberg, Inst Pathol, D-6900 Heidelberg, Germany; [Schmidt, M. H. H.] Goethe Univ Frankfurt, Inst Neurol, Frankfurt, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Texas System; University of Texas Southwestern Medical Center Dallas; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Goethe University Frankfurt	Roth, W (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	W.Roth@dkfz.de	Tagscherer, Katrin/AAS-3809-2021; Parada, luis F/B-9400-2014; Diaz, Mauricio Berriel/AAF-8285-2021; Fassl, Anne/AAA-5249-2022; Schmidt, Mirko H. H./ABI-6650-2020	Tagscherer, Katrin/0000-0002-0657-6399; Schmidt, Mirko H. H./0000-0001-7411-8835; Berriel Diaz, Mauricio/0000-0003-4670-919X; Alcantara, Sheila/0000-0002-1586-4384; Herzig, Stephan/0000-0003-3950-3652	Deutsche Krebshilfe (German Cancer Aid)	Deutsche Krebshilfe (German Cancer Aid)(Deutsche Krebshilfe)	We thank Tabea Sinkovic and Martina Keith for technical assistance. We further thank Anja Reimann (Molecular Metabolic Control, DKFZ, Heidelberg, Germany) for help with purification of recombinant adenoviruses, David Capper, David Reuss and Andreas v Deimling (Department of Neuropathology, University of Heidelberg, Germany) for providing histological sections of glioblastomas and Tamara Quandel, Lodovica Borghese, Philipp Koch and Oliver Brustle (Institute of Reconstructive Neurobiology, Life and Brain, Bonn, Germany) for providing cell pellets and RNA from neural stem cells. This work was supported by a grant from the Deutsche Krebshilfe to WR (German Cancer Aid, Max Eder Program).	Arbour N, 2008, J NEUROSCI, V28, P6068, DOI 10.1523/JNEUROSCI.4940-07.2008; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800; Capper D, 2009, ACTA NEUROPATHOL, V117, P445, DOI 10.1007/s00401-009-0494-3; Chen J, 2010, RADIAT PROT DOSIM, V142, P1, DOI 10.1093/rpd/ncq205; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Kanamori M, 2007, J NEUROSURG, V106, P417, DOI 10.3171/jns.2007.106.3.417; Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648; Koch P, 2009, P NATL ACAD SCI USA, V106, P3225, DOI 10.1073/pnas.0808387106; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krajewski S, 1997, AM J PATHOL, V150, P805; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Liu WH, 2007, EMBO J, V26, P1660, DOI 10.1038/sj.emboj.7601611; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Masuoka HC, 2009, J BIOL CHEM, V284, P30039, DOI 10.1074/jbc.M109.039545; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Opferman JT, 2006, CELL DEATH DIFFER, V13, P1260, DOI 10.1038/sj.cdd.4401978; Pierfelice TJ, 2008, COLD SH Q B, V73, P367, DOI 10.1101/sqb.2008.73.013; Purow BW, 2008, CARCINOGENESIS, V29, P918, DOI 10.1093/carcin/bgn079; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Schmidt MHH, 2009, NAT CELL BIOL, V11, P873, DOI 10.1038/ncb1896; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Sheng Z, 2010, NAT MED, V16, P671, DOI 10.1038/nm.2158; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Tetering G, 2009, J BIOL CHEM, V284, P31018, DOI 10.1074/jbc.M109.006775; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Xu P, 2010, J NEURO-ONCOL, V97, P41, DOI 10.1007/s11060-009-0007-1; Yoon JH, 2002, CANCER RES, V62, P6500; Zhang XP, 2008, MOL CELL BIOCHEM, V307, P101, DOI 10.1007/s11010-007-9589-0; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004	50	53	55	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	44					4698	4708		10.1038/onc.2011.615	http://dx.doi.org/10.1038/onc.2011.615			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249262				2022-12-28	WOS:000310724400005
J	Brimer, N; Lyons, C; Wallberg, AE; Vande Pol, SB				Brimer, N.; Lyons, C.; Wallberg, A. E.; Vande Pol, S. B.			Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling	ONCOGENE			English	Article						CBF1; RBP-J; RBP-Jk; squamous; epithelial; transformation	SQUAMOUS-CELL CARCINOMA; CERVICAL-CANCER CELLS; TUMOR-SUPPRESSOR FUNCTION; TERMINAL DIFFERENTIATION; GROWTH ARREST; TYPE-1 E6; TRANSCRIPTIONAL COACTIVATOR; HUMAN KERATINOCYTES; NEOPLASTIC LESIONS; HUMAN HOMOLOG	Papillomavirus E6 oncoproteins associate with LXXLL motifs on target cellular proteins to alter their function. Using a proteomic approach, we found the E6 oncoproteins of cutaneous papillomaviruses Bovine Papillomavirus Type 1 (BPV-1) E6 and human papillomavirus (HPV) types 1 and 8 (1E6 and 8E6) associated with the MAML1 transcriptional co-activator. All three E6 proteins bind to an acidic LXXLL motif at the carboxy-terminus of MAML1 and repress transactivation by MAML1. MAML1 is best known as the co-activator and effector of NOTCH-induced transcription, and BPV-1 E6 represses synthetic NOTCH-responsive promoters, endogenous NOTCH-responsive promoters, and is found in a complex with MAML1 in stably transformed cells. BPV-1-induced papillomas show characteristics of repressed NOTCH signal transduction, including suprabasal expression of integrins, talin and basal type keratins, and delayed expression of the NOTCH-dependent HES1 transcription factor. These observations give rise to a model whereby papillomavirus oncoproteins, including BPV-1 E6, and the cancer-associated HPV-8 E6 repress NOTCH-induced transcription, thereby delaying keratinocyte differentiation.	[Brimer, N.; Lyons, C.; Vande Pol, S. B.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; [Wallberg, A. E.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	University of Virginia; Karolinska Institutet	Vande Pol, SB (corresponding author), Univ Virginia, Dept Pathol, POB 800904, Charlottesville, VA 22908 USA.	vandepol@virginia.edu	Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NIH [CA120352, CA08093]; Swedish Research Council; NATIONAL CANCER INSTITUTE [R01CA134737, R01CA120352] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swedish Research Council(Swedish Research CouncilEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	SVP, NB and CL were supported by NIH grants (CA120352 and CA08093) to SVP, and institutional support from the University of Virginia and the Department of Pathology Mass Spectrometry Facility. AEW is supported by the Swedish Research Council. We would like to thank Janet Cross and Benjamin Purow at UVA for helpful discussions and critical reading of the manuscript.	ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Allen-Hoffmann BL, 2000, J INVEST DERMATOL, V114, P444, DOI 10.1046/j.1523-1747.2000.00869.x; Alves-Guerra MC, 2007, CANCER RES, V67, P8690, DOI 10.1158/0008-5472.CAN-07-1720; Artayanis-Tsakonas S, 2010, CURR TOP DEV BIOL, V92, P1, DOI 10.1016/S0070-2153(10)92001-2; Baldus CD, 2009, HAEMATOL-HEMATOL J, V94, P1383, DOI 10.3324/haematol.2008.005272; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Bohl J, 2000, VIROLOGY, V271, P163, DOI 10.1006/viro.2000.0316; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; CHOW LT, 1994, INTERVIROLOGY, V37, P150, DOI 10.1159/000150373; Cooper B, 2006, VIROLOGY, V355, P102, DOI 10.1016/j.virol.2006.06.032; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Das K, 2000, J VIROL, V74, P812, DOI 10.1128/JVI.74.2.812-816.2000; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jin YH, 2009, MOL CELLS, V27, P15, DOI 10.1007/s10059-009-0001-7; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; KAISER HW, 1993, J INVEST DERMATOL, V101, P789, DOI 10.1111/1523-1747.ep12371696; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lathion S, 2003, CANCER RES, V63, P8687; Lee SY, 2009, CANCER SCI, V100, P920, DOI 10.1111/j.1349-7006.2009.01130.x; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Moriyama M, 2008, DEV CELL, V14, P594, DOI 10.1016/j.devcel.2008.01.017; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohashi S, 2010, GASTROENTEROLOGY, V139, P2113, DOI 10.1053/j.gastro.2010.08.040; Orth G, 2006, SEMIN IMMUNOL, V18, P362, DOI 10.1016/j.smim.2006.07.008; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066; Peng S, 2011, CELL BIOL INT, V35, P587, DOI 10.1042/CBI20100452; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Ramdass B, 2007, GYNECOL ONCOL, V104, P352, DOI 10.1016/j.ygyno.2006.08.054; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Rasul S, 2009, BRIT J CANCER, V100, P1879, DOI 10.1038/sj.bjc.6605034; Ribeiro MSJ, 2009, CURR PROTEIN PEPT SC, V10, P570; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Rous P, 1935, J EXP MED, V62, P523, DOI 10.1084/jem.62.4.523; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Stubenrauch F, 1999, SEMIN CANCER BIOL, V9, P379, DOI 10.1006/scbi.1999.0141; Sun Xiao-mei, 2009, Zhonghua Fu Chan Ke Za Zhi, V44, P369; Talora C, 2005, EXP CELL RES, V305, P343, DOI 10.1016/j.yexcr.2005.01.015; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanigaki K, 2010, CURR TOP DEV BIOL, V92, P231, DOI 10.1016/S0070-2153(10)92007-3; Tong X, 1998, J VIROL, V72, P476, DOI 10.1128/JVI.72.1.476-482.1998; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Vande Pol SB, 1998, ONCOGENE, V16, P43, DOI 10.1038/sj.onc.1201504; Wade R, 2008, J VIROL, V82, P5962, DOI 10.1128/JVI.02747-07; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang L, 2007, INT J GYNECOL CANCER, V17, P1283, DOI 10.1111/j.1525-1438.2007.00927.x; Watt FM, 2008, CURR OPIN CELL BIOL, V20, P171, DOI 10.1016/j.ceb.2008.01.010; WATT FM, 1993, J CELL SCI, V106, P175; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yamamoto N, 2003, CURR BIOL, V13, P333, DOI 10.1016/S0960-9822(03)00081-2; Yao J, 2007, INT J GYNECOL CANCER, V17, P502, DOI 10.1111/j.1525-1438.2007.00872.x; YEDVOBNICK B, 1988, GENETICS, V118, P483; Yu Hai, 2007, Ai Zheng, V26, P148; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhao YT, 2007, J BIOL CHEM, V282, P11969, DOI 10.1074/jbc.M608974200; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	77	93	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4639	4646		10.1038/onc.2011.589	http://dx.doi.org/10.1038/onc.2011.589			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22249263	Green Accepted			2022-12-28	WOS:000310528200007
J	Dallosso, AR; Oster, B; Greenhough, A; Thorsen, K; Curry, TJ; Owen, C; Hancock, AL; Szemes, M; Paraskeva, C; Frank, M; Andersen, CL; Malik, K				Dallosso, A. R.; Oster, B.; Greenhough, A.; Thorsen, K.; Curry, T. J.; Owen, C.; Hancock, A. L.; Szemes, M.; Paraskeva, C.; Frank, M.; Andersen, C. L.; Malik, K.			Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways	ONCOGENE			English	Article						colorectal cancer; protocadherin; epigenetic silencing; Wnt; mTOR	DNA METHYLATION; MICROSATELLITE INSTABILITY; GAMMA-PROTOCADHERINS; HOMOPHILIC INTERACTION; CYTOPLASMIC DOMAIN; TUMOR-SUPPRESSOR; HUMAN BREAST; CANCER; GENE; CARCINOMA	Loss of tumour suppressor gene function can occur as a result of epigenetic silencing of large chromosomal regions, referred to as long-range epigenetic silencing (LRES), and genome-wide analyses have revealed that LRES is present in many cancer types. Here we utilize Illumina Beadchip methylation array analysis to identify LRES across 800 kb of chromosome 5q31 in colorectal adenomas and carcinomas (n = 34) relative to normal colonic epithelial DNA (n = 6). This region encompasses 53 individual protocadherin (PCDH) genes divided among three gene clusters. Hypermethylation within these gene clusters is asynchronous; while most PCDH hypermethylation occurs early, and is apparent in adenomas, PCDHGC3 promoter methylation occurs later in the adenoma-carcinoma transition. PCDHGC3 was hypermethylated in 17/28 carcinomas (60.7%) according to methylation array analysis. Quantitative real-time reverse transcription-polymerase chain reaction showed that PCDHGC3 is the highest expressed PCDH in normal colonic epithelium, and that there was a strong reciprocal relationship between PCDHGC3 methylation and expression in carcinomas (R = -0.84). PCDH LRES patterns are reflected in colorectal tumour cell lines; adenoma cell lines are not methylated at PCDHGC3 and show abundant expression at the mRNA and protein level, while the expression is suppressed in hypermethylated carcinoma cell lines (R = -0.73). Short-interfering RNA-mediated reduction of PCDHGC3 led to a decrease of apoptosis in RG/C2 adenoma cells, and overexpression of PCDHGC3 in HCT116 cells resulted in the reduction of colony formation, consistent with tumour suppressor capabilities for PCDHGC3. Further functional analysis showed that PCDHGC3 can suppress Wnt and mammalian target of rapamycin signalling in colorectal cancer cell lines. Taken together, our data suggest that the PCDH LRES is an important tumour suppressor locus in colorectal cancer, and that PCDHGC3 may be a strong marker and driver for the adenoma-carcinoma transition. Oncogene (2012) 31, 4409-4419; doi: 10.1038/onc.2011.609; published online 16 January 2012	[Oster, B.; Thorsen, K.; Andersen, C. L.] Aarhus Univ Hosp, Dept Mol Med, DK-8200 Skejby, Denmark; [Dallosso, A. R.; Curry, T. J.; Owen, C.; Hancock, A. L.; Szemes, M.; Malik, K.] Univ Bristol, Sch Cellular & Mol Med, Canc Epigenet Lab, Bristol BS8 1TD, Avon, England; [Greenhough, A.; Paraskeva, C.] Univ Bristol, Sch Cellular & Mol Med, Colorectal Canc Lab, Bristol, Avon, England; [Frank, M.] Univ Freiburg, Inst Biol 1, Freiburg, Germany	Aarhus University; University of Bristol; University of Bristol; University of Freiburg	Andersen, CL (corresponding author), Aarhus Univ Hosp, Dept Mol Med, DK-8200 Skejby, Denmark.	cla@ki.au.dk; k.t.a.malik@bristol.ac.uk	Andersen, Claus L/C-1477-2017; Greenhough, Alexander/Y-6728-2019; Greenhough, Alexander/J-9308-2012; Andersen, Claus Lindbjerg/A-9217-2012	Greenhough, Alexander/0000-0002-8306-811X; Greenhough, Alexander/0000-0002-8306-811X; Andersen, Claus Lindbjerg/0000-0002-7406-2103; Dallosso, Anthony/0000-0002-1460-2550; Malik, Karim/0000-0002-8965-200X	Wellcome Trust VIP award; Cancer Research UK [C20791/A12743, C19/A11975]; Kidney Research UK; Cancer and Leukaemia in Childhood-Sargent Trust; John and Birthe Meyer Foundation; Lundbeck Foundation; European Union [SYSCOL HEALTHF5-2010-258236]; Cancer Research UK [12743, 11975] Funding Source: researchfish; Kidney Research UK [RP42/2009] Funding Source: researchfish	Wellcome Trust VIP award(Wellcome Trust); Cancer Research UK(Cancer Research UK); Kidney Research UK(Kidney Research UK (KRUK)); Cancer and Leukaemia in Childhood-Sargent Trust; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); European Union(European Commission); Cancer Research UK(Cancer Research UK); Kidney Research UK(Kidney Research UK (KRUK))	This work was supported by a Wellcome Trust VIP award, Cancer Research UK Grants C20791/A12743 and C19/A11975, Kidney Research UK and the Cancer and Leukaemia in Childhood-Sargent Trust. Further funding was from the John and Birthe Meyer Foundation, the Lundbeck Foundation and The European Union's Seventh Framework Program (SYSCOL HEALTHF5-2010-258236). We thank Dr Greg Phillips for the antibody towards the gamma-PCDH constant domain, Professor Moon for reporter plasmids and Professor Vogelstein for mutant HCT116 cells. We also thank Dr Andrea Buda, Dr Katy Petherick, Dr Zsombor Melegh, Dr Newton Wong and Professor Andrew Silver for helpful discussions and comments.	Ahuja N, 1997, CANCER RES, V57, P3370; Ashton GH, 2010, DEV CELL, V19, P259, DOI 10.1016/j.devcel.2010.07.015; Bass T, 2007, DEV GENES EVOL, V217, P337, DOI 10.1007/s00427-007-0145-4; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745; Elder DJE, 1996, CANCER RES, V56, P2273; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fernandez-Monreal M, 2009, MOL CELL NEUROSCI, V40, P344, DOI 10.1016/j.mcn.2008.12.002; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Greenhough A, 2010, ONCOGENE, V29, P3398, DOI 10.1038/onc.2010.94; Greenspan EJ, 2006, CARCINOGENESIS, V27, P1316, DOI 10.1093/carcin/bgi373; Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hambsch B, 2005, J BIOL CHEM, V280, P15888, DOI 10.1074/jbc.M414359200; Han MH, 2010, MOL CELL PROTEOMICS, V9, P71, DOI 10.1074/mcp.M900343-MCP200; Hanson HH, 2010, J BIOL CHEM, V285, P20982, DOI 10.1074/jbc.M109.092031; Hitchins MP, 2007, CANCER RES, V67, P9107, DOI 10.1158/0008-5472.CAN-07-0869; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Javierre BM, 2011, MOL CANCER RES, V9, P1139, DOI 10.1158/1541-7786.MCR-10-0515; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kobayashi Y, 2011, GENOME RES, V21, P1017, DOI 10.1101/gr.119487.110; Lin CY, 2010, J BIOL CHEM, V285, P41675, DOI 10.1074/jbc.M110.179895; Lind GE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-85; Matsuzaki K, 2005, CLIN CANCER RES, V11, P8564, DOI 10.1158/1078-0432.CCR-05-0859; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; O'Leary R, 2011, MOL BIOL CELL, V22, P4362, DOI 10.1091/mbc.E11-04-0283; OBATA S, 1995, J CELL SCI, V108, P3765; Oster B, 2011, INT J CANCER, V129, P2855, DOI 10.1002/ijc.25951; PARASKEVA C, 1989, CANCER RES, V49, P1282; Paz MF, 2003, CANCER RES, V63, P1114; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Schalm SS, 2010, P NATL ACAD SCI USA, V107, P13894, DOI 10.1073/pnas.1007182107; Schmidt WM, 2007, MOL CARCINOGEN, V46, P766, DOI 10.1002/mc.20307; Schreiner D, 2010, P NATL ACAD SCI USA, V107, P14893, DOI 10.1073/pnas.1004526107; Smith LT, 2006, P NATL ACAD SCI USA, V103, P982, DOI 10.1073/pnas.0510171102; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Wang XZ, 2009, J BIOL CHEM, V284, P2880; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wong JJL, 2011, MODERN PATHOL, V24, P396, DOI 10.1038/modpathol.2010.212; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154	57	50	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4409	4419		10.1038/onc.2011.609	http://dx.doi.org/10.1038/onc.2011.609			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249255	Green Accepted			2022-12-28	WOS:000309591300007
J	Ferreira, LMR; Hebrant, A; Dumont, JE				Ferreira, L. M. R.; Hebrant, A.; Dumont, J. E.			Metabolic reprogramming of the tumor	ONCOGENE			English	Review						cancer; metabolism; microenvironment; evolution	ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITIONS; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; ATP CITRATE LYASE; MESSENGER-RNA; AEROBIC GLYCOLYSIS; LACTIC-ACID; STEM-CELLS; OXIDATIVE-PHOSPHORYLATION	Cancer is classically considered as a genetic and, more recently, epigenetic multistep disease. Despite seminal studies in the 1920s by Warburg showing a characteristic metabolic pattern for tumors, cancer bioenergetics has often been relegated to the backwaters of cancer biology. This review aims to provide a historical account on cancer metabolism research, and to try to integrate and systematize the metabolic strategies in which cancer cells engage to overcome selective pressures during their inception and evolution. Implications of this renovated view on some common concepts and in therapeutics are also discussed. Oncogene (2012) 31, 3999-4011; doi:10.1038/onc.2011.576; published online 9 January 2012	[Ferreira, L. M. R.] Univ Coimbra, Fac Sci & Technol, Dept Life Sci, P-3001401 Coimbra, Portugal; [Hebrant, A.; Dumont, J. E.] Univ Libre Bruxelles, Sch Med, Inst Interdisciplinary Res IRIBHM, B-1070 Brussels, Belgium	Universidade de Coimbra; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Ferreira, LMR (corresponding author), Univ Coimbra, Fac Sci & Technol, Dept Life Sci, Rua Estudos, P-3001401 Coimbra, Portugal.	leonardo_m_r_ferreira@yahoo.com; jedumont@ulb.ac.be	Ferreira, Leonardo/J-7984-2019	Ferreira, Leonardo/0000-0003-2491-9866				Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; Akakura N, 2001, CANCER RES, V61, P6548; Alexander S, 2008, HISTOCHEM CELL BIOL, V130, P1147, DOI 10.1007/s00418-008-0529-1; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Berardi MJ, 2011, CURR OPIN GENET DEV, V21, P59, DOI 10.1016/j.gde.2010.10.001; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Boyland E, 1935, BIOCHEM J, V30, P224; Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bucay AH, 2009, MED HYPOTHESES, V73, P271, DOI 10.1016/j.mehy.2009.03.018; BURK D, 1956, SCIENCE, V124, P270; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Carrel A, 1921, J EXP MED, V34, P599, DOI 10.1084/jem.34.6.599; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Cori CF, 1925, J BIOL CHEM, V64, P11; Cori CF, 1925, J BIOL CHEM, V65, P397; Cramer W, 1926, BMJ-BRIT MED J, V1926, P175; D'Errico I, 2011, P NATL ACAD SCI USA, V108, P6603, DOI 10.1073/pnas.1016354108; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; De Bari L, 2010, INT J ONCOL, V37, P1607, DOI 10.3892/ijo_00000815; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; ECK HP, 1989, J CANCER RES CLIN, V115, P571, DOI 10.1007/BF00391360; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; ERECINSKA M, 1995, J NEUROCHEM, V65, P2765; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Ferreira LMR, 2010, EXP MOL PATHOL, V89, P372, DOI 10.1016/j.yexmp.2010.08.006; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184; Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104; Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Geschwind JFH, 2002, CANCER RES, V62, P3909; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; GOLDBLATT H, 1953, J EXP MED, V97, P525, DOI 10.1084/jem.97.4.525; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Guppy M, 2002, BIOCHEM BIOPH RES CO, V299, P676, DOI 10.1016/S0006-291X(02)02710-9; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; HOLLEY RW, 1974, P NATL ACAD SCI USA, V71, P2942, DOI 10.1073/pnas.71.8.2942; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu S, 2011, CELL METAB, V14, P131, DOI 10.1016/j.cmet.2011.04.012; HUEBNER RJ, 1969, P NATL ACAD SCI USA, V64, P1087, DOI 10.1073/pnas.64.3.1087; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; Johnston LA, 2009, SCIENCE, V324, P1679, DOI 10.1126/science.1163862; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307; KNOX WE, 1969, CANCER RES, V29, P669; KNOX WE, 1967, CANCER RES, V27, P1456; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondoh H, 2005, CANCER RES, V65, P177; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260; KREBS H. A., 1937, Enzymologia, V4, P148; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lin CM, 1999, NUTRITION, V15, P687, DOI 10.1016/S0899-9007(99)00153-7; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo J, 2009, CELL SCI REV, V6, P49; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lynen F, 1942, NATURWISSENSCHAFTEN, V30, P398, DOI 10.1007/BF01475305; Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Milovanova TN, 2008, MOL CELL BIOL, V28, P6248, DOI 10.1128/MCB.00795-08; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Newberne PM, 2002, TOXICOL SCI, V67, P1; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200; Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pasteur L, 1876, CR HEBD ACAD SCI, V52, P1260; Pauwels EKJ, 2000, J CANCER RES CLIN, V126, P549, DOI 10.1007/PL00008465; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; RACKER E, 1981, SCIENCE, V213, P303, DOI 10.1126/science.6264596; Ralph SJ, 2010, MOL ASPECTS MED, V31, P29, DOI 10.1016/j.mam.2009.12.006; Ramos-Montoya A, 2006, INT J CANCER, V119, P2733, DOI 10.1002/ijc.22227; Ravi R, 2000, GENE DEV, V14, P34; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rischin D, 2005, J CLIN ONCOL, V23, P79, DOI 10.1200/JCO.2005.01.072; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Ronzoni E, 1936, J BIOL CHEM, V115, P749; Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200; SCHUMAN VL, 1982, INT J RADIAT ONCOL, V8, P589, DOI 10.1016/0360-3016(82)90690-3; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; SONG CW, 1978, BRIT J CANCER, V37, P136; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STEHELIN D, 1976, J MOL BIOL, V101, P349, DOI 10.1016/0022-2836(76)90152-2; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; Stewart TJ, 2008, ONCOGENE, V27, P5894, DOI 10.1038/onc.2008.268; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Tjio J. H., 1956, HEREDITAS, V42, P1, DOI [10.1007/978-94-011-6621-8_13, DOI 10.1111/J.1601-5223.1956.TB03010.X]; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Tubiana Maurice, 2008, Nat Rev Cancer, V8, P990, DOI 10.1038/nrc2419-c1; VANDERHEIDEN MG, 2010, LOGIC CIRCUITS CARBO, V329, P1492; Varum S, 2009, STEM CELL RES, V3, P142, DOI 10.1016/j.scr.2009.07.002; WARBURG O, 1952, Z NATURFORSCH B, V7, P193; Warburg O, 1930, BIOCHEM Z, V228, P257; WARBURG O, 1956, SCIENCE, V124, P269; Warburg O, 1923, BIOCHEM Z, V142, P317; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Warburg O, 1929, BIOCHEM Z, V204, P482; Warburg O, 1923, KLIN WOCHENSCHR, V2, P776, DOI [DOI 10.1007/BF01712130, 10.1007/BF01712130]; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267; WENNER CE, 1953, CANCER RES, V13, P21; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu KJ, 2009, ACTA PHARMACOL SIN, V30, P1162, DOI 10.1038/aps.2009.94; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003	178	81	83	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					3999	4011		10.1038/onc.2011.576	http://dx.doi.org/10.1038/onc.2011.576			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22231450				2022-12-28	WOS:000308688800001
J	Tkocz, D; Crawford, NT; Buckley, NE; Berry, FB; Kennedy, RD; Gorski, JJ; Harkin, DP; Mullan, PB				Tkocz, D.; Crawford, N. T.; Buckley, N. E.; Berry, F. B.; Kennedy, R. D.; Gorski, J. J.; Harkin, D. P.; Mullan, P. B.			BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers	ONCOGENE			English	Article						BRCA1; GATA3; FOXC1; basal-like; corepression	EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION PATTERNS; PROGNOSTIC-SIGNIFICANCE; MAMMARY-GLAND; CELLS; TUMORS; DIFFERENTIATION; METASTASIS; DOCETAXEL; SUBTYPES	In this study we describe a novel interaction between the breast/ovarian tumor suppressor gene BRCA1 and the transcription factor GATA3, an interaction, which is important for normal breast differentiation. We show that the BRCA1-GATA3 interaction is important for the repression of genes associated with triple-negative and basal-like breast cancer (BLBCs) including FOXC1, and that GATA3 interacts with a C-terminal region of BRCA1. We demonstrate that FOXC1 is an essential survival factor maintaining the proliferation of BLBCs cell lines. We define the mechanistic basis of this corepression and identify the GATA3-binding site within the FOXC1 distal promoter region. We show that BRCA1 and GATA3 interact on the FOXC1 promoter and that BRCA1 requires GATA3 for recruitment to this region. This interaction requires fully functional BRCA1 as a mutant BRCA1 protein is unable to localize to the FOXC1 promoter or repress FOXC1 expression. We demonstrate that this BRCA1-GATA3 repression complex is not a FOXC1-specific phenomenon as a number of other genes associated with BLBCs such as FOXC2, CXCL1 and p-cadherin were also repressed in a similar manner. Finally, we demonstrate the importance of our findings by showing that loss of GATA3 expression or aberrant FOXC1 expression contributes to the drug resistance and epithelial-to-mesenchymal transition-like phenotypes associated with aggressive BLBCs. Oncogene (2012) 31, 3667-3678; doi:10.1038/onc.2011.531; published online 28 November 2011	[Tkocz, D.; Crawford, N. T.; Buckley, N. E.; Kennedy, R. D.; Gorski, J. J.; Harkin, D. P.; Mullan, P. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Berry, F. B.] Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada	Queens University Belfast; University of Alberta	Mullan, PB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, CCRCB Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	p.mullan@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513	Action Cancer Northern Ireland; Breast Cancer Campaign; Medical Research Council [G0600267] Funding Source: researchfish; MRC [G0600267] Funding Source: UKRI	Action Cancer Northern Ireland; Breast Cancer Campaign; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We would like to acknowledge the kind gift of mouse antihuman fibronectin antibody from Professor Philip Rudland (University of Liverpool). This work was supported by grants from the Action Cancer Northern Ireland (DT) and the Breast Cancer Campaign (NTC).	Ademuyiwa FO, 2010, MODERN PATHOL, V23, P270, DOI 10.1038/modpathol.2009.172; Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Arnold JM, 2010, BREAST CANCER RES TR, V119, P491, DOI 10.1007/s10549-008-0269-x; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Berry FB, 2008, HUM MOL GENET, V17, P490, DOI 10.1093/hmg/ddm326; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Buckley NE, 2007, MOL CANCER RES, V5, P261, DOI 10.1158/1541-7786.MCR-06-0250; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Campora E, 2008, ANTICANCER RES, V28, P3993; D'Anello L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-300; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jacquemier J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2249; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kouroussis C, 1999, ANN ONCOL, V10, P547, DOI 10.1023/A:1026441804889; Laakso M, 2005, MODERN PATHOL, V18, P1321, DOI 10.1038/modpathol.3800456; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Marchini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014131; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Wang HQ, 2010, CHINESE MED J-PEKING, V123, P3212, DOI 10.3760/cma.j.issn.0366-6999.2010.22.007; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yang QF, 2001, CANCER-AM CANCER SOC, V92, P54, DOI 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	50	57	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3667	3678		10.1038/onc.2011.531	http://dx.doi.org/10.1038/onc.2011.531			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22120723				2022-12-28	WOS:000307653800002
J	Bian, Y; Hall, B; Sun, ZJ; Molinolo, A; Chen, W; Gutkind, JS; Waes, CV; Kulkarni, AB				Bian, Y.; Hall, B.; Sun, Z-J; Molinolo, A.; Chen, W.; Gutkind, J. S.; Waes, C. V.; Kulkarni, A. B.			Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation	ONCOGENE			English	Article						TGF-beta; PI3K/Akt; head and neck squamous cell carcinoma; conditional knockout; cancer mouse model	GROWTH-FACTOR-BETA; FACTOR-KAPPA-B; MAMMARY-CARCINOMA; TUMOR-SUPPRESSOR; COLON-CANCER; ACTIVATION; PATHWAYS; GENE; EXPRESSION; EPITHELIA	The molecular mechanisms that contribute to the initiation and progression of head and neck squamous cell carcinoma (HNSCC) have not been completely delineated. Our observations indicate that defects in the transforming growth factor-beta and PI3K/Akt signaling pathways are common in human HNSCCs. Conditional activation of the PI3K/Akt pathway due to Pten deletion in the mouse head and neck epithelia gives rise to hyperproliferation, but only a few lesions progress to HNSCC. However, Pten-deficient mice developed full-penetrance HNSCC in combination with type I TGF-beta receptor (Tgfbr1) deletion. Molecular analysis revealed enhanced cell proliferation, decreased apoptosis, and increased expression of CCND1 in the basal layer of the head and neck epithelia, as well as in the tumors of Tgfbr1/Pten double conditional knockout (2cKO) mice. Furthermore, neoplastic transformation involves senescence evasion, and is associated with an increased number of putative cancer stem cells. In addition, the nuclear factor-kappa B pathway activation, myeloid-derived suppressor cell infiltration, angiogenesis and immune suppression in the tumor microenvironment, all of which are characteristics of human HNSCCs, contribute significantly to head and neck carcinogenesis in 2cKO mice. These tumors display pathology and multiple molecular alterations resembling human HNSCCs. This suggests that the Tgfbr1/Pten 2cKO mouse model is suitable for preclinical intervention, and that it has significant implications in the development of diagnostic cancer biomarkers and effective strategies for prevention and treatment of HNSCCs. Oncogene (2012) 31, 3322-3332; doi: 10.1038/onc.2011.494; published online 31 October 2011	[Kulkarni, A. B.] Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA; [Molinolo, A.; Gutkind, J. S.] Oral & Pharyngeal Canc Branch, Bethesda, MD USA; [Chen, W.] Natl Inst Dent & Craniofacial Res, Mucosal Immun Sect, Oral Immun & Infect Branch, Bethesda, MD 20892 USA; [Bian, Y.; Waes, C. V.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Kulkarni, AB (corresponding author), Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, 30 Convent Dr,Bldg 30,Room 130, Bethesda, MD 20892 USA.	ak40m@nih.gov	Sun, Zhi-Jun/AAD-8791-2022; Gutkind, J. Silvio/J-1201-2016	Sun, Zhi-Jun/0000-0003-0932-8013; Gutkind, J. Silvio/0000-0002-5150-4482	Divisions of Intramural Research, National Institute of Dental and Craniofacial Research [Z01-DE-000698]; National Institute on Deafness and Communication Disorders, NIH [ZIA-DC-000073]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000664, ZIADE000101, ZIADE000723, ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073] Funding Source: NIH RePORTER	Divisions of Intramural Research, National Institute of Dental and Craniofacial Research; National Institute on Deafness and Communication Disorders, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We would like to thank Dr Stefan Karlsson for providing us with the Tgfbr1 flox mice, Drs Raj Puri and Lalage Wakefield for critical reading of the manuscript, Drs Juan Du, Ping Zhang, Zhong Chen and Anita Terse for technical help, and Shelagh Johnson for the expert editorial assistance. This work was supported by the Divisions of Intramural Research, National Institute of Dental and Craniofacial Research (Z01-DE-000698), and National Institute on Deafness and Communication Disorders (ZIA-DC-000073), NIH.	Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen Z, 2009, J ONCOL, V2009, DOI 10.1155/2009/894064; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Curado MP, 2009, CURR OPIN ONCOL, V21, P194, DOI 10.1097/CCO.0b013e32832a68ca; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Deshpande AM, 2008, EXPERT REV ANTICANC, V8, P799, DOI 10.1586/14737140.8.5.799; Engle SJ, 1999, CANCER RES, V59, P3379; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Henderson YC, 1998, LARYNGOSCOPE, V108, P1553, DOI 10.1097/00005537-199810000-00024; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Lee JY, 2009, ONCOGENE, V28, P824, DOI 10.1038/onc.2008.451; Lee JI, 2001, ARCH OTOLARYNGOL, V127, P1441, DOI 10.1001/archotol.127.12.1441; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Molinolo AA, 2009, ORAL ONCOL, V45, P324, DOI 10.1016/j.oraloncology.2008.07.011; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Pasche B, 2005, JAMA-J AM MED ASSOC, V294, P1634, DOI 10.1001/jama.294.13.1634; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO;2-8; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Tang B, 2007, CANCER RES, V67, P8643, DOI 10.1158/0008-5472.CAN-07-0982; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Vijayachandra K, 2009, MOL CARCINOGEN, V48, P181, DOI 10.1002/mc.20472; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Xie W, 2003, ONCOL RES, V14, P61, DOI 10.3727/000000003108748612; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	51	120	124	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3322	3332		10.1038/onc.2011.494	http://dx.doi.org/10.1038/onc.2011.494			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22037217	Green Accepted			2022-12-28	WOS:000306367600002
J	Noll, JE; Jeffery, J; Al-Ejeh, F; Kumar, R; Khanna, KK; Callen, DF; Neilsen, PM				Noll, J. E.; Jeffery, J.; Al-Ejeh, F.; Kumar, R.; Khanna, K. K.; Callen, D. F.; Neilsen, P. M.			Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11	ONCOGENE			English	Article						ANKRD11; centrosome aberrations; gain of function; invasion; mutant p53	GAIN-OF-FUNCTION; HUMAN BREAST-CANCER; TUMOR-SUPPRESSOR; CORE DOMAIN; GENETIC INSTABILITY; KAPPA-B; CELLS; COMPLEX; MUTATIONS; PROTEIN	Mutations of p53 in cancer can result in a gain of function associated with tumour progression and metastasis. We show that inducible expression of several p53 'hotspot' mutants promote a range of centrosome abnormalities, including centrosome amplification, increased centrosome size and loss of cohesion, which lead to mitotic defects and multinucleation. These mutant p53-expressing cells also show a change in morphology and enhanced invasive capabilities. Consequently, we sought for a means to specifically target the function of mutant p53 in cancer cells. This study has identified ANKRD11 as a key regulator of the oncogenic potential of mutant p53. Loss of ANKRD11 expression with p53 mutation defines breast cancer patients with poor prognosis. ANKRD11 alleviates the mitotic defects driven by mutant p53 and suppresses mutant p53-mediated mesenchymal-like transformation and invasion. Mechanistically, we show that ANKRD11 restores a native conformation to the mutant p53 protein and causes dissociation of the mutant p53-p63 complex. This represents the first evidence of an endogenous protein with the capacity to suppress the oncogenic properties of mutant p53. Oncogene (2012) 31, 2836-2848; doi:10.1038/onc.2011.456; published online 10 October 2011	[Noll, J. E.; Kumar, R.; Callen, D. F.; Neilsen, P. M.] Univ Adelaide, Canc Therapeut Lab, Discipline Med, Adelaide, SA 5000, Australia; [Jeffery, J.; Al-Ejeh, F.; Khanna, K. K.] Queensland Inst Med Res, Signal Transduct Lab, Brisbane, Qld 4006, Australia; [Neilsen, P. M.] Univ Adelaide, Discipline Med, Sarcoma Res Grp, Adelaide, SA, Australia; [Neilsen, P. M.] Hanson Inst, Adelaide, SA, Australia	University of Adelaide; QIMR Berghofer Medical Research Institute; University of Adelaide; Hanson Institute	Noll, JE (corresponding author), Univ Adelaide, Canc Therapeut Lab, Discipline Med, Frome Rd, Adelaide, SA 5000, Australia.	jacqueline.noll@adelaide.edu.au	Kumar, Raman/AHE-0538-2022; Al-Ejeh, Fares/M-7032-2016; Callen, David F/G-1975-2012; Khanna, Kum Kum/I-1747-2013	Kumar, Raman/0000-0001-7976-8386; Al-Ejeh, Fares/0000-0002-1553-0077; Noll, Jacqueline/0000-0001-7375-635X; Neilsen, Paul/0000-0001-7937-3675; Callen, David/0000-0002-6189-9991; Khanna, Kum Kum/0000-0001-8650-5381	Cancer Council of South Australia and San Remo; NHMRC Program grant; Cancer Council NSW; Cure Cancer Foundation Australia; Cancer Council SA	Cancer Council of South Australia and San Remo(Cancer Council South Australia); NHMRC Program grant(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Cure Cancer Foundation Australia; Cancer Council SA(Cancer Council South Australia)	We thank Vivek Mittal for the ecdysone-inducible constructs; Karen Vousden and Patricia Muller for the p63 and p73 constructs; Maria Lung, Sumitra Deb and Chikashi Ishioka for the mutant p53 constructs; Jeffrey Salisbury for the anti-centrin antibody; Anne-Marie Cleton-Jansen for providing patient material; and Darryl Russell and Kira Height for technical assistance. We acknowledge the Cancer Council of South Australia and San Remo for financial support. KKK is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow, and this work is supported by an NHMRC Program grant to KKK. FA is supported by the Cancer Council NSW, the Cure Cancer Foundation Australia and the Cancer Council SA.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Caulin C, 2007, J CLIN INVEST, V117, P1893, DOI 10.1172/JCI31721; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Agostino S, 2008, CELL CYCLE, V7, P3440, DOI 10.4161/cc.7.21.6995; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Hadjihannas MV, 2010, EMBO REP, V11, P317, DOI 10.1038/embor.2010.23; Hansen LL, 1998, CANCER RES, V58, P2166; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105; Kumar R, 2005, CANCER RES, V65, P11304, DOI 10.1158/0008-5472.CAN-05-0936; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; MILNER J, 1987, ONCOGENE, V1, P453; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Neilsen PM, 2008, J CELL SCI, V121, P3541, DOI 10.1242/jcs.026351; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pishas KI, 2011, CLIN CANCER RES, V17, P494, DOI 10.1158/1078-0432.CCR-10-1587; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059	48	47	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2836	2848		10.1038/onc.2011.456	http://dx.doi.org/10.1038/onc.2011.456			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986947	Green Published			2022-12-28	WOS:000305277900004
J	Chen, BB; Glasser, JR; Coon, TA; Mallampalli, RK				Chen, B. B.; Glasser, J. R.; Coon, T. A.; Mallampalli, R. K.			F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest	ONCOGENE			English	Article						ubiquitin; camodulin; lung	CALCIUM-CONCENTRATION; REGULATORY ENZYME; D1 DEGRADATION; CALMODULIN; CANCER; PHOSPHORYLATION; EXPRESSION; KINASE; IDENTIFICATION; ALPHA	Dysregulated behavior of cell cycle proteins and their control by ubiquitin E3 ligases is an emerging theme in human lung cancer. Here, we identified and characterized the activity of a novel F-box protein, termed FBXL2, belonging to the SCF (Skip-Cullin1-F-box protein) E3 ligase family. Ectopically expressed FBXL2 triggered G2/M-phase arrest, induced chromosomal anomalies and increased apoptosis of transformed lung epithelia by mediating polyubiquitination and degradation of the mitotic regulator, cyclin D3. Unlike other F-box proteins that target phosphodegrons within substrates, FBXL2 uniquely recognizes a canonical calmodulin (CaM)-binding motif within cyclin D3 to facilitate its polyubiquitination. CaM bound and protected cyclin D3 from FBXL2 by direct intermolecular competition with the F-box protein for access within this motif. The chemotherapeutic agent vinorelbine increased apoptosis of human lung carcinoma cells by inducing FBXL2 expression and cyclin D3 degradation, an effect accentuated by CaM knockdown. Depletion of endogenous FBXL2 stabilized cyclin D3 levels, accelerated cancer cell growth and increased cell viability after vinorelbine treatment. Last, ectopic expression of FBXL2 significantly inhibited the growth and migration of tumorogenic cells and tumor formation in athymic nude mice. These observations implicate SCFFBXL2 as an indispensible regulator of mitosis that serves as a tumor suppressor. Oncogene (2012) 31, 2566-2579; doi:10.1038/onc.2011.432; published online 24 October 2011	[Mallampalli, R. K.] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, UPMC Montefiore,Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA; [Mallampalli, R. K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA; [Mallampalli, R. K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Mallampalli, RK (corresponding author), Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care Med, UPMC Montefiore,Acute Lung Injury Ctr Excellence, NW 628, Pittsburgh, PA 15213 USA.	mallampallirk@upmc.edu			US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; US Department of Veterans Affairs; National Institutes of Health [HL096376, HL097376, HL098174]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096376, R01HL097376, R01HL098174] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002200] Funding Source: NIH RePORTER	US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development(US Department of Veterans Affairs); US Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Veterans Affairs(US Department of Veterans Affairs)	We thank AF Stewart for critical review of the manuscript and helpful suggestions. This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs and National Institutes of Health R01 grants HL096376, HL097376 and HL098174 (to RKM). The contents presented do not represent the views of the Department of Veterans Affairs or the United States Government.	Agassandian M, 2010, FASEB J, V24, P1271, DOI 10.1096/fj.09-136044; Brown E M, 1984, Prog Clin Biol Res, V168, P139; Butler PL, 2010, J BIOL CHEM, V285, P6246, DOI 10.1074/jbc.M109.017350; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chen BB, 2011, MOL CELL BIOL, V22, P22; Chen BB, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706472200; Chen BB, 2009, MOL CELL BIOL, V29, P3062, DOI 10.1128/MCB.01824-08; Choi J, 2006, CELL CYCLE, V5, P2183, DOI 10.4161/cc.5.19.3265; Choi J, 2006, CIRC RES, V98, P1273, DOI 10.1161/01.RES.0000223059.19250.91; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Duan YN, 2010, INFLAMMATION, V33, P189, DOI 10.1007/s10753-009-9173-8; Fang MZ, 2002, J VET MED SCI, V64, P201, DOI 10.1292/jvms.64.201; Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hansen DV, 2004, MOL BIOL CELL, V15, P5623, DOI 10.1091/mbc.E04-07-0598; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Hu DL, 2007, J CELL SCI, V120, P2424, DOI 10.1242/jcs.007963; Ilyin GP, 1999, FEBS LETT, V459, P75, DOI 10.1016/S0014-5793(99)01211-9; Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008; Korkotian E, 1996, J PHYSIOL-LONDON, V496, P39, DOI 10.1113/jphysiol.1996.sp021663; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; LU KP, 1992, MOL ENDOCRINOL, V6, P365, DOI 10.1210/me.6.3.365; Malard V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-147; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Papay J, 2007, APPL IMMUNOHISTO M M, V15, P19, DOI 10.1097/01.pai.0000213143.32030.f5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Pszczolkowski MA, 1999, MOL CELL ENDOCRINOL, V158, P163, DOI 10.1016/S0303-7207(99)00167-7; Ray NB, 2010, NAT MED, V16, P1120, DOI 10.1038/nm.2213; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; Rosario CO, 2010, P NATL ACAD SCI USA, V107, P6888, DOI 10.1073/pnas.0910941107; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Skaar JR, 2009, CELL, V137, DOI 10.1016/j.cell.2009.05.039; Sterlacci W, 2010, J THORAC ONCOL, V5, P1325, DOI 10.1097/JTO.0b013e3181e77efc; Tanaka Y, 2008, MOL CELL BIOL, V28, P4805, DOI 10.1128/MCB.01784-07; Tanguay DA, 2001, J IMMUNOL, V166, P4273, DOI 10.4049/jimmunol.166.7.4273; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tsang WY, 2006, MOL BIOL CELL, V17, P3423, DOI 10.1091/mbc.E06-04-0371; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Weiderpass Elisabete, 2010, J Prev Med Public Health, V43, P459, DOI 10.3961/jpmph.2010.43.6.459; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; Zhang QX, 2005, FEBS LETT, V579, P3932, DOI 10.1016/j.febslet.2005.06.012; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	56	59	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2566	2579		10.1038/onc.2011.432	http://dx.doi.org/10.1038/onc.2011.432			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	22020328	Green Accepted			2022-12-28	WOS:000304191800007
J	Darini, CY; Pisani, DF; Hofman, P; Pedeutour, F; Sudaka, I; Chomienne, C; Dani, C; Ladoux, A				Darini, C. Y.; Pisani, D. F.; Hofman, P.; Pedeutour, F.; Sudaka, I.; Chomienne, C.; Dani, C.; Ladoux, A.			Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential	ONCOGENE			English	Article						tumour-initiating cells; Oct-4; metastasis; gene tracking	CANCER STEM-CELLS; MYELOID-LEUKEMIA; BONE-MARROW; EXPRESSION; GROWTH; DIFFERENTIATION; IDENTIFICATION; OCT-3/4; CXCR4; HETEROGENEITY	Tumour-initiating cells (TICs) are rare cancer cells isolated from tumours of different origins including high-grade tumours that sustain neoplasic progression and development of metastatic disease. They harbour deregulated stem cells pathways and exhibit an unchecked ability to self-renew, a property essential for tumour progression. Among the essential factors maintaining embryonic stem (ES) cells properties, OCT-4 (also known as POU5F1) has been detected in tumours of different origins. Although ectopic expression results in dysplasic growth restricted to epithelial tissues, overexpression expands the proportion of immature cells in teratomas. However, OCT-4-expressing cells have not been purified from spontaneously occurring tumours, thus information concerning their properties is rather scant. Here, using p53-/- mice expressing green fluorescent protein and the puromycin resistance gene under the control of the Oct-4 promoter, we show that OCT-4 is expressed in 5% onwards of the undifferentiated tumour cell populations derived from different organs. OCT-4 expression was low as compared with ES cells, but was associated with a 'stemness' signature and expression of the chemokine receptor CXCR4. These cells displayed cancer stem cell features, including increased self-renewal and differentiation ability in vitro and in vivo. They not only formed allografts containing immature bone regions but also disseminated into different organs, including lung, liver and bone. Experiments based on RNA interference revealed that Oct-4 expression drives both their engraftment and metastasis formation. This work points out the crucial contribution of Oct-4-expressing TICs in the hierarchical organization of the malignant potential, leading to metastasis formation. Consequently, it provides an appropriate model to develop novel therapies aiming to strike down TICs by targeting self-renewal genes, therefore efficient to reduce tumour growth and metastatic disease. Oncogene (2012) 31, 2438-2449; doi: 10.1038/onc.2011.421; published online 19 September 2011	[Darini, C. Y.; Pisani, D. F.; Pedeutour, F.; Dani, C.; Ladoux, A.] Univ Nice Sophia Antipolis, CNRS, Inst Biol Dev & Canc, F-06107 Nice 2, France; [Hofman, P.] Univ Nice Sophia Antipolis, Fac Med, INSERM, ERI 21,EA 4319, F-06107 Nice 2, France; [Hofman, P.] Univ Nice Sophia Antipolis, Fac Med, Human Biobank, F-06107 Nice 2, France; [Hofman, P.] Univ Nice Sophia Antipolis, CHU Nice, Pasteur Hosp, F-06107 Nice 2, France; [Pedeutour, F.] Univ Nice Sophia Antipolis, Nice Univ Hosp, Fac Med, F-06107 Nice 2, France; [Sudaka, I.] Cimiez Hosp, CHU Nice, Haematol Lab, Nice, France; [Chomienne, C.] Paris Diderot Univ, Hop St Louis, INSERM, UMRS 940, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Ladoux, A (corresponding author), Univ Nice Sophia Antipolis, CNRS, Inst Biol Dev & Canc, 28 Ave Valombrose, F-06107 Nice 2, France.	ladoux@unice.fr	DANI, Christian/G-3639-2014; Hofman, Paul/P-7654-2018; LADOUX, ANNIE/O-4267-2016; LADOUX, ANNIE/S-2077-2019; Pisani, Didier/AAC-2997-2019	DANI, Christian/0000-0003-3228-0230; Hofman, Paul/0000-0003-0431-9353; LADOUX, ANNIE/0000-0003-3857-2621; LADOUX, ANNIE/0000-0003-3857-2621; Pisani, Didier/0000-0001-5879-8527; CHOMIENNE, Christine/0000-0001-5513-5752	Association pour la Recherche contre le Cancer; Institut National du Cancer [CT 30008187, PL-96-007]; Conseil General des Alpes-Maritimes	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Conseil General des Alpes-Maritimes(Region Provence-Alpes-Cote d'Azur)	We are grateful to Professor Austin Smith and Dr Jenny Nichols for generously providing Oct-4-GiP mice and for useful comments. The contributions of Drs Ez-Zoubir Amri and Gilles Pages for in vivo imaging analyses are appreciated. We thank our colleagues, Dr Katrina Podsypanina and Dr Alain Aurias, for helpful suggestions and discussions. We are indebted to Drs Pascal Peraldi, Nathalie Mazure, Jean-Francois Peyron, Marie-Christine De Vernejoul and Minoo Rassoulzadegan for a careful reading of this manuscript, and to Drs Amanda Patel and Eric Lingueglia for valuable help in editing this manuscript. We acknowledge expert technical assistance of Katia Havet with histology; Agnes Loubat with flow cytometry; Mansour Djedaini with in vivo imaging; Thibault Fabas and Annie-Claude Peyron with genetic analysis; and Franck Paput, Cendrine Dubaud and Jacky Paput with animal care. Our lab receives financial support from Association pour la Recherche contre le Cancer and Institut National du Cancer (grant numbers: CT 30008187 and PL-96-007). We thank Conseil General des Alpes-Maritimes for financial support for the animal imaging equipment (SkyScan).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Altaba ARI, 2009, EMBO REP, V10, P832, DOI 10.1038/embor.2009.169; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Carlisle AJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-126; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Felsher DW, 2004, CURR OPIN GENET DEV, V14, P37, DOI 10.1016/j.gde.2003.12.008; Gassmann P, 2009, NEOPLASIA, V11, P651, DOI 10.1593/neo.09272; Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8; Harris MA, 2008, CANCER RES, V68, P10051, DOI 10.1158/0008-5472.CAN-08-0786; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Hochedlinger K, 2009, DEVELOPMENT, V136, P509, DOI 10.1242/dev.020867; Huang CY, 2009, J CELL PHYSIOL, V221, P204, DOI 10.1002/jcp.21846; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Kaufman DS, 2006, ANN ONCOL, V17, pV106, DOI 10.1093/annonc/mdj963; Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lee J, 2007, BIOCHEM J, V406, P519, DOI 10.1042/BJ20070243; Lengner CJ, 2007, CELL STEM CELL, V1, P403, DOI 10.1016/j.stem.2007.07.020; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Marangoni E, 2009, BRIT J CANCER, V100, P918, DOI 10.1038/sj.bjc.6604953; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Monteiro J, 2010, EUR J CANCER, V46, P1198, DOI 10.1016/j.ejca.2010.02.030; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2009, SEMIN RADIAT ONCOL, V19, P71, DOI 10.1016/j.semradonc.2008.11.001; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Rajagopalan V, 2005, J NEURO-ONCOL, V72, P157, DOI 10.1007/s11060-004-3346-y; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez AM, 2005, J EXP MED, V201, P1397, DOI 10.1084/jem.20042224; Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zeelenberg IS, 2001, J CLIN INVEST, V108, P269, DOI 10.1172/JCI200111330; Zeineddine D, 2006, DEV CELL, V11, P535, DOI 10.1016/j.devcel.2006.07.013; Zhang YF, 2010, CANCER LETT, V292, P1, DOI 10.1016/j.canlet.2009.11.003	53	17	18	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2438	2449		10.1038/onc.2011.421	http://dx.doi.org/10.1038/onc.2011.421			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21927026				2022-12-28	WOS:000303985300006
J	Fraile, JM; Quesada, V; Rodriguez, D; Freije, JMP; Lopez-Otin, C				Fraile, J. M.; Quesada, V.; Rodriguez, D.; Freije, J. M. P.; Lopez-Otin, C.			Deubiquitinases in cancer: new functions and therapeutic options	ONCOGENE			English	Review						deubiquitinases; cancer; degradome	NF-KAPPA-B; UBIQUITIN-SPECIFIC PROTEASES; SMALL-MOLECULE INHIBITOR; TUMOR-SUPPRESSOR; IN-VIVO; SOMATIC MUTATIONS; TGF-BETA; HEPATOCELLULAR-CARCINOMA; DEUBIQUITYLATING ENZYME; CELL-PROLIFERATION	Deubiquitinases (DUBs) have fundamental roles in the ubiquitin system through their ability to specifically deconjugate ubiquitin from targeted proteins. The human genome encodes at least 98 DUBs, which can be grouped into 6 families, reflecting the need for specificity in their function. The activity of these enzymes affects the turnover rate, activation, recycling and localization of multiple proteins, which in turn is essential for cell homeostasis, protein stability and a wide range of signaling pathways. Consistent with this, altered DUB function has been related to several diseases, including cancer. Thus, multiple DUBs have been classified as oncogenes or tumor suppressors because of their regulatory functions on the activity of other proteins involved in tumor development. Therefore, recent studies have focused on pharmacological intervention on DUB activity as a rationale to search for novel anticancer drugs. This strategy may benefit from our current knowledge of the physiological regulatory mechanisms of these enzymes and the fact that growth of several tumors depends on the normal activity of certain DUBs. Further understanding of these processes may provide answers to multiple remaining questions on DUB functions and lead to the development of DUB-targeting strategies to expand the repertoire of molecular therapies against cancer. Oncogene (2012) 31, 2373-2388; doi: 10.1038/onc.2011.443; published online 26 September 2011	[Fraile, J. M.; Quesada, V.; Rodriguez, D.; Freije, J. M. P.; Lopez-Otin, C.] Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain.	clo@uniovi.es	Freije, José M.P./A-6535-2008; Quesada, Víctor/B-6557-2014; López-Otín, Carlos/AAB-2106-2020; Rodríguez, David/K-3872-2017	Freije, José M.P./0000-0002-4688-8266; Quesada, Víctor/0000-0002-8398-3457; López-Otín, Carlos/0000-0001-6964-1904; Rodríguez, David/0000-0002-7530-2770	Ministerio de Ciencia e Innovacion-Spain; Fundacion 'M Botin'; PCTI-FICYT Asturias; European Union; Obra Social Cajastur; Accion Transversal del Cancer-RTICC	Ministerio de Ciencia e Innovacion-Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion 'M Botin'; PCTI-FICYT Asturias; European Union(European Commission); Obra Social Cajastur; Accion Transversal del Cancer-RTICC	Our study is supported by grants from Ministerio de Ciencia e Innovacion-Spain, Fundacion 'M Botin', PCTI-FICYT Asturias and European Union (FP7 MicroEnviMet). The Instituto Universitario de Oncologia is supported by Obra Social Cajastur and Accion Transversal del Cancer-RTICC.	Adler AS, 2008, CANCER RES, V68, P506, DOI 10.1158/0008-5472.CAN-07-3060; Al-Hakim A, 2010, DNA REPAIR, V9, P1229, DOI 10.1016/j.dnarep.2010.09.011; Al-Hakim AK, 2008, BIOCHEM J, V411, P249, DOI 10.1042/BJ20080067; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Aressy B, 2010, CELL CYCLE, V9, P3815, DOI 10.4161/cc.9.18.13133; Atanassov BS, 2011, FEBS LETT, V585, P2016, DOI 10.1016/j.febslet.2010.10.042; Atanassov BS, 2009, MOL CELL, V35, P352, DOI 10.1016/j.molcel.2009.06.015; Baek KH, 2006, CURR PROTEIN PEPT SC, V7, P171, DOI 10.2174/138920306776359740; Baek KH, 2004, J BIOL CHEM, V279, P2368, DOI 10.1074/jbc.M304774200; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Bremm A, 2010, NAT STRUCT MOL BIOL, V17, P939, DOI 10.1038/nsmb.1873; Brooks CL, 2007, ONCOGENE, V26, P7262, DOI 10.1038/sj.onc.1210531; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Burrows JF, 2004, J BIOL CHEM, V279, P13993, DOI 10.1074/jbc.M311291200; Cao ZW, 2007, MOL CELL BIOL, V27, P2180, DOI 10.1128/MCB.01245-06; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Clague MJ, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-202; Colland F, 2010, BIOCHEM SOC T, V38, P137, DOI 10.1042/BST0380137; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Colombo M, 2010, CHEMMEDCHEM, V5, P552, DOI 10.1002/cmdc.200900409; Cooper EM, 2009, EMBO J, V28, P621, DOI 10.1038/emboj.2009.27; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Crawford LJ, 2011, J CELL COMMUN SIGNAL, V5, P101, DOI 10.1007/s12079-011-0121-7; Dammer EB, 2011, J BIOL CHEM, V286, P10457, DOI 10.1074/jbc.M110.149633; Daviet L, 2008, BIOCHIMIE, V90, P270, DOI 10.1016/j.biochi.2007.09.013; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; de la Vega M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1243; Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053; Duex JE, 2011, J BIOL CHEM, V286, P25377, DOI 10.1074/jbc.M111.222760; Duex JE, 2009, MOL BIOL CELL, V20, P1833, DOI 10.1091/mbc.E08-08-0880; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Durkop H, 2003, J PATHOL, V200, P229, DOI 10.1002/path.1351; Eletr ZM, 2011, CELL BIOCHEM BIOPHYS, V60, P3, DOI 10.1007/s12013-011-9184-6; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Enesa K, 2008, J BIOL CHEM, V283, P18582, DOI 10.1074/jbc.M801312200; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Fan YH, 2011, CELL DEATH DIFFER, V18, P1547, DOI 10.1038/cdd.2011.11; Feng L, 2010, J BIOL CHEM, V285, P30982, DOI 10.1074/jbc.M110.135392; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Freije JMP, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00025; Gao JM, 2010, BLOOD, V115, P4130, DOI 10.1182/blood-2009-10-248526; Gilbert RE, 2011, KIDNEY INT, V79, P1312, DOI 10.1038/ki.2011.39; Glinsky GV, 2005, CELL CYCLE, V4, P1171, DOI 10.4161/cc.4.9.2001; Gonzalez-Navajas JM, 2010, J EXP MED, V207, P2799, DOI 10.1084/jem.20101326; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; GRAY DA, 1995, ONCOGENE, V10, P2179; Guedat P, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S14; Guervilly JH, 2011, HUM MOL GENET, V20, P2171, DOI 10.1093/hmg/ddr103; GUPTA K, 1994, ONCOGENE, V9, P1729; Guterman A, 2004, CURR PROTEIN PEPT SC, V5, P201, DOI 10.2174/1389203043379756; Guterman A, 2004, J BIOL CHEM, V279, P1729, DOI 10.1074/jbc.M307050200; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hirayama K, 2007, BIOORGAN MED CHEM, V15, P6810, DOI 10.1016/j.bmc.2007.07.016; Honma K, 2009, BLOOD, V114, P2467, DOI 10.1182/blood-2008-12-194852; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Huang XH, 2009, J MOL BIOL, V391, P691, DOI 10.1016/j.jmb.2009.06.066; Hussain S, 2010, LEUKEMIA, V24, P1641, DOI 10.1038/leu.2010.138; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Hymowitz SG, 2010, NAT REV CANCER, V10, P332, DOI 10.1038/nrc2775; Ibarrola N, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-2; Ikeda F, 2008, EMBO REP, V9, P536, DOI 10.1038/embor.2008.93; Jang MJ, 2011, CANCER LETT, V302, P128, DOI 10.1016/j.canlet.2011.01.006; Jaster R, 1999, BBA-GENE STRUCT EXPR, V1446, P308, DOI 10.1016/S0167-4781(99)00095-0; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kapuria V, 2010, CANCER RES, V70, P9265, DOI 10.1158/0008-5472.CAN-10-1530; Kessler BM, 2011, CELL BIOCHEM BIOPHYS, V60, P21, DOI 10.1007/s12013-011-9176-6; Kim YS, 2005, BIOCHEM BIOPH RES CO, V330, P797, DOI 10.1016/j.bbrc.2005.03.051; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55; Kon N, 2010, ONCOGENE, V29, P1270, DOI 10.1038/onc.2009.427; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Kuhlbrodt K, 2011, NAT CELL BIOL, V13, P273, DOI 10.1038/ncb2200; Kuphal S, 2011, ONCOGENE, V30, P4523, DOI 10.1038/onc.2011.163; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Lee HJ, 2005, FEBS LETT, V579, P4867, DOI 10.1016/j.febslet.2005.07.048; Li LY, 2009, BBA-MOL CELL RES, V1793, P346, DOI 10.1016/j.bbamcr.2008.09.013; Li ZB, 2005, EMBO REP, V6, P373, DOI 10.1038/sj.embor.7400377; Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641; Liu H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005544; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Liu YC, 2003, CHEM BIOL, V10, P837, DOI 10.1016/j.chembiol.2003.08.010; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Lu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015936; Lu Y, 2009, MOL CELL BIOL, V29, P547, DOI 10.1128/MCB.00329-08; Lui TTH, 2011, MOL CELL BIOL, V31, P2053, DOI 10.1128/MCB.01094-10; Luise C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015891; Luna-Vargas MPA, 2011, EMBO REP, V12, P365, DOI 10.1038/embor.2011.33; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Mao Y, 2005, P NATL ACAD SCI USA, V102, P12700, DOI 10.1073/pnas.0506344102; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Mauri PL, 2006, FEBS J, V273, P4277, DOI 10.1111/j.1742-4658.2006.05419.x; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; McFarlane C, 2010, CANCER RES, V70, P3329, DOI 10.1158/0008-5472.CAN-09-4152; Mcnally RS, 2011, J BIOL CHEM, V286, P4098, DOI 10.1074/jbc.M110.147371; Meray RK, 2007, J BIOL CHEM, V282, P10567, DOI 10.1074/jbc.M611153200; Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124; Meulmeester E, 2008, MOL CELL, V30, P610, DOI 10.1016/j.molcel.2008.03.021; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mullally JE, 2002, MOL PHARMACOL, V62, P351, DOI 10.1124/mol.62.2.351; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Nagai H, 2009, MOL CELL, V36, P805, DOI 10.1016/j.molcel.2009.10.016; Nakamura N, 2008, MOL BIOL CELL, V19, P1903, DOI 10.1091/mbc.E07-11-1103; Navon A, 2009, J BIOL CHEM, V284, P33713, DOI 10.1074/jbc.R109.018481; Nicastro G, 2005, P NATL ACAD SCI USA, V102, P10493, DOI 10.1073/pnas.0501732102; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Oh KH, 2011, CELL DEATH DIFFER, V18, P1326, DOI 10.1038/cdd.2011.3; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Parsons JL, 2011, MOL CELL, V41, P609, DOI 10.1016/j.molcel.2011.02.016; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; PICKART CM, 1985, J BIOL CHEM, V260, P7903; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050; Quesada V, 2009, NUCLEIC ACIDS RES, V37, pD239, DOI 10.1093/nar/gkn570; Rajan N, 2011, ONCOGENE, V30, P4243, DOI 10.1038/onc.2011.133; Ramakrishna S, 2011, J BIOL CHEM, V286, P10505, DOI 10.1074/jbc.M110.162321; Ramakrishna S, 2011, CELL MOL LIFE SCI, V68, P15, DOI 10.1007/s00018-010-0504-6; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Saggar S, 2008, J MED GENET, V45, P298, DOI 10.1136/jmg.2007.056127; Sato Y, 2008, NATURE, V455, P358, DOI 10.1038/nature07254; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Sun HS, 2011, BLOOD, V117, P3151, DOI 10.1182/blood-2010-03-276477; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Tian XF, 2011, ASSAY DRUG DEV TECHN, V9, P165, DOI 10.1089/adt.2010.0317; Todi SV, 2009, EMBO J, V28, P372, DOI 10.1038/emboj.2008.289; Tran H, 2008, GENE DEV, V22, P528, DOI 10.1101/gad.463208; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Urbanik T, 2011, INT J ONCOL, V38, P121, DOI 10.3892/ijo_00000831; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Vendrell JA, 2007, ONCOGENE, V26, P4656, DOI 10.1038/sj.onc.1210269; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Verstrepen L, 2009, BIOCHEM PHARMACOL, V78, P105, DOI 10.1016/j.bcp.2009.02.009; Virdee S, 2010, NAT CHEM BIOL, V6, P750, DOI [10.1038/NCHEMBIO.426, 10.1038/nchembio.426]; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wicks SJ, 2005, ONCOGENE, V24, P8080, DOI 10.1038/sj.onc.1208944; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Winborn BJ, 2008, J BIOL CHEM, V283, P26436, DOI 10.1074/jbc.M803692200; Xu GF, 2010, J BIOL CHEM, V285, P969, DOI 10.1074/jbc.M109.042689; Xu ML, 2009, BIOCHEM BIOPH RES CO, V388, P366, DOI 10.1016/j.bbrc.2009.08.015; Yamaguchi T, 2007, J BIOL CHEM, V282, P33943, DOI 10.1074/jbc.M706282200; Yang YL, 2007, INT J NANOTECHNOL, V4, P4, DOI 10.1504/IJNT.2007.012313; Yao T, 2008, MOL CELL, V31, P909, DOI 10.1016/j.molcel.2008.08.027; Yoshida A, 2010, FEBS LETT, V584, P4545, DOI 10.1016/j.febslet.2010.10.039; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang C, 2011, MOL CANCER THER, V10, P1264, DOI 10.1158/1535-7163.MCT-10-1091; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhang XN, 2011, EMBO J, V30, P2177, DOI 10.1038/emboj.2011.125; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhao B, 2009, J CELL MOL MED, V13, P1886, DOI 10.1111/j.1582-4934.2009.00682.x; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Zhu X, 2007, PROTEINS, V69, P1, DOI 10.1002/prot.21546	207	320	347	6	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2373	2388		10.1038/onc.2011.443	http://dx.doi.org/10.1038/onc.2011.443			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996736	Green Published			2022-12-28	WOS:000303985300001
J	Gajate, C; Matos-da-Silva, M; Dakir, EH; Fonteriz, RI; Alvarez, J; Mollinedo, F				Gajate, C.; Matos-da-Silva, M.; Dakir, El-H; Fonteriz, R. I.; Alvarez, J.; Mollinedo, F.			Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum	ONCOGENE			English	Article						endoplasmic reticulum stress; apoptotic signaling; pancreatic cancer; xenograft animal model; alkyl-lysophospholipid analog; edelfosine	FAS/CD95 DEATH RECEPTOR; CYTOCHROME-C RELEASE; INTACT HELA-CELLS; BCL-X-L; LIPID RAFTS; ET-18-OCH3 EDELFOSINE; TUMOR-CELLS; BH3-ONLY PROTEINS; MULTIPLE-MYELOMA; LEUKEMIC-CELLS	Pancreatic cancer remains as one of the most deadly cancers, and responds poorly to current therapies. The prognosis is extremely poor, with a 5-year survival of less than 5%. Therefore, search for new effective therapeutic drugs is of pivotal need and urgency to improve treatment of this incurable malignancy. Synthetic alkyl-lysophospholipid analogs (ALPs) constitute a heterogeneous group of unnatural lipids that promote apoptosis in a wide variety of tumor cells. In this study, we found that the anticancer drug edelfosine was the most potent ALP in killing human pancreatic cancer cells, targeting endoplasmic reticulum (ER). Edelfosine was taken up in significant amounts by pancreatic cancer cells and induced caspase-and mitochondrial-mediated apoptosis. Pancreatic cancer cells show a prominent ER and edelfosine accumulated in this subcellular structure, inducing a potent ER stress response, with caspase-4, BAP31 and c-Jun NH2-terminal kinase (JNK) activation, CHOP/GADD153 upregulation and phosphorylation of eukaryotic translation initiation factor 2 alpha-subunit that eventually led to cell death. Oral administration of edelfosine in xenograft mouse models of pancreatic cancer induced a significant regression in tumor growth and an increase in apoptotic index, as assessed by TUNEL assay and caspase-3 activation in the tumor sections. The ER stress-associated marker CHOP/GADD153 was visualized in the pancreatic tumor isolated from edelfosine-treated mice, indicating a strong in vivo ER stress response. These results suggest that edelfosine exerts its pro-apoptotic action in pancreatic cancer cells, both in vitro and in vivo, through its accumulation in the ER, which leads to ER stress and apoptosis. Thus, we propose that the ER could be a key target in pancreatic cancer, and edelfosine may constitute a prototype for the development of a new class of antitumor drugs targeting the ER. Oncogene (2012) 31, 2627-2639; doi:10.1038/onc.2011.446; published online 7 November 2011	[Gajate, C.; Matos-da-Silva, M.; Dakir, El-H; Mollinedo, F.] Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, E-37007 Salamanca, Spain; [Gajate, C.; Matos-da-Silva, M.] Hosp Univ Salamanca, Unidad Invest, Salamanca, Spain; [Fonteriz, R. I.; Alvarez, J.] Univ Valladolid, CSIC, Dept Bioquim & Biol Mol, Inst Biol & Genet Mol, Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Gajate, C (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.	cgajate@usal.es	Fonteriz, Rosalba I/L-1212-2014; Alvarez, Javier/K-8210-2014; DAKIR, EL HABIB/O-1383-2015; Fonteriz, Rosalba/ABE-3175-2021	Fonteriz, Rosalba I/0000-0001-8349-6264; Alvarez, Javier/0000-0003-0636-5521; DAKIR, EL HABIB/0000-0002-8482-3412; Fonteriz, Rosalba/0000-0001-8349-6264; Gajate, Consuelo/0000-0003-0604-6459	Fondo de Investigacion Sanitaria; European Commission [FIS-FEDER PS09/01915]; Ministerio de Ciencia e Innovacion (from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III) [SAF2008-02251, BFU 2008-01871, RD06/0020/1037]; European Community [HEALTH-F2-2011-256986]; Junta de Castilla y Leon [CSI052A11-2, GR15]; Ministerio de Ciencia e Innovacion of Spain	Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); European Commission(European CommissionEuropean Commission Joint Research Centre); Ministerio de Ciencia e Innovacion (from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III); European Community(European Commission); Junta de Castilla y Leon(Junta de Castilla y Leon); Ministerio de Ciencia e Innovacion of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants from Fondo de Investigacion Sanitaria and European Commission (FIS-FEDER PS09/01915), Ministerio de Ciencia e Innovacion (SAF2008-02251, BFU 2008-01871 and RD06/0020/1037 from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III), European Community's Seventh Framework Programme FP7-2007-2013 (Grant HEALTH-F2-2011-256986) and Junta de Castilla y Leon (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, Biomedicine Project 2009 and Biomedicine Project 2010-2011). CG is supported by the Ramon y Cajal Program from the Ministerio de Ciencia e Innovacion of Spain.	Alvarez J, 2002, CELL CALCIUM, V32, P251, DOI 10.1016/S0143416002001860; Ausili A, 2008, J PHYS CHEM B, V112, P11643, DOI 10.1021/jp802165n; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Busto JV, 2007, BBA-BIOMEMBRANES, V1768, P1855, DOI 10.1016/j.bbamem.2007.04.025; Busto Jon V, 2008, J Chem Biol, V1, P89, DOI 10.1007/s12154-008-0009-z; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062; de Mendoza AEH, 2009, CLIN CANCER RES, V15, P858, DOI 10.1158/1078-0432.CCR-08-1654; Fonseca SG, 2009, CURR OPIN PHARMACOL, V9, P763, DOI 10.1016/j.coph.2009.07.003; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044; Gajate C, 2009, BIOCHEM BIOPH RES CO, V380, P780, DOI 10.1016/j.bbrc.2009.01.147; Hirota Morihiko, 2006, Journal of Toxicological Sciences, V31, P149, DOI 10.2131/jts.31.149; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; KLIMSTRA DS, 1992, AM J SURG PATHOL, V16, P815, DOI 10.1097/00000478-199209000-00001; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; Mollinedo F, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.41; Mollinedo F, 2010, ONCOGENE, V29, P3748, DOI 10.1038/onc.2010.131; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Mollinedo F, 2010, FUTURE ONCOL, V6, P811, DOI [10.2217/fon.10.34, 10.2217/FON.10.34]; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; Neoptolemos JP, 2003, ANN ONCOL, V14, P675, DOI 10.1093/annonc/mdg207; Nieto-Miguel T, 2007, CANCER RES, V67, P10368, DOI 10.1158/0008-5472.CAN-07-0278; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SKARDA JS, 1994, DIAGN CYTOPATHOL, V10, P20, DOI 10.1002/dc.2840100106; Torrecillas A, 2006, INT J PHARMACEUT, V318, P28, DOI 10.1016/j.ijpharm.2006.03.008; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Riel JMGH, 1999, ANN ONCOL, V10, P157, DOI 10.1023/A:1008342315262; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200; Zerp SF, 2008, ANTI-CANCER DRUG, V19, P65, DOI 10.1097/CAD.0b013e3282f16d36; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	57	59	60	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2627	2639		10.1038/onc.2011.446	http://dx.doi.org/10.1038/onc.2011.446			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	22056873	Green Submitted			2022-12-28	WOS:000304523500003
J	Wang, Y; Sheng, Q; Spillman, MA; Behbakht, K; Gu, H				Wang, Y.; Sheng, Q.; Spillman, M. A.; Behbakht, K.; Gu, H.			Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells	ONCOGENE			English	Article						Gab2; PI3K; Zeb1; E-cadherin; EMT; ovarian cancer	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; HIGH-FREQUENCY; PIK3CA GENE; METASTASIS; PROLIFERATION; TUMORIGENESIS; AMPLIFICATION	Ovarian cancer, the most deadly gynecologic malignancy, is often diagnosed late and at the advanced stage when the cancer cells have already migrated and invaded into other tissues and organs. Better understanding of the mechanism of metastasis in ovarian cancer cells is essential to the design of effective therapy. In this study, we investigated the function of scaffolding adaptor protein Gab2 in ovarian cancer cells. Gab2 is found to be overexpressed in a subset of ovarian tumors and cancer cell lines. Gab2 expression mainly regulates the migratory behaviors of ovarian cancer cells. Overexpression of Gab2 promotes the migration and invasion, and downregulates E-cadherin expression in ovarian cancer cells with low-Gab2 expression. Conversely, knockdown of Gab2 expression inhibits the migration and invasion, and promotes E-cadherin expression in ovarian cancer cells with high-Gab2 expression. By expressing Gab2 wild-type and Gab2 mutants that are defective in activation of the PI3K and Shp2-Erk pathways, we find that Gab2 inhibits E-cadherin expression and enhances the expression of Zeb1, a transcription factor involved in epithelial-to-mesenchymal transition (EMT), and cell migration and invasion through the activation of the PI3K pathway. Knockdown of Zeb1 expression blocks Gab2-induced suppression of E-cadherin expression and increase in cell invasion. LY294002 and GDC-0941, inhibitors of PI3K, or Rapamycin, an inhibitor of PI3K downstream target mTOR, can reverse the effects of Gab2 on migration and invasion. Overall, our studies reveal that Gab2 overexpression, via activation of the PI3K-Zeb1 pathway, promotes characteristics of EMT in ovarian cancer cells. Oncogene (2012) 31, 2512-2520; doi:10.1038/onc.2011.435; published online 26 September 2011	[Wang, Y.; Gu, H.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Sheng, Q.] Univ Colorado Denver, Div Bas Reprod Sci & Gynecol Oncol, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Spillman, M. A.; Behbakht, K.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Spillman, M. A.; Behbakht, K.] Harvard Univ, Sch Med, Boston, MA USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Gu, H (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,Mail Stop 8104,POB 6511, Aurora, CO 80045 USA.	haihua.gu@ucdenver.edu	ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Behbakht, Kian/0000-0003-4793-9958	Department of Pathology, University of Colorado, Anschutz Medical Campus; National Institutes of Health [R01-AI51612]; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612] Funding Source: NIH RePORTER	Department of Pathology, University of Colorado, Anschutz Medical Campus; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Sam Mok for the HOSE lines. This work is supported by the Department of Pathology, University of Colorado, Anschutz Medical Campus and in part by the National Institutes of Health grant R01-AI51612 (to HG).	Abreu MTH, 2011, MOL BIOL CELL, V22, P105, DOI 10.1091/mbc.E10-03-0185; Agarwal R, 2010, CURR OPIN INVEST DR, V11, P615; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Cheng JC, 2011, ONCOGENE, V30, P1020, DOI 10.1038/onc.2010.486; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fleuren EDG, 2010, INT J CANCER, V127, P1486, DOI 10.1002/ijc.25172; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kolasa IK, 2009, CANCER BIOL THER, V8, P21, DOI 10.4161/cbt.8.1.7209; Kong DX, 2010, EUR J CANCER, V46, P1111, DOI 10.1016/j.ejca.2010.01.005; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ries LAG, 2007, SEER SURVIVAL MONOGR, P133; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Tan DSP, 2008, ADV EXP MED BIOL, V622, P153, DOI 10.1007/978-0-387-68969-2_13; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	40	63	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2512	2520		10.1038/onc.2011.435	http://dx.doi.org/10.1038/onc.2011.435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996746	Green Accepted			2022-12-28	WOS:000304191800002
J	Aimbetov, R; Chen, CH; Bulgakova, O; Abetov, D; Bissenbaev, AK; Bersimbaev, RI; Sarbassov, DD				Aimbetov, R.; Chen, C-H; Bulgakova, O.; Abetov, D.; Bissenbaev, A. K.; Bersimbaev, R. I.; Sarbassov, D. D.			Integrity of mTORC2 is dependent on the rictor Gly-934 site	ONCOGENE			English	Article						cell signaling; mTORC2; Akt; complex assembly; kinase	PROTEIN-KINASE B; CAENORHABDITIS-ELEGANS; TYROSINE KINASE; GROWTH-FACTORS; BREAST-CANCER; PHOSPHORYLATION; ACTIVATION; PATHWAY; COMPONENT; AKT/PKB	Growth factor signaling coupled to activation of the phosphatidylinositol-3-OH kinase (PI3K)/Akt pathway plays a crucial role in the regulation of cell proliferation and survival. The key regulatory kinase of Akt has been identified as mammalian target of rapamycin complex 2 (mTORC2), which functions as the PI3K-dependent Ser-473 kinase of Akt. This kinase complex is assembled by mTOR and its essential components rictor, Sin1 and mLST8. The recent genetic screening study in Caenorhabditis elegans has linked a specific point mutation of rictor to an elevated storage of fatty acids that resembles the rictor deficiency phenotype. In our study, we show that in mammalian cells the analogous single rictor point mutation (G934E) prevents the binding of rictor to Sin1 and the assembly of mTORC2, but this mutation does not interfere with the binding of the rictor-interacting protein Protor. A substitution of the rictor Gly-934 residue to a charged amino acid prevents formation of the rictor/Sin1 heterodimer. The cells expressing the rictor G934E mutant remain deficient in the mTORC2 signaling, as detected by the reduced phosphorylation of Akt on Ser-473 and a low cell proliferation rate. Thus, although a full length of rictor is required to interact with its binding partner Sin1, a single amino acid of rictor Gly-934 controls its interaction with Sin1 and assembly of mTORC2. Oncogene (2012) 31, 2115-2120; doi: 10.1038/onc.2011.404; published online 12 September 2011	[Aimbetov, R.; Chen, C-H; Bulgakova, O.; Abetov, D.; Sarbassov, D. D.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Aimbetov, R.; Abetov, D.; Bissenbaev, A. K.] al Farabi Kazakh Natl Univ, Dept Genet & Mol Biol, Alma Ata, Kazakhstan; [Chen, C-H; Sarbassov, D. D.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Bulgakova, O.; Bersimbaev, R. I.] LN Gumilyov Eurasian Natl Univ, Dept Nat Sci, Astana, Kazakhstan	University of Texas System; UTMD Anderson Cancer Center; Al-Farabi Kazakh National University; L.N. Gumilyov Eurasian National University	Sarbassov, DD (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dsarbass@mdanderson.org	Abetov, Danysh/P-7853-2014; Sarbassov, Dos/AAS-4950-2020; Aimbetov, Rakhan/H-2966-2015; Bulgakova, Olga/P-7825-2014; Bissenbaev, Amangeldy/B-1767-2015	Aimbetov, Rakhan/0000-0003-0131-4530; Bulgakova, Olga/0000-0003-3272-0638; Sarbassov, Dos/0000-0002-6848-1133; Bissenbaev, Amangeldy/0000-0001-7837-8685	MD Anderson Trust; NIH [CA133522]; Ph.D. training grants from Kazakhstan; NATIONAL CANCER INSTITUTE [R01CA133522] Funding Source: NIH RePORTER	MD Anderson Trust; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ph.D. training grants from Kazakhstan; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the MD Anderson Trust Fellow Fund and NIH grant CA133522 (DDS). R Aimbetov and O Bulgakova have been partially supported by the Ph.D. training grants from Kazakhstan. We are thankful to our laboratory member Dr Tattym Shaikenov for providing the Akt substrate. We are also thankful to Dr Dario Alessi (University of Dundee, Dundee, England) for providing the Protor 1 alpha expression plasmid.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen C-H, 2011, J BIOL CHEM UNPUB; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gross JM, 2003, CANCER METAST REV, V22, P327, DOI 10.1023/A:1023720928680; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200; Zhang XH, 2000, BREAST CANCER RES, V2, P170, DOI 10.1186/bcr50	27	15	15	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2115	2120		10.1038/onc.2011.404	http://dx.doi.org/10.1038/onc.2011.404			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909137	Green Published, Green Accepted			2022-12-28	WOS:000303008600011
J	Chu, IM; Michalowski, AM; Hoenerhoff, M; Szauter, KM; Luger, D; Sato, M; Flanders, K; Oshima, A; Csiszar, K; Green, JE				Chu, I. M.; Michalowski, A. M.; Hoenerhoff, M.; Szauter, K. M.; Luger, D.; Sato, M.; Flanders, K.; Oshima, A.; Csiszar, K.; Green, J. E.			GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells	ONCOGENE			English	Article						GATA3; basal triple-negative breast cancer; lysyl oxidase; differentiation; gene expression profiling	GENE-EXPRESSION; MESENCHYMAL TRANSITION; ENZYME-ACTIVITY; MAMMARY-GLAND; DIFFERENTIATION; GROWTH; MORPHOGENESIS; PROPEPTIDE; MIGRATION; SUBTYPES	Discovery of mechanisms that impede the aggressive and metastatic phenotype of human basal triple-negative-type breast cancers (BTNBCs) could provide novel targets for therapy for this form of breast cancer that has a relatively poor prognosis. Previous studies have demonstrated that expression of GATA3, the master transcriptional regulator of mammary luminal differentiation, can reduce the tumorigenicity and metastatic propensity of the human BTNBC MDA-MB-231 cell line (MB231), although the mechanism for reduced metastases was not elucidated. We demonstrate through gene expression profiling that GATA3 expression in 231 cells resulted in the dramatic reduction in the expression of lysyl oxidase (LOX), a metastasis-promoting, matrix-remodeling protein, in part, through methylation of the LOX promoter. Suppression of LOX expression by GATA3 was further confirmed in the BTNBC Hs578T cell line. Conversely, reduction of GATA3 expression by small interfering RNA in luminal BT474 cells increased LOX expression. Reconstitution of LOX expression in 231-GATA3 cells restored metastatic propensity. A strong inverse association between LOX and GATA3 expression was confirmed in a panel of 51 human breast cancer cell lines. Similarly, human breast cancer microarray data demonstrated that high LOX/low GATA3 expression is associated with the BTNBC subtype of breast cancer and poor patient prognosis. Expression of GATA3 reprograms BTNBCs to a less aggressive phenotype and inhibits a major mechanism of metastasis through inhibition of LOX. Induction of GATA3 in BTNBC cells or novel approaches that inhibit LOX expression or activity could be important strategies for treating BTNBCs. Oncogene (2012) 31, 2017-2027; doi: 10.1038/onc.2011.382; published online 5 September 2011	[Green, J. E.] NCI, Transgen Oncogenesis & Genom Sect, Lab Canc Biol & Genet, Bethesda, MD 20892 USA; [Hoenerhoff, M.] NIEHS, Cellular & Mol Pathol Branch, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA; [Szauter, K. M.; Csiszar, K.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Hawaii System	Green, JE (corresponding author), NCI, Transgen Oncogenesis & Genom Sect, Lab Canc Biol & Genet, Bldg 37,Room 4054,37 Convent Dr, Bethesda, MD 20892 USA.	jegreen@nih.gov			Center for Cancer Research, NCI, NIH; Department of Defense [W81XWH-10-2-0030]; NATIONAL CANCER INSTITUTE [ZIABC005740] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584] Funding Source: NIH RePORTER	Center for Cancer Research, NCI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We thank Drs Lalage Wakefield and Li Yang for helpful scientific discussions. We also thank Lara El-Touny, Dalit Barkan, Zi-Yao Liu, TingHu Qiu, Anthony Vieira, Christina Bennett, Christine Tomlinson, Steven Austin, Christian Mustroph and Wei-Chu Lai for technical assistance; Paul Meltzer for sharing unpublished data; the LRBGE Fluorescence Imaging Core and Chand Khanna for the use of fluorescence microscopy equipment; and Julie Foley and Norris Flagler for technical assistance with image analysis. This research was supported in part by the Intramural Research Program, Center for Cancer Research, NCI, NIH. IMC acknowledges support from the Department of Defense Breast Cancer Research Program (W81XWH-10-2-0030).	Abourbih DA, 2010, MELANOMA RES, V20, P97, DOI 10.1097/CMR.0b013e328336edfe; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620; Chu I, 2005, CANCER RES, V65, P18; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Grimsby JL, 2010, J CELL BIOCHEM, V111, P1231, DOI 10.1002/jcb.22845; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kaneda A, 2004, CANCER RES, V64, P6410, DOI 10.1158/0008-5472.CAN-04-1543; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kouros-Mehr H, 2006, DEV DYNAM, V235, P3404, DOI 10.1002/dvdy.20978; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Palamakumbura AH, 2009, ONCOGENE, V28, P3390, DOI 10.1038/onc.2009.203; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Payne SL, 2005, CANCER RES, V65, P11429, DOI 10.1158/0008-5472.CAN-05-1274; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Zhou M, 2003, IMMUNOL RES, V28, P25, DOI 10.1385/IR:28:1:25	34	39	39	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2017	2027		10.1038/onc.2011.382	http://dx.doi.org/10.1038/onc.2011.382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21892208	Green Accepted			2022-12-28	WOS:000303008600003
J	Mamo, A; Cavallone, L; Tuzmen, S; Chabot, C; Ferrario, C; Hassan, S; Edgren, H; Kallioniemi, O; Aleynikova, O; Przybytkowski, E; Malcolm, K; Mousses, S; Tonin, PN; Basik, M				Mamo, A.; Cavallone, L.; Tuzmen, S.; Chabot, C.; Ferrario, C.; Hassan, S.; Edgren, H.; Kallioniemi, O.; Aleynikova, O.; Przybytkowski, E.; Malcolm, K.; Mousses, S.; Tonin, P. N.; Basik, M.			An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer	ONCOGENE			English	Article						ARID1A; nonsense-mediated mRNA decay; tumor-suppressor gene; breast cancer	CHROMATIN REMODELING COMPLEXES; SWI/SNF-RELATED COMPLEXES; DNA-BINDING PROPERTIES; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATORS; SACCHAROMYCES-CEREVISIAE; FAMILY PROTEINS; IN-VIVO; MUTATIONS; EXPRESSION	Tumor-suppressor genes (TSGs) have been classically defined as genes whose loss of function in tumor cells contributes to the formation and/or maintenance of the tumor phenotype. TSGs containing nonsense mutations may not be expressed because of nonsense-mediated RNA decay (NMD). We combined inhibition of the NMD process, which clears transcripts that contain nonsense mutations, with the application of high-density single-nucleotide polymorphism arrays analysis to discriminate allelic content in order to identify candidate TSGs in five breast cancer cell lines. We identified ARID1A as a target of NMD in the T47D breast cancer cell line, likely as a consequence of a mutation in exon-9, which introduces a premature stop codon at position Q944. ARID1A encodes a human homolog of yeast SWI1, which is an integral member of the hSWI/SNF complex, an ATP-dependent, chromatin-remodeling, multiple-subunit enzyme. Although we did not find any somatic mutations in 11 breast tumors, which show DNA copy-number loss at the 1p36 locus adjacent to ARID1A, we show that low ARID1A RNA or nuclear protein expression is associated with more aggressive breast cancer phenotypes, such as high tumor grade, in two independent cohorts of over 200 human breast cancer cases each. We also found that low ARID1A nuclear expression becomes more prevalent during the later stages of breast tumor progression. Finally, we found that ARID1A re-expression in the T47D cell line results in significant inhibition of colony formation in soft agar. These results suggest that ARID1A may be a candidate TSG in breast cancer. Oncogene (2012) 31, 2090-2100; doi: 10.1038/onc.2011.386; published online 5 September 2011	[Mamo, A.; Chabot, C.; Ferrario, C.; Hassan, S.; Przybytkowski, E.; Malcolm, K.; Basik, M.] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Cavallone, L.; Tonin, P. N.] McGill Univ, Dept Human Genet, Montreal, PQ H3T 1E2, Canada; [Tuzmen, S.; Mousses, S.] Translat Genom Res Inst, Pharmaceut Genom Div, Scottsdale, AZ USA; [Edgren, H.; Kallioniemi, O.] Univ Helsinki, Inst Mol Med FIMM, Helsinki, Finland; [Edgren, H.; Kallioniemi, O.] VTT Tech Res Ctr Finland, Turku, Finland; [Edgren, H.; Kallioniemi, O.] Univ Turku, Turku, Finland; [Aleynikova, O.] McGill Univ, Jewish Gen Hosp, Dept Pathol, Montreal, PQ H3T 1E2, Canada; [Tonin, P. N.] McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; [Tonin, P. N.] McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; Translational Genomics Research Institute; University of Helsinki; VTT Technical Research Center Finland; University of Turku; McGill University; McGill University; McGill University	Basik, M (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst, Dept Oncol, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	markbasik@gmail.com	Kallioniemi, Olli P/H-5111-2011; Tuzmen, Sukru/I-5663-2013; Tüzmen, Şükrü/AAH-9916-2021	Kallioniemi, Olli P/0000-0002-3231-0332; Tuzmen, Sukru/0000-0003-4822-396X; Tüzmen, Şükrü/0000-0003-4822-396X; Hassan, Saima/0000-0003-0232-2807	Quebec Breast Cancer Foundation; McGill Integrated Cancer Research Training Program; Fonds de Recherche en Sante du Quebec (FRSQ) through the Reseau de Cancer-Axe cancer du sein et de l'ovaire	Quebec Breast Cancer Foundation; McGill Integrated Cancer Research Training Program; Fonds de Recherche en Sante du Quebec (FRSQ) through the Reseau de Cancer-Axe cancer du sein et de l'ovaire	This study was supported by a grant from the Quebec Breast Cancer Foundation to Mark Basik and Patricia N Tonin. EP is supported by the McGill Integrated Cancer Research Training Program. The tumor bank was supported by the Fonds de Recherche en Sante du Quebec (FRSQ) through the Reseau de Cancer-Axe cancer du sein et de l'ovaire to MB.	Adler HT, 1999, MOL CELL BIOL, V19, P7050; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Biegel Jaclyn A, 2004, Curr Oncol Rep, V6, P445, DOI 10.1007/s11912-004-0075-5; Campeau PM, 2008, HUM GENET, V124, P31, DOI 10.1007/s00439-008-0529-1; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Grand F, 1999, CANCER RES, V59, P3870; Hassan S, 2008, CLIN CANCER RES, V14, P446, DOI 10.1158/1078-0432.CCR-07-1189; Hassan S, 2009, AM J PATHOL, V175, P66, DOI 10.2353/ajpath.2009.080948; HIRSCHHORN JN, 1995, MOL CELL BIOL, V15, P1999; Hosein AN, 2010, CANCER RES, V70, P5770, DOI 10.1158/0008-5472.CAN-10-0673; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Li XS, 2010, MOL CELL BIOL, V30, P1673, DOI 10.1128/MCB.00540-09; Medina PP, 2008, EPIGENETICS-US, V3, P64, DOI 10.4161/epi.3.2.6153; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Orlando FA, 2009, ANN SURG ONCOL, V16, P2270, DOI 10.1245/s10434-009-0500-y; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145; Presneau N, 2003, CURR MOL MED, V3, P605, DOI 10.2174/1566524033479500; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; Rodriguez-Nieto S, 2009, CARCINOGENESIS, V30, P547, DOI 10.1093/carcin/bgp035; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Staden R, 2000, Methods Mol Biol, V132, P115; Strumane K, 2004, HANDB EXP PHARM, V165, P69, DOI 10.1007/978-3-540-68170-0_4; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Takeuchi T, 1997, GENE, V204, P71, DOI 10.1016/S0378-1119(97)00525-8; Takeuchi T, 1998, GENE, V213, P189, DOI 10.1016/S0378-1119(98)00194-2; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Van Rechem C, 2009, BIOCHEM BIOPH RES CO, V385, P586, DOI 10.1016/j.bbrc.2009.05.115; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang XM, 2004, BIOCHEM J, V383, P319, DOI 10.1042/BJ20040524; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilsker D, 2004, NUCLEIC ACIDS RES, V32, P1345, DOI 10.1093/nar/gkh277; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Yuge M, 2000, CANCER GENET CYTOGEN, V122, P37, DOI 10.1016/S0165-4608(00)00274-0; Zhang B, 2007, ONCOGENE, V26, P7153, DOI 10.1038/sj.onc.1210509	49	94	99	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2090	2100		10.1038/onc.2011.386	http://dx.doi.org/10.1038/onc.2011.386			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21892209				2022-12-28	WOS:000303008600009
J	Peric, D; Chvalova, K; Rousselet, G				Peric, D.; Chvalova, K.; Rousselet, G.			Identification of microprocessor-dependent cancer cells allows screening for growth-sustaining micro-RNAs	ONCOGENE			English	Article						microprocessor; growth arrest; drosha; DGCR8; PTEN; micro-RNA	TUMOR-SUPPRESSOR; STABLE EXPRESSION; BREAST-CANCER; IN-VIVO; COMPLEX; DGCR8; GENE; TRANSFORMATION; BIOGENESIS; LET-7	Micro-RNAs are deregulated in cancer cells, and some are either tumor suppressive or oncogenic. In addition, a link has been established between decreased expression of micro-RNAs and transformation, and several proteins of the RNA interference pathway have been shown to be haploinsufficient tumor suppressors. Oncogenic microRNAs (oncomiRs) could represent new therapeutic targets, and their identification is therefore crucial. However, structural and functional redundancy between micro-RNAs hampers approaches relying on individual micro-RNA inhibition. We reasoned that in cancer cells that depend on oncomiRs, impairing the micro-RNA pathway could lead to growth perturbation rather than increased tumorigenesis. Identifying such cells could allow functional analyses of individual micro-RNAs by complementation of the phenotypes observed upon global micro-RNA inhibition. Therefore, we developed episomal vectors coding for small hairpin RNAs targeting either Drosha or DGCR8, the two components of the microprocessor, the nuclear micro-RNA maturation complex. We identified cancer cell lines in which both vectors induced colony growth arrest. We then screened for individual micro-RNAs complementing this growth arrest, and identified miR-19a, miR-19b, miR-20a and miR-27b as major growth-sustaining micro-RNAs. However, the effect of miR-19a and miR-19b was only transient. In addition, embryonic stem cell-derived micro-RNAs with miR-20a seeds were much less efficient than miR-20a in sustaining cancer cell growth, a finding that contrasted with results obtained in stem cells. Finally, we showed that the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10, a shared target of miR-19 and miR-20, was functionally involved in the growth arrest induced by microprocessor inhibition. We conclude that our approach allowed to identify microprocessor-dependent cancer cells, which could be used to screen for growth-sustaining micro-RNAs. This complementation screen unveiled functional differences between homologous micro-RNAs. Phenotypic characterization of the complemented cells will allow precise functional studies of these micro-RNAs. Oncogene (2012) 31, 2039-2048; doi:10.1038/onc.2011.391; published online 12 September 2011	[Peric, D.; Chvalova, K.; Rousselet, G.] CEA, DSV, IRCM, LGR, F-92265 Fontenay Aux Roses, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Rousselet, G (corresponding author), CEA, DSV, IRCM, LGR, Bat 5 P 219,18 Route Panorama, F-92265 Fontenay Aux Roses, France.	germain.rousselet@cea.fr	Rousselet, Germain/E-3525-2018	Rousselet, Germain/0000-0002-1710-1639	Angulo laboratory; Electricite De France [V3-104]	Angulo laboratory; Electricite De France	We thank V Neuville for assistance with the in vivo experiments, B Vogelstein and B Bugler for the HCT116 cell lines, J Lebeau for the A549, T-47D, ZR751, MDA-MB-157 and MDA-MB-231 cell lines, and DSF Biard for the pEBP and pEBH vectors and advice for their use. We also thank M Mangeney, C Pique and all members of the Angulo laboratory for helpful discussions and support. This work was supported by the Electricite De France grant no. V3-104 to G.R.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Biard DSF, 2007, NUCLEIC ACIDS RES, V35, P3535, DOI 10.1093/nar/gkm195; Biard DSF, 2005, MOL CANCER RES, V3, P519, DOI 10.1158/1541-7786.MCR-05-0044; Boehler C, 2011, P NATL ACAD SCI USA, V108, P2783, DOI 10.1073/pnas.1016574108; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Colmont C, 2001, AM J PHYSIOL-CELL PH, V280, pC614, DOI 10.1152/ajpcell.2001.280.3.C614; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Desaint S, 2004, J BIOL CHEM, V279, P31157, DOI 10.1074/jbc.M401888200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han J, 2009, CELL, V136, P75, DOI 10.1016/j.cell.2008.10.053; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hand NJ, 2009, HEPATOLOGY, V49, P618, DOI 10.1002/hep.22656; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012; Kadener S, 2009, RNA, V15, P537, DOI 10.1261/rna.1319309; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kuchenbauer F, 2011, BLOOD, DOI 10.1182; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Le May N, 2010, MOL CELL, V38, P54, DOI 10.1016/j.molcel.2010.03.004; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Qi JL, 2009, CELL CYCLE, V8, P3729, DOI 10.4161/cc.8.22.10033; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Shenoy A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006971; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Triboulet R, 2009, RNA, V15, P1005, DOI 10.1261/rna.1591709; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Weng LP, 1999, CANCER RES, V59, P5808	56	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2039	2048		10.1038/onc.2011.391	http://dx.doi.org/10.1038/onc.2011.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909134				2022-12-28	WOS:000303008600005
J	Sala, G; Traini, S; D'Egidio, M; Vianale, G; Rossi, C; Piccolo, E; Lattanzio, R; Piantelli, M; Tinari, N; Natali, PG; Muraro, R; Iacobelli, S				Sala, G.; Traini, S.; D'Egidio, M.; Vianale, G.; Rossi, C.; Piccolo, E.; Lattanzio, R.; Piantelli, M.; Tinari, N.; Natali, P. G.; Muraro, R.; Iacobelli, S.		CINBO	An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling	ONCOGENE			English	Article						ErbB-3 receptor; ErbB-3/Akt pathway; monoclonal antibody; targeted therapy	RECEPTOR TYROSINE KINASES; BREAST-CANCER; PHOSPHOLIPASE C-GAMMA-1; MONOCLONAL-ANTIBODIES; LUNG-CANCER; CELL-LINES; EXPRESSION; HER3; RESISTANCE; CARCINOMAS	The ErbB receptors, such as ErbB-1 and ErbB-2, have been intensely pursued as targets for cancer therapeutics. Although initially efficacious in a subset of patients, drugs targeting these receptors led invariably to resistance, which is often associated with reactivation of the ErbB-3-PI3K-Akt signaling. This may be overcome by an ErbB-3 ligand that abrogates receptor-mediated signaling. Toward this end, we have generated a mouse monoclonal antibody, MP-RM-1, against the extracellular domain (ECD) of ErbB-3 receptor. Assessment of human tumor cell lines, as well as early passage tumor cells revealed that MP-RM-1 effectively inhibited both NRG-1 beta-dependent and -independent ErbB-3 activation. The antagonizing effect of MP-RM-1 was of non-competitive type, as binding of [I-125]-labeled NRG-1 beta to ErbB-3 was not influenced by the antibody. MP-RM-1 treatment led, in most instances, to decreased ErbB-3 expression. In addition, MP-RM-1 was able to inhibit the colony formation ability of tumor cells and tumor growth in two human tumor xenograft nude mouse models. Treatment with the antibody was associated with a decreased ErbB-3 and Akt phosphorylation and ErbB-3 expression in the excised tumor tissue. Collectively, these results indicate that MP-RM-1 has the potential to interfere with signaling by ErbB-3 and reinforce the notion that ErbB-3 could be a key target in cancer-drug design. Oncogene (2012) 31, 1275-1286; doi: 10.1038/onc.2011.322; published online 8 August 2011	[Sala, G.; Traini, S.; D'Egidio, M.; Vianale, G.; Rossi, C.; Piccolo, E.; Lattanzio, R.; Piantelli, M.; Tinari, N.; Muraro, R.; Iacobelli, S.] Univ Fdn G DAnnunzio, Dept Oncol & Expt Med, I-66100 Chieti, Italy; [Sala, G.; Traini, S.; D'Egidio, M.; Piccolo, E.; Piantelli, M.; Tinari, N.; Natali, P. G.; Muraro, R.; Iacobelli, S.] MediaPharma Srl, Chieti, Italy	G d'Annunzio University of Chieti-Pescara	Sala, G (corresponding author), Univ Fdn G DAnnunzio, Dept Oncol & Expt Med, Via Colle Ara 1, I-66100 Chieti, Italy.	g.sala@unich.it	Lattanzio, Rossano/K-1927-2018; Sala, Gianluca/C-2056-2017	Lattanzio, Rossano/0000-0001-9803-4476; Sala, Gianluca/0000-0002-4494-915X; Tinari, Nicola/0000-0001-8449-5407; Traini, Sara/0000-0003-3233-4833; Piantelli, Mauro/0000-0003-0154-482X	AIRC	AIRC(Fondazione AIRC per la ricerca sul cancro)	We thank Dr F Petronzelli (Sigma-Tau Pomezia, Italy) for the measurement of MP-RM-1 affinity by surface plasmonic resonance; Dr O Segatto, Dr S Anastasi and Dr M Sallese for advice and reagents, R La Sorda and MR Nicotra for the immunohistochemical analysis, Dr A Sala and Professor V De Laurenzi for discussion. PGN and MP partially supported by AIRC.	ALIMANDI M, 1995, ONCOGENE, V10, P1813; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bianchi S, 2006, J CELL PHYSIOL, V206, P702, DOI 10.1002/jcp.20535; Chen LQ, 2010, CANCER RES, V70, P5994, DOI 10.1158/0008-5472.CAN-09-4440; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGIESI G, 1992, HYBRIDOMA, V11, P519, DOI 10.1089/hyb.1992.11.519; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Giampaglia M, 2010, CANCER TREAT REV, V36, pS72, DOI 10.1016/S0305-7372(10)70024-4; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hynes Nancy E., 2007, V172, P45; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Karamouzis MV, 2007, INT J BIOCHEM CELL B, V39, P851, DOI 10.1016/j.biocel.2006.11.017; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003; MOTTOLESE M, 1988, EUR J CANCER CLIN ON, V24, P1277, DOI 10.1016/0277-5379(88)90215-5; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Prewett M, 1998, CLIN CANCER RES, V4, P2957; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; Reschke M, 2008, CLIN CANCER RES, V14, P5188, DOI 10.1158/1078-0432.CCR-08-0186; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Sala G, 2008, CANCER RES, V68, P10187, DOI 10.1158/0008-5472.CAN-08-1181; Saxena R, 2010, MED RES REV; Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sithanandam G, 2005, ONCOGENE, V24, P1847, DOI 10.1038/sj.onc.1208381; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Tanner B, 2006, J CLIN ONCOL, V24, P4317, DOI 10.1200/JCO.2005.04.8397; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEINSTEIN JN, 1992, CANCER RES, V52, pS2747; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Wu WKK, 2009, ANTICANCER RES, V29, P229; Yi ES, 1997, MODERN PATHOL, V10, P142; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	48	26	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1275	1286		10.1038/onc.2011.322	http://dx.doi.org/10.1038/onc.2011.322			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21822299				2022-12-28	WOS:000301344600007
J	Farabaugh, SM; Micalizzi, DS; Jedlicka, P; Zhao, R; Ford, HL				Farabaugh, S. M.; Micalizzi, D. S.; Jedlicka, P.; Zhao, R.; Ford, H. L.			Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties	ONCOGENE			English	Article						Six1; Eya; TGF-beta; epithelial-mesenchymal transition; cancer stem cells	BRANCHIOOTORENAL BOR SYNDROME; HOMEOBOX GENE-EXPRESSION; EYES-ABSENT; BREAST-CANCER; HOMEOPROTEIN SIX1; CARCINOMA CELLS; COFACTOR EYA2; TUMOR-GROWTH; MUTATIONS; PROTEIN	Six1 is a critical regulator of embryonic development that requires interaction with the Eya family of proteins (Eya1-4) to activate the transcription of genes involved in neurogenesis, myogenesis and nephrogenesis. Although expression of Six1 and Eya family members is predominantly observed in development, their overexpression is observed in numerous cancers. Importantly, both Six1 and Eya have independently been shown to mediate breast cancer metastasis, but whether they functionally interact during tumor progression has not been explored. Herein, we demonstrate that knockdown of Eya2 in MCF7 mammary carcinoma cells reverses the ability of Six1 to induce transforming growth factor-beta signaling, as well as to induce characteristics associated with epithelial-mesenchymal transition and cancer stem cells, suggesting that Six1 is dependent on Eya2 to mediate numerous pro-metastatic characteristics. The importance of the Six1-Eya interaction in human breast cancer is underscored by the finding that high levels of Six1 correlate with shortened time to relapse and metastasis as well as decreased survival only when co-expressed with high levels of Eya2. Overall, these data implicate Eya2 as a necessary co-factor for many of the metastasis promoting functions of Six1, suggesting that targeting the Six1-Eya interaction may inhibit breast cancer progression. As Six1 and Eya2 are not highly expressed in most adult tissues, the Six1-Eya interaction may be a valuable future therapeutic target whose inhibition would be expected to impair breast cancer progression while conferring limited side effects. Oncogene (2012) 31, 552-562; doi:10.1038/onc.2011.259; published online 27 June 2011	[Ford, H. L.] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Farabaugh, S. M.; Zhao, R.; Ford, H. L.] Univ Colorado, Dept Biochem & Mol Genet, Aurora, CO 80045 USA; [Micalizzi, D. S.; Ford, H. L.] Univ Colorado, Program Mol Biol, Aurora, CO 80045 USA; [Micalizzi, D. S.; Ford, H. L.] Univ Colorado, Med Scientist Training Program, Aurora, CO 80045 USA; [Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Ford, HL (corresponding author), Univ Colorado, Sch Med, Dept Obstet & Gynecol, Anschutz Med Campus,RC1 N,Room 5102, Aurora, CO 80045 USA.	heide.ford@ucdenver.edu		Micalizzi, Douglas/0000-0002-0306-9914	National Cancer Institute [2RO1-CA095277]; American Cancer Society [RSG-07-183-01-DDC]; Department of Defense [BC084105, W81XWH-08-1-0332, W81XWH-06-1-0757]; NATIONAL CANCER INSTITUTE [R01CA095277, R01CA157790] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by grants from the National Cancer Institute (2RO1-CA095277) and the American Cancer Society (#RSG-07-183-01-DDC) to HLF, and the Department of Defense Breast Cancer Synergistic Idea Award (BC084105) to HLF and RZ. SMF and DSM were funded by predoctoral fellowships from the Department of Defense Breast Cancer Research Program (W81XWH-08-1-0332 and W81XWH-06-1-0757, respectively). We would like to thank Alana Welm for training in microarray datamining techniques, database sharing and helpful datamining discussions, and Katherine Martin, of Bioarray Therapeutics, for data analysis of the Wang data set.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abdelhak S, 1997, HUM MOL GENET, V6, P2247, DOI 10.1093/hmg/6.13.2247; Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ando Z, 2005, FEBS J, V272, P3026, DOI 10.1111/j.1742-4658.2005.04716.x; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Embry AC, 2004, MOL PHARMACOL, V66, P1325, DOI 10.1124/mol.104.004093; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Ford HL, 1998, CELL BIOL INT, V22, P397, DOI 10.1006/cbir.1998.0329; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769; Jemc J, 2007, DEV BIOL, V310, P416, DOI 10.1016/j.ydbio.2007.07.024; Kochhar A, 2008, HUM MUTAT, V29, P565, DOI 10.1002/humu.20714; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krishnan N, 2009, J BIOL CHEM, V284, P16066, DOI 10.1074/jbc.C900032200; Laclef C, 2003, MECH DEVELOP, V120, P669, DOI 10.1016/S0925-4773(03)00065-0; Laclef C, 2003, DEVELOPMENT, V130, P2239, DOI 10.1242/dev.00440; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Miller SJ, 2010, ONCOGENE, V29, P368, DOI 10.1038/onc.2009.360; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Ohto H, 1999, MOL CELL BIOL, V19, P6815; Okabe Y, 2009, NATURE, V460, P520, DOI 10.1038/nature08138; Orten DJ, 2008, HUM MUTAT, V29, P537, DOI 10.1002/humu.20691; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122; Patrick AN, 2009, J BIOL CHEM, V284, P20781, DOI 10.1074/jbc.M109.016832; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Ruf RG, 2004, P NATL ACAD SCI USA, V101, P8090, DOI 10.1073/pnas.0308475101; Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014; Schonberger J, 2005, NAT GENET, V37, P418, DOI 10.1038/ng1527; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vincent C, 1997, EUR J HUM GENET, V5, P242, DOI 10.1159/000484770; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wayne S, 2001, HUM MOL GENET, V10, P195, DOI 10.1093/hmg/10.3.195; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Xiong WJ, 2009, DEV CELL, V16, P271, DOI 10.1016/j.devcel.2008.12.005; Xu PX, 1999, NAT GENET, V23, P113, DOI 10.1038/12722; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536; Xu PX, 2002, DEVELOPMENT, V129, P3033; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang L, 2005, CANCER RES, V65, P925; Zhang YZ, 2004, JARO-J ASSOC RES OTO, V5, P295, DOI 10.1007/s10162-004-4044-3; Zheng XH, 2010, INT J GYNECOL CANCER, V20, P1587, DOI 10.1111/IGC.0b013e3181f9defb; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	57	92	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					552	562		10.1038/onc.2011.259	http://dx.doi.org/10.1038/onc.2011.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706047	Green Accepted			2022-12-28	WOS:000300221800002
J	Li, H; Wittwer, T; Weber, A; Schneider, H; Moreno, R; Maine, GN; Kracht, M; Schmitz, ML; Burstein, E				Li, H.; Wittwer, T.; Weber, A.; Schneider, H.; Moreno, R.; Maine, G. N.; Kracht, M.; Schmitz, M. L.; Burstein, E.			Regulation of NF-kappa B activity by competition between RelA acetylation and ubiquitination	ONCOGENE			English	Article						NF-kappa B; RelA; p65; acetylation; ubiquitination; transcription	TRANSCRIPTION FACTOR; DEPENDENT TRANSCRIPTION; CANCER DEVELOPMENT; P65 SUBUNIT; PHOSPHORYLATION; ACTIVATION; ALPHA; INFLAMMATION; DEGRADATION; PROGRESSION	The nuclear factor (NF)-kappa B transcription factor has essential roles in inflammation and oncogenesis. Its ubiquitous RelA subunit is regulated by several post-translational modifications, including phosphorylation, ubiquitination and acetylation. Ubiquitination promotes the termination of RelA-dependent transcription, but its regulation is incompletely understood. Through mass spectrometry analysis of ubiquitinated RelA, we identified seven lysines that were attached to degradative and non-degradative forms of polyubiquitin. Interestingly, lysines targeted for acetylation were among the residues identified as ubiquitin acceptor sites. Mutation of these particular sites resulted in decreased polyubiquitination. Acetylation and ubiquitination were found to inhibit each other, consistent with their use of overlapping sites. Reconstitution of rela(-/-) fibroblasts with wild-type and mutant forms of RelA revealed that modifications at these residues can have activating and inhibitory functions depending on the target gene context. Altogether, this study elucidates that ubiquitination and acetylation can modulate each other and regulate nuclear NF-kappa B function in a gene-specific manner. Oncogene (2012) 31, 611-623; doi:10.1038/onc.2011.253; published online 27 June 2011	[Li, H.; Burstein, E.] UT SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; [Wittwer, T.; Moreno, R.; Schmitz, M. L.] Univ Giessen, Fac Med, Inst Biochem, D-35392 Giessen, Germany; [Weber, A.; Kracht, M.] Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany; [Schneider, H.] Hannover Med Sch, Inst Biochem, D-3000 Hannover, Germany; [Maine, G. N.] William Beaumont Hosp, Dept Clin Pathol, Royal Oak, MI 48072 USA; [Burstein, E.] UT SW Med Ctr, Dept Mol Biol, Dallas, TX 75230 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Justus Liebig University Giessen; Justus Liebig University Giessen; Hannover Medical School; Beaumont Health; University of Texas System; University of Texas Southwestern Medical Center Dallas	Burstein, E (corresponding author), UT SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75230 USA.	Lienhard.Schmitz@biochemie.med.uni-giessen.de; ezra.burstein@utsouthwestern.edu	Li, Haiying/B-1879-2012; Burstein, Ezra/B-7247-2016; Schmitz, M. Lienhard/D-9328-2017	Burstein, Ezra/0000-0003-4341-6367; Schmitz, M. Lienhard/0000-0002-6984-7192; Kracht, Michael/0000-0002-8501-043X	NIH [R01 DK073639]; CCFA; UTSW DOCS; DFG; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073639] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CCFA; UTSW DOCS; DFG(German Research Foundation (DFG)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Zhijian 'James' Chen, Maria S Soengas and Marty W Mayo for providing cell lines that were utilized in these studies. We also thank Doris Newel and Oliver Dittrich for their technical assistance with the microarray experiments. This work was supported by an NIH R01 DK073639, a CCFA Senior Research Award and a UTSW DOCS Award to EB. The work of MLS and MK is supported by grants from the DFG.	BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Buerki C, 2008, NUCLEIC ACIDS RES, V36, P1665, DOI 10.1093/nar/gkn003; Burstein E, 2005, J BIOL CHEM, V280, P22222, DOI 10.1074/jbc.M501928200; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106; Fan YH, 2009, J BIOL CHEM, V284, P29290, DOI 10.1074/jbc.M109.018994; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Maine GN, 2007, EMBO J, V26, P436, DOI 10.1038/sj.emboj.7601489; Maine Gabriel N, 2009, Cold Spring Harb Protoc, V2009, DOI 10.1101/pdb.prot5318; Maine GN, 2010, NAT PROTOC, V5, P1447, DOI 10.1038/nprot.2010.109; Mao XC, 2009, GENE DEV, V23, P849, DOI 10.1101/gad.1748409; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Rothgiesser KM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-22; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Wright CW, 2009, SCIENCE, V323, P251, DOI 10.1126/science.1162818; Xu M, 2009, MOL CELL, V36, P302, DOI 10.1016/j.molcel.2009.10.002; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	40	49	51	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					611	623		10.1038/onc.2011.253	http://dx.doi.org/10.1038/onc.2011.253			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706061	Green Accepted			2022-12-28	WOS:000300221800007
J	Smirnova, T; Zhou, ZN; Flinn, RJ; Wyckoff, J; Boimel, PJ; Pozzuto, M; Coniglio, SJ; Backer, JM; Bresnick, AR; Condeelis, JS; Hynes, NE; Segall, JE				Smirnova, T.; Zhou, Z. N.; Flinn, R. J.; Wyckoff, J.; Boimel, P. J.; Pozzuto, M.; Coniglio, S. J.; Backer, J. M.; Bresnick, A. R.; Condeelis, J. S.; Hynes, N. E.; Segall, J. E.			Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis	ONCOGENE			English	Article						ErbB3; breast cancer; metastasis; in vivo invasion; intravasation; PI3-Kinase	MAMMARY-TUMORS; ERBB2/ERBB3 CORECEPTOR; LUNG-CANCER; INTRAVASATION; ERBB3; INVASION; RECEPTOR; KINASE; INHIBITION; EXPRESSION	Many malignancies show increased expression of the epidermal growth factor (EGF) receptor family member ErbB3 (HER3). ErbB3 binds heregulin beta-1 (HRG beta 1) and forms a heterodimer with other ErbB family members, such as ErbB2 (HER2) or EGF receptor (EGFR; HER1), enhancing phosphorylation of specific C-terminal tyrosine residues and activation of downstream signaling pathways. ErbB3 contains six YXXM motifs that bind the p85 subunit of phosphoinositide 3 (PI3)-kinase. Previous studies demonstrated that overexpression of ErbB3 in mammary tumor cells can significantly enhance chemotaxis to HRG beta 1 and overall metastatic potential. We tested the hypothesis that ErbB3-mediated PI3-kinase signaling is critical for heregulin-induced motility, and therefore crucial for ErbB3-mediated invasion, intravasation and metastasis. The tyrosines in the six YXXM motifs on the ErbB3 C-terminus were replaced with phenylalanine. In contrast to overexpression of the wildtype ErbB3, overexpression of the mutant ErbB3 did not enhance chemotaxis towards HRGb1 in vitro or in vivo. We also observed reduced tumor cell motility in the primary tumor by multiphoton microscopy, as well as a dramatically reduced ability of these cells to cross the endothelium and intravasate into the circulation. Moreover, whereas mutation of the ErbB3 C-terminus had no effect on tumor growth, it had a dramatic effect on spontaneous metastatic potential. Treatment with the PI3-kinase inhibitor PIK-75 similarly inhibited motility and invasion in vitro and in vivo. Our results indicate that stimulation of the early metastatic steps of motility and invasion by ErbB3 requires activation of the PI3-kinase pathway by the ErbB3 receptor. Oncogene (2012) 31, 706-715; doi:10.1038/onc.2011.275; published online 4 July 2011	[Smirnova, T.; Zhou, Z. N.; Wyckoff, J.; Boimel, P. J.; Coniglio, S. J.; Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10801 USA; [Flinn, R. J.; Backer, J. M.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10801 USA; [Wyckoff, J.; Condeelis, J. S.; Segall, J. E.] Albert Einstein Coll Med, Gruss Lipper Ctr Biophoton, Bronx, NY 10801 USA; [Pozzuto, M.; Bresnick, A. R.] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10801 USA; [Hynes, N. E.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Friedrich Miescher Institute for Biomedical Research	Segall, JE (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, Price 201,1300 Morris Pk Ave, Bronx, NY 10801 USA.	jeffrey.segall@einstein.yu.edu		Boimel, Pamela/0000-0002-9771-1700	NIH [CA77522, CA100324, CA1U01105490, RO1 GM55692, P01 CA100324]; NATIONAL CANCER INSTITUTE [P01CA100324, U01CA105490, R01CA077522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055692, T32GM007288] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank John Koland and the members of the Segall, Condeelis, Cox, Hodgson, and Hynes laboratories for comments and suggestions. JES is the Betty and Sheldon Feinberg Senior Faculty Scholar in Cancer Research. This work was supported by grants from the NIH (JES: CA77522 and CA100324); CA1U01105490 and CA100324 (JS Condeelis and J Wyckoff); RO1 GM55692 (JB); NIH P01 CA100324 (JB and ARB).	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079; Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chausovsky A, 2000, ONCOGENE, V19, P878, DOI 10.1038/sj.onc.1203410; Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003; Chiu CG, 2010, ANN SURG, V251, P1107, DOI 10.1097/SLA.0b013e3181dbb77e; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977; Hayakawa M, 2007, BIOORGAN MED CHEM, V15, P5837, DOI 10.1016/j.bmc.2007.05.070; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hernandez L, 2009, METHODS MOL BIOL, V571, P227, DOI 10.1007/978-1-60761-198-1_15; Hernandez L, 2009, CANCER RES, V69, P3221, DOI 10.1158/0008-5472.CAN-08-2871; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Iivanainen E, 2007, EXP CELL RES, V313, P2896, DOI 10.1016/j.yexcr.2007.03.042; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kalinowski A, 2010, FASEB J, V24, P2567, DOI 10.1096/fj.08-129072; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Ky B, 2009, CIRCULATION, V120, P310, DOI 10.1161/CIRCULATIONAHA.109.856310; NERI A, 1982, J NATL CANCER I, V68, P507; Olayioye MA, 2001, EXP CELL RES, V267, P81, DOI 10.1006/excr.2001.5242; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Sassen A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1843; Schade B, 2007, CANCER RES, V67, P7579, DOI 10.1158/0008-5472.CAN-06-4724; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Wyckoff JB, 2000, CANCER RES, V60, P2504; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Zhang JF, 2006, ARTERIOSCL THROM VAS, V26, pE23, DOI 10.1161/01.ATV.0000202661.61837.93	37	48	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					706	715		10.1038/onc.2011.275	http://dx.doi.org/10.1038/onc.2011.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725367	Green Accepted			2022-12-28	WOS:000300222100004
J	Rowh, MAW; DeMicco, A; Horowitz, JE; Yin, B; Yang-Iott, KS; Fusello, AM; Hobeika, E; Reth, M; Bassing, CH				Rowh, M. A. W.; DeMicco, A.; Horowitz, J. E.; Yin, B.; Yang-Iott, K. S.; Fusello, A. M.; Hobeika, E.; Reth, M.; Bassing, C. H.			Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations	ONCOGENE			English	Article						p53; B lineage lymphomas; Igh/c-myc translocations	DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; V(D)J RECOMBINATION; TRANSGENIC MICE; DNA BREAKS; GENE AMPLIFICATION; CRE RECOMBINASE; HISTONE H2AX; P53; MYC	Inactivating Tp53 mutations are frequent genetic lesions in human tumors that harbor genomic instability, including B lineage lymphomas with IG translocations. Antigen receptor genes are assembled and modified in developing lymphocytes by RAG/AID-initiated genomic rearrangements that involve the induction of DNA double strand breaks (DSBs). Although TP53 inhibits the persistence of DSBs and induces apoptosis to protect cells from genomic instability and transformation, the development of spontaneous tumors harboring clonal translocations has not been reported in mice that only lack wild-type Tp53 protein or express Tp53 mutants. Tp53-deficient (Tp53(-/-)) mice succumb to T lineage lymphomas lacking clonal translocations but develop B lymphoid tumors containing immunoglobulin (Ig) translocations upon combined inactivation of DSB repair factors, RAG mutation or AID overexpression; mice expressing apoptosis-defective Tp53 mutants develop B cell lymphomas that have not been characterized for potential genomic instability. As somatic rather than germline inactivating mutations of TP53 are typically associated with human cancers and Tp53 deletion has cellular context dependent effects upon lymphocyte transformation, we generated mice with conditional Tp53 deletion in lineage-committed B lymphocytes to avoid complications associated with defective Tp53 responses during embryogenesis and/or in multilineage potential cells and, thereby, directly evaluate the potential physiological role of Tp53 in suppressing translocations in differentiated cells. These mb1-cre: Tp53(flox)/(flox) mice succumbed to lymphoid tumors containing Ig gene rearrangements and immunophenotypes characteristic of B cells from various developmental stages. Most mb1-cre: Tp53(flox)/(flox) tumors harbored clonal translocations, including Igh/c-myc or other oncogenic translocations generated by the aberrant repair of RAG/AID-generated DSBs. Our data indicate that Tp53 serves critical functions in B lineage lymphocytes to prevent transformation caused by translocations in cell populations experiencing physiological levels of RAG/AID-initiated DSB intermediates, and provide evidence that the somatic TP53 mutations found in diffuse large B-cell lymphoma and Burkitt's lymphoma may contribute to the development of these human malignancies. Oncogene (2011) 30, 4757-4764; doi:10.1038/onc.2011.191; published online 30 May 2011	[Bassing, C. H.] Univ Penn, Dept Pathol, CHOP, Immunol Grad Grp,Sch Med, Philadelphia, PA 19104 USA; [Rowh, M. A. W.; DeMicco, A.; Horowitz, J. E.; Yin, B.; Yang-Iott, K. S.; Fusello, A. M.; Bassing, C. H.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Dept Pathol & Lab Med, Div Canc Pathobiol, Philadelphia, PA 19104 USA; [Rowh, M. A. W.; DeMicco, A.; Horowitz, J. E.; Yin, B.; Yang-Iott, K. S.; Fusello, A. M.; Bassing, C. H.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [DeMicco, A.; Yin, B.; Bassing, C. H.] Univ Penn, Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; [Hobeika, E.; Reth, M.] Univ Freiburg, BIOSS, Ctr Biol Signaling Studies, D-79106 Freiburg, Germany; [Hobeika, E.; Reth, M.] Max Planck Inst Immunobiol, Freiburg, Germany	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Freiburg; Max Planck Society	Bassing, CH (corresponding author), Univ Penn, Dept Pathol, CHOP, Immunol Grad Grp,Sch Med, 4054 Colket Translat Res Bldg,421 Curie Blvd,3501, Philadelphia, PA 19104 USA.	bassing@email.chop.edu	hobeika, elias/AAV-6663-2021	Rowh, Marta/0000-0001-9584-7826	University of Pennsylvania [5T32-AR007442-23, GM-07229]; Cancer Research Institute; Department of Pathology and Laboratory Medicine; Center for Childhood Cancer Research of the Children's Hospital of Philadelphia Research Institute; Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine; Pennsylvania Department of Health; Leukemia and Lymphoma Society; National Institutes of Health [R01 CA125195]; NATIONAL CANCER INSTITUTE [R01CA125195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007442] Funding Source: NIH RePORTER	University of Pennsylvania; Cancer Research Institute; Department of Pathology and Laboratory Medicine; Center for Childhood Cancer Research of the Children's Hospital of Philadelphia Research Institute; Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine; Pennsylvania Department of Health; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the Training Program Rheumatic Disease of the University of Pennsylvania (5T32-AR007442-23 to MAWR), the Training Grant TG GM-07229 of the University of Pennsylvania (AD), the Cancer Research Institute Pre-doctoral Emphasis Pathway in Tumor Immunology Training Grant awarded to the University of Pennsylvania (BY); the Department of Pathology and Laboratory Medicine and the Center for Childhood Cancer Research of the Children's Hospital of Philadelphia Research Institute, the Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine, a grant from the Pennsylvania Department of Health, a Leukemia and Lymphoma Society Scholar Award (CHB), and the National Institutes of Health Grant R01 CA125195 (CHB).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2008, BLOOD, V111, P2163, DOI 10.1182/blood-2007-08-104760; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cheung AMY, 2002, CANCER RES, V62, P6194; Cheung KJJ, 2009, BRIT J HAEMATOL, V146, P257, DOI 10.1111/j.1365-2141.2009.07739.x; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dujka ME, 2010, ONCOGENE, V29, P957, DOI 10.1038/onc.2009.394; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Gladdy RA, 2003, CANCER CELL, V3, P37, DOI 10.1016/S1535-6108(02)00236-2; Hobeika E, 2006, P NATL ACAD SCI USA, V103, P13789, DOI 10.1073/pnas.0605944103; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; MacPherson D, 2004, EMBO J, V23, P3689, DOI 10.1038/sj.emboj.7600363; Nepal RM, 2008, ONCOGENE, V27, P4752, DOI 10.1038/onc.2008.111; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Robbiani DF, 2009, MOL CELL, V36, P631, DOI 10.1016/j.molcel.2009.11.007; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Ryu CJ, 2006, CANCER CELL, V9, P109, DOI 10.1016/j.ccr.2006.01.004; Santos MA, 2010, J EXP MED, V207, P973, DOI 10.1084/jem.20092308; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Slatter TL, 2010, CELL DEATH DIFFER, V17, P540, DOI 10.1038/cdd.2009.136; Smith DP, 2005, ONCOGENE, V24, P3544, DOI 10.1038/sj.onc.1208399; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang JH, 2009, NATURE, V460, P231, DOI 10.1038/nature08159; Wang JH, 2008, J EXP MED, V205, P3079, DOI 10.1084/jem.20082271; Wu C, 2003, IMMUNITY, V18, P75, DOI 10.1016/S1074-7613(02)00515-0; Yin B, 2010, BLOOD OCT, V117, P175; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	39	18	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4757	4764		10.1038/onc.2011.191	http://dx.doi.org/10.1038/onc.2011.191			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21625223				2022-12-28	WOS:000298033700008
J	Yi, C; Wang, Q; Wang, L; Huang, Y; Li, L; Liu, L; Zhou, X; Xie, G; Kang, T; Wang, H; Zeng, M; Ma, J; Zeng, Y; Yun, JP				Yi, C.; Wang, Q.; Wang, L.; Huang, Y.; Li, L.; Liu, L.; Zhou, X.; Xie, G.; Kang, T.; Wang, H.; Zeng, M.; Ma, J.; Zeng, Y.; Yun, J-P			MiR-663, a microRNA targeting p21(waf1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma	ONCOGENE			English	Article						microRNAs; miR-663; cell cycle; p21; nasopharyngeal carcinoma	EPSTEIN-BARR-VIRUS; CELL-GROWTH; POSTTRANSCRIPTIONAL REGULATION; EXPRESSION PROFILES; C-MYC; P21; ARREST; INHIBITION; GENES; P53	MicroRNAs (miRNAs) may function as either oncogenes or tumor suppressors in the malignant progression of different tumor types. MiR-663 was recently reported to be decreased and identified as a tumor suppressor in gastric cancer. We also verified its role in repressing cell proliferation of a gastric cancer cell line. In this study, however, miR-663 was found to be upregulated in nasopharyngeal carcinoma (NPC) cells compared with human immortalized nasopharyngeal epithelium cells, using a miRNA microarray, and this higher expression was confirmed in NPC tissue samples. Indeed, inhibition of miR-663 impaired the proliferation of NPC cells in vitro and the NPC tumor growth of xenografts in nude mice. Mechanistically, miR-663 directly targeted p21(WAF1/CIP1) to promote the cellular G1/S transition, as the inhibitory effects of miR-663 on the G1/S transition could be rescued by p21(WAF1/CIP1) silencing. Our results imply that miR-663 may act as an oncogene in NPC. The newly identified miR-663/p21(WAF1/CIP1) axis clarifies the molecular mechanism of NPC cell proliferation and represents a novel strategy for the diagnosis and treatment of patients with NPC. Oncogene (2012) 31, 4421-4433; doi: 10.1038/onc.2011.629; published online 16 January 2012	[Yi, C.; Wang, Q.; Wang, L.; Huang, Y.; Li, L.; Liu, L.; Zhou, X.; Xie, G.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Yi, C.; Wang, Q.; Wang, L.; Huang, Y.; Li, L.; Liu, L.; Zhou, X.; Xie, G.; Kang, T.; Wang, H.; Zeng, M.; Ma, J.; Zeng, Y.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China; [Kang, T.; Wang, H.; Zeng, M.; Zeng, Y.] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510060, Guangdong, Peoples R China; [Ma, J.] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Yun, JP (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	yunjp@mail.sysu.edu.cn	Wang, Linli/R-5688-2018	Wang, Linli/0000-0002-8380-6135	National Natural Science Foundation of China [30973506, 81172345]; 863 Project [2006AA02A404]; Science Foundation of Key Hospital Clinical Program of Ministry of Health, China [2010-178]; Project of State Key Laboratory of Oncology in South China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 Project(National High Technology Research and Development Program of China); Science Foundation of Key Hospital Clinical Program of Ministry of Health, China; Project of State Key Laboratory of Oncology in South China	We thank Jun Li for kindly providing the human gastric cancer cells MKN-45 and SCG-7901. This work was supported by grants from the National Natural Science Foundation of China (30973506 and 81172345), the 863 Project (2006AA02A404), the Science Foundation of Key Hospital Clinical Program of Ministry of Health, China (2010-178), and the Project of State Key Laboratory of Oncology in South China.	Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bei JX, 2010, NAT GENET, V42, P599, DOI 10.1038/ng.601; Borgdorff V, 2010, ONCOGENE, V29, P2262, DOI 10.1038/onc.2009.497; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Chen H, 2010, NEUROL RES, V32, P603, DOI 10.1179/174313209X455691; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gottwein E, 2010, J VIROL, V84, P5229, DOI 10.1128/JVI.00202-10; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Kong QL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000940; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lehmann U, 2007, Verh Dtsch Ges Pathol, V91, P214; Lei X, 1999, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V13, P406; Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002; Li HM, 2004, ONCOGENE, V23, P4488, DOI 10.1038/sj.onc.1207580; Li XS, 1996, CANCER RES, V56, P5055; Liao Wen-Ting, 2005, Ai Zheng, V24, P1317; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Lung RWM, 2009, NEOPLASIA, V11, P1174, DOI 10.1593/neo.09888; Maes OC, 2009, J CELL PHYSIOL, V221, P109, DOI 10.1002/jcp.21834; Marasa BS, 2010, AGING-US, V2, P333, DOI 10.18632/aging.100159; McDermott AL, 2001, CLIN OTOLARYNGOL, V26, P82, DOI 10.1046/j.1365-2273.2001.00449.x; Mei J, 2011, MOL CELL BIOL, V31, P3584, DOI 10.1128/MCB.05821-11; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Ni CW, 2011, AM J PHYSIOL-HEART C, V300, pH1762, DOI 10.1152/ajpheart.00829.2010; Orom UA, 2006, GENE, V372, P137, DOI 10.1016/j.gene.2005.12.031; Pan JA, 2010, ONCOL REP, V24, P105, DOI 10.3892/or_00000834; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pizzimenti S, 2009, FREE RADICAL BIO MED, V46, P282, DOI 10.1016/j.freeradbiomed.2008.10.035; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Te JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010344; Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003; Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Min, 2005, Ai Zheng, V24, P1230; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wang ZZ, 2010, INT J ONCOL, V37, P1315, DOI 10.3892/ijo_00000783; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wong P, 2010, CANCER RES, V70, P3833, DOI 10.1158/0008-5472.CAN-09-3268; Wong TS, 2011, J CANCER RES CLIN, V137, P415, DOI 10.1007/s00432-010-0898-4; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Xu S, 2011, ONCOGENE, V30, P2219, DOI 10.1038/onc.2010.596; Yun JP, 2007, BRIT J CANCER, V96, P477, DOI 10.1038/sj.bjc.6603574; Zeng YX, 2002, SEMIN CANCER BIOL, V12, P443, DOI 10.1016/S1044579X02000871; Zhang LM, 2010, CARCINOGENESIS, V31, P559, DOI 10.1093/carcin/bgp335; Zhang MF, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-110; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou YH, 2008, INT J CANCER, V123, P2065, DOI 10.1002/ijc.23727	76	125	131	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4421	4433		10.1038/onc.2011.629	http://dx.doi.org/10.1038/onc.2011.629			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22249270				2022-12-28	WOS:000309704500001
J	Jeong, KJ; Park, SY; Cho, KH; Sohn, JS; Lee, J; Kim, YK; Kang, J; Park, CG; Han, JW; Lee, HY				Jeong, K. J.; Park, S. Y.; Cho, K. H.; Sohn, J. S.; Lee, J.; Kim, Y. K.; Kang, J.; Park, C. G.; Han, J. W.; Lee, H. Y.			The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion	ONCOGENE			English	Article						LPA; Rho/ROCK; invasion; uPA; MMP-9; ovarian cancer	NF-KAPPA-B; MATRIX-DEGRADING PROTEINASES; HUMAN UROKINASE GENE; RHO-GTPASES; CARCINOMA CELLS; MATRIX-METALLOPROTEINASE-9 EXPRESSION; PLASMINOGEN-ACTIVATOR; MEMBRANE-VESICLES; FOCAL ADHESION; GROWTH-FACTORS	Lysophosphatidic acid (LPA) is a biolipid that has diverse biological activities implicated in ovarian cancer initiation and progression. Previous studies have shown the critical role of the Rho/Rho-associated kinase (ROCK) pathway in LPA-induced ovarian cancer progression. However, detailed underlying mechanism by which the Rho/ROCK pathway induces ovarian cancer cell invasion is still incompletely understood. In the present study, we observed that the Rho/ROCK pathway is implicated in the production of proteolytic enzymes, leading to LPA-induced ovarian cancer cell invasion. LPA induced matrix metalloproteinase (MMP)-9 expression in CAOV-3 and PA-1 cells and urokinase-type plasminogen activator (uPA) expression in SKOV-3 cells. LPA-induced proteolytic enzyme expression was required for the invasion of ovarian cancer cells expressing corresponding enzymes. Pretreatment of cells with a pharmacological inhibitor of Rho/ROCK (Y-27632) or overexpression of a dominant-negative mutant of Rho (Rho N19) profoundly inhibited LPA-induced proteolytic enzyme expression as well as the invasive potential of ovarian cancer cells. In addition, transfection with dominant-negative Ras (Ras N17) significantly inhibited LPA-induced Rho activation as well as MMP-9 and uPA expression. Consistently, Y-27632 reduced LPA-induced nuclear factor (NF)-kappa B activation that is critical for proteolytic enzyme expression and cellular invasion. Collectively, we demonstrate a mechanism by which LPA promotes ovarian cancer progression through coordinate activation of a Ras/Rho/ROCK/NF-kappa B signaling pathway and the proteolytic enzyme secretion, providing novel biomarkers and promising therapeutic targets for ovarian cancer cell progression. Oncogene (2012) 31, 4279-4289; doi:10.1038/onc.2011.595; published online 16 January 2012	[Jeong, K. J.; Park, S. Y.; Cho, K. H.; Kang, J.; Park, C. G.; Lee, H. Y.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pharmacol, Taejon 302718, South Korea; [Sohn, J. S.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pathol, Taejon 302718, South Korea; [Lee, J.] Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Microbiol, Taejon 302718, South Korea; [Kim, Y. K.] Sookmyung Womens Univ, Coll Pharm, Dept Pharmacol, Seoul, South Korea; [Han, J. W.] Sungkyunkwan Univ, Sch Pharm, Dept Biochem & Mol Biol, Suwon, South Korea	Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; Konyang University; Konyang University Hospital; Sookmyung Women's University; Sungkyunkwan University (SKKU)	Lee, HY (corresponding author), Konyang Univ, Coll Med, Myunggok Med Res Inst, Dept Pharmacol, Taejon 302718, South Korea.	hoi@konyang.ac.kr	Jeong, Kangjin/HGT-9268-2022; Kang, Jaeku/D-4933-2011	Kang, Jaeku/0000-0002-8660-7940	Ministry of Education, Science and Technology [2011-0025912, 2011-0015761, 2011-0028284]	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2011-0025912 and 2011-0015761, HYL; 2011-0028284, JWH). We thank Professor Gordon B Mills for a plasmid-containing uPA promoter and invaluable discussion, Professor Aree Moon for Ras V12 and Ras N17 and Professor Taeg Kyu Kwon for MMP-9 promoters.	Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bese T, 2010, J GYNECOL ONCOL, V21, P248, DOI 10.3802/jgo.2010.21.4.248; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Chang HR, 2010, CHEM-BIOL INTERACT, V183, P172, DOI 10.1016/j.cbi.2009.10.018; DOLO V, 1995, CLIN EXP METASTAS, V13, P277, DOI 10.1007/BF00133483; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Fishman DA, 1997, CANCER-AM CANCER SOC, V80, P1457, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1457::AID-CNCR13>3.0.CO;2-4; Fishman DA, 2001, CANCER RES, V61, P3194; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; Graves LE, 2004, CANCER RES, V64, P7045, DOI 10.1158/0008-5472.CAN-04-1800; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; Hodge JC, 2003, CANCER RES, V63, P1359; Horiuchi A, 2008, CANCER SCI, V99, P2532, DOI 10.1111/j.1349-7006.2008.00977.x; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kohn EC, 2003, INT J GYNECOL OBSTET, V83, P203, DOI 10.1016/S0020-7292(03)90122-6; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Mills GB, 2003, GYNECOL ONCOL, V88, pS88, DOI 10.1006/gyno.2002.6692; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Mukai M, 2003, INT J ONCOL, V22, P1247; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; Park SY, 2011, ONCOGENE, V30, P1351, DOI 10.1038/onc.2010.517; Park SY, 2011, INT J CANCER, V128, P2306, DOI 10.1002/ijc.25589; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sedlakova I, 2011, TUMOR BIOL, V32, P311, DOI 10.1007/s13277-010-0123-8; Seo JH, 2010, CANCER LETT, V288, P50, DOI 10.1016/j.canlet.2009.06.023; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Young TN, 1996, GYNECOL ONCOL, V62, P89, DOI 10.1006/gyno.1996.0195	41	89	98	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4279	4289		10.1038/onc.2011.595	http://dx.doi.org/10.1038/onc.2011.595			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22249252				2022-12-28	WOS:000309520200003
J	Shahar, OD; Ram, EVSR; Shimshoni, E; Hareli, S; Meshorer, E; Goldberg, M				Shahar, O. D.; Ram, E. V. S. Raghu; Shimshoni, E.; Hareli, S.; Meshorer, E.; Goldberg, M.			Live imaging of induced and controlled DNA double-strand break formation reveals extremely low repair by homologous recombination in human cells	ONCOGENE			English	Article						DNA double-strand breaks; DNA repair; homologous recombination; genomic stability; ISceI	MAMMALIAN-CELLS; MITOTIC CYCLINS; PATHWAY CHOICE; S-PHASE; END; DEGRADATION; STABILITY; ONSET	DNA double-strand breaks (DSBs), the most hazardous DNA lesions, may result in genomic instability, a hallmark of cancer cells. The main DSB repair pathways are non-homologous end joining (NHEJ) and homologous recombination (HR). In mammalian cells, NHEJ, which can lead to inaccurate repair, predominates. HR repair (HRR) is considered accurate and is restricted to S, G2 and M phases of the cell cycle. Despite its importance, many aspects regarding HRR remain unknown. Here, we developed a novel inducible on/off switch cell system that enables, for the first time, to induce a DSB in a rapid and reversible manner in human cells. By limiting the duration of DSB induction, we found that non-persistent endonuclease-induced DSBs are rarely repaired by HR, whereas persistent DSBs result in the published HRR frequencies (non-significant HR frequency versus frequency of similar to 10%, respectively). We demonstrate that these DSBs are repaired by an accurate repair mechanism, which is distinguished from HRR (most likely, error-free NHEJ). Notably, our data reveal that HRR frequencies of endonuclease-induced DSBs in human cells are >10-fold lower than what was previously estimated by prevailing methods, which resulted in recurrent DSB formation. Our findings suggest a role for HRR mainly in repairing challenging DSBs, in contrast to uncomplicated lesions that are frequently repaired by NHEJ. Preventing HR from repairing DSBs in the complex and repetitive human genome probably has an essential role in maintaining genomic stability. Oncogene (2012) 31, 3495-3504; doi:10.1038/onc.2011.516; published online 21 November 2011	[Shahar, O. D.; Ram, E. V. S. Raghu; Shimshoni, E.; Hareli, S.; Meshorer, E.; Goldberg, M.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Meshorer, E (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.	meshorer@cc.huji.ac.il; goldbergm@vms.huji.ac.il	Edupuganti, Venkata/AAG-6486-2019; Shahar, Or/ABG-9168-2020	Edupuganti, Venkata/0000-0001-9414-2672; Shahar, Or/0000-0002-5039-8307; Meshorer, Eran/0000-0003-4777-986X; Goldberg, Michal/0000-0001-9397-2383	AFHU; United States Binational Science Foundation [2009286]; Israel Cancer Association; Israel Science Foundation [943/09]; Israel Cancer Research Foundation; Israel Ministry of Health [6007]; European Union [IRG-206872, 238176]; HU; Israel Psychobiology Institute; Lady Davies Fellowship program; Edmond J Safra Foundation	AFHU; United States Binational Science Foundation; Israel Cancer Association; Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Foundation; Israel Ministry of Health; European Union(European Commission); HU; Israel Psychobiology Institute; Lady Davies Fellowship program; Edmond J Safra Foundation	We thank members of our laboratories, Sagiv Shifman and Liran Carmel for discussions, Naomi Melamed-Book for assistance in confocal analyses, Maya Schuldiner and Yifat Cohen for technical help. Stephan P Jackson, Tom Misteli, Amir Eden and Agnes Klochendler-Yeivin for reagents, Ilana Livyatan for critical reading of the manuscript, Evi Soutoglou for discussions and reagents, and the Edmond J Safra Foundation for financial support. MG is supported by the AFHU, The United States Binational Science Foundation (2009286) and the Israel Cancer Association. EM is a Joseph H and Belle R Braun senior lecturer in life sciences and is supported by the Israel Science Foundation (943/09), the Israel Cancer Research Foundation, the Israel Ministry of Health (6007), the European Union (IRG-206872 and 238176), the Internal Applicable Medical Grants of the HU and the Israel Psychobiology Institute. EVSRR is supported by the Lady Davies Fellowship program.	Barlow JH, 2008, MOL CELL, V30, P73, DOI 10.1016/j.molcel.2008.01.016; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Covo S, 2009, NUCLEIC ACIDS RES, V37, P6737, DOI 10.1093/nar/gkp703; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Hartlerode AJ, 2009, BIOCHEM J, V423, P157, DOI 10.1042/BJ20090942; Honma M, 2007, DNA REPAIR, V6, P781, DOI 10.1016/j.dnarep.2007.01.004; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Lukusa T, 2008, BBA-GENE REGUL MECH, V1779, P3, DOI 10.1016/j.bbagrm.2007.10.005; Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saleh-Gohari N, 2004, NUCLEIC ACIDS RES, V32, P3683, DOI 10.1093/nar/gkh703; Salpeter SJ, 2011, ENDOCRINOLOGY, V152, P2589, DOI 10.1210/en.2010-1372; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Takashima Y, 2009, ENVIRON MOL MUTAGEN, V50, P815, DOI 10.1002/em.20481; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Villalobos Michael J, 2006, Methods Mol Biol, V314, P109; Wersto RP, 2001, CYTOMETRY, V46, P296, DOI 10.1002/cyto.1171; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	29	36	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3495	3504		10.1038/onc.2011.516	http://dx.doi.org/10.1038/onc.2011.516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105360				2022-12-28	WOS:000306844100002
J	Kanno, T; Kamba, T; Yamasaki, T; Shibasaki, N; Saito, R; Terada, N; Toda, Y; Mikami, Y; Inoue, T; Kanematsu, A; Nishiyama, H; Ogawa, O; Nakamura, E				Kanno, T.; Kamba, T.; Yamasaki, T.; Shibasaki, N.; Saito, R.; Terada, N.; Toda, Y.; Mikami, Y.; Inoue, T.; Kanematsu, A.; Nishiyama, H.; Ogawa, O.; Nakamura, E.			JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma	ONCOGENE			English	Article						renal-cell carcinoma; VHL gene; JunB invasion; angiogenesis	TUMOR-SUPPRESSOR PROTEIN; NF-KAPPA-B; MATRIX METALLOPROTEINASES-2; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; IDENTIFICATION; CANCER; PVHL; PHEOCHROMOCYTOMA; LYMPHOMA	Inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene causes both hereditary and sporadic clear-cell renal-cell carcinoma (ccRCC). Although the best-characterized function of the VHL protein (pVHL) is regulation of hypoxia-inducible factor-alpha (HIF alpha), pVHL also controls the development of pheochromocytoma through HIF-independent pathways by regulating JunB. However, it is largely unknown how these pathways contribute to the development and progression of ccRCC. In the present study, we confirmed that JunB was upregulated in VHL-defective ccRCC specimens by immunostaining. Short-hairpin RNA (shRNA)-mediated knockdown of JunB in 786-O and A498 VHL null ccRCC cells suppressed their invasiveness. In addition, JunB knockdown significantly repressed tumor growth and microvessel density in xenograft tumor assays. Conversely, forced expression of wild-type, but not dimerization-defective, JunB in a VHL-restored 786-O subclone promoted invasion in vitro and tumor growth and vessel formation in vivo. Quantitative PCR array analysis revealed that JunB regulated multiple genes relating to tumor invasion and angiogenesis such as matrix metalloproteinase-2 (MMP-2), MMP-9 and chemokine (C-C motif) ligand-2 (CCL2) in 786-O cells. JunB knockdown in these cells reduced the proteolytic activity of both MMPs in gelatin zymography and the amount of CCL2 in the culture supernatant. Moreover, shRNA-mediated knockdown of MMP-2 or inhibition of CCL2 activity with a neutralizing antibody repressed xenograft tumor growth and angiogenesis. Collectively, these results suggest that JunB promotes tumor invasiveness and enhances angiogenesis in VHL-defective ccRCCs. Oncogene (2012) 31, 3098-3110; doi: 10.1038/onc.2011.475; published online 24 October 2011	[Nakamura, E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Nakamura, E.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Kanno, T.; Kamba, T.; Yamasaki, T.; Shibasaki, N.; Saito, R.; Terada, N.; Inoue, T.; Kanematsu, A.; Nishiyama, H.; Ogawa, O.] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan; [Toda, Y.] Kyoto Univ, Grad Sch Med, Anat Ctr, Kyoto, Japan; [Mikami, Y.] Kyoto Univ, Grad Sch Med, Anat Pathol Lab, Kyoto, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Kyoto University; Kyoto University; Kyoto University	Nakamura, E (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 457, Boston, MA 02115 USA.	Nakamura_Eijiro@dfci.harvard.edu	Terada, Naoki/ABD-2387-2020		Ministry of Education, Culture, Sports, Science and Technology, Japan	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr William G Kaelin, Jr, for critical comments and for providing us with the different RCC cell lines. We appreciate all members of Cancer Research Courses for Integrated Research Training at Kyoto University Graduate School of Medicine for helpful advice and discussion. We also thank Tomoko Matsushita, Megumi Kuraguchi and Yuko Fujieda for technical assistance. Grant support: Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Brugarolas J, 2007, NEW ENGL J MED, V356, P185, DOI 10.1056/NEJMe068263; Calzada MJ, 2010, CLIN TRANSL ONCOL, V12, P160, DOI 10.1007/s12094-010-0485-9; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Keeley EC, 2008, ARTERIOSCL THROM VAS, V28, P1928, DOI 10.1161/ATVBAHA.108.162925; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Linehan WM, 2007, CLIN CANCER RES, V13, p671S, DOI 10.1158/1078-0432.CCR-06-1870; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Lu X, 2009, J BIOL CHEM, V284, P29087, DOI 10.1074/jbc.M109.035899; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Nakamura E, 2006, AM J PATHOL, V168, P574, DOI 10.2353/ajpath.2006.050867; Nakamura E, 2006, ENDOCR PATHOL, V17, P97, DOI 10.1385/EP:17:2:97; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Passegue E, 2002, NAT GENET, V30, P158, DOI 10.1038/ng790; Perez-Gracia JL, 2009, BRIT J CANCER, V101, P1876, DOI 10.1038/sj.bjc.6605409; Piechaczyk M, 2008, BIOCHEM SOC T, V36, P864, DOI 10.1042/BST0360864; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Roberts AM, 2008, CURR OPIN ONCOL, V20, P83, DOI 10.1097/CCO.0b013e3282f310de; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Schmidt D, 2007, EMBO J, V26, P710, DOI 10.1038/sj.emboj.7601539; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Song H, 2006, CANCER RES, V66, P10487, DOI 10.1158/0008-5472.CAN-06-1461; Staber PB, 2007, BLOOD, V110, P3374, DOI 10.1182/blood-2007-02-071258; Struckmann K, 2008, J PATHOL, V214, P464, DOI 10.1002/path.2310; Takahashi M, 2002, INT J UROL, V9, P531, DOI 10.1046/j.1442-2042.2002.00516.x; Terada N, 2010, CANCER RES, V70, P1606, DOI 10.1158/0008-5472.CAN-09-2984; Watanabe M, 2005, CANCER RES, V65, P7628, DOI 10.1158/0008-5472.CAN-05-0925; WEIDNER N, 1995, AM J PATHOL, V147, P9; Woodward ER, 2006, ENDOCR-RELAT CANCER, V13, P415, DOI 10.1677/erc.1.00683; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078-0432.CCR-09-2131	48	38	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3098	3110		10.1038/onc.2011.475	http://dx.doi.org/10.1038/onc.2011.475			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020339	Green Submitted			2022-12-28	WOS:000305705900008
J	Torchia, EC; Caulin, C; Acin, S; Terzian, T; Kubick, BJ; Box, NF; Roop, DR				Torchia, E. C.; Caulin, C.; Acin, S.; Terzian, T.; Kubick, B. J.; Box, N. F.; Roop, D. R.			Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma	ONCOGENE			English	Article						Aurora Kinase A; genomic instability; Myc; p53; SCC; tumor progression	LI-FRAUMENI-SYNDROME; PSORALEN-PLUS-ULTRAVIOLET; SQUAMOUS-CELL CARCINOMAS; C-MYC; CHROMOSOMAL INSTABILITY; GENE-EXPRESSION; PHARMACOLOGICAL ACTIVATION; PSORIASIS PATIENTS; COLORECTAL-CANCER; LUNG-CANCER	Clinical observations, as well as data obtained from the analysis of genetically engineered mouse models, firmly established the gain-of-function (GOF) properties of certain p53 mutations. However, little is known about the underlying mechanisms. We have used two independent microarray platforms to perform a comprehensive and global analysis of tumors arising in a model of metastatic skin cancer progression, which compares the consequences of a GOF p53R(172H) mutant vs p53 deficiency. DNA profiling revealed a higher level of genomic instability in GOF vs loss-of-function (LOF) p53 squamous cell carcinomas (SCCs). Moreover, GOF p53 SCCs showed preferential amplification of Myc with a corresponding increase in its expression and deregulation of Aurora Kinase A. Fluorescent in situ hybridization confirmed amplification of Myc in primary GOF p53 SCCs and its retention in metastatic tumors. We also identified by RNA profiling distinct gene expression profiles in GOF p53 tumors, which included enriched integrin and Rho signaling, independent of tumor stage. Thus, the progression of GOF p53 papillomas to carcinoma was marked by the acquisition of epithelial-to-mesenchymal transition and metastatic signatures. In contrast, LOF p53 tumors showed enrichment of genes associated with cancer proliferation and chromosomal instability. Collectively, these observations suggest that genomic instability has a prominent role in the early stages of GOF p53 tumor progression (that is, papillomas), whereas it is implicated at a later stage in LOF p53 tumors (that is, SCCs). This model will allow us to identify specific targets in mutant p53 SCCs, which may lead to the development of new therapeutic agents for the treatment of metastatic SCCs. Oncogene (2012) 31, 2680-2690; doi:10.1038/onc.2011.441; published online 3 October 2011	[Torchia, E. C.; Terzian, T.; Kubick, B. J.; Box, N. F.; Roop, D. R.] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA; [Torchia, E. C.; Terzian, T.; Kubick, B. J.; Box, N. F.; Roop, D. R.] Univ Colorado, Ctr Regenerat Med & Stem Cell Biol, Aurora, CO 80045 USA; [Caulin, C.; Acin, S.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Texas System; UTMD Anderson Cancer Center	Roop, DR (corresponding author), Univ Colorado, Dept Dermatol, Anschutz Med Campus,POB 6511, Aurora, CO 80045 USA.	Dennis.Roop@UCDenver.edu	Acin, Sergio/S-5185-2017; Box, Neil/F-3591-2010	Acin, Sergio/0000-0001-7335-2865; Box, Neil/0000-0002-3486-0346	NIH [DE015344, CA52607, CA105491]; National Institute of Cancer, USA; NATIONAL CANCER INSTITUTE [R01CA052607, U01CA105491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015344] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Cancer, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Grant Support: NIH grants: DE015344 (CC), CA52607 and CA105491 (DRR). We acknowledge Dr Lisa White and Laura Liles for their assistance with microarray experiments; Dr Leila Garcia for her assistance with the FISH experiments and Dr Ariefdjohan for the reading of the manuscript. This work was funded by grants from the National Institute of Cancer, USA.	Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048; Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Birkenfeld J, 2008, TRENDS CELL BIOL, V18, P210, DOI 10.1016/j.tcb.2008.02.006; Birkenfeld J, 2007, DEV CELL, V12, P699, DOI 10.1016/j.devcel.2007.03.014; Boelens MC, 2009, LUNG CANCER, V66, P372, DOI 10.1016/j.lungcan.2009.02.017; Bougeard G, 2008, J MED GENET, V45, P535, DOI 10.1136/jmg.2008.057570; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Caulin C, 2007, J CLIN INVEST, V117, P1893, DOI 10.1172/JCI31721; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Cheok CF, 2010, CELL DEATH DIFFER, V17, P1486, DOI 10.1038/cdd.2010.18; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Daya-Grosjean L, 2005, MUTAT RES-FUND MOL M, V571, P43, DOI 10.1016/j.mrfmmm.2004.11.013; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Denys H, 2009, CURR PHARM DESIGN, V15, P1373, DOI 10.2174/138161209787846711; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HAUGHEY BH, 1992, AM J OTOLARYNG, V13, P168, DOI 10.1016/0196-0709(92)90117-C; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; KOZMA L, 1994, CANCER LETT, V81, P165, DOI 10.1016/0304-3835(94)90198-8; Kreimer-Erlacher H, 2003, J INVEST DERMATOL, V120, P676, DOI 10.1046/j.1523-1747.2003.12085.x; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ozakyol A, 2006, HEPATO-GASTROENTEROL, V53, P192; Paterson IC, 1996, ORAL ONCOL, V32B, P150, DOI 10.1016/0964-1955(95)00065-8; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Rao CV, 2009, CARCINOGENESIS, V30, P1469, DOI 10.1093/carcin/bgp081; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Saha MN, 2010, J CLIN PATHOL, V63, P204, DOI 10.1136/jcp.2009.070961; Salvatore G, 2007, CANCER RES, V67, P10148, DOI 10.1158/0008-5472.CAN-07-1887; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Shen H, 2011, CURR PHARM DESIGN, V17, P560, DOI 10.2174/138161211795222603; Shi J, 2009, BIOORG MED CHEM LETT, V19, P6038, DOI 10.1016/j.bmcl.2009.09.044; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Torchia EC, 2009, CANCER RES, V69, P7207, DOI 10.1158/0008-5472.CAN-09-1059; van der Meel R, 2011, DRUG DISCOV TODAY, V16, P219, DOI 10.1016/j.drudis.2011.01.005; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wolf P, 2004, J INVEST DERMATOL, V122, P190, DOI 10.1046/j.0022-202X.2004.22118.x; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Yakut T, 2003, LUNG, V181, P245, DOI 10.1007/s00408-003-1026-x; Yang SB, 2010, EXP MOL MED, V42, P759, DOI 10.3858/emm.2010.42.11.077; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493	71	23	24	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2680	2690		10.1038/onc.2011.441	http://dx.doi.org/10.1038/onc.2011.441			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21963848	Green Accepted			2022-12-28	WOS:000304523500007
J	Dawson, JC; Timpson, P; Kalna, G; Machesky, LM				Dawson, J. C.; Timpson, P.; Kalna, G.; Machesky, L. M.			Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells	ONCOGENE			English	Article						Mtss1; HNSCC; epidermal growth factor receptor	HEDGEHOG-RESPONSIVE GENE; MISSING-IN-METASTASIS; SUPPRESSOR 1 MTSS1; FACTOR RECEPTOR; CANCER-CELLS; COPY NUMBER; DIFFERENTIAL REGULATION; ADHERENS JUNCTIONS; SURFACE DYNAMICS; DOWN-REGULATION	Mtss1 is located within chromosomal region 8q23-24, which is one of the three most commonly amplified regions in head and neck squamous cell carcinoma (HNSCC). Mtss1 is lost in metastatic cells, but confusingly is commonly overexpressed in primary tumors. Here we address possible reasons why Mtss1 is positively selected for in primary tumors. We find that Mtss1 enhances the localization of the epidermal growth factor (EGF) receptor to the plasma membrane, prolonging EGF signaling and resulting in enhanced proliferation in HNSCC. Depletion of Mtss1 results in decreased EGF receptor levels and decreased phosphorylation of Erk1/2 and Akt. However, when cells are at high density and adherent to each other, analogous to conditions in a solid tumor, Mtss1 does not confer any growth advantage, either in basal conditions or following EGF stimulation. This could indicate why Mtss1 might be lost in metastases, but preserved in early primary tumors. This is supported by an organotypic assay showing that Mtss1-expressing cells display a less proliferative more epithelial-like morphology on top of a collagen matrix. Furthermore, xenograft tumors expressing Mtss1 initially grow more rapidly, but later show less proliferation and more differentiation. Mtss1 positively modulates EGF signaling at low cell densities to promote proliferation and, therefore, may be beneficial for the early stages of primary HNSCC tumor growth. However, at high cell densities, Mtss1 impacts negatively on EGF signaling and this suggests why it inhibits metastasis. Oncogene (2012) 31, 1781-1793; doi: 10.1038/onc.2011.376; published online 19 September 2011	[Dawson, J. C.; Timpson, P.; Kalna, G.; Machesky, L. M.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Dawson, JC (corresponding author), Beatson Inst Canc Res, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	j.dawson@beatson.gla.ac.uk; l.machesky@beatson.gla.ac.uk	Timpson, Paul/A-9429-2016; Dawson, John/HDM-6702-2022; Machesky, Laura/Z-4554-2019	Machesky, Laura/0000-0002-7592-9856; Dawson, John/0000-0001-5713-1026; Timpson, Paul/0000-0002-5514-7080	AICR [07-0438]; MRC [G117/569]; CRUK; Cancer Research UK [15673] Funding Source: researchfish; Medical Research Council [G117/569] Funding Source: researchfish	AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	JD was funded by an AICR Grant to LMM (07-0438). LMM received funding from an MRC Senior Research fellowship (G117/569) and a CRUK core grant. We thank Roger Daly for HNSCC cell lines and Heather Spence for technical help.	Basu D, 2010, ONCOGENE, V29, P4170, DOI 10.1038/onc.2010.170; Bershteyn M, 2010, DEV CELL, V19, P270, DOI 10.1016/j.devcel.2010.07.009; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Canel M, 2006, CLIN CANCER RES, V12, P3272, DOI 10.1158/1078-0432.CCR-05-1583; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; Cooper JB, 2009, HEAD NECK-J SCI SPEC, V31, P1086, DOI 10.1002/hed.21109; Danglot L, 2010, J CELL SCI, V123, P723, DOI 10.1242/jcs.062497; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Edward M, 2005, CARCINOGENESIS, V26, P1215, DOI 10.1093/carcin/bgi064; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; Gonzalez-Quevedo R, 2005, J CELL BIOL, V168, P453, DOI 10.1083/jcb.200409078; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Kelley LC, 2008, CLIN EXP METASTAS, V25, P289, DOI 10.1007/s10585-008-9154-6; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Loberg RD, 2005, INT J ONCOL, V26, P1699; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; Machesky LM, 2007, J MOL MED-JMM, V85, P569, DOI 10.1007/s00109-007-0207-0; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Quinones GA, 2010, J CELL BIOL, V189, P353, DOI 10.1083/jcb.200910136; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Thurlow JK, 2010, J CLIN ONCOL, V28, P2881, DOI 10.1200/JCO.2009.24.8724; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; Timpson P, 2007, CANCER RES, V67, P9304, DOI 10.1158/0008-5472.CAN-07-0798; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691	44	34	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1781	1793		10.1038/onc.2011.376	http://dx.doi.org/10.1038/onc.2011.376			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21927027	Green Accepted			2022-12-28	WOS:000302785200004
J	Harma, V; Knuuttila, M; Virtanen, J; Mirtti, T; Kohonen, P; Kovanen, P; Happonen, A; Kaewphan, S; Ahonen, I; Kallioniemi, O; Grafstrom, R; Lotjonen, J; Nees, M				Harma, V.; Knuuttila, M.; Virtanen, J.; Mirtti, T.; Kohonen, P.; Kovanen, P.; Happonen, A.; Kaewphan, S.; Ahonen, I.; Kallioniemi, O.; Grafstrom, R.; Lotjonen, J.; Nees, M.			Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models	ONCOGENE			English	Article						prostate cancer; epithelial plasticity; bioactive lipids; G-protein coupled receptors; lysophosphatidic acid; sphingosine-1-phosphate	SMALL-MOLECULE INHIBITOR; HUMAN OVARIAN-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; SPHINGOSINE 1-PHOSPHATE; PHOSPHOLIPASE A(2); GENE-EXPRESSION; KINASE PATHWAY; RECEPTOR 2; LPA; ACTIVATION	Normal prostate and some malignant prostate cancer (PrCa) cell lines undergo acinar differentiation and form spheroids in three-dimensional (3-D) organotypic culture. Acini formed by PC-3 and PC-3M, less pronounced also in other PrCa cell lines, spontaneously undergo an invasive switch, leading to the disintegration of epithelial structures and the basal lamina, and formation of invadopodia. This demonstrates the highly dynamic nature of epithelial plasticity, balancing epithelial-to-mesenchymal transition against metastable acinar differentiation. This study assessed the role of lipid metabolites on epithelial maturation. PC-3 cells completely failed to form acinar structures in delipidated serum. Adding back lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) rescued acinar morphogenesis and repressed invasion effectively. Blocking LPA receptor 1 (LPAR1) functions by siRNA (small interference RNA) or the specific LPAR1 inhibitor Ki16425 promoted invasion, while silencing of other G-protein-coupled receptors responsive to LPA or S1P mainly caused growth arrest or had no effects. The G-proteins G alpha(12/13) and G alpha(i) were identified as key mediators of LPA signalling via stimulation of RhoA and Rho kinases ROCK1 and 2, activating Rac1, while inhibition of adenylate cyclase and accumulation of cAMP may be secondary. Interfering with these pathways specifically impeded epithelial polarization in transformed cells. In contrast, blocking the same pathways in non-transformed, normal cells promoted differentiation. We conclude that LPA and LPAR1 effectively promote epithelial maturation and block invasion of PrCa cells in 3-D culture. The analysis of clinical transcriptome data confirmed reduced expression of LPAR1 in a subset of PrCa's. Our study demonstrates a metastasis-suppressor function for LPAR1 and G alpha(12/13) signalling, regulating cell motility and invasion versus epithelial maturation. Oncogene (2012) 31, 2075-2089; doi: 10.1038/onc.2011.396; published online 26 September 2011	[Harma, V.; Virtanen, J.; Grafstrom, R.; Nees, M.] VTT Tech Res Ctr Finland, Med Biotechnol Knowledge Ctr, FI-20520 Turku, Finland; [Knuuttila, M.; Virtanen, J.; Kohonen, P.; Ahonen, I.] Univ Turku, Ctr Biotechnol, Turku, Finland; [Mirtti, T.; Kallioniemi, O.] Univ Helsinki, FIMM, Helsinki, Finland; [Mirtti, T.; Kovanen, P.] Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki, Finland; [Mirtti, T.; Kovanen, P.] Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland; [Happonen, A.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Kaewphan, S.] Univ Turku, Dept Informat Technol, Turku, Finland; [Grafstrom, R.] Karolinska Inst, Toxicol Lab, Stockholm, Sweden; [Lotjonen, J.] VTT Tech Res Ctr Finland, Knowledge Intens Serv, Tampere, Finland	VTT Technical Research Center Finland; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; University of Turku; Karolinska Institutet; VTT Technical Research Center Finland	Nees, M (corresponding author), VTT Tech Res Ctr Finland, Med Biotechnol Knowledge Ctr, POB 106, FI-20520 Turku, Finland.	matthias.nees@vtt.fi	Kohonen, Pekka/F-9596-2011; Happonen, Antti/M-7644-2014; Nees, Matthias/W-6596-2018; Kallioniemi, Olli P/H-5111-2011; Nees, Matthias/AAT-5577-2020; Grafström, Roland C/N-7217-2016	Kohonen, Pekka/0000-0002-7845-3611; Nees, Matthias/0000-0002-9034-301X; Kallioniemi, Olli P/0000-0002-3231-0332; Knuuttila, Matias/0000-0002-9953-5755; Mirtti, Tuomas/0000-0003-0455-9891; Harma, Ville/0000-0001-5767-5226	Academy of Finland [134472]	Academy of Finland(Academy of Finland)	We would like to thank Leena Saikko for expert technical assistance. This work was funded by the Academy of Finland (grant to MN), number 134472.	Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; Aziziyeh AI, 2009, CELL SIGNAL, V21, P1207, DOI 10.1016/j.cellsig.2009.03.011; Bagga S, 2004, BLOOD, V104, P4080, DOI 10.1182/blood-2004-03-1166; Brekhman V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-415; Brizuela L, 2010, FASEB J, V24, P3882, DOI 10.1096/fj.10-160838; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; Devine KM, 2008, GYNECOL ONCOL, V110, P237, DOI 10.1016/j.ygyno.2008.04.013; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Evelyn CR, 2010, BIOORG MED CHEM LETT, V20, P665, DOI 10.1016/j.bmcl.2009.11.056; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fishman DA, 2001, CANCER RES, V61, P3194; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Gibbs TC, 2009, PROSTATE, V69, P1493, DOI 10.1002/pros.20994; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Goetzl EJ, 1999, CANCER RES, V59, P4732; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Groves-Kirkby N, 2010, NAT REV UROL, V7, P420; Guo R, 2006, ENDOCRINOLOGY, V147, P4883, DOI 10.1210/en.2005-1635; Hao F, 2007, BBA-MOL CELL BIOL L, V1771, P883, DOI 10.1016/j.bbalip.2007.04.010; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Hasegawa Y, 2008, MOL ONCOL, V2, P54, DOI 10.1016/j.molonc.2008.03.009; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hope JM, 2009, GYNECOL ONCOL, V112, P215, DOI 10.1016/j.ygyno.2008.09.019; Hwang YS, 2006, MOL CARCINOGEN, V45, P518, DOI 10.1002/mc.20183; Inman Jamie L, 2010, J Biol, V9, P2, DOI 10.1186/jbiol213; Jeong KJ, 2008, EXP MOL MED, V40, P607, DOI 10.3858/emm.2008.40.6.607; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kim EK, 2008, EXP MOL MED, V40, P445, DOI 10.3858/emm.2008.40.4.445; Kim J, 2002, CANCER RES, V62, P1549; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Li H, 2009, MOL CANCER THER, V8, P1692, DOI 10.1158/1535-7163.MCT-08-1106; Li SY, 2005, INT J ONCOL, V27, P1329; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; Liu SY, 2009, CELL CYCLE, V8, P3695, DOI 10.4161/cc.8.22.9937; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morin P, 2011, EUR J CELL BIOL, V90, P13, DOI 10.1016/j.ejcb.2010.09.009; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nouh MAAM, 2009, CANCER SCI, V100, P1631, DOI 10.1111/j.1349-7006.2009.01234.x; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322; Pchejetski D, 2010, CANCER RES, V70, P8651, DOI 10.1158/0008-5472.CAN-10-1388; Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417; Reuter JA, 2009, CANCER CELL, V15, P477, DOI 10.1016/j.ccr.2009.04.002; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sekine Y, 2011, PROSTATE, V71, P690, DOI 10.1002/pros.21285; Seo JH, 2010, CANCER LETT, V288, P50, DOI 10.1016/j.canlet.2009.06.023; Sequeira L, 2008, CLIN EXP METASTAS, V25, P569, DOI 10.1007/s10585-008-9173-3; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Shida D, 2003, CANCER RES, V63, P1706; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Smicun Y, 2007, GYNECOL ONCOL, V107, P298, DOI 10.1016/j.ygyno.2007.06.024; Snider AJ, 2010, BIOCHIMIE, V92, P707, DOI 10.1016/j.biochi.2010.02.008; Snider AJ, 2010, AM J PHYSIOL-CELL PH, V298, pC163, DOI 10.1152/ajpcell.00001.2009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sved P, 2004, CANCER RES, V64, P6934, DOI 10.1158/0008-5472.CAN-03-3018; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; van Golen KL, 2008, J CELL BIOCHEM, V104, P1587, DOI 10.1002/jcb.21652; Vogler R, 2003, J INVEST DERMATOL, V120, P693, DOI 10.1046/j.1523-1747.2003.12096.x; Wang D, 2008, MOL CANCER THER, V7, P1993, DOI 10.1158/1535-7163.MCT-08-0088; Wang FQ, 2010, GYNECOL ONCOL, V117, P88, DOI 10.1016/j.ygyno.2009.12.012; Waters CM, 2006, BIOCHEM J, V398, P55, DOI 10.1042/BJ20060155; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Zeng Y, 2009, PROSTATE, V69, P283, DOI 10.1002/pros.20879; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	83	35	40	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2075	2089		10.1038/onc.2011.396	http://dx.doi.org/10.1038/onc.2011.396			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21996742	Green Published, hybrid			2022-12-28	WOS:000303008600008
J	Pakay, JL; Diesch, J; Gilan, O; Yip, YY; Sayan, E; Kolch, W; Mariadason, JM; Hannan, RD; Tulchinsky, E; Dhillon, AS				Pakay, J. L.; Diesch, J.; Gilan, O.; Yip, Y-Y; Sayan, E.; Kolch, W.; Mariadason, J. M.; Hannan, R. D.; Tulchinsky, E.; Dhillon, A. S.			A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells	ONCOGENE			English	Article						Fra-1; turnover; TBP-1; cancer; ERK; RAS	TAT-BINDING PROTEIN-1; UBIQUITIN-INDEPENDENT DEGRADATION; C-FOS; 26S PROTEASOME; IN-VITRO; RAS; TRANSCRIPTION; GROWTH; AP-1; TRANSFORMATION	Fos-related antigen-1 (Fra-1) is a member of the Activator Protein-1 (AP-1) transcription factor superfamily that is overexpressed in a variety of cancers, including colon, breast, lung, bladder and brain. High Fra-1 levels are associated with enhanced cell proliferation, survival, migration and invasion. Despite its frequent overexpression, the molecular mechanisms that regulate the accumulation of Fra-1 proteins in tumour cells are not well understood. Here, we show that turnover of Fra-1, which does not require ubiquitylation, is cooperatively regulated by two distinct mechanisms-association with the 19S proteasomal subunit, TBP-1, and by a C-terminal degron, which acts independently of TBP-1, but is regulated by RAS-ERK (extracellular signal-regulated kinase) signalling. TBP-1 depletion stabilized Fra-1 and further increased its levels in tumour cells expressing RAS-ERK pathway oncogenes. These effects correlated with increased AP-1 transcriptional activity. We suggest that during Fra-1 degradation, association with TBP-1 provides a mechanism for ubiquitin-independent proteasomal recognition, while the C terminus of the protein regulates its subsequent proteolytic processing. Oncogene (2012) 31, 1817-1824; doi: 10.1038/onc.2011.375; published online 29 August 2011	[Diesch, J.; Gilan, O.; Hannan, R. D.; Dhillon, A. S.] Univ Melbourne, Div Res, Peter MacCallum Canc Ctr, Melbourne, Vic 3002, Australia; [Pakay, J. L.; Diesch, J.; Gilan, O.; Yip, Y-Y; Hannan, R. D.] Univ Melbourne, Inst Bio21, Parkville, Vic 3052, Australia; [Sayan, E.; Tulchinsky, E.] Univ Leicester, Leicester LE1 9HN, Leics, England; [Kolch, W.] Univ Coll Dublin, Dublin 2, Ireland; [Mariadason, J. M.] Austin Hlth, Ludwig Inst Canc Res, Heidelberg, Vic, Australia; [Hannan, R. D.] Monash Univ, Clayton, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; University of Leicester; University College Dublin; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Monash University	Dhillon, AS (corresponding author), Univ Melbourne, Div Res, Peter MacCallum Canc Ctr, St Andrews Pl, Melbourne, Vic 3002, Australia.	et32@leicester.ac.uk; Amardeep.Dhillon@petermac.org	Kolch, Walter/ABF-2102-2021; SAYAN, A. EMRE/H-7330-2012; Tulchinsky, Eugene/ABD-7070-2021; Mariadason, John/N-2003-2013; Admin, SBI/HGB-2738-2022; Diesch, Jeannine/J-8558-2017	SAYAN, A. EMRE/0000-0002-5291-1485; Diesch, Jeannine/0000-0002-4667-3468; Dhillon, Amardeep/0000-0002-6065-663X; Hannan, Ross/0000-0002-2166-4493; Kolch, Walter/0000-0001-5777-5016; Mariadason, John/0000-0001-9123-7684	National Health and Medical Research Council of Australia; Association for International Cancer Research	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Association for International Cancer Research	We thank Drs Nishida, Satoh, Greer and Gillespie for generously providing reagents used in this study, and Dr Willie Bienvenut for assistance with the mass spectrometry experiments. This work was supported by grants from the National Health and Medical Research Council of Australia (to ASD and RDH) and the Association for International Cancer Research (to ET).	Acquaviva C, 2001, ONCOGENE, V20, P7563, DOI 10.1038/sj.onc.1204880; Adiseshaiah P, 2007, CANCER RES, V67, P6204, DOI 10.1158/0008-5472.CAN-06-4687; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Basbous J, 2008, BIOCHIMIE, V90, P296, DOI 10.1016/j.biochi.2007.07.016; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Baugh JM, 2009, J MOL BIOL, V386, P814, DOI 10.1016/j.jmb.2008.12.081; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Burch PM, 2004, MOL CELL BIOL, V24, P4696, DOI 10.1128/MCB.24.11.4696-4709.2004; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chen CS, 2007, FEBS LETT, V581, P1124, DOI 10.1016/j.febslet.2007.02.018; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cohn MA, 2001, NUCLEIC ACIDS RES, V29, P3335, DOI 10.1093/nar/29.16.3335; Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254; Debinski W, 2005, MOL CANCER RES, V3, P237; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Gallastegui N, 2010, TRENDS BIOCHEM SCI, V35, P634, DOI 10.1016/j.tibs.2010.05.005; Gomard T, 2008, BIOCHEM SOC T, V36, P858, DOI 10.1042/BST0360858; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Ishizuka T, 2001, MOL ENDOCRINOL, V15, P1329, DOI 10.1210/me.15.8.1329; Jariel-Encontre I, 2008, BBA-REV CANCER, V1786, P153, DOI 10.1016/j.bbcan.2008.05.004; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Park BW, 1999, P NATL ACAD SCI USA, V96, P6434, DOI 10.1073/pnas.96.11.6434; Pollice A, 2007, ONCOGENE, V26, P5154, DOI 10.1038/sj.onc.1210313; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Satoh T, 2009, ENDOCRINOLOGY, V150, P3283, DOI 10.1210/en.2008-1122; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Takeuchi J, 2007, EMBO J, V26, P123, DOI 10.1038/sj.emboj.7601476; Talotta F, 2010, ONCOGENE, V29, P4732, DOI 10.1038/onc.2010.211; Terasawa K, 2003, GENES CELLS, V8, P263, DOI 10.1046/j.1365-2443.2003.00631.x; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	50	19	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1817	1824		10.1038/onc.2011.375	http://dx.doi.org/10.1038/onc.2011.375			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21874050	Green Submitted			2022-12-28	WOS:000302785200007
J	Stossi, F; Madak-Erdogan, Z; Katzenellenbogen, BS				Stossi, F.; Madak-Erdogan, Z.; Katzenellenbogen, B. S.			Macrophage-elicited loss of estrogen receptor-alpha in breast cancer cells via involvement of MAPK and c-Jun at the ESR1 genomic locus	ONCOGENE			English	Article						estrogen receptor; macrophages; MAPK; breast cancer; jun	TUMOR-ASSOCIATED MACROPHAGES; TARGET GENES; DNA-BINDING; IN-VITRO; PROGRESSION; POLARIZATION; RESISTANCE; EXPRESSION; PHENOTYPE; DISTINCT	Estrogen receptor-alpha (ER alpha, ESR1) is a pivotal transcriptional regulator of breast cancer physiology and is targeted by endocrine therapies. Loss of ER alpha activity or expression is an indication of endocrine resistance and is associated with increased risk of tumor recurrence and worse prognosis. In this study, we sought to investigate whether elements of the tumor microenvironment, namely macrophages, would impact on ER alpha and we found that macrophage-derived factors caused loss of ER alpha expression in breast cancer cells. Conditioned media from macrophages caused activation of several intracellular pathways in breast cancer cells of which c-Src, protein kinase c and mitogen-activated protein kinase (MAPK) were essential for loss of ER alpha expression. Moreover, a prolonged hyperactivation of MAPK was observed. The activation of this kinase cascade resulted in recruitment of extracellular signal regulated kinase 2 (ERK2) directly to chromatin at the ESR1 gene locus in a process that was dependent upon activation and recruitment of the c-Jun transcription factor. Thus, we identify a novel mechanism for loss of ER alpha expression in breast cancer cells via macrophage activation of kinase cascades in the cancer cells causing transcriptional repression of the ESR1 gene by a direct chromatin action of a c-Jun/ERK2 complex. The findings in this study support an alternative mechanism, not intrinsic to the tumor cell but derived from the crosstalk with the tumor microenvironment, that could lead to endocrine resistance and might be targeted therapeutically to prevent loss of ER alpha expression in breast tumors. Oncogene (2012) 31, 1825-1834; doi: 10.1038/onc.2011.370; published online 22 August 2011	[Stossi, F.; Madak-Erdogan, Z.; Katzenellenbogen, B. S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	katzenel@illinois.edu		Madak-Erdogan, Zeynep/0000-0003-2607-1643	Breast Cancer Research Foundation; ODS, NIH [P50 AT006268]; NCCAM; NCI; National Center for Complementary & Integrative Health [P50AT006268] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; ODS, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the Breast Cancer Research Foundation and NIH P50 AT006268 from ODS, NCCAM, and NCI (to BSK).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x; AUWERX J, 1991, EXPERIENTIA, V47, P22, DOI 10.1007/BF02041244; Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587; Beck AH, 2009, CLIN CANCER RES, V15, P778, DOI 10.1158/1078-0432.CCR-08-1283; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Cheung KL, 1997, BREAST CANCER RES TR, V45, P219, DOI 10.1023/A:1005828731462; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Daigneault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008668; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; Lawrence MC, 2009, P NATL ACAD SCI USA, V106, P22181, DOI 10.1073/pnas.0912596106; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; Leek RD, 1996, CANCER RES, V56, P4625; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112; Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708; Pupa SM, 1996, J CLIN ONCOL, V14, P85, DOI 10.1200/JCO.1996.14.1.85; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Redente EF, 2010, AM J PATHOL, V176, P2972, DOI 10.2353/ajpath.2010.090879; Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527; Sharma M, 2010, BREAST CANCER RES TR, V123, P397, DOI 10.1007/s10549-009-0654-0; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; Stossi F, 2004, ENDOCRINOLOGY, V145, P3473, DOI 10.1210/en.2003-1682; Stossi F, 2009, MOL CELL BIOL, V29, P1749, DOI 10.1128/MCB.01476-08; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; Yuan A, 2008, ADV CLIN CHEM, V45, P199, DOI 10.1016/S0065-2423(07)00008-X; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	49	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1825	1834		10.1038/onc.2011.370	http://dx.doi.org/10.1038/onc.2011.370			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860415	Green Accepted			2022-12-28	WOS:000302785200008
J	Pyonteck, SM; Gadea, BB; Wang, HW; Gocheva, V; Hunter, KE; Tang, LH; Joyce, JA				Pyonteck, S. M.; Gadea, B. B.; Wang, H-W; Gocheva, V.; Hunter, K. E.; Tang, L. H.; Joyce, J. A.			Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development	ONCOGENE			English	Article						cancer; tumor-associated macrophage; tumor microenvironment; human PNET; myeloid cell	COLONY-STIMULATING FACTOR-1; MOUSE MODEL; ANGIOGENIC SWITCH; SURVIVAL BENEFIT; RECEPTOR; PROGRESSION; MICE; INFLAMMATION; RESPONSES	Tumor-associated macrophages have recently emerged as a key regulatory cell type during cancer progression, and have been found to promote tumor malignancy in the majority of studies performed to date. We show in this study that CD68(+) macrophages positively correlate with tumor grade and liver metastasis in human pancreatic neuroendocrine tumors (PNETs). To investigate the potential mechanisms whereby macrophages can promote PNET progression, we crossed the RIP1-Tag2 (RT2) mouse model of pancreatic islet cancer to colony-stimulating factor-1 (CSF-1)-deficient Csf1(op/op) mice, which have reduced numbers of tissue macrophages. Csf1(op/op) RT2 mice had a substantial reduction in cumulative tumor burden, which interestingly resulted from a significant decrease in angiogenic switching and tumor number, rather than an evident effect on tumor growth. In the tumors that did develop in CSF-1-deficient animals, however, there were no significant differences in tumor cell proliferation, apoptosis, angiogenesis or invasion. CSF-1 deficiency decreased macrophage infiltration by approximately 50% during all stages of RT2 tumor progression. Interestingly, several cytokines were upregulated in CSF-1-deficient RT2 tumors, and neutrophil infiltration was increased. These results show that macrophages are important for promoting PNET development and suggest that additional factors contribute to the recruitment and survival of myeloid cells in RT2 tumors in the absence of CSF-1. Oncogene (2012) 31, 1459-1467; doi:10.1038/onc.2011.337; published online 8 August 2011	[Pyonteck, S. M.; Gadea, B. B.; Wang, H-W; Gocheva, V.; Hunter, K. E.; Joyce, J. A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Tang, L. H.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA; [Pyonteck, S. M.; Wang, H-W; Gocheva, V.] Cornell Univ, Weill Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10065 USA.	joycej@mskcc.org		Pyonteck, Stephanie/0000-0002-4143-0969	National Cancer Institute TMEN [NIH U54-CA126518]; NCI [CA125162]; Geoffrey Beene Foundation; NIH; American Cancer Society; Frank L. Horsfall Fellowship; Geoffrey Beene Fellowship; NATIONAL CANCER INSTITUTE [R01CA125162, U54CA126518] Funding Source: NIH RePORTER	National Cancer Institute TMEN; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Geoffrey Beene Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Frank L. Horsfall Fellowship; Geoffrey Beene Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Xiaoping Chen and Kenishana Simpson for excellent technical assistance; Dr Jeffrey Pollard, Albert Einstein College of Medicine for the Csf1<SUP>op</SUP> pyrosequencing protocol; Drs Jan Hendrikx and Jennifer Wilshire, MSKCC Flow Cytometry Core Facility for assistance with flow cytometric sorting; Drs Agnes Viale, Juan Li, Magali Cavatore, Liliana Villafania, MSKCC Genomics Core Facility for assistance with RT-PCR and pyrosequencing; Drs Guangli Li and Ouathek Ouerfelli, MSKCC Organic Synthesis Core Facility for synthesis of the Cy3B-Cathepsin-ABP; and Elyn Reidel, MSKCC Epidemiology and Biostatistics Department, for statistical analysis of tumor size distribution. This research was supported by the following: National Cancer Institute TMEN Grant (NIH U54-CA126518), NCI R01 (CA125162), and the Geoffrey Beene Foundation (JAJ); NIH T32 Training Fellowship (SMP); American Cancer Society Postdoctoral Fellowship (BBG); Frank L. Horsfall Fellowship (HWW, VG); and Geoffrey Beene Fellowship (VG).	Abboud SL, 2002, ENDOCRINOLOGY, V143, P1942, DOI 10.1210/en.143.5.1942; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006; Chiu CW, 2010, J CLIN ONCOL, V28, P4425, DOI 10.1200/JCO.2010.28.0198; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Gocheva V, 2010, BIOL CHEM, V391, P937, DOI 10.1515/BC.2010.080; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Greenbaum D, 2002, MOL CELL PROTEOMICS, V1, P60, DOI 10.1074/mcp.T100003-MCP200; Halfdanarson TR, 2008, ENDOCR-RELAT CANCER, V15, P409, DOI 10.1677/ERC-07-0221; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hu Wenwei, 2010, Genes Cancer, V1, P360; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Lin EY, 2007, MOL ONCOL, V1, P288, DOI 10.1016/j.molonc.2007.10.003; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Mantovani A, 2010, CYTOKINE GROWTH F R, V21, P27, DOI 10.1016/j.cytogfr.2009.11.007; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Pahler J, 2008, NEOPLASIA, V10, P329, DOI 10.1593/neo.07871; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825; Reidy DL, 2009, NAT CLIN PRACT ONCOL, V6, P143, DOI 10.1038/ncponc1326; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Steiner GE, 2000, J IMMUNOL METHODS, V237, P39, DOI 10.1016/S0022-1759(99)00240-9; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Wei SW, 2010, J LEUKOCYTE BIOL, V88, P495, DOI 10.1189/jlb.1209822; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	41	91	97	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1459	1467		10.1038/onc.2011.337	http://dx.doi.org/10.1038/onc.2011.337			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822305				2022-12-28	WOS:000301780000012
J	De Cola, A; Bongiorno-Borbone, L; Bianchi, E; Barcaroli, D; Carletti, E; Knight, RA; Di Ilio, C; Melino, G; Sette, C; De Laurenzi, V				De Cola, A.; Bongiorno-Borbone, L.; Bianchi, E.; Barcaroli, D.; Carletti, E.; Knight, R. A.; Di Ilio, C.; Melino, G.; Sette, C.; De Laurenzi, V.			FLASH is essential during early embryogenesis and cooperates with p73 to regulate histone gene transcription	ONCOGENE			English	Article						Histone Locus Bodies; Cajal bodies; FLASH; NPAT	CYCLIN E/CDK2 SUBSTRATE; CELL-CYCLE; CAJAL BODIES; SELECTIVE DEGRADATION; MESSENGER-RNA; HINF-P; EXPRESSION; P220(NPAT); APOPTOSIS; TAP73	Replication-dependent histone gene expression is a fundamental process occurring in S-phase under the control of the cyclin-E/CDK2 complex. This process is regulated by a number of proteins, including Flice-Associated Huge Protein (FLASH) (CASP8AP2), concentrated in specific nuclear organelles known as HLBs. FLASH regulates both histone gene transcription and mRNA maturation, and its downregulation in vitro results in the depletion of the histone pull and cell-cycle arrest in S-phase. Here we show that the transcription factor p73 binds to FLASH and is part of the complex that regulates histone gene transcription. Moreover, we created a novel gene trap to disrupt FLASH in mice, and we show that homozygous deletion of FLASH results in early embryonic lethality, owing to arrest of FLASH(-/-) embryos at the morula stage. These results indicate that FLASH is an essential, non-redundant regulator of histone transcription and cell cycle during embryogenesis. Oncogene (2012) 31, 573-582; doi:10.1038/onc.2011.274; published online 4 July 2011	[De Laurenzi, V.] Univ G dAnnunzio, CeSI, Dipartimento Sci Biomed, I-66100 Chieti, Italy; [De Cola, A.; Bongiorno-Borbone, L.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Bianchi, E.; Sette, C.] Univ Roma Tor Vergata, Dept Publ Hlth & Cell Biol, Rome, Italy; [Bianchi, E.; Sette, C.] IRCCS Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy; [Carletti, E.] Univ G dAnnunzio, Dipartimento Sci Movimento Umano, I-66100 Chieti, Italy; [Knight, R. A.; Melino, G.] Univ Leicester, Med Res Council, Toxicol Unit, Leicester, Leics, England; [Di Ilio, C.; De Laurenzi, V.] Fdn G DAnnunzio, CeSI, I-66100 Chieti, Italy	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia; G d'Annunzio University of Chieti-Pescara; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; G d'Annunzio University of Chieti-Pescara	De Laurenzi, V (corresponding author), Univ G dAnnunzio, CeSI, Dipartimento Sci Biomed, Via Colle Ara 1, I-66100 Chieti, Italy.	delaurenzi@unich.it	Bianchi, Enrica/P-2379-2019; Sette, Claudio/S-4307-2019; De Laurenzi, Vincenzo/K-7471-2016	Bianchi, Enrica/0000-0001-8124-7328; Sette, Claudio/0000-0003-2864-8266; De Laurenzi, Vincenzo/0000-0002-7506-1743; De Cola, Antonella/0000-0002-3202-5339	AIRC; MIUR; AIRC, EU-EPISTEM; FIRB, MIUR; MinSan; Telethon; Alleanza Contro il Cancro; FIRC; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); AIRC, EU-EPISTEM(Fondazione AIRC per la ricerca sul cancro); FIRB, MIUR(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); MinSan; Telethon(Fondazione Telethon); Alleanza Contro il Cancro; FIRC(Fondazione AIRC per la ricerca sul cancro); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from AIRC, MIUR, to VDL, and AIRC, EU-EPISTEM; FIRB, MIUR; MinSan; Telethon and Alleanza Contro il Cancro to GM. DB is supported by a FIRC scholarship.	Alizadeh Z, 2005, MOL REPROD DEV, V72, P281, DOI 10.1002/mrd.20340; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Bongiorno-Borbone L, 2010, ONCOGENE, V29, P802, DOI 10.1038/onc.2009.388; Bongiorno-Borbone L, 2008, CELL CYCLE, V7, P2357, DOI 10.4161/cc.6344; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DiFruscio M, 1997, MOL CELL BIOL, V17, P4080, DOI 10.1128/MCB.17.7.4080; Ghule PN, 2008, P NATL ACAD SCI USA, V105, P16964, DOI 10.1073/pnas.0809273105; Ghule PN, 2007, J CELL PHYSIOL, V213, P9, DOI 10.1002/jcp.21119; GIEBELHAUS DH, 1983, DEV BIOL, V98, P148, DOI 10.1016/0012-1606(83)90343-3; Gottifredi V, 1999, J VIROL, V73, P1427, DOI 10.1128/JVI.73.2.1427-1437.1999; GRAVES RA, 1985, P NATL ACAD SCI USA, V82, P5685, DOI 10.1073/pnas.82.17.5685; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; Hamatani T, 2004, HUM MOL GENET, V13, P2263, DOI 10.1093/hmg/ddh241; Hogan B, 1994, MANIPULATING MOUSE E; Joyner AL, 2000, GENE TARGETING PRACT; Levrero M, 2000, J CELL SCI, V113, P1661; Liu JL, 2006, J CELL BIOL, V172, P875, DOI 10.1083/jcb.200511038; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Matera AG, 2006, J CELL BIOL, V172, P791, DOI 10.1083/jcb.200602002; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Miele A, 2005, MOL CELL BIOL, V25, P6140, DOI 10.1128/MCB.25.14.6140-6153.2005; Mitra P, 2003, MOL CELL BIOL, V23, P8110, DOI 10.1128/MCB.23.22.8110-8123.2003; Munarriz E, 2004, MOL CELL BIOL, V24, P10593, DOI 10.1128/MCB.24.24.10593-10610.2004; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Paynton BV, 1998, DEV GENET, V23, P285, DOI 10.1002/(SICI)1520-6408(1998)23:4&lt;285::AID-DVG4&gt;3.0.CO;2-W; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Vernole P, 2009, CELL CYCLE, V8, P421, DOI 10.4161/cc.8.3.7623; Wei Y, 2003, MOL CELL BIOL, V23, P3669, DOI 10.1128/MCB.23.10.3669-3680.2003; Xie RL, 2009, P NATL ACAD SCI USA, V106, P12359, DOI 10.1073/pnas.0905651106; Yang XC, 2009, MOL CELL, V36, P267, DOI 10.1016/j.molcel.2009.08.016; Ye X, 2003, MOL CELL BIOL, V23, P8586, DOI 10.1128/MCB.23.23.8586-8600.2003; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 2004, CELL CYCLE, V3, P695	43	22	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					573	582		10.1038/onc.2011.274	http://dx.doi.org/10.1038/onc.2011.274			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725362				2022-12-28	WOS:000300221800004
J	Giovinazzi, S; Lindsay, CR; Morozov, VM; Escobar-Cabrera, E; Summers, MK; Han, HS; McIntosh, LP; Ishov, AM				Giovinazzi, S.; Lindsay, C. R.; Morozov, V. M.; Escobar-Cabrera, E.; Summers, M. K.; Han, H. S.; McIntosh, L. P.; Ishov, A. M.			Regulation of mitosis and taxane response by Daxx and Rassf1	ONCOGENE			English	Article						Daxx; Rassf1A/C; taxane chemotherapy; mitosis; SAC; APC	TUMOR-SUPPRESSOR RASSF1A; TRANSCRIPTION REPRESSOR DAXX; SPINDLE ASSEMBLY CHECKPOINT; BREAST-CANCER PATIENTS; BETA-TUBULIN; PACLITAXEL RESISTANCE; INTERACTING PROTEIN; MITOTIC CHECKPOINT; NUCLEAR-STRUCTURE; DOWN-REGULATION	Current theories suggest that mitotic checkpoint proteins are essential for proper cellular response to taxanes, a widely used family of chemotherapeutic compounds. We recently showed that absence or depletion of protein Daxx increases cellular taxol (paclitaxel) resistance-a common trait of patients diagnosed with several malignancies, including breast cancer. Further investigation of Daxx-mediated taxol response revealed that Daxx is important for the proper timing of mitosis progression and cyclin B stability. Daxx interacts with mitotic checkpoint protein RAS-association domain family protein 1 (Rassf1) and partially colocalizes with this protein during mitosis. Rassf1/Daxx depletion or expression of Daxx-binding domain of Rassf1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models. In breast cancer patients, we observed the inverse correlation between Daxx and clinical response to taxane-based chemotherapy. These data suggest that Daxx and Rassf1 define a mitotic stress checkpoint that enables cells to exit mitosis as micronucleated cells (and eventually die) when encountered with specific mitotic stress stimuli, including taxol. Surprisingly, depletion of Daxx or Rassf1 does not change the activity of E3 ubiquitin ligase anaphase promotion complex/C in in vitro settings, suggesting the necessity of mitotic cellular environment for proper activation of this checkpoint. Daxx and Rassf1 may become useful predictive markers for the proper selection of patients for taxane chemotherapy. Oncogene (2012) 31, 13-26; doi: 10.1038/onc.2011.211; published online 6 June 2011	[Giovinazzi, S.; Lindsay, C. R.; Morozov, V. M.; Ishov, A. M.] Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Escobar-Cabrera, E.; McIntosh, L. P.] Univ British Columbia, Dept Chem, Vancouver, BC, Canada; [Escobar-Cabrera, E.; McIntosh, L. P.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC, Canada; [Summers, M. K.] Genentech Inc, Dept Cellular Regulat, San Francisco, CA 94080 USA; [Han, H. S.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of Florida; University of British Columbia; University of British Columbia; Roche Holding; Genentech; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Ishov, AM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, 2033 Mowry Rd,Room 358, Gainesville, FL 32610 USA.	ishov@ufl.edu		Morozov, Viacheslav/0000-0002-4901-7722	NIH/NCI [R01 CA127378-01A1]; Canadian Cancer Society [017308]; NATIONAL CANCER INSTITUTE [R01CA127378] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Cancer Society(Canadian Cancer Society (CCS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gerd Pfeifer, Beckman Research Institute, for the generous gift of anti-Rassf1 antibodies and Dr Frank Rauscher, The Wistar Institute, for HP1 antibodies. This work was supported by NIH/NCI R01 CA127378-01A1 for CRL, SG, VMM and AMI, by the Canadian Cancer Society (017308) for EE and LPM. NMR spectroscopy support was provided by the Canadian Institutes for Health Research (CIHR), the Canadian Foundation for Innovation (CFI), the British Columbia Knowledge Development Fund (BCKDF), the UBC Blusson Fund and the Michael Smith Foundation for Health Research (MSFHR).	Aapro MS, 2001, ONCOLOGIST, V6, P36, DOI 10.1634/theoncologist.6-4-376; Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Amaar YG, 2005, J BONE MINER RES, V20, P1430, DOI 10.1359/JBMR.050311; Bonneterre J, 1999, EUR J CANCER, V35, P1431, DOI 10.1016/S0959-8049(99)00174-4; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chang JC, 2005, J CLIN ONCOL, V23, P1169, DOI 10.1200/JCO.2005.03.156; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Crown J, 2004, ONCOLOGIST, V9, P24, DOI 10.1634/theoncologist.9-suppl_2-24; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; De Mulder P H, 1999, Acta Otorhinolaryngol Belg, V53, P247; Escobar-Cabrera E, 2010, STRUCTURE, V18, P1642, DOI 10.1016/j.str.2010.09.016; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; Hari M, 2003, CELL MOTIL CYTOSKEL, V56, P45, DOI 10.1002/cm.10132; Hari M, 2003, MOL CANCER THER, V2, P597; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Iwao-Koizumi K, 2005, J CLIN ONCOL, V23, P422, DOI 10.1200/JCO.2005.09.078; Kitagawa D, 2006, EMBO J, V25, P3286, DOI 10.1038/sj.emboj.7601212; Kubota T, 1997, J SURG ONCOL, V64, P115, DOI 10.1002/(SICI)1096-9098(199702)64:2<115::AID-JSO5>3.3.CO;2-1; Lee EA, 2004, MOL CANCER THER, V3, P661; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Lindsay CR, 2008, FRONT BIOSCI-LANDMRK, V13, P7132, DOI 10.2741/3216; Lindsay CR, 2007, CELL CYCLE, V6, P1200, DOI 10.4161/cc.6.10.4244; Lindsay CR, 2009, CELL CYCLE, V8, P1544, DOI 10.4161/cc.8.10.8379; Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316; Mauriac L, 2005, BREAST, V14, P617, DOI 10.1016/j.breast.2005.08.013; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Miyoshi Y, 2004, CLIN CANCER RES, V10, P8163, DOI 10.1158/1078-0432.CCR-04-1310; Morozov VM, 2008, ONCOGENE, V27, P2177, DOI 10.1038/sj.onc.1210865; Niikura Y, 2007, J CELL BIOL, V178, P283, DOI 10.1083/jcb.200702134; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; O'Shaughnessy J, 2005, ONCOLOGIST, V10, P20, DOI 10.1634/theoncologist.10-90003-20; RAVDIN P, 2003, EJC SUPPL, V1, P32; Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Saffert RT, 2008, FUTURE VIROL, V3, P265, DOI 10.2217/17460794.3.3.265; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Summers MK, 2008, MOL CELL, V31, P544, DOI 10.1016/j.molcel.2008.07.014; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Wang YQ, 2005, BBA-MOL CELL RES, V1744, P245, DOI 10.1016/j.bbamcr.2004.12.003; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322	55	22	23	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					13	26		10.1038/onc.2011.211	http://dx.doi.org/10.1038/onc.2011.211			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643015	Green Accepted, Bronze			2022-12-28	WOS:000299176200002
J	Kim, J; Roh, M; Doubinskaia, I; Algarroba, GN; Eltoum, IEA; Abdulkadir, SA				Kim, J.; Roh, M.; Doubinskaia, I.; Algarroba, G. N.; Eltoum, I-E A.; Abdulkadir, S. A.			A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53	ONCOGENE			English	Article						c-MYC; Pten; p53; prostate cancer; rate of mutations	TUMOR-SUPPRESSOR GENE; GENOMIC DELETION; TRANSGENIC MICE; ADVANCED-STAGE; IN-VIVO; MUTATIONS; EXPRESSION; CARCINOMA; PROGRESSION; TUMORIGENESIS	Human tumors are heterogeneous and evolve through a dynamic process of genetic mutation and selection. During this process, the effects of a specific mutation on the incipient cancer cell may dictate the nature of subsequent mutations that can be tolerated or selected for, affecting the rate at which subsequent mutations occur. Here we have used a new mouse model of prostate cancer that recapitulates several salient features of the human disease to examine the relative rates in which the remaining wildtype alleles of Pten and p53 tumor suppressor genes are lost. In this model, focal overexpression of c-MYC in a few prostate luminal epithelial cells provokes a mild proliferative response. In the context of compound Pten/p53 heterozygosity, c-MYC-initiated cells progress to prostatic intraepithelial neoplasia (mPIN) and adenocarcinoma lesions with marked heterogeneity within the same prostate glands. Using laser capture microdissection and gene copy number analyses, we found that the frequency of Pten loss was significantly higher than that of p53 loss in mPIN but not invasive carcinoma lesions. c-MYC overexpression, unlike Pten loss, did not activate the p53 pathway in transgenic mouse prostate cells, explaining the lack of selective pressure to lose p53 in the c-MYC-overexpressing cells. This model of heterogeneous prostate cancer based on alterations in genes relevant to the human disease may be useful for understanding pathogenesis of the disease and testing new therapeutic agents. Oncogene (2012) 31, 322-332; doi:10.1038/onc.2011.236; published online 20 June 2011	[Kim, J.; Roh, M.; Doubinskaia, I.; Algarroba, G. N.; Abdulkadir, S. A.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Algarroba, G. N.] Univ Florida, Coll Agr & Life Sci, Gainesville, FL USA; [Eltoum, I-E A.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	Vanderbilt University; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham	Abdulkadir, SA (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr N, Dept Pathol, Rm B3321, Nashville, TN 37232 USA.	sarki.abdulkadir@vanderbilt.edu		Kim, Jongchan/0000-0002-9733-9881; Algarroba, Gabriela/0000-0001-9401-5905	National Cancer Institute of the National Institutes of Health [CA094858, CA123484]; NATIONAL CANCER INSTITUTE [R01CA123484, R01CA094858] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank the members of the Abdulkadir Lab for helpful discussions. This work was supported by Grants CA094858 and CA123484 (SAA) from the National Cancer Institute of the National Institutes of Health.	Abdulkadir SA, 2001, HUM PATHOL, V32, P935, DOI 10.1053/hupa.2001.27102; Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Andreoiu M, 2010, HUM PATHOL, V41, P781, DOI 10.1016/j.humpath.2010.02.011; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; Brooks JD, 1996, CANCER RES, V56, P3814; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; Cheung TH, 2004, GYNECOL ONCOL, V93, P621, DOI 10.1016/j.ygyno.2004.03.013; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; Dong JT, 2001, CLIN CANCER RES, V7, P304; EFFERT PJ, 1993, J UROLOGY, V150, P257, DOI 10.1016/S0022-5347(17)35458-7; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Fenic I, 2004, J PATHOL, V203, P559, DOI 10.1002/path.1545; Fernandez-Marcos PJ, 2009, P NATL ACAD SCI USA, V106, P12962, DOI 10.1073/pnas.0813055106; GREENE DR, 1991, BRIT J UROL, V68, P499, DOI 10.1111/j.1464-410X.1991.tb15394.x; GRIZZLE WE, 1994, J CELL BIOCHEM, P259; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Han B, 2009, MODERN PATHOL, V22, P1083, DOI 10.1038/modpathol.2009.69; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kim J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000542; KONISHI N, 1995, JPN J CANCER RES, V86, P57, DOI 10.1111/j.1349-7006.1995.tb02988.x; McCall P, 2008, BRIT J CANCER, V99, P1296, DOI 10.1038/sj.bjc.6604680; McMenamin ME, 1999, CANCER RES, V59, P4291; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Mentor-Marcel R, 2001, CANCER RES, V61, P6777; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Preacher K.J., 2001, CALCULATION CHI SQUA; Qian JQ, 2002, MODERN PATHOL, V15, P35, DOI 10.1038/modpathol.3880487; Roh M, 2006, GENESIS, V44, P447, DOI 10.1002/dvg.20235; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Schmitz M, 2007, INT J CANCER, V120, P1284, DOI 10.1002/ijc.22359; Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Suzuki H, 1998, CANCER RES, V58, P204; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T; VOELLER HJ, 1994, J UROLOGY, V151, P492; Wang L, 2007, HEPATOL RES, V37, P389, DOI 10.1111/j.1872-034X.2007.00042.x; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985; Yoshimoto M, 2007, BRIT J CANCER, V97, P678, DOI 10.1038/sj.bjc.6603924	51	42	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					322	332		10.1038/onc.2011.236	http://dx.doi.org/10.1038/onc.2011.236			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685943	Green Accepted			2022-12-28	WOS:000299542100005
J	Zoppoli, G; Solier, S; Reinhold, WC; Liu, H; Connelly, JW; Monks, A; Shoemaker, RH; Abaan, OD; Davis, SR; Meltzer, PS; Doroshow, JH; Pommier, Y				Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Connelly, J. W., Jr.; Monks, A.; Shoemaker, R. H.; Abaan, O. D.; Davis, S. R.; Meltzer, P. S.; Doroshow, J. H.; Pommier, Y.			CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute	ONCOGENE			English	Article						Chk2; centrosome; H2AX; p53; BRCA1; Fanconi anemia	DNA-DAMAGE RESPONSE; CHK2 PROTEIN-KINASE; LI-FRAUMENI-SYNDROME; TUMOR-SUPPRESSOR; BREAST-CANCER; THREONINE-68 PHOSPHORYLATION; CHECKPOINT PATHWAY; LUNG-CANCER; IN-VITRO; EXPRESSION	CHEK2 encodes a serine/threonine kinase (Chk2) activated by ATM in response to DNA double-strand breaks. On the one hand, CHEK2 has been described as a tumor suppressor with proapoptotic, cell-cycle checkpoint and mitotic functions. On the other hand, Chk2 is also commonly activated (phosphorylated at T68) in cancers and precancerous lesions. Here, we report an extensive characterization of CHEK2 across the panel of 60 established cancer cell lines from the NCI Anticancer Screen (the NCI-60) using genomic and proteomic analyses, including exon-specific mRNA expression, DNA copy-number variation (CNV) by aCGH, exome sequencing, as well as western blot analyses for total and activated (pT68-Chk2) Chk2. We show that the high heterogeneity of Chk2 levels in cancer cells is primarily due to its inactivation (owing to low gene expression, alternative splicing, point mutations, copy-number alterations and premature truncation) or reduction of protein levels. Moreover, we observe that a significant percentage of cancer cells (12% of the NCI-60 and HeLa cells) show high endogenous Chk2 activation, which is always associated with p53 inactivation, and which is accompanied by downregulation of the Fanconi anemia and homologous recombination pathways. We also report the presence of activated Chk2 (pT68-Chk2) along with histone gamma-H2AX in centrosomes. Oncogene (2012) 31, 403-418; doi: 10.1038/onc.2011.283; published online 18 July 2011	[Zoppoli, G.] Univ Genoa, Dept Internal Med DiMI, I-16132 Genoa, Italy; [Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Doroshow, J. H.; Pommier, Y.] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Liu, H.] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA; [Connelly, J. W., Jr.; Monks, A.] SAIC Frederick Inc, Lab Funct Genom, NCI Frederick, Frederick, MD USA; [Shoemaker, R. H.] NCI, Screening Technol Branch, Dev Therapeut Program, Div Canc Treatment & Diag,NIH, Frederick, MD 21701 USA; [Abaan, O. D.; Davis, S. R.; Meltzer, P. S.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Doroshow, J. H.] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA	University of Genoa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zoppoli, G (corresponding author), Univ Genoa, Dept Internal Med DiMI, Avancorpo 2 Piano,Vle Benedetto XV,Room 223,6, I-16132 Genoa, Italy.	gabriele.zoppoli@unige.it; pommier@nih.gov	Shoemaker, Robert/GPK-1314-2022; Zoppoli, Gabriele/B-6935-2016; SOLIER, STEPHANIE/AAA-6851-2020; Davis, Sean/AAD-1801-2021; Reinhold, William/J-6704-2017; Zoppoli, Gabriele/B-6935-2016	Zoppoli, Gabriele/0000-0003-3890-5588; Davis, Sean/0000-0002-8991-6458; Reinhold, William/0000-0001-5513-9323; Zoppoli, Gabriele/0000-0002-1619-1708; SOLIER, Stephanie/0000-0003-3867-4644	Center for Cancer Research; National Cancer Institute; Division of Cancer Treatment and Diagnosis; National Cancer Institute (National Institutes of Health); AIRC MFAG [10570]; University of Genova (Genova, Italy); NATIONAL CANCER INSTITUTE [ZIABC011091, ZIABC011078, ZIABC006150] Funding Source: NIH RePORTER	Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Division of Cancer Treatment and Diagnosis(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis); National Cancer Institute (National Institutes of Health)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIRC MFAG(Fondazione AIRC per la ricerca sul cancro); University of Genova (Genova, Italy); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Center for Cancer Research, Intramural Program of the National Cancer Institute, and by the Division of Cancer Treatment and Diagnosis, Extramural Program of the National Cancer Institute (National Institutes of Health), and by AIRC MFAG grant no. 10570 (GZ). GZ was also supported by a PhD fellowship grant (XXIII Ciclo) from the University of Genova (Genova, Italy).	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Albert JM, 2007, CLIN CANCER RES, V13, P3033, DOI 10.1158/1078-0432.CCR-06-2872; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2004, ONCOGENE, V23, P8545, DOI 10.1038/sj.onc.1207878; Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Berge EO, 2010, BBA-MOL CELL RES, V1803, P386, DOI 10.1016/j.bbamcr.2010.01.005; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Chehab NH, 2000, GENE DEV, V14, P278; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fan C, 2006, BBA-MOL CELL RES, V1763, P1090, DOI 10.1016/j.bbamcr.2006.08.026; Ghosh JC, 2006, CANCER RES, V66, P11576, DOI 10.1158/0008-5472.CAN-06-3095; Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259; Gmeiner WH, 2010, MOL CANCER THER, V9, P3105, DOI 10.1158/1535-7163.MCT-10-0674; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hattori H, 2004, PATHOL INT, V54, P26, DOI 10.1111/j.1440-1827.2004.01585.x; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Holbeck SL, 2010, MOL CANCER THER, V9, P1451, DOI 10.1158/1535-7163.MCT-10-0106; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Jobson AG, 2009, J PHARMACOL EXP THER, V331, P816, DOI 10.1124/jpet.109.154997; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kim DS, 2009, LUNG CANCER, V65, P247, DOI 10.1016/j.lungcan.2009.03.011; Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060; Lee SB, 2001, CANCER RES, V61, P8062; Li J, 2005, J BIOL CHEM, V280, P12041, DOI 10.1074/jbc.M412445200; Li J, 2008, J BIOL CHEM, V283, P36019, DOI 10.1074/jbc.M804075200; Lukas C, 2001, CANCER RES, V61, P4990; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Niida H, 2010, EMBO J, V29, P3558, DOI 10.1038/emboj.2010.218; Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Pfister TD, 2009, MOL CANCER THER, V8, P1878, DOI 10.1158/1535-7163.MCT-09-0016; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Powers JT, 2004, MOL CANCER RES, V2, P203; Reinhold WC, 2010, CANCER RES, V70, P2191, DOI 10.1158/0008-5472.CAN-09-3528; Ribeiro-Silva A, 2006, HISTOL HISTOPATHOL, V21, P373, DOI 10.14670/HH-21.373; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Roschke AV, 2003, CANCER RES, V63, P8634; Sarbia M, 2007, BRIT J CANCER, V97, P1404, DOI 10.1038/sj.bjc.6604037; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Sedelnikova OA, 2006, CELL CYCLE, V5, P2909, DOI 10.4161/cc.5.24.3569; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Solier S, 2009, CELL CYCLE, V8, P1853, DOI 10.4161/cc.8.12.8865; Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Yang ST, 2006, J BIOL CHEM, V281, P26645, DOI 10.1074/jbc.M604391200; YEE C, 1985, AM J PATHOL, V119, P361; Yu Q, 2001, FEBS LETT, V505, P7, DOI 10.1016/S0014-5793(01)02756-9; Zhang SS, 2007, J CELL BIOCHEM, V101, P451, DOI 10.1002/jcb.21195; Zhao H, 2008, CYTOM PART A, V73A, P480, DOI 10.1002/cyto.a.20574; Zhao H, 2007, CYTOM PART A, V71A, P905, DOI 10.1002/cyto.a.20469; Zhou M, 2007, ANAL CHEM, V79, P7603, DOI 10.1021/ac071584r	84	16	16	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					403	418		10.1038/onc.2011.283	http://dx.doi.org/10.1038/onc.2011.283			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21765476	Green Accepted			2022-12-28	WOS:000300219300001
J	Su, Y; Li, J; Witkiewicz, AK; Brennan, D; Neill, T; Talarico, J; Radice, GL				Su, Y.; Li, J.; Witkiewicz, A. K.; Brennan, D.; Neill, T.; Talarico, J.; Radice, G. L.			N-cadherin haploinsufficiency increases survival in a mouse model of pancreatic cancer	ONCOGENE			English	Article						cell adhesion; apoptosis; invasion; matrix metalloproteinase	CELL-MIGRATION; DUCTAL ADENOCARCINOMA; SIGNALING PATHWAY; HEDGEHOG; METASTASIS; GROWTH; INVASION; KI-RAS(G12V); ADHESION; MATRIX	Pancreatic ductal adenocarcinoma (PDA) is often detected at a late stage, hence the identification of new therapies that have potential to block tumor progression is critical for this lethal disease. N-cadherin upregulation has been observed in many cancers including PDA, however, a causal role for this cell adhesion receptor in disease progression has yet to be defined. The concomitant expression of oncogenic Kras(G12D) and mutant p53 (Trp53(R172H)) in the murine pancreas results in metastatic PDA that recapitulates the cognate features of human pancreatic cancer providing an excellent animal model to identify genes required for tumor progression. Here we determine the consequences of genetically manipulating N-cadherin expression in a mouse model of PDA. Remarkably, mice with reduced N-cadherin expression (that is, Ncad(-/+)) survived 25% longer (177 vs 142 days, P<0.05) than animals expressing two wild-type N-cadherin (Cdh2) alleles. The survival benefit is likely due to a cumulative effect of N-cadherin's role in different aspects of tumorigenesis including tumor-cell survival, growth, migration and invasion. Interestingly, reduced hedgehog signaling may contribute to the better prognosis for the Ncad(-/+) mice. Moreover, the matrix metalloproteinase MMP-7, associated with poor prognosis in PDA, was reduced in Ncad(-/+) tumors. Finally, Ncad(-/+) tumor cells exhibited decreased FGF-stimulated ERK1/2 activation consistent with N-cadherin's ability to promote FGFR signaling. These data support a critical role for N-cadherin in PDA and its potential prognostic value. Additionally, this study provides in vivo genetic evidence that the cell-surface protein N-cadherin represents a promising therapeutic target for the treatment of pancreatic cancer. Oncogene (2012) 31, 4484--4489; doi: 10.1038/onc.2011.574; published online 12 December 2011	[Su, Y.; Li, J.; Brennan, D.; Neill, T.; Talarico, J.; Radice, G. L.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Translat Med, Philadelphia, PA 19107 USA; [Witkiewicz, A. K.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Radice, GL (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Ctr Translat Med, Coll Bldg,Room 309,1025 Walnut St, Philadelphia, PA 19107 USA.	glenn.radice@jefferson.edu			Center for Molecular Studies in Digestive and Liver Disease [NIH P30DK050306]; University Research Foundation-University of Pennsylvania; NIH [R21 CA133609]; Pilot Research Award-Thomas Jefferson University; NATIONAL CANCER INSTITUTE [R21CA133609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	Center for Molecular Studies in Digestive and Liver Disease; University Research Foundation-University of Pennsylvania; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pilot Research Award-Thomas Jefferson University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr D Tuveson (Cancer Research UK, Cambridge) for the LSL-K-ras<SUP>G12D</SUP> and LSL-Trp53<SUP>R172H</SUP> mice and Dr A Lowy (UCSD) for the Pdx1/Cre mice. We are grateful to Han Du, Craig Riley, David Kurz, Leeanne Griffith and Andrew Ho for technical assistance. This work was supported by the Center for Molecular Studies in Digestive and Liver Disease (NIH P30DK050306) and University Research Foundation-University of Pennsylvania, NIH R21 CA133609, Pilot Research Award-Thomas Jefferson University (to GLR).	Agbunag C, 2004, CANCER RES, V64, P5659, DOI 10.1158/0008-5472.CAN-04-0807; Augustine CK, 2008, CANCER RES, V68, P3777, DOI 10.1158/0008-5472.CAN-07-5949; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Brembeck FH, 2003, CANCER RES, V63, P2005; Cavallaro U, 2001, NAT CELL BIOL, V3, P650, DOI 10.1038/35083041; Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051; Deramaudt TB, 2006, MOL CELL BIOL, V26, P4185, DOI 10.1128/MCB.01055-05; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Johansson JK, 2010, GENESIS, V48, P374, DOI 10.1002/dvg.20628; Kang JS, 2003, P NATL ACAD SCI USA, V100, P3989, DOI 10.1073/pnas.0736565100; Karafin MS, 2010, INT J CLIN EXP PATHO, V3, P47; Kostetskii I, 2005, CIRC RES, V96, P346, DOI 10.1161/01.RES.0000156274.72390.2c; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; Luo Y, 2005, DEV DYNAM, V232, P336, DOI 10.1002/dvdy.20241; Morton JP, 2007, P NATL ACAD SCI USA, V104, P5103, DOI 10.1073/pnas.0701158104; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nomura S, 2008, BRIT J CANCER, V99, P305, DOI 10.1038/sj.bjc.6604473; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shintani Y, 2008, INT J CANCER, V122, P71, DOI 10.1002/ijc.23027; Shintani Y, 2006, CANCER RES, V66, P11745, DOI 10.1158/0008-5472.CAN-06-2322; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Tenzen T, 2006, DEV CELL, V10, P647, DOI 10.1016/j.devcel.2006.04.004; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455	31	26	26	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4484	4489		10.1038/onc.2011.574	http://dx.doi.org/10.1038/onc.2011.574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22158044	Green Accepted			2022-12-28	WOS:000309704500006
J	Taccioli, C; Chen, H; Jiang, Y; Liu, XP; Huang, K; Smalley, KJ; Farber, JL; Croce, CM; Fong, LY				Taccioli, C.; Chen, H.; Jiang, Y.; Liu, X. P.; Huang, K.; Smalley, K. J.; Farber, J. L.; Croce, C. M.; Fong, L. Y.			Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature	ONCOGENE			English	Article						inflammation; esophageal squamous cell carcinoma; zinc deficiency; transcriptome profiling	NF-KAPPA-B; SQUAMOUS-CELL CARCINOMA; EXPRESSION; PROGRESSION; S100A8; GENES; NITROSOMETHYLBENZYLAMINE; SUPPLEMENTATION; OVEREXPRESSION; CARCINOGENESIS	Chronic inflammation is implicated in the pathogenesis of esophageal squamous cell carcinoma (ESCC). The causes of inflammation in ESCC, however, are undefined. Dietary zinc (Zn)-deficiency (ZD) increases the risk of ESCC. We have previously shown that short-term ZD (6 weeks) in rats induces overexpression of the proinflammatory mediators S100a8 and S100a9 in the esophageal mucosa with accompanying esophageal epithelial hyperplasia. Here we report that prolonged ZD (21 weeks) in rats amplified this inflammation that when combined with non-carcinogenic low doses of the environmental carcinogen, N-nitrosomethylbenzylamine (NMBA) elicited a 66.7% (16/24) incidence of ESCC. With Zn-sufficiency, NMBA produced no cancers (0/21) (P<0.001). At tumor endpoint, the neoplastic ZD esophagus, as compared with Zn-sufficient esophagus, had an inflammatory gene signature with upregulation of numerous cancer-related inflammation genes (CXC and CC chemokines, chemokine receptors, cytokines and Cox-2) in addition to S100a8 and S100a9. This signature was already activated in the earlier dysplastic stage. Additionally, time-course bioinformatics analysis of expression profiles at tumor endpoint and before NMBA exposure revealed that this sustained inflammation was due to ZD rather than carcinogen exposure. Importantly, Zn replenishment reversed this inflammatory signature at both the dysplastic and neoplastic stages of ESCC development, and prevented cancer formation. Thus, the molecular definition of ZD-induced inflammation as a critical factor in ESCC development has important clinical implications with regard to development and prevention of this deadly disease.	[Chen, H.; Jiang, Y.; Fong, L. Y.] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA; [Taccioli, C.; Liu, X. P.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Smalley, K. J.; Fong, L. Y.] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Farber, J. L.] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Jefferson University; Jefferson University	Fong, LY (corresponding author), Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Room 420,Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	louise.fong@jefferson.edu	Huang, Kun/E-3272-2011; Young, Richard A/F-6495-2012; Taccioli, Cristian/F-8801-2010; Smalley, Karl/AGF-1390-2022; Taccioli, Cristian/ABC-3379-2020	Young, Richard A/0000-0001-8855-8647; Taccioli, Cristian/0000-0003-2995-5612; Taccioli, Cristian/0000-0003-2995-5612; Chen, Hongping/0000-0002-1670-5449; Fong, Louise/0000-0001-7654-7035; Smalley, Karl J./0000-0003-1502-6759	NIH [R01CA118560, R01CA115965]; NATIONAL CANCER INSTITUTE [R01CA118560, R01CA115965] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kay Huebner (The Ohio State University) for reading and critical discussion of the manuscript. We thank Shao-gui Wan's assistance with animal care and validation of the array data. The microarray data were submitted to ArrayExpress (Accession number: E-MTAB-428). This work was supported by NIH grants R01CA118560 (LYYF) and R01CA115965 (CMC).	Abnet CC, 2005, JNCI-J NATL CANCER I, V97, P301, DOI 10.1093/jnci/dji042; Allavena P, 2011, EXP CELL RES, V317, P664, DOI 10.1016/j.yexcr.2010.11.013; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Cintorino M, 2001, ANTICANCER RES, V21, P4195; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fong LYY, 2011, CARCINOGENESIS, V32, P554, DOI 10.1093/carcin/bgr004; Fong LYY, 2005, J NATL CANCER I, V97, P40, DOI 10.1093/jnci/dji006; Fong LYY, 2001, JNCI-J NATL CANCER I, V93, P1525, DOI 10.1093/jnci/93.20.1525; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; KMET J, 1972, SCIENCE, V175, P846, DOI 10.1126/science.175.4024.846; Kumar A, 2007, INT J CANCER, V120, P230, DOI 10.1002/ijc.22246; LOZANO JC, 1994, MOL CARCINOGEN, V9, P33, DOI 10.1002/mc.2940090107; MAGEE PN, 1989, CANCER SURV, V8, P207; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398; Nemeth J, 2009, HEPATOLOGY, V50, P1251, DOI 10.1002/hep.23099; PEGG AE, 1984, CANCER INVEST, V2, P223, DOI 10.3109/07357908409104376; Poschl G, 2004, ALCOHOL ALCOHOLISM, V39, P155, DOI 10.1093/alcalc/agh057; Prasad AS, 2002, CANCER METAST REV, V21, P291, DOI 10.1023/A:1021215111729; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rink L, 2007, TRENDS IMMUNOL, V28, P1, DOI 10.1016/j.it.2006.11.005; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; STINSON SF, 1978, JNCI-J NATL CANCER I, V61, P1471; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Sun J, 2011, CARCINOGENESIS, V32, P351, DOI 10.1093/carcin/bgq251; Taccioli C, 2009, GASTROENTEROLOGY, V136, P953, DOI 10.1053/j.gastro.2008.11.039; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wang B, 2006, CANCER RES, V66, P3071, DOI 10.1158/0008-5472.CAN-05-2871; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamamoto K, 2004, EXP TOXICOL PATHOL, V56, P145, DOI 10.1016/j.etp.2004.07.001; YANG CS, 1980, CANCER RES, V40, P2633; Zimmermann KC, 1999, CANCER RES, V59, P198	47	55	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4550	4558		10.1038/onc.2011.592	http://dx.doi.org/10.1038/onc.2011.592			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22179833	Green Submitted, Green Accepted			2022-12-28	WOS:000309982100006
J	Geutjes, EJ; Bajpe, PK; Bernards, R				Geutjes, E-J; Bajpe, P. K.; Bernards, R.			Targeting the epigenome for treatment of cancer	ONCOGENE			English	Review						cancer epigenetics; epigenetic therapy; DNA methylation; histone modifications; nucleosome remodelling	HISTONE-DEACETYLASE INHIBITOR; TUMOR-SUPPRESSOR GENE; PHASE-II TRIAL; POLYCOMB-GROUP PROTEIN; CHROMATIN-REMODELING FACTOR; SUBEROYLANILIDE HYDROXAMIC ACID; DEMETHYLASE JMJD3 CONTRIBUTES; TRANSITIONAL-CELL CARCINOMA; CONVENTIONAL CARE REGIMENS; MESSENGER-RNA EXPRESSION	Cancer genome analyses have revealed that the enzymes involved in epigenetic gene regulation are frequently deregulated in cancer. Here we describe the enzymes that control the epigenetic state of the cell, how they are affected in cancer and how this knowledge can be exploited to treat cancer with a new arsenal of selective therapies. Oncogene (2012) 31, 3827-3844; doi: 10.1038/onc.2011.552; published online 5 December 2011	[Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; [Bernards, R.] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl		Bernards, Rene/0000-0001-8677-3423				Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Andersen JB, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001338; Nguyen AT, 2011, BLOOD, V117, P6912, DOI 10.1182/blood-2011-02-334359; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aribi A, 2007, CANCER-AM CANCER SOC, V109, P713, DOI 10.1002/cncr.22457; Arif M, 2010, CHEM BIOL, V17, P903, DOI 10.1016/j.chembiol.2010.06.014; Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Baek SH, 2011, MOL CELL, V42, P274, DOI 10.1016/j.molcel.2011.03.022; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Bea S, 2001, CANCER RES, V61, P2409; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Biegel Jaclyn A, 2004, Curr Oncol Rep, V6, P445, DOI 10.1007/s11912-004-0075-5; Blum KA, 2009, BRIT J HAEMATOL, V147, P507, DOI 10.1111/j.1365-2141.2009.07881.x; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Boumber Y, 2011, ONCOLOGY-NY, V25, P220; Bradley D, 2009, CANCER-AM CANCER SOC, V115, P5541, DOI 10.1002/cncr.24597; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247; Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Buszczak M, 2009, SCIENCE, V323, P248, DOI 10.1126/science.1165678; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Chang YQ, 2009, NAT STRUCT MOL BIOL, V16, P312, DOI 10.1038/nsmb.1560; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Coste A, 2006, EMBO J, V25, P2453, DOI 10.1038/sj.emboj.7601106; Crump M, 2008, ANN ONCOL, V19, P964, DOI 10.1093/annonc/mdn031; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Datta J, 2009, CANCER RES, V69, P4277, DOI 10.1158/0008-5472.CAN-08-3669; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dickinson M, 2009, BRIT J HAEMATOL, V147, P97, DOI 10.1111/j.1365-2141.2009.07837.x; Drost J, 2010, NAT CELL BIOL, V12, P380, DOI 10.1038/ncb2038; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Eliazer S, 2011, P NATL ACAD SCI USA, V108, P7064, DOI 10.1073/pnas.1015874108; Eliseeva ED, 2007, MOL CANCER THER, V6, P2391, DOI 10.1158/1535-7163.MCT-07-0159; Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Fujita T, 2008, JNCI-J NATL CANCER I, V100, P940, DOI 10.1093/jnci/djn176; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Galanis E, 2009, J CLIN ONCOL, V27, P2052, DOI 10.1200/JCO.2008.19.0694; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251; Geutjes EJ, 2011, BREAST CANC RES TREA; Giaccone G, 2011, J CLIN ONCOL, V29, P2052, DOI 10.1200/JCO.2010.32.4467; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Grand F, 1999, CANCER RES, V59, P3870; Griffiths DS, 2011, NAT CELL BIOL, V13, P13, DOI 10.1038/ncb2135; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Haberland M, 2009, P NATL ACAD SCI USA, V106, P7751, DOI 10.1073/pnas.0903139106; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655; Hauschild A, 2008, MELANOMA RES, V18, P274, DOI 10.1097/CMR.0b013e328307c248; He LS, 1998, CANCER RES, V58, P4238; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Huang Y, 2011, BREAST CANC RES TREA; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jackson EM, 2009, CLIN CANCER RES, V15, P1923, DOI 10.1158/1078-0432.CCR-08-2091; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Jin Ke Long, 2008, J Gynecol Oncol, V19, P185, DOI 10.3802/jgo.2008.19.3.185; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Kilpivaara O, 2008, LEUKEMIA, V22, P1813, DOI 10.1038/leu.2008.229; Kirschbaum M, 2011, J CLIN ONCOL, V29, P1198, DOI 10.1200/JCO.2010.32.1398; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 2001, LEUKEMIA, V15, P89, DOI 10.1038/sj.leu.2401983; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037; Koontz JI, 2001, P NATL ACAD SCI USA, V98, P6348, DOI 10.1073/pnas.101132598; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kuck D, 2010, MOL CANCER THER, V9, P3015, DOI 10.1158/1535-7163.MCT-10-0609; Kung AL, 2000, GENE DEV, V14, P272; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Langemeijer SMC, 2009, NAT GENET, V41, P838, DOI 10.1038/ng.391; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Mesa RA, 2011, CANCER-AM CANCER SOC, V117, P4869, DOI 10.1002/cncr.26129; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Miller CT, 2003, CLIN CANCER RES, V9, P4819; Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013; Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009; Molife LR, 2010, ANN ONCOL, V21, P109, DOI 10.1093/annonc/mdp270; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mulero-Navarro S, 2008, EPIGENETICS-US, V3, P210, DOI 10.4161/epi.3.4.6610; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107; Nicassio F, 2007, CURR BIOL, V17, P1972, DOI 10.1016/j.cub.2007.10.034; Niesvizky R, 2011, CANCER-AM CANCER SOC, V117, P336, DOI 10.1002/cncr.25584; Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Oki Y, 2008, BLOOD, V111, P2382, DOI 10.1182/blood-2007-07-103960; Otterson GA, 2010, J THORAC ONCOL, V5, P1644, DOI 10.1097/JTO.0b013e3181ec1713; Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pasqualucci L, 2011, NATURE, V471, P189, DOI 10.1038/nature09730; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Piekarz RL, 2009, CLIN CANCER RES, V15, P3918, DOI 10.1158/1078-0432.CCR-08-2788; Quintas-Cardama A, 2008, LEUKEMIA, V22, P965, DOI 10.1038/leu.2008.91; Quintas-Cardama A, 2010, NAT REV CLIN ONCOL, V7, P433, DOI 10.1038/nrclinonc.2010.87; Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003; Rahman N, 2005, CURR OPIN GENET DEV, V15, P227, DOI 10.1016/j.gde.2005.04.007; Ramalingam SS, 2009, J THORAC ONCOL, V4, P97, DOI 10.1097/JTO.0b013e318191520c; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Rambaldi A, 2010, BRIT J HAEMATOL, V150, P446, DOI 10.1111/j.1365-2141.2010.08266.x; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Roesch A, 2005, MODERN PATHOL, V18, P1249, DOI 10.1038/modpathol.3800413; Rousseau-Merck MF, 1999, CANCER RES, V59, P3152; Rubio-Moscardo F, 2005, BLOOD, V105, P4445, DOI 10.1182/blood-2004-10-3907; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sakakura C, 2000, INT J CANCER, V89, P217; Santos FPS, 2010, BLOOD, V115, P1131, DOI 10.1182/blood-2009-10-246363; Schaefer EW, 2009, HAEMATOL-HEMATOL J, V94, P1375, DOI 10.3324/haematol.2009.009217; Schrump DS, 2008, CLIN CANCER RES, V14, P188, DOI 10.1158/1078-0432.CCR-07-0135; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x; Sonpavde G, 2007, CLIN GENITOURIN CANC, V5, P457, DOI 10.3816/CGC.2007.n.036; Stadler WM, 2006, CLIN GENITOURIN CANC, V5, P57, DOI 10.3816/CGC.2006.n.018; Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Steine EJ, 2011, J CLIN INVEST, V121, P1748, DOI 10.1172/JCI43169; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; van der Knaap JA, 2010, MOL CELL BIOL, V30, P736, DOI 10.1128/MCB.01121-09; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Vansteenkiste J, 2008, INVEST NEW DRUG, V26, P483, DOI 10.1007/s10637-008-9131-6; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Voso MT, 2009, CLIN CANCER RES, V15, P5002, DOI 10.1158/1078-0432.CCR-09-0494; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610; Wang L, 2011, SCIENCE, V333, P765, DOI 10.1126/science.1201662; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wartman LD, 2011, J CLIN INVEST, V121, P1445, DOI 10.1172/JCI45284; Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047; Weikert S, 2005, INT J MOL MED, V16, P349; Whitehead RP, 2009, INVEST NEW DRUG, V27, P469, DOI 10.1007/s10637-008-9190-8; Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200/JCO.2010.28.9066; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wijermans PW, 2008, LEUKEMIA RES, V32, P587, DOI 10.1016/j.leukres.2007.08.004; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Woyach JA, 2009, J CLIN ENDOCR METAB, V94, P164, DOI 10.1210/jc.2008-1631; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Yang ZQ, 2000, CANCER RES, V60, P4735; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251; Yuge M, 2000, CANCER GENET CYTOGEN, V122, P37, DOI 10.1016/S0165-4608(00)00274-0; Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004; Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371; Zhu WG, 2001, CANCER RES, V61, P1327; Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	257	45	47	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	34					3827	3844		10.1038/onc.2011.552	http://dx.doi.org/10.1038/onc.2011.552			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139071				2022-12-28	WOS:000307925000001
J	Wu, S; Lin, Y; Xu, D; Chen, J; Shu, M; Zhou, Y; Zhu, W; Su, X; Zhou, Y; Qiu, P; Yan, G				Wu, S.; Lin, Y.; Xu, D.; Chen, J.; Shu, M.; Zhou, Y.; Zhu, W.; Su, X.; Zhou, Y.; Qiu, P.; Yan, G.			MiR-135a functions as a selective killer of malignant glioma	ONCOGENE			English	Article						malignant glioma; microRNA; apoptosis; nucleic-acid drug	PROSTATE-CANCER CELLS; GENE-EXPRESSION; SELF-RENEWAL; APOPTOSIS; MICRORNAS; MOUSE; IDENTIFICATION; PROLIFERATION; DISRUPTION; ACTIVATION	Glioma is the most common and fatal primary brain tumor. Thus far, therapeutic strategies to efficiently and specifically antagonize glioma are limited and poorly developed. Here we report that glia-enriched miR-135a, a microRNA that is dramatically downregulated in malignant glioma and correlated with the pathological grading, is capable of inducing mitochondria-dependent apoptosis of malignant glioma by regulating various genes including STAT6, SMAD5 and BMPR2, as well as affecting the signaling pathway downstream. Moreover, this lethal effect is selectively towards malignant glioma cells, but not neurons and glial cells, through a novel mechanism. Our findings suggest an important role of miR-135a in glioma etiology and provide a potential candidate for malignant glioma therapy. Oncogene (2012) 31, 3866-3874; doi:10.1038/onc.2011.551; published online 5 December 2011	[Wu, S.; Lin, Y.; Xu, D.; Chen, J.; Shu, M.; Zhou, Y.; Zhu, W.; Su, X.; Zhou, Y.; Qiu, P.; Yan, G.] Sun Yat Sen Univ, Dept Pharmacol, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University	Yan, G (corresponding author), Sun Yat Sen Univ, Dept Pharmacol, Zhongshan Sch Med, 74 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	ygm@mail.sysu.edu.cn		Lin, Yuan/0000-0002-7152-0965; Wu, Sihan/0000-0001-8329-7492	Key program, National Natural Science Foundation of China [30830111]; Guangzhou Scientific and Technological program [2008Z1-E561]; Guangdong Natural Science Foundation [S2011040004371]	Key program, National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Scientific and Technological program; Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	This work was supported by Key program, National Natural Science Foundation of China (No. 30830111), Guangzhou Scientific and Technological program (No. 2008Z1-E561) and Guangdong Natural Science Foundation (No. S2011040004371).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Beduneau A, 2007, BIOMATERIALS, V28, P4947, DOI 10.1016/j.biomaterials.2007.06.011; Bomben VC, 2010, GLIA, V58, P1145, DOI 10.1002/glia.20994; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Girard M, 2008, J HEPATOL, V48, P648, DOI 10.1016/j.jhep.2008.01.019; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Hsu SD, 2008, NUCLEIC ACIDS RES, V36, pD165, DOI 10.1093/nar/gkm1012; Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714; Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumar B, 2001, IN VITRO CELL DEV-AN, V37, P259; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li KKW, 2009, HUM PATHOL, V40, P1234, DOI 10.1016/j.humpath.2009.02.003; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; Lim M, 2010, LAB INVEST, V90, P222, DOI 10.1038/labinvest.2009.128; Liu ZP, 2009, BBA-MOL CELL RES, V1793, P1819, DOI 10.1016/j.bbamcr.2009.09.012; Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x; Maragkakis M, 2009, NUCLEIC ACIDS RES, V37, pW273, DOI 10.1093/nar/gkp292; Masuda A, 2001, J BIOL CHEM, V276, P26107, DOI 10.1074/jbc.M011475200; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Nahreini P, 2003, CELL MOL NEUROBIOL, V23, P27, DOI 10.1023/A:1022541017085; Navarro A, 2009, BLOOD, V114, P2945, DOI 10.1182/blood-2009-02-204842; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Rebholz-Schuhmann D, 2007, BIOINFORMATICS, V23, pE237, DOI 10.1093/bioinformatics/btl302; Ritchie W, 2010, BIOINFORMATICS, V26, P223, DOI 10.1093/bioinformatics/btp649; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Sun YX, 2005, EXP CELL RES, V306, P85, DOI 10.1016/j.yexcr.2005.02.012; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wurster AL, 2002, J BIOL CHEM, V277, P27169, DOI 10.1074/jbc.M201207200; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Zhang WJ, 2008, CYTOKINE, V42, P39, DOI 10.1016/j.cyto.2008.01.016; Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109-008-0403-6	38	71	75	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3866	3874		10.1038/onc.2011.551	http://dx.doi.org/10.1038/onc.2011.551			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139076				2022-12-28	WOS:000307925000004
J	Hayashi, I; Takatori, S; Urano, Y; Miyake, Y; Takagi, J; Sakata-Yanagimoto, M; Iwanari, H; Osawa, S; Morohashi, Y; Li, T; Wong, PC; Chiba, S; Kodama, T; Hamakubo, T; Tomita, T; Iwatsubo, T				Hayashi, I.; Takatori, S.; Urano, Y.; Miyake, Y.; Takagi, J.; Sakata-Yanagimoto, M.; Iwanari, H.; Osawa, S.; Morohashi, Y.; Li, T.; Wong, P. C.; Chiba, S.; Kodama, T.; Hamakubo, T.; Tomita, T.; Iwatsubo, T.			Neutralization of the gamma-secretase activity by monoclonal antibody against extracellular domain of nicastrin	ONCOGENE			English	Article						Notch; gamma-secretase; functional antibody; membrane protein; intramembrane cleavage	AMYLOID PRECURSOR PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; BUDDED BACULOVIRUS; MEMBRANE-PROTEINS; BETA-APP; NOTCH; COMPLEX; PRESENILIN; CELLS; INHIBITION	Several lines of evidence suggest that aberrant Notch signaling contributes to the development of several types of cancer. Activation of Notch receptor is executed through intramembrane proteolysis by gamma-secretase, which is a multimeric membrane-embedded protease comprised of presenilin, nicastrin (NCT), anterior pharynx defective 1 and PEN-2. In this study, we report the neutralization of the gamma-secretase activity by a novel monoclonal antibody A5226A against the extracellular domain of NCT, generated by using a recombinant budded baculovirus as an immunogen. This antibody recognized fully glycosylated mature NCT in the active gamma-secretase complex on the cell surface, and inhibited the gamma-secretase activity by competing with the substrate binding in vitro. Moreover, A5226A abolished the gamma-secretase activity-dependent growth of cancer cells in a xenograft model. Our data provide compelling evidence that NCT is a molecular target for the mechanism-based inhibition of gamma-secretase, and that targeting NCT might be a novel therapeutic strategy against cancer caused by aberrant gamma-secretase activity and Notch signaling. Oncogene (2012) 31, 787-798; doi:10.1038/onc.2011.265; published online 4 July 2011	[Tomita, T.] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; [Urano, Y.; Iwanari, H.; Kodama, T.; Hamakubo, T.] Univ Tokyo, Res Ctr Adv Sci & Technol, Dept Syst Biol & Med, Tokyo 1130033, Japan; [Miyake, Y.; Sakata-Yanagimoto, M.; Chiba, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Clin & Expt Hematol, Tsukuba, Ibaraki, Japan; [Takagi, J.] Osaka Univ, Inst Prot Res, Lab Prot Synth & Express, Osaka, Japan; [Iwanari, H.] Perseus Prote Inc, Tokyo, Japan; [Li, T.; Wong, P. C.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Tomita, T.; Iwatsubo, T.] Japan Sci & Technol Agcy, Saitama, Japan; [Iwatsubo, T.] Univ Tokyo, Grad Sch Med, Dept Neuropathol, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tsukuba; Osaka University; Johns Hopkins University; Japan Science & Technology Agency (JST); University of Tokyo	Tomita, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	taisuke@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015; Mamiko, Sakata-yanagimoto/AAP-3298-2020	Tomita, Taisuke/0000-0002-0075-5943; Urano, Yasuomi/0000-0002-4901-1937	Japan Society for the Promotion of Science (JSPS); National Institute of Biomedical Innovation; Ministry of Education, Culture, Sports, Science and Technology (MEXT); MEXT; MEXT, Japan; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23791068, 20221010] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Institute of Biomedical Innovation(National Institute of Biomedical Innovation); Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are grateful to Drs T Fukuyama, S Yokoshima (The University of Tokyo), C Haass (Ludwig-Maximilians-University Munchen), H Natsugari (Teikyo University), R Kopan (Washington University in St Louis), G Thinakaran (The University of Chicago), M Vooijs (University Medical Center Southwestern Medical Center) for valuable reagents and our current and previous laboratory members for helpful discussions. We also would like to thank Keiko Tamura-Kawakami and Maiko Nampo for their excellent technical support. This work is supported in part by Grants-in-Aid for Young Scientists (S) (for TT) from Japan Society for the Promotion of Science (JSPS), by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (for TT, TI), Scientific Research on Priority Areas 'Research on Pathomechanisms of Brain Disorders' from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) (for TT, TI), by Targeted Proteins Research Program grant from the MEXT (for TT, TI, JT), by Core Research for Evolutional Science and Technology grant from the MEXT (for TT, TI), Japan. IH and ST were research fellows of JSPS.	Boesze-Battaglia Kathleen, 2006, V332, P169; Chavez-Gutierrez L, 2008, J BIOL CHEM, V283, P20096, DOI 10.1074/jbc.M803040200; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; Dries DR, 2009, J BIOL CHEM, V284, P29714, DOI 10.1074/jbc.M109.038737; Dunn CD, 2010, P NATL ACAD SCI USA, V107, P5907, DOI 10.1073/pnas.1001647107; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Ferrando Adolfo A, 2009, Hematology Am Soc Hematol Educ Program, P353, DOI 10.1182/asheducation-2009.1.353; Filipovic A, 2011, BREAST CANCER RES TR, V125, P43, DOI 10.1007/s10549-010-0823-1; Hayashi I, 2004, J BIOL CHEM, V279, P38040, DOI 10.1074/jbc.M405597200; Hayashi I, 2009, J BIOL CHEM, V284, P27838, DOI 10.1074/jbc.M109.055061; Imamura Y, 2009, J AM CHEM SOC, V131, P7353, DOI 10.1021/ja9001458; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimura K, 2007, CANCER SCI, V98, P155, DOI 10.1111/j.1349-7006.2006.00369.x; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; Li T, 2003, J NEUROSCI, V23, P3272; Luistro L, 2009, CANCER RES, V69, P7672, DOI 10.1158/0008-5472.CAN-09-1843; Masuda K, 2003, J BIOL CHEM, V278, P24552, DOI 10.1074/jbc.M302801200; Masuda S, 2009, CANCER SCI, V100, P2444, DOI 10.1111/j.1349-7006.2009.01328.x; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Saitoh R, 2006, PROTEIN EXPRES PURIF, V46, P130, DOI 10.1016/j.pep.2005.08.008; Saitoh R, 2007, J IMMUNOL METHODS, V322, P104, DOI 10.1016/j.jim.2007.02.005; Samaranayake H, 2009, ANN MED, V41, P322, DOI 10.1080/07853890802698842; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shirotani K, 2004, J NEUROCHEM, V89, P1520, DOI 10.1111/j.1471-4159.2004.02447.x; Shirotani K, 2003, J BIOL CHEM, V278, P16474, DOI 10.1074/jbc.C300095200; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2009, EXPERT REV NEUROTHER, V9, P661, DOI [10.1586/ern.09.24, 10.1586/ERN.09.24]; Urano Y, 2005, J LIPID RES, V46, P904, DOI 10.1194/jlr.M400333-JLR200; Urano Y, 2003, BIOCHEM BIOPH RES CO, V308, P191, DOI 10.1016/S0006-291X(03)01355-X; van Es JH, 2005, TRENDS MOL MED, V11, P496, DOI 10.1016/j.molmed.2005.09.008; van Tetering G, 2009, J BIOL CHEM, V284, P31018, DOI 10.1074/jbc.M109.006775; Vetrivel KS, 2010, BBA-MOL CELL BIOL L, V1801, P860, DOI 10.1016/j.bbalip.2010.03.007; Wakabayashi T, 2009, NAT CELL BIOL, V11, P1340, DOI 10.1038/ncb1978; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhao GJ, 2010, J NEUROSCI, V30, P1648, DOI 10.1523/JNEUROSCI.3826-09.2010	46	55	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					787	798		10.1038/onc.2011.265	http://dx.doi.org/10.1038/onc.2011.265			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725355	Green Accepted			2022-12-28	WOS:000300222100011
J	Wang, D; Ning, W; Xie, D; Guo, L; DuBois, RN				Wang, D.; Ning, W.; Xie, D.; Guo, L.; DuBois, R. N.			Peroxisome proliferator-activated receptor delta confers resistance to peroxisome proliferator-activated receptor gamma-induced apoptosis in colorectal cancer cells	ONCOGENE			English	Article						peroxisome proliferator-activated receptors; colorectal cancer; survivin; apoptosis	INTESTINAL ADENOMA GROWTH; PPAR-GAMMA; COLON CARCINOGENESIS; SURVIVIN EXPRESSION; C57BL/6J-APC(MIN)/+ MICE; THERAPEUTIC TARGET; GENETIC DISRUPTION; PANCREATIC-CANCER; SIGNALING PATHWAY; PTEN EXPRESSION	Peroxisome proliferator-activated receptor gamma (PPAR gamma) may serve as a useful target for drug development in nondiabetic diseases. However, some colorectal cancer cells are resistant to PPAR gamma agonists by mechanisms that are poorly understood. Here, we provide the first evidence that elevated PPAR delta expression and/or activation of PPAR delta antagonize the ability of PPAR gamma to induce colorectal carcinoma cell death. More importantly, the opposing effects of PPAR delta and PPAR gamma in regulating programmed cell death are mediated by survivin and caspase-3. We found that activation of PPAR gamma results in decreased survivin expression and increased caspase-3 activity, whereas activation of PPAR delta counteracts these effects. Our findings suggest that PPAR delta and PPAR gamma coordinately regulate cancer cell fate by controlling the balance between the cell death and survival and demonstrate that inhibition of PPAR delta can reprogram PPAR gamma ligand-resistant cells to respond to PPAR gamma agonists. Oncogene (2012) 31, 1013-1023; doi:10.1038/onc.2011.299; published online 18 July 2011	[DuBois, R. N.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 1492, Houston, TX 77030 USA; [Wang, D.; Xie, D.; Guo, L.; DuBois, R. N.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Ning, W.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	DuBois, RN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Unit 1492, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rdubois@mdanderson.org	DuBois, Raymond N./AAX-8869-2020		National Colorectal Cancer Research Alliance (NCCRA); NIH MERIT [R37 DK47297, RO1 DK 62112, NCI P01 CA77839, CPRIT RP100960]; NATIONAL CANCER INSTITUTE [R01CA184820, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062112, R37DK047297] Funding Source: NIH RePORTER	National Colorectal Cancer Research Alliance (NCCRA); NIH MERIT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the National Colorectal Cancer Research Alliance (NCCRA) for its generous support (RND). This work is supported, in part, by the NIH MERIT award R37 DK47297, RO1 DK 62112, NCI P01 CA77839 and CPRIT RP100960.	Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Burstein HJ, 2003, BREAST CANCER RES TR, V79, P391, DOI 10.1023/A:1024038127156; Cellai I, 2006, BRIT J CANCER, V95, P879, DOI 10.1038/sj.bjc.6603344; Di-Poi N, 2003, J STEROID BIOCHEM, V85, P257, DOI 10.1016/S0960-0760(03)00215-2; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Han SW, 2006, MOL CANCER THER, V5, P430, DOI 10.1158/1535-7163.MCT-05-0347; Hao CM, 2002, J BIOL CHEM, V277, P21341, DOI 10.1074/jbc.M200695200; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Kato Y, 2006, ONCOGENE, V25, P2736, DOI 10.1038/sj.onc.1209299; Kawasaki H, 1998, CANCER RES, V58, P5071; Kim EJ, 2003, J PHARMACOL EXP THER, V307, P505, DOI 10.1124/jpet.103.053876; Kulke MH, 2002, CANCER J, V8, P395, DOI 10.1097/00130404-200209000-00010; Kuo PC, 2004, J BIOL CHEM, V279, P55875, DOI 10.1074/jbc.M407985200; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Li MY, 2005, J CELL BIOCHEM, V96, P760, DOI 10.1002/jcb.20474; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Olie RA, 2000, CANCER RES, V60, P2805; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Panigrahy D, 2005, CANCER BIOL THER, V4, P687, DOI 10.4161/cbt.4.7.2014; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Pino MV, 2004, TOXICOL PATHOL, V32, P58, DOI 10.1080/01926230490261320; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sarela AI, 2001, ANN SURG ONCOL, V8, P305; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Takayama O, 2006, BRIT J CANCER, V95, P889, DOI 10.1038/sj.bjc.6603343; Teresi RE, 2006, INT J CANCER, V118, P2390, DOI 10.1002/ijc.21799; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103; Wang DZ, 2006, J EXP MED, V203, P941, DOI 10.1084/jem.20052124; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yin YZ, 2005, CANCER RES, V65, P3950, DOI 10.1158/0008-5472.CAN-04-3990; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang T, 2001, CANCER RES, V61, P8664; Zhao J, 2000, J CELL SCI, V113, P4363; Zuo XS, 2009, JNCI-J NATL CANCER I, V101, P762, DOI 10.1093/jnci/djp078	48	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1013	1023		10.1038/onc.2011.299	http://dx.doi.org/10.1038/onc.2011.299			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765467	Green Accepted			2022-12-28	WOS:000300709700007
J	Girnita, A; Zheng, H; Gronberg, A; Girnita, L; Stahle, M				Girnita, A.; Zheng, H.; Gronberg, A.; Girnita, L.; Stahle, M.			Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor	ONCOGENE			English	Article						LL-37; breast cancer; IGF-1R; invasion; metastasis	ANTIMICROBIAL PROTEIN HCAP18/LL-37; INNATE IMMUNE-SYSTEM; BREAST-CANCER CELLS; BETA-ARRESTIN; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; IGF-1 RECEPTOR; 7-TRANSMEMBRANE RECEPTORS; UVEAL MELANOMA; PICROPODOPHYLLIN; KINASE	The human cathelicidin antimicrobial protein-18 and its C terminal peptide, LL-37, displays broad antimicrobial activity that is mediated through direct contact with the microbial cell membrane. In addition, recent studies reveal that LL-37 is involved in diverse biological processes such as immunomodulation, apoptosis, angiogenesis and wound healing. An intriguing role for LL-37 in carcinogenesis is also beginning to emerge and the aim of this paper was to explore if and how LL-37 contributes to the signaling involved in tumor development. To this end, we investigated the putative interaction between LL-37 and growth factor receptors known to be involved in tumor growth and progression. Among several receptors tested, LL-37 bound with the highest affinity to insulin-like growth factor 1 receptor (IGF-1R), a receptor that is strongly linked to malignant cellular transformation. Furthermore, this interaction resulted in a dose-dependent phosphorylation and ubiquitination of IGF-1R, with downstream signaling confined to the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK)-pathway but not affecting phosphatidylinositol 3 kinase/Akt signaling. We found that signaling induced by LL-37 was dependent on the recruitment of beta-arrestin to the fully functional IGF-1R and by using mutant receptors we demonstrated that LL-37 signaling is dependent on beta-arrestin-1 binding to the C-terminus of IGF-1R. When analyzing the biological consequences of increased ERK activation induced by LL-37, we found that it resulted in enhanced migration and invasion of malignant cells in an IGF-1R/beta-arrestin manner, but did not affect cell proliferation. These results indicate that LL-37 may act as a partial agonist for IGF-1R, with subsequent intra-cellular signaling activation driven by the binding of beta-arrestin-1 to the IGF-1R. Functional experiments show that LL-37-dependent activation of the IGF-1R signaling resulted in increased migratory and invasive potential of malignant cells. Oncogene (2012) 31, 352-365; doi:10.1038/onc.2011.239; published online 20 June 2011	[Girnita, A.; Zheng, H.; Girnita, L.] Karolinska Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, S-17176 Stockholm, Sweden; [Girnita, A.; Gronberg, A.; Stahle, M.] Karolinska Inst, Dept Med, Unit Dermatol, Stockholm, Sweden; [Girnita, A.; Gronberg, A.; Stahle, M.] Karolinska Univ Hosp, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Girnita, A (corresponding author), Karolinska Hosp, Karolinska Inst, Canc Ctr Karolinska, Dept Pathol & Oncol, CCK R8 04, S-17176 Stockholm, Sweden.	Ada.Girnita@ki.se	Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Girnita, Leonard/0000-0003-0280-9500; Zheng, Huiyuan/0000-0003-1431-1590	Swedish Cancer Society; Swedish Medical Council; Children Cancer Society; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Vinnova; Stockholm Cancer Society; Stockholm County; Karolinska Institute	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Council(Swedish Medical Research Council (SMRC)); Children Cancer Society; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Vinnova(Vinnova); Stockholm Cancer Society; Stockholm County(Stockholm County Council); Karolinska Institute(Karolinska Institutet)	This work was supported by grants funded by the Swedish Cancer Society, Swedish Medical Council, Children Cancer Society, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, Vinnova, Stockholm Cancer Society, the Stockholm County, and the Karolinska Institute. Dr Renato Baserga is greatly acknowledged for providing us with IGF-1R positive and negative cell lines as well as IGF-1R mutants' cells.	Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barlow PG, 2006, J LEUKOCYTE BIOL, V80, P509, DOI 10.1189/jlb.1005560; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Baserga R, 2009, EXP CELL RES, V315, P727, DOI 10.1016/j.yexcr.2008.09.017; Chamorro CI, 2009, J INVEST DERMATOL, V129, P937, DOI 10.1038/jid.2008.321; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Coffelt SB, 2008, CANCER RES, V68, P6482, DOI 10.1158/0008-5472.CAN-08-0044; Coffelt SB, 2008, INT J CANCER, V122, P1030, DOI 10.1002/ijc.23186; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 2001, CANCER RES, V61, P1367; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Gennaro R, 2000, BIOPOLYMERS, V55, P31, DOI 10.1002/1097-0282(2000)55:1<31::AID-BIP40>3.3.CO;2-0; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Heilborn JD, 2005, INT J CANCER, V114, P713, DOI 10.1002/ijc.20795; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Hubbard SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI 10.1016/j.ceb.2007.02.010; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Mader JS, 2006, EXPERT OPIN INV DRUG, V15, P933, DOI 10.1517/13543784.15.8.933; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Natalishvili N, 2009, EXP CELL RES, V315, P1458, DOI 10.1016/j.yexcr.2009.01.008; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Radek K, 2007, SEMIN IMMUNOPATHOL, V29, P27, DOI 10.1007/s00281-007-0064-5; Rajagopal S, 2010, NAT REV DRUG DISCOV, V9, P373, DOI 10.1038/nrd3024; Razuvaev A, 2007, J VASC SURG, V46, P108, DOI 10.1016/j.jvs.2007.02.066; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shaykhiev R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001393; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; Tornkvist M, 2008, BIOCHEM BIOPH RES CO, V368, P793, DOI 10.1016/j.bbrc.2008.01.162; Tokumaru S, 2005, J IMMUNOL, V175, P4662, DOI 10.4049/jimmunol.175.7.4662; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Violin JD, 2007, TRENDS PHARMACOL SCI, V28, P416, DOI 10.1016/j.tips.2007.06.006; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Weber G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2221; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Yin SC, 2010, NEURO-ONCOLOGY, V12, P19, DOI 10.1093/neuonc/nop008; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	60	72	76	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					352	365		10.1038/onc.2011.239	http://dx.doi.org/10.1038/onc.2011.239			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685939	Green Published, hybrid			2022-12-28	WOS:000299542100008
J	Maquoi, E; Assent, D; Detilleux, J; Pequeux, C; Foidart, JM; Noel, A				Maquoi, E.; Assent, D.; Detilleux, J.; Pequeux, C.; Foidart, J-M; Noel, A.			MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis	ONCOGENE			English	Article						breast cancer; MT1-MMP; apoptosis; type I collagen; BIK	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; GROWTH-FACTOR; CANCER-CELLS; MESENCHYMAL TRANSITION; BH3-ONLY PROTEIN; UP-REGULATION; TUMOR-GROWTH; ACTIVATION	As invading breast carcinoma cells breach their underlying basement membrane, they become confronted with a dense three-dimensional reactive stroma dominated by type I collagen. To develop metastatic capabilities, invading tumor cells must acquire the capacity to negotiate this novel microenvironment. Collagen influences the fate of epithelial cells by inducing apoptosis. However, the mechanisms used by invading tumor cells to evade collagen-induced apoptosis remain to be defined. We demonstrate that membrane type-1 matrix metalloproteinase (MT1-MMP/MMP-14) confers breast cancer cells with the ability to escape apoptosis when embedded in a collagen gel and after orthotopic implantation in vivo. In the absence of MMP-14-dependent proteolysis, type I collagen triggers apoptosis by inducing the expression of the pro-apoptotic Bcl-2-interacting killer in luminal-like breast cancer cells. These findings reveal a new mechanism whereby MMP-14 activity promotes tumor progression by circumventing apoptosis. Oncogene (2012) 31, 480-493; doi: 10.1038/onc.2011.249; published online 27 June 2011	[Maquoi, E.; Assent, D.; Detilleux, J.; Pequeux, C.; Foidart, J-M; Noel, A.] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Inst Pathol, B-4000 Liege, Belgium	University of Liege	Maquoi, E (corresponding author), Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Inst Pathol, CHU B23, B-4000 Liege, Belgium.	erik.maquoi@ulg.ac.be		Pequeux, Christel/0000-0001-8275-1489; Noel, Agnes/0000-0002-7670-6179	MICROENVIMET [FP7-HEALTH-2007-A, 201279]; Fonds de la Recherche Scientifique Medicale; Fonds de la Recherche Scientifique - FNRS (FRS-FNRS, Belgium); Foundation against Cancer (foundation of public interest, Belgium); CGRI-FNRS-INSERM Cooperation; Fonds speciaux de la Recherche (University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege); Direction Generale Operationnelle de l'Economie; SPW (Region Wallonne, Belgium); Fonds Social Europeen (FSE, Belgium); Fonds d'Investissements de la Recherche Scientifique (FIRS, CHU Liege, Belgium); Belgian Science Policy (Brussels, Belgium)	MICROENVIMET; Fonds de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Fonds de la Recherche Scientifique - FNRS (FRS-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Foundation against Cancer (foundation of public interest, Belgium); CGRI-FNRS-INSERM Cooperation(Fonds de la Recherche Scientifique - FNRS); Fonds speciaux de la Recherche (University of Liege)(University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege)(University of Liege); Direction Generale Operationnelle de l'Economie; SPW (Region Wallonne, Belgium); Fonds Social Europeen (FSE, Belgium)(European Social Fund (ESF)); Fonds d'Investissements de la Recherche Scientifique (FIRS, CHU Liege, Belgium); Belgian Science Policy (Brussels, Belgium)(Belgian Federal Science Policy Office)	We thank M Fringuellini, P Gavitelli, E Konradovski and N Lefin for their excellent technical assistance. This work was supported by grants from the FP7-HEALTH-2007-A Proposal No 201279 'MICROENVIMET', the Fonds de la Recherche Scientifique Medicale, the Fonds de la Recherche Scientifique - FNRS (FRS-FNRS, Belgium), the Foundation against Cancer (foundation of public interest, Belgium), the CGRI-FNRS-INSERM Cooperation, the Fonds speciaux de la Recherche (University of Liege), the Centre Anticancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the Direction Generale Operationnelle de l'Economie, de l'Emploi et de la Recherche from the SPW (Region Wallonne, Belgium), the Fonds Social Europeen (FSE, Belgium), the Fonds d'Investissements de la Recherche Scientifique (FIRS, CHU Liege, Belgium), the Interuniversity Attraction Poles Program - Belgian Science Policy (Brussels, Belgium). EM is a Research Associate from the F.R.S.-FNRS (Belgium).	Bao WJ, 2004, J CELL BIOL, V167, P745, DOI 10.1083/jcb.200404018; Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008; Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; BIRKEDALHANSEN H, 1987, METHOD ENZYMOL, V144, P140; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Butler GS, 2008, MOL CELL BIOL, V28, P4896, DOI 10.1128/MCB.01775-07; Chinnadurai G, 2008, ONCOGENE, V27, pS20, DOI 10.1038/onc.2009.40; Eccles SA, 1996, CANCER RES, V56, P2815; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Figueira RCS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-20; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Giam M, 2008, ONCOGENE, V27, pS128, DOI 10.1038/onc.2009.50; Gingras D, 2010, BBA-MOL CELL RES, V1803, P142, DOI 10.1016/j.bbamcr.2009.04.011; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Koshikawa N, 2011, CANCER SCI, V102, P111, DOI 10.1111/j.1349-7006.2010.01748.x; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lomonosova E, 2009, MOL CANCER RES, V7, P1268, DOI 10.1158/1541-7786.MCR-08-0183; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180; Mizushima H, 2009, J CELL SCI, V122, P4277, DOI 10.1242/jcs.054551; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morrison CJ, 2006, J BIOL CHEM, V281, P26528, DOI 10.1074/jbc.M603331200; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; Noel A, 2008, SEMIN CELL DEV BIOL, V19, P52, DOI 10.1016/j.semcdb.2007.05.011; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Ota I, 2009, P NATL ACAD SCI USA, V106, P20318, DOI 10.1073/pnas.0910962106; Perumal S, 2008, P NATL ACAD SCI USA, V105, P2824, DOI 10.1073/pnas.0710588105; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rodriguez D, 2010, BBA-MOL CELL RES, V1803, P39, DOI 10.1016/j.bbamcr.2009.09.015; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sabeh F, 2009, J BIOL CHEM, V284, P23001, DOI 10.1074/jbc.M109.002808; Sabeh F, 2009, J CELL BIOL, V185, P11, DOI 10.1083/jcb.200807195; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; Sodek KL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-223; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006; Zou YY, 2002, CANCER RES, V62, P8	65	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					480	493		10.1038/onc.2011.249	http://dx.doi.org/10.1038/onc.2011.249			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706048				2022-12-28	WOS:000300219300007
J	Sun, L; Yao, Y; Liu, B; Lin, Z; Lin, L; Yang, M; Zhang, W; Chen, W; Pan, C; Liu, Q; Song, E; Li, J				Sun, L.; Yao, Y.; Liu, B.; Lin, Z.; Lin, L.; Yang, M.; Zhang, W.; Chen, W.; Pan, C.; Liu, Q.; Song, E.; Li, J.			MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1	ONCOGENE			English	Article						chemotherapy resistance; EMT; microRNA; BMI1; tongue squamous cell carcinoma	BREAST-CANCER; TAMOXIFEN RESISTANCE; MULTIDRUG-RESISTANCE; SELF-RENEWAL; EXPRESSION; MICRORNAS; APOPTOSIS; CHEMORESISTANCE; TUMORIGENICITY; OVEREXPRESSION	Chemotherapy has been reported to induce epithelial-mesenchymal transition (EMT) in tumor cells, which is a critical step in the process of metastasis leading to cancer spreading and treatment failure. However, the underlying mechanisms of chemotherapy-induced EMT remain unclear, and the involvement of microRNAs (miRNA) in this process is poorly understood. To address these questions, we established stable chemotherapy-resistant tongue squamous cell carcinoma (TSCC) cell lines CAL27-res and SCC25-res by exposing the parental CAL27 and SCC25 lines to escalating concentrations of cisplatin for 6 months. CAL27-res and SCC25-res cells displayed mesenchymal features with enhanced invasiveness and motility. MiRNA microarray illustrated that miR-200b and miR-15b were the most significantly downregulated microRNAs in CAL27-res cells. Ectopic expression of miR-200b and miR-15b with miRNA mimics effectively reversed the phenotype of EMT in CAL27-res and SCC25-res cells, and sensitized them to chemotherapy, but inhibition of miR-200b and miR-15b in the sensitive lines with anti-sense oligonucleotides induced EMT and conferred chemoresistance. Retrieving the expression of B lymphoma Mo-MLV insertion region 1 homolog (BMI1), a target for miR-200b and miR-15b, in the presence of the miRNA mimics by transfecting CAL27-res cells with pcDNA3.1-BMI1-carrying mutated seed sequences of miR-200b or miR-15b at its 3'-UTR recapitulated chemotherapy-induced EMT. In vivo, enforced miR-200b or miR-15b expression suppressed metastasis of TSCC xenografts established by CAL27-res cells. Clinically, reduced miR-200b or miR-15b expression was associated with chemotherapeutic resistance in TSCCs and poor patient survival. Our data suggest that reduced expression of miR-200b and miR-15b underscores the mechanisms of chemotherapy-induced EMT in TSCC, and may serve as therapeutic targets to reverse chemotherapy resistance in tongue cancers. Oncogene (2012) 31, 432-445; doi: 10.1038/onc.2011.263; published online 4 July 2011	[Sun, L.; Yao, Y.; Liu, B.; Lin, L.; Yang, M.; Song, E.] Sun Yat Sen Univ, Dept Breast Tumor Ctr, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Lin, Z.; Zhang, W.; Chen, W.; Pan, C.; Li, J.] Sun Yat Sen Univ, Dept Oral & Maxillofacial Surg, Sun Yat Sen Mem Hosp, Guangzhou 510275, Guangdong, Peoples R China; [Liu, Q.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Song, E.] Sun Yat Sen Univ, Key Lab Gene Engn, Minist Educ, State Key Lab Biocontrol,Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Sun Yat Sen University	Song, E (corresponding author), Sun Yat Sen Univ, Breast Tumor Ctr, Sun Yat Sen Mem Hosp, 107 Yanjiang W Rd, Gz 510120, Peoples R China.	songerwei02@yahoo.com.cn; lijinsong1967@163.com	Liu, Bodu/AAR-9402-2021; Liu, Bodu/G-5222-2016	Liu, Bodu/0000-0003-2097-725X; Liu, Bodu/0000-0003-2097-725X; Liu, Qiang/0000-0002-5451-4862; Sun, Lijuan/0000-0003-0080-7886	National Natural Science Foundation of China [81072225, 30921140312, 30831160515, 30830110, 81072177]; Natural Science Foundation of Guangdong Province [10251008901000022, 9151008901000201, 8251008901000011]; Guangzhou Science and Technology Bureau [2008Z1-E201]; Ministry of Science and Technology of China [2010CB912800, 2011CB504203, 2009CB521706]; Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University [KLB09001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Bureau; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University	This work was supported by Grants to JL from National Natural Science Foundation of China (81072225), Natural Science Foundation of Guangdong Province (10251008901000022, 9151008901000201) and Guangzhou Science and Technology Bureau (2008Z1-E201); and to ES from '973' Program Projects (2010CB912800, 2011CB504203, 2009CB521706) from Ministry of Science and Technology of China, National Natural Science Foundation of China (30921140312, 30831160515, 30830110), and Natural Science Foundation of Guangdong Province (8251008901000011), Key Laboratory of malignant tumor gene regulation and target therapy of Guangdong Higher Education Institutes, Sun Yat-sen University (KLB09001), and to LL from National Natural Science Foundation of China (81072177).	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Chua KN, 2008, DRUG DISCOV TODAY, V4, P261; Crea F, 2011, INT J CANCER, V128, P1946, DOI 10.1002/ijc.25522; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Gibson MK, 2005, J CLIN ONCOL, V23, P3562, DOI 10.1200/JCO.2005.01.057; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Gosepath EM, 2008, INT J CANCER, V123, P2013, DOI 10.1002/ijc.23721; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Jeyaseelan K, 2007, EXPERT OPIN THER TAR, V11, P1119, DOI 10.1517/14728222.11.8.1119; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Li JH, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-36; Li JS, 2009, CLIN CANCER RES, V15, P3998, DOI 10.1158/1078-0432.CCR-08-3053; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Mihic-Probst D, 2007, INT J CANCER, V121, P1764, DOI 10.1002/ijc.22891; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Seve P, 2005, CLIN CANCER RES, V11, P5481, DOI 10.1158/1078-0432.CCR-05-0285; Shida T, 2006, CANCER BIOL THER, V5, P1530, DOI 10.4161/cbt.5.11.3458; Song E, 2001, BRIT J CANCER, V85, P1047, DOI 10.1038/sj.bjc.6692042; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toner M, 2009, HEAD NECK PATHOL, V3, P249, DOI 10.1007/s12105-009-0137-y; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008-5472.CAN-07-3063; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054	43	210	223	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					432	445		10.1038/onc.2011.263	http://dx.doi.org/10.1038/onc.2011.263			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21725369				2022-12-28	WOS:000300219300003
J	Wang, J; Ray, PS; Sim, MS; Zhou, XZ; Lu, KP; Lee, AV; Lin, X; Bagaria, SP; Giuliano, AE; Cui, X				Wang, J.; Ray, P. S.; Sim, M-S; Zhou, X. Z.; Lu, K. P.; Lee, A. V.; Lin, X.; Bagaria, S. P.; Giuliano, A. E.; Cui, X.			FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-kappa B signaling	ONCOGENE			English	Article						basal-like breast cancer; FOXC1; NF-kappa B; p65/RelA; Pin1; protein stability	FORKHEAD/WINGED-HELIX GENE; CONSTITUTIVE ACTIVATION; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; EXPRESSION; TUMORS; SUBTYPES; PROGRESSION; CARCINOMAS; PHENOTYPE	Human basal-like breast cancer (BLBC) is an enigmatic and aggressive malignancy with a poor prognosis. There is an urgent need to identify therapeutic targets for BLBC, because current treatment modalities are limited and not effective. The forkhead box transcription factor FOXC1 has recently been identified as a critical functional biomarker for BLBC. However, how it orchestrates BLBC cells was not clear. Here we show that FOXC1 activates the transcription factor nuclear factor-kappa B (NF-kappa B) in BLBC cells by increasing p65/RelA protein stability. High NF-kappa B activity has been associated with estrogen receptor-negative breast cancer, particularly BLBC. The effect of FOXC1 on p65/RelA protein stability is mediated by increased expression of Pin1, a peptidyl-prolyl isomerase. FOXC1 requires NF-kappa B for its regulation of cell proliferation, migration and invasion. Notably, FOXC1 overexpression renders breast cancer cells more susceptible to pharmacological inhibition of NF-kappa B. These results suggest that BLBC cells may rely on FOXC1-driven NF-kappa B signaling. Interventions of this pathway may provide modalities for the treatment of BLBC.	[Cui, X.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Womens Canc Program, Samuel Oschin Comprehens Canc Inst,Dept Surg, Los Angeles, CA 90048 USA; [Wang, J.; Cui, X.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA USA; [Ray, P. S.; Bagaria, S. P.; Giuliano, A. E.] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Surg Oncol, Santa Monica, CA USA; [Sim, M-S] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Biostat, Santa Monica, CA USA; [Zhou, X. Z.; Lu, K. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Canc Biol Program,Dept Med, Boston, MA 02215 USA; [Lee, A. V.] Univ Pittsburgh, Inst Canc, Womens Canc Res Ctr, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Lin, X.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	Cedars Sinai Medical Center; John Wayne Cancer Institute; John Wayne Cancer Institute; John Wayne Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center	Cui, X (corresponding author), Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Womens Canc Program, Samuel Oschin Comprehens Canc Inst,Dept Surg, 8635 W 3rd St,Suite 290W, Los Angeles, CA 90048 USA.	Xiaojiang.cui@cshs.org		Lee, Adrian/0000-0001-9917-514X	National Institutes of Health [CA151610]; QVC and the Fashion Footwear Association of New York Charitable Foundation; Associates for Breast & Prostate Cancer Studies; Avon Foundation [02-2010-068]; NATIONAL CANCER INSTITUTE [R01CA151610] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); QVC and the Fashion Footwear Association of New York Charitable Foundation; Associates for Breast & Prostate Cancer Studies; Avon Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Yixian Zheng for the HA-ubiquitin plasmid, Fred Miller for 4T1 breast cancer cells, Inder M Verma for IKK double-knockout MEFs, Amer A Beg for p65-null MEFs, and Dave Hoon and Myles Cabot for technical support. This work was supported by National Institutes of Health (CA151610), QVC and the Fashion Footwear Association of New York Charitable Foundation, Associates for Breast & Prostate Cancer Studies, and the Avon Foundation (02-2010-068) to XC.	Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Collett K, 2005, CANCER EPIDEM BIOMAR, V14, P1108, DOI 10.1158/1055-9965.EPI-04-0394; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Gershtein ES, 2010, B EXP BIOL MED+, V150, P71, DOI 10.1007/s10517-010-1072-3; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Kidson SH, 1999, DEV BIOL, V211, P306, DOI 10.1006/dbio.1999.9314; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Kume T, 1998, CELL, V93, P985, DOI 10.1016/S0092-8674(00)81204-0; Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Moulder SL, 2010, CLIN BREAST CANCER, V10, pS66, DOI 10.3816/CBC.2010.s.014; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; Peng SL, 2005, CELL DEATH DIFFER, V12, P699, DOI 10.1038/sj.cdd.4401640; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Rexer BN, 2009, CLIN CANCER RES, V15, P4518, DOI 10.1158/1078-0432.CCR-09-0872; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Seewaldt VL, 2007, NEW ENGL J MED, V356, pE12, DOI 10.1056/NEJMicm063760; Smith RS, 2000, HUM MOL GENET, V9, P1021, DOI 10.1093/hmg/9.7.1021; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; WETZELS RHW, 1989, AM J PATHOL, V134, P571; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x	32	74	80	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4798	4802		10.1038/onc.2011.635	http://dx.doi.org/10.1038/onc.2011.635			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22249250	Green Accepted			2022-12-28	WOS:000311033000008
J	Yamadori, T; Ishii, Y; Homma, S; Morishima, Y; Kurishima, K; Itoh, K; Yamamoto, M; Minami, Y; Noguchi, M; Hizawa, N				Yamadori, T.; Ishii, Y.; Homma, S.; Morishima, Y.; Kurishima, K.; Itoh, K.; Yamamoto, M.; Minami, Y.; Noguchi, M.; Hizawa, N.			Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers	ONCOGENE			English	Article						Nrf2; Keap1; EGFR; cell proliferation; oxidative stress	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OXIDATIVE STRESS; GEFITINIB; KEAP1; NRF2; MUTATIONS; PATHWAY; GENE	We previously demonstrated that the transcription factor NF-E2-related factor2 (Nrf2), expressed abundantly in non-small-cell lung cancer (NSCLC) cells, plays a pivotal role in the proliferation and chemoresistance of NSCLC. Here we show that Nrf2-mediated NSCLC cell proliferation is dually regulated by epidermal growth factor receptor (EGFR) signaling and an Nrf2 repressor protein Keap1 (Kelch-like ECH-associated protein-1). NSCLC cells expressing wild-type EGFR and Keap1 genes show enhanced proliferation on stimulation with EGFR ligand under non-stress conditions. Exposure to cigarette smoke extract (CSE) enhanced cell proliferation by modification of the Nrf2/Keap1 interaction. Although EGFR-tyrosine kinase inhibitor (TKI) inhibited the proliferation of these cells, exposure to CSE attenuated its efficacy. In NSCLC cells with Keap1 gene mutations, Nrf2 was constitutively activated owing to dysfunction of Keap1 and cells proliferated independently of EGFR signaling. Furthermore, EGFR-TKI was unable to inhibit their proliferation. In NSCLC cells with EGFR gene mutations, Nrf2 was constitutively activated by EGFR signaling. In these cells, proliferation was largely dependent on the EGFR signaling pathway. Although these cells were highly sensitive to EGFR-TKI, exposure to CSE or knockdown of Keap1 mRNA reduced sensitivity to EGFR-TKI. We found a case of NSCLC showing resistance to EGFR-TKI despite having EGFR-TKI-sensitive EGFR gene mutation because of dysfunctional mutation in Keap1 gene. Results indicate that oxidative stress reduces the anticancer effects of EGFR-TKI in wild-type Keap1 NSCLC cells. Analysis of Keap1 dysfunction may become a novel molecular marker to predict resistance to EGFR-TKI in NSCLC cells having EGFR-TKI-sensitive EGFR mutations. Finally, as the downstream molecule of both EGFR and Keap1 signaling, Nrf2 is an important molecular target for the treatment of NSCLC, where cells have mutations in EGFR, KRAS or Keap1 genes.	[Yamadori, T.; Ishii, Y.; Homma, S.; Morishima, Y.; Kurishima, K.; Hizawa, N.] Univ Tsukuba, Inst Clin Med, Dept Resp Med, Tsukuba, Ibaraki 305, Japan; [Itoh, K.] Hirosaki Univ, Sch Med, Ctr Adv Med Res, Hirosaki, Aomori 036, Japan; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Minami, Y.; Noguchi, M.] Univ Tsukuba, Dept Pathol, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; Hirosaki University; Tohoku University; University of Tsukuba	Ishii, Y (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Resp Med, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305, Japan.	ishii-y@md.tsukuba.ac.jp	Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436	Smoking Research Foundation	Smoking Research Foundation	This work was partially supported by a grant from the Smoking Research Foundation.	De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Huber RM, 2004, LUNG CANCER, V45, pS209, DOI 10.1016/j.lungcan.2004.07.973; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Janmaat ML, 2006, INT J CANCER, V118, P209, DOI 10.1002/ijc.21290; Kim KC, 2010, INT J BIOCHEM CELL B, V42, P297, DOI 10.1016/j.biocel.2009.11.009; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kode A, 2008, AM J PHYSIOL-LUNG C, V294, pL478, DOI 10.1152/ajplung.00361.2007; Kreuzer KA, 2003, ANN HEMATOL, V82, P284, DOI 10.1007/s00277-003-0644-y; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; MITCHELL CE, 1995, ANAL BIOCHEM, V224, P148, DOI 10.1006/abio.1995.1020; Muscarella LA, 2011, EPIGENETICS-US, V6, P710, DOI 10.4161/epi.6.6.15773; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Sakai K, 2006, FASEB J, V20, P311, DOI 10.1096/fj.05-4034fje; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Xu Y, 2010, CANCER BIOL THER, V9, P572, DOI 10.4161/cbt.9.8.11881; Yageta Y, 2011, J VIROL, V85, P4679, DOI 10.1128/JVI.02456-10; Yao HW, 2008, AM J PATHOL, V172, P1222, DOI 10.2353/ajpath.2008.070765; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974	33	121	129	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4768	4777		10.1038/onc.2011.628	http://dx.doi.org/10.1038/onc.2011.628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22249257				2022-12-28	WOS:000311033000005
J	Balogh, K; Asa, SL; Zheng, L; Cassol, C; Cheng, S; Ezzat, S				Balogh, K.; Asa, S. L.; Zheng, L.; Cassol, C.; Cheng, S.; Ezzat, S.			The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression	ONCOGENE			English	Article						Grb14; RET; thyroid cancer; cancer progression	TYROSINE KINASE; EXPRESSION; ENDOCRINE; ASSOCIATION; FAMILY; GROWTH; ROLES	The growth factor receptor-bound protein (Grb) 14 is an adaptor molecule of the Grb7/10/14 family with characteristic Between Plekstrin and SH2 (BPS) domains serving to avidly bind tyrosine kinases. Grb14 inhibits insulin receptor (IR) catalytic activity through interaction with the BPS domain and impedes peptide substrate binding. Members of this Grb family have also been shown to interact with other kinases through their SH2 domain. Here we examined the functional role of Grb14 in thyroid cancer using loss- and gain-of-function approaches. Stable knockdown of Grb14 in thyroid cancer cells facilitated IR signaling. In contrast, RET phosphorylation was diminished in concert with reduced activation of Akt and signal transducer and activator of transcription 3 (STAT3). Loss of Grb14 also resulted in diminished cell proliferation and invasion both in vitro and in mouse flank xenografts. In complementary studies, forced expression of Grb14 interrupted IR signaling but facilitated RET activation, STAT3 and Akt phosphorylation. Consistent with these findings Grb14 overexpression enhanced cell invasion and resulted in striking metastases in an orthotopic thyroid cancer mouse xenograft model. Primary human thyroid cancer microarrays revealed a positive correlation between Grb14 expression and invasive behavior. Our findings uncover a new role for Grb14 in finely tuning receptor signaling and modulating thyroid cancer progression. Oncogene (2012) 31, 4012-4021; doi:10.1038/onc.2011.569; published online 12 December 2011	[Balogh, K.; Zheng, L.; Cheng, S.; Ezzat, S.] Univ Hlth Network, Ontario Canc Inst, Dept Med, Toronto, ON M5G 2M9, Canada; [Asa, S. L.; Cassol, C.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Pathol & Endocrine Oncol Site Grp, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Ezzat, S (corresponding author), Univ Hlth Network, Ontario Canc Inst, Dept Med, 610 Univ Ave,8-327, Toronto, ON M5G 2M9, Canada.	shereen.ezzat@utoronto.ca		Cassol, Clarissa/0000-0001-7536-6806; Asa, Sylvia/0000-0001-8418-5054	Canadian Institutes of Health Research (CIHR) [MOP-86493]; Princess Margaret Hospital Foundation; Ontario Ministry of Health and Long Term Care (OMOHLTC)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Princess Margaret Hospital Foundation; Ontario Ministry of Health and Long Term Care (OMOHLTC)(Ministry of Health and Long-Term Care, Ontario)	We thank Kelvin So for his technical assistance. This work was supported by the Canadian Institutes of Health Research (CIHR)(Grant MOP-86493), the Princess Margaret Hospital Foundation and the Ontario Ministry of Health and Long Term Care (OMOHLTC).	Asa SL, 2001, MODERN PATHOL, V14, P246, DOI 10.1038/modpathol.3880293; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Bai T, 2008, CARCINOGENESIS, V29, P473, DOI 10.1093/carcin/bgm221; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Briese J, 2010, ANTICANCER RES, V30, P1681; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Cheng S, 2011, CLIN CANCER RES, V17, P2385, DOI 10.1158/1078-0432.CCR-10-2837; Cheng S, 2009, ENDOCR-RELAT CANCER, V16, P455, DOI 10.1677/ERC-09-0002; Cooney GJ, 2004, EMBO J, V23, P582, DOI 10.1038/sj.emboj.7600082; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Engelmann D, 2009, ENDOCR-RELAT CANCER, V16, P211, DOI 10.1677/ERC-08-0158; Ezzat S, 2005, J CLIN INVEST, V115, P1021, DOI 10.1172/JCI22486; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Marchini S, 2008, CLIN CANCER RES, V14, P7850, DOI 10.1158/1078-0432.CCR-08-0523; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; Nouaille S, 2006, EMBO REP, V7, P512, DOI 10.1038/sj.embor.7400668; O-Sullivan I, 2008, CANCER RES, V68, P2463, DOI 10.1158/0008-5472.CAN-07-5685; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Wang YJ, 2010, CLIN CANCER RES, V16, P2529, DOI 10.1158/1078-0432.CCR-10-0018; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	30	11	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					4012	4021		10.1038/onc.2011.569	http://dx.doi.org/10.1038/onc.2011.569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158039	Bronze, Green Accepted			2022-12-28	WOS:000308688800002
J	Kim, K; Jeong, KW; Kim, H; Choi, J; Lu, W; Stallcup, MR; An, W				Kim, K.; Jeong, K. W.; Kim, H.; Choi, J.; Lu, W.; Stallcup, M. R.; An, W.			Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription	ONCOGENE			English	Article						H1.2; p53; acetylation; phosphorylation; DNA-PK; transcription	LINKER HISTONE H1; C-TERMINAL DOMAIN; IN-VITRO; CHROMATIN-STRUCTURE; DNA-BINDING; RECRUITMENT; ACTIVATION; MOBILITY; FAMILY; VIVO	Linker histone H1.2 has been shown to suppress p53-dependent transcription through the modulation of chromatin remodeling; however, little is known about the mechanisms governing the antagonistic effects of H1.2 in DNA damage response. Here, we show that the repressive action of H1.2 on p53 function is negatively regulated via acetylation of p53 C-terminal regulatory domain and phosphorylation of H1.2 C-terminal tail. p53 acetylation by p300 impairs the interaction of p53 with H1.2 and triggers a rapid activation of p53-dependent transcription. Similarly, DNA-PK-mediated phosphorylation of H1.2 at T146 enhances p53 transcriptional activity by impeding H1.2 binding to p53 and thereby attenuating its suppressive effects on p53 transactivation. Consistent with these findings, point mutations mimicking modification states of H1.2 and p53 lead to a significant increase in p53-induced apoptosis. These data suggest that p53 acetylation-H1.2 phosphorylation cascade serves as a unique mechanism for triggering p53-dependent DNA damage response pathways. Oncogene (2012) 31, 4290-4301; doi:10.1038/onc.2011.605; published online 16 January 2012	[Kim, K.; Jeong, K. W.; Kim, H.; Choi, J.; Lu, W.; Stallcup, M. R.; An, W.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA; [Kim, K.; Jeong, K. W.; Kim, H.; Choi, J.; Stallcup, M. R.; An, W.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; [Lu, W.] Univ So Calif, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Keck Sch Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	An, W (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA.	woojinan@usc.edu			ACS RSG [DMC-1005001];  [NIH-R01GM84209];  [NIH-RO1DK04393]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084209] Funding Source: NIH RePORTER	ACS RSG(American Cancer Society); ; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge Michael Lieber for DNA-PK and Daniela Rhodes for p601-7. This research was supported by NIH-R01GM84209 (WA), ACS RSG DMC-1005001 (WA) and NIH-RO1DK04393 (MRS).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Ausio Juan, 2006, Briefings in Functional Genomics & Proteomics, V5, P228, DOI 10.1093/bfgp/ell020; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Caterino TL, 2011, BIOCHEM CELL BIOL, V89, P35, DOI 10.1139/O10-024; Contreras A, 2003, MOL CELL BIOL, V23, P8626, DOI 10.1128/MCB.23.23.8626-8636.2003; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Georgel PT, 2001, BIOCHEM CELL BIOL, V79, P313, DOI 10.1139/bcb-79-3-313; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hale TK, 2006, MOL CELL, V22, P693, DOI 10.1016/j.molcel.2006.04.016; Happel N, 2009, GENE, V431, P1, DOI 10.1016/j.gene.2008.11.003; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Izzo A, 2008, BIOL CHEM, V389, P333, DOI 10.1515/BC.2008.037; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kim K, 2008, J BIOL CHEM, V283, P9113, DOI 10.1074/jbc.M708205200; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Lennox RW, 1984, H1 SUBTYPES MAMMALS; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Ma YM, 2006, METHOD ENZYMOL, V408, P502, DOI 10.1016/S0076-6879(06)08031-1; McBryant SJ, 2010, CELL RES, V20, P519, DOI 10.1038/cr.2010.35; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Ni JQ, 2006, GENE DEV, V20, P1959, DOI 10.1101/gad.390106; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vila R, 2000, PROTEIN SCI, V9, P627; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Zheng YP, 2010, J CELL BIOL, V189, P407, DOI 10.1083/jcb.201001148	35	35	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4290	4301		10.1038/onc.2011.605	http://dx.doi.org/10.1038/onc.2011.605			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22249259	Green Accepted			2022-12-28	WOS:000309520200004
J	Zwolinska, AK; Whiting, AH; Beekman, C; Sedivy, JM; Marine, JC				Zwolinska, A. K.; Whiting, A. Heagle; Beekman, C.; Sedivy, J. M.; Marine, J-C			Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency	ONCOGENE			English	Article						nucleostemin; c-Myc; p53; lymphoma; transgenic mice	TARGETED HOMOLOGOUS RECOMBINATION; RIBOSOMAL-PROTEIN L23; CELL-CYCLE ARREST; C-MYC; STEM-CELLS; IN-VIVO; GENE-EXPRESSION; DNA-DAMAGE; TRANSCRIPTIONAL REGULATION; INDUCED LYMPHOMAGENESIS	Nucleostemin (NS), a nucleolar GTPase, is highly expressed in stem/progenitor cells and in most cancer cells. However, little is known about the regulation of its expression. Here, we identify the NS gene as a novel direct transcriptional target of the c-Myc oncoprotein. We show that Myc overexpression enhances NS transcription in cultured cells and in pre-neoplastic B cells from El-myc transgenic mice. Consistent with NS being downstream of Myc, NS expression parallels that of Myc in a large panel of human cancer cell lines. Using chromatin immunoprecipitation we show that c-Myc binds to a well-conserved E-box in the NS promoter. Critically, we show NS haploinsufficiency profoundly delays Myc-induced cancer formation in vivo. NS+/- El-myc transgenic mice have much slower rates of B-cell lymphoma development, with life spans twice that of their wild-type littermates. Moreover, we demonstrate that NS is essential for the proliferation of Myc-overexpressing cells in cultured cells and in vivo: impaired lymphoma development was associated with a drastic decrease of c-Myc-induced proliferation of pre-tumoural B cells. Finally, we provide evidence that in cell culture NS controls cell proliferation independently of p53 and that NS haploinsufficiency significantly delays lymphomagenesis in p53-deficient mice. Together these data indicate that NS functions downstream of Myc as a rate-limiting regulator of cell proliferation and transformation, independently from its putative role within the p53 pathway. Targeting NS is therefore expected to compromise early tumour development irrespectively of the p53 status. Oncogene (2012) 31, 3311-3321; doi: 10.1038/onc.2011.507; published online 14 November 2011	[Zwolinska, A. K.; Marine, J-C] VIB KULeuven, Lab Mol Canc Biol, Dept Mol & Dev Genet, B-3000 Louvain, Belgium; [Zwolinska, A. K.; Beekman, C.; Marine, J-C] VIB UGent, Lab Mol Canc Biol, Dept Biomed Mol Biol, Ghent, Belgium; [Whiting, A. Heagle; Sedivy, J. M.] Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University; Brown University	Marine, JC (corresponding author), VIB KULeuven, Lab Mol Canc Biol, Dept Mol & Dev Genet, Campus Gasthuisberg,Herestr 49,Box 602, B-3000 Louvain, Belgium.	JeanChristophe.Marine@cme.vib-kuleuven.be	Marine, Jean-Christophe/K-3292-2016; Marine, Jean Christophe/J-2237-2015	Marine, Jean-Christophe/0000-0003-2433-9837; Heagle Whiting, Amy/0000-0003-4392-1451	NIH [R01 GM041690]; COBRE [P20 RR015578];  [T32 GM007601]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007601, R01GM041690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG016694] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); COBRE; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by the Geconcerteerde Onderzoeksacties (GOA, University Ghent, Belgium). A K Zwolinska is a recipient of a FWO fellowship. Work in the Sedivy lab was supported by grant R01 GM041690 from the NIH. A Whiting was supported in part by training grant T32 GM007601. The Genomics Core Facility at Brown University was supported in part by the COBRE grant P20 RR015578.	ADAMS JM, 1986, CURR TOP MICROBIOL, V132, P1; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Bernardi R, 2003, NAT MED, V9, P24, DOI 10.1038/nm0103-24; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Brodsky AS, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r64; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chen YH, 2008, EXPERT REV ANTICANC, V8, P1689, DOI 10.1586/14737140.8.10.1689; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; De Clercq S, 2010, MOL CELL BIOL, V30, P5394, DOI 10.1128/MCB.00330-10; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Han CX, 2005, INT J MOL MED, V16, P205; Huang M, 2009, CANCER RES, V69, P3004, DOI 10.1158/0008-5472.CAN-08-3413; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Izumi H, 2001, J CELL SCI, V114, P1533; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jafarnejad SM, 2008, CELL PROLIFERAT, V41, P28, DOI 10.1111/j.1365-2184.2007.00505.x; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Liu SJ, 2004, WORLD J GASTROENTERO, V10, P1246; Lo D, 2010, CELL CYCLE, V9, P3227, DOI 10.4161/cc.9.16.12605; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Malakootian M, 2010, MOL CARCINOGEN, V49, P818, DOI 10.1002/mc.20658; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marine JC, 2010, CANCER CELL, V18, P399, DOI 10.1016/j.ccr.2010.10.026; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meyer N, 2006, SEMIN CANCER BIOL, V16, P275, DOI 10.1016/j.semcancer.2006.07.011; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Perna D, 2012, ONCOGENE, V31, P1695, DOI 10.1038/onc.2011.359; PROUTY SM, 1993, ONCOGENE, V8, P899; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Romanova L, 2009, J BIOL CHEM, V284, P4968, DOI 10.1074/jbc.M804594200; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Sijin L, 2004, J EXP CLIN CANC RES, V23, P529; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang JH, 2008, J EXP MED, V205, P3079, DOI 10.1084/jem.20082271; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zhang JY, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-10; Zhang X, 2005, PNAS, V102, P13969; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	70	16	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	28					3311	3321		10.1038/onc.2011.507	http://dx.doi.org/10.1038/onc.2011.507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22081066	Green Accepted			2022-12-28	WOS:000306367600001
J	Davalos, V; Moutinho, C; Villanueva, A; Boque, R; Silva, P; Carneiro, F; Esteller, M				Davalos, V.; Moutinho, C.; Villanueva, A.; Boque, R.; Silva, P.; Carneiro, F.; Esteller, M.			Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis	ONCOGENE			English	Article						miR-200; cancer; EMT; epigenetic; CpG methylation	MIR-200 FAMILY; DNA METHYLATION; TGF-BETA; TUMOR PROGRESSION; REPRESSORS ZEB1; CELL POLARITY; CANCER; EXPRESSION; METASTASIS; EMT	Epithelial-mesenchymal (EMT) and mesenchymal-epithelial (MET) transitions occur in the development of human tumorigenesis and are part of the natural history of the process to adapt to the changing microenvironment. In this setting, the miR-200 family is recognized as a master regulator of the epithelial phenotype by targeting ZEB1 and ZEB2, two important transcriptional repressors of the cell adherence (E-cadherin) and polarity (CRB3 and LGL2) genes. Recently, the putative DNA methylation associated inactivation of various miR-200 members has been described in cancer. Herein, we show that the miR-200ba429 and miR-200c141 transcripts undergo a dynamic epigenetic regulation linked to EMT or MET phenotypes in tumor progression. The 5'-CpG islands of both miR-200 loci were found unmethylated and coupled to the expression of the corresponding miRNAs in human cancer cell lines with epithelial features, such as low levels of ZEB1/ZEB2 and high expression of E-cadherin, CRB3 and LGL2, while CpG island hypermethylation-associated silencing was observed in transformed cells with mesenchymal characteristics. The recovery of miR-200ba429 and miR-200c141 expression by stable transfection in the hypermethylated cells restored the epithelial markers and inhibited migration in cell culture and tumoral growth and metastasis formation in nude mice. We also discovered, using both cell culture and animal models, that the miR-200 epigenetic silencing is not an static and fixed process but it can be shifted to hypermethylated or unmethylated 5'-CpG island status corresponding to the EMT and MET phenotypes, respectively. In fact, careful laser microdissection in human primary colorectal tumorigenesis unveiled that in normal colon mucosa crypts (epithelia) and stroma (mesenchyma) already are unmethylated and methylated at these loci, respectively; and that the colorectal tumors undergo selective miR-200 hypermethylation of their epithelial component. These findings indicate that the epigenetic silencing plasticity of the miR-200 family contributes to the evolving and adapting phenotypes of human tumors. Oncogene (2012) 31, 2062-2074; doi:10.1038/onc.2011.383; published online 29 August 2011	[Davalos, V.; Moutinho, C.; Boque, R.; Esteller, M.] Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain; [Villanueva, A.] IDIBELL Inst Catala Oncol, Translat Res Lab, Barcelona, Spain; [Silva, P.; Carneiro, F.] Univ Porto IPATIMUP, Inst Pathol & Mol Immunol, Oporto, Portugal; [Silva, P.; Carneiro, F.] Fac Med, Oporto, Portugal; [Esteller, M.] Univ Barcelona, Sch Med, Dept Ciencies Fisiol 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Universidade do Porto; Universidade do Porto; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Av Gran Via 199-203, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Davalos, Veronica/AAR-8547-2020; Carneiro, Fatima/AAV-8677-2021; Xie, Huangming/B-2260-2012; Carneiro, Fatima/J-6432-2013; Boque-Sastre, Raquel/AAA-6548-2020; Esteller, Manel/L-5956-2014; Davalos, Veronica/S-1668-2016	Carneiro, Fatima/0000-0002-1964-1006; Carneiro, Fatima/0000-0002-1964-1006; Esteller, Manel/0000-0003-4490-6093; Davalos, Veronica/0000-0003-4077-5137; , Raquel Boque-Sastre/0000-0002-0214-8848	Fondo de Investigaciones Sanitarias [PI08-1345]; Olga Torres Foundation; Consolider Grant [MEC09-05]; Dr Josef Steiner Cancer Research Foundation; Lilly Foundation; European Research Council; Health Department of the Catalan Government (Generalitat de Catalunya); Instituto de Salud Carlos III; ICREA Funding Source: Custom	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Olga Torres Foundation; Consolider Grant(Spanish Government); Dr Josef Steiner Cancer Research Foundation; Lilly Foundation; European Research Council(European Research Council (ERC)European Commission); Health Department of the Catalan Government (Generalitat de Catalunya)(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); ICREA(ICREA)	We thank Dr Balazs Balint for bioinformatic support. This study was supported by Fondo de Investigaciones Sanitarias Grant PI08-1345, Olga Torres Foundation Grant, Consolider Grant MEC09-05, Dr Josef Steiner Cancer Research Foundation Award, Lilly Foundation Biomedical Research Award, European Research Council Advanced Grant EPINORC and the Health Department of the Catalan Government (Generalitat de Catalunya). VD is supported by Instituto de Salud Carlos III, Sara Borrell postdoctoral contract. ME is an Institucio Catalana de Recerca i Estudis Avancats (ICREA) Research Professor.	Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008; Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Agami R, 2010, EUR J CLIN INVEST, V40, P370, DOI 10.1111/j.1365-2362.2010.02279.x; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Aokage K, 2011, INT J CANCER, V128, P1585, DOI 10.1002/ijc.25500; Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chou JL, 2010, EXPERT OPIN THER TAR, V14, P1213, DOI 10.1517/14728222.2010.525353; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Fujimoto K, 2002, GASTROENTEROLOGY, V123, P1941, DOI 10.1053/gast.2002.37065; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Hurteau GJ, 2006, CELL CYCLE, V5, P1951, DOI 10.4161/cc.5.17.3133; Issa JPJ, 2007, CLIN CANCER RES, V13, P1634, DOI 10.1158/1078-0432.CCR-06-2076; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kaiser J, 2010, SCIENCE, V330, P576, DOI 10.1126/science.330.6004.577; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447; Medina PP, 2008, CELL CYCLE, V7, P2485, DOI 10.4161/cc.7.16.6453; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Pakala SB, 2011, ONCOGENE, V30, P2230, DOI 10.1038/onc.2010.608; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	63	258	270	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2062	2074		10.1038/onc.2011.383	http://dx.doi.org/10.1038/onc.2011.383			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21874049	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000303008600007
J	Heffernan-Stroud, LA; Helke, KL; Jenkins, RW; De Costa, AM; Hannun, YA; Obeid, LM				Heffernan-Stroud, L. A.; Helke, K. L.; Jenkins, R. W.; De Costa, A-M; Hannun, Y. A.; Obeid, L. M.			Defining a role for sphingosine kinase 1 in p53-dependent tumors	ONCOGENE			English	Article						ceramide; sphingosine-1-phosphate; p53; sphingosine kinase; cancer; senescence	PROGRAMMED CELL-DEATH; CERAMIDE-INDUCED APOPTOSIS; TANDEM MASS-SPECTROMETRY; BIOACTIVE SPHINGOLIPIDS; QUANTITATIVE-ANALYSIS; GENOTOXIC STRESS; HIGH EXPRESSION; DOWN-REGULATION; MICE DEFICIENT; CYCLE ARREST	p53 is a crucial tumor suppressor that is mutated or deleted in a majority of cancers. Exactly how p53 prevents tumor progression has proved elusive for many years; however, this information is crucial to define targets for chemotherapeutic development that can effectively restore p53 function. Bioactive sphingolipids have recently emerged as important regulators of proliferative, apoptotic and senescent cellular processes. In this study, we demonstrate that the enzyme sphingosine kinase 1 (SK1), a critical enzyme in the regulation of the key bioactive sphingolipids ceramide, sphingosine and sphingosine-1-phosphate (S1P), serves as a key downstream target for p53 action. Our results show that SK1 is proteolysed in response to genotoxic stress in a p53-dependent manner. p53 null mice display elevation of SK1 levels and a tumor-promoting dysregulation of bioactive sphingolipids in which the anti-growth sphingolipid ceramide is decreased and the pro-growth sphingolipid S1P is increased. Importantly, deletion of SK1 in p53 null mice completely abrogated thymic lymphomas in these mice and prolonged their life span by similar to 30%. Deletion of SK1 also significantly attenuated the formation of other cancers in p53 heterozygote mice. The mechanism of p53 tumor suppression by loss of SK1 is mediated by elevations of sphingosine and ceramide, which in turn were accompanied by increased expression of cell cycle inhibitors and tumor cell senescence. Thus, targeting SK1 may restore sphingolipid homeostasis in p53-dependent tumors and provide insights into novel therapeutic approaches to cancer. Oncogene (2012) 31, 1166-1175; doi:10.1038/onc.2011.302; published online 18 July 2011	[Obeid, L. M.] Med Univ S Carolina, Dept Med, Charleston, SC 29403 USA; [Heffernan-Stroud, L. A.; Obeid, L. M.] Med Univ S Carolina, Dept Mol & Cellular Biol & Pathobiol, Charleston, SC 29403 USA; [Helke, K. L.] Med Univ S Carolina, Dept Comparat Med Lab Anim Resources, Charleston, SC 29403 USA; [Jenkins, R. W.; Hannun, Y. A.; Obeid, L. M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29403 USA; [De Costa, A-M] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29403 USA; [Obeid, L. M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Obeid, LM (corresponding author), Med Univ S Carolina, Dept Med, 114 Doughty St, Charleston, SC 29403 USA.	obeidl@musc.edu		Helke, Kris/0000-0001-9746-0764; obeid, lina/0000-0002-0734-0847	Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX000156]; NIH/NIGMS [R01 GM062887]; NIH/NCI [P01 CA097132-project 3, P01 CA097132-project 1]; American Heart Association [AHA 081509E]; NIH MSTP [GM08716]; MUSC Hollings Cancer Center Abney Foundation; NIH/NIEHS [T32 ES012878, F30ES017379]; NCI [IPO1CA097132, P30 CA 138313]; NIH/NCRR SC COBRE [P20 RR017677]; NIH [C06 RR018823]; National Center for Research Resources; NATIONAL CANCER INSTITUTE [P30CA138313, P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES012878, F30ES017379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062887, T32GM008716] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000156] Funding Source: NIH RePORTER	Biomedical Laboratory Research and Development Service of the VA Office of Research and Development; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Heart Association(American Heart Association); NIH MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MUSC Hollings Cancer Center Abney Foundation; NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCRR SC COBRE; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported, in part, by Award Number I01BX000156 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development, NIH/NIGMS R01 GM062887, NIH/NCI P01 CA097132-project 3 (to LMO). NIH/NCI P01 CA097132-project 1 (to YAH). American Heart Association Pre-Doctoral Fellowship AHA 081509E (to RWJ), NIH MSTP Training Grant GM08716 (to RWJ, AMDC, LAHS), MUSC Hollings Cancer Center Abney Foundation Scholarship (to RWJ, LAHS), NIH/NIEHS TG T32 ES012878, and NIH/NIEHS National Research Service Award Individual Predoctoral Fellowship F30ES017379 (to LAHS). Liquid chromatography-mass spectrometry analysis of sphingolipids was performed by Lipidomics Shared Resource, MUSC (Methods 2006, 39: 82-91) supported by NCI Grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20 RR017677 as specified in Supplementary Information. Laboratory space in the CRI building of MUSC was supported by the NIH, Grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. Refer to Supplementary Information for individual acknowledgements and the VA disclaimer.	Akao Y, 2006, BIOCHEM BIOPH RES CO, V342, P1284, DOI 10.1016/j.bbrc.2006.02.070; Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Baptiste-Okoh N, 2008, CELL CYCLE, V7, P1133, DOI 10.4161/cc.7.9.5805; Bayerl MG, 2008, LEUKEMIA LYMPHOMA, V49, P948, DOI 10.1080/10428190801911654; Bergelin N, 2009, ENDOCRINOLOGY, V150, P2055, DOI 10.1210/en.2008-0625; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Bielawski J, 2009, METHODS MOL BIOL, V579, P443, DOI 10.1007/978-1-60761-322-0_22; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; CHAO R, 1992, J BIOL CHEM, V267, P23459; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2003, PHARMACOL RES, V47, P439, DOI 10.1016/S1043-6618(03)00053-7; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Debacq-Chainiaux F, 2010, ADV EXP MED BIOL, V694, P126; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; El-Assaad W, 2003, BIOCHEM J, V376, P725, DOI 10.1042/BJ20030888; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Heffernan-Stroud LA, 2011, ADV ENZYME REGUL, V51, P219, DOI 10.1016/j.advenzreg.2010.10.003; Hengst JA, 2010, BIOORG MED CHEM LETT, V20, P7498, DOI 10.1016/j.bmcl.2010.10.005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kapitonov D, 2009, CANCER RES, V69, P6915, DOI 10.1158/0008-5472.CAN-09-0664; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kim SS, 2002, ONCOGENE, V21, P2020, DOI 10.1038/sj.onc.1205037; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lees JA, 1999, P NATL ACAD SCI USA, V96, P4221, DOI 10.1073/pnas.96.8.4221; Li W, 2009, CLIN CANCER RES, V15, P1393, DOI 10.1158/1078-0432.CCR-08-1158; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Long JS, 2010, MOL CELL BIOL, V30, P3827, DOI 10.1128/MCB.01133-09; Lopez-Marure R, 2000, EUR J BIOCHEM, V267, P4325, DOI 10.1046/j.1432-1327.2000.01436.x; Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993; Lozano G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001115; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Mathews TP, 2010, J MED CHEM, V53, P2766, DOI 10.1021/jm901860h; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103; Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958; Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Pruett ST, 2008, J LIPID RES, V49, P1621, DOI 10.1194/jlr.R800012-JLR200; Pruschy M, 1999, BRIT J CANCER, V80, P693, DOI 10.1038/sj.bjc.6690411; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Ryland LK, 2011, CANCER BIOL THER, V11, P138, DOI 10.4161/cbt.11.2.14624; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Taha TA, 2005, J BIOL CHEM, V280, P17196, DOI 10.1074/jbc.M413744200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Taha TA, 2006, BBA-BIOMEMBRANES, V1758, P2027, DOI 10.1016/j.bbamem.2006.10.018; Vadas M, 2008, BBA-MOL CELL BIOL L, V1781, P442, DOI 10.1016/j.bbalip.2008.06.007; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watson C, 2010, AM J PATHOL, V177, P2205, DOI 10.2353/ajpath.2010.100220; Weigert A, 2009, INT J CANCER, V125, P2114, DOI 10.1002/ijc.24594; Weisz L, 2007, ONCOGENE, V26, P2202, DOI 10.1038/sj.onc.1210294; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yoon CH, 2009, MOL CANCER RES, V7, P361, DOI 10.1158/1541-7786.MCR-08-0069; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	72	51	52	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1166	1175		10.1038/onc.2011.302	http://dx.doi.org/10.1038/onc.2011.302			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765468	Green Accepted			2022-12-28	WOS:000300945900009
J	Huertas, D; Soler, M; Moreto, J; Villanueva, A; Martinez, A; Vidal, A; Charlton, M; Moffat, D; Patel, S; McDermott, J; Owen, J; Brotherton, D; Krige, D; Cuthill, S; Esteller, M				Huertas, D.; Soler, M.; Moreto, J.; Villanueva, A.; Martinez, A.; Vidal, A.; Charlton, M.; Moffat, D.; Patel, S.; McDermott, J.; Owen, J.; Brotherton, D.; Krige, D.; Cuthill, S.; Esteller, M.			Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin	ONCOGENE			English	Article						epigenetics; histone; inhibitor	SPINDLE-ASSEMBLY CHECKPOINT; MYELOID-LEUKEMIA CELLS; AURORA-B; MYELODYSPLASTIC SYNDROMES; DEACETYLASE INHIBITORS; THR-3 PHOSPHORYLATION; CANCER THERAPEUTICS; CHROMOSOME COHESION; TUMOR-GROWTH; DRUG TARGET	The approval of histone deacetylase inhibitors for treatment of lymphoma subtypes has positioned histone modifications as potential targets for the development of new classes of anticancer drugs. Histones also undergo phosphorylation events, and Haspin is a protein kinase the only known target of which is phosphorylation of histone H3 at Thr3 residue (H3T3ph), which is necessary for mitosis progression. Mitotic kinases can be blocked by small drugs and several clinical trials are underway with these agents. As occurs with Aurora kinase inhibitors, Haspin might be an optimal candidate for the pharmacological development of these compounds. A high-throughput screening for Haspin inhibitors identified the CHR-6494 compound as being one promising such agent. We demonstrate that CHR-6494 reduces H3T3ph levels in a dose-dependent manner and causes a mitotic catastrophe characterized by metaphase misalignment, spindle abnormalities and centrosome amplification. From the cellular standpoint, the identified small-molecule Haspin inhibitor causes arrest in G2/M and subsequently apoptosis. Importantly, ex vivo assays also demonstrate its anti-angiogenetic features; in vivo, it shows antitumor potential in xenografted nude mice without any observed toxicity. Thus, CHR-6494 is a first-in-class Haspin inhibitor with a wide spectrum of anticancer effects that merits further preclinical research as a new member of the family of mitotic kinase inhibitors. Oncogene (2012) 31, 1408-1418; doi:10.1038/onc.2011.335; published online 1 August 2011	[Huertas, D.; Soler, M.; Moreto, J.; Esteller, M.] Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, Barcelona 08908, Catalonia, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Translat Res Lab, Inst Catala Oncol, Barcelona, Catalonia, Spain; [Martinez, A.] Ctr Biomed Res La Rioja CIBIR, Oncol Area, Logrono, Spain; [Vidal, A.] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Barcelona 08908, Catalonia, Spain; [Charlton, M.; Moffat, D.; Patel, S.; McDermott, J.; Owen, J.; Brotherton, D.; Krige, D.; Cuthill, S.] Chroma Therapeut, Abingdon, Oxon, England; [Esteller, M.] Univ Barcelona, Dept Physiol Sci 2, Sch Med, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst IDIBELL, 3rd Floor,Avda Gran Via LHospitalet 199-203, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Soler, Marta/AEW-9527-2022; Vidal, August/N-4662-2016; Esteller, Manel/L-5956-2014; Soler, Marta/AAF-1232-2021; Martinez, Alfredo/GQH-5998-2022	Vidal, August/0000-0001-5727-2099; Esteller, Manel/0000-0003-4490-6093; Soler, Marta/0000-0002-6656-957X; Martinez, Alfredo/0000-0003-4882-4044	European Community [LSHG-CT-2006-037415, SAF2007-00027-65134, CSD2006-49]; Steiner Cancer Research Foundation; ICREA Funding Source: Custom	European Community(European Commission); Steiner Cancer Research Foundation; ICREA(ICREA)	The research leading to these results has received funding from the European Community's Sixth Framework Programme (FP6/2000-2006) under grant agreement no. LSHG-CT-2006-037415-SMARTER project, grant numbers SAF2007-00027-65134, Consolider CSD2006-49 and Dr. Josef Steiner Cancer Research Foundation. ME is an ICREA Research Professor.	Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bryan J, 2010, DRUGS, V70, P1381, DOI 10.2165/11537920-000000000-00000; Carpinelli P, 2008, ADV EXP MED BIOL, V610, P54, DOI 10.1007/978-0-387-73898-7_5; Cheng AY, 1998, CANCER RES, V58, P3611; Chopra P, 2010, EXPERT OPIN INV DRUG, V19, P27, DOI 10.1517/13543780903483191; Cuny GD, 2010, BIOORG MED CHEM LETT, V20, P3491, DOI 10.1016/j.bmcl.2010.04.150; D'Alise AM, 2008, MOL CANCER THER, V7, P1140, DOI 10.1158/1535-7163.MCT-07-2051; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gleixner KV, 2010, CANCER RES, V70, P1513, DOI 10.1158/0008-5472.CAN-09-2181; Gotze K, 2010, ANN HEMATOL, V89, P841, DOI 10.1007/s00277-010-1015-0; Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Higgins JMG, 2001, PROTEIN SCI, V10, P1677, DOI 10.1110/ps.49901; Johnson EF, 2007, BIOCHEMISTRY-US, V46, P9551, DOI 10.1021/bi7008745; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000; Macurek L, 2009, CANCER RES, V69, P4555, DOI 10.1158/0008-5472.CAN-09-0142; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008; Martinez A, 2004, CANCER RES, V64, P6489, DOI 10.1158/0008-5472.CAN-04-0103; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nakai R, 2009, CANCER RES, V69, P3901, DOI 10.1158/0008-5472.CAN-08-4373; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Oke A, 2009, CANCER RES, V69, P4150, DOI 10.1158/0008-5472.CAN-08-3203; Patnaik D, 2008, J BIOMOL SCREEN, V13, P1025, DOI 10.1177/1087057108326081; Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663; Rosasco-Nitcher SE, 2008, SCIENCE, V319, P469, DOI 10.1126/science.1148980; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Stemmann O, 2006, CELL CYCLE, V5, P11, DOI 10.4161/cc.5.1.2296; Takeuchi T, 2009, BIOORGAN MED CHEM, V17, P8113, DOI 10.1016/j.bmc.2009.09.050; Tao YG, 2009, CELL CYCLE, V8, P3172, DOI 10.4161/cc.8.19.9729; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Villa F, 2009, P NATL ACAD SCI USA, V106, P20204, DOI 10.1073/pnas.0908485106; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Zubia A, 2009, ONCOGENE, V28, P1477, DOI 10.1038/onc.2008.501	48	79	82	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1408	1418		10.1038/onc.2011.335	http://dx.doi.org/10.1038/onc.2011.335			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804608	hybrid, Green Published			2022-12-28	WOS:000301780000008
J	Ratushny, V; Pathak, HB; Beeharry, N; Tikhmyanova, N; Xiao, F; Li, T; Litwin, S; Connolly, DC; Yen, TJ; Weiner, LM; Godwin, AK; Golemis, EA				Ratushny, V.; Pathak, H. B.; Beeharry, N.; Tikhmyanova, N.; Xiao, F.; Li, T.; Litwin, S.; Connolly, D. C.; Yen, T. J.; Weiner, L. M.; Godwin, A. K.; Golemis, E. A.			Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death	ONCOGENE			English	Article						SRC; NEDD9; Aurora; drug; mitosis; attachment	CANCER-CELLS; TARGETED THERAPIES; COLORECTAL-CANCER; CHRONIC-PHASE; PROTEIN HEF1; A KINASE; ACTIVATION; CYTOKINESIS; DASATINIB; ADHESION	Increased activity of SRC family kinases promotes tumor invasion and metastasis, and overexpression of the mitotic regulator Aurora kinase A (AURKA) drives tumor aneuploidy and chromosomal instability. These functions nominate SRC and AURKA as valuable therapeutic targets for cancer, and inhibitors for SRC and Aurora kinases are now being used in the clinic. In this study, we demonstrate potent synergy between multiple inhibitors of Aurora and SRC kinases in ovarian and colorectal cancer cell lines, but not in normal ovarian epithelial cell lines. Combination of Aurora and SRC inhibitors selectively killed cells that have undergone a preceding aberrant mitosis, and was associated with a postmitotic reattachment defect, and selective removal of aneuploid cell populations. Combined inhibition of Aurora kinase and SRC potentiated dasatinib-dependent loss of activated (Y416-phosphorylated) SRC. SRC and AURKA share a common interaction partner, NEDD9, which serves as a scaffolding protein with activities in cell attachment and mitotic control, suggesting SRC and AURKA might interact directly. In vitro, we observed physical interaction and mutual cross-phosphorylation between SRC and AURKA that enhanced SRC kinase activity. Together, these findings suggest that combination of SRC and Aurora-targeting inhibitors in the clinic may be a productive strategy. Oncogene (2012) 31, 1217-1227; doi:10.1038/onc.2011.314; published online 25 July 2011	[Ratushny, V.; Pathak, H. B.; Beeharry, N.; Tikhmyanova, N.; Xiao, F.; Li, T.; Litwin, S.; Connolly, D. C.; Yen, T. J.; Godwin, A. K.; Golemis, E. A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Ratushny, V.] Drexel Univ, Coll Med, Program Mol & Cell Biol & Genet, Philadelphia, PA USA; [Weiner, L. M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	Fox Chase Cancer Center; Drexel University; Georgetown University	Golemis, EA (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave,W406, Philadelphia, PA 19111 USA.	EA_Golemis@fccc.edu		Yen, Tim/0000-0003-2159-0997; Golemis, Erica/0000-0003-3618-3673	Army Materiel Command [DOD W81XWH-07-1-0676]; State of Pennsylvania; Ovarian Cancer Research Fund; Ovarian SPORE [P50 CA083638]; Commonwealth of Pennsylvania; Greenberg Fund; NCI [CA06927]; Pew Charitable Fund; Fox Chase Cancer Center;  [R01-CA63366];  [R01-CA113342];  [R01-CA140323];  [R01-GM86877];  [R01-CA136596];  [R01-CA151374];  [R01-CA50633]; NATIONAL CANCER INSTITUTE [R01CA113342, R01CA136596, R01CA140323, P50CA083638, R01CA151374, P30CA006927, R01CA063366, R01CA050633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086877] Funding Source: NIH RePORTER	Army Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); State of Pennsylvania; Ovarian Cancer Research Fund; Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth of Pennsylvania; Greenberg Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pew Charitable Fund; Fox Chase Cancer Center; ; ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Lisa Vanderveer for assistance with maintaining EOC cell lines; Carolyn Slater for isolating and producing the primary HOSE cultures; Christine Klimowicz for assistance with the drug synergy assays; and Ilya Serebriiskii for assistance with editing the figures. This work was supported by R01-CA63366 and R01-CA113342; DOD W81XWH-07-1-0676 from the Army Materiel Command; and Tobacco Settlement funding from the State of Pennsylvania (to EAG); R01-CA140323 and the Ovarian Cancer Research Fund (to AKG); Ovarian SPORE P50 CA083638 (Project 4, to EAG, AKG, and DCC); R01-GM86877, an appropriation from the Commonwealth of Pennsylvania, and the Greenberg Fund (to TJY); R01-CA136596 and R01-CA151374 (to DCC); R01-CA50633 (to LMW); and by NCI CA06927 and support from the Pew Charitable Fund (to Fox Chase Cancer Center). Additional funds were provided by Fox Chase Cancer Center via institutional support of the Head and Neck Cancer Keystone Program.	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Bagnyukova T, 2010, CANCER BIOL THER, V10, P843, DOI 10.4161/cbt.10.9.13738; Bellacosa A, 2010, CANCER PREV RES, V3, P48, DOI 10.1158/1940-6207.CAPR-09-0078; BENZEEV A, 1981, CELL, V26, P107, DOI 10.1016/0092-8674(81)90038-6; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Brandsma D, 2007, CURR OPIN ONCOL, V19, P598, DOI 10.1097/CCO.0b013e3282f0313b; Cao YH, 2007, ADV CANCER RES, V97, P203, DOI 10.1016/S0065-230X(06)97009-2; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dadke D, 2006, MOL BIOL CELL, V17, P1204, DOI 10.1091/mbc.E05-03-0237; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; Fei F, 2010, MOL CANCER THER, V9, P1318, DOI 10.1158/1535-7163.MCT-10-0069; Fernandez-Miranda G, 2011, DEVELOPMENT, V138, P2661, DOI 10.1242/dev.066381; Friedman A, 2007, CELL, V128, P225, DOI 10.1016/j.cell.2007.01.007; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hochhaus A, 2008, LEUKEMIA, V22, P1200, DOI 10.1038/leu.2008.84; Huang X, 2005, CELL CYCLE, V4, P801, DOI 10.4161/cc.4.6.1695; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Kasahara K, 2007, J BIOL CHEM, V282, P5327, DOI 10.1074/jbc.M608396200; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MUSTELIN T, 2002, SCI STKE, pPE3; Ng MM, 2005, DEV CELL, V9, P781, DOI 10.1016/j.devcel.2005.11.002; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; ORLY J, 1979, CELL, V17, P295, DOI 10.1016/0092-8674(79)90155-7; Pfeiffer P, 2007, ONCOGENE, V26, P3661, DOI 10.1038/sj.onc.1210377; Plotnikova OV, 2011, J CELL BIOL, V193, P1021, DOI 10.1083/jcb.201012061; Plotnikova OV, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1061; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Soncini C, 2006, CLIN CANCER RES, V12, P4080, DOI 10.1158/1078-0432.CCR-05-1964; Wong ST, 2009, PHARMACOTHERAPY, V29, P954, DOI 10.1592/phco.29.8.954; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	50	24	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1217	1227		10.1038/onc.2011.314	http://dx.doi.org/10.1038/onc.2011.314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785464	Green Accepted			2022-12-28	WOS:000301344600002
J	Dentelli, P; Rosso, A; Olgasi, C; Camussi, G; Brizzi, MF				Dentelli, P.; Rosso, A.; Olgasi, C.; Camussi, G.; Brizzi, M. F.			IL-3 is a novel target to interfere with tumor vasculature	ONCOGENE			English	Article						IL-3; tumor angiogenesis; Akt; inflammatory cells; mbKitL	ENDOTHELIAL PROGENITOR CELLS; POTENTIAL ROLE; C-KIT; ANGIOGENESIS; EXPRESSION; BETA-1-INTEGRIN; PROLIFERATION; RECRUITMENT; MACROPHAGES; ACTIVATION	Angiogenesis inhibiting agents are currently integral component of anticancer therapy. However, tumors, initially responsive to anti-angiogenic drugs or vascular targeting agents, can acquire resistance. The limited clinical efficacy might result from the heterogeneous nature of tumors or alternatively from the unique phenotype of tumor vascular cells, widely diverse from so-called 'normal' endothelium. Hence, defining the molecular mechanisms driving this diversity might provide a rational basis to design combinatory therapies that should be more effective in avoiding resistance. Herein, we demonstrated that tumor-derived endothelial cells (TECs) isolated from breast and kidney carcinomas retained an endothelial phenotype, but outspread independently of growth factors. Applying small interfering RNA approach, we demonstrated that interleukin (IL)-3, but not vascular endothelial growth factor, released by TECs, supports their autocrine growth and promotes in vivo vessel formation and tumor angiogenesis. Meanwhile, we found that the expression of the membrane-bound kit ligand (mbKitL) depends on IL-3, and it is crucial for adhesion of endothelial progenitor cells (EPCs) and inflammatory cells to TECs. These events required Akt activation. Finally, the finding that depletion of the mbKitL prevented EPC and inflammatory cell trafficking into vascular microenvironment, indicates that, as in bone marrow, the mbKitL can act as a membrane/adhesion molecule for c-Kit-expressing cells. These data provide evidences that an IL-3 autocrine loop can drive a tumor endothelial switch and that targeting IL-3 might confer a significant therapeutic advantage to hamper tumor angiogenesis. Oncogene (2011) 30, 4930-4940; doi:10.1038/onc.2011.204; published online 6 June 2011	[Dentelli, P.; Rosso, A.; Olgasi, C.; Camussi, G.; Brizzi, M. F.] Univ Turin, Dept Internal Med, I-10126 Turin, Italy	University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	Brizzi, Maria Felice/J-7882-2016; Camussi, Giovanni/J-7624-2016; olgasi, cristina/J-2934-2018	Camussi, Giovanni/0000-0003-2795-232X; olgasi, cristina/0000-0002-5738-213X	Italian Association for Cancer Research (AIRC); MIUR (Ministero dell'Universita e Ricerca Scientifica)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); MIUR (Ministero dell'Universita e Ricerca Scientifica)(Ministry of Education, Universities and Research (MIUR))	This work was supported by grants of the Italian Association for Cancer Research (AIRC) to MFB and GC and by MIUR (Ministero dell'Universita e Ricerca Scientifica) to MFB and GC.	AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; Baluk P, 2003, AM J PATHOL, V163, P1801, DOI 10.1016/S0002-9440(10)63540-7; Biancone L, 2004, J IMMUNOL, V173, P5268, DOI 10.4049/jimmunol.173.8.5268; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Bussolati B, 2006, J MOL MED-JMM, V84, P852, DOI 10.1007/s00109-006-0075-z; Bussolati B, 2010, CURR VASC PHARMACOL, V8, P220, DOI 10.2174/157016110790887036; Butler JM, 2010, NAT REV CANCER, V10, P138, DOI 10.1038/nrc2791; De Palma M, 2006, BBA-REV CANCER, V1766, P159, DOI 10.1016/j.bbcan.2006.06.003; Defilippi P, 2005, J CELL BIOL, V168, P1099, DOI 10.1083/jcb.200405116; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Dentelli P, 2007, BLOOD, V109, P4264, DOI 10.1182/blood-2006-06-029603; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Gao DC, 2009, BBA-REV CANCER, V1796, P33, DOI 10.1016/j.bbcan.2009.05.001; Grange C, 2006, ONCOL REP, V15, P381; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MATSUDA R, 1993, AM J PATHOL, V142, P339; Nishie A, 1999, CLIN CANCER RES, V5, P1107; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Ribatti D, 2007, CANCER LETT, V248, P18, DOI 10.1016/j.canlet.2006.06.007; Shchors K, 2007, CANCER RES, V67, P7059, DOI 10.1158/0008-5472.CAN-07-2053; Sica A, 2007, EXPERT OPIN THER TAR, V11, P1219, DOI 10.1517/14728222.11.9.1219; St Croix B, 2000, SCIENCE, V289, P1197; Takakura N, 2006, CANCER SCI, V97, P568, DOI 10.1111/j.1349-7006.2006.00223.x; Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005; Togliatto G, 2010, DIABETES, V59, P1016, DOI 10.2337/db09-0858; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Uberti B, 2010, ONCOGENE, V29, P6581, DOI 10.1038/onc.2010.384; Vajkoczy P, 2003, J EXP MED, V197, P1755, DOI 10.1084/jem.20021659; van Beijnum Judy R, 2009, Front Biosci (Schol Ed), V1, P216; Verfaillie CM, 2008, CANCER CELL, V14, P193, DOI 10.1016/j.ccr.2008.08.005; Weber C, 2006, TRENDS IMMUNOL, V27, P268, DOI 10.1016/j.it.2006.04.002; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoder MC, 2009, BBA-REV CANCER, V1796, P50, DOI 10.1016/j.bbcan.2009.04.002; Zeoli A, 2008, BLOOD, V112, P350, DOI 10.1182/blood-2007-12-128215	45	42	44	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4930	4940		10.1038/onc.2011.204	http://dx.doi.org/10.1038/onc.2011.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21643009				2022-12-28	WOS:000298346500002
J	Eng, CH; Abraham, RT				Eng, C. H.; Abraham, R. T.			The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming	ONCOGENE			English	Review						autophagy; cancer metabolism; glutaminolysis; glycolysis	TUMOR-CELL SURVIVAL; FATTY-ACID SYNTHASE; KAPPA-B ACTIVATION; SIGNALING PATHWAYS; ENERGY-METABOLISM; NEURODEGENERATIVE DISEASES; REGULATING AUTOPHAGY; GLUTAMINE-METABOLISM; HUNTINGTONS-DISEASE; AEROBIC GLYCOLYSIS	Tumorigenesis is often accompanied by metabolic changes that favor rapid energy production and increased biosynthetic capabilities. These metabolic adaptations promote the survival and proliferation of tumor cells, and in conjunction with the hypoxic and metabolically challenged tumor microenvironment, influence autophagic activity. Autophagy is a catabolic process that allows cellular macromolecules to be broken down and re-utilized as metabolic precursors. Stimulation of autophagy promotes the survival of tumor cells under stressful metabolic and environmental conditions, and counters the potentially deleterious effects of mitochondrial dysfunction and the ROS that these organelles generate. However, inhibition of autophagy has also been reported to fuel tumorigenesis. In spite of the advances in our understanding of the relationship between autophagy and tumorigenesis, it remains unclear whether the therapeutic approaches targeting autophagy should aim to increase or decrease autophagic flux in tumor tissues in human patients. Here, we review how metabolic reprogramming influences autophagic activity in tumors, and discuss how inhibition of autophagy might be exploited to target tumor cells that show altered metabolism. Oncogene (2011) 30, 4687-4696; doi: 10.1038/onc. 2011.220; published online 13 June 2011	[Eng, C. H.; Abraham, R. T.] Pfizer Oncol Res Unit, Pearl River, NY 10965 USA	Pfizer	Eng, CH (corresponding author), Pfizer Oncol Res Unit, 401 N Middletown Rd,Bldg 200,Room 4603, Pearl River, NY 10965 USA.	christina.eng@pfizer.com						Abraham RT, 2008, EXPERT OPIN THER TAR, V12, P209, DOI [10.1517/14728222.12.2.209, 10.1517/14728222.12.2.209 ]; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Brest P, 2010, CURR MOL MED, V10, P486, DOI 10.2174/156652410791608252; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042; Deretic V, 2010, CURR OPIN CELL BIOL, V22, P252, DOI 10.1016/j.ceb.2009.12.009; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Eng CH, 2010, AUTOPHAGY, V6, P968, DOI 10.4161/auto.6.7.13082; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; Filimonenko M, 2010, MOL CELL, V38, P265, DOI 10.1016/j.molcel.2010.04.007; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248; Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151; Hubbard VM, 2010, J IMMUNOL, V185, P7349, DOI 10.4049/jimmunol.1000576; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958; Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020; Kondoh H, 2005, CANCER RES, V65, P177; Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kundu M, 2008, BLOOD, V112, P1493, DOI 10.1182/blood-2008-02-137398; Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394; Lee MN, 2009, MOL CELL BIOL, V29, P3991, DOI 10.1128/MCB.00165-09; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Marino G, 2011, MOL CELL, V42, P1, DOI 10.1016/j.molcel.2011.03.003; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008; Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McAllister SS, 2010, J CLIN ONCOL, V28, P4022, DOI 10.1200/JCO.2010.28.4257; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Meng M, 2010, CELL CYCLE, V9, P3921, DOI 10.4161/cc.9.19.13139; Mordier S, 2000, J BIOL CHEM, V275, P29900, DOI 10.1074/jbc.M003633200; Morselli E, 2011, ANTIOXID REDOX SIGN, V14, P2251, DOI 10.1089/ars.2010.3478; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; Ravitz MJ, 2007, CANCER RES, V67, P11209, DOI 10.1158/0008-5472.CAN-06-4351; Renna M, 2010, J BIOL CHEM, V285, P11061, DOI 10.1074/jbc.R109.072181; Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027; Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029; Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Telang S, 2006, ONCOGENE, V25, P7225, DOI 10.1038/sj.onc.1209709; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104	107	73	74	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4687	4696		10.1038/onc.2011.220	http://dx.doi.org/10.1038/onc.2011.220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21666712				2022-12-28	WOS:000298033700001
J	Ruptier, C; De Gasperis, A; Ansieau, S; Granjon, A; Taniere, P; Lafosse, I; Shi, H; Petitjean, A; Taranchon-Clermont, E; Tribollet, V; Voeltzel, T; Scoazec, JY; Maguer-Satta, V; Puisieux, A; Hainaut, P; Cavard, C; de Fromentel, CC				Ruptier, C.; De Gasperis, A.; Ansieau, S.; Granjon, A.; Taniere, P.; Lafosse, I.; Shi, H.; Petitjean, A.; Taranchon-Clermont, E.; Tribollet, V.; Voeltzel, T.; Scoazec, J-Y; Maguer-Satta, V.; Puisieux, A.; Hainaut, P.; Cavard, C.; de Fromentel, C. Caron			TP63 P2 promoter functional analysis identifies beta-catenin as a key regulator of Delta Np63 expression	ONCOGENE			English	Article						beta-catenin; p53 family; promoter; transcriptional regulation; tumour progression	SQUAMOUS-CELL CARCINOMA; STEM-CELLS; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; SIGNALING PATHWAY; UP-REGULATION; P53 FAMILY; P63; CANCER; P73	The Delta Np63 protein, a product of the TP63 gene that lacks the N-terminal domain, has a critical role in the maintenance of self renewal and progenitor capacity in several types of epithelial tissues. Delta Np63 is frequently overexpressed in squamous cell carcinoma (SCC) and in some other epithelial tumours. This overexpression may contribute to tumour progression through dominant-negative effects on the transcriptionally active (TA) isoforms of the p53 family (TAp63, TAp73 and p53), as well as through independent mechanisms. However, the molecular basis of Delta Np63 overexpression is not fully understood. Here, we show that the expression of Delta Np63 is regulated by the Wnt/beta-catenin pathway in human hepatocellular carcinoma (HCC) and SCC cell lines. This regulation operates in particular through TCF/LEF sites present in the P2 promoter of TP63. In addition, we show that Delta Np63 and beta-catenin are frequently coexpressed and accumulated in oesophageal SCC, but not in HCC. These results suggest that activation of the b-catenin pathway may contribute to overexpression of Delta Np63 during tumour progression, in a cell type-specific manner. Oncogene (2011) 30, 4656-4665; doi:10.1038/onc.2011.171; published online 6 June 2011	[de Fromentel, C. Caron] CNRS5286, UMR INSERM U1052, Ctr Rech Cancerol Lyon, F-69008 Lyon, France; [Ruptier, C.; De Gasperis, A.; Ansieau, S.; Granjon, A.; Lafosse, I.; Tribollet, V.; Voeltzel, T.; Scoazec, J-Y; Maguer-Satta, V.; Puisieux, A.; de Fromentel, C. Caron] Univ Lyon, Lyon, France; [Ruptier, C.; De Gasperis, A.; Ansieau, S.; Granjon, A.; Lafosse, I.; Tribollet, V.; Voeltzel, T.; Scoazec, J-Y; Maguer-Satta, V.; Puisieux, A.; de Fromentel, C. Caron] Ctr Rech Cancerol Lyon, INSERM U1052, Lyon, France; [Taniere, P.; Shi, H.; Petitjean, A.; Taranchon-Clermont, E.; Hainaut, P.] Int Agcy Res Canc, F-69372 Lyon, France; [Scoazec, J-Y] Hop Edouard Herriot, Hosp Civils Lyon, Serv Cent Anat & Cytol Pathol, Lyon, France; [Puisieux, A.] Ctr Leon Berard, F-69373 Lyon, France; [Puisieux, A.] Inst Univ France, Paris, France; [Cavard, C.] Univ Paris 05, Inst Cochin, Dept Endocrinol Metab & Canc, CNRS UMR 8104, Paris, France; [Cavard, C.] INSERM U567, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; World Health Organization; International Agency for Research on Cancer (IARC); CHU Lyon; UNICANCER; Centre Leon Berard; Institut Universitaire de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	de Fromentel, CC (corresponding author), CNRS5286, UMR INSERM U1052, Ctr Rech Cancerol Lyon, 151 Cours Albert Thomas, F-69008 Lyon, France.	carondef@lyon.fnclcc.fr	Hainaut, Pierre/B-6018-2012; Ansieau, Stephane/I-6195-2016; Maguer-Satta, Veronique/U-8857-2019; de Fromentel, Claude Caron/Y-9715-2019	Hainaut, Pierre/0000-0002-1303-1610; Maguer-Satta, Veronique/0000-0002-1556-068X; de Fromentel, Claude Caron/0000-0001-7566-3958; PUISIEUX, Alain/0000-0002-9938-3798; ANSIEAU, Stephane/0000-0003-0989-2108	INSERM; Association pour la Recherche contre le Cancer [3117]; French Ligue Nationale Contre le Cancer; French Ministere de l'Enseignement et de la Recherche; International Agency for Research on Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); French Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); French Ministere de l'Enseignement et de la Recherche; International Agency for Research on Cancer	We thank Drs W Dinjens (University Medical Center, Rotterdam, The Netherlands) and A Costanzo (University of Rome, Italy) for the generous gift of TE-10 cells and pGL3-P2 plasmid, respectively; Drs J Zucmann-Rossi (INSERM U674, Paris, France) and B Terris (Institut Cochin, Paris, France) for the analysis of Delta Np63 expression in HCC samples; Dr B Abedi for her help for IHC experiments; Dr G Martel-Planche and A Masquelet and Ms A Durand and A Charnay for technical assistance; Drs S Sentis, G Hinkal and S and D Cox for critical reading of the manuscript. This project was supported by INSERM and the Association pour la Recherche contre le Cancer (grant number 3117). CR and HS were funded by the French Ligue Nationale Contre le Cancer, AP by the French Ministere de l'Enseignement et de la Recherche, and ET, PT, and VT by the International Agency for Research on Cancer.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ai D, 2007, MOL CELL BIOL, V27, P5765, DOI 10.1128/MCB.01848-06; Ambler CA, 2009, J PATHOL, V217, P206, DOI 10.1002/path.2468; Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Cavard C, 2006, ONCOGENE, V25, P599, DOI 10.1038/sj.onc.1208860; Cavard C, 2008, FUTURE ONCOL, V4, P647, DOI 10.2217/14796694.4.5.647; Chu WK, 2008, J BIOL CHEM, V283, P7328, DOI 10.1074/jbc.M800183200; Chu WK, 2006, BIOCHEM BIOPH RES CO, V342, P1356, DOI 10.1016/j.bbrc.2006.02.111; Drewelus I, 2010, CELL CYCLE, V9, P580, DOI 10.4161/cc.9.3.10593; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kudo Junjo, 2007, World J Surg Oncol, V5, P21, DOI 10.1186/1477-7819-5-21; Lanza M, 2006, CELL CYCLE, V5, P1996, DOI 10.4161/cc.5.17.3188; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Moll UM, 2004, MOL CANCER RES, V2, P371; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Petitjean A, 2008, CARCINOGENESIS, V29, P273, DOI 10.1093/carcin/bgm258; Petitjean A, 2005, ONCOGENE, V24, P512, DOI 10.1038/sj.onc.1208215; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2006, J INVEST DERMATOL, V126, P1469, DOI 10.1038/sj.jid.5700297; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Taniere P, 2001, BRIT J CANCER, V85, P721, DOI 10.1054/bjoc.2001.1990; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Wu GJ, 2005, CANCER RES, V65, P758; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Zucchi I, 2008, P NATL ACAD SCI USA, V105, P16940, DOI 10.1073/pnas.0808978105	45	22	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4656	4665		10.1038/onc.2011.171	http://dx.doi.org/10.1038/onc.2011.171			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21643019				2022-12-28	WOS:000297252100005
J	Datta, J; Smith, A; Lang, JC; Islam, M; Dutt, D; Teknos, TN; Pan, Q				Datta, J.; Smith, A.; Lang, J. C.; Islam, M.; Dutt, D.; Teknos, T. N.; Pan, Q.			microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase C epsilon	ONCOGENE			English	Article						head and neck cancer; protein kinase C; microRNA; miR-107	EXPRESSION; APOPTOSIS; INVASION	Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide with about 600 000 new cases diagnosed each year. Understanding the molecular pathways that lead to HNSCC is crucial to identify new targets for anti-cancer drug development. Protein kinase C epsilon (PKC epsilon) is elevated in HNSCC and regulates the activation of Akt, Stat3 and Rho GTPases. To date, the molecular mechanism of PKC epsilon dysregulation in HNSCC remains to be elucidated. In silico analysis identified three putative microRNA-107 (miR-107) binding sites in the 3'-untranslated region (UTR) of PKC epsilon. An inverse relationship was revealed between miR-107 and PKCe in HNSCC cell lines. Delivery of miR-107 reduced PKCe levels in SCC15, SCC25 and CAL27, three HNSCC cell lines with high PKC epsilon and low miR-107. The activity of a luciferase reporter construct containing the 3'-UTR of PKCe was downregulated by miR-107 and mutations in the three cognate miR-107 binding sites completely ablated the regulation by miR-107. Treatment with miR-107 significantly blocked cell proliferation, DNA replication, colony formation and invasion in SCC25 and CAL27 cells. Ectopic expression of miR-resistant PKCe was sufficient to partially rescue the loss-of-function phenotype in miR-107-overexpressing SCC25 cells. Tumor growth in nude mice was retarded by 93 +/- 7% in CAL27/miR-107 cells compared with CAL27/miR-control cells. Last, human primary HNSCC tumors with elevated PKCe had reduced miR-107 expression. Our results demonstrate that PKCe is directly regulated by miR-107 and, moreover, suggest that miR-107 may be a potential anti-cancer therapeutic for HNSCC. Oncogene (2012) 31, 4045-4053; doi:10.1038/onc.2011.565; published online 12 December 2011	[Datta, J.; Lang, J. C.; Islam, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA; [Datta, J.; Smith, A.; Lang, J. C.; Islam, M.; Dutt, D.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Datta, J.; Smith, A.; Lang, J. C.; Islam, M.; Dutt, D.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Dutt, D.] VIT Univ, Sch Biosci & Technol, Dept Biomed Genet, Vellore, Tamil Nadu, India	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Vellore Institute of Technology	Pan, Q (corresponding author), Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 442 Tzagournis Med Res,420 W 12th Ave, Columbus, OH 43210 USA.	Quintin.Pan@osumc.edu	Reever, Larson/H-9685-2019; Pan, Quintin/E-3808-2011	Reever, Larson/0000-0002-5692-4793; 	National Cancer Institute at the National Institutes of Health [R01CA135096]; American Cancer Society [RSG0821901]; Michelle Theado Memorial Grant; John Young Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA135096] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Michelle Theado Memorial Grant; John Young Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Cancer Institute at the National Institutes of Health (R01CA135096); American Cancer Society (RSG0821901); the Michelle Theado Memorial Grant and the John Young Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center.	Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Aziz MH, 2010, ONCOGENE, V29, P3100, DOI 10.1038/onc.2010.63; Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cohen EEW, 2009, CANCER RES, V69, P65, DOI 10.1158/0008-5472.CAN-08-0377; Cohen EEW, 2006, CANCER RES, V66, P6296, DOI 10.1158/0008-5472.CAN-05-3139; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de la Pena FA, 2011, J BIOL CHEM, V286, P20778, DOI 10.1074/jbc.M110.198069; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Feng L, 2012, MED ONCOL, V29, P856, DOI 10.1007/s12032-011-9823-1; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li XH, 2011, J CELL MOL MED, V15, P1887, DOI 10.1111/j.1582-4934.2010.01194.x; Liu XQ, 2009, CANCER LETT, V286, P217, DOI 10.1016/j.canlet.2009.05.030; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; MARTINEZGIMENO C, 1995, HEAD NECK-J SCI SPEC, V17, P516, DOI 10.1002/hed.2880170609; Nasser MW, 2008, J BIOL CHEM, V283, P33394, DOI 10.1074/jbc.M804788200; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107	29	61	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					4045	4053		10.1038/onc.2011.565	http://dx.doi.org/10.1038/onc.2011.565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158047	Green Accepted			2022-12-28	WOS:000308688800005
J	Paris, O; Ferraro, L; Grober, OMV; Ravo, M; De Filippo, MR; Giurato, G; Nassa, G; Tarallo, R; Cantarella, C; Rizzo, F; Di Benedetto, A; Mottolese, M; Benes, V; Ambrosino, C; Nola, E; Weisz, A				Paris, O.; Ferraro, L.; Grober, O. M. V.; Ravo, M.; De Filippo, M. R.; Giurato, G.; Nassa, G.; Tarallo, R.; Cantarella, C.; Rizzo, F.; Di Benedetto, A.; Mottolese, M.; Benes, V.; Ambrosino, C.; Nola, E.; Weisz, A.			Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer	ONCOGENE			English	Article						estrogen receptor beta; microRNA; breast cancer; hormones; gene transcription	CELLS; ALPHA; NUCLEAR; COMPLEX; SIGNATURE; MULTIPLE; NETWORK; TARGETS; PROTEIN; TUMORS	Estrogen effects on mammary epithelial and breast cancer (BC) cells are mediated by the nuclear receptors ER alpha and ER beta, transcription factors that display functional antagonism with each other, with ER beta acting as oncosuppressor and interfering with the effects of ER alpha on cell proliferation, tumor promotion and progression. Indeed, hormone-responsive, ER alpha + BC cells often lack ER beta, which when present associates with a less aggressive clinical phenotype of the disease. Recent evidences point to a significant role of microRNAs (miRNAs) in BC, where specific miRNA expression profiles associate with distinct clinical and biological phenotypes of the lesion. Considering the possibility that ER beta might influence BC cell behavior via miRNAs, we compared miRNome expression in ER beta + vs ER beta- hormone-responsive BC cells and found a widespread effect of this ER subtype on the expression pattern of these non-coding RNAs. More importantly, the expression pattern of 67 miRNAs, including 10 regulated by ER beta in BC cells, clearly distinguishes ER beta+, node-negative, from ER beta-, metastatic, mammary tumors. Molecular dissection of miRNA biogenesis revealed multiple mechanisms for direct regulation of this process by ER beta+ in BC cell nuclei. In particular, ER beta downregulates miR-30a by binding to two specific sites proximal to the gene and thereby inhibiting pri-miR synthesis. On the other hand, the receptor promotes miR-23b, -27b and 24-1 accumulation in the cell by binding in close proximity of the corresponding gene cluster and preventing in situ the inhibitory effects of ER alpha on pri-miR maturation by the p68/DDX5-Drosha microprocessor complex. These results indicate that cell autonomous regulation of miRNA expression is part of the mechanism of action of ER beta in BC cells and could contribute to establishment or maintenance of a less aggressive tumor phenotype mediated by this nuclear receptor.	[Ravo, M.; De Filippo, M. R.; Giurato, G.; Nassa, G.; Tarallo, R.; Cantarella, C.; Rizzo, F.; Weisz, A.] Univ Salerno, Lab Mol Med & Genom, I-84081 Baronissi, SA, Italy; [Paris, O.; Ferraro, L.; De Filippo, M. R.; Giurato, G.; Nola, E.; Weisz, A.] Univ Naples 2, Dept Gen Pathol, Naples, Italy; [Di Benedetto, A.; Mottolese, M.] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Benes, V.] European Mol Biol Lab, Genom Core Facil, Heidelberg, Germany; [Ambrosino, C.] Univ Sannio, Dept Biol & Environm Sci, Benevento, Italy; [Weisz, A.] Univ Salerno, SS Giovanni Dio & Ruggi Aragona Hosp, Div Mol Pathol & Med Genom, I-84100 Salerno, Italy	University of Salerno; Universita della Campania Vanvitelli; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; European Molecular Biology Laboratory (EMBL); University of Sannio; University of Salerno	Weisz, A (corresponding author), Univ Salerno, Lab Mol Med & Genom, Via Allende, I-84081 Baronissi, SA, Italy.	aweisz@unisa.it	Rizzo, Francesca/K-3057-2016; Giurato, Giorgio/K-3859-2018; ambrosino, concetta/AAB-3452-2019; Nassa, Giovanni/AAB-2059-2022; Weisz, Alessandro/A-1317-2014; Tarallo, Roberta/C-2600-2014	Rizzo, Francesca/0000-0003-1783-5015; Giurato, Giorgio/0000-0002-0538-8978; Weisz, Alessandro/0000-0003-0455-2083; Tarallo, Roberta/0000-0001-9668-3632; Di Benedetto, Anna/0000-0002-9853-8671; Benes, Vladimir/0000-0002-0352-2547; Ravo, Maria/0000-0003-1003-2922	Italian Association for Cancer Research [IG-8586, IG-8706]; European Union (CRESCENDO IP) [LSHM-CT2005-018652]; Italian Ministry for Education, University and Research [PRIN 2008CJ4SYW_004]; University of Salerno (Fondi FARB); Fondazione con il Sud [2009-PdP-22]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); European Union (CRESCENDO IP)(European Commission); Italian Ministry for Education, University and Research(Ministry of Education, Universities and Research (MIUR)); University of Salerno (Fondi FARB); Fondazione con il Sud	We thank Manuela Ferracin and Massimo Negrini for help with analysis of miRNA expression data from primary tumor samples and useful suggestions, and Luigi Cicatiello, Margherita Mutarelli and Maria Francesca Papa for technical assistance. Work supported by: Italian Association for Cancer Research (grants IG-8586 to AW and IG-8706 to MM), European Union (CRESCENDO IP, contract number LSHM-CT2005-018652), Italian Ministry for Education, University and Research (grant PRIN 2008CJ4SYW_004), University of Salerno (Fondi FARB 2011) and Fondazione con il Sud (grant 2009-PdP-22). CC, FR, GN, MR and RT are fellows of Fondazione con il Sud.	Ambrosino C, 2010, MOL CELL PROTEOMICS, V9, P1352, DOI 10.1074/mcp.M900519-MCP200; [Anonymous], 2003, WHO CLASSIFICATION T; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106; Chang EC, 2006, ENDOCRINOLOGY, V147, P4831, DOI 10.1210/en.2006-0563; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Cicatiello L, 2000, MOL CELL ENDOCRINOL, V165, P199, DOI 10.1016/S0303-7207(00)00243-4; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Fejes AP, 2008, BIOINFORMATICS, V24, P1729, DOI 10.1093/bioinformatics/btn305; Ferraro L, 2011, HORM CANC IN PRESS; Ferraro L, 2010, AM J PATHOL, V177, pS34; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Nakamura T, 2007, P NATL ACAD SCI USA, V104, P10980, DOI 10.1073/pnas.0704559104; Nassa G, 2011, PROTEOMICS, V11, P159, DOI 10.1002/pmic.201000344; Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710; Novelli F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2139; Okamura K, 2008, NAT STRUCT MOL BIOL, V15, P354, DOI 10.1038/nsmb.1409; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Ravo M, 2008, LAB INVEST, V88, P430, DOI 10.1038/labinvest.2008.11; Roger P, 2001, CANCER RES, V61, P2537; Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528; Sugiura H, 2007, JPN J CLIN ONCOL, V37, P820, DOI 10.1093/jjco/hym114; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yamagata K, 2009, MOL CELL, V36, P340, DOI 10.1016/j.molcel.2009.08.017; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028	43	76	78	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4196	4206		10.1038/onc.2011.583	http://dx.doi.org/10.1038/onc.2011.583			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22231442				2022-12-28	WOS:000308975800003
J	McDonnell, SRP; Hwang, SR; Basrur, V; Conlon, KP; Fermin, D; Wey, E; Murga-Zamalloa, C; Zeng, Z; Zu, Y; Elenitoba-Johnson, KSJ; Lim, MS				McDonnell, S. R. P.; Hwang, S. R.; Basrur, V.; Conlon, K. P.; Fermin, D.; Wey, E.; Murga-Zamalloa, C.; Zeng, Z.; Zu, Y.; Elenitoba-Johnson, K. S. J.; Lim, M. S.			NPM-ALK signals through glycogen synthase kinase 3 beta to promote oncogenesis	ONCOGENE			English	Article						NPM-ALK; GSK3; ALCL; oncogenesis	ANAPLASTIC LYMPHOMA KINASE; TYROSINE KINASE; APOPTOSIS; CELLS; PHOSPHORYLATION; INHIBITION; PROTEIN; CDC25A; INACTIVATION; CAL-101	Anaplastic large cell lymphoma (ALCL) is the most common type of pediatric peripheral T-cell lymphoma. In 70-80% of cases, the chromosomal aberration t(2;5)(p23;q35) results in the juxtaposition of anaplastic lymphoma kinase (ALK) with nucleophosmin (NPM) and the subsequent expression of the NPM-ALK fusion protein. NPM-ALK is a chimeric tyrosine kinase, which induces numerous signaling pathways that drive proliferation and abrogate apoptosis. However, the mechanisms that lead to activation of downstream growth regulatory molecules have not been completely elucidated. Using a mass spectrometry-based phosphoproteomic screen, we identified GSK3 beta as a signaling mediator of NPM-ALK. Using a selective inhibitor of ALK, we demonstrated that the tyrosine kinase activity of ALK regulates the serine-9 phosphorylation of GSK3 beta. Expression of NPM-ALK in 293T cells led to an increase of pS(9)-GSK3 beta (glycogen synthase kinase 3 beta) compared with kinase-defective K210R mutant NPM-ALK, but did not affect total GSK3 beta levels. Phosphorylation of pS(9)-GSK3 beta by NPM-ALK was mediated by the PI3K/AKT signaling pathway. ALK inhibition resulted in degradation of GSK3 beta substrates Mcl-1 and CDC25A, which was recovered upon chemical inhibition of the proteasome (MG132). Furthermore, the degradation of Mcl-1 was recoverable with inhibition of GSK3 beta. ALK inhibition also resulted in decreased cell viability, which was rescued by GSK3 beta inhibition. Furthermore, stable knockdown of GSK3 beta conferred resistance to the growth inhibitory effects of ALK inhibition using viability and colony formation assays. pS(9)-GSK3 beta and CDC25A were selectively expressed in neoplastic cells of ALK + ALCL tissue biopsies, and showed a significant correlation (P<0.001). Conversely, ALK-ALCL tissue biopsies did not show significant correlation of pS(9)-GSK3 beta and CDC25A expression (P<0.2). Our results demonstrate that NPM-ALK regulates the phosphorylation of S-9-GSK3 beta by PI3K/AKT. The subsequent inhibition of GSK3 beta activity results in accumulation of CDC25A and Mcl-1, which confers the advantage of growth and protection from apoptosis. These findings provide support for the role of GSK3 beta as a mediator of NPM-ALK oncogenesis. Oncogene (2012) 31, 3733-3740; doi:10.1038/onc.2011.542; published online 19 December 2011	[McDonnell, S. R. P.; Hwang, S. R.; Basrur, V.; Conlon, K. P.; Fermin, D.; Wey, E.; Murga-Zamalloa, C.; Elenitoba-Johnson, K. S. J.; Lim, M. S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Zeng, Z.; Zu, Y.] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA	University of Michigan System; University of Michigan; The Methodist Hospital System; The Methodist Hospital - Houston	Lim, MS (corresponding author), Biomed Sci Res Bldg,Room 2039,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	meganlim@med.umich.edu	Murga-Zamalloa, Carlos/AAX-9387-2021	Murga-Zamalloa, Carlos/0000-0002-2238-5066; Hwang, Steven/0000-0002-6536-1291; Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867	NIH [5R01CA140806-02, R01DE119249, R01CA136905]; NATIONAL CANCER INSTITUTE [R01CA136905, R01CA140806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by funding from the NIH (5R01CA140806-02) awarded to MS Lim, MD/PhD and (R01DE119249 and R01CA136905) KSJ Elenitoba-Johnson, MD. Mangeng Cheng, PhD of Cephalon, Inc provided the small molecule ALK inhibitor.	Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Boccalatte FE, 2009, BLOOD, V113, P2776, DOI 10.1182/blood-2008-06-161018; BOSTOCK CJ, 1971, EXP CELL RES, V68, P163, DOI 10.1016/0014-4827(71)90599-4; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Fernandez-Vidal A, 2009, CELL CYCLE, V8, P1373, DOI 10.4161/cc.8.9.8302; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Herman SEM, 2010, BLOOD, V116, P2078, DOI 10.1182/blood-2010-02-271171; Ito M, 2010, CANCER GENE THER, V17, P633, DOI 10.1038/cgt.2010.20; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Lannutti BJ, 2011, BLOOD, V117, P591, DOI 10.1182/blood-2010-03-275305; Lim MS, 2009, BLOOD, V114, P1585, DOI 10.1182/blood-2009-02-204735; Marzec M, 2007, ONCOGENE, V26, P813, DOI 10.1038/sj.onc.1209843; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Ott GR, 2010, ACS MED CHEM LETT, V1, P493, DOI 10.1021/ml100158s; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Ruchatz H, 2003, EXP HEMATOL, V31, P309, DOI 10.1016/S0301-472X(03)00007-9; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Slupianek A, 2001, CANCER RES, V61, P2194; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhao Y, 2007, MOL CELL BIOL, V27, P4328, DOI 10.1128/MCB.00153-07	32	26	27	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	32					3733	3740		10.1038/onc.2011.542	http://dx.doi.org/10.1038/onc.2011.542			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22179823	Green Accepted			2022-12-28	WOS:000307653800007
J	Muehlich, S; Hampl, V; Khalid, S; Singer, S; Frank, N; Breuhahn, K; Gudermann, T; Prywes, R				Muehlich, S.; Hampl, V.; Khalid, S.; Singer, S.; Frank, N.; Breuhahn, K.; Gudermann, T.; Prywes, R.			The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1	ONCOGENE			English	Article						DLC1; MKL1; MKL2; MRTF; Rho; SRF	SERUM RESPONSE FACTOR; TISSUE GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; HUMAN HEPATOCARCINOGENESIS; ACTIN CYTOSKELETON; CELL-MIGRATION; TARGET GENES; METASTASIS; SRF; PROGRESSION	Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor whose allele is lost in 50% of liver, breast, lung and 70% of colon cancers. Here, we show that the transcriptional coactivators Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are constitutively localized to the nucleus in hepatocellular and mammary carcinoma cells that lack DLC1. Moreover, DLC1 loss and MKL1 nuclear localization correlate in primary human hepatocellular carcinoma. Nuclear accumulation of MKL1 in DLC1 deficient cancer cells is accomplished by activation of the RhoA/actin signaling pathway and concomitant impairment of MKL1 phosphorylation, which results in constitutive activation of MKL1/2 target genes. We provide evidence that MKL1/2 mediates cancerous transformation in DLC1-deficient hepatocellular and mammary carcinoma cells. Depletion of MKL1/2 suppresses cell migration, cell proliferation and anchorage-independent cell growth induced by DLC1 loss. Oncogene (2012) 31, 3913-3923; doi:10.1038/onc.2011.560; published online 5 December 2011	[Muehlich, S.; Hampl, V.; Khalid, S.; Frank, N.; Gudermann, T.] Univ Munich, Walther Straub Inst Pharmacol & Toxicol, D-80336 Munich, Germany; [Singer, S.; Breuhahn, K.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Prywes, R.] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Munich; Ruprecht Karls University Heidelberg; Columbia University	Muehlich, S (corresponding author), Univ Munich, Walther Straub Inst Pharmacol & Toxicol, Goethestr 33, D-80336 Munich, Germany.	susanne.muehlich@lrz.uni-muenchen.de		Breuhahn, Kai/0000-0002-2462-1229	German Research Foundation (DFG) [MU 2737/2-1]; National Cancer Institute [CA050329]; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	German Research Foundation (DFG)(German Research Foundation (DFG)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Scott Lowe for the DLC1 knockdown hepatocytes and Dr Monilola Olayioye for DLC1 vectors. Breast carcinoma cell lines were kindly provided by Dr Ramon Parsons. This work was funded by grant MU 2737/2-1 from the German Research Foundation (DFG) to SM and grant CA050329 from the National Cancer Institute to RP.	Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hanna M, 2009, J BIOL CHEM, V284, P23125, DOI 10.1074/jbc.M109.019059; Heering J, 2009, EXP CELL RES, V315, P2505, DOI 10.1016/j.yexcr.2009.05.022; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Knoll B, 2010, BIOL CHEM, V391, P591, DOI 10.1515/BC.2010.061; Knoll B, 2006, NAT NEUROSCI, V9, P195, DOI 10.1038/nn1627; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Lee SM, 2010, J BIOL CHEM, V285, P22036, DOI 10.1074/jbc.M110.108878; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mazzocca A, 2010, HEPATOLOGY, V51, P523, DOI 10.1002/hep.23285; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Morin P, 2009, EUR J CELL BIOL, V88, P495, DOI 10.1016/j.ejcb.2009.04.005; Muehlich S, 2008, MOL CELL BIOL, V28, P6302, DOI 10.1128/MCB.00427-08; Muehlich S, 2007, AM J PHYSIOL-CELL PH, V292, pC1732, DOI 10.1152/ajpcell.00552.2006; Pipes GCT, 2006, GENE DEV, V20, P1545, DOI 10.1101/gad.1428006; Porter KE, 2004, CARDIOVASC RES, V61, P745, DOI 10.1016/j.cardiores.2003.11.032; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Singer S, 2007, HEPATOLOGY, V46, P759, DOI 10.1002/hep.21736; Truong H, 2009, CELL ADHES MIGR, V3, P179, DOI 10.4161/cam.3.2.8036; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xie D, 2001, CANCER RES, V61, P8917; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yuan BZ, 1998, CANCER RES, V58, P2196	37	38	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3913	3923		10.1038/onc.2011.560	http://dx.doi.org/10.1038/onc.2011.560			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22139079				2022-12-28	WOS:000308342800001
J	Rzymski, T; Petry, A; Kracun, D; Riess, F; Pike, L; Harris, AL; Gorlach, A				Rzymski, T.; Petry, A.; Kracun, D.; Riess, F.; Pike, L.; Harris, A. L.; Goerlach, A.			The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress	ONCOGENE			English	Article						ADAM17/TACE; hypoxia; ER stress; unfolded protein response; TNF alpha receptor; cancer	TUMOR-NECROSIS-FACTOR; ENDOPLASMIC-RETICULUM STRESS; ALPHA-CONVERTING-ENZYME; NF-KAPPA-B; UP-REGULATED EXPRESSION; ISOLATED LIMB PERFUSION; SOLUBLE RECEPTORS; TNF-ALPHA; SIGNALING PATHWAYS; PROGNOSTIC-FACTORS	The family of ADAM (a disintegrin and metalloproteinase) proteins has been implicated in tumor initiation and progression. ADAM17/tumor necrosis factor-alpha (TNF alpha)-converting enzyme (TACE) has been initially recognized to release TNF alpha as well as its receptors (TNFRs) from the membrane. ADAM17, TNF alpha and TNFR have been found upregulated in cancer patients, although the underlying mechanisms remain largely unknown. As hypoxia is a hallmark of cancer that can lead to severe stress conditions accumulating in endoplasmic reticulum (ER) stress and the unfolded protein response (UPR), we investigated the role of these stress conditions in the regulation of ADAM17 and release of TNFR1. We found that severe hypoxia induced ADAM17 expression and activity. Although hypoxia-inducible factor 1 alpha (HIF1 alpha) was important to maintain basal ADAM17 mRNA levels during moderate hypoxia, it was not sufficient to induce ADAM17 levels under severe hypoxia. Instead, we found that ADAM17 induction by severe hypoxia can be mimicked by ER stressors such as Thapsigargin and occurs as a consequence of the activation of the PERK/eIF2 alpha/ATF4 and activating transcription factor 6 (ATF6) arms of UPR in several tumor cell lines. ADAM17 expression was also increased in xenografts displaying ER stress because of treatment with the vascular endothelial growth factor (VEGF) inhibitory antibody Bevacizumab. Additionally, severe hypoxia and ER stress activated ADAM17 and ectodomain shedding of TNFR1 involving mitogen-activated protein (MAP) kinases and reactive oxygen species (ROS). Collectively, these results show that ADAM17 is a novel UPR-regulated gene in response to severe hypoxia and ER stress, which is actively involved in the release of TNFR1 under these conditions. These data provide a novel link between severe hypoxic stress conditions and inflammation in the tumor environment. Oncogene (2012) 31, 3621-3634; doi:10.1038/onc.2011.522; published online 21 November 2011	[Rzymski, T.; Petry, A.; Kracun, D.; Riess, F.; Goerlach, A.] Tech Univ Munich, German Heart Ctr Munich, D-80636 Munich, Bavaria, Germany; [Pike, L.; Harris, A. L.] John Radcliffe Hosp, Weatherall Inst Mol Med, Univ Dept Med Oncol, Mol Oncol Labs, Oxford OX3 9DU, England	German Heart Centre Munich; Technical University of Munich; University of Oxford	Gorlach, A (corresponding author), Tech Univ Munich, German Heart Ctr Munich, Lazarettstr 36, D-80636 Munich, Bavaria, Germany.	goerlach@dhm.mhn.de	Gorlach, Agnes/B-3494-2013; Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409	EU 7th FP Metoxia [222471]; Fondation Leducq; DFG [GO709/4-4]	EU 7th FP Metoxia; Fondation Leducq(Leducq Foundation); DFG(German Research Foundation (DFG))	We thank Merel Gijsen, Francesca Buffa and Ji-Liang Li for help with tumor sample preparation, bioinformatics and xenograft work. This work was supported by EU 7th FP 222471 Metoxia, DFG GO709/4-4 and Fondation Leducq.	ADERKA D, 1991, CANCER RES, V51, P5602; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Arsenault D, 2012, J CELL PHYSIOL, V227, P789, DOI 10.1002/jcp.22792; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06; Blanchot-Jossic F, 2005, J PATHOL, V207, P156, DOI 10.1002/path.1814; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Burton Elizabeth R, 2009, J Biol, V8, P85, DOI 10.1186/jbiol189; Charbonneau M, 2007, J BIOL CHEM, V282, P33714, DOI 10.1074/jbc.M704041200; Chen YJ, 2005, MOL CANCER RES, V3, P669, DOI 10.1158/1541-7786.MCR-05-0181; Coleman ML, 2007, ESSAYS BIOCHEM, V43, P1; Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200; Dai RY, 2009, INT J ONCOL, V34, P1749, DOI 10.3892/ijo_00000306; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Diebold I, 2010, MOL BIOL CELL, V21, P2087, DOI 10.1091/mbc.E09-12-1003; DIEZRUIZ A, 1995, EUR J HAEMATOL, V54, P1, DOI 10.1111/j.1600-0609.1995.tb01618.x; Eggermont AMM, 2003, LANCET ONCOL, V4, P429, DOI 10.1016/S1470-2045(03)01141-0; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FEINBERG B, 1988, J CLIN ONCOL, V6, P1328, DOI 10.1200/JCO.1988.6.8.1328; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Fraker DL, 1996, J CLIN ONCOL, V14, P479, DOI 10.1200/JCO.1996.14.2.479; Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Kornfeld JW, 2011, BRIT J CANCER, V104, P138, DOI 10.1038/sj.bjc.6606017; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Koumenis C, 2006, MOL CANCER RES, V4, P423, DOI 10.1158/1541-7786.MCR-06-0150; LANGKOPF F, 1994, LANCET, V344, P57, DOI 10.1016/S0140-6736(94)91078-2; Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1; McGowan PM, 2007, CLIN CANCER RES, V13, P2335, DOI 10.1158/1078-0432.CCR-06-2092; McMahon S, 2005, J BIOL CHEM, V280, P6561, DOI 10.1074/jbc.M413248200; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Mujcic H, 2009, RADIOTHER ONCOL, V92, P450, DOI 10.1016/j.radonc.2009.08.017; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Myers TJ, 2009, MOL BIOL CELL, V20, P5236, DOI 10.1091/mbc.E08-12-1256; Nakagawa M, 2009, CANCER SCI, V100, P654, DOI 10.1111/j.1349-7006.2009.01089.x; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Peters LR, 2011, J IMMUNOL, V187, P919, DOI 10.4049/jimmunol.1100690; REIBNEGGER G, 1994, LANCET, V344, P681, DOI 10.1016/S0140-6736(94)92115-6; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rzymski T, 2008, ONCOGENE, V27, P4532, DOI 10.1038/onc.2008.100; Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191; Rzymski T, 2007, CLIN CANCER RES, V13, P2537, DOI 10.1158/1078-0432.CCR-06-2126; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Srour N, 2003, FEBS LETT, V554, P275, DOI 10.1016/S0014-5793(03)01159-1; Szalad A, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-129; Szlosarek PW, 2003, LANCET ONCOL, V4, P565, DOI 10.1016/S1470-2045(03)01196-3; Tanaka Y, 2005, CLIN CANCER RES, V11, P4783, DOI 10.1158/1078-0432.CCR-04-1426; Vahdat AM, 2010, LEUKEMIA, V24, P51, DOI 10.1038/leu.2009.230; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Viac J, 1996, EUR J CANCER, V32A, P447, DOI 10.1016/0959-8049(95)00541-2; Waetzig GH, 2004, FASEB J, V18, P91, DOI 10.1096/fj.04-2073fje; Willems SH, 2010, BIOCHEM J, V428, P439, DOI 10.1042/BJ20100179; Xu PL, 2010, MOL CELL, V37, P551, DOI 10.1016/j.molcel.2010.01.034; Xue X, 2005, J BIOL CHEM, V280, P33917, DOI 10.1074/jbc.M505818200; Yoshimura T, 2002, J INFECT DIS, V185, P332, DOI 10.1086/338191; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhang ZL, 2001, FASEB J, V15, P303; Zheng X, 2009, CANCER BIOL THER, V8, P1045, DOI 10.4161/cbt.8.11.8539	83	54	56	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	31					3621	3634		10.1038/onc.2011.522	http://dx.doi.org/10.1038/onc.2011.522			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22105359				2022-12-28	WOS:000307245600005
J	Astle, MV; Hannan, KM; Ng, PY; Lee, RS; George, AJ; Hsu, AK; Haupt, Y; Hannan, RD; Pearson, RB				Astle, M. V.; Hannan, K. M.; Ng, P. Y.; Lee, R. S.; George, A. J.; Hsu, A. K.; Haupt, Y.; Hannan, R. D.; Pearson, R. B.			AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy	ONCOGENE			English	Article						PI3K; AKT; stress; senescence; p53; mTOR	ONCOGENE-INDUCED SENESCENCE; HUMAN-DIPLOID FIBROBLASTS; HEMATOPOIETIC STEM-CELLS; RAS-INDUCED SENESCENCE; RIBOSOMAL-PROTEIN L11; CELLULAR SENESCENCE; HUMAN CANCER; PREMATURE SENESCENCE; TRANSLATIONAL CONTROL; SIGNALING PATHWAY	The phosphatidylinositol 3-kinase (PI3K)/AKT and RAS oncogenic signalling modules are frequently mutated in sporadic human cancer. Although each of these pathways has been shown to play critical roles in driving tumour growth and proliferation, their activation in normal human cells can also promote cell senescence. Although the mechanisms mediating RAS-induced senescence have been well characterised, those controlling PI3K/AKT-induced senescence are poorly understood. Here we show that PI3K/AKT pathway activation in response to phosphatase and tensin homolog (PTEN) knockdown, mutant PI3K, catalytic, alpha polypeptide (PIK3CA) or activated AKT expression, promotes accumulation of p53 and p21, increases cell size and induces senescence-associated beta-galactosidase activity. We demonstrate that AKT-induced senescence is p53-dependent and is characterised by mTORC1-dependent regulation of p53 translation and stabilisation of p53 protein following nucleolar localisation and inactivation of MDM2. The underlying mechanisms of RAS and AKT-induced senescence appear to be distinct, demonstrating that different mediators of senescence may be deregulated during transformation by specific oncogenes. Unlike RAS, AKT promotes rapid proliferative arrest in the absence of a hyperproliferative phase or DNA damage, indicating that inactivation of the senescence response is critical at the early stages of PI3K/AKT-driven tumourigenesis. Furthermore, our data imply that chronic activation of AKT signalling provides selective pressure for the loss of p53 function, consistent with observations that PTEN or PIK3CA mutations are significantly associated with p53 mutation in a number of human tumour types. Importantly, the demonstration that mTORC1 is an essential mediator of AKT-induced senescence raises the possibility that targeting mTORC1 in tumours with activated PI3K/AKT signalling may exert unexpected detrimental effects due to inactivation of a senescence brake on potential cancer-initiating cells. Oncogene (2012) 31, 1949-1962; doi:10.1038/onc.2011.394; published online 12 September 2011	[Pearson, R. B.] Peter MacCallum Canc Ctr, Prot Chem Lab, Growth Control & Differentiat Program, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; [George, A. J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [George, A. J.; Haupt, Y.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Hsu, A. K.] Peter MacCallum Canc Ctr, Hematol Immunol Translat Res Lab, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; [Hannan, R. D.; Pearson, R. B.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Haupt, Y.; Hannan, R. D.; Pearson, R. B.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; University of Queensland; University of Melbourne; Peter Maccallum Cancer Center; Monash University; University of Melbourne	Pearson, RB (corresponding author), Peter MacCallum Canc Ctr, Prot Chem Lab, Growth Control & Differentiat Program, Trescowthick Res Labs, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	rick.pearson@petermac.org	Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090; Haupt, Ygal/0000-0001-5925-0096; George, Amee/0000-0002-0265-4476; Hannan, Ross/0000-0002-2166-4493; Hannan, Katherine/0000-0003-4186-8167	National Health and Medical Research Council (NHMRC) of Australia [166908, 251688, 509087, 400116]; Cancer Council Victoria	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	We acknowledge the Victorian Centre for Functional Genomics for the use of equipment and advice. This work was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia to RDH (NHMRC Nos. 166908 and 251688) and to RBP (NHMRC Nos. 509087 and 400116) and from Cancer Council Victoria to RBP. RDH and RBP are NHMRC Senior Research Fellows. We thank Professor Stephen Jane and Loretta Cerruti for assistance with retrovirus production.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Andjelkovic T, 2011, TRANSL RES, V157, P19, DOI 10.1016/j.trsl.2010.09.004; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bellodi C, 2010, EMBO J, V29, P1865, DOI 10.1038/emboj.2010.83; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082; Brachmann S, 2009, CURR OPIN CELL BIOL, V21, P194, DOI 10.1016/j.ceb.2008.12.011; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5; Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Cristiano BE, 2006, CANCER RES, V66, P11718, DOI 10.1158/0008-5472.CAN-06-1968; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003; Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannan KM, 2011, IUBMB LIFE, V63, P79, DOI 10.1002/iub.428; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Korotchkina LG, 2010, AGING-US, V2, P344, DOI 10.18632/aging.100160; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900; Leontieva OV, 2010, AGING, V31, P31; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Nardella C, 2011, NAT REV CANCER, V11, P503, DOI 10.1038/nrc3057; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oki E, 2005, CANCER LETT, V227, P33, DOI 10.1016/j.canlet.2004.12.006; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Solomon B, 2009, J THORAC ONCOL, V4, P787, DOI 10.1097/JTO.0b013e3181a74dba; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Xu Z, 2011, J BIOL CHEM, V286, P21401, DOI 10.1074/jbc.M110.198630; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	95	165	172	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	15					1949	1962		10.1038/onc.2011.394	http://dx.doi.org/10.1038/onc.2011.394			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21909130	Green Published, hybrid			2022-12-28	WOS:000302809900007
J	Chen, Y; Yang, D; Li, S; Gao, Y; Jiang, R; Deng, L; Frankel, FR; Sun, B				Chen, Y.; Yang, D.; Li, S.; Gao, Y.; Jiang, R.; Deng, L.; Frankel, F. R.; Sun, B.			Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma	ONCOGENE			English	Article						Listeria monocytogenes; hepatocellular carcinoma; immunotherapy; epitope; cancer vaccines	T-CELL RESPONSES; ALPHA-FETOPROTEIN; IMMUNE-RESPONSES; CANCER-IMMUNOTHERAPY; ANTITUMOR IMMUNITY; DENDRITIC CELLS; TRANSGENIC MICE; PEPTIDE ELISA; IN-VIVO; PROTEIN	Live attenuated Listeria monocytogenes (LM) is a promising bacterial vector able to induce a T-cell response to tumor-associated antigens and demonstrates great potential for use in vaccine development. A novel recombinant LM-based vaccine (Lmdd (LM Delta dal Delta dat)-MPFG (multiple peptide fusing genes)) was developed with the ability to express and secrete hepatocellular carcinoma (HCC)-related tumor-associated antigens fragments due to the insertion of hepatitis B virus (HBV)-X protein (HBx)-derived epitopes HBx(52-60) and HBx(140-148), the universal T-helper epitope, alpha-fetoprotein (AFP) epitope AFP(158-166), and melanoma antigen gene (MAGE)-3(271-279) into the HBV core protein. Following immunization with the Lmdd-MPFG vaccine, macrophages exhibited uptake of the bacteria; the vaccine was then nearly cleared 3 days after the first administration. It disappeared even more quickly following subsequent vaccinations. However, recombinant Lmdd-MPFG allowed for the full development of an antitumor response towards the human leukocyte antigen (HLA)-A0201 epitopes of MPFG. Each epitope stimulated an augmented T-cell proliferation and enhanced the supernatant level of interferon (IFN)-gamma in vitro. In addition, IFN-gamma-producing CD8(+) T cells as well as in vivo cytolytic activity were significantly increased in HLA-A2 transgenic mice. Additionally, the Lmdd-MPFG developed a strong antitumor response, as indicated by the significant resistance of immunized mice to MPFG-positive Hepa1-6 cell challenge in both a prophylactic and therapeutic setting. Tumor regression was accompanied by an enhanced cytotoxic T lymphocyte response and a decrease of regulatory T cells in the tumor. Collectively, these results suggest that utilizing attenuated LM as a vaccine vector, able to carry the MPFG gene, presents a potentially feasible strategy for prevention of HCC. Oncogene (2012) 31, 2140-2152; doi:10.1038/onc.2011.395; published online 19 September 2011	[Chen, Y.; Yang, D.; Gao, Y.; Jiang, R.; Deng, L.; Sun, B.] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China; [Li, S.; Frankel, F. R.] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	Nanjing Medical University; University of Pennsylvania	Sun, B (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, 300 Guangzhou Rd, Nanjing, Jiangsu, Peoples R China.	sunbc@njmu.edu.cn	Jiang, Runqiu/T-8844-2018	Jiang, Runqiu/0000-0003-2720-1366	National Basic Research Program of China [2012CB910800]; National Natural Science Foundation [81072029, 30901750]; Major Research Plan of the National Natural Science Foundation [91029721]; New Century Excellent Talents in University, Ministry of Education [NCET-09-0160]; Natural Science Foundation of Jiangsu Province [BK201 0532]; Ministry of Health, China [W201001]; National Institutes of Health [R21-AI-071774]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI071774] Funding Source: NIH RePORTER	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Major Research Plan of the National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); New Century Excellent Talents in University, Ministry of Education(Program for New Century Excellent Talents in University (NCET)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Ministry of Health, China; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from National Basic Research Program of China (2012CB910800 to BS), the National Natural Science Foundation (81072029 to BS and 30901750 to YC), Major Research Plan of the National Natural Science Foundation (91029721 to BS), the New Century Excellent Talents in University, Ministry of Education (NCET-09-0160 to BS), Natural Science Foundation of Jiangsu Province (BK201 0532 to YC), Ministry of Health, China (W201001 to LD), and National Institutes of Health grant (R21-AI-071774 to FRF).	Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; Badvie S, 2000, POSTGRAD MED J, V76, P4, DOI 10.1136/pmj.76.891.4; Bai X, 2011, CARCINOGENESIS, V32, P63, DOI 10.1093/carcin/bgq195; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; Blasco H, 2007, J IMMUNOL METHODS, V325, P127, DOI 10.1016/j.jim.2007.06.011; Butterfield LH, 2001, J IMMUNOL, V166, P5300, DOI 10.4049/jimmunol.166.8.5300; Butterfield LH, 1999, CANCER RES, V59, P3134; Chen Y, 2009, CELL MOL IMMUNOL, V6, P269, DOI 10.1038/cmi.2009.36; Cheng ZQ, 1997, HEPATOLOGY, V26, P1351; Ding FX, 2009, HEPATOLOGY, V49, P1492, DOI 10.1002/hep.22816; Duvoux C, 1998, ANN CHIR, V52, P511; FRANKEL FR, 1995, J IMMUNOL, V155, P4775; Friedman RS, 2000, J VIROL, V74, P9987, DOI 10.1128/JVI.74.21.9987-9993.2000; Furukawa S, 2004, IMMUNOBIOLOGY, V209, P551, DOI 10.1016/j.imbio.2004.07.001; Gedde MM, 2000, INFECT IMMUN, V68, P999, DOI 10.1128/IAI.68.2.999-1003.2000; Greten TF, 2010, J IMMUNOTHER, V33, P211, DOI 10.1097/CJI.0b013e3181bb499f; Hussain SA, 2001, ANN ONCOL, V12, P161, DOI 10.1023/A:1008370324827; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kong J, 2007, ONCOL REP, V18, P279; Kursar M, 2002, J IMMUNOL, V168, P6382, DOI 10.4049/jimmunol.168.12.6382; Li ZX, 2008, J IMMUNOL, V180, P2504, DOI 10.4049/jimmunol.180.4.2504; Lin SM, 2005, GUT, V54, P1151, DOI 10.1136/gut.2004.045203; MACKANESS GB, 1969, J EXP MED, V129, P973, DOI 10.1084/jem.129.5.973; Menetrier-Caux C, 2009, CANCER RES, V69, P7895, DOI 10.1158/0008-5472.CAN-09-1642; Nieters A, 2005, CANCER, V103, P740, DOI 10.1002/cncr.20842; Olkhanud PB, 2009, CANCER RES, V69, P5996, DOI 10.1158/0008-5472.CAN-08-4619; Pamer EG, 2004, NAT REV IMMUNOL, V4, P812, DOI 10.1038/nri1461; Pamer EG, 1997, IMMUNOL REV, V158, P129, DOI 10.1111/j.1600-065X.1997.tb00999.x; Peters C, 2003, VACCINE, V21, P1187, DOI 10.1016/S0264-410X(02)00554-6; Ritter M, 2004, J HEPATOL, V41, P999, DOI 10.1016/j.jhep.2004.08.013; Sanyal AJ, 2010, ONCOLOGIST, V15, P14, DOI 10.1634/theoncologist.2010-S4-14; Sciaranghella G, 2011, VACCINE, V29, P476, DOI 10.1016/j.vaccine.2010.10.072; Seavey MM, 2009, CLIN CANCER RES, V15, P924, DOI 10.1158/1078-0432.CCR-08-2283; Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053; Shen F, 1999, VACCINE, V17, P3039, DOI 10.1016/S0264-410X(99)00148-6; Shen XH, 2010, J CANCER RES CLIN, V136, P1745, DOI 10.1007/s00432-010-0833-8; Shen YN, 2010, INFECT IMMUN, V78, P2857, DOI 10.1128/IAI.01138-09; Singh R, 2006, EXPERT REV VACCINES, V5, P541, DOI 10.1586/14760584.5.4.541; Skoberne M, 2008, J CLIN INVEST, V118, P3990, DOI 10.1172/JCI31350; SMITH K, 1992, BIOCHIMIE, V74, P705, DOI 10.1016/0300-9084(92)90143-3; Song SX, 2007, VACCINE, V25, P4853, DOI 10.1016/j.vaccine.2006.12.029; Souders NC, 2006, DNA CELL BIOL, V25, P142, DOI 10.1089/dna.2006.25.142; Spears PA, 2008, INFECT IMMUN, V76, P4046, DOI 10.1128/IAI.00283-08; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Thompson RJ, 1998, INFECT IMMUN, V66, P3552, DOI 10.1128/IAI.66.8.3552-3561.1998; Vollmer CM, 1999, CANCER RES, V59, P3064; Wallecha A, 2009, CLIN VACCINE IMMUNOL, V16, P96, DOI 10.1128/CVI.00274-08; Williams JC, 2010, J IMMUNOL, V184, P6637, DOI 10.4049/jimmunol.0902784; Yamamoto K, 2006, CLIN EXP IMMUNOL, V144, P475, DOI 10.1111/j.1365-2249.2006.03092.x; Yoshimura K, 2006, CANCER RES, V66, P1096, DOI 10.1158/0008-5472.CAN-05-2307; Yoshimura K, 2007, CANCER RES, V67, P10058, DOI 10.1158/0008-5472.CAN-07-0573; Zerbini A, 2004, J HEPATOL, V40, P102, DOI 10.1016/S0168-8278(03)00484-7; Zhao XY, 2005, INFECT IMMUN, V73, P5789, DOI 10.1128/IAI.73.9.5789-5798.2005; Zhou L, 2010, J GASTROENTEROL, V45, P968, DOI 10.1007/s00535-010-0243-3; Zhou M, 2005, IMMUNOL LETT, V99, P113, DOI 10.1016/j.imlet.2005.02.007	56	28	30	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2140	2152		10.1038/onc.2011.395	http://dx.doi.org/10.1038/onc.2011.395			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927025				2022-12-28	WOS:000303415900003
J	Levav-Cohen, Y; Wolyniec, K; Alsheich-Bartok, O; Chan, AL; Woods, SJ; Jiang, YH; Haupt, S; Haupt, Y				Levav-Cohen, Y.; Wolyniec, K.; Alsheich-Bartok, O.; Chan, A-L; Woods, S. J.; Jiang, Y-H; Haupt, S.; Haupt, Y.			E6AP is required for replicative and oncogene-induced senescence in mouse embryo fibroblasts	ONCOGENE			English	Article						E6AP; cellular senescence; stress; p53; Ras	UBIQUITIN-PROTEIN LIGASE; HUMAN-PAPILLOMAVIRUS TYPE-16; CELLULAR SENESCENCE; TUMOR SUPPRESSION; G(1) CONTROL; P53; GROWTH; CELLS; ANGELMAN; E6-AP	Cellular senescence is important for the maintenance of tissue homeostasis, and has recently been shown to pose a natural barrier to tumorigenesis. The E3 ubiquitin ligase, E6AP, has been linked to a number of protein regulators of the cell cycle as well as the cellular stress response. We therefore explored the role of E6AP in the cellular response to stress. We found that mouse embryo fibroblasts (MEFs) lacking E6AP escape replicative senescence, as well as Ras-induced senescence associated with impaired markers. E6AP-deficient MEFs exhibit a range of transformed phenotypes: these include the ability to grow under stress conditions (such as low serum and DNA damage), enhanced proliferation, anchorage independent growth and enhanced growth of xenografts in mice. The transformed phenotype of E6AP-deficient MEFs is associated with lower basal and stress-induced accumulation of p53. Overall, our study implicates E6AP as an important regulator of the cellular response to stress, in particular through the regulation of replicative and oncogene-induced senescence. Oncogene (2012) 31, 2199-2209; doi:10.1038/onc.2011.402; published online 19 September 2011	[Wolyniec, K.; Chan, A-L; Woods, S. J.; Haupt, S.; Haupt, Y.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3002, Australia; [Levav-Cohen, Y.; Alsheich-Bartok, O.] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91010 Jerusalem, Israel; [Jiang, Y-H] Duke Univ, Sch Med, Dept Pediat & Neurobiol, Div Med Genet, Durham, NC USA	Peter Maccallum Cancer Center; Hebrew University of Jerusalem; Duke University	Haupt, Y (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3002, Australia.	ygal.haupt@petermac.org		Chan, Ai-Leen/0000-0003-3553-7249; Haupt, Ygal/0000-0001-5925-0096	NHMRC [509196]; Cancer Council Victoria; VESKI; European commission [503576]	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); VESKI; European commission(European CommissionEuropean Commission Joint Research Centre)	We express our thanks to Scott Lowe and Martin Scheffner for the generous gifts of expression plasmids, and to Mariam Mansour for critical comments on the manuscript. Work in the authors laboratory is supported by an NHMRC project grant (grant No. 509196), by a grant from the Cancer Council Victoria, by the VESKI award and by the EC FP6 funding of the European commission (contract 503576). This publication reflects only the authors' views. The European commission is not liable for any use that may be made of the information herein.	Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Di Micco R, 2008, CELL CYCLE, V7, P3601, DOI 10.4161/cc.7.22.7152; Di Micco R, 2007, TRENDS CELL BIOL, V17, P529, DOI 10.1016/j.tcb.2007.07.012; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Howley Peter M, 2006, Trans Am Clin Climatol Assoc, V117, P113; Howley PM., 2006, T AM CLIN CLIMAT ASS, V117, P126; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Jiang YH, 1998, CURR OPIN GENET DEV, V8, P334, DOI 10.1016/S0959-437X(98)80091-9; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Maezawa Y, 2006, DIABETES-METAB RES, V22, P313, DOI 10.1002/dmrr.612; Matentzoglu K, 2008, BIOCHEM SOC T, V36, P797, DOI 10.1042/BST0360797; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mishra A, 2008, CELL MOL LIFE SCI, V65, P656, DOI 10.1007/s00018-007-7476-1; Mishra A, 2009, NEUROBIOL DIS, V36, P26, DOI 10.1016/j.nbd.2009.06.010; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; Papazoglu C, 2007, J PATHOL, V211, P124, DOI 10.1002/path.2086; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherman M, 2007, FEBS LETT, V581, P3711, DOI 10.1016/j.febslet.2007.05.036; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; SMITH JR, 1984, INT REV CYTOL, V89, P151, DOI 10.1016/S0074-7696(08)61303-0; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Zuckerman V, 2009, J PATHOL, V219, P3, DOI 10.1002/path.2584; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	57	17	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2199	2209		10.1038/onc.2011.402	http://dx.doi.org/10.1038/onc.2011.402			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927031				2022-12-28	WOS:000303415900008
J	Fu, K; Ren, H; Wang, Y; Fei, E; Wang, H; Wang, G				Fu, K.; Ren, H.; Wang, Y.; Fei, E.; Wang, H.; Wang, G.			DJ-1 inhibits TRAIL-induced apoptosis by blocking pro-caspase-8 recruitment to FADD	ONCOGENE			English	Article						DJ-1; TRAIL; FADD; caspase-8; DISC; apoptosis	P53 TRANSCRIPTIONAL ACTIVITY; FAMILIAL PARKINSONS-DISEASE; CANCER-CELLS; ANDROGEN RECEPTOR; DEATH RECEPTORS; TNF-FAMILY; PROTEIN; IDENTIFICATION; EXPRESSION; REGULATOR	DJ-1 was initially identified as an oncogene product involved in human tumorigenesis in cooperation with Ras. Increased DJ-1 expression is associated with tumorigenesis in many cancers, whereas the loss of DJ-1 function is linked to an autosomal recessive form of Parkinson's disease (PD). It has been reported that DJ-1 protects cells from TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis. However, the mechanism by which DJ-1 is involved is still largely unknown. Here we show that DJ-1 inhibits TRAIL-induced apoptosis by blocking Fas-associated protein death domain (FADD)-mediated pro-caspase-8 activation. Wild-type DJ-1, but not the PD-associated mutant L166P, binds to FADD to inhibit the formation of the death-inducing signaling complex (DISC). DJ-1 competes with pro-caspase-8 to bind to FADD at the death effector domain, thereby repressing the recruitment and activation of pro-caspase-8 to the active form of caspase-8. Thus, our study suggests that DJ-1 protects against TRAIL-induced apoptosis through the regulation of DISC formation. Oncogene (2012) 31, 1311-1322; doi:10.1038/onc.2011.315; published online 25 July 2011	Univ Sci & Technol China, Chinese Acad Sci, Lab Mol Neuropathol, Dept Neurobiol,Key Lab Brain Funct & Dis, Hefei, Anhui, Peoples R China; Univ Sci & Technol China, Chinese Acad Sci, Sch Life Sci, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, G (corresponding author), Univ Sci & Technol China, Chinese Acad Sci, Lab Mol Neuropathol, Dept Neurobiol,Key Lab Brain Funct & Dis, 443 Huangshan Rd, Hefei 230027, Anhui, Peoples R China.	wghui@ustc.edu.cn	FEI, Erkang/AAI-9825-2021; Ren, Haigang/U-6034-2017; Wang, Guanghui/U-3979-2017	Ren, Haigang/0000-0001-8844-4754; Wang, Guanghui/0000-0001-8551-6468; FEI, Erkang/0000-0002-3581-9521	National Natural Sciences Foundation of China [30970921]; National High-tech Research and Development program of China 973 [2011CB5004102]	National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); National High-tech Research and Development program of China 973	We grateful to Dr Juha Klefstrom (University of Helsinki, Finland) and Dr Xiaolu Yang (University of Pennsylvania) for the kind gifts of pC4M-Fv2E-caspase-8 and the pC4M-Fv2E-caspase-8 C-A mutant and Mian Wu (University of Science and Technology of China, China) for the pGBKT7- FADD plasmid. The ARGENT Regulated Homodimerization Kit was kindly provided by ARIAD Pharmaceuticals (www.ariad.com/regulationkits). This work was supported in part by the National Natural Sciences Foundation of China (No. 30970921) and the National High-tech Research and Development program of China 973-projects (2011CB5004102).	Agata N, 2008, CANCER RES, V68, P6136, DOI 10.1158/0008-5472.CAN-08-0464; Andres-Mateos E, 2007, P NATL ACAD SCI USA, V104, P14807, DOI 10.1073/pnas.0703219104; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Bretaud S, 2007, J NEUROCHEM, V100, P1626, DOI 10.1111/j.1471-4159.2006.04291.x; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Davidson B, 2008, HUM PATHOL, V39, P87, DOI 10.1016/j.humpath.2007.05.014; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fan J, 2008, FEBS LETT, V582, P1151, DOI 10.1016/j.febslet.2008.03.003; Fan J, 2008, J BIOL CHEM, V283, P4022, DOI 10.1074/jbc.M707176200; Foti R, 2010, J BIOL CHEM, V285, P18565, DOI 10.1074/jbc.M109.088294; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Giaime E, 2010, CELL DEATH DIFFER, V17, P158, DOI 10.1038/cdd.2009.116; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hod Y, 2004, J CELL BIOCHEM, V92, P1221, DOI 10.1002/jcb.20159; Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465; Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; MacKeigan JP, 2003, CANCER RES, V63, P6928; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miller DW, 2003, J BIOL CHEM, V278, P36588, DOI 10.1074/jbc.M304272200; Mo JS, 2008, CELL DEATH DIFFER, V15, P1030, DOI 10.1038/cdd.2008.26; Moore DJ, 2003, J NEUROCHEM, V87, P1558, DOI 10.1111/j.1471-4159.2003.02265.x; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nieminen AI, 2007, EMBO J, V26, P1055, DOI 10.1038/sj.emboj.7601551; Niki T, 2003, MOL CANCER RES, V1, P247; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pardo M, 2006, INT J CANCER, V119, P1014, DOI 10.1002/ijc.21942; Ren HG, 2010, CANCER LETT, V297, P101, DOI 10.1016/j.canlet.2010.05.001; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Shinbo Y, 2006, CELL DEATH DIFFER, V13, P96, DOI 10.1038/sj.cdd.4401704; Sitaram RT, 2009, INT J CANCER, V125, P783, DOI 10.1002/ijc.24335; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Vasseur S, 2009, P NATL ACAD SCI USA, V106, P1111, DOI 10.1073/pnas.0812745106; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Xu J, 2005, HUM MOL GENET, V14, P1231, DOI 10.1093/hmg/ddi134; Zhang HY, 2008, ENDOCR-RELAT CANCER, V15, P535, DOI 10.1677/ERC-07-0195	52	26	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1311	1322		10.1038/onc.2011.315	http://dx.doi.org/10.1038/onc.2011.315			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785459	Bronze			2022-12-28	WOS:000301344600010
J	Lee, J; Li, L; Gretz, N; Gebert, J; Dihlmann, S				Lee, J.; Li, L.; Gretz, N.; Gebert, J.; Dihlmann, S.			Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers	ONCOGENE			English	Article						IFN-gamma; AIM2; HLA class II; tumor immunity; interferon-stimulated genes; ISG	CLASS-II TRANSACTIVATOR; GAMMA IN-SITU; MICROSATELLITE INSTABILITY; ANTIGEN-EXPRESSION; CYTOPLASMIC DNA; FRANCISELLA-TULARENSIS; POSITIVE FEEDBACK; INNATE IMMUNITY; GOOD PROGNOSIS; COMMON TARGET	Absent in Melanoma 2 (AIM2) is a member of the HIN-200 family of hematopoietic, IFN-inducible, nuclear proteins, associated with both, infection defense and tumor pathology. Recently, AIM2 was found to act as a DNA sensor in innate immunity. In addition, we and others have previously demonstrated a high frequency of AIM2-alterations in microsatellite unstable (MSI-H) tumors. To further elucidate AIM2 function in colorectal tumors, we here addressed AIM2-responsive target genes by microarray based gene expression profiling of 22 244 human genes. A total of 111 transcripts were significantly upregulated, whereas 80 transcripts turned out to be significantly downregulated in HCT116 cells, constitutively expressing AIM2, compared with AIM2-negative cells. Among the upregulated genes that were validated by quantitative PCR and western blotting we recognized several interferon-stimulated genes (ISGs: IFIT1, IFIT2, IFIT3, IFI6, IRF7, ISG15, HLA-DRA, HLA-DRB, TLR3 and CIITA), as well as genes involved in intercellular adhesion and matrix remodeling. Expression of ISGs correlated with expression of AIM2 in 10 different IFN-gamma treated colorectal cancer cell lines. Moreover, small interfering RNA-mediated knock-down of AIM2 resulted in reduced expression of HLA-DRA, HLA-DRB and CIITA in IFN-gamma-treated cells. IFN-gamma independent induction of HLA-DR genes and their encoded proteins was also demonstrated upon doxy-cyclin-regulated transient induction of AIM2. Luciferase reporter assays revealed induction of the HLA-DR promoter upon AIM2 transfection in different cell lines. STAT-signaling was not involved in IFN-gamma independent induction of ISGs, arguing against participation of cytokines released in an autostimulating manner. Our data indicate that AIM2 mediates both IFN-gamma dependent and independent induction of several ISGs, including genes encoding the major histocompatibility complex (MHC) class II antigens HLA-DR-alpha and -beta. This suggests a novel role of the IFN/AIM2/ISG cascade likewise in cancer cells. Oncogene (2012) 31, 1242-1253; doi:10.1038/onc.2011.320; published online 1 August 2011	[Lee, J.; Gebert, J.] Univ Heidelberg, Inst Pathol, Dept Appl Tumor Biol, D-6900 Heidelberg, Germany; [Li, L.; Gretz, N.] Univ Heidelberg, Fac Clin Med, Ctr Med Res ZMF, D-6800 Mannheim, Germany; [Dihlmann, S.] Univ Heidelberg, Inst Pathol, Dept Gen Pathol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Dihlmann, S (corresponding author), Univ Heidelberg Hosp, Dept Vasc Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	susanne.dihlmann@med.uni-heidelberg.de		Dihlmann, Susanne/0000-0002-3737-7755	Deutsche Forschungsgmeinschaft, DFG [Di-933 4/1]	Deutsche Forschungsgmeinschaft, DFG(German Research Foundation (DFG))	The work was funded by a grant of the Deutsche Forschungsgmeinschaft, DFG to Dr S Dihlmann (Di-933 4/1).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; ANDERSEN SN, 1993, BRIT J CANCER, V68, P80, DOI 10.1038/bjc.1993.290; Brennan K, 2010, CURR OPIN MICROBIOL, V13, P503, DOI 10.1016/j.mib.2010.05.007; Buckowitz A, 2005, BRIT J CANCER, V92, P1746, DOI 10.1038/sj.bjc.6602534; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Chen IF, 2006, MOL CANCER THER, V5, P1, DOI 10.1158/1535-7163.MCT-05-0310; Cheriyath V, 2007, J CLIN INVEST, V117, P3107, DOI 10.1172/JCI31122; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Diederichsen ACP, 2003, CANCER IMMUNOL IMMUN, V52, P423, DOI 10.1007/s00262-003-0388-5; Dihlmann S, 1999, CANCER RES, V59, P1857; Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101; Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garrity-Park MM, 2009, GUT, V58, P1226, DOI 10.1136/gut.2008.166686; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jones JW, 2010, P NATL ACAD SCI USA, V107, P9771, DOI 10.1073/pnas.1003738107; Krawczyk M, 2006, TISSUE ANTIGENS, V67, P183, DOI 10.1111/j.1399-0039.2006.00557.x; Lee JH, 2010, GUT, V59, P907, DOI 10.1136/gut.2009.194068; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Matsushita K, 2006, CANCER SCI, V97, P57, DOI 10.1111/j.1349-7006.2006.00137.x; Matsushita K, 1996, BRIT J CANCER, V73, P644, DOI 10.1038/bjc.1996.112; Michel S, 2010, INT J CANCER, V127, P889, DOI 10.1002/ijc.25106; Michel S, 2010, MOL CARCINOGEN, V49, P175, DOI 10.1002/mc.20587; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Oshita F, 2006, ONCOL REP, V16, P817; Patsos G, 2010, INT J CANCER, V126, P1838, DOI 10.1002/ijc.24905; PFIZENMAIER K, 1985, CANCER RES, V45, P3503; Pitha-Rowe IF, 2007, CYTOKINE GROWTH F R, V18, P409, DOI 10.1016/j.cytogfr.2007.06.017; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; Sauer JD, 2010, CELL HOST MICROBE, V7, P412, DOI 10.1016/j.chom.2010.04.004; Schroder K, 2009, CURR BIOL, V19, pR262, DOI 10.1016/j.cub.2009.02.011; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; Tsuchiya K, 2010, J IMMUNOL, V185, P1186, DOI 10.4049/jimmunol.1001058; Walsh MD, 2009, INT J CANCER, V125, P1231, DOI 10.1002/ijc.24484; Welman A, 2005, J CELL BIOCHEM, V94, P1148, DOI 10.1002/jcb.20342; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Woerner SM, 2007, GENE CHROMOSOME CANC, V46, P1080, DOI 10.1002/gcc.20493; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700	51	35	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1242	1253		10.1038/onc.2011.320	http://dx.doi.org/10.1038/onc.2011.320			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804607	hybrid, Green Published			2022-12-28	WOS:000301344600004
J	Visser-Grieve, S; Hao, Y; Yang, X				Visser-Grieve, S.; Hao, Y.; Yang, X.			Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway	ONCOGENE			English	Article						expanded; FRMD6; Willin; Hippo; LATS1; tumor suppressor	REGULATE GROWTH; PROLIFERATION; MERLIN; PROTEIN; LATS1; TUMORIGENESIS; INHIBITION; TRANSITION; APOPTOSIS; DOMAIN	The Hippo signaling network is proving to be an essential regulator within the cell, participating in multiple cellular phenotypes including cell proliferation, apoptosis, cell migration and organ size control. Much of this pathway is conserved from flies to mammals; however, how the upstream components, namely Expanded, affect downstream processes in mammalian systems has remained elusive. Only recently has human Expanded (hEx), also known as FRMD6 or Willin, been identified. However, its functional significance with respect to its putative tumor suppressor function and activation of the Hippo pathway has not been studied. In this study, we show for the first time that hEx possesses several tumor suppressor properties. First, hEx dramatically inhibits cell proliferation in two human cancer cell lines, MDA-MB-231 and MDA-MB-436 cells, and sensitizes these cells to the chemotherapeutic drug Taxol. Furthermore, downregulation of hEx in the immortalized MCF10A breast cell line leads to enhanced proliferation and resistance to Taxol treatment. As evidence for its tumor suppressor function, overexpression of hEx inhibits colony formation, soft agar colony growth in vitro and in vivo tumor growth in nude mice. Although Drosophila expanded (ex) can activate the Hippo pathway, surprisingly no significant alterations were discovered in the phosphorylation status of any of the Hippo pathway components, including downstream tumor suppressor LATS1, upon overexpression of hEx. In addition, knockdown of both LATS1 and LATS2 in hEx-overexpressing cells was unable to rescue the hEx phenotype, suggesting that hEx functions independently of the Hippo pathway in this cell line. Alternatively, we propose a mechanism through which hEx inhibits progression through the S phase of the cell cycle by upregulating p21(Cip1) and downregulating Cyclin A. This is the first study to functionally characterize hEx and show that hEx acts in a distinct manner compared with Drosophila expanded. Oncogene (2012) 31, 1189-1195; doi:10.1038/onc.2011.318; published online 25 July 2011	[Yang, X.] Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Yang, X (corresponding author), Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, 88 Stuart St, Kingston, ON K7L 3N6, Canada.	yang@cliff.path.queensu.ca		Grieve, Stacy/0000-0003-3090-5583	Canadian Institute of Health Research; Ontario Ministry of Research and Innovation, Canada; Ontario Graduate Scholarship	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Research and Innovation, Canada(Ministry of Research and Innovation, Ontario); Ontario Graduate Scholarship(Ontario Graduate Scholarship)	This work was supported by a grant from the Canadian Institute of Health Research, a New Investigator Award from the Canadian Institute of Health Research and an Early Researcher Award from the Ontario Ministry of Research and Innovation, Canada, to Xiaolong Yang; and an Ontario Graduate Scholarship to Stacy Visser-Grieve. We would like to thank Matt Gordon at the Queen's Cancer Research Institute for performing the FACS analysis and Dr Frank Gunn-Moore for providing the hEx-GFP plasmid.	Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Blaumueller CM, 2000, MECH DEVELOP, V92, P251, DOI 10.1016/S0925-4773(00)00246-X; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Feng YQ, 2007, P NATL ACAD SCI USA, V104, P20362, DOI 10.1073/pnas.0706722105; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Gunn-Moore FJ, 2005, FEBS LETT, V579, P5089, DOI 10.1016/j.febslet.2005.07.097; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li WQ, 2011, CANCER RES, V71, P2162, DOI 10.1158/0008-5472.CAN-10-3268; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; McCartney BM, 2000, DEVELOPMENT, V127, P1315; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pellock BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Radu M, 2009, CURR BIOL, V19, pR421, DOI 10.1016/j.cub.2009.04.022; Stern C, 1926, GENETICS, V11, P503; Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386; Visser S, 2010, GENE, V449, P22, DOI 10.1016/j.gene.2009.09.008; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210	37	36	36	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1189	1195		10.1038/onc.2011.318	http://dx.doi.org/10.1038/onc.2011.318			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21785462				2022-12-28	WOS:000300945900012
J	Benes, CH; Poulogiannis, G; Cantley, LC; Soltoff, SP				Benes, C. H.; Poulogiannis, G.; Cantley, L. C.; Soltoff, S. P.			The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility	ONCOGENE			English	Article						signaling; mass spectrometry; SRC; adhesion; motility; metastasis	TYROSINE-PHOSPHATASE SHP-2; HUMAN COLORECTAL-CANCER; HUMAN-COLON CARCINOMA; FOCAL-ADHESION; KINASE-ACTIVITY; CELL-MIGRATION; SIGNAL-TRANSDUCTION; FAMILY KINASES; GROWTH-FACTOR; TUMOR-CELLS	Multiple SRC-family kinases (SFKs) are commonly activated in carcinoma and appear to have a role in metastasis through incompletely understood mechanisms. Recent studies have shown that CDCP1 (CUB (complement C1r/C1s, Uegf, Bmp1) Domain-Containing Protein-1) is a transmembrane protein and an SRC substrate potentially involved in metastasis. Here we show that increased SFK and CDCP1 tyrosine phosphorylation is, surprisingly, associated with a decrease in FAK phosphorylation. This appears to be true in human tumors as shown by our correlation analysis of a mass spectrometric data set of affinity-purified phosphotyrosine peptides obtained from normal and cancer lung tissue samples. Induction of tyrosine phosphorylation of CDCP1 in cell culture, including by a mAb that binds to its extracellular domain, promoted changes in SFK and FAK tyrosine phosphorylation, as well as in PKC (TM), a protein known to associate with CDCP1, and these changes are accompanied by increases in adhesion and motility. Thus, signaling events that accompany the CDCP1 tyrosine phosphorylation observed in cell lines and human lung tumors may explain how the CDCP1/SFK complex regulates motility and adhesion. Oncogene (2012) 31, 653-663; doi:10.1038/onc.2011.262; published online 4 July 2011	[Benes, C. H.; Poulogiannis, G.; Cantley, L. C.; Soltoff, S. P.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, Boston, MA 02215 USA; [Poulogiannis, G.; Cantley, L. C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Soltoff, SP (corresponding author), Beth Israel Deaconess Med Ctr, Div Signal Transduct, Dept Med, 330 Brookline Ave,CLS-406, Boston, MA 02215 USA.	ssoltoff@bidmc.harvard.edu	Poulogiannis, George/AAE-1966-2019; Cantley, Lewis C/D-1800-2014; Poulogiannis, George/AAY-2210-2021	Poulogiannis, George/0000-0002-0529-8614; Cantley, Lewis C/0000-0002-1298-7653; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Buhring HJ, 2004, STEM CELLS, V22, P334, DOI 10.1634/stemcells.22-3-334; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Cooper JA, 2008, BIOCHEMISTRY-US, V47, P5681, DOI 10.1021/bi8003044; Courtneidge SA, 2002, BIOCHEM SOC T, V30, P11, DOI 10.1042/bst0300011; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; ILLC D, 1995, NATURE, V377, P539; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; Manes S, 1999, MOL CELL BIOL, V19, P3125; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Perry SE, 2007, FEBS LETT, V581, P1137, DOI 10.1016/j.febslet.2007.02.025; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382; Serrels B, 2007, NAT CELL BIOL, V9, P1046, DOI 10.1038/ncb1626; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Spassov DS, 2009, AM J PATHOL, V174, P1756, DOI 10.2353/ajpath.2009.080890; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Vitale S, 2008, EUR J CELL BIOL, V87, P569, DOI 10.1016/j.ejcb.2008.04.002; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zheng YH, 2009, MOL CELL, V35, P11, DOI 10.1016/j.molcel.2009.06.013	52	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					653	663		10.1038/onc.2011.262	http://dx.doi.org/10.1038/onc.2011.262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725358	Green Accepted			2022-12-28	WOS:000300221800011
J	Damiano, L; Le Devedec, SE; Di Stefano, P; Repetto, D; Lalai, R; Truong, H; Xiong, JL; Danen, EH; Yan, K; Verbeek, FJ; De Luca, E; Attanasio, F; Buccione, R; Turco, E; van de Water, B; Defilippi, P				Damiano, L.; Le Devedec, S. E.; Di Stefano, P.; Repetto, D.; Lalai, R.; Truong, H.; Xiong, J. L.; Danen, E. H.; Yan, K.; Verbeek, F. J.; De Luca, E.; Attanasio, F.; Buccione, R.; Turco, E.; van de Water, B.; Defilippi, P.			p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation	ONCOGENE			English	Article						p140Cap; cortactin; tumor invasion; metastasis; breast cancer	ACTIN; DYNAMICS; INVADOPODIA; DEGRADATION; MOTILITY; SITES	We have recently shown that the adaptor protein p140Cap regulates tumor properties in terms of cell motility and growth. Here, by using the highly metastatic rat adenocarcinoma cell line MTLn3-epidermal growth factor receptor (EGFR), we assess the role of p140Cap in metastasis formation. Orthotopic transplantation of MTLn3-EGFR cells over-expressing p140Cap in Rag2(-/-)gamma(-/-)(c) mice resulted in normal primary tumor growth compared with the controls. Strikingly, p140Cap over-expression causes an 80% inhibition in the number of lung metastases. p140Cap over-expressing cells display a 50% reduction in directional cell migration, an increased number and size of focal adhesions, and a strong impairment in the ability to invade in a 3D matrix. p140Cap overexpression affects EGFR signaling and tyrosine phosphorylation of cortactin in response to EGF stimulation. Intriguingly, p140Cap associates with cortactin via interaction with its second proline-rich domain to the cortactin SH3 domain. The phosphomimetic cortactin tyrosine 421 mutant rescues migration and invasive properties in p140Cap over-expressing cells. Taken together, these data demonstrate that p140Cap suppresses the invasive properties of highly metastatic breast carcinoma cells by inhibiting cortactin-dependent cell motility. Oncogene (2012) 31, 624-633; doi:10.1038/onc.2011.257; published online 4 July 2011	[Le Devedec, S. E.; Lalai, R.; Truong, H.; Xiong, J. L.; Danen, E. H.; van de Water, B.] Leiden Univ, LACDR, Div Toxicol, Leiden, Netherlands; [Damiano, L.; Di Stefano, P.; Repetto, D.; De Luca, E.; Turco, E.; Defilippi, P.] Univ Turin, Dept Genet Biol & Biochem, Mol Biotechnol Ctr, I-10126 Turin, Italy; [Yan, K.; Verbeek, F. J.] Leiden Univ, Leiden Inst Adv Comp Sci, Leiden, Netherlands; [Attanasio, F.; Buccione, R.] Consorzio Mario Negri Sud, Tumour Cell Invas Lab, Chieti, Italy	Leiden University; Leiden University - Excl LUMC; University of Turin; Leiden University; Leiden University - Excl LUMC; Consorzio Mario Negri Sud	van de Water, B (corresponding author), Leiden Univ, LACDR, Div Toxicol, Leiden, Netherlands.	paola.defilippi@unito.it	DEFILIPPI, Paola/L-2232-2014; De Luca, Elisa/L-2491-2017	De Luca, Elisa/0000-0001-9849-0703; Le Devedec, Sylvia/0000-0002-0615-9616; Yan, Kuan/0000-0003-4143-3569; Defilippi, Paola/0000-0001-6427-4906; danen, erik/0000-0002-0491-6345; Buccione, Roberto/0000-0001-9210-5261	EU; AIRC; MUR (PRIN); Regione Piemonte - Progetti Sanita; Oncoprot; PiSTEM; Druidi; CIPE, Compagnia San Paolo, Torino; Dutch Cancer Society [UL 2006-3521, UL 2007-3860, UL 2010-4670]; Netherlands Genomics Initiative	EU; AIRC; MUR (PRIN); Regione Piemonte - Progetti Sanita; Oncoprot; PiSTEM; Druidi; CIPE, Compagnia San Paolo, Torino; Dutch Cancer Society; Netherlands Genomics Initiative	We thank Stefan Huveneers for help with the in vitro angiogenesis assay. This work was supported by EU FP7 Metafight project, AIRC, MUR (PRIN), Regione Piemonte - Progetti Sanita, Oncoprot, PiSTEM, Druidi and CIPE, Compagnia San Paolo, Torino, the Dutch Cancer Society (UL 2006-3521, UL 2007-3860 and UL 2010-4670) and the Netherlands Genomics Initiative grant to the Netherlands Toxicogenomics Center grant.	Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Baldassarre M, 2006, EUR J CELL BIOL, V85, P1217, DOI 10.1016/j.ejcb.2006.08.003; Bowden ET, 2001, METHOD CELL BIOL, V63, P613; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Chin LS, 2000, J BIOL CHEM, V275, P1191, DOI 10.1074/jbc.275.2.1191; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Damiano L, 2010, ONCOGENE, V29, P3677, DOI 10.1038/onc.2010.128; Di Stefano P, 2004, MOL BIOL CELL, V15, P787, DOI 10.1091/mbc.E03-09-0689; Di Stefano P, 2007, EMBO J, V26, P2843, DOI 10.1038/sj.emboj.7601724; Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; ILLC D, 1995, NATURE, V377, P539; Jaworski J, 2009, NEURON, V61, P85, DOI 10.1016/j.neuron.2008.11.013; Le Devedec SE, 2009, CLIN EXP METASTAS, V26, P673, DOI 10.1007/s10585-009-9267-6; Li YS, 2001, CANCER RES, V61, P6906; Lim ST, 2008, CELL CYCLE, V7, P2306, DOI 10.4161/cc.6367; Lorenz M, 2004, CELL MOTIL CYTOSKEL, V57, P207, DOI 10.1002/cm.10171; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Marxfeld H, 2006, EXP TOXICOL PATHOL, V58, P133, DOI 10.1016/j.etp.2006.05.003; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; NERI A, 1981, INT J CANCER, V28, P731, DOI 10.1002/ijc.2910280612; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Vicente-Manzanares M, 2005, J CELL SCI, V118, DOI 10.1242/jcs.02662; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Webb Donna J., 2004, V294, P3; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Wolfenson H, 2009, CELL MOTIL CYTOSKEL, V66, P1017, DOI 10.1002/cm.20410; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242	35	17	17	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					624	633		10.1038/onc.2011.257	http://dx.doi.org/10.1038/onc.2011.257			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725361				2022-12-28	WOS:000300221800008
J	Kawamata, N; Pennella, MA; Woo, JL; Berk, AJ; Koeffler, HP				Kawamata, N.; Pennella, M. A.; Woo, J. L.; Berk, A. J.; Koeffler, H. P.			Dominant-negative mechanism of leukemogenic PAX5 fusions	ONCOGENE			English	Article						PAX5 fusions; DNA binding; multimerization	ACUTE PROMYELOCYTIC LEUKEMIA; UNBALANCED TRANSLOCATIONS; INTRANUCLEAR MOBILITY; HISTONE DEACETYLASE; DECREASED MOBILITY; PAIRED DOMAIN; PROTEINS; BINDING; RAR; CHROMATIN	PAX5 encodes a master regulator of B-cell development. It fuses to other genes associated with acute lymphoblastoid leukemia (ALL). These fusion products are potent dominant-negative (DN) inhibitors of wild-type PAX5, resulting in a blockade of B-cell differentiation. Here, we show that multimerization of PAX5 DNA-binding domain (DBD) is necessary and sufficient to cause extremely stable chromatin binding and DN activity. ALL-associated PAX5-C20S results from fusion of the N-terminal region of PAX5, including its paired DBD, to the C-terminus of C20orf112, a protein of unknown function. We report that PAX5-C20S is a tetramer, which interacts extraordinarily stably with chromatin as determined by Fluorescence Recovery After Photobleaching in living cells. Tetramerization, stable chromatin binding and DN activity all require a putative five-turn amphipathic a-helix at the C-terminus of C20orf112, and does not require potential corepressor binding peptides elsewhere in the sequence. In vitro, the monomeric PAX5 DBD and PAX5-C20S binds a PAX5-binding site with equal affinity when it is at the center of an oligonucleotide too short to bind to more than one PAX5 DBD. But, PAX5-C20S binds the same sequence with 10-fold higher affinity than the monomeric PAX5 DBD when it is in a long DNA molecule. We suggest that the increased affinity results from interactions of one or more of the additional DBDs with neighboring non-specific sites in a long DNA molecule, and that this can account for the increased stability of PAX5-C20S chromatin binding compared with wild-type PAX5, resulting in DN activity by competition for binding to PAX5-target sites. Consistent with this model, the ALL-associated PAX5 fused to ETV6 or the multimerization domain of ETV6 SAM results in stable chromatin binding and DN activity. In addition, PAX5 DBD fused to artificial dimerization, trimerization and tetramerization domains results in parallel increases in the stability of chromatin binding and DN activity. Our studies suggest that oncogenic fusion proteins that retain the DBD of the transcription factor (TF) and the multimerization sequence of the partner protein can act in a DN manner by multimerizing and binding avidly to gene targets, preventing the normal TF from binding and inducing expression of its target genes. Inhibition of this multimeriztion may provide a novel therapeutic approach for cancers with this or similar fusion proteins. Oncogene (2012) 31, 966-977; doi:10.1038/onc.2011.291; published online 18 July 2011	[Kawamata, N.] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA; [Pennella, M. A.; Woo, J. L.; Berk, A. J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Inst Mol Biol, Los Angeles, CA 90048 USA; [Woo, J. L.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; [Koeffler, H. P.] Natl Univ Singapore, Natl Canc Inst, Singapore 117548, Singapore; [Koeffler, H. P.] Natl Univ Singapore, Canc Inst Singapore, Singapore 117548, Singapore	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Regeneron; National University of Singapore; National University of Singapore	Kawamata, N (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Inst Med Genet, 8700 Beverly Blvd,Room D5068, Los Angeles, CA 90048 USA.	Norihiko.Kawamata@cshs.org; berk@mbi.ucla.edu	BERK, ARNOLD/AAF-7052-2020		NIH [R01CA026038-32, U54CA143930, GM008243]; A*STAR [R37CA25235]; Tower Cancer Foundation; ACS [PF0804801GMC]; NATIONAL CANCER INSTITUTE [U54CA143930, R01CA026038, R37CA025235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008243] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); A*STAR(Agency for Science Technology & Research (A*STAR)); Tower Cancer Foundation; ACS(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants R01CA026038-32, U54CA143930, and A*STAR Investigator Grant to HPK and R37CA25235 to AJB, the Tower Cancer Foundation grant and NIH grant GM008243 to NK, and ACS postdoctoral fellowship PF0804801GMC to MAP. We thank Kolja A Wawrowsky in the Confocal Microscopy Unit, and BK Bernstein for Core Unit, Patricia Lin in the FACS Core Unit for their technical assistance. FRAP experiments were performed at the California Nano Systems Institute Advanced Light Microscopy/Spectroscopy (CNSI-ALMS) at UCLA.	An Q, 2008, P NATL ACAD SCI USA, V105, P17050, DOI 10.1073/pnas.0803494105; Antolini F, 2003, PROTEIN EXPRES PURIF, V29, P94, DOI 10.1016/S1046-5928(03)00004-4; Bousquet M, 2007, BLOOD, V109, P3417, DOI 10.1182/blood-2006-05-025221; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Davison TS, 2001, J MOL BIOL, V307, P605, DOI 10.1006/jmbi.2001.4450; Delorenzi M, 2002, BIOINFORMATICS, V18, P617, DOI 10.1093/bioinformatics/18.4.617; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Edwards PAW, 2010, J PATHOL, V220, P244, DOI 10.1002/path.2632; Elvenes J, 2010, CELL MOL LIFE SCI, V67, P4079, DOI 10.1007/s00018-010-0429-0; Fazio G, 2008, CANCER RES, V68, P181, DOI 10.1158/0008-5472.CAN-07-2778; Gasparini P, 2007, J CELL BIOCHEM, V102, P320, DOI 10.1002/jcb.21481; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Gruber M, 2005, NUCLEIC ACIDS RES, V33, pW239, DOI 10.1093/nar/gki405; Huang Y, 2008, BIOCHEM BIOPH RES CO, V365, P258, DOI 10.1016/j.bbrc.2007.10.184; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kawamata N, 2008, P NATL ACAD SCI USA, V105, P11921, DOI 10.1073/pnas.0711039105; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Letarov AV, 1999, BIOCHEMISTRY-MOSCOW+, V64, P817; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Martens JHA, 2010, CANCER CELL, V17, P173, DOI 10.1016/j.ccr.2009.12.042; McDonnell AV, 2006, BIOINFORMATICS, V22, P356, DOI 10.1093/bioinformatics/bti797; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; O'Neil J, 2007, ONCOGENE, V26, P6838, DOI 10.1038/sj.onc.1210766; Pabst T, 2007, ONCOGENE, V26, P6829, DOI 10.1038/sj.onc.1210765; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Qiu J, 2006, ONCOGENE, V25, P3982, DOI 10.1038/sj.onc.1209431; Qiu JJ, 2011, ONCOGENE, V30, P967, DOI 10.1038/onc.2010.473; Schebesta A, 2007, IMMUNITY, V27, P49, DOI 10.1016/j.immuni.2007.05.019; Siegel R M, 2000, Sci STKE, V2000, ppl1, DOI 10.1126/stke.2000.38.pl1; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Sprague BL, 2005, TRENDS CELL BIOL, V15, P84, DOI 10.1016/j.tcb.2004.12.001; Strefford JC, 2009, CELL CYCLE, V8, P2175, DOI 10.4161/cc.8.14.9103; Wang G, 2001, MOL CELL BIOL, V21, P4604, DOI 10.1128/MCB.21.14.4604-4613.2001; Wichmann C, 2007, CANCER RES, V67, P2280, DOI 10.1158/0008-5472.CAN-06-3360; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103	44	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					966	977		10.1038/onc.2011.291	http://dx.doi.org/10.1038/onc.2011.291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765475	Green Accepted, Green Submitted			2022-12-28	WOS:000300709700003
J	Kim, K; Chadalapaka, G; Lee, SO; Yamada, D; Sastre-Garau, X; Defossez, PA; Park, YY; Lee, JS; Safe, S				Kim, K.; Chadalapaka, G.; Lee, S-O; Yamada, D.; Sastre-Garau, X.; Defossez, P-A; Park, Y-Y; Lee, J-S; Safe, S.			Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer	ONCOGENE			English	Article						ZBTB4; miR-17-92 cluster; breast cancer; prognostic; Sp transcription factors	MICRORNA EXPRESSION PROFILES; ZINC-FINGER PROTEINS; B-CELL LYMPHOMAS; REPRESSES TRANSCRIPTION; 5'-FLANKING REGION; GENE-EXPRESSION; METHYLATED DNA; MESSENGER-RNA; TUMOR-GROWTH; SP1	The human POK family members are transcription factors with a POZ domain and zinc-fingers that act primarily as transcriptional repressors. Several members of this family are involved in oncogenesis and this prompted us to assess whether expression levels of individual POK family members are associated with clinical outcomes in cancer. We have observed that ZBTB4 (zinc-finger and BTB domain containing 4) is downregulated in breast cancer patients, and that its expression is significantly correlated with relapse-free survival. Further integrative analysis of mRNA and microRNA (miR) expression data from the NCI-60 cell lines revealed an inverse correlation between ZBTB4 and oncogenic miRs derived from the miR-17-92 cluster and its paralogs. The experimental results using MDA-MB-231 and MCF-7 human breast cancer cells confirm that miRNAs derived from these clusters, containing miR-17-5p, miR-20a, miR-106a, miR-106b and miR-93, negatively regulate ZBTB4 expression. Overexpression of ZBTB4 or restoration of ZBTB4 by using an antagomir inhibit growth and invasion of breast cancer cells, and this effect is due, in part, to ZBTB4-dependent repression of the specificity protein 1 (Sp1), Sp3 and Sp4 genes, and subsequent downregulation of several Sp-dependent oncogenes, in part, through competition between ZBTB4 and Sp transcription factors for GC-rich promoter sequences. These results confirm that ZBTB4 functions as a novel tumor-suppressor gene with prognostic significance for breast cancer survival, and the oncogenic miR-17-92/ZBTB4/Sp axis may be a potential therapeutic target. Oncogene (2012) 31, 1034-1044; doi:10.1038/onc.2011.296; published online 18 July 2011	[Chadalapaka, G.; Safe, S.] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; [Kim, K.; Lee, S-O; Safe, S.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Yamada, D.; Defossez, P-A] Univ Paris 07, CNRS, UMR7216, Paris, France; [Sastre-Garau, X.] Inst Curie, Dept Tumor Biol, Paris, France; [Park, Y-Y; Lee, J-S] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, Vet Res Bldg 410, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu		Sastre-Garau, Xavier/0000-0001-5992-2083; Defossez, Pierre-Antoine/0000-0002-6463-9263; Kim, Kyounghyun/0000-0002-7240-2768; Lee, Syng-Ook/0000-0002-8958-8634	National Institutes of Health [CA136571]; Association pour la Recherche sur le Cancer; Ligue contre le Cancer; Institut National du Cancer; NATIONAL CANCER INSTITUTE [R01CA136571] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the National Institutes of Health (CA136571) and is gratefully acknowledged. PAD is supported by Association pour la Recherche sur le Cancer, Ligue contre le Cancer and Institut National du Cancer. DY was supported by a postdoctoral fellowship from Association pour la Recherche sur le Cancer.	Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Abdelrahim M, 2007, CANCER RES, V67, P3286, DOI 10.1158/0008-5472.CAN-06-3831; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chadalapaka G, 2008, CANCER RES, V68, P5345, DOI 10.1158/0008-5472.CAN-07-6805; Chadalapaka G, 2010, MOL CANCER RES, V8, P739, DOI 10.1158/1541-7786.MCR-09-0493; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Costoya Jose A., 2007, Briefings in Functional Genomics & Proteomics, V6, P8, DOI 10.1093/bfgp/elm002; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Jeon BN, 2009, J BIOL CHEM, V284, P17935, DOI 10.1074/jbc.M809559200; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Jutooru I, 2010, MOL PHARMACOL, V78, P226, DOI 10.1124/mol.110.064451; Koh DI, 2009, J BIOL CHEM, V284, P19856, DOI 10.1074/jbc.M109.025817; Kojima S, 2001, DEVELOPMENT, V128, P57; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Perez-Torrado R, 2006, BIOESSAYS, V28, P1194, DOI 10.1002/bies.20500; Sasai N, 2010, NUCLEIC ACIDS RES, V38, P5015, DOI 10.1093/nar/gkq280; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tapias A, 2008, BBA-GENE REGUL MECH, V1779, P318, DOI 10.1016/j.bbagrm.2008.02.006; Tillotson LG, 1999, J BIOL CHEM, V274, P8123, DOI 10.1074/jbc.274.12.8123; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107	47	143	149	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	8					1034	1044		10.1038/onc.2011.296	http://dx.doi.org/10.1038/onc.2011.296			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765466	Green Accepted			2022-12-28	WOS:000300709700009
J	Xing, F; Persaud, Y; Pratilas, CA; Taylor, BS; Janakiraman, M; She, QB; Gallardo, H; Liu, C; Merghoub, T; Hefter, B; Dolgalev, I; Viale, A; Heguy, A; De Stanchina, E; Cobrinik, D; Bollag, G; Wolchok, J; Houghton, A; Solit, DB				Xing, F.; Persaud, Y.; Pratilas, C. A.; Taylor, B. S.; Janakiraman, M.; She, Q-B; Gallardo, H.; Liu, C.; Merghoub, T.; Hefter, B.; Dolgalev, I.; Viale, A.; Heguy, A.; De Stanchina, E.; Cobrinik, D.; Bollag, G.; Wolchok, J.; Houghton, A.; Solit, D. B.			Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF	ONCOGENE			English	Article						BRAF; PTEN; RB1; MEK inhibitor; BRAF inhibitor; CDKN2A	RETINOBLASTOMA GENE-PRODUCT; METASTATIC MELANOMA; HUMAN CANCER; AZD6244 ARRY-142886; INHIBITOR PLX4032; CELL LINES; BRAF; KINASE; MUTATIONS; PROTEIN	Identifying the spectrum of genetic alterations that cooperate with critical oncogenes to promote transformation provides a foundation for understanding the diversity of clinical phenotypes observed in human cancers. Here, we performed integrated analyses to identify genomic alterations that co-occur with oncogenic BRAF in melanoma and abrogate cellular dependence upon this oncogene. We identified concurrent mutational inactivation of the PTEN and RB1 tumor suppressors as a mechanism for loss of BRAF/MEK dependence in melanomas harboring (V600E)BRAF mutations. RB1 alterations were mutually exclusive with loss of p16(INK4A), suggesting that whereas p16(INK4A) and RB1 may have overlapping roles in preventing tumor formation, tumors with loss of RB1 exhibit diminished dependence upon BRAF signaling for cell proliferation. These findings provide a genetic basis for the heterogeneity of clinical outcomes in patients treated with targeted inhibitors of the mitogen-activated protein kinase pathway. Our results also suggest a need for comprehensive screening for RB1 and PTEN inactivation in patients treated with RAF and MEK-selective inhibitors to determine whether these alterations are associated with diminished clinical benefit in patients whose cancers harbor mutant BRAF. Oncogene (2012) 31, 446-457; doi: 10.1038/onc.2011.250; published online 4 July 2011	[Merghoub, T.; Wolchok, J.; Solit, D. B.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Xing, F.; Persaud, Y.; Janakiraman, M.; Dolgalev, I.; Heguy, A.; Solit, D. B.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Pratilas, C. A.; Cobrinik, D.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Pratilas, C. A.; She, Q-B; Hefter, B.; De Stanchina, E.] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10065 USA; [Taylor, B. S.] Mem Sloan Kettering Canc Ctr, Dept Computat Biol, New York, NY 10065 USA; [Gallardo, H.; Liu, C.; Merghoub, T.; Wolchok, J.; Houghton, A.] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10065 USA; [Viale, A.] Mem Sloan Kettering Canc Ctr, Dept Mol Biol, New York, NY 10065 USA; [Bollag, G.] Plexxikon Inc, Berkeley, CA USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Plexxikon	Solit, DB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	solitd@mskcc.org	Dolgalev, Igor/AAY-6406-2020; Heguy, Adriana/GPP-3907-2022; Persaud, Yogindra/AAZ-7032-2021; Merghoub, Taha/ABD-8362-2021; Solit, David B./AAC-5309-2019	Dolgalev, Igor/0000-0003-4451-126X; Persaud, Yogindra/0000-0001-8266-9434; She, Qing-Bai/0000-0002-7207-0599; Janakiraman, Manickam/0000-0003-4423-6237	AstraZeneca; National Institutes of Health; Kimmel Foundation; Golfers-Against-Cancer; Melanoma Research Alliance; STARR Foundation; NATIONAL CANCER INSTITUTE [K08CA127350, P30CA008748, R01CA127240] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kimmel Foundation; Golfers-Against-Cancer; Melanoma Research Alliance; STARR Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	David Solit has received honoraria and research funding from AstraZeneca, and had an advisory role with Roche. Gideon Bollag is an employee of Plexxikon Inc.; We thank Drs Meenhard Herlyn and Kate Nathanson (University of Pennsylvania) and Dr Oystein Fodstad (Department of Tumor Biology of The Norwegian Radium Hospital, Norway) for kindly providing cell lines. This study was supported by grants from the National Institutes of Health (DBS), the Kimmel Foundation (DBS), Golfers-Against-Cancer (DBS), the Melanoma Research Alliance (DBS) and STARR Foundation (DBS). BST is the David H Koch Fellow in cancer genomics.	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; Dummer R, 2008, J CLIN ONCOL S, V2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gonzalgo ML, 1997, CANCER RES, V57, P5336; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hingorani SR, 2003, CANCER RES, V63, P5198; Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NUSSE M, 1990, CYTOMETRY, V11, P813, DOI 10.1002/cyto.990110707; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; OHTA M, 1994, CANCER RES, V54, P5269; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sondergaard JN, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-39; Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Tsai J, 2006, AACR M ABSTR, V2006, p571a; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433	43	142	143	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					446	457		10.1038/onc.2011.250	http://dx.doi.org/10.1038/onc.2011.250			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21725359	Green Accepted			2022-12-28	WOS:000300219300004
J	Lemaitre, C; Fischer, B; Kalousi, A; Hoffbeck, AS; Guirouilh-Barbat, J; Shahar, OD; Genet, D; Goldberg, M; Bertrand, P; Lopez, B; Brino, L; Soutoglou, E				Lemaitre, C.; Fischer, B.; Kalousi, A.; Hoffbeck, A-S; Guirouilh-Barbat, J.; Shahar, O. D.; Genet, D.; Goldberg, M.; Bertrand, P.; Lopez, B.; Brino, L.; Soutoglou, E.			The nucleoporin 153, a novel factor in double-strand break repair and DNA damage response	ONCOGENE			English	Article						DNA repair; nuclear pore; 53BP1	MAMMALIAN-CELLS; 53BP1; ATM; REPLICATION; STABILITY; DISTINCT; PATHWAY; COMPLEX; MDC1	DNA repair is essential in maintaining genome integrity and defects in different steps of the process have been linked to cancer and aging. It is a long lasting question how DNA repair is spatially and temporarily organized in the highly compartmentalized nucleus and whether the diverse nuclear compartments regulate differently the efficiency of repair. Increasing evidence suggest the involvement of nuclear pore complexes in repair of double-strand breaks (DSBs) in yeast. Here, we show that the human nucleoporin 153 (NUP153) has a role in repair of DSBs and in the activation of DNA damage checkpoints. We explore the mechanism of action of NUP153 and we propose its potential as a novel therapeutic target in cancers.	[Soutoglou, E.] CU Strasbourg, INSERM U964, UMR CNRS 7104, IGBMC,UdS, F-67404 Illkirch Graffenstaden, France; [Fischer, B.; Brino, L.] CU Strasbourg, UMR CNRS 7104, IGBMC, High Throughput Screening Facil, F-67404 Illkirch Graffenstaden, France; [Guirouilh-Barbat, J.; Genet, D.; Bertrand, P.; Lopez, B.] CNRS, UMR217, Inst Cellular & Mol Radiobiol, Fontenay Aux Roses, France; [Shahar, O. D.; Goldberg, M.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Hebrew University of Jerusalem	Soutoglou, E (corresponding author), CU Strasbourg, INSERM U964, UMR CNRS 7104, IGBMC,UdS, BP 10142, F-67404 Illkirch Graffenstaden, France.	evisou@igbmc.fr	Boumendil, Charlene/GPS-4811-2022; guirouilh-barbat, josée/AAX-7140-2020; Shahar, Or/ABG-9168-2020; Lopez, Bernard S/O-7308-2017; guirouilh-barbat, josee/O-7286-2017	Boumendil, Charlene/0000-0002-1953-3902; Lopez, Bernard S/0000-0001-5088-0155; Shahar, Or/0000-0002-5039-8307; guirouilh-barbat, josee/0000-0002-8845-7333; Goldberg, Michal/0000-0001-9397-2383; BERTRAND, Pascale/0000-0002-9019-742X; Brino, laurent/0000-0002-9036-1461; Soutoglou, Evi/0000-0002-3724-5613	Region Alsace; CNRS; ANR; INCA; HFSP	Region Alsace(Region Grand-Est); CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR(French National Research Agency (ANR)); INCA(Institut National du Cancer (INCA) France); HFSP(Human Frontier Science Program)	We thank Amelie Weiss, Laure Froidevaux and Audrey Furst for excellent technical assistance. The GFP-NUP153 vector was provided by Ian Ellenberg (EMBL, Heidelberg). We are grateful to Zita Nagy and Tibor Pankotai for critical reading of the manuscript. C.L. is supported by the Region Alsace. The research in E.S. lab is funded by CNRS, ANR, INCA and HFSP. We thank the imaging center of IGBMC and particularly Marc Koch for the help with the multi photon laser experiments.	Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bermejo R, 2011, CELL, V146, P233, DOI 10.1016/j.cell.2011.06.033; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Lee JH, 2010, EMBO J, V29, P574, DOI 10.1038/emboj.2009.372; Lisby M, 2003, NAT CELL BIOL, V5, P572, DOI 10.1038/ncb997; Loeillet S, 2005, DNA REPAIR, V4, P459, DOI 10.1016/j.dnarep.2004.11.010; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Minter-Dykhouse K, 2008, J CELL BIOL, V181, P727, DOI 10.1083/jcb.200801083; Misteli T, 2009, NAT REV MOL CELL BIO, V10, P243, DOI 10.1038/nrm2651; Mochan TA, 2003, CANCER RES, V63, P8586; Moudry P, 2012, CELL DEATH DIFFER, V19, P798, DOI 10.1038/cdd.2011.150; Nagai S, 2008, SCIENCE, V322, P597, DOI 10.1126/science.1162790; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Oza P, 2009, GENE DEV, V23, P912, DOI 10.1101/gad.1782209; Palancade B, 2007, MOL BIOL CELL, V18, P2912, DOI 10.1091/mbc.E07-02-0123; Rass E, 2009, NAT STRUCT MOL BIOL, V16, P819, DOI 10.1038/nsmb.1641; Reddy KL, 2008, METHODS, V45, P242, DOI 10.1016/j.ymeth.2008.06.013; Soutoglou E, 2008, SCIENCE, V320, P1507, DOI [10.1126/science.1159051, 10.1126/science.ll59051]; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Xie AY, 2007, MOL CELL, V28, P1045, DOI 10.1016/j.molcel.2007.12.005; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	27	43	43	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4803	4809		10.1038/onc.2011.638	http://dx.doi.org/10.1038/onc.2011.638			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22249246				2022-12-28	WOS:000311033000009
J	Huang, S; Gulzar, ZG; Salari, K; Lapointe, J; Brooks, JD; Pollack, JR				Huang, S.; Gulzar, Z. G.; Salari, K.; Lapointe, J.; Brooks, J. D.; Pollack, J. R.			Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness	ONCOGENE			English	Article						prostate cancer; genomic profiling; tumor suppressor; chromatin remodeling; cell invasion	MOLECULAR ASPECTS; COPY NUMBER; MUTATIONS; CHROMATIN; ABERRATIONS; REVEALS; ARID1A; FAMILY	Though prostate cancer is often indolent, it is nonetheless a leading cause of cancer death. Defining the underlying molecular genetic alterations may lead to new strategies for prevention or treatment. Towards this goal, we performed array-based comparative genomic hybridization (CGH) on 86 primary prostate tumors. Among the most frequent alterations not associated with a known cancer gene, we identified focal deletions within 5q21 in 15 out of 86 (17%) cases. By high-resolution tiling array CGH, the smallest common deletion targeted just one gene, the chromatin remodeler chromodomain helicase DNA-binding protein 1 (CHD1). Expression of CHD1 was significantly reduced in tumors with deletion (P = 0.03), and compared with normal prostate (P = 0.04). Exon sequencing analysis also uncovered nonsynonymous mutations in 1 out of 7 (14%) cell lines (LAPC4) and in 1 out of 24 (4%) prostate tumors surveyed. RNA interference-mediated knockdown of CHD1 in two nontumorigenic prostate epithelial cell lines, OPCN2 and RWPE-1, did not alter cell growth, but promoted cell invasiveness, and in OPCN2-enhanced cell clonogenicity. Taken together, our findings suggest that CHD1 deletion may underlie cell invasiveness in a subset of prostate cancers, and indicate a possible novel role of altered chromatin remodeling in prostate tumorigenesis. Oncogene (2012) 31, 4164-4170; doi:10.1038/onc.2011.590; published online 19 December 2011	[Huang, S.; Salari, K.; Pollack, J. R.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Gulzar, Z. G.; Brooks, J. D.] Stanford Univ, Dept Urol, Stanford, CA 94305 USA; [Lapointe, J.] McGill Univ, Dept Surg, Div Urol, Montreal, PQ H3A 2T5, Canada	Stanford University; Stanford University; McGill University	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, 269 Campus Dr,CCSR 3245A, Stanford, CA 94305 USA.	pollack1@stanford.edu			NIH [CA122246, CA111782, CA130472]; Burroughs Wellcome Fund [1007519]; American Cancer Society [PF-08-078-01-MGO]; Prostate Cancer Canada; Stanford Cancer Center; NATIONAL CANCER INSTITUTE [P30CA124435, F32CA130472, R01CA111782, R01CA122246] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Cancer Society(American Cancer Society); Prostate Cancer Canada; Stanford Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank the members of the Pollack lab for helpful discussion. Supported by grants from the NIH (CA122246 to JRP; CA111782 to JDB; CA130472 to SH), the Burroughs Wellcome Fund (1007519 to JRP), the American Cancer Society (PF-08-078-01-MGO to SH), Prostate Cancer Canada (to JL) and the Stanford Cancer Center (to JRP).	Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Binkley J, 2010, GENOME RES, V20, P142, DOI 10.1101/gr.097121.109; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Gaspar-Maia A, 2009, NATURE, V460, P863, DOI 10.1038/nature08212; Hall JA, 2007, BIOCHEM CELL BIOL, V85, P463, DOI 10.1139/O07-063; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Marfella CGA, 2007, MUTAT RES-FUND MOL M, V618, P30, DOI 10.1016/j.mrfmmm.2006.07.012; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Menon T, 2010, MOL ENDOCRINOL, V24, P1165, DOI 10.1210/me.2009-0421; Nagarajan P, 2009, ONCOGENE, V28, P1053, DOI 10.1038/onc.2008.440; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433	28	80	82	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4164	4170		10.1038/onc.2011.590	http://dx.doi.org/10.1038/onc.2011.590			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22179824	Green Accepted			2022-12-28	WOS:000308688900008
J	Kong, D; Piao, YS; Yamashita, S; Oshima, H; Oguma, K; Fushida, S; Fujimura, T; Minamoto, T; Seno, H; Yamada, Y; Satou, K; Ushijima, T; Ishikawa, TO; Oshima, M				Kong, D.; Piao, Y-S; Yamashita, S.; Oshima, H.; Oguma, K.; Fushida, S.; Fujimura, T.; Minamoto, T.; Seno, H.; Yamada, Y.; Satou, K.; Ushijima, T.; Ishikawa, T-O; Oshima, M.			Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells	ONCOGENE			English	Article						miR-7; gastric cancer; inflammation; macrophages	PROSTAGLANDIN E-2 PATHWAY; GROWTH-FACTOR RECEPTOR; ACTIVATED MACROPHAGES; NEURITE OUTGROWTH; DNA METHYLATION; CANCER; MICRORNA-7; TARGETS; INDUCTION; ELEMENT	Inflammation has an important role in cancer development through various mechanisms. It has been shown that dysregulation of microRNAs (miRNAs) that function as oncogenes or tumor suppressors contributes to tumorigenesis. However, the relationship between inflammation and cancer-related miRNA expression in tumorigenesis has not yet been fully understood. Using K19-C2mE and Gan mouse models that develop gastritis and gastritis-associated tumors, respectively, we found that 21 miRNAs were upregulated, and that 29 miRNAs were downregulated in gastric tumors in an inflammation-dependent manner. Among these miRNAs, the expression of miR-7, a possible tumor suppressor, significantly decreased in both gastritis and gastric tumors. Moreover, the expression of miR-7 in human gastric cancer was inversely correlated with the levels of interleukin-1 beta and tumor necrosis factor-alpha, suggesting that miR-7 downregulation is related to the severity of inflammatory responses. In the normal mouse stomach, miR-7 expression was at a basal level in undifferentiated gastric epithelial cells, and was induced during differentiation. Moreover, transfection of a miR-7 precursor into gastric cancer cells suppressed cell proliferation and soft agar colony formation. These results suggest that suppression of miR- 7 expression is important for maintaining the undifferentiated status of gastric epithelial cells, and thus contributes to gastric tumorigenesis. Although epigenetic changes were not found in the CpG islands around miR-7-1 of gastritis and gastric tumor cells, we found that activated macrophage-derived small molecule(s) ( <3kDa) are responsible for miR-7 repression in gastric cancer cells. Furthermore, the miR-7 expression level significantly decreased in the inflamed gastric mucosa of Helicobacter-infected mice, whereas it increased in the stomach of germfree K19-C2mE and Gan mice wherein inflammatory responses were suppressed.	[Kong, D.; Piao, Y-S; Oshima, H.; Oguma, K.; Ishikawa, T-O; Oshima, M.] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan; [Yamashita, S.; Ushijima, T.] Natl Canc Ctr, Res Inst, Div Epigen, Tokyo 104, Japan; [Fushida, S.; Fujimura, T.] Kanazawa Univ Hosp, Dept Gastroenterol Surg, Kanazawa, Ishikawa, Japan; [Minamoto, T.] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 9201192, Japan; [Seno, H.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan; [Yamada, Y.; Satou, K.] Kanazawa Univ, Inst Sci & Engn, Fac Elect & Comp Engn, Kanazawa, Ishikawa 9201192, Japan; [Piao, Y-S] Yanbian Univ, Med Coll, Dept Pathophysiol, Yanji 133002, Peoples R China	Kanazawa University; National Cancer Center - Japan; Kanazawa University; Kanazawa University; Kyoto University; Kanazawa University; Yanbian University	Oshima, M (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	oshimam@kenroku.kanazawa-u.ac.jp	Satou, Kenji/C-3316-2015; Ushijima, Toshikazu/AAP-5742-2021; Oshima, Masanobu/F-9958-2014	Satou, Kenji/0000-0001-5474-7087; Ushijima, Toshikazu/0000-0003-3405-7817; Oshima, Masanobu/0000-0002-3304-0004; Oshima, Hiroko/0000-0001-6855-4008; Seno, Hiroshi/0000-0002-8509-8128	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research [22500996, 23659643] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Manami Watanabe for her excellent technical assistance. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and the Ministry of Health, Labour and Welfare of Japan.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen HL, 2010, BIOCHEM BIOPH RES CO, V394, P921, DOI 10.1016/j.bbrc.2010.03.076; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; Chou YT, 2010, CANCER RES, V70, P8822, DOI 10.1158/0008-5472.CAN-10-0638; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Itadani H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-615; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Korshunova I, 2008, J NEUROSCI RES, V86, P2201, DOI 10.1002/jnr.21678; Nguyen HTT, 2010, J BIOL CHEM, V285, P1479, DOI 10.1074/jbc.M109.057141; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Oshima H, 2009, CANCER RES, V69, P2729, DOI 10.1158/0008-5472.CAN-08-4394; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Saydam O, 2011, CANCER RES, V71, P852, DOI 10.1158/0008-5472.CAN-10-1219; Sonkoly E, 2011, MUTAT RES-FUND MOL M, V717, P46, DOI 10.1016/j.mrfmmm.2011.02.002; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200; Wu H, 2010, MOL CELL, V38, P67, DOI 10.1016/j.molcel.2010.02.021; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282	39	88	92	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	35					3949	3960		10.1038/onc.2011.558	http://dx.doi.org/10.1038/onc.2011.558			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22139078	Green Submitted			2022-12-28	WOS:000308342800004
J	Yoon, S; Woo, SU; Kang, JH; Kim, K; Shin, HJ; Gwak, HS; Park, S; Chwae, YJ				Yoon, S.; Woo, S. U.; Kang, J. H.; Kim, K.; Shin, H-J; Gwak, H-S; Park, S.; Chwae, Y-J			NF-kappa B and STAT3 cooperatively induce IL6 in starved cancer cells	ONCOGENE			English	Article						cancer; ER stress; IL6; NF-kappa B; STAT3	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ACTIVATES TRANSCRIPTION; INDUCED AUTOPHAGY; NADPH OXIDASE; PATHWAY; BINDING; SURVIVAL; INHIBITION; MECHANISMS	A number of genes involved in tumorigenesis have been known to be controlled by signal transducer and activator of transcription 3 (STAT3) and NF-kappa B, either synergistically or individually. In starved cancer cells, we found that NF-kappa B was activated through endoplasmic reticulum stress signals, which depend on reactive oxygen species, cytosolic calcium and preserved translation of NF-kappa B p65 subunit, but independent of I kappa B alpha serine phosphorylation, thereby resulting in IL6 induction. STAT3 was required for proper induction of IL6 by NF-kappa B. They existed as identical nuclear complexes in proximal IL6 promoters, and STAT3 had critical roles in binding to IL6 promoters as well as nuclear retention of NF-kappa B. The conditioned media from starved cancer cells contained various secretory factors, such as IL6, IL9, VWF (von Willebrand factor), FREM1 (FRAS1 related extracellular matrix 1), SAA1 (serum amyloid A1), SDK1 (sidekick homolog 1) and ADAM12 (ADAM metallopeptidase domain 12), induced by NF-kappa B and STAT3 and promoted clonogenic capacities of cancer cells, and proliferation and migration of human umbilical vein endothelial cells. These results suggest novel survival strategies of cancer cells by which two oncogenic transcriptional factors, NF-kappa B and STAT3, are activated simultaneously by an intrinsic mechanism during stressful conditions of cancer cells, and they cooperatively induce various survival factors. Oncogene (2012) 31, 3467-3481; doi:10.1038/onc.2011.517; published online 21 November 2011	[Yoon, S.; Woo, S. U.; Kang, J. H.; Kim, K.; Shin, H-J; Park, S.; Chwae, Y-J] Ajou Univ, Sch Med, Dept Microbiol, Suwon 443721, Gyeonggi Do, South Korea; [Gwak, H-S] Natl Canc Ctr Korea, Neurooncol Clin, Koyang, South Korea	Ajou University; National Cancer Center - Korea (NCC)	Chwae, YJ (corresponding author), Ajou Univ, Sch Med, Dept Microbiol, San 5 Woncheon Dong, Suwon 443721, Gyeonggi Do, South Korea.	ponggo67@ajou.ac.kr			National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0005804, 2009-0076174, 2011-0089971]; Korea Science and Engineering Foundation (KOSEF) through the Chronic Inflammatory Disease Research Center (CIDRC) [R13-2003-019]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korea Science and Engineering Foundation (KOSEF) through the Chronic Inflammatory Disease Research Center (CIDRC)(Korea Science and Engineering Foundation)	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (No. 2011-0005804, No. 2009-0076174, and No. 2011-0089971), and a Korea Science and Engineering Foundation (KOSEF) Grant (R13-2003-019) through the Chronic Inflammatory Disease Research Center (CIDRC). We are grateful to Mogam Biotechnology Research Institute (Yongin, Korea) for providing us with HUVEC and U87MG cell lines. We are very thankful to Professor Kyung-Sup Kim (Yonsei University College of Medicine, Seoul, Korea) and Professor Woon Ki Baek for critical reading and proofreading of the manuscript.	Ba XQ, 2010, J BIOL CHEM, V285, P11596, DOI 10.1074/jbc.M109.076984; Bosco N, 2010, CANCER GENET CYTOGEN, V202, P47, DOI 10.1016/j.cancergencyto.2010.06.008; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Frank David A, 2003, Cancer Treat Res, V115, P267; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gil-Bazo I, 2003, Rev Med Univ Navarra, V47, P22; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Goswami R, 2011, J IMMUNOL, V186, P3283, DOI 10.4049/jimmunol.1003049; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jacobsen J, 2009, CURR PHARM DESIGN, V15, P2300, DOI 10.2174/138161209788682389; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008; Kitamura M, 2009, ANTIOXID REDOX SIGN, V11, P2353, DOI 10.1089/ARS.2008.2391; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee JK, 2007, GASTROENTEROLOGY, V133, P1637, DOI 10.1053/j.gastro.2007.08.022; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Mattarollo SR, 2010, NAT IMMUNOL, V11, P981, DOI 10.1038/ni1110-981; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; Shang J, 2004, BIOCHEMISTRY-US, V43, P9576, DOI 10.1021/bi049358o; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Smyth I, 2004, P NATL ACAD SCI USA, V101, P13560, DOI 10.1073/pnas.0402760101; Souza V, 2009, TOXICOL LETT, V187, P180, DOI 10.1016/j.toxlet.2009.02.021; Vales LD, 2002, J BIOL CHEM, V277, P42438, DOI 10.1074/jbc.M207363200; Wu TY, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-160; Xiao GT, 2011, AM J CANCER RES, V1, P192; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yang XR, 2009, INT J CANCER, V125, P2912, DOI 10.1002/ijc.24622; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Yoon S, 2010, AUTOPHAGY, V6, P1125, DOI 10.4161/auto.6.8.13547; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203	47	98	100	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3467	3481		10.1038/onc.2011.517	http://dx.doi.org/10.1038/onc.2011.517			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22105366				2022-12-28	WOS:000306566400007
J	Jeanblanc, M; Ragu, S; Gey, C; Contrepois, K; Courbeyrette, R; Thuret, JY; Mann, C				Jeanblanc, M.; Ragu, S.; Gey, C.; Contrepois, K.; Courbeyrette, R.; Thuret, J-Y; Mann, C.			Parallel pathways in RAF-induced senescence and conditions for its reversion	ONCOGENE			English	Article						senescence; DNA damage; oxidative stress; RAF kinase; CKI	ONCOGENE-INDUCED SENESCENCE; NORMAL HUMAN FIBROBLASTS; CELL-CYCLE ARREST; PREMATURE SENESCENCE; HETEROCHROMATIN FORMATION; SIGNALING PATHWAY; IN-VITRO; S-PHASE; KINASE; P53	We developed a clonal WI-38hTERT/GFP-RAF1-ER immortal cell line to study RAF-induced senescence of human fibroblasts. Activation of the GFP-RAF1-ER kinase by addition of 4-hydroxy-tamoxifen led to a robust induction of senescence within one population doubling, accompanied by the assembly of heterochromatic foci. At least two pathways contribute in parallel to this senescence leading to the accumulation of p15, p16, p21 and p27 inhibitors of cyclin-dependent kinases (CKIs). Cells that traversed S phase after RAF1 kinase activation experienced a replicative stress manifested by phosphorylation of H2AX and Chk2 and synthesis of p21. However, about half the cells in the population were blocked without passing through S phase and did not show activation of DNA-damage checkpoints. When the cells were cultivated in 5% oxygen, RAF1 activation generated minimal reactive oxygen species, but RAF-induced senescence occurred efficiently in these conditions even in the presence of anti-oxidants or inhibitors of DNA checkpoint pathways. Despite the presence of heterochromatic foci, simultaneous knockdown of p16 and p21 with inactivation of the GFP-RAF1-ER kinase led to rapid reversion of the senescent state with the majority of cells becoming competent for long-term proliferation. These results demonstrate that replicative and oxidative stresses are not required for RAF-induced senescence, and this senescence is readily reversed upon loss of CKIs. Oncogene (2012) 31, 3072-3085; doi: 10.1038/onc.2011.481; published online 24 October 2011	[Jeanblanc, M.; Ragu, S.; Gey, C.; Contrepois, K.; Courbeyrette, R.; Thuret, J-Y; Mann, C.] CEA Saclay, CEA, Serv Biol Integrat & Genet Mol, iBiTec S, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Mann, C (corresponding author), CEA Saclay, CEA, Serv Biol Integrat & Genet Mol, iBiTec S, Bat 142, F-91191 Gif Sur Yvette, France.	carl.mann@cea.fr		Thuret, Jean-Yves/0000-0001-5385-7620; Mann, Carl/0000-0001-7212-1512	French National Research Agency [ANR-07-BLAN-0098-CSD8]; French Association for Cancer Research [ARC 4917]; French Association for Cancer Research; CEA Irtelis doctoral fellowship through the CEA Plasticity and Instability of the Genome Intramural Program	French National Research Agency(French National Research Agency (ANR)); French Association for Cancer Research; French Association for Cancer Research; CEA Irtelis doctoral fellowship through the CEA Plasticity and Instability of the Genome Intramural Program	We thank Chiara Castelli (Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy) for pLXSN-hTERT, Marco Crescenzi (Istituto Superiore di Sanita, Rome, Italy) for GST-CKI plasmids, and Martin McMahon (University of California San Francisco, USA) for the RAF1-ER plasmids, the IMR90/GFP-RAF1-ER cells and for invaluable advice. JYT thanks Masashi Narita for fruitful discussions and we also thank Michel Toledano for comments on the manuscript. This work was supported by grants from the French National Research Agency (ANR-07-BLAN-0098-CSD8) and the French Association for Cancer Research (ARC 4917), and benefited from discussions within the CEA/Curie network on Replication, Chromosomal Instability, and Cancer. SR is the recipient of a postdoctoral fellowship from the French Association for Cancer Research, and KC received a CEA Irtelis doctoral fellowship through the CEA Plasticity and Instability of the Genome Intramural Program.	[Anonymous], 2010, R LANG ENV STAT COMP; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Brahimi-Horn MC, 2007, FEBS LETT, V581, P3582, DOI 10.1016/j.febslet.2007.06.018; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Contrepois K, 2010, J PROTEOME RES, V9, P5501, DOI 10.1021/pr100497a; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dalerba P, 2005, CANCER RES, V65, P2321, DOI 10.1158/0008-5472.CAN-04-3678; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Forsyth NR, 2003, AGING CELL, V2, P235, DOI 10.1046/j.1474-9728.2003.00057.x; Funayama R, 2006, J CELL BIOL, V175, P869, DOI 10.1083/jcb.200604005; Galvani A, 2008, MOL CELL BIOL, V28, P3672, DOI 10.1128/MCB.00510-07; Hahne F, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-106; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jun JI, 2010, NAT CELL BIOL, V12, P676, DOI 10.1038/ncb2070; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Pajalunga D, 2007, J CELL BIOL, V176, P807, DOI 10.1083/jcb.200608109; Popov N, 2010, EPIGENETICS-US, V5, P685, DOI 10.4161/epi.5.8.12996; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Robles SJ, 1999, BIOCHEM PHARMACOL, V58, P675, DOI 10.1016/S0006-2952(99)00127-6; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Satyanarayana A, 2004, MOL CELL BIOL, V24, P5459, DOI 10.1128/MCB.24.12.5459-5474.2004; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Terry NHA, 2006, NAT PROTOC, V1, P859, DOI 10.1038/nprot.2006.113; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wei S, 1999, CANCER RES, V59, P1539; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu Q, 2002, CANCER RES, V62, P5743; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	52	42	42	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3072	3085		10.1038/onc.2011.481	http://dx.doi.org/10.1038/onc.2011.481			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020327				2022-12-28	WOS:000305705900006
J	Basu-Roy, U; Seo, E; Ramanathapuram, L; Rapp, TB; Perry, JA; Orkin, SH; Mansukhani, A; Basilico, C				Basu-Roy, U.; Seo, E.; Ramanathapuram, L.; Rapp, T. B.; Perry, J. A.; Orkin, S. H.; Mansukhani, A.; Basilico, C.			Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas	ONCOGENE			English	Article						osteosarcoma; wnt signaling; cancer stem cell; mesenchymal tumors; differentiation; sarcosphere	CANCER STEM-CELLS; TRANSCRIPTION FACTOR SOX2; OSTEOBLAST DIFFERENTIATION; PROGENITOR CELLS; BETA-CATENIN; MOUSE MODEL; WNT; GROWTH; SARCOMA; LINEAGE	Tumors are thought to be sustained by a reservoir of self-renewing cells, termed tumor-initiating cells or cancer stem cells. Osteosarcomas are high-grade sarcomas derived from osteoblast progenitor cells and are the most common pediatric bone malignancy. In this report we show that the stem cell transcription factor Sox2 is highly expressed in human and murine osteosarcoma (mOS) cell lines as well as in the tumor samples. Osteosarcoma cells have increased ability to grow in suspension as osteospheres, that are greatly enriched in expression of Sox2 and the stem cell marker, Sca-1. Depletion of Sox2 by short-hairpin RNAs in independent mOS-derived cells drastically reduces their transformed properties in vitro and their ability to form tumors. Sox2-depleted osteosarcoma cells can no longer form osteospheres and differentiate into mature osteoblasts. Concomitantly, they exhibit decreased Sca-1 expression and upregulation of the Wnt signaling pathway. Thus, despite other mutations, these cells maintain a requirement for Sox2 for tumorigenicity. Our data indicate that Sox2 is required for osteosarcoma cell self renewal, and that Sox2 antagonizes the pro-differentiation Wnt pathway that can in turn reduce Sox2 expression. These studies define Sox2 as a survival factor and a novel biomarker of self renewal in osteosarcomas, and support a tumor suppressive role for the Wnt pathway in tumors of mesenchymal origin. Our findings could provide the basis for novel therapeutic strategies based on inhibiting Sox2 or enhancing Wnt signaling for the treatment of osteosarcomas. Oncogene (2012) 31, 2270-2282; doi:10.1038/onc.2011.405; published online 19 September 2011	[Basu-Roy, U.; Seo, E.; Mansukhani, A.; Basilico, C.] NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; [Ramanathapuram, L.] NYU, Coll Dent, New York, NY 10016 USA; [Rapp, T. B.] NYU, Sch Med, Dept Orthoped Surg, New York, NY 10016 USA; [Perry, J. A.; Orkin, S. H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Harvard Stem Cell Inst, Boston, MA 02115 USA; [Perry, J. A.; Orkin, S. H.] Howard Hughes Med Inst, Boston, MA 02115 USA; [Perry, J. A.; Orkin, S. H.] Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston, Boston, MA USA	New York University; New York University; New York University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Mansukhani, A (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	Alka.Mansukhani@med.nyu.edu; Claudio.Basilico@med.nyu.edu		Mansukhani, Alka/0000-0003-1020-3242; , Tim/0000-0002-1444-0803	PHS from the NIAMS [AR051358]; NIDCR [DE013745]; NCI; Children's Cancer Research Fund; St Baldrick's Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051358] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013745] Funding Source: NIH RePORTER	PHS from the NIAMS; NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Children's Cancer Research Fund; St Baldrick's Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr E De Stanchina (Antitumor Assessment Facility, Memorial Sloan Kettering Cancer Center, New York, NY) for excellent services and advice with the xenograft assays. Thanks to Dr J Durbin, NYU TABS, for help with tissue acquisition. This investigation was supported by PHS Grants AR051358 from the NIAMS and DE013745 from the NIDCR, and by an NCI UO1 award (to SHO). UBR is a recipient of a fellowship from The Children's Cancer Research Fund in memory of Dr A Rausen. AM is a recipient of a research grant from St Baldrick's Foundation. JAP is a postdoctoral fellow of the American Cancer Society. SHO is an Investigator of the Howard Hughes Medical Institute.	Adams JM, 2008, COLD SH Q B, V73, P451, DOI 10.1101/sqb.2008.73.004; Ambrosetti D, 2008, MOL CELL BIOL, V28, P4759, DOI 10.1128/MCB.01849-07; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Basu-Roy U, 2010, CELL DEATH DIFFER, V17, P1345, DOI 10.1038/cdd.2010.57; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Buzzeo MP, 2007, LEUKEMIA, V21, P1619, DOI 10.1038/sj.leu.2404768; Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Cantiani L, 2007, CANCER RES, V67, P7675, DOI 10.1158/0008-5472.CAN-06-4697; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cleton-Jansen AM, 2009, BRIT J CANCER, V101, P1909, DOI 10.1038/sj.bjc.6605405; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cormier JN, 2004, CA-CANCER J CLIN, V54, P94, DOI 10.3322/canjclin.54.2.94; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Fujii H, 2009, INT J ONCOL, V34, P1381, DOI 10.3892/ijo_00000265; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Gillette JM, 2008, IN VITRO CELL DEV-AN, V44, P87, DOI 10.1007/s11626-007-9075-8; Gong C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015630; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Heare T, 2009, CURR OPIN PEDIATR, V21, P365, DOI 10.1097/MOP.0b013e32832b1111; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hong JH, 2006, CELL CYCLE, V5, P176, DOI 10.4161/cc.5.2.2362; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jia SF, 1999, CLIN EXP METASTAS, V17, P501, DOI 10.1023/A:1006623001465; Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim CF, 2008, CELL STEM CELL, V3, P147, DOI 10.1016/j.stem.2008.07.012; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Mansukhani A, 2005, J CELL BIOL, V168, P1065, DOI 10.1083/jcb.200409182; Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378-1119(03)00748-0; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Milat F, 2009, MOL CELL ENDOCRINOL, V310, P52, DOI 10.1016/j.mce.2009.06.002; Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018; Que JW, 2009, DEVELOPMENT, V136, P1899, DOI 10.1242/dev.034629; Rainusso N, 2011, CANCER BIOL THER, V12, P278, DOI 10.4161/cbt.12.4.15951; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; TABONE MD, 1994, J CLIN ONCOL, V12, P2614, DOI 10.1200/JCO.1994.12.12.2614; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Takada I, 2009, NAT REV RHEUMATOL, V5, P442, DOI 10.1038/nrrheum.2009.137; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; WADAYAMA B, 1994, CANCER RES, V54, P3042; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	59	177	187	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2270	2282		10.1038/onc.2011.405	http://dx.doi.org/10.1038/onc.2011.405			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21927024	Green Submitted, Green Accepted			2022-12-28	WOS:000303610800003
J	Schepeler, T; Holm, A; Halvey, P; Nordentoft, I; Lamy, P; Riising, EM; Christensen, LL; Thorsen, K; Liebler, DC; Helin, K; Orntoft, TF; Andersen, CL				Schepeler, T.; Holm, A.; Halvey, P.; Nordentoft, I.; Lamy, P.; Riising, E. M.; Christensen, L. L.; Thorsen, K.; Liebler, D. C.; Helin, K.; Orntoft, T. F.; Andersen, C. L.			Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes	ONCOGENE			English	Article						microRNA; Wnt; cancer; miR-30e-3p; PIK3C2A; TCF4	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; PROSTATE-CANCER; EXPRESSION; PROLIFERATION; BLADDER; CONTRIBUTES; OSTEOBLASTS; DOWNSTREAM; TRANSITION	Aberrant activation of the Wnt signaling pathway is causally involved in the formation of most colorectal cancers (CRCs). Although detailed knowledge exists regarding Wnt-regulated protein-coding genes, much less is known about the possible involvement of non-coding RNAs. Here we used TaqMan Array MicroRNA Cards, capable of detecting 664 unique human microRNAs (miRNAs), to describe changes of the miRNA transcriptome following disruption of beta-catenin/TCF4 activity in DLD1 CRC cells. Most miRNAs appeared to respond independent of host gene regulation and proximal TCF4 chromatin occupancy as inferred from expression microarray and ChIP-chip data. A module of miRNAs induced by abrogated Wnt signaling in vitro was downregulated in two independent series of human primary CRCs (n = 76) relative to normal adjacent mucosa (n = 34). Several of these miRNAs (miR-145, miR-126, miR-30e-3p and miR-139-5p) markedly inhibited CRC cell growth in vitro when ectopically expressed. By using an integrative approach of proteomics and expression microarrays, we found numerous mRNAs and proteins to be affected by ectopic miR-30e-3p levels. This included HELZ and PIK3C2A that were directly repressed by several miRNA binding sites as confirmed by luciferase reporter assays in combination with mutational analyses. Finally, small interfering RNA-mediated downregulation of PIK3C2A, but not HELZ, was sufficient on its own to restrict CRC cell growth. Collectively, our study demonstrates that multiple miRNAs are upregulated as a consequence of forced attenuation of Wnt signaling in CRC cells, and some of these miRNAs inhibit cell growth with concomitant suppression of several growth-stimulatory cancer-related genes. Oncogene (2012) 31, 2750-2760; doi: 10.1038/onc.2011.453; published online 3 October 2011	[Schepeler, T.; Holm, A.; Nordentoft, I.; Lamy, P.; Christensen, L. L.; Thorsen, K.; Orntoft, T. F.; Andersen, C. L.] Aarhus Univ Hosp, Dept Mol Med MOMA, DK-8200 Aarhus N, Denmark; [Halvey, P.; Liebler, D. C.] Vanderbilt Univ, Sch Med, Dept Biochem, Jim Ayers Inst Precanc Detect & Diag, Nashville, TN 37212 USA; [Riising, E. M.; Helin, K.] Univ Copenhagen, BRIC, Copenhagen, Denmark	Aarhus University; Vanderbilt University; University of Copenhagen	Andersen, CL (corresponding author), Aarhus Univ Hosp, Dept Mol Med MOMA, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.	cla@ki.au.dk	Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022; Nordentoft, Iver/C-6345-2017; Holm, Anja/AAN-7702-2020; Andersen, Claus L/C-1477-2017; Andersen, Claus Lindbjerg/A-9217-2012	Helin, Kristian/0000-0003-1975-6097; Madi Riising, Eva/0000-0003-3152-5769; Nordentoft, Iver Kristiansen/0000-0003-4856-4086; Holm, Anja/0000-0001-8796-1872; Andersen, Claus Lindbjerg/0000-0002-7406-2103; Liebler, Daniel/0000-0002-7873-3031	Desiree and Niels Yde's Foundation; John and Birthe Meyer Foundation; Lundbeck Foundation; Danish Council for Independent Research Medical Sciences; Danish Council for Strategic Research; Danish Agency for Science, Technology and Innovation; Danish Ministry of the Interior and Health	Desiree and Niels Yde's Foundation; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Danish Council for Independent Research Medical Sciences(Det Frie Forskningsrad (DFF)); Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Agency for Science, Technology and Innovation; Danish Ministry of the Interior and Health	We thank Misti Martinez, Hanne Steen, Inge-Lis Thorsen and Pamela Celis for technical assistance. TOPflash/FOPflash plasmids were kindly provided by Philippe Blache, and the CLINT1 luciferase reporter plasmid was generously provided by Jesper B Bramsen. This work was supported by the Desiree and Niels Yde's Foundation, the John and Birthe Meyer Foundation, the Lundbeck Foundation, the Danish Council for Independent Research Medical Sciences, the Danish Council for Strategic Research, the Danish Agency for Science, Technology and Innovation, and the Danish Ministry of the Interior and Health.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen F, 2010, ONCOL REP, V23, P1457, DOI 10.3892/or_00000784; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cselenyi CS, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.18pe10; Dehner M, 2008, J BIOL CHEM, V283, P19201, DOI 10.1074/jbc.M710366200; Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79; Elis W, 2008, MOL CANCER RES, V6, P614, DOI 10.1158/1541-7786.MCR-07-0262; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Heintzman ND, 2009, CURR OPIN GENET DEV, V19, P541, DOI 10.1016/j.gde.2009.09.006; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Herranz H, 2008, EMBO J, V27, P1633, DOI 10.1038/emboj.2008.84; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137; Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Li HB, 2009, J BIOL CHEM, V284, P2012, DOI 10.1074/jbc.M805612200; Liao Y, 2010, CELL MOL LIFE SCI, V67, P2969, DOI 10.1007/s00018-010-0366-y; Martello G, 2007, NATURE, V449, P183, DOI 10.1038/nature06100; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Ng SKL, 2009, BIOCHEM BIOPH RES CO, V387, P310, DOI 10.1016/j.bbrc.2009.07.013; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Ostenfeld MS, 2010, ONCOGENE, V29, P1073, DOI 10.1038/onc.2009.395; Railo A, 2009, EXP CELL RES, V315, P2690, DOI 10.1016/j.yexcr.2009.06.021; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Slaby O, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-102; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Theisen H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000142; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Tsuchiya K, 2007, GASTROENTEROLOGY, V132, P208, DOI 10.1053/j.gastro.2006.10.031; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Vlad A, 2008, CELL SIGNAL, V20, P795, DOI 10.1016/j.cellsig.2007.10.031; Wang X, 2009, BIOCHEM BIOPH RES CO, V387, P376, DOI 10.1016/j.bbrc.2009.07.034; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08	52	64	68	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	22					2750	2760		10.1038/onc.2011.453	http://dx.doi.org/10.1038/onc.2011.453			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963845				2022-12-28	WOS:000304769000005
J	Bakthavatchalu, V; Dey, S; Xu, Y; Noel, T; Jungsuwadee, P; Holley, AK; Dhar, SK; Batinic-Haberle, I; St Clair, DK				Bakthavatchalu, V.; Dey, S.; Xu, Y.; Noel, T.; Jungsuwadee, P.; Holley, A. K.; Dhar, S. K.; Batinic-Haberle, I.; St Clair, D. K.			Manganese superoxide dismutase is a mitochondrial fidelity protein that protects Pol gamma against UV-induced inactivation	ONCOGENE			English	Article						fidelity gene; polymerase gamma; p53; MnSOD; oxidative/nitrative stresses; (MnTE)-T-III-2-PyP5+	DNA-POLYMERASE GAMMA; BASE EXCISION-REPAIR; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; OXIDATIVE STRESS; HUMAN SKIN; P53 PROTEIN; MOUSE KERATINOCYTES; SUNLIGHT EXPOSURE; ACCESSORY SUBUNIT; B IRRADIATION	Manganese superoxide dismutase is a nuclear encoded primary antioxidant enzyme localized exclusively in the mitochondrial matrix. Genotoxic agents, such as ultraviolet (UV) radiation, generates oxidative stress and cause mitochondrial DNA (mtDNA) damage. The mtDNA polymerase (Pol gamma), a major constituent of nucleoids, is responsible for the replication and repair of the mitochondrial genome. Recent studies suggest that the mitochondria contain fidelity proteins and MnSOD constitutes an integral part of the nucleoid complex. However, it is not known whether or how MnSOD participates in the mitochondrial repair processes. Using skin tissue from C57BL/6 mice exposed to UVB radiation, we demonstrate that MnSOD has a critical role in preventing mtDNA damage by protecting the function of Pol gamma. Quantitative-PCR analysis shows an increase in mtDNA damage after UVB exposure. Immunofluorescence and immunoblotting studies demonstrate p53 translocation to the mitochondria and interaction with Pol gamma after UVB exposure. The mtDNA immunoprecipitation assay with Pol gamma and p53 antibodies in p53(+/+) and p53(-/-) mice demonstrates an interaction between MnSOD, p53 and Pol gamma. The results suggest that these proteins form a complex for the repair of UVB-associated mtDNA damage. The data also demonstrate that UVB exposure injures the mtDNA D-loop in a p53-dependent manner. Using MnSOD-deficient mice we demonstrate that UVB-induced mtDNA damage is MnSOD dependent. Exposure to UVB results in nitration and inactivation of Pol gamma, which is prevented by addition of the MnSOD mimetic (MnTE)-T-III-2-PyP5+. These results demonstrate for the first time that MnSOD is a fidelity protein that maintains the activity of Pol gamma by preventing UVB-induced nitration and inactivation of Pol gamma. The data also demonstrate that MnSOD has a role along with p53 to prevent mtDNA damage. Oncogene (2012) 31, 2129-2139; doi:10.1038/onc.2011.407; published online 12 September 2011	[Bakthavatchalu, V.; Xu, Y.; Noel, T.; Jungsuwadee, P.; Holley, A. K.; Dhar, S. K.; St Clair, D. K.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Dey, S.] Proctor & Gamble, Cincinnati, OH USA; [Jungsuwadee, P.] Husson Univ, Dept Pharmacol & Toxicol, Bangor, ME USA; [Batinic-Haberle, I.] Duke Univ, Med Ctr, Durham, NC USA	University of Kentucky; Procter & Gamble; Duke University	St Clair, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 1095 VA Dr,HSRB 454, Lexington, KY 40536 USA.	dstcl00@uky.edu	Jungsuwadee, Paiboon/AAE-4038-2020	Jungsuwadee, Paiboon/0000-0002-5430-6887	National Institutes of Health [RO1CA073599-11]; NATIONAL CANCER INSTITUTE [R01CA073599, R01CA049797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the National Institutes of Health (RO1CA073599-11). The National Cancer Institute CA 073599.	Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Aitken GR, 2007, CLIN EXP DERMATOL, V32, P722, DOI 10.1111/j.1365-2230.2007.02474.x; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Bakhanashvili M, 2008, CELL DEATH DIFFER, V15, P1865, DOI 10.1038/cdd.2008.122; Batinic-Haberle I, 1999, INORG CHEM, V38, P4011, DOI 10.1021/ic990118k; Batinic-Haberle I, 2010, ANTIOXID REDOX SIGN, V13, P877, DOI 10.1089/ars.2009.2876; Batinic-Haberle IR, 2010, HDB PORPHYRIN SCI 2, P291; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Birch-Machin MA, 1998, J INVEST DERMATOL, V110, P149, DOI 10.1046/j.1523-1747.1998.00099.x; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOLDEN A, 1977, J BIOL CHEM, V252, P3351; Bonifacino J.S., 2001, CURR PROTOC MOL BIOL, V10; Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967; Cabiscol E, 2000, J BIOL CHEM, V275, P27393; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708; Decraene D, 2004, J INVEST DERMATOL, V122, P484, DOI 10.1046/j.0022-202X.2004.22215.x; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; Ferrer-Sueta G, 1999, CHEM RES TOXICOL, V12, P442, DOI 10.1021/tx980245d; Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399; GRAY H, 1992, J BIOL CHEM, V267, P5835; Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; HALL PA, 1993, ONCOGENE, V8, P203; Harbottle A, 2006, BRIT J CANCER, V94, P1887, DOI 10.1038/sj.bjc.6603178; Heyne K, 2004, FEBS LETT, V578, P198, DOI 10.1016/j.febslet.2004.10.099; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Kienhofer J, 2009, FASEB J, V23, P2034, DOI 10.1096/fj.08-113571; Kovalenko O.A., 2009, CURR PROTOC HUM GENE, V62; Krishnan KJ, 2004, J INVEST DERMATOL, V123, P1020, DOI 10.1111/j.0022-202X.2004.23457.x; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kulawiec Mariola, 2009, J Carcinog, V8, P8, DOI 10.4103/1477-3163.50893; Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004; Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134; Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523; LI G, 1995, CANCER RES, V55, P2070; Li G, 1997, AM J PATHOL, V150, P1457; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Longley Matthew J, 2002, Methods Mol Biol, V197, P245, DOI 10.1385/1-59259-284-8:245; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Maglio DHG, 2005, PHOTODERMATOL PHOTO, V21, P311, DOI 10.1111/j.1600-0781.2005.00185.x; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mihara Motohiro, 2003, Methods Mol Biol, V234, P203; O'Brien KM, 2004, J BIOL CHEM, V279, P51817, DOI 10.1074/jbc.M405958200; Ouhtit A, 2000, AM J PATHOL, V156, P201, DOI 10.1016/S0002-9440(10)64720-7; Ozden O, 2011, AGING-US, V3, P102, DOI 10.18632/aging.100291; Ray AJ, 2000, J INVEST DERMATOL, V115, P674, DOI 10.1046/j.1523-1747.2000.00092.x; Renzing J, 1996, J CELL SCI, V109, P1105; Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100; Stuart JA, 2004, FASEB J, V18, P595, DOI 10.1096/fj.03-0890fje; Taanman JW, 2010, METHODS, V51, P374, DOI 10.1016/j.ymeth.2010.03.002; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005; Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95; Waster PK, 2009, J INVEST DERMATOL, V129, P1769, DOI 10.1038/jid.2008.421; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; Wu SY, 2010, PHOTOCHEM PHOTOBIOL, V86, P389, DOI 10.1111/j.1751-1097.2009.00682.x; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zhao YF, 2002, ONCOGENE, V21, P3836, DOI 10.1038/sj.onc.1205477	75	42	43	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2129	2139		10.1038/onc.2011.407	http://dx.doi.org/10.1038/onc.2011.407			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21909133	Green Accepted			2022-12-28	WOS:000303415900002
J	Buijs, JT; van der Horst, G; van den Hoogen, C; Cheung, H; de Rooij, B; Kroon, J; Petersen, M; van Overveld, PGM; Pelger, RCM; van der Pluijm, G				Buijs, J. T.; van der Horst, G.; van den Hoogen, C.; Cheung, H.; de Rooij, B.; Kroon, J.; Petersen, M.; van Overveld, P. G. M.; Pelger, R. C. M.; van der Pluijm, G.			The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation	ONCOGENE			English	Article						cancer stem cell; bone morphogenetic protein; heterodimer; breast cancer; bone metastasis; transforming growth factor-beta	ALDEHYDE DEHYDROGENASE-ACTIVITY; COMBINATORIAL GENE-THERAPY; MESENCHYMAL TRANSITION; PROSPECTIVE IDENTIFICATION; MORPHOGENETIC PROTEIN-7; INITIATING CELLS; HUMAN PROSTATE; TGF-BETA; RESISTANCE; BMP7	Accumulating evidence suggests that a subpopulation of breast cancer cells, referred to as cancer stem cells (CSCs), have the ability to propagate a tumor and potentially seed new metastases. Furthermore, stimulation of an epithelialto-mesenchymal transition by factors like transforming growth factor-beta (GF beta) is accompanied with the generation of breast CSCs. Previous observations indicated that bone morphogenetic protein-7 (BMP7) antagonizes the protumorigenic and prometastatic actions of TGF beta, but whether BMP7 action is mechanistically linked to breast CSCs has remained elusive. Here, we have studied the effects of BMP7, BMP2 and a BMP2/7 heterodimer on the formation of human breast CSCs (ALDH(hi)/CD44(hi)/CD24(-/low)) and bone metastases formation in a preclinical model of intra-cardiac injection of MDA-MB-231 cells in athymic nude (Balb/c nu/nu) mice. The BMP2/7 heterodimer was the most efficient stimulator of BMP signaling and very effectively reduced TGF beta-driven Smad signaling and cancer cell invasiveness. The tested BMPs-particularly the heterodimeric BMP2/7-srongly reduced the size of the ALDH(hi)/CD44(hi)/CD24(-/low) CSC subpopulation. In keeping with these in vitro observations, pretreatment of cancer cells with BMPs for 72 h prior to systemic inoculation of the cancer cells inhibited the formation of bone metastases. Collectively, our data support the notion that breast CSCs are involved in bone metastasis formation and describe heterodimeric BMP2/7 as a powerful TGFb antagonist with anti-metastatic potency. Oncogene (2012) 31, 2164-2174; doi:10.1038/onc.2011.400; published online 26 September 2011	[Buijs, J. T.; van der Horst, G.; van den Hoogen, C.; Cheung, H.; de Rooij, B.; Kroon, J.; Petersen, M.; van Overveld, P. G. M.; Pelger, R. C. M.; van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Urol, NL-2333 ZA Leiden, Zuid Holland, Netherlands; [van der Pluijm, G.] Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Zuid Holland, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van der Pluijm, G (corresponding author), Leiden Univ, Med Ctr, Dept Urol, J3-100,Albinusdreef 2, NL-2333 ZA Leiden, Zuid Holland, Netherlands.	G.van_der_Pluijm@lumc.nl	Buijs, Jeroen/E-6082-2011; Pelger, Rob/ABF-9029-2021	Buijs, Jeroen/0000-0001-5816-9739; Pelger, Rob/0000-0001-6328-6462; van der Horst, Geertje/0000-0003-1696-160X; van Overveld, Petra GM/0000-0003-0216-5004; de Rooij, Bob/0000-0002-6424-0025	PRIMA; PROMET; BRECOSM; Dutch Cancer Society (KWF) [UL-2004-3028]	PRIMA; PROMET; BRECOSM; Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	We are grateful to Professor Dr P ten Dijke for providing the reporter constructs. JTB and GvdH were sponsored by the European Sixth Framework Programme PRIMA; CvdH and HC were sponsored by the European Sixth Framework Programme PROMET; MP was sponsored by the European Sixth Framework Programme BRECOSM and PGMvO was sponsored by a grant from Dutch Cancer Society (KWF project UL-2004-3028).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alison MR, 2010, J PATHOL, V222, P335, DOI 10.1002/path.2772; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Buijs JT, 2007, CLIN EXP METASTAS, V24, P609, DOI 10.1007/s10585-007-9118-2; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Buijs JT, 2007, AM J PATHOL, V171, P1047, DOI 10.2353/ajpath.2007.070168; Cheung AMS, 2007, LEUKEMIA, V21, P1423, DOI 10.1038/sj.leu.2404721; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Cook C, 2007, DEV BIOL, V312, P217, DOI 10.1016/j.ydbio.2007.09.038; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grishina IB, 2005, DEV BIOL, V288, P334, DOI 10.1016/j.ydbio.2005.08.018; HAZAMA M, 1995, BIOCHEM BIOPH RES CO, V209, P859, DOI 10.1006/bbrc.1995.1578; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Israel DI, 1996, GROWTH FACTORS, V13, P291, DOI 10.3109/08977199609003229; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Klose A, 2011, NEOPLASIA, V13, P276, DOI 10.1593/neo.101540; Koh JT, 2008, J DENT RES, V87, P845, DOI 10.1177/154405910808700906; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Notting IC, 2005, INVEST OPHTH VIS SCI, V46, P1581, DOI 10.1167/iovs.04-0245; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Petersen M, 2010, ONCOGENE, V29, P1351, DOI 10.1038/onc.2009.426; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Schwaninger R, 2007, AM J PATHOL, V170, P160, DOI 10.2353/ajpath.2007.051276; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1; ten Dijke P, 2006, CURR MED RES OPIN, V22, pS7, DOI 10.1185/030079906X80576; Uchino M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-414; Valera E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011167; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008-5472.CAN-04-4188; van der Pluijm G, 2011, BONE, V48, P37, DOI 10.1016/j.bone.2010.07.023; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Winquist RJ, 2009, BIOCHEM PHARMACOL, V78, P326, DOI 10.1016/j.bcp.2009.03.020; Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104; Zhao M, 2005, J CELL BIOCHEM, V95, P1, DOI 10.1002/jcb.20411; Zhu W, 2004, J BONE MINER RES, V19, P2021, DOI 10.1359/JBMR.040821	49	89	92	0	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2164	2174		10.1038/onc.2011.400	http://dx.doi.org/10.1038/onc.2011.400			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21996751				2022-12-28	WOS:000303415900005
J	Caldwell, ME; DeNicola, GM; Martins, CP; Jacobetz, MA; Maitra, A; Hruban, RH; Tuveson, DA				Caldwell, M. E.; DeNicola, G. M.; Martins, C. P.; Jacobetz, M. A.; Maitra, A.; Hruban, R. H.; Tuveson, D. A.			Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer	ONCOGENE			English	Article						senescence; Kras; PanIN; ADM; PDA; SA beta gal	ONCOGENE-INDUCED SENESCENCE; BARRIER; CELLS; MODEL; KRAS; PROGRESSION; MUTATIONS	During tumor initiation, oncogene-induced senescence (OIS) is proposed to limit the progression of preneoplasms to invasive carcinoma unless circumvented by the acquisition of certain tumor suppressor mutations. Using a variety of biomarkers, OIS has been previously reported in a wide range of human and murine precursor lesions, including the pancreas, lung, colon and skin. Here, we have characterized a panel of potential OIS biomarkers in human and murine pancreatic intraepithelial neoplasia (PanIN), and found that only senescence-associated beta-galactosidase (SA beta gal) activity is specifically enriched in these precursors, compared with pancreatic ductal adenocarcinoma (PDA). Indeed, many of the other proposed OIS biomarkers are detected in actively proliferating PanIN epithelium and in cells within the microenvironment. Surprisingly, acinar to ductal metaplasia (ADM), a distinct preneoplasm that is potentially a precursor for PanIN, also exhibits SA beta gal activity and contains a higher content of p21 and p53 than PanIN. Therefore, SA beta gal activity is the only biomarker that accurately identifies a small and heterogeneous population of non-proliferating premalignant cells in the pancreas, and the concomitant expression of p53 and p21 in ADM supports the possibility that PanIN and ADM each exhibit discrete senescence blocks. Oncogene (2012) 31, 1599-1608; doi:10.1038/onc.2011.350; published online 22 August 2011	[Caldwell, M. E.; DeNicola, G. M.; Martins, C. P.; Jacobetz, M. A.; Tuveson, D. A.] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 ORE, England; [Maitra, A.; Hruban, R. H.] Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA	Cancer Research UK; CRUK Cambridge Institute; Johns Hopkins University	Tuveson, DA (corresponding author), Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 ORE, England.	david.tuveson@cancer.org.uk		DeNicola, Gina/0000-0001-6611-6696	The Li Ka Shing Foundation; Hutchison Whampoa Limited; NIHR Cambridge Biomedical Research Centre; NIH [CA101973, CA111294, CA084291, CA105490]; University of Cambridge; Cancer Research UK; NATIONAL CANCER INSTITUTE [U01CA105490, R01CA101973, U01CA084291, U01CA111294] Funding Source: NIH RePORTER	The Li Ka Shing Foundation; Hutchison Whampoa Limited; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank P Krimpenfort, A Berns, R Taneja, F Alt, A Harris, M Malumbres C, Trejo, M McMahon, M Ferreira and F Watt for tissues and reagents. We thank Frances Connor and other members of the Tuveson lab for assistance and advice, the CRI animal care staff; S Vowler for statistical advice; Cancer Research UK Histopathology and In situ Hybridization Core, and the Microscopy and Imaging Core. This research was supported by the University of Cambridge and Cancer Research UK, The Li Ka Shing Foundation and Hutchison Whampoa Limited, the NIHR Cambridge Biomedical Research Centre and the NIH (grants CA101973, CA111294, CA084291 and CA105490) to DAT.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chien Y, 2008, CELL, V132, P339, DOI 10.1016/j.cell.2008.01.022; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Ivanova A, 2005, J MED GENET, V42, P565, DOI 10.1136/jmg.2004.029835; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Lee KE, 2010, CANCER CELL, V18, P448, DOI 10.1016/j.ccr.2010.10.020; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Moskaluk CA, 1997, CANCER RES, V57, P2140; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541-7786.MCR-08-0206; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhu LQ, 2007, AM J PATHOL, V171, P263, DOI 10.2353/ajpath.2007.061176	43	60	60	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1599	1608		10.1038/onc.2011.350	http://dx.doi.org/10.1038/onc.2011.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860420	Green Accepted			2022-12-28	WOS:000302132000012
J	Gaude, H; Aznar, N; Delay, A; Bres, A; Buchet-Poyau, K; Caillat, C; Vigouroux, A; Rogon, C; Woods, A; Vanacker, JM; Hohfeld, J; Perret, C; Meyer, P; Billaud, M; Forcet, C				Gaude, H.; Aznar, N.; Delay, A.; Bres, A.; Buchet-Poyau, K.; Caillat, C.; Vigouroux, A.; Rogon, C.; Woods, A.; Vanacker, J-M; Hoehfeld, J.; Perret, C.; Meyer, P.; Billaud, M.; Forcet, C.			Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1	ONCOGENE			English	Article						LKB1; Hsp90; CHIP; tumor suppressor; chaperones	ACTIVATED PROTEIN-KINASE; PEUTZ-JEGHERS-SYNDROME; E3 UBIQUITIN LIGASE; HEAT-SHOCK PROTEINS; QUALITY-CONTROL; SPLICE VARIANT; CELL STRUCTURE; HSP90; CHIP; INHIBITION	LKB1 is a tumor suppressor that is constitutionally mutated in a cancer-prone condition, called Peutz-Jeghers syndrome, as well as somatically inactivated in a sizeable fraction of lung and cervical neoplasms. The LKB1 gene encodes a serine/threonine kinase that associates with the pseudokinase STRAD (STE-20-related pseudokinase) and the scaffolding protein MO25, the formation of this heterotrimeric complex promotes allosteric activation of LKB1. We have previously reported that the molecular chaperone heat shock protein 90 (Hsp90) binds to and stabilizes LKB1. Combining pharmacological studies and RNA interference approaches, we now provide evidence that the co-chaperone Cdc37 participates to the regulation of LKB1 stability. It is known that the Hsp90-Cdc37 complex recognizes a surface within the N-terminal catalytic lobe of client protein kinases. In agreement with this finding, we found that the chaperones Hsp90 and Cdc37 interact with an LKB1 isoform that differs in the C-terminal region, but not with a novel LKB1 variant that lacks a portion of the kinase N-terminal lobe domain. Reconstitution of the two complexes LKB1-STRAD and LKB1-Hsp90-Cdc37 with recombinant proteins revealed that the former is catalytically active whereas the latter is inactive. Furthermore, consistent with a documented repressor function of Hsp90, LKB1 kinase activity was transiently stimulated upon dissociation of Hsp90. Finally, disruption of the LKB1-Hsp90 complex favors the recruitment of both Hsp/Hsc70 and the U-box dependent E3 ubiquitin ligase CHIP (carboxyl terminus of Hsc70-interacting protein) that triggers LKB1 degradation. Taken together, our results establish that the Hsp90-Cdc37 complex controls both the stability and activity of the LKB1 kinase. This study further shows that two chaperone complexes with antagonizing activities, Hsp90-Cdc37 and Hsp/Hsc70-CHIP, finely control the cellular level of LKB1 protein. Oncogene (2012) 31, 1582-1591; doi:10.1038/onc.2011.342; published online 22 August 2011	[Billaud, M.] UFJ, Inst Albert Bonniot, CRI, INSERM,U823, F-38706 La Tronche, France; [Gaude, H.; Aznar, N.; Delay, A.; Bres, A.; Buchet-Poyau, K.] CRCL, CNRS, INSERM, U1052,UMR 5286, Lyon, France; [Caillat, C.; Vigouroux, A.; Meyer, P.] Ctr Rech, CNRS Gif Sur Yvette, Lab Enzymol & Biochim Struct, UPR 3082, Gif Sur Yvette, France; [Rogon, C.; Hoehfeld, J.] Univ Bonn, Inst Cell Biol & Bonner Forum Biomed, Bonn, Germany; [Woods, A.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Cellular Stress Grp, London, England; [Vanacker, J-M; Forcet, C.] Ecole Normale Super Lyon, Inst Genom Fonctionnelle Lyon, CNRS UCBL ENS UMR 5242, F-69364 Lyon, France; [Perret, C.] Univ Paris 05, Inst Cochin, CNRS, UMR 8104, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); University of Bonn; Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Billaud, M (corresponding author), UFJ, Inst Albert Bonniot, CRI, INSERM,U823, F-38706 La Tronche, France.	Marc.Billaud@ujf-grenoble.fr; christelle.forcet@ens-lyon.fr	Meyer, Philippe/AAC-6038-2019; Perret-Mayeux, Christine/L-3297-2017; Billaud, Marc N/M-6954-2013	Meyer, Philippe/0000-0002-6220-0679; Aznar, Nicolas/0000-0003-3338-9932; perret, christine/0000-0003-4710-7051; christophe, caillat/0000-0003-2959-1871	Ligue Nationale Contre le Cancer; Association de Recherche sur le Cancer; Comite de l'Isere; Fondation pour la Recherche Medicale; CNRS	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association de Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Comite de l'Isere; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); CNRS(Centre National de la Recherche Scientifique (CNRS))	We thank Len Neckers and Dirk Bohmann for the kind gifts of the CHIP and HA-ubiquitin vectors, respectively. This work was supported by the Ligue Nationale Contre le Cancer, and Association de Recherche sur le Cancer. During this work HG, NA and CC have been the recipients of fellowship from the Ligue Nationale Contre le Cancer, Ligue Nationale Contre le Cancer, Comite de l'Isere, Association de Recherche sur le Cancer and Fondation pour la Recherche Medicale and CNRS, respectively.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beers M, 2006, DEVELOPMENT, V133, P3745, DOI 10.1242/dev.02544; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Brajenovic M, 2004, J BIOL CHEM, V279, P12804, DOI 10.1074/jbc.M312171200; Caplan AJ, 2007, TRENDS CELL BIOL, V17, P87, DOI 10.1016/j.tcb.2006.12.002; Citri A, 2006, J BIOL CHEM, V281, P14361, DOI 10.1074/jbc.M512613200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Denison FC, 2009, J BIOL CHEM, V284, P67, DOI 10.1074/jbc.M806153200; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Ehrlich ES, 2009, P NATL ACAD SCI USA, V106, P20330, DOI 10.1073/pnas.0810571106; Fan MY, 2005, MOL ENDOCRINOL, V19, P2901, DOI 10.1210/me.2005-0111; Hardie DG, 2008, FEBS LETT, V582, P81, DOI 10.1016/j.febslet.2007.11.018; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Jansen M, 2009, PHYSIOL REV, V89, P777, DOI 10.1152/physrev.00026.2008; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Koga F, 2006, P NATL ACAD SCI USA, V103, P11318, DOI 10.1073/pnas.0604705103; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2003, INT J BIOCHEM CELL B, V35, P572, DOI 10.1016/S1357-2725(02)00394-1; Nony P, 2003, ONCOGENE, V22, P9165, DOI 10.1038/sj.onc.1207179; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sreeramulu S, 2009, ANGEW CHEM INT EDIT, V48, P5853, DOI 10.1002/anie.200900929; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Towler MC, 2008, BIOCHEM J, V416, P1, DOI 10.1042/BJ20081447; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yano A, 2008, P NATL ACAD SCI USA, V105, P15541, DOI 10.1073/pnas.0805354105; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532	46	34	36	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	12					1582	1591		10.1038/onc.2011.342	http://dx.doi.org/10.1038/onc.2011.342			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860411				2022-12-28	WOS:000302132000010
J	Haapa-Paananen, S; Kiviluoto, S; Waltari, M; Puputti, M; Mpindi, JP; Kohonen, P; Tynninen, O; Haapasalo, H; Joensuu, H; Perala, M; Kallioniemi, O				Haapa-Paananen, S.; Kiviluoto, S.; Waltari, M.; Puputti, M.; Mpindi, J. P.; Kohonen, P.; Tynninen, O.; Haapasalo, H.; Joensuu, H.; Perala, M.; Kallioniemi, O.			HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation	ONCOGENE			English	Article						HES6; glioma; astrocytoma; glioblastoma; TMA; RNAi	BINDING PROTEIN; NEURONAL DIFFERENTIATION; GLIOBLASTOMA-MULTIFORME; CELL-PROLIFERATION; PROMOTES; RECEPTOR; GROWTH; EXPRESSION; PATHWAYS; KIT	Malignant glioma is the most common brain tumor with 16 000 new cases diagnosed annually in the United States. We performed a systematic large-scale transcriptomics data mining study of 9783 tissue samples from the GeneSapiens database to systematically identify genes that are most glioma-specific. We searched for genes that were highly expressed in 322 glioblastoma multiforme tissue samples and 66 anaplastic astrocytomas as compared with 425 samples from histologically normal central nervous system. Transcription cofactor HES6 (hairy and enhancer of split 6) emerged as the most glioma-specific gene. Immunostaining of a tissue micro-array showed HES6 expression in 335 (98.8%) out of the 339 glioma samples. HES6 was expressed in endothelial cells of the normal brain and glioma tissue. Recurrent grade 2 astrocytomas and grade 2 or 3 oligodendrogliomas showed higher levels of HES6 immunoreactivity than the corresponding primary tumors. High HES6 mRNA expression correlated with the proneural subtype that generally has a favorable outcome but is prone to recur. Functional studies suggested an important role for HES6 in supporting survival of glioma cells, as evidenced by reduction of cancer cell proliferation and migration after HES6 silencing. The biological role and consequences of HES6 silencing and overexpression was explored with genome-wide analyses, which implicated a role for HES6 in p53, c-myc and nuclear factor-kappa B transcriptional networks. We conclude that HES6 is important for glioma cell proliferation and migration, and may have a role in angiogenesis. Oncogene (2012) 31, 1299-1310; doi:10.1038/onc.2011.316; published online 25 July 2011	[Haapa-Paananen, S.; Kiviluoto, S.; Mpindi, J. P.; Kohonen, P.; Perala, M.; Kallioniemi, O.] Univ Turku, Dept Med Biotechnol, VTT Tech Res Ctr Finland, FI-20521 Turku, Finland; [Haapa-Paananen, S.; Kiviluoto, S.; Mpindi, J. P.; Kohonen, P.; Perala, M.; Kallioniemi, O.] Univ Turku, Ctr Biotechnol, FI-20521 Turku, Finland; [Waltari, M.; Puputti, M.; Joensuu, H.] Univ Helsinki, Dept Oncol, Helsinki, Finland; [Tynninen, O.] Helsinki Univ Cent Hosp, Dept Pathol, Helsinki, Finland; [Mpindi, J. P.; Kallioniemi, O.] Univ Helsinki, FIMM Inst Mol Med Finland, Helsinki, Finland; [Tynninen, O.] Univ Helsinki, Haartman Inst, Helsinki, Finland; [Haapasalo, H.] Tampere Univ Hosp, Dept Pathol, Tampere, Finland	University of Turku; VTT Technical Research Center Finland; University of Turku; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Tampere University; Tampere University Hospital	Haapa-Paananen, S (corresponding author), Univ Turku, Dept Med Biotechnol, VTT Tech Res Ctr Finland, Itainen Pitkakatu 4C,POB 106, FI-20521 Turku, Finland.	saija.haapa-paananen@vtt.fi	Kohonen, Pekka/F-9596-2011; Kallioniemi, Olli P/H-5111-2011; Kiviluoto, Santeri/M-2743-2014; Haapa-Paananen, Saija/D-3075-2012	Kohonen, Pekka/0000-0002-7845-3611; Kallioniemi, Olli P/0000-0002-3231-0332; Kiviluoto, Santeri/0000-0001-5010-5327; Joensuu, Heikki/0000-0003-0281-2507	Academy of Finland Translational Genome-Scale Biology Center of Excellence; Sigrid Juselius foundation; EU [LSHB-CT-2004-005276]; Cancer Foundation Finland sr [120084, 110071] Funding Source: researchfish	Academy of Finland Translational Genome-Scale Biology Center of Excellence(Academy of Finland); Sigrid Juselius foundation(Sigrid Juselius Foundation); EU(European Commission); Cancer Foundation Finland sr	This work was supported by the Academy of Finland Translational Genome-Scale Biology Center of Excellence, the Sigrid Juselius foundation and EU-FP6 project RIGHT (LSHB-CT-2004-005276). We acknowledge Dr Bokkee Eun for the generous gift of the HES6 overexpression plasmid pEYFP-C1-Hes6 (Eun et al., 2008). We also acknowledge the Finnish DNA Microarray Centre for their excellent technical assistance.	Bae SK, 2000, DEVELOPMENT, V127, P2933; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; Cossins J, 2002, DEVELOPMENT, V129, P2195; Eun B, 2008, J BIOL CHEM, V283, P5939, DOI 10.1074/jbc.M707683200; Eun B, 2010, BRAIN RES, V1313, P1, DOI 10.1016/j.brainres.2009.11.078; Gratton MO, 2003, MOL CELL BIOL, V23, P6922, DOI 10.1128/MCB.23.19.6922-6935.2003; Haapasalo JA, 2006, CLIN CANCER RES, V12, P473, DOI 10.1158/1078-0432.CCR-05-0848; Hartman J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2446; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Illi B, 2000, CIRC RES, V86, pE110; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Jhas S, 2006, J NEUROSCI, V26, P11061, DOI 10.1523/JNEUROSCI.1358-06.2006; Joensuu H, 2005, J PATHOL, V207, P224, DOI 10.1002/path.1823; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; Kumar Hari R, 2008, Expert Rev Neurother, V8, P1497, DOI 10.1586/14737175.8.10.1497; Lassman AB, 2004, NEURON GLIA BIOL, V1, P157, DOI 10.1017/S1740925X04000249; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Margolin AA, 2009, P NATL ACAD SCI USA, V106, P244, DOI 10.1073/pnas.0806445106; Mpindi JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017259; Naumann U, 2008, INT J ONCOL, V33, P759, DOI 10.3892/ijo_00000062; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ohgaki H, 2009, CANCER SCI, V100, P2235, DOI 10.1111/j.1349-7006.2009.01308.x; Ovaska K, 2010, GENOME MED, V2, DOI 10.1186/gm186; Panicker SP, 2010, ONCOTARGET, V1, P289; Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085; Schiffer D, 2010, ANTICANCER RES, V30, P1977; Sihto H, 2009, HISTOPATHOLOGY, V55, P544, DOI 10.1111/j.1365-2559.2009.03418.x; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Strojnik T, 2007, SURG NEUROL, V68, P133, DOI 10.1016/j.surneu.2006.10.050; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vias M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-17; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Watson PA, 2002, ENDOCRINOLOGY, V143, P2922, DOI 10.1210/en.143.8.2922; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Wu JM, 2009, NAT METHODS, V6, P75, DOI [10.1038/nmeth.1282, 10.1038/NMETH.1282]	39	23	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1299	1310		10.1038/onc.2011.316	http://dx.doi.org/10.1038/onc.2011.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785461				2022-12-28	WOS:000301344600009
J	Joha, S; Nugues, AL; Hetuin, D; Berthon, C; Dezitter, X; Dauphin, V; Mahon, FX; Roche-Lestienne, C; Preudhomme, C; Quesnel, B; Idziorek, T				Joha, S.; Nugues, A-L; Hetuin, D.; Berthon, C.; Dezitter, X.; Dauphin, V.; Mahon, F-X; Roche-Lestienne, C.; Preudhomme, C.; Quesnel, B.; Idziorek, T.			GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells	ONCOGENE			English	Article						GILZ; imatinib; dasatinib; BCR-ABL; mTORC2; AKT	PROTECTS T-LYMPHOCYTES; LEUCINE-ZIPPER GILZ; DORMANT TUMOR-CELLS; BCR-ABL; GLUCOCORTICOID-RECEPTOR; MAMMALIAN TARGET; INDUCE APOPTOSIS; LEUKEMIC-CELLS; TOR COMPLEX-2; RAPAMYCIN	The malignant phenotype of chronic myeloid leukemia (CML) is due to the abnormal tyrosine kinase activity of the BCR-ABL oncoprotein, which signals several downstream cell survival pathways, including phosphoinositide 3-kinase/AKT, signal transducer and activator of transcription 5 and extracellular signal-regulated kinase 1/2. In patients with CML, tyrosine kinase inhibitors (TKIs) are used to suppress the BCR-ABL tyrosine kinase, resulting in impressive response rates. However, resistance can occur, especially in acute-phase CML, through various mechanisms. Here, we show that the glucocorticoid-induced leucine zipper protein (GILZ) modulates imatinib and dasatinib resistance and suppresses tumor growth by inactivating the mammalian target of rapamycin complex-2 (mTORC2)/AKT signaling pathway. In mouse and human models, GILZ binds to mTORC2, but not to mTORC1, inhibiting phosphorylation of AKT (at Ser473) and activating FoxO3a-mediated transcription of the pro-apoptotic protein Bim; these results demonstrate that GILZ is a key inhibitor of the mTORC2 pathway. Furthermore, CD34(+) stem cells isolated from relapsing CML patients underwent apoptosis and showed inhibition of mTORC2 after incubation with glucocorticoids and imatinib. Our findings provide new mechanistic insights into the role of mTORC2 in BCR-ABL(+) cells and indicate that regulation by GILZ may influence TKI sensitivity. Oncogene (2012) 31, 1419-1430; doi:10.1038/onc.2011.328; published online 1 August 2011	[Quesnel, B.] CHU Lille, Serv Malad Sang, F-59037 Lille, France; [Joha, S.; Nugues, A-L; Hetuin, D.; Berthon, C.; Dezitter, X.; Dauphin, V.; Roche-Lestienne, C.; Preudhomme, C.; Quesnel, B.; Idziorek, T.] Univ Lille Nord de France, INSERM, U837, Inst Rech Canc Lille, Lille, France; [Mahon, F-X] Univ Victor Segalen, INSERM, U876, Bordeaux, France	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Quesnel, B (corresponding author), CHU Lille, Serv Malad Sang, Rue Polonovski, F-59037 Lille, France.	brunoquesnel@hotmail.com	Quesnel, Bruno/D-5533-2018; Preudhomme, Claude/T-8553-2018; Dezitter, Xavier/H-6923-2018	Quesnel, Bruno/0000-0002-6563-2709; Preudhomme, Claude/0000-0002-1267-9546; Dezitter, Xavier/0000-0001-6932-6947; Roche-Lestienne, Catherine/0000-0002-7998-3817	Ligue Nationale Contre le Cancer (Equipe labellisee); Fondation de France; Institut National du Cancer; Ministere des Relations Exterieures; Institut de Recherche sur le Cancer de Lille; Region Nord Pas de Calais	Ligue Nationale Contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); Fondation de France(Fondation de France); Institut National du Cancer(Institut National du Cancer (INCA) France); Ministere des Relations Exterieures; Institut de Recherche sur le Cancer de Lille; Region Nord Pas de Calais(Region Hauts-de-France)	We are grateful to Professor Carlo Riccardi (University of Perugia, Perugia, Italy) for providing the mouse GILZ antibodies and plasmids and to Professor Michael Hall (Biozentrum, University of Basel, Basel, Switzerland) for providing the mouse Rictor plasmid. This work was supported by the Ligue Nationale Contre le Cancer (Equipe labellisee), the Fondation de France, Region Nord Pas de Calais and the Institut National du Cancer (project IMMUDORM). SJ was supported by the Ministere des Relations Exterieures and Institut de Recherche sur le Cancer de Lille.	Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09-134684; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107; Cohen N, 2006, BLOOD, V107, P2037, DOI 10.1182/blood-2005-07-2760; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Dayyani F, 2003, J LEUKOCYTE BIOL, V74, P33, DOI 10.1189/jlb.1202612; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Delfino DV, 2011, CELL DEATH DIFFER, V18, P183, DOI 10.1038/cdd.2010.86; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Grugan KD, 2008, J STEROID BIOCHEM, V110, P244, DOI 10.1016/j.jsbmb.2007.11.003; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hicsonmez G, 2006, LEUKEMIA RES, V30, P60, DOI 10.1016/j.leukres.2005.05.015; Hietakangas V, 2007, GENE DEV, V21, P632, DOI 10.1101/gad.416307; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kawauchi K, 2003, BLOOD CELL MOL DIS, V31, P11, DOI 10.1016/S1079-9796(03)00070-6; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Liu J, 2008, LEUKEMIA, V22, P791, DOI 10.1038/leu.2008.3; Ly C, 2003, CANCER RES, V63, P5716; Mancini M, 2010, J CELL BIOCHEM, V109, P320, DOI 10.1002/jcb.22380; Martin J, 2008, BIOCHEM BIOPH RES CO, V372, P578, DOI 10.1016/j.bbrc.2008.05.086; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Miyoshi H, 1997, LEUKEMIA RES, V21, P45, DOI 10.1016/S0145-2126(96)00089-6; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Perez SA, 2005, BLOOD, V106, P158, DOI 10.1182/blood-2004-08-3232; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pocaly M, 2008, PROTEOMICS, V8, P2394, DOI 10.1002/pmic.200701035; Polak P, 2006, DEV CELL, V11, P433, DOI 10.1016/j.devcel.2006.09.005; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saudemont A, 2005, BLOOD, V105, P2428, DOI 10.1182/blood-2004-09-3458; Saudemont A, 2004, BLOOD, V104, P2124, DOI 10.1182/blood-2004-01-0064; Saudemont A, 2007, CANCER RES, V67, P4491, DOI 10.1158/0008-5472.CAN-06-1627; Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Vakana E, 2010, AUTOPHAGY, V6, P966, DOI 10.1073/pnas.1005114107; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang SW, 2005, APOPTOSIS, V10, P341, DOI 10.1007/s10495-005-0808-4; Yu CR, 2002, CANCER RES, V62, P188; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833	54	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1419	1430		10.1038/onc.2011.328	http://dx.doi.org/10.1038/onc.2011.328			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804606	Green Published, hybrid			2022-12-28	WOS:000301780000009
J	Kumar, SM; Zhang, G; Bastian, BC; Arcasoy, MO; Karande, P; Pushparajan, A; Acs, G; Xu, X				Kumar, S. M.; Zhang, G.; Bastian, B. C.; Arcasoy, M. O.; Karande, P.; Pushparajan, A.; Acs, G.; Xu, X.			Erythropoietin receptor contributes to melanoma cell survival in vivo	ONCOGENE			English	Article						erythropoietin; erythropoietin receptor; melanoma; hypoxia	RECOMBINANT ERYTHROPOIETIN; BREAST-CANCER; CARCINOMA CELLS; TUMOR-GROWTH; NECK-CANCER; EXPRESSION; HYPOXIA; HEAD; PROMOTES; MODELS	Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer. Data from several clinical trials suggest significant adverse effect of Epo treatment on cancer patient survival. However, controversy exists whether Epo receptor (EpoR) is functional in cancer cells. In this study, we demonstrated that EpoR mRNA expression was detectable in 90.1% of 65 melanoma cell lines, and increased copy number of the Epo and EpoR loci occurred in 30 and 24.6% of 130 primary melanomas, respectively. EpoR knockdown in melanoma cells resulted in diminished ERK phosphorylation in response to Epo stimulation, decreased cell proliferation and increased response to the inhibitory effect of hypoxia and cisplatin in vitro. EpoR knockdown significantly decreased melanoma xenograft size and tumor invasion in vivo. On the contrary, constitutive activation of EpoR activated cell proliferation pathways in melanoma cells and resulted in increased cell proliferation and resistance to hypoxia and cisplatin treatment in vitro. EpoR activation resulted in significantly larger xenografts with increased tumor invasion of surrounding tissue in vivo. Daily administration of recombinant Epo fails to stimulate melanoma growth in vivo, but the treatment increased vascular size in the xenografts. Increased local recurrence after excision of the primary tumors was observed after Epo treatment. Epo induced angiogenesis in Matrigel plug assays, and neutralization of Epo secreted by melanoma cells results in decreased angiogenesis. These data support that EpoR is functional in melanoma and EpoR activation may promote melanoma progression, and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo. Oncogene (2012) 31, 1649-1660; doi:10.1038/onc.2011.366; published online 22 August 2011	[Kumar, S. M.; Pushparajan, A.; Xu, X.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Zhang, G.] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; [Bastian, B. C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Bastian, B. C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Arcasoy, M. O.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Karande, P.] Rensselaer Polytechnol Inst, Dept Chem Engn, Troy, NY USA; [Karande, P.] Rensselaer Polytechnol Inst, Dept Biol Engn, Troy, NY USA; [Acs, G.] Moffitt Canc, Dept Anat Pathol, Tampa, FL USA; [Acs, G.] Moffitt Canc, Dept Womens Oncol, Tampa, FL USA	University of Pennsylvania; The Wistar Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Xu, X (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 3400 Spruce St,6 Founders Bldg, Philadelphia, PA 19104 USA.	xug@mail.med.upenn.edu	Zhang, Gao/D-3471-2017	Bastian, Boris/0000-0003-1836-6062	Melanoma Research Foundation;  [CA-093372];  [CA-116103];  [AR-054593];  [CA-100844]; NATIONAL CANCER INSTITUTE [R21CA116103, R01CA100844, P50CA093372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054593] Funding Source: NIH RePORTER	Melanoma Research Foundation; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We are grateful to M Herlyn from the Wistar Institute for providing melanoma cell lines. Financial support was provided by CA-093372, CA-116103, AR-054593 and Melanoma Research Foundation (to X Xu) and CA-100844 (to MO Arcasoy).	Acs G, 2004, CANCER LETT, V214, P243, DOI 10.1016/j.canlet.2004.04.027; Acs G, 2004, CANCER-AM CANCER SOC, V100, P2376, DOI 10.1002/cncr.20244; Acs G, 2001, CANCER RES, V61, P3561; Arcasoy MO, 2005, CLIN CANCER RES, V11, P20; Arcasoy MO, 2003, BIOCHEM BIOPH RES CO, V307, P999, DOI 10.1016/S0006-291X(03)01303-2; Arcasoy MO, 2002, LAB INVEST, V82, P911, DOI 10.1097/01.LAB.0000020415.72863.40; Arcasoy MO, 2008, CLIN CANCER RES, V14, P4685, DOI 10.1158/1078-0432.CCR-08-0264; Beldo-Iniesta C, 2007, CANCER BIOL THER, V6, P1600, DOI 10.4161/cbt.6.10.4726; Bennett CL, 2008, JAMA-J AM MED ASSOC, V299, P914, DOI 10.1001/jama.299.8.914; Blau CA, 2007, STEM CELLS, V25, P2094, DOI 10.1634/stemcells.2007-0229; Bohlius J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007303.pub2; Carlin S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010857; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniel RJ, 2002, J INVEST DERMATOL, V119, P1304, DOI 10.1046/j.1523-1747.2002.19533.x; Fu P, 2009, BIOCHEM BIOPH RES CO, V379, P696, DOI 10.1016/j.bbrc.2008.12.146; Hardee ME, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000549; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Jelkmann W, 2008, CRIT REV ONCOL HEMAT, V67, P39, DOI 10.1016/j.critrevonc.2008.03.006; Jeong JY, 2009, MOL CANCER RES, V7, P1150, DOI 10.1158/1541-7786.MCR-08-0243; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Koritzinsky M, 2007, METHOD ENZYMOL, V435, P247, DOI 10.1016/S0076-6879(07)35013-1; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Lai SY, 2005, ONCOGENE, V24, P4442, DOI 10.1038/sj.onc.1208635; LaMontagne KR, 2006, MOL CANCER THER, V5, P347, DOI 10.1158/1535-7163.MCT-05-0203; Ley CD, 2004, MICROVASC RES, V68, P161, DOI 10.1016/j.mvr.2004.06.002; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Mirmohammadsadegh A, 2010, J INVEST DERMATOL, V130, P201, DOI 10.1038/jid.2009.162; Mohyeldin A, 2005, NEOPLASIA, V7, P537, DOI 10.1593/neo.04685; Noguchi Constance Tom, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000860; Okazaki T, 2008, NEOPLASIA, V10, P932, DOI 10.1593/neo.08140; Paragh G, 2009, AM J PATHOL, V174, P1504, DOI 10.2353/ajpath.2009.080592; PHARR PN, 1993, P NATL ACAD SCI USA, V90, P938, DOI 10.1073/pnas.90.3.938; Reynolds CP, 2005, METH MOLEC MED, V111, P335; Seaman ME, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020807; Sinclair AM, 2007, CANCER-AM CANCER SOC, V110, P477, DOI 10.1002/cncr.22832; Sytkowski AJ, 2007, SCI STKE, V2007, ppe38, DOI DOI 10.1126/STKE.3952007PE38; Tovari J, 2005, CANCER RES, V65, P7186, DOI 10.1158/0008-5472.CAN-04-2498; Tovari J, 2008, CURR MOL MED, V8, P481, DOI 10.2174/156652408785747979; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Um M, 2007, CELL SIGNAL, V19, P634, DOI 10.1016/j.cellsig.2006.08.014; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Wright GL, 2004, FASEB J, V18, P1031, DOI 10.1096/fj.03-1289fje; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Yates CM, 2006, J ENDOCRINOL INVEST, V29, P320, DOI 10.1007/BF03344103; Yu TW, 2008, FRONT BIOSCI-LANDMRK, V13, P2714, DOI 10.2741/2878	48	39	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1649	1660		10.1038/onc.2011.366	http://dx.doi.org/10.1038/onc.2011.366			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860424	Green Published, Green Accepted			2022-12-28	WOS:000302231400004
J	Miyake, T; Parsons, SJ				Miyake, T.; Parsons, S. J.			Functional interactions between Choline kinase alpha, epidermal growth factor receptor and c-Src in breast cancer cell proliferation	ONCOGENE			English	Article						choline kinase; proliferation; c-Src; EGFR; breast cancer; tyrosine phosphorylation	TYROSINE KINASES; PHOSPHORYLATION; ACTIVATION; SITES; EGFR; OVEREXPRESSION; ONCOGENESIS; EXPRESSION; LUNG; Y845	Epidermal growth factor receptor (EGFR) family members and c-Src are co-overexpressed in many cancers. The synergistic effect of EGFR and c-Src has been shown in the tumorigenesis of breast and other cancers. Reported mechanisms of synergy include transcriptional regulation by STAT5b and the regulation of cellular ATP production by mitochondrial protein COX II. Here, we report a new mechanism of EGFR-c-Src synergy through choline kinase alpha (CHKA). The first enzyme of the phosphatidyl choline production pathway, CHKA, is overexpressed in many cancers, and the product of the enzyme, phosphocholine, is also increased in tumor cells. In this report, we find that CHKA forms a complex with EGFR in a c-Src-dependent manner. Endogenous CHKA and EGFR co-immunoprecipitated from a variety of breast cancer cell lines and immortalized mammary epithelial cells. CHKA interacted with the EGFR kinase domain upon c-Src co-overexpression and was phosphorylated in a c-Src-dependent manner on Y197 and Y333. Overexpression of EGFR and c-Src increased total cellular activity and protein levels of CHKA. Mutation of CHKA Y197 and Y333 reduced complex formation, EGFR-dependent activation of CHKA enzyme activity and epidermal growth factor (EGF)-dependent DNA synthesis. Furthermore, small interfering RNA-mediated knockdown of CHKA in MCF-7 and MCF-10A cells reduced EGF-dependent cell proliferation. Together, these results strongly implicate a new c-Src-dependent link between CHKA and EGFR, which contributes to the regulation of cell proliferation and tumorigenesis. Oncogene (2012) 31, 1431-1441; doi:10.1038/onc.2011.332; published online 8 August 2011	[Parsons, S. J.] Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; [Parsons, S. J.] Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, POB 800734,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	sap@virginia.edu			NIH-NCI [R01CA123037]; NATIONAL CANCER INSTITUTE [R01CA123037] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nicholas E Sherman in the WM Keck Biomedical Mass Spectrometry Laboratory for analysis of CHKA2 phosphorylation sites, and Drs Jill Slack-Davis and John DaSilva for their critical comments. We also thank members of Sarah J Parsons' laboratory and the Women's Oncology Group in the University of Virginia Cancer Center for helpful discussions. This work was supported by NIH-NCI grant R01CA123037(SJP).	Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Chua BT, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-131; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Demory ML, 2009, J BIOL CHEM, V284, P36592, DOI 10.1074/jbc.M109.000760; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Glunde K, 2006, MOL PHARMACEUT, V3, P496, DOI 10.1021/mp060067e; Grigera PR, 2005, J CELL SCI, V118, P4931, DOI 10.1242/jcs.02696; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hernando E, 2009, ONCOGENE, V28, P2425, DOI 10.1038/onc.2009.91; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Krishnamachary B, 2009, CANCER RES, V69, P3464, DOI 10.1158/0008-5472.CAN-08-4120; Liao HN, 2006, BBA-MOL CELL BIOL L, V1761, P111, DOI 10.1016/j.bbalip.2006.01.005; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Malito E, 2006, J MOL BIOL, V364, P136, DOI 10.1016/j.jmb.2006.08.084; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Morse DL, 2009, NMR BIOMED, V22, P114, DOI 10.1002/nbm.1318; Peisach D, 2003, STRUCTURE, V11, P703, DOI 10.1016/S0969-2126(03)00094-7; Qiu C, 2009, BIOCHEMISTRY-US, V48, P6624, DOI 10.1021/bi900755n; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2004, CANCER RES, V64, P6732, DOI 10.1158/0008-5472.CAN-04-0489; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; Ramirez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Wu GS, 2010, BIOCHEM CELL BIOL, V88, P559, DOI 10.1139/O09-160; Yalcin A, 2010, ONCOGENE, V29, P139, DOI 10.1038/onc.2009.317; Yanga S, 2008, EXP CELL RES, V314, P413, DOI 10.1016/j.yexcr.2007.09.002	42	54	56	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1431	1441		10.1038/onc.2011.332	http://dx.doi.org/10.1038/onc.2011.332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822308	Green Accepted			2022-12-28	WOS:000301780000010
J	Mura, M; Swain, RK; Zhuang, X; Vorschmitt, H; Reynolds, G; Durant, S; Beesley, JFJ; Herbert, JMJ; Sheldon, H; Andre, M; Sanderson, S; Glen, K; Luu, NT; McGettrick, HM; Antczak, P; Falciani, F; Nash, GB; Nagy, Z; Bicknell, R				Mura, M.; Swain, R. K.; Zhuang, X.; Vorschmitt, H.; Reynolds, G.; Durant, S.; Beesley, J. F. J.; Herbert, J. M. J.; Sheldon, H.; Andre, M.; Sanderson, S.; Glen, K.; Luu, N-T; McGettrick, H. M.; Antczak, P.; Falciani, F.; Nash, G. B.; Nagy, Zs; Bicknell, R.			Identification and angiogenic role of the novel tumor endothelial marker CLEC14A	ONCOGENE			English	Article						tumor vasculature; gene expression; cell migration; shear stress	GENE-EXPRESSION; SOLID TUMORS; MAGIC ROUNDABOUT; CELL GENES; FLOW; THROMBOMODULIN; PROGRESSION; RESPONSES; RECEPTOR; SURFACE	Tumor endothelial markers (TEMs) that are highly expressed in human tumor vasculature compared with vasculature in normal tissue hold clear therapeutic potential. We report that the C-type lectin CLEC14A is a novel TEM. Immunohistochemical and immunofluorescence staining of tissue arrays has shown that CLEC14A is strongly expressed in tumor vasculature when compared with vessels in normal tissue. CLEC14A overexpression in tumor vessels was seen in a wide range of solid tumor types. Functional studies showed that CLEC14A induces filopodia and facilitates endothelial migration, tube formation and vascular development in zebrafish that is, CLEC14A regulates pro-angiogenic phenotypes. CLEC14A antisera inhibited cell migration and tube formation, suggesting that anti-CLEC14A antibodies may have anti-angiogenic activity. Finally, in endothelial cultures, expression of CLEC14A increased at low shear stress, and we hypothesize that low shear stress due to poor blood flow in the disorganized tumor vasculature induces expression of CLEC14A on tumor vessels and pro-angiogenic phenotypes. Oncogene (2012) 31, 293-305; doi:10.1038/onc.2011.233; published online 27 June 2011	[Mura, M.; Swain, R. K.; Zhuang, X.; Vorschmitt, H.; Durant, S.; Beesley, J. F. J.; Herbert, J. M. J.; Bicknell, R.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect Sci, Angiogenesis Grp,Ctr Cardiovasc Sci,Inst Biomed R, Birmingham B15 2TT, W Midlands, England; [Mura, M.; Swain, R. K.; Zhuang, X.; Vorschmitt, H.; Durant, S.; Beesley, J. F. J.; Herbert, J. M. J.; Bicknell, R.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Angiogenesis Grp,Ctr Cardiovasc Sci,Inst Biomed R, Birmingham B15 2TT, W Midlands, England; [Reynolds, G.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Liver Labs,Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Sheldon, H.; Andre, M.; Sanderson, S.; Bicknell, R.] Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Canc Res UK Angiogenesis Grp, Oxford OX3 9DU, England; [Glen, K.; Luu, N-T; McGettrick, H. M.; Nash, G. B.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Res, Ctr Cardiovasc Sci, Birmingham B15 2TT, W Midlands, England; [Antczak, P.; Falciani, F.] Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; [Nagy, Zs] Univ Birmingham, Coll Med & Dent, Sch Clin & Expt Med, Neurodegenerat & Repair Grp, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Oxford; University of Birmingham; University of Birmingham; University of Birmingham	Bicknell, R (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect Sci, Angiogenesis Grp,Ctr Cardiovasc Sci,Inst Biomed R, Vincent Dr, Birmingham B15 2TT, W Midlands, England.	r.bicknell@bham.ac.uk	Reynolds, Gary/F-8641-2014; Nagy, Zsuzsanna/L-8446-2013; Nash, Gerard B/E-4182-2010; McGettrick, Helen M/H-3442-2011; Antczak, Philipp/L-5879-2019	Reynolds, Gary/0000-0002-3250-0582; Nagy, Zsuzsanna/0000-0002-6700-4829; Nash, Gerard B/0000-0002-5935-2831; McGettrick, Helen M/0000-0002-5950-8840; Antczak, Philipp/0000-0001-9600-7757; Swain, Rajeeb/0000-0003-4815-8221; Sheldon, Helen/0000-0002-0945-5496; Bicknell, Roy/0000-0002-0941-8919; Zhuang, Alan Xiaodong/0000-0002-6870-9003	Cancer Research UK [C4719/A6766, C4719/A9601]; British Heart Foundation; Medical Research Council [G9818340] Funding Source: researchfish; MRC [G9818340] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Professor Maria Grazia Lampugnani, IFOM-FIRC Institute for Molecular Oncology, Milan, for the gift of the BU9 anti-human VE cadherin mouse monoclonal antibody; and Dr Raj Mehta, Cancer Research Technology for helpful discussions. This work was supported by program grant number C4719/A6766 and project grant number C4719/A9601 from the Cancer Research UK to RB. RB and GBN acknowledge financial support from the British Heart Foundation. Umbilical cords were collected with the assistance of the Birmingham Women's Health Care NHS Trust.	Ando J, 2009, CIRC J, V73, P1983, DOI 10.1253/circj.CJ-09-0583; Armstrong LJ, 2008, ARTERIOSCL THROM VAS, V28, P1640, DOI 10.1161/ATVBAHA.108.162511; Bohlson SS, 2005, J IMMUNOL, V175, P1239, DOI 10.4049/jimmunol.175.2.1239; BURROWS FJ, 1993, P NATL ACAD SCI USA, V90, P8996, DOI 10.1073/pnas.90.19.8996; Chaplin DJ, 1997, TUMOUR ANGIOGENESIS, P61; Chen-Konak L, 2003, FASEB J, V17, P2121, DOI 10.1096/fj.02-1151fje; Chinnasamy D, 2010, J CLIN INVEST, V120, P3953, DOI 10.1172/JCI43490; Chu TJ, 2008, PHYSIOL GENOMICS, V34, P185, DOI 10.1152/physiolgenomics.90201.2008; Dachs GU, 1998, SEMIN RADIAT ONCOL, V8, P208, DOI 10.1016/S1053-4296(98)80046-5; Dekker RJ, 2002, BLOOD, V100, P1689, DOI 10.1182/blood-2002-01-0046; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Gomez GA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004994; Gullino PM., 1975, CANCER, V3, P327; He J, 2009, CLIN CANCER RES, V15, P6871, DOI 10.1158/1078-0432.CCR-09-1499; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Herbert JMJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-153; Ho M, 2003, PHYSIOL GENOMICS, V13, P249, DOI 10.1152/physiolgenomics.00186.2002; HOLTHOFER H, 1982, LAB INVEST, V47, P60; Huang XM, 1997, SCIENCE, V275, P547, DOI 10.1126/science.275.5299.547; Huijbers EJM, 2010, FASEB J, V24, P4535, DOI 10.1096/fj.10-163022; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Huminiecki L, 2000, GENOME RES, V10, P1796, DOI 10.1101/gr.150700; JAIN RK, 1988, CANCER RES, V48, P2641; MacFadyen JR, 2005, FEBS LETT, V579, P2569, DOI 10.1016/j.febslet.2005.03.071; MARUYAMA I, 1985, J CELL BIOL, V101, P363, DOI 10.1083/jcb.101.2.363; Matharu NM, 2008, J CELL PHYSIOL, V216, P732, DOI 10.1002/jcp.21457; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; Pham VN, 2007, DEV BIOL, V303, P772, DOI 10.1016/j.ydbio.2006.10.030; Porat RM, 2004, CIRC RES, V94, P394, DOI 10.1161/01.RES.0000111803.92923.D6; Reynolds GM, 2002, BRIT J HAEMATOL, V118, P195, DOI 10.1046/j.1365-2141.2002.03575.x; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Sheikh S, 2004, J IMMUNOL METHODS, V288, P35, DOI 10.1016/j.jim.2004.02.005; Siemann DW, 2011, CANCER TREAT REV, V37, P63, DOI 10.1016/j.ctrv.2010.05.001; St Croix B, 2000, SCIENCE, V289, P1197; Sumanas S, 2005, BLOOD, V106, P534, DOI 10.1182/blood-2004-12-4653; Thisse C, 2008, NAT PROTOC, V3, P59, DOI 10.1038/nprot.2007.514; Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Wasserman SM, 2004, VASC MED, V9, P35, DOI 10.1191/1358863x04vm521ra; Woo KV, 2011, J CLIN INVEST, V121, P1624, DOI 10.1172/JCI42040; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	46	77	82	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					293	305		10.1038/onc.2011.233	http://dx.doi.org/10.1038/onc.2011.233			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21706054				2022-12-28	WOS:000299542100003
J	Nairismagi, ML; Vislovukh, A; Meng, Q; Kratassiouk, G; Beldiman, C; Petretich, M; Groisman, R; Fuchtbauer, EM; Harel-Bellan, A; Groisman, I				Nairismagi, M-L; Vislovukh, A.; Meng, Q.; Kratassiouk, G.; Beldiman, C.; Petretich, M.; Groisman, R.; Fuchtbauer, E-M; Harel-Bellan, A.; Groisman, I.			Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression	ONCOGENE			English	Article						breast cancer; CPEB; microRNA; translational regulation; TWIST1	CYTOPLASMIC POLYADENYLATION; MESSENGER-RNA; TRANSCRIPTION FACTORS; PROTEIN; CPEB; METASTASIS; PROMOTES; MORPHOGENESIS; ONCOGENE; MCF10AT	TWIST1 is a highly conserved basic helix-loop-helix transcription factor that promotes epithelial-mesenchymal transition (EMT). Its misregulation has been observed in various types of tumors. Using the MCF-10A-series of cell lines that recapitulate the early stages of breast cancer formation and EMT, we found TWIST1 to be upregulated during EMT and downregulated early in carcinogenesis. The TWIST1 3'UTR contains putative regulatory elements, including miRNA target sites and two cytoplasmic polyadenylation elements (CPE). We found that miR-580, CPEB1, and CPEB2 act as negative regulators of TWIST1 expression in a sequence-specific and additive/cooperative manner.	[Nairismagi, M-L; Kratassiouk, G.; Beldiman, C.; Petretich, M.; Groisman, R.; Harel-Bellan, A.; Groisman, I.] CEA Saclay, CNRS FRE 3377, F-91191 Gif Sur Yvette, France; [Meng, Q.] Harbin Med Univ, Affiliated Hosp 3, Breast Dept, Harbin, Peoples R China; [Vislovukh, A.] Natl Acad Sci Ukraine, Inst Mol Biol & Genet, Dept Translat Mechanisms, Kiev, Ukraine; [Nairismagi, M-L; Fuchtbauer, E-M] Aarhus Univ, Dept Mol Biol & Genet, Aarhus, Denmark	CEA; UDICE-French Research Universities; Universite Paris Saclay; Harbin Medical University; National Academy of Sciences Ukraine; Institute of Molecular Biology & Genetics of NASU; Aarhus University	Groisman, I (corresponding author), CEA Saclay, CNRS FRE 3377, F-91191 Gif Sur Yvette, France.	irina.groisman@gmail.com	Harel-Bellan, Annick/M-9795-2015	Kratassiouk, Gueorgui/0000-0003-1174-004X; Groisman, Irina/0000-0001-8909-678X; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622; Groisman, Sonia/0000-0003-1153-3841	European Commission [LSHG-CT-2006-037900]; Danish Cancer Society [DP08036]	European Commission(European CommissionEuropean Commission Joint Research Centre); Danish Cancer Society(Danish Cancer Society)	We thank Valentina Evdokimova for providing us with the MCF-10ANeoT-MSCV and MCF-10ANeoT-YB-1 cell lines, Linda Louise Pritchard for editorial and scientific advice, and Leslie-Ann Largitte for technical assistance. This work was supported in part by grant no LSHG-CT-2006-037900 from the European Commission Sixth Framework Programme to AHB and by grant no DP08036 from The Danish Cancer Society to EMF.	BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Dawson PJ, 1996, AM J PATHOL, V148, P313; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; Germanguz I, 2007, DEV DYNAM, V236, P2615, DOI 10.1002/dvdy.21267; Gitelman I, 1997, DEV BIOL, V189, P205, DOI 10.1006/dbio.1997.8614; Hagele S, 2009, BIOCHEM J, V417, P235, DOI 10.1042/BJ20081353; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Richter JD, 2007, TRENDS BIOCHEM SCI, V32, P279, DOI 10.1016/j.tibs.2007.04.004; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981; Si K, 2003, CELL, V115, P893, DOI 10.1016/S0092-8674(03)01021-3; SOULE HD, 1990, CANCER RES, V50, P6075; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691	27	60	66	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4960	4966		10.1038/onc.2011.650	http://dx.doi.org/10.1038/onc.2011.650			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266852				2022-12-28	WOS:000311430200007
J	Astanehe, A; Finkbeiner, MR; Krzywinski, M; Fotovati, A; Dhillon, J; Berquin, IM; Mills, GB; Marra, MA; Dunn, SE				Astanehe, A.; Finkbeiner, M. R.; Krzywinski, M.; Fotovati, A.; Dhillon, J.; Berquin, I. M.; Mills, G. B.; Marra, M. A.; Dunn, S. E.			MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition	ONCOGENE			English	Article						trastuzumab resistance; breast cancer; MNK; RSK; YB-1	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; PROTEIN-1 SERINE 102; INTERACTING KINASE 1; RIBOSOMAL S6 KINASE; BINDING; MNK1; EXPRESSION; PHOSPHORYLATION; CONTRIBUTES	Trastuzumab (Herceptin) resistance is a major obstacle in the treatment of patients with HER2-positive breast cancers. We recently reported that the transcription factor Y-box binding protein-1 (YB-1) leads to acquisition of resistance to trastuzumab in a phosphorylation-dependent manner that relies on p90 ribosomal S6 kinase (RSK). To explore how this may occur we compared YB-1 target genes between trastuzumab-sensitive cells (BT474) and those with acquired resistance (HR5 and HR6) using genome-wide chromatin immunoprecipitation sequencing (ChIP-sequencing), which identified 1391 genes uniquely bound by YB-1 in the resistant cell lines. We then examined differences in protein expression and phosphorylation between these cell lines using the Kinexus Kinex antibody microarrays. Cross-referencing these two data sets identified the mitogen-activated protein kinase-interacting kinase (MNK) family as potentially being involved in acquired resistance downstream from YB-1. MNK1 and MNK2 were subsequently shown to be overexpressed in the resistant cell lines; however, only the former was a YB-1 target based on ChIP-PCR and small interfering RNA (siRNA) studies. Importantly, loss of MNK1 expression using siRNA enhanced sensitivity to trastuzumab. Further, MNK1 overexpression was sufficient to confer resistance to trastuzumab in cells that were previously sensitive. We then developed a de novo model of acquired resistance by exposing BT474 cells to trastuzumab for 60 days (BT474LT). Similar to the HR5/HR6 cells, the BT474LT cells had elevated MNK1 levels and were dependent on it for survival. In addition, we demonstrated that RSK phosphorylated MNK1, and that this phosphorylation was required for ability of MNK1 to mediate resistance to trastuzumab. Furthermore, inhibition of RSK with the small molecule BI-D1870 repressed the MNK1-mediated trastuzumab resistance. In conclusion, this unbiased integrated approach identified MNK1 as a player in mediating trastuzumab resistance as a consequence of YB-1 activation, and demonstrated RSK inhibition as a means to overcome recalcitrance to trastuzumab. Oncogene (2012) 31, 4434-4446; doi: 10.1038/onc.2011.617; published online 16 January 2012	[Astanehe, A.; Finkbeiner, M. R.; Fotovati, A.; Dhillon, J.; Dunn, S. E.] Univ British Columbia, Dept Paediat, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Krzywinski, M.; Marra, M. A.] Univ British Columbia, BC Canc Agcy, Genome Sci Ctr, Vancouver, BC V5Z 4H4, Canada; [Berquin, I. M.] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27109 USA; [Mills, G. B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	Child & Family Research Institute; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; Wake Forest University; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center	Dunn, SE (corresponding author), Univ British Columbia, Dept Paediat, Child & Family Res Inst, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	sedunn@mail.ubc.ca	Marra, Marco A/B-5987-2008	Marra, Marco A/0000-0001-7146-7175	Canadian Institute of Health Research; Canadian Cancer Research Institute; Canadian Institute of Health Research MD/PhD; Michael Smith Foundation for Health Research (MSFHR) Studentships;  [RO1 CA114017]; NATIONAL CANCER INSTITUTE [R01CA114017] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Research Institute; Canadian Institute of Health Research MD/PhD(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR) Studentships; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Canadian Institute of Health Research (SED), the Canadian Cancer Research Institute (formerly National Cancer Institute of Canada (SED)) and RO1 CA114017 (IMB and SED). AA was a recipient of the Canadian Institute of Health Research MD/PhD and the Michael Smith Foundation for Health Research (MSFHR) Studentships. MAM is a scholar of MSFHR.	Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Buxade M, 2008, J BIOL CHEM, V283, P57, DOI 10.1074/jbc.M705286200; Camirand Anne, 2002, Med Sci Monit, V8, pBR521; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chrestensen CA, 2007, J BIOL CHEM, V282, P4243, DOI 10.1074/jbc.M607368200; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Davies AH, 2011, ONCOGENE, V30, P3649, DOI 10.1038/onc.2011.82; Dhillon J, 2010, ONCOGENE, V29, P6294, DOI 10.1038/onc.2010.365; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485; Foster FM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2328; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Guil S, 2006, MOL CELL BIOL, V26, P5744, DOI 10.1128/MCB.00224-06; Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156; Halatsch ME, 2009, J NEUROSURG, V111, P211, DOI 10.3171/2008.9.JNS08551; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mahalingam M, 2001, PROG MOLEC, V27, P131; Martin AP, 2008, MOL PHARMACOL, V74, P807, DOI 10.1124/mol.108.047365; Motoyama AB, 2002, CANCER RES, V62, P3151; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nguyen TL, 2008, ANTI-CANCER AGENT ME, V8, P710, DOI 10.2174/187152008785914770; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smith JA, 2005, CANCER RES, V65, P1027; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Treeck O, 2004, ANTI-CANCER DRUG, V15, P787, DOI 10.1097/00001813-200409000-00008; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	52	42	42	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4434	4446		10.1038/onc.2011.617	http://dx.doi.org/10.1038/onc.2011.617			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22249268				2022-12-28	WOS:000309704500002
J	Qin, W; Dong, P; Ma, C; Mitchelson, K; Deng, T; Zhang, L; Sun, Y; Feng, X; Ding, Y; Lu, X; He, J; Wen, H; Cheng, J				Qin, W.; Dong, P.; Ma, C.; Mitchelson, K.; Deng, T.; Zhang, L.; Sun, Y.; Feng, X.; Ding, Y.; Lu, X.; He, J.; Wen, H.; Cheng, J.			MicroRNA-133b is a key promoter of cervical carcinoma development through the activation of the ERK and AKT1 pathways	ONCOGENE			English	Article						miR-133b; tumorigenesis and metastasis; signal pathways; cervical carcinoma	SQUAMOUS-CELL CARCINOMA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; IN-VIVO; CANCER; EXPRESSION; GROWTH; NEOPLASIA; SURVIVAL; TARGETS	We report that elevated microRNA-133b (miR-133b) acts as an oncogene in human cervical carcinoma to promote tumorigenesis and metastasis. In situ hybridization confirmed that miR-133b is localized in proliferating human cervical carcinoma cells with levels progressively elevating throughout advancing stages. Cellular studies showed that miR-133b enhances cell proliferation and colony formation by targeting mammalian sterile 20-like kinase 2 (MST2), cell division control protein 42 homolog (CDC42) and ras homolog gene family member A (RHOA), which subsequently results in activation of the tumorigenic protein kinase B alpha (AKT1) and mitogen-activated protein kinase (ERK1 and ERK2, here abbreviated as ERK) signaling pathways. Mouse experiments revealed that upregulation of miR-133b in cervical carcinoma cells strongly promotes both in vivo tumorigenesis and independent metastasis to the mouse lung. The data indicates that upregulation of miR-133b shortens the latency of cervical carcinoma. Together, these findings suggest that miR-133b could be a potent marker for the early onset of cervical carcinoma. Oncogene (2012) 31, 4067-4075; doi: 10.1038/onc.2011.561; published online 19 December 2011	[Wen, H.] Xinjiang Med Univ, Affiliated Hosp 1, State Key Lab Incubat Base Xinjiang Major Dis Res, Urumqi 830054, Peoples R China; [Qin, W.; Dong, P.; Mitchelson, K.; Deng, T.; Cheng, J.] Tsinghua Univ, Sch Med, Med Syst Biol Res Ctr, Beijing 100084, Peoples R China; [Mitchelson, K.; Deng, T.; Zhang, L.; Sun, Y.; Cheng, J.] Natl Engn Res Ctr Beijing Biochip Technol, Beijing, Peoples R China; [Feng, X.] Peking Union Med Coll, Canc Hosp & Inst, Dept Pathol, Beijing 100021, Peoples R China; [He, J.] Peking Union Med Coll, Canc Hosp & Inst, Dept Thorac Surg, Beijing 100021, Peoples R China; [Feng, X.; He, J.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Cheng, J.] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China	Xinjiang Medical University; Tsinghua University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Tsinghua University	Wen, H (corresponding author), Xinjiang Med Univ, Affiliated Hosp 1, State Key Lab Incubat Base Xinjiang Major Dis Res, Urumqi 830054, Peoples R China.	dr.wenhao@163.com; jcheng@mail.tsinghua.edu.cn	DONG, PENG/H-8016-2018	DONG, PENG/0000-0003-4946-1409	National High-tech Program of China [2006AA020701, 2009AA022701]	National High-tech Program of China	We thank Drs Youyong Lu and Yun Zhang for discussions and comments on the manuscript; Suqiong Wang, Zhaoli Chen and Dapeng Ding for help with mouse experiments; Jiantao Cui and Dr Bing Dong for help with IHC and ISH experiments. This study was supported by the National High-tech Program of China (grant no. 2006AA020701 and grant no. 2009AA022701).	Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Bertelsen BI, 2006, INT J CANCER, V118, P1877, DOI 10.1002/ijc.21461; Burk RD, 1999, NEW ENGL J MED, V341, P1687, DOI 10.1056/NEJM199911253412209; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Crawford M, 2009, BIOCHEM BIOPH RES CO, V388, P483, DOI 10.1016/j.bbrc.2009.07.143; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; GOOD M, 1978, CANCER RES, V38, P4671; Guo HY, 2011, HEPATOLOGY, V54, P808, DOI 10.1002/hep.24441; Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186; Kahn JA, 2009, NEW ENGL J MED, V361, P271, DOI 10.1056/NEJMct0806938; Kohrenhagen N, 2008, J OBSTET GYNAECOL RE, V34, P293, DOI 10.1111/j.1447-0756.2008.00749.x; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Liu XQ, 2009, COMP FUNCT GENOM, DOI 10.1155/2009/837514; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Schiffman M, 2005, NEW ENGL J MED, V353, P2101, DOI 10.1056/NEJMp058171; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Watanabe T, 2005, FEBS LETT, V579, P318, DOI 10.1016/j.febslet.2004.11.067; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	40	93	96	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4067	4075		10.1038/onc.2011.561	http://dx.doi.org/10.1038/onc.2011.561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22179829				2022-12-28	WOS:000308688800007
J	Li, X; Cheung, KF; Ma, X; Tian, L; Zhao, J; Go, MYY; Shen, B; Cheng, ASL; Ying, J; Tao, Q; Sung, JJY; Kung, HF; Yu, J				Li, X.; Cheung, K. F.; Ma, X.; Tian, L.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Ying, J.; Tao, Q.; Sung, J. J. Y.; Kung, H-F; Yu, J.			Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients	ONCOGENE			English	Article						paired box gene 5; gastric cancer; tumor suppressor gene; epigenetic alteration; prognosis	TRANSCRIPTION FACTOR BSAP; HEPATOCYTE GROWTH-FACTOR; CPG ISLAND METHYLATION; DOWN-REGULATION; BREAST-CANCER; MATRIX METALLOPROTEINASES; MET PROTOONCOGENE; CELL-DEVELOPMENT; B-LYMPHOPOIESIS; LUNG-CANCER	Using genome-wide methylation screening, we identified that paired box gene 5 (PAX5) is involved in human cancer development. However, the function of PAX5 in gastric cancer (GC) development is largely unclear. We analyzed its epigenetic inactivation, biological functions and clinical application in GC. PAX5 was silenced in seven out of eight GC cell lines. A significant downregulation was also detected in paired gastric tumors compared with adjacent non-cancerous tissues. The downregulation of PAX5 was closely linked to the promoter hypermethylation status and could be restored with demethylation treatment. Ectopic expression of PAX5 in silenced GC cell lines (AGS and BGC823) inhibited colony formation and cell viability, arrested cell cycle, induced apoptosis, suppressed cell migration and invasion and repressed tumorigenicity in nude mice. Consistent with the induction of apoptosis by PAX5 in vitro, terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) staining showed significantly enhanced apoptotic cells in PAX5-expressed tumors compared with the vector control tumors. On the other hand, knockdown of PAX5 by PAX5-short hairpin RNA increased the cell viability and proliferation. The anti-tumorigenic function of PAX5 was revealed to be mediated by upregulating downstream targets of tumor protein 53 (p53), p21, BCL2-associated X protein, metastasis suppressor 1 and tissue inhibitors of metalloproteinase 1, and downregulating BCL2, cyclin D1, mesenchymal-epithelial transition factor (MET) and matrix metalloproteinase 1. Immunoprecipitation assay demonstrated that PAX5 directly bound to the promoters of p53 and MET. Moreover, PAX5 hypermethylation was detected in 77% (144 of 187) of primary GCs compared with 10.5% (2/19) of normal gastric tissues (P<0.0001). GC patients with PAX5 methylation had a significant poor survival compared with the unmethylated cases as demonstrated by Cox regression model and log-rank test. In conclusion, PAX5 is a novel functional tumor suppressor in gastric carcinogenesis. Detection of methylated PAX5 can be utilized as an independent prognostic factor in GC. Oncogene (2012) 31, 3419-3430; doi:10.1038/onc.2011.511; published online 21 November 2011	[Li, X.; Cheung, K. F.; Ma, X.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Shatin, Hong Kong, Peoples R China; [Li, X.; Cheung, K. F.; Ma, X.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Ma, X.] Hebei Med Univ, Hosp 1, Dept Neurol, Shijiazhuang, Peoples R China; [Tian, L.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Shen, B.] Guangzhou First Municipal Peoples Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Ying, J.; Tao, Q.] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Kung, H-F] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Hebei Medical University; Chinese University of Hong Kong; South China University of Technology; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Li, Xiao-xing/B-9114-2008; Yu, Jun/D-8569-2015; Tao, Qian/T-4743-2018; Cheng, Alfred SL/C-3327-2014; Tian, Linwei/A-9736-2009	Sung, Joseph J. Y./0000-0003-3125-5199; Li, Xiao-xing/0000-0001-8791-7505; Yu, Jun/0000-0001-5008-2153; Tao, Qian/0000-0001-5383-4808; Cheng, Alfred SL/0000-0003-2345-6951; Tian, Linwei/0000-0002-4739-1534; Tian, Linwei/0000-0003-2240-8886	National Basic Research Program of China (973 Program) [2010CB529305]; Hong Kong General Research Fund [473008]; RFCID [11100022, 10090942]; CUHK Group Research Scheme [3110043]; Scheme C	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Hong Kong General Research Fund; RFCID; CUHK Group Research Scheme; Scheme C	This study was supported by research grants of National Basic Research Program of China (973 Program, 2010CB529305), Hong Kong General Research Fund (473008), RFCID (11100022, 10090942), CUHK Group Research Scheme (3110043) and Scheme C.	ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Carotta S, 2006, CELL CYCLE, V5, P2452, DOI 10.4161/cc.5.21.3396; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; HALDAR S, 1994, CANCER RES, V54, P2095; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Holmes ML, 2006, GENE DEV, V20, P933, DOI 10.1101/gad.1396206; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kanteti R, 2009, LAB INVEST, V89, P301, DOI 10.1038/labinvest.2008.168; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190; Lazzi S, 2009, HUM PATHOL, V40, P1252, DOI 10.1016/j.humpath.2009.01.007; Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232; Lee JH, 2004, ONCOGENE, V23, P4646, DOI 10.1038/sj.onc.1207588; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Levine A J, 1989, Princess Takamatsu Symp, V20, P221; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; MALKIN D, 1994, CANCER RES, V54, P2077; Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P709, DOI 10.1136/jcp.2006.039917; MIYASHITA T, 1995, CELL, V80, P293; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Sauter W, 2008, CANCER EPIDEM BIOMAR, V17, P1127, DOI 10.1158/1055-9965.EPI-07-2840; Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu J, 2010, GASTROENTEROLOGY, V138, P694, DOI 10.1053/j.gastro.2009.09.058; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	49	57	60	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	29					3419	3430		10.1038/onc.2011.511	http://dx.doi.org/10.1038/onc.2011.511			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22105368				2022-12-28	WOS:000306566400003
J	Lorenzon, E; Colladel, R; Andreuzzi, E; Marastoni, S; Todaro, F; Schiappacassi, M; Ligresti, G; Colombatti, A; Mongiat, M				Lorenzon, E.; Colladel, R.; Andreuzzi, E.; Marastoni, S.; Todaro, F.; Schiappacassi, M.; Ligresti, G.; Colombatti, A.; Mongiat, M.			MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway	ONCOGENE			English	Article						angiogenesis; extracellular matrix; VEGF	AORTIC RING MODEL; ENDOTHELIAL-CELLS; MICROENVIRONMENTAL REGULATION; THERAPEUTIC IMPLICATIONS; TYROSINE KINASE; RECEPTOR; VEGF; THROMBOSPONDIN-1; IDENTIFICATION; GLYCOPROTEIN	MULTIMERIN2 (MMRN2), also known as Endoglyx-1, is an extracellular matrix glycoprotein whose function has so far remained elusive. Given its specific localization in tight association with the endothelium we hypothesized that this protein could modulate neo-angiogenesis. By multiple assays we showed that MMRN2 significantly impaired endothelial cell (EC) migration and organization of a functional vessel network. The interaction of ECs with MMRN2 induced a striking impairment of VEGFR1 and VEGFR2 activation. We focused our attention on VEGFR2, a chief regulator of angiogenesis, and clarified that MMRN2 interfered with the VEGF/VEGFR2 axis through a direct binding with VEGF-A. This novel interaction was assessed in several assays and the affinity was estimated (Kd similar to 50 nM). We next questioned whether the anti-angiogenic properties of MMRN2 could impair tumor growth. Although overexpression of MMRN2 by HT1080 cells did not affect their growth and apoptotic rate in vitro, it remarkably affected their growth in vivo. In fact, MMRN2-positive cells failed to efficiently grow and form well-vascularized tumors; a similar outcome was observed following treatment of established tumors with a MMRN2 adenoviral construct. Tumor-section immunostaining revealed a strong co-localization of VEGF-A with the ectopically expressed MMRN2. These novel findings suggest that VEGF may be sequestered by MMRN2 and be less available for the engagement to the receptors. Taken together these results highlight MMRN2 as a crucial player in the regulation of EC function, neo-angiogenesis and hence tumor growth. We hypothesize that secreted and deposited MMRN2 may function as a homeostatic barrier halting the sprouting of novel vessels, and suggest that these studies may embody the potential for the development of novel tools for cancer treatment. Oncogene (2012) 31, 3136-3147; doi:10.1038/onc.2011.487; published online 24 October 2011	[Colombatti, A.; Mongiat, M.] CRO IRCCS, Dept Mol Oncol & Translat Res, Expt Oncol Div 2, Aviano, PN, Italy; [Andreuzzi, E.; Colombatti, A.] Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy; [Ligresti, G.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	IRCCS Aviano (CRO); University of Udine; University of Washington; University of Washington Seattle	Mongiat, M (corresponding author), CRO IRCCS, Dept Mol Oncol & Translat Res, Expt Oncol Div 2, Via Franco Gallini 2, Aviano, PN, Italy.	acolombatti@cro.it; mmongiat@cro.it	Andreuzzi, Eva/AAX-5692-2020; Mongiat, Maurizio/H-8297-2018; Ligresti, Giovanni/AAB-9881-2019; Schiappacassi, Monica/AAX-5505-2020	Andreuzzi, Eva/0000-0002-5925-5230; Mongiat, Maurizio/0000-0001-6509-0068; Schiappacassi, Monica/0000-0003-4804-4291; colombatti, alfonso/0000-0002-3676-2379	ISS-ACC; AIRC; MIUR [RBRN07BMCT]	ISS-ACC; AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR))	We thank Dr Philip Thorpe and Dr Rolf Brekken for the generous gift of the Gv39M antibody. We thank the ISS-ACC Program 2, AIRC and MIUR (grant no.RBRN07BMCT) for supporting this work.	Anghelina M, 2006, AM J PATHOL, V168, P529, DOI 10.2353/ajpath.2006.050255; Aplin AC, 2008, METHOD ENZYMOL, V443, P119, DOI 10.1016/S0076-6879(08)02007-7; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Braghetta P, 2004, MATRIX BIOL, V22, P549, DOI 10.1016/j.matbio.2003.10.005; Brekken RA, 1998, CANCER RES, V58, P1952; Campbell NE, 2010, J ONCOL, V2010, DOI 10.1155/2010/586905; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Cheresh DA, 2008, ONCOGENE, V27, P6285, DOI 10.1038/onc.2008.304; Christian S, 2001, J BIOL CHEM, V276, P48588, DOI 10.1074/jbc.M106152200; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Greenaway J, 2007, J CELL PHYSIOL, V210, P807, DOI 10.1002/jcp.20904; Hirama M, 2003, CANCER LETT, V198, P107, DOI 10.1016/S0304-3835(03)00286-6; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Hotz B, 2010, NEOPLASIA, V12, P797, DOI 10.1593/neo.10418; Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006; Huber MA, 2006, J CUTAN PATHOL, V33, P145, DOI 10.1111/j.0303-6987.2006.00446.x; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Koperek O, 2007, INT J ONCOL, V31, P59; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Ligresti G, 2011, ARTERIOSCL THROM VAS, V31, P1151, DOI 10.1161/ATVBAHA.111.223917; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nicosia RF, 2009, J CELL MOL MED, V13, P4113, DOI 10.1111/j.1582-4934.2009.00891.x; Nyberg P, 2008, FRONT BIOSCI, V13, P6537, DOI 10.2741/3173; Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Sahni A, 2000, BLOOD, V96, P3772, DOI 10.1182/blood.V96.12.3772.h8003772_3772_3778; SANZMONCASI MP, 1994, LAB INVEST, V71, P366; Spessotto P, 2000, METH MOL B, V139, P321; Sun JF, 2009, AM J PHYSIOL-HEART C, V296, pH1344, DOI 10.1152/ajpheart.01246.2008; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Ventura E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009145; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Zoeller JJ, 2009, MATRIX BIOL, V28, P284, DOI 10.1016/j.matbio.2009.04.010	43	54	57	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3136	3147		10.1038/onc.2011.487	http://dx.doi.org/10.1038/onc.2011.487			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22020326	Bronze			2022-12-28	WOS:000305934400003
J	Wang, LY; Kung, HJ				Wang, L-Y; Kung, H-J			Male germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/C-CDH1	ONCOGENE			English	Article						APC/C complex; CDH1/FZR1; MAK; mitosis; prostate cancer	ANAPHASE-PROMOTING COMPLEX; CHROMOSOMAL INSTABILITY; CENTROSOME AMPLIFICATION; PHOSPHORYLATION SITES; GENOMIC INSTABILITY; ANDROGEN RECEPTOR; PHOSPHATASE CDC14; ACTIVATING KINASE; MECHANISM; CDH1	Male germ cell-associated kinase (MAK), a direct transcriptional target of androgen receptor (AR), is a co-activator of AR. In this study, we determined the activating mechanism of MAK and identified a previously unknown AR-independent role of MAK in mitosis. We found that MAK kinase activity requires dual phosphorylation of the conserved TDY motif and that the phosphorylation is dynamic during cell cycle. MAK associates with CDH1 (FZR1, fizzy/cell division cycle 20 related 1) and phosphorylates CDH1 at sites phosphorylated by cyclin-dependent kinases. When MAK is overexpressed, the binding of CDH1 to anaphase promoting complex/cyclosome decreased, resulting in an attenuation of anaphase-promoting complex/C ubiquitin ligase activity and the consequential stabilization of the CDH1 targets such as Aurora kinase A and Polo-like kinase 1. As such, overexpression of MAK leads to mitotic defects such as centrosome amplification and lagging chromosomes. Our immunohistochemistry result showed that MAK is overexpressed in prostate tumor tissues, suggesting a role of MAK in prostate carcinogenesis. Taken with our previous results, our data implicate MAK in both AR activation and chromosomal instability, acting in both early and late prostate cancer development.	[Kung, H-J] Univ Calif Davis, Ctr Canc, Dept Biochem & Mol Med, Sch Med, Sacramento, CA 95817 USA	University of California System; University of California Davis	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Dept Biochem & Mol Med, Sch Med, UCDMC Res 3,95 Room 2400B,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013	Wang, Ling-Yu/0000-0002-1413-817X	NCI NIH HHS [R01 CA150197, CA150197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052659, R01 DK078243, DK078243, DK526529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA150197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078243, R01DK052659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bolte M, 2002, P NATL ACAD SCI USA, V99, P4385, DOI 10.1073/pnas.072385099; Brown NR, 1999, J BIOL CHEM, V274, P8746, DOI 10.1074/jbc.274.13.8746; Buschhorn HM, 2005, PROSTATE, V64, P341, DOI 10.1002/pros.20247; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Clark JP, 2009, NAT REV UROL, V6, P429, DOI 10.1038/nrurol.2009.127; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fu Z, 2005, MOL CELL BIOL, V25, P6047, DOI 10.1128/MCB.25.14.6047-6064.2005; Fu Z, 2006, MOL CELL BIOL, V26, P8639, DOI 10.1128/MCB.00816-06; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; GIBAS Z, 1984, CANCER GENET CYTOGEN, V11, P399, DOI 10.1016/0165-4608(84)90020-7; Gregory CW, 2001, CANCER RES, V61, P4315; Holt LJ, 2007, MOL CELL, V25, P689, DOI 10.1016/j.molcel.2007.02.012; Honigberg SM, 2004, J CELL BIOCHEM, V92, P1025, DOI 10.1002/jcb.20131; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; KOJI T, 1992, CELL BIOCHEM FUNCT, V10, P273, DOI 10.1002/cbf.290100411; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Ma AH, 2006, CANCER RES, V66, P8439, DOI 10.1158/0008-5472.CAN-06-1636; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Pan Y, 1999, CYTOGENET CELL GENET, V87, P225, DOI 10.1159/000015432; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Pihan GA, 2001, CANCER RES, V61, P2212; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Roh M, 2003, CANCER RES, V63, P8079; Ross KE, 2003, GENETICS, V165, P489; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; TRIBUKAIT B, 1991, ACTA ONCOL, V30, P187, DOI 10.3109/02841869109092348; Wang X, 2008, ONCOGENE, V27, P4456, DOI 10.1038/onc.2008.87; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; Wohlbold L, 2006, CELL CYCLE, V5, P546, DOI 10.4161/cc.5.5.2541; Xia L, 2002, J BIOL CHEM, V277, P35422, DOI 10.1074/jbc.M203940200; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200	43	16	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2907	2918		10.1038/onc.2011.464	http://dx.doi.org/10.1038/onc.2011.464			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	21986944	Green Accepted			2022-12-28	WOS:000305388400001
J	Fan, H; Chen, L; Zhang, F; Quan, Y; Su, X; Qiu, X; Zhao, Z; Kong, KL; Dong, S; Song, Y; Chan, THM; Guan, XY				Fan, H.; Chen, L.; Zhang, F.; Quan, Y.; Su, X.; Qiu, X.; Zhao, Z.; Kong, K. L.; Dong, S.; Song, Y.; Chan, T. H. M.; Guan, X-Y			MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma	ONCOGENE			English	Article						DNMT3B; MTSS1; cell cycle; methylation; TSG; HCC	DE-NOVO METHYLATION; PERICENTROMERIC SATELLITE REGIONS; CANCER CELL-LINES; HUMAN HEPATOCARCINOGENESIS; BLADDER-CANCER; BREAST-CANCER; MESSENGER-RNA; CYCLIN-B; EXPRESSION; DNMT3B	DNA methyltransferase 3B (DNMT3B) mediates gene silencing via epigenetic mechanisms during hepatocellular carcinoma (HCC) progression. We aimed to identify novel targets of DNMT3B and their potential regulatory mechanisms in HCC. Metastasis suppressor 1 (MTSS1) was one of the DNMT3B targets and selected for further study. DNMT3B overexpression was detected in 81.25% of clinical HCC specimens and was negatively associated with MTSS1 in HCC cells and clinical samples. The underlying mechanism by which DNMT3B silences MTSS1 was studied using a combination of methylation-specific polymerase chain reaction (PCR) and bisulfite genome sequencing, chromatin immunoprecipitation-PCR and luciferase reporter assays. We found that the MTSS1 promoter region was sparsely methylated, and the methylation inhibitors failed to abolish DNMT3B-mediated MTSS1 silencing. DNMT3B protein bound directly to the 5'-flanking region (-865/-645) of the MTSS1 gene to inhibit its transcription. The functional role of MTSS1 was investigated using in vitro and in vivo tumorigenicity assays. As a result, MTSS1 exerted tumor suppressor effects and arrested cells in the G2/M phase, but not the G1/S phase of the cell cycle when it was depleted or overexpressed in HCC cells. Taken together, MTSS1, a novel target of DNMT3B, is repressed by DNMT3B via a DNA methylation-independent mechanism. MTSS1 was further characterized as a novel tumor suppressor gene in HCC. These findings highlight how DNMT3B regulates MTSS1, and such data may be useful for the development of new treatment options for HCC. Oncogene (2012) 31, 2298-2308; doi:10.1038/onc.2011.411; published online 12 September 2011	[Fan, H.; Zhang, F.; Quan, Y.; Su, X.; Qiu, X.] Southeast Univ, Sch Med, Key Lab Dev Genes & Human Dis, Minist Educ,Dept Med Genet & Dev Biol, Nanjing 210009, Peoples R China; [Chen, L.; Chan, T. H. M.; Guan, X-Y] Univ Hong Kong, State Key Lab Liver Canc, Pokfulam, Hong Kong, Peoples R China; [Chen, L.; Zhao, Z.; Kong, K. L.; Dong, S.; Song, Y.; Chan, T. H. M.; Guan, X-Y] Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; [Chen, L.; Guan, X-Y] Sun Yat Sen Univ, State Key Lab Oncol So China, Dept Clin Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China	Southeast University - China; University of Hong Kong; University of Hong Kong; Sun Yat Sen University	Fan, H (corresponding author), Southeast Univ, Sch Med, Key Lab Dev Genes & Human Dis, Minist Educ,Dept Genet & Dev Biol, Nanjing 210009, Peoples R China.	fanh@seu.edu.cn; xyguan@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805	National Natural Science Foundation of China [30971605]; HKU Li Ka Shing Faculty of Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); HKU Li Ka Shing Faculty of Medicine	This work was supported by The National Natural Science Foundation of China, No. 30971605, and in part by the Dr Cheng Yu Tung Fellowships 2007/08 under the HKU Li Ka Shing Faculty of Medicine. We are grateful to Professor Dianqing WU in UConn Health Center USA for providing siRNA expression vector. We are also grateful to Dr Stephanie Ma in Department of Pathology in University of Hong Kong for helping in MTSS1 antibody.	Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5; Claus R, 2003, ONCOGENE, V22, P6489, DOI 10.1038/sj.onc.1206814; Cross FR, 2005, MOL BIOL CELL, V16, P2129, DOI 10.1091/mbc.E04-10-0897; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Girault I, 2003, CLIN CANCER RES, V9, P4415; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Huang Xiu-yan, 2010, Zhonghua Gan Zang Bing Za Zhi, V18, P915, DOI 10.3760/cma.j.issn.1007-3418.2010.12.008; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jun Xu, 2005, Acta Genetica Sinica, V32, P1115; Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Oh BK, 2007, INT J MOL MED, V20, P65; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Potapova TA, 2006, NATURE, V440, P954, DOI 10.1038/nature04652; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Saito Y, 2002, P NATL ACAD SCI USA, V99, P10060, DOI 10.1073/pnas.152121799; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Shafiei F, 2008, ONCOGENE, V27, P2602, DOI 10.1038/sj.onc.1210917; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Simao TDA, 2006, HUM EXP TOXICOL, V25, P515, DOI 10.1191/0960327106het649oa; Takeshima H, 2006, J BIOCHEM, V139, P503, DOI 10.1093/jb/mvj044; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Utikal J, 2006, INT J CANCER, V119, P2287, DOI 10.1002/ijc.22106; Wang J, 2007, CANCER RES, V67, P10647, DOI 10.1158/0008-5472.CAN-07-1337; Weisenberger DJ, 2004, MOL CANCER RES, V2, P62	48	49	56	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2298	2308		10.1038/onc.2011.411	http://dx.doi.org/10.1038/onc.2011.411			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21909138				2022-12-28	WOS:000303610800005
J	Karadedou, CT; Gomes, AR; Chen, J; Petkovic, M; Ho, KK; Zwolinska, AK; Feltes, A; Wong, SY; Chan, KYK; Cheung, YN; Tsang, JWH; Brosens, JJ; Khoo, US; Lam, EWF				Karadedou, C. T.; Gomes, A. R.; Chen, J.; Petkovic, M.; Ho, K-K; Zwolinska, A. K.; Feltes, A.; Wong, S. Y.; Chan, K. Y. K.; Cheung, Y-N; Tsang, J. W. H.; Brosens, J. J.; Khoo, U-S; Lam, E. W-F			FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer	ONCOGENE			English	Article						VEGF; FOXO3a; FOXM1; breast cancer; transcription	TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR FOXO3A; LEUKEMIC-CELLS; GROWTH-INHIBITION; GEFITINIB IRESSA; GENE-EXPRESSION; DUAL INHIBITOR; SOLID TUMORS; LUNG-CANCER; LAPATINIB	Vascular endothelial growth factor (VEGF) has a central role in breast cancer development and progression, but the mechanisms that control its expression are poorly understood. Breast cancer tissue microarrays revealed an inverse correlation between the Forkhead transcription factor Forkhead box class O (FOXO)3a and VEGF expression. Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated by FOXO3a. Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression. Transient transfection and inducible expression experiments showed that FOXO3a represses the proximal VEGF promoter, whereas another Forkhead member, FOXM1, induces VEGF expression. Chromatin immunoprecipitation and oligonucleotide pull-down assays showed that both FOXO3a and FOXM1 bind a consensus Forkhead response element (FHRE) in the VEGF promoter. Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF. These results show that FOXO3a-dependent repression of target genes in breast cancer cells, such as VEGF, involves competitive displacement of DNA-bound FOXM1 and active recruitment of transcriptional repressor complexes. Oncogene (2012) 31, 1845-1858; doi: 10.1038/onc.2011.368; published online 22 August 2011	[Karadedou, C. T.; Gomes, A. R.; Chen, J.; Petkovic, M.; Ho, K-K; Zwolinska, A. K.; Feltes, A.; Brosens, J. J.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Canc Res UK Labs, London W12 0NN, England; [Chen, J.; Wong, S. Y.; Chan, K. Y. K.; Cheung, Y-N; Khoo, U-S] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, J. W. H.] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China	Cancer Research UK; Imperial College London; University of Hong Kong; University of Hong Kong	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Canc Res UK Labs, MRC Hammersmith Hosp Campus,Cyclotron Bldg,Du Can, London W12 0NN, England.	eric.lam@imperial.ac.uk	Khoo, Ui Soon/C-4293-2009; Khoo, Ui Soon/C-1345-2014; Chan, Kelvin/HGA-3097-2022; Khoo, Ui Soon/K-2041-2019; Lam, Eric W-F/AAW-8566-2020	Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Brosens, Jan/0000-0003-0116-9329	Cancer Research UK; Breast Cancer Campaign; Portuguese Science and Technology Foundation (FCT); Cancer Research UK [12011] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Portuguese Science and Technology Foundation (FCT)(Portuguese Foundation for Science and Technology); Cancer Research UK(Cancer Research UK)	This study was supported by the Cancer Research UK (M Petkovic, KK Ho and EW-F Lam), Breast Cancer Campaign (EW-F Lam), the Portuguese Science and Technology Foundation (FCT; AR Gomes).	Arden KC, 2008, ONCOGENE, V27, P2345, DOI 10.1038/onc.2008.27; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Burgering B, 2008, ONCOGENE, V27, P2258, DOI 10.1038/onc.2008.29; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Ciardiello Fortunato, 2005, Future Oncol, V1, P221, DOI 10.1517/14796694.1.2.221; DAVIE JR, 1978, P NATL ACAD SCI USA, V75, P3574, DOI 10.1073/pnas.75.8.3574; Davis R, 2009, ONCOL REP, V22, P1473, DOI 10.3892/or_00000589; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Delpuech O, 2007, MOL CELL BIOL, V27, P4917, DOI 10.1128/MCB.01789-06; Diaz R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-188; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essafi Abdelkader, 2009, V462, P201, DOI 10.1007/978-1-60327-115-8_13; de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Hegde PS, 2007, MOL CANCER THER, V6, P1629, DOI 10.1158/1535-7163.MCT-05-0399; Heist RS, 2008, J CLIN ONCOL, V26, P856, DOI 10.1200/JCO.2007.13.5947; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Ikezoe T, 2006, MOL CANCER THER, V5, P2522, DOI 10.1158/1535-7163.MCT-06-0071; Ikezoe T, 2006, CANCER SCI, V97, P945, DOI 10.1111/j.1349-7006.2006.00263.x; Jain L, 2009, MOL CANCER THER, V8, P2496, DOI 10.1158/1535-7163.MCT-09-0302; Kitadai Y, 2010, J ONCOL, V2010, DOI 10.1155/2010/468725; Kondo N, 2010, ONCOL REP, V23, P957, DOI 10.3892/or_00000720; Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Lentzsch S, 2004, LEUKEMIA, V18, P1883, DOI 10.1038/sj.leu.2403486; Littler DR, 2010, NUCLEIC ACIDS RES, V38, P4527, DOI 10.1093/nar/gkq194; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Maiese K, 2008, TRENDS MOL MED, V14, P219, DOI 10.1016/j.molmed.2008.03.002; Makrilia N, 2009, EUR J INTERN MED, V20, P663, DOI 10.1016/j.ejim.2009.07.009; Margolin Kim, 2002, Curr Oncol Rep, V4, P20, DOI 10.1007/s11912-002-0044-9; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Montemurro F, 2007, EXPERT OPIN BIOL TH, V7, P257, DOI 10.1517/14712598.7.2.257; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nelson MH, 2006, ANN PHARMACOTHER, V40, P261, DOI 10.1345/aph.1G387; Nordigarden A, 2009, BLOOD, V113, P2302, DOI 10.1182/blood-2008-07-167023; Nott A, 2008, NATURE, V455, P411, DOI 10.1038/nature07238; Park SH, 2009, BIOCHEM BIOPH RES CO, V390, P861, DOI 10.1016/j.bbrc.2009.10.063; Pytel D, 2009, ANTI-CANCER AGENT ME, V9, P66, DOI 10.2174/187152009787047752; Reedquist KA, 2006, BIOCHEM SOC T, V34, P727, DOI 10.1042/BST0340727; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Schneider BP, 2007, NAT CLIN PRACT ONCOL, V4, P181, DOI 10.1038/ncponc0740; Srivastava RK, 2010, MOL CELL BIOCHEM, V337, P201, DOI 10.1007/s11010-009-0300-5; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Wakeling AE, 2002, CURR OPIN PHARMACOL, V2, P382, DOI 10.1016/S1471-4892(02)00183-2; Yamaguchi T, 2007, CANCER SCI, V98, P405, DOI 10.1111/j.1349-7006.2007.00402.x; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhang YJ, 2008, CANCER RES, V68, P8733, DOI 10.1158/0008-5472.CAN-08-1968	59	118	131	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1845	1858		10.1038/onc.2011.368	http://dx.doi.org/10.1038/onc.2011.368			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860419	Green Submitted, Green Accepted			2022-12-28	WOS:000302785200010
J	Lu, C; Zhu, X; Willingham, MC; Cheng, SY				Lu, C.; Zhu, X.; Willingham, M. C.; Cheng, S-Y			Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma	ONCOGENE			English	Article						thyroid hormone; follicular thyroid carcinoma; animal model; protein kinase B/AKT; PTEN	BETA-CATENIN; GENETIC ALTERATIONS; RECEPTOR-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; METASTATIC SPREAD; TRANSFORMING GENE; PROTEIN-KINASE; GROWTH-FACTOR; PATHWAY; CANCER	Thyroid cancers are the most common malignancy of the endocrine system in humans. To understand the molecular genetic events underlying thyroid carcinogenesis, we have generated a mouse model that spontaneously develops follicular thyroid carcinoma similar to human thyroid cancer (Thrb(PV/PV) mouse). This mutant mouse harbors a dominant-negative mutated thyroid hormone receptor beta (denoted PV). The PV mutation was identified in a patient with resistance to thyroid hormone (TH). Thrb(PV/PV) mice exhibit highly elevated serum thyroid-stimulating hormone levels and increased TH. We have previously shown that thyroid-stimulating hormone is required, but not sufficient to induce metastatic follicular thyroid cancer in Thrb(PV/PV) mice. However, whether the elevated TH also contributes to the thyroid carcinogenesis of Thrb(PV/PV) mice was not elucidated. To understand the role of TH in thyroid carcinogenesis, we blocked the production of TH by treating Thrb(PV/PV) mice with propylthiouracil (Thrb(PV/PV)-PTU mice) and compared the development of thyroid cancer in Thrb(PV/PV)-PTU and untreated ThrbPV/PV mice. We found that thyroid tumor growth was reduced by similar to 42% in Thrb(PV/PV)-PTU mice as compared with Thrb(PV/PV) mice. Analysis by bromodeoxyuridine-nuclear labeling showed decreased incorporation of bromodeoxyuridine in thyroid tumor cells of Thrb(PV/PV)-PTU mice, indicative of decreased tumor cell proliferation. However, cleaved-caspase 3 staining showed no apparent changes in apoptosis of tumor cells in Thrb(PV/PV)-PTU mice. Molecular studies identified a marked attenuation of the PI3K-AKT-beta-catenin signaling pathway that led to decreased protein levels of cyclin D2, thereby decreasing tumor cell proliferation in Thrb(PV/PV)-PTU mice. Furthermore, matrix metalloproteinase-2, a downstream target of beta-catenin and a key regulator during tumor invasion and metastasis, was also decreased. Thus, the present study uncovers a critical role of TH in promoting the thyroid carcinogenesis of Thrb(PV/PV) mice via membrane signaling events. Importantly, these findings suggest that anti-thyroid drugs could be considered as possible therapeutic agents of thyroid cancer. Oncogene (2012) 31, 2007-2016; doi: 10.1038/onc.2011.390; published online 12 September 2011	[Lu, C.; Zhu, X.; Cheng, S-Y] NCI, Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; [Willingham, M. C.] Wake Forest Univ, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011191] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of National Institutes of Health, National Cancer Institute, Center for Cancer Research.	Abbosh PH, 2005, THYROID, V15, P551, DOI 10.1089/thy.2005.15.551; Antico-Arciuch VG, 2010, ONCOGENE, V29, P5678, DOI 10.1038/onc.2010.308; Bergh JJ, 2005, ENDOCRINOLOGY, V146, P2864, DOI 10.1210/en.2005-0102; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Cao X, 2005, MOL ENDOCRINOL, V19, P102, DOI 10.1210/me.2004-0093; Castellone MD, 2009, CANCER RES, V69, P1867, DOI 10.1158/0008-5472.CAN-08-1982; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Davis FB, 2004, CIRC RES, V94, P1500, DOI 10.1161/01.RES.0000130784.90237.4a; Davis PJ, 2009, AM J PHYSIOL-ENDOC M, V297, pE1238, DOI 10.1152/ajpendo.00480.2009; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Furuya F, 2007, CARCINOGENESIS, V28, P2451, DOI 10.1093/carcin/bgm174; Glinskii AB, 2009, CELL CYCLE, V8, P3562, DOI 10.4161/cc.8.21.9963; Guigon CJ, 2008, MOL CELL BIOL, V28, P4598, DOI 10.1128/MCB.02192-07; Guigon CJ, 2010, ENDOCRINOLOGY, V151, P5528, DOI 10.1210/en.2010-0475; Guigon CJ, 2009, MOL CELL ENDOCRINOL, V308, P63, DOI 10.1016/j.mce.2009.01.007; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Lin HY, 2007, STEROIDS, V72, P180, DOI 10.1016/j.steroids.2006.11.014; Lin HY, 2009, AM J PHYSIOL-CELL PH, V296, pC980, DOI 10.1152/ajpcell.00305.2008; Lu CX, 2011, AM J CANCER RES, V1, P1; Lu CX, 2011, STEROIDS, V76, P885, DOI 10.1016/j.steroids.2011.03.016; Lu CX, 2010, ENDOCRINOLOGY, V151, P1929, DOI 10.1210/en.2009-1017; Mousa SA, 2006, INT ANGIOL, V25, P407; Nikiforov YE, 2004, ENDOCR PATHOL, V15, P319, DOI 10.1385/EP:15:4:319; Nikiforova MN, 2009, THYROID, V19, P1351, DOI 10.1089/thy.2009.0240; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Puxeddu E, 2011, CURR OPIN ONCOL, V23, P13, DOI 10.1097/CCO.0b013e328340cf94; Rego-Iraeta A, 2009, THYROID, V19, P333, DOI 10.1089/thy.2008.0210; Rowlands TM, 2004, CELL CYCLE, V3, P145; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Sassolas G, 2009, EUR J ENDOCRINOL, V160, P71, DOI 10.1530/EJE-08-0624; Sipos JA, 2010, CLIN ONCOL-UK, V22, P395, DOI 10.1016/j.clon.2010.05.004; Sonderegger S, 2010, ENDOCRINOLOGY, V151, P211, DOI 10.1210/en.2009-0557; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Verga Falzacappa C, 2007, J MOL ENDOCRINOL, V38, P221, DOI DOI 10.1677/JME.1.02166; Weinberger PM, 2007, ARCH OTOLARYNGOL, V133, P503, DOI 10.1001/archotol.133.5.503; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Yalcin M, 2010, THYROID, V20, P281, DOI 10.1089/thy.2009.0249; Ying H, 2008, ONCOGENE, V27, P823, DOI 10.1038/sj.onc.1210680; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2006, J CLIN INVEST, V116, P2972, DOI 10.1172/JCI28598	50	14	15	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2007	2016		10.1038/onc.2011.390	http://dx.doi.org/10.1038/onc.2011.390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909131	Green Accepted			2022-12-28	WOS:000303008600002
J	Woo, JK; Choi, Y; Oh, SH; Jeong, JH; Choi, DH; Seo, HS; Kim, CW				Woo, J. K.; Choi, Y.; Oh, S-H; Jeong, J-H; Choi, D-H; Seo, H-S; Kim, C-W			Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway	ONCOGENE			English	Article						breast cancer; angiogenesis; MUC1; PI3K/AKT; VEGF	ENDOTHELIAL-GROWTH-FACTOR; FACTOR EXPRESSION; ANTIGEN-EXPRESSION; FACTOR RECEPTOR; FACTOR-I; INDUCTION; PHOSPHORYLATION; METASTASIS; INHIBITION; SUGGESTS	Although the hyper-glycosylated transmembrane protein Mucin 1 (MUC1) is aberrantly overexpressed in human breast carcinoma, the biological significance of MUC1 overexpression is unclear. This study showed that MUC1 expression promoted the synthesis and secretion of vascular endothelial growth factor (VEGF) through the AKT signaling pathway. Increase VEGF production through MUC1 expression had a number of effect. First, MUC1 transfection increased expression of VEGF in breast cancer cells. Second, MUC1-mediated VEGF induction was attenuated by a chemical inhibitor of AKT or MUC1 knock-down by MUC1 siRNA. Third, MUC1 expression led to the activation of insulin-like growth factor-1 receptor, which correlated with VEGF expression. In addition, when MDA-MB-231 human breast cancer cells were directly injected into NOD/SCID mice, MUC1 expression accelerated xenograft tumor growth in vivo. Finally, MUC1 expression enhanced tumor growth and angiogenesis in a PyMT-MMTV/hMUC1 transgenic mouse model. Concurrent with these results, analysis of a human tissue microarray identified a high correlation between MUC1 and VEGF expression in human breast carcinoma. The current report is the first to demonstrate that MUC1 expression promotes angiogenesis in human breast cancer in vivo and in vitro. Oncogene (2012) 31, 2187-2198; doi:10.1038/onc.2011.410; published online 19 September 2011	[Woo, J. K.; Kim, C-W] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; [Woo, J. K.; Choi, Y.; Choi, D-H; Kim, C-W] Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul 110799, South Korea; [Woo, J. K.; Choi, Y.; Choi, D-H; Kim, C-W] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; [Oh, S-H] Gachon Univ Med & Sci, Coll Pharm, Inchon, South Korea; [Jeong, J-H] Korea Inst Radiol & Med Sci, Res Ctr Radiotherapy, Seoul, South Korea; [Seo, H-S] Kyung Hee Univ, Dept Oriental Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Gachon University; Korea Institute of Radiological & Medical Sciences; Kyung Hee University	Kim, CW (corresponding author), Seoul Natl Univ, Coll Med, Dept Pathol, 28 Yeongeon Dong, Seoul 110799, South Korea.	cwkim@snu.ac.kr	Kim, Chul-Woo/F-7008-2011	Woo, Jong Kyu/0000-0002-3374-6488	Ministry of Knowledge Economy (MOST) [10035353]; Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University college of Medicine, Republic of Korea	Ministry of Knowledge Economy (MOST)(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea); Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University college of Medicine, Republic of Korea(Korea Science and Engineering Foundation)	We are grateful to Drs Dong-Young Noh and Hyeong-Gon Moon for providing the human breast cancer tissues microarray. This work was supported in part by grants from the R&D Project, the Ministry of Knowledge Economy (MOST, 10035353) and the Korean Science and Engineering Foundation (KOSEF) through the Tumor Immunity Medical Research Center at Seoul National University college of Medicine, Republic of Korea	BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Borgstrom P, 1996, CANCER RES, V56, P4032; Brayman Melissa, 2004, Reprod Biol Endocrinol, V2, P4, DOI 10.1186/1477-7827-2-4; Cho JA, 2005, INT J CANCER, V114, P613, DOI 10.1002/ijc.20757; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Duffy MJ, 2000, INT J BIOL MARKER, V15, P330, DOI 10.1177/172460080001500410; Duraisamy S, 2007, INT J ONCOL, V31, P671; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.3.CO;2-X; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fessler SP, 2009, BREAST CANCER RES TR, V118, P113, DOI 10.1007/s10549-009-0412-3; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Geddis AE, 2006, EXP HEMATOL, V34, P82, DOI 10.1016/j.exphem.2005.09.008; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Giatromanolaki A, 2000, CLIN CANCER RES, V6, P1917; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hattrup CL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1515; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kimura T, 2000, INT J ONCOL, V16, P55; KOHNO N, 1992, CHEST, V102, P117, DOI 10.1378/chest.102.1.117; Kucab Jill E, 2003, Breast Dis, V17, P41; Kurmasheva RT, 2009, CANCER RES, V69, P7662, DOI 10.1158/0008-5472.CAN-09-1693; Lee HY, 2005, J NATL CANCER I, V97, P1695, DOI 10.1093/jnci/dji377; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Mikami Y, 2009, BIOCHEM BIOPH RES CO, V379, P1060, DOI 10.1016/j.bbrc.2009.01.002; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Okajima E, 2000, BIOCHEM BIOPH RES CO, V270, P108, DOI 10.1006/bbrc.2000.2386; Papadopoulos I, 2001, CLIN CANCER RES, V7, P1533; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Pochampalli MR, 2007, CANCER RES, V67, P6591, DOI 10.1158/0008-5472.CAN-06-4518; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Pollak MN, 2004, NOVART FDN SYMP, V262, P265, DOI DOI 10.1002/0470869976.CH6; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Poulaki V, 2003, J CLIN ENDOCR METAB, V88, P5392, DOI 10.1210/jc.2003-030389; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren J, 2006, MOL CANCER RES, V4, P873, DOI 10.1158/1541-7786.MCR-06-0204; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sakamoto H, 1997, HUM PATHOL, V28, P1056, DOI 10.1016/S0046-8177(97)90059-9; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tang YC, 2003, CANCER RES, V63, P1166; Wang Bao-Feng, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P425; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yoshiji H, 1997, CANCER RES, V57, P3924; Yu H, 2007, BIOCHEM BIOPH RES CO, V361, P946, DOI 10.1016/j.bbrc.2007.07.114; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474	55	48	50	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2187	2198		10.1038/onc.2011.410	http://dx.doi.org/10.1038/onc.2011.410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927028				2022-12-28	WOS:000303415900007
J	Carrascosa, C; Obula, RG; Missiaglia, E; Lehr, HA; Delorenzi, M; Frattini, M; Ruegg, C; Mariotti, A				Carrascosa, C.; Obula, R. G.; Missiaglia, E.; Lehr, H-A; Delorenzi, M.; Frattini, M.; Rueegg, C.; Mariotti, A.			MFG-E8/lactadherin regulates cyclins D1/D3 expression and enhances the tumorigenic potential of mammary epithelial cells	ONCOGENE			English	Article						MFG-E8; mammary tumorigenesis; neoplastic transformation; cyclin D; N-cadherin	MILK-FAT GLOBULE; BREAST-CANCER; N-CADHERIN; PREOPERATIVE CHEMOTHERAPY; MONOCLONAL-ANTIBODIES; ESTROGEN-RECEPTOR; APOPTOTIC CELLS; TUMOR; CARCINOMA; PROTEIN	Milk fat globule-EGF factor 8 (MFG-E8) is a glycoprotein highly expressed in breast cancer that contributes to tumor progression through largely undefined mechanisms. By analyzing publicly available gene expression profiles of breast carcinomas, we found that MFG-E8 is highly expressed in primary and metastatic breast carcinomas, associated with absent estrogen receptor expression. Immunohistochemistry analysis of breast cancer biopsies revealed that MFG-E8 is expressed on the cell membrane as well as in the cytoplasm and nucleus. We also show that increased expression of MFG-E8 in mammary carcinoma cells increases their tumorigenicity in immunodeficient mice, and conversely, its downregulation reduces their in vivo growth. Moreover, expression of MFG-E8 in immortalized mammary epithelial cells promotes their growth and branching in three-dimensional collagen matrices and induces the expression of cyclins D1/D3 and N-cadherin. A mutant protein unable to bind integrins can in part exert these effects, indicating that MFG-E8 function is only partially dependent on integrin activation. We conclude that MFG-E8-dependent signaling stimulates cell proliferation and the acquisition of mesenchymal properties and contributes to mammary carcinoma development. Oncogene (2012) 31, 1521-1532; doi:10.1038/onc.2011.356; published online 15 August 2011	[Carrascosa, C.; Mariotti, A.] Univ Lausanne, Div Expt Oncol, Ctr Pluridisciplinaire Oncol, Lausanne Canc Ctr, CH-1066 Epalinges, Switzerland; [Missiaglia, E.; Delorenzi, M.] Univ Lausanne, Swiss Inst Bioinformat, Lausanne, Switzerland; [Lehr, H-A] CHUV, Inst Pathol, Lausanne, Switzerland; [Delorenzi, M.; Mariotti, A.] Univ Lausanne, Dept Format & Rech, CHUV, Lausanne, Switzerland; [Frattini, M.] Inst Pathol, Lab Mol Diagnost, Locarno, Switzerland; [Rueegg, C.] Univ Fribourg, Dept Med, CH-1700 Fribourg, Switzerland	University of Lausanne; Swiss Institute of Bioinformatics; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Fribourg	Mariotti, A (corresponding author), Univ Lausanne, Div Expt Oncol, Ctr Pluridisciplinaire Oncol, Lausanne Canc Ctr, 155 Ch Boveresses,Room D203, CH-1066 Epalinges, Switzerland.	Agnese.Mariotti@unil.ch		missiaglia, edoardo/0000-0001-9221-0117; Mariotti, Agnese/0000-0002-3704-7908	MEDIC Foundation	MEDIC Foundation	This work was supported by a grant from the MEDIC Foundation to AM. We thank J-C Stehle and J Horlbeck of the UNIL Mouse Pathology facility for help with immunohistochemistry, F Botta for help in obtaining the breast carcinoma biopsies, C Brisken for reagents and T Petrova for discussions and support.	Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Atabai K, 2005, MOL BIOL CELL, V16, P5528, DOI 10.1091/mbc.E05-02-0128; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; CERIANI RL, 1982, P NATL ACAD SCI-BIOL, V79, P5420, DOI 10.1073/pnas.79.17.5420; CERIANI RL, 1977, P NATL ACAD SCI USA, V74, P582, DOI 10.1073/pnas.74.2.582; CERIANI RL, 1987, CANCER RES, V47, P532; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Ensslin MA, 2007, P NATL ACAD SCI USA, V104, P2715, DOI 10.1073/pnas.0610296104; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hanayama R, 2005, P NATL ACAD SCI USA, V102, P16886, DOI 10.1073/pnas.0508599102; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jinushi M, 2008, CANCER RES, V68, P8889, DOI 10.1158/0008-5472.CAN-08-2147; Jinushi M, 2009, J EXP MED, V206, P1317, DOI 10.1084/jem.20082614; Joel PB, 1998, J BIOL CHEM, V273, P13317, DOI 10.1074/jbc.273.21.13317; LAROCCA D, 1991, CANCER RES, V51, P4994; Lee MH, 2003, CANCER METAST REV, V22, P435, DOI 10.1023/A:1023785332315; Lincoln DW, 2003, BREAST CANCER RES TR, V78, P167, DOI 10.1023/A:1022904624054; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Neutzner M, 2007, CANCER RES, V67, P6777, DOI 10.1158/0008-5472.CAN-07-0165; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima K, 1999, BIOCHEM BIOPH RES CO, V254, P522, DOI 10.1006/bbrc.1998.0107; Peintinger F, 2007, CLIN CANCER RES, V13, P4078, DOI 10.1158/1078-0432.CCR-06-2600; PETERSON JA, 1990, HYBRIDOMA, V9, P221, DOI 10.1089/hyb.1990.9.221; Raymond A, 2009, J CELL BIOCHEM, V106, P957, DOI 10.1002/jcb.22076; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Symmans WF, 2003, CANCER, V97, P2960, DOI 10.1002/cncr.11435; Taubenberger AV, 2010, BIOMATERIALS, V31, P2827, DOI 10.1016/j.biomaterials.2009.12.051; Taylor MR, 1997, DNA CELL BIOL, V16, P861, DOI 10.1089/dna.1997.16.861; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yang CW, 2011, CANCER RES, V71, P937, DOI 10.1158/0008-5472.CAN-10-1471; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	40	32	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	12					1521	1532		10.1038/onc.2011.356	http://dx.doi.org/10.1038/onc.2011.356			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21841820	Green Submitted			2022-12-28	WOS:000302132000005
J	Khromova, N; Kopnin, P; Rybko, V; Kopnin, BP				Khromova, N.; Kopnin, P.; Rybko, V.; Kopnin, B. P.			Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms	ONCOGENE			English	Article						metastasis; epithelial-mesenchymal transition (EMT); cancer stem cells (CSCs); cell migration; tumor vascularization; VEGF-C	EPITHELIAL-MESENCHYMAL TRANSITIONS; STEM-CELLS; CLINICAL-SIGNIFICANCE; FACTOR RECEPTOR-3; NUDE-MICE; LYMPHANGIOGENESIS; AUTOCRINE; PROMOTES; CARCINOMA; AXIS	Experimental and clinical studies positively correlate expression of vascular endothelial growth factor (VEGF)-C in cancer cells with accelerated tumor progression and/or unfavorable clinical outcome. However, many aspects of tumor-promoting activity of VEGF-C and consequences of its downregulation for tumor progression remain poorly understood. To clarify these points, we created a set of VEGF receptor 3-positive lung carcinoma A549 and colon carcinoma HCT116 cell sublines with stable repression of VEGF-C synthesis. Analysis of the behavior of these cells revealed multiple effects of VEGF-C downregulation, which, in addition to deceleration of cell proliferation and invasion in vitro and inhibition of lymphangiogenesis in tumor and surrounding tissues observed earlier, included previously undescribed effects, in particular, partial restoration of epithelial phenotype, reduction in the percentage of tumor-initiating cells (cancer stem cells) in the cell population and inhibition of metastasis of orthotopic lung cancer xenografts to other lung lobes. These results are consistent with the idea of high potentiality of VEGF-C as a cancer drug target. Oncogene (2012) 31, 1389-1397; doi:10.1038/onc.2011.330; published online 1 August 2011	[Khromova, N.; Kopnin, P.; Rybko, V.; Kopnin, B. P.] Blokhin Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	N.N. Blokhin Russian Cancer Research Center	Kopnin, BP (corresponding author), Blokhin Russian Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 115478, Russia.	bkopnin@mail.ru	Kopnin, Pavel/R-8213-2019; Kopnin, Boris/R-8240-2019	Kopnin, Pavel/0000-0002-2078-4274; Kopnin, Boris/0000-0003-3100-2212	Russian Fund for Basic Research [08-04-00252]; PROTEK-CRC; Russian Federal Program 'Scientific and pedagogical personnel of innovative Russia' [02.740.11.0085]	Russian Fund for Basic Research(Russian Foundation for Basic Research (RFBR)); PROTEK-CRC; Russian Federal Program 'Scientific and pedagogical personnel of innovative Russia'	The work was supported by grants from Russian Fund for Basic Research (BK, # 08-04-00252), PROTEK-CRC Program for Basic Research in Oncology and Russian Federal Program 'Scientific and pedagogical personnel of innovative Russia' (BK, # 02.740.11.0085).	Arinaga M, 2003, CANCER-AM CANCER SOC, V97, P457, DOI 10.1002/cncr.11073; Bahram Fuad, 2010, Pathophysiology, V17, P253, DOI 10.1016/j.pathophys.2009.10.004; Chen YL, 2010, MOL CELL BIOCHEM, V345, P77, DOI 10.1007/s11010-010-0562-y; Gu Y, 2008, CLIN EXP METASTAS, V25, P717, DOI 10.1007/s10585-008-9180-4; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jackson MW, 2002, CANCER RES, V62, P854; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com; Khromova NV, 2009, CANCER LETT, V276, P143, DOI 10.1016/j.canlet.2008.10.049; Kodama M, 2008, CLIN CANCER RES, V14, P7205, DOI 10.1158/1078-0432.CCR-08-0818; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Miyazaki T, 2008, JPN J CLIN ONCOL, V38, P839, DOI 10.1093/jjco/hyn106; Orlandini M, 2006, J BIOL CHEM, V281, P17961, DOI 10.1074/jbc.M600413200; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Su JL, 2008, CANCER CELL, V13, P557, DOI 10.1016/j.ccr.2008.04.021; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Timoshenko AV, 2007, BRIT J CANCER, V97, P1090, DOI 10.1038/sj.bjc.6603993; WANG XE, 1992, ANTICANCER RES, V12, P1399; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Yamashita T, 2010, LUNG CANCER, V70, P320, DOI 10.1016/j.lungcan.2010.02.013; Yamaura T, 2000, NEOPLASIA, V2, P315, DOI 10.1038/sj.neo.7900098; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	36	56	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1389	1397		10.1038/onc.2011.330	http://dx.doi.org/10.1038/onc.2011.330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804602				2022-12-28	WOS:000301780000006
J	Saha, B; Adhikary, A; Ray, P; Saha, S; Chakraborty, S; Mohanty, S; Das, K; Mukherjee, S; Mazumdar, M; Lahiri, L; Hossain, DMS; Sa, G; Das, T				Saha, B.; Adhikary, A.; Ray, P.; Saha, S.; Chakraborty, S.; Mohanty, S.; Das, K.; Mukherjee, S.; Mazumdar, M.; Lahiri, L.; Hossain, D. M. S.; Sa, G.; Das, T.			Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells	ONCOGENE			English	Article						apoptosis; celecoxib; Cox-2; HPV-18; E6; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CARCINOMA-CELLS; CYCLOOXYGENASE-2 EXPRESSION; CYTOPLASMIC SEQUESTRATION; SIGNALING PATHWAY; DOWN-REGULATION; POSTTRANSLATIONAL MODIFICATIONS; NITRIC-OXIDE; COLON-CANCER	Abrogation of functional p53 is responsible for malignant cell transformation and maintenance of human papilloma virus (HPV)-infected cancer cells. Restoration of p53 has, therefore, been regarded as an important strategy for molecular intervention of HPV-associated malignancies. Here we report that differential regulation of pro-and anti-p53 setups not only upregulates p53 transcription but also stabilizes and activates p53 protein to ensure p53-induced apoptosis in HPV-18-infected cervical cancer. Functional restoration of p53 can be achieved by nonsteroidal anti-inflammatory drug celecoxib via multiple molecular mechanisms: (i) inhibition of p53 degradation by suppressing viral oncoprotein E6 expression, (ii) promoting p53 transcription by downmodulating cycloxygenase-2 (Cox-2) and simultaneously retrieving p53 from Cox-2 association and (iii) activation of p53 via ataxia telangiectasia mutated-/p38 mitogen-activated protein kinase-mediated phosphorylations at serine-15/-46 residues. That restored p53 is functional has been confirmed by its ability of transactivating Bax and p53-upregulated modulator of apoptosis, which in turn switch on the apoptotic machinery in these cells. Studies undertaken in biopsy samples of cervical carcinoma further validated celecoxib effect. Our approaches involving gene manipulation and pharmacological interference finally highlight that celecoxib alters pro-and anti-p53 networks, not in isolation but in concert, to rejuvenate p53-dependent apoptotic program in HPV-infected cervical cancer cells. Oncogene (2012) 31, 173-186; doi:10.1038/onc.2011.234; published online 18 July 2011	[Saha, B.; Adhikary, A.; Ray, P.; Saha, S.; Chakraborty, S.; Mohanty, S.; Das, K.; Mukherjee, S.; Mazumdar, M.; Lahiri, L.; Hossain, D. M. S.; Sa, G.; Das, T.] Bose Inst, Div Mol Med, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Das, T (corresponding author), Bose Inst, Div Mol Med, P-1-12 Calcutta Improvement Trust Scheme VIIM, Kolkata 700054, W Bengal, India.	tanya@boseinst.ernet.in	Chakraborty, Samik/Q-1779-2018	Chakraborty, Samik/0000-0002-5232-0474	DST; CSIR; UGC, Govt of India	DST(Department of Science & Technology (India)); CSIR(Council of Scientific & Industrial Research (CSIR) - India); UGC, Govt of India(University Grants Commission, India)	We gratefully acknowledge Dr S Biswas, Department of Surgery, SSKM Hospital, Kolkata, for providing primary lesions of cervical cancer and normal cervical tissues. We are thankful to R Sarkar for editing the manuscript. Thanks are also due to U Ghosh and R Dutta for technical help. This work was supported by the grants from DST, CSIR and UGC, Govt of India.	Adhikary A, 2010, FEBS LETT, V584, P7, DOI 10.1016/j.febslet.2009.10.081; Amano T, 2009, J NEURO-ONCOL, V92, P357, DOI 10.1007/s11060-009-9844-1; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Becker K, 2007, CELL DEATH DIFFER, V14, P1350, DOI 10.1038/sj.cdd.4402126; Bhattacharyya S, 2007, J BIOL CHEM, V282, P15954, DOI 10.1074/jbc.M608189200; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Chakrabarti O, 2003, J BIOSCIENCES, V28, P337, DOI 10.1007/BF02970152; Chakraborty J, 2010, J BIOL CHEM, V285, P33104, DOI 10.1074/jbc.M110.122705; Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; Das T, 2008, J IMMUNOL, V180, P4687, DOI 10.4049/jimmunol.180.7.4687; Das T, 2008, CANCER RES, V68, P2014, DOI 10.1158/0008-5472.CAN-07-6037; de Moraes E, 2007, INT J CANCER, V121, P929, DOI 10.1002/ijc.22899; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Frank S, 2006, EXP DERMATOL, V15, P130, DOI 10.1111/j.1600-0625.2005.00397.x; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Grosch S, 2005, BIOCHEM PHARMACOL, V69, P831, DOI 10.1016/j.bcp.2004.11.026; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Ichwan SJA, 2006, ONCOGENE, V25, P1216, DOI 10.1038/sj.onc.1209158; Ishida K, 2003, BIOCHEM BIOPH RES CO, V300, P201, DOI 10.1016/S0006-291X(02)02790-0; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Kang KB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-66; Kastan MB, 2007, CELL, V128, P837, DOI 10.1016/j.cell.2007.02.022; Kawamata Y, 2002, INT J ONCOL, V21, P561; Kuperwasser C, 2000, CANCER RES, V60, P2723; Lahiry L, 2008, APOPTOSIS, V13, P771, DOI 10.1007/s10495-008-0213-x; Lahiry L, 2010, CARCINOGENESIS, V31, P259, DOI 10.1093/carcin/bgp240; Lee HC, 2008, MOL CANCER RES, V6, P996, DOI 10.1158/1541-7786.MCR-08-0113; Malanchi I, 2002, ONCOGENE, V21, P5665, DOI 10.1038/sj.onc.1205617; Mestre JR, 1997, CANCER RES, V57, P2890; Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337; Molina MA, 1999, CANCER RES, V59, P4356; Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605; Munkarah A, 2005, CURR OPIN OBSTET GYN, V17, P49; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Narayanan BA, 2006, MOL CANCER THER, V5, P1117, DOI 10.1158/1535-7163.MCT-05-0520; Park SW, 2005, ONCOGENE, V24, P6689, DOI 10.1038/sj.onc.1208816; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Prince ME, 2007, HEAD NECK-J SCI SPEC, V29, P465, DOI 10.1002/hed.20547; Reddy BS, 2000, CANCER RES, V60, P293; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Ryu HS, 2000, GYNECOL ONCOL, V76, P320, DOI 10.1006/gyno.1999.5690; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sato T, 1997, PROSTAGLANDINS, V53, P355, DOI 10.1016/0090-6980(97)00036-1; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sigal A, 2000, CANCER RES, V60, P6788; Subbaramaiah K, 2007, CANCER RES, V67, P3976, DOI 10.1158/0008-5472.CAN-06-4273; Swamy MV, 2003, CANCER RES, V63, P5239; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker C, 2006, AM J PATHOL, V168, P1526, DOI 10.2353/ajpath.2006.050603; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; Zhao CY, 2010, CANCER RES, V70, P3372, DOI 10.1158/0008-5472.CAN-09-2787; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003	60	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					173	186		10.1038/onc.2011.234	http://dx.doi.org/10.1038/onc.2011.234			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21765464				2022-12-28	WOS:000299307400004
J	Wu, J; Liu, S; Liu, G; Dombkowski, A; Abrams, J; Martin-Trevino, R; Wicha, MS; Ethier, SP; Yang, ZQ				Wu, J.; Liu, S.; Liu, G.; Dombkowski, A.; Abrams, J.; Martin-Trevino, R.; Wicha, M. S.; Ethier, S. P.; Yang, Z-Q			Identification and functional analysis of 9p24 amplified genes in human breast cancer	ONCOGENE			English	Article						chromosome 9p24; GASC1; UHRF2; gene amplification	HISTONE LYSINE METHYLATION; TUMOR-SUPPRESSOR GENE; CELL-LINES; JMJD2 FAMILY; DNA METHYLATION; AMPLICON; PROTEIN; AMPLIFICATION; PTPRD; DEMETHYLATION	Previously, our group identified a novel amplicon at chromosome 9p24 in human esophageal and breast cancers, and cloned the novel gene, GASC1 (gene amplified in squamous cell carcinoma 1, also known as JMJD2C/KDM4C), from this amplicon. GASC1 is a histone demethylase involved in the deregulation of histone methylation in cancer cells. In the current study, we aimed to comprehensively characterize the genes in the 9p24 amplicon in human breast cancer. We performed extensive genomic analyses on a panel of cancer cell lines and narrowed the shortest region of overlap to approximately 2 Mb. Based on statistical analysis of copy number increase and overexpression, the 9p24 amplicon contains six candidate oncogenes. Among these, four genes (GASC1 UHRF2, KIAA1432 and C9orf123) are overexpressed only in the context of gene amplification while two genes (ERMP1 and IL33) are overexpressed independent of the copy number increase. We then focused our studies on the UHRF2 gene, which has a potential involvement in both DNA methylation and histone modification. Knocking down UHRF2 expression inhibited the growth of breast cancer cells specifically with 9p24 amplification. Conversely, ectopic overexpression of UHRF2 in non-tumorigenic MCF10A cells promoted cell proliferation. Furthermore, we demonstrated that UHRF2 has the ability to suppress the expression of key cell-cycle inhibitors, such as p16(INK4a), p21(Waf1/Cip1) and p27(Kip1). Taken together, our studies support the notion that the 9p24 amplicon contains multiple oncogenes that may integrate genetic and epigenetic codes and have important roles in human tumorigenesis. Oncogene (2012) 31, 333-341; doi:10.1038/onc.2011.227; published online 13 June 2011	[Wu, J.; Liu, G.; Ethier, S. P.; Yang, Z-Q] Wayne State Univ, Breast Canc Program, Detroit, MI 48201 USA; [Liu, S.; Martin-Trevino, R.; Wicha, M. S.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Dombkowski, A.] Wayne State Univ, Dept Pediat, Detroit, MI 48201 USA; [Abrams, J.; Yang, Z-Q] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA	Wayne State University; University of Michigan System; University of Michigan; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Yang, ZQ (corresponding author), Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R St,HWCRC 815, Detroit, MI 48201 USA.	yangz@karmanos.org	Liu, Sheng/K-2815-2013; LIU, GANG/AAR-4584-2021; Liu, Suling/N-2796-2013; Wicha, Max/AAE-7268-2019	LIU, GANG/0000-0001-6620-176X; Liu, Suling/0000-0002-0475-0242; Dombkowski, Alan/0000-0002-0312-8750	Department of Defense [BC086177, BC083945]; National Institutes of Health [RO1 CA100724, P30-CA022453-29]; Taubman Institute; NATIONAL CANCER INSTITUTE [P30CA022453, R01CA100724] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taubman Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from the Department of Defense Breast Cancer Program (BC086177 and BC083945) to Zeng-Quan Yang, a grant from the National Institutes of Health grant RO1 CA100724 to Stephen P. Ethier, and the Taubman Scholar Award from Taubman Institute to Max S. Wicha. The Biostatistics Core of the Karmanos Cancer Institute is supported by the National Institutes of Health Grant P30-CA022453-29. We thank Michele L. Dziubinski for technical assistance on the cell culture. We thank Dr Steve Guest, Dr Aliccia Bollig-Fischer and Kimberly Lyons for discussions and careful reading of a draft manuscript.	Akiyama M, 2005, BIOCHEM BIOPH RES CO, V335, P1264, DOI 10.1016/j.bbrc.2005.08.019; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Chan DW, 2009, PROTEOMICS, V9, P2343, DOI 10.1002/pmic.200800600; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Garcia-Rudaz C, 2007, DEVELOPMENT, V134, P945, DOI 10.1242/dev.02795; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; He XY, 2009, FEBS LETT, V583, P3501, DOI 10.1016/j.febslet.2009.10.007; Hopfner R, 2000, CANCER RES, V60, P121; Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155; Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katoh M, 2004, INT J ONCOL, V24, P1623; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Kurowska-Stolarska M, 2011, J INTERN MED, V269, P29, DOI 10.1111/j.1365-2796.2010.02316.x; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Qian CM, 2008, J BIOL CHEM, V283, P34490, DOI 10.1074/jbc.C800169200; Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Vinatzer U, 2008, CLIN CANCER RES, V14, P6426, DOI 10.1158/1078-0432.CCR-08-0702; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang JL, 2010, BIOL REPROD, V82, P105, DOI 10.1095/biolreprod.109.078055; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Yang ZQ, 2000, CANCER RES, V60, P4735	56	63	65	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					333	341		10.1038/onc.2011.227	http://dx.doi.org/10.1038/onc.2011.227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21666724	Green Accepted			2022-12-28	WOS:000299542100006
J	Camus, S; Quevedo, C; Menendez, S; Paramonov, I; Stouten, PFW; Janssen, RAJ; Rueb, S; He, S; Snaar-Jagalska, BE; Laricchia-Robbio, L; Belmonte, JCI				Camus, S.; Quevedo, C.; Menendez, S.; Paramonov, I.; Stouten, P. F. W.; Janssen, R. A. J.; Rueb, S.; He, S.; Snaar-Jagalska, B. E.; Laricchia-Robbio, L.; Belmonte, J. C. Izpisua			Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish	ONCOGENE			English	Article						phosphorylase kinase; PhK; angiogenesis; zebrafish; cancer	ANTIANGIOGENIC COMPOUNDS; CLINICAL RESISTANCE; GENE AMPLIFICATION; CANCER; GROWTH; METHOTREXATE	Angiogenesis is essential for development and tumor progression. With the aim of identifying new compound inhibitors of the angiogenesis process, we used an established enhanced green fluorescent protein-transgenic zebrafish line to develop an automated assay that enables high-throughput screening of compound libraries in a whole-organism setting. Using this system, we have identified novel kinase inhibitor compounds that show anti-angiogenic properties in both zebrafish in-vivo system and in human endothelial cell in-vitro angiogenesis models. Furthermore, we have determined the kinase target of these compounds and have identified and validated a previously uncharacterized involvement of phosphorylase kinase subunit G1 (PhKG1) in angiogenesis in vivo. In addition, we have found that PhKG1 is upregulated in human tumor samples and that aberrations in gene copy number of PhK subunits are a common feature of human tumors. Our results provide a novel insight into the angiogenesis process, as well as identify new potential targets for anti-angiogenic therapies. Oncogene (2012) 31, 4333-4342; doi:10.1038/onc.2011.594; published online 19 December 2011	[Belmonte, J. C. Izpisua] Salk Inst Biol Studies, La Jolla, CA 92037 USA; [Camus, S.; Menendez, S.; Paramonov, I.; Laricchia-Robbio, L.; Belmonte, J. C. Izpisua] Ctr Regenerat Med Barcelona, Barcelona, Spain; [Quevedo, C.] Biobide SL, San Sebastian, Spain; [Stouten, P. F. W.] Galapagos NV, Mechelen, Belgium; [Janssen, R. A. J.] Galapagos BV, Leiden, Netherlands; [Rueb, S.; He, S.; Snaar-Jagalska, B. E.] Leiden Univ, Inst Biol, Leiden, Netherlands	Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of Barcelona; Galapagos NV; Galapagos NV; Leiden University; Leiden University - Excl LUMC	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu		Stouten, Pieter/0000-0002-5203-2202; Menendez, Sergio/0000-0002-7929-8641	European Community [HEALTH-F2-2008-201439]; MICINN; Fundacion Cellex	European Community(European Commission); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Fundacion Cellex(Foundation CELLEX)	We would like to thank Cornel Catana of Galapagos for molecular modeling efforts and acknowledge the support and intellectual contribution of the Scientific Director of Biobide, Carles Callol. This project was financially supported by the European Community under the FP7 ZF-Cancer project (HEALTH-F2-2008-201439), MICINN and Fundacion Cellex.	Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; CARMAN MD, 1984, J CLIN ONCOL, V2, P16, DOI 10.1200/JCO.1984.2.1.16; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cascante M, 2010, BIOCHEM SOC T, V38, P1302, DOI 10.1042/BST0381302; Edmunds SC, 2002, INVEST OPHTH VIS SCI, V43, P2845; Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; FERGUSON PJ, 1991, J OTOLARYNGOL, V20, P130; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Graves D, 1999, PHARMACOL THERAPEUT, V82, P143, DOI 10.1016/S0163-7258(98)00049-7; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995; Kidd KR, 2003, BRIT J PHARMACOL, V140, P585, DOI 10.1038/sj.bjp.0705496; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Letamendia A, PLOS ONE UNPUB; Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Marshall KE, 2010, DEV DYNAM, V239, P3000, DOI 10.1002/dvdy.22437; Parng C, 2002, ASSAY DRUG DEV TECHN, V1, P41, DOI 10.1089/154065802761001293; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tran TC, 2007, CANCER RES, V67, P11386, DOI 10.1158/0008-5472.CAN-07-3126; Vizan P, 2009, CARCINOGENESIS, V30, P946, DOI 10.1093/carcin/bgp083; Wang CY, 2010, EUR UROL, V58, P418, DOI 10.1016/j.eururo.2010.05.024	29	37	40	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4333	4342		10.1038/onc.2011.594	http://dx.doi.org/10.1038/onc.2011.594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179836				2022-12-28	WOS:000309520200007
J	Hognas, G; Tuomi, S; Veltel, S; Mattila, E; Murumagi, A; Edgren, H; Kallioniemi, O; Ivaska, J				Hognas, G.; Tuomi, S.; Veltel, S.; Mattila, E.; Murumagi, A.; Edgren, H.; Kallioniemi, O.; Ivaska, J.			Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo	ONCOGENE			English	Article						integrin traffic; cytokinesis; aneuploidy; cancer	MAMMALIAN-CELLS; CHROMOSOMAL INSTABILITY; TUMORIGENESIS; MICE; CANCER; P53; ENDOCYTOSIS; PROGRESSION; INVASION; MUTATION	Aneuploidy is frequently detected in solid tumors but the mechanisms regulating the generation of aneuploidy and their relevance in cancer initiation remain under debate and are incompletely characterized. Spatial and temporal regulation of integrin traffic is critical for cell migration and cytokinesis. Impaired integrin endocytosis, because of the loss of Rab21 small GTPase or mutations in the integrin beta-subunit cytoplasmic tail, induces failure of cytokinesis in vitro. Here, we describe that repeatedly failed cytokinesis, because of impaired traffic, is sufficient to trigger the generation of aneuploid cells, which display characteristics of oncogenic transformation in vitro and are tumorigenic in vivo. Furthermore, in an in vivo mouse xenograft model, non-transformed cells with impaired integrin traffic formed tumors with a long latency. More detailed investigation of these tumors revealed that the tumor cells were aneuploid. Therefore, abnormal integrin traffic was linked with generation of aneuploidy and cell transformation also in vivo. In human prostate and ovarian cancer samples, downregulation of Rab21 correlates with increased malignancy. Loss-of-function experiments demonstrate that long-term depletion of Rab21 is sufficient to induce chromosome number aberrations in normal human epithelial cells. These data are the first to demonstrate that impaired integrin traffic is sufficient to induce conversion of non-transformed cells to tumorigenic cells in vitro and in vivo. Oncogene (2012) 31, 3597-3606; doi:10.1038/onc.2011.527; published online 28 November 2011	[Hognas, G.; Tuomi, S.; Veltel, S.; Mattila, E.; Ivaska, J.] Univ Turku, VTT Tech Res Ctr Finland, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Murumagi, A.; Edgren, H.; Kallioniemi, O.] Univ Helsinki, Inst Mol Med, FIMM, Helsinki, Finland; [Ivaska, J.] Univ Turku, Dept Biochem & Food Chem, FIN-20520 Turku, Finland	University of Turku; VTT Technical Research Center Finland; University of Helsinki; University of Turku	Ivaska, J (corresponding author), Univ Turku, VTT Tech Res Ctr Finland, Turku Ctr Biotechnol, FIN-20520 Turku, Finland.	Johanna.ivaska@vtt.fi	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Ivaska, Johanna/0000-0002-6295-6556; Veltel, Stefan/0000-0002-4925-3776	ERC starting grant; Academy of Finland; Finnish Cancer Organizations; Sigrid Juselius Foundation; Turku Graduate School for Biomedical Sciences; VTT Medical Biotechnology; EMBO LTF; Alexander von Humboldt foundation	ERC starting grant(European Research Council (ERC)); Academy of Finland(Academy of Finland); Finnish Cancer Organizations; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Turku Graduate School for Biomedical Sciences; VTT Medical Biotechnology; EMBO LTF(European Molecular Biology Organization (EMBO)); Alexander von Humboldt foundation(Alexander von Humboldt Foundation)	We thank Dr M Karin for DNA constructs; H Marttila, J Siivonen and L Lahtinen for excellent technical assistance. I Ahonen is thanked for help with the statistical analysis. This research has been supported by ERC starting grant, Academy of Finland, Finnish Cancer Organizations and Sigrid Juselius Foundation. GH is supported by Turku Graduate School for Biomedical Sciences, ST by VTT Medical Biotechnology and SV is supported by EMBO LTF and Alexander von Humboldt foundation. The Central Animal Laboratory of the University of Turku is acknowledged for the animal experiments.	Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; BENZEEV A, 1981, CELL, V26, P107, DOI 10.1016/0092-8674(81)90038-6; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Czuchra A, 2006, J CELL BIOL, V174, P889, DOI 10.1083/jcb.200604060; Evans RD, 2003, J CELL BIOL, V160, P589, DOI 10.1083/jcb.200209016; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Ivaska J, 2010, CELL TISSUE RES, V339, P111, DOI 10.1007/s00441-009-0857-z; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Kanada M, 2005, MOL BIOL CELL, V16, P3865, DOI 10.1091/mbc.E05-03-0233; Li RH, 2000, P NATL ACAD SCI USA, V97, P3236, DOI 10.1073/pnas.040529797; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Olaharski AJ, 2006, CARCINOGENESIS, V27, P337, DOI 10.1093/carcin/bgi218; Parsons M, 2002, MOL CELL BIOL, V22, P5897, DOI 10.1128/MCB.22.16.5897-5911.2002; Pellinen T, 2008, DEV CELL, V15, P371, DOI 10.1016/j.devcel.2008.08.001; Reverte CG, 2006, J CELL BIOL, V174, P491, DOI 10.1083/jcb.200603069; Rosario CO, 2010, P NATL ACAD SCI USA, V107, P6888, DOI 10.1073/pnas.0910941107; Scita G, 2010, NATURE, V463, P464, DOI 10.1038/nature08910; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Thullberg M, 2007, P NATL ACAD SCI USA, V104, P20338, DOI 10.1073/pnas.0706609105; Torres EM, 2008, GENETICS, V179, P737, DOI 10.1534/genetics.108.090878; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058	35	38	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3597	3606		10.1038/onc.2011.527	http://dx.doi.org/10.1038/onc.2011.527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120710	Green Published, hybrid			2022-12-28	WOS:000307245600003
J	Slee, RB; Steiner, CM; Herbert, BS; Vance, GH; Hickey, RJ; Schwarz, T; Christan, S; Radovich, M; Schneider, BP; Schindelhauer, D; Grimes, BR				Slee, R. B.; Steiner, C. M.; Herbert, B-S; Vance, G. H.; Hickey, R. J.; Schwarz, T.; Christan, S.; Radovich, M.; Schneider, B. P.; Schindelhauer, D.; Grimes, B. R.			Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability	ONCOGENE			English	Article						pericentromeric heterochromatin; chromosome instability; JMJD2 demethylase	ALPHA-SATELLITE DNA; CENP-B BOX; HISTONE DEMETHYLASES; HUMAN KINETOCHORE; CHROMATIN; CENTROMERE; DISTINCT; OVEREXPRESSION; INACTIVATION; ORGANIZATION	Many tumors exhibit elevated chromosome mis-segregation termed chromosome instability (CIN), which is likely to be a potent driver of tumor progression and drug resistance. Causes of CIN are poorly understood but probably include prior genome tetraploidization, centrosome amplification and mitotic checkpoint defects. This study identifies epigenetic alteration of the centromere as a potential contributor to the CIN phenotype. The centromere controls chromosome segregation and consists of higher-order repeat (HOR) alpha-satellite DNA packaged into two chromatin domains: the kinetochore, harboring the centromere-specific H3 variant centromere protein A (CENP-A), and the pericentromeric heterochromatin, considered important for cohesion. Perturbation of centromeric chromatin in model systems causes CIN. As cancer cells exhibit widespread chromatin changes, we hypothesized that pericentromeric chromatin structure could also be affected, contributing to CIN. Cytological and chromatin immunoprecipitation and PCR (ChIP-PCR)-based analyses of HT1080 cancer cells showed that only one of the two HORs on chromosomes 5 and 7 incorporate CENP-A, an organization conserved in all normal and cancer-derived cells examined. Contrastingly, the heterochromatin marker H3K9me3 (trimethylation of H3 lysine 9) mapped to all four HORs and ChIP-PCR showed an altered pattern of H3K9me3 in cancer cell lines and breast tumors, consistent with a reduction on the kinetochore-forming HORs. The JMJD2B demethylase is overexpressed in breast tumors with a CIN phenotype, and overexpression of exogenous JMJD2B in cultured breast epithelial cells caused loss of centromere-associated H3K9me3 and increased CIN. These findings suggest that impaired maintenance of pericentromeric heterochromatin may contribute to CIN in cancer and be a novel therapeutic target. Oncogene (2012) 31, 3244-3253; doi:10.1038/onc.2011.502; published online 28 November 2011	[Slee, R. B.; Steiner, C. M.; Herbert, B-S; Vance, G. H.; Radovich, M.; Schneider, B. P.; Grimes, B. R.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Slee, R. B.; Herbert, B-S; Vance, G. H.; Hickey, R. J.; Schneider, B. P.; Grimes, B. R.] Indiana Univ Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA; [Hickey, R. J.; Schneider, B. P.] IUSM, Dept Med, Indianapolis, IN 46202 USA; [Schwarz, T.; Christan, S.; Schindelhauer, D.] Univ Munich, Dept Med Genet, Munich, Germany	Indiana University System; Indiana University Bloomington; University of Munich	Grimes, BR (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.	brgrimes@iupui.edu			INGEN (Indiana Genomics Initiative); IUSM Cytogenetics Division; US DOD BCRP [W81XWH-09-1-0424]; American Cancer Society [IRG-84-002-24]; IUSM Biomedical Research Grants; NCI [N01 CN-43300]; Deutsche Forschungsgemeinschaft; Friedrich Baur Institute; Lilly Endowment; NIH [NRSA 1 T32 CA 111198]; NATIONAL CANCER INSTITUTE [T32CA111198] Funding Source: NIH RePORTER	INGEN (Indiana Genomics Initiative); IUSM Cytogenetics Division; US DOD BCRP; American Cancer Society(American Cancer Society); IUSM Biomedical Research Grants; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Friedrich Baur Institute; Lilly Endowment; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Kinya Yoda for advice with ChIP assays; Simone Schuffenhauer and Jan Murken for BF cells; Hunt Willard, Mariano Rocci and Theo Hulsebos for centromere plasmid probes; Tim Yen for CENP-E antibodies; Mervin Yoder for HUVEC samples; Virginia Thurston for advice on the patient BF sample and Andrew Ross, Nikki Collins, Janak Bhavsar, Tony Brown, Waylan Bessler and Laura Mead for technical assistance. This research was supported in part by INGEN (Indiana Genomics Initiative), the IUSM Cytogenetics Division and grants from the US DOD BCRP (W81XWH-09-1-0424) and American Cancer Society (IRG-84-002-24) awarded to BRG, IUSM Biomedical Research Grants awarded to RBS and an NCI grant (N01 CN-43300) to BSH. DS was supported by Deutsche Forschungsgemeinschaft and the Friedrich Baur Institute. INGEN is supported in part by Lilly Endowment. MR was supported by an NIH pre-doctoral fellowship (NRSA 1 T32 CA 111198 Cancer Biology Training Program).	Alonso A, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-6; Amato A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-119; ARCHIDIACONO N, 1995, GENOMICS, V25, P477, DOI 10.1016/0888-7543(95)80048-Q; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bergmann JH, 2011, EMBO J, V30, P328, DOI 10.1038/emboj.2010.329; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Bourgo RJ, 2009, MOL BIOL CELL, V20, P3192, DOI 10.1091/mbc.E08-12-1224; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cardinale S, 2009, MOL BIOL CELL, V20, P4194, DOI 10.1091/mbc.E09-06-0489; David G, 2006, ONCOGENE, V25, P7354, DOI 10.1038/sj.onc.1209734; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Finelli P, 1996, GENOMICS, V38, P325, DOI 10.1006/geno.1996.0635; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; Grimes BR, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-11-r89; Grimes BR, 2009, STEM CELLS DEV, V18, P717, DOI 10.1089/scd.2008.0255; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; HAAF T, 1994, HUM MOL GENET, V3, P697, DOI 10.1093/hmg/3.5.697; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Hochreiter AE, 2006, CLIN CANCER RES, V12, P3184, DOI 10.1158/1078-0432.CCR-05-2760; HULSEBOS T, 1988, CYTOGENET CELL GENET, V47, P144, DOI 10.1159/000132533; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Lohse B, 2011, BIOORGAN MED CHEM, V19, P3625, DOI 10.1016/j.bmc.2011.01.046; Malorni L, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.10621; Mitelman F., 1994, CATALOG CHROMOSOME A; Mravinac B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006602; Nakano M, 2008, DEV CELL, V14, P507, DOI 10.1016/j.devcel.2008.02.001; Ohzeki J, 2002, J CELL BIOL, V159, P765, DOI 10.1083/jcb.200207112; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Radovich M, TRANSCRIPTIONA UNPUB; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Rosandic M, 2006, CHROMOSOME RES, V14, P735, DOI 10.1007/s10577-006-1078-x; Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b; SCHINDELHAUER D, 1995, GENOMICS, V28, P605, DOI 10.1006/geno.1995.1202; Schuffenhauer S, 1996, AM J MED GENET, V65, P56, DOI 10.1002/(SICI)1096-8628(19961002)65:1<56::AID-AJMG9>3.3.CO;2-X; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; SULLIVAN BA, 1999, PRACT APPROACH SER, V200, P81; Sullivan LL, 2011, CHROMOSOME RES, V19, P457, DOI 10.1007/s10577-011-9208-5; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801; Tomonaga T, 2003, CANCER RES, V63, P3511; Vafa O, 1997, CURR BIOL, V7, P897, DOI 10.1016/S0960-9822(06)00381-2; Verdaasdonk JS, 2011, NAT REV MOL CELL BIO, V12, P320, DOI 10.1038/nrm3107; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Warburton PE, 1996, HUMAN GENOME EVOLUTI, P121; WAYE JS, 1987, MOL CELL BIOL, V7, P349, DOI 10.1128/MCB.7.1.349; WEVRICK R, 1991, NUCLEIC ACIDS RES, V19, P2295, DOI 10.1093/nar/19.9.2295; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wong LH, 2007, GENOME RES, V17, P1146, DOI 10.1101/gr.6022807; Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413; Yoda K, 2004, METHOD ENZYMOL, V375, P253	61	72	72	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3244	3253		10.1038/onc.2011.502	http://dx.doi.org/10.1038/onc.2011.502			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22081068				2022-12-28	WOS:000306113400004
J	Ahn, SM; Cha, JY; Kim, J; Kim, D; Trang, HTH; Kim, YM; Cho, YH; Park, D; Hong, S				Ahn, S-M; Cha, J-Y; Kim, J.; Kim, D.; Trang, H. T. H.; Kim, Y-M; Cho, Y-H; Park, D.; Hong, S.			Smad3 regulates E-cadherin via miRNA-200 pathway	ONCOGENE			English	Article						Smad3; miRNA-200; E-cadherin; ZEB1/2; gastric cancer	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN GASTRIC-CANCER; II RECEPTOR GENE; TGF-BETA; MIR-200 FAMILY; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; REPRESSORS ZEB1; TUMOR INVASION	To identify potential microRNA (miRNA) links between Smad3, a mediator of TGF-beta (transforming growth factor-beta) signaling, and E-cadherin, we characterized the miRNA profiles of two gastric cancer cell lines: SNU484-LPCX, which does not express Smad3, and SNU484-Smad3, in which Smad3 is overexpressed. We found that among differentially expressed miRNAs, miR-200 family members are overexpressed in SNU484-Smad3 cells. Subsequent studies, including analysis of the effects of silencing Smad3 in SNU484-Smad3 cells and a luciferase reporter assay, revealed that Smad3 directly binds to a Smad-binding element located in the promoter region of miR-200b/a, where it functions as a transcriptional activator. TGF-beta did not affect the regulatory role of Smad3 in transcription of miR-200 and expression of epithelial-mesenchymal transition markers. We conclude that Smad3 regulates, at the transcriptional level, miR-200 family members, which themselves regulate ZEB1 and ZEB2, known transcriptional repressors of E-cadherin, at the posttranscriptional level in a TGF-beta-independent manner. This represents a novel link between Smad3 and posttranscriptional regulation by miRNAs in epithelial-mesenchymal transition in gastric cancer cells. Oncogene (2012) 31, 3051-3059; doi: 10.1038/onc.2011.484; published online 24 October 2011	[Park, D.] Gachon Univ Gil Hosp, Dept Gastroenterol, Inchon, South Korea; [Ahn, S-M; Cha, J-Y; Kim, J.; Kim, D.; Trang, H. T. H.; Kim, Y-M; Cho, Y-H; Hong, S.] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Canc Cell Biol Lab, Dept Mol Med, Yeonsu 406840, Incheon, South Korea; [Ahn, S-M] Gachon Univ Gil Hosp, Dept Translat Med, Inchon, South Korea	Gachon University; Gachon University; Gachon University	Park, D (corresponding author), Gachon Univ Gil Hosp, Dept Gastroenterol, Inchon, South Korea.	pdk66@gilhospital.com; sthong@gachon.ac.kr		Ahn, Sung-Min/0000-0002-5031-1929; Cha, JI-Young/0000-0002-8557-6214	National Research Foundation; Korea government (MEST) [KRF-2008-313-C00676, 2009-0081756, 2009-0081789]; department of gastroenterology, Gachon University Gil Hospital	National Research Foundation; Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); department of gastroenterology, Gachon University Gil Hospital	We thank Dr GJ Goodall for kindly providing the DNA constructs. This work was supported by the National Research Foundation grant funded by the Korea government (MEST) to S Hong (KRF-2008-313-C00676 and no. 2009-0081756), JY Cha and SM Ahn (no. 2009-0081789) and by the generous funding from the department of gastroenterology, Gachon University Gil Hospital to D Park.	Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chung ACK, 2010, J AM SOC NEPHROL, V21, P249, DOI 10.1681/ASN.2009010018; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Fink SP, 2001, CANCER RES, V61, P256; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Humar B, 2009, CANCER RES, V69, P2050, DOI 10.1158/0008-5472.CAN-08-2457; Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, GENE DEV, V14, P627; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; PARSONS R, 1995, CANCER RES, V55, P5548; Pohl M, 2010, ANTICANCER RES, V30, P2603; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Saika S, 2004, AM J PATHOL, V164, P651, DOI 10.1016/S0002-9440(10)63153-7; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang FY, 2009, HYPERTENSION, V54, P877, DOI 10.1161/HYPERTENSIONAHA.109.136531; Zhu EL, 2010, NUCLEIC ACIDS RES, V38, pW392, DOI 10.1093/nar/gkq393	46	81	83	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3051	3059		10.1038/onc.2011.484	http://dx.doi.org/10.1038/onc.2011.484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020340				2022-12-28	WOS:000305705900004
J	Whipple, CA; Young, AL; Korc, M				Whipple, C. A.; Young, A. L.; Korc, M.			A Kras(G12D)-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis	ONCOGENE			English	Article						pancreatic cancer; glypican-1; proliferation; angiogenesis; tumor microenvironment	FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE; CARCINOMA CELLS; K-RAS; EXPRESSION; PROGRESSION; ADENOCARCINOMA; PROTEOGLYCAN; CHEMOTHERAPY; METASTASIS	Pancreatic ductal adenocarcinomas (PDACs) exhibit multiple molecular alterations and overexpress heparin-binding growth factors (HBGFs) and glypican-1 (GPC1), a heparan sulfate proteoglycan that promotes efficient signaling by HBGFs. It is not known, however, whether GPC1 has a role in genetic mouse models of PDAC. Therefore, we generated a GPC1 null mouse that combines pancreas-specific Cre-mediated activation of oncogenic Kras (Kras(G12D)) with deletion of a conditional INK4A/Arf allele (Pdx1-Cre; LSL-Kras(G12D); INK4A/Arf(lox/lox); GPC1(-/-) mice). By comparison with Pdx1-Cre; LSL-Kras(G12D); INK4A/Arf(lox/lox) mice that were wild type for GPC1, the Pdx1-Cre; LSL-Kras(G12D); INK4A/Arf(lox/lox); GPC1(-/-) mice exhibited attenuated pancreatic tumor growth and invasiveness, decreased cancer cell proliferation and mitogen-activated protein kinase activation. These mice also exhibited suppressed angiogenesis in conjunction with decreased expression of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular endothelial growth factor-A (VEGF-A), SRY-box containing gene (SOX17), chemokine C-X3-C motif ligand 1 (CX3CL1) and integrin beta 3 (ITGB3). Moreover, pancreatic cancer cells isolated from the tumors of GPC1(-/-) mice were not as invasive in response to fibroblast growth factor-2 (FGF-2) as cancer cells isolated from wild-type mice, and formed smaller tumors that exhibited an attenuated metastatic potential. Similarly, VEGF-A and FGF-2 did not enhance the migration of hepatic endothelial cells and immortalized murine embryonic fibroblasts isolated from GPC1 null mice. These data demonstrate in an oncogenic Kras-driven genetic mouse model of PDAC that tumor growth, angiogenesis and invasion are enhanced by GPC1, and suggest that suppression of GPC1 may be an important component of therapeutic strategies in PDAC. Oncogene (2012) 31, 2535-2544; doi:10.1038/onc.2011.430; published online 26 September 2011	[Korc, M.] Dartmouth Hitchcock Med Ctr, Dept Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; [Whipple, C. A.; Young, A. L.; Korc, M.] Dartmouth Med Sch, Dept Med, Hanover, NH USA; [Whipple, C. A.; Young, A. L.; Korc, M.] Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Korc, M (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, Norris Cotton Canc Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	murray.korc@dartmouth.edu			US Public Health Service [CA-R37-075059]; National Cancer Institute [F32 CA-144579]; NATIONAL CANCER INSTITUTE [R01CA075059, F32CA144579, R37CA075059] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Daniel Longnecker (Dartmouth Medical School) for his expert assistance in the evaluation of pancreatic tumor pathology. This work was supported by two US Public Health Service Grant (CA-R37-075059) awarded to MK. CAW was supported by a Ruth L Kirschstein National Research Service Award, F32 CA-144579 from the National Cancer Institute.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Arnold NB, 2004, CANCER RES, V64, P3599, DOI 10.1158/0008-5472.CAN-03-2999; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; Cepko CP, 1996, RETROVIRUS INFECT CE, P91411; CHANG SC, 1990, J NUTR, V120, P1228, DOI 10.1093/jn/120.10.1228; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cheng N, 2002, MOL CANCER RES, V1, P2; Ding K, 2005, J CELL BIOL, V171, P729, DOI 10.1083/jcb.200508010; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gu GQ, 2003, MECH DEVELOP, V120, P35, DOI 10.1016/S0925-4773(02)00330-1; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jen YHLD, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-33; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kim I, 2007, CELL, V130, P470, DOI 10.1016/j.cell.2007.06.011; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kleeff J, 1999, PANCREAS, V19, P281, DOI 10.1097/00006676-199910000-00009; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Korc M, 2003, Mol Cancer, V2, P8, DOI 10.1186/1476-4598-2-8; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Lander AD, 2002, DEV CELL, V2, P785, DOI 10.1016/S1534-5807(02)00179-X; Le Mercier M, 2009, NEOPLASIA, V11, P485, DOI 10.1593/neo.81526; Li AH, 2011, TRANSL ONCOL, V4, P20, DOI 10.1593/tlo.10184; Matsuda K, 2001, CANCER RES, V61, P5562; Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Preis M, 2010, CANCER BIOL THER, V9, P754, DOI 10.4161/cbt.9.10.11534; Rowland-Goldsmith MA, 2002, MOL CANCER THER, V1, P161; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Schneider Gunter, 2003, Mol Cancer, V2, P15, DOI 10.1186/1476-4598-2-15; Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Suyama E, 2003, P NATL ACAD SCI USA, V100, P5616, DOI 10.1073/pnas.1035850100; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; Vilar E, 2007, ENDOCR-RELAT CANCER, V14, P221, DOI 10.1677/ERC-06-0074; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; Vonlaufen A, 2008, CANCER RES, V68, P7707, DOI 10.1158/0008-5472.CAN-08-1132; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811	46	57	63	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	20					2535	2544		10.1038/onc.2011.430	http://dx.doi.org/10.1038/onc.2011.430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996748	Green Accepted			2022-12-28	WOS:000304191800004
J	Grepin, R; Guyot, M; Jacquin, M; Durivault, J; Chamorey, E; Sudaka, A; Serdjebi, C; Lacarelle, B; Scoazec, JY; Negrier, S; Simonnet, H; Pages, G				Grepin, R.; Guyot, M.; Jacquin, M.; Durivault, J.; Chamorey, E.; Sudaka, A.; Serdjebi, C.; Lacarelle, B.; Scoazec, J-Y; Negrier, S.; Simonnet, H.; Pages, G.			Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines	ONCOGENE			English	Article						angiogenesis; bevacizumab; CXCL cytokines; VEGF	PHASE-II TRIAL; TUMOR-GROWTH; IN-VITRO; CANCER; INTERLEUKIN-8; CHEMOKINES; RECEPTORS; ERLOTINIB; ANGIOGENESIS; COMBINATION	The anti-VEGF targeted antibody bevacizumab (BVZ) has been approved for treating renal cell carcinomas (RCCs). Although BVZ increases the progression-free survival of patients with metastatic RCC, the effect on overall survival is poor. To gain insight into the limited efficacy of BVZ on overall survival, we analyzed patient samples of RCC for angiogenic factors that may participate in escape from anti-VEGF therapy. Our study shows that the level of vascular endothelial growth factor (VEGF) in tumors was increased compared with normal tissue. The level of interleukin-8/CXCL8, a pro-angiogenic member of the CXCL family of cytokines, was also increased in tumors. These observations gave us a good reason to analyze the combined effects of BVZ and anti-CXCL8 antibodies on tumor growth. Surprisingly, we report that BVZ accelerates the growth of RCC in nude mice with in vivo selection of tumor cells with an increased growth capacity. Downregulation of receptor tyrosine phosphatase-kappa, a phosphatase implicated in EGF receptor regulation, may partly explain this phenomenon. Modification of the vascular network and development of lymphatic vessels through VEGF-C production and compensatory production of pro-angiogenic CXCL cytokines were also observed. The apparent normalization of the vascular network prompted us to associate BVZ with the chemotherapeutic agent paclitaxel. While efficient in vitro, paclitaxel did not reverse the anti-VEGF effects in vivo. Anti-CXCL8-targeting antibodies were promising as they decreased intra-tumor VEGF production; decreased the pro-angiogenic CXCL/anti-angiogenic CXCL ratio and did not induce lymphangiogenesis. These observations hold clinical implication as they highlight putative markers implicated in escape from BVZ treatment. They also recommend proceeding with caution in the use of anti-VEGF therapy alone for treatment of RCC. Oncogene (2012) 31, 1683-1694; doi:10.1038/onc.2011.360; published online 12 September 2011	[Pages, G.] Univ Nice Sophia Antipolis, CNRS, UMR 6543, IBDC,Ctr Antoine Lacassagne, F-06189 Nice, France; [Chamorey, E.; Sudaka, A.] Ctr Antoine Lacassagne, Dept Stat EC, F-06054 Nice, France; [Chamorey, E.; Sudaka, A.] Ctr Antoine Lacassagne, Dept Anatomopathol AS, F-06054 Nice, France; [Serdjebi, C.; Lacarelle, B.] Univ Marseille, UFR Pharm, Lab Pharmacocinet, Marseille, France; [Scoazec, J-Y] Fac Laennec, IFR62, INSERM, UMR S865, Lyon, France; [Negrier, S.] Ctr Leon Berard, F-69373 Lyon, France; [Simonnet, H.] Fac Med Grange Blanche, UMR 5201, Lille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; UNICANCER; Centre Antoine Lacassagne; UNICANCER; Centre Antoine Lacassagne; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Pages, G (corresponding author), Univ Nice Sophia Antipolis, CNRS, UMR 6543, IBDC,Ctr Antoine Lacassagne, 33 Ave Valombrose, F-06189 Nice, France.	gpages@unice.fr	Pages, Gilles/N-7135-2017; lacarelle, bruno/C-5585-2015; Chamorey, Emmanuel/AGO-9982-2022	lacarelle, bruno/0000-0002-7122-5851; Durivault, Jerome/0000-0002-8228-2915	National Institute of Cancer (INCA); French Association for Cancer Research (ARC) [4932]; Roche France	National Institute of Cancer (INCA)(Institut National du Cancer (INCA) France); French Association for Cancer Research (ARC); Roche France(Roche Holding)	We thank Dr Marc Colombel (patients' informed consent), Dr Jean Claude Chambard (lentivirus expressing the luciferase gene), Dr Elodie Delaplanche (biopsy management), Dr Florence Mege-Lechevallier (anatomo-pathology determination), Ms Cendrine Dubaud (animal studies) and Dr M Christiane Brahimi-Horn (careful reading of the manuscript). Financial support: Contract VEGFIL from the National Institute of Cancer (INCA), the French Association for Cancer Research (ARC, contract no. 4932) and Roche France.	Bertini R, 2004, P NATL ACAD SCI USA, V101, P11791, DOI 10.1073/pnas.0402090101; Bieche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Cascone T, 2011, J CLIN INVEST, V121, P1313, DOI 10.1172/JCI42405; Cervi D, 2008, BLOOD, V111, P1201, DOI 10.1182/blood-2007-04-084798; Cohen EEW, 2009, LANCET ONCOL, V10, P247, DOI 10.1016/S1470-2045(09)70002-6; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hainsworth JD, 2007, CLIN GENITOURIN CANC, V5, P427, DOI 10.3816/CGC.2007.n.030; Hainsworth JD, 2007, J CLIN ONCOL, V25, P1747, DOI 10.1200/JCO.2006.09.3047; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kim JY, 2008, MOL CELL PROTEOMICS, V7, P431, DOI 10.1074/mcp.M700194-MCP200; Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Levashova ZB, 2007, J AM SOC NEPHROL, V18, P2359, DOI 10.1681/ASN.2006040380; Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075; Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024; Mestas J, 2005, J IMMUNOL, V175, P5351, DOI 10.4049/jimmunol.175.8.5351; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Oliver G, 2010, DEVELOPMENT, V137, P363, DOI 10.1242/dev.035360; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pillai MM, 2006, BLOOD, V107, P3520, DOI 10.1182/blood-2005-10-4285; Quatrale AE, 2011, FRONT BIOSCI-LANDMRK, V16, P1962, DOI 10.2741/3833; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	37	40	46	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1683	1694		10.1038/onc.2011.360	http://dx.doi.org/10.1038/onc.2011.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21909141				2022-12-28	WOS:000302231400007
J	Lopez-Serra, P; Esteller, M				Lopez-Serra, P.; Esteller, M.			DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer	ONCOGENE			English	Review						DNA methylation; microRNAs; tumor-suppressor genes	EPITHELIAL OVARIAN-CANCER; DOWN-REGULATION; MESSENGER-RNAS; LET-7 MICRORNA; EPIGENETIC INACTIVATION; CIRCULATING MICRORNAS; DICER1 MUTATIONS; LUNG-CANCER; EXPRESSION; GENE	MicroRNAs (miRNAs) are recognized as being central players in many biological processes and cellular pathways. Their roles in disease have been highlighted first by observation of their aberrant expression profiles in human tumors, and then by in vitro and in vivo functional studies in transformed cells and model organisms. One of the most commonly observed features of miRNAs in malignancies is a defect in their production. Although several causes may be associated with this phenomenon, such as upstream oncogenic/tumor-suppressor defects and alterations in the miRNA-processing machinery, epigenetic inactivation is the prime suspect. The number of miRNAs with putative growth-inhibitory functions undergoing promoter CpG island hypermethylation in human cancer is growing fast and more detailed biological studies are necessary. The recognition of miR-124a and miR-34b/c as bona fide tumor-suppressor miRNAs undergoing DNA methylation-associated silencing in a wide spectrum of human neoplasms is a good starting point to be followed by other candidate miRNAs. Most importantly, even at this early stage, the transcriptional repression of miRNAs by hypermethylation of their corresponding promoter loci seems to be a common feature of all human tumors. This will have translational consequences for the management of the disease. Oncogene (2012) 31, 1609-1622; doi:10.1038/onc.2011.354; published online 22 August 2011	[Lopez-Serra, P.; Esteller, M.] Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Barcelona 08908, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran i Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, 3rd Floor,Avda Gran Via S-N, Barcelona 08908, Spain.	mesteller@idibell.cat	Lopez-Serra, Paula/M-6835-2015; Esteller, Manel/L-5956-2014	Lopez-Serra, Paula/0000-0001-7231-3426; Esteller, Manel/0000-0003-4490-6093	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; European Research Council;  [SAF2007-00027-65134];  [Consolider CSD2006-49]; ICREA Funding Source: Custom	Lilly Foundation; Dr Josef Steiner Cancer Research Foundation; European Research Council(European Research Council (ERC)European Commission); ; ; ICREA(ICREA)	This work was supported by grants SAF2007-00027-65134, Consolider CSD2006-49, the Lilly Foundation, the Dr Josef Steiner Cancer Research Foundation and the European Research Council Advanced Grant EPINORC.	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; Bahubeshi A, 2010, J MED GENET, V47, P863, DOI 10.1136/jmg.2010.081216; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167; Borchert GM, 2009, HUM MOL GENET, V18, P4801, DOI 10.1093/hmg/ddp443; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Cheung HH, 2011, ONCOGENE, V30, P3404, DOI 10.1038/onc.2011.60; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Dangi-Garimella S, 2011, ONCOGENE, V30, P1002, DOI 10.1038/onc.2010.485; Das H, 2000, BRIT J CANCER, V82, P1682; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Frio TR, 2011, JAMA-J AM MED ASSOC, V305, P68, DOI 10.1001/jama.2010.1910; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Gao XN, 2011, ONCOGENE, V30, P3416, DOI 10.1038/onc.2011.62; Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013; Heinzelmann J, 2011, WORLD J UROL, V29, P367, DOI 10.1007/s00345-010-0633-4; Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Hu ZB, 2008, J CLIN INVEST, V118, P2600, DOI 10.1172/JCI34934; Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Hurteau GJ, 2006, CELL CYCLE, V5, P1951, DOI 10.4161/cc.5.17.3133; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Iizasa H, 2010, J BIOL CHEM, V285, P33358, DOI 10.1074/jbc.M110.138362; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kalimutho M, 2011, BRIT J CANCER, V104, P1770, DOI 10.1038/bjc.2011.82; Kamimae S, 2011, CANCER PREV RES, V4, P674, DOI 10.1158/1940-6207.CAPR-10-0214; Kindler T, 2004, BLOOD, V103, P3644, DOI 10.1182/blood-2003-06-2071; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krueger A, 2003, IMMUNOL REV, V193, P58, DOI 10.1034/j.1600-065X.2003.00047.x; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Langevin SM, 2010, CARCINOGENESIS, V31, P864, DOI 10.1093/carcin/bgq051; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim PK, 2011, CANCER RES, V71, P1550, DOI 10.1158/0008-5472.CAN-10-2372; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mears R, 2004, PROTEOMICS, V4, P4019, DOI 10.1002/pmic.200400876; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Melo S, 2011, P NATL ACAD SCI USA, V108, P4394, DOI 10.1073/pnas.1014720108; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Ottaviano AJ, 2006, CANCER RES, V66, P7032, DOI 10.1158/0008-5472.CAN-05-4421; Pagano JS, 2002, NEW ENGL J MED, V347, P78, DOI 10.1056/NEJMp020056; Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paroo Z, 2009, CELL, V139, P112, DOI 10.1016/j.cell.2009.06.044; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441; Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tan HX, 2010, MED ONCOL, V27, P654, DOI 10.1007/s12032-009-9264-2; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Tsai KW, 2011, INT J CANC IN PRESS; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Urdinguio RG, 2010, EPIGENETICS-US, V5, P656, DOI 10.4161/epi.5.7.13055; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vazquez I, 2010, P NATL ACAD SCI USA, V107, pE167, DOI 10.1073/pnas.1011540107; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wang S, 2011, GENES IMMUN, V12, P149, DOI 10.1038/gene.2010.53; Wendler A, 2011, ONCOL REP, V25, P273, DOI 10.3892/or_00001071; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Willis L, 2010, CANCER RES, V70, P4310, DOI 10.1158/0008-5472.CAN-09-3144; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Xu N, 2007, NAT GENET, V39, P1390, DOI 10.1038/ng.2007.5; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Yin G, 2010, ONCOGENE, V29, P3545, DOI 10.1038/onc.2010.111; Yu CC, 2011, ORAL ONCOL, V47, P202, DOI 10.1016/j.oraloncology.2010.12.001; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	151	263	274	0	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1609	1622		10.1038/onc.2011.354	http://dx.doi.org/10.1038/onc.2011.354			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860412	Green Published, hybrid			2022-12-28	WOS:000302231400001
J	Mackintosh, C; Ordonez, JL; Garcia-Dominguez, DJ; Sevillano, V; Llombart-Bosch, A; Szuhai, K; Scotlandi, K; Alberghini, M; Sciot, R; Sinnaeve, F; Hogendoorn, PCW; Picci, P; Knuutila, S; Dirksen, U; Debiec-Rychter, M; Schaefer, KL; de Alava, E				Mackintosh, C.; Ordonez, J. L.; Garcia-Dominguez, D. J.; Sevillano, V.; Llombart-Bosch, A.; Szuhai, K.; Scotlandi, K.; Alberghini, M.; Sciot, R.; Sinnaeve, F.; Hogendoorn, P. C. W.; Picci, P.; Knuutila, S.; Dirksen, U.; Debiec-Rychter, M.; Schaefer, K-L; de Alava, E.			1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; 1q Gain; CDT2; clinical outcome; microarrays	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOME-TRANSLOCATION; GENETIC CHANGES; DNA-DAMAGE; CELL-LINES; ARRAY CGH; S-PHASE; TUMORS; DEGRADATION; ABERRATIONS	Despite extensive characterization of the role of the EWS-ETS fusions, little is known about secondary genetic alterations and their clinical contribution to Ewing sarcoma (ES). It has been demonstrated that the molecular structure of EWS-ETS lacks prognostic value. Moreover, CDKN2A deletion and TP53 mutation, despite carrying a poor prognosis, are infrequent. In this scenario identifying secondary genetic alterations with a significant prevalence could contribute to understand the molecular mechanisms underlying the most aggressive forms of ES. We screened a 67 ES tumor set for copy number alterations by array comparative genomic hybridization. 1q gain (1qG), detected in 31% of tumor samples, was found markedly associated with relapse and poor overall and disease-free survival and demonstrated a prognostic value independent of classical clinical parameters. Reanalysis of an expression dataset belonging to an independent tumor set (n = 37) not only validated this finding but also led us to identify a transcriptomic profile of severe cell cycle deregulation in 1qG ES tumors. Consistently, a higher proliferation rate was detected in this tumor subset by Ki-67 immunohistochemistry. CDT2, a 1q-located candidate gene encoding a protein involved in ubiquitin ligase activity and significantly overexpressed in 1qG ES tumors, was validated in vitro and in vivo proving its major contribution to this molecular and clinical phenotype. This integrative genomic study of 105 ES tumors in overall renders the potential value of 1qG and CDT2 overexpression as prognostic biomarkers and also affords a rationale for the application of already available new therapeutic compounds selectively targeting the protein-ubiquitin machinery. Oncogene (2012) 31, 1287-1298; doi: 10.1038/onc.2011.317; published online 8 August 2011	[Mackintosh, C.; Ordonez, J. L.; Garcia-Dominguez, D. J.; Sevillano, V.; de Alava, E.] Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Salamanca 37007, Spain; [Llombart-Bosch, A.] Univ Valencia, Dept Pathol, Valencia, Spain; [Szuhai, K.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands; [Scotlandi, K.; Picci, P.] Ist Ortoped Rizzoli, Lab Oncol Res, Bologna, Italy; [Alberghini, M.] Ist Ortoped Rizzoli, Dept Pathol, Bologna, Italy; [Sciot, R.] Catholic Univ Louvain, Dept Pathol, B-3000 Louvain, Belgium; [Sinnaeve, F.] Catholic Univ Louvain, Dept Orthoped Surg, B-3000 Louvain, Belgium; [Hogendoorn, P. C. W.] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands; [Knuutila, S.] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Knuutila, S.] Helsinki Univ Cent Hosp, Helsinki, Finland; [Dirksen, U.] Univ Childrens Hosp Muenster, Dept Pediat Hematol & Oncol, Munster, Germany; [Debiec-Rychter, M.] Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; [Schaefer, K-L] Univ Dusseldorf, Inst Pathol, Dusseldorf, Germany; [de Alava, E.] Univ Hosp Salamanca, Dept Pathol, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Valencia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; Universite Catholique Louvain; Universite Catholique Louvain; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Munster; Universite Catholique Louvain; Heinrich Heine University Dusseldorf; University of Salamanca	Mackintosh, C (corresponding author), Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Campus Miguel de Unamuno S-N, Salamanca 37007, Spain.	cmackintosh@usal.es; edealava@usal.es	IBIS, SARCOMAS/O-1893-2015; Hogendoorn, Pancras/O-6494-2019; Dirksen, Uta/AGX-8472-2022; Scotlandi, Katia/J-9009-2016; Garcia, Daniel Jose/B-5366-2016; Ordóñez, José Luis/B-6069-2017; Garcia, Daniel Jose/X-6857-2019; Hogendoorn, Pancras C.W./H-5859-2015; de Alava, Enrique/GOH-0368-2022; Szuhai, Karoly/A-1100-2008; Picci, Piero/J-5979-2016	Hogendoorn, Pancras/0000-0002-1513-8104; Scotlandi, Katia/0000-0001-6114-9499; Garcia, Daniel Jose/0000-0001-8150-2747; Ordóñez, José Luis/0000-0002-3791-4215; Hogendoorn, Pancras C.W./0000-0002-1513-8104; de Alava, Enrique/0000-0001-8400-046X; Szuhai, Karoly/0000-0002-1228-4245; Picci, Piero/0000-0002-8519-4101; sciot, raf/0000-0003-2244-5839; Sinnaeve, Friedl/0000-0003-4321-7771; Mackintosh, Carlos/0000-0002-6786-9558	European Commission; Maria Garcia-Estrada Foundation; Ministry of Science and Innovation of Spain [PI081828, RD06/0020/0059]; Deutsche Krebshilfe [50-2551 Ju3, 50-2551-Ju4]; Federal Ministry of Education and Research Germany, BMBF (TranSaRNet) [01GM0869]; Deutsches Zentrum fur Luft- und Raumfahrt e.V.	European Commission(European CommissionEuropean Commission Joint Research Centre); Maria Garcia-Estrada Foundation; Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Deutsche Krebshilfe(Deutsche Krebshilfe); Federal Ministry of Education and Research Germany, BMBF (TranSaRNet)(Federal Ministry of Education & Research (BMBF)); Deutsches Zentrum fur Luft- und Raumfahrt e.V.(Helmholtz AssociationGerman Aerospace Centre (DLR))	Centro de Investigacion del Cancer-IBMCC, Heinrich-Heine-University Duesseldorf, Catholic University of Leuven, University of Valencia, Istituti Ortopedici Rizzoli, University of Helsinki, Leiden University Medical Center and University Children's Hospital Muenster are partners of the EuroBoNeT consortium, a network of excellence granted by the European Commission for studying the pathology and genetics of bone tumors. Daniel J Garcia-Dominguez is supported by a grant from the Maria Garcia-Estrada Foundation. Research in Enrique de Alava's lab is also supported by the Ministry of Science and Innovation of Spain-FEDER (PI081828, RD06/0020/0059). Trial center Muenster is supported by grants from Deutsche Krebshilfe, 50-2551 Ju3 und 50-2551-Ju4 and Federal Ministry of Education and Research Germany, BMBF (TranSaRNet) 01GM0869, Deutsches Zentrum fur Luft- und Raumfahrt e.V. We thank Dr Hung-Wei Pan and Dr Hey-Chi Hsu (Department of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan) for the anti-CDT2 antibody and pBABE-CDT2 construction. Thanks are due to Cristina Teodosio and Martin Perez de Andres for their kind help with the flow cytometer, to Andreas Ranft for helping with the clinical data, to Agustin Mayo Iscar for his help with statistics, and to Antonella Chiechi, Alicia Ginel and Alberto de Luis for their advice.	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; Balcarkova J, 2009, CANCER GENET CYTOGEN, V192, P68, DOI 10.1016/j.cancergencyto.2009.02.020; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Brisset S, 2001, CANCER GENET CYTOGEN, V130, P57, DOI 10.1016/S0165-4608(01)00454-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ferreira BI, 2008, ONCOGENE, V27, P2084, DOI 10.1038/sj.onc.1210845; Friedrichs N, 2006, DIAGN MOL PATHOL, V15, P83, DOI 10.1097/00019606-200606000-00004; HAAS AL, 1982, J BIOL CHEM, V257, P329; Haeusler J, 2010, CANCER-AM CANCER SOC, V116, P443, DOI 10.1002/cncr.24740; Hattinger CM, 1996, GENE CHROMOSOME CANC, V17, P141, DOI 10.1002/(SICI)1098-2264(199611)17:3<141::AID-GCC1>3.0.CO;2-4; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Kjellman P, 2001, GENE CHROMOSOME CANC, V32, P43, DOI 10.1002/gcc.1165; Knuutila S, 1998, CANCER GENET CYTOGEN, V100, P25, DOI 10.1016/S0165-4608(97)00001-0; Kullendorff CM, 1999, MED PEDIATR ONCOL, V32, P79, DOI 10.1002/(SICI)1096-911X(199902)32:2<79::AID-MPO1>3.0.CO;2-R; Le Deley MC, 2010, J CLIN ONCOL, V28, P1982, DOI 10.1200/JCO.2009.23.3585; Liu CL, 2007, J BIOL CHEM, V282, P1109, DOI 10.1074/jbc.M606535200; Lo KC, 2007, CLIN CANCER RES, V13, P7022, DOI 10.1158/1078-0432.CCR-07-1420; Ordonez JL, 2009, CANCER RES, V69, P7140, DOI 10.1158/0008-5472.CAN-08-4041; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Pezzolo A, 2009, NEURO-ONCOLOGY, V11, P192, DOI 10.1215/15228517-2008-086; Ralph E, 2006, EMBO REP, V7, P1134, DOI 10.1038/sj.embor.7400827; Roberts P, 2008, GENE CHROMOSOME CANC, V47, P207, DOI 10.1002/gcc.20523; Sansam CL, 2006, GENE DEV, V20, P3117, DOI 10.1101/gad.1482106; Savola S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-17; Scotlandi K, 2009, J CLIN ONCOL, V27, P2209, DOI 10.1200/JCO.2008.19.2542; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tarkkanen M, 1999, CANCER GENET CYTOGEN, V114, P35, DOI 10.1016/S0165-4608(99)00031-X; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; van de Wiel MA, 2005, BIOINFORMATICS, V21, P3193, DOI 10.1093/bioinformatics/bti489; van de Wiel MA, 2007, CANCER INFORM, V3, P55; van de Wiel MA, 2007, BIOINFORMATICS, V23, P892, DOI 10.1093/bioinformatics/btm030; van Doorninck JA, 2010, J CLIN ONCOL, V28, P1989, DOI 10.1200/JCO.2009.24.5845; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907	45	65	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1287	1298		10.1038/onc.2011.317	http://dx.doi.org/10.1038/onc.2011.317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21822310	Green Published			2022-12-28	WOS:000301344600008
J	Arzumanyan, A; Friedman, T; Kotei, E; Ng, IOL; Lian, Z; Feitelson, MA				Arzumanyan, A.; Friedman, T.; Kotei, E.; Ng, I. O. L.; Lian, Z.; Feitelson, M. A.			Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer	ONCOGENE			English	Article						hepatocellular carcinoma; mSin3A; Snail-1; HDAC; miR-373	NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CARRIER PATIENTS; GENE-EXPRESSION; DOWN-REGULATION; UP-REGULATION; IN-VIVO; PROTEIN; CELLS; SNAIL	Loss of E-cadherin is associated with acquisition of metastatic capacity. Numerous studies suggest that histone deacetylation and/or hypermethylation of CpG islands in E-cadherin gene (CDH1) are major mechanisms responsible for E-cadherin silencing in different tumors and cancer cell lines. The hepatitis B virus (HBV)-encoded X antigen, HBx, contributes importantly to the development of hepatocellular carcinoma using multiple mechanisms. Experiments were designed to test if in addition to CDH1 hypermethylation HBx promotes epigenetic modulation of E-cadherin transcriptional activity through histone deacetylation and miR-373. The relationships between HBx, E-cadherin, mSin3A, Snail-1 and miR-373 were evaluated in HBx expressing (HepG2X) and control (HepG2CAT) cells by western blotting, immunoprecipitation (IP), chromatin IP as well as by immunohistochemical staining of liver and tumor tissue sections from HBV-infected patients. In HepG2X cells, decreased levels of E-cadherin and elevated levels of mSin3A and Snail-1 were detected. Reciprocal IP with anti-HBx and anti-mSin3A demonstrated mutual binding. Furthermore, HBx-mSin3A colocalization was detected by immunofluorescent staining. HBx downregulated E-cadherin expression by the recruitment of the mSin3A/histone deacetylase complex to the Snail-binding sites in human CDH1. Histone deacetylation inhibition by Trichostatin-A treatment restored E-cadherin expression. Mir-373, a positive regulator of E-cadherin expression, was downregulated by HBx in HepG2X cells and tissue sections from HBV-infected patients. Thus, histone deacetylation of CDH1 and downregulation of miR-373, together with the previously demonstrated hypermethylation of CDH1 by HBx, may be important for the understanding of HBV-related carcinogenesis. Oncogene (2012) 31, 563-572; doi:10.1038/onc.2011.255; published online 27 June 2011	[Arzumanyan, A.; Friedman, T.; Kotei, E.; Lian, Z.; Feitelson, M. A.] Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; [Arzumanyan, A.; Feitelson, M. A.] Temple Univ, Coll Sci & Technol, Sbarro Hlth Res Org, Ctr Biotechnol, Philadelphia, PA 19122 USA; [Ng, I. O. L.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam, Hong Kong, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Hong Kong	Arzumanyan, A (corresponding author), Temple Univ, Coll Sci & Technol, Dept Biol, 1900 N 12th St,Suite 419,BioLife Sci Bldg, Philadelphia, PA 19122 USA.	alla.arzumanyan@temple.edu	Ibrahim, Essam Hassan/G-1960-2018; Lian, Zhaorui/AAW-2379-2020	Ibrahim, Essam Hassan/0000-0003-0130-2257; Ng, Irene Oi-lin/0000-0001-7532-2029	NIH [5R01CA104025, 5R01CA111427]; NATIONAL CANCER INSTITUTE [R01CA104025, R01CA111427] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Grants 5R01CA104025 and 5R01CA111427 (to M Feitelson). We thank Drs Yongwen Chen and Cheng-ying Yang from the Third Military Medical University for the paraffin blocks of human liver tissue, and Dr Eugeney Bichenkov for assistance with the figures.	Agami R, 2010, EUR J CLIN INVEST, V40, P370, DOI 10.1111/j.1365-2362.2010.02279.x; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; FEITELSON MA, 1988, J MED VIROL, V24, P121, DOI 10.1002/jmv.1890240202; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Kanai Y, 1997, INT J CANCER, V71, P355; Keasler VV, 2009, VIROLOGY, V390, P122, DOI 10.1016/j.virol.2009.05.001; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103; Lian ZR, 2006, HEPATOLOGY, V43, P415, DOI 10.1002/hep.21053; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nomura T, 1999, BBA-MOL BASIS DIS, V1453, P330, DOI 10.1016/S0925-4439(99)00004-6; Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627; Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032; Pan JB, 2004, J GEN VIROL, V85, P275, DOI 10.1099/vir.0.19650-0; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Park NH, 2006, POSTGRAD MED J, V82, P507, DOI 10.1136/pgmj.2006.047431; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeno S, 2004, AM J CLIN PATHOL, V122, P78, DOI 10.1309/WJL90JPEM17RBUHT; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Weil R, 1999, MOL CELL BIOL, V19, P6345; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zeng PY, 2006, BIOTECHNIQUES, V41, P694, DOI 10.2144/000112297; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	55	87	95	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					563	572		10.1038/onc.2011.255	http://dx.doi.org/10.1038/onc.2011.255			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706058	Green Accepted			2022-12-28	WOS:000300221800003
J	McInnes, N; Sadlon, TJ; Brown, CY; Pederson, S; Beyer, M; Schultze, JL; McColl, S; Goodall, GJ; Barry, SC				McInnes, N.; Sadlon, T. J.; Brown, C. Y.; Pederson, S.; Beyer, M.; Schultze, J. L.; McColl, S.; Goodall, G. J.; Barry, S. C.			FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells	ONCOGENE			English	Article						SATB1; FOXP3; microRNA; gene regulation networks; breast cancer; tumour suppressor	MESSENGER-RNA EXPRESSION; REGULATORY T-CELLS; TARGET GENES; GASTRIC-CANCER; CUTTING EDGE; RECEPTOR; GROWTH; RESISTANCE; REPRESSOR; MIRNAS	The transcription factor FOXP3 has been identified as a tumour suppressor in the breast and prostate epithelia, but little is known about its specific mechanism of action. We have identified a feed-forward regulatory loop in which FOXP3 suppresses the expression of the oncogene SATB1. In particular, we demonstrate that SATB1 is not only a direct target of FOXP3 repression, but that FOXP3 also induces two miRs, miR-7 and miR-155, which specifically target the 30-UTR of SATB1 to further regulate its expression. We conclude that FOXP3-regulated miRs form part of the mechanism by which FOXP3 prevents the transformation of the healthy breast epithelium to a cancerous phenotype. Approaches aimed at restoring FOXP3 function and the miRs it regulates could help provide new approaches to target breast cancer. Oncogene (2012) 31, 1045-1054; doi:10.1038/onc.2011.293; published online 11 July 2011	[McInnes, N.; Sadlon, T. J.; Brown, C. Y.; Pederson, S.; Barry, S. C.] Womens & Childrens Hosp, Womens & Childrens Hlth Res Inst, Mol Immunol Lab, Adelaide, SA 5006, Australia; [McInnes, N.; Pederson, S.; Barry, S. C.] Univ Adelaide, Dept Paediat, Adelaide, SA, Australia; [Beyer, M.; Schultze, J. L.] Univ Bonn, Lab Genom & Immunoregulat, LIMES Inst, Bonn, Germany; [McColl, S.] Univ Adelaide, Dept Immunol, Adelaide, SA, Australia; [Goodall, G. J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Goodall, G. J.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia; [Barry, S. C.] Womens & Childrens Hosp, Dept Gastroenterol, Adelaide, SA 5006, Australia	University of Adelaide; University of Bonn; University of Adelaide; Centre for Cancer Biology; SA Pathology; University of Adelaide; Womens & Childrens Hospital Australia	Barry, SC (corresponding author), Womens & Childrens Hosp, Womens & Childrens Hlth Res Inst, Mol Immunol Lab, 72 King William Rd, Adelaide, SA 5006, Australia.	simon.barry@adelaide.edu.au	barry, simon/Y-4529-2019; Beyer, Marc/ABE-1408-2021; Schultze, Joachim L./ABA-8176-2020; Schultze, Joachim L/D-7794-2011	barry, simon/0000-0002-0597-7609; Beyer, Marc/0000-0001-9704-148X; Schultze, Joachim L./0000-0003-2812-9853; Schultze, Joachim L/0000-0003-2812-9853; Goodall, Gregory/0000-0003-1294-0692; Pederson, Stephen/0000-0001-8197-3303	NHMRC [565314]; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	We acknowledge the contributions to this research made by the following co-workers: Danika Hill, Silvia Nobbs, Elizabeth Melville, Suzanne Bresatz, Nicola Eastaff-Leung, Bridget Wilkinson and Marlena Sekutowski. This work was funded by NHMRC Grant 565314 (SCB).	Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65; Brown CY, 2010, HUM GENE THER, V21, P1005, DOI 10.1089/hum.2009.107; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Cheng C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r90; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hanker LC, 2010, BREAST, DOI org/10.1016/j.breast.2010.10.002; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Jung DJ, 2010, J BIOL CHEM, V285, P7995, DOI 10.1074/jbc.M109.047985; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162; Kohwi-Shigematsu T, 2010, J NATL CANCER I, V102, P1879, DOI 10.1093/jnci/djq440; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Ladoire S, 2011, BREAST CANCER RES TR, V125, P65, DOI 10.1007/s10549-010-0831-1; Li QQ, 2011, CELL DEATH DIFFER, V18, P16, DOI 10.1038/cdd.2010.103; Li QQ, 2010, CANCER SCI, V101, P80, DOI 10.1111/j.1349-7006.2009.01372.x; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Liu Y, 2010, TRENDS GENET, V26, P260, DOI 10.1016/j.tig.2010.03.004; Lu LF, 2009, IMMUNITY, V30, P80, DOI 10.1016/j.immuni.2008.11.010; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Patani N, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-18; Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191; Re A, 2009, MOL BIOSYST, V5, P854, DOI 10.1039/b900177h; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Richon VM, 2008, NAT BIOTECHNOL, V26, P655, DOI 10.1038/nbt0608-655; Sadlon TJ, 2010, J IMMUNOL, V185, P1071, DOI 10.4049/jimmunol.1000082; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Selcuklu SD, 2009, CANCER GENET CYTOGEN, V189, P15, DOI 10.1016/j.cancergencyto.2008.09.009; Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Williams LM, 2007, NAT IMMUNOL, V8, P277, DOI 10.1038/ni1437; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zheng Y, 2007, NATURE, V445, P936, DOI 10.1038/nature05563; Zuo T, 2007, J CLIN INVEST, V117, P3765, DOI 10.1172/JCI32538; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	57	80	88	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					1045	1054		10.1038/onc.2011.293	http://dx.doi.org/10.1038/onc.2011.293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21743493	Green Published			2022-12-28	WOS:000300709700010
J	Mor, I; Carlessi, R; Ast, T; Feinstein, E; Kimchi, A				Mor, I.; Carlessi, R.; Ast, T.; Feinstein, E.; Kimchi, A.			Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase	ONCOGENE			English	Article						DAPk; PKM2; cancer metabolism; glycolysis	DAP-KINASE; CELL-METABOLISM; CANCER-THERAPY; TUMOR-GROWTH; M2; DOMAIN; PHOSPHORYLATION; APOPTOSIS; ISOFORM; PROMOTE	Death-associated protein kinase (DAPk), a multi-domain serine/threonine kinase, regulates numerous cell death mechanisms and harbors tumor suppressor functions. In this study, we report that DAPk directly binds and functionally activates pyruvate kinase M2 (PKM2), a key glycolytic enzyme, which contributes to the regulation of cancer cell metabolism. PKM2 was identified as a novel binding partner of DAPk by a yeast two-hybrid screen. This interaction was validated in vitro by enzyme-linked immunosorbent assay using purified proteins and in vivo by co-immunoprecipitation of the two endogenous proteins from cells. In vitro interaction with full-length DAPk resulted in a significant increase in the activity of PKM2. Conversely, a fragment of DAPk harboring only the functional kinase domain (KD) could neither bind PKM2 in cells nor activate it in vitro. Indeed, DAPk failed to phosphorylate PKM2. Notably, transfection of cells, with a truncated DAPk lacking the KD, elevated endogenous PKM2 activity, suggesting that PKM2 activation by DAPk occurs independently of its kinase activity. DAPk-transfected cells displayed changes in glycolytic activity, as reflected by elevated lactate production, whereas glucose uptake remained unaltered. A mild reduction in cell proliferation was detected as well in these transfected cells. Altogether, this work identifies a new role for DAPk as a metabolic regulator, suggesting the concept of direct interactions between a tumor suppressor and a key glycolytic enzyme to limit cell growth. Moreover, the work documents a unique function of DAPk that is independent of its catalytic activity and a novel mechanism to activate PKM2 by protein-protein interaction. Oncogene (2012) 31, 683-693; doi:10.1038/onc.2011.264; published online 4 July 2011	[Mor, I.; Carlessi, R.; Ast, T.; Feinstein, E.; Kimchi, A.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer 209, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il	Carlessi, Rodrigo/J-1757-2012; Mor, Inbal/GON-5297-2022	Mor, Inbal/0000-0003-4564-9690; Carlessi, Rodrigo/0000-0003-0038-7391	Flight Attendant Medical Research Institute; European Union; Israel Science Foundation	Flight Attendant Medical Research Institute; European Union(European Commission); Israel Science Foundation(Israel Science Foundation)	We thank Dr Shani Bialik for critical reading of the manuscript. GFP-PKM2-containing plasmid was the kind gift of A Ullrich (Max Planck Institute, Martinsried, Germany). A549 cells were the kind gift of M Oren (Weizmann Institute of Science, Rehovot, Israel). This work was supported by the Center of Excellence grant from the Flight Attendant Medical Research Institute, by a grant from the European Union FP7 to APO-SYS and by a grant from the Israel Science Foundation. AK is the incumbent of Helena Rubinstein Chair of Cancer Research.	Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; Bialik S, 2008, MOL CELL PROTEOMICS, V7, P1089, DOI 10.1074/mcp.M700579-MCP200; Bialik S, 2010, CURR OPIN CELL BIOL, V22, P199, DOI 10.1016/j.ceb.2009.11.004; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Eisenberg-Lerner A, 2007, CELL DEATH DIFFER, V14, P1908, DOI 10.1038/sj.cdd.4402212; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Mason EF, 2011, BBA-MOL CELL RES, V1813, P645, DOI 10.1016/j.bbamcr.2010.08.011; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Real-Hohn A, 2010, BIOCHIMIE, V92, P538, DOI 10.1016/j.biochi.2010.01.023; Spoden GA, 2008, INT J CANCER, V123, P312, DOI 10.1002/ijc.23512; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246	34	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					683	693		10.1038/onc.2011.264	http://dx.doi.org/10.1038/onc.2011.264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725354				2022-12-28	WOS:000300222100002
J	Oka, T; Schmitt, AP; Sudol, M				Oka, T.; Schmitt, A. P.; Sudol, M.			Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP	ONCOGENE			English	Article						angiomotin family; WW domains; PDZ domains; YAP as scaffold; cell detachment; apoptosis	YES-ASSOCIATED PROTEIN; HIPPO SIGNALING PATHWAY; NUCLEAR-LOCALIZATION; TUMOR-SUPPRESSOR; JUNCTIONS; COMPONENT; FAMILY; MST2	YAP (Yes-associated protein) oncogene has been found to form a stable complex with members of the Angiomotin (Amot) family of proteins, which bind WW domains of YAP and sequester the protein in the cytoplasm and junctional complexes. The Amot-mediated retention of YAP in the cytoplasm results in the inhibition of its proliferative function. Using apoptotic 'read-out' of YAP in HEK293 cells, we confirmed the molecular mode by which Amot regulates YAP. We showed that a representative member of the Amot family, AmotL1 (Angiomotin-like-1), uses its PPxY motifs to bind WW domains of YAP and inhibit YAP's nuclear translocation and pro-apoptotic function. Recently we also showed that YAP uses its PDZ-binding motif to interact with zona occludens-2 (ZO-2) protein, which promotes YAP's translocation to the nucleus. We also asked if AmotL1, YAP and ZO-2 signal together. We report here that AmotL1 and ZO-2 form a tripartite complex with YAP and regulate its function in HEK293 cells in opposite directions. AmotL1 inhibits proapoptotic function of YAP, whereas ZO-2 enhances it. As YAP is a potent oncogene, the identification and characterization of its regulators is important. AmotL1 and ZO-2 are two candidates that could be harnessed to control the oncogenic function of YAP. Oncogene (2012) 31, 128-134; doi: 10.1038/onc.2011.216; published online 20 June 2011	[Oka, T.; Sudol, M.] Geisinger Med Clin, Weis Ctr Res, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Schmitt, A. P.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	Geisinger Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Geisinger Med Clin, Weis Ctr Res, Lab Signal Transduct & Prote Profiling, 100 N Acad Ave, Danville, PA 17822 USA.	msudol1@geisinger.edu		Schmitt, Anthony/0000-0001-9272-058X	PA Breast Cancer Coalition grants [60707, 9200903]; Geisinger Clinic	PA Breast Cancer Coalition grants; Geisinger Clinic	This research was supported by PA Breast Cancer Coalition grants(#60707 and #9200903) and by Geisinger Clinic.	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Matallanas D, 2007, MOL CELL, V27, P962, DOI 10.1016/j.molcel.2007.08.008; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; Nishimura M, 2002, J BIOL CHEM, V277, P5583, DOI 10.1074/jbc.M110154200; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Oka T, 2009, GENES CELLS, V14, P607, DOI 10.1111/j.1365-2443.2009.01292.x; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pei ZF, 2010, VIROLOGY, V397, P155, DOI 10.1016/j.virol.2009.11.002; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sudol Marius, 2010, Genes Cancer, V1, P1115, DOI 10.1177/1947601911401911; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; Sugihara-Mizuno Y, 2007, GENES CELLS, V12, P473, DOI 10.1111/j.1365-2443.2007.01066.x; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111	23	90	92	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					128	134		10.1038/onc.2011.216	http://dx.doi.org/10.1038/onc.2011.216			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21685940				2022-12-28	WOS:000299176200012
J	Swaminathan, G; Cartwright, CA				Swaminathan, G.; Cartwright, C. A.			Rack1 promotes epithelial cell-cell adhesion by regulating E-cadherin endocytosis	ONCOGENE			English	Article						RACK1; Src; E-cadherin; adhesion; endocytosis; invasion	PROTEIN-TYROSINE-PHOSPHATASE; COLON-CANCER CELLS; SRC FAMILY KINASES; PTP-MU; MESENCHYMAL TRANSITION; CARCINOMA-CELLS; SIGNAL-TRANSDUCTION; MEDIATED ADHESION; CATENIN COMPLEX; DOWN-REGULATION	E-cadherin and its cytoplasmic partners, catenins, mediate epithelial cell-cell adhesion. Disruption of this adhesion allows cancer cells to invade and metastasize. Aberrant activation of the Src tyrosine kinase disrupts cell-cell contacts through an E-cadherin/catenin-dependent mechanism. Previously we showed that Rack1 regulates the growth of colon cells by suppressing Src activity at G(1) and mitotic checkpoints, and in the intrinsic apoptotic and Akt cell survival pathways. Here we show that Rack1, partly by inhibiting Src, promotes cell-cell adhesion and reduces the invasive potential of colon cancer cells. Rack1 stabilizes E-cadherin and catenins at cell-cell contacts by inhibiting the Src phosphorylation of E-cadherin, the ubiquitination of E-cadherin by the E3 ligase Hakai and the endocytosis of E-cadherin. Upon depletion and restoration of extracellular calcium, Rack1 facilitates the re-assembly of E-cadherin-containing cell-cell contacts. Rack1 also blocks HGF-induced endocytosis of E-cadherin, disruption of cell-cell contacts and cell scatter. Our results uncover a novel function of Rack1 in maintaining the junctional homeostasis of intestinal epithelial cells by regulation of the Src- and growth factor-induced endocytosis of E-cadherin. Oncogene (2012) 31, 376-389; doi:10.1038/onc.2011.242; published online 20 June 2011	[Swaminathan, G.; Cartwright, C. A.] Stanford Univ, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, M211 Alway Bldg,MC 5187,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			NIH [DK43743]; NIH Digestive Disease Center [DK56339]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043743, P30DK056339, R01DK043743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Digestive Disease Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Toufan Parman for performing initial preliminary experiments. We are grateful to Jenny Cheng, James Nelson, Anson Lowe and Manuel Amieva for helpful discussions and reagents. We thank James Nelson for the gift of MDCK cells and the members of the Lipsick laboratory for help with confocal imaging. We thank Jenny Cheng for critical review of the data and the manuscript. This work was supported by the NIH Grant DK43743 (CAC) and the NIH Digestive Disease Center Grant DK56339.	Avizienyte E, 2004, MOL BIOL CELL, V15, P2794, DOI 10.1091/mbc.E03-12-0879; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bertotti A, 2010, CLIN CANCER RES, V16, P3933, DOI 10.1158/1078-0432.CCR-10-0106; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Cox EA, 2003, MOL BIOL CELL, V14, P658, DOI 10.1091/mbc.E02-03-0142; Delva E, 2009, TRAFFIC, V10, P259, DOI 10.1111/j.1600-0854.2008.00862.x; Doan AT, 2007, EXP CELL RES, V313, P2667, DOI 10.1016/j.yexcr.2007.05.013; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Fan SJ, 2009, J BIOL CHEM, V284, P7561, DOI 10.1074/jbc.M807497200; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Herynk MH, 2007, J EXP THER ONCOL, V6, P205; Irby RB, 2002, CANCER RES, V62, P2669; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2009, ONCOGENE, V28, P4421, DOI 10.1038/onc.2009.293; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Ohgaki R, 2008, J BIOL CHEM, V283, P4417, DOI 10.1074/jbc.M705146200; Orlichenko L, 2009, MOL BIOL CELL, V20, P4140, DOI 10.1091/mbc.E08-10-1043; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Parent A, 2008, TRAFFIC, V9, P394, DOI 10.1111/j.1600-0854.2007.00692.x; Rengifo-Cam W, 2004, ONCOGENE, V23, P289, DOI 10.1038/sj.onc.1207041; Saitoh M, 2009, BIOCHEM BIOPH RES CO, V381, P560, DOI 10.1016/j.bbrc.2009.02.098; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schill NJ, 2009, BIOCHEM J, V418, P247, DOI 10.1042/BJ20081844; Serrels B, 2010, CURR BIOL, V20, P1086, DOI 10.1016/j.cub.2010.04.042; Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200; Skoudy A, 1996, BIOCHEM J, V317, P279, DOI 10.1042/bj3170279; Varghese B, 2008, MOL CELL BIOL, V28, P5275, DOI 10.1128/MCB.00350-08; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wadhawan A, 2011, CANCER TREAT REV, V37, P234, DOI 10.1016/j.ctrv.2010.08.003; Woodcock SA, 2009, MOL CELL, V33, P639, DOI 10.1016/j.molcel.2009.02.012; Yap AS, 2007, CURR OPIN CELL BIOL, V19, P508, DOI 10.1016/j.ceb.2007.09.008; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	61	32	34	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					376	389		10.1038/onc.2011.242	http://dx.doi.org/10.1038/onc.2011.242			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685945	Bronze			2022-12-28	WOS:000299542100010
J	Yao, R; Natsume, Y; Saiki, Y; Shioya, H; Takeuchi, K; Yamori, T; Toki, H; Aoki, I; Saga, T; Noda, T				Yao, R.; Natsume, Y.; Saiki, Y.; Shioya, H.; Takeuchi, K.; Yamori, T.; Toki, H.; Aoki, I.; Saga, T.; Noda, T.			Disruption of Tacc3 function leads to in vivo tumor regression	ONCOGENE			English	Article						TACC3; mitosis; spindle; p53; tumor regression	SUPPRESSOR GENE; BREAST-CANCER; COILED-COIL; ZYG-9 FORM; PROTEIN; P53; EXPRESSION; MUTATIONS; CELLS; TAC-1	The formation of the bipolar spindle is responsible for accurate chromosomal segregation during mitosis. The dynamic instability of microtubules has an important role in this process, and has been shown to be an effective target for cancer chemotherapy. Several agents that target non-microtubule mitotic proteins, including the motor protein Eg5, Aurora kinases and Polo-like kinases, are currently being developed as chemotherapeutic drugs. However, because the efficacies of these drugs remain elusive, new molecular targets that have essential roles in tumor cells are desired. Here, we provide in vivo evidence that transforming acidic coiled-coil-3 (Tacc3) is a potential target for cancer chemotherapy. Using MRI, we showed that Tacc3 loss led to the regression of mouse thymic lymphoma in vivo, which was accompanied by massive apoptosis. By contrast, normal tissues, including the thymus, showed no overt abnormalities, despite high Tacc3 expression. in vitro analysis indicated that Tacc3 depletion induced multi-polar spindle formation, which led to mitotic arrest, followed by apoptosis. Similar responses have been observed in Burkitt's lymphoma and T-ALL. These results show that Tacc3 is a vulnerable component of the spindle assembly in lymphoma cells and is a promising cancer chemotherapy target. Oncogene (2012) 31, 135-148; doi:10.1038/onc.2011.235; published online 20 June 2011	[Yao, R.] Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Koto Ku, Tokyo 1358550, Japan; [Takeuchi, K.] Japanese Fdn Canc Res, Dept Pathol, Inst Canc, Tokyo 1358550, Japan; [Yamori, T.] Japanese Fdn Canc Res, Div Mol Pharmacol, Ctr Canc Chemotherapy, Tokyo 1358550, Japan; [Toki, H.; Noda, T.] RIKEN, Bioresource Ctr, Team Adv Dev & Evaluat Human Dis Models, Ibaraki, Japan; [Aoki, I.; Saga, T.] Natl Inst Radiol Sci, Diagnost Imaging Program, Mol Imaging Ctr, Chiba 260, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; RIKEN; National Institutes for Quantum Science & Technology	Yao, R (corresponding author), Japanese Fdn Canc Res, Dept Cell Biol, Inst Canc, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ryao@jfcr.or.jp	Aoki, Ichio/ABF-7336-2020; Aoki, Ichio/G-2529-2011; Noda, Tetsuo/B-1667-2016; Takeuchi, Kengo/C-3614-2008	Aoki, Ichio/0000-0002-4429-5053; Takeuchi, Kengo/0000-0002-1599-5800	Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank T Jacks for providing the R26CreERT2 mice; S Shibata, T Nakahara T Shimomura, S Saito and F Yamagishi for MRI imaging; S Hasegawa for helpful discussions; and Y Terui for the donation of human lymphoma cells. We also thank Y Inoue and T Hirota for critically reading the manuscript. This work was supported by a Grant-in-Aid for cancer research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barr AR, 2008, MOL CELL BIOL, V28, P7199, DOI 10.1128/MCB.01040-08; Bellanger JM, 2003, CURR BIOL, V13, P1488, DOI 10.1016/S0960-9822(03)00582-7; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Cinti C, 2000, ONCOGENE, V19, P5098, DOI 10.1038/sj.onc.1203848; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Fielding AB, 2011, ONCOGENE, V30, P521, DOI 10.1038/onc.2010.431; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Jacquemier J, 2005, CANCER RES, V65, P767; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Le Bot N, 2003, CURR BIOL, V13, P1499, DOI 10.1016/S0960-9822(03)00577-3; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Oliferenko S, 2002, NAT CELL BIOL, V4, P816, DOI 10.1038/ncb861; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Sato M, 2004, MOL BIOL CELL, V15, P1609, DOI 10.1091/mbc.e03-11-0837; Schmidt S, 2010, ONCOGENE, V29, P6184, DOI 10.1038/onc.2010.354; Schneider L, 2008, ONCOGENE, V27, P116, DOI 10.1038/sj.onc.1210628; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Srayko M, 2003, CURR BIOL, V13, P1506, DOI 10.1016/S0960-9822(03)00597-9; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Sudakin V, 2007, BIODRUGS, V21, P225, DOI 10.2165/00063030-200721040-00003; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	45	32	32	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					135	148		10.1038/onc.2011.235	http://dx.doi.org/10.1038/onc.2011.235			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685933				2022-12-28	WOS:000299307400001
J	Heiska, L; Melikova, M; Zhao, F; Saotome, I; McClatchey, AI; Carpen, O				Heiska, L.; Melikova, M.; Zhao, F.; Saotome, I.; McClatchey, A. I.; Carpen, O.			Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment	ONCOGENE			English	Article						Src; ezrin; ERM proteins; invasion; 3D matrix	HUMAN COLORECTAL-CANCER; HUMAN COLON-CANCER; ELEVATED C-SRC; CELL-MIGRATION; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; PROTEIN EZRIN; ERM PROTEINS; EXPRESSION; ACTIVATION	The oncogenic tyrosine kinase Src has a role in cancer development, especially by promoting invasive and metastatic behavior. It is, however, unclear which of the Src-regulated signaling cascades induce malignant phenotype in three-dimensional environment. One of Src substrates is ezrin, a cytoskeletal organiser and regulator of signal transduction. Ezrin expression correlates with poor outcome of diverse cancers and is essential in experimental metastatic osteosarcoma. We reconstituted genetically ezrin-deficient cells with wild-type (WT) or phosphorylation-deficient Y477F ezrin together with constitutively active Src. In two-dimensional cultures, Src induced malignant features regardless of the presence or absence of ezrin. In contrast, only WT ezrin-expressing cells grew efficiently in soft agar or in suspension. In Matrigel, only WT ezrin significantly promoted growth and invasion, and was targeted to specific regions on the plasma membrane. WT and Y477F ezrin-expressing cells showed marked differences only when growing or scattering in three-dimensional matrix. Additional experiments showed that Y477-phosphorylated ezrin is also needed for the growth of Src-transformed epithelial cells in three-dimensional matrix. Cells lacking functional ezrin had reduced cyclin D levels and fewer cells in G2+S phase, possibly as a consequence of abnormal mTOR signaling, as ezrin Y477F cells showed lower expression of phosphorylated intermediates downstream of mTOR than WT cells. We conclude that the pathways activated by Src depend on the type of environment and that ezrin is a crucial element of Src-induced malignant features in cells growing inside three-dimensional environment. Oncogene (2011) 30, 4953-4962; doi:10.1038/onc.2011.207; published online 13 June 2011	[Carpen, O.] Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; [Heiska, L.; Melikova, M.; Zhao, F.; Carpen, O.] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Saotome, I.; McClatchey, A. I.] MGH Canc Ctr, Charlestown, MA USA; [Saotome, I.; McClatchey, A. I.] Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA USA; [Melikova, M.] Turku Univ Hosp, FIN-20520 Turku, Finland	University of Turku; University of Helsinki; Harvard University; University of Turku	Carpen, O (corresponding author), Univ Turku, Dept Pathol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	olli.carpen@utu.fi			Finnish Cancer Organizations, US Department of Defense [W81XWH-05-1-046]; Turku University Central Hospital District	Finnish Cancer Organizations, US Department of Defense; Turku University Central Hospital District	We thank JA Cooper for the pLXSH-SrcY527F plasmid; SL Fu for the RK3E cells, Sa Tsukita for the anti-moesin antibody; and H Ahola for technical assistance. The study was supported by Finnish Cancer Organizations, US Department of Defense grant W81XWH-05-1-046, and the Medical Research Fund of Turku University Central Hospital District to OC.	Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Autero M, 2003, FEBS LETT, V535, P82, DOI 10.1016/S0014-5793(02)03861-9; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Boyd DD, 2004, CLIN CANCER RES, V10, P1545, DOI 10.1158/1078-0432.CCR-1565-02; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eleveld-Trancikova D, 2002, INT J ONCOL, V20, P501; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Fu SL, 2005, BIOCHEM BIOPH RES CO, V338, P830, DOI 10.1016/j.bbrc.2005.10.045; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Heiska L, 2005, J BIOL CHEM, V280, P10244, DOI 10.1074/jbc.M411353200; Ilmonen S, 2005, MODERN PATHOL, V18, P503, DOI 10.1038/modpathol.3800300; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kobel M, 2006, MODERN PATHOL, V19, P581, DOI 10.1038/modpathol.3800567; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; KRIEG J, 1992, J BIOL CHEM, V267, P19258; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Naba A, 2008, EMBO J, V27, P38, DOI 10.1038/sj.emboj.7601943; Ohtani K, 2002, CANCER LETT, V179, P79, DOI 10.1016/S0304-3835(01)00857-6; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360	46	26	28	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4953	4962		10.1038/onc.2011.207	http://dx.doi.org/10.1038/onc.2011.207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21666723				2022-12-28	WOS:000298346500004
J	Archibald, KM; Kulbe, H; Kwong, J; Chakravarty, P; Temple, J; Chaplin, T; Flak, MB; McNeish, IA; Deen, S; Brenton, JD; Young, BD; Balkwill, F				Archibald, K. M.; Kulbe, H.; Kwong, J.; Chakravarty, P.; Temple, J.; Chaplin, T.; Flak, M. B.; McNeish, I. A.; Deen, S.; Brenton, J. D.; Young, B. D.; Balkwill, F.			Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium	ONCOGENE			English	Article						CXCR4; CXCL12; malignant transformation; high-grade serous ovarian cancer; p53	DNA COPY NUMBER; SEROUS CARCINOMA; GENOMIC ANALYSES; CANCER-CELLS; LOW-GRADE; EXPRESSION; P53; MUTATIONS; BREAST; CXCL12	Early genetic events in the development of high-grade serous ovarian cancer (HGSOC) may define the molecular basis of the profound structural and numerical instability of chromosomes in this disease. To discover candidate genetic changes we sequentially passaged cells from a karyotypically normal hTERT immortalised human ovarian surface epithelial line (IOSE25) resulting in the spontaneous formation of colonies in soft agar. Cell lines transformed ovarian surface epithelium 1 and 4 (TOSE 1 and 4) established from these colonies had an abnormal karyotype and altered morphology, but were not tumourigenic in immunodeficient mice. TOSE cells showed loss of heterozygosity (LOH) at TP53, increased nuclear p53 immunoreactivity and altered expression profile of p53 target genes. The parental IOSE25 cells contained a missense, heterozygous R175H mutation in TP53, whereas TOSE cells had LOH at the TP53 locus with a new R273H mutation at the previous wild-type TP53 allele. Cytogenetic and array CGH analysis of TOSE cells also revealed a focal genomic amplification of CXCR4, a chemokine receptor commonly expressed by HGSOC cells. TOSE cells had increased functional CXCR4 protein and its abrogation reduced epidermal growth factor receptor (EGFR) expression, as well as colony size and number. The CXCR4 ligand, CXCL12, was epigenetically silenced in TOSE cells and its forced expression increased TOSE colony size. TOSE cells had other cytogenetic changes typical of those seen in HGSOC ovarian cancer cell lines and biopsies. In addition, enrichment of CXCR4 pathway in expression profiles from HGSOC correlated with enrichment of a mutated TP53 gene expression signature and of EGFR pathway genes. Our data suggest that mutations in TP53 and amplification of the CXCR4 gene locus may be early events in the development of HGSOC, and associated with chromosomal instability. Oncogene (2012) 31, 4987-4995; doi:10.1038/onc.2011.653; published online 23 January 2012	[Balkwill, F.] Queen Mary Univ London, Barts Canc Inst, Ctr Canc & Inflammat, London EC1M 6BQ, England; [Archibald, K. M.; Kulbe, H.; Balkwill, F.] Queen Mary Univ London, Barts Canc Inst, Ctr Canc & Inflammat, London EC1M 6BQ, England; [Kwong, J.] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Chakravarty, P.] Bioinformat & Biostat Serv, London, England; [Temple, J.; Brenton, J. D.] Cambridge Res Inst, Li Ka Shing Ctr, Canc Res UK, Funct Genom Ovarian Canc Lab, Cambridge, England; [Flak, M. B.; McNeish, I. A.] Queen Mary Univ London, Ctr Mol Oncol, Barts Canc Inst, London EC1M 6BQ, England; [Deen, S.] Univ Nottingham Hosp, Dept Histopathol, Nottingham NG7 2UH, England; [Chaplin, T.; Young, B. D.] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London; Chinese University of Hong Kong; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of London; Queen Mary University London; University of Nottingham; University of London; Queen Mary University London	Balkwill, F (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Canc & Inflammat, Charterhouse Sq, London EC1M 6BQ, England.	f.balkwill@qmul.ac.uk	Flak, Magdalena B/M-7106-2016; Brenton, James D/B-3174-2008; Flak, Magdalena/AAG-5272-2020; Kwong, Joseph/H-2368-2013	Flak, Magdalena B/0000-0002-8238-9835; Brenton, James D/0000-0002-5738-6683; Flak, Magdalena/0000-0002-8238-9835; Kwong, Joseph/0000-0002-3380-6882; Balkwill, Frances/0000-0002-5587-9759; chakravarty, probir/0000-0003-1146-8824; McNeish, Iain/0000-0002-9387-7586	Cancer Research UK; Association for International Cancer Research; HEFCE; MRC [G0601891] Funding Source: UKRI; Cancer Research UK [15601] Funding Source: researchfish; Medical Research Council [G0601891] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Association for International Cancer Research; HEFCE(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Nitzan Rosenfeld and Davina Gale for their expert advice and analysis for the TP53 quantification. We also thank Debra Lillington for karyotyping TOSE cells, and the Genome Centre at Barts and the London School of Medicine and Dentistry for microsatellite analysis. This work was supported by Cancer Research UK, the Association for International Cancer Research and HEFCE.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Ansieau S, 2008, CELL CYCLE, V7, P3659, DOI 10.4161/cc.7.23.7049; Balabanian K, 2005, J BIOL CHEM, V280, P35760, DOI 10.1074/jbc.M508234200; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardini MQ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-237; Cooke SL, 2010, ONCOGENE, V29, P4905, DOI 10.1038/onc.2010.245; Dimova I, 2009, TUMORI, V95, P357; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Farley J, 2008, CELL RES, V18, P538, DOI 10.1038/cr.2008.52; Flak MB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-175; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Kajiyama H, 2008, INT J CANCER, V122, P91, DOI 10.1002/ijc.23083; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Katoh M, 2010, INT J ONCOL, V36, P415, DOI 10.3892/ijo_00000514; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Kulbe H, 2005, CANCER RES, V65, P10355, DOI 10.1158/0008-5472.CAN-05-0957; Kulbe H, 2007, CANCER RES, V67, P585, DOI 10.1158/0008-5472.CAN-06-2941; Kulbe H, 2012, CANCER RES, V72, P66, DOI 10.1158/0008-5472.CAN-11-2178; Kuo KT, 2009, CANCER RES, V69, P4036, DOI 10.1158/0008-5472.CAN-08-3913; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Li NF, 2007, CELL PROLIFERAT, V40, P780, DOI 10.1111/j.1365-2184.2007.00462.x; Maia AT, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2458; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120; Micci F, 2010, J ONCOL, V2010, DOI 10.1155/2010/646340; Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Roh HJ, 2000, CANCER RES, V60, P6496; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stoczynska-Fidelus E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-243; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Team RDC, 2008, R FDN STAT COMP; TESTA JR, 1994, CANCER RES, V54, P2778; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751; Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505; Zlotnik A, 2006, INT J CANCER, V119, P2026, DOI 10.1002/ijc.22024	55	13	14	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4987	4995		10.1038/onc.2011.653	http://dx.doi.org/10.1038/onc.2011.653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22266861	Green Accepted			2022-12-28	WOS:000311888600003
J	Rothschild, SI; Tschan, MP; Federzoni, EA; Jaggi, R; Fey, MF; Gugger, M; Gautschi, O				Rothschild, S. I.; Tschan, M. P.; Federzoni, E. A.; Jaggi, R.; Fey, M. F.; Gugger, M.; Gautschi, O.			MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma	ONCOGENE			English	Article						miR-29b; inhibitor of differentiation protein 1; ID1; Src; c-Myc; lung cancer	CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN BREAST-CANCER; TUMOR-GROWTH; EXPRESSION; SRC; GENES; CELLS; ID1; SIGNATURE; CARCINOMA	The c-Src kinase regulates cancer cell invasion through inhibitor of DNA binding/differentiation 1 (ID1). Src and ID1 are frequently overexpressed in human lung adenocarcinoma. The current study aimed at identifying microRNAs (miRNAs) involved in the Src-ID1 signaling in lung cancer. Incubation of lung cancer cells with the Src inhibitor saracatinib led to the upregulation of several miRNAs including miR-29b, which was the most highly upregulated miRNA with predicted binding to the ID1 3'-untranslated region (UTR). Luciferase reporter assays confirmed direct binding of miR-29b to the ID1 3'-UTR. Expression of miR-29b suppressed ID1 levels and significantly reduced migration and invasion. Expression of antisense-miR-29b (anti-miR-29b), on the other hand, enhanced ID1 mRNA and protein levels, and significantly increased lung cancer cell migration and invasion, a hallmark of the Src-ID1 pathway. The ectopic expression of ID1 in miR-29b-overexpressing cells was able to rescue the migratory potential of these cells. Both, anti-miR-29b and ID1 overexpression diminished the effects of the Src inhibitors saracatinib and dasatinib on migration and invasion. Saracatinib and dasatinib decreased c-Myc transcriptional repression on miR-29b and led to increased ID1 protein levels, whereas forced expression of c-Myc repressed miR-29b and induced ID1. In agreement, we showed direct recruitment of c-Myc to the miR-29b promoter. miR-29b was significantly downregulated in primary lung adenocarcinoma samples compared with matched alveolar lung tissue, and miR-29b expression was a significant prognostic factor for patient outcome. These results suggest that miR-29b is involved in the Src-ID1 signaling pathway, is dysregulated in lung adenocarcinoma and is a potential predictive marker for Src kinase inhibitors. Oncogene (2012) 31, 4221-4232; doi:10.1038/onc.2011.578; published online 16 January 2012	[Rothschild, S. I.; Tschan, M. P.; Federzoni, E. A.; Jaggi, R.; Gautschi, O.] Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; [Rothschild, S. I.] Univ Basel Hosp, Dept Med Oncol, CH-4031 Basel, Switzerland; [Tschan, M. P.; Fey, M. F.] Univ Hosp Bern, Inselspital, Dept Med Oncol, CH-3010 Bern, Switzerland; [Gugger, M.] Univ Bern, Inst Pathol, Bern, Switzerland; [Gautschi, O.] Luzerner Kantonsspital, Klin Onkol, Luzern, Switzerland	University of Bern; University of Basel; University of Bern; University Hospital of Bern; University of Bern; Lucerne Cantonal Hospital	Gautschi, O (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.	oliver.gautschi@onkologie.ch	Rothschild, Sacha/AAV-4003-2020	Rothschild, Sacha/0000-0003-1304-9340; Tschan, Mario P./0000-0001-5897-3647	Swiss Cancer League [KLS 02164-02-2008]; Bernese Cancer League; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bernese Foundation of Cancer Research; Marlies-Schwegler Foundation; Ursula-Hecht-Foundation for Leukemia Research	Swiss Cancer League; Bernese Cancer League; Werner and Hedy Berger-Janser Foundation of Cancer Research; Bernese Foundation of Cancer Research; Marlies-Schwegler Foundation; Ursula-Hecht-Foundation for Leukemia Research	Deborah Shan is gratefully acknowledged for excellent technical support. We acknowledge Dr John Minna (UT Southwestern, Medical Center, Dallas, TX, USA) and Dr Yitzhak Zimmer for providing us with cell lines. We thank Wieslawa Blank for support with Western blotting and Dr Daniel Betticher for providing us with primary tumors from the tumor tissue bank. We also thank Dr Jasmin Batliner for support with luciferase assays. We thank AstraZeneca (Manchester, UK) for providing saracatinib. This study was supported by Swiss Cancer League (Grant KLS 02164-02-2008 to OG and MG), the Bernese Cancer League (to MG, OG and MPT), the Werner and Hedy Berger-Janser Foundation of Cancer Research (to MFF and MPT), the Bernese Foundation of Cancer Research, the Marlies-Schwegler Foundation and the Ursula-Hecht-Foundation for Leukemia Research (to MFF).	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; Bishop JA, 2010, CLIN CANCER RES, V16, P610, DOI 10.1158/1078-0432.CCR-09-2638; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Fong S, 2004, TRENDS MOL MED, V10, P387, DOI 10.1016/j.molmed.2004.06.008; Garzon R, 2008, P NATL ACAD SCI USA, V105, P3945, DOI 10.1073/pnas.0800135105; Gautschi O, 2008, CANCER RES, V68, P2250, DOI 10.1158/0008-5472.CAN-07-6403; Geback T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lebanony D, 2009, J CLIN ONCOL, V27, P2030, DOI 10.1200/JCO.2008.19.4134; Leighl NB, 2005, J CLIN ONCOL, V23, P2831, DOI 10.1200/JCO.2005.04.044; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Muniyappa MK, 2009, EUR J CANCER, V45, P3104, DOI 10.1016/j.ejca.2009.09.014; Oberli A, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-9; Patnaik SK, 2010, CANCER RES, V70, P36, DOI 10.1158/0008-5472.CAN-09-3153; Pekarsky Y, 2006, CANCER RES, V66, P11590, DOI 10.1158/0008-5472.CAN-06-3613; Rothschild SI, 2011, LUNG CANCER, V71, P306, DOI 10.1016/j.lungcan.2010.06.018; Rothschild SI, 2010, CLIN LUNG CANCER, V11, P238, DOI 10.3816/CLC.2010.n.030; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Sun XL, 2009, CARCINOGENESIS, V30, P2109, DOI 10.1093/carcin/bgp251; Swarbrick A, 2005, ONCOGENE, V24, P381, DOI 10.1038/sj.onc.1208188; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Voortman J, 2010, CANCER RES, V70, P8288, DOI 10.1158/0008-5472.CAN-10-1348; Wu X, 2009, J THORAC ONCOL, V4, P1028, DOI 10.1097/JTO.0b013e3181a99c77; Xu H, 2009, CANCER RES, V69, P6275, DOI 10.1158/0008-5472.CAN-08-4517; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008	50	59	66	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	38					4221	4232		10.1038/onc.2011.578	http://dx.doi.org/10.1038/onc.2011.578			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22249264				2022-12-28	WOS:000308975800005
J	Sidler, D; Brockmann, A; Mueller, J; Nachbur, U; Corazza, N; Renzulli, P; Hemphill, A; Brunner, T				Sidler, D.; Brockmann, A.; Mueller, J.; Nachbur, U.; Corazza, N.; Renzulli, P.; Hemphill, A.; Brunner, T.			Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel	ONCOGENE			English	Article						apoptosis; colon cancer; glutathione S-transferase; Bim; TRAIL; chemotherapy	N-TERMINAL KINASE; BAX-DEPENDENT APOPTOSIS; ETHACRYNIC-ACID; FLOW-CYTOMETRY; LIVER-DAMAGE; JNK; TRAIL; DEATH; PI; PHOSPHORYLATION	Glutathione-S-transferase of the Pi class (GSTP1) is frequently overexpressed in a variety of solid tumors and has been identified as a potential therapeutic target for cancer therapy. GSTP1 is a phase II detoxification enzyme and conjugates the tripeptide glutathione to endogenous metabolites and xenobiotics, thereby limiting the efficacy of antitumor chemotherapeutic treatments. In addition, GSTP1 regulates cellular stress responses and apoptosis by sequestering and inactivating c-Jun N-terminal kinase (JNK). Thiazolides are a novel class of antibiotics for the treatment of intestinal pathogens with no apparent side effects on the host cells and tissue. Here we show that thiazolides induce a GSTP1-dependent and glutathione-enhanced cell death in colorectal tumor cell lines. Downregulation of GSTP1 reduced the apoptotic activity of thiazolides, whereas overexpression enhanced it. Thiazolide treatment caused strong Jun kinase activation and Jun kinase-dependent apoptosis. As a critical downstream target of Jun kinase we identified the proapoptotic Bcl-2 homolog Bim. Thiazolides induced Bim expression and activation in a JNK-dependent manner. Downregulation of Bim in turn significantly blocked thiazolide-induced apoptosis. Whereas low concentrations of thiazolides failed to induce apoptosis directly, they potently sensitized colon cancer cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic drug-induced cell death. Although GSTP1 overexpression generally limits chemotherapy and thus antitumor treatment, our study identifies GSTP1 as Achilles' heel and thiazolides as novel interesting apoptosis sensitizer for the treatment of colorectal tumors. Oncogene (2012) 31, 4095-4106; doi:10.1038/onc.2011.575; published online 12 December 2011	[Brockmann, A.; Brunner, T.] Univ Konstanz, Dept Biol, Div Biochem Pharmacol, D-78457 Constance, Germany; [Mueller, J.; Hemphill, A.] Univ Bern, Inst Parasitol, Vetsuisse Fac, Bern, Switzerland; [Nachbur, U.] Walter & Eliza Hall Inst Med Res, Div Cell Signalling & Cell Death, Parkville, Vic, Australia; [Renzulli, P.] Cantonal Hosp, Dept Surg, Munsterlingen, Switzerland; [Sidler, D.; Corazza, N.; Brunner, T.] Univ Bern, Inst Pathol Expt Pathol, Bern, Switzerland	University of Konstanz; University of Bern; Walter & Eliza Hall Institute; University of Bern	Brunner, T (corresponding author), Univ Konstanz, Dept Biol, Div Biochem Pharmacol, Box 660, D-78457 Constance, Germany.	thomas.brunner@uni-konstanz.de	Sidler, Daniel/G-2447-2019; Renzulli, Pietro/GQH-9366-2022	Renzulli, Pietro/0000-0001-5557-5512; Hemphill, Andrew/0000-0002-0622-2128; Nachbur, Ueli/0000-0001-5968-2235	Swiss National Science Foundation; Oncosuisse; AFF grant from the University of Konstanz; Graduate School Chemical Biology of the University of Konstanz	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Oncosuisse; AFF grant from the University of Konstanz; Graduate School Chemical Biology of the University of Konstanz	The authors thank the members of the Brunner and Corazza lab for their excellent technical help and scientific advice, Thomas Kaufmann from the Institute of Pharmacology, University of Berne for providing the antibodies, Philippe Bouillet from the Walter and Eliza Hall Institute, Melbourne, for the Bim promoter construct, Christian Leumann from the Department of Chemistry and Biochemistry, University of Bern for the synthesis of RM4819, and Vicky Hatzig and Thomas Herdegen, University of Kiel for expression plasmids. This work was supported by grants from the Swiss National Science Foundation, Oncosuisse and AFF grant from the University of Konstanz to Thomas Brunner. Daniel Sidler was supported by an MD-PhD fellowship from the Swiss National Science Foundation. Anette Brockmann was supported by a fellowship from the Graduate School Chemical Biology of the University of Konstanz.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Badmann A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.55; Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen YR, 2000, INT J ONCOL, V16, P651; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Elsby R, 2003, J BIOL CHEM, V278, P22243, DOI 10.1074/jbc.M301211200; Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839; Garrett CR, 2011, EXPERT OPIN BIOL TH, V11, P937, DOI 10.1517/14712598.2011.582464; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; Ishimoto TM, 2002, PHARMACOGENETICS, V12, P543, DOI 10.1097/00008571-200210000-00006; Jakob S, 2008, METHODS, V44, P255, DOI 10.1016/j.ymeth.2007.11.004; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann T, 2009, IMMUNITY, V30, P56, DOI 10.1016/j.immuni.2008.10.017; Kuo CT, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-43; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; McIlwain CC, 2006, ONCOGENE, V25, P1639, DOI 10.1038/sj.onc.1209373; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Muller J, 2008, INT J CANCER, V123, P1797, DOI 10.1002/ijc.23755; Muller J, 2008, EXP PARASITOL, V118, P80, DOI 10.1016/j.exppara.2007.06.008; Mueller M, 2007, ENDOCRINOLOGY, V148, P1445, DOI 10.1210/en.2006-0591; Muller J, 2006, ANTIMICROB AGENTS CH, V50, P162, DOI 10.1128/AAC.50.1.162-170.2006; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ODWYER PJ, 1991, CANCER RES, V51, P6059; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; PETRINI M, 1993, BRIT J HAEMATOL, V85, P409, DOI 10.1111/j.1365-2141.1993.tb03187.x; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ritchie KJ, 2009, P NATL ACAD SCI USA, V106, P20859, DOI 10.1073/pnas.0911351106; Ruzza P, 2009, ANTI-CANCER AGENT ME, V9, P763, DOI 10.2174/187152009789056895; Schneider-Jakob S, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.66; Steensma DP, 2010, HEMATOL ONCOL CLIN N, V24, P423, DOI 10.1016/j.hoc.2010.02.010; Strahl BD, 1997, ENDOCRINOLOGY, V138, P2621, DOI 10.1210/en.138.6.2621; Tew KD, 2005, EXPERT OPIN INV DRUG, V14, P1047, DOI 10.1517/13543784.14.8.1047; TEW KD, 1988, CANCER RES, V48, P3622; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Villafania A, 2000, ANN CLIN LAB SCI, V30, P57; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Webb C, 2006, VET IMMUNOL IMMUNOP, V112, P129, DOI 10.1016/j.vetimm.2006.02.009; Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X; Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003; Yin ZM, 2000, CANCER RES, V60, P4053; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	49	23	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	37					4095	4106		10.1038/onc.2011.575	http://dx.doi.org/10.1038/onc.2011.575			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158036	Green Submitted			2022-12-28	WOS:000308688900002
J	Cronan, MR; Nakamura, K; Johnson, NL; Granger, DA; Cuevas, BD; Wang, JG; Mackman, N; Scott, JE; Dohlman, HG; Johnson, GL				Cronan, M. R.; Nakamura, K.; Johnson, N. L.; Granger, D. A.; Cuevas, B. D.; Wang, J-G; Mackman, N.; Scott, J. E.; Dohlman, H. G.; Johnson, G. L.			Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis	ONCOGENE			English	Article						MAP3K; metastasis; MAPK network; MEKK2; MLK3	SIGNAL-REGULATED KINASE-5; BREAST-CANCER; PROSTATE-CANCER; TISSUE FACTOR; EXPRESSION; ACTIVATION; ERK5; PROGRESSION; CARCINOMA; APOPTOSIS	Analysis of patient tumors suggests that multiple MAP3 kinases (MAP3Ks) are critical for growth and metastasis of cancer cells. MAP3Ks selectively control the activation of extracellular signal-regulated kinase 1/2 (ERK1/2), Jun N-terminal kinase (JNK), p38 and ERK5 in response to receptor tyrosine kinases and GTPases. We used MDA-MB-231 cells because of their ability to metastasize from the breast fat pad to distant lymph nodes for an orthotopic xenograft model to screen the function of seven MAP3Ks in controlling tumor growth and metastasis. Stable short hairpin RNA (shRNA) knockdown was used to inhibit the expression of each of the seven MAP3Ks, which were selected for their differential regulation of the MAPK network. The screen identified two MAP3Ks, MEKK2 and MLK3, whose shRNA knockdown caused significant inhibition of both tumor growth and metastasis. Neither MEKK2 nor MLK3 have been previously shown to regulate tumor growth and metastasis in vivo. These results demonstrated that MAP3Ks, which differentially activate JNK, p38 and ERK5, are necessary for xenograft tumor growth and metastasis of MDA-MB-231 tumors. The requirement for MAP3Ks signaling through multiple MAPK pathways explains why several members of the MAPK network are activated in cancer. MEKK2 was required for epidermal growth factor receptor and Her2/Neu activation of ERK5, with ERK5 being required for metastasis. Loss of MLK3 expression increased mitotic infidelity and apoptosis in vitro. Knockdown of MEKK2 and MLK3 resulted in increased apoptosis in orthotopic xenografts relative to control tumors in mice, inhibiting both tumor growth and metastasis; MEKK2 and MLK3 represent untargeted kinases in tumor biology for potential therapeutic development. Oncogene (2012) 31, 3889-3900; doi:10.1038/onc.2011.544; published online 5 December 2011	[Cronan, M. R.; Nakamura, K.; Johnson, N. L.; Granger, D. A.; Johnson, G. L.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA; [Cronan, M. R.; Dohlman, H. G.] Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA; [Cronan, M. R.; Nakamura, K.; Johnson, N. L.; Granger, D. A.; Wang, J-G; Mackman, N.; Dohlman, H. G.; Johnson, G. L.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; [Cuevas, B. D.] Loyola Univ Chicago, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL USA; [Mackman, N.] Univ N Carolina, McAllister Heart Inst, Sch Med, Div Hematol & Oncol,Dept Med, Chapel Hill, NC 27599 USA; [Scott, J. E.] N Carolina Cent Univ, Dept Pharmaceut Sci, Biomfg Res Inst & Technol Enterprise, Durham, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Loyola University Chicago; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; North Carolina Central University	Johnson, GL (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA.	glj@med.unc.edu		Cronan, Mark/0000-0002-3760-1649; Dohlman, Henrik/0000-0003-2443-0729; Mackman, Nigel/0000-0002-9170-7700	NIH [GM30324, DK37871, GM059167, U54CA156735, CA120881]; University of North Carolina; RNAi Screening Core; Lentiviral shRNA Core; NATIONAL CANCER INSTITUTE [K01CA120881, U54CA156735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324, R01GM059167] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of North Carolina; RNAi Screening Core; Lentiviral shRNA Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH Grants GM30324 (GLJ), DK37871 (GLJ), GM059167 (HGD), U54CA156735 (GLJ and JES) and CA120881 (BC) and the University of North Carolina Cancer Research Fund (GLJ). We acknowledge the RNAi Screening Core and Lentiviral shRNA Core for support of this research.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Brancho D, 2005, MOL CELL BIOL, V25, P3670, DOI 10.1128/MCB.25.9.3670-3681.2005; Montero JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005565; Cazares LH, 2009, CLIN CANCER RES, V15, P5541, DOI 10.1158/1078-0432.CCR-08-2892; Cha HJ, 2006, CELL SIGNAL, V18, P93, DOI 10.1016/j.cellsig.2005.03.028; Chang S, 2011, COMPOS MATH, V147, P375, DOI 10.1112/S0010437X1000504X; Chen J, 2010, ONCOGENE, V29, P4399, DOI 10.1038/onc.2010.198; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Cuevas BD, 2006, ONCOGENE, V25, P4998, DOI 10.1038/sj.onc.1209507; Davidson B, 2006, GYNECOL ONCOL, V102, P453, DOI 10.1016/j.ygyno.2006.01.034; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Fedorov O, 2010, NAT CHEM BIOL, V6, P166, DOI 10.1038/nchembio.297; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Jaeschke A, 2007, MOL CELL, V27, P498, DOI 10.1016/j.molcel.2007.07.008; Kasthuri RS, 2009, J CLIN ONCOL, V27, P4834, DOI 10.1200/JCO.2009.22.6324; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; Khorana AA, 2008, J THROMB HAEMOST, V6, P1983, DOI 10.1111/j.1538-7836.2008.03156.x; Kim KY, 2004, J BIOL CHEM, V279, P29478, DOI 10.1074/jbc.M313947200; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; McCracken SRC, 2008, ONCOGENE, V27, P2978, DOI 10.1038/sj.onc.1210963; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mishra R, 2007, J BIOL CHEM, V282, P30393, DOI 10.1074/jbc.M705895200; Nakamura K, 2010, J BIOL CHEM, V285, P2077, DOI 10.1074/jbc.M109.065102; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sartorius CA, 2003, BREAST CANCER RES TR, V79, P287, DOI 10.1023/A:1024031731269; Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Sticht C, 2008, NEOPLASIA, V10, P462, DOI 10.1593/neo.08164; Sun WY, 2003, MOL CELL BIOL, V23, P2298, DOI 10.1128/MCB.23.7.2298-2308.2003; Tatake RJ, 2008, BIOCHEM BIOPH RES CO, V377, P120, DOI 10.1016/j.bbrc.2008.09.087; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Waldmeier P, 2006, BIOCHEM PHARMACOL, V72, P1197, DOI 10.1016/j.bcp.2006.06.031; Wang X, 2010, HUM PATHOL, V41, P401, DOI 10.1016/j.humpath.2009.08.018; Wo JY, 2011, J CLIN ONCOL, V29, P2619, DOI 10.1200/JCO.2010.29.5907; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008; Yu JL, 2005, BLOOD, V105, P1734, DOI 10.1182/blood-2004-05-2042; Zen K, 2009, GENE CHROMOSOME CANC, V48, P109, DOI 10.1002/gcc.20624	44	47	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3889	3900		10.1038/onc.2011.544	http://dx.doi.org/10.1038/onc.2011.544			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139075	Green Submitted, Green Accepted			2022-12-28	WOS:000307925000006
J	Hsu, TI; Wang, MC; Chen, SY; Yeh, YM; Su, WC; Chang, WC; Hung, JJ				Hsu, T-I; Wang, M-C; Chen, S-Y; Yeh, Y-M; Su, W-C; Chang, W-C; Hung, J-J			Sp1 expression regulates lung tumor progression	ONCOGENE			English	Article						Sp1; metastasis; E-cadherin	TRANSCRIPTION FACTOR SP1; FACTOR-I-RECEPTOR; E-CADHERIN; BETA-CATENIN; SPECIFICITY PROTEIN-1; GENE-EXPRESSION; DOWN-REGULATION; CELL-GROWTH; CANCER; METASTASIS	The role of specificity protein 1 (Sp1) in controlling gene expression in lung tumor development and metastasis is not well understood. In this study, we showed that the Sp1 level was highly increased and required for lung tumor growth in transgenic mice bearing Kras-induced lung tumors under the control of doxycycline. Furthermore, the Sp1 level was highly upregulated in lung adenocarcinoma cells with low invasiveness and in patients with stage I lung cancer. We also demonstrated that Sp1 was downregulated in lung adenocarcinoma cells with high invasiveness and in patients with stage IV lung adenocarcinoma. Moreover, Sp1 inversely regulated migration, invasion and metastasis of lung adenocarcinoma cells in vivo. In addition, a decrease in the Sp1 level in highly invasive lung adenocarcinoma cells resulted from instability of the Sp1 protein. Furthermore, overexpression of Sp1 in highly invasive lung adenocarcinoma cells increased expression of E-cadherin, a suppressor of metastasis, and attenuated the translocation of beta-catenin into the cellular nucleus that leads to tumor malignancy. Taken together, Sp1 level accumulated strongly in early stage and then declined in late stage, which is important for lung cancer cell proliferation and metastasis during tumorigenesis. Oncogene (2012) 31, 3973-3988; doi: 10.1038/onc.2011.568; published online 12 December 2011	[Hung, J-J] Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan; [Hsu, T-I; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 701, Taiwan; [Wang, M-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; [Hsu, T-I; Chen, S-Y; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Biosci Biotechnol, Inst Bioinformat & Biosignal Transduct, Tainan 701, Taiwan; [Yeh, Y-M; Su, W-C] Natl Cheng Kung Univ, Coll Med & Hosp, Dept Internal Med, Tainan 701, Taiwan; [Chang, W-C] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Coll Biosci & Biotechnol, Inst Bioinformat & Biosignal Transduct, Ctr Gene Regulat & Signal Transduct, 1 Univ Rd, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Hsu, Tsung-I/AAK-9942-2020	Hsu, Tsung-I/0000-0002-7524-7740; Su, Wu-Chou/0000-0003-2953-4105	National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan [NSC 97-2320-B-006-016-MY3, NSC 97-2311-B-006-002-MY3]; Department of Health, Executive Yuan, Taiwan [DOH99-TD-B-111-002, DOH99-TD-B111-003]	National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Executive Yuan, Taiwan	This work was supported by the National Cheng-Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with Grants NSC 97-2320-B-006-016-MY3 and NSC 97-2311-B-006-002-MY3 obtained from the National Science Council, Taiwan. The clinical work in this study was supported by the Department of Health, Executive Yuan, Taiwan (Grants DOH99-TD-B-111-002 and DOH99-TD-B111-003).	Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Bu YH, 2011, INT J CANCER, V128, P1836, DOI 10.1002/ijc.25524; Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen JF, 2010, ANTICANCER RES, V30, P1113; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Chuang JY, 2009, INT J CANCER, V125, P2066, DOI 10.1002/ijc.24563; Clair SS, 2006, CELL CYCLE, V5, P709, DOI 10.4161/cc.5.7.2628; DeFino MC, 2010, BIOCHEM BIOPH RES CO, V393, P603, DOI 10.1016/j.bbrc.2010.02.026; Denlinger CE, 2010, J THORAC CARDIOV SUR, V140, P505, DOI 10.1016/j.jtcvs.2010.02.061; Duverger V, 2004, BRIT J CANCER, V90, P2025, DOI 10.1038/sj.bjc.6601824; Esteve PO, 2007, J BIOL CHEM, V282, P2615, DOI 10.1074/jbc.M606203200; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213; Hung TL, 2003, CLIN CANCER RES, V9, P2605; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jiang YX, 2004, CLIN EXP METASTAS, V21, P755, DOI 10.1007/s10585-005-1198-2; Kumar AP, 1999, CANCER LETT, V137, P159, DOI 10.1016/S0304-3835(98)00351-6; Kwak HJ, 2006, MOL CANCER RES, V4, P209, DOI 10.1158/1541-7786.MCR-05-0140; Lee YC, 2011, AM J RESP CELL MOL, V45, P270, DOI 10.1165/rcmb.2010-0313OC; Leroy I, 2006, APOPTOSIS, V11, P113, DOI 10.1007/s10495-005-3089-z; Lin RK, 2007, ANTI-CANCER DRUG, V18, P1157, DOI 10.1097/CAD.0b013e3282a215e9; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Lou Z, 2005, CANCER RES, V65, P1007; Maor S, 2006, J ENDOCRINOL, V191, P605, DOI 10.1677/joe.1.07016; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Mitchell DC, 2007, ONCOGENE, V26, P1739, DOI 10.1038/sj.onc.1209963; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nicolas M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200; Remsing LL, 2003, BIOCHEMISTRY-US, V42, P8313, DOI 10.1021/bi034091z; Rivard N, 2009, FRONT BIOSCI-LANDMRK, V14, P510, DOI 10.2741/3259; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Sun XJ, 2009, CANCER RES, V69, P6445, DOI 10.1158/0008-5472.CAN-09-1001; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Wang YT, 2008, J MOL BIOL, V380, P869, DOI 10.1016/j.jmb.2008.05.043; Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074; Yi TF, 2010, J BIOL CHEM, V285, P17811, DOI 10.1074/jbc.M110.130740; Zheng Y, 2009, CANCER RES, V69, P896, DOI 10.1158/0008-5472.CAN-08-2677	44	108	108	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	35					3973	3988		10.1038/onc.2011.568	http://dx.doi.org/10.1038/onc.2011.568			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22158040	Green Published, hybrid			2022-12-28	WOS:000308342800006
J	Kosa, P; Szabo, R; Molinolo, AA; Bugge, TH				Kosa, P.; Szabo, R.; Molinolo, A. A.; Bugge, T. H.			Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis	ONCOGENE			English	Article						inflammatory bowel disease; intestinal barrier; colon carcinogenesis	INFLAMMATORY-BOWEL-DISEASE; SERINE-PROTEASE MATRIPTASE; HEPATOCYTE GROWTH-FACTOR; COLORECTAL-CANCER; ULCERATIVE-COLITIS; MOUSE MODEL; MATRIX METALLOPROTEINASES; PLASMINOGEN ACTIVATION; INTESTINAL HOMEOSTASIS; BARRIER FUNCTION	Colitis-associated colorectal cancers are an etiologically distinct subgroup of colon cancers that occur in individuals suffering from inflammatory bowel disease and arise as a consequence of persistent exposure of hyperproliferative epithelial stem cells to an inflammatory microenvironment. An intrinsic defect in the intestinal epithelial barrier has been proposed to be one of several factors that contribute to the inappropriate immune response to the commensal microbiota that underlies inflammatory bowel disease. Matriptase is a membrane-anchored serine protease encoded by Suppression of Tumorigenicity-14 (ST14) that strengthens the intestinal epithelial barrier by promoting tight junction formation. Here, we show that intestinal epithelial-specific ablation of St14 in mice causes formation of colon adenocarcinoma with very early onset and high penetrance. Neoplastic progression is preceded by a chronic inflammation of the colon that resembles human inflammatory bowel disease and is promoted by the commensal microbiota. This study demonstrates that inflammation-associated colon carcinogenesis can be initiated and promoted solely by an intrinsic intestinal permeability barrier perturbation, establishes St14 as a critical tumor-suppressor gene in the mouse gastrointestinal tract and adds matriptase to the expanding list of pericellular proteases with tumor-suppressive functions. Oncogene (2012) 31, 3679-3695; doi:10.1038/onc.2011.545; published online 5 December 2011	[Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, Natl Inst Hlth, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov			NIDCR Intramural Research Program; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER	NIDCR Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Drs Jerrold M Ward, Robert D Cardiff and Stephen M Hewitt for pathology advice, Drs Vyomesh Patel and Kantima Leelahavanichkul for help with the array analysis, Dr Myrna Mandel for helicobacter testing, as well as Drs Silvio Gutkind and Mary Jo Danton for critically reviewing this manuscript. Histology was performed by Histoserv Inc. (Germantown, MD, USA). This study was supported by the NIDCR Intramural Research Program (THB).	Acuff HB, 2006, CANCER RES, V66, P7968, DOI 10.1158/0008-5472.CAN-05-4279; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bhatt AS, 2007, P NATL ACAD SCI USA, V104, P5771, DOI 10.1073/pnas.0606514104; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Buzza MS, 2010, P NATL ACAD SCI USA, V107, P4200, DOI 10.1073/pnas.0903923107; Cheng HX, 2009, CANCER RES, V69, P1828, DOI 10.1158/0008-5472.CAN-08-3728; Danese S, 2010, ONCOGENE, V29, P3313, DOI 10.1038/onc.2010.109; de Lau W, 2007, FRONT BIOSCI-LANDMRK, V12, P471, DOI 10.2741/2076; Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622; Engle SJ, 2002, CANCER RES, V62, P6362; Erdman SE, 2003, AM J PATHOL, V162, P691, DOI 10.1016/S0002-9440(10)63863-1; Feng SL, 2005, CLIN DIAGN LAB IMMUN, V12, P531, DOI 10.1128/CDLI.12.4.531-536.2005; Forbs D, 2005, INT J ONCOL, V27, P1061; Garrett WS, 2009, CANCER CELL, V16, P208, DOI 10.1016/j.ccr.2009.07.015; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; Hale LP, 2007, HELICOBACTER, V12, P598, DOI 10.1111/j.1523-5378.2007.00552.x; Hardwick JC, 2008, NAT REV CANCER, V8, P806, DOI 10.1038/nrc2467; Ihara S, 2002, J BIOL CHEM, V277, P16960, DOI 10.1074/jbc.M200673200; Jin XL, 2006, CANCER SCI, V97, P1327, DOI 10.1111/j.1349-7006.2006.00328.x; Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilpatrick LM, 2006, BLOOD, V108, P2616, DOI 10.1182/blood-2006-02-001073; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2009, AM J PATHOL, V175, P1453, DOI 10.2353/ajpath.2009.090240; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Lopez-Otin C, 2009, CELL CYCLE, V8, P3657, DOI 10.4161/cc.8.22.9956; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448; McCawley LJ, 2008, AM J PATHOL, V173, P1528, DOI 10.2353/ajpath.2008.080132; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Netzel-Arnett S, 2006, J BIOL CHEM, V281, P32941, DOI 10.1074/jbc.C600208200; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Okayasu I, 2002, J GASTROEN HEPATOL, V17, P1078, DOI 10.1046/j.1440-1746.2002.02853.x; Okayasu I, 1996, GUT, V39, P87, DOI 10.1136/gut.39.1.87; Owen KA, 2010, BIOCHEM J, V426, P219, DOI 10.1042/BJ20091448; Palavalli LH, 2009, NAT GENET, V41, P518, DOI 10.1038/ng.340; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riley LK, 1996, J CLIN MICROBIOL, V34, P942, DOI 10.1128/JCM.34.4.942-946.1996; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sales KU, 2010, NAT GENET, V42, P676, DOI 10.1038/ng.629; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Schreiber S, 2005, NAT REV GENET, V6, P376, DOI 10.1038/nrg1607; Shah SA, 1998, INFLAMM BOWEL DIS, V4, P196, DOI 10.1097/00054725-199808000-00004; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Su LP, 2009, GASTROENTEROLOGY, V136, P551, DOI 10.1053/j.gastro.2008.10.081; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2011, ANNU REV CELL DEV BI, V27, P213, DOI 10.1146/annurev-cellbio-092910-154247; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Van Limbergen J, 2009, ANNU REV GENOM HUM G, V10, P89, DOI 10.1146/annurev-genom-082908-150013; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Zeki SS, 2011, NAT REV GASTRO HEPAT, V8, P90, DOI 10.1038/nrgastro.2010.211; Zhang Y, 1998, CYTOGENET CELL GENET, V83, P56, DOI 10.1159/000015125	75	42	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3679	3695		10.1038/onc.2011.545	http://dx.doi.org/10.1038/onc.2011.545			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22139080	Green Accepted			2022-12-28	WOS:000307653800003
J	Paget, JA; Restall, IJ; Daneshmand, M; Mersereau, JA; Simard, MA; Parolin, DAE; Lavictoire, SJ; Amin, MS; Islam, S; Lorimer, IAJ				Paget, J. A.; Restall, I. J.; Daneshmand, M.; Mersereau, J. A.; Simard, M. A.; Parolin, D. A. E.; Lavictoire, S. J.; Amin, M. S.; Islam, S.; Lorimer, I. A. J.			Repression of cancer cell senescence by PKC iota	ONCOGENE			English	Article						atypical protein kinase-C; PIK3CA; breast cancer; glioblastoma; senescence; aurora kinase	KINASE-C-IOTA; SUPPRESSES TUMOR-GROWTH; BREAST-CANCER; IN-VIVO; PIK3CA MUTATIONS; CYCLE ARREST; AURORA-A; PROTEIN; ONCOGENE; PHOSPHORYLATION	Senescence is an irreversible growth arrest phenotype adopted by cells that has a key role in protecting organisms from cancer. There is now considerable interest in therapeutic strategies that reactivate this process to control the growth of cancer cells. Protein kinase-C iota (PKC iota) is a member of the atypical PKC family and an important downstream mediator in the phosphoinositide-3-kinase (PI-3-kinase) pathway. PKC iota expression was found to be upregulated in a subset of breast cancers and breast cancer cell lines. Activation of the PI-3-kinase pathway by introduction of mutant, oncogenic PIK3CA into breast mammary epithelial cells increased both the expression and activation of PKC iota. In breast cancer cells lines overexpressing PKC iota, depletion of PKC iota increased the number of senescent cells, as assessed by senescence-associated beta-galactosidase, morphology and bromodeoxyuridine incorporation. This phenomenon was not restricted to breast cancer cells, as it was also seen in glioblastoma cells in which PKC iota is activated by loss of PTEN. Senescence occurred in the absence of a detectable DNA-damage response, was dependent on p21 and was enhanced by the aurora kinase inhibitor VX-680, suggesting that senescence is triggered by defects in mitosis. Depletion of PKCi had no effect on senescence in normal mammary epithelial cell lines. We conclude that PKC iota is overexpressed in a subset of cancers where it functions to suppress premature senescence. This function appears to be restricted to cancer cells and inhibition of PKC iota may therefore be an effective way to selectively activate premature senescence in cancer cells. Oncogene (2012) 31, 3584-3596; doi:10.1038/onc.2011.524; published online 28 November 2011	[Lorimer, I. A. J.] Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, Res Inst, Ottawa, ON K1H 8L6, Canada; [Paget, J. A.; Restall, I. J.; Lorimer, I. A. J.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Amin, M. S.; Islam, S.] Ottawa Hosp, Dept Pathol, Ottawa, ON K1H 8L6, Canada; [Lorimer, I. A. J.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp, Reg Canc Ctr, Ctr Canc Therapeut, Res Inst, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca		Simard, Manon/0000-0001-5363-1699	Canadian Institutes of Health Research; Ottawa Regional Cancer Foundation; Canadian Institutes of Health Research Banting; Best MSc Scholarship; Ontario Graduate Scholarship in Science and Technology	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ottawa Regional Cancer Foundation; Canadian Institutes of Health Research Banting(Canadian Institutes of Health Research (CIHR)); Best MSc Scholarship; Ontario Graduate Scholarship in Science and Technology	This work was supported by grants from the Canadian Institutes of Health Research and the Ottawa Regional Cancer Foundation (to IAJL). JP was supported by a Canadian Institutes of Health Research Banting and Best MSc Scholarship. IR is supported by an Ontario Graduate Scholarship in Science and Technology. We thank Sharon Rowan and Mara Coiciu for their work on the initial characterization of PKC iota activation in breast cancer cells.	Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baldwin RM, 2008, ONCOGENE, V27, P3587, DOI 10.1038/sj.onc.1211027; Baldwin RM, 2006, ONCOGENE, V25, P2909, DOI 10.1038/sj.onc.1209312; Baldwin RM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-233; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Crowder RJ, 2009, CANCER RES, V69, P3955, DOI 10.1158/0008-5472.CAN-08-4450; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Freeley M, 2011, CELL SIGNAL, V23, P753, DOI 10.1016/j.cellsig.2010.10.013; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024; Gorgun G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; HERMAN JG, 1995, CANCER RES, V55, P4525; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Lawless C, 2010, EXP GERONTOL, V45, P772, DOI 10.1016/j.exger.2010.01.018; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lorimer IAJ, 2000, J IMMUNOL METHODS, V237, P147, DOI 10.1016/S0022-1759(99)00219-7; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; OConnor PM, 1997, CANCER RES, V57, P4285; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Peifer C, 2008, CHEMMEDCHEM, V3, P1810, DOI 10.1002/cmdc.200800195; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Xu LJ, 2006, J BIOL CHEM, V281, P4457, DOI 10.1074/jbc.M510721200; Yuan TL, 2011, CURR BIOL, V21, P173, DOI 10.1016/j.cub.2010.12.047; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	51	25	26	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3584	3596		10.1038/onc.2011.524	http://dx.doi.org/10.1038/onc.2011.524			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120720				2022-12-28	WOS:000307245600002
J	Bjorkman, M; Ostling, P; Harma, V; Virtanen, J; Mpindi, JP; Rantala, J; Mirtti, T; Vesterinen, T; Lundin, M; Sankila, A; Rannikko, A; Kaivanto, E; Kohonen, P; Kallioniemi, O; Nees, M				Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Mirtti, T.; Vesterinen, T.; Lundin, M.; Sankila, A.; Rannikko, A.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.			Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion	ONCOGENE			English	Article						prostate cancer; epigenetics; histone demethylase; migration; invasion; PHF8	LINKED MENTAL-RETARDATION; ANDROGEN-RECEPTOR; GLOBAL LEVELS; PREDICT RISK; PHD FINGERS; GENE; LYSINE-4; METHYLATION; H3; TRANSCRIPTION	Our understanding of key epigenetic regulators involved in specific biological processes and cancers is still incomplete, despite great progress in genome-wide studies of the epigenome. Here, we carried out a systematic, genome-wide analysis of the functional significance of 615 epigenetic proteins in prostate cancer (PrCa) cells. We used the high-content cell-spot microarray technology and siRNA silencing of PrCa cell lines for functional screening of cell proliferation, survival, androgen receptor (AR) expression, histone methylation and acetylation. Our study highlights subsets of epigenetic enzymes influencing different cancer cell phenotypes. Plant homeo domain (PHD) finger proteins have a key role in cell survival and histone methylation, whereas histone deacetylases were primarily involved in regulating AR expression. In contrast, JumonjiC-domain (JmjC) containing histone lysine demethylases (KDMs) mainly had an impact on cell proliferation. Our results show that the KDMs JARID1B, PHF8, KDM3A, KDM3B and KDM4A were highly expressed in clinical PrCa samples. The PHD-finger protein 8 (PHF8), a transcriptional coactivator with both PHD- and JmjC-domains, was moderately to strongly expressed in 80% of clinical PrCa samples, whereas 76% of normal and benign samples were negative or only showed weak PHF8 expression. Strong PHF8 expression correlated significantly with high Gleason grade and was borderline significant for poor prognosis. The results of functional PHF8 knockdown implicate a role in cell migration and invasion, as shown by cell motility and 3-D invasion assays. Our study suggests that various cellular phenotypes are regulated by distinct subsets of epigenetic enzymes. Proteins interpreting and modifying histone methylation, such as JmjC-domain and particularly PHD-finger proteins like PHF8, are activated in subsets of PrCa's and promote cancer relevant phenotypes. Oncogene (2012) 31, 3444-3456; doi:10.1038/onc.2011.512; published online 28 November 2011	[Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.] VTT Tech Res Ctr Finland, FI-20520 Turku, Varsinais Suomi, Finland; [Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.] Univ Turku, Ctr Biotechnol, FI-20520 Turku, Varsinais Suomi, Finland; [Bjorkman, M.; Ostling, P.; Harma, V.; Virtanen, J.; Mpindi, J-P; Rantala, J.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M.] Abo Akad Univ, FI-20520 Turku, Varsinais Suomi, Finland; [Ostling, P.; Mpindi, J-P; Mirtti, T.; Vesterinen, T.; Lundin, M.; Sankila, A.; Kallioniemi, O.] Univ Helsinki, FIMM, Helsinki, Finland; [Rannikko, A.] Univ Helsinki, Dept Urol, HUSLAB, Helsinki, Finland	VTT Technical Research Center Finland; University of Turku; Abo Akademi University; University of Helsinki; University of Helsinki	Nees, M (corresponding author), VTT Tech Res Ctr Finland, FI-20520 Turku, Varsinais Suomi, Finland.	matthias.nees@vtt.fi	Rannikko, Antti/ABB-8453-2020; Kohonen, Pekka/F-9596-2011; Nees, Matthias/AAT-5577-2020; Kallioniemi, Olli P/H-5111-2011; Vesterinen, Tiina J/O-8922-2016; Nees, Matthias/W-6596-2018	Rannikko, Antti/0000-0002-4261-3484; Kohonen, Pekka/0000-0002-7845-3611; Kallioniemi, Olli P/0000-0002-3231-0332; Nees, Matthias/0000-0002-9034-301X; Ostling, Paivi/0000-0001-5501-466X; Vesterinen, Tiina/0000-0003-2997-0337; Harma, Ville/0000-0001-5767-5226; Mirtti, Tuomas/0000-0003-0455-9891; Rantala, Juha/0000-0002-4999-5585	Academy of Finland [111456]; EU-EPITRON [LSHC-CT-2005-518417]; Marie Curie Canceromics [MEXT-CT-2003-2728]; Cancer Organizations Finland; Sigrid Juselius Foundation	Academy of Finland(Academy of Finland); EU-EPITRON(European Commission); Marie Curie Canceromics(European Commission); Cancer Organizations Finland; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	We thank Professor Tony Kouzarides from The Gurdon Institute, University of Cambridge for valuable suggestions and insights in constructing the epigenetic siRNA library. We thank Daniela Kleine-Kohlbrecher and Professor Kristian Helin from Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark, for insightful discussions, sharing unpublished results and PHF8 over expression construct. We thank Arho Virkki and Elmar Bucher for assistance with gene expression data normalization. This study was supported by grants from Academy of Finland (grant Nr. 111456 to MN, VH), EU-EPITRON (contract # LSHC-CT-2005-518417 to MB, OK), Marie Curie Canceromics (MEXT-CT-2003-2728 to OK), Cancer Organizations Finland and Sigrid Juselius Foundation (JPM, JR).	Abbott A, 2010, NATURE, V463, P596, DOI 10.1038/463596b; Abidi FE, 2007, CLIN GENET, V72, P19, DOI 10.1111/j.1399-0004.2007.00817.x; Baker LA, 2008, MUTAT RES-FUND MOL M, V647, P3, DOI 10.1016/j.mrfmmm.2008.07.004; Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Bjorkman M, 2008, INT J CANCER, V123, P2774, DOI 10.1002/ijc.23885; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860; Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662; Feng WJ, 2010, NAT STRUCT MOL BIOL, V17, P445, DOI 10.1038/nsmb.1778; Flamand V, 2010, J CANCER RES CLIN, V136, P1761, DOI 10.1007/s00432-010-0835-6; Fortschegger K, 2010, MOL CELL BIOL, V30, P3286, DOI 10.1128/MCB.01520-09; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Holst CR, 2003, CANCER RES, V63, P1596; Horton JR, 2010, NAT STRUCT MOL BIOL, V17, P38, DOI 10.1038/nsmb.1753; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kleine-Kohlbrecher D, 2010, MOL CELL, V38, P165, DOI 10.1016/j.molcel.2010.03.002; Koivisto AM, 2007, CLIN GENET, V72, P145, DOI 10.1111/j.1399-0004.2007.00836.x; Lange SS, 2008, P NATL ACAD SCI USA, V105, P10320, DOI 10.1073/pnas.0803181105; Laumonnier F, 2005, J MED GENET, V42, P780, DOI 10.1136/jmg.2004.029439; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Liu W, 2010, NATURE, V466, P508, DOI 10.1038/nature09272; Loenarz C, 2010, HUM MOL GENET, V19, P217, DOI 10.1093/hmg/ddp480; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Qi HH, 2010, NATURE, V466, P503, DOI 10.1038/nature09261; Qiao Y, 2008, CLIN GENET, V74, P134, DOI 10.1111/j.1399-0004.2008.01028.x; Rantala JK, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-162; Rantala JK, 2010, NEOPLASIA, V12, P877, DOI 10.1593/neo.10548; Rose NR, 2008, J MED CHEM, V51, P7053, DOI 10.1021/jm800936s; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Shi XB, 2007, J BIOL CHEM, V282, P2450, DOI 10.1074/jbc.C600286200; Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179; Smith EH, 2007, HUM MOL GENET, V16, P3136, DOI 10.1093/hmg/ddm275; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wolf SS, 2007, ARCH BIOCHEM BIOPHYS, V460, P56, DOI 10.1016/j.abb.2007.01.017; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; Zhu ZQ, 2010, CELL RES, V20, P794, DOI 10.1038/cr.2010.75	58	80	84	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3444	3456		10.1038/onc.2011.512	http://dx.doi.org/10.1038/onc.2011.512			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22120715				2022-12-28	WOS:000306566400005
J	Galluzzi, L; Kepp, O; Kroemer, G				Galluzzi, L.; Kepp, O.; Kroemer, G.			Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy	ONCOGENE			English	Editorial Material							INDEPENDENT CELL-DEATH; APOPTOTIC CELLS; PHOSPHOLIPASE A(2); VITAL FUNCTIONS; REGENERATION; PROLIFERATION; MECHANISMS; MIGRATION; EFFECTORS; RELEASE	Chemo- and radio-therapeutic regimens frequently kill cancer cells by inducing apoptosis, a cell-death subroutine that involves the activation of a particular class of proteases called caspases. In a recent issue of Nature Medicine, Huang et al. (2011) show that caspase activation in dying tumor cells causes the release of soluble lipid messengers, notably prostaglandin E-2, that stimulate tumor cell proliferation. In this short review, we will discuss the clinical and therapeutic implications of these findings. Oncogene (2012) 31, 2805-2808; doi:10.1038/onc.2011.459; published online 3 October 2011	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, PR1, F-94805 Villejuif, France; [Galluzzi, L.; Kepp, O.] Univ Paris 11, Le Kremlin Bicetre, France; [Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	Galluzzi, Lorenzo/AAG-6432-2019; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi, Lorenzo/K-2709-2012; Kepp, Oliver/GPX-8627-2022	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Galluzzi, Lorenzo/0000-0003-2257-8500; 				Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chera S, 2009, DEV CELL, V17, P279, DOI 10.1016/j.devcel.2009.07.014; Fan Y, 2008, DEV CELL, V14, P399, DOI 10.1016/j.devcel.2008.01.003; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Galluzzi L, 2009, BBA-BIOENERGETICS, V1787, P402, DOI 10.1016/j.bbabio.2008.09.006; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Tait SWG, 2008, ONCOGENE, V27, P6452, DOI 10.1038/onc.2008.311; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200	31	56	68	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2805	2808		10.1038/onc.2011.459	http://dx.doi.org/10.1038/onc.2011.459			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21963852				2022-12-28	WOS:000305277900001
J	Sun, Z; Cao, X; Jiang, MM; Qiu, Y; Zhou, H; Chen, L; Qin, B; Wu, H; Jiang, F; Chen, J; Liu, J; Dai, Y; Chen, HF; Hu, QY; Wu, Z; Zeng, JZ; Yao, XS; Zhang, XK				Sun, Z.; Cao, X.; Jiang, M-M; Qiu, Y.; Zhou, H.; Chen, L.; Qin, B.; Wu, H.; Jiang, F.; Chen, J.; Liu, J.; Dai, Y.; Chen, H-F; Hu, Q-Y; Wu, Z.; Zeng, J-Z; Yao, X-S; Zhang, X-K			Inhibition of beta-catenin signaling by nongenomic action of orphan nuclear receptor Nur77	ONCOGENE			English	Article						Nur77; beta-catenin; nongenomic; cardenolide; cancer	COLON-CANCER CELLS; GENE-EXPRESSION; BREAST-CANCER; RXR-ALPHA; NGFI-B; APOPTOSIS; WNT; DEGRADATION; PATHWAY; PROTEIN	Dysregulation of beta-catenin turnover due to mutations of its regulatory proteins including adenomatous polyposis coli (APC) and p53 is implicated in the pathogenesis of cancer. Thus, intensive effort is being made to search for alternative approaches to reduce abnormally activated beta-catenin in cancer cells. Nur77, an orphan member of the nuclear receptor superfamily, has a role in the growth and apoptosis of cancer cells. Here, we reported that Nur77 could inhibit transcriptional activity of beta-catenin by inducing beta-catenin degradation via proteasomal degradation pathway that is glycogen synthase kinase 3 beta and Siah-1 independent. Nur77 induction of beta-catenin degradation required both the N-terminal region of Nur77, which was involved in Nur77 ubiquitination, and the C-terminal region, which was responsible for beta-catenin binding. Nur77/DDBD, a Nur77 mutant lacking its DNA-binding domain, resided in the cytoplasm, interacted with beta-catenin, and induced beta-catenin degradation, demonstrating that Nur77-mediated beta-catenin degradation was independent of its DNA binding and transactivation, and might occur in the cytoplasm. In addition, we reported our identification of two digitalis-like compounds (DLCs), H-9 and ATE-i2-b4, which potently induced Nur77 expression and beta-catenin degradation in SW620 colon cancer cells expressing mutant APC protein in vitro and in animals. DLC-induced Nur77 protein was mainly found in the cytoplasm, and inhibition of Nur77 nuclear export by the CRM1-dependent nuclear export inhibitor leptomycin B or Jun N-terminal kinase inhibitor prevented the effect of DLC on inducing beta-catenin degradation. Together, our results demonstrate that beta-catenin can be degraded by cytoplasmic Nur77 through their interaction and identify H-9 and ATE-i2-b4 as potent activators of the Nur77-mediated pathway for beta-catenin degradation. Oncogene (2012) 31, 2653-2667; doi:10.1038/onc.2011.448; published online 10 October 2011	[Dai, Y.; Yao, X-S] Jinan Univ, Inst Tradit Chinese Med, Guangzhou 510632, Guangdong, Peoples R China; [Dai, Y.; Yao, X-S] Jinan Univ, Inst Nat Prod, Guangzhou 510632, Guangdong, Peoples R China; [Sun, Z.; Qiu, Y.; Zhou, H.; Chen, L.; Qin, B.; Wu, H.; Jiang, F.; Liu, J.; Chen, H-F; Wu, Z.; Zeng, J-Z] Xiamen Univ, Sch Pharmaceut Sci, Xiamen, Peoples R China; [Cao, X.; Zhou, H.; Chen, J.; Liu, J.; Hu, Q-Y; Zhang, X-K] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA; [Jiang, M-M] Guangdong Pharmaceut Univ, Guangzhou, Guangdong, Peoples R China	Jinan University; Jinan University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute; Guangdong Pharmaceutical University	Yao, XS (corresponding author), Jinan Univ, Inst Tradit Chinese Med, Guangzhou 510632, Guangdong, Peoples R China.	yaoxinsheng@vip.tom.com; xzhang@sanfordburnham.org	Wu, Hua/W-4204-2019; Wu, Z/G-3993-2010; Zeng, JZ/G-3377-2010; Chen, HF/G-3376-2010		National Institutes of Health [CA140980, GM089927]; US Army Medical Research and Material Command; Xiamen University; National Natural Science Foundation of China (NSFC) [30971445, NSCF-81001373]; NSFC/Hong Kong Research Grants Council (RGC) [30931160431]; Natural Science Foundation of Fujian Province [2009J01198]; NATIONAL CANCER INSTITUTE [R01CA140980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089927] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Xiamen University(Xiamen University); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); NSFC/Hong Kong Research Grants Council (RGC)(Hong Kong Research Grants CouncilNational Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Zhuohua Zhang for providing beta-catenin expression vectors and TOPFLASH reporter plasmid. This work is in part supported by grants from the National Institutes of Health (CA140980, GM089927), the US Army Medical Research and Material Command, the 985 Project from Xiamen University, the National Natural Science Foundation of China (NSFC; 30971445 and NSCF-81001373) and NSFC/Hong Kong Research Grants Council (RGC; 30931160431) and the Natural Science Foundation of Fujian Province (2009J01198).	Camacho CP, 2009, CLIN ENDOCRINOL, V70, P475, DOI 10.1111/j.1365-2265.2008.03349.x; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Chao LC, 2008, MOL ENDOCRINOL, V22, P2596, DOI 10.1210/me.2008-0161; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Chtarbova S, 2002, BIOCHEM J, V367, P723, DOI 10.1042/BJ20020699; Dawson MI, 2001, CANCER RES, V61, P4723; Dillard AC, 2008, NUTR CANCER, V60, P97, DOI 10.1080/01635580701586754; Dillard AC, 2007, MOL CARCINOGEN, V46, P315, DOI 10.1002/mc.20280; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hutchinson DA, 2007, P NATL ACAD SCI USA, V104, P2265, DOI 10.1073/pnas.0610785104; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jiang MM, 2008, CHEM PHARM BULL, V56, P1005, DOI 10.1248/cpb.56.1005; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kitagawa H, 2007, MOL CELL BIOL, V27, P7486, DOI 10.1128/MCB.00409-07; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liang B, 2007, EXP CELL RES, V313, P2833, DOI 10.1016/j.yexcr.2007.04.032; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mullican SE, 2007, NAT MED, V13, P730, DOI 10.1038/nm1579; Nesher M, 2007, LIFE SCI, V80, P2093, DOI 10.1016/j.lfs.2007.03.013; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Safe S, 2008, CANCER LETT, V269, P326, DOI 10.1016/j.canlet.2008.04.021; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Steyn PS, 1998, NAT PROD REP, V15, P397; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Ward RD, 2009, BIOFACTORS, V35, P528, DOI 10.1002/biof.66; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu FT, 2007, FRONT BIOSCI-LANDMRK, V12, P700, DOI 10.2741/2094; Wu H, 2011, FASEB J, V25, P192, DOI 10.1096/fj.10-166462; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yochum GS, 2007, J BIOL CHEM, V282, P871, DOI 10.1074/jbc.M609391200; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhang XK, 2007, EXPERT OPIN THER TAR, V11, P69, DOI 10.1517/14728222.11.1.69; Zhao HY, 2010, J ASIAN NAT PROD RES, V12, P793, DOI 10.1080/10286020.2010.505187; Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023	61	42	45	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	21					2653	2667		10.1038/onc.2011.448	http://dx.doi.org/10.1038/onc.2011.448			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21986938	Green Accepted			2022-12-28	WOS:000304523500005
J	Santo, EE; Ebus, ME; Koster, J; Schulte, JH; Lakeman, A; van Sluis, P; Vermeulen, J; Gisselsson, D; Ora, I; Lindner, S; Buckley, PG; Stallings, RL; Vandesompele, J; Eggert, A; Caron, HN; Versteeg, R; Molenaar, JJ				Santo, E. E.; Ebus, M. E.; Koster, J.; Schulte, J. H.; Lakeman, A.; van Sluis, P.; Vermeulen, J.; Gisselsson, D.; Ora, I.; Lindner, S.; Buckley, P. G.; Stallings, R. L.; Vandesompele, J.; Eggert, A.; Caron, H. N.; Versteeg, R.; Molenaar, J. J.			Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma	ONCOGENE			English	Article						FOXR1; FOXO; forkhead-box; neuroblastoma; MLL; 11q23	FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR GENE; ALVEOLAR RHABDOMYOSARCOMA; EXPRESSION PATTERNS; CELL-SURVIVAL; IN-SILICO; IDENTIFICATION; CANCER; COMMON; MLL	Neuroblastoma tumors frequently show loss of heterozygosity of chromosome 11q with a shortest region of overlap in the 11q23 region. These deletions are thought to cause inactivation of tumor suppressor genes leading to haploinsufficiency. Alternatively, micro-deletions could lead to gene fusion products that are tumor driving. To identify such events we analyzed a series of neuroblastomas by comparative genomic hybridization and single-nucleotide polymorphism arrays and integrated these data with Affymetrix mRNA profiling data with the bioinformatic tool R2 (http://r2.amc.nl). We identified three neuroblastoma samples with small interstitial deletions at 11q23, upstream of the forkhead-box R1 transcription factor (FOXR1). Genes at the proximal side of the deletion were fused to FOXR1, resulting in fusion transcripts of MLL-FOXR1 and PAFAH1B2-FOXR1. FOXR1 expression has only been detected in early embryogenesis. Affymetrix microarray analysis showed high FOXR1 mRNA expression exclusively in the neuroblastomas with micro-deletions and rare cases of other tumor types, including osteosarcoma cell line HOS. RNAi silencing of FOXR1 strongly inhibited proliferation of HOS cells and triggered apoptosis. Expression profiling of these cells and reporter assays suggested that FOXR1 is a negative regulator of fork-head box factor-mediated transcription. The neural crest stem cell line JoMa1 proliferates in culture conditional to activity of a MYC-ER transgene. Over-expression of the wild-type FOXR1 could functionally replace MYC and drive proliferation of JoMa1. We conclude that FOXR1 is recurrently activated in neuroblastoma by intrachromosomal deletion/fusion events, resulting in overexpression of fusion transcripts. Forkhead-box transcription factors have not been previously implicated in neuroblastoma pathogenesis. Furthermore, this is the first identification of intrachromosomal fusion genes in neuroblastoma. Oncogene (2012) 31, 1571-1581; doi:10.1038/onc.2011.344; published online 22 August 2011	[Santo, E. E.; Ebus, M. E.; Koster, J.; Lakeman, A.; van Sluis, P.; Versteeg, R.; Molenaar, J. J.] Univ Amsterdam, Acad Med Ctr, Dept Oncogenom, NL-1105 AZ Amsterdam, Netherlands; [Schulte, J. H.; Lindner, S.; Eggert, A.] Univ Childrens Hosp Essen, Dept Pediat Oncol, Essen, Germany; [Vermeulen, J.; Vandesompele, J.] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium; [Gisselsson, D.; Ora, I.] Lund Univ, Dept Clin Genet, Lund, Sweden; [Buckley, P. G.; Stallings, R. L.] Royal Coll Surgeons Ireland, Natl Childrens Res Ctr, Dept Canc Genet, Dublin, Ireland; [Caron, H. N.] Univ Amsterdam, Acad Med Ctr, Dept Pediat Oncol, Emma Kinderziekenhuis, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; Ghent University; Ghent University Hospital; Lund University; National Children's Research Centre (NCRC); Royal College of Surgeons - Ireland; Trinity College Dublin; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam	Molenaar, JJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Oncogenom, M1-132,Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.	j.j.molenaar@amc.uva.nl	Eggert, Angelika/AAE-6907-2022; Koster, Jan/C-5934-2008; Schulte, Johannes H./V-2474-2018; Schulte, Johannes H/G-3981-2010; Øra, Ingrid/J-2596-2013; Vandesompele, Jo/W-3411-2018; Stallings, Raymond/A-7213-2008; Versteeg, Rogier/AAQ-1765-2020	Eggert, Angelika/0000-0003-3476-8184; Koster, Jan/0000-0002-0890-7585; Øra, Ingrid/0000-0002-3931-4125; Vandesompele, Jo/0000-0001-6274-0184; Schulte, Johannes Hubertus/0000-0003-0671-1201; Versteeg, Rogier/0000-0001-7172-0388	Stichting Koningin Wilhelmina Fonds (KWF); Stichting Kindergeneeskundig Kankeronderzoek (SKK); Stichting Kinderen Kankervrij (KiKa)	Stichting Koningin Wilhelmina Fonds (KWF); Stichting Kindergeneeskundig Kankeronderzoek (SKK); Stichting Kinderen Kankervrij (KiKa)	This work was supported by the Stichting Koningin Wilhelmina Fonds (KWF), Stichting Kindergeneeskundig Kankeronderzoek (SKK) and the Stichting Kinderen Kankervrij (KiKa).	Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; DAVIS RJ, 1994, CANCER RES, V54, P2869; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gomez-Ferreria MA, 2003, J MOL BIOL, V329, P631, DOI 10.1016/S0022-2836(03)00524-2; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; HAMPTON GM, 1994, CANCER RES, V54, P4586; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hoeller S, 2010, HISTOPATHOLOGY, V57, P73, DOI 10.1111/j.1365-2559.2010.03600.x; Katoh M, 2004, INT J MOL MED, V14, P463; Katoh M, 2004, INT J ONCOL, V25, P219; Katoh M, 2004, INT J ONCOL, V24, P1339; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lee ASG, 2000, BRIT J CANCER, V83, P750, DOI 10.1054/bjoc.2000.1366; Lefever S, 2009, NUCLEIC ACIDS RES, V37, pD942, DOI 10.1093/nar/gkn777; Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924; Mahony S, 2007, NUCLEIC ACIDS RES, V35, pW253, DOI 10.1093/nar/gkm272; Martinez MJ, 2007, BIOINFORMATICS, V23, P21, DOI 10.1093/bioinformatics/btl531; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Maurer J, 2007, DIFFERENTIATION, V75, P580, DOI 10.1111/j.1432-0436.2007.00164.x; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nowacki S, 2008, ONCOGENE, V27, P3329, DOI 10.1038/sj.onc.1210996; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Pulido HA, 2000, CANCER RES, V60, P6677; Schones DE, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-19; Schuller U, 2007, MOL CELL BIOL, V27, P8259, DOI 10.1128/MCB.00707-07; Schuff M, 2006, INT J DEV BIOL, V50, P429, DOI 10.1387/ijdb.052126ms; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Wakaguri H, 2008, NUCLEIC ACIDS RES, V36, pD97, DOI 10.1093/nar/gkm901; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Wlodarska I, 2005, LEUKEMIA, V19, P1299, DOI 10.1038/sj.leu.2403813; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245	41	43	44	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	12					1571	1581		10.1038/onc.2011.344	http://dx.doi.org/10.1038/onc.2011.344			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860421				2022-12-28	WOS:000302132000009
J	Chao, A; Lin, CY; Lee, YS; Tsai, CL; Wei, PC; Hsueh, S; Wu, TI; Tsai, CN; Wang, CJ; Chao, AS; Wang, TH; Lai, CH				Chao, A.; Lin, C-Y; Lee, Y-S; Tsai, C-L; Wei, P-C; Hsueh, S.; Wu, T-I; Tsai, C-N; Wang, C-J; Chao, A-S; Wang, T-H; Lai, C-H			Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2	ONCOGENE			English	Article						microRNA; miR-187; Dab2; epithelial-mesenchymal transition (EMT)	MESENCHYMAL TRANSITION; STEM-CELLS; EXPRESSION; CARCINOMA; EMT; GENE; OVEREXPRESSION; RESISTANCE; SIGNATURES; PROGNOSIS	MicroRNAs (miRNAs) play important roles in tumorigenesis by regulating oncogenes and tumor-suppressor genes. In this study, miR-187 and miR-200a were found to be expressed at higher levels in ovarian cancers than in benign tumors. In patients with ovarian cancer, however, higher levels of miR-187 and miR-200a expression were paradoxically associated with better OS and recurrence-free survival. Further, multivariate analysis showed that miR-187 served as an independent prognostic factor for patients with ovarian cancer (n = 176). Computational prediction and microarray results indicated that miR-187 directly targeted Disabled homolog-2 (Dab2), and luciferase reporter assays confirmed that the target site of miR-187 was located at the 3'-UTR of the Dab2 gene. Generally considered as a tumor-suppressor gene, Dab2 may actually promote tumor progression in advanced cancers through epithelial-to-mesenchymal transition (EMT). Ectopic expression of miR-187 in cancer cells promoted cell proliferation, but continued overexpression of miR-187 suppressed Dab2 and inhibited migration. Suppression of miR-187 upregulated Dab2, which, by inhibiting E-cadherin levels while stimulating vimentin and phospho-FAK levels, promoted EMT. Reduced ovarian cancer Dab2 histoscores correlated with high miR-187 levels and improved outcomes of patients. Collectively, these results demonstrate distinct dual roles of Dab2 in cell proliferation and tumor progression. In the initial steps of tumorigenesis, upregulated miR-187 suppresses Dab2, promoting cell proliferation. During the later stages, however, continued increased levels of miR-187 inhibits the Dab2-dependent EMT that is associated with tumor invasiveness, which is presumed to be the reason why cancers with high miR-187 levels were associated with better survivals. Oncogene (2012) 31, 764-775; doi:10.1038/onc.2011.269; published online 4 July 2011	[Chao, A.; Lin, C-Y; Tsai, C-L; Wei, P-C; Wu, T-I; Wang, C-J; Chao, A-S; Wang, T-H; Lai, C-H] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Tao Yuan 333, Taiwan; [Chao, A.; Lin, C-Y; Tsai, C-L; Wei, P-C; Hsueh, S.; Wu, T-I; Wang, C-J; Chao, A-S; Wang, T-H; Lai, C-H] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Lee, Y-S; Wang, T-H] Chang Gung Mem Hosp, Genom Med Res Core Lab, Gwei Shan, Taiwan; [Lee, Y-S] Ming Chuan Univ, Dept Biotechnol, Tao Yuan, Taiwan; [Wei, P-C; Wang, T-H] Chang Gung Univ, Grad Inst Biomed Sci, Gwei Shan, Taiwan; [Hsueh, S.] Chang Gung Mem Hosp, Dept Clin Pathol, Tao Yuan 333, Taiwan; [Tsai, C-N] Chang Gung Univ, Grad Inst Clin Med Sci, Gwei Shan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Ming Chuan University; Chang Gung Memorial Hospital	Wang, TH (corresponding author), Chang Gung Mem Hosp, Dept Obstet & Gynecol, 5 Fu Hsing St, Tao Yuan 333, Taiwan.	knoxtn@cgmh.org.tw; sh46erry@ms6.hinet.net	Tsai, Chi-Neu/AAZ-2558-2020; Tsai, Chi neu/C-3373-2011; Lai, Chyong-Huey/AAE-5731-2022	Tsai, Chi-Neu/0000-0002-5940-0696; Tsai, Chi neu/0000-0002-5940-0696; Lai, Chyong-Huey/0000-0002-9977-9645	National Science Council [NSC99-2314-B-182A-087-MY3]; National Research Program for Genomic Medicine [NSC97-3112-B-001-020]; Chang Gung Medical Foundation [CMRPG360953/4, 391451, 95-1364B, 97-1444C, 99-2072C, 99-2411C]; Department of Health [DOH99-TD-B-111-005, DOH99-TD-C-111-006]	National Science Council(Ministry of Science and Technology, Taiwan); National Research Program for Genomic Medicine(Ministry of Science and Technology, Taiwan); Chang Gung Medical Foundation; Department of Health	We thank Ching-Ling Wang, Jung-Erh Yang and Ying-Yu Lin for technical assistance; the Division of Gynecologic Oncology of Chang Gung Memorial Hospital for clinical data retrieval; Shih-Yee Mimi Wang (University of Illinois College of Medicine, Rockford) for language editing and Professor Ching-Ping Tseng (Chang Gung University) for discussion and advices. This study was supported by grants from the National Science Council (NSC99-2314-B-182A-087-MY3 to AC), the National Research Program for Genomic Medicine (NSC97-3112-B-001-020 to Y-SL), the Chang Gung Medical Foundation (CMRPG360953/4, 391451 to AC; IRB No. 95-1364B, 97-1444C, 99-2072C, 99-2411C) and the Department of Health (DOH99-TD-B-111-005 to C-HL; DOH99-TD-C-111-006 to AC and T-HW).	[Anonymous], 2007, PRED MICRORNA TARG; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Berek JS, 2010, BEREK HACKERS GYNECO, P444; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Chao A, 2006, INT J CANCER, V119, P91, DOI 10.1002/ijc.21813; Chao A, 2010, CANCER LETT, V291, P99, DOI 10.1016/j.canlet.2009.10.005; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Choi JH, 2006, ENDOCR-RELAT CANCER, V13, P641, DOI 10.1677/erc.1.01057; Chung CM, 2005, MOL CARCINOGEN, V43, P165, DOI 10.1002/mc.20098; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; Hu XX, 2009, GYNECOL ONCOL, V114, P457, DOI 10.1016/j.ygyno.2009.05.022; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Lee YS, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp168; Liao CJ, 2011, GYNECOL ONCOL, V120, P135, DOI 10.1016/j.ygyno.2010.10.005; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai MS, 2007, STEM CELLS, V25, P2511, DOI 10.1634/stemcells.2007-0023; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang WL, 2004, CANCER RES, V64, P1534, DOI 10.1158/0008-5472.CAN-03-2928	40	114	122	3	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					764	775		10.1038/onc.2011.269	http://dx.doi.org/10.1038/onc.2011.269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725366				2022-12-28	WOS:000300222100009
J	Lu, D; Han, C; Wu, T				Lu, D.; Han, C.; Wu, T.			Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/beta-catenin signaling axis	ONCOGENE			English	Article						microsomal prostaglandin E synthase-1; beta-catenin; early growth response 1; hepatocellular carcinoma; liver	HUMAN HEPATOCELLULAR-CARCINOMA; BETA-CATENIN; CELL-GROWTH; CYCLIN D1; HEPATITIS-B; EXPRESSION; CYCLOOXYGENASE-2; TRANSCRIPTION; COX-2; INHIBITION	Microsomal prostaglandin E synthase-1 (mPGES-1) is a key enzyme that couples with cyclooxygenase-2 (COX-2) for the production of PGE2. Although COX-2 is known to mediate the growth and progression of several human cancers including hepatocellular carcinoma (HCC), the role of mPGES-1 in hepatocarcinogenesis is not well established. This study provides novel evidence for a key role of mPGES-1 in HCC growth and progression. Forced overexpression of mPGES-1 in two HCC cell lines (Hep3B and Huh7) increased tumor cell growth, clonogenic formation, migration and invasion, whereas knockdown of mPGES-1 inhibited these parameters, in vitro. In a mouse tumor xenograft model, mPGES-1 overexpressed cells formed palpable tumors at earlier time points and developed larger tumors when compared with the control (P<0.01); in contrast, mPGES-1 knockdown delayed tumor development and reduced tumor size (P<0.01). Mechanistically, mPGES-1-induced HCC cell proliferation, invasion and migration involve PGE2 production and activation of early growth response 1 (EGR1) and beta-catenin. Specifically, mPGES1-derived PGE2 induces the formation of EGR1-beta-catenin complex, which interacts with T-cell factor 4/lymphoid enhancer factor 1 transcription factors and activates the expression of b-catenin downstream genes. Our findings depict a novel crosstalk between mPGES-1/PGE2 and EGR1/beta-catenin signaling that is critical for hepatocarcinogenesis. Oncogene (2012) 31, 842-857; doi: 10.1038/onc.2011.287; published online 11 July 2011	[Lu, D.; Han, C.; Wu, T.] Tulane Univ, Sch Med, Dept Pathol & Lab Med, New Orleans, LA 70112 USA; [Lu, D.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tulane University; Tongji University	Wu, T (corresponding author), Tulane Univ, Sch Med, Dept Pathol & Lab Med, 1430 Tulane Ave,SL-79, New Orleans, LA 70112 USA.	twu@tulane.edu			National Institutes of Health [CA106280, CA102325, CA134568, DK077776, CA137729]; NATIONAL CANCER INSTITUTE [R03CA137729, R01CA134568, R01CA106280, R01CA102325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK077776, R01DK077776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by the National Institutes of Health grants CA106280, CA102325, CA134568 and DK077776 (to TW) and CA137729 (to CH).	Bae SH, 2001, CLIN CANCER RES, V7, P1410; Baron JA, 2006, GASTROENTEROLOGY, V131, P1674, DOI 10.1053/j.gastro.2006.08.079; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Branda M, 2006, HEPATOLOGY, V43, P891, DOI 10.1002/hep.21196; Caspi M, 2008, ONCOGENE, V27, P3546, DOI 10.1038/sj.onc.1211026; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cheng ASL, 2004, INT J ONCOL, V24, P853; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Couzin J, 2004, SCIENCE, V306, P1673, DOI 10.1126/science.306.5702.1673; DANESCH U, 1994, J BIOL CHEM, V269, P27258; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI 10.2217/FON.09.67; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045; Kang YJ, 2007, PROG LIPID RES, V46, P108, DOI 10.1016/j.plipres.2007.01.001; Kapoor M, 2007, J BIOL CHEM, V282, P5356, DOI 10.1074/jbc.M610153200; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Kondo M, 1999, CLIN CANCER RES, V5, P4005; Lee KH, 2009, CLIN EXP METASTAS, V26, P685, DOI 10.1007/s10585-009-9266-7; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008-5472.CAN-07-2295; Lim K, 2009, MOL CANCER THER, V8, P3046, DOI 10.1158/1535-7163.MCT-09-0551; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Ma JJ, 2009, J BIOL CHEM, V284, P34600, DOI 10.1074/jbc.M109.016246; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Monga SPS, 2006, HEPATOLOGY, V43, P401, DOI 10.1002/hep.21110; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moon Y, 2007, BIOCHEM PHARMACOL, V73, P125, DOI 10.1016/j.bcp.2006.08.017; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; Murakami M, 2006, CURR PHARM DESIGN, V12, P943, DOI 10.2174/138161206776055912; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Ngiam N, 2010, AM J RESP CRIT CARE, V181, P947, DOI 10.1164/rccm.200908-1297OC; Parra E, 2009, ONCOL REP, V22, P1513, DOI 10.3892/or_00000595; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Rahman MA, 2001, CLIN CANCER RES, V7, P1325; Saegusa M, 2004, AM J PATHOL, V164, P1739, DOI 10.1016/S0002-9440(10)63732-7; Saegusa M, 2008, J PATHOL, V216, P521, DOI 10.1002/path.2404; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Shiota G, 1999, HEPATO-GASTROENTEROL, V46, P407; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Takii Y, 2007, LIVER INT, V27, P989, DOI 10.1111/j.1478-3231.2007.01530.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiel G, 2010, CELL CALCIUM, V47, P397, DOI 10.1016/j.ceca.2010.02.005; Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651; Thoren S, 2003, J BIOL CHEM, V278, P22199, DOI 10.1074/jbc.M303227200; Vanchieri C, 2004, J NATL CANCER I, V96, P1734, DOI 10.1093/jnci/96.23.1734; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wu T, 2006, CANCER TREAT REV, V32, P28, DOI 10.1016/j.ctrv.2005.10.004; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	67	33	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					842	857		10.1038/onc.2011.287	http://dx.doi.org/10.1038/onc.2011.287			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743491	Green Accepted			2022-12-28	WOS:000300615800004
J	Gu, Y; Lin, S; Li, JL; Nakagawa, H; Chen, Z; Jin, B; Tian, L; Ucar, DA; Shen, H; Lu, J; Hochwald, SN; Kaye, FJ; Wu, L				Gu, Y.; Lin, S.; Li, J-L; Nakagawa, H.; Chen, Z.; Jin, B.; Tian, L.; Ucar, D. A.; Shen, H.; Lu, J.; Hochwald, S. N.; Kaye, F. J.; Wu, L.			Altered LKB1/CREB-regulated transcription co-activator (CRTC) signaling axis promotes esophageal cancer cell migration and invasion	ONCOGENE			English	Article						esophageal cancer; LKB1; CRTC co-activator; LYPD3; migration; invasion	PEUTZ-JEGHERS-SYNDROME; TUMOR-SUPPRESSOR; GENETIC ALTERATIONS; HUMAN HOMOLOG; LKB1; GROWTH; CREB; EXPRESSION; LKB1/STK11; TUMORIGENESIS	LKB1 is a tumor susceptibility gene for the Peutz-Jeghers cancer syndrome and is a target for mutational inactivation in sporadic human malignancies. LKB1 encodes a serine/threonine kinase that has critical roles in cell growth, polarity and metabolism. A novel and important function of LKB1 is its ability to regulate the phosphorylation of CREB-regulated transcription co-activators (CRTCs) whose aberrant activation is linked with oncogenic activities. However, the roles and mechanisms of LKB1 and CRTC in the pathogenesis of esophageal cancer have not been previously investigated. In this study, we observed altered LKB1-CRTC signaling in a subset of human esophageal cancer cell lines and patient samples. LKB1 negatively regulates esophageal cancer cell migration and invasion in vitro. Mechanistically, we determined that CRTC signaling becomes activated because of LKB1 loss, which results in the transcriptional activation of specific downstream targets including LYPD3, a critical mediator for LKB1 loss-of-function. Our data indicate that de-regulated LKB1-CRTC signaling might represent a crucial mechanism for esophageal cancer progression. Oncogene (2012) 31, 469-479; doi: 10.1038/onc.2011.247; published online 27 June 2011	[Gu, Y.; Lin, S.; Chen, Z.; Jin, B.; Tian, L.; Shen, H.; Wu, L.] Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, Gainesville, FL 32610 USA; [Li, J-L] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA; [Nakagawa, H.] Univ Penn, Dept Med, Div Gastroenterol, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Ucar, D. A.; Hochwald, S. N.] Univ Florida, Dept Surg, Shands Canc Ctr, Gainesville, FL 32610 USA; [Lu, J.] Univ Florida, Dept Biochem & Mol Biol, Shands Canc Ctr, Gainesville, FL 32610 USA; [Kaye, F. J.] Univ Florida, Dept Med, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; Sanford Burnham Prebys Medical Discovery Institute; University of Pennsylvania; Pennsylvania Medicine; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, L (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, 2033 Mowry Rd,Room 362, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019; chen, zirong/S-4042-2016; Lu, Jianrong/F-5240-2013	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X; chen, zirong/0000-0002-0589-4619; Lu, Jianrong/0000-0002-4969-6040; /0000-0002-0949-5068	University of Florida Shands Cancer Center	University of Florida Shands Cancer Center	We thank Jenny Huang for critical reading of our paper, Marda Jorgensen for helping with immunohistochemical staining and the University of Florida CTSI Biorepository for providing human esophageal tumor samples. This work was supported in part by the University of Florida Shands Cancer Center Startup fund (L Wu).	Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Altarejos JY, 2008, NAT MED, V14, P1112, DOI 10.1038/nm.1866; Altarejos JY, 2011, NAT REV MOL CELL BIO, V12, P141, DOI 10.1038/nrm3072; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Breuillaud L, 2009, NAT MED, V15, P989, DOI 10.1038/nm0909-989; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026; Chen Jie, 2010, Genes Cancer, V1, P822, DOI 10.1177/1947601910383564; Chen Y, 2005, CANCER RES, V65, P10838, DOI 10.1158/0008-5472.CAN-05-1091; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228; Guldberg P, 1999, ONCOGENE, V18, P1777, DOI 10.1038/sj.onc.1202486; Hansen LV, 2008, INT J CANCER, V122, P734, DOI 10.1002/ijc.23082; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Iourgenko V, 2003, P NATL ACAD SCI USA, V100, P12147, DOI 10.1073/pnas.1932773100; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; Katoh Y, 2006, FEBS J, V273, P2730, DOI 10.1111/j.1742-4658.2006.05291.x; Klein CA, 2009, CANCER RES, V69, P5285, DOI 10.1158/0008-5472.CAN-08-4586; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Komiya T, 2010, ONCOGENE, V29, P1672, DOI 10.1038/onc.2009.453; Kuwano H, 2005, SURG TODAY, V35, P7, DOI 10.1007/s00595-004-2885-3; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; Launonen V, 2000, CANCER RES, V60, P546; Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326; Liu L, 2004, CANCER RES, V64, P3491, DOI 10.1158/0008-5472.CAN-03-2106; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI 10.2217/FON.09.174; Mahoney CL, 2009, BRIT J CANCER, V100, P370, DOI 10.1038/sj.bjc.6604886; Makowski L, 2008, BRIT J CANCER, V99, P683, DOI 10.1038/sj.bjc.6604515; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; Paret C, 2005, INT J CANCER, V115, P724, DOI 10.1002/ijc.20977; Rodriguez Luis G., 2004, V294, P23; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Rowan A, 1999, J INVEST DERMATOL, V112, P509, DOI 10.1046/j.1523-1747.1999.00551.x; Rustgi AK, 2006, SEMIN ONCOL, V33, pS57, DOI 10.1053/j.seminoncol.2006.10.013; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Seiter S, 2001, J INVEST DERMATOL, V116, P344, DOI 10.1046/j.1523-1747.2001.01230.x; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Vallbohmer D, 2010, J GASTROINTEST SURG, V14, P75, DOI 10.1007/s11605-009-1021-5; van Lier MGF, 2010, AM J GASTROENTEROL, V105, P1258, DOI 10.1038/ajg.2009.725; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Wurfel J, 2001, GENE, V262, P35, DOI 10.1016/S0378-1119(00)00515-1	54	67	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	4					469	479		10.1038/onc.2011.247	http://dx.doi.org/10.1038/onc.2011.247			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706049				2022-12-28	WOS:000300219300006
J	Okubo, J; Takita, J; Chen, Y; Oki, K; Nishimura, R; Kato, M; Sanada, M; Hiwatari, M; Hayashi, Y; Igarashi, T; Ogawa, S				Okubo, J.; Takita, J.; Chen, Y.; Oki, K.; Nishimura, R.; Kato, M.; Sanada, M.; Hiwatari, M.; Hayashi, Y.; Igarashi, T.; Ogawa, S.			Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; ALK; truncated form ALK; amplification	RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL-GROWTH-FACTOR; EXPRESSION; GENE; IDENTIFICATION; MUTATIONS; CHEMOTHERAPY; DIAGNOSIS; VARIANTS	Anaplastic lymphoma kinase (ALK) was originally identified from a rare subtype of non-Hodgkin's lymphomas carrying t(2;5)(p23;q35) translocation, where ALK was constitutively activated as a result of a fusion with nucleophosmin (NPM). Aberrant ALK fusion proteins were also generated in inflammatory fibrosarcoma and a subset of non-small-cell lung cancers, and these proteins are implicated in their pathogenesis. Recently, ALK has been demonstrated to be constitutively activated by gene mutations and/or amplifications in sporadic as well as familial cases of neuroblastoma. Here we describe another mechanism of aberrant ALK activation observed in a neuroblastoma-derived cell line (NB-1), in which a short-form ALK protein (ALK(del2-3)) having a truncated extracellular domain is overexpressed because of amplification of an abnormal ALK gene that lacks exons 2 and 3. ALK(del2-3) was autophosphorylated in NB-1 cells as well as in ALK(del2-3)-transduced cells and exhibited enhanced in vitro kinase activity compared with the wild-type kinase. ALK(del2-3)-transduced NIH3T3 cells exhibited increased colony-forming capacity in soft agar and tumorigenicity in nude mice. RNAi-mediated ALK knockdown resulted in the growth suppression of ALK(del2-3)-expressing cells, arguing for the oncogenic role of this mutant. Our findings provide a novel insight into the mechanism of deregulation of the ALK kinase and its roles in neuroblastoma pathogenesis.	[Takita, J.] Univ Tokyo, Grad Sch Med, Cell Therapy & Transplantat Med, Bunkyo Ku, Tokyo 1138655, Japan; [Okubo, J.; Takita, J.; Chen, Y.; Oki, K.; Nishimura, R.; Kato, M.; Hiwatari, M.; Igarashi, T.] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo 1138655, Japan; [Sanada, M.; Ogawa, S.] Univ Tokyo, Grad Sch Med, Canc Genom Project, Tokyo 1138655, Japan; [Hayashi, Y.] Gunma Childrens Med Ctr, Maebashi, Gunma, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Gunma Children's Medical Centre	Takita, J (corresponding author), Univ Tokyo, Grad Sch Med, Cell Therapy & Transplantat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	jtakita-tky@umin.ac.jp	Chen, Yuyan/V-7279-2019; HIWATARI, Mitsuteru/HDM-0869-2022; Nishimura, Riki/K-1672-2019; Ogawa, Seishi/AAE-7088-2019	Chen, Yuyan/0000-0002-2894-1430; Kato, Motohiro/0000-0001-5145-1774; Hiwatari, Mitsuteru/0000-0003-3683-4472	Research on Measures for Intractable Diseases, Health and Labor Sciences Research Grants; Ministry of Health, Labor and Welfare, Research on Health Sciences focusing on Drug Innovation; Japan Health Sciences Foundation; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency; Grants-in-Aid for Scientific Research [22591171, 22659196] Funding Source: KAKEN	Research on Measures for Intractable Diseases, Health and Labor Sciences Research Grants(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor and Welfare, Research on Health Sciences focusing on Drug Innovation; Japan Health Sciences Foundation; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Mrs Matsumura, Mrs Hoshino, Mrs Yin, Miss Ogino and Mrs Saito for their excellent technical assistance. We would also thank Dr Tanaka, Dr Saito, Mr Shiosaka and Mrs Mori for useful advice concerning biological analysis; Dr AT Look, Harvard Medical University, and Dr A Inoue, St Jude Children's Research Hospital, for their generous gifts of neuroblastoma cell lines. This work was supported by Research on Measures for Intractable Diseases, Health and Labor Sciences Research Grants, Ministry of Health, Labor and Welfare, Research on Health Sciences focusing on Drug Innovation, the Japan Health Sciences Foundation and Core Research for Evolutional Science and Technology, Japan Science and Technology Agency.	BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Chen YQ, 2000, EXP CELL RES, V261, P229, DOI 10.1006/excr.2000.5012; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; De Bernardi B, 2003, J CLIN ONCOL, V21, P1592, DOI 10.1200/JCO.2003.05.191; Donella-Deana A, 2005, BIOCHEMISTRY-US, V44, P8533, DOI 10.1021/bi0472954; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Griffin CA, 1999, CANCER RES, V59, P2776; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jazii FR, 2006, WORLD J GASTROENTERO, V12, P7104, DOI 10.3748/wjg.v12.i44.7104; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Lu Y, 2007, CANCER LETT, V257, P157, DOI 10.1016/j.canlet.2007.08.007; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Pearson ADJ, 2008, LANCET ONCOL, V9, P247, DOI 10.1016/S1470-2045(08)70069-X; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; RONSIN C, 1993, ONCOGENE, V8, P1195; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Smith JL, 2011, AM J PHYSIOL-CELL PH, V301, pC75, DOI 10.1152/ajpcell.00494.2010; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Wang MH, 2000, CARCINOGENESIS, V21, P1507, DOI 10.1093/carcin/21.8.1507; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075	37	34	35	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4667	4676		10.1038/onc.2011.616	http://dx.doi.org/10.1038/onc.2011.616			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249260				2022-12-28	WOS:000310724400002
J	Sahraei, M; Roy, LD; Curry, JM; Teresa, TL; Nath, S; Besmer, D; Kidiyoor, A; Dalia, R; Gendler, SJ; Mukherjee, P				Sahraei, M.; Roy, L. D.; Curry, J. M.; Teresa, T. L.; Nath, S.; Besmer, D.; Kidiyoor, A.; Dalia, R.; Gendler, S. J.; Mukherjee, P.			MUC1 regulates PDGFA expression during pancreatic cancer progression	ONCOGENE			English	Article						pancreatic cancer; MUC1; PDGFA; beta-catenin	GROWTH-FACTOR RECEPTOR; CELL-SURFACE; SIGNAL-TRANSDUCTION; TUMOR PROGRESSION; CYTOPLASMIC TAIL; RANDOMIZED-TRIAL; MOUSE MODEL; MUCINS; ADENOCARCINOMA; CARCINOMA	Pancreatic ductal adenocarcinoma (PDA) has one of the worst prognoses of all cancers. Mucin 1 (MUC1), a transmembrane mucin glycoprotein, is a key modulator of several signaling pathways that affect oncogenesis, motility and metastasis. Its expression is known to be associated with poor prognosis in patients. However, the precise mechanism remains elusive. We report a novel association of MUC1 with platelet-derived growth factor-A (PDGFA). PDGFA is one of the many drivers of tumor growth, angiogenesis and metastasis in PDA. Using mouse PDA models as well as human samples, we show clear evidence that MUC1 regulates the expression and secretion of PDGFA. This, in turn, influences proliferation and invasion of pancreatic cancer cells leading to higher tumor burden in vivo. In addition, we reveal that MUC1 overexpressing cells are heavily dependent on PDGFA both for proliferation and invasion, whereas MUC1-null cells are not. Moreover, PDGFA and MUC1 are critical for translocation of beta catenin to the nucleus for oncogenesis to ensue. Finally, we elucidate the underlying mechanism by which MUC1 regulates PDGFA expression and secretion in pancreatic cancer cells. We show that MUC1 associates with Hif1-alpha, a known transcription factor involved in controlling PDGFA expression. Furthermore, MUC1 facilitates Hif1-alpha translocation to the nucleus. In summary, we have demonstrated that MUC1-induced invasion and proliferation occurs via increased exogenous production of PDGFA. Thus, impeding MUC1 regulation of PDGFA signaling may be therapeutically beneficial for patients with PDA.	[Sahraei, M.; Roy, L. D.; Curry, J. M.; Teresa, T. L.; Nath, S.; Besmer, D.; Kidiyoor, A.; Dalia, R.; Mukherjee, P.] Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; [Gendler, S. J.] Mayo Clin, Ctr Canc, Dept Biochem & Mol Biol, Scottsdale, AZ USA	University of North Carolina; University of North Carolina Charlotte; Mayo Clinic; Mayo Clinic Phoenix	Mukherjee, P (corresponding author), Univ N Carolina, Dept Biol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	pmukherj@uncc.edu	Nath, Sritama/J-7725-2019		NIH;  [RO1 CA118944];  [P50CA102701]; NATIONAL CANCER INSTITUTE [R01CA118944, P50CA102701] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs Mukherjee's and Gendler's work has been funded by the NIH. The remaining authors declare no conflict of interest.; We acknowledge the Mayo Clinic Histology Core and the UNC-Charlotte vivarium staff for maintaining our mouse colonies. This study is supported by RO1 CA118944 and P50CA102701.	Adsay NV, 2005, SEMIN RADIAT ONCOL, V15, P254, DOI 10.1016/j.semradonc.2005.04.001; Adsay NV, 2002, MODERN PATHOL, V15, P1087, DOI 10.1097/01.MP.0000028647.98725.8B; Al Masri A, 2005, ONCOGENE, V24, P5799, DOI 10.1038/sj.onc.1208738; Al-Batran SE, 2007, CANCER, V109, P1897, DOI 10.1002/cncr.22622; Appelmann I, 2010, RECENT RESULTS CANC, V180, P51, DOI 10.1007/978-3-540-78281-0_5; Baldus SE, 1998, CANCER, V82, P1019, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1019::AID-CNCR3>3.0.CO;2-9; Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; Chhieng DC, 2003, CANCER CYTOPATHOL, V99, P365, DOI 10.1002/cncr.11857; Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121; Fujimoto K, 1998, EUR J CANCER, V34, P1439, DOI 10.1016/S0959-8049(98)00069-0; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LAN MS, 1990, CANCER RES, V50, P2997; Levi E, 2004, J CLIN PATHOL, V57, P456, DOI 10.1136/jcp.2003.013292; Mantur Maria, 2008, Pol Merkur Lekarski, V24, P173; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Moon SW, 2009, BIOCHEM BIOPH RES CO, V388, P167, DOI 10.1016/j.bbrc.2009.07.144; Mukherjee P, 2009, J IMMUNOL, V182, P216, DOI 10.4049/jimmunol.182.1.216; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Reiser-Erkan C, 2008, CANCER BIOL THER, V7, P1352, DOI 10.4161/cbt.7.9.6418; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Sener SF, 1999, J AM COLL SURGEONS, V189, P1, DOI 10.1016/S1072-7515(99)00075-7; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh PK, 2008, J BIOL CHEM, V283, P26985, DOI 10.1074/jbc.M805036200; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Society AC, 2010, AM CANC SOC CANC FAC; SPICER AP, 1995, J BIOL CHEM, V270, P30093; Szajda SD, 2011, BIOCHEM SOC T, V39, P340, DOI 10.1042/BST0390340; Thompson EJ, 2006, MOL CANCER RES, V4, P489, DOI 10.1158/1541-7786.MCR-06-0038; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Wang CC, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.4	44	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4935	4945		10.1038/onc.2011.651	http://dx.doi.org/10.1038/onc.2011.651			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266848	Green Accepted			2022-12-28	WOS:000311430200005
J	Lee, DW; Futami, M; Carroll, M; Feng, Y; Wang, Z; Fernandez, M; Whichard, Z; Chen, Y; Kornblau, S; Shpall, EJ; Bueso-Ramos, CE; Corey, SJ				Lee, D. W.; Futami, M.; Carroll, M.; Feng, Y.; Wang, Z.; Fernandez, M.; Whichard, Z.; Chen, Y.; Kornblau, S.; Shpall, E. J.; Bueso-Ramos, C. E.; Corey, S. J.			Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155	ONCOGENE			English	Article						SHIP-1; Akt; leukemia	CELL-SURVIVAL; BONE-MARROW; PTEN; GENE; TEC; HEMATOPOIESIS; PHOSPHATASES; PATHOGENESIS; AKT/PKB; TARGETS	The myelodysplastic syndromes (MDSs) comprise a group of disorders characterized by multistage progression from cytopenias to acute myeloid leukemia (AML). They display exaggerated apoptosis in early stages, but lose this behavior during evolution to AML. The molecular basis for loss of apoptosis is unknown. To investigate this critical event, we analyzed phosphatidylinositol (PI) 3'kinase signaling, implicated as a critical pathway of cell survival control in epithelial and hematological malignancies. PI 3'kinase activates Akt through its production of 3' phosphoinositides. In turn, the phosphoinositides are dephosphorylated by two lipid phosphatases, PTEN and SHIP-1, in myeloid cells. We studied primary MDS-enriched bone marrow cells and bone marrow sections by western blotting, immunohistochemistry, immunocytochemistry and quantitative PCR for components of the SHIP/PTEN/PI 3'kinase signaling circuit. We reported constitutively activated Akt, variable levels of PTEN and uniformly decreased SHIP-1 expression in MDS progenitor cells. Overexpression of SHIP-1, but not the phosphatase-deficient form, inhibited myeloid leukemic growth. Levels of microRNA (miR)-210 and miR-155 transcripts, which target SHIP-1, were increased in CD34(+) MDS cells compared with their normal counterparts. Direct binding of miR-210 to the 3' untranslated region of SHIP-1 was confirmed by luciferase reporter assay. Transfection of a myeloid cell line with miR-210 resulted in loss of SHIP-1 protein expression. These data suggest that miR-155 and miR-210/SHIP-1/Akt pathways could serve as clinical biomarkers for disease progression, and that miR-155 and miR-210 might serve as novel therapeutic targets in MDS. Oncogene (2012) 31, 4085-4094; doi:10.1038/onc.2011.579; published online 16 January 2012	[Futami, M.; Feng, Y.; Wang, Z.; Whichard, Z.; Chen, Y.; Corey, S. J.] Northeastern Univ, Feinberg Sch Med, Div Pediat, Chicago, IL 60611 USA; [Futami, M.; Feng, Y.; Wang, Z.; Whichard, Z.; Chen, Y.; Corey, S. J.] Northeastern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Carroll, M.] Univ Penn, Div Hematol Oncol, Philadelphia, PA 19104 USA; [Fernandez, M.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Kornblau, S.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Shpall, E. J.] Univ Texas MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA; [Lee, D. W.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; University of Pennsylvania; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Corey, SJ (corresponding author), Northeastern Univ, Dept Pediat, Childrens Mem Hosp & Robert H Lurie Comprehens Ca, Lurie 5-107,303 E Super St, Chicago, IL 60611 USA.	s-corey@northwestern.edu			NIH [KO2-HL03794, RO1-CA108992, PO1CA55164]; American Cancer Society [DHP-135]; Ladies Leukemia League; JP McCarthy Foundation; Leukemia SPORE [CA100632]; AA/MDS International Foundation; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA108992, P01CA055164, P50CA100632] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K02HL003794] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Ladies Leukemia League; JP McCarthy Foundation; Leukemia SPORE; AA/MDS International Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Martin H Nguyen for technical assistance. We thank Drs Gerald Krystal for providing the cDNA for SHIP-1 and Maria-Magdalena Georgescu for control lysates. SJC was funded by the NIH Independent Scientist Award KO2-HL03794, RO1-CA108992, American Cancer Society Research Scholar Grant DHP-135, Ladies Leukemia League, JP McCarthy Foundation, NIH PO1CA55164 and Leukemia SPORE CA100632. Funding also came from the AA/MDS International Foundation to both SJC and MF.	Aul C, 1998, LEUKEMIA RES, V22, P93, DOI 10.1016/S0145-2126(97)00089-1; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Corey SJ, 2007, NAT REV CANCER, V7, P118, DOI 10.1038/nrc2047; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Fenaux P, 2004, SEMIN HEMATOL, V41, P6, DOI 10.1053/j.seminhematol.2004.02.002; Follo MY, 2007, CANCER RES, V67, P4287, DOI 10.1158/0008-5472.CAN-06-4409; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; Gilby DC, 2007, LEUKEMIA, V21, P2390, DOI 10.1038/sj.leu.2404864; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Greenberg PL, 1998, LEUKEMIA RES, V22, P1123, DOI 10.1016/S0145-2126(98)00112-X; Hazen AL, 2009, BLOOD, V113, P2924, DOI 10.1182/blood-2008-02-138008; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Kalesnikoff J, 2004, REV PHYSIOL BIOCH P, V149, P87, DOI 10.1007/s10254-003-0016-y; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; Lakhanpal GK, 2010, BLOOD, V116, P428, DOI 10.1182/blood-2009-10-250217; Luo Jian-Min, 2004, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V12, P420; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Matsuda M, 2004, LEUKEMIA, V18, P1038, DOI 10.1038/sj.leu.2403301; Melcher M, 2008, J IMMUNOL, V180, P8048, DOI 10.4049/jimmunol.180.12.8048; Moody JL, 2004, BLOOD, V103, P4503, DOI 10.1182/blood-2003-09-3262; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nyakern M, 2006, LEUKEMIA, V20, P230, DOI 10.1038/sj.leu.2404057; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Pons A, 2009, LEUKEMIA LYMPHOMA, V50, P1854, DOI 10.3109/10428190903147645; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Rosenfeld C, 2000, LEUKEMIA, V14, P2, DOI 10.1038/sj.leu.2401618; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Ruschmann J, 2010, EXP HEMATOL, V38, P392, DOI 10.1016/j.exphem.2010.03.010; SATO K, 1994, LEUKEMIA, V8, P1663; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Thompson JE, 2007, EXP HEMATOL, V35, P21, DOI 10.1016/j.exphem.2006.08.017; Tomlinson MG, 2004, J BIOL CHEM, V279, P55089, DOI 10.1074/jbc.M408141200; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Whichard ZL, 2011, J BIOL CHEM, V286, P4742, DOI 10.1074/jbc.M110.166348; Worm J, 2009, NUCLEIC ACIDS RES, V37, P5784, DOI 10.1093/nar/gkp577; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4	45	49	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4085	4094		10.1038/onc.2011.579	http://dx.doi.org/10.1038/onc.2011.579			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22249254				2022-12-28	WOS:000308688900001
J	Khanal, P; Yun, HJ; Lim, SC; Ahn, SG; Yoon, HE; Kang, KW; Hong, R; Choi, HS				Khanal, P.; Yun, H. J.; Lim, S. C.; Ahn, S. G.; Yoon, H. E.; Kang, K. W.; Hong, R.; Choi, H. S.			Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						Pin1; CDK10; ubiquitination; Raf-1; tamoxifen resistance	ESTROGEN-RECEPTOR; GROWTH-FACTOR; INDEPENDENT GROWTH; THERAPEUTIC TARGET; ENDOCRINE THERAPY; ALPHA EXPRESSION; RAF-1 KINASE; PHOSPHORYLATION; PATHWAY; IDENTIFICATION	Endocrine therapies that inhibit estrogen receptor (ER)-alpha signaling are the most common and effective treatment for ER-a-positive breast cancer. However, the use of these agents is limited by the frequent development of resistance. The aim of this study was to elucidate the mechanisms by which downregulation of CDK10 expression confers resistance to tamoxifen in breast cancer. Here, we show that peptidyl-prolyl isomerase Pin1 downregulates CDK10 protein as a result of its interaction with and ubiquitination of CDK10, thereby affecting CDK10-dependent Raf-1 phosphorylation (S338). Pin1(-/-) mouse embryonic fibroblasts (MEFs) show higher CDK10 expression than Pin1(+/+) MEFs, whereas CDK10 protein was downregulated in the rescued Pin1(-/-) MEFs after reexpression of Pin1. Pin1 silencing in SKBR-3 and MCF7 cells increased the CDK10 expression. In human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 cells, immunohistochemical staining and immunoblotting analysis shows an inverse correlation between the expression of CDK10 and the degree of tamoxifen resistance. There was also a positive correlation between the high level of P-Raf-1 (Ser338) and Pin1 in human tamoxifen-resistant breast cancer and tamoxifen-resistant MCF7 (TAMR-MCF7) cells. Importantly, 4-OH tamoxifen (4-OHT), when used in combination with overexpressed CDK10 or Raf-1 inhibitor, increased cleaved PARP and DNA fragmentation to inhibit cologenic growth of MCF7 cells and Tamoxifen-resistant MCF7 cells, respectively. On the basis of these findings, we suggest that the Pin1-mediated CDK10 ubiquitination is a major regulator of tamoxifen-resistant breast cancer cell growth and survival. Oncogene (2012) 31, 3845-3856; doi:10.1038/onc.2011.548; published online 12 December 2011	[Khanal, P.; Yun, H. J.; Kang, K. W.; Choi, H. S.] Chosun Univ, Coll Pharm, Project Team BK21, Kwangju 501759, South Korea; [Lim, S. C.; Hong, R.] Chosun Univ, Sch Med, Dept Pathol, Kwangju 501759, South Korea; [Ahn, S. G.; Yoon, H. E.] Chosun Univ, Sch Dent, Dept Pathol, Kwangju 501759, South Korea	Chosun University; Chosun University; Chosun University	Choi, HS (corresponding author), Chosun Univ, Coll Pharm, Project Team BK21, Kwangju 501759, South Korea.	chs@chosun.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science, and Technology [2009-0073468, 2010-0009728]	Basic Science Research Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science, and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2009-0073468 and 2010-0009728).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1; Heller G, 2009, ANTICANCER RES, V29, P3939; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; Lee M, 2003, CANCER LETT, V193, P57, DOI 10.1016/S0304-3835(02)00722-X; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LI S, 1995, CANCER RES, V55, P3992; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; McGlynn LM, 2009, CLIN CANCER RES, V15, P1487, DOI 10.1158/1078-0432.CCR-07-4967; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Namgoong GM, 2010, J BIOL CHEM, V285, P23829, DOI 10.1074/jbc.M109.092874; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Osborne CK, 2005, CLIN CANCER RES, V11, p865S; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Stanya KJ, 2008, J CELL BIOL, V183, P49, DOI 10.1083/jcb.200806172; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Valabrega G, 2011, BREAST CANCER RES TR, V130, P29, DOI 10.1007/s10549-010-1281-5; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Yoshiji H, 2004, HEPATOLOGY, V39, P1517, DOI 10.1002/hep.20218; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	39	34	36	6	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	34					3845	3856		10.1038/onc.2011.548	http://dx.doi.org/10.1038/onc.2011.548			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22158035	Bronze			2022-12-28	WOS:000307925000002
J	Tailler, M; Senovilla, L; Lainey, E; Thepot, S; Metivier, D; Sebert, M; Baud, V; Billot, K; Fenaux, P; Galluzzi, L; Boehrer, S; Kroemer, G; Kepp, O				Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Baud, V.; Billot, K.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kroemer, G.; Kepp, O.			Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; necrosis; myeloblasts; HL-60; HCS	CELL-DEATH; CARDIAC-GLYCOSIDES; MITOCHONDRIAL ALTERATIONS; CANCER-CELLS; DIFFERENTIATION; APOPTOSIS; ASSAYS; INHIBITION; EXPRESSION; GUIDELINES	Despite recent progress in the treatment of acute myeloid leukemia (AML), the prognosis of this rather heterogeneous disease remains poor and novel chemotherapeutics that specifically target leukemic cells must be developed. To address this need at the preclinical level, we implemented a high content imaging-based screen for the identification of small agents that induce AML cell death in vitro. Among a panel of 1040 Food and Drug Administration-approved agents, we identified pyrithione zinc (PZ) and ouabain (OUA) as potential antileukemic compounds. Both PZ and OUA efficiently induced cell death associated with apoptotic chromatin condensation and inhibition of nuclear factor-kappa B survival signaling, leading to reduced expression of antiapoptotic proteins, in several AML cell lines. PZ- and OUA-induced cell death was associated with the permeabilization of the outer mitochondrial membrane and led to the release of cytochrome c followed by caspase activation. Both PZ and OUA exerted significant anticancer effects in vivo, on human AML cells xenografts as well as ex vivo, on CD34(+) (but not CD34(-)) malignant myeloblasts from AML patients. Altogether, our results suggest that PZ and OUA may exhibit antileukemic effects by inducing the apoptotic demise of AML cells. Oncogene (2012) 31, 3536-3546; doi:10.1038/onc.2011.521; published online 21 November 2011	[Kroemer, G.] Inst Gustave Roussy, INSERM, PR1, U848, F-94805 Villejuif, Val De Marne, France; [Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kepp, O.] Univ Paris Sud, F-94275 Le Kremlin Bicetre, France; [Thepot, S.; Sebert, M.; Fenaux, P.; Boehrer, S.] Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; [Baud, V.; Billot, K.] INSERM, Inst Cochin, U1016, Paris, France; [Baud, V.; Billot, K.] CNRS, UMR8104, Paris, France; [Baud, V.; Billot, K.; Kroemer, G.] Univ Paris 05, Paris, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, PR1, U848, 114 Rue Edouard Vaillant, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr; oliver.kepp@igr.fr	KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAH-3286-2021; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAG-6432-2019; Senovilla, Laura/AAX-5599-2021; Baud, Veronique/F-7699-2013; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/K-2709-2012; Kepp, Oliver/GPX-8627-2022; THEPOT, Sylvain/L-3078-2015; Baud, Veronique/AAL-3950-2020; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Baud, Veronique/0000-0002-4090-718X; Galluzzi, Lorenzo/0000-0003-2257-8500; Baud, Veronique/0000-0002-4090-718X; Senovilla, Laura/0000-0001-6887-2436; thepot, sylvain/0000-0003-3492-2778	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; Fondation Bettencourt-Schueller; LabEx Onco-Immunology; Agence Nationale pour la Recherche; Association pour la Recherche sur le Cancer; Belgian InterUniversity Attraction Pole; Universite Paris Descartes; Ligue Nationale contre le Cancer; Apo-Sys	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Fondation Bettencourt-Schueller; LabEx Onco-Immunology; Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Belgian InterUniversity Attraction Pole(Belgian Federal Science Policy Office); Universite Paris Descartes; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Apo-Sys(European CommissionEuropean Commission Joint Research Centre)	This work is supported by grants to GK from the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa), Canceropole Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Onco-Immunology; to VB from Agence Nationale pour la Recherche, Association pour la Recherche sur le Cancer, Belgian InterUniversity Attraction Pole and Universite Paris Descartes. MT is supported by the Ligue Nationale contre le Cancer. LG is funded by Apo-Sys; KB is supported by Agence Nationale pour la Recherche.	Bielawski K, 2006, BIOL PHARM BULL, V29, P1493, DOI 10.1248/bpb.29.1493; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chan G, 2007, BLOOD, V110, P1079, DOI 10.1182/blood-2007-01-069856; Edwards Bruce S., 2009, V486, P151, DOI 10.1007/978-1-60327-545-3_11; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Hahn CK, 2009, CANCER CELL, V16, P281, DOI 10.1016/j.ccr.2009.08.018; Hallbook H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015718; Hoffmann J, 2008, CANCER RES, V68, P5301, DOI 10.1158/0008-5472.CAN-08-0237; Juncker T, 2011, BIOCHEM PHARMACOL, V81, P13, DOI 10.1016/j.bcp.2010.08.025; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Lamore SD, 2011, BIOMETALS, V24, P875, DOI 10.1007/s10534-011-9441-6; Lamore SD, 2010, CELL STRESS CHAPERON, V15, P309, DOI 10.1007/s12192-009-0145-6; Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8; Newman RA, 2006, J EXP THER ONCOL, V5, P167; Perne A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008292; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Smits ELJ, 2011, CANCER IMMUNOL IMMUN, V60, P757, DOI 10.1007/s00262-011-1022-6; Stegmaier K, 2005, BLOOD, V106, P2841, DOI 10.1182/blood-2005-02-0488; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34; Vitale I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001337; Wald DN, 2008, CANCER RES, V68, P4369, DOI 10.1158/0008-5472.CAN-07-6559; Wang Z, 2009, CANCER RES, V69, P6556, DOI 10.1158/0008-5472.CAN-09-0891; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Yin W, 2009, BIOCHEM PHARMACOL, V78, P191, DOI 10.1016/j.bcp.2009.03.025; ZHANG LS, 1992, CANCER RES, V52, P4634	34	47	48	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3536	3546		10.1038/onc.2011.521	http://dx.doi.org/10.1038/onc.2011.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105358				2022-12-28	WOS:000306844100006
J	Zeineldin, M; Cunningham, J; McGuinness, W; Alltizer, P; Cowley, B; Blanchat, B; Xu, W; Pinson, D; Neufeld, KL				Zeineldin, M.; Cunningham, J.; McGuinness, W.; Alltizer, P.; Cowley, B.; Blanchat, B.; Xu, W.; Pinson, D.; Neufeld, K. L.			A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt signal inhibition and tumor suppression	ONCOGENE			English	Article						adenomatous polyposis coli; polyp; Wnt; nuclear; mouse model; NLS	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; SUBCELLULAR-LOCALIZATION; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN; GENE; MUTATION; MICE; DNA; PHOSPHORYLATION	Mutation of the tumor suppressor adenomatous polyposis coli (APC) is considered an initiating step in the genesis of the vast majority of colorectal cancers. APC inhibits the Wnt-signaling pathway by targeting the proto-oncogene beta-catenin for destruction by cytoplasmic proteasomes. In the presence of a Wnt signal, or in the absence of functional APC, beta-catenin can serve as a transcription cofactor for genes required for cell proliferation such as cyclin-D1 and c-Myc. In cultured cells, APC shuttles between the nucleus and the cytoplasm, with nuclear APC implicated in the inhibition of Wnt target gene expression. Adopting a genetic approach to evaluate the functions of nuclear APC in the context of a whole organism, we generated a mouse model with mutations that inactivate the nuclear localization signals (NLSs) of Apc (Apc(mNLS)). Apc(mNLS/mNLS) mice are viable and fractionation of mouse embryonic fibroblasts (MEFs) isolated from these mice revealed a significant reduction in nuclear Apc as compared with Apc(+/+) MEFs. The levels of Apc and beta-catenin protein were not significantly altered in small intestinal epithelia from Apc(mNLS/mNLS) mice. Compared with Apc(+/+) mice, Apc(mNLS/mNLS) mice showed increased proliferation in epithelial cells from the jejunum, ileum and colon. These same tissues from Apc(mNLS/mNLS) mice showed more mRNA from three genes upregulated in response to canonical Wnt signal, c-Myc, axin-2 and cyclin-D1, and less mRNA from Hath-1, which is downregulated in response to Wnt. These observations suggest a role for nuclear Apc in the inhibition of canonical Wnt signaling and the control of epithelial proliferation in intestinal tissue. Furthermore, we found Apc(Min/+) mice, which harbor a mutation that truncates Apc, to have an increased polyp size and multiplicity if they also carry the Apc(mNLS) allele. Taken together, this analysis of the novel Apc(mNLS) mouse model supports a role for nuclear Apc in the control of Wnt target genes, intestinal epithelial cell proliferation and polyp formation. Oncogene (2012) 31, 2423-2437; doi: 10.1038/onc.2011.434; published online 26 September 2011	[Zeineldin, M.; McGuinness, W.; Alltizer, P.; Blanchat, B.; Neufeld, K. L.] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; [Cowley, B.] Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT USA; [Xu, W.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Pinson, D.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	University of Kansas; Utah System of Higher Education; University of Utah; University of Virginia; University of Kansas; University of Kansas Medical Center	Neufeld, KL (corresponding author), Univ Kansas, Dept Mol Biosci, 7049 Haworth Hall,1200 Sunnyside Ave, Lawrence, KS 66045 USA.	klneuf@ku.edu	Zeineldin, Maged/AAU-1040-2021	Neufeld, Kristi/0000-0003-3653-9385	National Cancer Institute [RO1 CA10922];  [5P20 RR15563]; NATIONAL CANCER INSTITUTE [R01CA109220] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by RO1 CA10922 from the National Cancer Institute and 5P20 RR15563. We extend our gratitude to Alan Godwin, Kirk Thomas and Mario Capecchi for advice on the generation of the knock-in mouse and for the lambda phage library, and the tACE-Cre-Neo<SUP>r</SUP>- and Tk<SUP>HSV</SUP>-containing constructs. We thank Marc Roth, Areli Monarrez, Ashrita Abraham and Travis Friesen for technical assistance; the staff at the University of Kansas Animal Care Unit for excellent mouse husbandry and David Davido for critical reading of the manuscript. We also thank Reka Nagy and Drs Andras Nagy, Janet Rossant and Wanda Abramow-Newerly (Mount Sinai Hospital) for the mouse R1 ES cells.	Anderson CB, 2002, P NATL ACAD SCI USA, V99, P8683, DOI 10.1073/pnas.122235399; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Cheung AF, 2010, ONCOGENE, V29, P1857, DOI 10.1038/onc.2009.457; Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Jaiswal AS, 2008, CANCER LETT, V271, P272, DOI 10.1016/j.canlet.2008.06.024; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Magnus HA, 1937, J PATHOL BACTERIOL, V44, P389, DOI 10.1002/path.1700440214; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 2003, MANIPULATING MOUSE E; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; Neufeld KL, 2009, ADV EXP MED BIOL, V656, P13, DOI 10.1007/978-1-4419-1145-2_2; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; Pollard P, 2009, GASTROENTEROLOGY, V136, P2204, DOI 10.1053/j.gastro.2009.02.058; Qian J, 2008, GASTROENTEROLOGY, V135, P152, DOI 10.1053/j.gastro.2008.03.074; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Sasai H, 2000, CARCINOGENESIS, V21, P953, DOI 10.1093/carcin/21.5.953; Sena P, 2006, CANCER LETT, V241, P203, DOI 10.1016/j.canlet.2005.10.011; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang Y, 2008, MOL BIOL CELL, V19, P4076, DOI 10.1091/mbc.E07-12-1296; Wang Y, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-75; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Yang K, 1997, J EXP ZOOL, V277, P245, DOI 10.1002/(SICI)1097-010X(19970215)277:3<245::AID-JEZ5>3.3.CO;2-N; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	50	22	23	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2423	2437		10.1038/onc.2011.434	http://dx.doi.org/10.1038/onc.2011.434			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996741	Green Submitted, Green Accepted			2022-12-28	WOS:000303985300005
J	Berezov, A; Cai, Z; Freudenberg, JA; Zhang, H; Cheng, X; Thompson, T; Murali, R; Greene, MI; Wang, Q				Berezov, A.; Cai, Z.; Freudenberg, J. A.; Zhang, H.; Cheng, X.; Thompson, T.; Murali, R.; Greene, M. I.; Wang, Q.			Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin	ONCOGENE			English	Article						mitosis; cancer; therapeutic; survivin	KINETOCHORE FIBERS CONTRIBUTES; THERAPEUTIC TARGET; SIGNALING PATHWAY; INNER CENTROMERE; MOTOR PROTEINS; CELL-DIVISION; BINDING-SITE; AURORA B; APOPTOSIS; MITOSIS	Survivin is a member of the inhibitor of apoptosis protein family and has an essential role in mitosis. Survivin is overexpressed in a large variety of human cancers and represents an attractive target for cancer therapy. Epidermal growth factor receptor and Her/neu-transformed human tumors in particular exhibit high levels of survivin. The survivin protein forms dimers through a conserved region that is critical for subcellular localization and biological functions of the protein. We identified small molecules that target a specific cavity adjacent to the survivin dimerization surfaces. S12, a lead compound identified in the screen, can bind to the survivin protein at the intended target site. Moreover, S12 alters spindle formation, causing mitotic arrest and cell death, and inhibits tumor growth in vitro and in vivo. Cell death occurs in premetaphase stage following mitotic arrest and is not a consequence of general toxicity. Thus, the study validates a novel therapeutic target site in the survivin protein and provides a promising strategy to develop a new class of therapeutic small molecules for the treatment of human cancers. Oncogene (2012) 31, 1938-1948; doi:10.1038/onc.2011.377; published online 5 September 2011	[Berezov, A.; Cai, Z.; Freudenberg, J. A.; Zhang, H.; Cheng, X.; Thompson, T.; Murali, R.; Greene, M. I.; Wang, Q.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu; Qiang.Wang@cshs.org	Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049; Neely, Jaclyn/0000-0001-7137-3953; Murali, Ramachandran/0000-0002-8384-2793	Abramson Family Cancer Research Institute of the University of Pennsylvania; The National Cancer Institute; Breast Cancer Research Foundation; Nidus Laboratories, Inc.; NATIONAL CANCER INSTITUTE [R01CA055306, R01CA089481] Funding Source: NIH RePORTER	Abramson Family Cancer Research Institute of the University of Pennsylvania; The National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Nidus Laboratories, Inc.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert L Margolis (the Sanford-Burnham Medical Research Institute, La Jolla, CA, USA) for providing the pGEX-survivin plasmid. This work was supported by grants from the Abramson Family Cancer Research Institute of the University of Pennsylvania, The National Cancer Institute, the Breast Cancer Research Foundation and the Nidus Laboratories, Inc.	Ainsztein AM, 1998, J CELL BIOL, V143, P1763, DOI 10.1083/jcb.143.7.1763; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Asanuma H, 2005, CANCER RES, V65, P11018, DOI 10.1158/0008-5472.CAN-05-0491; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; DESJARLAIS RL, 1988, J MED CHEM, V31, P722, DOI 10.1021/jm00399a006; Giodini A, 2002, CANCER RES, V62, P2462; Goshima G, 2005, J CELL BIOL, V171, P229, DOI 10.1083/jcb.200505107; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Kappler M, 2004, CANCER GENE THER, V11, P186, DOI 10.1038/sj.cgt.7700677; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; Maiato H, 2004, CHROMOSOME RES, V12, P585, DOI 10.1023/B:CHRO.0000036587.26566.81; Murali R, 2005, P NATL ACAD SCI USA, V102, P10970, DOI 10.1073/pnas.0504301102; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Noton EA, 2006, J BIOL CHEM, V281, P1286, DOI 10.1074/jbc.M508773200; Rieder CL, 2005, CHROMOSOMA, V114, P310, DOI 10.1007/s00412-005-0028-2; Rodel F, 2005, CANCER RES, V65, P4881, DOI 10.1158/0008-5472.CAN-04-3028; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Sun CH, 2005, BIOCHEMISTRY-US, V44, P11, DOI 10.1021/bi0485171; Tamm I, 1998, CANCER RES, V58, P5315; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Wang Q, 2005, EXP MOL PATHOL, V79, P100, DOI 10.1016/j.yexmp.2005.05.002; Wendt MD, 2007, BIOORG MED CHEM LETT, V17, P3122, DOI 10.1016/j.bmcl.2007.03.042; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498	38	29	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	15					1938	1948		10.1038/onc.2011.377	http://dx.doi.org/10.1038/onc.2011.377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21892210	Green Accepted			2022-12-28	WOS:000302809900006
J	Fanale, D; Amodeo, V; Corsini, LR; Rizzo, S; Bazan, V; Russo, A				Fanale, D.; Amodeo, V.; Corsini, L. R.; Rizzo, S.; Bazan, V.; Russo, A.			Breast cancer genome-wide association studies: there is strength in numbers	ONCOGENE			English	Review						FGFR2; GWAS; H19; LSP1; MAP3K1; TNRC9	FIBROBLAST-GROWTH-FACTOR; BRCA2 MUTATION CARRIERS; SUSCEPTIBILITY LOCI; COMMON VARIANTS; GENE-EXPRESSION; CONFER SUSCEPTIBILITY; GERMLINE MUTATIONS; CHROMOSOME 5P12; TUMOR SUBTYPES; RISK	Breast cancer (BC) is a heterogeneous disease that exhibits familial aggregation. Family linkage studies have identified high-penetrance genes, BRCA1, BRCA2, PTEN and TP53, that are responsible for inherited BC syndromes. Moreover, a combination of family-based and population-based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, BRIP and PALB2, are associated with moderate risk. Therefore, all of these known genes account for only 25% of the familial aggregation cases. Recently, genome wide association studies (GWAS) in BC revealed single nucleotide polymorphisms (SNPs) in five novel genes associated to susceptibility: TNRC9, FGFR2, MAP3K1, H19 and lymphocyte-specific protein 1 (LSP1). The most strongly associated SNP was in intron 2 of the FGFR2 gene that is amplified and overexpressed in 5-10% of BC. rs3803662 of TNRC9 gene has been shown to be the SNP with the strongest association with BC, in particular, this polymorphism seems to be correlated with bone metastases and estrogen receptor positivity. Relevant data indicate that SNP rs889312 in MAP3K1 is correlated with BC susceptibility only in BRCA2 mutation carriers, but is not associated with an increased risk in BRCA1 carriers. Finally, different SNPs in LSP1 and H19 and in minor genes probably were associated with BC risk. New susceptibility allelic variants associated with BC risk were recently discovered including potential causative genes involved in regulation of cell cycle, apoptosis, metabolism and mitochondrial functions. In conclusion, the identification of disease susceptibility loci may lead to a better understanding of the biological mechanism for BC to improve prevention, early detection and treatment. Oncogene (2012) 31, 2121-2128; doi:10.1038/onc.2011.408; published online 26 September 2011	[Fanale, D.; Amodeo, V.; Corsini, L. R.; Rizzo, S.; Bazan, V.; Russo, A.] Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, I-90127 Palermo, Italy; [Bazan, V.; Russo, A.] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	University of Palermo; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Russo, A (corresponding author), Univ Palermo, Sect Med Oncol, Dept Surg & Oncol Sci, Via Vespro 129, I-90127 Palermo, Italy.	lab-oncobiologia@usa.net	Fanale, Daniele/K-8630-2016	Fanale, Daniele/0000-0001-7668-737X				ADNANE J, 1991, ONCOGENE, V6, P659; Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Antoniou AC, 2008, AM J HUM GENET, V82, P937, DOI 10.1016/j.ajhg.2008.02.008; Antoniou AC, 2009, HUM MOL GENET, V18, P4442, DOI 10.1093/hmg/ddp372; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Braun R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002101; Broeks A, 2011, HUM MOL GENET, V20, P3289, DOI 10.1093/hmg/ddr228; Cerhan JR, 2007, BLOOD, V110, P4455, DOI 10.1182/blood-2007-05-088682; Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363; Dite GS, 2003, J NATL CANCER I, V95, P448, DOI 10.1093/jnci/95.6.448; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Easton DF, 2008, HUM MOL GENET, V17, pR109, DOI 10.1093/hmg/ddn287; FitzGerald MG, 1998, ONCOGENE, V17, P727, DOI 10.1038/sj.onc.1201984; Fu YP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-113; Garcia-Closas M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000054; Garcia-Closas M, 2008, CLIN CANCER RES, V14, P8000, DOI 10.1158/1078-0432.CCR-08-0975; Gold B, 2008, P NATL ACAD SCI USA, V105, P4340, DOI 10.1073/pnas.0800441105; Hashimoto T, 1996, J BIOCHEM-TOKYO, V119, P1196; Hirshfield KM, 2010, J ONCOL, V2010, DOI 10.1155/2010/297671; Hollestelle A, 2010, CURR OPIN GENET DEV, V20, P268, DOI 10.1016/j.gde.2010.02.009; Houlston RS, 2004, ONCOGENE, V23, P6471, DOI 10.1038/sj.onc.1207951; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Ingersoll RG, 2001, CYTOGENET CELL GENET, V94, P121, DOI 10.1159/000048802; Kristensen VN, 2008, MOL ONCOL, V2, P12, DOI 10.1016/j.molonc.2008.02.003; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Rosa-Rosa JM, 2009, AM J HUM GENET, V84, P115, DOI 10.1016/j.ajhg.2008.12.013; Marafioti T, 2003, BRIT J HAEMATOL, V120, P671, DOI 10.1046/j.1365-2141.2003.04137.x; Mcinerney N, 2009, BREAST CANCER RES TR, V117, P151, DOI 10.1007/s10549-008-0235-7; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meyer KB, 2008, PLOS BIOL, V6, P1098, DOI 10.1371/journal.pbio.0060108; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moffa AB, 2007, J CELL PHYSIOL, V210, P720, DOI 10.1002/jcp.20880; Nordgard SH, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1784; Orr N, 2008, ADV GENET, V62, P1, DOI 10.1016/S0065-2660(08)00601-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peto J, 2002, CANCER CELL, V1, P411, DOI 10.1016/S1535-6108(02)00079-X; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Ricol D, 1999, ONCOGENE, V18, P7234, DOI 10.1038/sj.onc.1203186; Ruiz-Narvaez EA, 2010, BREAST CANCER RES TR, V123, P525, DOI 10.1007/s10549-010-0775-5; SIDRANSKY D, 1992, CANCER RES, V52, P2984; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stacey SN, 2008, NAT GENET, V40, P703, DOI 10.1038/ng.131; Stacey SN, 2007, NAT GENET, V39, P865, DOI 10.1038/ng2064; Tamaru N, 2004, LAB INVEST, V84, P1460, DOI 10.1038/labinvest.3700166; Tannheimer SL, 2000, BREAST CANCER RES, V2, P311, DOI 10.1186/bcr73; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Wang XS, 2010, HUM MOL GENET, V19, P2886, DOI 10.1093/hmg/ddq174; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang YZ, 1999, GENE, V230, P69, DOI 10.1016/S0378-1119(99)00047-5	57	80	84	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	17					2121	2128		10.1038/onc.2011.408	http://dx.doi.org/10.1038/onc.2011.408			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21996731	Green Published			2022-12-28	WOS:000303415900001
J	Galluzzi, L; Senovilla, L; Vitale, I; Michels, J; Martins, I; Kepp, O; Castedo, M; Kroemer, G				Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.			Molecular mechanisms of cisplatin resistance	ONCOGENE			English	Review						ATP7B; CTR1; ERCC1; glutathione; metallothioneins; TP53	CELL LUNG-CANCER; NUCLEOTIDE EXCISION-REPAIR; MESSENGER-RNA EXPRESSION; ADENOSINE-TRIPHOSPHATASE ATP7B; SIGNAL-TRANSDUCTION PATHWAY; ANTICANCER DRUG CISPLATIN; HAMSTER OVARY CELLS; DNA MISMATCH REPAIR; MULTIDRUG-RESISTANCE; GENE-EXPRESSION	Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications. Oncogene (2012) 31, 1869-1883; doi:10.1038/onc.2011.384; published online 5 September 2011	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G.] INSERM, Apoptosis Canc & Immun U848, Villejuif, France; [Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.] Univ Paris 11, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	Vitale, Ilio/M-3960-2017; Galluzzi, Lorenzo/AAH-3286-2021; Michels, Judith/Q-5693-2018; Kroemer, Guido/AAY-9859-2020; Galluzzi, Lorenzo/K-2709-2012; KROEMER, Guido/B-4263-2013; Senovilla, Laura/AAX-5599-2021; Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/AAG-6432-2019; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAG-6294-2019	Vitale, Ilio/0000-0002-5918-1841; Michels, Judith/0000-0002-9640-0222; Galluzzi, Lorenzo/0000-0003-2257-8500; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Senovilla, Laura/0000-0001-6887-2436	European Commission (Apo-Sys); Fondation pour la Recherche Medicale (FRM); Ligue Nationale contre le Cancer; Ligue Nationale contre le Cancer (equipe labellisee); AXA Chair for Longevity Research; Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Agence National de la Recherche; LabEx Immuno-Oncology; European Commission (Apo-Sys, ArtForce, ChemoRes. Death-Train)	European Commission (Apo-Sys)(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Ligue Nationale contre le Cancer (equipe labellisee)(Ligue nationale contre le cancer); AXA Chair for Longevity Research(AXA Research Fund); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Agence National de la Recherche(French National Research Agency (ANR)); LabEx Immuno-Oncology; European Commission (Apo-Sys, ArtForce, ChemoRes. Death-Train)(European CommissionEuropean Commission Joint Research Centre)	LG and LS are supported by the European Commission (Apo-Sys) and the Fondation pour la Recherche Medicale (FRM), respectively. IV is funded by the Ligue Nationale contre le Cancer. GK is supported by Ligue Nationale contre le Cancer (equipe labellisee), AXA Chair for Longevity Research, Canceropole Ile-de-France, Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, FRM, Agence National de la Recherche, LabEx Immuno-Oncology and the European Commission (Apo-Sys, ArtForce, ChemoRes. Death-Train).	Aebi S, 1996, CANCER RES, V56, P3087; Ahmad A, 2008, MOL CELL BIOL, V28, P5082, DOI 10.1128/MCB.00293-08; Aida T, 2005, GYNECOL ONCOL, V97, P41, DOI 10.1016/j.ygyno.2004.12.042; Alt A, 2007, SCIENCE, V318, P967, DOI 10.1126/science.1148242; Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Baekelandt MM, 2000, ANTICANCER RES, V20, P1061; Bassett E, 2002, DNA REPAIR, V1, P1003, DOI 10.1016/S1568-7864(02)00150-7; Bellmunt J, 2007, ANN ONCOL, V18, P522, DOI 10.1093/annonc/mdl435; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; Ben David Y, 2002, J CLIN ONCOL, V20, P463, DOI 10.1200/JCO.20.2.463; Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132; BIGGERSTAFF M, 1992, J BIOL CHEM, V267, P6879; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; BRAMSON J, 1993, CANCER RES, V53, P3237; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Ceppi P, 2009, CLIN CANCER RES, V15, P1039, DOI 10.1158/1078-0432.CCR-08-1227; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Chen Helen H. W., 2010, Metal-Based Drugs, P430939, DOI 10.1155/2010/430939; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Choy H, 2006, EXPERT REV ANTICANC, V6, P973, DOI 10.1586/14737140.6.7.973; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; Cui YH, 1999, MOL PHARMACOL, V55, P929; CVITKOVIC E, 1977, CANCER, V39, P1357, DOI 10.1002/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Deng XB, 2009, CANCER RES, V69, P3317, DOI 10.1158/0008-5472.CAN-08-2903; Dent P, 2001, CLIN CANCER RES, V7, P775; Donnelly A, 2008, CURR MED CHEM, V15, P2702, DOI 10.2174/092986708786242895; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; EASTMAN A, 1987, CHEM-BIOL INTERACT, V61, P241, DOI 10.1016/0009-2797(87)90004-4; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Eckardt JR, 2009, J CLIN ONCOL, V27, P2046, DOI 10.1200/JCO.2008.19.3235; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; El-Khateeb M, 1999, J INORG BIOCHEM, V77, P13, DOI 10.1016/S0162-0134(99)00146-4; Erovic BM, 2005, CLIN CANCER RES, V11, P8632, DOI 10.1158/1078-0432.CCR-05-1170; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feldman DR, 2008, JAMA-J AM MED ASSOC, V299, P672, DOI 10.1001/jama.299.6.672; Fijolek J, 2006, INT J BIOL MARKER, V21, P81, DOI 10.1177/172460080602100203; Fink D, 1998, CLIN CANCER RES, V4, P1; Friedman E, 2007, J CELL BIOCHEM, V102, P274, DOI 10.1002/jcb.21451; Furuta T, 2002, CANCER RES, V62, P4899; Gadducci A, 2002, EUR J GYNAECOL ONCOL, V23, P390; Galanski M, 2006, RECENT PAT ANTI-CANC, V1, P285, DOI 10.2174/157489206777442287; Galluzzi L, 2011, ANTIOXID REDOX SIGN, V15, P1691, DOI 10.1089/ars.2010.3504; Gao JC, 2009, CANCER BIOL THER, V8, P1678; Gaur S, 2011, CANC LETT IN PRESS; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Giaccone G, 2000, DRUGS, V59, P9, DOI 10.2165/00003495-200059004-00002; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Gillet LCJ, 2006, CHEM REV, V106, P253, DOI 10.1021/cr040483f; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Gourley C, 2010, J CLIN ONCOL, V28, P2505, DOI 10.1200/JCO.2009.25.1082; Han JY, 2003, MED ONCOL, V20, P355, DOI 10.1385/MO:20:4:355; Handra-Luca A, 2007, CLIN CANCER RES, V13, P3855, DOI 10.1158/1078-0432.CCR-07-0252; HARRAP KR, 1985, CANCER TREAT REV, V12, P21, DOI 10.1016/0305-7372(85)90015-5; Hengstler JG, 1999, CANCER RES, V59, P3206; Hengstler JG, 2001, INT J CANCER, V95, P121, DOI 10.1002/1097-0215(20010320)95:2<121::AID-IJC1021>3.0.CO;2-N; Holzer AK, 2006, CANCER RES, V66, P10944, DOI 10.1158/0008-5472.CAN-06-1710; Holzer AK, 2006, MOL PHARMACOL, V70, P1390, DOI 10.1124/mol.106.022624; Hu Jing, 2010, Genes Cancer, V1, P803; Ikeguchi M, 2001, INT J MOL MED, V8, P661; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Ishida S, 2010, CANCER CELL, V17, P574, DOI 10.1016/j.ccr.2010.04.011; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; Jain HV, 2011, CANCER RES, V71, P705, DOI 10.1158/0008-5472.CAN-10-3174; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Janson V, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.54; Jin J, 2005, CANCER CHEMOTH PHARM, V55, P179, DOI 10.1007/s00280-004-0868-0; Jun HJ, 2008, BRIT J CANCER, V99, P167, DOI 10.1038/sj.bjc.6604464; Kamal NS, 2010, CLIN CANCER RES, V16, P1206, DOI 10.1158/1078-0432.CCR-09-2204; Karczmarek-Borowska B, 2005, FOLIA HISTOCHEM CYTO, V43, P237; KASAHARA K, 1991, CANCER RES, V51, P3237; Katano K, 2002, CANCER RES, V62, P6559; Kato J, 2001, INT J CANCER, V95, P92; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kelland LR, 2000, DRUGS, V59, P1, DOI 10.2165/00003495-200059004-00001; Kelland LR, 2000, DRUGS, V59, P37; KELLAND LR, 1993, CANCER RES, V53, P2581; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KELMAN AD, 1979, CANCER TREAT REP, V63, P1445; Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4; KIDANI Y, 1978, J MED CHEM, V21, P1315, DOI 10.1021/jm00210a029; Kim MK, 2008, CLIN CANCER RES, V14, P4225, DOI 10.1158/1078-0432.CCR-07-4848; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004; Koike K, 1997, CANCER RES, V57, P5475; Korita PV, 2010, ONCOL REP, V23, P965, DOI 10.3892/or_00000721; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; LEWIS AD, 1988, CARCINOGENESIS, V9, P1283, DOI 10.1093/carcin/9.7.1283; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; Li QD, 2000, ANTICANCER RES, V20, P645; Liedert B, 2003, J INVEST DERMATOL, V121, P172, DOI 10.1046/j.1523-1747.2003.12313.x; LOH SY, 1992, BRIT J CANCER, V66, P1109, DOI 10.1038/bjc.1992.419; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500; MELLISH KJ, 1993, BRIT J CANCER, V68, P240, DOI 10.1038/bjc.1993.322; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Michalke B, 2010, J TRACE ELEM MED BIO, V24, P69, DOI 10.1016/j.jtemb.2010.01.006; Michaud WA, 2009, CLIN CANCER RES, V15, P1645, DOI 10.1158/1078-0432.CCR-08-2581; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Miyazaki T, 2005, ANTICANCER RES, V25, P2749; Molnar J, 2010, CURR TOP MED CHEM, V10, P1757; More SS, 2010, J NEUROSCI, V30, P9500, DOI 10.1523/JNEUROSCI.1544-10.2010; Nakamura M, 2004, CANCER SCI, V95, P44, DOI 10.1111/j.1349-7006.2004.tb03169.x; Nakayama K, 2004, CLIN CANCER RES, V10, P2804, DOI 10.1158/1078-0432.CCR-03-0454; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; OConnor PM, 1997, CANCER RES, V57, P4285; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Olaussen KA, 2009, CANCER BIOL THER, V8, P1922, DOI 10.4161/cbt.8.20.9785; OZOLS RF, 1991, CANCER TREAT REV, V18, P77, DOI 10.1016/0305-7372(91)90027-W; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; PENG HQ, 1993, CANCER RES, V53, P3574; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pinho MB, 2009, UROL ONCOL-SEMIN ORI, V27, P382, DOI 10.1016/j.urolonc.2008.03.016; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; PRESTAYKO AW, 1979, CANCER TREAT REV, V6, P17, DOI 10.1016/S0305-7372(79)80057-2; Raez LE, 2010, CLIN LUNG CANCER, V11, P18, DOI 10.3816/CLC.2010.n.003; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Roos WP, 2009, MOL PHARMACOL, V76, P927, DOI 10.1124/mol.109.058131; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Ryan BM, 2009, CANCER TREAT REV, V35, P553, DOI 10.1016/j.ctrv.2009.05.003; Safaei R, 2004, J INORG BIOCHEM, V98, P1607, DOI 10.1016/j.jinorgbio.2004.05.006; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakamoto M, 2001, Hum Cell, V14, P305; Samimi G, 2004, CLIN CANCER RES, V10, P4661, DOI 10.1158/1078-0432.CCR-04-0137; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sanderson BJS, 1996, MUTAT RES-FUND MOL M, V355, P59, DOI 10.1016/0027-5107(96)00022-X; Serrano FA, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-296; Shachar S, 2009, EMBO J, V28, P383, DOI 10.1038/emboj.2008.281; Shen DW, 2010, J CELL PHYSIOL, V225, P822, DOI 10.1002/jcp.22287; Shieh SY, 2000, GENE DEV, V14, P289; Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298; Shuck SC, 2008, CELL RES, V18, P64, DOI 10.1038/cr.2008.2; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH CD, 1993, CANCER RES, V53, P1343; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Stordal B, 2007, CANCER TREAT REV, V33, P347, DOI 10.1016/j.ctrv.2007.01.009; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Timerbaev AR, 2006, CHEM REV, V106, P2224, DOI 10.1021/cr040704h; Usanova S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-248; Vaisman A, 1998, CANCER RES, V58, P3579; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vitale I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001337; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wada H, 1999, EXP HEMATOL, V27, P99, DOI 10.1016/S0301-472X(98)00027-7; Wang HB, 2009, NEURO-ONCOLOGY, V11, P790, DOI 10.1215/15228517-2009-015; Wang JZ, 2006, AM J PHYSIOL-RENAL, V291, pF1300, DOI 10.1152/ajprenal.00509.2005; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang Y, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.79; Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026; Wittschieben JP, 2006, CANCER RES, V66, P134, DOI 10.1158/0008-5472.CAN-05-2982; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Yamamoto K, 2001, CANCER LETT, V168, P173, DOI 10.1016/S0304-3835(01)00532-8; Yamasaki M, 2011, BRIT J CANCER, V104, P707, DOI 10.1038/sj.bjc.6606071; Yang ZJ, 2006, CLIN CANCER RES, V12, P5817, DOI 10.1158/1078-0432.CCR-06-1037; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; YOSHIDA M, 1994, CANCER RES, V54, P3468; Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019; Yuan M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.15; Zhang Y, 2007, CLIN CANCER RES, V13, P2855, DOI 10.1158/1078-0432.CCR-06-2090; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; ZHEN WP, 1992, MOL CELL BIOL, V12, P3689, DOI 10.1128/MCB.12.9.3689; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	193	1691	1731	30	563	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1869	1883		10.1038/onc.2011.384	http://dx.doi.org/10.1038/onc.2011.384			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21892204				2022-12-28	WOS:000302809900001
J	Anensen, N; Hjelle, SM; Van Belle, W; Haaland, I; Silden, E; Bourdon, JC; Hovland, R; Tasken, K; Knappskog, S; Lonning, PE; Bruserud, O; Gjertsen, BT				Anensen, N.; Hjelle, S. M.; Van Belle, W.; Haaland, I.; Silden, E.; Bourdon, J-C; Hovland, R.; Tasken, K.; Knappskog, S.; Lonning, P. E.; Bruserud, O.; Gjertsen, B. T.			Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia	ONCOGENE			English	Article						p53 protein isoform; p53 beta; p53 gamma; acute myeloid leukemia/NPM1/FLT3-ITD	ACUTE MYELOGENOUS LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER PATIENTS; WILD-TYPE P53; AML 10 TRIAL; FUNCTIONAL-CHARACTERIZATION; FAVORABLE PROGNOSIS; NUCLEOPHOSMIN NPM1; NORMAL KARYOTYPE; KINASE-ACTIVITY	The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle progression and tumor suppression is well established, the clinical significance of p53 isoform expression is unknown. A novel bioinformatic analysis of p53 isoform expression in 68 patients with acute myeloid leukemia revealed distinct p53 protein biosignatures correlating with clinical outcome. Furthermore, we show that mutated FLT3, a prognostic marker for short survival in AML, is associated with expression of full-length p53. In contrast, mutated NPM1, a prognostic marker for long-term survival, correlated with p53 isoforms beta and gamma expression. In conclusion, p53 biosignatures contain useful information for cancer evaluation and prognostication. Oncogene (2012) 31, 1533-1545; doi:10.1038/onc.2011.348; published online 22 August 2011	[Gjertsen, B. T.] Univ Bergen, Haukeland Univ Hosp, Hematol Sect, Dept Internal Med,Inst Med, N-5021 Bergen, Norway; [Van Belle, W.] Norut IT, Tromso, Norway; [Bourdon, J-C] Univ Dundee, Sch Med, Dept Surg & Mol Oncol, Inserm European Associated Lab Inserm, Dundee, Scotland; [Hovland, R.] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway; [Tasken, K.] Univ Oslo, Biotechnol Ctr, Oslo, Norway; [Tasken, K.] Univ Oslo, Ctr Mol Med Norway, Nord EMBL Partnership, Oslo, Norway; [Knappskog, S.; Lonning, P. E.] Univ Bergen, Sect Oncol, Inst Med, N-5021 Bergen, Norway; [Knappskog, S.; Lonning, P. E.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Anensen, N.; Hjelle, S. M.; Haaland, I.; Silden, E.; Bruserud, O.; Gjertsen, B. T.] Univ Bergen, Inst Med, Hematol Sect, N-5021 Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Dundee; University of Bergen; Haukeland University Hospital; University of Oslo; University of Oslo; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen	Gjertsen, BT (corresponding author), Univ Bergen, Haukeland Univ Hosp, Hematol Sect, Dept Internal Med,Inst Med, N-5021 Bergen, Norway.	bjorn.gjertsen@med.uib.no	Hjelle, Sigrun M./AAZ-5585-2020; JC, Bourdon/A-4439-2008; Gjertsen, Bjorn T/O-1542-2015; Gjertsen, Bjørn T/AAP-3281-2020	JC, Bourdon/0000-0003-4623-9386; Gjertsen, Bjorn T/0000-0001-9358-9704; Gjertsen, Bjørn T/0000-0001-9358-9704; Lonning, Per Eystein/0000-0002-8890-6303; Tasken, Kjetil/0000-0003-2841-4697; Knappskog, Stian/0000-0002-4153-1655; Haaland, Ingvild/0000-0002-9974-2308	Research Council of Norway; Western Norway Regional Health Authority; Norwegian Cancer Society	Research Council of Norway(Research Council of Norway); Western Norway Regional Health Authority; Norwegian Cancer Society(Norwegian Cancer Society)	This study was supported by grants from the Research Council of Norway's National Program for Research in Functional Genomics, the Western Norway Regional Health Authority and the Norwegian Cancer Society.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Bruserud O, 2003, HAEMATOLOGICA, V88, P416; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Chrisanthar R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003062; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gale RE, 2005, BLOOD, V106, P3768, DOI 10.1182/blood-2005-04-1746; Gale RE, 2005, BLOOD, V106, P3658, DOI 10.1182/blood-2005-03-1323; GJERTSEN BT, 1994, J CELL SCI, V107, P3363; Gjertsen BT, 2002, J HEMATOTH STEM CELL, V11, P469, DOI 10.1089/15258160260090933; Graupner V, 2009, CELL CYCLE, V8, P1238, DOI 10.4161/cc.8.8.8251; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Haferlach C, 2008, LEUKEMIA, V22, P1539, DOI 10.1038/leu.2008.143; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; Hall PA, 2006, J PATHOL, V208, P1, DOI 10.1002/path.1913; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Irish JM, 2007, BLOOD, V109, P2589, DOI 10.1182/blood-2006-02-004234; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; Komeno Y, 2005, LEUKEMIA, V19, P930, DOI 10.1038/sj.leu.2403736; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Lowenberg B, 2003, NEW ENGL J MED, V349, P743, DOI 10.1056/NEJMoa025406; Lowenberg Bob, 2008, Hematology Am Soc Hematol Educ Program, P1, DOI 10.1182/asheducation-2008.1.1; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Pardee TS, 2011, EXP HEMATOL, V39, P473, DOI 10.1016/j.exphem.2011.01.009; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Preudhomme C, 1997, BRIT J HAEMATOL, V98, P502, DOI 10.1046/j.1365-2141.1997.2403057.x; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Schnittger S, 2005, BLOOD, V106, P3733, DOI 10.1182/blood-2005-06-2248; SCHOTTELIUS A, 1994, LEUKEMIA, V8, P1673; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Srinivasa SP, 2002, LEUKEMIA, V16, P244, DOI 10.1038/sj.leu.2402367; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Van Belle Werner, 2006, BMC Bioinformatics, V7, P198, DOI 10.1186/1471-2105-7-198; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wahlin A, 1997, EUR J HAEMATOL, V58, P233; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Yeh PY, 2004, ONCOGENE, V23, P3580, DOI 10.1038/sj.onc.1207426	51	46	47	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1533	1545		10.1038/onc.2011.348	http://dx.doi.org/10.1038/onc.2011.348			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860418				2022-12-28	WOS:000302132000006
J	Brennan, D; Peltonen, S; Dowling, A; Medhat, W; Green, KJ; Wahl, JK; Del Galdo, F; Mahoney, MG				Brennan, D.; Peltonen, S.; Dowling, A.; Medhat, W.; Green, K. J.; Wahl, J. K., III; Del Galdo, F.; Mahoney, M. G.			A role for caveolin-1 in desmoglein binding and desmosome dynamics	ONCOGENE			English	Article						carcinogenesis; caveolin; caveolae; desmoglein; keratinocyte	PLASMA-MEMBRANE; LIPID RAFTS; SIGNAL-TRANSDUCTION; CELL-MIGRATION; BREAST-CANCER; GENE FAMILY; MOUSE SKIN; IN-VIVO; EXPRESSION; GROWTH	Desmoglein-2 (Dsg2) is a desmosomal cadherin that is aberrantly expressed in human skin carcinomas. In addition to its well-known role in mediating intercellular desmosomal adhesion, Dsg2 regulates mitogenic signaling that may promote cancer development and progression. However, the mechanisms by which Dsg2 activates these signaling pathways and the relative contribution of its signaling and adhesion functions in tumor progression are poorly understood. In this study we show that Dsg2 associates with caveolin-1 (Cav-1), the major protein of specialized membrane microdomains called caveolae, which functions in both membrane protein turnover and intracellular signaling. Sequence analysis revealed that Dsg2 contains a putative Cav-1-binding motif. A permeable competing peptide resembling the Cav-1 scaffolding domain bound to Dsg2, disrupted normal Dsg2 staining and interfered with the integrity of epithelial sheets in vitro. Additionally, we observed that Dsg2 is proteolytically processed; resulting in a 95-kDa ectodomain shed product and a 65-kDa membrane-spanning fragment, the latter of which localizes to lipid rafts along with full-length Dsg2. Disruption of lipid rafts shifted Dsg2 to the non-raft fractions, leading to the accumulation of these proteins. Interestingly, Dsg2 proteolytic products are elevated in vivo in skin tumors from transgenic mice overexpressing Dsg2. Collectively, these data are consistent with the possibility that accumulation of truncated Dsg2 protein interferes with desmosome assembly and/or maintenance to disrupt cell-cell adhesion. Furthermore, the association of Dsg2 with Cav-1 may provide a mechanism for regulating mitogenic signaling and modulating the cell-surface presentation of an important adhesion molecule, both of which could contribute to malignant transformation and tumor progression. Oncogene (2012) 31, 1636-1648; doi:10.1038/onc.2011.346; published online 15 August 2011	[Mahoney, M. G.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; [Peltonen, S.] Univ Turku, Dept Dermatol, Turku, Finland; [Peltonen, S.] Turku Univ Hosp, FIN-20520 Turku, Finland; [Green, K. J.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; [Green, K. J.] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wahl, J. K., III] Univ Nebraska Med Ctr, Dept Oral Biol, Lincoln, NE USA; [Del Galdo, F.] Univ Leeds, LMBU, Leeds Inst Mol Med, Scleroderma Res Ctr, Leeds, W Yorkshire, England	Jefferson University; University of Turku; University of Turku; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Leeds	Mahoney, MG (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, 233 S 10th St,Suite 428 BLSB, Philadelphia, PA 19107 USA.	my.mahoney@jefferson.edu	Del+Galdo, Francesco/ABD-9872-2021; Peltonen, Sirkku/C-3133-2008	Del+Galdo, Francesco/0000-0002-8528-2283; Peltonen, Sirkku/0000-0003-0990-1430; Medhat, Walid/0000-0002-6704-2171	National Institutes of Health [R01 AR47938, R01 DE01905, R01 CA122151]; NATIONAL CANCER INSTITUTE [R01CA122151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056067] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Dr Abhilasha Gupta for critically reading the paper and insightful discussions. This work was supported by grants from the National Institutes of Health to M Mahoney (R01 AR47938), J Wahl (R01 DE01905) and K Green (R01 CA122151).	Allen E, 1996, J CELL BIOL, V133, P1367, DOI 10.1083/jcb.133.6.1367; Andl CD, 2001, J INVEST DERMATOL, V117, P1068, DOI 10.1046/j.0022-202x.2001.01528.x; Arribas J, 2006, CANCER METAST REV, V25, P57, DOI 10.1007/s10555-006-7889-6; Bech-Serra JJ, 2006, MOL CELL BIOL, V26, P5086, DOI 10.1128/MCB.02380-05; Biedermann K, 2005, J PATHOL, V207, P199, DOI 10.1002/path.1821; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brennan D, 2009, CELL ADHES MIGR, V3, P148, DOI 10.4161/cam.3.2.7539; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Chen ST, 2004, INT J MOL MED, V14, P577; Cheng X, 2004, J DERMATOL, V31, P171, DOI 10.1111/j.1346-8138.2004.tb00654.x; Cirillo N, 2008, J CELL BIOCHEM, V103, P598, DOI 10.1002/jcb.21431; Del Galdo F, 2008, CURR OPIN RHEUMATOL, V20, P713, DOI 10.1097/BOR.0b013e3283103d27; Delva E, 2008, J BIOL CHEM, V283, P18303, DOI 10.1074/jbc.M710046200; Denault Jean-Bernard, 2008, V414, P191; Denning MF, 1998, EXP CELL RES, V239, P50, DOI 10.1006/excr.1997.3890; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Eshkind L, 2002, EUR J CELL BIOL, V81, P592, DOI 10.1078/0171-9335-00278; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1994, J BIOL CHEM, V269, P30745; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gassmann MG, 2000, EXP CELL RES, V258, P23, DOI 10.1006/excr.2000.4904; Harada H, 1996, ACTA DERM-VENEREOL, V76, P417; Keim SA, 2008, HYBRIDOMA, V27, P249, DOI 10.1089/hyb.2008.0020; Kenny PA, 2007, J CLIN INVEST, V117, P337, DOI 10.1172/JCI29518; Klessner JL, 2009, MOL BIOL CELL, V20, P328, DOI 10.1091/mbc.E08-04-0356; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Kurzen H, 2003, J CUTAN PATHOL, V30, P621, DOI 10.1034/j.1600-0560.2003.00122.x; Lajoie P, 2010, INT REV CEL MOL BIO, V282, P135, DOI 10.1016/S1937-6448(10)82003-9; Laughlin RC, 2004, INFECT IMMUN, V72, P5349, DOI 10.1128/IAI.72.9.5349-5357.2004; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Lorch JH, 2007, CANCER RES, V67, P727, DOI 10.1158/0008-5472.CAN-06-2162; Mahoney MG, 2002, EXP DERMATOL, V11, P115, DOI 10.1034/j.1600-0625.2002.110203.x; Mahoney MG, 2006, EXP DERMATOL, V15, P101, DOI 10.1111/j.1600-0625.2006.00391.x; Nava P, 2007, MOL BIOL CELL, V18, P4565, DOI 10.1091/mbc.E07-05-0426; Okamoto CT, 1998, ADV DRUG DELIVER REV, V29, P215, DOI 10.1016/S0169-409X(97)00080-X; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Rupinder SK, 2007, VASC PHARMACOL, V46, P383, DOI 10.1016/j.vph.2007.01.006; Santiago-Josefat B, 2007, J BIOL CHEM, V282, P8325, DOI 10.1074/jbc.M608826200; SCHAFER S, 1994, EXP CELL RES, V211, P391, DOI 10.1006/excr.1994.1103; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schnitzer JE, 1996, AM J PHYSIOL-HEART C, V270, pH416, DOI 10.1152/ajpheart.1996.270.1.H416; Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f; SEVERS NJ, 1988, J CELL SCI, V90, P341; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song JP, 1996, BIOCHEMISTRY-US, V35, P14806, DOI 10.1021/bi961846b; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trojan L, 2005, ANTICANCER RES, V25, P183; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; Wang PY, 2003, EMBO J, V22, P2658, DOI 10.1093/emboj/cdg255; Whittock NV, 2003, J INVEST DERMATOL, V120, P970, DOI 10.1046/j.1523-1747.2003.12257.x; Zheng XJ, 2003, BBA-MOL CELL RES, V1643, P25, DOI 10.1016/j.bbamcr.2003.08.006	61	51	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1636	1648		10.1038/onc.2011.346	http://dx.doi.org/10.1038/onc.2011.346			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841821	Green Accepted, Green Published			2022-12-28	WOS:000302231400003
J	Nakatake, M; Monte-Mor, B; Debili, N; Casadevall, N; Ribrag, V; Solary, E; Vainchenker, W; Plo, I				Nakatake, M.; Monte-Mor, B.; Debili, N.; Casadevall, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I.			JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms	ONCOGENE			English	Article						JAK2(V617F); p53; MDM2; La protein; myeloproliferative neoplasms	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; HOMOLOGOUS RECOMBINATION; MYELOID METAPLASIA; ESSENTIAL THROMBOCYTHEMIA; PROGNOSTIC-SIGNIFICANCE; HEMATOPOIETIC-CELLS; CANCER-THERAPY; DISORDERS	JAK2(V617F) is a gain of function mutation that promotes cytokine-independent growth of myeloid cells and accounts for a majority of myeloproliferative neoplasms (MPN). Mutations in p53 are rarely found in these diseases before acute leukemia transformation, but this does not rule out a role for p53 deregulation in disease progression. Using Ba/F3-EPOR cells and ex vivo cultured CD34(+) cells from MPN patients, we demonstrate that expression of JAK2(V617F) affected the p53 response to DNA damage. We show that E3 ubiquitin ligase MDM2 accumulated in these cells, due to an increased translation of MDM2 mRNA. Accumulation of the La autoantigen, which interacts with MDM2 mRNA and promotes its translation, was responsible for the increase in MDM2 protein level and the subsequent degradation of p53 after DNA damage. Downregulation of La protein or cell treatment with nutlin-3, a MDM2 antagonist, restored the p53 response to DNA damage and the cytokine-dependence of Ba/F3-EPOR-JAK2(V617F) cells. Altogether, these data indicate that the JAK2(V617F) mutation affects p53 response to DNA damage through the upregulation of La antigen and accumulation of MDM2. They also suggest that p53 functional inactivation accounts for the cytokine hypersensitivity of JAK2(V617F) MPN and might have a role in disease progression. Oncogene ( 2012) 31, 1323-1333; doi:10.1038/onc.2011.313; published online 25 July 2011	[Nakatake, M.; Monte-Mor, B.; Debili, N.; Casadevall, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I.] INSERM, UMR 1009, Villejuif, France; [Nakatake, M.; Monte-Mor, B.; Debili, N.; Ribrag, V.; Solary, E.; Vainchenker, W.; Plo, I.] Univ Paris 11, Inst Gustave Roussy, UMR1009, Villejuif, France; [Plo, I.] Inst Gustave Roussy, INSERM, U1009, F-94805 Villejuif, France; [Casadevall, N.] Hop St Antoine, AP HP, Hematol Lab, F-75571 Paris, France; [Casadevall, N.] Univ Paris 06, F-75252 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Plo, I (corresponding author), Inst Gustave Roussy, INSERM, U1009, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	isabelle.plo@igr.fr	Da Costa Reis Monte Mor, Barbara DCR/A-9909-2015; Plo, Isabelle/C-9056-2017; Plo, Isabelle/AAT-6742-2021	Plo, Isabelle/0000-0002-5915-6910; Vainchenker, William/0000-0003-4705-202X; Solary, Eric/0000-0002-8629-1341	Ligue Nationale Contre le Cancer; INCa; INSERM; Fondation pour la Recherche Medicale	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); INCa(Institut National du Cancer (INCA) France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	We thank all the patients and the controls who participated in the study, and AstraZeneca for the gift of the JAK2 inhibitor (AZD1480). We are grateful to Drs LT Vassilev and R Fahraeus for fruitful discussion. We also thank Dr F Wendling for critical reading of the manuscript. This work was supported by grants from the Ligue Nationale Contre le Cancer (equipe labellisee 2007-2010 et 2010-2012), INCa (projets libres 2007) and INSERM. IP was a recipient from INCA, MN from the Ligue Nationale Contre le Cancer, BMM from the Fondation pour la Recherche Medicale.	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Barosi G, 1999, BRIT J HAEMATOL, V104, P730, DOI 10.1046/j.1365-2141.1999.01262.x; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; Berthebaud M, 2005, BLOOD, V106, P2962, DOI 10.1182/blood-2005-02-0526; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; Cummings WJ, 2007, PLOS BIOL, V5, P2145, DOI 10.1371/journal.pbio.0050246; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Gaidano G, 1997, GENE CHROMOSOME CANC, V19, P250; Gangat N, 2008, EUR J HAEMATOL, V80, P197, DOI 10.1111/j.1600-0609.2007.01003.x; Goetz AW, 2001, CANCER RES, V61, P7635; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Ishiguro K, 2005, MOL CANCER THER, V4, P1755, DOI 10.1158/1535-7163.MCT-05-0169; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jastrzebski K, 2007, GROWTH FACTORS, V25, P209, DOI 10.1080/08977190701779101; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; Kawamata N, 2008, EXP HEMATOL, V36, P1471, DOI 10.1016/j.exphem.2008.06.006; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030; Le Scolan E, 2001, ONCOGENE, V20, P5484, DOI 10.1038/sj.onc.1204708; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Liu R, 2000, ONCOGENE, V19, P571, DOI 10.1038/sj.onc.1203364; Maetens M, 2007, BLOOD, V109, P2630, DOI 10.1182/blood-2006-03-013656; Mendrysa SM, 2001, GENE, V264, P139, DOI 10.1016/S0378-1119(00)00589-8; Michiels JJ, 2000, LEUKEMIA LYMPHOMA, V36, P239, DOI 10.3109/10428190009148845; Perrotti D, 2007, CLIN CANCER RES, V13, P1638, DOI 10.1158/1078-0432.CCR-06-2320; Plo I, 2008, BLOOD, V112, P1402, DOI 10.1182/blood-2008-01-134114; Reilly JT, 2005, SEMIN ONCOL, V32, P359, DOI 10.1053/j.seminoncol.2005.04.007; Seliger B, 1996, EUR J HAEMATOL, V57, P230; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shide K, 2008, LEUKEMIA, V22, P87, DOI 10.1038/sj.leu.2405043; Sieff CA, 2010, BRIT J HAEMATOL, V148, P611, DOI 10.1111/j.1365-2141.2009.07993.x; Smith ML, 2002, MUTAGENESIS, V17, P149, DOI 10.1093/mutage/17.2.149; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tefferi A, 2009, LEUKEMIA RES, V33, P662, DOI 10.1016/j.leukres.2008.09.009; Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Tsurumi S, 2002, AM J HEMATOL, V71, P131, DOI 10.1002/ajh.10188; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wernig G, 2006, BLOOD, V107, P4274, DOI 10.1182/blood-2005-12-4824; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Zhao R, 2008, NEW ENGL J MED, V359, P2778, DOI 10.1056/NEJMoa0804953; Zhou M, 2000, LEUKEMIA, V14, P61, DOI 10.1038/sj.leu.2401619	49	80	82	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1323	1333		10.1038/onc.2011.313	http://dx.doi.org/10.1038/onc.2011.313			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785463				2022-12-28	WOS:000301344600011
J	Xu, Y; Zhao, F; Wang, Z; Song, Y; Luo, Y; Zhang, X; Jiang, L; Sun, Z; Miao, Z; Xu, H				Xu, Y.; Zhao, F.; Wang, Z.; Song, Y.; Luo, Y.; Zhang, X.; Jiang, L.; Sun, Z.; Miao, Z.; Xu, H.			MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1	ONCOGENE			English	Article						MicroRNA; gastric cancer; miR-335; SP1; Bcl-w	TRANSCRIPTION FACTOR SP1; SINGLE NUCLEOTIDE POLYMORPHISM; DOWN-REGULATION; TUMOR-SUPPRESSOR; EXPRESSION; GENE; FAMILY; RISK; PROLIFERATION; APOPTOSIS	Aberrant expression of miR-335 has been frequently reported in cancer studies, suggesting that there is a close correlation between miR-335 and cancer during its development, progression, metastasis and prognosis. The expression of miR-335 in gastric cancer and its effects are not known. Relative expression of miR-335 in 4 gastric cancer cell lines and in 70 gastric cancer tissues was confirmed by real-time quantitative reverse transcriptase-PCR compared with controls. Transwell cell migration and Matrigel invasion assay in vitro and metastasis formation assay in vivo were used to examine the effects of miR-335 expression on gastric cancer cell invasion and metastasis. The effect of miR-335 expression on gastric cancer cell proliferation was estimated by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. Luciferase reporter assay and western blot were used to examine the potential target genes and related pathways. Gene silencing with small-interfering RNA was used to examine the effects of target genes on gastric cancer cell invasion. miR-335 was dramatically down-regulated in gastric cancer cell lines than in the normal gastric cell line GES-1. Low expression of miR-335 was significantly associated with lymph-node metastasis, poor pT stage, poor pN stage and invasion of lymphatic vessels. Overexpression of miR-335 suppressed gastric cancer cell invasion and metastasis in vitro and in vivo, but has no significant effects on cell proliferation. Furthermore, miR-335 might suppress gastric cancer invasion and metastasis by targeting Bcl-w and specificity protein 1 (SP1). Taken together, our results provide evidence that miR-335 might function as a metastasis suppressor in gastric cancer by targeting SP1 directly and indirectly through the Bcl-w-induced phosphoinositide 3-kinase-Akt-Sp1 pathway. miR-335 showing altered expression at different stages of gastric cancer could be a target for gastric cancer therapies and could be further developed as a potential prognostic factor. Oncogene (2012) 31, 1398-1407; doi:10.1038/onc.2011.340; published online 8 August 2011	[Xu, Y.; Zhao, F.; Wang, Z.; Song, Y.; Sun, Z.; Miao, Z.; Xu, H.] China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, Shenyang 110001, Peoples R China; [Xu, Y.] China Med Univ, Dept Breast Surg, Hosp 1, Shenyang 110001, Peoples R China; [Luo, Y.; Zhang, X.; Jiang, L.] China Med Univ, Res Ctr Med Genom, Shenyang 110001, Peoples R China; [Luo, Y.; Zhang, X.; Jiang, L.] China Med Univ, MOH Key Lab Cell Biol, Shenyang 110001, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University	Xu, H (corresponding author), China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, 155 N Nanjing St, Shenyang 110001, Peoples R China.	huimianxu@yahoo.cn	wang, zhen ning/E-1878-2011; Gao, Peng/B-8031-2013; Xu, Yingying/E-3884-2018	wang, zhen ning/0000-0003-0557-3097; Xu, Yingying/0000-0003-4924-9379	National Science Foundation of China [81000943, 30873043]; Scientific Research Foundation for Doctors of Liaoning Province [20101146]; Key Laboratory Programme of Education Department of Liaoning Province [LS2010165]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for Doctors of Liaoning Province; Key Laboratory Programme of Education Department of Liaoning Province	We thank the Department of Surgical Oncology of the First Hospital of China Medical University for providing human gastric tissue samples. We also thank the College of China Medical University for technical assistance in experiments. This work was supported by the National Science Foundation of China (no. 81000943 and no. 30873043), the Scientific Research Foundation for Doctors of Liaoning Province (no. 20101146) and the Key Laboratory Programme of Education Department of Liaoning Province (LS2010165).	Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254; Bae IH, 2009, CANCER LETT, V277, P22, DOI 10.1016/j.canlet.2008.11.022; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2; Chiang YP, 2011, J GASTROINTEST SURG, V15, P63, DOI 10.1007/s11605-010-1367-8; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Du Y, 2009, J GASTROENTEROL, V44, P556, DOI 10.1007/s00535-009-0037-7; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Jiang CG, 2010, J SURG ONCOL, V102, P737, DOI 10.1002/jso.21678; Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Lee HW, 2003, CANCER RES, V63, P1093; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lou Z, 2005, CANCER RES, V65, P1007; Marcucci G, 2008, J CLIN ONCOL, V26, P5078, DOI 10.1200/JCO.2008.17.5554; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ronchetti D, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-37; Song YX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-1; Soon PSH, 2009, CLIN CANCER RES, V15, P7684, DOI 10.1158/1078-0432.CCR-09-1587; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; Sun Z, 2010, ANN SURG ONCOL, V17, P1278, DOI 10.1245/s10434-009-0890-x; Sun Z, 2009, ANN SURG ONCOL, V16, P3028, DOI 10.1245/s10434-009-0624-0; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Uren RT, 2007, J CELL BIOL, V177, P277, DOI 10.1083/jcb.200606065; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126; Wang FJ, 2010, GYNECOL ONCOL, V119, P586, DOI 10.1016/j.ygyno.2010.07.021; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang LW, 2005, CLIN EXP METASTAS, V22, P205, DOI 10.1007/s10585-005-5684-3; Wang YX, 2010, J DIGEST DIS, V11, P50, DOI 10.1111/j.1751-2980.2009.00413.x; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Wu Q, 2010, BIOCHEM BIOPH RES CO, V392, P340, DOI 10.1016/j.bbrc.2009.12.182; Xu YY, 2007, WORLD J GASTROENTERO, V13, P5133, DOI 10.3748/wjg.v13.i38.5133; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Yao MZ, 2005, J NEUROSCI, V25, P1149, DOI 10.1523/JNEUROSCI.4736-04.2005; Yu CY, 2002, CANCER RES, V62, P6430; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826	49	163	175	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1398	1407		10.1038/onc.2011.340	http://dx.doi.org/10.1038/onc.2011.340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822301	Green Published, hybrid			2022-12-28	WOS:000301780000007
J	Martens-Uzunova, ES; Jalava, SE; Dits, NF; van Leenders, GJLH; Moller, S; Trapman, J; Bangma, CH; Litman, T; Visakorpi, T; Jenster, G				Martens-Uzunova, E. S.; Jalava, S. E.; Dits, N. F.; van Leenders, G. J. L. H.; Moller, S.; Trapman, J.; Bangma, C. H.; Litman, T.; Visakorpi, T.; Jenster, G.			Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer	ONCOGENE			English	Article						prostate cancer; microRNA; snoRNA; microarray; deep sequencing; Q-PCR	MICRORNA EXPRESSION; GENE-EXPRESSION; UP-REGULATION; RECEPTOR; SNORNA; ACTIVATION; INVASION; REVEALS; PROFILE; KINASE	Prostate cancer (PCa) is the most frequent male malignancy and the second most common cause of cancer-related death in Western countries. Current clinical and pathological methods are limited in the prediction of postoperative outcome. It is becoming increasingly evident that small non-coding RNA (ncRNA) species are associated with the development and progression of this malignancy. To assess the diversity and abundance of small ncRNAs in PCa, we analyzed the composition of the entire small transcriptome by Illumina/Solexa deep sequencing. We further analyzed the microRNA (miRNA) expression signatures of 102 fresh-frozen patient samples during PCa progression by miRNA microarrays. Both platforms were cross-validated by quantitative reverse transcriptase-PCR. Besides the altered expression of several miRNAs, our deep sequencing analyses revealed strong differential expression of small nucleolar RNAs (snoRNAs) and transfer RNAs (tRNAs). From microarray analysis, we derived a miRNA diagnostic classifier that accurately distinguishes normal from cancer samples. Furthermore, we were able to construct a PCa prognostic predictor that independently forecasts postoperative outcome. Importantly, the majority of miRNAs included in the predictor also exhibit high sequence counts and concordant differential expression in Illumina PCa samples, supported by quantitative reverse transcriptase-PCR. Our findings provide miRNA expression signatures that may serve as an accurate tool for the diagnosis and prognosis of PCa. Oncogene (2012) 31, 978-991; doi:10.1038/onc.2011.304; published online 18 July 2011	[Martens-Uzunova, E. S.; Dits, N. F.; Bangma, C. H.; Jenster, G.] Erasmus MC, Dept Urol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands; [Jalava, S. E.; Visakorpi, T.] Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; [Jalava, S. E.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [van Leenders, G. J. L. H.; Trapman, J.] Erasmus MC, Dept Pathol, Josephine Nefkens Inst, NL-3000 CA Rotterdam, Netherlands; [Moller, S.; Litman, T.] Exiqon AS, Vedbaek, Denmark	Erasmus University Rotterdam; Erasmus MC; Tampere University; Tampere University; Tampere University Hospital; Erasmus University Rotterdam; Erasmus MC; Exiqon	Jenster, G (corresponding author), Erasmus MC, Dept Urol, Josephine Nefkens Inst, Room BE362A,POB 2040, NL-3000 CA Rotterdam, Netherlands.	g.jenster@erasmusmc.nl	Martens-Uzunova, Elena/D-9768-2012	Martens-Uzunova, Elena/0000-0002-5363-2525; Visakorpi, Tapio/0000-0002-5004-0364; Litman, Thomas/0000-0002-6068-901X	European Community [HEALTH-F2-2007-201438]; Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; Tampere University Hospital	European Community(European Commission); Academy of Finland(Academy of Finland); Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Tampere University Hospital	We thank Theo van der Kwast for histo-pathological examination of patient samples. We also thank Mark Wildhagen for providing the coded clinical data. We acknowledge the European Community's Seventh Framework Program (FP7/2007-2013), grant agreement No HEALTH-F2-2007-201438, the Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; and the Medical Research Fund of Tampere University Hospital for their support.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Catto JWF, 2011, EUR UROL, V59, P671, DOI 10.1016/j.eururo.2011.01.044; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de Wit E, 2009, GENOME RES, V19, P2064, DOI 10.1101/gr.093781.109; Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; Git A, 2010, RNA, V16, P991, DOI 10.1261/rna.1947110; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Lee JT, 2008, CELL CYCLE, V7, P1745, DOI 10.4161/cc.7.12.6166; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488; Marberger M, 2009, EUR UROL SUPPL, V8, P89, DOI 10.1016/j.eursup.2008.10.003; Marshall L, 2008, NAT REV CANCER, V8, P911, DOI 10.1038/nrc2539; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Michael MZ, 2003, MOL CANCER RES, V1, P882; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Paronetto MP, 2004, AM J PATHOL, V164, P1243, DOI 10.1016/S0002-9440(10)63212-9; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786; Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592; Reis EM, 2004, ONCOGENE, V23, P6684, DOI 10.1038/sj.onc.1207880; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Royo H, 2006, CYTOGENET GENOME RES, V113, P99, DOI 10.1159/000090820; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Szczyrba J, 2010, MOL CANCER RES, V8, P529, DOI 10.1158/1541-7786.MCR-09-0443; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Willenbrock H, 2009, RNA, V15, P2028, DOI 10.1261/rna.1699809; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200	50	197	213	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					978	991		10.1038/onc.2011.304	http://dx.doi.org/10.1038/onc.2011.304			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765474				2022-12-28	WOS:000300709700004
J	Rao, S; Lyons, LS; Fahrenholtz, CD; Wu, F; Farooq, A; Balkan, W; Burnstein, KL				Rao, S.; Lyons, L. S.; Fahrenholtz, C. D.; Wu, F.; Farooq, A.; Balkan, W.; Burnstein, K. L.			A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer	ONCOGENE			English	Article						Vav3; pleckstrin homology; coactivator; androgen receptor; castration-resistant prostate cancer; guanine nucleotide exchange factor	PLECKSTRIN-HOMOLOGY DOMAINS; MOLECULAR DETERMINANTS; STRUCTURAL BASIS; ACTIVATION; BINDING; RECOGNITION; PROGRESSION; ONCOGENE; FAMILY; PH	Increased androgen receptor (AR) transcriptional activity mediated by coactivator proteins may drive castration-resistant prostate cancer (CRPC) growth. Vav3, a Rho GTPase guanine nucleotide exchange factor (GEF), is overexpressed in human prostate cancers, particularly in models of CRPC progression. Vav3 coactivates AR in a Vav3 pleckstrin homology (PH) domain-dependent but GEF-independent manner. Ectopic expression of Vav3 in androgen-dependent human prostate cancer cells conferred robust castration-resistant xenograft tumor growth. Vav3 but not a Vav3 PH mutant greatly stimulated interaction between the AR amino and carboxyl termini (N-C interaction), which is required for maximal receptor transcriptional activity. Vav3 was distributed between the cytoplasm and nucleus with nuclear localization-dependent on the Vav3 PH domain. Membrane targeting of Vav3 abolished Vav3 potentiation of AR activity, whereas nuclear targeting of a Vav3 PH mutant rescued AR coactivation, suggesting that nuclear localization is an important function of the Vav3 PH domain. A nuclear role for Vav3 was further demonstrated by sequential chromatin immunoprecipitation assays, which revealed that Vav3 and AR were recruited to the same transcriptional complexes of an AR target gene enhancer. These data demonstrate the importance of Vav3 in CRPC and define a novel nuclear function of Vav3 in regulating AR activity. Oncogene (2012) 31, 716-727; doi:10.1038/onc.2011.273; published online 18 July 2011	[Rao, S.; Fahrenholtz, C. D.; Wu, F.; Burnstein, K. L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Lyons, L. S.] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Farooq, A.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Balkan, W.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; Nova Southeastern University; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,R-189, Miami, FL 33136 USA.	kburnstein@med.miami.edu	Rao, Shuyun/AAE-9724-2019; Fahrenholtz, Cale/GWZ-4512-2022; Farooq, Amjad/B-5084-2012		National Institutes of Health [RO1CA132200]; US Department of Defense [PC060504];  [T32-HL007188];  [R01GM083897]; NATIONAL CANCER INSTITUTE [R01CA132200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083897] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Zafar Nawaz and his laboratory for advice on ChIP assays. We thank Drs Adena Rosenblatt, Omar Flores and Carlos Perez-Stable for helpful suggestions. Zhe Ma provided assistance with the mammalian two-hybrid assays. A National Institutes of Health Grant RO1CA132200 (to KLB) supported this work. LSL and FW were supported by US Department of Defense post-doctoral fellowship (PC060504); SR was an American Heart Association Pre-doctoral Fellow; CDF was supported by T32-HL007188 and AF acknowledges funding from R01GM083897.	Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Banach-Petrosky W, 2007, CANCER RES, V67, P9089, DOI 10.1158/0008-5472.CAN-07-2887; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Brantley-Sieders DM, 2009, MOL CANCER RES, V7, P615, DOI 10.1158/1541-7786.MCR-08-0401; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Dong ZY, 2006, MOL ENDOCRINOL, V20, P2315, DOI 10.1210/me.2006-0048; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Korenchuk S, 2001, IN VIVO, V15, P163; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lemmon MA, 1999, BIOCHEM SOC T, V27, P617, DOI 10.1042/bst0270617; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Lemmon MA, 2007, BIOCHEM SOC SYMP, V74, P81, DOI 10.1042/BSS2007c08; Liu Y, 2008, CANCER RES, V68, P6396, DOI 10.1158/0008-5472.CAN-08-0645; Liu Y, 2010, INT J ONCOL, V36, P623, DOI 10.3892/ijo_00000538; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lyons LS, 2008, MOL ENDOCRINOL, V22, P597, DOI 10.1210/me.2007-0158; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Maffucci T, 2003, MOL ENDOCRINOL, V17, P1568, DOI 10.1210/me.2001-0211; Mahadevan D, 2008, MOL CANCER THER, V7, P2621, DOI 10.1158/1535-7163.MCT-07-2276; Marques RB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013500; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Miller SL, 2005, MOL ENDOCRINOL, V19, P939, DOI 10.1210/me.2004-0443; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Movilla N, 1999, MOL CELL BIOL, V19, P7870; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Patel V, 2007, CARCINOGENESIS, V28, P1145, DOI 10.1093/carcin/bgm008; Rapley J, 2008, EMBO REP, V9, P655, DOI 10.1038/embor.2008.80; Sartor O, 2002, UROLOGY, V60, P138; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Schmidt LJ, 2009, PROSTATE, V69, P1730, DOI 10.1002/pros.21022; Shen HC, 2005, BIOL CHEM, V386, P69, DOI 10.1515/BC.2005.009; Tindall DJ, 2001, UROLOGY, V57, P28, DOI 10.1016/S0090-4295(00)00932-8; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Xi SL, 2010, FEBS LETT, V584, P1223, DOI 10.1016/j.febslet.2010.02.036; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	57	36	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					716	727		10.1038/onc.2011.273	http://dx.doi.org/10.1038/onc.2011.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21765461	Green Accepted			2022-12-28	WOS:000300222100005
J	Kondratyev, M; Kreso, A; Hallett, RM; Girgis-Gabardo, A; Barcelon, ME; Ilieva, D; Ware, C; Majumder, PK; Hassell, JA				Kondratyev, M.; Kreso, A.; Hallett, R. M.; Girgis-Gabardo, A.; Barcelon, M. E.; Ilieva, D.; Ware, C.; Majumder, P. K.; Hassell, J. A.			Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer	ONCOGENE			English	Article						breast cancer; tumor-initiating cells; cancer stem cells; gamma-secretase inhibitors; Notch signaling; transgenic mouse models	MAMMARY STEM/PROGENITOR CELLS; LYMPHOBLASTIC-LEUKEMIA CELLS; NOTCH SIGNALING PATHWAY; SUSPENSION BIOREACTORS; NEU PROTOONCOGENE; STEM-CELLS; IN-VITRO; FATE; ACTIVATION; EXPRESSION	Human breast tumors comprise a minor sub-population of tumor-initiating cells (TICs), commonly termed cancer stem cells. TICs are thought to sustain tumor growth and to confer resistance to current anticancer therapies. Hence, targeting TIC may be essential to achieving durable cancer cures. To identify molecular targets in breast TIC, we employed a transgenic mouse model of ERBB2 breast cancer; tumors arising in this model comprise a very high frequency of TIC, which is maintained in tumor cell populations propagated in vitro as non-adherent tumor-spheres. The Notch pathway is dysregulated in human breast tumors and overexpression of constitutively active Notch proteins induces mammary tumors in mice. The Notch pathway has also been implicated in stem cell processes including those of mammary epithelial stem cells. Hence, we investigated the potential that the Notch pathway is required for TIC activity. We found that an antagonist of Notch signaling, a gamma (gamma)-secretase inhibitor termed MRK-003, inhibited the survival of tumorsphere-derived cells in vitro and eliminated TIC as assessed by cell transplantation into syngeneic mice. Whereas MRK-003 also inhibited the self-renewal and/or proliferation of mammosphere-resident cells, this effect of the inhibitor was reversible thus suggesting that it did not compromise the survival of these cells. MRK-003 administration to tumor-bearing mice eliminated tumor-resident TIC and resulted in rapid and durable tumor regression. MRK-003 inhibited the proliferation of tumor cells, and induced their apoptosis and differentiation. These findings suggest that MRK-003 targets breast TIC and illustrate that eradicating these cells in breast tumors ensures long-term, recurrence-free survival. Oncogene (2012) 31, 93-103; doi: 10.1038/onc.2011.212; published online 13 June 2011	[Kondratyev, M.; Kreso, A.; Hallett, R. M.; Girgis-Gabardo, A.; Barcelon, M. E.; Ilieva, D.; Hassell, J. A.] McMaster Univ, Dept Biochem & Biomed Sci, Ctr Funct Genom, Hamilton, ON L8N 3Z5, Canada; [Ware, C.] Merck Res Labs, Dept Biomol Markers, Boston, MA USA; [Majumder, P. K.] Merck Res Labs, Dept Oncol, Boston, MA USA; [Majumder, P. K.] Merck Res Labs, Dept Pharmacol, Boston, MA USA	McMaster University; Merck & Company; Merck & Company; Merck & Company	Hassell, JA (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Ctr Funct Genom, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	hassell@mcmaster.ca			Stem Cell Network; Canadian Breast Cancer Foundation (CBCF); Terry Fox Research Institute/Ontario Institute for Cancer Research	Stem Cell Network; Canadian Breast Cancer Foundation (CBCF); Terry Fox Research Institute/Ontario Institute for Cancer Research	The Stem Cell Network, Canadian Breast Cancer Foundation (CBCF) and the Terry Fox Research Institute/Ontario Institute for Cancer Research provided operating grants to JAH to support the research described herein. MK is the recipient of a CBCF fellowship.	Borowsky AD, 2004, COMPARATIVE MED, V54, P258; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Cardiff RD, 2003, COMPARATIVE MED, V53, P250; Cardiff RD, 2001, VET PATHOL, V38, P357, DOI 10.1354/vp.38-4-357; Chang JC, 2005, J CLIN ONCOL, V23, P1169, DOI 10.1200/JCO.2005.03.156; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cullion K, 2009, BLOOD, V113, P6172, DOI 10.1182/blood-2008-02-136762; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Efferson CL, 2010, CANCER RES, V70, P2476, DOI 10.1158/0008-5472.CAN-09-3114; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kurpios NA, 2009, DEV BIOL, V325, P106, DOI 10.1016/j.ydbio.2008.09.033; Lewis HD, 2007, CHEM BIOL, V14, P209, DOI 10.1016/j.chembiol.2006.12.010; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Rao SS, 2009, CANCER RES, V69, P3060, DOI 10.1158/0008-5472.CAN-08-4295; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Sawey ET, 2008, CELL CYCLE, V7, P566, DOI 10.4161/cc.7.5.5531; Sawey ET, 2007, P NATL ACAD SCI USA, V104, P19327, DOI 10.1073/pnas.0705953104; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Smalley MJ, 1998, IN VITRO CELL DEV-AN, V34, P711; Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1111/j.1432-0436.1998.00201.x; Tammam J, 2009, BRIT J PHARMACOL, V158, P1183, DOI 10.1111/j.1476-5381.2009.00389.x; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Youn BS, 2006, BIOTECHNOL PROGR, V22, P801, DOI 10.1021/bp050430z; Youn BS, 2005, BIOTECHNOL PROGR, V21, P984, DOI 10.1021/bp050059f; Zhang P, 2010, ONCOGENE, V29, P2916, DOI 10.1038/onc.2010.62	44	80	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					93	103		10.1038/onc.2011.212	http://dx.doi.org/10.1038/onc.2011.212			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666715				2022-12-28	WOS:000299176200009
J	Germann, S; Gratadou, L; Zonta, E; Dardenne, E; Gaudineau, B; Fougere, M; Samaan, S; Dutertre, M; Jauliac, S; Auboeuf, D				Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Gaudineau, B.; Fougere, M.; Samaan, S.; Dutertre, M.; Jauliac, S.; Auboeuf, D.			Dual role of the ddx5/ddx17 RNA helicases in the control of the pro-migratory NFAT5 transcription factor	ONCOGENE			English	Article						ddx5; ddx17; NFAT5; cancer; transcriptional coregulator; splicing	CANCER CELL MOTILITY; DEAD-BOX PROTEINS; BINDING-PROTEIN; SPLICING REGULATION; LIPOCALIN 2; P68; EXPRESSION; S100A4; GENE; COACTIVATOR	Ddx5 and ddx17 are two highly related RNA helicases involved in both transcription and splicing. These proteins coactivate transcription factors involved in cancer such as the estrogen receptor alpha, p53 and beta-catenin. Ddx5 and ddx17 are part of the splicing machinery and can modulate alternative splicing, the main mechanism increasing the proteome diversity. Alternative splicing also has a role in gene expression level regulation when it is coupled to the nonsense-mediated mRNA decay (NMD) pathway. In this work, we report that ddx5 and ddx17 have a dual role in the control of the pro-migratory NFAT5 transcription factor. First, ddx5 and ddx17 act as transcriptional coactivators of NFAT5 and are required for activating NFAT5 target genes involved in tumor cell migration. Second, at the splicing level, ddx5 and ddx17 increase the inclusion of NFAT5 exon 5. As exon 5 contains a pre-mature translation termination codon, its inclusion leads to the regulation of NFAT5 mRNAs by the NMD pathway and to a decrease in NFAT5 protein level. Therefore, we demonstrated for the first time that a transcriptional coregulator can simultaneously regulate the transcriptional activity and alternative splicing of a transcription factor. This dual regulation, where ddx5 and ddx17 enhance the transcriptional activity of NFAT5 although reducing its protein expression level, suggests a critical role for ddx5 and ddx17 in tumor cell migration through the fine regulation of NFAT5 pathway. Oncogene (2012) 31, 4536-4549; doi:10.1038/onc.2011.618; published online 23 January 2012	[Auboeuf, D.] Ctr Leon Berard, Ctr Rech Cancerol Lyon, F-69008 Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] Univ Lyon, Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] INSERM, U1052, F-69008 Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] CNRS, UMR5286, Lyon, France; [Germann, S.; Gratadou, L.; Zonta, E.; Dardenne, E.; Samaan, S.; Dutertre, M.; Auboeuf, D.] Univ Lyon 1, F-69365 Lyon, France; [Gaudineau, B.; Fougere, M.; Jauliac, S.] Univ Paris Diderot, Hop St Louis, Inst Hematol, CNRS,UMR7212,INSERM,U944, Paris, France	UNICANCER; Centre Leon Berard; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Auboeuf, D (corresponding author), Ctr Leon Berard, Ctr Rech Cancerol Lyon, 28 Rue Laennec, F-69008 Lyon, France.	didier.auboeuf@inserm.fr	DUTERTRE, Martin/Q-1815-2019; Dutertre, Martin/N-7060-2017; Jauliac, Sebastien/B-7847-2010; Auboeuf, Didier/M-4610-2014; Zonta, E/B-8928-2013	DUTERTRE, Martin/0000-0003-0278-4120; Dutertre, Martin/0000-0003-0278-4120; Jauliac, Sebastien/0000-0002-1712-3416; Zonta, E/0000-0001-8106-0504; Auboeuf, Didier/0000-0002-3757-0002	EC (NoE EURASNET); Institut National du Cancer; Association pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; Agence Nationale de la Recherche; French Ministry of Education	EC (NoE EURASNET); Institut National du Cancer(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche(French National Research Agency (ANR)); French Ministry of Education	We thank S Kato and J Marie for providing wild-type and mutant ddx5 and ddx17 expression vectors. We thank Emanuele Buratti for providing pTB minigene construct. We thank Coralie Poulard and Muriel Le Romancer-Cherifi for their help with PLA. This work was supported by EC (NoE EURASNET), Institut National du Cancer, Association pour la Recherche sur le Cancer, Ligue Nationale Contre le Cancer and Agence Nationale de la Recherche. S Germann, B Gaudineau and M Fougere were supported by Association pour la Recherche sur le Cancer; L Gratadou by Agence Nationale de la Recherche; E Zonta by the French Ministry of Education; E Dardenne by Ligue Nationale Contre le Cancer.	Allemand E, 2008, CURR OPIN GENET DEV, V18, P145, DOI 10.1016/j.gde.2008.01.006; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Auboeuf D, 2007, TRENDS ENDOCRIN MET, V18, P122, DOI 10.1016/j.tem.2007.02.003; Ayers M, 2004, J CLIN ONCOL, V22, P2284, DOI 10.1200/JCO.2004.05.166; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Barbier J, 2007, MOL CELL BIOL, V27, P7315, DOI 10.1128/MCB.00272-07; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Bittencourt D, 2008, MOL CELL BIOL, V28, P5811, DOI 10.1128/MCB.02231-07; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Camats M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002926; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Carter CL, 2010, ONCOGENE, V29, P5427, DOI 10.1038/onc.2010.276; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chang YF, 2007, J BIOL CHEM, V282, P29738, DOI 10.1074/jbc.M704372200; Chen M, 2011, AM J PHYSIOL-CELL PH, V300, pC1155, DOI 10.1152/ajpcell.00407.2010; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Chen Y, 2007, AM J PHYSIOL-RENAL, V292, pP981, DOI 10.1152/ajprenal.00493.2005; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Dalski A, 2002, CYTOGENET GENOME RES, V97, P179, DOI 10.1159/000066604; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; Davies MPA, 1996, ONCOGENE, V13, P1631; Dutertre M, 2010, RNA BIOL, V7, P403, DOI 10.4161/rna.7.4.12152; Dutertre M, 2010, CANCER RES, V70, P3760, DOI 10.1158/0008-5472.CAN-09-3988; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; FLOWER DR, 1994, FEBS LETT, V354, P7, DOI 10.1016/0014-5793(94)01078-1; Fougere M, 2010, ONCOGENE, V29, P2292, DOI 10.1038/onc.2009.499; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Honig A, 2002, MOL CELL BIOL, V22, P5698, DOI 10.1128/MCB.22.16.5698-5707.2002; Irarrazabal CE, 2010, P NATL ACAD SCI USA, V107, P906, DOI 10.1073/pnas.0913415107; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Kar A, 2011, MOL CELL BIOL, V31, P1812, DOI 10.1128/MCB.01149-10; Leng XH, 2011, J CELL PHYSIOL, V226, P309, DOI 10.1002/jcp.22403; Leng XH, 2009, CANCER RES, V69, P8579, DOI 10.1158/0008-5472.CAN-09-1934; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Lewis BP, 2003, P NATL ACAD SCI USA, V100, P189, DOI 10.1073/pnas.0136770100; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Maouyo D, 2002, AM J PHYSIOL-RENAL, V282, pF802, DOI 10.1152/ajprenal.00123.2001; McGlincy NJ, 2008, TRENDS BIOCHEM SCI, V33, P385, DOI 10.1016/j.tibs.2008.06.001; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mooney SM, 2010, J BIOL CHEM, V285, P30443, DOI 10.1074/jbc.M110.143792; Mooney SM, 2010, BIOCHEMISTRY-US, V49, P1, DOI 10.1021/bi901263m; Moore HC, 2010, ONCOGENE, V29, P6475, DOI 10.1038/onc.2010.381; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Neu-Yilik G, 2008, ADV GENET, V62, P185, DOI 10.1016/S0065-2660(08)00604-4; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stamm S, 2005, GENE, V344, P1, DOI 10.1016/j.gene.2004.10.022; Warner DR, 2004, BIOCHEM BIOPH RES CO, V324, P70, DOI 10.1016/j.bbrc.2004.09.017; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Wortham NC, 2009, ONCOGENE, V28, P4053, DOI 10.1038/onc.2009.261; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yang LQ, 2007, J BIOL CHEM, V282, P16811, DOI 10.1074/jbc.M610488200; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang LQ, 2005, MOL CANCER RES, V3, P355, DOI 10.1158/1541-7786.MCR-05-0022; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	75	46	47	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4536	4549		10.1038/onc.2011.618	http://dx.doi.org/10.1038/onc.2011.618			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22266867				2022-12-28	WOS:000309982100005
J	Miao, B; Skidan, I; Yang, J; You, Z; Fu, X; Famulok, M; Schaffhausen, B; Torchilin, V; Yuan, J; Degterev, A				Miao, B.; Skidan, I.; Yang, J.; You, Z.; Fu, X.; Famulok, M.; Schaffhausen, B.; Torchilin, V.; Yuan, J.; Degterev, A.			Inhibition of cell migration by PITENINs: the role of ARF6	ONCOGENE			English	Article						ARF6 guanine nucleotide exchange factor; ARNO/GRP1 membrane translocation; lamellipodia suppression; anti-angiogenesis; anti-metastasis	GUANINE-NUCLEOTIDE-EXCHANGE; RIBOSYLATION FACTOR 6; PLECKSTRIN-HOMOLOGY DOMAINS; PLASMA-MEMBRANE; MAMMALIAN-CELLS; PATHWAY; PROTEINS; BINDING; SEC7; ARNO	We have reported previously the development of small-molecule phosphatidylinositol-3,4,5-trisphosphate (PIP3) antagonists (PITs) that block pleckstrin homology (PH) domain interaction, including activation of Akt, and show anti-tumor potential. Here we show that the same molecules inhibit growth factor-induced actin remodeling, lamellipodia formation and, ultimately, cell migration and invasion, consistent with an important role of PIP3 in these processes. In vivo, a PIT-1 analog displays significant inhibition on tumor angiogenesis and metastasis. ADP ribosylation factor 6 (ARF6) was recently identified as an important mediator of cytoskeleton and cell motility, which is regulated by PIP3-dependent membrane translocation of the guanine nucleotide exchange factors (GEFs), such as ADP-ribosylation factor nucleotide binding site opener (ARNO) and general receptor for 3-phosphoinositides (GRP1). We demonstrate that PITs inhibit PIP3/ARNO or GRP1 PH domain binding and membrane localization, resulting in the inhibition of ARF6 activation. Importantly, we show that expression of the constitutively active mutant of ARF6 attenuates inhibition of lamellipodia formation and cell migration by PITs, confirming that inhibition of ARF6 contributes to inhibition of these processes by PITs. Overall, our studies demonstrate the feasibility of developing specific small-molecule targeting PIP3 binding by PH domains as potential anticancer agents that can simultaneously interfere with cancer development at multiple points. Oncogene (2012) 31, 4317-4332; doi:10.1038/onc.2011.593; published online 19 December 2011	[Miao, B.; You, Z.; Schaffhausen, B.; Degterev, A.] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; [Skidan, I.; Torchilin, V.] Northeastern Univ, Dept Pharmaceut Sci, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA; [Skidan, I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Ctr, Charlestown, MA USA; [Fu, X.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; [Famulok, M.] Univ Bonn, Program Unit Chem Biol & Med Chem, LIMES Inst, Bonn, Germany; [Yuan, J.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	Tufts University; Northeastern University; Harvard University; Massachusetts General Hospital; Tufts University; United States Department of Agriculture (USDA); University of Bonn; Harvard University; Harvard Medical School	Degterev, A (corresponding author), Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA.	alexei.degterev@tufts.edu	fu, xueyan/C-1126-2012		Smith Family Award for Excellence in Biomedical Research; National Institute on Aging Mentored Research Scientist Career Development Award; US Army [DAMD17-02-1-0403]; National Cancer Institute [RO1 CA34722/PO1-50661]; National Institute on Aging [R37 AG012859]; NATIONAL CANCER INSTITUTE [R01CA034722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012859] Funding Source: NIH RePORTER	Smith Family Award for Excellence in Biomedical Research; National Institute on Aging Mentored Research Scientist Career Development Award; US Army(United States Department of DefenseUnited States Army); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Joan Brugge (Harvard Medical School), Dr Tamas Balla (National Institutes of Health) and Dr Philippe Chavrier (Institut Curie) for the gifts of plasmids and cells. We thank Dr Jeff Peterson (Fox Chase Cancer Center, Philadelphia, PA, USA) for providing valuable comments. This work was supported by Smith Family Award for Excellence in Biomedical Research and National Institute on Aging Mentored Research Scientist Career Development Award (to AD), an Innovator Award from US Army (DAMD17-02-1-0403), National Cancer Institute (RO1 CA34722/PO1-50661) (to BSS) and the National Institute on Aging (R37 AG012859) (to JY).	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Balana ME, 2005, J CELL SCI, V118, P2201, DOI 10.1242/jcs.02351; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caumon AS, 2000, J BIOL CHEM, V275, P15637, DOI 10.1074/jbc.M908347199; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cox R, 2004, MOL BIOL CELL, V15, P1487, DOI 10.1091/mbc.E03-06-0443; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Esteban PF, 2006, J CELL BIOL, V173, P291, DOI 10.1083/jcb.200512013; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; Gillingham AK, 2007, ANNU REV CELL DEV BI, V23, P579, DOI 10.1146/annurev.cellbio.23.090506.123209; Hafner M, 2006, NATURE, V444, P941, DOI 10.1038/nature05415; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hornstein I, 2004, CELL SIGNAL, V16, P1, DOI 10.1016/S0898-6568(03)00110-4; Hu B, 2009, CANCER RES, V69, P794, DOI 10.1158/0008-5472.CAN-08-2110; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; Macia E, 2004, J CELL SCI, V117, P2389, DOI 10.1242/jcs.01090; Macia E, 2008, J BIOL CHEM, V283, P19836, DOI 10.1074/jbc.M800781200; Miao BC, 2010, P NATL ACAD SCI USA, V107, P20126, DOI 10.1073/pnas.1004522107; Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Park WS, 2008, MOL CELL, V30, P381, DOI 10.1016/j.molcel.2008.04.008; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Tague SE, 2004, P NATL ACAD SCI USA, V101, P9671, DOI 10.1073/pnas.0403531101; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Viaud J, 2007, P NATL ACAD SCI USA, V104, P10370, DOI 10.1073/pnas.0700773104; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	38	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4317	4332		10.1038/onc.2011.593	http://dx.doi.org/10.1038/onc.2011.593			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179837	Green Accepted, Green Submitted			2022-12-28	WOS:000309520200006
J	Jun, HJ; Acquaviva, J; Chi, D; Lessard, J; Zhu, H; Woolfenden, S; Bronson, RT; Pfannl, R; White, F; Housman, DE; Iyer, L; Whittaker, CA; Boskovitz, A; Raval, A; Charest, A				Jun, H. J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Bronson, R. T.; Pfannl, R.; White, F.; Housman, D. E.; Iyer, L.; Whittaker, C. A.; Boskovitz, A.; Raval, A.; Charest, A.			Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma; genetically engineered mouse model; EGFR; PTEN; c-MET	GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; FACTOR-ALPHA CDNA; HUMAN GLIOMAS; KINASE INHIBITORS; TGF-ALPHA; IN-VIVO; NUCLEAR TRANSLOCATION; LENTIVIRAL VECTORS; MALIGNANT GLIOMAS	Glioblastoma multiforme (GBM) is an aggressive brain tumor for which there is no cure. Overexpression of wild-type epidermal growth factor receptor (EGFR) and loss of the tumor suppressor genes Ink4a/Arf and PTEN are salient features of this deadly cancer. Surprisingly, targeted inhibition of EGFR has been clinically disappointing, demonstrating an innate ability for GBM to develop resistance. Efforts at modeling GBM in mice using wild-type EGFR have proven unsuccessful to date, hampering endeavors at understanding molecular mechanisms of therapeutic resistance. Here, we describe a unique genetically engineered mouse model of EGFR-driven gliomagenesis that uses a somatic conditional overexpression and chronic activation of wild-type EGFR in cooperation with deletions in the Ink4a/Arf and PTEN genes in adult brains. Using this model, we establish that chronic activation of wild-type EGFR with a ligand is necessary for generating tumors with histopathological and molecular characteristics of GBMs. We show that these GBMs are resistant to EGFR kinase inhibition and we define this resistance molecularly. Inhibition of EGFR kinase activity using tyrosine kinase inhibitors in GBM tumor cells generates a cytostatic response characterized by a cell cycle arrest, which is accompanied by a substantial change in global gene expression levels. We demonstrate that an important component of this pattern is the transcriptional activation of the MET receptor tyrosine kinase and that pharmacological inhibition of MET overcomes the resistance to EGFR inhibition in these cells. These findings provide important new insights into mechanisms of resistance to EGFR inhibition and suggest that inhibition of multiple targets will be necessary to provide therapeutic benefit for GBM patients. Oncogene (2012) 31, 3039-3050; doi: 10.1038/onc.2011.474; published online 24 October 2011	[Jun, H. J.; Acquaviva, J.; Chi, D.; Lessard, J.; Zhu, H.; Woolfenden, S.; Charest, A.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Bronson, R. T.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Pfannl, R.; Boskovitz, A.; Raval, A.; Charest, A.] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA; [White, F.; Housman, D. E.; Whittaker, C. A.; Charest, A.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [White, F.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Housman, D. E.; Charest, A.] MIT, Dept Biol, Cambridge, MA USA; [Iyer, L.] Tufts Univ, Sch Med, Tufts Ctr Neurosci Res, Boston, MA 02111 USA	Tufts Medical Center; Harvard University; Harvard Medical School; Tufts University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Tufts University	Charest, A (corresponding author), Tufts Med Ctr, Mol Oncol Res Inst, 800 Washington St,Box 5609, Boston, MA 02111 USA.	alain.charest@tufts.edu		Whittaker, Charles/0000-0002-2400-0094; Iyer, Lakshmanan/0000-0001-9167-6396; White, Forest/0000-0002-1545-1651	NIH Grant [NCI U01 CA141556, U54 CA119349]; American Cancer Society Research Scholar Award [117409]; NINDS [P30 NS047243]; NCI [T32 CA009429]; NATIONAL CANCER INSTITUTE [T32CA009429, U54CA119349, U01CA141556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047243] Funding Source: NIH RePORTER	NIH Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society Research Scholar Award(American Cancer Society); NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs Bill Chiu and Ken Hung for helpful comments and Dr Robert R Langley (MD Anderson Cancer Center, Houston, TX, USA) for human TGF alpha cDNA. Dr Jason Coleman (MIT, Cambridge, MA, USA) for the pTyf vector and iCre cDNA. Dr John Alberta (DFCI, Boston, MA, USA) for the Olig2 antibody. This work was supported by NIH Grant NCI U01 CA141556 (AC and FW), American Cancer Society Research Scholar Award 117409 (AC), NIH Grant U54 CA119349 (DH and AC), NINDS P30 NS047243 (LI) and NCI T32 CA009429 (DC).	Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cheng J, 2002, CANCER RES, V62, P4157; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Coleman JE, 2003, PHYSIOL GENOMICS, V12, P221, DOI 10.1152/physiolgenomics.00135.2002; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1990, NAT IMMUN CELL GROW, V9, P209; DIMARCO E, 1989, ONCOGENE, V4, P831; Ding H, 2003, CANCER RES, V63, P1106; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fan QW, 2007, CANCER RES, V67, P7960, DOI 10.1158/0008-5472.CAN-07-2154; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Friedman HS, 2005, NEW ENGL J MED, V353, P1997, DOI 10.1056/NEJMp058186; Guillamo JS, 2009, CLIN CANCER RES, V15, P3697, DOI 10.1158/1078-0432.CCR-08-2042; Huang PH, 2007, CELL CYCLE, V6, P2750, DOI 10.4161/cc.6.22.4922; Huang TT, 2009, NEUROTHERAPEUTICS, V6, P500, DOI 10.1016/j.nurt.2009.04.008; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Liang HY, 2004, INT J ONCOL, V24, P1057; Ling YH, 2007, MOL PHARMACOL, V72, P248, DOI 10.1124/mol.107.034827; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mellinghoff IK, 2007, CLIN CANCER RES, V13, P378, DOI 10.1158/1078-0432.CCR-06-1992; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Mueller KL, 2008, CANCER RES, V68, P3314, DOI 10.1158/0008-5472.CAN-08-0132; Mueller Kelly L, 2010, J Mol Signal, V5, P8, DOI 10.1186/1750-2187-5-8; Peng D, 1996, CANCER RES, V56, P3666; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAMUELS V, 1989, AM J PATHOL, V134, P895; Sarkaria JN, 2007, MOL CANCER THER, V6, P1167, DOI 10.1158/1535-7163.MCT-06-0691; SCHLEGEL U, 1990, ONCOGENE, V5, P1839; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; Shimshek DR, 2002, GENESIS, V32, P19, DOI 10.1002/gene.10023; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984; vanderValk P, 1997, ANN ONCOL, V8, P1023, DOI 10.1023/A:1008265905505; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; Woolfenden S, 2009, GENESIS, V47, P659, DOI 10.1002/dvg.20545; YUNG WKA, 1990, CANCER COMMUN, V2, P201, DOI 10.3727/095535490820874416; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zhu XC, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-98	55	60	62	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3039	3050		10.1038/onc.2011.474	http://dx.doi.org/10.1038/onc.2011.474			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020333	Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000305705900003
J	Liao, YC; Ruan, JW; Lua, I; Li, MH; Chen, WL; Wang, JRY; Kao, RH; Chen, JH				Liao, Y. C.; Ruan, J. W.; Lua, I.; Li, M. H.; Chen, W. L.; Wang, J. R. Y.; Kao, R. H.; Chen, J. H.			Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling	ONCOGENE			English	Article						hPTTG1; GEF-H1; RhoA; tumour metastasis; cytoskeleton regulation	TUMOR-TRANSFORMING GENE; TRANSCRIPTIONAL ACTIVATION FUNCTION; SISTER-CHROMATID SEPARATION; NUCLEOTIDE EXCHANGE FACTOR; RHO-GTPASES; HUMAN SECURIN; ACTIN CYTOSKELETON; BINDING-FACTOR; PTTG; EXPRESSION	Human pituitary tumour-transforming gene 1 (hPTTG1) is an oncogenic transcription factor that is overexpressed in many tumour types, especially tumours with metastatic abilities. However, how hPTTG1 overexpression drives metastasis is not yet clear. As a transcription factor, hPTTG1 may promote metastasis by activating target genes that are involved in the metastatic process. Here, we showed that Rho guanine nucleotide exchange factor-H1 (GEF-H1) was transcriptionally activated by hPTTG1, thereby promoting breast cancer metastasis. Luciferase reporter analyses and chromatin immunoprecipitation (ChIP) assays showed that hPTTG1 directly bound and activated the GEF-H1 gene promoter. In this study, RNA interference-mediated knockdown of hPTTG1 in highly metastatic breast tumour cells decreased GEF-H1 expression and RhoA activation, thereby reducing cell motility and invasion, and interfering with cytoskeletal remodelling in vitro, and impairing the tumour metastasis in vivo. The restoration of GEF-H1 expression in hPTTG1-knockdown cells rescued the hPTTG1-knockdown effects on cytoskeletal changes in vitro and tumour metastasis in vivo. Conversely, ectopic expression of hPTTG1 in non-metastatic breast tumour cells induced cytoskeletal rearrangements, and allowed these cells to metastasise in a mouse model by orthotopic implantation. In human tumour samples, hPTTG1 expression was also correlated to GEF-H1 expression in aggressive breast carcinoma. Altogether, these findings definitively establish a role for hPTTG1 in activating the GEF-H1/RhoA pathway as a newly identified mechanism in breast cancer metastasis. Oncogene (2012) 31, 3086-3097; doi: 10.1038/onc.2011.476; published online 17 October 2011	[Lua, I.; Chen, J. H.] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien 97004, Hualien County, Taiwan; [Liao, Y. C.; Ruan, J. W.; Chen, J. H.] Tzu Chi Univ, Inst Med Sci, Hualien 97004, Hualien County, Taiwan; [Li, M. H.] Buddhist Tzu Chi Gen Hosp, Dept Pathol, Hualien, Taiwan; [Chen, W. L.] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Wang, J. R. Y.; Kao, R. H.] Buddhist Tzu Chi Gen Hosp, Dept Hematol Oncol, Taipei, Taiwan	Tzu Chi University; Tzu Chi University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; National Defense Medical Center; Buddhist Tzu Chi General Hospital	Chen, JH (corresponding author), Tzu Chi Univ, Dept Mol Biol & Human Genet, Rm D416,701,Sec 3,Zhongyang Rd, Hualien 97004, Hualien County, Taiwan.	noli401029@gmail.com	Ruan, Jhen-Wei/N-2624-2017; Ruan, Jhen-Wei/G-6647-2014	Ruan, Jhen-Wei/0000-0002-0636-1937; 	National Science Council of Taiwan [NSC96-2320-B-320-013-MY3]; National Health Research Institutes of Taiwan [NHRI-EX99-9928BI]; Tzu-Chi Foundation	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan); Tzu-Chi Foundation	Ms Lily Chen, Ms Vicky Chang and Ms Shi-Rong Lin provided expert technical assistance. We thank Dr Lu-Hai Wang's suggestions during the preparation of this manuscript. This study was supported by grants from the National Science Council of Taiwan (NSC96-2320-B-320-013-MY3), the National Health Research Institutes of Taiwan (NHRI-EX99-9928BI) and also partially by the Tzu-Chi Foundation.	Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Birkenfeld J, 2008, TRENDS CELL BIOL, V18, P210, DOI 10.1016/j.tcb.2008.02.006; Birukova AA, 2006, AM J PHYSIOL-LUNG C, V290, pL540, DOI 10.1152/ajplung.00259.2005; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07-12-1269; Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105; Chesnokova V, 2010, MOL CELL ENDOCRINOL, V326, P55, DOI 10.1016/j.mce.2010.02.012; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; del Peso L, 1997, ONCOGENE, V15, P3047; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Gil-Bernabe AM, 2006, MOL CELL BIOL, V26, P4017, DOI 10.1128/MCB.01904-05; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hornig NCD, 2002, CURR BIOL, V12, P973, DOI 10.1016/S0960-9822(02)00847-3; Ito T, 2008, CANCER RES, V68, P3214, DOI 10.1158/0008-5472.CAN-07-3043; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kim DS, 2007, CARCINOGENESIS, V28, P749, DOI 10.1093/carcin/bgl202; Krendel M, 2002, NAT CELL BIOL, V4, P294, DOI 10.1038/ncb773; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Ogbagabriel S, 2005, MODERN PATHOL, V18, P985, DOI 10.1038/modpathol.3800382; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; Ridley AJ, 2001, J CELL SCI, V114, P2713; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Smith VE, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399410001699; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Tong YG, 2009, J MOL ENDOCRINOL, V43, P179, DOI 10.1677/JME-08-0176; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wennerberg K, 2004, J CELL SCI, V117, P1301, DOI 10.1242/jcs.01118; Wittmann T, 2001, J CELL SCI, V114, P3795; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	46	50	52	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3086	3097		10.1038/onc.2011.476	http://dx.doi.org/10.1038/onc.2011.476			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002306	Green Published, hybrid			2022-12-28	WOS:000305705900007
J	Piccione, EC; Lieu, TJ; Gentile, CF; Williams, TR; Connolly, AJ; Godwin, AK; Koong, AC; Wong, AJ				Piccione, E. C.; Lieu, T. J.; Gentile, C. F.; Williams, T. R.; Connolly, A. J.; Godwin, A. K.; Koong, A. C.; Wong, A. J.			A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors	ONCOGENE			English	Article						EGFR; GRP78; ER stress; unfolded protein response; transcription	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; HUMAN-BRAIN TUMORS; CELL LUNG-CANCER; EGF-RECEPTOR; ER STRESS; NUCLEAR-LOCALIZATION; MALIGNANT GLIOMAS; OXIDATIVE STRESS	The epidermal growth factor receptor (EGFR) is essential to multiple physiological and neoplastic processes via signaling by its tyrosine kinase domain and subsequent activation of transcription factors. EGFR overexpression and alteration, including point mutations and structural variants, contribute to oncogenesis in many tumor types. In this study, we identified an in-frame splice variant of the EGFR called mini-LEEK (mLEEK) that is more broadly expressed than the EGFR and is overexpressed in several cancers. Unlike previously characterized EGFR variants, mLEEK lacks the extracytoplasmic, transmembrane and tyrosine kinase domains. mLEEK localizes in the nucleus and functions as a transcription factor to regulate target genes involved in the cellular response to endoplasmic reticulum (ER) stress, including the master regulator of the unfolded protein response (UPR) pathways, molecular chaperone GRP78/Bip. We demonstrated that mLEEK regulates GRP78 transcription through direct interaction with a cis-regulatory element within the gene promoter. Several UPR pathways were interrogated and mLEEK expression was found to attenuate the induction of all pathways upon ER stress. Conversely, knockdown of mLEEK resulted in caspase-mediated cell death and sensitization to ER stress. These findings indicate that mLEEK levels determine cellular responses to unfavorable conditions that cause ER stress. This information, along with the overexpression of mLEEK in tumors, suggests unique strategies for therapeutic intervention. Furthermore, the identification of mLEEK expands the known mechanisms by which the EGFR gene contributes to oncogenesis and represents the first link between two previously disparate areas in cancer cell biology: EGFR signaling and the UPR.	[Piccione, E. C.; Lieu, T. J.; Gentile, C. F.; Williams, T. R.; Wong, A. J.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Piccione, E. C.; Lieu, T. J.; Gentile, C. F.; Williams, T. R.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Connolly, A. J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Koong, A. C.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; University of Kansas; University of Kansas Medical Center; Stanford University	Wong, AJ (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, 1201 Welch Rd,MSLS P105, Stanford, CA 94305 USA.	ajwong@stanford.edu		Piccione, Emilio/0000-0001-7754-7395; Koong, Albert/0000-0001-9824-1643; Lieu, Tiffany/0000-0001-7430-4064	NIH from NINDS [F31 NS056581, R01 CA69495, R01 CA096539, R01 CA124832]; Ovarian SPORE at FCCC [P50 CA083638]; National Brain Tumor Foundation; California Breast Cancer Program [15IB-0080]; NATIONAL CANCER INSTITUTE [R01CA124832, R01CA096539, R01CA069495, R01CA140323, P50CA083638, T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS056581] Funding Source: NIH RePORTER	NIH from NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Ovarian SPORE at FCCC; National Brain Tumor Foundation; California Breast Cancer Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank R Nitta, G Li, S Mitra, C Del Vecchio and M Holgado-Madruga for comments. We thank K Mori, K Kokame, R Prywes and G Nolan for reagents. This work was supported by the NIH under Ruth L Kirschstein National Research Service Award F31 NS056581 from the NINDS to ECP, the Ovarian SPORE at FCCC (P50 CA083638) to AKG and AJW, NIH Grants R01 CA69495, R01 CA096539 and R01 CA124832, as well as a research grant from the National Brain Tumor Foundation and Grant 15IB-0080 from the California Breast Cancer Program to AJW.	Allen TD, 2000, J CELL SCI, V113, P1651; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cai Y, 2007, NAT STRUCT MOL BIOL, V14, P872, DOI 10.1038/nsmb1276; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Demeter J, 2007, NUCLEIC ACIDS RES, V35, pD766, DOI 10.1093/nar/gkl1019; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Eley G, 1998, GENE CHROMOSOME CANC, V23, P248, DOI 10.1002/(SICI)1098-2264(199811)23:3<248::AID-GCC7>3.0.CO;2-1; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HALEY J, 1987, ONCOGENE RES, V1, P375; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Kandul NP, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-67; Kim J, 2005, CANCER RES, V65, P8242, DOI 10.1158/0008-5472.CAN-05-0942; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Koumenis C, 2007, METHOD ENZYMOL, V435, P275, DOI 10.1016/S0076-6879(07)35014-3; Kudo T, 2008, CELL DEATH DIFFER, V15, P364, DOI 10.1038/sj.cdd.4402276; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; LIBERMANN TA, 1984, CANCER RES, V44, P753; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2005, CANCER RES, V65, P338; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MALDEN LT, 1988, CANCER RES, V48, P2711; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Mu TW, 2008, CELL, V134, P769, DOI 10.1016/j.cell.2008.06.037; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Pedersen MW, 2005, J CELL BIOCHEM, V96, P412, DOI 10.1002/jcb.20554; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Pedersen MW, 2001, BRIT J CANCER, V85, P1211, DOI 10.1054/bjoc.2001.2053; Pines G, 2010, ONCOGENE, V29, P5850, DOI 10.1038/onc.2010.313; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Roy M, 2008, RNA, V14, P2261, DOI 10.1261/rna.1024908; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xie W, 1997, ANTICANCER RES, V17, P2627; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	68	11	11	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2953	2967		10.1038/onc.2011.465	http://dx.doi.org/10.1038/onc.2011.465			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	21986942	Green Accepted			2022-12-28	WOS:000305388400005
J	Werner, H				Werner, H.			Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer	ONCOGENE			English	Review						insulin-like growth factors; IGF; IGF-1 receptor; tumor suppressors; p53; BRCA1	FACTOR-I RECEPTOR; ROUND-CELL TUMOR; TRANSCRIPTION FACTOR SP1; VON-HIPPEL-LINDAU; GENE-EXPRESSION; IGF-I; PROSTATE-CANCER; BREAST-CANCER; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; DIFFERENTIAL REGULATION	The insulin-like growth factor (IGF) axis mediates growth, differentiation and developmental processes, and is also involved in control of metabolic activities. Deregulation of IGF axis expression and action is linked to a number of pathologies, ranging from metabolic disorders to growth deficits and cancer development. Activation of the IGF signaling pathway is a crucial prerequisite for malignant transformation. In addition, overexpression of the IGF-1 receptor (IGF-1R) constitutes a typical hallmark of most types of cancer. A series of tumor suppressors have been identified whose mechanisms of action involve transcriptional suppression of the IGF-1R gene. These tumor suppressors include the p53/p63/p73 family, breast cancer gene-1, von-Hippel Lindau protein, Wilms' tumor-1 and others. Comprehensive analyses have identified a complex bidirectional interplay between the IGF and tumor-suppressor signaling pathways. These interactions are of major importance in terms of cancer development and may also predict responsiveness to IGF-1R-targeted therapies. Furthermore, the insulin/IGF system has a pivotal role in the regulation of cancer cell metabolism. Deregulation of IGF axis components by mutated tumor-suppressor proteins may lead to metabolic perturbations, with ensuing pathological consequences. Oncogene (2012) 31, 2703-2714; doi: 10.1038/onc.2011.447; published online 3 October 2011	Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Werner, H (corresponding author), Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Sch Med, IL-69978 Tel Aviv, Israel.	hwerner@post.tau.ac.il			Israel Science Foundation; Israel Cancer Association; Insulin-Dependent Diabetes Trust (IDDT, UK); Israel Cancer Research Fund (ICRF, New York and Montreal); US-Israel Binational Science Foundation	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Insulin-Dependent Diabetes Trust (IDDT, UK); Israel Cancer Research Fund (ICRF, New York and Montreal); US-Israel Binational Science Foundation(US-Israel Binational Science Foundation)	Work in the laboratory of HW is supported by grants from the Israel Science Foundation, Israel Cancer Association, Insulin-Dependent Diabetes Trust (IDDT, UK), Israel Cancer Research Fund (ICRF, New York and Montreal) and US-Israel Binational Science Foundation.	Abramovitch S, 2003, FEBS LETT, V541, P149, DOI 10.1016/S0014-5793(03)00315-6; Abuzzahab MJ, 2003, NEW ENGL J MED, V349, P2211, DOI 10.1056/NEJMoa010107; Aylon Y, 2011, CURR OPIN GENET DEV, V21, P86, DOI 10.1016/j.gde.2010.10.002; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Belfiore A, 2011, ENDOCR-RELAT CANCER, V18, pR125, DOI 10.1530/ERC-11-0074; Belfiore A, 2008, J MAMMARY GLAND BIOL, V13, P381, DOI 10.1007/s10911-008-9099-z; Bentov Itay, 2004, Pediatr Endocrinol Rev, V1, P352; Bentov I, 2008, ENDOCRINOLOGY, V149, P1890, DOI 10.1210/en.2007-0844; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; Boulton SJ, 2006, BIOCHEM SOC T, V34, P633, DOI 10.1042/BST0340633; Brase JC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-306; Bruchim I, 2009, EXPERT OPIN THER TAR, V13, P1179, DOI 10.1517/14728220903201702; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Conaway RC, 2002, ADV CANCER RES, V85, P1, DOI 10.1016/S0065-230X(02)85001-1; Dossus L, 2008, BEST PRACT RES CL EN, V22, P551, DOI 10.1016/j.beem.2008.08.003; ESHET R, 1993, J MOL ENDOCRINOL, V10, P115, DOI 10.1677/jme.0.0100115; Finkeltov I, 2002, ONCOGENE, V21, P1890, DOI 10.1038/sj.onc.1205042; Gerald WL, 2005, SEMIN CANCER BIOL, V15, P197, DOI 10.1016/j.semcancer.2005.01.005; Gerald WL, 1998, J CLIN ONCOL, V16, P3028, DOI 10.1200/JCO.1998.16.9.3028; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Gualberto A, 2009, ONCOGENE, V28, P3009, DOI 10.1038/onc.2009.172; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845; GULER HP, 1987, NEW ENGL J MED, V317, P137, DOI 10.1056/NEJM198707163170303; GULER HP, 1989, P NATL ACAD SCI USA, V86, P2868, DOI 10.1073/pnas.86.8.2868; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Happerfield LC, 1997, J PATHOL, V183, P412; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hellawell GO, 2002, CANCER RES, V62, P2942; HernandezSanchez C, 1997, J BIOL CHEM, V272, P4663, DOI 10.1074/jbc.272.8.4663; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hornstein E, 2006, NAT GENET, V38, pS20, DOI 10.1038/ng1803; Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002; Idelman G, 2003, J BIOL CHEM, V278, P3474, DOI 10.1074/jbc.M211606200; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Kim SO, 1996, CANCER RES, V56, P3831; Klammt J, 2011, BEST PRACT RES CL EN, V25, P191, DOI 10.1016/j.beem.2010.09.012; Klammt J, 2008, TRENDS ENDOCRIN MET, V19, P197, DOI 10.1016/j.tem.2008.03.003; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; Kruis T, 2010, J CLIN ENDOCR METAB, V95, P1137, DOI 10.1210/jc.2009-1433; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Laron Z, 2004, EUR J ENDOCRINOL, V151, P103, DOI 10.1530/eje.0.1510103; Laron Z, 2004, J CLIN ENDOCR METAB, V89, P1031, DOI 10.1210/jc.2003-031033; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LeRoith D, 2007, NAT CLIN PRACT ENDOC, V3, P302, DOI 10.1038/ncpendmet0427; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maki RG, 2010, J CLIN ONCOL, V28, P4985, DOI 10.1200/JCO.2009.27.5040; Maor S, 2007, HORM METAB RES, V39, P179, DOI 10.1055/s-2007-970415; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Maor S, 2007, CANCER LETT, V257, P236, DOI 10.1016/j.canlet.2007.07.019; Maor S, 2006, J ENDOCRINOL, V191, P605, DOI 10.1677/joe.1.07016; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Nahor I, 2005, GROWTH HORM IGF RES, V15, P388, DOI 10.1016/j.ghir.2005.07.005; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nana-Sinkam SP, 2011, TRANSL RES, V157, P216, DOI 10.1016/j.trsl.2011.01.013; Narod SA, 2010, NAT REV CLIN ONCOL, V7, P702, DOI 10.1038/nrclinonc.2010.166; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; REISS K, 1991, CANCER RES, V51, P5997; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; SALMON WD, 1957, J LAB CLIN MED, V49, P825; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sarfstein Rive, 2010, Cancers (Basel), V2, P233, DOI 10.3390/cancers2020233; Schayek H, 2010, MOL CELL ENDOCRINOL, V323, P239, DOI 10.1016/j.mce.2010.04.017; Schayek H, 2010, GROWTH HORM IGF RES, V20, P68, DOI 10.1016/j.ghir.2009.08.001; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Scotlandi K, 2008, CURR OPIN ONCOL, V20, P419, DOI 10.1097/CCO.0b013e328302edab; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V1, P90; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Steuerman R, 2011, EUR J ENDOCRINOL, V164, P485, DOI 10.1530/EJE-10-0859; Tang D, 2011, ONCOGENE, V30, P1851, DOI 10.1038/onc.2010.573; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; Ungewitter E, 2010, GENE DEV, V24, P2408, DOI 10.1101/gad.1987810; Voskuil DW, 2004, BREAST CANCER RES TR, V84, P225, DOI 10.1023/B:BREA.0000019954.59130.d3; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wallborn T, 2010, J CLIN ENDOCR METAB, V95, P2316, DOI 10.1210/jc.2009-2404; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WERNER H, 1989, ENDOCRINOLOGY, V125, P314, DOI 10.1210/endo-125-1-314; WERNER H, 1995, MOL CELL BIOL, V15, P3516; Werner H, 2003, GENE CHROMOSOME CANC, V36, P113, DOI 10.1002/gcc.10157; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Werner H, 2007, CANCER LETT, V247, P84, DOI 10.1016/j.canlet.2006.03.027; Werner Haim, 2009, Pediatr Endocrinol Rev, V7, P2; Werner H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-2; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Wiesener MS, 2009, J MOL MED-JMM, V87, P871, DOI 10.1007/s00109-009-0504-x; Yakar S, 2005, J Endocrinol Invest, V28, P19; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yerushalmi R., 2011, BREAST CANC RES TREA; Yuen JSP, 2007, ONCOGENE, V26, P6499, DOI 10.1038/sj.onc.1210474; Yuen JSP, 2008, EXPERT OPIN THER TAR, V12, P589, DOI 10.1517/14728222.12.5.589 ; Zalts Harel, 2011, Pediatr Endocrinol Rev, V8, P354; Zhang LJ, 1996, CANCER RES, V56, P1367; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	114	89	93	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2703	2714		10.1038/onc.2011.447	http://dx.doi.org/10.1038/onc.2011.447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963847				2022-12-28	WOS:000304769000001
J	Cheriyath, V; Kuhns, MA; Jacobs, BS; Evangelista, P; Elson, P; Downs-Kelly, E; Tubbs, R; Borden, EC				Cheriyath, V.; Kuhns, M. A.; Jacobs, B. S.; Evangelista, P.; Elson, P.; Downs-Kelly, E.; Tubbs, R.; Borden, E. C.			G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer	ONCOGENE			English	Article						G1P3; breast cancer; hyperplasia; apoptosis; tamoxifen resistance; interferon-stimulated genes	GENE-EXPRESSION; PROGNOSTIC MARKER; IMMUNE CELLS; APOPTOSIS; MORPHOGENESIS; INFLAMMATION; SIGNATURE; FAMILY; BCL2; IDENTIFICATION	Hormonally regulated survival factors can have an important role in breast cancer. Here we elucidate G1P3, a survival protein induced by interferons (IFNs), as a target of estrogen signaling and a contributor to poor outcomes in estrogen receptor-positive (ER+) breast cancer. Compared with normal breast tissue, G1P3 was upregulated in the malignant epithelium (50 x higher) and was induced by estrogen ex vivo. In accord with its overexpression in early stages of breast cancer (hyperplasia and ductal carcinoma in situ), in morphogenesis assays G1P3 enhanced the survival of MCF10A acinar luminal cells causing hyperplasia by suppressing detachment-induced loss of mitochondrial potential and apoptosis (anoikis). In cells undergoing anoikis, G1P3 attenuated the induction of Bim protein, a proapoptotic member of the Bcl-2 family and reversed the downmodulation of Bcl-2 protein. Downregulation of G1P3 induced spontaneous apoptosis in BT-549 breast cancer cells and significantly reduced the growth of ER+ breast cancer cell MCF7 (P <= 0.01), further suggesting its prosurvival activity. In agreement with its induction by estrogen, G1P3 antagonized tamoxifen, an inhibitor of ER in MCF7 cells. More importantly, elevated expression of G1P3 was significantly associated with decreased relapse-free and overall survival in ER+ breast cancer patients (P <= 0.01). Our studies suggest that elevated expression of G1P3 may perturb canonical tumor-suppressing activity of IFNs partly by affecting the balance of pro- and antiapoptotic members of Bcl-2 family proteins, leading to breast cancer development and resistance to therapies. Oncogene (2012) 31, 2222-2236; doi:10.1038/onc.2011.393; published online 26 September 2011	[Cheriyath, V.; Kuhns, M. A.; Jacobs, B. S.; Evangelista, P.; Borden, E. C.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Elson, P.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Downs-Kelly, E.; Tubbs, R.] Cleveland Clin, Dept Mol Pathol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Cheriyath, V (corresponding author), Cleveland Clin Fdn, Taussig Canc Inst, 9500 Euclid Ave,Mailcode R40, Cleveland, OH 44195 USA.	venu_cheriyath@tamu-commerce.edu; bordene@ccf.org			Clinical and Translational Science Collaborative (CTSC); NCI [CA043703]; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER	Clinical and Translational Science Collaborative (CTSC); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This study is supported by a Clinical and Translational Science Collaborative (CTSC) award to VC and by NCI CA043703 to ECB. We thank Drs Thomas Budd and Joseph Crowe and Mrs Joanne Lyons for their help in procuring biopsies. Our sincere thanks to Dr Judith Drazba, director of the Cleveland Clinic Imaging Core, Dr John Peterson and Eric Diskin for their kind help with the confocal and light microscopy. We thank Linda Vargo for preparing the specimens for in situ hybridization. We gratefully acknowledge Dr Aejaz Nasir at Eli Lilly and Dr Tim Huang at the Ohio State University for helpful discussions. We also thank Dr George Stark and Dr Thomas Budd at the Cleveland Clinic for critical reading of the manuscript.	Anderson LR, 2010, ONCOGENE, V29, P527, DOI 10.1038/onc.2009.362; Bae SI, 2008, ONCOGENE, V27, P490, DOI 10.1038/sj.onc.1210655; Bani MR, 2004, MOL CANCER THER, V3, P111; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; Bharadwaj S, 2005, ONCOGENE, V24, P8291, DOI 10.1038/sj.onc.1208993; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153; Calogero RA, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1745; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Cheriyath V, 2010, J INTERFERON CYTOKIN, V31, P173; Cheriyath V, 2007, J CLIN INVEST, V117, P3107, DOI 10.1172/JCI31122; Cheriyath V, 2011, J INTERF CYTOK RES, V31, P173, DOI 10.1089/jir.2010.0105; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746; DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Einav U, 2005, ONCOGENE, V24, P6367, DOI 10.1038/sj.onc.1208797; Eroles P, 2010, CLIN TRANSL ONCOL, V12, P246, DOI 10.1007/s12094-010-0500-1; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Gimenez-Bonafe P, 2009, CURR CANCER DRUG TAR, V9, P320, DOI 10.2174/156800909788166600; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Mailleux AA, 2008, M S-MED SCI, V24, P246, DOI 10.1051/medsci/2008243246; Mailleux AA, 2008, CELL CYCLE, V7, P57, DOI 10.4161/cc.7.1.5150; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001; Nuovo GJ, 2009, NAT PROTOC, V4, P107, DOI 10.1038/nprot.2008.215; Parker N, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-8; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Radisky ES, 2007, REV ENDOCR METAB DIS, V8, P279, DOI 10.1007/s11154-007-9037-1; RASMUSSEN UB, 1993, CANCER RES, V53, P4096; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Segara D, 2005, CLIN CANCER RES, V11, P3587, DOI 10.1158/1078-0432.CCR-04-1813; Sorbello V, 2003, INT J BIOL MARKER, V18, P123, DOI 10.1177/172460080301800205; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Swan EA, 2003, ORAL ONCOL, V39, P648, DOI 10.1016/S1368-8375(03)00049-6; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; Thomadaki H, 2008, CONNECT TISSUE RES, V49, P261, DOI 10.1080/03008200802147829; Thomadaki H, 2007, CANCER LETT, V247, P48, DOI 10.1016/j.canlet.2006.03.016; Tsai MH, 2007, CANCER RES, V67, P3845, DOI 10.1158/0008-5472.CAN-06-4250; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Weigelt B, 2008, SEMIN CANCER BIOL, V18, P311, DOI 10.1016/j.semcancer.2008.03.013; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Ye H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-69; Zhang HP, 1999, RECURSIVE PARTITIONI	62	39	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2222	2236		10.1038/onc.2011.393	http://dx.doi.org/10.1038/onc.2011.393			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21996729				2022-12-28	WOS:000303415900010
J	de Andrea, CE; Reijnders, CMA; Kroon, HM; de Jong, D; Hogendoorn, PCW; Szuhai, K; Bovee, JVMG				de Andrea, C. E.; Reijnders, C. M. A.; Kroon, H. M.; de Jong, D.; Hogendoorn, P. C. W.; Szuhai, K.; Bovee, J. V. M. G.			Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT	ONCOGENE			English	Article						chondrosarcoma; osteochondroma; EXT1; array-CGH; FISH; bone tumors	HEREDITARY MULTIPLE EXOSTOSES; HEPARAN-SULFATE; MOUSE MODEL; HETEROZYGOSITY; BONE; EXPRESSION; TUMORS; CHROMOSOME-11; INACTIVATION; PROGRESSION	Secondary peripheral chondrosarcoma is the result of malignant transformation of a pre-existing osteochondroma, the most common benign bone tumor. Osteochondromas are caused by genetic abnormalities in EXT1 or EXT2: homozygous deletion of EXT1 characterizes sporadic osteochondromas (non-familial/solitary), and germline mutations in EXT1 or EXT2 combined with loss of heterozygosity define hereditary multiple osteochondromas. While cells with homozygous inactivation of EXT and wild-type cells shape osteochondromas, the cellular composition of secondary peripheral chondrosarcomas and the role of EXT in their formation have remained unclear. We report using a targeted-tiling-resolution oligo-array-CGH (array comparative genomic hybridization) that homozygous deletions of EXT1 or EXT2 are much less frequently detected (2/17, 12%) in sporadic secondary peripheral chondrosarcomas than expected based on the assumption that they originate in sporadic osteochondromas, in which homozygous inactivation of EXT1 is found in similar to 80% of our cases. FISH with an EXT1 probe confirmed that, unlike sporadic osteochondromas, cells from sporadic secondary peripheral chondrosarcomas predominantly retained one (hemizygous deleted loci) or both copies (wild-type) of the EXT1 locus. By immunohistochemistry, we confirm the presence of cells with dysfunctional EXT1 in sporadic osteochondromas and show cells with functional EXT1 in sporadic secondary peripheral chondrosarcomas. These immuno results were verified in osteochondromas and secondary peripheral chondrosarcomas in the setting of hereditary multiple osteochondromas. Our data therefore point to a model of oncogenesis in which the osteochondroma creates a niche in which wild-type cells with functional EXT are predisposed to acquire other mutations giving rise to secondary peripheral chondrosarcoma, indicating that EXT-independent mechanisms are involved in the pathogenesis of secondary peripheral chondrosarcoma. Oncogene (2012) 31, 1095-1104; doi:10.1038/onc.2011.311; published online 1 August 2011	[de Andrea, C. E.; Reijnders, C. M. A.; Hogendoorn, P. C. W.; Bovee, J. V. M. G.] Leiden Univ, Dept Pathol, Med Ctr, NL-2300 RC Leiden, Netherlands; [Kroon, H. M.] Leiden Univ, Dept Radiol, Med Ctr, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bovee, JVMG (corresponding author), Leiden Univ, Dept Pathol, Med Ctr, POB 9600,L1-Q, NL-2300 RC Leiden, Netherlands.	j.v.m.g.bovee@lumc.nl	Hogendoorn, Pancras/O-6494-2019; Szuhai, Karoly/A-1100-2008; Hogendoorn, Pancras C.W./H-5859-2015	Hogendoorn, Pancras/0000-0002-1513-8104; Szuhai, Karoly/0000-0002-1228-4245; Hogendoorn, Pancras C.W./0000-0002-1513-8104; Bovee, Judith/0000-0003-1155-0481; de Jong, Danielle/0000-0003-4003-5593	Netherlands Organization for Scientific Research [917-76-315]; EuroBoNeT [LSHC-CT-2006-018814]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); EuroBoNeT(European CommissionEuropean Commission Joint Research Centre)	We acknowledge the expert technical work of Marja van der Burg, Inge Briaire-de Bruijn, Maayke van Ruler and Pauline M Wijers-Koster (Leiden University Medical Center, Leiden, The Netherlands). We also thank the Netherlands Committee on Bone Tumors. Professor E Bakker is acknowledged for EXT mutation analysis. This study was supported by Netherlands Organization for Scientific Research (917-76-315 to CMAR and JVMGB) and by EuroBoNeT (a European Commission-granted European Network of Excellence for studying the pathology and genetics of bone tumors; grant number: LSHC-CT-2006-018814 (to CEA, JVMGB, DJ, KS and PCWH).	Bernard SA, 2010, RADIOLOGY, V255, P857, DOI 10.1148/radiol.10082120; Bertoni F., 2002, WHO CLASSIFICATION T, P247; Bovee JVMG, 2010, NAT REV CANCER, V10, P481, DOI 10.1038/nrc2869; Bovee JVMG, 2000, AM J PATHOL, V157, P1587, DOI 10.1016/S0002-9440(10)64796-7; Bovee JVMG, 1999, GENE CHROMOSOME CANC, V26, P237; Bulow HE, 2006, ANNU REV CELL DEV BI, V22, P375, DOI 10.1146/annurev.cellbio.22.010605.093433; Clement A, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000136; de Andrea CE, 2011, J PATHOL, V224, P160, DOI 10.1002/path.2886; de Andrea CE, 2010, LAB INVEST, V90, P1091, DOI 10.1038/labinvest.2010.81; Dorfman HD, 2002, WHO CLASSIFICATION T, P226; EVANS HL, 1977, CANCER-AM CANCER SOC, V40, P818, DOI 10.1002/1097-0142(197708)40:2<818::AID-CNCR2820400234>3.0.CO;2-B; Hallor KH, 2009, CLIN CANCER RES, V15, P2685, DOI 10.1158/1078-0432.CCR-08-2330; Hameetman L, 2007, J PATHOL, V211, P399, DOI 10.1002/path.2127; Hameetman L, 2007, JNCI-J NATL CANCER I, V99, P396, DOI 10.1093/jnci/djk067; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Jones KB, 2010, P NATL ACAD SCI USA, V107, P2054, DOI 10.1073/pnas.0910875107; Khurana J, 2002, WHO CLASSIFICATION T, P234; Matsumoto K, 2010, P NATL ACAD SCI USA, V107, P10932, DOI 10.1073/pnas.0914642107; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Mohseny AB, 2010, GENE CHROMOSOME CANC, V49, P1095, DOI 10.1002/gcc.20817; Pansuriya TC, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-2; Raaijmakers MHGP, 2011, HAEMATOL-HEMATOL J, V96, P1041, DOI 10.3324/haematol.2010.028035; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Reijmers RM, 2010, BLOOD, V115, P601, DOI 10.1182/blood-2009-02-204396; Reijnders CMA, 2010, AM J PATHOL, V177, P1946, DOI 10.2353/ajpath.2010.100296; Szuhai K, 2011, HUM MUTAT, V32, pE2036, DOI 10.1002/humu.21423; Szuhai K, 2009, CLIN CANCER RES, V15, P2259, DOI 10.1158/1078-0432.CCR-08-2184; van den Berg H, 2008, J PEDIATR ORTHOPED, V28, P29, DOI 10.1097/BPO.0b013e3181558cb5; Ventura RA, 2006, J MOL DIAGN, V8, P141, DOI 10.2353/jmoldx.2006.050083; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6; Zuntini M, 2010, ONCOGENE, V29, P3827, DOI 10.1038/onc.2010.135	32	45	45	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1095	1104		10.1038/onc.2011.311	http://dx.doi.org/10.1038/onc.2011.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21804604	Green Published			2022-12-28	WOS:000300945900003
J	de la Cruz-Morcillo, MA; Valero, MLL; Callejas-Valera, JL; Arias-Gonzalez, L; Melgar-Rojas, P; Galan-Moya, EM; Garcia-Gil, E; Garcia-Cano, J; Sanchez-Prieto, R				de la Cruz-Morcillo, M. A.; Valero, M. L. L.; Callejas-Valera, J. L.; Arias-Gonzalez, L.; Melgar-Rojas, P.; Galan-Moya, E. M.; Garcia-Gil, E.; Garcia-Cano, J.; Sanchez-Prieto, R.			P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance	ONCOGENE			English	Article						5-fluorouracil; p38MAPK; autophagy; resistance; p53; apoptosis	ACTIVATED PROTEIN-KINASE; P38 MAP KINASE; COLORECTAL-CANCER CELLS; CISPLATIN-BASED THERAPY; DNA-DAMAGE; GENE-EXPRESSION; COLON-CANCER; CHEMOTHERAPEUTIC-AGENTS; P53-DEPENDENT APOPTOSIS; THYMIDYLATE SYNTHASE	5-Fluorouracil (5-FU), together with other drugs such as oxaliplatin, is one of the most important pharmacological agents in the treatment of colorectal cancer. Although mitogen-activated protein kinases (MAPKs) have been extensively connected with resistance to platinum compounds, no role has been established in 5-FU resistance. Here we demonstrate that p38MAPK activation is a key determinant in the cellular response to 5-FU. Thus, inhibition of p38MAPK alpha by SB203580 compound or by short-hairpin RNA interference-specific knockdown correlates with a decrease in the 5-FU-associated apoptosis and chemical resistance in both HaCaT and HCT116 cells. Activation of p38MAPK by 5-FU was dependent on canonical MAP2K, MAPK kinase (MKK)-3 and MKK6. In addition, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR) showed a redundancy of function for the final activation of p38MAPK. Resistance associated with p38MAPK inhibition correlates with an autophagic response that was mediated by a decrease in p53-driven apoptosis, without effect onto p53-dependent autophagy. Moreover, the results with colorectal cancer-derived cell lines with different p53 status and patterns of resistance to 5-FU suggest that de novo and acquired resistance was controlled by similar mechanisms. In summary, our data demonstrate a critical role for the p38MAPK signaling pathway in the cellular response to 5-FU by controlling the balance between apoptosis and autophagy. Oncogene (2012) 31, 1073-1085; doi:10.1038/onc.2011.321; published online 15 August 2011	[de la Cruz-Morcillo, M. A.; Valero, M. L. L.; Callejas-Valera, J. L.; Arias-Gonzalez, L.; Melgar-Rojas, P.; Galan-Moya, E. M.; Garcia-Gil, E.; Garcia-Cano, J.; Sanchez-Prieto, R.] UCLM, Oncol Mol Lab, CRIB, PCYTA, Albacete 02006, Spain	Universidad de Castilla-La Mancha	Sanchez-Prieto, R (corresponding author), UCLM, Oncol Mol Lab, CRIB, PCYTA, C Almansa 14, Albacete 02006, Spain.	ricardo.sanchez@uclm.es	Prieto, Ricardo/AAZ-7221-2021; Galan-Moya, Eva M/I-2912-2015; Sanchez-Prieto, Ricardo/AAY-4271-2021; Romo, José A./J-3024-2012; Garcia, Elena/GWR-0291-2022; García-Cano, Jesús/AAA-9257-2020; Sanchez-Prieto, Ricardo/B-6877-2008; Arias-González, Laura/D-9517-2016	Galan-Moya, Eva M/0000-0001-5758-7592; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Romo, José A./0000-0003-2907-580X; García-Cano, Jesús/0000-0002-8312-2622; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Arias-González, Laura/0000-0003-2132-9350; Garcia Gil, Elena/0000-0002-8952-0306; de la Cruz-Morcillo, Miguel Angel/0000-0002-6674-1333	Fundacion Leticia Castillejo Castillo; Ministerio de Ciencia e Innovacion [SAF2009-07329]; European Community	Fundacion Leticia Castillejo Castillo; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); European Community(European Commission)	This work was supported by grants from Fundacion Leticia Castillejo Castillo and Ministerio de Ciencia e Innovacion (SAF2009-07329) to RSP. RSP Research Institute, and the work carried out in his laboratory, received support from the European Community through the regional development funding program (FEDER). We appreciate the comments and suggestions of Drs G Almazan, E de la Casa-Esperon, S Gutkind, D Arango, A Cuenda, A Vazquez, I Sanchez and D Garcia-Olmo.	Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Callejas-Valera JL, 2008, J BIOL CHEM, V283, P13450, DOI 10.1074/jbc.M709230200; Chan A, 2009, EUR J CANCER, V45, P2253, DOI 10.1016/j.ejca.2009.04.031; Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003; Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Cuadrado A, 2007, EMBO J, V26, P2115, DOI 10.1038/sj.emboj.7601657; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Elsea CR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002355; Ewald B, 2008, ONCOGENE, V27, P6522, DOI 10.1038/onc.2008.316; Ewald B, 2008, CANCER RES, V68, P7947, DOI 10.1158/0008-5472.CAN-08-0971; Fedier A, 2003, ANN ONCOL, V14, P938, DOI 10.1093/annonc/mdg240; Galan-Moya EM, 2008, INT J CANCER, V122, P289, DOI 10.1002/ijc.23063; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Habiro A, 2004, BIOCHEM BIOPH RES CO, V316, P71, DOI 10.1016/j.bbrc.2004.02.017; Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002; Im JS, 2008, J BIOL CHEM, V283, P25171, DOI 10.1074/jbc.M802851200; Jardim MJ, 2009, MOL BIOL CELL, V20, P3801, DOI 10.1091/mbc.E09-04-0303; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kennedy AS, 2000, INT J CANCER, V90, P175, DOI 10.1002/1097-0215(20000820)90:4<175::AID-IJC1>3.0.CO;2-W; Koizumi K, 2005, ANTICANCER RES, V25, P3347; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021; Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Liu A, 2008, J CELL BIOCHEM, V105, P245, DOI 10.1002/jcb.21824; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Longley DB, 2002, CANCER RES, V62, P2644; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Mariadason JM, 2003, CANCER RES, V63, P8791; McClung JM, 2010, AM J PHYSIOL-CELL PH, V298, pC542, DOI 10.1152/ajpcell.00192.2009; McDonald GT, 2010, EXP CELL RES, V316, P3197, DOI 10.1016/j.yexcr.2010.08.007; Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066; OConnor PM, 1997, CANCER RES, V57, P4285; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Perfettini JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002458; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Raftery L, 2008, SEMIN ONCOL, V35, P561, DOI 10.1053/j.seminoncol.2008.08.004; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Sanchez-Arevalo LV, 2005, BIOCH J 1, V387, P231; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Specenier P, 2010, CURR OPIN ONCOL, V22, P200, DOI 10.1097/CCO.0b013e3283376e15; Tanida I, 2008, AUTOPHAGY, V4, P131, DOI 10.4161/auto.5233; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tominaga T, 2010, INT J CANCER, V126, P1691, DOI 10.1002/ijc.24929; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321; Wilsker D, 2007, MOL CANCER THER, V6, P1406, DOI 10.1158/1535-7163.MCT-06-0679; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039; Zeng XH, 2010, CELL RES, V20, P665, DOI 10.1038/cr.2010.40; Zhao HY, 2008, CANCER RES, V68, P7035, DOI 10.1158/0008-5472.CAN-07-6496; Zheng MH, 1999, J CANCER RES CLIN, V125, P357, DOI 10.1007/s004320050286	74	97	97	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1073	1085		10.1038/onc.2011.321	http://dx.doi.org/10.1038/onc.2011.321			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21841826				2022-12-28	WOS:000300945900001
J	Uemura, M; Zheng, Q; Koh, CM; Nelson, WG; Yegnasubramanian, S; De Marzo, AM				Uemura, M.; Zheng, Q.; Koh, C. M.; Nelson, W. G.; Yegnasubramanian, S.; De Marzo, A. M.			Overexpression of ribosomal RNA in prostate cancer is common but not linked to rDNA promoter hypomethylation	ONCOGENE			English	Article						epigenetics; rDNA; rRNA; DNA methylation; prostate cancer	POLYMERASE-I; C-MYC; TRANSCRIPTION; GENES; CELLS; NUCLEOLAR; DNA; HYPERMETHYLATION; METHYLATION; BIOLOGY	Alterations in nucleoli, including increased numbers, increased size, altered architecture and increased function are hallmarks of prostate cancer cells. The mechanisms that result in increased nucleolar size, number and function in prostate cancer have not been fully elucidated. The nucleolus is formed around repeats of a transcriptional unit encoding a 45S ribosomal RNA (rRNA) precursor that is then processed to yield the mature 18S, 5.8S and 28S RNA species. Although it has been generally accepted that tumor cells overexpress rRNA species, this has not been examined in clinical prostate cancer. We find that indeed levels of the 45S rRNA, 28S, 18S and 5.8S are overexpressed in the majority of human primary prostate cancer specimens as compared with matched benign tissues. One mechanism that can alter nucleolar function and structure in cancer cells is hypomethylation of CpG dinucleotides of the upstream rDNA promoter region. However, this mechanism has not been examined in prostate cancer. To determine whether rRNA overexpression could be explained by hypomethylation of these CpG sites, we also evaluated the DNA methylation status of the rDNA promoter in prostate cancer cell lines and the clinical specimens. Bisulfite sequencing of genomic DNA revealed two roughly equal populations of loci in cell lines consisting of those that contained densely methylated deoxycytidine residues within CpGs and those that were largely unmethylated. All clinical specimens also contained two populations with no marked changes in methylation of this region in cancer as compared with normal. We recently reported that MYC can regulate rRNA levels in human prostate cancer; here we show that MYC mRNA levels are correlated with 45S, 18S and 5.8S rRNA levels. Further, as a surrogate for nucleolar size and number, we examined the expression of fibrillarin, which did not correlate with rRNA levels. We conclude that rRNA levels are increased in human prostate cancer, but that hypomethylation of the rDNA promoter does not explain this increase, nor does hypomethylation explain alterations in nucleolar number and structure in prostate cancer cells. Rather, rRNA levels and nucleolar size and number relate more closely to MYC overexpression. Oncogene (2012) 31, 1254-1263; doi:10.1038/onc.2011.319; published online 8 August 2011	[Uemura, M.; Zheng, Q.; Koh, C. M.; Nelson, W. G.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; [Nelson, W. G.; Yegnasubramanian, S.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21287 USA; [Nelson, W. G.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21287 USA; [Nelson, W. G.; Yegnasubramanian, S.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21287 USA; [Nelson, W. G.; De Marzo, A. M.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	De Marzo, AM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, CRB 2-144,1550 Orleans St, Baltimore, MD 21287 USA.	ademarz@jhmi.edu	uemura, motohide/G-6101-2011		Patrick C Walsh Prostate Cancer Fund; Prostate SPORE [P50CA58236]; NATIONAL CANCER INSTITUTE [P30CA006973, P50CA058236] Funding Source: NIH RePORTER	Patrick C Walsh Prostate Cancer Fund; Prostate SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Patrick C Walsh Prostate Cancer Fund of which AMD is the Peter J Sharp Scholar, and Prostate SPORE P50CA58236. We wish to thank Helen Fedor and the Brady Urological Institute Prostate Specimen Repository for fresh prostate tissues.	Bostwick DG, 1996, PROSTATE, V29, P117; Derenzini M, 1998, AM J PATHOL, V152, P1291; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; EPSTEIN JI, 2002, PROSTATE BIOPSY INTE; Espada J, 2007, NUCLEIC ACIDS RES, V35, P2191, DOI 10.1093/nar/gkm118; Fischer AH, 2004, J CELL BIOCHEM, V91, P170, DOI 10.1002/jcb.10735; Gagnon-Kugler T, 2009, MOL CELL, V35, P414, DOI 10.1016/j.molcel.2009.07.008; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Grummt I, 2010, FEBS J, V277, P4626, DOI 10.1111/j.1742-4658.2010.07892.x; Grummt I, 2010, CELL CYCLE, V9, P225, DOI 10.4161/cc.9.2.10614; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; Koh C, 2010, AM J PATHOL, V4, P1824; McGowan PO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002085; McMahon M, 2010, J BIOL CHEM, V285, P18309, DOI 10.1074/jbc.M110.108555; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Shiue CN, 2009, ONCOGENE, V28, P1833, DOI 10.1038/onc.2009.21; Shiue CN, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.3.11376; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Williamson D, 2006, GENE CHROMOSOME CANC, V45, P839, DOI 10.1002/gcc.20347; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972	26	60	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	10					1254	1263		10.1038/onc.2011.319	http://dx.doi.org/10.1038/onc.2011.319			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21822302	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000301344600005
J	Xu, N; Libertini, S; Black, EJ; Lao, Y; Hegarat, N; Walker, M; Gillespie, DA				Xu, N.; Libertini, S.; Black, E. J.; Lao, Y.; Hegarat, N.; Walker, M.; Gillespie, D. A.			Cdk-mediated phosphorylation of Chk1 is required for efficient activation and full checkpoint proficiency in response to DNA damage	ONCOGENE			English	Article						Chk1; RPA; Cdk; DNA damage; checkpoint; cell cycle	END RESECTION; HOMOLOGOUS RECOMBINATION; REPAIR; CTIP; SURVIVAL	Here, we show that activation of the checkpoint effector kinase Chk1 in response to irradiation-induced DNA damage is minimal in G1, maximal during S-phase and diminishes as cells enter G2. In addition, formation of irradiation-induced replication protein A (RPA)-coated single-stranded DNA (RPA-ssDNA), a structure required for ATM and Rad3-related (ATR)-Chk1 activation, occurs in a broadly similar pattern. Cyclin-dependent kinase (Cdk) activity is thought to promote RPA-ssDNA formation by stimulating DNA strand resection at double-strand breaks (DSBs), providing one possible mechanism of imposing cell cycle dependence on DNA damage signaling. However, it has recently been shown that Chk1 itself is also subject to Cdk-mediated phosphorylation at serines 286 and 301 (S286 and 301). We show that Chk1 S301 phosphorylation increases as cells progress through S and G2 and that both Cdk1 and Cdk2 are likely to contribute to this modification in vivo. We also find that substitution of S286 and S301 with non-phosphorylatable alanine residues strongly attenuates DNA damage-induced Chk1 activation and G2 checkpoint proficiency, but does not eliminate the underlying cell cycle dependence of Chk1 regulation. Taken together, these data indicate that Cdk activity regulates multiple steps in the DNA damage response pathway including full activation of Chk1 and checkpoint proficiency. Oncogene (2012) 31, 1086-1094; doi:10.1038/onc.2011.310; published online 18 July 2011	[Xu, N.] Tsinghua Univ, Div Life Sci, Grad Sch Shenzhen, Shenzhen 518055, Guang Dong, Peoples R China; [Xu, N.; Libertini, S.; Black, E. J.; Lao, Y.; Walker, M.; Gillespie, D. A.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Gillespie, D. A.] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland	Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Beatson Institute; University of Glasgow	Xu, N (corresponding author), Tsinghua Univ, Div Life Sci, Grad Sch Shenzhen, Room 409,Bldg L,Tsinghua Campus, Shenzhen 518055, Guang Dong, Peoples R China.	xu.naihan@sz.tsinghua.edu.cn; d.gillespie@beatson.gla.ac.uk	Xu, Naihan/C-2778-2018; Libertini, Silvana/A-3531-2011; Gillespie, David/R-4771-2019; , Yuanzhi/D-3936-2015	Libertini, Silvana/0000-0003-2633-1564; Gillespie, David/0000-0002-6338-0544; , Yuanzhi/0000-0002-7803-4484; Lao, Yuanzhi/0000-0002-0994-8303	Cancer Research UK (CR-UK); Medical Research Council of the United Kingdom (MRC); CR-UK China Fellowships; Marie Curie Fellowship	Cancer Research UK (CR-UK)(Cancer Research UK); Medical Research Council of the United Kingdom (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CR-UK China Fellowships; Marie Curie Fellowship(European Commission)	We wish to thank Cancer Research UK (CR-UK) and the Medical Research Council of the United Kingdom (MRC) for financial support. N Xu and Y Lao were the recipients of CR-UK China Fellowships, S Libertini was the recipient of a Marie Curie Fellowship. We thank Helfrid Hochegger for many stimulating discussions.	Bourke E, 2010, ONCOGENE, V29, P616, DOI 10.1038/onc.2009.340; Cerqueira A, 2009, J CELL BIOL, V187, P773, DOI 10.1083/jcb.200903033; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Enomoto M, 2009, J BIOL CHEM, V284, P34223, DOI 10.1074/jbc.C109.051540; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hochegger H, 2007, J CELL BIOL, V178, P257, DOI 10.1083/jcb.200702034; Huertas P, 2008, NATURE, V455, P689, DOI 10.1038/nature07215; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Ikegami Y, 2008, BIOCHEM BIOPH RES CO, V377, P1227, DOI 10.1016/j.bbrc.2008.10.119; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Rainey MD, 2008, ONCOGENE, V27, P896, DOI 10.1038/sj.onc.1210702; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Shiromizu T, 2006, GENES CELLS, V11, P477, DOI 10.1111/j.1365-2443.2006.00955.x; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Walker M, 2009, ONCOGENE, V28, P2314, DOI 10.1038/onc.2009.102; Wohlbold L, 2009, DNA REPAIR, V8, P1018, DOI 10.1016/j.dnarep.2009.04.009; Xu NH, 2010, J CELL BIOL, V190, P297, DOI 10.1083/jcb.201003004; Yata K, 2009, DNA REPAIR, V8, P6, DOI 10.1016/j.dnarep.2008.09.002; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060	27	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1086	1094		10.1038/onc.2011.310	http://dx.doi.org/10.1038/onc.2011.310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765472				2022-12-28	WOS:000300945900002
J	Li, X; Law, JWS; Lee, AYW				Li, X.; Law, J. W. S.; Lee, A. Y. W.			Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton	ONCOGENE			English	Article						glioblastoma; invasion; glial differentiation; GTPases; fascin	FIBRILLARY ACIDIC PROTEIN; HUMAN ASTROCYTOMA-CELLS; AXON GUIDANCE; INDUCED ANGIOGENESIS; PANCREATIC-CANCER; COMPLEMENTARY-DNA; INVASIVE GROWTH; GENE-EXPRESSION; TUMOR-GROWTH; R-RAS	Semaphorins are implicated in glioma progression, although little is known about the underlying mechanisms. We have reported plexin-B3 expression in human gliomas, which upon stimulation by Sema5A causes significant inhibition of cell migration and invasion. The concomitant inactivation of Rac1 is of mechanistic importance because forced expression of constitutively active Rac1 abolishes these inhibitory effects. Furthermore, Sema5A induces prominent cell collapse and ramification of processes reminiscent of astrocytic morphology, which temporally associate with extensive disassembly of actin stress fibers and disruption of focal adhesions, followed by accumulation of actin patches in protrusions. Mechanistically, Sema5A induces transient protein kinase C (PKC) phosphorylation of fascin-1, which can reduce its actin-binding/bundling activities and temporally parallels its translocation from cell body to extending processes. PKC inhibition or fascin-1 knockdown is sufficient to abrogate Sema5A-induced morphological differentiation, whereas the process is hastened by forced expression of fascin-1. Intriguingly, Sema5A induces re-expression of glial fibrillary acidic protein (GFAP), which when silenced restricts differentiation of glioma cells to bipolar instead of multipolar morphology. Therefore, we hypothesize complementary functions of fascin-1 and GFAP in the early and late phases of Sema5A-induced astrocytic differentiation of gliomas, respectively. In summary, Sema5A and plexin-B3 impede motility but promote differentiation of human gliomas. These effects are plausibly compromised in high-grade human astrocytomas in which Sema5A expression is markedly reduced, hence leading to infiltrative and anaplastic characteristics. This is evident by increased invasiveness of glioma cells when endogenous Sema5A is silenced. Therefore, Sema5A and plexin-B3 represent potential novel targets in counteracting glioma progression. Oncogene (2012) 31, 595-610; doi:10.1038/onc.2011.256; published online 27 June 2011	[Lee, A. Y. W.] Natl Univ Singapore, Ctr Life Sci, Inst Life Sci, Dept Physiol,Yong Loo Lin Sch Med,Neurobiol Agein, Singapore 117456, Singapore	National University of Singapore	Lee, AYW (corresponding author), Natl Univ Singapore, Ctr Life Sci, Inst Life Sci, Dept Physiol,Yong Loo Lin Sch Med,Neurobiol Agein, 28 Med Dr, Singapore 117456, Singapore.	phsleeyw@nus.edu.sg	LEE, Alan Yiu Wah/AAE-1845-2022; Lee, Alan/E-8554-2011; Lee, Alan Yiu Wah/AAD-4541-2020	Lee, Alan Yiu Wah/0000-0003-0635-4179	National University of Singapore; Biomedical Research Council of Singapore	National University of Singapore(National University of Singapore); Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR))	We are indebted to Dr David Srevatan for providing the Sema5A-Fc expression construct and to Dr Danijela Vignijevic for the pEGFP-fascin plasmid. This work was supported by research grants from the National University of Singapore and the Biomedical Research Council of Singapore.	Adams JC, 2004, CURR OPIN CELL BIOL, V16, P590, DOI 10.1016/j.ceb.2004.07.009; Anilkumar N, 2003, EMBO J, V22, P5390, DOI 10.1093/emboj/cdg521; Artigiani S, 2004, EMBO REP, V5, P710, DOI 10.1038/sj.embor.7400189; Bagci T, 2009, ONCOGENE, V28, P3537, DOI 10.1038/onc.2009.204; Balakrishnan A, 2009, HUM MUTAT, V30, P1167, DOI 10.1002/humu.21017; Banu N, 2006, FASEB J, V20, P2150, DOI 10.1096/fj.05-5698fje; Barberis D, 2004, FASEB J, V18, P592, DOI 10.1096/fj.03-0957fje; Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Brun M, 2009, J MOL BIOL, V391, P282, DOI 10.1016/j.jmb.2009.06.041; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Catalano A, 2004, FASEB J, V18, P1740, DOI 10.1096/fj.04-2258fje; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chedotal A, 2007, PROG EXP TUMOR RES, V39, P78, DOI 10.1159/000100048; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Coma S, 2010, CANCER RES, V70, P3823, DOI 10.1158/0008-5472.CAN-09-3048; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; Correa RG, 2001, GENOMICS, V73, P343, DOI 10.1006/geno.2001.6525; Crowe DL, 2004, ANTICANCER RES, V24, P593; DECK JHN, 1978, ACTA NEUROPATHOL, V42, P183, DOI 10.1007/BF00690355; Deryugina EI, 1997, J CELL SCI, V110, P2473; Dhanabal M, 2005, CANCER BIOL THER, V4, P659, DOI 10.4161/cbt.4.6.1733; Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014-5793(02)03323-9; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; DUFFY PE, 1982, EXP CELL RES, V139, P145, DOI 10.1016/0014-4827(82)90328-7; Elobeid A, 2000, J NEUROSCI RES, V60, P245, DOI 10.1002/(SICI)1097-4547(20000415)60:2<245::AID-JNR14>3.0.CO;2-1; Feldkamp MM, 1999, ONCOGENE, V18, P7514, DOI 10.1038/sj.onc.1203105; Goldberg JL, 2004, J NEUROSCI, V24, P4989, DOI 10.1523/JNEUROSCI.4390-03.2004; Hilario JD, 2009, DEV BIOL, V326, P190, DOI 10.1016/j.ydbio.2008.11.007; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; INAGAKI M, 1990, J BIOL CHEM, V265, P4722; Iwadate Y, 2004, CANCER RES, V64, P2496, DOI 10.1158/0008-5472.CAN-03-1254; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; Karayan-Tapon L, 2008, BRIT J CANCER, V99, P1153, DOI 10.1038/sj.bjc.6604641; Kureishy N, 2002, BIOESSAYS, V24, P350, DOI 10.1002/bies.10070; Kusy S, 2005, NEOPLASIA, V7, P457, DOI 10.1593/neo.04721; Li XH, 2010, J BIOL CHEM, V285, P32436, DOI 10.1074/jbc.M110.120451; Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332; McDonough WS, 2005, NEOPLASIA, V7, P862, DOI 10.1593/neo.05190; Mondal S, 2010, BRAIN PATHOL, V20, P190, DOI 10.1111/j.1750-3639.2008.00261.x; Murakami M, 2001, INT J ONCOL, V18, P721; Nakada M, 2006, CANCER RES, V66, P8492, DOI 10.1158/0008-5472.CAN-05-4211; Nasarre C, 2009, CELL ADHES MIGR, V3, P383, DOI 10.4161/cam.3.4.9934; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545; Oinuma I, 2006, J CELL BIOL, V173, P601, DOI 10.1083/jcb.200508204; Oster SF, 2003, DEVELOPMENT, V130, P775, DOI 10.1242/dev.00299; Pan GQ, 2009, WORLD J GASTROENTERO, V15, P2800, DOI 10.3748/wjg.15.2800; Pan GQ, 2010, LIFE SCI, V86, P139, DOI 10.1016/j.lfs.2009.12.004; Restrepo A, 2011, NEURO-ONCOLOGY, V13, P42, DOI 10.1093/neuonc/noq145; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rickman DS, 2001, CANCER RES, V61, P6885; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; RUTKA JT, 1993, CANCER RES, V53, P3624; RUTKA JT, 1994, CANCER RES, V54, P3267; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Sadanandam A, 2007, OMICS, V11, P41, DOI 10.1089/omi.2006.0004; Sadanandam A, 2010, INT J CANCER, V127, P1373, DOI 10.1002/ijc.25166; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Swiercz JM, 2008, J BIOL CHEM, V283, P1893, DOI 10.1074/jbc.M706822200; Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Walzer T, 2005, EUR J IMMUNOL, V35, P391, DOI 10.1002/eji.200425669; Webb DJ, 2003, CURR OPIN CELL BIOL, V15, P614, DOI 10.1016/S0955-0674(03)00105-4; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wong CCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002779; Woodhouse EC, 2003, P NATL ACAD SCI USA, V100, P11463, DOI 10.1073/pnas.2031202100; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	73	39	46	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					595	610		10.1038/onc.2011.256	http://dx.doi.org/10.1038/onc.2011.256			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706053				2022-12-28	WOS:000300221800006
J	Huang, B; Qu, Z; Ong, CW; Tsang, YHN; Xiao, G; Shapiro, D; Salto-Tellez, M; Ito, K; Ito, Y; Chen, LF				Huang, B.; Qu, Z.; Ong, C. W.; Tsang, Y-H N.; Xiao, G.; Shapiro, D.; Salto-Tellez, M.; Ito, K.; Ito, Y.; Chen, L-F			RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha	ONCOGENE			English	Article						breast cancer; degradation; ER alpha; RUNX3; tumor suppressor	EPITHELIAL-CELLS; EXPRESSION; PROTEASOME; BETA; TRANSACTIVATION; TUMORIGENESIS; TURNOVER; DEGRADATION; APOPTOSIS; GROWTH	Transcription factor RUNX3 is inactivated in a number of malignancies, including breast cancer, and is suggested to function as a tumor suppressor. How RUNX3 functions as a tumor suppressor in breast cancer remains undefined. Here, we show that about 20% of female Runx3(+/-) mice spontaneously developed ductal carcinoma at an average age of 14.5 months. Additionally, RUNX3 inhibits the estrogen-dependent proliferation and transformation potential of ER alpha-positive MCF-7 breast cancer cells in liquid culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice. Furthermore, RUNX3 inhibits ER alpha-dependent transactivation by reducing the stability of ER alpha. Consistent with its ability to regulate the levels of ER alpha, expression of RUNX3 inversely correlates with the expression of ER alpha in breast cancer cell lines, human breast cancer tissues and Runx3(+/-) mouse mammary tumors. By destabilizing ER alpha, RUNX3 acts as a novel tumor suppressor in breast cancer. Oncogene (2012) 31, 527-534; doi: 10.1038/onc.2011.252; published online 27 June 2011	[Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528588, Japan; [Chen, L-F] Univ Illinois, Dept Biochem, Coll Med, Urbana, IL 61801 USA; [Qu, Z.; Xiao, G.] Univ Pittsburgh, Med Ctr, Inst Canc, Pittsburgh, PA USA; [Ong, C. W.; Salto-Tellez, M.] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore; [Ong, C. W.; Salto-Tellez, M.; Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Tsang, Y-H N.; Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Nagasaki University; University of Illinois System; University of Illinois Urbana-Champaign; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Ito, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528588, Japan.	itok@nagasaki-u.ac.jp; lfchen@life.illinois.edu		Salto-Tellez, Manuel/0000-0001-8586-282X	UIUC; NIH [DK-085158, CA116616, DK-071909]; NATIONAL CANCER INSTITUTE [R01CA116616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085158, R01DK071909] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank W Xu for reagents; W Xu, A Nardulli and members in the Chen lab for discussion. This work is supported in part by fund provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC), CA116616 (to GTX) and DK-071909 (to DS). YHT is an A*STAR-Illinois Partnership fellow.	Anderson E, 2002, BREAST CANCER RES, V4, P197, DOI 10.1186/bcr452; Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Ekena K, 1996, J BIOL CHEM, V271, P20053, DOI 10.1074/jbc.271.33.20053; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Frech MS, 2005, CANCER RES, V65, P681; Ito K, 2009, ONCOGENE, V28, P1379, DOI 10.1038/onc.2008.496; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jerry DJ, 2010, CELL MOL LIFE SCI, V67, P1017, DOI 10.1007/s00018-009-0244-7; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; KHAN SA, 1994, CANCER RES, V54, P993; LaMarca HL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1740; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sakuma A, 2008, MOL REPROD DEV, V75, P1653, DOI 10.1002/mrd.20904; Shoker BS, 2000, J CLIN PATHOL, V53, P778, DOI 10.1136/jcp.53.10.778; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yan PR, 2009, BLOOD, V113, P4370, DOI 10.1182/blood-2008-10-185660; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zhang DH, 2003, LIFE SCI, V73, P3189, DOI 10.1016/j.lfs.2003.05.006	28	53	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					527	534		10.1038/onc.2011.252	http://dx.doi.org/10.1038/onc.2011.252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706051	Green Accepted			2022-12-28	WOS:000300219300011
J	Yu, YP; Luo, JH				Yu, Y-P; Luo, J-H			Phosphorylation and interaction of myopodin by integrin-link kinase lead to suppression of cell growth and motility in prostate cancer cells	ONCOGENE			English	Article						myopodin; ILK; phosphorylation; tumor suppression; prostate cancer	LIVER-SPECIFIC ABLATION; BLADDER-CANCER; EXPRESSION; ILK; PROLIFERATION; ADHESION; PROTEIN; PARVIN; PINCH	Myopodin is a tumor-suppressor gene that suppresses growth of prostate and urothelial carcinomas. However, the mechanism of myopodin tumor-suppressor activity or signaling that leads to activation of myopodin remains unclear. In this report, we showed that the N-terminus of myopodin binds integrin-linked kinase (ILK) both in vivo and in vitro. An ILK interaction motif of 78 amino acids (amino acids 82-157) was identified in the N-terminus region of myopodin. Induction of ILK-dependent kinase activity by integrin alpha 7 led to phosphorylation of myopodin both in vivo and in vitro. Knocking down ILK dramatically reduced the inhibition of cell growth and motility mediated by myopodin. A mutant of myopodin lacking the ILK interaction motif is inactive in suppressing the growth and motility of PC3 cells. As a result, this study showed a novel and critical signaling pathway that leads to activation of myopodin. Oncogene (2011) 30, 4855-4863; doi:10.1038/onc.2011.200; published online 6 June 2011	[Yu, Y-P; Luo, J-H] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, YP (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, BST S-416,3550 Terrace St, Pittsburgh, PA 15261 USA.	ypyu@pitt.edu			National Cancer Institute [R56 CA098249, RO1 CA098249]; American Cancer Society [RSG-08-137-01-CNE]; NATIONAL CANCER INSTITUTE [R56CA098249, R01CA098249] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from National Cancer Institute (R56 CA098249 and RO1 CA098249 to JHL) and American Cancer Society (RSG-08-137-01-CNE to YPY).	Acconcia F, 2007, P NATL ACAD SCI USA, V104, P6782, DOI 10.1073/pnas.0701999104; Apte U, 2009, HEPATOLOGY, V50, P844, DOI 10.1002/hep.23059; Cebrian V, 2008, J PATHOL, V216, P111, DOI 10.1002/path.2390; Deng JT, 2001, J BIOL CHEM, V276, P16365, DOI 10.1074/jbc.M011634200; Donthamsetty S, 2010, TOXICOL SCI, V113, P358, DOI 10.1093/toxsci/kfp281; Gkretsi V, 2008, HEPATOLOGY, V48, P1932, DOI 10.1002/hep.22537; Han YC, 2010, CANCER RES, V70, P4375, DOI 10.1158/0008-5472.CAN-09-4403; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Jing L, 2004, AM J PATHOL, V164, P1799, DOI 10.1016/S0002-9440(10)63738-8; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Lin F, 2001, AM J PATHOL, V159, P1603, DOI 10.1016/S0002-9440(10)63006-4; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ren BG, 2007, J NATL CANCER I, V99, P868, DOI 10.1093/jnci/djk199; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Sanchez-Carbayo M, 2003, ONCOGENE, V22, P5298, DOI 10.1038/sj.onc.1206616; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yu YP, 2006, UROLOGY, V68, P578, DOI 10.1016/j.urology.2006.03.027; Yu YP, 2006, CANCER RES, V66, P7414, DOI 10.1158/0008-5472.CAN-06-0227	19	16	18	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	49					4855	4863		10.1038/onc.2011.200	http://dx.doi.org/10.1038/onc.2011.200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21643011	Green Accepted			2022-12-28	WOS:000298346400002
J	Pradeep, CR; Zeisel, A; Kostler, WJ; Lauriola, M; Jacob-Hirsch, J; Haibe-Kains, B; Amariglio, N; Ben-Chetrit, N; Emde, A; Solomonov, I; Neufeld, G; Piccart, M; Sagi, I; Sotiriou, C; Rechavi, G; Domany, E; Desmedt, C; Yarden, Y				Pradeep, C-R; Zeisel, A.; Koestler, W. J.; Lauriola, M.; Jacob-Hirsch, J.; Haibe-Kains, B.; Amariglio, N.; Ben-Chetrit, N.; Emde, A.; Solomonov, I.; Neufeld, G.; Piccart, M.; Sagi, I.; Sotiriou, C.; Rechavi, G.; Domany, E.; Desmedt, C.; Yarden, Y.			Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions	ONCOGENE			English	Article						adhesion; breast cancer; EGF; HER2; hypoxia	CARCINOMA IN-SITU; LYSYL OXIDASE; ANOIKIS RESISTANCE; FACTOR-BETA; EXPRESSION; ERBB2; RECEPTOR; SURVIVAL; CELLS; HER2	The HER2/neu oncogene encodes a receptor-like tyrosine kinase whose overexpression in breast cancer predicts poor prognosis and resistance to conventional therapies. However, the mechanisms underlying aggressiveness of HER2 (human epidermal growth factor receptor 2)-overexpressing tumors remain incompletely understood. Because it assists epidermal growth factor (EGF) and neuregulin receptors, we overexpressed HER2 in MCF10A mammary cells and applied growth factors. HER2-overexpressing cells grown in extracellular matrix formed filled spheroids, which protruded outgrowths upon growth factor stimulation. Our transcriptome analyses imply a two-hit model for invasive growth: HER2-induced proliferation and evasion from anoikis generate filled structures, which are morphologically and transcriptionally analogous to preinvasive patients' lesions. In the second hit, EGF escalates signaling and transcriptional responses leading to invasive growth. Consistent with clinical relevance, a gene expression signature based on the HER2/EGF-activated transcriptional program can predict poorer prognosis of a subgroup of HER2-overexpressing patients. In conclusion, the integration of a three-dimensional cellular model and clinical data attributes progression of HER2-overexpressing lesions to EGF-like growth factors acting in the context of the tumor's microenvironment. Oncogene (2012) 31, 3569-3583; doi:10.1038/onc.2011.547; published online 5 December 2011	[Pradeep, C-R; Koestler, W. J.; Lauriola, M.; Ben-Chetrit, N.; Emde, A.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Zeisel, A.; Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; [Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.] Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematooncol & Funct Genom, IL-69978 Tel Aviv, Israel; [Jacob-Hirsch, J.; Amariglio, N.; Rechavi, G.] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Haibe-Kains, B.; Piccart, M.; Sotiriou, C.; Desmedt, C.] Inst Jules Bordet, Translat Res Unit, B-1000 Brussels, Belgium; [Haibe-Kains, B.] Univ Libre Bruxelles, Machine Learning Grp, Brussels, Belgium; [Solomonov, I.; Sagi, I.] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; [Neufeld, G.] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc Res & Vasc Biol Ctr, IL-31096 Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Institut Jules Bordet; Universite Libre de Bruxelles; Weizmann Institute of Science; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Neufeld, Gera/F-1524-2019; Desmedt, Christine/P-7438-2017; lauriola, mattia/N-6435-2014; YARDEN, YOSEF/K-1467-2012; Haibe-Kains, Benjamin/D-3702-2011; DOMANY, EYTAN/K-1560-2012	Desmedt, Christine/0000-0002-5223-5579; Haibe-Kains, Benjamin/0000-0002-7684-0079; lauriola, mattia/0000-0002-7966-0065	National Cancer Institute [CA72981]; M.D. Moross Institute for Cancer Research; Kekst Family Institute for Medical Genetics; Women's Health Research Center; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Harry and Jeanette Weinberg Women's Health Research Endowment; Oprah Winfrey Biomedical Research Fund; Arresto Biosciences; European Commission; German Research Foundation; NATIONAL CANCER INSTITUTE [R01CA072981, R37CA072981] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); M.D. Moross Institute for Cancer Research; Kekst Family Institute for Medical Genetics; Women's Health Research Center; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Harry and Jeanette Weinberg Women's Health Research Endowment; Oprah Winfrey Biomedical Research Fund; Arresto Biosciences; European Commission(European CommissionEuropean Commission Joint Research Centre); German Research Foundation(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Carlos Arteaga and Ittai Ben-Porath for reagents and helpful insights. Our laboratories are supported by research grants from the National Cancer Institute (Grant CA72981), the M.D. Moross Institute for Cancer Research, Kekst Family Institute for Medical Genetics, Women's Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Harry and Jeanette Weinberg Women's Health Research Endowment, Oprah Winfrey Biomedical Research Fund, Arresto Biosciences, the European Commission, and the German Research Foundation. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. ED is the incumbent of the Henry J Leir Professorial Chair.	Akiri G, 2003, CANCER RES, V63, P1657; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Balleine RL, 2008, CLIN CANCER RES, V14, P8244, DOI 10.1158/1078-0432.CCR-08-0939; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Cox DR, 1972, J R STAT SOC B, V4, P102; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Desmedt C, 2008, EUR J CANCER, V44, P2714, DOI 10.1016/j.ejca.2008.09.011; Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756; Ensslin MA, 2007, P NATL ACAD SCI USA, V104, P2715, DOI 10.1073/pnas.0610296104; Erler JT, 2009, CLIN EXP METASTAS, V26, P35, DOI 10.1007/s10585-008-9209-8; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Haibe-Kains B, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-394; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Kirschmann DA, 2002, CANCER RES, V62, P4478; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; LONARDO F, 1990, New Biologist, V2, P992; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shi LM, 2006, NAT BIOTECHNOL, V24, P1151, DOI 10.1038/nbt1239; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smigal C, 2006, CA-CANCER J CLIN, V56, P168, DOI 10.3322/canjclin.56.3.168; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tagliabue E, 2003, LANCET, V362, P527, DOI 10.1016/S0140-6736(03)14112-8; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Therneau TM, 2000, MODELING SURVIVAL DA; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Valabrega G, 2005, ONCOGENE, V24, P3002, DOI 10.1038/sj.onc.1208478; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	47	28	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	31					3569	3583		10.1038/onc.2011.547	http://dx.doi.org/10.1038/onc.2011.547			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22139081	Green Accepted			2022-12-28	WOS:000307245600001
J	Merino, D; Strasser, A; Bouillet, P				Merino, D.; Strasser, A.; Bouillet, P.			Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression	ONCOGENE			English	Article						Myc; bim; tumor suppression; lymphoma; apoptosis	B-CELL LYMPHOMAGENESIS; TRANSGENIC MICE; C-MYC; MEMBRANE PERMEABILIZATION; PROTEINS; DEATH; PUMA; EXPRESSION; LEUKEMIA; DRIVEN	Overexpression of the transcriptional regulator Myc is thought to be the cause or a contributing factor in the development of a large number of human lymphomas and certain other cancers. Apoptotic cell death constitutes a tumor suppressive mechanism, particularly in the context of Myc overexpression. Accordingly, lymphoma development in El-Myc transgenic mice, which mimic the Myc/ IgH chromosomal translocation that causes Burkitt lymphoma, is accelerated by concomitant overexpression of anti-apoptotic Bcl-2 family members or loss of proapoptotic BH3-only proteins, such as Bim. Bim binds with high affinity to all pro-survival Bcl-2-like proteins and can also interact with Bax/ Bak, but it remains unclear which of these interactions are critical for its tumor suppressive function. We have previously generated knock-in mutant mice in which the BH3 region of Bim has been exchanged with that for Bad, Noxa or Puma so that it can only bind to select pro-survival Bcl-2-like proteins: Bim(Bad) binding to Bcl-2, Bcl-xL and Bcl-w, but not Mcl-1 or A1; Bim(Noxa) binding only to Mcl-1 and A1 and as a control, Bim(Puma), which can still bind all pro-survival Bcl-2-like proteins. We have now inter-crossed these Bim mutant mice with El-Myc transgenic mice, and found that both the Bim(Bad) and the Bim(Noxa) mutations but not the Bim(Puma) mutation greatly accelerate Myc-induced lymphoma development and increase leukemic burden. These results demonstrate that for optimal tumor suppressive activity, Bim must be able to interact with all and not just select pro-survival Bcl-2 family members. Oncogene (2012) 31, 3392-3396; doi: 10.1038/onc.2011.508; published online 14 November 2011	[Merino, D.; Strasser, A.; Bouillet, P.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3010, Australia; [Merino, D.; Strasser, A.; Bouillet, P.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; University of Melbourne	Bouillet, P (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3010, Australia.	bouillet@wehi.edu.au	Strasser, Andreas/C-7581-2013; Merino, Delphine/L-9159-2017; Bouillet, Philippe/E-1241-2013	Strasser, Andreas/0000-0002-5020-4891; Merino, Delphine/0000-0002-8075-6275; Bouillet, Philippe/0000-0002-9012-6058	Australian National Health and Medical Research Council [461221]; National Cancer Institute [CA43540]; Australian Research Council; Leukemia and Lymphoma Society [7015]; Australian Government (IRISS); Victorian State Government (OIS); NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Australian Research Council(Australian Research Council); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Australian Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government (OIS); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mikara Robati and Owen Siggs for help with experiments; Jerry Adams, Suzanne Cory, Clare Scott and Cyril Clybouw for insightful discussions; and Em-Myc mice, Bruno Helbert and Carley Young for mouse genotyping; Emily Sutherland and Giovanni Siciliano for mouse husbandry; and Jason Corbin for blood sample analysis. This work was supported by the Australian National Health and Medical Research Council (program grant 461221, Australia Fellowship (AS) and Career Development Award (PB)), the National Cancer Institute (CA43540), the Australian Research Council (DM), the Leukemia and Lymphoma Society (LLS Specialized Center of Research grant 7015) and operational infrastructure grants through the Australian Government (IRISS) and the Victorian State Government (OIS).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Anderton E, 2008, ONCOGENE, V27, P421, DOI 10.1038/sj.onc.1210668; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Frenzel A, 2010, BLOOD, V115, P995, DOI 10.1182/blood-2009-03-212670; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Merino D, 2009, J CELL BIOL, V186, P355, DOI 10.1083/jcb.200905153; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Xiang ZF, 2010, J CLIN INVEST, V120, P2109, DOI 10.1172/JCI39964; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	22	17	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	28					3392	3396		10.1038/onc.2011.508	http://dx.doi.org/10.1038/onc.2011.508			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22081075	Green Accepted			2022-12-28	WOS:000306367600008
J	Mahata, B; Sundqvist, A; Xirodimas, DP				Mahata, B.; Sundqvist, A.; Xirodimas, D. P.			Recruitment of RPL11 at promoter sites of p53-regulated genes upon nucleolar stress through NEDD8 and in an Mdm2-dependent manner	ONCOGENE			English	Article						RPL11; nucleolar stress; NEDD8; Mdm2; p53	RIBOSOMAL-PROTEIN L11; P53 ACTIVATION; DNA-DAMAGE; ACTINOMYCIN-D; IN-VIVO; C-MYC; ACETYLATION; TRANSCRIPTION; UBIQUITIN; RNA	Ribosomal proteins (RPs) activate the p53 tumour-suppressor protein upon disruption of the nucleolus. However, the exact mechanisms for p53 transcriptional activation through RPs are not well understood. We show that the RPL11 is rapidly but transiently recruited at promoter sites of p53-regulated genes upon nucleolar stress induced by actinomycin D (ActD). Characterisation of molecular events at p53 promoter sites shows that L11 is required for the recruitment of p53 transcriptional co-activators p300/CBP and p53 K382 acetylation. We found that direct binding to Mdm2 E3 ligase and NEDDylation of L11 are critical regulators for L11 promoter recruitment. Our data suggest that binding of L11 to Mdm2 at the promoter results in relief from Mdm2-mediated transcriptional repression of p53. Analysis of chromatin and RNA polymerase II markers suggests that L11 is involved in the initiation step of transcriptional activation. Furthermore, analysis of 36 ActD-induced genes shows that L11 and NEDD8 are global regulators of the p53 activation response. The studies provide insights on how nucleolar stress through L11 and NEDD8 can activate the transcriptional activity of p53. Oncogene (2012) 31, 3060-3071; doi: 10.1038/onc.2011.482; published online 14 November 2011	[Xirodimas, D. P.] CNRS, Ctr Rech Biochim Macromol, UMR 5237, F-34293 Montpellier 5, France; [Mahata, B.; Sundqvist, A.; Xirodimas, D. P.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Dundee	Xirodimas, DP (corresponding author), CNRS, Ctr Rech Biochim Macromol, UMR 5237, F-34293 Montpellier 5, France.	dimitris.xirodimas@crbm.cnrs.fr		Mahata, Bidesh/0000-0002-4506-0184; Xirodimas, Dimitris/0000-0001-9275-1140	Association for International Cancer Research (AICR); INSERM	Association for International Cancer Research (AICR); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Our research in the DPX laboratory is supported by the Association for International Cancer Research (AICR) and INSERM. DPX is an AICR Research Fellow.	Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Choong ML, 2009, CELL CYCLE, V8, P2810, DOI 10.4161/cc.8.17.9503; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2010, J BIOL CHEM, V285, P12587, DOI 10.1074/jbc.M109.056259; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Espinosa JM, 2008, ONCOGENE, V27, P4013, DOI 10.1038/onc.2008.37; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fuchs SM, 2009, BBA-GENE REGUL MECH, V1789, P26, DOI 10.1016/j.bbagrm.2008.07.008; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lennartsson A, 2009, BBA-GEN SUBJECTS, V1790, P863, DOI 10.1016/j.bbagen.2008.12.006; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Lindstrom MS, 2009, BIOCHEM BIOPH RES CO, V379, P167, DOI 10.1016/j.bbrc.2008.12.083; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Perry RP, 2007, GENE, V401, P1, DOI 10.1016/j.gene.2007.07.007; PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202; Phatnani HP, 2006, GENE DEV, V20, P2922, DOI 10.1101/gad.1477006; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang M, 2011, EXPERT OPIN THER TAR, V15, P253, DOI 10.1517/14728222.2011.550877; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Xirodimas DP, 2008, BIOCHEM SOC T, V36, P802, DOI 10.1042/BST0360802; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024	48	52	55	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3060	3071		10.1038/onc.2011.482	http://dx.doi.org/10.1038/onc.2011.482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22081073				2022-12-28	WOS:000305705900005
J	Beekman, JM; Vervoort, SJ; Dekkers, F; van Vessem, ME; Vendelbosch, S; Brugulat-Panes, A; van Loosdregt, J; Braat, AK; Coffer, PJ				Beekman, J. M.; Vervoort, S. J.; Dekkers, F.; van Vessem, M. E.; Vendelbosch, S.; Brugulat-Panes, A.; van Loosdregt, J.; Braat, A. K.; Coffer, P. J.			Syntenin-mediated regulation of Sox4 proteasomal degradation modulates transcriptional output	ONCOGENE			English	Article						Sox4; syntenin; proteasomal degradation; metastasis	PROTEIN-DEGRADATION; CANCER METASTASIS; ADAPTER PROTEIN; KAPPA-B; CELLS; GENE; MDA-9/SYNTENIN; UBIQUITIN; MICE; DIFFERENTIATION	The transcription factor Sox4 is aberrantly expressed in many human tumors and can modulate tumorigenesis and metastases of murine tumors in vivo. However, mechanisms that control Sox4 function remain poorly defined. It has recently been observed that DNA damage increases Sox4 protein expression independently of Sox4 mRNA levels, suggesting an as yet undefined post-transcriptional mechanism regulating Sox4 expression and functionality. Here, we show that Sox4 protein is rapidly degraded by the proteasome as indicated by pharmacological inhibition with Mg132 and epoxymycin. Sox4 half-life was found to be less than 1 h as evident by inhibition of protein synthesis using cycloheximide. Ectopic expression of Sox4 deletion mutants revealed that the C-terminal 33 residues of Sox4 were critical in modulating its degradation in a polyubiquitin-independent manner. Syntenin, a Sox4 binding partner, associates with this domain and was found to stabilize Sox4 expression. Syntenin-induced stabilization of Sox4 correlated with Sox4-syntenin relocalization to the nucleus, where both proteins accumulate. Syntenin overexpression or knockdown in human tumor cell lines was found to reciprocally modulate Sox4 protein expression and transcriptional activity implicating its role as a regulator of Sox4. Taken together, our data demonstrate that the Sox4 C-terminal domain regulates polyubiquitin-independent proteasomal degradation of Sox4 that can be modulated by interaction with syntenin. As aberrant Sox4 expression has been found associated with many human cancers, modulation of Sox4 proteasomal degradation may impact oncogenesis and metastatic properties of tumors. Oncogene (2012) 31, 2668-2679; doi:10.1038/onc.2011.445; published online 10 October 2011	[Beekman, J. M.; van Vessem, M. E.; Vendelbosch, S.; Brugulat-Panes, A.; van Loosdregt, J.; Braat, A. K.; Coffer, P. J.] Univ Med Ctr Utrecht, Dept Immunol, NL-3584 EA Utrecht, Netherlands; [Beekman, J. M.; Vervoort, S. J.; Dekkers, F.; Coffer, P. J.] Univ Med Ctr Utrecht, Ctr Mol & Cellular Intervent, Wilhelmina Childrens Hosp, NL-3584 EA Utrecht, Netherlands; [Vervoort, S. J.; Coffer, P. J.] Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 EA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, KC 02-085-2,Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	p.j.coffer@umcutrecht.nl	Beekman, Jeffrey M/I-7781-2014; Coffer, Paul/AAF-7970-2020; Vervoort, Stephin/AAP-7854-2020	Beekman, Jeffrey M/0000-0003-4886-3756; van Loosdregt, Jorg/0000-0003-1411-3754; Vervoort, Stephin/0000-0001-7459-126X; Brugulat Panes, Anna/0000-0003-4102-1417				Asher G, 2006, ISR MED ASSOC J, V8, P229; Asher G, 2006, BIOESSAYS, V28, P844, DOI 10.1002/bies.20447; Basbous J, 2008, BIOCHIMIE, V90, P296, DOI 10.1016/j.biochi.2007.07.016; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Beekman JM, 2009, BLOOD, V114, P3917, DOI 10.1182/blood-2009-03-208850; Beekman JM, 2004, P NATL ACAD SCI USA, V101, P10392, DOI 10.1073/pnas.0401217101; Belizario JE, 2008, CURR PROTEIN PEPT SC, V9, P210, DOI 10.2174/138920308784534023; Bergsland M, 2006, GENE DEV, V20, P3475, DOI 10.1101/gad.403406; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Boukerche H, 2010, ONCOGENE, V29, P3054, DOI 10.1038/onc.2010.65; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Fietta P, 2010, RIV BIOL-BIOL FORUM, V103, P29; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hoser M, 2008, MOL CELL BIOL, V28, P4675, DOI 10.1128/MCB.00338-08; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; Kruger E, 2001, BIOCHIMIE, V83, P289, DOI 10.1016/S0300-9084(01)01241-X; Kwak J., 2010, BIOCHIM BIOPHYS ACTA, V1809, P88; Lambaerts K, 2009, CURR OPIN CELL BIOL, V21, P662, DOI 10.1016/j.ceb.2009.05.002; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Malki S, 2010, INT J BIOCHEM CELL B, V42, P411, DOI 10.1016/j.biocel.2009.09.020; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Nissen-Meyer LSH, 2007, J CELL SCI, V120, P2785, DOI 10.1242/jcs.003855; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Penzo-Mendez AI, 2010, INT J BIOCHEM CELL B, V42, P425, DOI 10.1016/j.biocel.2009.07.018; Potzner MR, 2010, DEVELOPMENT, V137, P775, DOI 10.1242/dev.042101; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sarkar D, 2004, PHARMACOL THERAPEUT, V104, P101, DOI 10.1016/j.pharmthera.2004.08.004; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wilson ME, 2005, DIABETES, V54, P3402, DOI 10.2337/diabetes.54.12.3402; Ziegler EC, 2005, SCI STKE, V2005, P1	50	34	36	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	21					2668	2679		10.1038/onc.2011.445	http://dx.doi.org/10.1038/onc.2011.445			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21986941				2022-12-28	WOS:000304523500006
J	Arias, A; Lame, MW; Santarelli, L; Hen, R; Greene, LA; Angelastro, JM				Arias, A.; Lame, M. W.; Santarelli, L.; Hen, R.; Greene, L. A.; Angelastro, J. M.			Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas	ONCOGENE			English	Article						ATF5; PDGF-B; tumorigenesis; glioma	GROWTH-FACTOR-B; TRANSCRIPTION FACTOR ATF5; NEURAL PROGENITOR CELLS; GLIAL PROGENITORS; BRAIN-TUMORS; STEM-CELLS; AUTOCRINE STIMULATION; GENE-EXPRESSION; DNA-BINDING; GLIOBLASTOMA	Glioblastomas are among the most incurable cancers. Our past findings indicated that glioblastoma cells, but not neurons or glia, require the transcription factor ATF5 (activating transcription factor 5) for survival. However, it was unknown whether interference with ATF5 function can prevent or promote regression/eradication of malignant gliomas in vivo. To address this issue, we created a mouse model by crossing a human glial fibrillary acidic protein (GFAP) promoter-tetracycline transactivator mouse line with tetracycline operon-dominant negative-ATF5 (d/n-ATF5) mice to establish bi-transgenic mice. In this model, d/n-ATF5 expression is controlled by doxycycline and the promoter for GFAP, a marker for stem/progenitor cells as well as gliomas. Endogenous gliomas were produced with high efficiency by retroviral delivery of platelet-derived growth factor (PDGF)-B and p53-short hairpin RNA (shRNA) in adult bi-transgenic mice in which expression of d/n-ATF5 was spatially and temporally regulated. Induction of d/n-ATF5 before delivery of PDGF-B/p53-shRNA virus greatly reduced the proportion of mice that formed tumors. Moreover, d/n-ATF5 induction after tumor formation led to regression/eradication of detectable gliomas without evident damage to normal brain cells in all 24 mice assessed. Oncogene (2012) 31, 739-751; doi:10.1038/onc.2011.276; published online 4 July 2011	[Arias, A.; Lame, M. W.; Angelastro, J. M.] Univ Calif Davis, Davis Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; [Santarelli, L.; Hen, R.] Columbia Univ, Dept Neurosci, New York, NY USA; [Greene, L. A.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA	University of California System; University of California Davis; Columbia University; Columbia University	Angelastro, JM (corresponding author), Univ Calif Davis, Davis Sch Vet Med, Dept Mol Biosci, 2165 Haring Hall,1 Shields Ave, Davis, CA 95616 USA.	jmangelastro@ucdavis.edu			NIH [NS-33689]; Alexander and Margaret Stewart Trust; NIH-NCI [F31 CA123711-01A1, R21CA126924]; UCD Cancer Center [5P30CA093373-06S1]; NATIONAL CANCER INSTITUTE [R21CA126924, P30CA093373, F31CA123711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033689] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alexander and Margaret Stewart Trust; NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UCD Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by NIH Grant NS-33689 and an award from the Alexander and Margaret Stewart Trust (to LAG); NIH-NCI F31 CA123711-01A1 (to ADA); and in part support of the UCD Cancer Center Support Grant 5P30CA093373-06S1 (to JMA) and in full NIH-NCI R21CA126924 (to JMA). We thank Benjamin Pyles for his technical assistance in management of the mouse colony, genotyping, surgeries and anesthesia, as well as planning experimental end points. We thank Dr Stephen Noctor for the use of the Olympus FV-1000 confocal microscope and Fluoview software. We are indebted to Dr Robert Higgins (Neuropathologist, DVM/PhD) for assessment and evaluation of gliomas in mice with and without induced expression of d/n-ATF5.	Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Angelastro JM, 2003, J NEUROSCI, V23, P4590; Angelastro JM, 2006, ONCOGENE, V25, P907, DOI 10.1038/sj.onc.1209116; Angelastro JM, 2005, J NEUROSCI, V25, P3889, DOI 10.1523/JNEUROSCI.3447-04.2005; Assanah MC, 2009, GLIA, V57, P1835, DOI 10.1002/glia.20895; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Canoll P, 2008, ACTA NEUROPATHOL, V116, P465, DOI 10.1007/s00401-008-0432-9; Ciaccio NA, 2008, PROTEIN EXPRES PURIF, V62, P235, DOI 10.1016/j.pep.2008.07.011; Ciaccio NA, 2009, MOL PHARMACEUT, V6, P1205, DOI 10.1021/mp900058t; Concannon CG, 2003, APOPTOSIS, V8, P61, DOI 10.1023/A:1021601103096; Concannon CG, 2001, GENE EXPRESSION, V9, P195, DOI 10.3727/000000001783992605; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Dai CK, 2001, BBA-REV CANCER, V1551, pM19, DOI 10.1016/S0304-419X(01)00027-0; David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017; Dluzen D, 2011, J BIOL CHEM, V286, P7705, DOI 10.1074/jbc.M110.207639; Dong SM, 2005, J NEUROPATH EXP NEUR, V64, P948, DOI 10.1097/01.jnen.0000186940.14779.90; Elstrand MB, 2009, INT J GYNECOL PATHOL, V28, P211, DOI 10.1097/PGP.0b013e31818b0f5e; Fiacco TA, 2007, NEURON, V54, P611, DOI 10.1016/j.neuron.2007.04.032; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; Ghashghaei HT, 2007, GENE DEV, V21, P3258, DOI 10.1101/gad.1580407; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Greene LA, 2009, J NEUROCHEM, V108, P11, DOI 10.1111/j.1471-4159.2008.05749.x; Hede SM, 2009, GLIA, V57, P1143, DOI 10.1002/glia.20837; Hesselager G, 2003, CANCER RES, V63, P4305; Jackson EL, 2008, CELLS TISSUES ORGANS, V188, P212, DOI 10.1159/000114541; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; Li GF, 2009, MOL CANCER RES, V7, P933, DOI 10.1158/1541-7786.MCR-08-0365; Mason JL, 2005, MOL CELL NEUROSCI, V29, P372, DOI 10.1016/j.mcn.2005.03.004; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Moll JR, 2000, J BIOL CHEM, V275, P34826, DOI 10.1074/jbc.M004545200; Monaco SE, 2007, INT J CANCER, V120, P1883, DOI 10.1002/ijc.22469; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Persengiev SP, 2002, GENE DEV, V16, P1806, DOI 10.1101/gad.992202; Riquelme PA, 2008, PHILOS T R SOC B, V363, P123, DOI 10.1098/rstb.2006.2016; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Schrot RJ, 2007, J NEURO-ONCOL, V85, P149, DOI 10.1007/s11060-007-9401-8; Sheng Z, 2010, NAT MED, V16, P671, DOI 10.1038/nm.2158; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2003, CANCER RES, V63, P5821; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sweger EJ, 2007, J NEUROSCI, V27, P2309, DOI 10.1523/JNEUROSCI.4565-06.2007; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Uhrbom L, 1998, CANCER RES, V58, P5275; Uhrbom L, 2000, INT J CANCER, V85, P398, DOI 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L; Vescovi AL, 2006, NAT REV CANCER, V6, P425, DOI 10.1038/nrc1889; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wang H, 2007, CELL BIOL INT, V31, P1309, DOI 10.1016/j.cellbi.2007.05.002; Wang Z, 2010, BBA-REV CANCER, V1806, P122, DOI 10.1016/j.bbcan.2010.04.003; Wei YY, 2010, J BIOCHEM, V148, P171, DOI 10.1093/jb/mvq047	54	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					739	751		10.1038/onc.2011.276	http://dx.doi.org/10.1038/onc.2011.276			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725368	hybrid, Green Published			2022-12-28	WOS:000300222100007
J	Pradeep, CR; Kostler, WJ; Lauriola, M; Granit, RZ; Zhang, F; Jacob-Hirsch, J; Rechavi, G; Nair, HB; Hennessy, BT; Gonzalez-Angulo, AM; Tekmal, RR; Ben-Porath, I; Mills, GB; Domany, E; Yarden, Y				Pradeep, C-R; Koestler, W. J.; Lauriola, M.; Granit, R. Z.; Zhang, F.; Jacob-Hirsch, J.; Rechavi, G.; Nair, H. B.; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Tekmal, R. R.; Ben-Porath, I.; Mills, G. B.; Domany, E.; Yarden, Y.			Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling	ONCOGENE			English	Article						breast cancer; DCIS; growth factor; spheroids; receptor tyrosine kinase; signal transduction	HUMAN-BREAST-CANCER; MAMMARY-GLAND DEVELOPMENT; STEM-CELL; 3-DIMENSIONAL CULTURES; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; NEU ONCOGENE; NOTCH; ACTIVATION; OVEREXPRESSION	A large fraction of ductal carcinoma in situ ( DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts of DCIS are abnormally filled with cells that evade apoptosis, but the underlying mechanisms remain incompletely understood. We overexpressed HER2 in mammary epithelial cells and observed growth factor-independent proliferation. When grown in extracellular matrix as three-dimensional spheroids, control cells developed a hollow lumen, but HER2-overexpressing cells populated the lumen by evading apoptosis. We demonstrate that HER2 overexpression in this cellular model of DCIS drives transcriptional upregulation of multiple components of the Notch survival pathway. Importantly, luminal filling required upregulation of a signaling pathway comprising Notch3, its cleaved intracellular domain and the transcriptional regulator HES1, resulting in elevated levels of c-MYC and cyclin D1. In line with HER2-Notch3 collaboration, drugs intercepting either arm reverted the DCIS-like phenotype. In addition, we report upregulation of Notch3 in hyperplastic lesions of HER2 transgenic animals, as well as an association between HER2 levels and expression levels of components of the Notch pathway in tumor specimens of breast cancer patients. Therefore, it is conceivable that the integration of the Notch and HER2 signaling pathways contributes to the pathophysiology of DCIS. Oncogene ( 2012) 31, 907-917; doi: 10.1038/onc.2011.279; published online 11 July 2011	[Pradeep, C-R; Koestler, W. J.; Lauriola, M.; Yarden, Y.] Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; [Granit, R. Z.; Ben-Porath, I.] Hebrew Univ Jerusalem, Hadassah Sch Med, Dept Dev Biol & Canc Res, Inst Med Res Israel Canada, Jerusalem, Israel; [Zhang, F.; Hennessy, B. T.; Gonzalez-Angulo, A. M.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Jacob-Hirsch, J.; Rechavi, G.] Chaim Sheba Med Ctr, Sheba Canc Res Ctr, IL-52621 Tel Hashomer, Israel; [Jacob-Hirsch, J.; Rechavi, G.] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Nair, H. B.] SW Natl Primate Res Ctr, San Antonio, TX USA; [Hennessy, B. T.] Beaumont Hosp, Dept Med Oncol, Dublin 9, Ireland; [Gonzalez-Angulo, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Tekmal, R. R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, San Antonio, TX 78229 USA; [Domany, E.] Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem; University of Texas System; UTMD Anderson Cancer Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Texas Biomedical Research Institute; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health San Antonio; Weizmann Institute of Science	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, Candiotty Bldg,Room 302,1 Hertzl St, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	lauriola, mattia/N-6435-2014; DOMANY, EYTAN/K-1560-2012; YARDEN, YOSEF/K-1467-2012	lauriola, mattia/0000-0002-7966-0065; Bhaskaran Nair, Hareesh Babu/0000-0002-4309-9560; Granit, Roy Zvi/0000-0002-6487-2559; Hennessy, Bryan/0000-0002-7871-6477	National Cancer Institute [CA072981, CA121994-01, CA120248-01]; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Leir Charitable Foundation; MD. Moross Institute for Cancer Research; Susan G Komen Foundation [FAS0703849]; Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE [K23CA121994, R37CA072981, R01CA072981, R21CA120248, P30CA016672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Kekst Family Institute for Medical Genetics; Kirk Center for Childhood Cancer and Immunological Disorders; Bennett-Pritzker Endowment Fund; Marvelle Koffler Program for Breast Cancer Research; Leir Charitable Foundation; MD. Moross Institute for Cancer Research; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); Linda and Michael Jacobs Charitable Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Amit Zeisel and Sara Lavi for help, Brenda Lilly for the Notch3 reporter, and Powel Brown, Corey Speers and the Kleberg Center for Molecular Markers at MD Anderson Cancer Center (CCSG grant NCI CA16672) for providing tumors for the RPPA analysis. We acknowledge research funding by the National Cancer Institute (CA072981, CA121994-01 and CA120248-01), the Israel Cancer Research Fund, Dr Miriam and Sheldon G Adelson Medical Research Foundation, Kekst Family Institute for Medical Genetics, Kirk Center for Childhood Cancer and Immunological Disorders, the Women's Health Research Center funded by Bennett-Pritzker Endowment Fund, Marvelle Koffler Program for Breast Cancer Research, Leir Charitable Foundation and the MD. Moross Institute for Cancer Research, the Susan G Komen Foundation (FAS0703849 to AMG, BTH and GBM), and a fellowship for PhD track for specialist medical doctors by the Linda and Michael Jacobs Charitable Trust (WJK). YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair and ED of the Henry J Leir Professorial Chair.	Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Chen YY, 1997, J BIOL CHEM, V272, P14110, DOI 10.1074/jbc.272.22.14110; Clemenz AZ, 2009, CANCER RES, V69, p362s; Cohen B, 2010, BREAST CANCER RES TR, V123, P113, DOI 10.1007/s10549-009-0621-9; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Howlin J, 2006, J MAMMARY GLAND BIOL, V11, P283, DOI 10.1007/s10911-006-9024-2; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Ignatiadis M, 2009, CLIN CANCER RES, V15, P1848, DOI 10.1158/1078-0432.CCR-08-1844; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Jechlinger M, 2009, GENE DEV, V23, P1677, DOI 10.1101/gad.1801809; Katz M, 2007, NAT CELL BIOL, V9, P961, DOI 10.1038/ncb1622; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Liu JN, 2010, CURR TOP DEV BIOL, V92, P367, DOI [10.1016/S0070-2153(10)92012-7, 10.1016/S0070-2153(10)91012-7]; LONARDO F, 1990, New Biologist, V2, P992; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609; Palomero T, 2008, CELL CYCLE, V7, P965, DOI 10.4161/cc.7.8.5753; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Speers C, 2009, CLIN CANCER RES, V15, P6327, DOI 10.1158/1078-0432.CCR-09-1107; Sriuranpong V, 2001, CANCER RES, V61, P3200; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Tekmal RR, 2007, J STEROID BIOCHEM, V106, P111, DOI 10.1016/j.jsbmb.2007.05.009; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Whelan JT, 2007, CELL CYCLE, V6, P80, DOI 10.4161/cc.6.1.3648; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yin L, 2010, BIOCHEM PHARMACOL, V80, P690, DOI 10.1016/j.bcp.2010.03.026; Zardawi SJ, 2010, HISTOPATHOLOGY, V56, P286, DOI 10.1111/j.1365-2559.2009.03475.x; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081	57	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					907	917		10.1038/onc.2011.279	http://dx.doi.org/10.1038/onc.2011.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743488	Green Accepted, Bronze			2022-12-28	WOS:000300615800009
J	Bourguignon, LYW; Earle, C; Wong, G; Spevak, CC; Krueger, K				Bourguignon, L. Y. W.; Earle, C.; Wong, G.; Spevak, C. C.; Krueger, K.			Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells	ONCOGENE			English	Article						nanog; Stat-3; miR-21; hyaluronan; CD44; head & neck cancer	NF-KAPPA-B; CANCER STATISTICS; GENE-EXPRESSION; TUMOR-CELLS; RHO-KINASE; HYALURONAN; BREAST; PROGRESSION; ACTIVATION; TRANSCRIPTION	MicroRNAs are often associated with the pathogenesis of many cancers, including head and neck squamous cell carcinoma (HNSCC). In particular, microRNA-21 (miR-21) appears to have a critical role in tumor cell survival, chemoresistance and HNSCC progression. In this study, we investigated matrix hyaluronan (HA)-induced CD44 (a primary HA receptor) interaction with the stem cell markers, Nanog and Stat-3, in HNSCC cells (HSC-3 cells). Our results indicate that HA binding to CD44 promotes Nanog-Stat-3 (also tyrosine phosphorylated Stat-3) complex formation, nuclear translocation and transcriptional activation. Further analyses reveal that miR-21 is controlled by an upstream promoter containing Stat-3 binding site(s), while chromatin immunoprecipitation assays demonstrate that stimulation of miR-21 expression by HA/CD44 signaling is Nanog/Stat-3-dependent in HNSCC cells. This process results in a decrease of a tumor suppressor protein (PDCD4), and an upregulation of i nhibitors of the apoptosis family of proteins (IAPs) as well as chemoresistance in HSC-3 cells. Treatment of HSC-3 cells with Nanog- and/or Stat-3-specific small interfering RNAs effectively blocks HA-mediated Nanog-Stat-3 signaling events, abrogates miR-21 production and increases PDCD4 expression. Subsequently, this Nanog-Stat-3 signaling inhibition causes downregulation of survival protein (IAP) expression and enhancement of chemosensitivity. To further evaluate the role of miR-21 in tumor cell-specific functions, HSC-3 cells were also transfected with a specific anti-miR-21 inhibitor in order to silence miR-21 expression and block its target functions. Our results demonstrate that anti-miR-21 inhibitor not only upregulates PDCD4 expression but also decreases IAP expression and enhances chemosensitivity in HA-treated HNSCC cells. Together, these findings indicate that the HA-induced CD44 interaction with Nanog and Stat-3 has a pivotal role in miR-21 production leading to PDCD4 reduction, IAP upregulation and chemoresistance in HNSCC cells. This novel Nanog/Stat-3 signaling pathway-specific mechanism involved in miR-21 production is significant for the formation of future intervention strategies in the treatment of HA/CD44-activated HNSCC. Oncogene (2012) 31, 149-160; doi:10.1038/onc.2011.222; published online 20 June 2011	[Bourguignon, L. Y. W.] Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lilly.bourguignon@ucsf.edu			Veterans Affairs (VA) Merit Review grant; United States Public Health grants [R01 CA66163, R01 CA78633, P01 AR39448]; NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448, R01AR050023] Funding Source: NIH RePORTER	Veterans Affairs (VA) Merit Review grant; United States Public Health grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We gratefully acknowledge the assistance of Drs Gerard J Bourguignon and Walter M Holleran in the preparation and review of this manuscript. We are grateful for Ms Christina Camacho for her assistance in preparing graphs and illustrations. We would also like to thank for Dr Shaomeng Wang from the University of Michigan for providing us an IAP inhibitor, SM164. This work was supported by Veterans Affairs (VA) Merit Review grant and United States Public Health grants (R01 CA66163, R01 CA78633 and P01 AR39448). LYWB is a VA Senior Research Career Scientist.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Bourguignon LYW, 2008, SEMIN CANCER BIOL, V18, P251, DOI 10.1016/j.semcancer.2008.03.007; Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305; Bourguignon LYW, 2009, J BIOL CHEM, V284, P26533, DOI 10.1074/jbc.M109.027466; Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074/jbc.M806708200; Chang SS, 2008, INT J CANCER, V123, P2791, DOI 10.1002/ijc.23831; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008-5472.CAN-08-2655; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nakamura M, 2005, ONCOL REP, V14, P1281; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Toole BP, 2002, AM J PATHOL, V161, P745, DOI 10.1016/S0002-9440(10)64232-0; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Torre C, 2010, ARCH OTOLARYNGOL, V136, P493, DOI 10.1001/archoto.2010.25; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang SJ, 2011, AM J PATHOL, V178, P956, DOI 10.1016/j.ajpath.2010.11.077; Wang SJ, 2009, LARYNGOSCOPE, V119, P1518, DOI 10.1002/lary.20506; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9	30	174	182	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	2					149	160		10.1038/onc.2011.222	http://dx.doi.org/10.1038/onc.2011.222			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685938	Green Submitted, Green Accepted			2022-12-28	WOS:000299307400002
J	HuangFu, WC; Qian, J; Liu, C; Liu, J; Lokshin, AE; Baker, DP; Rui, H; Fuchs, SY				HuangFu, W-C; Qian, J.; Liu, C.; Liu, J.; Lokshin, A. E.; Baker, D. P.; Rui, H.; Fuchs, S. Y.			Inflammatory signaling compromises cell responses to interferon alpha	ONCOGENE			English	Article						inflammation; cancer; interferon; receptor; ubiquitin; melanoma	HUMAN-MELANOMA CELLS; CANCER-RELATED INFLAMMATION; HUMAN-MALIGNANT MELANOMA; TUMOR-NECROSIS-FACTOR; I-INTERFERON; ADJUVANT THERAPY; MULTIPLEX ANALYSIS; INNATE IMMUNITY; RECEPTOR; EXPRESSION	Interferon alpha (IFN alpha) is widely used for treatment of melanoma and certain other malignancies. This cytokine as well as the related IFN beta exerts potent anti-tumorigenic effects; however, their efficacy in patients is often suboptimal. Here, we report that inflammatory signaling impedes the effects of IFN alpha/beta. Melanoma cells can secrete pro-inflammatory cytokines that inhibit cellular responses to IFN alpha/beta via activating the ligand-independent pathway for the phosphorylation and subsequent ubiquitination and accelerated degradation of the IFNAR1 chain of type I IFN receptor. Catalytic activity of the p38 protein kinase was required for IFNAR1 downregulation and inhibition of IFN alpha/beta signaling induced by proinflammatory cytokines such as interleukin 1 (IL-1). Activation of p38 kinase inversely correlated with protein levels of IFNAR1 in clinical melanoma specimens. Inhibition of p38 kinase augmented the inhibitory effects of IFN alpha/beta on cell viability and growth in vitro and in vivo. The roles of inflammation and p38 protein kinase in regulating cellular responses to IFN alpha/beta in normal and tumor cells are discussed. Oncogene (2012) 31, 161-172; doi:10.1038/onc.2011.221; published online 13 June 2011	[HuangFu, W-C; Qian, J.; Liu, J.; Fuchs, S. Y.] Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; [HuangFu, W-C; Qian, J.; Liu, J.; Fuchs, S. Y.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; [Liu, C.; Rui, H.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Lokshin, A. E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Lokshin, A. E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA; [Lokshin, A. E.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Lokshin, A. E.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; [Baker, D. P.] Biogen Idec Inc, Cambridge, MA USA	University of Pennsylvania; University of Pennsylvania; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Biogen	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 380 S Univ Ave,Hill 316, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu		Liu, Jianghuai/0000-0002-2382-9140	NIH [CA092900, CA142425]; NATIONAL CANCER INSTITUTE [R01CA142425, R01CA092900] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs M Gaestel, LM Duncan, RJ Davis, M Herlyn, M May, E Meggers, A Nebreda, J Ninomiya-Tsuji and Z Ronai for reagents. This work was supported by NIH grants CA092900 and CA142425 (to SYF).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alonso-Curbelo D, 2010, AUTOPHAGY, V6, P148, DOI 10.4161/auto.6.1.10464; Ascierto PA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-62; Balkwill F, 2010, CLIN PHARMACOL THER, V87, P401, DOI 10.1038/clpt.2009.312; BENNICELLI JL, 1989, CANCER RES, V49, P930; Bhattacharya S, 2010, J BIOL CHEM, V285, P2318, DOI 10.1074/jbc.M109.071498; Bracarda S, 2010, EUR J CANCER, V46, P284, DOI 10.1016/j.ejca.2009.10.013; Bregman H, 2006, J AM CHEM SOC, V128, P877, DOI 10.1021/ja055523r; Coccia EM, 2006, CELL MOL BIOL, V52, P77, DOI 10.1170/T701; Fecher LA, 2009, J NATL COMPR CANC NE, V7, P295, DOI 10.6004/jnccn.2009.0022; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gu Y, 2009, CYTOKINE, V45, P44, DOI 10.1016/j.cyto.2008.10.014; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HuangFu WC, 2010, PIGM CELL MELANOMA R, V23, P838, DOI 10.1111/j.1755-148X.2010.00770.x; Hui LJ, 2007, CELL CYCLE, V6, P2429, DOI 10.4161/cc.6.20.4774; Kaehler KC, 2010, EUR J CANCER, V46, P41, DOI 10.1016/j.ejca.2009.10.004; KOCK A, 1989, J NATL CANCER I, V81, P36, DOI 10.1093/jnci/81.1.36; Kumar KGS, 2007, CANCER BIOL THER, V6, P1437; Kumar KGS, 2007, J CELL BIOL, V179, P935, DOI 10.1083/jcb.200706034; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8; Li JL, 2007, J BIOMED SCI, V14, P303, DOI 10.1007/s11373-007-9148-4; Li Y, 2006, ONCOGENE, V25, P1896, DOI 10.1038/sj.onc.1209214; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Linkov F, 2008, PROTEOM CLIN APPL, V2, P1575, DOI 10.1002/prca.200780095; Liu J, 2007, ONCOGENE, V26, P1954, DOI 10.1038/sj.onc.1209994; Liu J, 2008, BIOCHEM BIOPH RES CO, V367, P388, DOI 10.1016/j.bbrc.2007.12.137; Liu JH, 2009, MOL CELL BIOL, V29, P6401, DOI 10.1128/MCB.00478-09; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marijanovic Z, 2006, BIOCHEM J, V397, P31, DOI 10.1042/BJ20060272; Megason SG, 2002, DEVELOPMENT, V129, P2087; Melnikova VO, 2009, PIGM CELL MELANOMA R, V22, P257, DOI 10.1111/j.1755-148X.2009.00570.x; Messina Jane L, 2008, Cancer Control, V15, P196; Mocellin S, 2010, JNCI-J NATL CANCER I, V102, P493, DOI 10.1093/jnci/djq009; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rigualt NR, 2008, EXPERT REV ANTICANC, V8, P403, DOI 10.1586/14737140.8.3.403; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sander B, 1996, INT J CANCER, V66, P42, DOI 10.1002/(SICI)1097-0215(19960328)66:1<42::AID-IJC8>3.0.CO;2-Z; Smalley KSM, 2009, CANCER RES, V69, P3241, DOI 10.1158/0008-5472.CAN-08-4305; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.3.CO;2-D; Uze G, 2007, CURR TOP MICROBIOL, V316, P71; Weber A., 2010, SCI SIGNAL, V3; Yao K, 2009, SURG CLIN N AM, V89, P267, DOI 10.1016/j.suc.2008.11.002; Yurkovetsky ZR, 2007, CLIN CANCER RES, V13, P2422, DOI 10.1158/1078-0432.CCR-06-1805; Zheng H, 2011, MOL CELL BIOL, V31, P710, DOI 10.1128/MCB.01154-10; Zwang Y, 2006, EMBO J, V25, P4195, DOI 10.1038/sj.emboj.7601297	55	54	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					161	172		10.1038/onc.2011.221	http://dx.doi.org/10.1038/onc.2011.221			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666722	Green Published, Green Accepted			2022-12-28	WOS:000299307400003
J	McKinsey, EL; Parrish, JK; Irwin, AE; Niemeyer, BF; Kern, HB; Birks, DK; Jedlicka, P				McKinsey, E. L.; Parrish, J. K.; Irwin, A. E.; Niemeyer, B. F.; Kern, H. B.; Birks, D. K.; Jedlicka, P.			A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs	ONCOGENE			English	Article						microRNA; oncoprotein; Ewing; sarcoma; IGF	FACTOR-I-RECEPTOR; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTORS; CELL-PROLIFERATION; GROWTH; EXPRESSION; TUMOR; GENE; SUPPRESSES; GLIOMA	MicroRNAs (miRs) are a novel class of cellular bioactive molecules with critical functions in the regulation of gene expression in normal biology and disease. MiRs are frequently misexpressed in cancer, with potent biological consequences. However, relatively little is known about miRs in pediatric cancers, including sarcomas. Moreover, the mechanisms behind aberrant miR expression in cancer are poorly understood. Ewing sarcoma is an aggressive pediatric malignancy driven by EWS/Ets fusion oncoproteins, which are gain-of-function transcriptional regulators. We employed stable silencing of EWS/Fli1, the most common of the oncogenic fusions, and global miR profiling to identify EWS/Fli1-regulated miRs with oncogenesis-modifying roles in Ewing sarcoma. In this report, we characterize a group of miRs (100, 125b, 22, 221/222, 27a and 29a) strongly repressed by EWS/Fli1. Strikingly, all of these miRs have predicted targets in the insulin-like growth factor (IGF) signaling pathway, a pivotal driver of Ewing sarcoma oncogenesis. We demonstrate that miRs in this group negatively regulate the expression of multiple pro-oncogenic components of the IGF pathway, namely IGF-1, IGF-1 receptor, mammalian/mechanistic target of rapamycin and ribosomal protein S6 kinase A1. Consistent with tumor-suppressive functions, these miRs manifest growth inhibitory properties in Ewing sarcoma cells. Our studies thus uncover a novel oncogenic mechanism in Ewing sarcoma, involving post-transcriptional derepression of IGF signaling by the EWS/Fli1 fusion oncoprotein via miRs. This novel pathway may be amenable to innovative therapeutic targeting in Ewing sarcoma and other malignancies with activated IGF signaling. Oncogene (2011) 30, 4910-4920; doi:10.1038/onc.2011.197; published online 6 June 2011	[McKinsey, E. L.; Parrish, J. K.; Irwin, A. E.; Niemeyer, B. F.; Kern, H. B.; Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Birks, D. K.] Univ Colorado, Dept Neurosurg, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Jedlicka, P (corresponding author), Univ Colorado, Dept Pathol, Anschutz Med Campus,POB 6511,MS 8104, Aurora, CO 80045 USA.	paul.jedlicka@ucdenver.edu		Niemeyer, Brian/0000-0002-2020-2238; Kern, Hanna/0000-0001-7505-7130	Alex's Lemonade Stand Foundation for Childhood Cancer; Boettcher Foundation; University of Colorado Cancer Center and School of Medicine; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER	Alex's Lemonade Stand Foundation for Childhood Cancer; Boettcher Foundation; University of Colorado Cancer Center and School of Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Steve Lessnick for Ewing sarcoma cell lines; James DeGregori and Yosef Refaeli for lentiviral and retroviral reagents; Lynne Bemis, Dawn Cochrane, Heide Ford, Jennifer Richer and Rajeev Vibhakar for helpful suggestions/discussions. Funding for this work was provided by Alex's Lemonade Stand Foundation for Childhood Cancer, the Boettcher Foundation's Webb-Waring Biomedical Research Program, and the University of Colorado Cancer Center and School of Medicine. These studies were inspired by the memory of Zeljko Nikolic.	Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Benini S, 2004, INT J CANCER, V108, P358, DOI 10.1002/ijc.11576; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848; Chintharlapalli S, 2009, INT J CANCER, V125, P1965, DOI 10.1002/ijc.24530; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; Ciuffreda L, 2010, CURR CANCER DRUG TAR, V10, P484, DOI 10.2174/156800910791517172; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; Dahl KDC, 2009, NEOPLASIA, V11, P1208, DOI 10.1593/neo.09942; Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-18; Eyholzer M, 2010, BRIT J CANCER, V103, P275, DOI 10.1038/sj.bjc.6605751; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gefen N, 2010, LEUKEMIA, V24, P89, DOI 10.1038/leu.2009.208; Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575; Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Im YH, 2000, CANCER RES, V60, P1536; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jedlicka P, 2010, INT J CLIN EXP PATHO, V3, P338; Jedlicka P, 2009, AM J PATHOL, V174, P1280, DOI 10.2353/ajpath.2009.080409; Kim SY, 2009, ONCOLOGIST, V14, P83, DOI 10.1634/theoncologist.2008-0189; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Li J, 2010, GYNECOL ONCOL, V119, P543, DOI 10.1016/j.ygyno.2010.08.034; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Ludwig JA, 2008, CURR OPIN ONCOL, V20, P412, DOI 10.1097/CCO.0b013e328303ba1d; Luo W, 2009, ONCOGENE, V28, P4126, DOI 10.1038/onc.2009.262; Manara MC, 2007, CLIN CANCER RES, V13, P1322, DOI 10.1158/1078-0432.CCR-06-1518; Martins AS, 2006, CLIN CANCER RES, V12, P3532, DOI 10.1158/1078-0432.CCR-05-1778; Mateo-Lozano S, 2006, CLIN CANCER RES, V12, P6781, DOI 10.1158/1078-0432.CCR-06-0609; Mayoral RJ, 2009, J IMMUNOL, V182, P433, DOI 10.4049/jimmunol.182.1.433; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Muniyappa MK, 2009, EUR J CANCER, V45, P3104, DOI 10.1016/j.ejca.2009.09.014; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Patel JB, 2011, ONCOGENE, V30, P1290, DOI 10.1038/onc.2010.510; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Porter CC, 2008, BLOOD, V112, P4466, DOI 10.1182/blood-2008-03-146571; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Schmidt D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003713; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1996, CANCER RES, V56, P4570; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi L, 2010, BRAIN RES, V1312, P120, DOI 10.1016/j.brainres.2009.11.056; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sokol NS, 2008, GENE DEV, V22, P1591, DOI 10.1101/gad.1671708; Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Swarbrick A, 2010, NAT MED, V16, P1134, DOI 10.1038/nm.2227; Ting Y, 2010, BIOCHEM BIOPH RES CO, V394, P606, DOI 10.1016/j.bbrc.2010.03.030; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toretsky JA, 1999, CANCER RES, V59, P5745; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Wang V, 2009, BIODRUGS, V23, P15, DOI 10.2165/00063030-200923010-00002; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Xiong J, 2010, ONCOGENE, V29, P4980, DOI 10.1038/onc.2010.241; Xiong JH, 2010, FEBS J, V277, P1684, DOI 10.1111/j.1742-4658.2010.07594.x; Yang L, 2010, BIOCHEM BIOPH RES CO, V402, P129, DOI 10.1016/j.bbrc.2010.09.129; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhang CZ, 2009, INT J ONCOL, V34, P1653, DOI 10.3892/ijo_00000296; Zhang J, 2010, BRIT J CANCER, V103, P1215, DOI 10.1038/sj.bjc.6605895; Zhang JX, 2010, INT J ONCOL, V36, P913, DOI 10.3892/ijo_00000570; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126	96	67	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4910	4920		10.1038/onc.2011.197	http://dx.doi.org/10.1038/onc.2011.197			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21643012	Green Accepted			2022-12-28	WOS:000298346400007
J	Sabatino, L; Fucci, A; Pancione, M; Carafa, V; Nebbioso, A; Pistore, C; Babbio, F; Votino, C; Laudanna, C; Ceccarelli, M; Altucci, L; Bonapace, IM; Colantuoni, V				Sabatino, L.; Fucci, A.; Pancione, M.; Carafa, V.; Nebbioso, A.; Pistore, C.; Babbio, F.; Votino, C.; Laudanna, C.; Ceccarelli, M.; Altucci, L.; Bonapace, I. M.; Colantuoni, V.			UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression	ONCOGENE			English	Article						UHRF1; PPARG; epigenetics; colorectal cancer prognosis	ISLAND METHYLATOR PHENOTYPE; PERIPHERAL-BLOOD; DNA METHYLATION; EXPRESSION; DNMT3B; NP95; CPG; PROMOTER	Peroxisome proliferator-activated receptor gamma (PPARG) inactivation has been identified as an important step in colorectal cancer (CRC) progression, although the events involved have been partially clarified. UHRF1 is emerging as a cofactor that coordinates the epigenetic silencing of tumor suppressor genes, but its role in CRC remains elusive. Here, we report that UHRF1 negatively regulates PPARG and is associated with a higher proliferative, clonogenic and migration potential. Consistently, UHRF1 ectopic expression induces PPARG repression through its recruitment on the PPARG promoter fostering DNA methylation and histone repressive modifications. In agreement, UHRF1 knockdown elicits PPARG re-activation, accompanied by positive histone marks and DNA demethylation, corroborating its role in PPARG silencing. UHRF1 overexpression, as well as PPARG-silencing, imparts higher growth rate and phenotypic features resembling those occurring in the epithelial-mesenchymal transition. In our series of 110 sporadic CRCs, high UHRF1-expressing tumors are characterized by an undifferentiated phenotype, higher proliferation rate and poor clinical outcome only in advanced stages III-IV. In addition, the inverse relationship with PPARG found in vitro is detected in vivo and UHRF1 prognostic significance appears closely related to PPARG low expression, as remarkably validated in an independent dataset. The results demonstrate that UHRF1 regulates PPARG silencing and both genes appear to be part of a complex regulatory network. These findings suggest that the relationship between UHRF1 and PPARG may have a relevant role in CRC progression. Oncogene (2012) 31, 5061-5072; doi:10.1038/onc.2012.3; published online 30 January 2012	[Sabatino, L.; Fucci, A.; Pancione, M.; Votino, C.; Laudanna, C.; Ceccarelli, M.; Colantuoni, V.] Univ Sannio, Dept Biol Geol & Environm Sci, I-82100 Benevento, Italy; [Carafa, V.; Nebbioso, A.; Altucci, L.] Univ Naples 2, Dept Gen Pathol, Naples, Italy; [Pistore, C.; Babbio, F.; Bonapace, I. M.] Univ Insubria, Dept Struct & Funct Biol, Busto Arsizio, Va, Italy	University of Sannio; Universita della Campania Vanvitelli; University of Insubria	Colantuoni, V (corresponding author), Univ Sannio, Dept Biol Geol & Environm Sci, Via PortArsa 11, I-82100 Benevento, Italy.	colantuoni@unisannio.it	Pancione, Massimo/AAF-2109-2019; Altucci, Lucia/S-8031-2019; NEBBIOSO, ANGELA/GVS-1294-2022; Ceccarelli, Michele/AGP-1739-2022; NEBBIOSO, Angela/C-3566-2016	BONAPACE, IAN MARC/0000-0001-6580-8893; PANCIONE, Massimo/0000-0003-1728-8816; altucci, lucia/0000-0002-7312-5387; LAUDANNA, Carmelo/0000-0002-0397-6020; carafa, vincenzo/0000-0002-8025-3758; Sabatino, Lina/0000-0001-5341-7430; NEBBIOSO, Angela/0000-0001-5374-3527; Ceccarelli, Michele/0000-0002-4702-6617	Associazione Italiana per la Ricerca sul Cancro (AIRC); Fondazione Cariplo 'Progetto Nobel'; European Union: CancerDip [200620]; European Union: Aposys [200767]; Associazione Italiana per la lotta ai linfomi e leucemie (AIL)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo 'Progetto Nobel'(Fondazione Cariplo); European Union: CancerDip(European Commission); European Union: Aposys(European CommissionEuropean Commission Joint Research Centre); Associazione Italiana per la lotta ai linfomi e leucemie (AIL)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) to LA and IMB; Fondazione Cariplo 'Progetto Nobel' to IMB; European Union: CancerDip contract no 200620, Aposys contract no 200767 to LA; Associazione Italiana per la lotta ai linfomi e leucemie (AIL) to VC. We wish to thank Prof N Zambrano for kindly providing the shRNA vectors employed.	Alhosin M, 2011, J EXP CLIN CANC RES, V15, P30; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; BURCHILL SA, 1995, BRIT J CANCER, V71, P278, DOI 10.1038/bjc.1995.56; Capaccio D, 2010, BBA-MOL BASIS DIS, V1802, P572, DOI 10.1016/j.bbadis.2010.01.012; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Feige JN, 2006, PROG LIPID RES, V45, P120, DOI 10.1016/j.plipres.2005.12.002; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Grommes C, 2004, LANCET ONCOL, V5, P419, DOI 10.1016/S1470-2045(04)01509-8; Hayashi K, 2001, JPN J CANCER RES, V92, P42, DOI 10.1111/j.1349-7006.2001.tb01046.x; Ibrahim AEK, 2011, GUT, V60, P499, DOI 10.1136/gut.2010.223602; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kumar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013390; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Lorenzato M, 2005, HUM PATHOL, V36, P1101, DOI 10.1016/j.humpath.2005.07.016; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Meilinger D, 2009, EMBO REP, V10, P1259, DOI 10.1038/embor.2009.201; Nakazawa T, 2011, HUM PATHOL; Nosho K, 2009, CLIN CANCER RES, V15, P3663, DOI 10.1158/1078-0432.CCR-08-2383; Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048; Pancione M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014229; Pancione M, 2010, HUM PATHOL, V41, P867, DOI 10.1016/j.humpath.2009.09.019; Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874; Phe V, 2010, BJU INT, V105, P1364, DOI 10.1111/j.1464-410X.2009.09167.x; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Sabatino L, 2005, J BIOL CHEM, V280, P26517, DOI 10.1074/jbc.M502716200; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shen CX, 2008, JPN J CLIN ONCOL, V38, P770, DOI 10.1093/jjco/hyn105; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Tien AL, 2011, BIOCHEM J, V435, P175, DOI 10.1042/BJ20100840; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; Wang DZ, 2008, PPAR RES, V2008, DOI 10.1155/2008/931074	40	73	82	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5061	5072		10.1038/onc.2012.3	http://dx.doi.org/10.1038/onc.2012.3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22286757				2022-12-28	WOS:000312000900002
J	Chuang, JY; Wang, SA; Yang, WB; Yang, HC; Hung, CY; Su, TP; Chang, WC; Hung, JJ				Chuang, J-Y; Wang, S-A; Yang, W-B; Yang, H-C; Hung, C-Y; Su, T-P; Chang, W-C; Hung, J-J			Sp1 phosphorylation by cyclin-dependent kinase 1/cyclin B1 represses its DNA-binding activity during mitosis in cancer cells	ONCOGENE			English	Article						Sp1; CDK1; PP2A; myosin; mitosis	TRANSCRIPTION FACTOR SP1; GENE-TRANSCRIPTION; HEAT-SHOCK; PROTEIN; EXPRESSION; PROMOTER; OVEREXPRESSION; ACTIVATION; STABILITY; FACTOR-1	Sp1 is important for the transcription of many genes. Our previous studies have shown that Sp1 is degraded in normal cell, but it is preserved in cancer cells during mitosis and exists a priori in the daughter cells, ready to engage in gene transcription and thereby contributes to the proliferation and survival of cancer cells. The mechanism by which Sp1 is preserved in cancer cells during mitosis remains unknown. In this study, we observed that Sp1 strongly colocalized with cyclin-dependent kinase 1 (CDK1)/cyclin B1 during mitosis. Moreover, we showed that Sp1 is a novel mitotic substrate of CDK1/cyclin B1 and is phosphorylated by it at Thr 739 before the onset of mitosis. Phospho-Sp1 reduced its DNA-binding ability and facilitated the chromatin condensation process during mitosis. Mutation of Thr739 to alanine resulted in Sp1 remaining in the chromosomes, delayed cell-cycle progression, and eventually led to apoptosis. Screening of Sp1-associated proteins during mitosis by using liquid chromatography/mass spectrometry indicated the tethering of Sp1 to myosin/F-actin. Furthermore, phospho-Sp1 and myosin/F-actin appeared to exist as a congregated ring at the periphery of the chromosome. However, at the end of mitosis and the beginning of interphase, Sp1 was dephosphorylated by PP2A and returned to the chromatin. These results indicate that cancer cells use CDK1 and PP2A to regulate the movement of Sp1 in and out of the chromosomes during cell-cycle progression, which may benefit cancer-cell proliferation. Oncogene (2012) 31, 4946-4959; doi:10.1038/onc.2011.649; published online 23 January 2012	[Chuang, J-Y; Wang, S-A; Yang, W-B; Yang, H-C; Hung, J-J] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan 701, Taiwan; [Hung, C-Y; Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Coll Med, Inst Med, Tainan 70101, Taiwan; [Su, T-P] Natl Inst Drug Abuse, NIH, Baltimore, MD USA; [Chang, W-C; Hung, J-J] Dept Pharmacol, Tainan, Taiwan; [Chang, W-C; Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan 701, Taiwan; [Chang, W-C] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); National Cheng Kung University; Taipei Medical University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Yang, Wen-Bin/AAO-3593-2021; Yang, Hsiao-Ching/AGI-3553-2022	Yang, Wen-Bin/0000-0002-6497-4176; Yang, Hsiao-Ching/0000-0002-7970-1357; Wang, Shao-an/0000-0002-5473-4195	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan [NSC 97-2320-B-006-016-MY3, NSC 97-2311-B-006-002-MY3]; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000206] Funding Source: NIH RePORTER	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with grants NSC 97-2320-B-006-016-MY3 and NSC 97-2311-B-006-002-MY3 obtained from the National Science Council, Taiwan.	Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Benasciutti E, 2004, BLOOD, V104, P256, DOI 10.1182/blood-2003-08-2661; Bonello MR, 2004, J BIOL CHEM, V279, P2377, DOI 10.1074/jbc.M308254200; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Chang LK, 2005, NUCLEIC ACIDS RES, V33, P6528, DOI 10.1093/nar/gki956; Chiefari E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-35; Chu SJ, 2005, GENE, V348, P1, DOI 10.1016/j.gene.2005.01.013; Chuang JY, 2008, MOL BIOL CELL, V19, P1139, DOI 10.1091/mbc.E07-09-0881; Chuang JY, 2011, BIOCHEM BIOPH RES CO, V407, P587, DOI 10.1016/j.bbrc.2011.03.068; Chuang JY, 2009, INT J CANCER, V125, P2066, DOI 10.1002/ijc.24563; Guo T, 2010, CIRC RES, V106, P1743, DOI 10.1161/CIRCRESAHA.110.219816; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; He SH, 2006, J CELL SCI, V119, P1063, DOI 10.1242/jcs.02829; Hosoi Y, 2004, INT J ONCOL, V25, P461; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Kugimiya F, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000837; Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010; Lou Z, 2005, CANCER RES, V65, P1007; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Saxena UH, 2010, J BIOL CHEM, V285, P31139, DOI 10.1074/jbc.M109.078808; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang YT, 2008, J MOL BIOL, V380, P869, DOI 10.1016/j.jmb.2008.05.043; Wang YT, 2011, J MOL BIOL, V414, P1, DOI 10.1016/j.jmb.2011.09.027; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200	31	31	32	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4946	4959		10.1038/onc.2011.649	http://dx.doi.org/10.1038/onc.2011.649			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22266860	Green Accepted			2022-12-28	WOS:000311430200006
J	Sos, ML; Thomas, RK				Sos, M. L.; Thomas, R. K.			Genetic insight and therapeutic targets in squamous-cell lung cancer	ONCOGENE			English	Review						squamous-cell lung cancer; FGFR1; DDR2	ACTIVATING MUTATIONS; NEVER-SMOKERS; PHASE-III; GEFITINIB; CARBOPLATIN; PACLITAXEL; INHIBITOR; ONCOGENE; SINGLE; GROWTH	Squamous-cell lung cancer is one of the most prevalent subtypes of lung cancer worldwide and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors that show exquisite activity in lung adenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4)-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 gene and mutations of the discoidin domain receptor 2 gene as potential novel targets for the treatment of squamous-cell lung cancer patients. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lung cancer assessing the value of novel therapeutics addressing these targets.	[Sos, M. L.; Thomas, R. K.] Univ Cologne, Max Planck Inst Neurol Res, Klaus Joachim Zulch Labs, Max Planck Soc, D-50931 Cologne, Germany; [Sos, M. L.; Thomas, R. K.] Univ Cologne, Fac Med, D-50931 Cologne, Germany; [Thomas, R. K.] Univ Cologne, Ctr Integrated Oncol Koln Bonn, Lab Translat Canc Genom, D-50931 Cologne, Germany; [Sos, M. L.; Thomas, R. K.] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany	Max Planck Society; University of Cologne; University of Cologne; University of Cologne; University of Cologne	Thomas, RK (corresponding author), Univ Cologne, Max Planck Inst Neurol Res, Dept Internal Med 1, Gleuelerstr 50, D-50931 Cologne Nrw, Germany.	nini@nf.mpg.de	Sos, Martin L/I-1852-2014		German Ministry of Science and Education (BMBF), NGFNplus program [01GS08100]; Max Planck Society [M.I.F. A.NEUR8061]; Deutsche Forschungsgemeinschaft (DFG) [SFB (TP6)]; Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT) [4000- 12 09]; Fritz-Thyssen-Stiftung [10.08.2.175]; IASLC Lung Cancer Fellowship; Sanofi-Aventis; Merck; Roche; Boehringer Ingelheim; Astra-Zeneca; Atlas-Biolabs; JohnsonJohnson; AstraZeneca	German Ministry of Science and Education (BMBF), NGFNplus program(Federal Ministry of Education & Research (BMBF)); Max Planck Society(Max Planck SocietyFoundation CELLEX); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT); Fritz-Thyssen-Stiftung; IASLC Lung Cancer Fellowship; Sanofi-Aventis(Sanofi-Aventis); Merck(Merck & Company); Roche(Roche Holding); Boehringer Ingelheim(Boehringer Ingelheim); Astra-Zeneca(AstraZeneca); Atlas-Biolabs; JohnsonJohnson(Johnson & JohnsonJohnson & Johnson USA); AstraZeneca(AstraZeneca)	RKT is supported by the German Ministry of Science and Education (BMBF) as part of the NGFNplus program (grant 01GS08100), by the Max Planck Society (M.I.F. A.NEUR8061 to RKT), by the Deutsche Forschungsgemeinschaft (DFG) through SFB (TP6), the Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT, 4000- 12 09), by the Fritz-Thyssen-Stiftung (grant 10.08.2.175) and by an anonymous foundation. MLS is supported by an IASLC Lung Cancer Fellowship Award. RKT received consulting and lecture fees (Sanofi-Aventis, Merck, Roche, Boehringer Ingelheim, Astra-Zeneca, Atlas-Biolabs, Johnson&Johnson), as well as research support (AstraZeneca, Merck).	Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Harris TD, 2008, SCIENCE, V320, P106, DOI 10.1126/science.1150427; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lipson D, 2009, NAT BIOTECHNOL, V27, P652, DOI 10.1038/nbt.1551; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Marek L, 2009, MOL PHARMACOL, V75, P196, DOI 10.1124/mol.108.049544; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Sarker D, 2008, CLIN CANCER RES, V14, P2075, DOI 10.1158/1078-0432.CCR-07-1466; Scagliotti G, 2010, J CLIN ONCOL, V28, P1835, DOI 10.1200/JCO.2009.26.1321; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Turner NC, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001942; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Yuan P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009112	38	23	27	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4811	4814		10.1038/onc.2011.640	http://dx.doi.org/10.1038/onc.2011.640			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266863				2022-12-28	WOS:000311210700001
J	Yoon, CH; Kim, MJ; Kim, RK; Lim, EJ; Choi, KS; An, S; Hwang, SG; Kang, SG; Suh, Y; Park, MJ; Lee, SJ				Yoon, C-H; Kim, M-J; Kim, R-K; Lim, E-J; Choi, K-S; An, S.; Hwang, S-G; Kang, S-G; Suh, Y.; Park, M-J; Lee, S-J			c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells	ONCOGENE			English	Article						c-Jun N-terminal kinase; glioma stem-like cells; Notch-2; resistance to anticancer treatments	TUMOR-INITIATING CELLS; HUMAN BRAIN-TUMORS; HUMAN GLIOBLASTOMA; GROWTH-FACTOR; NH2-TERMINAL KINASE; NOTCH; CANCER; ACTIVATION; PATHWAY; EXPRESSION	Uncovering the mechanisms that govern the maintenance of stem-like cancer cells is critical for developing therapeutic strategies for targeting these cells. Constitutive activation of c-Jun N-terminal kinase (JNK) has been reported in gliomas and correlates with histological grade. Here, we found that JNK signaling is crucial for the maintenance of 'stemness' in glioma cells. Sphere-cultured glioma cells showed more phosphorylation of JNK compared with serum-containing monolayer cultures. Importantly, blockade of JNK signaling with SP600125 or small interfering RNAs targeting JNK1 or JNK2 significantly reduced the CD133(+)/Nestin(+) population and suppressed sphere formation, colony formation in soft agar, and expression of stem cell markers in sphere-cultured glioma cells. Intriguingly, sphere-cultured glioma cells exhibited enhanced expression of Notch-2, but not Notch-1, -3 or -4, and JNK inhibition almost completely abrogated this increase. Blocking the phosphoinoside 3-kinase (PI3K)/Akt pathway with LY294002 or si-Akt also suppressed the self-renewal of sphere-cultured glioma cells. PI3K, but not Akt, had a role as an upstream kinase in JNK1/2 activation. In addition, treatment with si-JNK greatly increased etoposide- and ionizing radiation (IR)-induced cell death in glioma spheres. Consistent with glioma cell lines, glioma stem-like cells isolated from primary patient glioma cells also had a higher activity of JNK and Notch-2 expression. Importantly, inhibition of JNK2 led to a decrease of Notch-2 expression and suppressed the CD133(+)/Nestin(+) cell population in patient-derived primary glioma cells. Finally, downregulation of JNK2 almost completely suppressed intracranial tumor formation by glioma cells in nude mice. Taken together, these data demonstrate that JNK signaling is crucial for the maintenance of self-renewal and tumorigenicity of glioma stem-like cells and drug/IR resistance, and can be considered a promising target for eliminating stem-like cancer cells in gliomas.	[Hwang, S-G; Park, M-J] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea; [Yoon, C-H; Kim, R-K; Lim, E-J; Suh, Y.; Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Dept Chem, Seoul 133791, South Korea; [Kim, M-J] Korea Atom Energy Res Inst, Environm Radiat Res Grp, Dept Radiat Biol, Taejon, South Korea; [Choi, K-S] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Seoul, South Korea; [An, S.] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul, South Korea; [Kang, S-G] Catholic Univ, Seoul St Marys Hosp, Dept Neurosurg, Seoul, South Korea	Korea Institute of Radiological & Medical Sciences; Hanyang University; Korea Atomic Energy Research Institute (KAERI); Sungkyunkwan University (SKKU); Samsung Medical Center; Konkuk University; Catholic University of Korea; Seoul St. Mary's Hospital	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul 139706, South Korea.	mjpark@kcch.re.kr; sj0420@hanyang.ac.kr	Yoon, Changhwan/AAK-7842-2021	Yoon, Changhwan/0000-0002-8420-9818; Kang, Seok-Gu/0000-0001-5676-2037	Korea Research Foundation (KRF); Ministry of Education, Science and Technology (MEST), Korean government [2008-2003935]; Ministry for Health, Welfare and Family affairs, Republic of Korea [1020340]	Korea Research Foundation (KRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology (MEST), Korean government(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Ministry for Health, Welfare and Family affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	We thank Dr Akio Soeda (Department of Neurological Surgery, University of Virginia, USA) for providing patient-derived glioma cells. This work was supported by the Korea Research Foundation (KRF) and Ministry of Education, Science and Technology (MEST), Korean government, through its National Nuclear Technology Program (2008-2003935) and the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (1020340).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Chen JX, 2005, INT J BIOCHEM CELL B, V37, P2273, DOI 10.1016/j.biocel.2005.02.028; Chiba S, 2006, STEM CELLS, V24, P2437, DOI 10.1634/stemcells.2005-0661; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Eyler CE, 2011, CELL, V146, P53, DOI 10.1016/j.cell.2011.06.006; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Frosina G, 2009, MOL CANCER RES, V7, P989, DOI 10.1158/1541-7786.MCR-09-0030; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429; Hyun KH, 2011, TOXICOL APPL PHARM, V254, P32, DOI 10.1016/j.taap.2011.04.006; Joseph NM, 2005, DEV CELL, V9, P173, DOI 10.1016/j.devcel.2005.07.001; Kanamori M, 2007, J NEUROSURG, V106, P417, DOI 10.3171/jns.2007.106.3.417; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Li JY, 2008, J NEURO-ONCOL, V88, P11, DOI 10.1007/s11060-008-9529-1; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Mangiola A, 2007, CLIN CANCER RES, V13, P6970, DOI 10.1158/1078-0432.CCR-07-1229; Mishra OP, 2004, NEUROSCIENCE, V123, P179, DOI 10.1016/j.neuroscience.2003.08.008; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Salmaggi A, 2006, GLIA, V54, P850, DOI 10.1002/glia.20414; Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tsuiki H, 2003, CANCER RES, V63, P250; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030; Xu P, 2010, J NEURO-ONCOL, V97, P41, DOI 10.1007/s11060-009-0007-1; Yi L, 2007, MODERN PATHOL, V20, P1061, DOI 10.1038/modpathol.3800942; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475; Yu SC, 2008, CANCER LETT, V265, P124, DOI 10.1016/j.canlet.2008.02.010; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107; Zhang XP, 2008, MOL CELL BIOCHEM, V307, P101, DOI 10.1007/s11010-007-9589-0; Zhong Y, 2007, BIOCHEM BIOPH RES CO, V364, P338, DOI 10.1016/j.bbrc.2007.10.016; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	62	79	80	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	44					4655	4666		10.1038/onc.2011.634	http://dx.doi.org/10.1038/onc.2011.634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249269				2022-12-28	WOS:000310724400001
J	Patrick, BA; Jaiswal, AK				Patrick, B. A.; Jaiswal, A. K.			RETRACTED: Stress-induced NQO1 controls stability of C/EBP alpha against 20S proteasomal degradation to regulate p63 expression with implications in protection against chemical-induced skin cancer (Retracted article. See vol. 36, pg. 2920, 2017)	ONCOGENE			English	Article; Retracted Publication						NQO1; C/EBP alpha; 20S proteasome; skin differentiation; p63	QUINONE OXIDOREDUCTASE-1; NAD(P)H-QUINONE OXIDOREDUCTASE-1; SKIN CARCINOGENESIS; MICE LEADS; MOUSE SKIN; P53; GENE; APOPTOSIS; NAD(P)H; SUSCEPTIBILITY	Previously, we have shown a role of cytosolic NAD(P)H: quinone oxidoreductase 1 (NQO1) in the stabilization of p63 against 20S proteasomal degradation resulting in thinning of the epithelium and chemical-induced skin cancer (Oncogene (2011) 30, 1098-1107). Current studies have demonstrated that NQO1 control of CCAAT-enhancer binding protein (C/EBP alpha) against 20S proteasomal degradation also contributes to the upregulation of p63 expression and protection. Western and immunohistochemistry analysis revealed that disruption of the NQO1 gene in mice and mouse keratinocytes led to degradation of C/EBP alpha and loss of p63 gene expression. p63 promoter mutagenesis, transfection and chromatin immunoprecipitation assays identified a C/EBP alpha-binding site between nucleotide position -185 and -174 that bound to C/EBP alpha and upregulated p63 gene expression. Co-immunoprecipitation and immunoblot analysis demonstrated that 20S proteasomes directly interacted and degraded C/EBP alpha. NQO1 direct interaction with C/EBP alpha led to stabilization of C/EBP alpha against 20S proteasomal degradation. NQO1 protection of C/EBP alpha required binding of NADH with NQO1. Exposure of skin and keratinocytes to the chemical stress agent benzo(a)pyrene led to induction of NQO1 and stabilization of C/EBP alpha protein, resulting in an increase in p63 RNA and protein in wildtype but not in NQO1-/- mice. Collectively, the current data combined with previous data suggest that stress induction of NQO1 through both stabilization of C/EBP alpha and increase in p63 and direct stabilization of p63 controls keratinocyte differentiation, leading to protection against chemical-induced skin carcinogenesis. The studies are significant as 2-4% human individuals are homozygous and 23% are heterozygous for the NQO1P187S mutation and might be susceptible to stress-induced skin diseases. Oncogene (2012) 31, 4362-4371; doi:10.1038/onc.2011.600; published online 16 January 2012	[Patrick, B. A.; Jaiswal, A. K.] Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Jaiswal, AK (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St,Howard Hall 404, Baltimore, MD 21201 USA.	ajaiswal@som.umaryland.edu			NIH [RO1 ES007943]; NIEHS [RO1 ES007943]; NIEHS training grant [ES007263]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943, T32ES007263] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS training grant; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank our colleagues for helpful discussions and suggestions. This study was supported by NIH Grant RO1 ES007943. BAP was partly supported by grant ES007263. AKJ was supported by NIEHS grant RO1 ES007943. BAP was supported by grant RO1 ES007943 and also in part is supported by NIEHS training grant ES007263.	Adler J, 2010, MOL CELL BIOL, V30, P3767, DOI 10.1128/MCB.00899-09; Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Garate M, 2008, EMBO REP, V9, P576, DOI 10.1038/embor.2008.48; Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323; Higashikawa K, 2007, CANCER RES, V67, P9207, DOI 10.1158/0008-5472.CAN-07-0932; Iskander K, 2005, CANCER RES, V65, P2054, DOI 10.1158/0008-5472.CAN-04-3157; Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; King KE, 2007, MOL CARCINOGEN, V46, P716, DOI 10.1002/mc.20337; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; Patrick BA, 2011, ONCOGENE, V30, P1098, DOI 10.1038/onc.2010.491; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Ross D, 2004, DRUG METAB REV, V36, P639, DOI 10.1081/DMR-200033465; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Sigrist CJA, 2010, NUCLEIC ACIDS RES, V38, pD161, DOI 10.1093/nar/gkp885; TRAVER RD, 1992, CANCER RES, V52, P797; Vasiliou Vasilis, 2006, Human Genomics, V2, P329; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	26	15	17	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4362	4371		10.1038/onc.2011.600	http://dx.doi.org/10.1038/onc.2011.600			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249251	Green Accepted			2022-12-28	WOS:000309591300003
J	Wee, EJH; Peters, K; Nair, SS; Hulf, T; Stein, S; Wagner, S; Bailey, P; Lee, SY; Qu, WJ; Brewster, B; French, JD; Dobrovic, A; Francis, GD; Clark, SJ; Brown, MA				Wee, E. J. H.; Peters, K.; Nair, S. S.; Hulf, T.; Stein, S.; Wagner, S.; Bailey, P.; Lee, S. Y.; Qu, W. J.; Brewster, B.; French, J. D.; Dobrovic, A.; Francis, G. D.; Clark, S. J.; Brown, M. A.			Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer	ONCOGENE			English	Article						MicroRNA; miR-200b; promoter; DNA methylation; breast cancer; prognosis	EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA EXPRESSION; CPG METHYLATION; MIR-200 FAMILY; ESTROGEN-RECEPTOR; CELLS; TRANSCRIPTION; INACTIVATION; REPRESSION; INVASION	MicroRNAs (miRNAs) are small non-coding RNAs of similar to 20 nt in length that are capable of modulating gene expression post-transcriptionally. Although miRNAs have been implicated in cancer, including breast cancer, the regulation of miRNA transcription and the role of defects in this process in cancer is not well understood. In this study we have mapped the promoters of 93 breast cancer-associated miRNAs, and then looked for associations between DNA methylation of 15 of these promoters and miRNA expression in breast cancer cells. The miRNA promoters with clearest association between DNA methylation and expression included a previously described and a novel promoter of the Hsa-mir-200b cluster. The novel promoter of the Hsa-mir-200b cluster, denoted P2, is located similar to 2 kb upstream of the 5' stemloop and maps within a CpG island. P2 has comparable promoter activity to the previously reported promoter (P1), and is able to drive the expression of miR-200b in its endogenous genomic context. DNA methylation of both P1 and P2 was inversely associated with miR-200b expression in eight out of nine breast cancer cell lines, and in vitro methylation of both promoters repressed their activity in reporter assays. In clinical samples, P1 and P2 were differentially methylated with methylation inversely associated with miR-200b expression. P1 was hypermethylated in metastatic lymph nodes compared with matched primary breast tumours whereas P2 hypermethylation was associated with loss of either oestrogen receptor or progesterone receptor. Hypomethylation of P2 was associated with gain of HER2 and androgen receptor expression. These data suggest an association between miR-200b regulation and breast cancer subtype and a potential use of DNA methylation of miRNA promoters as a component of a suite of breast cancer biomarkers. Oncogene (2012) 31, 4182-4195; doi:10.1038/onc.2011.584; published online 9 January 2012	[Wee, E. J. H.; Peters, K.; Bailey, P.; Lee, S. Y.; Brewster, B.; French, J. D.; Brown, M. A.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Stein, S.; Wagner, S.; Francis, G. D.] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia; [Nair, S. S.; Hulf, T.; Qu, W. J.; Clark, S. J.] Garvan Inst Med Res, Canc Program, Epigenet Grp, Sydney, NSW, Australia; [Dobrovic, A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia	University of Queensland; Garvan Institute of Medical Research; Peter Maccallum Cancer Center	Brown, MA (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, Coopers Rd, St Lucia, Qld 4072, Australia.	melissa.brown@uq.edu.au	Clark, Susan J/B-2272-2008; Brown, Melissa A/F-1451-2010; French, Juliet D/A-4982-2011; French, Juliet/AAV-4435-2020; Clark, Susan J/U-7365-2019	Clark, Susan J/0000-0001-5925-5030; French, Juliet/0000-0002-9770-0198; Clark, Susan J/0000-0001-5925-5030; Dobrovic, Alexander/0000-0003-3414-112X	National Breast Cancer Foundation (NBCF); Cancer Australia; National Health and Medical Research Council (NHMRC)	National Breast Cancer Foundation (NBCF); Cancer Australia; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	This project was funded by grants from the National Breast Cancer Foundation (NBCF), Cancer Australia and National Health and Medical Research Council (NHMRC). We are grateful to Dr Maja Klug for generously providing the CpG-Less reporter plasmid.	[Anonymous], 2005, Nat Methods, V2, P629; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805; Boyd SD, 2008, LAB INVEST, V88, P569, DOI 10.1038/labinvest.2008.32; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Han L, 2007, CANCER BIOL THER, V6, P1284; Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x; Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558; Lee JW, 2011, GYNECOL ONCOL, V120, P56, DOI 10.1016/j.ygyno.2010.09.022; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang XW, 2009, GENOME RES, V19, P266, DOI 10.1101/gr.081638.108; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013; Xu G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015519; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	47	58	60	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4182	4195		10.1038/onc.2011.584	http://dx.doi.org/10.1038/onc.2011.584			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22231446	hybrid, Green Published			2022-12-28	WOS:000308975800002
J	Palmieri, D; D'Angelo, D; Valentino, T; De Martino, I; Ferraro, A; Wierinckx, A; Fedele, M; Trouillas, J; Fusco, A				Palmieri, D.; D'Angelo, D.; Valentino, T.; De Martino, I.; Ferraro, A.; Wierinckx, A.; Fedele, M.; Trouillas, J.; Fusco, A.			Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis	ONCOGENE			English	Article						HMGA; pituitary adenoma; microRNA	NATURAL-KILLER-CELL; MOBILITY GROUP A2; GENE-EXPRESSION; PROTEIN-SYNTHESIS; ADENOMAS; TUMORS; MOUSE; OVEREXPRESSION; TRANSFORMATION; PROLIFERATION	Previous studies have demonstrated that high mobility group A proteins have a critical role on the onset of human pituitary adenomas. Indeed, both high mobility group A (HMGA) genes are overexpressed in pituitary adenomas, and consistently transgenic mice overexpressing either the Hmga1 or the Hmga2 gene develop mixed growth hormone/prolactin (GH-PRL)-secreting pituitary adenomas. Trisomy of chromosome 12, where HMGA2 is located, and/or amplification of the HMGA2 gene locus account for the HMGA2 overexpression in most human prolactinomas. Conversely, HMGA1 over-expression is not associated to any rearrangement or amplification of the HMGA1 locus. We have first identified micro RNAs (miRNAs) able to target both HMGA1 and HMGA2 messenger RNAs. Then, all of these miRNAs have been found downregulated in pituitary adenomas of different histotypes, compared with normal pituitary. Interestingly, their downregulation was also observed in nonfunctioning pituitary adenomas where HMGA2 overexpression is not associated to any alteration of the HMGA2 locus. Functional studies show that all these HMGA-targeting miRNAs inhibit the proliferation of the rat pituitary adenoma cell line GH3. Therefore, these results indicate that the downregulation of the miRNAs able to target the HMGA genes could contribute to increase HMGA protein levels in human pituitary adenomas, and then to pituitary tumorigenesis. Oncogene (2012) 31, 3857-3865; doi:10.1038/onc.2011.557; published online 5 December 2011	[Palmieri, D.; D'Angelo, D.; Valentino, T.; De Martino, I.; Ferraro, A.; Fedele, M.; Fusco, A.] Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale,Fac Med & Chi, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; [Wierinckx, A.] Univ Lyon, Lyon, France; [Wierinckx, A.] Ctr Rech Cancerol Lyon, INSERM, U1052, Lyon, France; [Trouillas, J.] CNRS, INSERM, U1028, UMR 5292,Lyon Neurosci Res Ctr,Neurooncol & Neuro, Lyon, France; [Trouillas, J.] Univ Lyon 1, F-69365 Lyon, France; [Ferraro, A.; Fusco, A.] SEMM European Sch Mol Med Naples Site, Naples, Italy; [Ferraro, A.; Fusco, A.] NOGEC Naples Oncogen Ctr CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Fusco, A (corresponding author), Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale,Fac Med & Chi, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	alfusco@unina.it	Wierinckx, Anne/AAF-5233-2021; Ferraro, Angelo/H-3193-2019; D'Angelo, Daniela/GVT-9143-2022; Fedele, Monica/C-1417-2015; Ferraro, Angelo/A-4172-2014	Wierinckx, Anne/0000-0002-0186-6645; Ferraro, Angelo/0000-0002-2044-7569; Fedele, Monica/0000-0002-9171-1312; Ferraro, Angelo/0000-0002-2044-7569; Palmieri, Dario/0000-0002-0797-4268; Fusco, Alfredo/0000-0003-3332-5197	Associazione Italiana Ricerca sul Cancro (AIRC); Fondazione Italiana per la Ricerca sul Cancro (FIRC)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italiana per la Ricerca sul Cancro (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (AIRC). DP is recipient of a fellowship from Fondazione Italiana per la Ricerca sul Cancro (FIRC).	ASHAR HR, 1995, CELL, V82, P57; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chiappetta G, 1996, ONCOGENE, V13, P2439; Daly AF, 2006, J CLIN ENDOCR METAB, V91, P4769, DOI 10.1210/jc.2006-1668; Daly AF, 2009, BEST PRACT RES CL EN, V23, P543, DOI 10.1016/j.beem.2009.05.008; De Martino I, 2009, ONCOGENE, V28, P1432, DOI 10.1038/onc.2008.495; De Martino I, 2007, ENDOCR-RELAT CANCER, V14, P875, DOI 10.1677/ERC-07-0036; De Martino I, 2009, CANCER RES, V69, P1844, DOI 10.1158/0008-5472.CAN-08-4133; Fedele M, 2005, ONCOGENE, V24, P3427, DOI 10.1038/sj.onc.1208501; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 2006, CANCER CELL, V9, P459, DOI 10.1016/j.ccr.2006.04.024; Fedele M, 2010, MOL CELL ENDOCRINOL, V326, P19, DOI 10.1016/j.mce.2010.03.019; Fedele M, 2010, BBA-GENE REGUL MECH, V1799, P48, DOI 10.1016/j.bbagrm.2009.11.007; Fernandez A, 2010, CLIN ENDOCRINOL, V72, P377, DOI 10.1111/j.1365-2265.2009.03667.x; Finelli P, 2002, CANCER RES, V62, P2398; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kaddar T, 2009, BIOL CELL, V101, P511, DOI 10.1042/BC20080213; KOVACS K, 1986, SEMIN DIAGN PATHOL, V3, P18; Lagana A, 2009, DATABASE-OXFORD, DOI 10.1093/database/bap008; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee S, 2011, CELL MOL LIFE SCI, V68, P325, DOI 10.1007/s00018-010-0457-9; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Melmed S, 2011, NAT REV ENDOCRINOL, V7, P257, DOI 10.1038/nrendo.2011.40; Monson JP, 2000, ENDOCR-RELAT CANCER, V7, P29, DOI 10.1677/erc.0.0070029; Pierantoni GM, 2005, ENDOCR-RELAT CANCER, V12, P867, DOI 10.1677/erc.1.01049; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Qian ZR, 2009, MODERN PATHOL, V22, P431, DOI 10.1038/modpathol.2008.202; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Wang EL, 2010, HISTOPATHOLOGY, V56, P501, DOI 10.1111/j.1365-2559.2010.03495.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	41	79	82	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	34					3857	3865		10.1038/onc.2011.557	http://dx.doi.org/10.1038/onc.2011.557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV	22139073				2022-12-28	WOS:000307925000003
J	Wanka, C; Brucker, DP; Bahr, O; Ronellenfitsch, M; Weller, M; Steinbach, JP; Rieger, J				Wanka, C.; Brucker, D. P.; Baehr, O.; Ronellenfitsch, M.; Weller, M.; Steinbach, J. P.; Rieger, J.			Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death	ONCOGENE			English	Article						p53; SCO2; hypoxia; glioma; respiration	ENERGY-METABOLISM; P53; GENE; ANTIANGIOGENESIS; EXPRESSION; STRATEGIES; EVOLUTION; PATHWAYS; ARREST; SCO2	P53 has an important role in the processing of starvation signals. P53-dependent molecular mediators of the Warburg effect reduce glucose consumption and promote mitochondrial function. We therefore hypothesized that the retention of wild-type p53 characteristic of primary glioblastomas limits metabolic demands induced by deregulated signal transduction in the presence of hypoxia and nutrient depletion. Here we report that short hairpin RNA-mediated gene suppression of wild-type p53 or ectopic expression of mutant temperature-sensitive dominant-negative p53(V135A) increased glucose consumption and lactate production, decreased oxygen consumption and enhanced hypoxia-induced cell death in p53 wild-type human glioblastoma cells. Similarly, genetic knockout of p53 in HCT116 colon carcinoma cells resulted in reduced respiration and hypersensitivity towards hypoxia-induced cell death. Further, wild-type p53 gene silencing reduced the expression of synthesis of cytochrome c oxidase 2 (SCO2), an effector necessary for respiratory chain function. An SCO2 transgene reverted the metabolic phenotype and restored resistance towards hypoxia in p53-depleted and p53 mutant glioma cells in a rotenone-sensitive manner, demonstrating that this effect was dependent on intact oxidative phosphorylation. Supplementation with methyl-pyruvate, a mitochondrial substrate, rescued p53 wild-type but not p53 mutant cells from hypoxic cell death, demonstrating a p53-mediated selective aptitude to metabolize mitochondrial substrates. Further, SCO2 gene silencing in p53 wild-type glioma cells sensitized these cells towards hypoxia. Finally, lentiviral gene suppression of SCO2 significantly enhanced tumor necrosis in a subcutaneous HCT116 xenograft tumor model, compatible with impaired energy metabolism in these cells. These findings demonstrate that glioma and colon cancer cells with p53 wild-type status can skew the Warburg effect and thereby reduce their vulnerability towards tumor hypoxia in an SCO2-dependent manner. Targeting SCO2 may therefore represent a valuable strategy to enhance sensitivity towards hypoxia and may complement strategies targeting glucose metabolism. Oncogene (2012) 31, 3764-3776; doi:10.1038/onc.2011.530; published online 28 November 2011	[Wanka, C.; Brucker, D. P.; Baehr, O.; Ronellenfitsch, M.; Steinbach, J. P.; Rieger, J.] Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, D-60528 Frankfurt, Germany; [Wanka, C.; Brucker, D. P.; Steinbach, J. P.] Univ Tubingen Hosp, Dept Neurol, Tubingen, Germany; [Weller, M.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland	Goethe University Frankfurt; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Zurich; University Zurich Hospital	Rieger, J (corresponding author), Goethe Univ Frankfurt, Dr Senckenberg Inst Neurooncol, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	johannes.rieger@med.uni-frankfurt.de	Ronellenfitsch, Michael/AAW-8201-2020	Ronellenfitsch, Michael/0000-0002-1402-6290; Weller, Michael/0000-0002-1748-174X; Brucker, Daniel Peer/0000-0002-1808-5917; Rieger, Johannes/0000-0002-7918-1777	Deutsche Forschungsgemeinschaft [GRK 1302/1]; Hertie foundation; Dr Senckenberg foundation	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Hertie foundation; Dr Senckenberg foundation	We thank P Hwang for providing the SCO2 expression plasmid and B Vogelstein for the HCT116 p53<SUP>+/+</SUP> and p53<SUP>-/-</SUP> cell lines. This work was supported by The Deutsche Forschungsgemeinschaft (GRK 1302/1). The Dr Senckenberg Institute of Neurooncology is supported by the Hertie foundation and the Dr Senckenberg foundation. JPS is 'Hertie Professor for Neurooncology'.	Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Barnes K, 2002, J CELL SCI, V115, P2433; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhonde MR, 2006, ONCOGENE, V25, P165, DOI 10.1038/sj.onc.1209017; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447; Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394; Choe G, 2003, CANCER RES, V63, P2742; Corcoran CA, 2006, CANCER BIOL THER, V5, P1610, DOI 10.4161/cbt.5.12.3617; CURI R, 1988, BIOCHEM J, V250, P383, DOI 10.1042/bj2500383; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Ehrmann J, 1995, Cesk Patol, V31, P87; FULTS D, 1992, CANCER RES, V52, P674; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gottlieb E, 2009, NATURE, V461, P44, DOI 10.1038/461044a; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jansen M, 2004, BRAIN RES REV, V45, P143, DOI 10.1016/j.brainresrev.2004.03.001; Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030; Kondoh H, 2005, CANCER RES, V65, P177; KOPPER L, 1975, CANCER RES, V35, P2704; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Leary SC, 2009, HUM MOL GENET, V18, P2230, DOI 10.1093/hmg/ddp158; Liu T, 2007, CELL DEATH DIFFER, V14, P411, DOI 10.1038/sj.cdd.4402022; Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Puduvalli VK, 2000, J NEURO-ONCOL, V50, P189, DOI 10.1023/A:1006469830739; Rieger J, 2010, J NEURO-ONCOL, V99, P49, DOI 10.1007/s11060-009-0098-8; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Steinbach JP, 2003, CELL DEATH DIFFER, V10, P823, DOI 10.1038/sj.cdd.4401252; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sung HJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1003; Tohma Y, 1998, J NEUROPATH EXP NEUR, V57, P239, DOI 10.1097/00005072-199803000-00005; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Wischhusen J, 2004, CELL DEATH DIFFER, V11, P1150, DOI 10.1038/sj.cdd.4401477; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Yoon CH, 2009, P NATL ACAD SCI USA, V106, P7852, DOI 10.1073/pnas.0812148106; Zhao Y, 2009, J ZHEJIANG UNIV-SC B, V10, P404, DOI 10.1631/jzus.B0820293	52	40	41	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3764	3776		10.1038/onc.2011.530	http://dx.doi.org/10.1038/onc.2011.530			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120717	Green Accepted			2022-12-28	WOS:000307924900003
J	Donnini, S; Finetti, F; Terzuoli, E; Giachetti, A; Iniguez, MA; Hanaka, H; Fresno, M; Radmark, O; Ziche, M				Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Iniguez, M. A.; Hanaka, H.; Fresno, M.; Radmark, O.; Ziche, M.			EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity	ONCOGENE			English	Article						prostaglandinE-2; mPGES-1; epidermal growth factor; Egr-1; E-cadherin; vimentin	EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTION FACTOR EGR-1; FACTOR-RECEPTOR; LUNG-CANCER; COLORECTAL ADENOMAS; KAPPA-B; ACTIVATION; E-2; GENE; CYCLOOXYGENASE-2	In this report we describe the contribution of prostaglandin E-2 (PGE(2)) derived from the inducible microsomal PGE-synthase type-1 (mPGES-1) to the epidermal growth factor receptor (EGFR) oncogenic drive in tumor epithelial cells and in tumor-bearing mice. EGFR stimulation upregulated expression of mPGES-1 in HT-29, A431 and A549 cancer cells. Egr-1, a transcription factor induced by EGF, mediated this response. The Egr-1 rise provoked the overexpression of mPGES-1 messenger and protein, and enhanced PGE(2) formation. These changes were suppressed either by silencing Egr-1, or by upstream blockade of EGFR or ERK1/2 signals. Further, in a clonogenic assay on tumor cells, EGF induced a florid tumorigenic phenotype, which regressed when mPGES-1 was silenced or knocked down. EGF-induced mPGES-1 overexpression in epithelial cell reduced E-cadherin expression, whereas enhancing that of vimentin, suggesting an incipient mesenchymal phenotype. Additionally, inhibiting the EGFR in mice bearing the A431 tumor, the mPGES-1 expression and the tumor growth, exhibited a parallel decline. In conclusion, these findings provide novel evidence that a tight cooperation between the EGF/EGFR and mPGES-1 leads to a significant tumorigenic gain in epithelial cells, and provide clues for controlling the vicious association. Oncogene (2012) 31, 3457-3466; doi:10.1038/onc.2011.503; published online 14 November 2011	[Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Ziche, M.] Univ Siena, Dept Biotechnol, Pharmacol Sect, I-53100 Siena, Italy; [Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Ziche, M.] ITT, Siena, Italy; [Iniguez, M. A.; Fresno, M.] Univ Autonoma Madrid, CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Hanaka, H.; Radmark, O.] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden	University of Siena; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Karolinska Institutet	Ziche, M (corresponding author), Univ Siena, Dept Biotechnol, Pharmacol Sect, Via Aldo Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Finetti, Federica/J-9089-2016; Donnini, Sandra/K-9252-2019; Peña, Miguel Angel Iñiguez/J-8518-2012; Terzuoli, Erika/M-7346-2016	Donnini, Sandra/0000-0001-6617-1644; Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Ziche, Marina/0000-0002-9564-214X; Terzuoli, Erika/0000-0001-9248-4505; Fresno Escudero, Manuel/0000-0002-9223-5477	Associazione Italiana della Ricerca sul Cancro (AIRC) [IG10731]; Istituto Toscano Tumori (ITT); Comunidad de Madrid [S-SAL2006/0015]; Ministerio de Ciencia e Innovacion [SAF2010-18733, BFU2010-21055]; Ministerio de Ciencia e Innovacion	Associazione Italiana della Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Istituto Toscano Tumori (ITT); Comunidad de Madrid(Comunidad de Madrid); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank Dr MD Diaz-Munoz for the construction of mPGES-1 plasmids. This work has received financial support from the Associazione Italiana della Ricerca sul Cancro (AIRC) IG10731 (MZ), Istituto Toscano Tumori (ITT) (SD), Comunidad de Madrid S-SAL2006/0015, Ministerio de Ciencia e Innovacion SAF2010-18733 (MF), Ministerio de Ciencia e Innovacion BFU2010-21055 (MAI).	Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cheng S, 2004, J BIOL CHEM, V279, P22057, DOI 10.1074/jbc.M402828200; Choe MS, 2005, MOL CANCER THER, V4, P1448, DOI 10.1158/1535-7163.MCT-04-0251; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Dasari A, 2010, CLIN CANCER RES, V16, P3811, DOI 10.1158/1078-0432.CCR-09-2283; Deckmann K, 2010, BIOCHEM PHARMACOL, V80, P1365, DOI 10.1016/j.bcp.2010.07.032; Diaz-Munoz MD, 2010, CELL SIGNAL, V22, P1427, DOI 10.1016/j.cellsig.2010.05.011; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Donnini S, 2007, FASEB J, V21, P2418, DOI 10.1096/fj.06-7581com; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Finetti F, 2009, CIRC RES, V105, P657, DOI 10.1161/CIRCRESAHA.109.203760; Golijanin D, 2004, CLIN CANCER RES, V10, P1024, DOI 10.1158/1078-0432.CCR-1032-3; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045; Leone V, 2007, AM J PHYSIOL-GASTR L, V293, pG673, DOI 10.1152/ajpgi.00584.2006; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lu D, 2012, ONCOGENE, V31, P842, DOI 10.1038/onc.2011.287; Mann JR, 2006, CANCER RES, V66, P6649, DOI 10.1158/0008-5472.CAN-06-1787; Menter DG, 2010, CLIN CANCER RES, V16, P1384, DOI 10.1158/1078-0432.CCR-09-0788; Nah SS, 2010, RHEUMATOL INT, V30, P443, DOI 10.1007/s00296-009-0976-6; Nakanishi M, 2008, CANCER RES, V68, P3251, DOI 10.1158/0008-5472.CAN-07-6100; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pignatelli M, 1999, FEBS LETT, V461, P37, DOI 10.1016/S0014-5793(99)01420-9; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wiesner GL, 2001, J NATL CANCER I, V93, P635, DOI 10.1093/jnci/93.8.635; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669	38	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3457	3466		10.1038/onc.2011.503	http://dx.doi.org/10.1038/onc.2011.503			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22081067	Green Accepted			2022-12-28	WOS:000306566400006
J	Franks, SE; Campbell, CI; Barnett, EF; Siwicky, MD; Livingstone, J; Cory, S; Moorehead, RA				Franks, S. E.; Campbell, C. I.; Barnett, E. F.; Siwicky, M. D.; Livingstone, J.; Cory, S.; Moorehead, R. A.			Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature	ONCOGENE			English	Article						IGF-IR; mammary tumor; DNA microarray; EMT; claudin	ESTROGEN-RECEPTOR-ALPHA; HUMAN-BREAST-CANCER; PROGESTERONE-RECEPTORS; MOLECULAR PORTRAITS; PROFILES; CARCINOMAS; PATTERNS	Molecular profiling has allowed a more precise classification of human cancers. With respect to breast cancer, this approach has been used to identify five subtypes; luminal A, luminal B, HER2-enriched, basal-like and claudin-low. In addition, this approach can be used to determine the type of tumor represented by particular cell lines or transgenic animal models. Therefore, this approach was utilized to classify the mammary tumors that develop in MTB-IGFIR transgenic mice. It was determined that the primary mammary tumors, which develop due to elevated expression of the type I insulin-like growth factor receptor (IGF-IR) in mammary epithelial cells, most closely resemble murine tumors with basal-like or mixed gene expression profiles and with human basal-like breast cancers. Downregulation of IGF-IR transgene in MTB-IGFIR tumor-bearing mice leads to the regression of most of the tumors, followed by tumor reappearance in some of the mice. These tumors that reappear following IGF-IR transgene downregulation do not express the IGF-IR transgene and cluster with murine mammary tumors that express a mesenchymal gene expression profile and with human claudin-low breast cancers. Therefore, IGF-IR overexpression in murine mammary epithelial cells induces mammary tumors with primarily basal-like characteristics, whereas tumors that develop following IGF-IR downregulation express a gene signature that most closely resembles human claudin-low breast tumors. Oncogene (2012) 31, 3298-3309; doi:10.1038/onc.2011.486; published online 24 October 2011	[Franks, S. E.; Campbell, C. I.; Barnett, E. F.; Siwicky, M. D.; Moorehead, R. A.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N5A 7Z1, Canada; [Livingstone, J.; Cory, S.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Biochem Oncol, Montreal, PQ, Canada; [Livingstone, J.; Cory, S.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Dept Med, Montreal, PQ, Canada	University of Guelph; McGill University; McGill University	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, 50 Stone Rd E, Guelph, ON N5A 7Z1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295; Livingstone, Julie/0000-0002-8424-3768	Cancer Research Society; Canadian Institutes of Health Research	Cancer Research Society; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was funded by operating grants from the Cancer Research Society and the Canadian Institutes of Health Research awarded to RAM.	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gruvberger S, 2001, CANCER RES, V61, P5979; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Jones RA, 2007, ONCOGENE, V26, P1636, DOI 10.1038/sj.onc.1209955; Jones RA, 2009, ONCOGENE, V13, P407; Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106; Koda M, 2003, HORM METAB RES, V35, P794; Koda M, 2005, ONCOL REP, V14, P93; Lanzino M, 2008, CURR CANCER DRUG TAR, V8, P597, DOI 10.2174/156800908786241104; Lerma E, 2007, MODERN PATHOL, V20, P1200, DOI 10.1038/modpathol.3800961; Maki RG, 2010, J CLIN ONCOL, V28, P4985, DOI 10.1200/JCO.2009.27.5040; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PEYRAT JP, 1988, CANCER RES, V48, P6429; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sarfstein R, 2006, MOL CELL ENDOCRINOL, V252, P241, DOI 10.1016/j.mce.2006.03.018; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	29	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3298	3309		10.1038/onc.2011.486	http://dx.doi.org/10.1038/onc.2011.486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22020329	Green Published, hybrid			2022-12-28	WOS:000306113400009
J	Fransson, S; Uv, A; Eriksson, H; Andersson, MK; Wettergren, Y; Bergo, M; Ejeskar, K				Fransson, S.; Uv, A.; Eriksson, H.; Andersson, M. K.; Wettergren, Y.; Bergo, M.; Ejeskar, K.			p37 delta is a new isoform of PI3K p110 delta that increases cell proliferation and is overexpressed in tumors	ONCOGENE			English	Article						p110 delta; p37 delta; p85; RAS; ovarian cancer; colorectal cancer	P85 REGULATORY SUBUNIT; PHOSPHOINOSITIDE 3-KINASE; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3'-KINASE; NEUROBLASTOMA TUMORS; COLORECTAL-CANCER; CLASS IPI3K; KEY ROLE; MUCOSA; METABOLISM	The phosphatidylinositol 3-kinases (PI3Ks) regulate cell growth, proliferation and survival, and are frequently affected in human cancer. PI3K is composed of a catalytic subunit, p110, and a regulatory subunit, p85. The PI3K catalytic subunit p110 delta is encoded by PIK3CD and contains p85- and RAS-binding domains, and a kinase domain. Here we present an alternatively spliced PIK3CD transcript encoding a previously unknown protein, p37 delta, and demonstrate that this protein is expressed in human ovarian and colorectal tumors. p37 delta retains the p85-binding domain and a fraction of the RAS-binding domain, lacks the catalytic domain, and has a unique carboxyl-terminal region. In contrast to p110 delta, which stabilizes p85, p37 delta promoted p85 sequestering. Despite the truncated RAS-binding domain, p37 delta bound to RAS and we found a strong positive correlation between the protein levels of p37 delta and RAS. Overexpressing p37 delta, but not p110 delta, increased the proliferation and invasive properties of HEK-293 cells and mouse embryonic fibroblasts. Cells overexpressing p37 delta showed a quicker phosphorylation response of AKT and ERK1/2 following serum stimulation. Ubiquitous expression of human p37 delta in the fruit fly increased body size, DNA content and phosphorylated ERK1/2 levels. Thus, p37 delta appears to be a new tumor-specific isoform of p110 delta with growth-promoting properties. Oncogene (2012) 31, 3277-3286; doi: 10.1038/onc.2011.492; published online 24 October 2011	[Fransson, S.; Uv, A.; Eriksson, H.; Ejeskar, K.] Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Med & Clin Genet, SE-40530 Gothenburg, Sweden; [Andersson, M. K.] Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Pathol, SE-40530 Gothenburg, Sweden; [Wettergren, Y.] Univ Gothenburg, Dept Gen Surg, SE-40530 Gothenburg, Sweden; [Bergo, M.] Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Med, SE-40530 Gothenburg, Sweden; [Ejeskar, K.] Univ Skovde, Sch Life Sci, Skovde, Sweden	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Skovde	Ejeskar, K (corresponding author), Univ Gothenburg, Sahlgrenska Canc Ctr, Dept Med & Clin Genet, Box 425, SE-40530 Gothenburg, Sweden.	katarina.ejeskar@gu.se		Fransson, Susanne/0000-0002-9713-3074; Ejeskar, Katarina/0000-0001-8962-0860	Swedish Cancer Society [100405]; Swedish Children's Cancer Fund; Gunvor and Ivan Svensson's Foundation; Ake Wiberg's Foundation; Sahlgrenska University Hospital Foundation; Assar Gabrielsson Foundation; Mary Beves Stiftelse for Barncancerforskning; Frimurare Barnhusdirektionen; ALF Grants, County of Vastergotland	Swedish Cancer Society(Swedish Cancer Society); Swedish Children's Cancer Fund; Gunvor and Ivan Svensson's Foundation; Ake Wiberg's Foundation; Sahlgrenska University Hospital Foundation; Assar Gabrielsson Foundation; Mary Beves Stiftelse for Barncancerforskning; Frimurare Barnhusdirektionen; ALF Grants, County of Vastergotland	We thank the Genomics Core Facility for access to the ABI PRISM7900HT System, Magnus Pettersson, Maria Yhr and Grissel Faura for technical assistance. This work was supported by grants from the Swedish Cancer Society (K Ejeskar and 100405), the Swedish Children's Cancer Fund, Gunvor and Ivan Svensson's Foundation, Ake Wiberg's Foundation, the Sahlgrenska University Hospital Foundation, the Assar Gabrielsson Foundation, Mary Beves Stiftelse for Barncancerforskning, Frimurare Barnhusdirektionen and ALF Grants, County of Vastergotland.	Bilancio A, 2006, BLOOD, V107, P642, DOI 10.1182/blood-2005-07-3041; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Caren H, 2007, BRIT J CANCER, V97, P1416, DOI 10.1038/sj.bjc.6604032; Chagpar RB, 2010, P NATL ACAD SCI USA, V107, P5471, DOI 10.1073/pnas.0908899107; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Ciraolo E, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1161577; Denley A, 2008, ONCOGENE, V27, P2561, DOI 10.1038/sj.onc.1210918; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Foukas LC, 2010, P NATL ACAD SCI USA, V107, P11381, DOI 10.1073/pnas.0906461107; Fransson S, 2007, GENE CHROMOSOME CANC, V46, P45, DOI 10.1002/gcc.20387; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103; Kok K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005145; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Odin E, 2003, CLIN CANCER RES, V9, P6012; Patton DT, 2007, BIOCHEM SOC T, V35, P167, DOI 10.1042/BST0350167; Philp AJ, 2001, CANCER RES, V61, P7426; Polley ACJ, 2006, CANCER RES, V66, P6553, DOI 10.1158/0008-5472.CAN-06-0534; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Sawyer C, 2003, CANCER RES, V63, P1667; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Taniguchi CM, 2010, CANCER RES, V70, P5305, DOI 10.1158/0008-5472.CAN-09-3399; Vanhaesebroeck B, 2005, TRENDS BIOCHEM SCI, V30, P194, DOI 10.1016/j.tibs.2005.02.008; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vogt PK, 2009, CURR OPIN GENET DEV, V19, P12, DOI 10.1016/j.gde.2008.11.011; Wettergren Y, 2008, MOL MED, V14, P412, DOI 10.2119/2007-00096.Wettergren; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244	29	13	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3277	3286		10.1038/onc.2011.492	http://dx.doi.org/10.1038/onc.2011.492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22020336				2022-12-28	WOS:000306113400007
J	He, XX; Chang, Y; Meng, FY; Wang, MY; Xie, QH; Tang, F; Li, PY; Song, YH; Lin, JS				He, X-X; Chang, Y.; Meng, F-Y; Wang, M-Y; Xie, Q-H; Tang, F.; Li, P-Y; Song, Y-H; Lin, J-S			MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo	ONCOGENE			English	Article						microRNA-375; AEG-1; hepatocellular carcinoma	ASTROCYTE-ELEVATED GENE-1; NON-TUMOROUS TISSUES; HEPATOCYTE ISOLATION; PATIENT SURVIVAL; BREAST-CANCER; EXPRESSION; PROGRESSION; HEPATITIS; PATHOGENESIS; METASTASIS	MicroRNAs (miRNAs) are believed to have fundamental roles in tumorigenesis and have great potential for the diagnosis and treatment of cancer. However, the roles of miRNAs in hepatocellular carcinogenesis are still not fully elucidated. We investigated the aberrantly expressed miRNAs involved in hepatoma by comparison of miRNA expression profiles in cancerous hepatocytes with normal primary human hepatocytes, and 37 dysregulated miRNAs were screened out by twofold change with a significant difference (P<0.05). Clustering analysis based on 13 miRNAs with changes over 15-folds showed that the miRNA expression patterns between the cancerous and normal hepatocytes were clearly different. Among the 13 miRNAs, we found that miR-375 was significantly downregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Overexpression of miR-375 in liver cancer cells decreased cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest and apoptosis. To unveil the molecular mechanism of miR-375-mediated phenotype in hepatoma cells described above, we examined the putative targets using bioinformatics tools and found that astrocyte elevated gene-1 (AEG-1) was a potential target of miR-375. Then we demonstrated that miR-375 bound directly to the 30-untranslated region of AEG-1 and inhibited the expression of AEG-1. TaqMan quantitative reverse transcriptase-PCR and western blot analysis showed that miR-375 expression was inversely correlated with AEG-1 expression in HCC tissues. Knockdown of AEG-1 by RNAi in HCC cells, similar to miR-375 overexpression, suppressed tumor properties. Ectopic expression of AEG-1, conversely, could partially reverse the antitumor effects of miR-375. In a mouse model, therapeutic administration of cholesterol-conjugated 20-O-methyl-modified miR-375 mimics (Chol-miR375) could significantly suppress the growth of hepatoma xenografts in nude mice. In conclusion, our findings indicate that miR-375 targets AEG-1 in HCC and suppresses liver cancer cell growth in vitro and in vivo, and highlight the therapeutic potential of miR-375 in HCC treatment. Oncogene (2012) 31, 3357-3369; doi: 10.1038/onc.2011.500; published online 7 November 2011	[He, X-X; Chang, Y.; Xie, Q-H; Tang, F.; Li, P-Y; Song, Y-H; Lin, J-S] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver Dis, Tongji Med Coll, Wuhan 430030, Peoples R China; [Meng, F-Y] Huazhong Univ Sci & Technol, Tongji Hosp, Inst Organ Transplantat,Tongji Med Coll, Key Lab Organ Transplantat,Minist Educ,Minist Hlt, Wuhan 430030, Peoples R China; [Wang, M-Y] Huazhong Univ Sci & Technol, Dept Oncol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Lin, JS (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Inst Liver Dis, Tongji Med Coll, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China.	jslin@tjh.tjmu.edu.cn	He, Xing-Xing/G-9200-2014	He, Xing-Xing/0000-0003-0001-8473	National Basic Research Program of China [2007CB512903]; National Natural Science Foundation of China [81101824, 30872237]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Xin Chen of University of California, San Francisco for critical review of the manuscript. This work was financially supported by the National Basic Research Program of China (no. 2007CB512903) and the National Natural Science Foundation of China (no. 81101824 and 30872237).	Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Braconi C, 2008, HEPATOLOGY, V47, P1807, DOI 10.1002/hep.22326; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607; Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Huang YS, 2008, J GASTROEN HEPATOL, V23, P87, DOI 10.1111/j.1440-1746.2007.05223.x; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Li Y, 2004, J CANCER RES CLIN, V130, P460, DOI 10.1007/s00432-004-0564-9; Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malarkey DE, 2005, TOXICOL PATHOL, V33, P27, DOI 10.1080/01926230590881826; Maruyama M, 2003, CELL TRANSPLANT, V12, P593, DOI 10.3727/000000003108747190; Meng FY, 2010, WORLD J GASTROENTERO, V16, P1660, DOI 10.3748/wjg.v16.i13.1660; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Petri A, 2009, CANCER RES, V69, P393, DOI 10.1158/0008-5472.CAN-08-2749; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Santamaria E, 2007, LIVER INT, V27, P163, DOI 10.1111/j.1478-3231.2007.01447.x; Scherr M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm971; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Tili Esmerina, 2007, Future Oncol, V3, P521, DOI 10.2217/14796694.3.5.521; Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Xu JB, 2011, MED ONCOL, V28, P455, DOI 10.1007/s12032-010-9475-6; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yu CP, 2009, CARCINOGENESIS, V30, P894, DOI 10.1093/carcin/bgp064; Zhang B, 2011, CARCINOGENESIS, V32, P2, DOI 10.1093/carcin/bgq209	40	285	309	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3357	3369		10.1038/onc.2011.500	http://dx.doi.org/10.1038/onc.2011.500			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22056881				2022-12-28	WOS:000306367600005
J	Chen, HZ; Li, L; Wang, WJ; Du, XD; Wen, Q; He, JP; Zhao, BX; Li, GD; Zhou, W; Xia, Y; Yang, QY; Hew, CL; Liou, YC; Wu, Q				Chen, H-Z; Li, L.; Wang, W-J; Du, X-D; Wen, Q.; He, J-P; Zhao, B-X; Li, G-D; Zhou, W.; Xia, Y.; Yang, Q-Y; Hew, C-L; Liou, Y-C; Wu, Q.			Prolyl isomerase Pin1 stabilizes and activates orphan nuclear receptor TR3 to promote mitogenesis	ONCOGENE			English	Article						prolyl isomerase pin1; orphan receptor TR3; phosphorylation; cell proliferation	N-TERMINAL KINASE; CANCER CELL; NEGATIVE REGULATION; GROWTH-FACTORS; NGFI-B; APOPTOSIS; PHOSPHORYLATION; SUBSTRATE; TRANSLOCATION; DOMAINS	Pin1 regulates a subset of phosphoproteins by isomerizing phospho-Ser/Thr-Pro motifs via a 'post-phosphorylation' mechanism. Here, we characterize TR3 as a novel Pin1 substrate, and the mitogenic function of TR3 depends on Pin1-induced isomerization. There are at least three phospho-Ser-Pro motifs on TR3 that bind to Pin1. The Ser95-Pro motif of TR3 is the key site through which Pin1 enhances TR3 stability by retarding its degradation. Pin1 can also catalyze TR3 through phospho-Ser431-Pro motif, which is phosphorylated by extracellular signal-regulated kinase 2 (ERK2), resulting in enhanced TR3 transactivation. Furthermore, Pin1 not only facilitates TR3 targeting to the promoter of cyclin D2, a novel downstream target of TR3, but also promotes TR3 to recruit p300, thereby inducing cell proliferation. Importantly, we found that Pin1 is indispensable for TR3 to promote tumor growth both in vitro and in vivo. Our study thus suggests that Pin1 has an important role in cell proliferation by isomerizing TR3. Oncogene (2012) 31, 2876-2887; doi:10.1038/onc.2011.463; published online 17 October 2011	[Chen, H-Z; Li, L.; Wang, W-J; Du, X-D; Wen, Q.; He, J-P; Zhao, B-X; Li, G-D; Wu, Q.] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China; [Zhou, W.; Xia, Y.; Yang, Q-Y; Hew, C-L; Liou, Y-C] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Xiamen University; National University of Singapore	Wu, Q (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China.	dbslyc@nus.edu.sg; qiaow@xmu.edu.cn	Wu, Q/G-4646-2010; Hew, Choy Leong/I-1501-2012; Xia, Yun/K-4128-2015	Hew, Choy Leong/0000-0002-9441-0064; Xia, Yun/0000-0003-2184-4870; Li, Li/0000-0002-7720-6731	Ministry of Education, China [B06016]; Ministry of Science and Technology, China [2007CB914402]; National Natural Science Foundation of China [30810103905, 30871281, 31000620]; National Key New Drug Creation Program of China [2009ZX09103-083]; Fundamental Research Funds for the Central Universities, China [2010121096]; Science Planning program grant of Fujian Province, China [2009J1010]; Biomedical Research Council, the Agency for Science, Research and Technology, Singapore [09/1/21/19/604]	Ministry of Education, China(Ministry of Education, China); Ministry of Science and Technology, China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key New Drug Creation Program of China; Fundamental Research Funds for the Central Universities, China(Fundamental Research Funds for the Central Universities); Science Planning program grant of Fujian Province, China; Biomedical Research Council, the Agency for Science, Research and Technology, Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by grants from Ministry of Education, China (Project 111, B06016) to WQ and YCL; grants from the Ministry of Science and Technology, China (2007CB914402) to WQ; the National Natural Science Foundation of China (30810103905 and 30871281 to WQ, 31000620 to CHZ); grants from the National Key New Drug Creation Program of China (2009ZX09103-083) to WQ; grants from the Fundamental Research Funds for the Central Universities, China (2010121096) to CHZ; Science Planning program grant of Fujian Province, China (2009J1010); and the grant (09/1/21/19/604) from the Biomedical Research Council, the Agency for Science, Research and Technology, Singapore to YCL.	CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Chen HZ, 2008, CARCINOGENESIS, V29, P2078, DOI 10.1093/carcin/bgn197; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Fan G, 2009, CANCER RES, V69, P4589, DOI 10.1158/0008-5472.CAN-08-4117; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Lei NZ, 2009, NUCLEIC ACIDS RES, V37, P832, DOI 10.1093/nar/gkn941; Li GD, 2007, NUCLEIC ACIDS RES, V35, P7348, DOI 10.1093/nar/gkm870; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liu B, 2007, ENDOCRINOLOGY, V148, P34, DOI 10.1210/en.2006-0800; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Ryo A, 2007, J BIOL CHEM, V282, P36671, DOI 10.1074/jbc.M704145200; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Siepe D, 2009, NAT CELL BIOL, V11, P967, DOI 10.1038/ncb1908; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Yang QY, 2009, J BIOL CHEM, V284, P23980, DOI 10.1074/jbc.M109.022814; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	42	30	32	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2876	2887		10.1038/onc.2011.463	http://dx.doi.org/10.1038/onc.2011.463			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	22002310				2022-12-28	WOS:000305277900007
J	Basile, KJ; Abel, EV; Aplin, AE				Basile, K. J.; Abel, E. V.; Aplin, A. E.			Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells	ONCOGENE			English	Article						RAF inhibitor; ERK1/2; FOXD3; chemotherapeutic resistance	BRAF MUTATIONS; NEURAL CREST; SELF-RENEWAL; STEM-CELLS; KINASE; CANCER; INHIBITION; PLURIPOTENCY; REQUIREMENT; APOPTOSIS	Melanoma cells driven by mutant v-raf murine sarcoma viral oncogene homolog B1 (B-RAF) are highly resistant to chemotherapeutic treatments. Recent phase 1 results with PLX4032/RG7204/vemurafenib, which selectively inhibits B-RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)1/2 signaling in mutant B-RAF cells, has given encouragement to this struggling field. Nearly all patients in the phase 1-3 studies saw at least some response and the overall response rates ranged from 48 and 81%. However, despite initial tumor shrinkage, most responders in the trial experienced tumor relapse over time. These findings indicate that both intrinsic and acquired resistance may affect the clinical efficacy of PLX4032. It is critical to optimize PLX4032 activity to improve response rates and understand why some patients with the B-RAF mutation do not respond. We have previously shown that the stemness factor, Forkhead box D3 (FOXD3), is upregulated following inhibition of B-RAF-MEK signaling in mutant B-RAF melanoma cells. Here, we show that upregulation of FOXD3 following treatment with PLX4032 and PLX4720 (the non-clinical tool compound for PLX4032) confers resistance to cell death. Small interfering RNA-mediated knockdown of FOXD3 significantly enhanced the cell death response after PLX4032/4720 treatment in mutant B-RAF melanoma cell lines. Additionally, upregulation of FOXD3 after PLX4720 treatment was attenuated in non-adherent conditions and correlated with enhanced cell death. Ectopic expression of FOXD3 in non-adherent cells significantly reduced cell death in response to PLX4720 treatment. Together, these data indicate that upregulation of FOXD3 is an adaptive response to RAF inhibitors that promotes a state of drug resistance. Oncogene (2012) 31, 2471-2479; doi: 10.1038/onc.2011.424; published online 26 September 2011	[Basile, K. J.; Abel, E. V.; Aplin, A. E.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Aplin, A. E.] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Aplin, AE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, 233 S 10th St,BLSB 524, Philadelphia, PA 19107 USA.	Andrew.Aplin@KimmelCancerCenter.Org			National Institutes of Health [GM067893, CA125103]; American Cancer Society [RSG-08-03-01-CSM]; Joanna M Nicolay Melanoma Foundation; National Cancer Institute [1P30CA56036]; NATIONAL CANCER INSTITUTE [R01CA160495, P30CA056036, R01CA125103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Joanna M Nicolay Melanoma Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Gideon Bollag (Plexxikon, Berkeley, CA, USA) for providing PLX4720, Dr Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA) for WM melanoma cell lines, and Dr Fred Kaplan for critical comments on this paper. This work was supported by National Institutes of Health (GM067893, CA125103), American Cancer Society (RSG-08-03-01-CSM) and a Joanna M Nicolay Melanoma Foundation scholarship. The Kimmel Cancer Center is supported by National Cancer Institute Support Grant 1P30CA56036.	Abel EV, 2010, CANCER RES, V70, P2891, DOI 10.1158/0008-5472.CAN-09-3139; Aplin AE, 2011, J INVEST DERMATOL, V131, P1817, DOI 10.1038/jid.2011.147; Boisvert-Adamo K, 2006, ONCOGENE, V25, P4848, DOI 10.1038/sj.onc.1209493; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Hanna LA, 2002, GENE DEV, V16, P2650, DOI 10.1101/gad.1020502; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hoeflich KP, 2009, CANCER RES, V69, P3042, DOI 10.1158/0008-5472.CAN-08-3563; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liber D, 2010, CELL STEM CELL, V7, P114, DOI 10.1016/j.stem.2010.05.020; Liu Y, 2008, STEM CELLS, V26, P2475, DOI 10.1634/stemcells.2008-0269; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mundell NA, 2011, DEVELOPMENT, V138, P641, DOI 10.1242/dev.054718; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Pan GJ, 2006, FASEB J, V20, P1730, DOI 10.1096/fj.05-5543fje; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Ribas A, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8509; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Smalley KSM, 2010, NEW ENGL J MED, V363, P876, DOI 10.1056/NEJMe1005370; Sutton J, 1996, J BIOL CHEM, V271, P23126, DOI 10.1074/jbc.271.38.23126; Teng L, 2008, DEVELOPMENT, V135, P1615, DOI 10.1242/dev.012179; Thomas AJ, 2008, PIGM CELL MELANOMA R, V21, P598, DOI 10.1111/j.1755-148X.2008.00506.x; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665	33	48	48	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2471	2479		10.1038/onc.2011.424	http://dx.doi.org/10.1038/onc.2011.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996740	Green Accepted			2022-12-28	WOS:000303985300009
J	Thu, YM; Su, Y; Yang, J; Splittgerber, R; Na, S; Boyd, A; Mosse, C; Simons, C; Richmond, A				Thu, Y. M.; Su, Y.; Yang, J.; Splittgerber, R.; Na, S.; Boyd, A.; Mosse, C.; Simons, C.; Richmond, A.			NF-kappa B inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the beta-catenin pathway	ONCOGENE			English	Article						NIK; beta-catenin; melanoma; tumorigenesis; survival factors	INDUCED APOPTOSIS; TUMOR-GROWTH; C-MYC; ALPHA; TNF; ACTIVATION; CELLS; THERAPY; TARGET; INHIBITION	Nuclear factor-kappa B (NF-kappa B) inducing kinase (NIK) is a MAP3K that regulates the activation of NF-kappa B. NIK is often highly expressed in tumor cells, including melanoma, but the significance of this in melanoma progression has been unclear. Tissue microarray analysis of NIK expression reveals that dysplastic nevi (n = 22), primary (n = 15) and metastatic melanoma (n = 13) lesions showed a statistically significant elevation in NIK expression when compared with benign nevi (n = 30). Moreover, when short hairpin RNA techniques were used to knock-down NIK, the resultant NIK-depleted melanoma cell lines exhibited decreased proliferation, increased apoptosis, delayed cell cycle progression and reduced tumor growth in a mouse xenograft model. As expected, when NIK was depleted there was decreased activation of the non-canonical NF-kappa B pathway, whereas canonical NF-kappa B activation remained intact. NIK depletion also resulted in reduced expression of genes that contribute to tumor growth, including CXCR4, c-MYC and c-MET, and pro-survival factors such as BCL2 and survivin. These changes in gene expression are not fully explained by the attenuation of the non-canonical NF-kappa B pathway. Shown here for the first time is the demonstration that NIK modulates beta-catenin-mediated transcription to promote expression of survivin. NIK-depleted melanoma cells exhibited downregulation of survivin as well as other beta-catenin regulated genes including c-MYC, c-MET and CCND2. These data indicate that NIK mediates both beta-catenin and NF-kappa B regulated transcription to modulate melanoma survival and growth. Thus, NIK may be a promising therapeutic target for melanoma. Oncogene (2012) 31, 2580-2592; doi:10.1038/onc.2011.427; published online 3 October 2011	[Thu, Y. M.; Su, Y.; Yang, J.; Splittgerber, R.; Richmond, A.] Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; [Na, S.] Eli Lilly & Co, Oncol Res, Indianapolis, IN 46285 USA; [Boyd, A.] Vanderbilt Univ, Sch Med, Div Dermatol, Nashville, TN 37232 USA; [Mosse, C.; Simons, C.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Richmond, A.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Eli Lilly; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Richmond, A (corresponding author), Vanderbilt Univ, Dept Canc Biol, Sch Med, 771 PRB,2220 Pierce Ave, Nashville, TN 37232 USA.	ann.richmond@vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NIH [CA 098807-01]; Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA098807, R01CA116021, P30CA068485] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Robert Schreiber (Washington University) for generously sharing Nik<SUP>-/-</SUP> MEFs, and Vanderbilt Functional Genomic Shared Resource Core, VA Flow Cytometry Core and Vanderbilt Immunohistochemistry Core for technical help. We thank Dr Joseph T Roland (Epithelial Biology Center) for assistance with the ariol scanning and quantitation of TMAs. We thank Dr Mark Kelly and Vanderbilt melanoma group for providing melanoma tissues and Dr Sara Kantrow for reviewing some of the TMA slides. We thank Dr Fiona Yull and Dr Punita Dhawan for thoughtful discussion and Vanderbilt Editor Club for careful reading of the manuscript. Grant Support: This work is supported by NIH, CA 098807-01 and the Department of Veterans Affairs, Career Scientist Award and Merit Award (to AR).	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALENTIEN E, 1991, ONCOGENE, V6, P1115; Boon EMJ, 2002, CANCER RES, V62, P5126; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Conze DB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000518; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Devalaraja MN, 1999, CANCER RES, V59, P1372; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hilmi C, 2008, J INVEST DERMATOL, V128, P1499, DOI 10.1038/sj.jid.5701185; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002; Lecis D, 2010, BRIT J CANCER, V102, P1707, DOI 10.1038/sj.bjc.6605687; Lev DC, 2003, MOL CANCER THER, V2, P753; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Malbon Craig C, 2005, Sci STKE, V2005, ppe35, DOI 10.1126/stke.2922005pe35; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McGary EC, 2002, CANCER BIOL THER, V1, P459, DOI 10.4161/cbt.1.5.158; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Moore SR, 2008, CLIN CANCER RES, V14, P2927, DOI 10.1158/1078-0432.CCR-07-4068; Neely RJ, 2011, ONCOGENE, V30, P87, DOI 10.1038/onc.2010.396; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Pastorino F, 2003, CLIN CANCER RES, V9, P4595; Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029; Plenchette S, 2007, CURR OPIN INVEST DR, V8, P469; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Puzanov I, 2010, SEMIN CUTAN MED SURG, V29, P196, DOI 10.1016/j.sder.2010.06.005; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; Saitoh Y, 2008, BLOOD, V111, P5118, DOI 10.1182/blood-2007-09-110635; Saitoh Y, 2010, LUNG CANCER, V70, P263, DOI 10.1016/j.lungcan.2010.03.001; Scala S, 2006, CLIN CANCER RES, V12, P2427, DOI 10.1158/1078-0432.CCR-05-1940; Scala S, 2005, CLIN CANCER RES, V11, P1835, DOI 10.1158/1078-0432.CCR-04-1887; Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008-5472.CAN-10-0645; Smith C, 2001, J IMMUNOL, V167, P5895, DOI 10.4049/jimmunol.167.10.5895; Sullivan RJ, 2009, EXPERT REV ANTICANC, V9, P567, DOI [10.1586/era.09.20, 10.1586/ERA.09.20]; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Yang JM, 2007, CANCER RES, V67, P3127, DOI 10.1158/0008-5472.CAN-06-3547; Yang JM, 2010, J CLIN INVEST, V120, P2563, DOI 10.1172/JCI42358; Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078-0432.CCR-05-1220; Yang JM, 2001, CANCER RES, V61, P4901; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Zhang T, 2001, CANCER RES, V61, P8664	61	34	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2580	2592		10.1038/onc.2011.427	http://dx.doi.org/10.1038/onc.2011.427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21963849	Green Accepted			2022-12-28	WOS:000304191800008
J	Tong, ZT; Cai, MY; Wang, XG; Kong, LL; Mai, SJ; Liu, YH; Zhang, HB; Liao, YJ; Zheng, F; Zhu, W; Liu, TH; Bian, XW; Guan, XY; Lin, MC; Zeng, MS; Zeng, YX; Kung, HF; Xie, D				Tong, Z-T; Cai, M-Y; Wang, X-G; Kong, L-L; Mai, S-J; Liu, Y-H; Zhang, H-B; Liao, Y-J; Zheng, F.; Zhu, W.; Liu, T-H; Bian, X-W; Guan, X-Y; Lin, M. C.; Zeng, M-S; Zeng, Y-X; Kung, H-F; Xie, D.			EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin	ONCOGENE			English	Article						nasopharyngeal carcinoma; EZH2; E-cadherin; HDAC; Snail	TRANSCRIPTION FACTOR SNAIL; EMBRYONIC STEM-CELLS; GROUP PROTEIN EZH2; ZESTE HOMOLOG-2; DEVELOPMENTAL REGULATORS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; POOR-PROGNOSIS; GASTRIC-CANCER; POLYCOMB	The enhancer of zeste homolog 2 (EZH2) is upregulated and has an oncogenic role in several types of human cancer. However, the abnormalities of EZH2 and its underlying mechanisms in the pathogenesis of nasopharyngeal carcinoma (NPC) remain unknown. In this study, we found that high expression of EZH2 in NPC was associated closely with an aggressive and/or poor prognostic phenotype (P<0.05). In NPC cell lines, knockdown of EZH2 by short hairpin RNA was sufficient to inhibit cell invasiveness/metastasis both in vitro and in vivo, whereas ectopic overexpression of EZH2 supported NPC cell invasive capacity with a decreased expression of E-cadherin. In addition, ablation of endogenous Snail in NPC cells virtually totally prevented the repressive activity of EZH2 to E-cadherin, indicating that Snail might be a predominant mediator of EZH2 to suppress E-cadherin. Furthermore, co-immunoprecipitation (IP), chromatin IP and luciferase reporter assays demonstrated that in NPC cells, (1) EZH2 interacted with HDAC1/HDAC2 and Snail to form a repressive complex; (2) these components interact in a linear fashion, not in a triangular fashion, that is, HDAC1 or HDAC2 bridge the interaction between EZH2 and Snail; and (3) the EZH2/HDAC1/2/Snail complex could closely bind to the E-cadherin promoter by Snail, but not YY1, to repress E-cadherin. The data provided in this report suggest a critical role of EZH2 in the control of cell invasion and/or metastasis by forming a co-repressor complex with HDAC1/HDAC2/Snail to repress E-cadherin, an activity that might be responsible, at least in part, for the development and/or progression of human NPCs. Oncogene (2012) 31, 583-594; doi:10.1038/onc.2011.254; published online 20 June 2011	[Tong, Z-T; Cai, M-Y; Mai, S-J; Liao, Y-J; Zheng, F.; Zhu, W.; Liu, T-H; Guan, X-Y; Zeng, M-S; Zeng, Y-X; Kung, H-F; Xie, D.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China; [Tong, Z-T; Mai, S-J; Liao, Y-J; Zheng, F.; Zhu, W.; Liu, T-H; Guan, X-Y; Zeng, M-S; Zeng, Y-X; Xie, D.] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510060, Guangdong, Peoples R China; [Tong, Z-T; Kong, L-L] An Hui Med Univ, Affiliated Hosp 1, Dept Radiotherapy, Hefei, Peoples R China; [Wang, X-G] Sun Yat Sen Univ, Zhong Shan Sch Med, Dept Pharmacol, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Y-H] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Zhang, H-B] Guangdong Prov Peoples Hosp, Dept Otolaryngol, Guangzhou, Guangdong, Peoples R China; [Bian, X-W] Third Mil Med Univ, SW Hosp, Inst Pathol, Chongqing, Peoples R China; [Bian, X-W] Third Mil Med Univ, SW Hosp, SW Canc Ctr, Chongqing, Peoples R China; [Lin, M. C.; Kung, H-F] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Anhui Medical University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Army Medical University; Army Medical University; Chinese University of Hong Kong	Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, 651 Dongfeng Rd E,Room 634, Guangzhou 510060, Guangdong, Peoples R China.	xied@mail.sysu.edu.cn	mai, sj/HGE-8908-2022; LIAO, YIJI/Z-4902-2019; Bian, Xiu-Wu/D-4736-2017; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	LIAO, YIJI/0000-0002-0849-4573; Bian, Xiu-Wu/0000-0003-4383-0197; Zhu, Wei-Guo/0000-0001-8385-6581; Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805; zeng, musheng/0000-0003-3509-5591	Foundation of Guangzhou Science and Technology Bureau, China [2005Z1-E0131]; 973 Project of China [2010CB912802, 2010CB529400]	Foundation of Guangzhou Science and Technology Bureau, China; 973 Project of China(National Basic Research Program of China)	We thank Dr Clifford W Welsch (Michigan State University) for his valuable comments and extensive edit for the paper. This work was supported by the Foundation of Guangzhou Science and Technology Bureau, China (2005Z1-E0131 to DX and HFK) and the 973 Project of China (2010CB912802 to HFK and 2010CB529400 to XWB and MCL).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Caretti G, 2004, GENE DEV, V18, P2627, DOI 10.1101/gad.1241904; Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; FANDI A, 1994, SEMIN ONCOL, V21, P382; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x; Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001; Muller J, 2006, CURR OPIN GENET DEV, V16, P476, DOI 10.1016/j.gde.2006.08.005; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Schwartz YB, 2006, NAT GENET, V38, P700, DOI 10.1038/ng1817; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Wei William I, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P99, DOI 10.1097/MOO.0b013e3280148a06; Wilkinson F, 2010, J CELL BIOCHEM, V109, P478, DOI 10.1002/jcb.22424; Xie D, 2003, INT J CANCER, V107, P896, DOI 10.1002/ijc.11514	40	157	175	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	5					583	594		10.1038/onc.2011.254	http://dx.doi.org/10.1038/onc.2011.254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21685935				2022-12-28	WOS:000300221800005
J	Rego, MA; Harney, JA; Mauro, M; Shen, M; Howlett, NG				Rego, M. A.; Harney, J. A.; Mauro, M.; Shen, M.; Howlett, N. G.			Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor	ONCOGENE			English	Article						Fanconi anemia; ubiquitination; deubiquitination; genome stability; DNA repair	P53-MEDIATED G(1) ARREST; FRAGILE-SITE STABILITY; CELL NUCLEAR ANTIGEN; DNA-DAMAGE RESPONSE; CROSS-LINK REPAIR; MONOUBIQUITINATED FANCD2; UBIQUITIN LIGASE; COMPLEX; PROTEIN; GENE	Fanconi anemia (FA) is a rare disease characterized by congenital defects, progressive bone marrow failure and heightened cancer susceptibility. The FA proteins, BRCA1 and FANCD1/BRCA2 function cooperatively in the FA-BRCA pathway to repair damaged DNA. Activation of the FA-BRCA pathway occurs via the monoubiquitination of the FANCD2 and FANCI proteins, targeting these proteins to discrete nuclear foci where they function in DNA repair. The cellular regulation of FANCD2/I monoubiquitination, however, remains poorly understood. In this study, we have examined the roles of the p53 tumor suppressor protein, as well as its downstream target, the p21(Cip1/Waf1) cyclin-dependent kinase inhibitor, in the regulation of the activation of the FA-BRCA pathway. We demonstrate that, in contrast to p53, p21 has a major role in the regulation of the activation of the FA-BRCA pathway: p21 promotes S-phase and DNA damage-inducible FANCD2/I monoubiquitination and nuclear foci formation. Several lines of evidence establish that this effect is not a consequence of a defective G1-S checkpoint or altered cell-cycle progression in the absence of p21. Instead, we demonstrate that p21 is required for the transcriptional repression of the USP1 deubiquitinating enzyme upon exposure to DNA-damaging agents. In the absence of p21, persistent USP1 expression precludes the DNA damage-inducible accumulation of monoubiquitinated FANCD2 and FANCI. Consequently, p21(-/-) cells exhibit increased levels of mitomycin C-inducible complex chromosomal aberrations and elevated gamma H2AX nuclear foci formation. Our results demonstrate that p21 has a critical role in the regulation of the activation of the FA-BRCA pathway and suggest a broader role for p21 in the orchestration of DNA repair processes following exposure to DNA crosslinking agents. Oncogene (2012) 31, 366-375; doi:10.1038/onc.2011.237; published online 20 June 2011	[Howlett, N. G.] Univ Rhode Isl, Ctr Biotechnol & Life Sci 379, Dept Cell & Mol Biol, Kingston, RI 02881 USA	University of Rhode Island	Howlett, NG (corresponding author), Univ Rhode Isl, Ctr Biotechnol & Life Sci 379, Dept Cell & Mol Biol, 120 Flagg Rd, Kingston, RI 02881 USA.	nhowlett@mail.uri.edu		Mauro, Maurizio/0000-0002-5452-0795	Leukemia Research Foundation; RI-INBRE from the National Center for Research Resources [P20RR016457-09]; National Institutes of Health/National Heart, Lung and Blood Institute [R21HL095991-01]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016457] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL101977, R21HL095991] Funding Source: NIH RePORTER	Leukemia Research Foundation; RI-INBRE from the National Center for Research Resources; National Institutes of Health/National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank the members of the Howlett laboratory, Paul R Andreassen, Matthew Stoner and Patrick Sung for helpful discussions. We thank Tony T Huang and Patrick Sung for the anti-USP1 and anti-FANCI antibodies, respectively. We thank Bert Vogelstein for cells. This work was supported by a Leukemia Research Foundation New Investigator grant (NGH), RI-INBRE Grant P20RR016457-09 from the National Center for Research Resources (NGH) and National Institutes of Health/National Heart, Lung and Blood Institute Grant R21HL095991-01 (NGH).	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; Alpi A, 2007, MOL CELL BIOL, V27, P8421, DOI 10.1128/MCB.00504-07; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Arlt MF, 2004, MOL CELL BIOL, V24, P6701, DOI 10.1128/mcb.24.15.6701-6709.2004; AUERBACH AD, 1993, EXP HEMATOL, V21, P731; Avkin S, 2006, MOL CELL, V22, P407, DOI 10.1016/j.molcel.2006.03.022; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Cohn MA, 2007, MOL CELL, V28, P786, DOI 10.1016/j.molcel.2007.09.031; Collis SJ, 2007, NAT CELL BIOL, V9, P391, DOI 10.1038/ncb1555; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Harney JA, 2008, PEDIAT HLTH, V2, P175; Hoskins EE, 2008, ONCOGENE, V27, P4798, DOI 10.1038/onc.2008.121; Howlett NG, 2005, HUM MOL GENET, V14, P693, DOI 10.1093/hmg/ddi065; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Howlett NG, 2009, J BIOL CHEM, V284, P28935, DOI 10.1074/jbc.M109.016352; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Kee Y, 2010, GENE DEV, V24, P1680, DOI 10.1101/gad.1955310; Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Kratz K, 2010, CELL, V142, P77, DOI 10.1016/j.cell.2010.06.022; Liu T, 2010, SCIENCE, V329, P693, DOI 10.1126/science.1192656; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; MacKay C, 2010, CELL, V142, P65, DOI 10.1016/j.cell.2010.06.021; Mathew CG, 2006, ONCOGENE, V25, P5875, DOI 10.1038/sj.onc.1209878; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moldovan GL, 2009, ANNU REV GENET, V43, P223, DOI 10.1146/annurev-genet-102108-134222; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prives C, 2008, CELL CYCLE, V7, P3840, DOI 10.4161/cc.7.24.7243; Rego MA, 2009, MUTAT RES-FUND MOL M, V668, P27, DOI 10.1016/j.mrfmmm.2008.11.018; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sims AE, 2007, NAT STRUCT MOL BIOL, V14, P564, DOI 10.1038/nsmb1252; Smogorzewska A, 2007, CELL, V129, P289, DOI 10.1016/j.cell.2007.03.009; Smogorzewska A, 2010, MOL CELL, V39, P36, DOI 10.1016/j.molcel.2010.06.023; Stoepker C, 2011, NAT GENET, V43, P138, DOI 10.1038/ng.751; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XZ, 2007, MOL CELL BIOL, V27, P3098, DOI 10.1128/MCB.02357-06; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039	54	25	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					366	375		10.1038/onc.2011.237	http://dx.doi.org/10.1038/onc.2011.237			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685936	Green Accepted			2022-12-28	WOS:000299542100009
J	Storm, P; Aits, S; Puthia, MK; Urbano, A; Northen, T; Powers, S; Bowen, B; Chao, Y; Reindl, W; Lee, DY; Sullivan, NL; Zhang, J; Trulsson, M; Yang, H; Watson, JD; Svanborg, C				Storm, P.; Aits, S.; Puthia, M. K.; Urbano, A.; Northen, T.; Powers, S.; Bowen, B.; Chao, Y.; Reindl, W.; Lee, D. Y.; Sullivan, N. L.; Zhang, J.; Trulsson, M.; Yang, H.; Watson, J. D.; Svanborg, C.			Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis	ONCOGENE			English	Article						HAMLET; metabolism; c-Myc; glycolysis	APOPTOSIS-LIKE MECHANISM; HUMAN ALPHA-LACTALBUMIN; ENERGY-METABOLISM; GLUCOSE-METABOLISM; PYRUVATE-KINASE; TUMOR-CELLS; HYPOXIA; GROWTH; 3-BROMOPYRUVATE; INHIBITION	HAMLET is the first member of a new family of tumoricidal protein-lipid complexes that kill cancer cells broadly, while sparing healthy, differentiated cells. Many and diverse tumor cell types are sensitive to the lethal effect, suggesting that HAMLET identifies and activates conserved death pathways in cancer cells. Here, we investigated the molecular basis for the difference in sensitivity between cancer cells and healthy cells. Using a combination of small-hairpin RNA (shRNA) inhibition, proteomic and metabolomic technology, we identified the c-Myc oncogene as one essential determinant of HAMLET sensitivity. Increased c-Myc expression levels promoted sensitivity to HAMLET and shRNA knockdown of c-Myc suppressed the lethal response, suggesting that oncogenic transformation with c-Myc creates a HAMLET-sensitive phenotype. Furthermore, HAMLET sensitivity was modified by the glycolytic state of tumor cells. Glucose deprivation sensitized tumor cells to HAMLET-induced cell death and in the shRNA screen, hexokinase 1 (HK1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 and hypoxia-inducible factor 1 alpha modified HAMLET sensitivity. HK1 was shown to bind HAMLET in a protein array containing similar to 8000 targets, and HK activity decreased within 15min of HAMLET treatment, before morphological signs of tumor cell death. In parallel, HAMLET triggered rapid metabolic paralysis in carcinoma cells. Tumor cells were also shown to contain large amounts of oleic acid and its derivatives already after 15 min. The results identify HAMLET as a novel anti-cancer agent that kills tumor cells by exploiting unifying features of cancer cells such as oncogene addiction or the Warburg effect. Oncogene (2011) 30, 4765-4779; doi: 10.1038/onc.2011.196; published online 6 June 2011	[Storm, P.; Aits, S.; Trulsson, M.; Svanborg, C.] Lund Univ, Dept Lab Med, Div Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden; [Puthia, M. K.; Urbano, A.; Chao, Y.; Yang, H.] ASTAR, Inst Biomed Sci, Singapore Immunol Network SIgN, Singapore, Singapore; [Northen, T.; Bowen, B.; Reindl, W.; Lee, D. Y.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Powers, S.; Sullivan, N. L.; Zhang, J.; Watson, J. D.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Lund University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Cold Spring Harbor Laboratory	Svanborg, C (corresponding author), Lund Univ, Dept Microbiol Immunol & Glycobiol MIG, Inst Lab Med, Solvegatan 23, S-22362 Lund, Sweden.	catharina.svanborg@med.lu.se	Northen, Trent/K-3139-2012; Aits, Sonja/D-1496-2011	Aits, Sonja/0000-0002-1321-0678; Northen, Trent/0000-0001-8404-3259; Storm, Petter/0000-0002-7655-3731; Chao, Yinxia/0000-0003-1185-3511; Powers, Scott/0000-0003-2769-1932; Puthia, Manoj/0000-0001-6048-7234	Sharon D Lund foundation; American Cancer Society; Swedish Cancer Society; Swedish Medical Research Council; Medical Faculty (Lund University); Soderberg Foundation; Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research; Knut and Alice Wallenberg Foundation; Lund City Jubileumsfond; John and Augusta Persson Foundation for Medical Research; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society; Swedish Society for Medical Research; Network of Excellence: EuroPathoGenomics; Crafoord Foundation; Osterlund Foundation; US Department of Energy at Berkeley Lab [DE-AC02-05CH11231]; National Institutes of Health, National Cancer Institute [U54 CA 112970]; California Breast Cancer Research Program [15IB-0063]; NATIONAL CANCER INSTITUTE [U54CA112970] Funding Source: NIH RePORTER	Sharon D Lund foundation; American Cancer Society(American Cancer Society); Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Medical Faculty (Lund University); Soderberg Foundation; Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Lund City Jubileumsfond; John and Augusta Persson Foundation for Medical Research; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society; Swedish Society for Medical Research; Network of Excellence: EuroPathoGenomics; Crafoord Foundation; Osterlund Foundation; US Department of Energy at Berkeley Lab(United States Department of Energy (DOE)); National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); California Breast Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Sharon D Lund foundation grant and the American Cancer Society, the Swedish Cancer Society, the Swedish Medical Research Council, the Medical Faculty (Lund University), the Soderberg Foundation, the Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research, the Knut and Alice Wallenberg Foundation, the Lund City Jubileumsfond, the John and Augusta Persson Foundation for Medical Research, the Maggie Stephens Foundation, the Gunnar Nilsson Cancer Foundation, the Inga-Britt and Arne Lundberg Foundation, the HJ Forssman Foundation for Medical Research, the Royal Physiographic Society, the Swedish Society for Medical Research, the Network of Excellence: EuroPathoGenomics, the Crafoord Foundation, the Osterlund Foundation, the US Department of Energy Low Dose SFA Program at Berkeley Lab [DE-AC02-05CH11231], the National Institutes of Health, National Cancer Institute grant U54 CA 112970 and the California Breast Cancer Research Program [15IB-0063].	Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149; Baran R, 2009, CURR OPIN MICROBIOL, V12, P547, DOI 10.1016/j.mib.2009.07.004; Brest P, 2007, CANCER RES, V67, P11327, DOI 10.1158/0008-5472.CAN-07-1153; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Coleman MC, 2008, FREE RADICAL BIO MED, V44, P322, DOI 10.1016/j.freeradbiomed.2007.08.032; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV, 1999, MOL CELL BIOL, V19, P1; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fiehn O, 2005, LECT NOTES COMPUT SC, V3615, P224; Fischer W, 2004, CANCER RES, V64, P2105, DOI 10.1158/0008-5472.CAN-03-2661; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernlund E, 2008, INT J CANCER, V123, P476, DOI 10.1002/ijc.23525; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Ihrlund LS, 2008, MOL ONCOL, V2, P94, DOI 10.1016/j.molonc.2008.01.003; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Mossberg AK, 2010, J UROLOGY, V183, P1590, DOI 10.1016/j.juro.2009.12.008; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Satoh J, 2006, J NEUROSCI METH, V152, P278, DOI 10.1016/j.jneumeth.2005.09.015; Scholz M, 2007, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2007, P169; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Svanborg C, 2003, ADV CANCER RES, V88, P1; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; THOMAS DB, 1975, CELL, V5, P37, DOI 10.1016/0092-8674(75)90089-6; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATSON PH, 1991, CANCER RES, V51, P3996; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	52	35	36	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4765	4779		10.1038/onc.2011.196	http://dx.doi.org/10.1038/onc.2011.196			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21643007	Green Accepted			2022-12-28	WOS:000298134700001
J	Lu, Y; Muller, M; Smith, D; Dutta, B; Komurov, K; Iadevaia, S; Ruths, D; Tseng, JT; Yu, S; Yu, Q; Nakhleh, L; Balazsi, G; Donnelly, J; Schurdak, M; Morgan-Lappe, S; Fesik, S; Ram, PT; Mills, GB				Lu, Y.; Muller, M.; Smith, D.; Dutta, B.; Komurov, K.; Iadevaia, S.; Ruths, D.; Tseng, J-T; Yu, S.; Yu, Q.; Nakhleh, L.; Balazsi, G.; Donnelly, J.; Schurdak, M.; Morgan-Lappe, S.; Fesik, S.; Ram, P. T.; Mills, G. B.			Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling	ONCOGENE			English	Article						AKT; MAPK; proteomics; signaling networks; siRNA	RIBOSOMAL S6 KINASE; CANCER CELL-LINES; TUBEROUS-SCLEROSIS; BREAST-CANCER; PI3K PATHWAY; GROWTH; PHOSPHORYLATION; INHIBITION; PROTEIN; TSC2	To identify regulators of intracellular signaling, we targeted 541 kinases and kinase-related molecules with small interfering RNAs (siRNAs), and determined their effects on signaling with a functional proteomics reverse-phase protein array (RPPA) platform assessing 42 phospho and total proteins. The kinome-wide screen demonstrated a strong inverse correlation between phosphorylation of AKT and mitogen-activated protein kinase (MAPK) with 115 genes that, when targeted by siRNAs, demonstrated opposite effects on MAPK and AKT phosphorylation. Network-based analysis identified the MAPK subnetwork of genes along with p70S6K and FRAP1 as the most prominent targets that increased phosphorylation of AKT, a key regulator of cell survival. The regulatory loops induced by the MAPK pathway are dependent on tuberous sclerosis complex 2 but demonstrate a lesser dependence on p70S6K than the previously identified FRAP1 feedback loop. The siRNA screen also revealed novel bi-directionality in the AKT and GSK3 (Glycogen synthase kinase 3) interaction, whereby genetic ablation of GSK3 significantly blocks AKT phosphorylation, an unexpected observation as GSK3 has only been predicted to be downstream of AKT. This method uncovered novel modulators of AKT phosphorylation and facilitated the mapping of regulatory loops. Oncogene (2011) 30, 4567-4577; doi: 10.1038/onc.2011.164; published online 13 June 2011	[Lu, Y.; Muller, M.; Smith, D.; Dutta, B.; Komurov, K.; Iadevaia, S.; Tseng, J-T; Yu, S.; Yu, Q.; Balazsi, G.; Ram, P. T.; Mills, G. B.] UT MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA; [Ruths, D.; Nakhleh, L.] Rice Univ, Dept Comp Sci, Houston, TX USA; [Donnelly, J.; Schurdak, M.; Morgan-Lappe, S.; Fesik, S.] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA	University of Texas System; UTMD Anderson Cancer Center; Rice University; Abbott Laboratories	Ram, PT (corresponding author), UT MD Anderson Canc Ctr, Dept Syst Biol, 7435 Fannin St, Houston, TX 77054 USA.	pram@mdanderson.org		Balazsi, Gabor/0000-0002-6865-5818; Ram, Prahlad/0000-0003-4739-3166; Schurdak, Mark/0000-0002-1146-3268	Kleberg Center for Molecular Markers; Komen Foundation [SU2C-AACR- DT0209]; NIH [CCSG P30CA16672, T90DK070109, R01CA125109, P01CA099031, P50CA083639, U54 CA112970]; NIH Foundation [DPA86424-444938]; GBM; NIH CCTS; Komen fellowship [KG101547]; PTR; DOD [BC044268]; Seed Funding Program Collaborative Advances in Biomedical Computing (CAMC); John and Ann Doerr Fund; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA125109, U54CA112970, P01CA099031, P30CA016672, P50CA083639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T90DK070109] Funding Source: NIH RePORTER	Kleberg Center for Molecular Markers; Komen Foundation(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Foundation; GBM; NIH CCTS; Komen fellowship; PTR; DOD(United States Department of Defense); Seed Funding Program Collaborative Advances in Biomedical Computing (CAMC); John and Ann Doerr Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Kwiatkowski and J Woodgett for the knock out TSC2 and GSK3 cells, respectively. This study was funded in part by the Kleberg Center for Molecular Markers, the Komen Foundation, StandUp to Cancer/AmericanAssociation for Cancer Research Dream Team Translational Cancer Research Grant, Grant No. SU2C-AACR- DT0209, NIH CCSG P30CA16672, NIH Foundation DPA86424-444938 to BD and GBM, NIH CCTS support to DS, NIH T90DK070109 fellowship to J-TT and SI, Komen fellowship KG101547 to KK and PTR, DOD BC044268 and NIH R01CA125109 to PTR, NIH P01CA099031 and P50CA083639 to GBM, and U54 CA112970 to PTR and GBM. LN was supported by the Seed Funding Program Collaborative Advances in Biomedical Computing (CAMC), funded by the John and Ann Doerr Fund for Computational Biomedicine.	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Avruch J, 2006, ONCOGENE, V25, P6361, DOI 10.1038/sj.onc.1209882; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Iadevaia S, 2010, CANCER RES, V70, P6704, DOI 10.1158/0008-5472.CAN-10-0460; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Komurov K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000889; Komurov K, 2010, J BIOL CHEM, V285, P21134, DOI 10.1074/jbc.M110.137828; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma'ayan A, 2005, SCIENCE, V309, P1078, DOI 10.1126/science.1108876; MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Morgan-Lappe S, 2006, ONCOGENE, V25, P1340, DOI 10.1038/sj.onc.1209169; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Muller M, 2008, FASEB J, V22, P1393, DOI 10.1096/fj.07-9100com; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruths D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000005; Ruths D, 2008, BMC SYST BIOL, V2, DOI 10.1186/1752-0509-2-76; Sarthy AV, 2007, MOL CANCER THER, V6, P269, DOI 10.1158/1535-7163.MCT-06-0560; Song JJ, 2005, J CELL BIOL, V170, P61, DOI 10.1083/jcb.200502070; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Zheng M, 2008, CANCER RES, V68, P7570, DOI 10.1158/0008-5472.CAN-08-0632	37	48	51	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 10	2011	30	45					4567	4577		10.1038/onc.2011.164	http://dx.doi.org/10.1038/onc.2011.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21666717	Green Accepted			2022-12-28	WOS:000296890700004
J	Guijarro, MV; Vergel, M; Marin, JJ; Munoz-Galvan, S; Ferrer, I; Cajal, SRY; Roncador, G; Blanco-Aparicio, C; Carnero, A				Guijarro, M. V.; Vergel, M.; Marin, J. J.; Munoz-Galvan, S.; Ferrer, I.; Ramon y Cajal, S.; Roncador, G.; Blanco-Aparicio, C.; Carnero, A.			p38 alpha limits the contribution of MAP17 to cancer progression in breast tumors	ONCOGENE			English	Article						breast carcinoma; MAP17; ROS; p38	EPITHELIAL-CELL TRANSFORMATION; INDUCED GROWTH ARREST; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; INDUCED SENESCENCE; HUMAN CARCINOMAS; KINASE; P38	MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas. In the present work, we have analyzed the role of MAP17 expression during mammary cancer progression. We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias. MAP17 levels increased with breast tumor stage and were strongly correlated with mammary tumoral progression. A significant increase in the levels of reactive oxygen species (ROS) was observed in MAP17-expressing cells, as compared with parental cells. This increase was further paralleled by an increase in the tumorigenic capacity of carcinoma cells but not in immortal non-tumoral breast epithelial cells, which provides a selective advantage once tumorigenesis has begun. Expression of specific MAP17 shRNA in protein-expressing tumor cells reduced their tumorigenic capabilities, which suggests that this effect is dependent upon MAP17 protein expression. Our data show that ROS functions as a second messenger that enhances tumoral properties, which are inhibited in non-tumoral cells. We have found that p38 alpha activation mediates this response. MAP17 triggers a ROS-dependent, senescence-like response that is abolished in the absence of p38a activation. Furthermore, in human breast tumors, MAP17 activation is correlated with a lack of phosphorylation of p38a. Therefore, MAP17 is overexpressed in late-stage breast tumors, in which oncogenic activity relies on p38 insensitivity to induce intracellular ROS. Oncogene (2012) 31, 4447-4459; doi: 10.1038/onc.2011.619; published online 23 January 2012	[Carnero, A.] Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBIS HUVR, Seville 41013, Spain; [Guijarro, M. V.] NYU, Sch Med, Dept Pathol, New York, NY USA; [Marin, J. J.] Univ Seville, Dept Prevent Med & Publ Hlth, Seville, Spain; [Ferrer, I.] Inst Invest Biomed Bellvitge IDIBELL, Bellvitge, Spain; [Ramon y Cajal, S.] Recerca Hosp Vall Hebron, Fundacio Inst, Dept Pathol, Barcelona, Spain; [Roncador, G.] Spanish Natl Canc Ctr CNIO, Biotechnol Program, Madrid, Spain; [Carnero, A.] CSIC, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; New York University; University of Sevilla; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Universitari Vall d'Hebron; Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC)	Carnero, A (corresponding author), Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBIS HUVR, Avda Manuel Siurot S-N, Seville 41013, Spain.	acarnero@us.es	IBIS, CANCER/P-3323-2015; Ramon y Cajal, Santiago/H-4955-2016; Blanco-Aparicio, Carmen/I-3162-2015; Muñoz-Galván, Sandra/K-5827-2015; Roncador, Giovanna/L-1764-2014; Marín-López, Juan J./G-7123-2012; Ferrer, Irene/C-9418-2015	Ramon y Cajal, Santiago/0000-0002-3867-1390; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Roncador, Giovanna/0000-0002-9807-2875; Marín-López, Juan J./0000-0001-6072-739X; Ferrer, Irene/0000-0002-2748-2607; Carnero, Amancio/0000-0003-4357-3979; Munoz-Galvan, Sandra/0000-0003-0579-325X	Spanish Ministry of Science and Innovation; FEDER [SAF2009-08605]; Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia [CTS-6844, PI-0142]; Fundacion Oncologica FERO; Fundacio Josep Botet	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); FEDER(European Commission); Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia(Junta de Andalucia); Fundacion Oncologica FERO; Fundacio Josep Botet	We thank Augusto Silva and Ricardo Sanchez Prieto for their critical reading of the manuscript and valuable suggestions. This work was supported by grants from the Spanish Ministry of Science and Innovation and FEDER (SAF2009-08605), Consejeria de Ciencia e Innovacion and Consejeria de Salud of the Junta de Andalucia (CTS-6844 and PI-0142). AC's laboratory is also funded by a fellowship from the Fundacion Oncologica FERO, supported by Fundacio Josep Botet.	Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Blasco T, 2003, AM J PHYSIOL-RENAL, V285, pF799, DOI 10.1152/ajprenal.00149.2003; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Carnero A, 2004, ONCOGENE, V23, P6006, DOI 10.1038/sj.onc.1207839; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; England K, 2005, REDOX REP, V10, P237, DOI 10.1179/135100005X70224; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; Guijarro MV, 2007, J CELL BIOCHEM, V101, P112, DOI 10.1002/jcb.21163; Guijarro MV, 2007, CARCINOGENESIS, V28, P2443, DOI 10.1093/carcin/bgm154; Guijarro MV, 2007, CARCINOGENESIS, V28, P2096, DOI 10.1093/carcin/bgm124; Guijarro MV, 2007, CARCINOGENESIS, V28, P1646, DOI 10.1093/carcin/bgm083; Hancock JT, 2001, BIOFACTORS, V15, P99, DOI 10.1002/biof.5520150210; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jaeger C, 2000, J INVEST DERMATOL, V115, P375, DOI 10.1046/j.1523-1747.2000.00071.x; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Kocher O, 1996, AM J PATHOL, V149, P493; Kocher O, 1995, CLIN CANCER RES, V1, P1209; Lanaspa MA, 2007, AM J PHYSIOL-RENAL, V292, pF230, DOI 10.1152/ajprenal.00075.2006; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lewis CM, 2006, BREAST CANCER RES TR, V99, P103, DOI 10.1007/s10549-006-9189-9; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pribanic S, 2003, AM J PHYSIOL-RENAL, V285, pF784, DOI 10.1152/ajprenal.00109.2003; Ruiz L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003230; Samanta AK, 2009, CANCER-AM CANCER SOC, V115, P3897, DOI 10.1002/cncr.24445; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Yan T, 1996, CANCER RES, V56, P2864; Yoon SO, 2002, MECH AGEING DEV, V123, P1597, DOI 10.1016/S0047-6374(02)00095-7; Zuluaga S, 2007, CELL SIGNAL, V19, P62, DOI 10.1016/j.cellsig.2006.05.032	59	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4447	4459		10.1038/onc.2011.619	http://dx.doi.org/10.1038/onc.2011.619			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266858				2022-12-28	WOS:000309704500003
J	Zheng, ZY; Cheng, CM; Fu, XR; Chen, LY; Xu, L; Terrillon, S; Wong, ST; Bar-Sagi, D; Songyang, Z; Chang, EC				Zheng, Z-Y; Cheng, C-M; Fu, X-R; Chen, L-Y; Xu, L.; Terrillon, S.; Wong, S. T.; Bar-Sagi, D.; Songyang, Z.; Chang, E. C.			CHMP6 and VPS4A mediate the recycling of Ras to the plasma membrane to promote growth factor signaling	ONCOGENE			English	Article						signal transduction; tumorigenesis; trafficking; ESCRT-III	ENDOPLASMIC-RETICULUM; RECEPTOR ENDOCYTOSIS; LIVING CELLS; H-RAS; PROTEINS; TRAFFICKING; BINDING; RIN1; UBIQUITINATION; SEGREGATION	While Ras is well-known to function on the plasma membrane (PM) to mediate growth factor signaling, increasing evidence suggests that Ras has complex roles in the cytoplasm. To uncover these roles, we screened a cDNA library and isolated H-Ras-binding proteins that also influence Ras functions. Many isolated proteins regulate trafficking involving endosomes; CHMP6/VPS20 and VPS4A, which interact with ESCRT-III (Endosomal Sorting Complex Required for Transport-III), were chosen for further study. We showed that the binding is direct and occurs in endosomes. Furthermore, the binding is most efficient when H-Ras has a functional effector-binding loop, and is GTP-bound and ubiquitylated. CHMP6 and VPS4A also bound to N-Ras but not K-Ras. Repressing CHMP6 and VPS4A blocked Ras-induced transformation, which correlated with inefficient Ras localization to the PM as measured by cell fractionation and photobleaching. Moreover, silencing CHMP6 and VPS4A also blocked epidermal growth factor receptor (EGFR) recycling. These data suggest that Ras interacts with key ESCRT-III components to promote recycling of itself and EGFR back to the PM to create a positive feedback loop to enhance growth factor signaling.	[Cheng, C-M; Chang, E. C.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Chen, L-Y; Songyang, Z.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Xu, L.; Terrillon, S.; Bar-Sagi, D.] NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; [Wong, S. T.] Methodist Hosp, Res Inst, Dept Syst Med & Bioengn, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; New York University; The Methodist Hospital System; The Methodist Hospital - Houston	Chang, EC (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	echang1@bcm.tmc.edu	Chen, Liuh-Yow/AAA-3963-2021	Chen, Liuh-Yow/0000-0002-9857-068X; Bar-Sagi, Dafna/0000-0003-2597-8948	Susan G Komen for the Cure Foundation [PDF0707860]; Human Frontier Science Program [LT00147/2005]; NIH [U54CA149169, CA133249, GM081627, CA90464, CA107187, GM81627, P50-CA58183]; NATIONAL CANCER INSTITUTE [R01CA133249, R01CA107187, R00CA149169, K99CA149169, P50CA058183, R01CA055360, R01CA090464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095599, P01GM081627] Funding Source: NIH RePORTER	Susan G Komen for the Cure Foundation(Susan G. Komen Breast Cancer Foundation); Human Frontier Science Program(Human Frontier Science Program); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Gary Chamness and Evelin Young for thoughtfully reading the manuscript. We are particularly grateful for the generosity of Wesley Sundquist, Mark Philips and Juan Bonifacino for providing many reagents and for sharing unpublished results that are critical for this study. Z-Y Z is supported by a postdoctoral fellowship from the Susan G Komen for the Cure Foundation (PDF0707860). ST was supported by a fellowship from Human Frontier Science Program (LT00147/2005). STW is supported by a grant from NIH (U54CA149169). ZS is a Leukemia and Lymphoma Society Scholar and is supported by grants from NIH (CA133249 and GM081627). ECC is supported by grants from NIH (CA90464, CA107187, GM81627 and P50-CA58183).	Balbis A, 2007, ENDOCRINOLOGY, V148, P2944, DOI 10.1210/en.2006-1674; Baldys A, 2009, BIOCHEMISTRY-US, V48, P9321, DOI 10.1021/bi900865u; Barbieri MA, 2003, J BIOL CHEM, V278, P32027, DOI 10.1074/jbc.M304324200; Belgareh-Touze N, 2002, MOL BIOL CELL, V13, P1694, DOI 10.1091/mbc.01-12-0597; Castle A, 2005, J CELL SCI, V118, P3769, DOI 10.1242/jcs.02503; Chang EC, 2006, CELL CYCLE, V5, P1936, DOI 10.4161/cc.5.17.3187; Chen LY, 2007, MOL CELL BIOL, V27, P5898, DOI 10.1128/MCB.00603-07; Cheng CM, 2011, CELL CYCLE, V10, P1180, DOI 10.4161/cc.10.8.15259; Cheng CM, 2011, MOL CELL BIOL, V31, P983, DOI 10.1128/MCB.00137-10; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Howard TL, 2001, J CELL SCI, V114, P2395; Huang JR, 2007, J MOL BIOL, V370, P356, DOI 10.1016/j.jmb.2007.04.039; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kerppola TK, 2008, METHOD CELL BIOL, V85, P431, DOI 10.1016/S0091-679X(08)85019-4; Lamesch P, 2007, GENOMICS, V89, P307, DOI 10.1016/j.ygeno.2006.11.012; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186; Morita E, 2010, P NATL ACAD SCI USA, V107, P12889, DOI 10.1073/pnas.1005938107; Nebl G, 2004, CELL SIGNAL, V16, P235, DOI 10.1016/S0898-6568(03)00133-5; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Raiborg C, 2008, EXP CELL RES, V314, P801, DOI 10.1016/j.yexcr.2007.10.014; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Su Y, 2007, CANCER BIOL THER, V6, P202, DOI 10.4161/cbt.6.2.3628; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; Wakana Y, 2005, BIOCHEM BIOPH RES CO, V334, P1198, DOI 10.1016/j.bbrc.2005.07.012; Wouters FS, 2001, TRENDS CELL BIOL, V11, P203, DOI 10.1016/S0962-8924(01)01982-1; Xu LZ, 2010, CURR BIOL, V20, P1372, DOI 10.1016/j.cub.2010.06.051; Yan H, 2010, CURR BIOL, V20, P1378, DOI 10.1016/j.cub.2010.06.058	37	21	21	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	43					4630	4638		10.1038/onc.2011.607	http://dx.doi.org/10.1038/onc.2011.607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22231449	Green Accepted			2022-12-28	WOS:000310528200006
J	Lin, FC; Liu, YP; Lai, CH; Shan, YS; Cheng, HC; Hsu, PI; Lee, CH; Lee, YC; Wang, HY; Wang, CH; Cheng, JQ; Hsiao, M; Lu, PJ				Lin, F-C; Liu, Y-P; Lai, C-H; Shan, Y-S; Cheng, H-C; Hsu, P-I; Lee, C-H; Lee, Y-C; Wang, H-Y; Wang, C-H; Cheng, J. Q.; Hsiao, M.; Lu, P-J			RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells	ONCOGENE			English	Article						RUNX3; Akt; beta-catenin; cyclin D1; gastric cancer	HELICOBACTER-PYLORI INFECTION; EPITHELIAL-CELLS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; RUNX3 EXPRESSION; BETA-CATENIN; MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; GENE-EXPRESSION; STOMACH-CANCER	Activation of Akt signaling pathway has been suggested involving in chemoresistance, metastasis and tumorigenesis of gastric cancer. However, the mechanism of Akt regulation in gastric cancer is not fully understood. RUNX3, which was first identified as a transcription factor, suppresses gastric tumorigenesis through regulating expression of target genes. Here, we found that restoration of RUNX3 significantly downregulates the protein and mRNA expression of Akt1 in gastric cancer cell lines, AGS and SNU-1. Knockdown of RUNX3 upregulates protein and mRNA expression of Akt1 in normal gastric epithelial cell line, GES-1. The negative correlation of RUNX3 and Akt expression and downstream beta-catenin/cyclin D1 effectors was further confirmed in AGS and GES-1 cell lines, as well as clinical specimens of gastric cancer. We identified two RUNX3-binding sites in Akt1 promoter and the binding of RUNX3 on Akt1 promoter significantly inhibits Akt1 expression. The RUNX3-mediated inhibition of Akt1 caused beta-catenin protein degradation and then cyclin D1 downregulation. Restoration of cyclin D1 reverses cell growth inhibition and G1 phase arrest induced by RUNX3 in gastric cancer cells. Our results show that loss of RUNX3 expression can enhance the Akt1-mediated signaling pathway and promote the tumorigenesis process in human gastric cancer. Oncogene (2012) 31, 4302-4316; doi:10.1038/onc.2011.596; published online 9 January 2012	[Liu, Y-P; Lee, C-H; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lin, F-C; Liu, Y-P; Lai, C-H; Shan, Y-S; Cheng, H-C; Lee, Y-C; Wang, H-Y; Lu, P-J] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 704, Taiwan; [Lin, F-C] Natl Cheng Kung Univ Hosp, Dept Radiat Oncol, Tainan 70428, Taiwan; [Shan, Y-S] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan 70428, Taiwan; [Hsu, P-I] Kaohsiung Vet Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hsu, P-I] Natl Yang Ming Univ, Dept Internal Med, Taipei 112, Taiwan; [Wang, C-H] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan; [Cheng, J. Q.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL 33682 USA	Academia Sinica - Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; Kaohsiung Medical University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	mhsiao@gate.sinica.edu.tw; pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019; Lai, Chern-Hsiung/C-8662-2009	Hsiao, Michael/0000-0001-8529-9213; 	National Science Council of Taiwan [NSC 97-2311-B-006-003-MY3, NSC 99-2627-B-006-021]; National Cheng Kung University Hospital of Taiwan [NCKUH-9803004, NCKUH-9903051]; Chi Mei Medical Center of Taiwan [CMNCKU9901]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); National Cheng Kung University Hospital of Taiwan; Chi Mei Medical Center of Taiwan	The study was supported by grants from the National Science Council of Taiwan (NSC 97-2311-B-006-003-MY3 and NSC 99-2627-B-006-021), National Cheng Kung University Hospital of Taiwan (NCKUH-9803004 and NCKUH-9903051) and Chi Mei Medical Center of Taiwan (CMNCKU9901). We acknowledge Dr Xiang Hong Zhang from Hebei Medical University in China for kindly providing GES-1 cell line, and Dr Ching-Shih Chen from Ohio State University for kindly providing Akt, myr-Akt and DN-Akt constructs.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; CHYOU PH, 1990, CANCER RES, V50, P7501; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fang DC, 2003, WORLD J GASTROENTERO, V9, P655, DOI 10.3748/wjg.v9.i4.655; Fukamachi H, 2006, DEV GROWTH DIFFER, V48, P1, DOI 10.1111/j.1440-169x.2006.00832.x; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Gargano G, 2007, ANN ONCOL, V18, P103, DOI 10.1093/annonc/mdm236; Guo CC, 2005, INT J CANCER, V116, P155, DOI 10.1002/ijc.20919; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Hsu PI, 2009, ANN SURG ONCOL, V16, P1686, DOI 10.1245/s10434-009-0428-2; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Ke Yang, 1994, Zhonghua Zhongliu Zazhi, V16, P7; Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Misra UK, 2007, J CELL BIOCHEM, V100, P1022, DOI 10.1002/jcb.21086; NOMURA A, 1990, CANCER RES, V50, P627; Ogawa S, 2008, J BIOCHEM, V143, P695, DOI 10.1093/jb/mvn022; Oki E, 2005, INT J CANCER, V117, P376, DOI 10.1002/ijc.21170; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Park S, 2005, J BIOL CHEM, V280, P38932, DOI 10.1074/jbc.M504011200; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; SANO T, 1991, CANCER RES, V51, P2926; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Suzuki H, 2009, GASTRIC CANCER, V12, P79, DOI 10.1007/s10120-009-0507-x; Tsugane S, 2007, GASTRIC CANCER, V10, P75, DOI 10.1007/s10120-007-0420-0; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4; Xing X, 2011, MOL NUTR FOOD RES, V55, P749, DOI 10.1002/mnfr.201000344; Yanada M, 2005, ONCOL REP, V14, P817; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	63	35	37	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4302	4316		10.1038/onc.2011.596	http://dx.doi.org/10.1038/onc.2011.596			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22231444				2022-12-28	WOS:000309520200005
J	Bonnomet, A; Syne, L; Brysse, A; Feyereisen, E; Thompson, EW; Noel, A; Foidart, JM; Birembaut, P; Polette, M; Gilles, C				Bonnomet, A.; Syne, L.; Brysse, A.; Feyereisen, E.; Thompson, E. W.; Noel, A.; Foidart, J-M; Birembaut, P.; Polette, M.; Gilles, C.			A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer	ONCOGENE			English	Article						EMT; circulating tumor cells; metastases; vimentin; MDA-MB-468	GROWTH-FACTOR RECEPTOR-2; GENE-EXPRESSION; STEM-CELL; CARCINOMA CELLS; E-CADHERIN; BASAL; SNAIL; PHENOTYPE; INVASION; SUBTYPE	Epithelial-to-mesenchymal transition (EMT) processes endow epithelial cells with enhanced migratory/invasive properties and are therefore likely to contribute to tumor invasion and metastatic spread. Because of the difficulty in following EMT processes in human tumors, we have developed and characterized an animal model with transplantable human breast tumor cells (MDA-MB-468) uniquely showing spontaneous EMT events to occur. Using vimentin as a marker of EMT, heterogeneity was revealed in the primary MDA-MB-468 xenografts with vimentin-negative and vimentin-positive areas, as also observed on clinical human invasive breast tumor specimens. Reverse transcriptase-PCR after microdissection of these populations from the xenografts revealed EMT traits in the vimentin-positive zones characterized by enhanced 'mesenchymal gene' expression (Snail, Slug and fibroblast-specific protein-1) and diminished expression of epithelial molecules (E-cadherin, ZO-3 and JAM-A). Circulating tumor cells (CTCs) were detected in the blood as soon as 8 days after s.c. injection, and lung metastases developed in all animals injected as examined by in vivo imaging analyses and histology. High levels of vimentin RNA were detected in CTCs by reverse transcriptase-quantitative PCR as well as, to a lesser extent, Snail and Slug RNA. Von Willebrand Factor/vimentin double immunostainings further showed that tumor cells in vascular tumoral emboli all expressed vimentin. Tumoral emboli in the lungs also expressed vimentin whereas macrometastases displayed heterogenous vimentin expression, as seen in the primary xenografts. In conclusion, our data uniquely demonstrate in an in vivo context that EMT occurs in the primary tumors, and associates with an enhanced ability to intravasate and generate CTCs. They further suggest that mesenchymal-to-epithelial phenomena occur in secondary organs, facilitating the metastatic growth. Oncogene (2012) 31, 3741-3753; doi:10.1038/onc.2011.540; published online 28 November 2011	[Bonnomet, A.; Syne, L.; Brysse, A.; Feyereisen, E.; Noel, A.; Foidart, J-M; Gilles, C.] Univ Liege, GIGA Canc, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; [Thompson, E. W.] St Vincents Inst, Melbourne, Vic, Australia; [Thompson, E. W.] Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia; [Bonnomet, A.; Birembaut, P.; Polette, M.] INSERM, Unite U903, Lab Pol Bouin, Reims, France	University of Liege; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gilles, C (corresponding author), Univ Liege, CHU Sart Tilman, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.	cgilles@ulg.ac.be	Thompson, Erik W/A-1425-2009; BIREMBAUT, Philippe/P-5210-2016; POLETTE, Myriam/P-5147-2016; Thompson, Erik/GPK-2067-2022	Thompson, Erik W/0000-0002-9723-4924; Thompson, Erik/0000-0002-9723-4924; BONNOMET, Arnaud/0000-0002-4933-3338; Noel, Agnes/0000-0002-7670-6179; POLETTE, Myriam/0000-0001-8173-3246	Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium); Foundation against Cancer (foundation of public interest, Belgium); C.G.R.I.-F.N.R.S.-INSERM Cooperation; Fonds speciaux de la Recherche (University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege); Region Champagne-Ardenne; Ligue Contre le Cancer; Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante ACI INCa (Canceropole Grand-Est project); US. Army Medical Research and Materiel Command [BC0213201, BC084667]; Victorian Breast Cancer Research Consortium, Cancer Council Victoria [509295]; National Breast Cancer Foundation (Australia); National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium)(Fonds de la Recherche Scientifique - FNRS); Foundation against Cancer (foundation of public interest, Belgium); C.G.R.I.-F.N.R.S.-INSERM Cooperation(Fonds de la Recherche Scientifique - FNRS); Fonds speciaux de la Recherche (University of Liege)(University of Liege); Centre Anticancereux pres l'Universite de Liege; Fonds Leon Fredericq (University of Liege)(University of Liege); Region Champagne-Ardenne(Region Grand-Est); Ligue Contre le Cancer(Ligue nationale contre le cancer); Lions Club of Soissons; Un Euro contre le Cancer; Fond National pour la Sante ACI INCa (Canceropole Grand-Est project)(Region Grand-Est); US. Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Victorian Breast Cancer Research Consortium, Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Breast Cancer Foundation (Australia); National Breast Cancer Foundation	The research effort associated with this article was funded in part by the Fonds de la Recherche Scientifique-FNRS (F.R.S.-FNRS, Belgium), the Foundation against Cancer (foundation of public interest, Belgium), the 'C.G.R.I.-F.N.R.S.-INSERM Cooperation', the Fonds speciaux de la Recherche (University of Liege), the Centre Anticancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the 'Region Champagne-Ardenne', the 'Ligue Contre le Cancer', the Lions Club of Soissons, Un Euro contre le Cancer and the Fond National pour la Sante ACI 2004-2010 INCa (Canceropole Grand-Est project), the US. Army Medical Research and Materiel Command (BC0213201 and BC084667), the Victorian Breast Cancer Research Consortium, Cancer Council Victoria (#509295), the National Breast Cancer Foundation (Australia). CG is a Senior Research Associate from the F.R.S.-FNRS (Belgium). AB is supported by the 'Region Champagne-Ardenne'. We thank Nathalie Lefin and Benoit Brouwers for their technical assistance.	Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Bonnomet A, 2010, J MAMMARY GLAND BIOL, V15, P261, DOI 10.1007/s10911-010-9174-0; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Chen XD, 2008, J MOL HISTOL, V39, P283, DOI 10.1007/s10735-008-9164-3; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Kallergi G, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2896; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Mego M, 2011, INT J CANC; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Oltean S, 2006, P NATL ACAD SCI USA, V103, P14116, DOI 10.1073/pnas.0603090103; Pantel K, 2010, TRENDS MOL MED, V16, P398, DOI 10.1016/j.molmed.2010.07.001; Paterlini-Brechot P, 2007, CANCER LETT, V253, P180, DOI 10.1016/j.canlet.2006.12.014; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponzo MG, 2009, P NATL ACAD SCI USA, V106, P12903, DOI 10.1073/pnas.0810402106; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916; Reichert M, 2000, J BIOL CHEM, V275, P9492, DOI 10.1074/jbc.275.13.9492; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Xue CS, 2003, CANCER RES, V63, P3386; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Zhang A, 2008, ANTICANCER RES, V28, P621	40	145	151	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	33					3741	3753		10.1038/onc.2011.540	http://dx.doi.org/10.1038/onc.2011.540			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120722	Green Submitted			2022-12-28	WOS:000307924900001
J	Li, X; Gilkes, D; Li, B; Cheng, Q; Pernazza, D; Lawrence, H; Lawrence, N; Chen, J				Li, X.; Gilkes, D.; Li, B.; Cheng, Q.; Pernazza, D.; Lawrence, H.; Lawrence, N.; Chen, J.			Abnormal MDMX degradation in tumor cells due to ARF deficiency	ONCOGENE			English	Article						MDM2; MDMX; ARF; p53; ubiquitination; nutlin	AUTOREGULATORY FEEDBACK LOOP; SMALL-MOLECULE INHIBITORS; DNA-DAMAGE; EMBRYONIC LETHALITY; P53 ACTIVATION; IN-VIVO; MDM2-DEFICIENT MICE; ACIDIC DOMAIN; RING DOMAIN; UBIQUITINATION	MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation. Oncogene (2012) 31, 3721-3732; doi:10.1038/onc.2011.534; published online 28 November 2011	[Li, X.; Gilkes, D.; Li, B.; Cheng, Q.; Chen, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Li, X.] Tianjin Med Univ, Dept Head & Neck Tumor, Canc Inst & Hosp, Tianjin, Peoples R China; [Pernazza, D.; Lawrence, H.; Lawrence, N.] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; Tianjin Medical University; H Lee Moffitt Cancer Center & Research Institute	Chen, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org	Li, Baozong/ABD-4742-2020; Gilkes, Daniele M/AAI-8133-2020; li, baozong/K-4176-2012	Gilkes, Daniele M/0000-0003-3984-9338; 	National Institutes of Health [CA141244, CA109636, CA118210]; NATIONAL CANCER INSTITUTE [R01CA109636, R01CA141244, P01CA118210] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Dawn Quelle for NARF6 cells and Dr Yanping Zhang for ARF-null MEF. This work was supported in part by grants from the National Institutes of Health (CA141244, CA109636 and CA118210).	Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Cross B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.228981; Dang JJ, 2002, CANCER RES, V62, P1222; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Ding K, 2006, J MED CHEM, V49, P3432, DOI 10.1021/jm051122a; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Grier JD, 2006, MOL CELL BIOL, V26, P192, DOI 10.1128/MCB.26.1.192-198.2006; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Li BZ, 2010, CELL CYCLE, V9, P1411, DOI 10.4161/cc.9.7.11255; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUNA RMD, 1995, NATURE, V378, P203; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Maetens M, 2007, BLOOD, V109, P2630, DOI 10.1182/blood-2006-03-013656; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Millard M, 2011, CURR PHARM DESIGN, V17, P536, DOI 10.2174/138161211795222649; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Ramos YFM, 2001, CANCER RES, V61, P1839; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sivakolundu SG, 2008, J MOL BIOL, V384, P240, DOI 10.1016/j.jmb.2008.09.019; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xiong SB, 2010, CANCER RES, V70, P7148, DOI 10.1158/0008-5472.CAN-10-1457; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024	54	23	24	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3721	3732		10.1038/onc.2011.534	http://dx.doi.org/10.1038/onc.2011.534			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22120712	Green Accepted			2022-12-28	WOS:000307653800006
J	Sharma, SS; Ma, L; Bagui, TK; Forinash, KD; Pledger, WJ				Sharma, S. S.; Ma, L.; Bagui, T. K.; Forinash, K. D.; Pledger, W. J.			A p27(Kip1) mutant that does not inhibit CDK activity promotes centrosome amplification and micronucleation	ONCOGENE			English	Article						p27(Kip1); cyclin F; micronuclei; centrosome amplification	CYCLIN-DEPENDENT-KINASE; CELL-CYCLE; MITOTIC CATASTROPHE; LACKING P27(KIP1); MICE LACKING; P27; DEGRADATION; PHOSPHORYLATION; TRANSCRIPTION; DUPLICATION	Mitotic catastrophe occurs when cells enter mitosis with damaged DNA or excess centrosomes. Cells overexpressing the centrosome protein CP110 or depleted of cyclin F, which targets CP110 for destruction, have more than two centrosomes and undergo mitotic catastrophe. Our studies show centrosome reduplication and mitotic catastrophe in osteosarcoma cells inducibly expressing a p27(Kip1) mutant (termed p27K) that binds cyclins but not cyclin-dependent kinases (CDKs). p27K inhibited cell proliferation but not CDK activity or cell cycle progression. It did not induce apoptosis; however, cells expressing p27K had more than two centrosomes and, indicative of mitotic catastrophe, irregularly shaped nuclei or multiple micronuclei. p27K interacted with cyclin F in vivo (as did endogenous p27(Kip1)) and displaced cyclin F from CP110. Depletion of CP110 rescued p27K-expressing cells from centrosome reduplication and mitotic catastrophe. Collectively, our data show that p27(Kip1) can perturb mitosis and suggest that it does so by sequestering cyclin F, which prevents its interaction with and the subsequent degradation of CP110, ultimately resulting in centrosome reduplication, mitotic catastrophe and abrogation of cell proliferation. Oncogene (2012) 31, 3989 3998; doi: 10.1038/onc.2011.550; published online 12 December 2011	[Pledger, W. J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Gonzmart Res Lab,Sarcoma Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jack.pledger@moffitt.org			Team Science Grant [09KT-03-23121]; Cortner Couch Chair; Amandalee Weiss Foundation; V Foundation; Bankhead-Coley Post-doctoral Grant [IBD08-34209]; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	Team Science Grant; Cortner Couch Chair; Amandalee Weiss Foundation; V Foundation; Bankhead-Coley Post-doctoral Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Sources of Support: Team Science Grant no. 09KT-03-23121, the Cortner Couch Chair, the Amandalee Weiss Foundation and the V Foundation (WJP), and Bankhead-Coley Post-doctoral Grant no. IBD08-34209 (SSS).	Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Bagui TK, 2009, CELL CYCLE, V8, P115, DOI 10.4161/cc.8.1.7527; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Caruso R, 2011, ULTRASTRUCT PATHOL, V35, P66, DOI 10.3109/01913123.2010.543753; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; D'Angiolella V, 2010, NATURE, V466, P138, DOI 10.1038/nature09140; Dodson H, 2007, CELL CYCLE, V6, P364, DOI 10.4161/cc.6.3.3834; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fukasawa K, 2008, BBA-REV CANCER, V1786, P15, DOI 10.1016/j.bbcan.2008.04.002; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Khattar E, 2010, J BIOL CHEM, V285, P4554, DOI 10.1074/jbc.M109.029280; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Korzeniewski N, 2010, MOL BIOL CELL, V21, P3942, DOI 10.1091/mbc.E09-12-1049; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nallamshetty S, 2005, FEBS LETT, V579, P6529, DOI 10.1016/j.febslet.2005.10.028; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Singhal S, 2003, CANCER BIOL THER, V2, P291, DOI 10.4161/cbt.2.3.399; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sugihara E, 2006, CANCER RES, V66, P4020, DOI 10.1158/0008-5472.CAN-05-3250; Tetzlaff MT, 2004, MOL CELL BIOL, V24, P2487, DOI 10.1128/MCB.24.6.2487-2498.2004; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304	58	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	35					3989	3998		10.1038/onc.2011.550	http://dx.doi.org/10.1038/onc.2011.550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22158041	Green Published, hybrid			2022-12-28	WOS:000308342800007
J	Paroni, G; Fratelli, M; Gardini, G; Bassano, C; Flora, M; Zanetti, A; Guarnaccia, V; Ubezio, P; Centritto, F; Terao, M; Garattini, E				Paroni, G.; Fratelli, M.; Gardini, G.; Bassano, C.; Flora, M.; Zanetti, A.; Guarnaccia, V.; Ubezio, P.; Centritto, F.; Terao, M.; Garattini, E.			Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA	ONCOGENE			English	Article						targeted therapy; retinoic acid; differentiation; apoptosis; HER2/neu; lapatinib	PROMYELOCYTIC LEUKEMIA-CELLS; ACID RECEPTOR-ALPHA; GROWTH-FACTOR-BETA; TGF-BETA; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; TUMOR SUPPRESSION; APOPTOSIS; TRASTUZUMAB; INDUCTION	All-trans retinoic acid (ATRA), the only clinically available cyto-differentiating agent, has potential for the therapy/chemoprevention of breast carcinoma. Given the heterogeneous nature of this tumor, a rational use of ATRA and derivatives (retinoids) in the clinic requires the identification of patients that would benefit from retinoid-based protocols. Here, we demonstrate that 23-32% of the human ERBB2(+) breast cancers show coamplification of retinoic acid receptor alpha (RARA), encoding the retinoic acid receptor, RAR alpha. This represents a novel subtype of breast cancer characterized by remarkable sensitivity to ATRA and RAR alpha agonists, regardless of positivity to the estrogen receptor, a known modulator of retinoid sensitivity. In estrogen-receptor-negative cellular models showing coamplification of ERBB2 and RARA, simultaneous targeting of the corresponding gene products with combinations of lapatinib and ATRA causes synergistic growth inhibition, cyto-differentiation and apoptosis. This provides proof-of-principle that coamplification of ERBB2 and RARA can be exploited for the stratified and targeted therapy of a novel subtype of breast cancer patients, with an approach characterized by tumor cell selectivity and low predicted toxicity. The available cellular models were exploited to define the molecular mechanisms underlying the antitumor activity of combinations between lapatinib and ATRA. Global gene expression and functional approaches provide evidence for three components of the antiproliferative/apoptotic responses triggered by lapatinib+ATRA. Induction of the retinoid-dependent RARRES3 protein by ATRA stabilizes the effect of lapatinib inhibiting ERBB2 phosphorylation. Upregulation and activation of the transcription factor FOXO3A integrates ATRA-dependent transcriptional and lapatinib-dependent posttranscriptional signals, controlling the levels of effector proteins like the antiapoptotic factor, BIRC5. Stimulation of the TGF beta pathway by ATRA mediates other components of the apoptotic process set in motion by simultaneous targeting of ERBB2 and RAR alpha. Oncogene (2012) 31, 3431-3443; doi:10.1038/onc.2011.506; published online 7 November 2011	[Paroni, G.; Fratelli, M.; Zanetti, A.; Guarnaccia, V.; Centritto, F.; Terao, M.; Garattini, E.] Ist Ric Farmacol Mario Negri, Mol Biol Lab, I-20156 Milan, Italy; [Gardini, G.; Bassano, C.; Flora, M.] IRCCS Osped Santa Maria Nuova, Anat Pathol Unit, Reggio Emilia, Italy; [Ubezio, P.] Ist Ric Farmacol Mario Negri, Dept Oncol, I-20156 Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Garattini, E (corresponding author), Ist Ric Farmacol Mario Negri, Mol Biol Lab, Via La Masa 19, I-20156 Milan, Italy.	enrico.garattini@marionegri.it	adriana, zanetti/ABA-1189-2020; Ubezio, Paolo/AAA-6455-2020; Fratelli, Maddalena/AAA-6446-2020; Garattini, Enrico/AAI-1998-2019; Paroni, Gabriela/J-4848-2018; Terao, Mineko/AAA-6415-2020; ubezio, paolo/AAA-6704-2020; terao, mineko/AAU-8089-2020	adriana, zanetti/0000-0002-5825-9707; Ubezio, Paolo/0000-0003-0412-9891; Fratelli, Maddalena/0000-0002-1769-3427; Paroni, Gabriela/0000-0003-0132-0869; Terao, Mineko/0000-0002-9976-9869; Garattini, Enrico/0000-0001-8983-886X	Associazione Italiana per la Ricerca contro il Cancro (AIRC); Fondazione Italo Monzino; Negri-Weizmann Foundation; Ministero della Salute	Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Italo Monzino; Negri-Weizmann Foundation; Ministero della Salute(Ministry of Health, Italy)	The experimental work of our talented PhD student, Roberta Affatato, is acknowledged. We would like to thank Silvio Garattini and Rony Seger (Weizmann Institute, Rehovot, Israel) for the critical reading of the manuscript. Grants from the Associazione Italiana per la Ricerca contro il Cancro (AIRC), the Fondazione Italo Monzino and the Negri-Weizmann Foundation were fundamental for the completion of this work. The work was also partially supported with grants from the Ministero della Salute.	Abramson V, 2011, CLIN CANCER RES, V17, P952, DOI 10.1158/1078-0432.CCR-09-1947; Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Aryee MJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-409; Balmer JE, 2005, J STEROID BIOCHEM, V96, P347, DOI 10.1016/j.jsbmb.2005.05.005; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; Barral PM, 2009, PHARMACOL THERAPEUT, V124, P219, DOI 10.1016/j.pharmthera.2009.06.012; Baselga J, 2006, SCIENCE, V312, P1175, DOI 10.1126/science.1125951; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Colombo V, 2011, CANCER CHEMOTH PHARM, V67, P369, DOI 10.1007/s00280-010-1335-8; Danforth DN, 2004, J ENDOCRINOL, V183, P395, DOI 10.1677/joe.1.05497; Decensi A, 2000, J CELL BIOCHEM, P84; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; Dusek RL, 2011, NAT REV CANCER, V11, P317, DOI 10.1038/nrc3051; Esteva FJ, 2010, NAT REV CLIN ONCOL, V7, P98, DOI 10.1038/nrclinonc.2009.216; Fitzgerald P, 1997, CANCER RES, V57, P2642; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Garattini E, 2007, CURR PHARM DESIGN, V13, P1375, DOI 10.2174/138161207780618786; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; GIANNI M, 1993, BIOCHEM BIOPH RES CO, V196, P252, DOI 10.1006/bbrc.1993.2242; Gianni M, 1996, BIOCHEM BIOPH RES CO, V224, P50, DOI 10.1006/bbrc.1996.0983; Gianni M, 2009, CANCER RES, V69, P1016, DOI 10.1158/0008-5472.CAN-08-2603; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Huang SL, 2000, MOL CELL ENDOCRINOL, V159, P15, DOI 10.1016/S0303-7207(99)00207-5; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Koay DC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2625; Lupi M, 2004, CANCER RES, V64, P2825, DOI 10.1158/0008-5472.CAN-03-3810; Mariani G, 2009, NAT CLIN PRACT ONCOL, V6, P93, DOI 10.1038/ncponc1298; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Moreira C, 2010, EXPERT REV ANTICANC, V10, P1171, DOI 10.1586/ERA.10.113; Mucida D, 2007, CELL ADHES MIGR, V1, P142, DOI 10.4161/cam.1.3.5062; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Ou CC, 2008, CARCINOGENESIS, V29, P299, DOI 10.1093/carcin/bgm263; Paik J, 2003, CANCER INVEST, V21, P304, DOI 10.1081/CNV-120016425; Paroni G, 2011, METHODS MOL BIOL, V740, P65, DOI 10.1007/978-1-61779-108-6_9; Puntoni Matteo, 2009, Eur J Cancer, V45 Suppl 1, P346, DOI 10.1016/S0959-8049(09)70049-8; ROMAN SD, 1993, CANCER RES, V53, P5940; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; Shyu RY, 2005, ANTICANCER RES, V25, P2453; Srinivas H, 2006, BIOCHEM J, V395, P653, DOI 10.1042/BJ20051794; Sturniolo MT, 2003, J BIOL CHEM, V278, P48066, DOI 10.1074/jbc.M307215200; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Tan AR, 2009, BREAST CANCER RES TR, V115, P453, DOI 10.1007/s10549-008-0184-1; Terao M, 2011, J BIOL CHEM, V286, P4027, DOI 10.1074/jbc.M110.184994; Tsai FM, 2007, CELL SIGNAL, V19, P989, DOI 10.1016/j.cellsig.2006.11.005; Tsai FM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-15; Wang Y, 2007, EXP CELL RES, V313, P357, DOI 10.1016/j.yexcr.2006.10.016; Xiao S, 2008, J IMMUNOL, V181, P2277, DOI 10.4049/jimmunol.181.4.2277; Yang J, 2008, ONCOGENE, V27, P5326, DOI 10.1038/onc.2008.165; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yang QF, 2002, BREAST CANCER RES TR, V76, P167, DOI 10.1023/A:1020576606004; Zujewski J, 2001, BREAST CANCER RES, V3, P66, DOI 10.1186/bcr273	56	40	46	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	29					3431	3443		10.1038/onc.2011.506	http://dx.doi.org/10.1038/onc.2011.506			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22056878				2022-12-28	WOS:000306566400004
J	Kelly, KR; Espitia, CM; Mahalingam, D; Oyajobi, BO; Coffey, M; Giles, FJ; Carew, JS; Nawrocki, ST				Kelly, K. R.; Espitia, C. M.; Mahalingam, D.; Oyajobi, B. O.; Coffey, M.; Giles, F. J.; Carew, J. S.; Nawrocki, S. T.			Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma	ONCOGENE			English	Article						bortezomib; NOXA; ER stress; Reolysin; reovirus	PROTEASOME INHIBITOR BORTEZOMIB; PANCREATIC-CANCER CELLS; ONCOLYTIC VIRUS THERAPY; ER STRESS; MELANOMA-CELLS; VIRAL THERAPY; IFN-BETA; IN-VITRO; KAPPA-B; PHASE-I	Oncolytic virotherapy with reovirus has demonstrated anti-cancer activity and minimal toxicity in clinical trials, but the mechanisms underlying these effects have not been fully elucidated. Reolysin, a proprietary formulation of reovirus for cancer therapy, stimulated selective viral replication and apoptosis in multiple myeloma (MM) cells. Reolysin-mediated apoptosis was associated with an induction of endoplasmic reticular (ER) stress-related gene expression, swelling of the endoplasmic reticulum, increases in intracellular calcium levels and a strong induction of the Bcl-2 homology 3 (BH3)-only pro-apoptotic protein NOXA. Knockdown of NOXA expression by short hairpin RNA significantly reduced the pro-apoptotic effects of Reolysin. We next showed that co-administration of Reolysin and bortezomib resulted in the dual accumulation of viral and ubiquitinated proteins, which led to enhanced ER stress, NOXA induction and apoptosis. Importantly, the combination of reovirus infection and proteasomal inhibition significantly decreased tumor burden in a xenograft and syngeneic bone disease model of MM without exhibiting adverse side effects. Our study establishes ER stress stimulation and NOXA induction as novel mediators of reovirus-induced apoptosis. Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells. Oncogene (2012) 31, 3023-3038; doi: 10.1038/onc.2011.478; published online 17 October 2011	[Kelly, K. R.; Espitia, C. M.; Mahalingam, D.; Giles, F. J.; Carew, J. S.; Nawrocki, S. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, Dept Med, San Antonio, TX 78229 USA; [Oyajobi, B. O.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; [Coffey, M.] Oncolyt Biotech Inc, Calgary, AB, Canada	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Oncolytics Biotech	Nawrocki, ST (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, Dept Med, 7979 Wurzbach Rd, San Antonio, TX 78229 USA.	Nawrocki@uthscsa.edu		Oyajobi, Babatunde/0000-0002-1064-3072	Leukemia and Lymphoma Society of America [6319-11]; International Myeloma Foundation; William and Ella Owens Foundation; National Cancer Institute P30 Cancer Center Support Grant [CA054174]; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); International Myeloma Foundation; William and Ella Owens Foundation; National Cancer Institute P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Leukemia and Lymphoma Society of America (6319-11), The International Myeloma Foundation, The William and Ella Owens Foundation and the National Cancer Institute P30 Cancer Center Support Grant # CA054174.	Alain T, 2007, MOL THER, V15, P1512, DOI 10.1038/sj.mt.6300207; Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x; Carew JS, 2006, BLOOD, V107, P222, DOI 10.1182/blood-2005-05-1923; Clarke P, 2004, J VIROL, V78, P13132, DOI 10.1128/JVI.78.23.13132-13138.2004; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706; Etoh T, 2003, CLIN CANCER RES, V9, P1218; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403; Fribley AM, 2006, J BIOL CHEM, V281, P31440, DOI 10.1074/jbc.M604356200; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Hamamdzic D, 2001, AM J PHYSIOL-LUNG C, V280, pL18, DOI 10.1152/ajplung.2001.280.1.L18; Harrington KJ, 2010, CYTOKINE GROWTH F R, V21, P91, DOI 10.1016/j.cytogfr.2010.02.006; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Holm GH, 2007, J BIOL CHEM, V282, P21953, DOI 10.1074/jbc.M702112200; Homicsko K, 2005, CANCER RES, V65, P6882, DOI 10.1158/0008-5472.CAN-05-0309; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kelly K, 2009, EXPERT OPIN BIOL TH, V9, P817, DOI 10.1517/14712590903002039; Kottke T, 2010, J CLIN INVEST, V120, P1551, DOI 10.1172/JCI41431; Kumar SK, 2004, MAYO CLIN PROC, V79, P867, DOI 10.4065/79.7.867; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Libertini S, 2008, CLIN CANCER RES, V14, P6505, DOI 10.1158/1078-0432.CCR-08-0200; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nawrocki ST, 2002, MOL CANCER THER, V1, P1243; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nawrocki ST, 2008, BLOOD, V112, P2917, DOI 10.1182/blood-2007-12-130823; Nencioni A, 2006, BLOOD, V108, P551, DOI 10.1182/blood-2005-08-3494; Neubert K, 2008, NAT MED, V14, P748, DOI 10.1038/nm1763; Oyajobi BO, 2007, MOL CANCER THER, V6, P1701, DOI 10.1158/1535-7163.MCT-07-0121; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Qiao J, 2008, CLIN CANCER RES, V14, P259, DOI 10.1158/1078-0432.CCR-07-1510; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rhim JH, 2007, J NATL CANCER I, V99, P1739, DOI 10.1093/jnci/djm234; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Rudd P, 2005, J GEN VIROL, V86, P1489, DOI 10.1099/vir.0.80628-0; Sei S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-47; Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676; SIDKY YA, 1987, CANCER RES, V47, P5155; Smakman N, 2006, CANCER GENE THER, V13, P815, DOI 10.1038/sj.cgt.7700949; Steele L, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-20; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Sun K, 2004, P NATL ACAD SCI USA, V101, P8120, DOI 10.1073/pnas.0401563101; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Taylor KL, 2008, J INTERF CYTOK RES, V28, P733, DOI 10.1089/jir.2008.0030; Thirukkumaran Chandini, 2009, V542, P607, DOI 10.1007/978-1-59745-561-9_31; Thirukkumaran CM, 2003, BLOOD, V102, P377, DOI 10.1182/blood-2002-08-2508; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; van Houdt WJ, 2008, CANCER GENE THER, V15, P284, DOI 10.1038/cgt.2008.2; Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524; Wang Q, 2009, P NATL ACAD SCI USA, V106, P2200, DOI 10.1073/pnas.0807611106; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	59	54	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3023	3038		10.1038/onc.2011.478	http://dx.doi.org/10.1038/onc.2011.478			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002308				2022-12-28	WOS:000305705900002
J	Sugihara, E; Shimizu, T; Kojima, K; Onishi, N; Kai, K; Ishizawa, J; Nagata, K; Hashimoto, N; Honda, H; Kanno, M; Miwa, M; Okada, S; Andreeff, M; Saya, H				Sugihara, E.; Shimizu, T.; Kojima, K.; Onishi, N.; Kai, K.; Ishizawa, J.; Nagata, K.; Hashimoto, N.; Honda, H.; Kanno, M.; Miwa, M.; Okada, S.; Andreeff, M.; Saya, H.			Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor	ONCOGENE			English	Article						Myc; cell of origin; Ink4a; Arf; pre-B ALL/LBL; Mdm2 inhibitor	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; C-MYC; STEM-CELL; SELF-RENEWAL; APOPTOSIS; P53; OVEREXPRESSION; SUPPRESSION; MDM2	The cell of origin of tumors and the factors determining the cell of origin remain unclear. In this study, a mouse model of precursor B acute lymphoblastic leukemia/lymphoma (pre-B ALL/LBL) was established by retroviral transduction of Myc genes (N-Myc or c-Myc) into mouse bone marrow cells. Hematopoietic stem cells (HSCs) exhibited the highest susceptibility to N-Myc-induced pre-B ALL/LBL versus lymphoid progenitors, myeloid progenitors and committed progenitor B cells. N-Myc was able to induce pre-B ALL/LBL directly from progenitor B cells in the absence of Ink4a and Arf. Arf was expressed higher in progenitor B cells than Ink4a. In addition, N-Myc induced pre-B ALL/LBL from Arf(-/-) progenitor B cells suggesting that Arf has a predominant role in determining the cell of origin of pre-B ALL/LBL. Tumor cells derived from Ink4a/Arf(-/-) progenitor B cells exhibited a higher rate of proliferation and were more chemoresistant than those derived from wild-type HSCs. Furthermore, the Mdm2 inhibitor Nutlin-3 restored p53 and induced massive apoptosis in mouse pre-B ALL/LBL cells derived from Ink4a/Arf(-/-) cells and human B-ALL cell lines lacking Ink4a and Arf expression, suggesting that Mdm2 inhibition may be a novel therapeutic approach to the treatment of Ink4a/Arf(-/-) B-ALL/LBL, such as is frequently found in Ph+ ALL and relapsed ALL. Collectively, these findings indicate that Ink4a and Arf are critical determining factors of the cell of origin and the therapeutic sensitivity of Myc-induced lymphoid tumors. Oncogene (2012) 31, 2849-2861; doi:10.1038/onc.2011.462; published online 10 October 2011	[Saya, H.] Keio Univ, Div Gene Regulat, Inst Adv Med Res, Sch Med,Shinjuku Ku, Tokyo 1608582, Japan; [Sugihara, E.; Shimizu, T.; Saya, H.] CREST, Japan Sci & Technol Agcy, Tokyo, Japan; [Kojima, K.; Andreeff, M.] Univ Texas Houston, MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA; [Nagata, K.] Kyowa Hakko Kirin Co Ltd, Drug Discovery Res Labs, Shizuoka, Japan; [Honda, H.] Hiroshima Univ, Dept Dis Model, Res Inst Radiat Biol & Med, Hiroshima, Japan; [Kanno, M.] Hiroshima Univ, Dept Immunol, Grad Sch Biosci, Hiroshima, Japan; [Miwa, M.] Nagahama Inst Bio Sci & Technol, Shiga, Japan; [Okada, S.] Kumamoto Univ, Div Hemopoiesis, Ctr AIDS Res, Kumamoto, Japan	Keio University; Japan Science & Technology Agency (JST); University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Kyowa Kirin Ltd; Hiroshima University; Hiroshima University; Kumamoto University	Saya, H (corresponding author), Keio Univ, Div Gene Regulat, Inst Adv Med Res, Sch Med,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Saya, Hideyuki/J-4325-2013; Sugihara, Eiji/J-8058-2013; Okada, Seiji/F-5785-2013; ONISHI, Nobuyuki/L-6296-2013; Hashimoto, Norisato/J-5922-2013	Sugihara, Eiji/0000-0002-3233-1045; Kanno, masamoto/0000-0001-9169-3444; Saya, Hideyuki/0000-0001-6610-1902	NIH; Hoffmann-La Roche, Nutley, NJ; Ministry of Education, Culture, Sports, Science and Technology of Japan; US National Institutes of Health [CA55164, CA136411, CA100632]; Grants-in-Aid for Scientific Research [23616003] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA136411, P50CA100632, P01CA055164] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hoffmann-La Roche, Nutley, NJ; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Andreeff's work is supported by grants from the NIH and by Hoffmann-La Roche, Nutley, NJ.; We thank I Ishimatsu, Y Hata and S Suzuki for technical assistance, K Arai for help in the preparation of the manuscript, CJ Sherr (St Jude Children's Research Hospital) for providing Arf<SUP>-/-</SUP> mice, Dr A Kenny (Memorial Sloan-Kettering Cancer Center) for providing the N-Myc cDNA, Dr T Kitamura (The University of Tokyo) for providing the retroviral vector pMXs-IG and Plat-E cells and Dr A Iwama (Chiba University) for providing the Bmi1 cDNA. This work was supported by grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (HS) and the US National Institutes of Health CA55164, CA136411 and CA100632 (MA).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Ausserlechner MJ, 2001, J BIOL CHEM, V276, P10984, DOI 10.1074/jbc.M008188200; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Cano F, 2008, MOL CANCER THER, V7, P730, DOI 10.1158/1535-7163.MCT-07-2032; Cardone M, 2005, MOL CELL BIOL, V25, P2395, DOI 10.1128/MCB.25.6.2395-2405.2005; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cobaleda C, 2009, BIOESSAYS, V31, P600, DOI 10.1002/bies.200800234; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Gu L, 2008, LEUKEMIA, V22, P730, DOI 10.1038/leu.2008.11; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawagoe H, 2007, CANCER RES, V67, P10677, DOI 10.1158/0008-5472.CAN-07-1118; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Kojima K, 2006, BLOOD, V108, P993, DOI 10.1182/blood-2005-12-5148; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Luo H, 2005, BLOOD, V106, P2452, DOI 10.1182/blood-2005-02-0734; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Mullighan CG, 2008, GENE DEV, V22, P1411, DOI 10.1101/gad.1673908; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Sugihara E, 2006, CANCER RES, V66, P4020, DOI 10.1158/0008-5472.CAN-05-3250; Tsuji K, 2002, BIOCHEM BIOPH RES CO, V295, P621, DOI 10.1016/S0006-291X(02)00723-4; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang PY, 2008, BLOOD, V112, P4184, DOI 10.1182/blood-2008-02-142190; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Yasuda T, 2008, IMMUNITY, V28, P499, DOI 10.1016/j.immuni.2008.02.015	40	22	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	23					2849	2861		10.1038/onc.2011.462	http://dx.doi.org/10.1038/onc.2011.462			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21986948	Bronze, Green Accepted			2022-12-28	WOS:000305277900005
J	Berardi, S; Caivano, A; Ria, R; Nico, B; Savino, R; Terracciano, R; De Tullio, G; Ferrucci, A; De Luisi, A; Moschetta, M; Mangialardi, G; Catacchio, I; Basile, A; Guarini, A; Zito, A; Ditonno, P; Musto, P; Dammacco, F; Ribatti, D; Vacca, A				Berardi, S.; Caivano, A.; Ria, R.; Nico, B.; Savino, R.; Terracciano, R.; De Tullio, G.; Ferrucci, A.; De Luisi, A.; Moschetta, M.; Mangialardi, G.; Catacchio, I.; Basile, A.; Guarini, A.; Zito, A.; Ditonno, P.; Musto, P.; Dammacco, F.; Ribatti, D.; Vacca, A.			Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets	ONCOGENE			English	Article						angiogenesis; antiangiogenesis; endothelial cells; multiple myeloma; proteomic analysis	ALPHA-B-CRYSTALLIN; BONE-MARROW; LUNG-CANCER; VIMENTIN; ADHESION; FILAMIN; ANGIOGENESIS; NUCLEAR; MICROENVIRONMENT; LOCALIZATION	Bone marrow (BM) angiogenesis has an important role in the initiation and progression of multiple myeloma (MM). We looked at novel mechanisms of vessel formation in patients with MM through a comparative proteomic analysis between BM endothelial cells (ECs) of patients with active MM (MMECs) and ECs of patients with monoclonal gammopathy of undetermined significance (MGECs) and of subjects with benign anemia (normal ECs). Four proteins were found overexpressed in MMECs: filamin A, vimentin, alpha-crystallin B and 14-3-3 zeta/delta protein, not yet linked to overangiogenic phenotype. These proteins gave a typical distribution in the BM of MM patients and in MMECs versus MGECs, plausibly according to a different functional state. Their expression was enhanced by vascular endothelial growth factor, fibroblast growth factor 2, hepatocyte growth factor and MM plasma cell conditioned medium in step with enhancement of MMEC angiogenesis. Their silencing RNA knockdown affected critical MMEC angiogenesis-related functions, such as spreading, migration and tubular morphogenesis. A gradual stabilization of 14-33 zeta/delta protein was observed, with transition from normal ECs to MGECs and MMECs that may be a critical step for the angiogenic switch in MMECs and maintenance of the cell overangiogenic phenotype. These proteins were substantially impacted by anti-MM drugs, such as bortezomib, lenalidomide and panobinostat. Results suggest that these four proteins could be new targets for the antiangiogenic management of MM patients. Oncogene (2012) 31, 2258-2269; doi:10.1038/onc.2011.412; published online 3 October 2011	[Berardi, S.; Ria, R.; De Tullio, G.; Ferrucci, A.; De Luisi, A.; Moschetta, M.; Catacchio, I.; Basile, A.; Dammacco, F.; Vacca, A.] Univ Bari, Dept Biomed Sci & Human Oncol, Sch Med, I-70124 Bari, Italy; [Caivano, A.] IRCCS Referral Basilicata Canc Ctr, Dept Oncohematol, Mol Oncol Unit, Potenza, Italy; [Nico, B.; Ribatti, D.] Univ Bari, Dept Human Anat Histol & Embryol, Sch Med, I-70124 Bari, Italy; [Savino, R.; Terracciano, R.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Mangialardi, G.] Univ Bristol, Bristol Heart Inst, Dept Expt Cardiovasc Med, Bristol, Avon, England; [Guarini, A.] Natl Canc Inst Giovanni Paolo II, Hematol Unit, Bari, Italy; [Zito, A.] Di Venere Hosp, Pathol Unit, Bari, Italy; [Ditonno, P.] De Venere Hosp, Hematol Unit, Bari, Italy; [Musto, P.] IRCCS Referral Basilicata Canc Ctr, Unit Hematol & Stem Cell Transplantat, Potenza, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Magna Graecia University of Catanzaro; University of Bristol; IRCCS Istituto Tumori Bari Giovanni Paolo II	Vacca, A (corresponding author), Univ Bari, Dept Internal Med & Clin Oncol, Sch Med, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	a.vacca@dimo.uniba.it	Terracciano, Rosa/AAO-8649-2020; Vacca, Angelo/AAC-9558-2022; Zito, Francesco/AAQ-8972-2020; CAIVANO, ANTONELLA/J-8120-2018; DITONNO, PAOLO/AAG-5684-2020; Dammacco, Franco/ABG-5728-2020; Guarini, Attilio/AAK-3156-2020; Ria, Roberto/I-4263-2015	Vacca, Angelo/0000-0002-4567-8216; Zito, Francesco/0000-0003-4140-4020; Dammacco, Franco/0000-0003-2149-5471; Guarini, Attilio/0000-0002-9304-6651; Musto, Pellegrino/0000-0003-3277-6594; Savino, Rocco/0000-0002-4046-1472; Ria, Roberto/0000-0002-1515-0090; CAIVANO, ANTONELLA/0000-0003-2502-4060; Terracciano, Rosa/0000-0002-5175-1758	Associazione Italiana per la Ricerca sul Cancro; Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille, Milan [9965]; Ministry of Health, Progetto Oncologia, Humanitas Mirasole S.p.A., Rome, Italy	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille, Milan; Ministry of Health, Progetto Oncologia, Humanitas Mirasole S.p.A., Rome, Italy	This work was supported by Associazione Italiana per la Ricerca sul Cancro, Investigator Grant and Special Program Molecular Clinical Oncology 5 per mille n. 9965, Milan, and the Ministry of Health, Progetto Oncologia 2006, Humanitas Mirasole S.p.A., Rome, Italy. The sponsors of this study are public or non-profit organizations that support science in general. They had no role in gathering, analyzing or interpreting the data. The authors are fully responsible for the content and editorial decisions for this manuscript. We thank Dr Maurilio Ponzoni, San Raffaele Institute, Milan, Italy, for collaboration on the mouse model.	Aird WC, 2007, CIRC RES, V100, P174, DOI 10.1161/01.RES.0000255690.03436.ae; Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Andley UP, 2007, PROG RETIN EYE RES, V26, P78, DOI 10.1016/j.preteyeres.2006.10.003; Arrigo AP, 2007, FEBS LETT, V581, P3665, DOI 10.1016/j.febslet.2007.04.033; Bedolla RG, 2009, CLIN CANCER RES, V15, P788, DOI 10.1158/1078-0432.CCR-08-1402; Chan W, 2002, EUR J CELL BIOL, V81, P692, DOI 10.1078/0171-9335-00281; Coluccia AML, 2008, BLOOD, V112, P1346, DOI 10.1182/blood-2007-10-116590; De Luisi A, 2011, CLIN CANCER RES, V17, P1935, DOI 10.1158/1078-0432.CCR-10-2381; Dimberg A, 2008, BLOOD, V111, P2015, DOI 10.1182/blood-2007-04-087841; Dutsch-Wicherek M, 2010, AM J REPROD IMMUNOL, V63, P181, DOI 10.1111/j.1600-0897.2009.00803.x; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Feng YY, 2006, P NATL ACAD SCI USA, V103, P19836, DOI 10.1073/pnas.0609628104; Ge F, 2009, J PROTEOME RES, V8, P3006, DOI 10.1021/pr9001004; Gilles C, 1999, J CELL SCI, V112, P4615; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Gruvberger Saal SK, 2006, J CLIN INVEST, V116, P30; Head MW, 2000, NEUROREPORT, V11, P361, DOI 10.1097/00001756-200002070-00028; Hellebrekers DMEI, 2006, CANCER RES, V66, P10770, DOI 10.1158/0008-5472.CAN-06-1609; Hishiya A, 2008, ONCOGENE, V27, P6489, DOI 10.1038/onc.2008.314; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095; Kim H, 2010, AM J PHYSIOL-CELL PH, V298, pC221, DOI 10.1152/ajpcell.00323.2009; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Lee JW, 2008, EUR J CELL BIOL, V87, P377, DOI 10.1016/j.ejcb.2008.03.006; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu CH, 2010, J PROTEOM BIOINFORM, V3, P5; Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008-5472.CAN-05-4186; Matrone MA, 2010, CANCER RES, V70, P7737, DOI 10.1158/0008-5472.CAN-10-1569; Meriane M, 2000, J BIOL CHEM, V275, P33046, DOI 10.1074/jbc.M001566200; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Obermeyer N, 2003, ENDOTHELIUM-J ENDOTH, V10, P167, DOI 10.1080/713715224; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Popowicz GM, 2006, TRENDS BIOCHEM SCI, V31, P411, DOI 10.1016/j.tibs.2006.05.006; Ria R, 2009, CLIN CANCER RES, V15, P5369, DOI 10.1158/1078-0432.CCR-09-0040; Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468; Sluchanko NN, 2008, ARCH BIOCHEM BIOPHYS, V477, P305, DOI 10.1016/j.abb.2008.05.020; Tsuruta D, 2003, J CELL SCI, V116, P4977, DOI 10.1242/jcs.00823; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; van den IJssel P, 2003, EXP CELL RES, V287, P249, DOI 10.1016/S0014-4827(03)00092-2; van Rijk AF, 2003, EUR J CELL BIOL, V82, P361, DOI 10.1078/0171-9335-00321; Wang ZH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-308; Zhou AX, 2010, TRENDS CELL BIOL, V20, P113, DOI 10.1016/j.tcb.2009.12.001	49	22	22	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2258	2269		10.1038/onc.2011.412	http://dx.doi.org/10.1038/onc.2011.412			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21963844				2022-12-28	WOS:000303610800002
J	Leung, JY; Andrechek, ER; Cardiff, RD; Nevins, JR				Leung, J. Y.; Andrechek, E. R.; Cardiff, R. D.; Nevins, J. R.			Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence	ONCOGENE			English	Article						mouse; mammary; EMT; MYC; cancer	EPITHELIAL-MESENCHYMAL TRANSITIONS; HUMAN BREAST; GENOME; IDENTIFICATION; TUMORIGENESIS; INACTIVATION; CANCERS; MODELS; CELLS; EMT	A hallmark of human cancer is heterogeneity, reflecting the complex series of changes resulting in the activation of oncogenes coupled with inactivation of tumor suppressor genes. Breast cancer is no exception and indeed, many studies have revealed considerable complexity and heterogeneity in the population of primary breast tumors and substantial changes in a recurrent breast tumor that has acquired metastatic properties and drug resistance. We have made use of a Myc-inducible transgenic mouse model of breast cancer in which elimination of Myc activity following tumor development initially leads to a regression of a subset of tumors generally followed by de novo Myc-independent growth. We have observed that tumors that grow independent of Myc expression have gene profiles that are distinct from the primary tumors with characteristics indicative of an epithelial-mesenchymal transition (EMT) phenotype. Phenotypic analyses of Myc-independent tumors confirm the acquisition of an EMT phenotype suggested to be associated with invasive and migratory properties in human cancer cells. Further genomic analyses reveal mouse mammary tumors growing independent of myc have a higher probability of exhibiting a gene signature similar to that observed for human 'tumor-initiating' cells. Collectively, the data reveal genetic alterations that underlie tumor progression and an escape from Myc-dependent growth in a transgenic mouse model that can provide insights to what occurs in human cancers as they acquire drug resistance and metastatic properties. Oncogene (2012) 31, 2545-2554; doi:10.1038/onc.2011.433; published online 26 September 2011	[Leung, J. Y.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA; [Andrechek, E. R.] Michigan State Univ, Dept Biomed & Integrat Physiol, E Lansing, MI 48824 USA; [Cardiff, R. D.] Univ Calif Davis, Dept Pathol & Lab Med, Ctr Comparat Med, Davis, CA 95616 USA; [Nevins, J. R.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University; Michigan State University; University of California System; University of California Davis; Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Inst Genome Sci & Policy, 101 Sci Dr,Box 3382, Durham, NC 27710 USA.	j.nevins@duke.edu		Andrechek, Eran/0000-0002-8680-3423	NIH [CA104663, CA112952]; National Cancer Institute's Mouse Models of Human Cancers Consortium [U01 CA141541, U01 CA141582]; JRN from the National Cancer Institute [RO1-CA104663, U54-CA112952]; NATIONAL CANCER INSTITUTE [U54CA112952, U01CA141582, R01CA104663, U01CA141541, R01CA106520] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute's Mouse Models of Human Cancers Consortium; JRN from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The MTB/TOM mouse was a kind gift from Lewis A Chodosh. We thank Kenichiro Fujiwara for his assistance in animal husbandry and Rachel E Rempel for her helpful advice. We are grateful to Kaye Culler for her assistance with the manuscript. This work was supported by grants from the NIH (CA104663, CA112952) and grants U01 CA141541 and U01 CA141582 from the National Cancer Institute's Mouse Models of Human Cancers Consortium (RDC). We also thank Ms Katie Bell and Judith Walls of the CCM MMPL for their excellent immunohistochemistry. This work was also supported by grants from the JRN (RO1-CA104663 and U54-CA112952) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Damonte P, 2007, LAB INVEST, V87, P1218, DOI 10.1038/labinvest.3700683; Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Iseri OD, 2011, BIOMED PHARMACOTHER, V65, P40, DOI 10.1016/j.biopha.2010.10.004; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Lucas J, 2009, STAT APPL GENET MOL, V8, DOI 10.2202/1544-6115.1436; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nicolini A, 2011, CURR PHARM BIOTECHNO, V12, P196, DOI 10.2174/138920111794295657; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Radaelli E, 2009, FUTURE ONCOL, V5, P1113, DOI [10.2217/fon.09.93, 10.2217/FON.09.93]; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358	31	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2545	2554		10.1038/onc.2011.433	http://dx.doi.org/10.1038/onc.2011.433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996730	Green Accepted			2022-12-28	WOS:000304191800005
J	Darlington, Y; Nguyen, TA; Moon, SH; Herron, A; Rao, P; Zhu, C; Lu, X; Donehower, LA				Darlington, Y.; Nguyen, T-A; Moon, S-H; Herron, A.; Rao, P.; Zhu, C.; Lu, X.; Donehower, L. A.			Absence of Wip1 partially rescues Atm deficiency phenotypes in mice	ONCOGENE			English	Article						WIP1; PPM1D; ATM; ataxia telangiectasia; p53; thymic lymphoma	DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; PHOSPHATASE; PPM1D; CELLS; P53; IDENTIFICATION; TUMORIGENESIS	Wild-type p53-induced phosphatase 1 (WIP1) is a serine/threonine phosphatase that dephosphorylates proteins in the ataxia telangiectasia mutated (ATM)-initiated DNA damage response pathway. WIP1 may have a homeostatic role in ATM signaling by returning the cell to a normal pre-stress state following completion of DNA repair. To better understand the effects of WIP1 on ATM signaling, we crossed Atm-deficient mice to Wip1-deficient mice and characterized phenotypes of the double knockout progeny. We hypothesized that the absence of Wip1 might rescue Atm deficiency phenotypes. Atm null mice, like ATM-deficient humans with the inherited syndrome ataxia telangiectasia, exhibit radiation sensitivity, fertility defects, and are T-cell lymphoma prone. Most double knockout mice were largely protected from lymphoma development and had a greatly extended lifespan compared with Atm null mice. Double knockout mice had increased p53 and H2AX phosphorylation and p21 expression compared with their Atm null counterparts, indicating enhanced p53 and DNA damage responses. Additionally, double knockout splenocytes displayed reduced chromosomal instability compared with Atm null mice. Finally, doubly null mice were partially rescued from gametogenesis defects observed in Atm null mice. These results indicate that inhibition of WIP1 may represent a useful strategy for cancer treatment in general and A-T patients in particular. Oncogene (2012) 31, 1155-1165; doi:10.1038/onc.2011.303; published online 18 July 2011	[Darlington, Y.; Nguyen, T-A; Moon, S-H; Donehower, L. A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Darlington, Y.; Nguyen, T-A; Donehower, L. A.] Interdept Grad Program Cell & Mol Biol, Houston, TX USA; [Moon, S-H; Donehower, L. A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Herron, A.] Dept Pathol & Immunol, Houston, TX USA; [Herron, A.] Ctr Comparat Med, Houston, TX USA; [Rao, P.; Donehower, L. A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Zhu, C.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Lu, X.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	larryd@bcm.tmc.edu	Nguyen, Thuy-Ai/Q-4082-2019	Nguyen, Thuy-Ai/0000-0001-8778-0078	NIH [R01 CA100420, R01 CA136549]; DOD [BC050781]; NATIONAL CANCER INSTITUTE [R01CA100420, R01CA136549] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Corrine Spencer and Yi- Jue Zhao for technical assistance. This work was supported by NIH grants (R01 CA100420) to LAD and (R01 CA136549) to XL, and a DOD Breast Cancer Research Program Predoctoral Traineeship Award (BC050781) to T-AN	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Demidov ON, 2007, CELL STEM CELL, V1, P180, DOI 10.1016/j.stem.2007.05.020; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gurley KE, 2001, CURR BIOL, V11, P191, DOI 10.1016/S0960-9822(01)00048-3; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lu XB, 2005, CELL CYCLE, V4, P1060; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Moretti P, 2005, HUM MOL GENET, V14, P205, DOI 10.1093/hmg/ddi016; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Rao PH, 1998, BLOOD, V92, P1743; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shen KC, 2005, CANCER RES, V65, P8747, DOI 10.1158/0008-5472.CAN-05-1471; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Xia Y, 2009, J BIOL CHEM, V284, P17428, DOI 10.1074/jbc.M109.007823; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Yoda A, 2008, J BIOL CHEM, V283, P18969, DOI 10.1074/jbc.M800560200	54	10	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1155	1165		10.1038/onc.2011.303	http://dx.doi.org/10.1038/onc.2011.303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765465	Green Accepted			2022-12-28	WOS:000300945900008
J	Jennewein, C; Karl, S; Baumann, B; Micheau, O; Debatin, KM; Fulda, S				Jennewein, C.; Karl, S.; Baumann, B.; Micheau, O.; Debatin, K-M; Fulda, S.			Identification of a novel pro-apoptotic role of NF-kappa B in the regulation of TRAIL- and CD95-mediated apoptosis of glioblastoma cells	ONCOGENE			English	Article						TRAIL; apoptosis; NF-kappa B; glioblastoma; CD95	CANCER-THERAPY; INDUCTION; SENSITIZATION; CONTRIBUTES; EXPRESSION	We recently reported that nuclear factor-kappa B (NF-kappa B) promotes DNA damage-triggered apoptosis in glioblastoma, the most common brain tumor. In the present study, we investigated the role of NF-kappa B in death receptor-mediated apoptosis. Here, we identify a novel pro-apopotic function of NF-kappa B in TRAIL- and CD95-induced apoptosis. Inhibition of NF-kappa B by overexpression of the dominant-negative I kappa B alpha-superrepressor (I kappa B alpha-SR) significantly decreases tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)- or CD95-induced apoptosis. Vice versa, activation of NF-kappa B via overexpression of constitutively active I kappa B kinase complex (IKK)beta (IKK-EE) significantly increases TRAIL-mediated apoptosis. Intriguingly, NF-kappa B inhibition reduces the recruitment of Fas-associated death domain and caspase-8 and formation of the death-inducing signaling complex (DISC) upon stimulation of TRAIL receptors or CD95. This results in reduced TRAIL-mediated activation of caspases, loss of mitochondrial potential and cytochrome c release in I kappa B alpha-SR-expressing cells. In comparison, NF-kappa B inhibition strongly enhances TNF-alpha-mediated apoptosis. Comparative studies revealed that TNF-alpha rapidly stimulates transcriptional activation and upregulation of anti-apoptotic proteins, whereas TRAIL causes apoptosis before transcriptional activation. Thus, this study demonstrates for the first time that NF-kappa B exerts a pro-apoptotic role in TRAIL- and CD95-induced apoptosis in glioblastoma cells by facilitating DISC formation. Oncogene (2012) 31, 1468-1474; doi:10.1038/onc.2011.333; published online 8 August 2011	[Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Hesse, Germany; [Jennewein, C.; Karl, S.; Debatin, K-M; Fulda, S.] Univ Childrens Hosp, Ulm, Germany; [Baumann, B.] Univ Ulm, Inst Physiol Chem, Ulm, Germany; [Micheau, O.] INSERM, U866, Dijon, France	Goethe University Frankfurt; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de	; micheau, olivier/C-3574-2011; Debatin, Klaus-Michael/J-9704-2014	Fulda, Simone/0000-0002-0459-6417; micheau, olivier/0000-0001-8499-7984; Debatin, Klaus-Michael/0000-0002-8397-1886	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); International Graduate School of Molecular Medicine Ulm University;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); International Graduate School of Molecular Medicine Ulm University; 	We thank R Marienfeld (Ulm, Germany) for providing NEMO knockout mouse embryonic fibroblasts. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF), and by a scholarship of the International Graduate School of Molecular Medicine Ulm University (to CJ).	Ammann JU, 2009, INT J CANCER, V124, P1301, DOI 10.1002/ijc.24068; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Farhana L, 2005, CANCER RES, V65, P4909, DOI 10.1158/0008-5472.CAN-04-4124; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Kang S, 2010, BIOCHEM BIOPH RES CO, V396, P731, DOI 10.1016/j.bbrc.2010.05.004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kohlhaas SL, 2007, J BIOL CHEM, V282, P12831, DOI 10.1074/jbc.M700438200; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Mattson MP, 2005, NEUROCHEM RES, V30, P883, DOI 10.1007/s11064-005-6961-x; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004; Plantivaux A, 2009, ANN NY ACAD SCI, V1171, P38, DOI 10.1111/j.1749-6632.2009.04725.x; Poppelmann B, 2005, J BIOL CHEM, V280, P15635, DOI 10.1074/jbc.M413006200; Radhakrishnan SK, 2006, BBA-REV CANCER, V1766, P53, DOI 10.1016/j.bbcan.2006.02.001; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Shou Y, 2002, J NEUROCHEM, V81, P842, DOI 10.1046/j.1471-4159.2002.00880.x; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Zhao XY, 2011, J NEURO-ONCOL, V102, P367, DOI 10.1007/s11060-010-0346-y	23	46	48	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1468	1474		10.1038/onc.2011.333	http://dx.doi.org/10.1038/onc.2011.333			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822306				2022-12-28	WOS:000301780000013
J	Li, Z; Li, W; Song, L; Zhu, W				Li, Z.; Li, W.; Song, L.; Zhu, W.			Cilia, adenomatous polyposis coli and associated diseases	ONCOGENE			English	Review						cilia; adenomatous polyposis coli; familial adenomatous polyposis; mutation	TUMOR-SUPPRESSOR APC; BETA-CATENIN; SOMATIC MUTATIONS; GENE; PROTEIN; IDENTIFICATION; DROSOPHILA; DELETION; COMPLEX; PHENOTYPE	Cilium is a conservative cell organelle, found in many types of cell surfaces. Cilia are tail-like prominence protruding out of the cell surface, capable of locomotion and acting as the cell's signal transduction sensory organs with their complex structures and ingenious function. Studies have shown that ciliary pathological changes and defects are related to the development of many diseases, including renal cysts, infertility, organ reversal, obesity and so on. The inactivation and mutation of cilia-related proteins can cause tumors, such as neoplasms, intestinal cancer, myeloma, rhabdomyosarcoma and adenocarcinoma. Adenomatous polyposis coli (APC) is a kind of multifunctional protein encoded by the APC gene that participates in many vital activities of organisms. The mutation of APC can lead to familial adenomatous polyposis, and also has a role in the development of human tumors, such as gastric cancer, esophageal cancer and breast carcinoma. Recent studies indicate that the abnormal mutation of APC may lead to some diseases caused by abnormal growth of cilia. Herein, the development of studies on cilia, APC and associated diseases are summarized in brief. Oncogene (2012) 31, 1475-1483; doi:10.1038/onc.2011.351; published online 22 August 2011	[Li, Z.; Li, W.; Song, L.; Zhu, W.] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Educ Minist, Taiyuan 030006, Shanxi, Peoples R China	Shanxi University	Li, Z (corresponding author), Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Educ Minist, 92 Wucheng, Taiyuan 030006, Shanxi, Peoples R China.	lzy@sxu.edu.cn			National Natural Science Foundation of China [31040018]; Shanxi scholarship council of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanxi scholarship council of China	This project was supported by grants of National Natural Science Foundation of China (No. 31040018), and the research project was supported by Shanxi scholarship council of China (2010-2012). We wish to thank Dr Enmin Zou of the Department of Biological Sciences of Nicolls State University, USA, for improving the readability of the manuscript.	AFZELIUS BA, 1985, CRC CR REV BIOCH MOL, V19, P63, DOI 10.3109/10409238509086788; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Banizs B, 2005, DEVELOPMENT, V132, P5329, DOI 10.1242/dev.02153; Benzing T, 2007, J AM SOC NEPHROL, V18, P1389, DOI 10.1681/ASN.2006121355; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Bertario L, 2003, J CLIN ONCOL, V21, P1698, DOI 10.1200/JCO.2003.09.118; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bisgrove BW, 2006, DEVELOPMENT, V133, P4131, DOI 10.1242/dev.02595; Brault V, 2001, DEVELOPMENT, V128, P1253; CASPARI R, 1995, HUM MOL GENET, V4, P337, DOI 10.1093/hmg/4.3.337; Chodhari R, 2004, Paediatr Respir Rev, V5, P69, DOI 10.1016/j.prrv.2003.09.005; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; D'Angelo Anna, 2009, Pathogenetics, V2, P3, DOI 10.1186/1755-8417-2-3; Davenport JR, 2005, AM J PHYSIOL-RENAL, V289, pF1159, DOI 10.1152/ajprenal.00118.2005; Debinski HS, 1996, GASTROENTEROLOGY, V110, P1028, DOI 10.1053/gast.1996.v110.pm8612989; Eley L, 2005, CURR OPIN GENET DEV, V15, P308, DOI 10.1016/j.gde.2005.04.008; Escudier E, 2009, PAEDIATR RESPIR REV, V10, P51, DOI 10.1016/j.prrv.2009.02.001; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Freese JL, 2010, NEUROBIOL DIS, V38, P148, DOI 10.1016/j.nbd.2009.09.003; Galiatsatos P, 2006, AM J GASTROENTEROL, V101, P385, DOI 10.1111/j.1572-0241.2006.00375.x; Garcia EBG, 2009, LANCET ONCOL, V10, P727, DOI 10.1016/S1470-2045(09)70167-6; Gerdes JM, 2007, NAT GENET, V39, P1350, DOI 10.1038/ng.2007.12; Giardiello FM, 1997, GUT, V40, P521, DOI 10.1136/gut.40.4.521; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hemmer PH, 2004, ARCH SURG-CHICAGO, V139, P223, DOI 10.1001/archsurg.139.2.223; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klysik M, 2008, PATHOL RES PRACT, V204, P77, DOI 10.1016/j.prp.2007.10.013; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Lancaster MA, 2009, CURR OPIN GENET DEV, V19, P220, DOI 10.1016/j.gde.2009.04.008; Laurence J.Z., 1866, OPHTHALMIC REV, V2, P32; Mans DA, 2008, BBA-REV CANCER, V1786, P114, DOI 10.1016/j.bbcan.2008.02.002; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Michaud EJ, 2006, CANCER RES, V66, P6463, DOI 10.1158/0008-5472.CAN-06-0462; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Miyaki M, 2008, INT J CANCER, V122, P2491, DOI 10.1002/ijc.23390; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mykytyn K, 2003, AM J HUM GENET, V72, P429, DOI 10.1086/346172; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC; Ou GS, 2005, NATURE, V436, P583, DOI 10.1038/nature03818; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Robert A, 2007, J CELL SCI, V120, P628, DOI 10.1242/jcs.03366; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rubinfeld B, 1993, SCIENCE, V289, P1194; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Signoron S, 2007, CLIN CANCER RES, V13, P5034, DOI 10.1158/1078-0432.CCR-07-0336; Sloboda RD, 2005, J CELL BIOCHEM, V94, P266, DOI 10.1002/jcb.20323; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Tanaka Y, 2005, NATURE, V435, P172, DOI 10.1038/nature03494; Thliveris A, 1996, GENOMICS, V34, P268, DOI 10.1006/geno.1996.0285; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161	68	11	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1475	1483		10.1038/onc.2011.351	http://dx.doi.org/10.1038/onc.2011.351			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860414				2022-12-28	WOS:000302132000001
J	Aziz, MH; Shen, H; Maki, CG				Aziz, M. H.; Shen, H.; Maki, C. G.			Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3	ONCOGENE			English	Article						p53; Nutlin; resistance	TUMOR-CELLS; MUTANT P53; OVARIAN-CANCER; APOPTOSIS; MDM2; THERAPY; PATHWAY; PROTEIN; GENE; CHEMOSENSITIVITY	Wild-type p53 is a stress-responsive tumor suppressor and potent growth inhibitor. Genotoxic stresses (for example, ionizing and ultraviolet radiation or chemotherapeutic drug treatment) can activate p53, but also induce mutations in the P53 gene, and thus select for p53-mutated cells. Nutlin-3a (Nutlin) is pre-clinical drug that activates p53 in a non-genotoxic manner. Nutlin occupies the p53-binding pocket of murine double minute 2 (MDM2), activating p53 by blocking the p53-MDM2 interaction. Because Nutlin neither binds p53 directly nor introduces DNA damage, we hypothesized Nutlin would not induce P53 mutations, and, therefore, not select for p53-mutated cells. To test this, populations of SJSA-1 (p53 wild-type) cancer cells were expanded that survived repeated Nutlin exposures, and individual clones were isolated. Group 1 clones were resistant to Nutlin-induced apoptosis, but still underwent growth arrest. Surprisingly, while some Group 1 clones retained wild-type p53, others acquired a heterozygous p53 mutation. Apoptosis resistance in Group 1 clones was associated with decreased PUMA induction and decreased caspase 3/7 activation. Group 2 clones were resistant to both apoptosis and growth arrest induced by Nutlin. Group 2 clones had acquired mutations in the p53-DNA-binding domain and expressed only mutant p53s that were induced by Nutlin treatment, but were unable to bind the P21 and PUMA gene promoters, and unable to activate transcription. These results demonstrate that non-genotoxic p53 activation (for example, by Nutlin treatment) can lead to the acquisition of somatic mutations in p53 and select for p53-mutated cells. These findings have implications for the potential clinical use of Nutlin and other small molecule MDM2 antagonists. Oncogene (2011) 30, 4678-4686; doi:10.1038/onc.2011.185; published online 6 June 2011	[Aziz, M. H.; Shen, H.; Maki, C. G.] Rush Univ, Dept Anat & Cell Biol, Med Ctr, Chicago, IL 60612 USA	Rush University	Maki, CG (corresponding author), Rush Univ, Dept Anat & Cell Biol, Med Ctr, 1653 W Congress Pkwy,Jelke 1306,900 S Paulina,AcF, Chicago, IL 60612 USA.	Carl_Maki@rush.edu			National Cancer Institute [1RO1CA137598-01A1]; NATIONAL CANCER INSTITUTE [R01CA137598] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute grant 1RO1CA137598-01A1 to CGM.	Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Blagosklonny MV, 2005, CELL DEATH DIFFER, V12, P592, DOI 10.1038/sj.cdd.4401610; Blagosklonny MV, 2002, NAT REV CANCER, V2, P221, DOI 10.1038/nrc743; Brown L, 2007, CRIT REV EUKAR GENE, V17, P73, DOI 10.1615/CritRevEukarGeneExpr.v17.i1.50; Christiansen DH, 2001, J CLIN ONCOL, V19, P1405, DOI 10.1200/JCO.2001.19.5.1405; DeBenedetti VMG, 1996, CANCER EPIDEM BIOMAR, V5, P93; Drakos E, 2007, CLIN CANCER RES, V13, P3380, DOI 10.1158/1078-0432.CCR-06-2581; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumamoto K, 2008, CANCER RES, V68, P3193, DOI 10.1158/0008-5472.CAN-07-2780; Leonard DGB, 2002, CLIN CANCER RES, V8, P973; Lovric MM, 2010, ONCOGENE, V29, P5048, DOI 10.1038/onc.2010.242; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayelzadeh F, 2007, ONCOGENE, V26, P2955, DOI 10.1038/sj.onc.1210110; McDermott U, 2005, CANCER RES, V65, P8951, DOI 10.1158/0008-5472.CAN-05-0961; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pietenpol JA, 1996, P NATL ACAD SCI USA, V93, P8390, DOI 10.1073/pnas.93.16.8390; Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7; Shen H, 2008, CANCER RES, V68, P8260, DOI 10.1158/0008-5472.CAN-08-1901; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Vaseva AV, 2009, CELL CYCLE, V8, P1711, DOI 10.4161/cc.8.11.8596; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wu GS, 1996, CLIN CANCER RES, V2, P623; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020	36	96	96	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	46					4678	4686		10.1038/onc.2011.185	http://dx.doi.org/10.1038/onc.2011.185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21643018	Green Accepted			2022-12-28	WOS:000297252100007
J	Alberti, C; Pinciroli, P; Valeri, B; Ferri, R; Ditto, A; Umezawa, K; Sensi, M; Canevari, S; Tomassetti, A				Alberti, C.; Pinciroli, P.; Valeri, B.; Ferri, R.; Ditto, A.; Umezawa, K.; Sensi, M.; Canevari, S.; Tomassetti, A.			Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer	ONCOGENE			English	Article						epithelial ovarian cancer; EGFR; IL-6; PAI-1; NFkB	GROWTH-FACTOR-RECEPTOR; KAPPA-B; BREAST-CANCER; PLASMINOGEN-ACTIVATOR; CELLS; TUMOR; EXPRESSION; OVEREXPRESSION; MACROPHAGES; PROGRESSION	The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is expressed in up to 70% of epithelial ovarian cancers (EOCs), where it correlates with poor prognosis. The majority of EOCs are diagnosed at an advanced stage, and at least 50% present malignant ascites. High levels of IL-6 have been found in the ascites of EOC patients and correlate with shorter survival. Herein, we investigated the signaling cascade led by EGFR activation in EOC and assessed whether EGFR activation could induce an EOC microenvironment characterized by pro-inflammatory molecules. In vitro analysis of EOC cell lines revealed that ligand-stimulated EGFR activated NFkB-dependent transcription and induced secretion of IL-6 and plasminogen activator inhibitor (PAI-1). IL-6/PAI-1 expression and secretion were strongly inhibited by the tyrosine kinase inhibitor AG1478 and EGFR silencing. A significant reduction of EGF-stimulated IL-6/PAI-1 secretion was also obtained with the NFkB inhibitor dehydroxymethylepoxyquinomicin. Of 23 primary EOC tumors from advanced-stage patients with malignant ascites at surgery, 12 co-expressed membrane EGFR, IL-6 and PAI-1 by immunohistochemistry; both IL-6 and PAI-1 were present in 83% of the corresponding ascites. Analysis of a publicly available gene-expression data set from 204 EOCs confirmed a significant correlation between IL-6 and PAI-1 expression, and patients with the highest IL-6 and PAI-1 co-expression showed a significantly shorter progression-free survival time (P = 0.028). This suggests that EGFR/NFkB/IL-6-PAI-1 may have a significant impact on the therapy of a particular subset of EOC, and that IL-6/PAI-1 co-expression may be a novel prognostic marker. Oncogene (2012) 31, 4139-4149; doi:10.1038/onc.2011.572; published online 12 December 2011	[Canevari, S.; Tomassetti, A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Mol Therapies, Milan, Italy; [Valeri, B.] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy; [Ditto, A.] Fdn IRCCS Ist Nazl Tumori, Dept Gynecol Oncol, Milan, Italy; [Umezawa, K.] Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Tokyo 108, Japan; [Sensi, M.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Human Tumor Immunobiol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Keio University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Canevari, S (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Mol Therapies, Milan, Italy.	silvana.canevari@istitutotumori.mi.it; antonella.tomassetti@istitutotumori.mi.it	Ditto, Antonino/H-2219-2017; Ferri, Raffaele/B-5439-2013; Tomassetti, Antonella/G-7906-2015; Valeri, Barbara/C-1986-2017; Sensi, Marialuisa/K-5631-2014	Ditto, Antonino/0000-0002-5684-8225; Ferri, Raffaele/0000-0001-6937-3065; Tomassetti, Antonella/0000-0001-6772-9937; Valeri, Barbara/0000-0001-9143-7280; Sensi, Marialuisa/0000-0002-7643-0248	Italian Association for Cancer Research [IG4608]; Italian Ministry of Health	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	We thank the gynecologic clinical staff and the biorepository personnel at the Fondazione IRCCS Istituto Nazionale dei Tumori, whose activity made this study possible; we thank Dr. Patrick Moore for English editing of the manuscript. Financial Support: Italian Association for Cancer Research (IG4608 to SC) and Italian Ministry of Health (Grant Alleanza contro il Cancro, ACC and Progetto Oncologico di Medicina Molecolare: i Tumori Femminili to SC).	Anglesio MS, 2008, MOL CANCER RES, V6, P1678, DOI 10.1158/1541-7786.MCR-08-0193; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berchuck A, 2009, CLIN CANCER RES, V15, P2448, DOI 10.1158/1078-0432.CCR-08-2430; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Braun AH, 2005, CLIN CANCER RES, V11, P4639, DOI 10.1158/1078-0432.CCR-05-0973; Carey MS, 2010, CLIN CANCER RES, V16, P2852, DOI 10.1158/1078-0432.CCR-09-2502; Castellano G, 2006, CANCER RES, V66, P10709, DOI 10.1158/0008-5472.CAN-06-1327; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Conti M, 2006, MOL ENDOCRINOL, V20, P715, DOI 10.1210/me.2005-0185; De Santis G, 2009, ONCOGENE, V28, P1206, DOI 10.1038/onc.2008.470; Degl'Innocenti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012701; Guo YQ, 2010, CLIN CANCER RES, V16, P5759, DOI 10.1158/1078-0432.CCR-10-1095; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Hartman ZC, 2011, CANCER RES, V71, P4380, DOI 10.1158/0008-5472.CAN-11-0308; Hudson LG, 2009, CANCER TREAT RES, V149, P203, DOI 10.1007/978-0-387-98094-2_10; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kryczek I, 2000, BRIT J CANCER, V82, P621; Leissner P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-216; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Paugh BS, 2008, FASEB J, V22, P455, DOI 10.1096/fj.07-8276com; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Sheng Q, 2011, BRIT J CANCER, V104, P1241, DOI 10.1038/bjc.2011.62; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; Sternlicht MD, 2006, CANCER EPIDEM BIOMAR, V15, P2107, DOI 10.1158/1055-9965.EPI-06-0351; Tomassetti A, 2008, NEOPLASIA, V10, P1481, DOI 10.1593/neo.81004; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Umezawa K, 2006, CANCER SCI, V97, P990, DOI 10.1111/j.1349-7006.2006.00285.x; Van Laere SJ, 2007, BRIT J CANCER, V97, P659, DOI 10.1038/sj.bjc.6603906; Yamamoto M, 2008, J MED CHEM, V51, P5780, DOI 10.1021/jm8006245	35	84	87	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4139	4149		10.1038/onc.2011.572	http://dx.doi.org/10.1038/onc.2011.572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158046	hybrid			2022-12-28	WOS:000308688900006
J	Sasi, SP; Yan, X; Enderling, H; Park, D; Gilbert, HY; Curry, C; Coleman, C; Hlatky, L; Qin, G; Kishore, R; Goukassian, DA				Sasi, S. P.; Yan, X.; Enderling, H.; Park, D.; Gilbert, H-Y; Curry, C.; Coleman, C.; Hlatky, L.; Qin, G.; Kishore, R.; Goukassian, D. A.			Breaking the 'harmony' of TNF-alpha signaling for cancer treatment	ONCOGENE			English	Article						TNF-alpha; TNFR2/p75; cancer; angiogenesis; EPC; microenvironment	TUMOR-NECROSIS-FACTOR; ENDOTHELIAL PROGENITOR CELLS; ANGIOGENIC SWITCH; FACTOR-RECEPTOR; GROWTH-FACTOR; KAPPA-B; IN-VIVO; NEOVASCULARIZATION; ACTIVATION; APOPTOSIS	Tumor necrosis factor-alpha (TNF-alpha) binds to two distinct receptors, TNFR1/p55 and TNFR2/p75. TNF-alpha is implicated in the processes of tumor growth, survival, differentiation, invasion, metastases, secretion of cytokines and pro-angiogenic factors. We have shown that TNFR2/p75 signaling promotes ischemia-induced angiogenesis via modulation of several angiogenic growth factors. We hypothesized that TNFR2/p75 may promote tumor growth and angiogenesis. Growth of mouse Lewis lung carcinoma (LLC1) and/or mouse melanoma B16 cell was evaluated in wild type (WT), p75 knockout (KO) and double p55KO/p75KO mouse tumor xenograft models. Compared with WT and p55KO/p75KO mice, growth of tumors in p75KO mice was significantly decreased (twofold) in both LLC and B16 tumors. Tumor growth inhibition was correlated with decreases in vascular endothelial growth factor (VEGF) expression and capillary density, as well as bone marrow-derived endothelial progenitor cells incorporation into the functional capillary network, and an increase in apoptotic cells in LLC xenografts. Gene array analysis of tumor tissues showed a decrease in gene expression in pathways that promote tumor angiogenesis and cell survival. Blocking p75 by short-hairpin RNA in cultured LLCs led to increases in TNF-mediated apoptosis, as well as decreases in the constitutive and TNF-mediated expression of angiogenic growth factors (VEGF, HGF, PLGF), and SDF-1 alpha receptor CXCR4. In summary, p75 is essential for tumor angiogenesis and survival in highly vascularized murine lung tumor xenografts. Blocking p75 expression may lead to tumor regression. This may represent new and effective therapy against lung neoplasms and potentially tumors of other origin. Oncogene (2012) 31, 4117-4127; doi:10.1038/onc.2011.567; published online 12 December 2011	[Goukassian, D. A.] Tufts Univ, Sch Med, Ctr Canc Syst Biol, Brighton, MA 02135 USA; [Sasi, S. P.; Yan, X.; Park, D.; Gilbert, H-Y; Curry, C.; Coleman, C.; Goukassian, D. A.] Steward St Elizabeths Med Ctr, Cardiovasc Res Ctr, Brighton, MA USA; [Qin, G.; Kishore, R.] Northwestern Univ, Chicago, IL 60611 USA	Tufts University; St. Elizabeth's Medical Center; Northwestern University	Goukassian, DA (corresponding author), Tufts Univ, Sch Med, Ctr Canc Syst Biol, 736 Cambridge St,CBR 307, Brighton, MA 02135 USA.	david.goukassian@tufts.edu	Enderling, Heiko/AAA-2423-2021	Enderling, Heiko/0000-0002-9696-6410; Goukassian, David/0000-0001-5270-5270; Park, Daniel/0000-0001-5191-1371	NIH [HL091983]; NIH/NIA [5R21AG026777-02]; AHA SDG Award; NASA [NNX11AD22G]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091983] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG026777] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHA SDG Award; NASA(National Aeronautics & Space Administration (NASA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Marcy Silver and Sharon Kunder for their valuable technical support. This work was supported in part by grants from the NIH HL091983 (to RK), NIH/NIA 5R21AG026777-02, the AHA SDG Award and the NASA NNX11AD22G (all three to DAG).	Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964; Barbara JAJ, 1996, IMMUNOL CELL BIOL, V74, P434, DOI 10.1038/icb.1996.73; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Coleman C, 2010, J ONCOL, V2010, DOI 10.1155/2010/928628; De Plaen IG, 2006, IMMUNOLOGY, V118, P153, DOI 10.1111/j.1365-2567.2006.02344.x; Eisenthal Avi, 2003, Sarcoma, V7, P57, DOI 10.1080/13577140310001607275; ELBAZ O, 1994, LEUKEMIA LYMPHOMA, V12, P191, DOI 10.3109/10428199409059589; FAJARDO LF, 1992, AM J PATHOL, V140, P539; Fiers W., 1995, Journal of Inflammation, V47, P67; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Gao DC, 2008, SCIENCE, V319, P195, DOI 10.1126/science.1150224; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOILLOT E, 1992, CANCER RES, V52, P3194; Goukassian DA, 2007, CIRCULATION, V115, P752, DOI 10.1161/CIRCULATIONAHA.106.647255; Gupta S, 2003, MECH AGEING DEV, V124, P503, DOI 10.1016/S0047-6374(03)00028-9; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hohenberger P, 2003, ANN SURG ONCOL, V10, P562, DOI 10.1245/ASO.2003.10.005; JACOBSEN SEW, 1994, STEM CELLS, V12, P111; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kohno K, 1998, CLIN IMMUNOL IMMUNOP, V86, P11, DOI 10.1006/clin.1997.4475; KOMORI A, 1993, CANCER RES, V53, P1982; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Li B, 2009, CANCER RES, V69, P338, DOI 10.1158/0008-5472.CAN-08-1565; Liu RY, 1998, CANCER RES, V58, P2217; Luo DH, 2006, AM J PATHOL, V169, P1886, DOI 10.2353/ajpath.2006.060603; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Meng YR, 2010, CANCER RES, V70, P1534, DOI 10.1158/0008-5472.CAN-09-2995; Montesano R, 2005, J CELL SCI, V118, P3487, DOI 10.1242/jcs.02467; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Rafii S, 2008, SCIENCE, V319, P163, DOI 10.1126/science.1153615; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Rivas MA, 2008, EXP CELL RES, V314, P509, DOI 10.1016/j.yexcr.2007.10.005; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Santarelli JG, 2006, NEUROSURGERY, V59, P374, DOI 10.1227/01.NEU.0000222658.66878.CC; SATO N, 1987, J NATL CANCER I, V79, P1383; Sethi G, 2008, FRONT BIOSCI-LANDMRK, V13, P5094, DOI 10.2741/3066; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; Suganuma M, 1999, CANCER RES, V59, P4516; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WONG GHW, 1994, J IMMUNOL, V152, P1751; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zhang R, 2003, J BIOL CHEM, V278, P51267, DOI 10.1074/jbc.M310678200	47	45	48	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	37					4117	4127		10.1038/onc.2011.567	http://dx.doi.org/10.1038/onc.2011.567			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158049	hybrid, Green Accepted			2022-12-28	WOS:000308688900004
J	Lubbe, SJ; Pittman, AM; Olver, B; Lloyd, A; Vijayakrishnan, J; Naranjo, S; Dobbins, S; Broderick, P; Gomez-Skarmeta, JL; Houlston, RS				Lubbe, S. J.; Pittman, A. M.; Olver, B.; Lloyd, A.; Vijayakrishnan, J.; Naranjo, S.; Dobbins, S.; Broderick, P.; Gomez-Skarmeta, J. L.; Houlston, R. S.			The 14q22.2 colorectal cancer variant rs4444235 shows cis-acting regulation of BMP4	ONCOGENE			English	Article						bone morphogenetic protein-4; colorectal cancer; cis-regulatory	GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; GENE-EXPRESSION; CHROMOSOMAL INSTABILITY; GEL-ELECTROPHORESIS; RISK; COMMON; 8Q24; SCAN; PREDISPOSITION	Common genetic variation at human 14q22.2 tagged by rs4444235 is significantly associated with colorectal cancer (CRC) risk. Re-sequencing was used to comprehensively annotate the 17kb region of strong linkage disequilibrium encompassing rs4444235. Through bioinformatic analyses using H3K4Me1, H3K4Me3, and DNase-I hypersensitivity chromatin signatures and evolutionary conservation we identified seven candidate disease-causing single-nucleotide polymorphisms mapping to six regions within the 17-kb region predicted to have regulatory potential. Reporter gene studies of these regions demonstrated that the element to which rs4444235 maps acts as an allele-specific transcriptional enhancer. Allele-specific expression studies in CRC cell lines heterozygous for rs4444235 showed significantly increased expression of bone morphogenetic protein-4 (BMP4) associated with the risk allele (P<0.001). These data provide evidence for a functional basis for the non-coding risk variant rs4444235 at 14q22.2 and emphasizes the importance of genetic variation in the BMP pathway genes as determinants of CRC risk. Oncogene (2012) 31, 3777-3784; doi:10.1038/onc.2011.564; published online 12 December 2011	[Lubbe, S. J.; Pittman, A. M.; Olver, B.; Lloyd, A.; Vijayakrishnan, J.; Dobbins, S.; Broderick, P.; Houlston, R. S.] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; [Naranjo, S.; Gomez-Skarmeta, J. L.] CSIC UPO, Ctr Andaluz Biol Desarrollo, Seville, Spain	University of London; Institute of Cancer Research - UK; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD)	Houlston, RS (corresponding author), Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England.	Richard.houlston@icr.ac.uk	Pittman, Alan M/D-6231-2012; Gomez-Skarmeta, Jose Luis/B-5268-2014; Lubbe, Steven/L-8261-2013; Naranjo, Silvia/P-9845-2016; Pittman, Alan/AAP-2534-2020	Pittman, Alan M/0000-0002-8112-2987; Gomez-Skarmeta, Jose Luis/0000-0001-5125-4332; Lubbe, Steven/0000-0002-7103-6671; Naranjo, Silvia/0000-0002-4529-3332; Pittman, Alan/0000-0002-8112-2987; Broderick, Peter/0000-0002-8348-5829; Vijayakrishnan, Jayaram/0000-0002-8284-2249; Houlston, Richard/0000-0002-5268-0242	National Health Service (NHS); Bobby Moore Fund; Spanish Ministry of Education and Science [BFU2010-14839, CSD2007-00008]; Junta de Andalucia [CVI-3488]; PhD studentship from Cancer Research UK; European Union Seventh Framework Programme (FP7) [258236]	National Health Service (NHS); Bobby Moore Fund; Spanish Ministry of Education and Science(Spanish Government); Junta de Andalucia(Junta de Andalucia); PhD studentship from Cancer Research UK; European Union Seventh Framework Programme (FP7)	We acknowledge the National Health Service (NHS) funding to the National Institute for Health Research (NIHR) Biomedical Research Centre. Finally, we are grateful to all patients and individuals for participation. Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) provided principal funding for the study. JLG-S acknowledges grants from the Spanish Ministry of Education and Science (BFU2010-14839 and CSD2007-00008) and Junta de Andalucia (CVI-3488). SJL is in receipt of a PhD studentship from Cancer Research UK. The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/207-2013) under grant no. 258236, FP7 collaborative project SYSCOL.	Aaltonen L, 2007, CLIN CANCER RES, V13, P356, DOI 10.1158/1078-0432.CCR-06-1256; Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18; Deng HY, 2007, EXP CELL RES, V313, P1033, DOI 10.1016/j.yexcr.2006.12.020; Eisen T, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-244; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; Gomez-Skarmeta JL, 2006, DEV DYNAM, V235, P870, DOI 10.1002/dvdy.20659; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Houlston RS, 2010, NAT GENET, V42, P973, DOI 10.1038/ng.670; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; Jaeger E, 2008, NAT GENET, V40, P26, DOI 10.1038/ng.2007.41; Kawi K, 2002, GENE CHROMOSOME CANC, V34, P1, DOI 10.1002/gcc.10003; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Lubbe SJ, 2009, J CLIN ONCOL, V27, P2238, DOI 10.1200/JCO.2008.20.3364; Milani L, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1152; Palin K, 2006, NAT PROTOC, V1, P368, DOI 10.1038/nprot.2006.56; Penegar S, 2007, BRIT J CANCER, V97, P1305, DOI 10.1038/sj.bjc.6603997; Pittman AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001126; Pittman AM, 2009, GENOME RES, V19, P987, DOI 10.1101/gr.092668.109; Polakis P, 2000, GENE DEV, V14, P1837; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Pregizer S, 2009, CYTOKINE GROWTH F R, V20, P509, DOI 10.1016/j.cytogfr.2009.10.011; Takash W, 2001, NUCLEIC ACIDS RES, V29, P4274, DOI 10.1093/nar/29.21.4274; Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133; Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085; Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111; Tomlinson IPM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002105; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089	36	31	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3777	3784		10.1038/onc.2011.564	http://dx.doi.org/10.1038/onc.2011.564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22158048				2022-12-28	WOS:000307924900004
J	Mao, L; Ding, J; Perdue, A; Yang, L; Zha, Y; Ren, M; Huang, S; Cui, H; Ding, HF				Mao, L.; Ding, J.; Perdue, A.; Yang, L.; Zha, Y.; Ren, M.; Huang, S.; Cui, H.; Ding, H-F			Cyclin E1 is a common target of BMI1 and MYCN and a prognostic marker for neuroblastoma progression	ONCOGENE			English	Article						BMI1; cyclin E1; FBXW7; MYCN; neuroblastoma	CELL SELF-RENEWAL; GENE-EXPRESSION; STEM-CELLS; N-MYC; SENESCENCE; DIFFERENTIATION; INHIBITION; APOPTOSIS; GROWTH; IDENTIFICATION	The Polycomb transcription repressor BMI1 is highly expressed in human neuroblastomas and is required for the clonogenic self-renewal and tumorigenicity of human neuroblastoma cell lines. The molecular basis of BMI1 action in neuroblastoma cells is not well understood. Here we report that BMI1 has a critical role in stabilizing cyclin E1 by repressing the expression of FBXW7, a substrate-recognition subunit of the SCF E3 ubiquitin ligase that targets cyclin E1 for degradation. BMI1 binds to the FBXW7 locus in vivo and represses its mRNA expression. Overexpression of cyclin E1 or abrogation of FBXW7 induction rescues the cell-death phenotype of BMI1 knockdown. Moreover, MYCN, an oncoprotein in the pathogenesis of high-risk neuroblastomas, is able to counteract the death-inducing effect of BMI1 knockdown by activating CCNE1 transcription. We further show that high cyclin E1 expression is associated with Stage 4 neuroblastomas and poor prognosis in patients. These findings suggest a molecular mechanism for the oncogenic activity of BMI1 and MYCN in neuroblastoma pathogenesis and progression by maintaining cyclin E1 levels. Oncogene (2012) 31, 3785-3795; doi:10.1038/onc.2011.536; published online 28 November 2011	[Cui, H.] Southwest Univ, State Key Lab Silkworm Funct Genome Biol, Inst Sericulture & Syst Biol, Chongqing 400716, Peoples R China; [Mao, L.; Ding, J.; Perdue, A.; Yang, L.; Zha, Y.; Ren, M.; Ding, H-F] Georgia Hlth Sci Univ, Ctr Canc, Dept Pathol, Augusta, GA 30912 USA; [Mao, L.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurol, Wuhan 430074, Peoples R China; [Zha, Y.] Three Gorges Univ, Coll Med, Hosp Yichang 1, Dept Neurol, Yichang, Peoples R China; [Huang, S.] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	Southwest University - China; University System of Georgia; Augusta University; Huazhong University of Science & Technology; China Three Gorges University; University System of Georgia; Augusta University	Cui, H (corresponding author), Southwest Univ, State Key Lab Silkworm Genome Biol, Inst Sericulture & Syst Biol, 2 Tianshenqiao, Chongqing 400716, Peoples R China.	hcui@swu.edu.cn; hding@georgiahealth.edu		Ding, Han-Fei/0000-0001-5702-3439	NIH [CA124982]; Georgia Cancer Coalition Distinguished Scholar Award [H-FD]; National Basic Research Program of China [2012cb114603]; National Science Foundation of China [NSFC 81101905]; NATIONAL CANCER INSTITUTE [R01CA124982] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition Distinguished Scholar Award; National Basic Research Program of China(National Basic Research Program of China); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Q Du for pKMyc-cyclinE1, G Hannon and J Silva for shRNAmir Tet-Off, R Mulligan for pHDM-G and pMD.MLVogp, W Wei for pBabe-puro-p14<SUP>ARF</SUP> and J Khan for gene expression data sets from the Oncogenomics Database. This work was supported by the NIH grant CA124982 and a Georgia Cancer Coalition Distinguished Scholar Award (H-FD), and a grant from the National Basic Research Program of China (No. 2012cb114603) to HC. LM was supported in part by a grant from the National Science Foundation of China (NSFC 81101905).	Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Chang HH, 2010, CLIN CANCER RES, V16, P4411, DOI 10.1158/1078-0432.CCR-09-3360; Chen QR, 2008, GENOMICS, V92, P195, DOI 10.1016/j.ygeno.2008.05.014; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; Cui HJ, 2005, J BIOL CHEM, V280, P9474, DOI 10.1074/jbc.M410450200; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Cui HJ, 2006, J BIOL CHEM, V281, P34696, DOI 10.1074/jbc.M604009200; Ferrari-Toninelli G, 2010, NEURO-ONCOLOGY, V12, P1231, DOI 10.1093/neuonc/noq101; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Onoyama I, 2008, CELL CYCLE, V7, P3307, DOI 10.4161/cc.7.21.6931; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000	51	17	18	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3785	3795		10.1038/onc.2011.536	http://dx.doi.org/10.1038/onc.2011.536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120721	Green Accepted			2022-12-28	WOS:000307924900005
J	Pringle, LM; Young, R; Quick, L; Riquelme, DN; Oliveira, AM; May, MJ; Chou, MM				Pringle, L. M.; Young, R.; Quick, L.; Riquelme, D. N.; Oliveira, A. M.; May, M. J.; Chou, M. M.			Atypical mechanism of NF-kappa B activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis	ONCOGENE			English	Article						TRE17; USP6; aneurysmal bone cyst; NF-kappa B; I kappa B	ANEURYSMAL BONE-CYST; IKK-BETA; P65 PHOSPHORYLATION; SIGNALING PATHWAY; ANGIOTENSIN-II; KINASE ALPHA; CANCER; SERINE-536; TRANSCRIPTION; UBIQUITIN	The NF-kappa B transcription factor has a central role in diverse processes, including inflammation, proliferation and cell survival, and its activity is dysregulated in diseases such as autoimmunity and cancer. We recently identified the TRE17/ubiquitin-specific protease 6 (USP6) oncogene as the first deubiquitinating enzyme to activate NF-kappa B. TRE17/USP6 is translocated and overexpressed in aneurysmal bone cyst (ABC), a pediatric tumor characterized by extensive bone degradation and inflammatory recruitment. In the current study, we explore the mechanism by which TRE17 induces activation of NF-kappa B, and find that it activates the classical NF-kappa B pathway through an atypical mechanism that does not involve I kappa B degradation. TRE17 co-precipitates with I kappa B kinase (IKK), and IKK activity is augmented in stable cell lines overexpressing TRE17, in a USP-dependent manner. Optimal activation of NF-kappa B by TRE17 requires both catalytic subunits of IKK, distinguishing its mechanism from the classical and non-canonical pathways, which require either IKK beta or IKK alpha, respectively. TRE17 stimulates phosphorylation of p65 at serine 536, a modification that has been associated with enhanced transcriptional activity and nuclear retention. Induction of S536 phosphorylation by TRE17 requires both IKK alpha and IKK beta, as well as the IKK gamma/NEMO regulatory subunit of IKK. We further demonstrate that TRE17(long) is highly tumorigenic when overexpressed in NIH3T3 fibroblasts, and that inhibition of NF-kappa B significantly attenuates tumor formation. In summary, these studies uncover an unexpected signaling mechanism for activation of classical NF-kappa B by TRE17. They further reveal a critical role for NF-kappa B in TRE17-mediated tumorigenesis, and suggest that NF-kappa B inhibitors may function as effective therapeutic agents in the treatment of ABC. Oncogene (2012) 31, 3525-3535; doi:10.1038/onc.2011.520; published online 14 November 2011	[Pringle, L. M.; Young, R.; Quick, L.; Riquelme, D. N.; Chou, M. M.] Childrens Hosp Philadelphia, Dept Pathol & Lab, Philadelphia, PA 19104 USA; [Pringle, L. M.; Young, R.; Quick, L.; Riquelme, D. N.; Chou, M. M.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Oliveira, A. M.] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA; [Oliveira, A. M.] Mayo Fdn, Rochester, MN USA; [May, M. J.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [May, M. J.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Mayo Clinic; Mayo Clinic; University of Pennsylvania; University of Pennsylvania	Chou, MM (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab, ARC 816E, Philadelphia, PA 19104 USA.	mmc@mail.med.upenn.edu		May, Michael/0000-0002-2485-3716	National Institutes of Health [RO1 CA081415, P30 AS050950]; National Service Research Award Grant [F31CA126488]; NATIONAL CANCER INSTITUTE [F31CA126488, R01CA081415] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050950] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Service Research Award Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the National Institutes of Health Grant RO1 CA081415 (to MMC) and Grant P30 AS050950 (Penn Center for Musculoskeletal Disorders). This work was also supported by the National Service Research Award Grant F31CA126488 (to LMP).	BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Calzado MA, 2007, CURR MED CHEM, V14, P367, DOI 10.2174/092986707779941113; Choudhary S, 2007, MOL ENDOCRINOL, V21, P2203, DOI 10.1210/me.2006-0465; Cottalorda J, 2007, ARCH ORTHOP TRAUM SU, V127, P105, DOI 10.1007/s00402-006-0223-5; Dobrovolskaia MA, 2005, CURR CANCER DRUG TAR, V5, P325, DOI 10.2174/1568009054629645; Douillette A, 2006, J BIOL CHEM, V281, P13275, DOI 10.1074/jbc.M512815200; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hansberger MW, 2007, J VIROL, V81, P1360, DOI 10.1128/JVI.01860-06; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hu J, 2004, CARCINOGENESIS, V25, P1991, DOI 10.1093/carcin/bgh198; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Khandaker NA, 2004, J IMMUNOL, V173, P6965; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lau AW, 2010, J BIOL CHEM, V285, P37111, DOI 10.1074/jbc.M110.175133; Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078-0432.CCR-08-0123; Liu S, 2008, CELL RES, V21, P6; Mankin HJ, 2005, J CLIN ONCOL, V23, P6756, DOI 10.1200/JCO.2005.15.255; Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004; Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Mendenhall WM, 2006, AM J CLIN ONCOL-CANC, V29, P311, DOI 10.1097/01.coc.0000204403.13451.52; NAKAMURA T, 1992, ONCOGENE, V7, P733; Oliveira AM, 2005, ONCOGENE, V24, P3419, DOI 10.1038/sj.onc.1208506; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rollins BJ, 2006, EUR J CANCER, V42, P760, DOI 10.1016/j.ejca.2006.01.002; Saccomanni B, 2008, ARCH ORTHOP TRAUM SU, V128, P1145, DOI 10.1007/s00402-007-0477-6; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Shimada H, 2010, J BIOL CHEM, V285, P12536, DOI 10.1074/jbc.M109.099630; Sitcheran R, 2008, MOL CELL BIOL, V28, P5061, DOI 10.1128/MCB.00578-08; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Skaug B, 2009, ANNU REV BIOCHEM, V78, P769, DOI 10.1146/annurev.biochem.78.070907.102750; Solt LA, 2007, J BIOL CHEM, V282, P8724, DOI 10.1074/jbc.M609613200; Sun WJ, 2009, CELL SIGNAL, V21, P1488, DOI 10.1016/j.cellsig.2009.05.007; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Ye Y, 2010, ONCOGENE, V29, P3619, DOI 10.1038/onc.2010.116	48	48	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	30					3525	3535		10.1038/onc.2011.520	http://dx.doi.org/10.1038/onc.2011.520			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22081069	Green Submitted, Green Accepted			2022-12-28	WOS:000306844100005
J	Vesuna, F; Lisok, A; Kimble, B; Domek, J; Kato, Y; van der Groep, P; Artemov, D; Kowalski, J; Carraway, H; van Diest, P; Raman, V				Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; van der Groep, P.; Artemov, D.; Kowalski, J.; Carraway, H.; van Diest, P.; Raman, V.			Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha	ONCOGENE			English	Article						breast cancer; hormone resistance; Twist; ER transcriptional regulation; histone deacetylation; methylation	EPITHELIAL-CELL LINES; TRANSCRIPTIONAL REGULATION; CHROMOSOMAL INSTABILITY; AROMATASE INHIBITORS; DNA METHYLATION; EXPRESSION; PROTEIN; MUTATIONS; ANGIOGENESIS; ACTIVATION	The role of estrogen receptor-alpha (ER) in breast cancer development, and as a primary clinical marker for breast cancer prognosis, has been well documented. In this study, we identified the oncogenic protein, TWIST1 (Twist), which is overexpressed in high-grade breast cancers, as a potential negative regulator of ER expression. Functional characterization of ER regulation by Twist was performed using Twist low (MCF-7, T-47D) and Twist high (Hs 578T, MDA-MB-231, MCF-7/Twist) expressing cell lines. All Twist high expressing cell lines exhibited low ER transcript and protein levels. By chromatin immunoprecipitation and promoter assays, we demonstrated that Twist could directly bind to E-boxes in the ER promoter and significantly downregulate ER promoter activity in vitro. Functionally, Twist overexpression caused estrogen-independent proliferation of breast cells, and promoted hormone resistance to the selective estrogen receptor modulator tamoxifen and selective estrogen receptor down-regulator fulvestrant. Importantly, this effect was reversible on downregulating Twist. In addition, orthotopic tumors generated in mice using MCF-7/Twist cells were resistant to tamoxifen. These tumors had high vascular volume and permeability surface area, as determined by magnetic resonance imaging (MRI). Mechanistically, Twist recruited DNA methyltransferase 3B (DNMT3B) to the ER promoter, leading to a significantly higher degree of ER promoter methylation compared with parental cells. Furthermore, we demonstrated by co-immunoprecipitation that Twist interacted with histone deacetylase 1 (HDAC1) at the ER promoter, causing histone deacetylation and chromatin condensation, further reducing ER transcript levels. Functional re-expression of ER was achieved using the demethylating agent, 5-azacytidine, and the HDAC inhibitor, valproic acid. Finally, an inverse relationship was observed between Twist and ER expression in human breast tumors. In summary, the regulation of ER by Twist could be an underlying mechanism for the loss of ER activity observed in breast tumors, and may contribute to the generation of hormone-resistant, ER-negative breast cancer. Oncogene (2012) 31, 3223-3234; doi:10.1038/onc.2011.483; published online 7 November 2011	[Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; Artemov, D.; Raman, V.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [van der Groep, P.; van Diest, P.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Kowalski, J.; Carraway, H.; Raman, V.] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA	Johns Hopkins University; Utrecht University; Utrecht University Medical Center; Johns Hopkins University; Johns Hopkins Medicine	Raman, V (corresponding author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, 340 Traylor,720 Rutland Ave,340 Traylor Bldg, Baltimore, MD 21205 USA.	fvesuna1@jhmi.edu; vraman2@jhmi.edu	Carraway, Hetty/AAR-4977-2020; Vesuna, Farhad/G-3179-2010	Carraway, Hetty/0000-0001-5241-3614; Vesuna, Farhad/0000-0002-0356-5096; Kato, Yoshinori/0000-0002-6218-8710; Kowalski, Jeanne/0000-0003-3458-3024	National Institutes of Health [1RO1CA140226]; NATIONAL CANCER INSTITUTE [R01CA131250, R01CA140226] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the UMC Utrecht Biobank and M van Blokland for their help in obtaining the human breast cancer RNA. We also thank Flonne Wildes and Gary Cromwell for helping with mice, Yelena Mironchik for helping with cell culture, and Mary McAllister, Paul T Winnard Jr, and Balaji Krishnamachary for critically reading the manuscript. We also thank Kayleen Bailey for help with methylation experiments. ER promoter and ERE-luciferase constructs were kindly provided by Professor Nancy Davidson (Johns Hopkins University, MD). Twist mutant constructs were kindly provided by Professor Jacky Bonaventure (INSERM, France). This work was supported by the National Institutes of Health (1RO1CA140226 to VR).	Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Bhujwalla ZM, 2001, NEOPLASIA, V3, P143, DOI 10.1038/sj.neo.7900129; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bikfalvi A, 2002, TRENDS PHARMACOL SCI, V23, P576, DOI 10.1016/S0165-6147(02)02109-0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cho EY, 2006, INT J GYNECOL CANCER, V16, P1000, DOI 10.1111/j.1525-1438.2006.00553.x; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; FOX MH, 1980, CYTOMETRY, V1, P71, DOI 10.1002/cyto.990010114; Fuqua SAW, 2000, CANCER RES, V60, P4026; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; Herynk MH, 2007, ADV EXP MED BIOL, V608, P130; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; MORISSET M, 1986, ENDOCRINOLOGY, V119, P2773, DOI 10.1210/endo-119-6-2773; Murphy LC, 1997, J STEROID BIOCHEM, V62, P363, DOI 10.1016/S0960-0760(97)00084-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Osborne C, 2005, ANNU REV MED, V56, P103, DOI 10.1146/annurev.med.56.062804.103324; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Osborne CK, 2005, J STEROID BIOCHEM, V95, P183, DOI 10.1016/j.jsbmb.2005.04.021; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pilat MJP, 1998, ANTICANCER RES, V18, P2575; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; Rose CSP, 1997, TRENDS GENET, V13, P384, DOI 10.1016/S0168-9525(97)01296-1; Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2; Sengupta K, 2003, INT J ONCOL, V22, P609; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; Vesuna F, 2005, ANAL BIOCHEM, V342, P345, DOI 10.1016/j.ab.2005.04.047; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Vesuna F, 2006, CANCER GENET CYTOGEN, V167, P189, DOI 10.1016/j.cancergencyto.2006.01.014; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512	40	115	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3223	3234		10.1038/onc.2011.483	http://dx.doi.org/10.1038/onc.2011.483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22056872	Green Accepted			2022-12-28	WOS:000306113400002
J	Derocq, D; Prebois, C; Beaujouin, M; Laurent-Matha, V; Pattingre, S; Smith, GK; Liaudet-Coopman, E				Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Smith, G. K.; Liaudet-Coopman, E.			Cathepsin D is partly endocytosed by the LRP1 receptor and inhibits LRP1-regulated intramembrane proteolysis	ONCOGENE			English	Article						cancer; cathepsin D; LRP1; RIP; endocytosis; tyrosine phosphorylation	BREAST-CANCER CELLS; AMYLOID PRECURSOR PROTEIN; HUMAN PROCATHEPSIN-D; INTRACELLULAR DOMAIN; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CORECEPTOR FUNCTION; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; D INTERACTS	The aspartic protease cathepsin-D (cath-D) is a marker of poor prognosis in breast cancer that is overexpressed and hypersecreted by human breast cancer cells. Secreted pro-cath-D binds to the extracellular domain of the beta-chain of the LDL receptor-related protein-1 (LRP1) in fibroblasts. The LRP1 receptor has an 85-kDa transmembrane beta-chain and a noncovalently attached 515-kDa extracellular alpha-chain. LRP1 acts by (1) internalizing many ligands via its alpha-chain, (2) activating signaling pathways by phosphorylating the LRP1 beta-chain tyrosine and (3) modulating gene transcription by regulated intramembrane proteolysis (RIP) of its beta-chain. LRP1 RIP involves two cleavages: the first liberates the LRP1 ectodomain to give a membrane-associated form, LRP1 beta-CTF, and the second generates the LRP1 beta-intracellular domain, LRP1 beta-ICD, that modulates gene transcription. Here, we investigated the endocytosis of pro-cathD by LRP1 and the effect of pro-cath-D/LRP1 beta interaction on LRP1 beta tyrosine phosphorylation and/or LRP1 beta RIP. Our results indicate that pro-cath-D was partially endocytosed by LRP1 in fibroblasts. However, pro-cath-D and ectopic cath-D did not stimulate phosphorylation of the LRP1 beta-chain tyrosine. Interestingly, ectopic cath-D and its catalytically inactive (D231N)cath-D, and pro-(D231N)cath-D all significantly inhibited LRP1 RIP by preventing LRP1 beta-CTF production. Thus, cath-D inhibits LRP1 RIP independently of its catalytic activity by blocking the first cleavage. As cath-D triggers fibroblast outgrowth by LRP1, we propose that cath-D modulates the growth of fibroblasts by inhibiting LRP1 RIP in the breast tumor microenvironment. Oncogene (2012) 31, 3202-3212; doi:10.1038/onc.2011.501; published online 14 November 2011	[Liaudet-Coopman, E.] INSERM, U896, IRCM Val dAurelle Paul Lamarque, F-34298 Montpellier 5, France; [Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Liaudet-Coopman, E.] IRCM, Montpellier, France; [Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Liaudet-Coopman, E.] Univ Montpellier I, Montpellier, France; [Derocq, D.; Prebois, C.; Beaujouin, M.; Laurent-Matha, V.; Pattingre, S.; Liaudet-Coopman, E.] CRLC Val dAurelle Paul Lamarque, Montpellier, France; [Smith, G. K.] GlaxoSmithKline Inc, Screening & Compound Profiling, Res Triangle Pk, NC USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); GlaxoSmithKline	Liaudet-Coopman, E (corresponding author), INSERM, U896, IRCM Val dAurelle Paul Lamarque, F-34298 Montpellier 5, France.	emmanuelle.liaudet-coopman@inserm.fr	Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Valerie, LAURENT-MATHA/0000-0002-3277-7397; Pattingre, Sophie/0000-0001-6284-6050	Institut National de la Sante et de la Recherche Medicale; University of Montpellier I; ANR Jeunes Chercheuses; Jeunes Chercheurs; Ligue Nationale contre le Cancer; Association pour la Recherche sur le Cancer	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier I; ANR Jeunes Chercheuses(French National Research Agency (ANR)); Jeunes Chercheurs; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank Francoise Berthet and Nadia Kerdjadj for secretarial assistance, and Jean-Yves Cance for the photographs. We also thank Vincent Cavailles for pertinent suggestions for the gene reporter experiments, Herve Emonard for helpful discussions and Owen Parkes for English corrections. This work was supported by the Institut National de la Sante et de la Recherche Medicale, University of Montpellier I, ANR Jeunes Chercheuses, Jeunes Chercheurs and the Ligue Nationale contre le Cancer; the Association pour la Recherche sur le Cancer provided a fellowship for Melanie Beaujouin.	Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Beaujouin M, 2010, J CELL SCI, V123, P3336, DOI 10.1242/jcs.070938; Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Boucher P, 2004, TRENDS CARDIOVAS MED, V14, P55, DOI 10.1016/j.tcm.2003.12.001; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CAPONY F, 1989, CANCER RES, V49, P3904; CAPONY F, 1994, EXP CELL RES, V215, P154, DOI 10.1006/excr.1994.1327; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Emonard H, 2005, BIOCHIMIE, V87, P369, DOI 10.1016/j.biochi.2004.11.013; Fears CY, 2005, CANCER RES, V65, P9338, DOI 10.1158/0008-5472.CAN-05-1560; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, INT J CANCER, V84, P209, DOI 10.1002/(SICI)1097-0215(19990621)84:3<209::AID-IJC2>3.0.CO;2-9; FUSEK M, 1994, BIOCHEM J, V303, P775, DOI 10.1042/bj3030775; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Gonias SL, 2004, THROMB HAEMOSTASIS, V91, P1056, DOI 10.1160/TH04-01-0023; Hass MR, 2009, SEMIN CELL DEV BIOL, V20, P201, DOI 10.1016/j.semcdb.2008.11.014; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hu KB, 2006, J BIOL CHEM, V281, P2120, DOI 10.1074/jbc.M504988200; Hu L, 2008, CANCER RES, V68, P4666, DOI 10.1158/0008-5472.CAN-07-6276; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; Laurent-Matha V, 2002, EXP CELL RES, V277, P210, DOI 10.1006/excr.2002.5556; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007; Lillis AP, 2005, J THROMB HAEMOST, V3, P1884, DOI 10.1111/j.1538-7836.2005.01371.x; Liu CX, 2007, J BIOL CHEM, V282, P7504, DOI 10.1074/jbc.M608088200; Liu Q, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-17; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; May P, 2007, ANN MED, V39, P219, DOI 10.1080/07853890701214881; Mi KH, 2007, J NEUROCHEM, V101, P517, DOI 10.1111/j.1471-4159.2007.04447.x; Montel V, 2007, CANCER RES, V67, P9817, DOI 10.1158/0008-5472.CAN-07-0683; Newton CS, 2005, J BIOL CHEM, V280, P27872, DOI 10.1074/jbc.M505410200; Ohri SS, 2008, INT J ONCOL, V32, P491; Ohri SS, 2007, CANCER BIOL THER, V6, P1081, DOI 10.4161/cbt.6.7.4325; Polavarapu R, 2008, AM J PATHOL, V172, P1355, DOI 10.2353/ajpath.2008.070975; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P23586; Rochefort H, 1999, APMIS, V107, P86, DOI 10.1111/j.1699-0463.1999.tb01530.x; Rodriguez J, 2005, INT J BIOL MARKER, V20, P103, DOI 10.1177/172460080502000204; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Selvais C, 2011, FASEB J, V25, P2770, DOI 10.1096/fj.10-169508; Selvais C, 2009, ENDOCRINOLOGY, V150, P3792, DOI 10.1210/en.2009-0015; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Vashishta A, 2007, INT J ONCOL, V30, P1223; VETVICKA V, 1994, CANCER LETT, V79, P131; VIGNON F, 1986, ENDOCRINOLOGY, V118, P1537, DOI 10.1210/endo-118-4-1537; von Arnim CAF, 2005, J BIOL CHEM, V280, P17777, DOI 10.1074/jbc.M414248200; Wu LH, 2005, J CELL BIOCHEM, V96, P1021, DOI 10.1002/jcb.20596; Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje; Zhang HY, 2004, J BIOL CHEM, V279, P2221, DOI 10.1074/jbc.M310679200; Zurhove K, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164263	59	27	30	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3202	3212		10.1038/onc.2011.501	http://dx.doi.org/10.1038/onc.2011.501			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22081071	Green Accepted, Green Submitted			2022-12-28	WOS:000305934400008
J	Rygiel, TP; Karnam, G; Goverse, G; van der Marel, APJ; Greuter, MJ; van Schaarenburg, RA; Visser, WF; Brenkman, AB; Molenaar, R; Hoek, RM; Mebius, RE; Meyaard, L				Rygiel, T. P.; Karnam, G.; Goverse, G.; van der Marel, A. P. J.; Greuter, M. J.; van Schaarenburg, R. A.; Visser, W. F.; Brenkman, A. B.; Molenaar, R.; Hoek, R. M.; Mebius, R. E.; Meyaard, L.			CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor	ONCOGENE			English	Article						CD200R; immune regulation; anti-tumor responses; skin carcinogenesis; inhibitory receptors	REGULATORY T-CELLS; PROGNOSTIC-FACTOR; DENDRITIC CELLS; MOUSE SKIN; TH17 CELLS; TGF-BETA; HA-RAS; TOLERANCE; ANTIGEN; CANCER	Expression of CD200, the gene encoding the ligand for the inhibitory immune receptor CD200R, is an independent prognostic factor for various forms of leukemia predicting worse overall survival of the patients. The enhanced expression of CD200 on the tumors implies that anti-tumor responses can be enhanced by blockage of the CD200-CD200R interaction. Indeed, antibody-mediated blockade of the CD200-CD200R inhibitory axis is currently evaluated in clinical tests to boost immune responses against CD200-expressing tumors. Here, we show that mice lacking CD200, the exclusive ligand for CD200R, are resistant to chemical skin carcinogenesis. Importantly, CD200R controls tumor outgrowth independently of CD200 expression by the tumor cells themselves. Furthermore, Cd200(-/-) mice do not become tolerant to intranasally administered antigens, suggesting that tumor rejection is normally suppressed through CD200-induced immune tolerance. Decreased tumor outgrowth is accompanied by increased expression of the proinflammatory cytokines interleukin (IL)-1 beta and IL-6 by the lymph node (LN) dendritic cells. During carcinogenesis, skin-draining LNs of Cd200(-/-) mice contain increased numbers of IL-17-producing FoxP3(+) cells, which preferentially home to the tumors. Thus, the CD200-CD200R axis induces tolerance to external and tumor antigens and influences the T-regulatory/Th17 cell ratio. We demonstrate for the first time that the absence of CD200R signaling inhibits outgrowth of an endogenous tumor irrespective of CD200 expression by the tumor cells. This important paradigm shift leads to a much broader applicability of CD200-blockade in the treatment of tumors.	[Rygiel, T. P.; Karnam, G.; van Schaarenburg, R. A.; Meyaard, L.] Univ Med Ctr Utrecht, Dept Immunol, NL-3584 EA Utrecht, Netherlands; [Goverse, G.; van der Marel, A. P. J.; Greuter, M. J.; Molenaar, R.; Mebius, R. E.] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Visser, W. F.; Brenkman, A. B.] Netherlands Metabol Ctr, Utrecht, Netherlands; [Visser, W. F.; Brenkman, A. B.] Dept Metab & Endocrine Dis, Utrecht, Netherlands; [Hoek, R. M.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Meyaard, L (corresponding author), Univ Med Ctr Utrecht, Dept Immunol, Lundlaan 6,Room KC02-085-2, NL-3584 EA Utrecht, Netherlands.	l.meyaard@umcutrecht.nl		Rygiel, Tomasz/0000-0003-4746-6505; Meyaard, Linde/0000-0003-0707-4793; Mebius, Reina/0000-0003-0451-7464	Association for International Cancer Research [AICR 07-0086]; VICI [918.56.612]; Netherlands Organization for Scientific Research	Association for International Cancer Research; VICI(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	We thank Gerrit Spierenburg for cell sorting, Serge van de Pavert for assistance with the confocal microscope and Lewis Lanier, Frank Miedema, Berent Prakken and Erik Hack for critical review of versions of this manuscript. This research was supported by the Association for International Cancer Research (AICR 07-0086) to LM and TPR and by a VICI grant (918.56.612) (from the Netherlands Organization for Scientific Research) to REM, MJG and RM.	Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Fallarino F, 2004, J IMMUNOL, V173, P3748, DOI 10.4049/jimmunol.173.6.3748; Finch JS, 1996, CARCINOGENESIS, V17, P2551, DOI 10.1093/carcin/17.12.2551; Fouser LA, 2008, IMMUNOL REV, V226, P87, DOI 10.1111/j.1600-065X.2008.00712.x; Gorczynski RM, 1999, J IMMUNOL, V163, P1654; Hoek RM, 2000, SCIENCE, V290, P1768, DOI 10.1126/science.290.5497.1768; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Kretz-Rommel A, 2007, J IMMUNOL, V178, P5595, DOI 10.4049/jimmunol.178.9.5595; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Maniati E, 2010, ONCOGENE, V29, P5653, DOI 10.1038/onc.2010.367; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; McWhirter JR, 2006, P NATL ACAD SCI USA, V103, P1041, DOI 10.1073/pnas.0510081103; Meyer KC, 2008, BRIT J DERMATOL, V159, P1077, DOI 10.1111/j.1365-2133.2008.08818.x; Min WP, 2003, J IMMUNOL, V170, P1304, DOI 10.4049/jimmunol.170.3.1304; Molenaar R, 2009, J IMMUNOL, V183, P6395, DOI 10.4049/jimmunol.0900311; Moreaux J, 2006, BLOOD, V108, P4194, DOI 10.1182/blood-2006-06-029355; Mukhopadhyay S, 2010, CELL HOST MICROBE, V8, P236, DOI 10.1016/j.chom.2010.08.005; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; Pallasch CP, 2009, LEUKEMIA RES, V33, P460, DOI 10.1016/j.leukres.2008.08.021; Petermann KB, 2007, J CLIN INVEST, V117, P3922, DOI 10.1172/JCI32163; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ralph C, 2010, CLIN CANCER RES, V16, P1662, DOI 10.1158/1078-0432.CCR-09-2870; Rijkers ESK, 2008, MOL IMMUNOL, V45, P1126, DOI 10.1016/j.molimm.2007.07.013; Rosenblum MD, 2004, J INVEST DERMATOL, V123, P880, DOI 10.1111/j.0022-202X.2004.23461.x; Sharma MD, 2010, IMMUNITY, V33, P942, DOI 10.1016/j.immuni.2010.11.022; Sharma MD, 2009, BLOOD, V113, P6102, DOI 10.1182/blood-2008-12-195354; Siva A, 2008, CANCER IMMUNOL IMMUN, V57, P987, DOI 10.1007/s00262-007-0429-6; Snelgrove RJ, 2008, NAT IMMUNOL, V9, P1074, DOI 10.1038/ni.1637; Taylor N, 2005, J IMMUNOL, V174, P143, DOI 10.4049/jimmunol.174.1.143; Tonks A, 2007, LEUKEMIA, V21, P566, DOI 10.1038/sj.leu.2404559; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Unger WWJ, 2003, J IMMUNOL, V171, P4592, DOI 10.4049/jimmunol.171.9.4592; Unger WWJ, 2003, INT IMMUNOL, V15, P731, DOI 10.1093/intimm/dxg069; van der Marel APJ, 2007, J IMMUNOL, V179, P894, DOI 10.4049/jimmunol.179.2.894; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wilke CM, 2011, CARCINOGENESIS, V32, P643, DOI 10.1093/carcin/bgr019; Wolvers DAW, 1997, IMMUNOLOGY, V92, P328, DOI 10.1046/j.1365-2567.1997.00356.x; Wong KK, 2010, J LEUKOCYTE BIOL, V88, P361, DOI 10.1189/jlb.1009686; Wright GJ, 2001, IMMUNOLOGY, V102, P173, DOI 10.1046/j.1365-2567.2001.01163.x; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	44	53	53	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2979	2988		10.1038/onc.2011.477	http://dx.doi.org/10.1038/onc.2011.477			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22020332				2022-12-28	WOS:000305388400007
J	Zhou, AD; Diao, LT; Xu, H; Xiao, ZD; Li, JH; Zhou, H; Qu, LH				Zhou, A-D; Diao, L-T; Xu, H.; Xiao, Z-D; Li, J-H; Zhou, H.; Qu, L-H			beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway	ONCOGENE			English	Article						miR-372&373; Wnt/beta-catenin; LEF1; DKK1; feedback loop	EMBRYONIC STEM-CELLS; COLORECTAL-CANCER; BETA-CATENIN; EPIGENETIC INACTIVATION; NEGATIVE REGULATOR; COLON-CANCER; C-MYC; GENE; MICRORNAS; TARGET	The microRNA-371-373 (miR-371-373) cluster is specifically expressed in human embryonic stem cells (ESCs) and is thought to be involved in stem cell maintenance. Recently, microRNAs (miRNAs) of this cluster were shown to be frequently upregulated in several human tumors. However, the regulatory mechanism for the involvement of the miR-371-373 cluster in human ESCs or cancer cells remains unclear. In this study, we explored the relationship between this miRNA cluster and the Wnt/beta-catenin-signaling pathway, which has been shown to be involved in both stem cell maintenance and tumorigenesis. We show that miR-371-373 expression is induced by lithium chloride and is positively correlated with Wnt/beta-catenin-signaling activity in several human cancer cell lines. Mechanistically, three TCF/LEF1-binding elements (TBEs) were identified in the promoter region and shown to be required for Wnt-dependent activation of miR-371-373. Interestingly, we also found that miR-372&373, in turn, activate Wnt/beta-catenin signaling. In addition, four protein genes related to the Wnt/beta-catenin-signaling pathway were identified as direct targets of miR-372&373, including Dickkopf-1 (DKK1), a well-known inhibitor of Wnt/beta-catenin signaling. Using a lentiviral system, we showed that overexpression of miR-372 or miR-373 promotes cell growth and the invasive activity of tumor cells as knockdown of DKK1. Taken together, our study demonstrates a novel beta-catenin/LEF1-miR-372&373-DKK1 regulatory feedback loop, which may have a critical role in regulating the activity of Wnt/beta-catenin signaling in human cancer cells.	[Zhou, A-D; Diao, L-T; Xu, H.; Xiao, Z-D; Li, J-H; Zhou, H.; Qu, L-H] Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Qu, LH (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn, Minist Educ, 135 Xingangxi Rd, Guangzhou 510275, Guangdong, Peoples R China.	lssqlh@mail.sysu.edu.cn	Li, Junhao/AAI-2570-2019	Li, Junhao/0000-0001-6784-3780; Zhou, Hui/0000-0001-9157-3792; Zhou, Aidong/0000-0001-8389-9522; Xu, Hui/0000-0003-3424-1219	National Natural Science Foundation of China [30830066, 81070589, 30870530]; Ministry of Science and Technology of China [2011CB811300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Professor Mitsuyasu Kato at the University of Tsukuba for providing the pCAGGS-HA-LEF1 plasmid and Professor Mengfeng Li at the Second Affiliated Hospital of Sun Yat-Sen University for providing the Topflash/Fopflash plasmids. This work was supported by grants from the National Natural Science Foundation of China (30830066, 81070589 and 30870530) and the National Basic Research Program from the Ministry of Science and Technology of China (2011CB811300).	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Avvisato CL, 2007, J CELL SCI, V120, P2672, DOI 10.1242/jcs.03476; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005-0034; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Falk S, 2008, CELL STEM CELL, V2, P472, DOI 10.1016/j.stem.2008.03.006; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirata H, 2011, INT J CANCER, V128, P1793, DOI 10.1002/ijc.25507; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535; Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137; Kennell JA, 2008, P NATL ACAD SCI USA, V105, P15417, DOI 10.1073/pnas.0807763105; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lluis F, 2008, CELL STEM CELL, V3, P493, DOI 10.1016/j.stem.2008.08.017; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Palmer RD, 2010, CANCER RES, V70, P2911, DOI 10.1158/0008-5472.CAN-09-3301; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silver SJ, 2007, P NATL ACAD SCI USA, V104, P18151, DOI 10.1073/pnas.0706673104; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Xu H, 2010, HEPATOLOGY, V52, P1431, DOI 10.1002/hep.23818	39	113	124	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2968	2978		10.1038/onc.2011.461	http://dx.doi.org/10.1038/onc.2011.461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22020335				2022-12-28	WOS:000305388400006
J	Cheli, Y; Giuliano, S; Fenouille, N; Allegra, M; Hofman, V; Hofman, P; Bahadoran, P; Lacour, JP; Tartare-Deckert, S; Bertolotto, C; Ballotti, R				Cheli, Y.; Giuliano, S.; Fenouille, N.; Allegra, M.; Hofman, V.; Hofman, P.; Bahadoran, P.; Lacour, J-P; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.			Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells	ONCOGENE			English	Article						metastasis; MITF; mesenchymal transition; hypoxia; Bhlhb2; differentiation	EPITHELIAL-MESENCHYMAL TRANSITION; LESS-THAN-OR-EQUAL-TO-1 MM; CYCLE PROGRESSION; GENE-EXPRESSION; STEM-CELLS; IN-VITRO; DIFFERENTIATION; GROWTH; SPARC; DEC1	Melanomas are very aggressive neoplasms with notorious resistance to therapeutics. It was recently proposed that the remarkable phenotypic plasticity of melanoma cells allows for the rapid development of both resistance to chemotherapeutic drugs and invasive properties. Indeed, the capacity of melanoma cells to form distant metastases is the main cause of mortality in melanoma patients. Therefore, the identification of the mechanism controlling melanoma phenotype is of paramount importance. In the present report, we show that deletion of microphthalmia-associated transcription factor (MITF), the master gene in melanocyte differentiation, is sufficient to increase the metastatic potential of mouse and human melanoma cells. MITF silencing also increases fibronectin and Snail, two mesenchymal markers that might explain the increased invasiveness in vitro and in vivo. Furthermore, ablation of this population by Forskolin-induced differentiation or MITF-forced expression significantly decreases tumour and metastasis formation, suggesting that eradication of low-MITF cells might improve melanoma treatment. Moreover, we demonstrate that a hypoxic microenvironment decreases MITF expression through an indirect, hypoxia-inducible factor 1 (HIF1)alpha-dependant transcriptional mechanism, and increases the tumourigenic and metastatic properties of melanoma cells. We identified Bhlhb2, a new factor in melanoma biology, as the mediator of hypoxia/HIF1 alpha inhibitory effect on MITF expression. Our results reveal a hypoxia-HIF1 alpha-BHLHB2-MITF cascade controlling the phenotypic plasticity in melanoma cells and favouring metastasis development. Targeting this pathway might be helpful in the design of new anti-melanoma therapies. Oncogene (2012) 31, 2461-2470; doi:10.1038/onc.2011.425; published online 26 September 2011	[Ballotti, R.] INSERM, Equipe Labellisee Ligue Contre Canc, Ctr Mediterraneen Med Mol, Team 1,Equipe 1,U895, F-06204 Nice 3, France; [Cheli, Y.; Giuliano, S.; Fenouille, N.; Allegra, M.; Hofman, P.; Bahadoran, P.; Lacour, J-P; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.] Univ Nice Sophia Antipolis, UFR Med, Nice, France; [Hofman, V.; Hofman, P.] ERI21 EA 4319, Nice, France; [Hofman, V.; Hofman, P.] Human Biobank, Nice, France; [Bahadoran, P.; Lacour, J-P; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.] CHU NICE, Dept Dermatol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Ballotti, R (corresponding author), INSERM, Equipe Labellisee Ligue Contre Canc, Ctr Mediterraneen Med Mol, Team 1,Equipe 1,U895, 151 Route St Antoine de Ginestiere, F-06204 Nice 3, France.	ballotti@unice.fr	Hofman, Paul/P-7654-2018; Bertolotto, Corine/AAF-6634-2021; Fenouille, Nina/AAI-1027-2021; CHELI, Yann/O-5783-2016; TARTARE-DECKERT, Sophie/P-6057-2015	Hofman, Paul/0000-0003-0431-9353; Bertolotto, Corine/0000-0001-6971-7753; veronique, HOFMAN/0000-0003-0943-1627; CHELI, Yann/0000-0001-9839-4332; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; BALLOTTI, Robert/0000-0002-7322-4908; Bahadoran, Philippe/0000-0002-2481-0556	'Fondation de France'; Societe Francaise de Dermatologie; ARC	'Fondation de France'(Fondation de France); Societe Francaise de Dermatologie; ARC(Australian Research Council)	We thank Giorgetti-Peraldi Sophie, Regazzetti Claire and Karine Bille for their help. Bhlhb2 reporter plasmid and expression vector were a kind gift from Dr S Egan (Toronto, Canada). This work was supported by the 'Fondation de France', and Societe Francaise de Dermatologie. YC has been supported by ARC's fellowships. The authors greatly acknowledge the C3M Imaging core facility (microscopy and imaging platform Cote d'Azur, MICA) and the C3M animal room facility.	AGARWAL KC, 1983, INT J CANCER, V32, P801, DOI 10.1002/ijc.2910320622; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bhawal UK, 2011, J PATHOL, V224, P420, DOI 10.1002/path.2878; Botton T, 2009, J INVEST DERMATOL, V129, P1208, DOI 10.1038/jid.2008.346; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Cho Y, 2009, MOL PHARMACOL, V76, P1360, DOI 10.1124/mol.109.057000; Choi SM, 2008, NUCLEIC ACIDS RES, V36, P6372, DOI 10.1093/nar/gkn620; Corsetti RL, 2000, ANN SURG ONCOL, V7, P456, DOI 10.1007/s10434-000-0456-4; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Eichhoff OM, 2010, MELANOMA RES, V20, P349, DOI 10.1097/CMR.0b013e32833bd89e; Fenouille N, 2011, PIGM CELL MELANOMA R, V24, P219, DOI 10.1111/j.1755-148X.2010.00790.x; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; King R, 2001, AM J SURG PATHOL, V25, P51, DOI 10.1097/00000478-200101000-00005; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Nakashima A, 2008, MOL CELL BIOL, V28, P4080, DOI 10.1128/MCB.02168-07; Olbryt M, 2006, GENE EXPRESSION, V13, P191, DOI 10.3727/000000006783991818; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; SHAW HM, 1987, ARCH SURG-CHICAGO, V122, P1147; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059	40	135	141	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	19					2461	2470		10.1038/onc.2011.425	http://dx.doi.org/10.1038/onc.2011.425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996743				2022-12-28	WOS:000303985300008
J	Medema, RH; Macurek, L				Medema, R. H.; Macurek, L.			Checkpoint control and cancer	ONCOGENE			English	Review						DNA damage; checkpoint; cancer; checkpoint recovery	DNA-DAMAGE CHECKPOINT; POLO-LIKE KINASE-1; ACTIVATED PROTEIN-KINASE; CELL-CYCLE; WIP1 PHOSPHATASE; TUMOR-SUPPRESSOR; DEPENDENT DEGRADATION; IONIZING-RADIATION; CDC25A DEGRADATION; ANALYSIS REVEALS	DNA-damaging therapies represent the most frequently used non-surgical anticancer strategies in the treatment of human tumors. These therapies can kill tumor cells, but at the same time they can be particularly damaging and mutagenic to healthy tissues. The efficacy of DNA-damaging treatments can be improved if tumor cell death is selectively enhanced, and the recent application of poly-(ADP-ribose) polymerase inhibitors in BRCA1/2-deficient tumors is a successful example of this. DNA damage is known to trigger cell-cycle arrest through activation of DNA-damage checkpoints. This arrest can be reversed once the damage has been repaired, but irreparable damage can promote apoptosis or senescence. Alternatively, cells can reenter the cell cycle before repair has been completed, giving rise to mutations. In this review we discuss the mechanisms involved in the activation and inactivation of DNA-damage checkpoints, and how the transition from arrest and cell-cycle re-entry is controlled. In addition, we discuss recent attempts to target the checkpoint in anticancer strategies. Oncogene (2012) 31, 2601-2613; doi:10.1038/onc.2011.451; published online 3 October 2011	[Macurek, L.] Acad Sci Czech Republ, Inst Mol Genet, Dept Genome Integr, Prague 14200 4, Czech Republic; [Medema, R. H.] Univ Med Ctr, Dept Med Oncol, Utrecht, Netherlands	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Utrecht University; Utrecht University Medical Center	Macurek, L (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Dept Genome Integr, Videnska 1083, Prague 14200 4, Czech Republic.	libor.macurek@img.cas.cz	Medema, Rene H/E-2981-2013; Macurek, Libor/C-7865-2014	Macurek, Libor/0000-0002-0987-1238; Medema, Rene/0000-0002-6754-0381	Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research; Dutch Cancer Society [UU2009-4478]; Grant Agency of the Czech Republic [P301/10/1525, P305/10/P420]	Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research; Dutch Cancer Society(KWF Kankerbestrijding); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic)	RHM was funded by the Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research and by the Dutch Cancer Society (Grant UU2009-4478). LM was supported by the Grant Agency of the Czech Republic (P301/10/1525 and P305/10/P420).	Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2000, CANCER RES, V60, P5934; Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Anderson VE, 2011, CANCER RES, V71, P463, DOI 10.1158/0008-5472.CAN-10-1252; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Batchelor E, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.20; Batchelor E, 2009, NAT REV CANCER, V9, P371, DOI 10.1038/nrc2604; Bekker-Jensen S, 2010, DNA REPAIR, V9, P1219, DOI 10.1016/j.dnarep.2010.09.010; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Bennetzen MV, 2010, MOL CELL PROTEOMICS, V9, P1314, DOI 10.1074/mcp.M900616-MCP200; Bensimon A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001034; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chailleux C, 2010, BIOCHEM J, V426, P365, DOI 10.1042/BJ20091329; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cotta-Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430; Cuadrado M, 2009, CANCER RES, V69, P8726, DOI 10.1158/0008-5472.CAN-09-0729; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferguson AM, 2005, MOL CELL BIOL, V25, P2853, DOI 10.1128/MCB.25.7.2853-2860.2005; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Fracasso PM, 2011, CANCER CHEMOTH PHARM, V67, P1225, DOI 10.1007/s00280-010-1410-1; Freeman AK, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-27; Freeman AK, 2010, CELL CYCLE, V9, P736, DOI 10.4161/cc.9.4.10613; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gupta M, 2006, J BIOL CHEM, V281, P17552, DOI 10.1074/jbc.M600950200; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jin J, 2008, J BIOL CHEM, V283, P19322, DOI 10.1074/jbc.M802474200; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kuntz K, 2009, CANCER BIOL THER, V8, P1433, DOI 10.4161/cbt.8.15.9081; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Lee JH, 2010, EMBO J, V29, P574, DOI 10.1038/emboj.2009.372; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Liontos M, 2010, J CELL MOL MED, V14, P2264, DOI 10.1111/j.1582-4934.2010.01145.x; Liu QH, 2000, GENE DEV, V14, P1448; Liu XS, 2010, EMBO REP, V11, P626, DOI 10.1038/embor.2010.90; Lobjois V, 2009, BBA-MOL CELL RES, V1793, P462, DOI 10.1016/j.bbamcr.2008.12.015; Loewer A, 2010, CELL, V142, P89, DOI 10.1016/j.cell.2010.05.031; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Maya-Mendoza A, 2007, EMBO J, V26, P2719, DOI 10.1038/sj.emboj.7601714; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Menzel T, 2011, EMBO REP, V12, P705, DOI 10.1038/embor.2011.99; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Peng AM, 2010, CURR BIOL, V20, P387, DOI 10.1016/j.cub.2010.01.020; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Phong MS, 2010, MOL CELL BIOL, V30, P3816, DOI 10.1128/MCB.00949-09; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Satoh N, 2011, CANCER SCI, V102, P1101, DOI 10.1111/j.1349-7006.2011.01898.x; Secchiero P, 2011, CURR PHARM DESIGN, V17, P569, DOI 10.2174/138161211795222586; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shen H, 2011, CURR PHARM DESIGN, V17, P560, DOI 10.2174/138161211795222603; Shibata A, 2010, MOL CELL BIOL, V30, P3371, DOI 10.1128/MCB.01644-09; Shouse GP, 2011, ONCOGENE, V30, P3755, DOI 10.1038/onc.2011.95; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2011, CLIN CANCER RES, V17, P1521, DOI 10.1158/1078-0432.CCR-10-1688; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Tsvetkov L, 2005, CELL CYCLE, V4, P166, DOI 10.4161/cc.4.1.1348; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang P, 2011, J HUAZHONG U SCI-MED, V31, P94, DOI 10.1007/s11596-011-0157-1; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang YL, 2001, CANCER RES, V61, P8211; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhang XN, 2009, CANCER RES, V69, P7960, DOI 10.1158/0008-5472.CAN-09-0634; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	155	120	121	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2601	2613		10.1038/onc.2011.451	http://dx.doi.org/10.1038/onc.2011.451			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21963855				2022-12-28	WOS:000304523500001
J	Southern, SL; Collard, TJ; Urban, BC; Skeen, VR; Smartt, HJ; Hague, A; Oakley, F; Townsend, PA; Perkins, ND; Paraskeva, C; Williams, AC				Southern, S. L.; Collard, T. J.; Urban, B. C.; Skeen, V. R.; Smartt, H. J.; Hague, A.; Oakley, F.; Townsend, P. A.; Perkins, N. D.; Paraskeva, C.; Williams, A. C.			BAG-1 interacts with the p50-p50 homodimeric NF-kappa B complex: implications for colorectal carcinogenesis	ONCOGENE			English	Article						NF-kappa B; BAG-1; p50 homodimers; colorectal cancer; EGFR; COX2	ALTERNATIVE TRANSLATION INITIATION; SQUAMOUS-CELL CARCINOMA; DNA-BINDING; CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; ONCOPROTEIN BCL-3; P50 HOMODIMERS; PROTEIN; EXPRESSION; RECEPTOR	Understanding the mechanisms that promote aberrant tumour cell survival is critical for the determination of novel strategies to combat colorectal cancer (CRC). We have recently shown that the anti-apoptotic protein BAG-1, highly expressed in pre-malignant and CRC tissue, can potentiate cell survival through regulating NF-kappa B transcriptional activity. In this study, we identify a novel complex between BAG-1 and the p50-p50 NF-kappa B homodimers, implicating BAG-1 as a co-regulator of an atypical NF-kappa B pathway. Importantly, the BAG-1-p50 complex was detected at gene regulatory sequences including the epidermal growth factor receptor (EGFR) and COX-2 (PTGS2) genes. Suppression of BAG-1 expression using small interfering RNA was shown to increase EGFR and suppress COX-2 expression in CRC cells. Furthermore, mouse embryonic fibroblasts derived from the NF-kappa B1 (p105/p50) knock-out mouse were used to demonstrate that p50 expression was required for BAG-1 to suppress EGFR expression. This was shown to be functionally relevant as attenuation of BAG-1 expression increased ligand activated phosphorylation of EGFR in CRC cells. In summary, this paper identifies a novel role for BAG-1 in modulating gene expression through interaction with the p50-p50 NF-kappa B complexes. Data presented led us to propose that BAG-1 can act as a selective regulator of p50-p50 NF-kappa B responsive genes in colorectal tumour cells, potentially important for the promotion of cell survival in the context of the fluctuating tumour microenvironment. As BAG-1 expression is increased in the developing adenoma through to metastatic lesions, understanding the function of the BAG-1-p50 NF-kappa B complexes may aid in identifying strategies for both the prevention and treatment of CRC. Oncogene (2012) 31, 2761-2772; doi: 10.1038/onc.2011.452; published online 3 October 2011	[Southern, S. L.; Collard, T. J.; Urban, B. C.; Skeen, V. R.; Smartt, H. J.; Paraskeva, C.; Williams, A. C.] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England; [Hague, A.] Univ Bristol, Sch Oral & Dent Sci, Bristol BS8 1TD, Avon, England; [Oakley, F.; Perkins, N. D.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci ICaMB, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Townsend, P. A.] Univ Southampton, Sch Med, Southampton Gen Hosp, Div Canc Sci, Southampton, Hants, England	University of Bristol; University of Bristol; Newcastle University - UK; University of Southampton	Williams, AC (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Med Sci Bldg, Bristol BS8 1TD, Avon, England.	Ann.C.Williams@bristol.ac.uk	Townsend, Paul/AAF-8234-2020	Williams, Ann/0000-0002-6009-7137; Oakley, Fiona/0000-0001-8692-1836; Townsend, Paul/0000-0001-8956-9508; Urban, Bettina/0000-0002-9015-7583	Cancer Research UK; Citrina Foundation; Wellcome Trust; James Bristol Foundation; Medical Research Council; MRC [G0900535] Funding Source: UKRI; Cancer Research UK [11975] Funding Source: researchfish; Medical Research Council [G0900535] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Citrina Foundation; Wellcome Trust(Wellcome Trust); James Bristol Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was funded by a Cancer Research UK programme grant, the Citrina Foundation, The Wellcome Trust and by the John James Bristol Foundation. We thank the Medical Research Council for providing an Infrastructure Award to establish the School of Medical Sciences Cell Imaging Facility at the University of Bristol.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; Arlt A, 2002, CANCER RES, V62, P910; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnes JD, 2005, APOPTOSIS, V10, P301, DOI 10.1007/s10495-005-0804-8; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Cancer Research UK, 2007, BOW CANC FACTSH; Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Clemo NK, 2008, CARCINOGENESIS, V29, P849, DOI 10.1093/carcin/bgn004; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gehring U, 2009, INT J MOL SCI, V10, P906, DOI 10.3390/ijms10030906; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Glass CK, 2000, GENE DEV, V14, P121; Hinitt CAM, 2010, EXP CELL RES, V316, P2042, DOI 10.1016/j.yexcr.2010.04.016; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; Inan MS, 2000, AM J PHYSIOL-GASTR L, V279, pG1282, DOI 10.1152/ajpgi.2000.279.6.G1282; Jiang YX, 2009, CANCER-AM CANCER SOC, V115, P3609, DOI 10.1002/cncr.24434; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kikuchi R, 2002, BRIT J CANCER, V87, P1136, DOI 10.1038/sj.bjc.6600579; Knowlden JM, 2008, BREAST CANCER RES TR, V111, P79, DOI 10.1007/s10549-007-9763-9; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Maier JV, 2010, BIOCHEM BIOPH RES CO, V401, P406, DOI 10.1016/j.bbrc.2010.09.067; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Niyaz Y, 2001, J CELL SCI, V114, P1839; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pereira SG, 2008, INT J BIOCHEM CELL B, V40, P1425, DOI 10.1016/j.biocel.2007.05.004; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Shindoh M, 2000, ORAL ONCOL, V36, P444, DOI 10.1016/S1368-8375(00)00025-7; Smartt HJM, 2003, BRIT J CANCER, V89, P1358, DOI 10.1038/sj.bjc.6601266; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Takayama S, 1998, CANCER RES, V58, P3116; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornburg NJ, 2003, CANCER RES, V63, P8293; Tong X, 2004, MOL CELL BIOCHEM, V265, P171, DOI 10.1023/B:MCBI.0000044394.66951.4d; Townsend PA, 2005, INT J BIOCHEM CELL B, V37, P251, DOI 10.1016/j.biocel.2004.03.016; Weldon CB, 2001, SURGERY, V130, P143, DOI 10.1067/msy.2001.115512; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Wood J, 2009, ORAL ONCOL, V45, P94, DOI 10.1016/j.oraloncology.2008.07.013; Xiao GT, 2006, CYTOKINE GROWTH F R, V17, P281, DOI 10.1016/j.cytogfr.2006.04.005; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	66	22	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2761	2772		10.1038/onc.2011.452	http://dx.doi.org/10.1038/onc.2011.452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963853	Green Accepted			2022-12-28	WOS:000304769000006
J	Paranjape, AN; Mandal, T; Mukherjee, G; Kumar, MV; Sengupta, K; Rangarajan, A				Paranjape, A. N.; Mandal, T.; Mukherjee, G.; Kumar, M. V.; Sengupta, K.; Rangarajan, A.			Introduction of SV40ER and hTERT into mammospheres generates breast cancer cells with stem cell properties	ONCOGENE			English	Article						adenocarcinoma; breast cancer stem cells; EMT; mammospheres; SV40ER; telomerase	MAMMARY STEM/PROGENITOR CELLS; LARGE T-ANTIGEN; EPITHELIAL-CELLS; SELF-RENEWAL; TRANSFORMATION; EXPRESSION; CULTURE; NOTCH; P53; IMMORTALIZATION	Emerging evidence suggests that cancers arise in stem/progenitor cells. Yet, the requirements for transformation of these primitive cells remains poorly understood. In this study, we have exploited the 'mammosphere' system that selects for primitive mammary stem/progenitor cells to explore their potential and requirements for transformation. Introduction of Simian Virus 40 Early Region and hTERT into mammosphere-derived cells led to the generation of NBLE, an immortalized mammary epithelial cell line. The NBLEs largely comprised of bi-potent progenitors with long-term self-renewal and multi-lineage differentiation potential. Clonal and karyotype analyses revealed the existence of heterogeneous population within NBLEs with varied proliferation, differentiation and sphere-forming potential. Significantly, injection of NBLEs into immunocompromised mice resulted in the generation of invasive ductal adenocarcinomas. Further, these cells harbored a sub-population of CD44(+)/CD24(-) fraction that alone had sphere- and tumor-initiating potential and resembled the breast cancer stem cell gene signature. Interestingly, prolonged in vitro culturing led to their further enrichment. The NBLE cells also showed increased expression of stemness and epithelial to mesenchymal transition markers, deregulated self-renewal pathways, activated DNA-damage response and cancer-associated chromosomal aberrations-all of which are likely to have contributed to their tumorigenic transformation. Thus, unlike previous in vitro transformation studies that used adherent, more differentiated human mammary epithelial cells our study demonstrates that the mammosphere-derived, less-differentiated cells undergo tumorigenic conversion with only two genetic elements, without requiring oncogenic Ras. Moreover, the striking phenotypic and molecular resemblance of the NBLE-generated tumors with naturally arising breast adenocarcinomas supports the notion of a primitive breast cell as the origin for this subtype of breast cancer. Finally, the NBLEs represent a heterogeneous population of cells with striking plasticity, capable of differentiation, self-renewal and tumorigenicity, thus offering a unique model system to study the molecular mechanisms involved with these processes. Oncogene (2012) 31, 1896-1909; doi:10.1038/onc.2011.378; published online 29 August 2011	[Paranjape, A. N.; Mandal, T.; Rangarajan, A.] Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India; [Paranjape, A. N.; Mukherjee, G.; Kumar, M. V.] Kidwai Mem Inst Oncol, Dept Pathol, Bangalore, Karnataka, India; [Sengupta, K.] Indian Inst Sci Educ & Res, Dept Biol, Pune, Maharashtra, India	Indian Institute of Science (IISC) - Bangalore; Kidwai Memorial Institute of Oncology; Indian Institute of Science Education & Research (IISER) Pune	Rangarajan, A (corresponding author), Indian Inst Sci, Dept Mol Reprod Dev & Genet, CV Raman Ave, Bangalore 560012, Karnataka, India.	anu@mrdg.iisc.ernet.in	Paranjape, Anurag N./P-1255-2018; Mandal, Tamoghna/AAX-3710-2021	Paranjape, Anurag N./0000-0001-6119-0766; Mandal, Tamoghna/0000-0003-4372-6760; M, Vijayakumar/0000-0002-0711-1737; Mukherjee, Geetashree/0000-0003-4954-0035	DBT; UGC	DBT(Department of Biotechnology (DBT) India); UGC(University Grants Commission, India)	We thank Dr Robert A Weinberg (Whitehead Institute) for hTERT cDNA, HMLE and HMLER cells and Dr Inder M Verma (Salk Institute) for pCSCG lentiviral vector. We acknowledge Swati Maiti for insightful discussions, and thank D Alaguraj, Drs Omana Joy, William Surin (IISc) and H Krishnamurthy (NCBS) for help with flow cytometry. We also thank Dr Paturu Kondaiah and Imran Khan (IISc), and Mohammed Aiyaz (Genotypic India Pvt. Ltd) for help with microarray experiments and data analysis. This work was largely supported by research grants from DBT to AR for equipment and consumables. We acknowledge the confocal, IRIS, FACS and animal facilities at IISc, and grants from UGC to the Department of MRDG, IISc.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Ali-Seyed M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-54; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Bissell MJ, 1999, CANCER RES, V59, p1757S; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Dey D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005329; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jerry DJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2133; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pardal R, 2005, COLD SH Q B, V70, P177, DOI 10.1101/sqb.2005.70.057; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Phesse TJ, 2009, BRIT J CANCER, V100, P221, DOI 10.1038/sj.bjc.6604850; Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Salas NR, 2010, CLIN TRANSL ONCOL, V12, P395, DOI 10.1007/s12094-010-0526-4; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Uchino M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-414; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WOODS C, 1994, ONCOGENE, V9, P2943; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zhao XS, 2010, P NATL ACAD SCI USA, V107, P14146, DOI 10.1073/pnas.1009030107	41	25	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1896	1909		10.1038/onc.2011.378	http://dx.doi.org/10.1038/onc.2011.378			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874052				2022-12-28	WOS:000302809900003
J	Taketani, K; Kawauchi, J; Tanaka-Okamoto, M; Ishizaki, H; Tanaka, Y; Sakai, T; Miyoshi, J; Maehara, Y; Kitajima, S				Taketani, K.; Kawauchi, J.; Tanaka-Okamoto, M.; Ishizaki, H.; Tanaka, Y.; Sakai, T.; Miyoshi, J.; Maehara, Y.; Kitajima, S.			Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells	ONCOGENE			English	Article						DR5; ATF3; p53; CPT; TRAIL	ACTIVATING TRANSCRIPTION FACTOR-3; NECROSIS-FACTOR-ALPHA; APOPTOSIS-INDUCING LIGAND; RESPONSE GENE ATF3; ENDOTHELIAL-CELLS; P53 TRANSCRIPTION; STRESS RESPONSES; GENOTOXIC STRESS; KILLER/DR5 GENE; DEATH LIGAND	Stress response gene ATF3 is one of the p53 target genes and has a tumor suppressor role in cancer. However, the biological role of p53-ATF3 pathway is not well understood. Death receptor 5 (DR5) is a death domain-containing transmembrane receptor that triggers cell death upon binding to its ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), and a combination of TRAIL and agents that increase the expression of DR5 is expected as a novel anticancer therapy. In this report, we demonstrate that ATF3 is required for efficient DR5 induction upon DNA damage by camptothecin (CPT) in colorectal cancer cells. In the absence of ATF3, induction of DR5 messenger RNA and protein is remarkably abrogated, and this is associated with reduced cell death by TRAIL and CPT. By contrast, exogenous expression of ATF3 causes more rapid and elevated expression of DR5, resulting in enhanced sensitivity to apoptotic cell death by TRAIL/CPT. Reporter assay and DNA affinity precipitation assay demonstrate that at least three ATF/CRE motifs at the proximal promoter of the human DR5 gene are involved in the activation of DNA damage-induced DR5 gene transcription. Furthermore, ATF3 is shown to interact with p53 to form a complex on the DR5 gene by Re-chromatin immunoprecipitation assay. Taken together, our results provide a novel insight into the role of ATF3 as an essential co-transcription factor for p53 upon DNA damage, and this may represent a useful biomarker for TRAIL-based anticancer therapy. Oncogene (2012) 31, 2210-2221; doi:10.1038/onc.2011.397; published online 19 September 2011	[Kitajima, S.] Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; [Taketani, K.; Maehara, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; [Tanaka-Okamoto, M.; Ishizaki, H.; Miyoshi, J.] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Mol Biol, Osaka, Japan; [Sakai, T.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Targeting Canc Prevent, Kyoto, Japan	Tokyo Medical & Dental University (TMDU); Kyushu University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Kyoto Prefectural University of Medicine	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kita.bgen@mri.tmd.ac.jp		Tanaka-Okamoto, Miki/0000-0002-6429-7662	Ministry of Education, Culture, Sports, Science, and Technology of Japan [18012015, 18055008, 21590302, 22300330]; Grants-in-Aid for Scientific Research [22700878] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr WS El-Deiry for a kind gift of valuable plasmid pGL2-Full. This work was supported in part by a grant-in-aid for Research on Priority Areas from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [18012015, 18055008, 21590302] to SK and [22300330] to JM.	Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Ashkenazi A, 2008, J CLIN INVEST, V118, P1979, DOI 10.1172/JCI34359; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Farczadi E, 1999, NEOPLASMA, V46, P219; Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016/j.ctrv.2006.07.001; Gliniak B, 1999, CANCER RES, V59, P6153; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Hai T, 1999, GENE EXPRESSION, V7, P321; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Kawauchi J, 2002, J BIOL CHEM, V277, P39025, DOI 10.1074/jbc.M202974200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Legarza K, 2006, ANTICANCER RES, V26, P3301; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Miyazaki K, 2009, NUCLEIC ACIDS RES, V37, P1438, DOI 10.1093/nar/gkn1082; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naka T, 2002, CANCER RES, V62, P5800; Nesterov A, 2004, CANCER RES, V64, P3922, DOI 10.1158/0008-5472.CAN-03-2219; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nobori K, 2002, J MOL CELL CARDIOL, V34, P1387, DOI 10.1006/jmcc.2002.2091; PAN JL, 1993, J BIOL CHEM, V268, P22600; Pelzer AE, 2006, J UROLOGY, V175, P1517, DOI 10.1016/S0022-5347(05)00651-8; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Scott N, 1998, EUR J SURG ONCOL, V24, P169, DOI 10.1016/S0748-7983(98)92861-X; Sellers WR, 1999, J CLIN INVEST, V104, P1655, DOI 10.1172/JCI9053; Sheikh MS, 1998, CANCER RES, V58, P1593; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sussman RT, 2007, CANCER BIOL THER, V6, P1490, DOI 10.4161/cbt.6.9.4905; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Turchi L, 2008, CELL DEATH DIFFER, V15, P1472, DOI 10.1038/cdd.2008.74; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wei MC, 2000, GENE DEV, V14, P2060; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Yoon K, 2011, CARCINOGENESIS, V32, P836, DOI 10.1093/carcin/bgr040; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Zhang C, 2002, BIOCHEM BIOPH RES CO, V297, P1302, DOI 10.1016/S0006-291X(02)02382-3	55	59	59	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2210	2221		10.1038/onc.2011.397	http://dx.doi.org/10.1038/onc.2011.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21927023	Bronze			2022-12-28	WOS:000303415900009
J	Gu, L; Zhang, H; He, J; Li, J; Huang, M; Zhou, M				Gu, L.; Zhang, H.; He, J.; Li, J.; Huang, M.; Zhou, M.			MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells	ONCOGENE			English	Article						MYCN; MDM2; neuroblastoma	DIRECT TRANSCRIPTIONAL TARGET; RING FINGER DOMAIN; N-MYC; BINDING PROTEIN; IN-VIVO; EXPRESSION; P53; HUD; AMPLIFICATION; INDUCTION	The MYCN gene has a critical role in determining the clinical behavior of neuroblastoma. Although it is known that genomic amplification occurs in high-risk subsets, it remains unclear how MYCN expression is regulated in the pathogenesis of neuroblastomas. Here, we report that MYCN expression was regulated by the oncoprotein MDM2 at the post-transcriptional level and was associated with neuroblastoma cell growth. Increasing MDM2 by ectopic overexpression in the cytoplasm enhanced both mRNA and protein expression of MYCN. Mechanistic studies found that the C-terminal RING domain of the MDM2 protein bound to the MYCN mRNA's AREs within the 3 ' UTR and increased MYCN 3 ' UTR-mediated mRNA stability and translation. Conversely, MDM2 silencing by specific siRNA rendered the MYCN mRNA unstable and reduced the abundance of the MYCN protein in MYCN-amplified neuroblastoma cell lines. Importantly, this MDM2 silencing resulted in a remarkable inhibition of neuroblastoma cell growth and induction of cell death through a p53-independent pathway. Our results indicate that MDM2 has a p53-independent role in the regulation of both MYCN mRNA stabilization and its translation, suggesting that MDM2-mediated MYCN expression is one mechanism associated with growth of MYCN-associated neuroblastoma and disease progression. Oncogene (2012) 31, 1342-1353; doi:10.1038/onc.2011.343; published online 8 August 2011	[Zhou, M.] Emory Univ, Div Pediat Hematol Oncol, Sch Med, Dept Pediat,Aflac Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Blood Disorders Serv, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University	Zhou, M (corresponding author), Emory Univ, Div Pediat Hematol Oncol, Sch Med, Dept Pediat,Aflac Canc Ctr, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	mzhou@emory.edu			National Institutes of Health [R01 CA123490, R01CA143107]; CURE; NATIONAL CANCER INSTITUTE [R01CA143107, R01CA123490] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CURE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (R01 CA123490 and R01CA143107 to MZ) and CURE (MZ and LG).	Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Anderson JJ, 2007, INT J ONCOL, V31, P545; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Cattelani S, 2008, CLIN CANCER RES, V14, P3248, DOI 10.1158/1078-0432.CCR-07-4725; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen LD, 2010, CANCER RES, V70, P1377, DOI 10.1158/0008-5472.CAN-09-2598; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; CORVI R, 1995, ONCOGENE, V10, P1081; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fornaro M, 2007, ANN ANAT, V189, P223, DOI 10.1016/j.aanat.2006.11.004; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; Horvilleur E, 2008, NUCLEIC ACIDS RES, V36, P4222, DOI 10.1093/nar/gkn394; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Lai ZH, 1998, BIOCHEMISTRY-US, V37, P17005, DOI 10.1021/bi980596r; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; Manohar CF, 2002, J BIOL CHEM, V277, P1967, DOI 10.1074/jbc.M106966200; Matthay KK, 2000, J CLIN ONCOL, V18, P3591, DOI 10.1200/JCO.2000.18.21.3591; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Peirce SK, 2009, INT J ONCOL, V34, P1395, DOI 10.3892/ijo_00000267; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Ross RA, 1997, EUR J CANCER, V33, P2071, DOI 10.1016/S0959-8049(97)00331-6; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; Thompson J, 1997, CLIN CANCER RES, V3, P423; Wang XQ, 2001, NAT STRUCT BIOL, V8, P141, DOI 10.1038/84131; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618	39	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1342	1353		10.1038/onc.2011.343	http://dx.doi.org/10.1038/onc.2011.343			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822304	Green Accepted			2022-12-28	WOS:000301780000002
J	Weyemi, U; Lagente-Chevallier, O; Boufraqech, M; Prenois, F; Courtin, F; Caillou, B; Talbot, M; Dardalhon, M; Al Ghuzlan, A; Bidart, JM; Schlumberger, M; Dupuy, C				Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Caillou, B.; Talbot, M.; Dardalhon, M.; Al Ghuzlan, A.; Bidart, J-M; Schlumberger, M.; Dupuy, C.			ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence	ONCOGENE			English	Article						oncogenic H-RasV12; ROS; NADPH oxidase NOX4; DNA damage; senescence	SMOOTH-MUSCLE-CELLS; REACTIVE OXYGEN; PREMATURE SENESCENCE; GENOMIC INSTABILITY; CELLULAR SENESCENCE; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MAMMALIAN-CELLS; NAD(P)H OXIDASE; TUMORIGENESIS	Activated Ras oncogene induces DNA-damage response by triggering reactive oxygen species (ROS) production and this is critical for oncogene-induced senescence. Until now, little connections between oncogene expression, ROS-generating NADPH oxidases and DNA-damage response have emerged from different studies. Here we report that H-RasV12 positively regulates the NADPH oxidase system NOX4-p22(phox) that produces H2O2. Knocking down the NADPH oxidase with small interference RNA decreases H-RasV12-induced DNA-damage response detected by gamma-H2A.X foci analysis. Using HyPer, a specific probe for H2O2, we detected an increase in H2O2 in the nucleus correlated with NOX4-p22(phox) perinuclear localization. DNA damage response can be caused not only by H-RasV12-driven accumulation of ROS but also by a replicative stress due to a sustained oncogenic signal. Interestingly, NOX4 downregulation by siRNA abrogated H-RasV12 regulation of CDC6 expression, an essential regulator of DNA replication. Moreover, senescence markers, such as senescence-associated heterochromatin foci, PML bodies, HP1 beta foci and p21 expression, induced under H-RasV12 activation were decreased with NOX4 inactivation. Taken together, our data indicate that NADPH oxidase NOX4 is a critical mediator in oncogenic H-RasV12-induced DNA-damage response and subsequent senescence. Oncogene (2012) 31, 1117-1129; doi:10.1038/onc.2011.327; published online 15 August 2011	[Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Bidart, J-M; Schlumberger, M.; Dupuy, C.] CNRS, Inst Gustave Roussy, UMR8200, F-94805 Villejuif, France; [Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Talbot, M.; Al Ghuzlan, A.; Bidart, J-M; Schlumberger, M.; Dupuy, C.] Univ Paris 11, Orsay, France; [Dardalhon, M.] CNRS, Inst Curie, Sect Rech, UMR 3348, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Dupuy, C (corresponding author), CNRS, Inst Gustave Roussy, UMR8200, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	dupuy@igr.fr	Weyemi, Urbain/E-2083-2016; Boufraqech, Myriem/E-4823-2016		Electricite de France (EDF); Association pour la Recherche sur le Cancer (ARC); Ligue Contre le Cancer (comite du Val-de Marne); Agence Nationale de la Recherche (ANR)	Electricite de France (EDF)(Electricite de France (EDF)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Ligue Contre le Cancer (comite du Val-de Marne); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR))	Urbain Weyemi is the recipient of a grant from the Fondation pour la Recherche Medicale (FRM). We are indebted to Didier Methivier from Unite U848 INSERM, Villejuif, F-94805, France for his assistance in flow cytometry. This work was supported by grants from Electricite de France (EDF), Association pour la Recherche sur le Cancer (ARC), Ligue Contre le Cancer (comite du Val-de Marne) and Agence Nationale de la Recherche (ANR).	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Anilkumar N, 2008, ARTERIOSCL THROM VAS, V28, P1347, DOI 10.1161/ATVBAHA.108.164277; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; Boucher D, 2006, RADIAT ENVIRON BIOPH, V45, P267, DOI 10.1007/s00411-006-0070-3; Chiera F, 2008, FREE RADICAL BIO MED, V44, P332, DOI 10.1016/j.freeradbiomed.2007.09.018; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Debidda M, 2006, J BIOL CHEM, V281, P38519, DOI 10.1074/jbc.M604607200; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hemann MT, 2007, GENE DEV, V21, P1, DOI 10.1101/gad.1514207; Hilenski LL, 2004, ARTERIOSCL THROM VAS, V24, P677, DOI 10.1161/01.ATV.0000112024.13727.2c; Johnson DG, 2006, CURR MOL MED, V6, P731; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Kuroda J, 2005, GENES CELLS, V10, P1139, DOI 10.1111/j.1365-2443.2005.00907.x; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Lener B, 2009, BIOCHEM J, V423, P363, DOI 10.1042/BJ20090666; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Lyle AN, 2009, CIRC RES, V105, P249, DOI 10.1161/CIRCRESAHA.109.193722; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Nuciforo PG, 2007, CARCINOGENESIS, V28, P2082, DOI 10.1093/carcin/bgm108; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schilder YDC, 2009, FREE RADICAL BIO MED, V46, P1598, DOI 10.1016/j.freeradbiomed.2009.03.013; Serrander L, 2007, BIOCHEM J, V406, P105, DOI 10.1042/BJ20061903; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Weyemi U, 2010, ENDOCR-RELAT CANCER, V17, P27, DOI 10.1677/ERC-09-0175; Zhang L, 2008, FREE RADICAL BIO MED, V45, P679, DOI 10.1016/j.freeradbiomed.2008.05.019; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	47	207	211	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1117	1129		10.1038/onc.2011.327	http://dx.doi.org/10.1038/onc.2011.327			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21841825	Green Published, hybrid			2022-12-28	WOS:000300945900005
J	Lakshmanan, I; Ponnusamy, MP; Das, S; Chakraborty, S; Haridas, D; Mukhopadhyay, P; Lele, SM; Batra, SK				Lakshmanan, I.; Ponnusamy, M. P.; Das, S.; Chakraborty, S.; Haridas, D.; Mukhopadhyay, P.; Lele, S. M.; Batra, S. K.			MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells	ONCOGENE			English	Article						MUC16; JNK; Aurora kinase; Cyclin B1; G2/M arrest and breast cancer	N-TERMINAL DOMAIN; AURORA-A; C-JUN; TRANSCRIPTION FACTORS; CYCLE INHIBITORS; EPITHELIAL-CELLS; TYROSINE KINASE; MITOTIC ENTRY; DNA-DAMAGE; PHOSPHORYLATION	MUC16/CA125 is a tumor marker currently used in clinics for the follow-up of patients with ovarian cancer. However, MUC16 expression is not entirely restricted to ovarian malignancies and has been reported in other cancers including breast cancer. Although it is well established as a biomarker, function of MUC16 in cancer remains to be elucidated. In the present study, we investigated the role of MUC16 in breast cancer and its underlying mechanisms. Interestingly, our results showed that MUC16 is overexpressed in breast cancer tissues whereas not expressed in non-neoplastic ducts. Further, stable knockdown of MUC16 in breast cancer cells (MDA MB 231 and HBL100) resulted in significant decrease in the rate of cell growth, tumorigenicity and increased apoptosis. In search of a mechanism for breast cancer cell proliferation we found that MUC16 interacts with the ezrin/radixin/moesin domain-containing protein of Janus kinase ( JAK2) as demonstrated by the reciprocal immunoprecipitation method. These interactions mediate phosphorylation of STAT3 (Tyr705), which might be a potential mechanism for MUC16-induced proliferation of breast cancer cells by a subsequent co-transactivation of transcription factor c-Jun. Furthermore, silencing of MUC16 induced G2/M arrest in breast cancer cells through downregulation of Cyclin B1 and decreased phosphorylation of Aurora kinase A. This in turn led to enhanced apoptosis in the MUC16-knockdown breast cancer cells through Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated extrinsic apoptotic pathway with the help of c-Jun N-terminal kinase signaling. Collectively, our results suggest that MUC16 has a dual role in breast cancer cell proliferation by interacting with JAK2 and by inhibiting the apoptotic process through downregulation of TRAIL. Oncogene (2012) 31, 805-817; doi: 10.1038/onc.2011.297; published online 25 July 2011	[Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lele, S. M.; Batra, S. K.] Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu		Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X; Mukhopadhyay, Partha/0000-0001-5817-0174; lakshmanan, Imayavaramban/0000-0003-1733-2223	National Institutes of Health [CA78590, CA111294, CA133774, CA131944]; Department of Defense [BC101014]; NATIONAL CANCER INSTITUTE [R01CA133774, R01CA078590, U01CA111294, R01CA131944] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are supported by grants from the National Institutes of Health (CA78590, CA111294, CA133774 and CA131944) and Department of Defense (BC101014). We thank Dr Jessica Mercer, Editorial Grants Associate at UNMC, for carefully editing this manuscript. We also acknowledge Erik Moore and Kavita Mallya for their technical support. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at UNMC for their support.	Bafna S, 2008, CANCER RES, V68, P9231, DOI 10.1158/0008-5472.CAN-08-3135; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blalock TD, 2007, INVEST OPHTH VIS SCI, V48, P4509, DOI 10.1167/iovs.07-0430; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chen M, 1997, P NATL ACAD SCI USA, V94, P6910, DOI 10.1073/pnas.94.13.6910; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fendrick JL, 1997, TUMOR BIOL, V18, P278, DOI 10.1159/000218041; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; Fujimoto K, 1999, INT J CANCER, V81, P637, DOI 10.1002/(SICI)1097-0215(19990517)81:4<637::AID-IJC21>3.0.CO;2-4; Gamet-Payrastre L, 2000, CANCER RES, V60, P1426; Ginsberg M, 2007, MOL CELL BIOL, V27, P6300, DOI 10.1128/MCB.00613-07; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; He LL, 2008, J BIOL CHEM, V283, P31012, DOI 10.1074/jbc.M803547200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Huang YL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005397; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korgun ET, 2006, HISTOCHEM CELL BIOL, V125, P615, DOI 10.1007/s00418-006-0160-y; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Lin HH, 2007, INT J CANCER, V120, P2306, DOI 10.1002/ijc.22571; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Moritani S, 2008, HUM PATHOL, V39, P666, DOI 10.1016/j.humpath.2007.09.009; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Munro EG, 2009, INT J GYNECOL PATHOL, V28, P127, DOI 10.1097/PGP.0b013e318184f3e0; O'Brien TJ, 2002, TUMOR BIOL, V23, P154, DOI 10.1159/000064032; Orren DK, 1997, MOL BIOL CELL, V8, P1129, DOI 10.1091/mbc.8.6.1129; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Perez BH, 2008, EXP EYE RES, V87, P400, DOI 10.1016/j.exer.2007.12.008; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Rahman M, 2009, BREAST CANCER RES TR, V113, P217, DOI 10.1007/s10549-008-9924-5; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Singh PK, 2007, CANCER RES, V67, P5201, DOI 10.1158/0008-5472.CAN-06-4647; Tanaka H, 2002, J CELL BIOL, V158, P321, DOI 10.1083/jcb.200202071; Tong W, 1999, MOL CELL BIOL, V19, P2251; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; Wu YM, 2009, J PROTEOME RES, V8, P1876, DOI 10.1021/pr8008379; Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI 10.1517/13543780802565791 ; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8; Zhao LQ, 2010, BIOCHEM J, V426, P91, DOI 10.1042/BJ20090615	59	95	105	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					805	817		10.1038/onc.2011.297	http://dx.doi.org/10.1038/onc.2011.297			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21785467	Green Accepted			2022-12-28	WOS:000300615800001
J	Wu, WKK; Coffelt, SB; Cho, CH; Wang, XJ; Lee, CW; Chan, FKL; Yu, J; Sung, JJY				Wu, W. K. K.; Coffelt, S. B.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K. L.; Yu, J.; Sung, J. J. Y.			The autophagic paradox in cancer therapy	ONCOGENE			English	Review						autophagy; cell survival; cell death	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; CELL-DEATH; TUMOR-SUPPRESSOR; MAMMALIAN TARGET; PROSTATE-CANCER; BECLIN 1; REGULATES AUTOPHAGY; CYTOPROTECTIVE AUTOPHAGY; DEPENDENT INDUCTION	Autophagy, hallmarked by the formation of double-membrane bound organelles known as autophagosomes, is a lysosome-dependent pathway for protein degradation. The role of autophagy in carcinogenesis is context dependent. As a tumor-suppressing mechanism in early-stage carcinogenesis, autophagy inhibits inflammation and promotes genomic stability. Moreover, disruption of autophagy-related genes accelerates tumorigenesis in animals. However, autophagy may also act as a pro-survival mechanism to protect cancer cells from various forms of cellular stress. In cancer therapy, adaptive autophagy in cancer cells sustains tumor growth and survival in face of the toxicity of cancer therapy. To this end, inhibition of autophagy may sensitize cancer cells to chemotherapeutic agents and ionizing radiation. Nevertheless, in certain circumstances, autophagy mediates the therapeutic effects of some anticancer agents. Data from recent studies are beginning to unveil the apparently paradoxical nature of autophagy as a cell-fate decision machinery. Taken together, modulation of autophagy is a novel approach for enhancing the efficacy of existing cancer therapy, but its Janus-faced nature may complicate the clinical development of autophagy modulators as anticancer therapeutics. Oncogene (2012) 31, 939-953; doi:10.1038/onc.2011.295; published online 18 July 2011	[Wu, W. K. K.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K. L.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, LKS Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Wu, W. K. K.; Cho, C. H.; Wang, X. J.; Lee, C. W.; Chan, F. K. L.; Yu, J.; Sung, J. J. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Coffelt, S. B.] Univ Sheffield, Sch Med, Acad Unit Inflammat & Tumour Targeting, Dept Infect & Immun, Sheffield, S Yorkshire, England; [Cho, C. H.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Sheffield; Chinese University of Hong Kong	Wu, WKK (corresponding author), Prince Wales Hosp, 7-F,LKS Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	wukakei@cuhk.edu.hk; junyu@cuhk.edu.hk; joesung@cuhk.edu.hk	wu, william/HII-5817-2022; Wu, William K.K./A-3277-2009; Coffelt, Seth/O-9929-2019; Yu, Jun/D-8569-2015; Cho, Chi Hin/C-6543-2014; Chan, Francis K. L./F-4851-2010; Sung, Joseph J. Y./R-3203-2018	Wu, William K.K./0000-0002-5662-5240; Coffelt, Seth/0000-0003-2257-2862; Yu, Jun/0000-0001-5008-2153; Cho, Chi Hin/0000-0002-7658-3260; Chan, Francis K. L./0000-0001-7388-2436; Sung, Joseph J. Y./0000-0003-3125-5199	CUHK [3110043]	CUHK(Chinese University of Hong Kong)	This work was supported by research grant from the CUHK Group Research Scheme (3110043) and CUHK Focused Investments Scheme-Scheme C.	Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069; Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x; Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Altman BJ, 2011, ONCOGENE, V30, P1855, DOI 10.1038/onc.2010.561; Altman BJ, 2009, MOL BIOL CELL, V20, P1180, DOI 10.1091/mbc.E08-08-0829; Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Bhoopathi P, 2010, CELL DEATH DIFFER, V17, P1529, DOI 10.1038/cdd.2010.28; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802; Castino R, 2008, J NEUROENDOCRINOL, V20, P1165, DOI 10.1111/j.1365-2826.2008.01769.x; Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509; Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; CLIBY W, 1993, CANCER RES, V53, P2393; Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; de Haan CAM, 2010, AUTOPHAGY, V6, P994, DOI 10.4161/auto.6.7.13309; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Ding Y, 2010, J BIOL CHEM, V285, P37909, DOI 10.1074/jbc.M109.093724; Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915; Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95; ECCLES DM, 1992, ONCOGENE, V7, P2069; Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Fu L, 2009, CANCER RES, V69, P8967, DOI 10.1158/0008-5472.CAN-09-2190; Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x; Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; FUTREAL PA, 1992, CANCER RES, V52, P2624; Gajewska M, 2005, J Physiol Pharmacol, V56 Suppl 3, P143; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125; Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33; GAO X, 1995, CANCER RES, V55, P1002; Ghavami S, 2008, J CELL MOL MED, V12, P1005, DOI 10.1111/j.1582-4934.2008.00129.x; Gu YP, 2004, FEBS LETT, V577, P357, DOI 10.1016/j.febslet.2004.10.040; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200; Han WD, 2007, MOL CANCER THER, V6, P1641, DOI 10.1158/1535-7163.MCT-06-0511; Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8; Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240; Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666; Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124; Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051; Hwang J, 2010, J NEUROIMMUNOL, V226, P66, DOI 10.1016/j.jneuroim.2010.05.037; Indelicato M, 2010, J CELL PHYSIOL, V223, P359, DOI 10.1002/jcp.22041; Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Jiang H, 2010, AUTOPHAGY, V6, P1216, DOI 10.4161/auto.6.8.13695; Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Kamitsuji Y, 2008, CELL DEATH DIFFER, V15, P1712, DOI 10.1038/cdd.2008.107; Kandouz M, 2010, CELL CYCLE, V9, P398, DOI 10.4161/cc.9.2.10505; Kang C, 2007, GENE DEV, V21, P2161, DOI 10.1101/gad.1573107; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831; Kashuba VI, 1997, FEBS LETT, V419, P181, DOI 10.1016/S0014-5793(97)01449-X; Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058; Kim KW, 2009, CLIN CANCER RES, V15, P6096, DOI 10.1158/1078-0432.CCR-09-0589; Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013; Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157; Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401; Koesters R, 2010, AM J PATHOL, V177, P632, DOI 10.2353/ajpath.2010.091012; Komata T, 2003, BRIT J CANCER, V88, P1277, DOI 10.1038/sj.bjc.6600862; Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904; Kuo HP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000590; Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46; Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x; Lazova R, 2009, EXP DERMATOL, V18, P934, DOI 10.1111/j.1600-0625.2009.00933.x; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491; Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157; Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98; Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu D, 2011, CANCER-AM CANCER SOC, V117, P3763, DOI 10.1002/cncr.25959; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537; Lorin S, 2009, CANCER RES, V69, P6924, DOI 10.1158/0008-5472.CAN-09-1270; Lovas A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-606; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Ma X, 2011, CLIN CANCER RES, V17, P1; Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107; Mathieu V, 2007, J INVEST DERMATOL, V127, P2399, DOI 10.1038/sj.jid.5700869; McPhee CK, 2010, NATURE, V465, P1093, DOI 10.1038/nature09127; Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952; Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257; Miracco C, 2007, INT J ONCOL, V30, P429; Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Narita M, 2009, AUTOPHAGY, V5, P1046, DOI 10.4161/auto.5.7.9444; Negri T, 2010, GENE CHROMOSOME CANC, V49, P901, DOI 10.1002/gcc.20798; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Nivon M, 2009, AUTOPHAGY, V5, P766, DOI 10.4161/auto.8788; Noble CG, 2008, J BIOL CHEM, V283, P26274, DOI 10.1074/jbc.M804723200; Nomura H, 2009, HUM PATHOL, V40, P83, DOI 10.1016/j.humpath.2008.06.018; O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066; Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774; Othman EQG, 2009, J CLIN LAB ANAL, V23, P249, DOI 10.1002/jcla.20309; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Pankiv S, 2010, AUTOPHAGY, V6, P550, DOI 10.4161/auto.6.4.11670; Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015; Park MA, 2008, MOL PHARMACOL, V73, P1168, DOI 10.1124/mol.107.042697; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117; Portillo JAC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014472; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Reef S, 2007, ONCOGENE, V26, P6677, DOI 10.1038/sj.onc.1210485; Reef S, 2008, AUTOPHAGY, V4, P866, DOI 10.4161/auto.6691; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SAITO H, 1993, CANCER RES, V53, P3382; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030; Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049; Steffan JJ, 2010, J CELL SCI, V123, P1151, DOI 10.1242/jcs.063644; Steffan JJ, 2010, TRAFFIC, V11, P274, DOI 10.1111/j.1600-0854.2009.01012.x; Stenmark H, 2010, FEBS J, V277, P4837, DOI 10.1111/j.1742-4658.2010.07900.x; Suzuki HI, 2010, AUTOPHAGY, V6, P645, DOI 10.4161/auto.6.5.12046; Tangir J, 1996, ONCOGENE, V12, P735; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tormo D, 2009, CANCER CELL, V16, P103, DOI 10.1016/j.ccr.2009.07.004; Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Ueno T, 2008, AUTOPHAGY, V4, P692, DOI 10.4161/auto.6085; Voss V, 2010, MOL CANCER RES, V8, P1002, DOI 10.1158/1541-7786.MCR-09-0562; Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Wild P, 2010, NAT CELL BIOL, V12, P104, DOI 10.1038/ncb0210-104; Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003; Wu WKK, 2010, CANCER LETT, V293, P15, DOI 10.1016/j.canlet.2009.12.002; Wu WKK, 2010, AUTOPHAGY, V6, P228, DOI 10.4161/auto.6.2.11042; Xu DZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-536; Yacoub A, 2010, CANCER RES, V70, P1120, DOI 10.1158/0008-5472.CAN-09-4043; Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zeng XH, 2008, CANCER RES, V68, P2384, DOI 10.1158/0008-5472.CAN-07-6163; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104; Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9; Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x	180	184	198	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					939	953		10.1038/onc.2011.295	http://dx.doi.org/10.1038/onc.2011.295			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765470				2022-12-28	WOS:000300709700001
J	Katsurano, M; Niwa, T; Yasui, Y; Shigematsu, Y; Yamashita, S; Takeshima, H; Lee, MS; Kim, YJ; Tanaka, T; Ushijima, T				Katsurano, M.; Niwa, T.; Yasui, Y.; Shigematsu, Y.; Yamashita, S.; Takeshima, H.; Lee, M. S.; Kim, Y-J; Tanaka, T.; Ushijima, T.			Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction	ONCOGENE			English	Article						epigenetics; DNA methylation; inflammation; colon cancer; mouse	INFLAMMATORY-BOWEL-DISEASE; DEXTRAN SULFATE SODIUM; INTESTINAL EPITHELIAL-CELLS; PROMOTER HYPERMETHYLATION; HELICOBACTER-PYLORI; ULCERATIVE-COLITIS; GASTRIC MUCOSAE; CANCER; MICE; GENE	Epigenetic fields for cancerization are involved in development of human cancers, especially those associated with inflammation and multiple occurrences. However, it is still unclear when such field defects are formed and what component of inflammation is involved in induction of aberrant DNA methylation. Here, in a mouse colitis model induced by dextran sulfate sodium (DSS), we identified three CpG islands specifically methylated in colonic epithelial cells exposed to colitis. Their methylation levels started to increase as early as 8 weeks after DSS treatment and continued to increase until colon cancers developed at 15 weeks. In contrast to the temporal profile of DNA methylation levels, infiltration of inflammatory cells spiked immediately after the DSS treatment and then gradually decreased. Exposure of cultured colonic epithelial cells to DSS did not induce DNA methylation and it was indicated that inflammation triggered by the DSS treatment was responsible for methylation induction. To clarify components of inflammation involved, severe combined immunodeficiency (SCID) mice that lack functional T- and B-cells were similarly treated. Even in SCID mice, DNA methylation, along with colon tumors, were induced at the same levels as in their background strain of mice (C.B17). Comparative analysis of inflammation-related genes showed that Ifng, Il1b and Nos2 had expression concordant with methylation induction whereas Il2, Il6, Il10, Tnf did not. These results showed that an epigenetic field defect is formed at early stages of colitis-associated carcinogenesis and that functional T and B cells are non-essential for the formation. Oncogene (2012) 31, 342-351; doi:10.1038/onc.2011.241; published online 20 June 2011	[Ushijima, T.] Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, Tokyo 1040045, Japan; [Yasui, Y.; Tanaka, T.] Kanazawa Med Univ, Dept Oncol Pathol, Kanazawa, Ishikawa, Japan; [Lee, M. S.; Kim, Y-J] Yonsei Univ, Genome Regulat Ctr, Dept Biochem, Seoul 120749, South Korea	National Cancer Center - Japan; Kanazawa Medical University; Yonsei University	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817; Takeshima, Hideyuki/0000-0002-8552-2427	Ministry of Health, Labour and Welfare, Japan; Korea Foundation for International Cooperation of Science Technology; Foundation for Promotion of Cancer Research	Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Korea Foundation for International Cooperation of Science Technology; Foundation for Promotion of Cancer Research	We thank Dr H Fukamachi for his kind provision of the LIF-16 cell line. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan; and by the Global Research Laboratory Program from Korea Foundation for International Cooperation of Science & Technology. MK and YS are recipients of Research Resident Fellowships from the Foundation for Promotion of Cancer Research. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan (TU), and by the Global Research Laboratory Program from Korea Foundation for International Cooperation of Science & Technology (Y-JK and TU).	Araki Y, 2006, ONCOL REP, V16, P1357; Autschbach F, 2002, VIRCHOWS ARCH, V441, P500, DOI 10.1007/s00428-002-0684-z; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Braakhuis BJM, 2003, CANCER RES, V63, P1727; CAPPELLO M, 1992, GUT, V33, P1214, DOI 10.1136/gut.33.9.1214; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Garrity-Park MM, 2010, AM J GASTROENTEROL; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Hsieh CJ, 1998, CANCER RES, V58, P3942; Hur K, 2011, CARCINOGENESIS, V32, P35, DOI 10.1093/carcin/bgq219; Issa JPJ, 2001, CANCER RES, V61, P3573; Ito R, 2006, CLIN EXP IMMUNOL, V146, P330, DOI 10.1111/j.1365-2249.2006.03214.x; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kass DH, 1997, GENETICA, V99, P1, DOI 10.1023/A:1018350810791; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; McLaughlan JM, 1997, J PATHOL, V181, P87; Nagao M, 2001, MUTAT RES-FUND MOL M, V477, P119, DOI 10.1016/S0027-5107(01)00113-0; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Ni J, 1996, GUT, V39, P234, DOI 10.1136/gut.39.2.234; Niwa T, 2005, CANCER SCI, V96, P409, DOI 10.1111/j.1349-7006.2005.00068.x; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Qian XM, 2008, CANCER LETT, V263, P107, DOI 10.1016/j.canlet.2007.12.023; Riggs AD, 2004, P NATL ACAD SCI USA, V101, P4, DOI 10.1073/pnas.0307781100; Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Taniwaki K, 2007, CANCER RES, V67, P4311, DOI 10.1158/0008-5472.CAN-06-4761; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Vuillemenot BR, 2004, CARCINOGENESIS, V25, P623, DOI 10.1093/carcin/bgh038; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282; Yamashita S, 2009, DNA RES, V16, P275, DOI 10.1093/dnares/dsp017; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	51	57	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					342	351		10.1038/onc.2011.241	http://dx.doi.org/10.1038/onc.2011.241			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685942				2022-12-28	WOS:000299542100007
J	Lee, MH; Lahusen, T; Wang, RH; Xiao, C; Xu, X; Hwang, YS; He, WW; Shi, Y; Deng, CX				Lee, M-H; Lahusen, T.; Wang, R-H; Xiao, C.; Xu, X.; Hwang, Y-S; He, W-W; Shi, Y.; Deng, C-X			Yin Yang 1 positively regulates BRCA1 and inhibits mammary cancer formation	ONCOGENE			English	Article						BRCA1; breast cancer; promoter; nude mice; YY1	SPORADIC BREAST-CANCER; TUMOR-SUPPRESSOR; ADENOVIRUS E1A; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; FACTOR YY1; C-MYC; PROMOTER; BINDING; YIN-YANG-1	Expression of the breast cancer-associated gene 1 (BRCA1) in sporadic breast cancers is usually reduced, yet the underlying mechanisms remains elusive. To identify factors that are responsible for reduced BRCA1 expression, we screened 92 known transcription factors for their ability to regulate expression of BRCA1. Among several potential regulators, the Gli-Krueppel-related transcription factor Yin Yang 1 (YY1) showed the most dramatic transactivation of the BRCA1 promoter. YY1 binds to the promoter of BRCA1, and its overexpression resulted in increased expression of BRCA1 and a number of BRCA1 downstream genes. We further showed that overexpression of YY1 in cancer cells inhibited cell proliferation, foci formation and tumor growth in nude mice. To assess the clinical relevance between YY1 and BRCA1, we studied expression of YY1 and BRCA1 from human breast cancer samples and tissue arrays, and detected a significant positive correlation between the level of YY1 and BRCA1 expression in these cancers. Taken together, these findings suggest that YY1 is a key regulator of BRCA1 expression and may be causally linked to the molecular etiology of human breast cancer. Oncogene (2012) 31, 116-127; doi: 10.1038/onc.2011.217; published online 13 June 2011	[Lee, M-H; Lahusen, T.; Wang, R-H; Xiao, C.; Xu, X.; Deng, C-X] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; [Hwang, Y-S] NCI, Lab Cell & Dev Signaling, NIH, Frederick, MD 21701 USA; [He, W-W] Origene Technol Inc, Rockville, MD USA; [Shi, Y.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, 9000 Rockville Pike,Bldg 10,Rm 9N105, Bethesda, MD 20892 USA.	chuxiad@bdg10.niddk.nih.gov	deng, chuxia/N-6713-2016	Lee, Mi-Hye/0000-0002-5484-3383	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056011, ZIADK056001, ZIADK056004, ZIADK056010, ZIADK056009] Funding Source: NIH RePORTER	National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members of Dr Deng laboratory for their critical discussion of this work and technical assistance. This research was supported by the Intramural Research Program of the National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, USA.	Affar E, 2006, MOL CELL BIOL, V26, P3565, DOI 10.1128/MCB.26.9.3565-3581.2006; Alberg Anthony J., 1999, Current Opinion in Oncology, V11, P435, DOI 10.1097/00001622-199911000-00003; Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Castellano G, 2009, CELL CYCLE, V8, P1367, DOI 10.4161/cc.8.9.8314; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Drost RM, 2009, BRIT J CANCER, V101, P1651, DOI 10.1038/sj.bjc.6605350; Eccles DM, 2005, LANCET ONCOL, V6, P705, DOI 10.1016/S1470-2045(05)70318-1; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Ghosh Sagar, 2008, Int J Biomed Sci, V4, P260; Giacinti L, 2008, CLIN TER, V159, P347; Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534; Glait C, 2006, FEBS LETT, V580, P5268, DOI 10.1016/j.febslet.2006.08.071; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kluk BJ, 2010, INT J BIOL SCI, V6, P513; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200; MacDonald G, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1753; Man YG, 2005, BREAST CANCER RES TR, V90, P241, DOI 10.1007/s10549-004-4492-9; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Oliveira Andre M, 2005, Am J Clin Pathol, V124 Suppl, pS16; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Rauch T, 2005, CELL CYCLE, V4, P1078; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Rivenbark AG, 2009, FRONT BIOSCI-LANDMRK, V14, P453, DOI 10.2741/3254; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Suen TC, 2001, ONCOGENE, V20, P440, DOI 10.1038/sj.onc.1204078; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tan SH, 2003, VIROLOGY, V305, P486, DOI 10.1006/viro.2002.1779; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573; Wang CC, 2007, CANCER RES, V67, P4816, DOI 10.1158/0008-5472.CAN-07-0504; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wu S, 2007, NUCL ACIDS S SER OXF, V51, P347; Wu S, 2007, NAT STRUCT MOL BIOL, V14, P1165, DOI 10.1038/nsmb1332; Wu S, 2009, MOL CELL BIOL, V29, P6245, DOI 10.1128/MCB.00679-09; Wu WW, 2010, CANCER RES, V70, P6384, DOI 10.1158/0008-5472.CAN-10-1304; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 2003, DEVELOPMENT, V130, P2001, DOI 10.1242/dev.00410; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192	54	46	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					116	127		10.1038/onc.2011.217	http://dx.doi.org/10.1038/onc.2011.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21666725	Green Accepted			2022-12-28	WOS:000299176200011
J	Pla, AF; Ong, HL; Cheng, KT; Brossa, A; Bussolati, B; Lockwich, T; Paria, B; Munaron, L; Ambudkar, IS				Pla, A. Fiorio; Ong, H. L.; Cheng, K. T.; Brossa, A.; Bussolati, B.; Lockwich, T.; Paria, B.; Munaron, L.; Ambudkar, I. S.			TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling	ONCOGENE			English	Article						Ca2+ signals; TRP channels; endothelial cells; cell migration; actin remodeling; tumor angiogenesis	PROTEIN-KINASE; ION CHANNELS; CA2+ ENTRY; ANGIOGENESIS; GROWTH; TRANSLOCATION; EXPRESSION; CALCIUM; PROLIFERATION; CONTRIBUTES	Changes in intracellular calcium [Ca2+](i) levels control critical cytosolic and nuclear events that are involved in the initiation and progression of tumor angiogenesis in endothelial cells (ECs). Therefore, the mechanism(s) involved in agonist-induced Ca-i(2+) signaling is a potentially important molecular target for controlling angiogenesis and tumor growth. Several studies have shown that blood vessels in tumors differ from normal vessels in their morphology, blood flow and permeability. We had previously reported a key role for arachidonic acid (AA)-mediated Ca2+ entry in the initial stages of tumor angiogenesis in vitro. In this study we assessed the mechanism involved in AA-induced EC migration. We report that TRPV4, an AA-activated channel, is differentially expressed in EC derived from human breast carcinomas (BTEC) as compared with 'normal' EC (HMVEC). BTEC display a significant increase in TRPV4 expression, which was correlated with greater Ca2+ entry, induced by AA or 4 alpha PDD (a selective TRPV4 agonist) in the tumor-derived ECs. Wound-healing assays revealed a key role of TRPV4 in regulating cell migration of BTEC but not HMVEC. Knockdown of TRPV4 expression completely abolished AA-induced BTEC migration, suggesting that TRPV4 mediates the pro-angiogenic effects promoted by AA. Furthermore, pre-incubation of BTEC with AA induced actin remodeling and a subsequent increase in the surface expression of TRPV4. This was consistent with the increased plasma membrane localization of TRPV4 and higher AA-stimulated Ca2+ entry in the migrating cells. Together, the data presented herein demonstrate that: (1) TRPV4 is differentially expressed in tumor-derived versus 'normal' EC; (2) TRPV4 has a critical role in the migration of tumor-derived but not 'normal' EC migration; and (3) AA induces actin remodeling in BTEC, resulting in a corresponding increase of TRPV4 expression in the plasma membrane. We suggest that the latter is critical for migration of EC and thus in promoting angiogenesis and tumor growth. Oncogene (2012) 31, 200-212; doi:10.1038/onc.2011.231; published online 20 June 2011	[Pla, A. Fiorio; Brossa, A.; Munaron, L.] Univ Turin, Dept Anim & Human Biol, I-10123 Turin, Italy; [Pla, A. Fiorio; Munaron, L.] Ctr Complex Syst Mol Biol & Med SysBioM, Turin, Italy; [Pla, A. Fiorio; Munaron, L.] Nanostruct Interfaces & Surfaces Ctr Excellence, Turin, Italy; [Ong, H. L.; Cheng, K. T.; Lockwich, T.; Paria, B.; Ambudkar, I. S.] NIDCR, Secretory Physiol Sect, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA; [Brossa, A.; Bussolati, B.] Univ Turin, Ctr Mol Biotechnol, Dept Internal Med, Turin, Italy	University of Turin; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Turin	Pla, AF (corresponding author), Univ Turin, Dept Anim & Human Biol, V Accademia Albertina 13, I-10123 Turin, Italy.	alessandra.fiorio@unito.it	Bussolati, Benedetta/AAA-9058-2022; Fiorio Pla, Alessandra/B-6646-2012	Bussolati, Benedetta/0000-0002-3663-5134; Fiorio Pla, Alessandra/0000-0003-4576-1594; Ong, Hwei Ling/0000-0002-7551-6883; munaron, luca/0000-0001-9247-4446; Brossa, Alessia/0000-0002-5973-5007	University of Torino; Regione Piemonte (Ricerca Scientifica Applicata Sanita'); National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER	University of Torino; Regione Piemonte (Ricerca Scientifica Applicata Sanita')(Regione Piemonte); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the University of Torino, Regione Piemonte (Ricerca Scientifica Applicata Sanita') and the National Institute of Dental and Craniofacial Research (Intramural Research). We thank Dr Kenneth Yamada (NIDCR, NIH, Bethesda, MD, USA) for the beta-actin-mCherry and Dr Michael X. Zhu (Department of Physiology and Cell Biology, Ohio State University, OH, USA) for the TRPV4-GFP construct.	Antoniotti S, 2003, J CELL PHYSIOL, V197, P370, DOI 10.1002/jcp.10359; Becker D, 2005, J CELL SCI, V118, P2435, DOI 10.1242/jcs.02372; Becker D, 2009, EUR J CELL BIOL, V88, P141, DOI 10.1016/j.ejcb.2008.10.002; Bhati R, 2008, AM J PATHOL, V172, P1381, DOI 10.2353/ajpath.2008.070988; Birnbaumer L, 2009, ANNU REV PHARMACOL, V49, P395, DOI 10.1146/annurev.pharmtox.48.113006.094928; Boels K, 2001, J CELL SCI, V114, P3599; Bussolati B, 2006, EXP CELL RES, V312, P913, DOI 10.1016/j.yexcr.2005.12.004; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Bussolati B, 2011, FASEB J; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Collino F, 2008, AM J PHYSIOL-RENAL, V294, pF1185, DOI 10.1152/ajprenal.00442.2007; Everaerts W, 2010, PROG BIOPHYS MOL BIO, V103, P2, DOI 10.1016/j.pbiomolbio.2009.10.002; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Goswami C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011654; Grange C, 2006, ONCOL REP, V15, P381; Hamdollah Zadeh MA, 2008, MICROCIRCULATION, V15, P605, DOI 10.1080/10739680802220323; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Kwan HY, 2007, BBA-MOL BASIS DIS, V1772, P907, DOI 10.1016/j.bbadis.2007.02.013; Liedtke W, 2005, CELL MOL LIFE SCI, V62, P2985, DOI 10.1007/s00018-005-5181-5; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Ma X, 2010, ARTERIOSCL THROM VAS, V30, P2249, DOI 10.1161/ATVBAHA.110.212084; Meves H, 2008, BRIT J PHARMACOL, V155, P4, DOI 10.1038/bjp.2008.216; Moes M, 2010, CELL MOL LIFE SCI, V67, P1547, DOI 10.1007/s00018-010-0267-0; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Munaron L, 2009, CURR MED CHEM, V16, P4691, DOI 10.2174/092986709789878210; Mutai H, 2005, NEUROSCIENCE, V132, P1115, DOI 10.1016/j.neuroscience.2005.01.046; Nie D, 2002, CELL MOL LIFE SCI, V59, P799, DOI 10.1007/s00018-002-8468-9; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Patton AM, 2003, CURR PHARM DESIGN, V9, P543, DOI 10.2174/1381612033391559; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PEPPELENBOSCH MP, 1995, J NEUROSCI METH, V58, P49, DOI 10.1016/0165-0270(94)00158-D; Pla AF, 2005, J NEUROSCI, V25, P2687, DOI 10.1523/JNEUROSCI.0951-04.2005; Pla AF, 2001, CELL CALCIUM, V30, P235, DOI 10.1054/ceca.2001.0234; Pla AF, 2008, MOL CANCER RES, V6, P535, DOI 10.1158/1541-7786.MCR-07-0271; Pla AF, 2010, MOL CANCER RES, V8, P1466, DOI 10.1158/1541-7786.MCR-10-0002; Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Roberts LA, 2003, J CELL PHYSIOL, V196, P196, DOI 10.1002/jcp.10303; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; St Croix B, 2000, SCIENCE, V289, P1197; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Thodeti CK, 2009, CIRC RES, V104, P1123, DOI 10.1161/CIRCRESAHA.108.192930; Troidl C, 2009, J CELL MOL MED, V13, P2613, DOI 10.1111/j.1582-4934.2008.00579.x; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; Van Buren JJ, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-17; Waning J, 2007, CELL CALCIUM, V42, P17, DOI 10.1016/j.ceca.2006.11.005; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Yu PC, 2010, CIRC RES, V106, P1221, DOI 10.1161/CIRCRESAHA.109.207670	53	132	136	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					200	212		10.1038/onc.2011.231	http://dx.doi.org/10.1038/onc.2011.231			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685934	Green Accepted			2022-12-28	WOS:000299307400006
J	Shenoy, SK; Han, S; Zhao, YL; Hara, MR; Oliver, T; Cao, Y; Dewhirst, MW				Shenoy, S. K.; Han, S.; Zhao, Y. L.; Hara, M. R.; Oliver, T.; Cao, Y.; Dewhirst, M. W.			beta-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression	ONCOGENE			English	Article						arrestin; HIF-1; VEGF; hypoxia	NUCLEAR EXPORT SIGNAL; INDUCIBLE FACTOR-I; BETA-ARRESTIN; ENDOTHELIAL-CELLS; IMATINIB MESYLATE; PROSTATE-CANCER; GENE-EXPRESSION; RECEPTOR; HYPOXIA; ANGIOGENESIS	beta-Arrestins 1 and 2 are multifunctional adaptor proteins originally discovered for their role in desensitizing seven-transmembrane receptor signaling via the heterotrimeric guanine nucleotide-binding proteins. Recently identified roles of beta-arrestins include regulation of cancer cell chemotaxis and proliferation. Herein, we report that beta-arrestin1 expression regulates breast tumor colonization in nude mice and cancer cell viability during hypoxia. beta-Arrestin1 robustly interacts with nuclear hypoxia-induced factor-1 alpha (HIF-1 alpha) that is stabilized during hypoxia and potentiates HIF-1-dependent transcription of the angiogenic factor vascular endothelial growth factor-A (VEGF-A). Increased expression of beta-arrestin1 in human breast cancer (infiltrating ductal carcinoma or IDC and metastatic IDC) correlates with increased levels of VEGF-A. While the anti-angiogenic drug thalidomide inhibits HIF-1-dependent VEGF transcription in breast carcinoma cells, it does not prevent HIF-1 alpha stabilization, but leads to aberrant localization of HIF-1 alpha to the perinuclear compartments and surprisingly stimulates nuclear export of beta-arrestin1. Additionally, imatinib mesylate that inhibits release of VEGF induces nuclear export of beta-arrestin1-HIF-1 alpha complexes. Our findings suggest that beta-arrestin1 regulates nuclear signaling during hypoxia to promote survival of breast cancer cells via VEGF signaling and that drugs that induce its translocation from the nucleus to the cytoplasm could be useful in anti-angiogenic and breast cancer therapies. Oncogene (2012) 31, 282-292; doi:10.1038/onc.2011.238; published online 20 June 2011	[Shenoy, S. K.; Han, S.; Hara, M. R.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Shenoy, S. K.; Oliver, T.] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; [Zhao, Y. L.; Cao, Y.; Dewhirst, M. W.] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Shenoy, SK (corresponding author), Duke Univ, Med Ctr, Dept Med, Room 412,SANDS Bldg,POB 103204, Durham, NC 27710 USA.	sudha@receptor-biol.duke.edu	Dewhirst, Mark/Q-1302-2019; Shenoy, Sudha/AAN-4075-2021	Dewhirst, Mark/0000-0003-3459-6546; Shenoy, Sudha/0000-0002-2565-4663	NIH [HL080525, CA40355]; NATIONAL CANCER INSTITUTE [R01CA040355] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080525] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful to Dr Lefkowitz for his insightful comments. We thank Ms Vidya Venkat for technical support. We acknowledge grant support from the NIH (HL080525 to SKS and CA40355 to MWD).	Alvarez CJP, 2009, ENDOCR-RELAT CANCER, V16, P599, DOI 10.1677/ERC-08-0192; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Chuaqui RF, 1997, AM J PATHOL, V150, P297; DAAKA Y, 2004, SCI STKE, pRE2; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607; Ebos JML, 2002, MOL CANCER RES, V1, P89; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Figg WD, 2006, CLIN PHARMACOL THER, V79, P1, DOI 10.1016/j.clpt.2005.09.006; FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Ge L, 2004, J BIOL CHEM, V279, P55419, DOI 10.1074/jbc.M410312200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Holaday JW, 2009, MOL INTERV, V9, P157, DOI 10.1124/mi.9.4.2; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lakshmikanthan V, 2009, P NATL ACAD SCI USA, V106, P9379, DOI 10.1073/pnas.0900258106; Lal A, 2005, MOL CELL PROBE, V19, P385, DOI 10.1016/j.mcp.2005.06.007; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Mythreye K, 2009, P NATL ACAD SCI USA, V106, P8221, DOI 10.1073/pnas.0812879106; Niida A, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-71; Raghuwanshi SK, 2008, J IMMUNOL, V180, P5699, DOI 10.4049/jimmunol.180.8.5699; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; SEMENZA GL, 2007, SCI STKE, pCM8, DOI DOI 10.1126/STKE.4072007CM8; Shenoy SK, 2008, J BIOL CHEM, V283, P22166, DOI 10.1074/jbc.M709668200; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vlahovic G, 2006, BRIT J CANCER, V95, P1013, DOI 10.1038/sj.bjc.6603366; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Zou L, 2008, FASEB J, V22, P355, DOI 10.1096/fj.07-9046com	48	54	54	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					282	292		10.1038/onc.2011.238	http://dx.doi.org/10.1038/onc.2011.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685944	Green Accepted			2022-12-28	WOS:000299542100002
J	Angus, SP; Nevins, JR				Angus, S. P.; Nevins, J. R.			A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest	ONCOGENE			English	Article						tumor suppressor; cell cycle; senescence	RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; ONCOGENE-INDUCED SENESCENCE; IN-VIVO; S-PHASE; TRANSCRIPTIONAL REGULATION; TARGET GENES; C/EBP-BETA; ZNF217; PROTEIN	The Rb/E2F pathway is deregulated in virtually all human tumors. It is clear that, in addition to Rb itself, essential cofactors required for transcriptional repression and silencing of E2F target genes are mutated or lost in cancer. To identify novel cofactors required for Rb/E2F-mediated inhibition of cell proliferation, we performed a genome-wide short hairpin RNA screen. In addition to several known Rb cofactors, the screen identified components of the Mediator complex, a large multiprotein coactivator required for RNA polymerase II transcription. We show that the Mediator complex subunit MED13L is required for Rb/E2F control of cell growth, the complete repression of cell cycle target genes, and cell cycle inhibition.	[Angus, S. P.; Nevins, J. R.] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA.	j.nevins@duke.edu		Angus, Steven/0000-0002-7655-657X	National Cancer Institute Integrative Cancer Biology Program via grant National Institutes of Health [5-U54-CA112952]; NIH [F32CA113177]; NATIONAL CANCER INSTITUTE [U54CA112952, R01CA104663, F32CA113177] Funding Source: NIH RePORTER	National Cancer Institute Integrative Cancer Biology Program via grant National Institutes of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	All aspects of the research were supported under the National Cancer Institute Integrative Cancer Biology Program via grant National Institutes of Health 5-U54-CA112952. SPA was supported by NIH F32CA113177. We thank Lazlo Jakoi for technical assistance and all the members of the Nevins lab for their critical feedback and suggestions. We are grateful to Bernard Mathey-Prevot and Jeffrey Chang for comments on the manuscript. We thank Kaye Culler for assistance in submitting the manuscript. We are grateful to T Kitamura for providing Plat-E and Plat-A retroviral packaging cells, J DeCaprio for providing the T98G-EcoR cells, and E Knudsen for providing the -608Cyclin A-Luc and PSM-Rb plasmids.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Banck MS, 2009, EPIGENETICS-US, V4, P100, DOI 10.4161/epi.4.2.7953; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Conaway RC, 2005, TRENDS BIOCHEM SCI, V30, P250, DOI 10.1016/j.tibs.2005.03.002; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ding N, 2008, MOL CELL, V31, P347, DOI 10.1016/j.molcel.2008.05.023; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Greider Carol W., 2004, Cell, VS116, pS83, DOI 10.1016/S0092-8674(04)00053-4; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knuesel MT, 2009, GENE DEV, V23, P439, DOI 10.1101/gad.1767009; Kornberg RD, 2005, TRENDS BIOCHEM SCI, V30, P235, DOI 10.1016/j.tibs.2005.03.011; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901; Medina PP, 2008, EPIGENETICS-US, V3, P64, DOI 10.4161/epi.3.2.6153; Meloni AR, 2005, MOL CANCER RES, V3, P575, DOI 10.1158/1541-7786.MCR-05-0088; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Muncke N, 2003, CIRCULATION, V108, P2843, DOI 10.1161/01.CIR.0000103684.77636.CD; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nonet GH, 2001, CANCER RES, V61, P1250; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Sato S, 2004, MOL CELL, V14, P685, DOI 10.1016/j.molcel.2004.05.006; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Sun G, 2008, INT J ONCOL, V32, P1065; Wang L, 2008, GENETICS, V180, P269, DOI 10.1534/genetics.108.092478; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166; Wolyniec K, 2009, ONCOGENE, V28, P2502, DOI 10.1038/onc.2009.101; Yang H, 2002, MOL CELL BIOL, V22, P3103, DOI 10.1128/MCB.22.9.3103-3110.2002; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	62	21	21	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	44					4709	4717		10.1038/onc.2011.622	http://dx.doi.org/10.1038/onc.2011.622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22249253	Green Accepted			2022-12-28	WOS:000310724400006
J	Carpenter, EL; Haglund, EA; Mace, EM; Deng, D; Martinez, D; Wood, AC; Chow, AK; Weiser, DA; Belcastro, LT; Winter, C; Bresler, SC; Asgharzadeh, S; Seeger, RC; Zhao, H; Guo, R; Christensen, JG; Orange, JS; Pawel, BR; Lemmon, MA; Mosse, YP				Carpenter, E. L.; Haglund, E. A.; Mace, E. M.; Deng, D.; Martinez, D.; Wood, A. C.; Chow, A. K.; Weiser, D. A.; Belcastro, L. T.; Winter, C.; Bresler, S. C.; Asgharzadeh, S.; Seeger, R. C.; Zhao, H.; Guo, R.; Christensen, J. G.; Orange, J. S.; Pawel, B. R.; Lemmon, M. A.; Mosse, Y. P.			Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; anaplastic lymphoma kinase; immunotherapy; receptor tyrosine kinase	RECEPTOR TYROSINE KINASE; ALK KINASE; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; LAPATINIB GW572016; LUNG-CANCER; PHASE-I; INHIBITOR; IDENTIFICATION; RESISTANCE	Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase aberrantly expressed in neuroblastoma, a devastating pediatric cancer of the sympathetic nervous system. Germline and somatically acquired ALK aberrations induce increased autophosphorylation, constitutive ALK activation and increased downstream signaling. Thus, ALK is a tractable therapeutic target in neuroblastoma, likely to be susceptible to both small-molecule tyrosine kinase inhibitors and therapeutic antibodies-as has been shown for other receptor tyrosine kinases in malignancies such as breast and lung cancer. Small-molecule inhibitors of ALK are currently being studied in the clinic, but common ALK mutations in neuroblastoma appear to show de novo insensitivity, arguing that complementary therapeutic approaches must be developed. We therefore hypothesized that antibody targeting of ALK may be a relevant strategy for the majority of neuroblastoma patients likely to have ALK-positive tumors. We show here that an antagonistic ALK antibody inhibits cell growth and induces in vitro antibody-dependent cellular cytotoxicity of human neuroblastoma-derived cell lines. Cytotoxicity was induced in cell lines harboring either wild type or mutated forms of ALK. Treatment of neuroblastoma cells with the dual Met/ALK inhibitor crizotinib sensitized cells to antibody-induced growth inhibition by promoting cell surface accumulation of ALK and thus increasing the accessibility of antigen for antibody binding. These data support the concept of ALK-targeted immunotherapy as a highly promising therapeutic strategy for neuroblastomas with mutated or wild-type ALK.	[Mosse, Y. P.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med,Div Oncol, Ctr Childhood Canc Res,Dept Pediat, Philadelphia, PA 19104 USA; [Mace, E. M.; Lemmon, M. A.] Childrens Hosp Philadelphia, Res Inst, Philadelphia, PA 19104 USA; [Bresler, S. C.] Univ Penn, Perelman Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Asgharzadeh, S.; Seeger, R. C.] Univ So Calif, Childrens Hosp Angeles, Saban Res Inst, Div Hematol & Oncol, Los Angeles, CA USA; [Zhao, H.; Guo, R.] Childrens Hosp Philadelphia, Dept Pediat, Biostat & Data Management Core, Philadelphia, PA USA; [Christensen, J. G.] Pfizer Global Res & Dev, Dept Canc Biol, Jolla Labs, La Jolla, CA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Children's Hospital Los Angeles; University of Southern California; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pfizer	Mosse, YP (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med,Div Oncol, Ctr Childhood Canc Res,Dept Pediat, Colket Translat Res Bldg,3501 Civic Ctr Blvd,Off, Philadelphia, PA 19104 USA.	mosse@chop.edu	Weiser, Daniel A./B-6160-2016	Weiser, Daniel A./0000-0001-6673-5323; Mace, Emily/0000-0003-0226-7393; orange, jordan/0000-0001-7117-7725; Belcastro, Lili/0000-0002-8666-2376; Lemmon, Mark/0000-0002-3379-5319	NIH [R01-CA140198, 2R01 CA60104-16, 2R01 CA60104-16S1]; Children's Oncology Group; Carly Hillman Fund; NIH Training Grant in Structural Biology [T32-GM008275]; St Baldrick's Foundation; US Army Peer-Reviewed Medical Research Program [W81XWH-10-1-0212/3]; NATIONAL CANCER INSTITUTE [T32CA009615, R01CA060104, R01CA140198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008275] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Oncology Group; Carly Hillman Fund; NIH Training Grant in Structural Biology(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; US Army Peer-Reviewed Medical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Pfizer for their gift of crizotinib, and Dr Marc Vigny for his gift of the ALK monoclonal antibodies 30, 49, 46 and 14. This work was supported in part by NIH Grants R01-CA140198 (YPM), 2R01 CA60104-16 (RCS), 2R01 CA60104-16S1 (RCS), the Children's Oncology Group, the Carly Hillman Fund (YPM), NIH Training Grant in Structural Biology T32-GM008275 (SCB), a fellowship grant from the St Baldrick's Foundation (ACW) and the US Army Peer-Reviewed Medical Research Program (W81XWH-10-1-0212/3 to MAL/YPM).	Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Engelman JA, 2008, CURR OPIN GENET DEV, V18, P73, DOI 10.1016/j.gde.2008.01.004; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Griffin CA, 1999, CANCER RES, V59, P2776; HANK JA, 1990, CANCER RES, V50, P5234; Haupt R, 2010, J CLIN ONCOL, V28, P2331, DOI 10.1200/JCO.2009.24.8351; Hobbie WL, 2008, PEDIATR BLOOD CANCER, V51, P679, DOI 10.1002/pbc.21683; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hughes B, 2010, NAT REV DRUG DISCOV, V9, P665, DOI 10.1038/nrd3270; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jazii FR, 2006, WORLD J GASTROENTERO, V12, P7104, DOI 10.3748/wjg.v12.i44.7104; Johns TG, 2003, P NATL ACAD SCI USA, V100, P15871, DOI 10.1073/pnas.2036503100; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kurai J, 2007, CLIN CANCER RES, V13, P1552, DOI 10.1158/1078-0432.CCR-06-1726; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Matar P, 2004, CLIN CANCER RES, V10, P6487, DOI 10.1158/1078-0432.CCR-04-0870; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Niwa R, 2005, CLIN CANCER RES, V11, P2327, DOI 10.1158/1078-0432.CCR-04-2263; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Tabone-Eglinger S, 2008, CLIN CANCER RES, V14, P2285, DOI 10.1158/1078-0432.CCR-07-4102; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	49	34	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4859	4867		10.1038/onc.2011.647	http://dx.doi.org/10.1038/onc.2011.647			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266870	Green Accepted			2022-12-28	WOS:000311210700006
J	Li, Y; Hwang, TH; Oseth, LA; Hauge, A; Vessella, RL; Schmechel, SC; Hirsch, B; Beckman, KB; Silverstein, KA; Dehm, SM				Li, Y.; Hwang, T. H.; Oseth, L. A.; Hauge, A.; Vessella, R. L.; Schmechel, S. C.; Hirsch, B.; Beckman, K. B.; Silverstein, K. A.; Dehm, S. M.			AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression	ONCOGENE			English	Article						prostate cancer; androgen receptor variants; castration-resistant; intragenic rearrangement, AR alternative splicing	CIRCULATING TUMOR-CELLS; GENE AMPLIFICATION; PROTEIN EXPRESSION; COPY NUMBER; MUTATIONS; THERAPY; RESISTANCE; GROWTH; AXIS	Reactivation of the androgen receptor (AR) during androgen depletion therapy (ADT) underlies castration-resistant prostate cancer (CRPCa). Alternative splicing of the AR gene and synthesis of constitutively active COOH-terminally truncated AR variants lacking the AR ligand-binding domain has emerged as an important mechanism of ADT resistance in CRPCa. In a previous study, we demonstrated that altered AR splicing in CRPCa 22Rv1 cells was linked to a 35-kb intragenic tandem duplication of AR exon 3 and flanking sequences. In this study, we demonstrate that complex patterns of AR gene copy number imbalances occur in PCa cell lines, xenografts and clinical specimens. To investigate whether these copy number imbalances reflect AR gene rearrangements that could be linked to splicing disruptions, we carried out a detailed analysis of AR gene structure in the LuCaP 86.2 and CWR-R1 models of CRPCa. By deletion-spanning PCR, we discovered a 8579-bp deletion of AR exons 5, 6 and 7 in the LuCaP 86.2 xenograft, which provides a rational explanation for synthesis of the truncated AR v567es AR variant in this model. Similarly, targeted resequencing of the AR gene in CWR-R1 cells led to the discovery of a 48-kb deletion in AR intron 1. This intragenic deletion marked a specific CWR-R1 cell population with enhanced expression of the truncated AR-V7/AR3 variant, a high level of androgen-independent AR transcriptional activity and rapid androgen independent growth. Together, these data demonstrate that structural alterations in the AR gene are linked to stable gain-of-function splicing alterations in CRPCa.	[Hwang, T. H.; Silverstein, K. A.] Univ Minnesota, Masonic Canc Ctr, Biostat & Bioinformat Core, Minneapolis, MN 55455 USA; [Hauge, A.; Beckman, K. B.] Univ Minnesota, Biomed Genom Ctr, Minneapolis, MN 55455 USA; [Vessella, R. L.] Univ Washington, Med Ctr, Dept Urol, Seattle, WA 98195 USA; [Vessella, R. L.] Puget Sound VA Hlth Care Syst, Seattle, WA USA; [Schmechel, S. C.; Hirsch, B.; Dehm, S. M.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Hirsch, B.] Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; [Schmechel, S. C.] Univ Minnesota, BioNet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Dehm, SM (corresponding author), Univ Minnesota, Masonic Canc Ctr, Biostat & Bioinformat Core, Mayo Mail Code 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	dehm@umn.edu			comprehensive Masonic Cancer Center NIH [P30 CA077598]; Prostate Cancer Foundation; DOD [PC094384]; NCI [CA141011]; Institute of Human Genetics, University of Minnesota; NATIONAL CANCER INSTITUTE [P30CA077598, R21CA141011] Funding Source: NIH RePORTER	comprehensive Masonic Cancer Center NIH; Prostate Cancer Foundation; DOD(United States Department of Defense); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Institute of Human Genetics, University of Minnesota; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the Minnesota Supercomputing Institute and the Masonic Cancer Center Biostatistics and Bioinformatics Core for providing computing, bioinformatics, statistical, software and data storage support for this project. Cytogenetic analyses were performed in the Cytogenetics Shared Resource Laboratory at the University of Minnesota, with support from the comprehensive Masonic Cancer Center NIH Grant P30 CA077598. We thank Amanda Hemmingsen Jaeger for assistance with developing MLPA for AR gene structure analysis. SMD is a Masonic Scholar of the Masonic Cancer Center, University of Minnesota. This work was supported by a Young Investigator Award from the Prostate Cancer Foundation (SMD), DOD New Investigator Award PC094384 (SMD) NCI Grant CA141011 (SMD), and a seed grant from the Institute of Human Genetics, University of Minnesota.	Attard G, 2011, CLIN CANCER RES, V17, P1649, DOI 10.1158/1078-0432.CCR-10-0567; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; Dagvadorj A, 2008, CLIN CANCER RES, V14, P6062, DOI 10.1158/1078-0432.CCR-08-0979; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Ford OH, 2003, J UROLOGY, V170, P1817, DOI 10.1097/01.ju.0000091873.09677.f4; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Gregory CW, 2001, CANCER RES, V61, P2892; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Haapala K, 2001, LAB INVEST, V81, P1647, DOI 10.1038/labinvest.3780378; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hyytinen ER, 2002, LAB INVEST, V82, P1591, DOI 10.1097/01.LAB.0000038924.67707.75; Leversha MA, 2009, CLIN CANCER RES, V15, P2091, DOI 10.1158/1078-0432.CCR-08-2036; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Linja MJ, 2001, CANCER RES, V61, P3550; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Mohler JL, 2011, CANCER RES, V71, P1486, DOI 10.1158/0008-5472.CAN-10-1343; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Quinlan AR, 2010, GENOME RES, V20, P623, DOI 10.1101/gr.102970.109; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tarailo-Graovac M., 2009, CURR PROTOC BIOINFOR, V25, p4.10.11, DOI 10.1002/0471250953.bi0410s25; Thompson J, 2003, LAB INVEST, V83, P1709, DOI 10.1097/01.LAB.0000107262.40402.44; TILLEY WD, 1990, CANCER RES, V50, P5382; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107	42	140	144	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	45					4759	4767		10.1038/onc.2011.637	http://dx.doi.org/10.1038/onc.2011.637			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22266865	Green Accepted			2022-12-28	WOS:000311033000004
J	Lu, J; Hamze, Z; Bonnavion, R; Herath, N; Pouponnot, C; Assade, F; Fontaniere, S; Bertolino, P; Cordier-Bussat, M; Zhang, CX				Lu, J.; Hamze, Z.; Bonnavion, R.; Herath, N.; Pouponnot, C.; Assade, F.; Fontaniere, S.; Bertolino, P.; Cordier-Bussat, M.; Zhang, C. X.			Reexpression of oncoprotein MafB in proliferative beta-cells and Men1 insulinomas in mouse	ONCOGENE			English	Article						Maf; MafB; Men1; pancreatic beta-cells; proliferation; insulinoma	ENDOCRINE NEOPLASIA TYPE-1; MULTIPLE-MYELOMA; C-MAF; MICE; GENE; EXPRESSION; OVEREXPRESSION; REVEALS; TRANSLOCATION; SECRETION	MafB, a member of the large Maf transcription factor family, is essential for the embryonic and terminal differentiation of pancreatic alpha- and beta-cells. However, the role of MafB in the control of adult islet-cell proliferation remains unknown. Considering its oncogenic potential in several other tissues, we investigated the possible alteration of its expression in adult mouse beta-cells under different conditions of proliferation. We found that MafB, in general silenced in these cells, was reexpressed in similar to 30% of adaptive beta-cells both in gestational female mice and in mice fed with a high-fat diet. Importantly, reactivated MafB expression was also observed in the early beta-cell lesions and insulinomas that developed in beta-cell specific Men1 mutant mice, appearing in >80% of beta-cells in hyperplasic or dysplastic islets from the mutant mice > 4 months of age. Moreover, MafB expression could be induced by glucose stimulation in INS-1 rat insulinoma cells. The induction was further reinforced following Men1 knockdown by siRNA. Furthermore, MafB overexpression in cultured beta TC3 cells enhanced cell foci formation both in culture medium and on soft agar, accompanied with the increased expression of Cyclin B1 and D2. Conversely, MafB downregulation by siRNA transfection reduced BrdU incorporation in INS-1E cells. Taken together, our data reveal that Men1 inactivation leads to MafB reexpression in mouse beta-cells in vivo, and provides evidence that deregulated ectopic MafB expression may have a hitherto unknown role in adult beta-cell proliferation and Men1-related tumorigenesis. Oncogene (2012) 31, 3647-3654; doi:10.1038/onc.2011.538; published online 28 November 2011	[Zhang, C. X.] CNRS 5286, INSERM, U1052, Lyon Canc Res Ctr CRCL, F-69008 Lyon, France; [Lu, J.; Hamze, Z.; Bonnavion, R.; Assade, F.; Fontaniere, S.; Bertolino, P.; Cordier-Bussat, M.; Zhang, C. X.] CNRS, UMR5286, Lyon, France; [Lu, J.; Hamze, Z.; Bonnavion, R.; Assade, F.; Fontaniere, S.; Bertolino, P.; Cordier-Bussat, M.; Zhang, C. X.] Univ Lyon, Lyon, France; [Herath, N.; Pouponnot, C.] CNRS, UMR 3347, Inst Curie, INSERM,U1021, F-91405 Orsay, France; [Lu, J.; Zhang, C. X.] Ruijin Hosp, Sinofrench Life Sci & Genom Ctr, E Inst Shanghai, Shanghai, Peoples R China; [Lu, J.] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Shanghai 200030, Peoples R China	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, CX (corresponding author), CNRS 5286, INSERM, U1052, Lyon Canc Res Ctr CRCL, 28 Rue Laennec, F-69008 Lyon, France.	chang.zhang@lyon.unicancer.fr	Bertolino, philippe/D-4072-2018; Bertolino, philippe/M-8977-2019; Cordier-Bussat, Martine/G-4019-2014; ZHANG, Chang Xian/G-2905-2013	Bertolino, philippe/0000-0001-8064-8269; Bertolino, philippe/0000-0001-8064-8269; Bonnavion, Remy/0000-0002-7389-4282; Zhang, Chang Xian/0000-0002-5443-8951	Association pour la Recherche contre le Cancer (ARC), France; Ligue contre le Cancer du Rhone and de la Loire; MIRA program of Region Rhone-Alpes; National Science Foundation of China [NSFC30900700, 81170719, 30800537]; Science and Technology Commission of Shanghai Municipality [10140902900]; PhD-fellowship from ARC; Shanghai Pujiang Program [10PJ1408900]; Shanghai New Excellent Youth Program [XYQ2011009]	Association pour la Recherche contre le Cancer (ARC), France(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer du Rhone and de la Loire; MIRA program of Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); PhD-fellowship from ARC(Australian Research Council); Shanghai Pujiang Program(Shanghai Pujiang Program); Shanghai New Excellent Youth Program	We are grateful to Denis Ressnikoff for expert assistance of confocal microscopy, Jean-Michel Vicat and Martin Donnadieu for the maintenance of the mouse colonies, Dr Fabienne Rajas for help in high fat diet experiments, Pr. Jacques Philippe for Arx antibody, Dr Pierre Maechler for providing INS-1E line to M Cordier-Bussat. This study was supported by the Association pour la Recherche contre le Cancer (ARC), France, the Ligue contre le Cancer du Rhone and de la Loire, the MIRA program of Region Rhone-Alpes, National Science Foundation of China (NSFC30900700, 81170719, 30800537), and Science and Technology Commission of Shanghai Municipality (10140902900). J Lu and Z Hamze were the recipients of PhD-fellowship from ARC. J Lu was also the recipient of Shanghai Pujiang Program (10PJ1408900) and Shanghai New Excellent Youth Program (XYQ2011009).	Artner I, 2006, DIABETES, V55, P297, DOI 10.2337/diabetes.55.02.06.db05-0946; Artner I, 2007, P NATL ACAD SCI USA, V104, P3853, DOI 10.1073/pnas.0700013104; Bertolino P, 2003, MOL ENDOCRINOL, V17, P1880, DOI 10.1210/me.2003-0154; Bertolino P, 2003, CANCER RES, V63, P4836; Chesi M, 1998, BLOOD, V91, P4457, DOI 10.1182/blood.V91.12.4457.412k48_4457_4463; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Eychene A, 2008, NAT REV CANCER, V8, P683, DOI 10.1038/nrc2460; Fontaniere S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294; Fontaniere S, 2008, J ENDOCRINOL, V199, P287, DOI 10.1677/JOE-08-0289; Huang K, 2000, GENE, V242, P419, DOI 10.1016/S0378-1119(99)00500-4; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Hussein N, 2007, EUR J CANCER, V43, P402, DOI 10.1016/j.ejca.2006.08.038; Karnik SK, 2007, SCIENCE, V318, P806, DOI 10.1126/science.1146812; Loffler KA, 2007, INT J CANCER, V120, P259, DOI 10.1002/ijc.22288; Lu JL, 2010, GASTROENTEROLOGY, V138, P1954, DOI 10.1053/j.gastro.2010.01.046; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Morito N, 2006, CANCER RES, V66, P812, DOI 10.1158/0008-5472.CAN-05-2154; Morito N, 2011, CANCER RES, V71, P339, DOI 10.1158/0008-5472.CAN-10-1057; Mould AW, 2007, INT J CANCER, V121, P776, DOI 10.1002/ijc.22734; Nishimura W, 2008, DEV BIOL, V314, P443, DOI 10.1016/j.ydbio.2007.12.009; Nishimura W, 2006, DEV BIOL, V293, P526, DOI 10.1016/j.ydbio.2006.02.028; Nishizawa M, 2003, ONCOGENE, V22, P7882, DOI 10.1038/sj.onc.1206526; Pechhold S, 2009, NAT BIOTECHNOL, V27, P1038, DOI 10.1038/nbt.1579; Pouponnot C, 2006, ONCOGENE, V25, P1299, DOI 10.1038/sj.onc.1209171; Rocques N, 2007, MOL CELL, V28, P584, DOI 10.1016/j.molcel.2007.11.009; Schnepp RW, 2006, CANCER RES, V66, P5707, DOI 10.1158/0008-5472.CAN-05-4518; Teta M, 2007, DEV CELL, V12, P817, DOI 10.1016/j.devcel.2007.04.011; van Stralen E, 2009, EXP HEMATOL, V37, P78, DOI 10.1016/j.exphem.2008.08.006; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Xavier GD, 2010, BIOCHEM BIOPH RES CO, V402, P252, DOI 10.1016/j.bbrc.2010.10.010; Yang YM, 2010, J TAIWAN INST CHEM E, V41, P1, DOI 10.1016/j.jtice.2009.11.002; Yang YQ, 2007, MOL CELL ENDOCRINOL, V265, P34, DOI 10.1016/j.mce.2006.12.032; Zhang C, 2005, MOL CELL BIOL, V25, P4969, DOI 10.1128/MCB.25.12.4969-4976.2005	33	26	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	31					3647	3654		10.1038/onc.2011.538	http://dx.doi.org/10.1038/onc.2011.538			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985EG	22120711				2022-12-28	WOS:000307245600007
J	Senapati, S; Gnanapragassam, VS; Moniaux, N; Momi, N; Batra, SK				Senapati, S.; Gnanapragassam, V. S.; Moniaux, N.; Momi, N.; Batra, S. K.			Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells	ONCOGENE			English	Article						MUC4; pancreatic cancer; metastasis; NIDO domain; MUC4 domains	MUC4 EXPRESSION; ADENOCARCINOMA; EVOLUTION; DIAGNOSIS; BINDING	MUC4 is a large transmembrane type I glycoprotein that is overexpressed in pancreatic cancer (P =C) and has been shown to be associated with its progression and metastasis. However, the exact cellular and molecular mechanism(s) through which MUC4 promotes metastasis of PC cells has been sparsely studied. Here we showed that the nidogen-like (NIDO) domain of MUC4, which is similar to the G1-domain present in the nidogen or entactin (an extracellular matrix protein), contributes to the protein-protein interaction property of MUC4. By this interaction, MUC4 promotes breaching of basement membrane (BM) integrity, and spreading of cancer cells. These observations are corroborated with the data from our study using an engineered MUC4 protein without the NIDO domain, which was ectopically expressed in the MiaPaCa PC cells, lacking endogenous MUC4 and nidogen protein. The in vitro studies demonstrated an enhanced invasiveness of MiaPaCa cells expressing MUC4 (MiaPaCa-MUC4) compared with vector-transfected cells (MiaPaCa-Vec; P = 0.003) or cells expressing MUC4 without the NIDO domain (MiaPaCa-MUC4-NIDOD; P = 0.03). However, the absence of NIDO-domain has no significant role on cell growth and motility (P = 0.93). In the in vivo studies, all the mice orthotopically implanted with MiPaCa-MUC4 cells developed metastasis to the liver as compared with MiaPaCa-Vec or the MiaPaCaMUC4- NIDOD group, hence, supporting our in vitro observations. Additionally, a reduced binding (P = 0.0004) of MiaPaCa-MUC4-NIDOD cells to the fibulin-2 coated plates compared with MiaPaCa-MUC4 cells indicated a possible interaction between the MUC4-NIDO domain and fibulin-2, a nidogen-interacting protein. Furthermore, in PC tissue samples, MUC4 colocalized with the fibulin-2 present in the BM. Altogether, our findings demonstrate that the MUC4-NIDO domain significantly contributes to the MUC4-mediated metastasis of PC cells. This may be partly due to the interaction between the MUC4-NIDO domain and fibulin-2. Oncogene (2012) 31, 3346-3356; doi: 10.1038/onc.2011.505; published online 21 November 2011	[Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Eppley Inst Res Canc & Allied Dis, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Senapati, Shantibhusan/0000-0001-7108-8255	National Institutes of Health [CA78590, CA111294, CA127297, CA133774, CA131944]; NATIONAL CANCER INSTITUTE [R01CA133774, P50CA127297, R01CA078590, R01CA131944, U01CA111294] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the grants from National Institutes of Health (CA78590, CA111294, CA127297, CA133774 and CA131944). We thank Ms Kristi L Berger for editing the manuscript. We acknowledge the invaluable technical support from Mr Erik Moore and Kavita Mallya. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at the UNMC, for their support.	AUMAILLEY M, 1993, KIDNEY INT, V43, P7, DOI 10.1038/ki.1993.3; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Casey RC, 2000, CLIN EXP METASTAS, V18, P67, DOI 10.1023/A:1026519016213; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Duraisamy S, 2006, GENE, V373, P28, DOI 10.1016/j.gene.2005.12.021; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Langley RR, 2007, ENDOCR REV, V28, P297, DOI 10.1210/er.2006-0027; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Ma C, 2008, COLD SPRING HARB PRO, P5034; Ma C, 2008, GENE DEV, V22, P308, DOI 10.1101/gad.1632008; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Piscaglia F, 2009, CELL TISSUE RES, V337, P449, DOI 10.1007/s00441-009-0823-9; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Senapati S, 2008, BRIT J CANCER, V99, P949, DOI 10.1038/sj.bjc.6604632; Senapati S, 2010, TRENDS BIOCHEM SCI, V35, P236, DOI 10.1016/j.tibs.2009.10.003; Singh AP, 2007, ONCOGENE, V26, P30, DOI 10.1038/sj.onc.1209764; Singh AP, 2007, CANCER RES, V67, P433, DOI 10.1158/0008-5472.CAN-06-3114; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Ulazzi L, 2011, MOL CANCER, V6, P17; Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478	30	39	39	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3346	3356		10.1038/onc.2011.505	http://dx.doi.org/10.1038/onc.2011.505			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22105367	Green Accepted			2022-12-28	WOS:000306367600004
J	Huang, M; Anand, S; Murphy, EA; Desgrosellier, JS; Stupack, DG; Shattil, SJ; Schlaepfer, DD; Cheresh, DA				Huang, M.; Anand, S.; Murphy, E. A.; Desgrosellier, J. S.; Stupack, D. G.; Shattil, S. J.; Schlaepfer, D. D.; Cheresh, D. A.			EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation	ONCOGENE			English	Article						pancreatic cancer; Rap1; CAS; EGFR; metastasis; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION SITES; DOWN-REGULATION; INTEGRIN ACTIVATION; TUMOR PROGRESSION; CANCER-CELLS; CROSS-TALK; EXPRESSION; MIGRATION; RAS	Tyrosine kinase receptors have an essential role in various aspects of tumor progression. In particular, epidermal growth factor receptor (EGFR) and its ligands have been implicated in the growth and dissemination of a wide array of human carcinomas. Here, we describe an EGFR-mediated signaling pathway that regulates human pancreatic carcinoma cell invasion and metastasis, yet does not influence the growth of primary tumors. In fact, ligation/activation of EGFR induces Src-dependent phosphorylation of two critical tyrosine residues of p130CAS, leading to the assembly of a Crk-associated substrate (CAS)/Nck1 complex that promotes Ras-associated protein-1 (Rap1) signaling. Importantly, GTP loading of Rap1 is specifically required for pancreatic carcinoma cell migration on vitronectin but not on collagen. Furthermore, Rap1 activation is required for EGFR-mediated metastasis in vivo without impacting primary tumor growth. These findings identify a molecular pathway that promotes the invasive/metastatic properties of human pancreatic carcinomas driven by EGFR. Oncogene (2012) 31, 2783-2793; doi: 10.1038/onc.2011.450; published online 3 October 2011	[Huang, M.; Anand, S.; Murphy, E. A.; Desgrosellier, J. S.; Stupack, D. G.; Cheresh, D. A.] Moores Univ Calif San Diego, Ctr Canc, Dept Pathol, La Jolla, CA 92093 USA; [Shattil, S. J.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Cheresh, DA (corresponding author), Moores Univ Calif San Diego, Ctr Canc, Dept Pathol, Room 2344,3855 Hlth Sci Dr,MC 0803, La Jolla, CA 92093 USA.	dcheresh@ucsd.edu	ANAND, SUDARSHAN/I-5316-2019; Desgrosellier, Jay S/A-8756-2008	ANAND, SUDARSHAN/0000-0002-4969-6884; Huang, Miller/0000-0002-3371-0100	NIH [CA107263, HL56595, HL47900, CA102310, CA045726]; NATIONAL CANCER INSTITUTE [R01CA095262, R01CA045726, R01CA107263, T32CA121938, R01CA102310] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Dr Steven K Hanks for the donation of the CAS mutant plasmids and Dr David J Shields for helpful discussion. This work was supported by NIH Grants CA107263 (DGS), HL56595 and HL47900 (SJS), CA102310 (DDS), and CA045726 (DAC).	Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Bruns CJ, 2000, CANCER RES, V60, P2926; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Faller BA, 2009, BIOL-TARGETS THER, V3, P419; Frische EW, 2010, DEV BIOL, V340, P1, DOI 10.1016/j.ydbio.2009.12.043; Furstenau DK, 2011, BREAST CANCER RES TR, V129, P361, DOI 10.1007/s10549-010-1227-y; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Jenei V, 2005, EXP CELL RES, V310, P463, DOI 10.1016/j.yexcr.2005.08.010; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lotz M, 2003, J SURG RES, V109, P123, DOI 10.1016/S0022-4804(02)00100-2; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Matsumoto S, 2006, INT J CANCER, V119, P1491, DOI 10.1002/ijc.21940; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Morgan MA, 2008, CLIN CANCER RES, V14, P5142, DOI 10.1158/1078-0432.CCR-07-4072; Morgillo F, 2006, CANCER RES, V66, P10100, DOI 10.1158/0008-5472.CAN-06-1684; Ohba Y, 2003, EMBO J, V22, P859, DOI 10.1093/emboj/cdg087; Papouchado B, 2005, MODERN PATHOL, V18, P1329, DOI 10.1038/modpathol.3800427; Payne SL, 2006, J CELL BIOCHEM, V98, P827, DOI 10.1002/jcb.20792; Peace BE, 2003, EXP CELL RES, V289, P317, DOI 10.1016/S0014-4827(03)00280-5; Pryczynicz A, 2008, ANTICANCER RES, V28, P1399; Retta SF, 2006, EUR J CELL BIOL, V85, P283, DOI 10.1016/j.ejcb.2005.09.007; Ricono JM, 2009, CANCER RES, V69, P1383, DOI 10.1158/0008-5472.CAN-08-3612; Rivera F, 2009, CANCER TREAT REV, V35, P335, DOI 10.1016/j.ctrv.2008.11.007; Rivera GM, 2006, P NATL ACAD SCI USA, V103, P9536, DOI 10.1073/pnas.0603786103; Sakakibara A, 2002, J CELL SCI, V115, P4915, DOI 10.1242/jcs.00207; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shimonaka M, 2003, J CELL BIOL, V161, P417, DOI 10.1083/jcb.200301133; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; Thomas RM, 2007, CANCER RES, V67, P6075, DOI 10.1158/0008-5472.CAN-06-4128; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Tsygankova OM, 2010, MOL CELL BIOL, V30, P3262, DOI 10.1128/MCB.01345-09; Ueno Y, 2008, INT J CANCER, V123, P340, DOI 10.1002/ijc.23465; Wolpin BM, 2007, CANCER RES, V67, P7923, DOI 10.1158/0008-5472.CAN-07-0373; Xu JG, 2007, CELL SIGNAL, V19, P1575, DOI 10.1016/j.cellsig.2007.02.004; Yaman E, 2009, FEBS J, V276, P4607, DOI 10.1111/j.1742-4658.2009.07166.x; Zhang LZ, 2006, CANCER RES, V66, P898, DOI 10.1158/0008-5472.CAN-05-3025	51	47	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2783	2793		10.1038/onc.2011.450	http://dx.doi.org/10.1038/onc.2011.450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963850	Green Accepted			2022-12-28	WOS:000304769000008
J	Li, W; Melton, DW				Li, W.; Melton, D. W.			Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance	ONCOGENE			English	Article						chemotherapy; DNA damage; DUSP6 phosphatase; nucleotide excision repair; XPF	NUCLEOTIDE EXCISION-REPAIR; ACTIVATED PROTEIN-KINASES; OVARIAN-CANCER CELLS; SIGNALING PATHWAY; OXIDATIVE STRESS; RESISTANCE; INHIBITION; APOPTOSIS; PHOSPHATASES; GROWTH	The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. Melanoma is the second most common cancer among young adults in the UK, where incidence rates have more than quadrupled since the 1970s. Increased expression of a number of DNA repair genes has been reported in melanoma and this likely contributes to its extreme resistance to conventional DNA-damaging chemotherapeutics. One such chemotherapeutic that is effective against a range of other cancers, but not melanoma, is cisplatin. The DNA repair proteins ERCC1 and XPF are needed to remove cisplatin-induced DNA damage and we have investigated the response of these proteins to cisplatin in melanoma. The expression of both genes is induced by cisplatin. Use of a MEK inhibitor showed that ERCC1, but not XPF induction was regulated by the mitogen-activated protein kinase (MAPK) pathway, with reduction in expression of DUSP6, the phosphatase that inactivates the extracellular signal-regulated kinase (ERK), being particularly important. DUSP6 overexpression prevented cisplatin induction of both ERCC1 and XPF, resulting in increased sensitivity to cisplatin. A novel ERCC1 mRNA was found that initiated upstream of the normal transcription initiation site, and was strongly regulated by both cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study. The cisplatin induction of ERCC1 and XPF provides important insights into the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles to melanoma treatment. Oncogene (2012) 31, 2412-2422; doi: 10.1038/onc.2011.426; published online 26 September 2011	[Li, W.; Melton, D. W.] Univ Edinburgh, Inst Genet & Mol Med, Western Gen Hosp, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Inst Genet & Mol Med, Western Gen Hosp, MRC Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	David.Melton@ed.ac.uk		li, weiling/0000-0001-6681-9156	China Scholarship Council/University of Edinburgh; Charon Fund	China Scholarship Council/University of Edinburgh(China Scholarship Council); Charon Fund	The cisplatin colony-forming assay was carried out by Ann-Marie Ritchie. We are grateful to Professor Toru Furukawa (Tohoku University School of Medicine, Japan), who kindly provided the DUSP6 plasmid. WL was supported by a China Scholarship Council/University of Edinburgh Scholarship. This work was supported by the Charon Fund.	Agar N, 2005, MUTAT RES-FUND MOL M, V571, P121, DOI 10.1016/j.mrfmmm.2004.11.016; Andrieux LO, 2007, CANCER RES, V67, P2114, DOI 10.1158/0008-5472.CAN-06-3821; Bermudez O, 2010, AM J PHYSIOL-CELL PH, V299, pC189, DOI 10.1152/ajpcell.00347.2009; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007; Cancer Research UK, 2020, PANCR CANC STAT CANC, P1; Chan DW, 2008, CARCINOGENESIS, V29, P1742, DOI 10.1093/carcin/bgn167; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chapman PB, 1999, J CLIN ONCOL, V17, P2745, DOI 10.1200/JCO.1999.17.9.2745; Ciuffreda L, 2009, NEOPLASIA, V11, P720, DOI 10.1593/neo.09398; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Gozdz A, 2008, J NEUROCHEM, V106, P2056, DOI 10.1111/j.1471-4159.2008.05550.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jansen B, 1997, CANCER RES, V57, P362; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700; Kirschner K, 2010, ANTICANCER RES, V30, P3223; Ko JC, 2010, BIOCHEM PHARMACOL, V79, P655, DOI 10.1016/j.bcp.2009.09.024; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kuraoka I, 2000, J BIOL CHEM, V275, P26632, DOI 10.1074/jbc.C000337200; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Lee-Kwon W, 1998, BIOCHEM J, V331, P591, DOI 10.1042/bj3310591; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Mirmohammadsadegh A, 2007, J INVEST DERMATOL, V127, P2207, DOI 10.1038/sj.jid.5700870; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oliveria SA, 2006, ARCH DIS CHILD, V91, P131, DOI 10.1136/adc.2005.086918; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Rosell Rafael, 2003, Cancer Control, V10, P297; Selfridge J, 2010, DNA REPAIR, V9, P653, DOI 10.1016/j.dnarep.2010.02.018; Shahzad MMK, 2009, DRUG RESIST UPDATE, V12, P148, DOI 10.1016/j.drup.2009.09.001; Song L, 2011, TRANSGENIC RES, V20, P109, DOI 10.1007/s11248-010-9396-3; Stecca C, 1998, BIOCHEM PHARMACOL, V55, P941, DOI 10.1016/S0006-2952(97)00448-6; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; VANDUIN M, 1987, NUCLEIC ACIDS RES, V15, P9195, DOI 10.1093/nar/15.22.9195; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Welsh C, 2004, INT J CANCER, V110, P352, DOI 10.1002/ijc.20134; Winter AG, 2005, ONCOGENE, V24, P2110, DOI 10.1038/sj.onc.1208400; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2	51	70	72	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	19					2412	2422		10.1038/onc.2011.426	http://dx.doi.org/10.1038/onc.2011.426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996734				2022-12-28	WOS:000303985300004
J	Manser, C; Guillot, F; Vagnoni, A; Davies, J; Lau, KF; McLoughlin, DM; De Vos, KJ; Miller, CCJ				Manser, C.; Guillot, F.; Vagnoni, A.; Davies, J.; Lau, K-F; McLoughlin, D. M.; De Vos, K. J.; Miller, C. C. J.			Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo	ONCOGENE			English	Article						glycogen synthase kinase-3 beta; protein phosphatase-1C; transforming growth factor-beta; amyotrophic lateral sclerosis; Alzheimer's disease; axonal transport	GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN PHOSPHATASE-1; TGF-BETA; MYOSIN-VI; GENE-EXPRESSION; IDENTIFICATION; INACTIVATION; INHIBITOR; TRANSPORT; BRAIN	A recent genome-wide association study identified the gene encoding lemur tyrosine kinase-2 (LMTK2) as a susceptibility gene for prostate cancer. The identified genetic alteration is within intron 9, but the mechanisms by which LMTK2 may impact upon prostate cancer are not clear because the functions of LMTK2 are poorly understood. Here, we show that LMTK2 regulates a known pathway that controls phosphorylation of kinesin-1 light chain-2 (KLC2) by glycogen synthase kinase-3 beta (GSK3b). KLC2 phosphorylation by GSK3 beta induces the release of cargo from KLC2. LMTK2 signals via protein phosphatase-1C (PP1C) to increase inhibitory phosphorylation of GSK3 beta on serine-9 that reduces KLC2 phosphorylation and promotes binding of the known KLC2 cargo Smad2. Smad2 signals to the nucleus in response to transforming growth factor-beta (TGF beta) receptor stimulation and transport of Smad2 by kinesin-1 is required for this signalling. We show that small interfering RNA loss of LMTK2 not only reduces binding of Smad2 to KLC2, but also inhibits TGF beta-induced Smad2 signalling. Thus, LMTK2 may regulate the activity of kinesin-1 motor function and Smad2 signalling. Oncogene (2012) 31, 2773-2782; doi: 10.1038/onc.2011.437; published online 26 September 2011	[Manser, C.; Guillot, F.; Vagnoni, A.; Davies, J.; Lau, K-F; McLoughlin, D. M.; De Vos, K. J.; Miller, C. C. J.] Kings Coll London, Dept Neurosci P037, MRC Ctr Neurodegenerat Res, Inst Psychiat, London SE5 8AF, England; [Lau, K-F] Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; [McLoughlin, D. M.] St Patricks Hosp, Trinity Coll Inst Neurosci, Dept Psychiat, Dublin, Ireland	University of London; King's College London; Chinese University of Hong Kong; Trinity College Dublin	Miller, CCJ (corresponding author), Kings Coll London, Dept Neurosci P037, MRC Ctr Neurodegenerat Res, Inst Psychiat, De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@kcl.ac.uk	Miller, Christopher/H-5733-2012; De Vos, Kurt/D-8380-2011	De Vos, Kurt/0000-0003-2161-6309; Miller, Christopher/0000-0002-5130-1845; , Florence/0000-0002-8491-4269; Lau, Kwok-Fai/0000-0002-0193-1152; Vagnoni, Alessio/0000-0003-2947-9193; McLoughlin, Declan/0000-0003-4574-2799	Wellcome Trust; MRC; MNDA; BBSRC; MRC [G0501573] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C506913/1] Funding Source: researchfish; Medical Research Council [G0501573] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MNDA; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from the Wellcome Trust, MRC, MNDA and BBSRC. We thank Caroline Hill (Cancer Research UK London Research Institute) for EGFP-Smad2 plasmid, Peter ten Dijke (Leiden University Medical Centre) for Smad2 reporter plasmids, Folma Buss (University of Cambridge UK) for LMTK2 antibody and Manuel Mayr (KCL London) for assistance with analyses of Pro-Q labelling.	Bajaj NPS, 1999, PROG NEURO-PSYCHOPH, V23, P833, DOI 10.1016/S0278-5846(99)00044-5; Batut J, 2007, DEV CELL, V12, P261, DOI 10.1016/j.devcel.2007.01.010; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Chibalina MV, 2007, J CELL SCI, V120, P4278, DOI 10.1242/jcs.014217; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711; DeBoer SR, 2008, BIOCHEMISTRY-US, V47, P4535, DOI 10.1021/bi702445j; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; FitzGerald LM, 2009, CLIN CANCER RES, V15, P3231, DOI 10.1158/1078-0432.CCR-08-2190; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guidato S, 1998, J NEUROCHEM, V70, P335; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Harries LW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-315; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hernandez F, 2010, MOL CELL BIOCHEM, V344, P211, DOI 10.1007/s11010-010-0544-0; Hill CS, 2009, CELL RES, V19, P36, DOI 10.1038/cr.2008.325; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Inoue T, 2008, GENES CELLS, V13, P483, DOI 10.1111/j.1365-2443.2008.01184.x; Katsuno M, 2011, Curr Mol Med, V11, P48, DOI 10.2174/156652411794474356; Kawa S, 2004, GENES CELLS, V9, P219, DOI 10.1111/j.1356-9597.2004.00714.x; Kawa S, 2006, P NATL ACAD SCI USA, V103, P19344, DOI 10.1073/pnas.0603603103; Kesavapany S, 2003, J NEUROSCI, V23, P4975; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lau KF, 2008, J BIOL CHEM, V283, P34728, DOI 10.1074/jbc.M801874200; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li T, 2007, J BIOL CHEM, V282, P6619, DOI 10.1074/jbc.M606347200; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; McLoughlin DM, 1996, FEBS LETT, V397, P197; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; Mitsuhashi S, 2001, BIOCHEM BIOPH RES CO, V287, P328, DOI 10.1006/bbrc.2001.5596; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; Murakami M, 2009, GENES CELLS, V14, P469, DOI 10.1111/j.1365-2443.2009.01283.x; Noda D, 2006, ONCOGENE, V25, P5591, DOI 10.1038/sj.onc.1209571; Puri C, 2010, ONCOGENE, V29, P188, DOI 10.1038/onc.2009.328; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rahman-Roblick R, 2008, ONCOGENE, V27, P4854, DOI 10.1038/onc.2008.124; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Su AI, 2001, CANCER RES, V61, P7388; Su SC, 2011, ANNU REV CE IN PRESS; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tomomura M, 2007, NEUROSCIENCE, V148, P510, DOI 10.1016/j.neuroscience.2007.05.048; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vagnoni A, 2011, J CELL SCI, V124, P1032, DOI 10.1242/jcs.075168; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Wang H, 2006, MOL CELL PROTEOMICS, V5, P2124, DOI 10.1074/mcp.M600188-MCP200; Waters KM, 2009, CANCER EPIDEM BIOMAR, V18, P1285, DOI 10.1158/1055-9965.EPI-08-1142; Wozniak MJ, 2006, EMBO J, V25, P5457, DOI 10.1038/sj.emboj.7601427; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	59	36	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2773	2782		10.1038/onc.2011.437	http://dx.doi.org/10.1038/onc.2011.437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21996745	Green Accepted, Green Published			2022-12-28	WOS:000304769000007
J	Natsume, A; Kato, T; Kinjo, S; Enomoto, A; Toda, H; Shimato, S; Ohka, F; Motomura, K; Kondo, Y; Miyata, T; Takahashi, M; Wakabayashi, T				Natsume, A.; Kato, T.; Kinjo, S.; Enomoto, A.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Kondo, Y.; Miyata, T.; Takahashi, M.; Wakabayashi, T.			Girdin maintains the stemness of glioblastoma stem cells	ONCOGENE			English	Article						Girdin; glioblastoma; cancer stem cells; migration; stemness	INITIATING CELLS; PROTEIN GIRDIN; HUMAN CANCER; AKT; PATHWAY; GLIOMA; BRAIN; ACTIVATION; ANGIOGENESIS; SURVIVAL	Glioblastomas (GBMs) are the most common and aggressive type of brain tumor. GBMs usually show hyperactivation of the PI3K-Akt pathway, a pro-tumorigenic signaling cascade that contributes to pathogenesis. Girdin, an actin-binding protein identified as a novel substrate of Akt, regulates the sprouting of axons and the migration of neural progenitor cells during early postnatal-stage neurogenesis in the hippocampus. Here, we show that Girdin is highly expressed in human glioblastoma (GBM). Stable Girdin knockdown in isolated GBM stem cells resulted in decreased expression of stem cell markers, including CD133, induced multilineage neural differentiation, and inhibited in vitro cell motility, ex vivo invasion, sphere-forming capacity and in vivo tumor formation. Furthermore, exogenous expression of the Akt-binding domain of Girdin, which competitively inhibits its Akt-mediated phosphorylation, diminished the expression of stem cell markers, SOX2 and nestin, and migration on the brain slice and induced the expression of neural differentiation markers glial fibrillary acidic protein/beta III Tubulin. Our results reveal that Girdin is required for GBM-initiating stem cells to sustain the stemness and invasive properties. Oncogene (2012) 31, 2715-2724; doi: 10.1038/onc.2011.466; published online 24 October 2011	[Natsume, A.; Kato, T.; Kinjo, S.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Wakabayashi, T.] Nagoya Univ, Dept Neurosurg, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; [Enomoto, A.; Takahashi, M.] Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Kondo, Y.] Aichi Canc Ctr Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi, Japan; [Miyata, T.] Nagoya Univ, Dept Anat & Cell Biol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Aichi Cancer Center; Nagoya University	Natsume, A (corresponding author), Nagoya Univ, Dept Neurosurg, Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	anatsume@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Ohka, Fumiharu/A-3420-2016; MIYATA, TAKAKI/I-7066-2014; Motomura, Kazuya/AAF-8776-2021; Enomoto, Atsushi/I-7272-2014; Natsume, Atsushi/I-7364-2014; Wakabayashi, Toshihiko/I-3526-2012; Takahashi, Masahide/AAN-4770-2020	Motomura, Kazuya/0000-0002-4376-1104; Enomoto, Atsushi/0000-0002-9206-6116; Natsume, Atsushi/0000-0002-9113-0470; Wakabayashi, Toshihiko/0000-0001-5254-2088; Takahashi, Masahide/0000-0002-2803-2683; Ohka, Fumiharu/0000-0002-5569-5626	Grants-in-Aid for Scientific Research [22117005] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Castellino RC, 2007, NAT CLIN PRACT NEURO, V3, P682, DOI 10.1038/ncpneuro0661; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015; Eyler CE, 2008, STEM CELLS, V26, P3027, DOI 10.1634/stemcells.2007-1073; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008-5472.CAN-07-5111; Kato H, 2008, LAB INVEST, V88, P731, DOI 10.1038/labinvest.2008.42; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Matsumoto K, 2009, CANCER RES, V69, P7160, DOI 10.1158/0008-5472.CAN-09-1289; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Sonoda Y, 2001, CANCER RES, V61, P6674; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yuki K, 2009, CANCER LETT, V284, P71, DOI 10.1016/j.canlet.2009.04.020; Zhang BB, 2009, INT J CANCER, V125, P585, DOI 10.1002/ijc.24314	28	62	66	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	22					2715	2724		10.1038/onc.2011.466	http://dx.doi.org/10.1038/onc.2011.466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	22020337				2022-12-28	WOS:000304769000002
J	Shih, MC; Chen, JY; Wu, YC; Jan, YH; Yang, BM; Lu, PJ; Cheng, HC; Huang, MS; Yang, CJ; Hsiao, M; Lai, JM				Shih, M-C; Chen, J-Y; Wu, Y-C; Jan, Y-H; Yang, B-M; Lu, P-J; Cheng, H-C; Huang, M-S; Yang, C-J; Hsiao, M.; Lai, J-M			TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer	ONCOGENE			English	Article						TOPK; AKT; PTEN; migration; prognosis marker; lung adenocarcinoma	ORIGINATED PROTEIN-KINASE; PDZ-BINDING KINASE; MITOTIC KINASE; DISEASE RECURRENCE; EXPRESSION; PTEN; PHOSPHORYLATION; SURVIVAL; PBK/TOPK; INVASION	We integrated four gene expression profile data sets, namely two different pair-matched stage I lung adenocarcinoma data sets, secondary metastatic tumors vs benign tumors and lung tumor metastasizes to the brain, and we identified one kinase, T-LAK Cell-Originated Protein Kinase (TOPK), as a putative gene that promotes metastasis. To delineate the role of TOPK in lung cancer, we showed that overexpression of TOPK, but not a catalytically inactive form of TOPK, can enhance the migration and invasion of lung fibroblasts or cells with low TOPK expression. In addition, TOPK-induced cell migration was shown to be a PI3K/AKT-dependent event. TOPK concurrently promoted AKT phosphorylation at Ser(473) and decreased the phosphatase and tensin homolog (PTEN) levels, whereas TOPK knockdown had the reverse effects. LY294002, a PI3K inhibitor, did not inhibit the TOPK-induced decrease in PTEN, and co-expression of PTEN significantly reduced TOPK-induced AKT phosphorylation in a dose-dependent manner; these results indicate that the TOPK-mediated PTEN decrease has an upstream role in regulating PI3K/AKT-stimulated migration. Using immunohistochemical analysis of lung cancer tissue samples, we showed that a high TOPK expression level correlates strongly with reduced overall and disease-free survivals. Moreover, an inverse correlation between TOPK and PTEN expression was present and is consistent with the biochemical findings. Finally, a combination of high TOPK and low PTEN expression was inversely correlated with overall and disease-free survivals, independent of other pathologic staging factors. Our results suggest that TOPK is a potential therapeutic target in lung cancer that promotes cell migration by modulating a PI3K/PTEN/AKT-dependent signaling pathway; they also suggest that high TOPK expression, either alone or in combination with a low level of PTEN, may serve as a prognostic marker for lung cancer. Oncogene (2012) 31, 2389-2400; doi: 10.1038/onc.2011.419; published online 26 September 2011	[Shih, M-C; Chen, J-Y; Yang, B-M; Lai, J-M] Fu Jen Catholic Univ, Coll Sci & Engn, Dept Life Sci, New Taipei City 24205, Taiwan; [Wu, Y-C] Taipei Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taipei, Taiwan; [Jan, Y-H; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lu, P-J; Cheng, H-C] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan; [Huang, M-S; Yang, C-J] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan	Fu Jen Catholic University; Taipei Veterans General Hospital; Academia Sinica - Taiwan; National Cheng Kung University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Lai, JM (corresponding author), Fu Jen Catholic Univ, Coll Sci & Engn, Dept Life Sci, 510 Zhongzheng Rd, New Taipei City 24205, Taiwan.	jmlai@mail.fju.edu.tw	Lai, Jin-Mei/AAM-4119-2020; Hsiao, Michael/U-6238-2019	Hsiao, Michael/0000-0001-8529-9213; Jan, Yi-Hua/0000-0001-7344-7602	National Science Council (Taiwan) [NSC95-2311-B-030-002-MY3, NSC99-2627-B-030-001]; Center of Excellence for Cancer Research at Taipei Veterans General Hospital [DOH100-TD-C-111-007]	National Science Council (Taiwan)(Ministry of Science and Technology, Taiwan); Center of Excellence for Cancer Research at Taipei Veterans General Hospital(Taipei Veterans General Hospital)	We thank Dr Chi-Ying F Huang (Yang-Ming University, Taipei, Taiwan) for providing lung cancer microarray data. This work was supported by grants from National Science Council (Taiwan) (NSC95-2311-B-030-002-MY3 and NSC99-2627-B-030-001) to JM Lai and Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH100-TD-C-111-007) to YC Wu.	Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Abe Y, 2007, J MOL BIOL, V370, P231, DOI 10.1016/j.jmb.2007.04.067; Akca H, 2011, LUNG CANCER, V73, P302, DOI 10.1016/j.lungcan.2011.01.012; AlKattan K, 1997, EUR J CARDIO-THORAC, V12, P380, DOI 10.1016/S1010-7940(97)00198-X; Auperin A, 2010, LANCET, V375, P1267, DOI 10.1016/S0140-6736(10)60059-1; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Chen TC, 2009, J PROTEOME RES, V8, P4943, DOI 10.1021/pr900325f; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275; Hung JJ, 2009, THORAX, V64, P192, DOI 10.1136/thx.2007.094912; Kratz JR, 2009, CLIN LUNG CANCER, V10, P151, DOI 10.3816/CLC.2009.n.021; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Omuro AMP, 2005, CANCER-AM CANCER SOC, V103, P2344, DOI 10.1002/cncr.21033; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Sugimura H, 2007, ANN THORAC SURG, V83, P409, DOI 10.1016/j.athoracsur.2006.08.046; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048; Zlobec I, 2010, BRIT J CANCER, V102, P151, DOI 10.1038/sj.bjc.6605452; Zykova TA, 2006, CLIN CANCER RES, V12, P6884, DOI 10.1158/1078-0432.CCR-06-0410	33	134	138	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2389	2400		10.1038/onc.2011.419	http://dx.doi.org/10.1038/onc.2011.419			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996732				2022-12-28	WOS:000303985300002
J	Fischer, JM; Miller, AJ; Shibata, D; Liskay, RM				Fischer, J. M.; Miller, A. J.; Shibata, D.; Liskay, R. M.			Different phenotypic consequences of simultaneous versus stepwise Apc loss	ONCOGENE			English	Article						APC; cancer; simultaneous; stepwise intestine	FAMILIAL ADENOMATOUS POLYPOSIS; MULTIPLE INTESTINAL NEOPLASIA; SOMATIC MUTATIONS; MOUSE MODEL; STEM-CELLS; CANCER; SUPPRESSION; PROTEOME; SEQUENCE; CATALOG	APC is considered a gatekeeper for colorectal cancer (CRC). Cells with heterozygous APC mutations have altered expression profiles suggesting that the first APC hit may help set the stage for subsequent transformation. Therefore, we measured transformation efficiency following what we have designated as 'simultaneous' versus 'stepwise' Apc loss. We combined a conditional Apc allele (Apc(CKO)) with a Cre reporter gene and an out-of-frame Cre allele (Pms2(cre)) that stochastically becomes functional by a frameshift mutation in single cells. Loss of one Apc allele (Apc(CKO/+)) had little consequence, whereas simultaneous loss of both Apc alleles (Apc(CKO/CKO)) resulted in increased clonal expansion (crypt fission), consistent with the gatekeeper function of Apc. Interestingly, our analyses showed that most of the Apc-deficient crypts in Apc(CKO/CKO) mice appeared normal, with morphological transformation, including beta-catenin deregulation, occurring in only 17% of such crypts. To determine whether transformation efficiency was different following stepwise Apc loss, we combined Apc(CKO) with a germline mutant allele, either Apc(Min) or Apc(1638N). Transformation efficiency following stepwise Apc loss (Apc(Min/CKO) or Apc(1638N/CKO)) was increased five-fold and essentially all of the Apc-deficient cells were dysplastic. In summary, our data suggest that the gatekeeper function of Apc consists of two roles, clonal expansion and morphological transformation, because simultaneous Apc loss frequently leads to occult clonal expansion without morphological transformation, whereas stepwise Apc loss more often results in visible neoplasia. Finally, that Apc-deficient cells in certain scenarios can retain a normal phenotype is unexpected and may have clinical implications for surveillance strategies to prevent CRC. Oncogene (2012) 31, 2028-2038; doi: 10.1038/onc.2011.385; published online 5 September 2011	[Fischer, J. M.; Miller, A. J.; Liskay, R. M.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA; [Shibata, D.] Univ So Calif, Sch Med, Dept Pathol, Norris Canc Ctr, Los Angeles, CA 90033 USA	Oregon Health & Science University; University of Southern California	Liskay, RM (corresponding author), Oregon Hlth & Sci Univ, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	liskaym@ohsu.edu	Fischer, Jared/HCH-8013-2022	Fischer, Jared/0000-0002-0062-0870	NIH [2R01GM032741-28, 5T32HD046420-05]; ACS [PF-11-067-01-TBE]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD046420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032741] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS(American Cancer Society); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs James Stringer and Melissa Wong for critical reading of the manuscript. We also thank Drs Raju Kucherlapati and Winfried Edelmann for the Apc<SUP>CKO</SUP> and Apc<SUP>1638N</SUP> mice, respectively; John Swain and Dr Melissa Wong for Apc<SUP>Min</SUP> mice and Apc<SUP>580S</SUP> intestinal material; and Dan Lioy and Drs Gail Mandel and Paul Brehm for assistance with confocal microscopy. RML and DS were funded by NIH Grant 2R01GM032741-28. JMF was funded by NIH training Grant 5T32HD046420-05 and ACS postdoctoral fellow PF-11-067-01-TBE.	Akyol A, 2008, NAT METHODS, V5, P231, DOI 10.1038/NMETH.1182; Attolini CSO, 2010, P NATL ACAD SCI USA, V107, P17604, DOI 10.1073/pnas.1009117107; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Chan MF, 2001, MOL CELL BIOL, V21, P7587, DOI 10.1128/MCB.21.22.7587-7600.2001; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cruz-Correa M, 2002, GASTROENTEROLOGY, V122, P641, DOI 10.1053/gast.2002.31890; Eads CA, 2002, CANCER RES, V62, P1296; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kuraguchi M, 2006, PLOS GENET, V2, P1362, DOI 10.1371/journal.pgen.0020146; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; Lynch PM, 2010, EXPERT OPIN PHARMACO, V11, P1101, DOI 10.1517/14656561003698123; Miller AJ, 2008, NAT METHODS, V5, P227, DOI 10.1038/NMETH.1183; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Patel BB, 2011, ONCOTARGET, V2, P197, DOI 10.18632/oncotarget.241; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sasai H, 2000, CARCINOGENESIS, V21, P953, DOI 10.1093/carcin/21.5.953; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang DH, 2010, CANCER RES, V70, P5348, DOI 10.1158/0008-5472.CAN-09-4593; Yeung AT, 2008, CANCER RES, V68, P7579, DOI 10.1158/0008-5472.CAN-08-0856	35	16	16	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2028	2038		10.1038/onc.2011.385	http://dx.doi.org/10.1038/onc.2011.385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21892206	Green Accepted			2022-12-28	WOS:000303008600004
J	Jones, TS; Holland, EC				Jones, T. S.; Holland, E. C.			Standard of care therapy for malignant glioma and its effect on tumor and stromal cells	ONCOGENE			English	Review						glioblastoma; temozolomide; radiation; tumor stroma; dexamethasone	GROWTH-FACTOR-RECEPTOR; REGULATORY T-CELLS; STEM-LIKE CELLS; NOTCH SIGNALING PATHWAY; BLOOD-VESSEL FORMATION; HUMAN-BRAIN-TUMORS; CHEMOKINE RECEPTOR; HUMAN GLIOBLASTOMA; NITRIC-OXIDE; TGF-BETA	Glioblastoma is the most common and deadly of the primary central nervous system tumors. Recent advances in molecular characterization have subdivided these tumors into at least three main groups. In addition, these tumors are cellularly complex with multiple stromal cell types contributing to the biology of the tumor and treatment response. Because essentially all glioma patients are treated with radiation, various chemotherapies and steroids, the tumor that finally kills them has been modified by these treatments. Most of the investigation of the effects of therapy on these tumors has focused on the glioma cells per se. However, despite the importance of the stromal cells in these tumors, little has been done to understand the effects of treatment on stromal cells and their contribution to disease. Understanding how current standard therapy affects the biology of the tumor and the tumor stroma may provide insight into the mechanisms that are important to the inhibition of tumor growth as well as the biology of recurrent tumors. Oncogene (2012) 31, 1995-2006; doi: 10.1038/onc.2011.398; published online 12 September 2011	[Jones, T. S.] Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, Memphis, TN 38103 USA; [Jones, T. S.] Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, Memphis, TN 38103 USA; [Jones, T. S.] Univ Tennessee, Hlth Sci Ctr, Ctr Canc Res, Memphis, TN 38103 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, New York, NY 10065 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10065 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Brain Tumor Ctr, New York, NY 10065 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Jones, TS (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Clin Pharm, 19 S Manassas, Memphis, TN 38103 USA.	tjones@uthsc.edu; hollande@mskcc.org			NIH [RO1 CA100688, U54 CA126518-01, U01 CA141502-01, U54 CA143798]; NATIONAL CANCER INSTITUTE [U54CA126518, U01CA141502, U54CA143798, R01CA100688] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH grants RO1 CA100688, U54 CA126518-01, U01 CA141502-01 and U54 CA143798.	ALTERMAN RL, 1994, MOL CHEM NEUROPATHOL, V21, P177, DOI 10.1007/BF02815350; Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; [Anonymous], 2011, CBTRUS STAT REP PRIM; Arko L, 2010, PHARMACOL THERAPEUT, V128, P1, DOI 10.1016/j.pharmthera.2010.04.015; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 1999, ANN NY ACAD SCI, V876, P201, DOI 10.1111/j.1749-6632.1999.tb07640.x; Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Barbero S, 2002, ANN NY ACAD SCI, V973, P60, DOI 10.1111/j.1749-6632.2002.tb04607.x; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005; Bettinger I, 2002, ACTA NEUROPATHOL, V103, P351, DOI 10.1007/s00401-001-0472-x; Bhattacharya S, 2007, J CELL SCI, V120, P2652, DOI 10.1242/jcs.008417; Bjarnegard M, 2004, DEVELOPMENT, V131, P1847, DOI 10.1242/dev.01080; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; CAIRNCROSS JG, 1988, NEUROLOGY, V38, P724, DOI 10.1212/WNL.38.5.724; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Cavaliere R, 2005, LANCET NEUROL, V4, P760, DOI 10.1016/S1474-4422(05)70222-2; Chang JY, 2000, NEUROCHEM RES, V25, P903, DOI 10.1023/A:1007511221666; Charles N, 2009, EXPERT REV NEUROTHER, V9, P1447, DOI 10.1586/ERN.09.91; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Charles NA, 2011, GLIA, V59, P1169, DOI 10.1002/glia.21136; CHIANG CS, 1991, BRAIN RES, V566, P265, DOI 10.1016/0006-8993(91)91707-8; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cleaver O, 2003, NAT MED, V9, P661, DOI 10.1038/nm0603-661; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; Dix AR, 1999, J NEUROIMMUNOL, V100, P216, DOI 10.1016/S0165-5728(99)00203-9; Ehrenkranz JRL, 1980, ADRENOCORTICOSTEROID; EISENBERG HM, 1970, ARCH NEUROL-CHICAGO, V23, P18, DOI 10.1001/archneur.1970.00480250022004; El Andaloussi A, 2006, J NEUROSURG, V105, P430, DOI 10.3171/jns.2006.105.3.430; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Frederick L, 2000, CANCER RES, V60, P1383; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Goldstein LJ, 2005, SURGERY, V138, P439, DOI 10.1016/j.surg.2005.06.031; Gong X, 2011, NEUROLOGY, V76, P1126, DOI 10.1212/WNL.0b013e318212a89f; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; Grauer OM, 2007, INT J CANCER, V121, P95, DOI 10.1002/ijc.22607; GREEN SB, 1983, CANCER TREAT REP, V67, P121; Gutin P H, 1975, Semin Oncol, V2, P49; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hambardzumyan D, 2011, GLIA, V59, P1155, DOI 10.1002/glia.21142; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom NAK, 2011, MOL CELL NEUROSCI, V46, P710, DOI 10.1016/j.mcn.2011.02.001; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; Hong X, 2006, CANCER LETT, V236, P39, DOI 10.1016/j.canlet.2005.05.011; Huse JT, 2011, GLIA, V59, P1190, DOI 10.1002/glia.21165; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Hwang SY, 2006, NEUROBIOL DIS, V21, P457, DOI 10.1016/j.nbd.2005.08.006; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jones TS, 2011, TOXICOL PATHOL, V39, P158, DOI 10.1177/0192623310387617; Jordan JT, 2008, CANCER IMMUNOL IMMUN, V57, P123, DOI 10.1007/s00262-007-0336-x; Kalm M, 2009, RADIAT RES, V171, P66, DOI 10.1667/RR1269.1; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339; Kim JH, 2010, J NEUROCHEM, V115, P1161, DOI 10.1111/j.1471-4159.2010.07004.x; Kim SH, 2002, J KOREAN MED SCI, V17, P242, DOI 10.3346/jkms.2002.17.2.242; KOFMAN S, 1957, JAMA-J AM MED ASSOC, V163, P1473, DOI 10.1001/jama.1957.02970510039008; KURESHI SA, 1994, NEUROSURGERY, V35, P822, DOI 10.1227/00006123-199411000-00004; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729; Le DM, 2003, J NEUROSCI, V23, P4034; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Lohr J, 2011, CLIN CANCER RES, V17, P4296, DOI 10.1158/1078-0432.CCR-10-2557; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu C, 2008, MOL CELL BIOCHEM, V312, P71, DOI 10.1007/s11010-008-9722-8; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Markovic DS, 2005, J NEUROPATH EXP NEUR, V64, P754, DOI 10.1097/01.jnen.0000178445.33972.a9; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Okada M, 2009, INT J ONCOL, V34, P1621, DOI 10.3892/ijo_00000292; Ozerdem Ugur, 2004, Angiogenesis, V7, P269, DOI 10.1007/s10456-004-4182-6; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Ramirez-Castillejo C, 2006, NAT NEUROSCI, V9, P331, DOI 10.1038/nn1657; Ramnarain DB, 2006, CANCER RES, V66, P867, DOI 10.1158/0008-5472.CAN-05-2753; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Rong Y, 2006, J NEUROPATH EXP NEUR, V65, P529, DOI 10.1097/00005072-200606000-00001; ROVIT RL, 1968, J NEUROPATH EXP NEUR, V27, P277, DOI 10.1097/00005072-196804000-00007; Sameshima T, 2000, CANCER LETT, V157, P177, DOI 10.1016/S0304-3835(00)00485-7; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sciuscio D, 2011, CLIN CANCER RES, V17, P255, DOI 10.1158/1078-0432.CCR-10-1931; Seidel S, 2010, BRAIN, V133, P983, DOI 10.1093/brain/awq042; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suzuki Y, 2008, BIOMED RES-TOKYO, V29, P77, DOI 10.2220/biomedres.29.77; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; Vairano M, 2004, TOXICOL LETT, V148, P91, DOI 10.1016/j.toxlet.2003.12.058; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Villeneuve J, 2008, BRAIN PATHOL, V18, P401, DOI 10.1111/j.1750-3639.2008.00139.x; Virrey JJ, 2009, J NEURO-ONCOL, V95, P13, DOI 10.1007/s11060-009-9891-7; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; WATLING CJ, 1994, J CLIN ONCOL, V12, P1886, DOI 10.1200/JCO.1994.12.9.1886; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wiesenhofer B, 2000, ANTISENSE NUCLEIC A, V10, P311, DOI 10.1089/oli.1.2000.10.311; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; Xu Q, 2007, CLIN EXP PHARMACOL P, V34, P624, DOI 10.1111/j.1440-1681.2007.04619.x; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yeh WL, 2011, J CELL PHYSL; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zhu H, 2009, P NATL ACAD SCI USA, V106, P2712, DOI 10.1073/pnas.0813314106; Zuniga RM, 2009, J NEURO-ONCOL, V91, P329, DOI 10.1007/s11060-008-9718-y	122	34	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					1995	2006		10.1038/onc.2011.398	http://dx.doi.org/10.1038/onc.2011.398			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909136				2022-12-28	WOS:000303008600001
J	Claperon, A; Guedj, N; Mergey, M; Vignjevic, D; Desbois-Mouthon, C; Boissan, M; Saubamea, B; Paradis, V; Housset, C; Fouassier, L				Claperon, A.; Guedj, N.; Mergey, M.; Vignjevic, D.; Desbois-Mouthon, C.; Boissan, M.; Saubamea, B.; Paradis, V.; Housset, C.; Fouassier, L.			Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells	ONCOGENE			English	Article						NHERF-1; EGFR; biliary carcinoma; adherens junctions; cell motility	MOESIN-BINDING PHOSPHOPROTEIN-50; SCAFFOLD PROTEINS; TUMOR-SUPPRESSOR; NHE-RF; RECEPTOR; EXPRESSION; NHERF1/EBP50; CONTRIBUTES; MEMBRANE; INHIBITION	Scaffold proteins form multiprotein complexes that are central to the regulation of intracellular signaling. The scaffold protein ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) is highly expressed at the plasma membrane of normal biliary epithelial cells and binds epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with oncogenic properties. This study investigated EBP50-EGFR interplay in biliary cancer. We report that in a collection of 106 cholangio-carcinomas, EBP50 was delocalized to the cytoplasm of tumor cells in 66% of the cases. Ectopic expression of EBP50 was correlated with the presence of satellite nodules and with the expression of EGFR, which was at the plasma membrane, implying a loss of interaction with EBP50 in these cases. In vitro, loss of interaction between EBP50 and EGFR was mimicked by EBP50 depletion using a small interfering RNA approach in human biliary carcinoma cells co-expressing the two proteins at their plasma membrane, and in which interaction between EBP50 and EGFR was validated. EBP50 depletion caused an increase in EGFR expression at their surface, and a sustained activation of the receptor and of its downstream effectors (extracellular signal-regulated kinase 1/2, signal transducer and activator of transcription 3) in both basal and EGF-stimulated conditions. Cells lacking EBP50 showed epithelial-to-mesenchymal transition-associated features, including reduction in E-cadherin and cytokeratin-19 expression, induction of S100A4 and of the E-cadherin transcriptional repressor, Slug, and loss of cell polarity. Accordingly, depletion of EBP50 induced the disruption of adherens junctional complexes, the development of lamellipodia structures and the subsequent acquisition of motility properties. All these phenotypic changes were prevented upon inhibition of EGFR tyrosine kinase by gefitinib. These findings indicate that loss of EBP50 at the plasma membrane in tumor cells may contribute to biliary carcinogenesis through EGFR activation. Oncogene (2012) 31, 1376-1388; doi:10.1038/onc.2011.334; published online 8 August 2011	[Fouassier, L.] INSERM, Fac Med Pierre & Marie Curie, UMRS 938, F-75571 Paris, France; [Claperon, A.; Mergey, M.; Desbois-Mouthon, C.; Boissan, M.; Housset, C.; Fouassier, L.] Univ Paris 06, Paris, France; [Guedj, N.; Paradis, V.] Hop Beaujon, INSERM, UMRS U773, Clichy, France; [Guedj, N.; Paradis, V.] Hop Beaujon, AP HP, Serv Pathol, Clichy, France; [Vignjevic, D.] Inst Curie, CNRS, UMR 144, F-75231 Paris, France; [Boissan, M.] Hop Tenon, AP HP, Serv Biochim & Hormonol, F-75970 Paris, France; [Saubamea, B.] Univ Paris 05, INSERM, CNRS, U705,UMR 8206,Fac Pharm, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fouassier, L (corresponding author), INSERM, Fac Med Pierre & Marie Curie, UMRS 938, Site St Antoine,27 Rue Chaligny, F-75571 Paris, France.	laura.fouassier@inserm.fr	saubamea, bruno/H-6882-2017; Desbois-Mouthon, Christele/M-7076-2017; Paradis, Valerie/X-9097-2019; vignjevic, Danijela Matic/R-5160-2019; Vignjevic, Danijela/L-9721-2017; Fouassier, Laura/M-7556-2017	saubamea, bruno/0000-0002-6218-0460; Desbois-Mouthon, Christele/0000-0002-0772-1711; vignjevic, Danijela Matic/0000-0003-4250-703X; Fouassier, Laura/0000-0001-6377-5610; guedj, nathalie/0000-0002-1421-6297; Paradis, Valerie/0000-0003-3142-3762	Institut National du Cancer; Association pour la Recherche sur le Cancer; Fonds CSP	Institut National du Cancer(Institut National du Cancer (INCA) France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fonds CSP	We thank Yves Chretien, UMRS_938, for statistical analysis, Anne-Marie Faussat, IFR65, for flow cytometry experiments and the Nikon Imaging Center, Institut Curie-CNRS Paris, for time-lapse microscopy. Confocal imaging was performed at the Cellular and Molecular Imaging facility of the IFR71-IMTCE (Faculty of Pharmacy, Paris Descartes University, Paris, France). This work was supported by grants from the Institut National du Cancer, Association pour la Recherche sur le Cancer and Fonds CSP (to CH). LF dedicates this work to RB Doctor and JG Fitz.	Bhattacharyya RP, 2006, ANNU REV BIOCHEM, V75, P655, DOI 10.1146/annurev.biochem.75.103004.142710; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Cortese MS, 2008, PROG BIOPHYS MOL BIO, V98, P85, DOI 10.1016/j.pbiomolbio.2008.05.007; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; Dard N, 2006, BIOESSAYS, V28, P146, DOI 10.1002/bies.20351; Finzi L, 2009, J IMMUNOL, V182, P2269, DOI 10.4049/jimmunol.0801768; Fouassier L, 2001, HEPATOLOGY, V33, P166, DOI 10.1053/jhep.2001.21143; Fouassier L, 2009, AM J PATHOL, V174, P869, DOI 10.2353/ajpath.2009.080079; Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; Hoque MT, 2008, CANCER RES, V68, P4802, DOI 10.1158/0008-5472.CAN-07-6778; KNUTH A, 1985, J HEPATOL, V1, P579, DOI 10.1016/S0168-8278(85)80002-7; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Lambertini E, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-13; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Li M, 2010, J BIOL CHEM, V285, P19299, DOI 10.1074/jbc.M109.096081; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Masuda M, 2005, J BIOL CHEM, V280, P42164, DOI 10.1074/jbc.M507136200; Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Vondriska TM, 2004, J MOL CELL CARDIOL, V37, P391, DOI 10.1016/j.yjmcc.2004.04.021; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Werneburg NW, 2003, AM J PHYSIOL-GASTR L, V285, pG31, DOI 10.1152/ajpgi.00536.2002; Yoon JH, 2004, J HEPATOL, V41, P808, DOI 10.1016/j.jhep.2004.07.016; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129	36	44	48	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1376	1388		10.1038/onc.2011.334	http://dx.doi.org/10.1038/onc.2011.334			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21822312				2022-12-28	WOS:000301780000005
J	Ferrao, PT; Bukczynska, EP; Johnstone, RW; McArthur, GA				Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A.			Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells	ONCOGENE			English	Article						CHK inhibitors; DNA damage; p53; p19ARF; E mu-myc	DNA-DAMAGE RESPONSE; ONCOGENE-INDUCED SENESCENCE; CHECKPOINT KINASE 1; C-MYC; CANCER-THERAPY; SIGNALING PATHWAY; TUMOR-SUPPRESSOR; TRANSGENIC MICE; IN-VIVO; REPLICATION	CHK1 and CHK2 function as effectors of cell cycle checkpoint arrest following DNA damage. Small molecule inhibitors of CHK proteins are under clinical evaluation in combination with chemotherapeutic agents known to induce DNA damage. We examined whether CHK inhibitors could be effective as single agents in malignant cells with inherent DNA damage because of deregulated expression of the oncogene c-Myc. E mu-myc lymphoma cells showed a dramatic increase in the extent of DNA damage and DNA damage response (DDR) signalling within 1 h of treatment with CHK1 inhibitors followed by caspase-dependent apoptosis and cell death. In p53 wild-type/ARF null E mu-myc lymphoma cells, apoptotic cell death was preceded by accumulation of DNA damage and the amount of DNA damage correlated with the extent of cell death. This effect was not observed in normal B cells indicating that DNA damage accumulation following CHK inhibition was specific to E mu-myc lymphoma cells that exhibit inherent DNA damage because of MYC-induced replication stress. Similar results were obtained with another structurally distinct CHK-inhibitor. E mu-myc p53 null lymphoma cells were more sensitive to a dual CHK1/CHK2 inhibitor than to a CHK1-specific inhibitor. In all cases, the level of DNA damage following treatment was the most consistent indicator of drug sensitivity. Our results suggest that CHK inhibitors would be beneficial therapeutic agents in MYC-driven cancers. We propose that inhibitors of CHK can act in a synthetically lethal manner in cancers with replication stress as a result of these cancers being reliant on CHK proteins for an effective DDR and cell survival. Oncogene (2012) 31, 1661-1672; doi:10.1038/onc.2011.358; published online 15 August 2011	[Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A.] Peter MacCallum Canc Inst, Div Res, Mol Oncol Lab, Melbourne, Vic 3002, Australia; [Ferrao, P. T.; Bukczynska, E. P.; Johnstone, R. W.; McArthur, G. A.] Peter MacCallum Canc Inst, Div Res, Canc Therapeut Program, Melbourne, Vic 3002, Australia; [Ferrao, P. T.; McArthur, G. A.] Univ Melbourne, St Vincents Hosp, Dept Med, Melbourne, Vic, Australia; [Johnstone, R. W.; McArthur, G. A.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; St Vincent's Hospital Melbourne; University of Melbourne; University of Melbourne	Ferrao, PT (corresponding author), Peter MacCallum Canc Inst, Div Res, Mol Oncol Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	petranel.ferrao@petermac.org	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; McArthur, Grant/0000-0001-8908-6071	Pfizer Inc.; National Health and Medical Research Council of Australia; Cancer Council of Victoria	Pfizer Inc.(Pfizer); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria)	GAM, PTF and RWJ receive research support from Pfizer Inc.; This work was supported by grants from the National Health and Medical Research Council of Australia to GAM and to RWJ. GAM is a recipient of the Weary Dunlop Clinical Research Fellowship of the Cancer Council of Victoria. The statistical analysis and data presentation of dose response curves was performed by Dr Robert N Jorissen (LCCI, Ludwig Institute for Cancer Research). The MetaMorph Journal for measuring the Olive Tail Moment was provided by Cameron J Nowell of the Centre for Advanced Microscopy at the Ludwig Institute for Cancer Research. Pfizer Oncology, La Jolla, CA, USA provided PF-0477736 for this study. Dr Sreesha Srinivasa and Dr Wendy Levin (Pfizer Oncology) contributed to scientific discussion.	Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Ashwell S, 2008, CLIN CANCER RES, V14, P4032, DOI 10.1158/1078-0432.CCR-07-5138; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bertwistle D, 2007, BLOOD, V109, P792, DOI 10.1182/blood-2006-07-033985; Blasina A, 2008, MOL CANCER THER, V7, P2394, DOI 10.1158/1535-7163.MCT-07-2391; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chanoux RA, 2009, J BIOL CHEM, V284, P5994, DOI 10.1074/jbc.M806739200; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Deans AJ, 2006, CANCER RES, V66, P8219, DOI 10.1158/0008-5472.CAN-05-3945; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Enders GH, 2008, J BIOL CHEM, V283, P17749, DOI 10.1074/jbc.R800021200; Giroux V, 2006, FASEB J, V20, P1982, DOI 10.1096/fj.06-6239com; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Janetka JW, 2007, CURR OPIN DRUG DISC, V10, P473; Kastan MB, 2008, MOL CANCER RES, V6, P517, DOI 10.1158/1541-7786.MCR-08-0020; Lindemann RK, 2007, P NATL ACAD SCI USA, V104, P8071, DOI 10.1073/pnas.0702294104; Liu QH, 2000, GENE DEV, V14, P1448; Lord CJ, 2009, CLIN CANCER RES, V15, P3241, DOI 10.1158/1078-0432.CCR-09-0434; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Mallette FA, 2007, CELL CYCLE, V6, P1831, DOI 10.4161/cc.6.15.4516; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mercurio Ciro, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P190; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Newbold A, 2008, MOL CANCER THER, V7, P1066, DOI 10.1158/1535-7163.MCT-07-2256; Nguyen M, 2007, P NATL ACAD SCI USA, V104, P19512, DOI 10.1073/pnas.0709443104; Parsels LA, 2009, MOL CANCER THER, V8, P45, DOI 10.1158/1535-7163.MCT-08-0662; R Development Core Team, 2009, R LANG ENV STAT COMP; Redon CE, 2010, CLIN CANCER RES, V16, P4532, DOI 10.1158/1078-0432.CCR-10-0523; Reimann M, 2007, BLOOD, V110, P2996, DOI 10.1182/blood-2007-02-075614; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wall M, 2008, BLOOD, V112, P2305, DOI 10.1182/blood-2007-09-111856; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Zabludoff SD, 2008, MOL CANCER THER, V7, P2955, DOI 10.1158/1535-7163.MCT-08-0492; Zenvirt S, 2010, ONCOGENE, V29, P6149, DOI 10.1038/onc.2010.343; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	50	101	105	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1661	1672		10.1038/onc.2011.358	http://dx.doi.org/10.1038/onc.2011.358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841818				2022-12-28	WOS:000302231400005
J	Lee, KM; Choi, WI; Koh, DI; Kim, YJ; Jeon, BN; Yoon, JH; Lee, CE; Kim, SH; Oh, J; Hur, MW				Lee, K. M.; Choi, W. I.; Koh, D. I.; Kim, Y. J.; Jeon, B. N.; Yoon, J. H.; Lee, C. E.; Kim, S. H.; Oh, J.; Hur, M. W.			The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding	ONCOGENE			English	Article						MIZ-1; Kr-pok; CDKN1A; p21; competition; cell proliferation	ACUTE PROMYELOCYTIC LEUKEMIA; INTERACTION MOTIF; P53 PATHWAY; STEM-CELLS; GENE; DOMAIN; P21CIP1; BCL-6; SP1; P21	The BTB/POZ family of proteins has been implicated in multiple biological processes, including tumourigenesis, DNA damage responses and cell cycle progression and development. MIZ-1 (Myc-interacting zinc-finger protein 1) is known to activate transcription of CDKN1A. We recently found that a kidney cancer-related POK transcription factor, KR-POK, is highly expressed in kidney, brain and bone marrow cancer tissues and is a potential proto-oncoprotein. Mouse Kr-pok represses transcription of the CDKN1A by acting on the proximal promoter. The BiFC/FRET assay, co-immunoprecipitation and glutathione S-transferase-fusion protein pull-down assay indicate that MIZ-1 and Kr-pok interact via their POZ domains. Oligoucleotide pull-down assays and chromatin immunoprecipitation assays revealed that MIZ-1 binds to the proximal GC-box#3 (bp, -55 to -63) and the MIZ-1-binding elements, MRE-A (bp, -90 to -64) and MRE-B (bp, -27 to -17). Interestingly, MIZ-1 also binds to the distal p53-binding elements. Kr-pok binds to the proximal GC-box#1 (bp, -95 to -100) and #3 (bp, -55 to -63) relatively strongly. It also shows weak binding to the MREs and the distal p53-binding elements. Kr-pok competes with MIZ-1 in binding to these elements and represses transcription by inhibiting MIZ-1/p300 recruitment, which decreases the acetylation of histones H3 and H4. Our data indicate that Kr-pok stimulates cell proliferation by interfering with the function of MIZ-1 in CDKN1A gene transcription using a mechanism that is radically different from other MIZ-1-interacting proteins, such as B-cell lymphoma 6, c-Myc and Gfi-1. Oncogene (2012) 31, 1442-1458; doi:10.1038/onc.2011.331; published online 1 August 2011	[Lee, K. M.; Choi, W. I.; Koh, D. I.; Kim, Y. J.; Jeon, B. N.; Yoon, J. H.; Hur, M. W.] Yonsei Univ, Brain Korea Project Med Sci 21, Dept Biochem & Mol Biol, Severance Biomed Res Inst,Sch Med, Seoul 120752, South Korea; [Lee, C. E.; Kim, S. H.; Oh, J.] Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea	Yonsei University; Sungkyunkwan University (SKKU)	Hur, MW (corresponding author), Yonsei Univ, Brain Korea Project Med Sci 21, Dept Biochem & Mol Biol, Severance Biomed Res Inst,Sch Med, 134 ShinChon Dong, Seoul 120752, South Korea.	mwhur2@yuhs.ac		Hur, Man-Wook/0000-0002-3416-1334; CHOI, WONIL/0000-0002-4837-0436	Basic Science Research Grant [314-2008-1-E00030]; MRC from the National Research Foundation of Korea [R13-2002-054-05002-0]; Yonsei University School of Medicine	Basic Science Research Grant; MRC from the National Research Foundation of Korea(National Research Foundation of Korea); Yonsei University School of Medicine	This work was mainly funded by a Basic Science Research Grant (314-2008-1-E00030 to M-W Hur and C-E Lee), and MRC (R13-2002-054-05002-0) from the National Research Foundation of Korea, and also by a Faculty Research Grant from Yonsei University School of Medicine.	ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Basu S, 2009, P NATL ACAD SCI USA, V106, P1433, DOI 10.1073/pnas.0804863106; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Choi WI, 2008, J BIOL CHEM, V283, P29341, DOI 10.1074/jbc.M802477200; Choi WI, 2009, J BIOL CHEM, V284, P12633, DOI 10.1074/jbc.M809794200; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; He X, 2010, ANNU REV IMMUNOL, V28, P295, DOI 10.1146/annurev.immunol.25.022106.141715; Huynh KD, 2000, GENE DEV, V14, P1810; Issa JPJ, 1997, CANCER RES, V57, P1678; Jeon BN, 2009, J BIOL CHEM, V284, P17935, DOI 10.1074/jbc.M809559200; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kim MH, 2007, CELL PHYSIOL BIOCHEM, V20, P703, DOI 10.1159/000110431; Koh DI, 2009, J BIOL CHEM, V284, P19856, DOI 10.1074/jbc.M109.025817; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu Q, 2010, ONCOGENE, V29, P2843, DOI 10.1038/onc.2010.48; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Willenbring H, 2008, CANCER CELL, V14, P59, DOI 10.1016/j.ccr.2008.05.004; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077	44	11	11	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1442	1458		10.1038/onc.2011.331	http://dx.doi.org/10.1038/onc.2011.331			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804610				2022-12-28	WOS:000301780000011
J	Richards, JS; Fan, HY; Liu, Z; Tsoi, M; Lague, MN; Boyer, A; Boerboom, D				Richards, J. S.; Fan, H-Y; Liu, Z.; Tsoi, M.; Lague, M-N; Boyer, A.; Boerboom, D.			Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis	ONCOGENE			English	Article						CTNNB1; KRAS; PTEN; granulosa cell tumor; ovary; testis	BETA-CATENIN EXPRESSION; GROWTH-FACTOR NETWORK; TRANSCRIPTION FACTOR; CUMULUS CELLS; FOLLICLE DEVELOPMENT; TARGETED DISRUPTION; SIGNALING PATHWAY; FACTOR FOXL2; GERM-CELLS; PROLIFERATION	WNT, RAS or phosphoinositide 3-kinase signaling pathways control specific stages of ovarian follicular development. To analyze the functional interactions of these pathways in granulosa cells during follicular development in vivo, we generated specific mutant mouse models. Stable activation of the WNT signaling effector beta-catenin (CTNNB1) in granulosa cells results in the formation of premalignant lesions that develop into granulosa cell tumors (GCTs) spontaneously later in life or following targeted deletion of the tumor suppressor gene Pten. Conversely, expression of oncogenic KRAS(G12D) dramatically arrests proliferation, differentiation and apoptosis in granulosa cells, and consequently, small abnormal follicle-like structures devoid of oocytes accumulate in the ovary. Because of the potent anti-proliferative effects of KRAS(G12D) in granulosa cells, we sought to determine whether KRAS(G12D) would block precancerous lesion and tumor formation in follicles of the CTNNB1-mutant mice. Unexpectedly, transgenic Ctnnb1;Kras-mutant mice exhibited increased GC proliferation, decreased apoptosis and impaired differentiation and developed early-onset GCTs leading to premature death in a manner similar to the Ctnnb1; Pten-mutant mice. Microarray and reverse transcription-PCR analyses revealed that gene regulatory processes induced by CTNNB1 were mostly enhanced by either KRAS activation or Pten loss in remarkably similar patterns and degree. The concomitant activation of CTNNB1 and KRAS in Sertoli cells also caused testicular granulosa cell tumors that showed gene expression patterns that partially overlapped those observed in GCTs of the ovary. Although the mutations analyzed herein have not yet been linked to adult GCTs in humans, they may be related to juvenile GCTs or to tumors in other tissues where CTNNB1 is mutated. Importantly, the results provide strong evidence that CTNNB1 is the driver in these contexts and that KRAS(G12D) and Pten loss promote the program set in motion by the CTNNB1. Oncogene (2012) 31, 1504-1520; doi:10.1038/onc.2011.341; published online 22 August 2011	[Richards, J. S.; Fan, H-Y; Liu, Z.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Tsoi, M.; Lague, M-N; Boyer, A.; Boerboom, D.] Univ Montreal, Ctr Rech Reprod Anim, Dept Biomed Vet, St Hyacinthe, PQ, Canada	Baylor College of Medicine; Universite de Montreal	Richards, JS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	joanner@bcm.edu			Eunice Kennedy Shriver NICHD/NIH [U54-(HD07945)]; Canadian Institutes of Health Research; National Sciences and Engineering Research Council; Eunice Kennedy Shriver NICHD/NIH (SCCPIR) [U54-HD29034];  [NIH-HD-16229]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229, U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016272, R56HD016229, R37HD016229, F32HD007945] Funding Source: NIH RePORTER	Eunice Kennedy Shriver NICHD/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Eunice Kennedy Shriver NICHD/NIH (SCCPIR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank the Microarray Core Facility at Baylor College of Medicine (Lisa K White, director) for performing the microarray analyses. Supported, in part, by NIH-HD-16229 and the Eunice Kennedy Shriver NICHD/NIH cooperative agreement (U54-(HD07945)) as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research (JSR), an operating grant from the Canadian Institutes of Health Research (DB) and a Discovery Grant from the National Sciences and Engineering Research Council (DB). We also acknowledge that hormone assays were done by The University of Virginia Research in Reproduction Ligand Assay and Analysis Core supported by the Eunice Kennedy Shriver NICHD/NIH (SCCPIR) grant U54-HD29034.	Ashkenazi H, 2005, ENDOCRINOLOGY, V146, P77, DOI 10.1210/en.2004-0588; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Boerboom D, 2005, CANCER RES, V65, P9206, DOI 10.1158/0008-5472.CAN-05-1024; Boyer A, 2008, BIOL REPROD, V79, P475, DOI 10.1095/biolreprod.108.068627; Boyer A, 2010, FASEB J, V24, P3010, DOI 10.1096/fj.09-145789; Boyer A, 2010, TRENDS ENDOCRIN MET, V21, P25, DOI 10.1016/j.tem.2009.08.005; Boyer A, 2009, CARCINOGENESIS, V30, P869, DOI 10.1093/carcin/bgp051; Breloer M, 2008, TRENDS IMMUNOL, V29, P186, DOI 10.1016/j.it.2008.01.009; Broad KD, 2009, DEV NEUROBIOL, V69, P314, DOI 10.1002/dneu.20702; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Conti M, 2006, MOL ENDOCRINOL, V20, P715, DOI 10.1210/me.2005-0185; DILWORTH JP, 1991, UROLOGY, V37, P399, DOI 10.1016/0090-4295(91)80100-L; Drews-Elger K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005245; Edson MA, 2010, MOL ENDOCRINOL, V24, P1251, DOI 10.1210/me.2009-0461; Garcia-Ortiz JE, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-36; Eo J, 2008, J ENDOCRINOL, V198, P281, DOI 10.1677/JOE-08-0142; Fan HY, 2008, MOL ENDOCRINOL, V22, P2128, DOI 10.1210/me.2008-0095; Fan HY, 2008, DEVELOPMENT, V135, P2127, DOI 10.1242/dev.020560; Fan HY, 2010, MOL ENDOCRINOL, V24, P286, DOI 10.1210/me.2009-0251; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Fan HY, 2009, SCIENCE, V324, P938, DOI 10.1126/science.1171396; Fellenberg J, 2010, INT J CANCER, V127, P1804, DOI 10.1002/ijc.25205; Fleming NI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014389; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Heinrich MC, 2010, NATURE, V467, P796, DOI 10.1038/467796a; Hernandez-Gonzalez I, 2006, MOL ENDOCRINOL, V20, P1300, DOI 10.1210/me.2005-0420; Hsieh M, 2005, TRENDS ENDOCRIN MET, V16, P320, DOI 10.1016/j.tem.2005.07.005; Hsieh M, 2007, MOL CELL BIOL, V27, P1914, DOI 10.1128/MCB.01919-06; Hussain S, 2010, LEUKEMIA, V24, P1641, DOI 10.1038/leu.2010.138; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Jane-Valbuena J, 2010, CANCER RES, V70, P2075, DOI 10.1158/0008-5472.CAN-09-3092; Jiang XL, 2010, J BIOL CHEM, V285, P8472, DOI 10.1074/jbc.M109.069450; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Jubb I, 1993, PATHOLOGY DOMESTIC A; KALFA N, 2008, SEX DEV, V2, P142; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; Kobel M, 2009, CANCER RES, V69, P9160, DOI 10.1158/0008-5472.CAN-09-2669; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Li G, 2002, DEVELOPMENT, V129, P4159; Liu ZL, 2010, MOL ENDOCRINOL, V24, P1794, DOI 10.1210/me.2010-0086; Liu ZL, 2009, MOL ENDOCRINOL, V23, P649, DOI 10.1210/me.2008-0412; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Moumne L, 2008, MOL CELL ENDOCRINOL, V282, P2, DOI 10.1016/j.mce.2007.11.006; Ottolenghi C, 2007, HUM MOL GENET, V16, P2795, DOI 10.1093/hmg/ddm235; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Parakh TN, 2006, P NATL ACAD SCI USA, V103, P12435, DOI 10.1073/pnas.0603006103; Park, 2004, SCIENCE, V290, P395; Pisarska MD, 2011, ENDOCRINOLOGY, V152, P1199, DOI 10.1210/en.2010-1041; RAO MC, 1978, CELL, V14, P71, DOI 10.1016/0092-8674(78)90302-1; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Shimomura Y, 2010, NATURE, V464, P1043, DOI 10.1038/nature08875; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Takahashi M, 2002, CANCER RES, V62, P5651; Tania M, 2010, BIOCHEM BIOPH RES CO, V401, P493, DOI 10.1016/j.bbrc.2010.09.114; Tanwar PS, 2010, P NATL ACAD SCI USA, V107, P16142, DOI 10.1073/pnas.1011606107; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Trazzi S, 2010, J BIOL CHEM, V285, P10098, DOI 10.1074/jbc.M109.043711; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Tyagi G, 2009, BIOL REPROD, V81, P258, DOI 10.1095/biolreprod.108.075200; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wagner RT, 2010, STEM CELLS, V28, P1794, DOI 10.1002/stem.502; Wang HX, 2010, BIOL REPROD, V82, P865, DOI 10.1095/biolreprod.109.080903; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu M, 2009, ENDOCRINOLOGY, V150, P2064, DOI 10.1210/en.2008-1265	74	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1504	1520		10.1038/onc.2011.341	http://dx.doi.org/10.1038/onc.2011.341			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860425	Green Accepted			2022-12-28	WOS:000302132000004
J	Bertrand, J; Despeaux, M; Joly, S; Bourogaa, E; Gallay, N; Demur, C; Bonnevialle, P; Louache, F; Maguer-Satta, V; Vergnolle, N; Payrastre, B; Racaud-Sultan, C				Bertrand, J.; Despeaux, M.; Joly, S.; Bourogaa, E.; Gallay, N.; Demur, C.; Bonnevialle, P.; Louache, F.; Maguer-Satta, V.; Vergnolle, N.; Payrastre, B.; Racaud-Sultan, C.			Sex differences in the GSK3 beta-mediated survival of adherent leukemic progenitors	ONCOGENE			English	Article						cell survival; cell adhesion; GSK3 beta; leukemia	ACUTE MYELOID-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR-ALPHA CHAIN; STEM-CELLS; EXPRESSION; INTEGRIN; INHIBITION; PROTEIN; MICROENVIRONMENT; PROLIFERATION	Therapeutic resistance of acute myeloid leukemia stem cells, enriched in the CD34(+)38(-)123(+) progenitor population, is supported by extrinsic factors such as the bone marrow niche. Here, we report that when adherent onto fibronectin or osteoblast components, CD34(+)38(-)123(+) progenitors survive through an integrin-dependent activation of glycogen synthase kinase 3 beta (GSK3 beta) by serine 9-dephosphorylation. Strikingly, GSK3 beta-mediated survival was restricted to leukemic progenitors from female patients. GSK3 beta inhibition restored sensitivity to etoposide, and impaired the clonogenic capacities of adherent leukemic progenitors from female patients. In leukemic progenitors from female but not male patients, the scaffolding protein RACK1, activated downstream of alpha 5 beta 1- integrin engagement, was specifically upregulated and controlled GSK3 beta activation through the phosphatase protein phosphatase 2A (PP2A). In a mirrored manner, survival of adherent progenitors (CD34(+)38(-)) from male but not female healthy donors was partially dependent on this pathway. We conclude that the GSK3 beta-dependent survival pathway might be sex-specific in normal immature population and flip-flopped upon leukemogenesis. Taken together, our results strengthen GSK3 beta as a promising target for leukemic stem cell therapy and reveal gender differences as a new parameter in anti-leukemia therapy. Oncogene (2012) 31, 694-705; doi:10.1038/onc.2011.258; published online 4 July 2011	[Bertrand, J.; Despeaux, M.; Bourogaa, E.; Gallay, N.; Vergnolle, N.; Racaud-Sultan, C.] Univ Toulouse UPS, Inserm U1043, CNRS U5282, CPTP, F-31024 Toulouse 3, France; [Joly, S.; Maguer-Satta, V.] CRCL, CNRS U5286, Inserm U1052, Lyon, France; [Demur, C.] Univ Toulouse, Ctr Rech Cancerol Toulouse, Inserm UMR1037, CNRS ERL5294, Toulouse, France; [Demur, C.; Payrastre, B.] CHU Toulouse, Hematol Lab, Toulouse, France; [Bonnevialle, P.] CHU Toulouse, Serv Clin Chirurg Orthoped & Traumatol, Toulouse, France; [Louache, F.] Inst Gustave Roussy, Inserm U790, Villejuif, France; [Payrastre, B.] Univ Toulouse UPS, Inserm U1048, Inst Malad Metab & Cardiovasc, F-31024 Toulouse 3, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite Federale Toulouse Midi-Pyrenees (ComUE)	Racaud-Sultan, C (corresponding author), Univ Toulouse UPS, CHU Purpan, Hop Purpan, INSERM U1043,CNRS U5282,CPTP, Pl Dr Baylac, F-31024 Toulouse 3, France.	claire.racaud@inserm.fr	Vergnolle, Nathalie/C-7677-2018; Payrastre, Bernard/M-5295-2014; Maguer-Satta, Veronique/U-8857-2019	Vergnolle, Nathalie/0000-0003-1825-6015; Maguer-Satta, Veronique/0000-0002-1556-068X; Racaud-Sultan, Claire/0000-0002-6549-1088; , Nathalie GALLAY/0000-0002-4236-4780; , Bernard/0000-0002-8693-0190	Association de Recherche contre le Cancer [3638, 8407]; Institut National du Cancer [07/3D1616/IABC-23-8/NC-NG]; DGRSRT/INSERM cooperation	Association de Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); DGRSRT/INSERM cooperation(Institut National de la Sante et de la Recherche Medicale (Inserm))	We thank Dr Jean-Emmanuel Sarry for critical reading of the manuscript and the 'plateforme de cytometrie' of IFR150. Association de Recherche contre le Cancer (Contract Nos. 3638 and 8407), Institut National du Cancer (Contract no. 07/3D1616/IABC-23-8/NC-NG), DGRSRT/INSERM cooperation.	Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088; Bhatia R, 1996, BLOOD, V87, P3883, DOI 10.1182/blood.V87.9.3883.bloodjournal8793883; De Toni F, 2006, ONCOGENE, V25, P3113, DOI 10.1038/sj.onc.1209346; De Toni-Costes F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009807; de Vries JF, 2006, HAEMATOL-HEMATOL J, V91, P912; Del Vecchio I, 2009, GENE, V430, P17, DOI 10.1016/j.gene.2008.10.005; Despeaux M, 2011, LEUKEMIA, V25, P1789, DOI 10.1038/leu.2011.145; Dick JE, 2005, INT J HEMATOL, V82, P389, DOI 10.1532/IJH97.05144; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Edderkaoui M, 2007, J BIOL CHEM, V282, P26646, DOI 10.1074/jbc.M702836200; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Holmes T, 2008, STEM CELLS, V26, P1288, DOI 10.1634/stemcells.2007-0600; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood-2007-10-119438; Kubota T, 2002, J VIROL, V76, P12676, DOI 10.1128/JVI.76.24.12676-12682.2002; Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Mayack SR, 2010, NATURE, V463, P495, DOI 10.1038/nature08749; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Papasozomenos SC, 2002, P NATL ACAD SCI USA, V99, P1140, DOI 10.1073/pnas.032646799; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607; Sampaio ALF, 2010, J LEUKOCYTE BIOL, V87, P877, DOI 10.1189/jlb.1009670; SCHILLER G, 1994, LEUKEMIA LYMPHOMA, V15, P85, DOI 10.3109/10428199409051682; Sun M, 2008, CELL DEATH DIFFER, V15, P1887, DOI 10.1038/cdd.2008.124; Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339; Vialle-Castellano A, 2004, LEUKEMIA, V18, P426, DOI 10.1038/sj.leu.2403273; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Xu Q, 2005, BLOOD, V106, P4261, DOI 10.1182/blood-2004-11-4468; Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239	38	15	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					694	705		10.1038/onc.2011.258	http://dx.doi.org/10.1038/onc.2011.258			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725365				2022-12-28	WOS:000300222100003
J	Bulut, G; Hong, SH; Chen, K; Beauchamp, EM; Rahim, S; Kosturko, GW; Glasgow, E; Dakshanamurthy, S; Lee, HS; Daar, I; Toretsky, JA; Khanna, C; Uren, A				Bulut, G.; Hong, S-H; Chen, K.; Beauchamp, E. M.; Rahim, S.; Kosturko, G. W.; Glasgow, E.; Dakshanamurthy, S.; Lee, H-S; Daar, I.; Toretsky, J. A.; Khanna, C.; Ueren, A.			Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells	ONCOGENE			English	Article						ezrin; osteosarcoma; metastasis; small molecule screening; drug discovery	ERM PROTEINS; OSTEOGENIC-SARCOMA; PLASMA-MEMBRANE; BINDING-SITE; LINKER EZRIN; METASTASIS; EXPRESSION; SURVIVAL; IDENTIFICATION; CHEMOTHERAPY	Ezrin is a multifunctional protein that connects the actin cytoskeleton to the extracellular matrix through transmembrane proteins. High ezrin expression is associated with lung metastasis and poor survival in cancer. We screened small molecule libraries for compounds that directly interact with ezrin protein using surface plasmon resonance to identify lead compounds. The secondary functional assays used for lead compound selection included ezrin phosphorylation as measured by immunoprecipitation and in vitro kinase assays, actin binding, chemotaxis, invasion into an endothelial cell monolayer, zebrafish and Xenopus embryonic development, mouse lung organ culture and an in vivo lung metastasis model. Two molecules, NSC305787 and NSC668394, that directly bind to ezrin with low micromolar affinity were selected based on inhibition of ezrin function in multiple assays. They inhibited ezrin phosphorylation, ezrin-actin interaction and ezrin-mediated motility of osteosarcoma (OS) cells in culture. NSC305787 mimicked the ezrin morpholino phenotype, and NSC668394 caused a unique developmental defect consistent with reduced cell motility in zebrafish. Following tail vein injection of OS cells into mice, both molecules inhibited lung metastasis of ezrinsensitive cells, but not ezrin-resistant cells. The small molecule inhibitors NSC305787 and NSC668394 demonstrate a novel targeted therapy that directly inhibits ezrin protein as an approach to prevent tumor metastasis. Oncogene (2012) 31, 269-281; doi:10.1038/onc.2011.245; published online 27 June 2011	[Ueren, A.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, NRB, Washington, DC 20057 USA; [Hong, S-H; Khanna, C.] NCI, Tumor & Metastasis Biol Sect, Ctr Canc Res, Bethesda, MD 20892 USA; [Lee, H-S; Daar, I.] NCI, Lab Cell & Dev Signaling, Frederick, MD 21701 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, NRB, 3970 Reservoir Rd NW,Room E312, Washington, DC 20057 USA.	au26@georgetown.edu	BULUT, GULAY/J-3180-2012; Dakshanamurthy, Sivanesan/CAF-4258-2022; Lee, Hyun-Shik/G-3555-2011	Dakshanamurthy, Sivanesan/0000-0003-3681-4121; Daar, Ira/0000-0003-2657-526X; Glasgow, Eric/0000-0001-7729-3954	Children's Cancer Foundation of Baltimore; US Department of Defense [W81XWH-10-1-0137]; Brandon Carrington Lee Foundation; Go4theGoal; Dani's Foundation; Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Burroughs Wellcome Clinical Scientist Award in Translational Research; NIH [R01CA133662, R01CA138212]; Cancer Center [P30 CA051008]; NATIONAL CANCER INSTITUTE [R01CA133662, ZIABC011024, T32CA009686, ZIABC010958, ZIABC010566, P30CA051008, R01CA138212, ZIABC010006] Funding Source: NIH RePORTER	Children's Cancer Foundation of Baltimore; US Department of Defense(United States Department of Defense); Brandon Carrington Lee Foundation; Go4theGoal; Dani's Foundation; Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Burroughs Wellcome Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for our work came from the Children's Cancer Foundation of Baltimore (AU), US Department of Defense (W81XWH-10-1-0137, AU), Brandon Carrington Lee Foundation (G.K., AU), Go4theGoal, Dani's Foundation, Alex's Lemonade Stand Foundation, Liddy Shriver Sarcoma Initiative, Burroughs Wellcome Clinical Scientist Award in Translational Research (JT), and the NIH R01CA133662 (JT), R01CA138212 (JT) and Cancer Center Support Grant P30 CA051008 for use of Biacore Molecular Interaction Shared Resource. We would like to thank to Dr Anthony Bretscher (Cornell University) for providing the WT Ezrin construct, Developmental Therapeutics Program, NCI for providing the small molecule libraries.	Bacci G, 2006, CANCER-AM CANCER SOC, V106, P2701, DOI 10.1002/cncr.21937; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BOGER DL, 1987, J MED CHEM, V30, P1918, DOI 10.1021/jm00393a040; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CASE DA, 2004, AMBER 8; Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595; DUNN D, 1977, CANCER-AM CANCER SOC, V40, P3054, DOI 10.1002/1097-0142(197712)40:6<3054::AID-CNCR2820400644>3.0.CO;2-A; Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006; Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f; Fievet B, 2007, BBA-MOL CELL RES, V1773, P653, DOI 10.1016/j.bbamcr.2006.06.013; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Link V, 2006, J CELL SCI, V119, P2073, DOI 10.1242/jcs.02928; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Malmqvist M, 1999, BIOCHEM SOC T, V27, P335, DOI 10.1042/bst0270335; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mendoza A, 2010, J CLIN INVEST, V120, P2979, DOI 10.1172/JCI40252; OHNMACHT CJ, 1971, J MED CHEM, V14, P926; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Park HR, 2006, PATHOL RES PRACT, V202, P509, DOI 10.1016/j.prp.2006.01.015; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E; ten Klooster JP, 2009, DEV CELL, V16, P551, DOI 10.1016/j.devcel.2009.01.016; Wan X, 2009, ONCOGENE, V28, P3401, DOI 10.1038/onc.2009.206; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078-0432.CCR-07-1992	44	111	120	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					269	281		10.1038/onc.2011.245	http://dx.doi.org/10.1038/onc.2011.245			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21706056	Green Accepted, Bronze			2022-12-28	WOS:000299542100001
J	Lo, SS; Hung, PS; Chen, JH; Tu, HF; Fang, WL; Chen, CY; Chen, WT; Gong, NR; Wu, CW				Lo, S-S; Hung, P-S; Chen, J-H; Tu, H-F; Fang, W-L; Chen, C-Y; Chen, W-T; Gong, N-R; Wu, C-W			Overexpression of miR-370 and downregulation of its novel target TGF beta-RII contribute to the progression of gastric carcinoma	ONCOGENE			English	Article						carcinoma; microRNA; miR-370; plasma; stomach; TGF beta-RII	MICRORNA EXPRESSION; CANCER; SIGNATURE; GROWTH; RNA; SUPPRESSION; DIAGNOSIS; PATTERNS; PATHWAY; TUMORS	MicroRNAs (miRNAs) are endogenous non-coding RNAs that are known to be involved in the pathogenesis of tumors. Gastric carcinoma (GC) is a common malignancy worldwide. The aim of this study was the identification of the expression signature and functional roles of aberrant miRNAs in GC. Initial screening established a profile of aberrantly expressed miRNAs in tumors. miR-370 was confirmed to be overexpressed in GC tissues. Higher expression of miR-370 in GC tissues was associated with more advanced nodal metastasis and a higher clinical stage compared with controls. In addition, significantly higher level of miR-370 was noted in the plasma of GC patients compared with controls. Patients having more invasive or advanced tumors also exhibited a higher plasma level of miR-370. In vitro assays indicated that exogenous miR-370 expression enhanced the oncogenic potential of GC cells. The AGS-GFPM2 cells with exogenous miR-370 expression also exhibited enhanced abdominal metastatic dissemination in nude mice. Reporter assays confirmed that miR-370 targeted predicted sites in 3'UTR of transforming growth factor-beta receptor II (TGF beta-RII) gene. The exogenous miR-370 expression decreased TGF beta-RII expression and the phosphorylation of Smad3 elicited by TGF beta 1. The TGF beta 1-mediated repression in cell migration was reverted by exogenous miR-370 expression. A reverse correlation between miR-370 and TGF beta-RII expression was noted in GC tissues. This study concludes that miR-370 is a miRNA that is associated with GC progression by downregulating TGF beta-RII. The miRNA expression profile described in this study should contribute to future studies on the role of miRNAs in GC. Oncogene (2012) 31, 226-237; doi:10.1038/onc.2011.226; published online 13 June 2011	[Lo, S-S; Chen, C-Y; Chen, W-T] Natl Yang Ming Univ Hosp, Dept Surg, Yi Lan 26042, Taiwan; [Lo, S-S; Fang, W-L; Chen, C-Y; Chen, W-T; Wu, C-W] Natl Yang Ming Univ, Sch Med, Dept Med, Taipei 112, Taiwan; [Hung, P-S; Tu, H-F; Gong, N-R] Natl Yang Ming Univ Hosp, Dept Dent, Yi Lan 26042, Taiwan; [Chen, J-H; Fang, W-L; Wu, C-W] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Lo, SS (corresponding author), Natl Yang Ming Univ Hosp, Dept Surg, 152 Shin Min Rd, Yi Lan 26042, Taiwan.	sslo@ymuh.ym.edu.tw	Xie, Huangming/B-2260-2012		National Science Council [96-2314-B-010-055-MY3]; National Yang-Ming University Hospital [RD 2008-001]	National Science Council(Ministry of Science and Technology, Taiwan); National Yang-Ming University Hospital	We acknowledge helps from Dr Shu-Chun Lin, Dr Kuo-Wei Chang, Ms Yu-Pin Chen, Mr Shi-Wen Chen and Mr Chung-Sheng Chou. This study was supported by grant 96-2314-B-010-055-MY3 from National Science Council, and National Yang-Ming University Hospital Grant RD 2008-001.	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Lin HL, 2007, INT J CANCER, V121, P2547, DOI 10.1002/ijc.22963; Hsu KW, 2009, MOL BIOL CELL, V20, P5127, DOI 10.1091/mbc.E09-05-0386; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179; Kim YK, 2009, NUCLEIC ACIDS RES, V37, P1672, DOI 10.1093/nar/gkp002; Komuro A, 2009, JNCI-J NATL CANCER I, V101, P592, DOI 10.1093/jnci/djp058; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Liu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000804; Lo SS, 2009, SURGERY, V145, P280, DOI 10.1016/j.surg.2008.11.001; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; van den Brink GR, 2007, CANCER CELL, V11, P109, DOI 10.1016/j.ccr.2007.01.003; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wu CW, 2006, LANCET ONCOL, V7, P309, DOI 10.1016/S1470-2045(06)70623-4; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yoshino H, 2011, BRIT J CANCER, V104, P808, DOI 10.1038/bjc.2011.23; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	43	88	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					226	237		10.1038/onc.2011.226	http://dx.doi.org/10.1038/onc.2011.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21666718				2022-12-28	WOS:000299307400008
J	Vaira, V; Faversani, A; Dohi, T; Montorsi, M; Augello, C; Gatti, S; Coggi, G; Altieri, DC; Bosari, S				Vaira, V.; Faversani, A.; Dohi, T.; Montorsi, M.; Augello, C.; Gatti, S.; Coggi, G.; Altieri, D. C.; Bosari, S.			miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression	ONCOGENE			English	Article						miR-296; Scribble; cell plasticity; tumor progression; metastases	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN CANCERS; LEADING-EDGE; MICRORNAS; CARCINOMA; TUMORIGENESIS; EXPRESSION; MIGRATION; PROTEINS; INVASION	The expression of small, non-coding RNA or microRNAs (miR), is frequently deregulated in human cancer, but how these pathways affect disease progression is still largely elusive. Here, we report on a miR, miR-296, which is progressively lost during tumor progression and correlates with metastatic disease in colorectal, breast, lung, gastric, parathyroid, liver and bile ducts cancers. Functionally, miR-296 controls a global cell motility gene signature in epithelial cells by transcriptionally repressing the cell polarity-cell plasticity module, Scribble (Scrib). In turn, loss of miR-296 causes aberrantly increased and mislocalized Scrib in human tumors, resulting in exaggerated random cell migration and tumor cell invasiveness. Re-expression of miR-296 in MDA-MB231 cells inhibits tumor growth in vivo. Finally, miR-296 or Scrib levels predict tumor relapse in hepatocellular carcinoma patients. These data identify miR-296 as a global repressor of tumorigenicity and uncover a previously unexplored exploitation of Scrib in tumor progression in humans. Oncogene (2012) 31, 27-38; doi: 10.1038/onc.2011.209; published online 6 June 2011	[Vaira, V.; Faversani, A.; Augello, C.; Coggi, G.; Bosari, S.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, I-20132 Milan, Italy; [Faversani, A.; Augello, C.; Coggi, G.; Bosari, S.] Univ Milan, Sch Med, Div Pathol, Dept Med Surg & Dent, Milan, Italy; [Dohi, T.; Altieri, D. C.] Wistar Inst Canc Ctr, Prostate Canc Discovery & Dev Program, Philadelphia, PA USA; [Montorsi, M.] Univ Milan, Sch Med, Ist Clin Humanitas IRCCS, Div Gen Surg 3, Rozzano, Italy; [Gatti, S.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Surg Res Ctr, I-20132 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; The Wistar Institute; IRCCS Humanitas Research Hospital; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Bosari, S (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Via F Sforza 35, I-20132 Milan, Italy.	silvano.bosari@unimi.it	Bosari, Silvano/K-7744-2016; Vaira, Valentina/K-6499-2016; Faversani, Alice/K-6509-2016; Gatti, Stefano/AAE-3281-2022; Gatti, Stefano/M-1780-2015; Montorsi, Marco/GYD-3896-2022	Bosari, Silvano/0000-0002-9744-6951; Vaira, Valentina/0000-0003-4416-6216; Faversani, Alice/0000-0002-0970-6208; Gatti, Stefano/0000-0003-2209-4338; Gatti, Stefano/0000-0003-2209-4338; Montorsi, Marco/0000-0002-3887-3451	Doctorate School of Molecular Medicine at Universita degli Studi di Milano; Fondazione Invernizzi; Fondazione Berlucchi; National Institutes of Health [HL54131, CA140043, CA78810, CA118005]; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA118005, P01CA140043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER	Doctorate School of Molecular Medicine at Universita degli Studi di Milano; Fondazione Invernizzi; Fondazione Berlucchi; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Riccardo Ghidoni, Michele Samaja and Massimo Locati for availability of laboratory equipment and reagents, Patrizia Doi and Delfina Tosi for technical help. AF is supported by a fellowship of the Doctorate School of Molecular Medicine at Universita degli Studi di Milano. This work was supported by grants from the Fondazione Invernizzi (to GC), Fondazione Berlucchi (to SB), and from National Institutes of Health grants HL54131, CA140043, CA78810 and CA118005 (to DCA).	Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Augello C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-125; Bahri S, 2010, DEVELOPMENT, V137, P2023, DOI 10.1242/dev.045088; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pedersen IM, 2007, NATURE, V449, P919, DOI 10.1038/nature06205; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Romagnoli S, 2009, AM J PATHOL, V174, P762, DOI 10.2353/ajpath.2009.080721; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Wei JJ, 2011, CLIN CANCER RES, V17, P1297, DOI 10.1158/1078-0432.CCR-10-0993; Woo HG, 2009, CANCER RES, V69, P4059, DOI 10.1158/0008-5472.CAN-09-0164; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Yang HS, 2009, CLIN CANCER RES, V15, P5744, DOI 10.1158/1078-0432.CCR-09-0385; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zhuo OY, 2010, ONCOL RES, V18, P593, DOI 10.3727/096504010X12767359114045	39	65	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					27	38		10.1038/onc.2011.209	http://dx.doi.org/10.1038/onc.2011.209			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643016	Green Accepted			2022-12-28	WOS:000299176200003
J	Zhang, B; Qian, D; Ma, HH; Jin, R; Yang, PX; Cai, MY; Liu, YH; Liao, YJ; Deng, HX; Mai, SJ; Zhang, H; Zeng, YX; Lin, MC; Kung, HF; Xie, D; Huang, JJ				Zhang, B.; Qian, D.; Ma, H-H; Jin, R.; Yang, P-X; Cai, M-Y; Liu, Y-H; Liao, Y-J; Deng, H-X; Mai, S-J; Zhang, H.; Zeng, Y-X; Lin, M. C.; Kung, H-F; Xie, D.; Huang, J-J			Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation	ONCOGENE			English	Article						anthracyclines; telomere dysfunction; PinX1; telomerase; cancer	SENSITIZES CANCER-CELLS; REVERSE-TRANSCRIPTASE; MAMMALIAN TELOMERES; DNA-DAMAGE; IN-VIVO; THERAPEUTICS; TRAFFICKING; BIOGENESIS; SHELTERIN; SUBUNIT	Telomere maintenance is essential for cancer growth. Induction of telomere dysfunction, for example, by inhibition of telomeric proteins or telomerase, has been shown to strongly enhance cancer cells' sensitivity to chemotherapies. However, it is not clear whether modulations of telomere maintenance constitute cancer cellular responses to chemotherapies. Furthermore, the manner in which anti-cancer drugs affect telomere function remains unknown. In this study, we show that anthracyclines, a class of anti-cancer drugs widely used in clinical cancer treatments, have an active role in triggering telomere dysfunction specifically in telomerase-positive cancer cells. Anthracyclines interrupt telomere maintenance by telomerase through the down-regulation of PinX1, a protein factor responsible for targeting telomerase onto telomeres, thereby inhibiting telomerase association with telomeres. We further demonstrate that anthracyclines downregulate PinX1 by inducing this protein degradation through the ubiquitin-proteasome-dependent pathway. Our data not only reveal a novel action for anthracyclines as telomerase functional inhibitors but also provide a clue for the development of novel anti-cancer drugs based on telomerase/telomere targeting, which is actively investigated by many current studies. Oncogene (2012) 31, 1-12; doi: 10.1038/onc.2011.214; published online 6 June 2011	[Zhang, B.; Qian, D.; Cai, M-Y; Liao, Y-J; Deng, H-X; Mai, S-J; Zeng, Y-X; Kung, H-F; Xie, D.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China; [Ma, H-H; Jin, R.; Yang, P-X; Zhang, H.; Huang, J-J] Beijing Inst Biotechnol, Lab Tumor & Mol Biol, Beijing 100850, Peoples R China; [Liu, Y-H] Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Lin, M. C.; Kung, H-F] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China	Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Chinese University of Hong Kong	Xie, D (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Room 634,651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	hkung@cuhk.edu.hk; xied@mail.sysu.edu.cn; huangjun_j@yahoo.com	LIAO, YIJI/Z-4902-2019; mai, sj/HGE-8908-2022	LIAO, YIJI/0000-0002-0849-4573; 	Chinese NSFC [30901769, 30771074]; Guangdong National Science Foundation [9451008901002371]; China Postdoctoral Science Foundation [20090450900]; National Basic Research Program (973 program) of China [2010CB912802, 2010CB529404]	Chinese NSFC(National Natural Science Foundation of China (NSFC)); Guangdong National Science Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); National Basic Research Program (973 program) of China(National Basic Research Program of China)	This work is supported by grants from the Chinese NSFC (30901769), Guangdong National Science Foundation (9451008901002371) and the China Postdoctoral Science Foundation (20090450900) to B Zhang, and also partially by grants from the National Basic Research Program (973 program) of China (No. 2010CB912802) to H-F Kung and (No. 2010CB529404) to J-J Huang, the Chinese NSFC (30771074) to H Zhang.	Akiyama Y, 2004, ONCOL REP, V11, P871; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Bianchi A, 2008, MOL CELL, V31, P153, DOI 10.1016/j.molcel.2008.06.013; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Chang Q, 2004, INT J CANCER, V109, P309, DOI 10.1002/ijc.11689; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; Collins K, 2006, NAT REV MOL CELL BIO, V7, P484, DOI 10.1038/nrm1961; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Gallardo F, 2008, EMBO J, V27, P748, DOI 10.1038/emboj.2008.21; Goueli BS, 2004, MOL CELL BIOL, V24, P25, DOI 10.1128/MCB.24.1.25-35.2004; Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275; Hawkins GA, 2004, PROSTATE, V60, P298, DOI 10.1002/pros.20075; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Shay JW, 2006, NAT REV DRUG DISCOV, V5, P577, DOI 10.1038/nrd2081; Small GW, 2003, J PHARMACOL EXP THER, V307, P861, DOI 10.1124/jpet.103.055806; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tomlinson RL, 2006, MOL BIOL CELL, V17, P955, DOI 10.1091/mbc.E05-09-0903; Uziel O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009132; Wang C, 2010, EUR J CELL BIOL, V89, P748, DOI 10.1016/j.ejcb.2010.05.005; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Zhang B, 2009, CANCER RES, V69, P75, DOI 10.1158/0008-5472.CAN-08-1393; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	35	32	32	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	1					1	12		10.1038/onc.2011.214	http://dx.doi.org/10.1038/onc.2011.214			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643006				2022-12-28	WOS:000299176200001
J	Min, Y; Ghose, S; Boelte, K; Li, J; Yang, L; Lin, PC				Min, Y.; Ghose, S.; Boelte, K.; Li, J.; Yang, L.; Lin, P. C.			C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1 alpha	ONCOGENE			English	Article						C/EBP-delta; VEGF-C; HIF-1 alpha; lymphangiogenesis; metastasis	BINDING-PROTEIN-DELTA; GROWTH-FACTOR-C; LYMPHATIC ENDOTHELIAL-CELLS; FACTOR-ALPHA-RECEPTOR; SMOOTH-MUSCLE-CELLS; NODE METASTASIS; GENE-EXPRESSION; BREAST-CANCER; TUMOR LYMPHANGIOGENESIS; MICE LACKING	CCAAT/enhancer-binding protein-delta (C/EBP-delta), a transcription factor, is elevated in carcinoma compared with that in normal tissue. This study reports a novel function of C/EBP-delta in lymphangiogenesis and tumor metastasis. Genetic deletion of C/EBP-delta in mice resulted in a significant reduction of lymphangiogenesis and pulmonary metastases, with a dramatic reduction of vascular endothelial growth factor-C (VEGF-C) and its cognate receptor VEGF receptor-3 (VEGFR3) in lymphatic endothelial cells (LECs). By contrast, no difference of VEGF-C in tumor tissues and bone marrow was observed between null and wild-type mice. Consistently, forced expression of C/EBP-delta increased VEGF-C and VEGFR3 expression in cultured LECs. These findings suggest a specific and important role of C/EBP-delta in the regulation of VEGFR3 signaling in LECs. Furthermore, expression of C/EBP-delta in cultured LECs significantly increased cell motility, and knockdown of C/EBP-delta inhibited cell motility and lymphatic vascular network formation in vitro. Forced expression of VEGF-C, but not recombinant VEGF-C, rescued the knockdown of C/EBP-delta-induced cell apoptosis, indicative of autonomous VEGF-C autocrine signaling essential for LEC survival. Moreover, hypoxia induces C/EBP-delta expression and C/EBP-delta regulates HIF-1 alpha expression. Blocking HIF-1 alpha activity totally blocked CEBP-delta-induced VEGF-C and VEGFR3 expression in LECs. Together, these findings uncover a new function of CEBP-delta in lymphangiogenesis through regulation of VEGFR3 signaling in LECs. Oncogene (2011) 30, 4901-4909; doi:10.1038/onc.2011.187; published online 13 June 2011	[Min, Y.; Yang, L.; Lin, P. C.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21702 USA; [Ghose, S.; Li, J.] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN USA; [Boelte, K.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; Vanderbilt University	Lin, PC (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, 1050 Boyles St,Bldg 560,Room 12-89, Frederick, MD 21702 USA.	p.lin@nih.edu			NIH [CA108856, NS45888, AR053718]; NATIONAL CANCER INSTITUTE [R01CA108856, ZIABC011390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053718] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045888] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by grants from NIH (CA108856, NS45888 and AR053718).	Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480; Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Helotera H, 2007, CELL, V130, P591, DOI 10.1016/j.cell.2007.08.012; Irigoyen M, 2007, BBA-MOL CELL RES, V1773, P880, DOI 10.1016/j.bbamcr.2007.03.001; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kamiyama M, 2006, ONCOGENE, V25, P7019, DOI 10.1038/sj.onc.1209694; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; Katsuta M, 2005, EXP MOL PATHOL, V78, P123, DOI 10.1016/j.yexmp.2004.11.002; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kitami Y, 1999, CIRC RES, V84, P64; Kurokawa T, 2003, BRIT J CANCER, V89, P1042, DOI 10.1038/sj.bjc.6601186; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Ota H, 2007, FEBS LETT, V581, P5220, DOI 10.1016/j.febslet.2007.10.009; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rabek JP, 1998, BBA-GENE STRUCT EXPR, V1398, P137, DOI 10.1016/S0167-4781(98)00038-4; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Simiantonaki N, 2008, INT J ONCOL, V32, P585; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Takata Y, 2002, CIRC RES, V91, P427, DOI 10.1161/01.RES.0000031271.20771.4F; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Tang Y, 2006, NEUROBIOL DIS, V21, P18, DOI 10.1016/j.nbd.2005.06.002; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Yang ZH, 2001, CIRC RES, V89, P503, DOI 10.1161/hh1801.096265; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823	35	53	56	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2011	30	49					4901	4909		10.1038/onc.2011.187	http://dx.doi.org/10.1038/onc.2011.187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21666710	Green Accepted			2022-12-28	WOS:000298346400006
J	Belguise, K; Milord, S; Galtier, F; Moquet-Torcy, G; Piechaczyk, M; Chalbos, D				Belguise, K.; Milord, S.; Galtier, F.; Moquet-Torcy, G.; Piechaczyk, M.; Chalbos, D.			The PKC theta pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells	ONCOGENE			English	Article						Fra-1; PKC theta; phosphorylation; protein stability; breast cancer cells	KINASE-C-THETA; PROTEASOMAL DEGRADATION; EXPRESSION; AP-1; TRANSFORMATION; RECEPTOR; TARGET; GENE; TUMORIGENESIS; ACTIVATION	Fra-1 is aberrantly expressed in a large number of cancer cells and tissues, and emerging evidence suggests an important role for this Fos family protein in both oncogenesis and the progression or maintenance of many tumour types. Here, we show that the concentration of Fra-1 is high in invasive oestrogen receptor (ER)-negative (ER-) breast cancer cell lines, regardless of their Ras pathway status. All of the ER-cells express high levels of activated PKC theta, and the inhibition of PKC theta activity using RNA interference or the expression of a dominant-negative mutant results in a dramatic reduction in Fra-1 abundance. Conversely, the ectopic expression of constitutively active PKC theta leads to Fra-1 phosphorylation and accumulation in poorly invasive ER+ cells. This accumulation is due to the stabilisation of the Fra-1 protein through PKC theta signalling, whereas other members of the PKC family are ineffective. Both Ste20-related proline-alanine-rich kinase (SPAK) and ERK1/2, whose activities are upregulated by PKC theta, participate in PKC theta-driven Fra-1 stabilisation. Interestingly, their relative contributions appear to be different depending on the cell line studied. ERK1/2 signalling has a major role in ER- MDA-MB-231 cells, whereas Fra-1 accumulation occurs mainly through SPAK signalling in ER- BT549 cells. Fra-1 mutational analysis shows that the phosphorylation of S265, T223 and T230 is critical for PKC theta-driven Fra-1 stabilisation. Phosphorylation of the protein was confirmed using specific antisera against Fra-1 phosphorylated on T223 or S265. In addition, Fra-1 participates in PKC theta-induced cell invasion and is necessary for PKC theta-induced cell migration. In summary, we identified PKC theta signalling as an important regulator of Fra-1 accumulation in ER- breast cancer cells. Moreover, our results suggest that PKC theta could participate in progression of some breast cancers and could be a new therapeutic target.	[Belguise, K.; Milord, S.; Galtier, F.; Chalbos, D.] IRCM, F-34298 Montpellier 5, France; [Belguise, K.; Milord, S.; Galtier, F.; Chalbos, D.] INSERM, U896, Montpellier, France; [Moquet-Torcy, G.; Piechaczyk, M.] Univ Montpellier I, CNRS, Inst Genet Mol Montpellier, Montpellier, France; [Belguise, K.; Milord, S.; Galtier, F.; Chalbos, D.] CRLC Val dAurelle Paul Lamarque, Montpellier, France; [Moquet-Torcy, G.; Piechaczyk, M.] Univ Montpellier 2, CNRS, Inst Genet Mol Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Chalbos, D (corresponding author), IRCM, F-34298 Montpellier 5, France.	dany.chalbos@inserm.fr	PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597; Belguise, Karine/0000-0003-3426-8040	Institut National de la Sante et de la Recherche Medicale; University of Montpellier 1; Ligue Nationale Contre le Cancer-comite de l'Herault; Association pour la Recherche sur le Cancer; French Ministere de la Recherche et de l'Enseignement Superieur	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier 1; Ligue Nationale Contre le Cancer-comite de l'Herault(Ligue nationale contre le cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); French Ministere de la Recherche et de l'Enseignement Superieur	We are grateful to A Altman, J Pouyssegur and A Hipskind for providing plasmids and I Jariel-Encontre for critical reading of the manuscript. This work was supported by the 'Institut National de la Sante et de la Recherche Medicale', the University of Montpellier 1, the 'Ligue Nationale Contre le Cancer-comite de l'Herault', the 'Association pour la Recherche sur le Cancer' (fellowship to K. Belguise) and the French "Ministere de la Recherche et de l'Enseignement Superieur '(fellowship to S. Milord). M. Piechaczyk's laboratory was supported as an' Equipe Labellisee 'of the 'Ligue Nationale Contre le Cancer'.	BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Belguise K, 2007, J CLIN INVEST, V117, P4009, DOI 10.1172/JCI32424; Blay P, 2004, CLIN CANCER RES, V10, P4089, DOI 10.1158/1078-0432.CCR-04-0630; BRUNET A, 1994, ONCOGENE, V9, P3379; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chiappetta G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-17; Chuang HC, 2011, NAT IMMUNOL, V12, P1113, DOI 10.1038/ni.2121; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Debinski W, 2005, MOL CANCER RES, V3, P237; Delpire E, 2007, PHYSIOL GENOMICS, V28, P223, DOI 10.1152/physiolgenomics.00173.2006; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elsberger B, 2010, BRIT J CANCER, V103, P899, DOI 10.1038/sj.bjc.6605829; Harris TJR, 2010, NAT REV CLIN ONCOL, V7, P251, DOI 10.1038/nrclinonc.2010.41; Hayashi K, 2007, PHARMACOL RES, V55, P537, DOI 10.1016/j.phrs.2007.04.009; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Li YQ, 2004, EMBO J, V23, P1112, DOI 10.1038/sj.emboj.7600125; Logullo AF, 2011, HISTOPATHOLOGY, V58, P617, DOI 10.1111/j.1365-2559.2011.03785.x; Manicassamy S, 2006, CELL MOL IMMUNOL, V3, P263; Marsland BJ, 2008, TRENDS IMMUNOL, V29, P179, DOI 10.1016/j.it.2008.01.005; Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Milde-Langosch K, 2003, BREAST CANCER RES TR, V77, P265, DOI 10.1023/A:1021887100216; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Polek TC, 2006, BIOCHEM BIOPH RES CO, V343, P125, DOI 10.1016/j.bbrc.2006.02.125; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Song YH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-298; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vial E, 2003, J CELL SCI, V116, P4957, DOI 10.1242/jcs.00812; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001	45	44	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2012	31	47					4889	4897		10.1038/onc.2011.659	http://dx.doi.org/10.1038/onc.2011.659			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041VU	22286759	Green Submitted, Green Accepted			2022-12-28	WOS:000311430200001
J	Hromas, R; Williamson, EA; Fnu, S; Lee, YJ; Park, SJ; Beck, BD; You, JS; Laitao, A; Nickoloff, JA; Lee, SH				Hromas, R.; Williamson, E. A.; Fnu, S.; Lee, Y-J; Park, S-J; Beck, B. D.; You, J-S; Laitao, A.; Nickoloff, J. A.; Lee, S-H			Chk1 phosphorylation of Metnase enhances DNA repair but inhibits replication fork restart	ONCOGENE			English	Article						Chk1; Metnase; SETMAR; phosphorylation; DNA repair; replication fork	TRANSPOSASE DOMAIN; IONIZING-RADIATION; PROTEIN-KINASE; CHROMATIN IMMUNOPRECIPITATION; BIOCHEMICAL-CHARACTERIZATION; CHROMOSOME DECATENATION; ATM KINASE; SET; DAMAGE; CELLS	Chk1 both arrests replication forks and enhances repair of DNA damage by phosphorylating downstream effectors. Although there has been a concerted effort to identify effectors of Chk1 activity, underlying mechanisms of effector action are still being identified. Metnase (also called SETMAR) is a SET and transposase domain protein that promotes both DNA double-strand break (DSB) repair and restart of stalled replication forks. In this study, we show that Metnase is phosphorylated only on Ser495 (S495) in vivo in response to DNA damage by ionizing radiation. Chk1 is the major mediator of this phosphorylation event. We had previously shown that wild-type (wt) Metnase associates with chromatin near DSBs and methylates histone H3 Lys36. Here we show that a Ser495Ala (S495A) Metnase mutant, which is not phosphorylated by Chk1, is defective in DSB-induced chromatin association. The S495A mutant also fails to enhance repair of an induced DSB when compared with wt Metnase. Interestingly, the S495A mutant demonstrated increased restart of stalled replication forks compared with wt Metnase. Thus, phosphorylation of Metnase S495 differentiates between these two functions, enhancing DSB repair and repressing replication fork restart. In summary, these data lend insight into the mechanism by which Chk1 enhances repair of DNA damage while at the same time repressing stalled replication fork restart. Oncogene (2012) 31, 4245-4254; doi:10.1038/onc.2011.586; published online 9 January 2012	[Hromas, R.; Williamson, E. A.; Fnu, S.] Univ Florida, Dept Med, Gainesville, FL 32610 USA; [Hromas, R.; Williamson, E. A.; Fnu, S.] Shands Hlth Care Syst, Gainesville, FL USA; [Lee, Y-J; Park, S-J; Beck, B. D.; You, J-S; Lee, S-H] Indiana Univ, Med Ctr, Ctr Canc, Dept Biochem Mol Biol & Med, Indianapolis, IN USA; [Laitao, A.] Univ Sao Paulo, Inst Quim Sao Carlos, Grp Estudos Quim Med Prod Nat NEQUIMED PN, Sao Carlos, SP, Brazil; [Nickoloff, J. A.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Indiana University System; Indiana University-Purdue University Indianapolis; Universidade de Sao Paulo; Colorado State University	Hromas, R (corresponding author), Univ Florida, Dept Med, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	robert.hromas@medicine.ufl.edu; slee@ipui.edu	Leitao, Andrei/B-7942-2012	Leitao, Andrei/0000-0002-6601-6609	NIH [CA92111, CA151367, NIDDK 1 T32 DK 0719-15, R01 GM084020, R01 CA100862, R01 CA102283, R01 HL075783, R01 CA139429]; IU Cancer Center; Walther Oncology Center; APRC [CA100862]; Leukemia and Lymphoma Society SCOR [7388-06]; NATIONAL CANCER INSTITUTE [R01CA102283, R01CA139429, R01CA100862, R01CA151367] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084020] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IU Cancer Center; Walther Oncology Center; APRC; Leukemia and Lymphoma Society SCOR(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank Dr H Chun for providing purified ATM kinase. This research was supported by grants from NIH (CA92111 and CA151367 to S-HL), the IU Cancer Center and the Walther Oncology Center. BDB was supported by NIH predoctoral training grant (NIDDK 1 T32 DK 0719-15). We acknowledge K Valerie for the kind gift of the adenovirus I-SceI system, the support of NIH R01 GM084020 and NIH R01 CA100862 (J.N.), an APRC supplement CA100862 (JN and RH), NIH R01 CA102283 (RH), NIH R01 HL075783 (RH), NIH R01 CA139429 (RH), and the Leukemia and Lymphoma Society SCOR 7388-06 (RH).	Arnold Konstantin, 2009, Journal of Structural and Functional Genomics, V10, P1, DOI 10.1007/s10969-008-9048-5; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Beck BD, 2011, BIOCHEMISTRY-US, V50, P4360, DOI 10.1021/bi200333k; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Cordaux R, 2006, P NATL ACAD SCI USA, V103, P8101, DOI 10.1073/pnas.0601161103; De Haro LP, 2010, NUCLEIC ACIDS RES, V38, P5681, DOI 10.1093/nar/gkq339; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Feng JJ, 2009, MOL CELL BIOL, V29, P5696, DOI 10.1128/MCB.00191-09; Firulli Beth A., 2004, Biol Proced Online, V6, P16, DOI 10.1251/bpo69; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Goodwin KD, 2010, BIOCHEMISTRY-US, V49, P5705, DOI 10.1021/bi100171x; Hromas R, 2008, DNA REPAIR, V7, P1927, DOI 10.1016/j.dnarep.2008.08.002; Jordan IK, 2006, P NATL ACAD SCI USA, V103, P7941, DOI 10.1073/pnas.0602656103; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lee SH, 2005, P NATL ACAD SCI USA, V102, P18075, DOI 10.1073/pnas.0503676102; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Liu DX, 2007, MOL CELL BIOL, V27, P1125, DOI 10.1128/MCB.01899-06; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Reyland ME, 2009, FRONT BIOSCI-LANDMRK, V14, P2386, DOI 10.2741/3385; Robertson HM, 1997, GENE, V205, P203, DOI 10.1016/S0378-1119(97)00472-1; Roig J, 1999, J BIOL CHEM, V274, P31119, DOI 10.1074/jbc.274.44.31119; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Wang HC, 2001, CANCER RES, V61, P270; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Williamson EA, 2008, NUCLEIC ACIDS RES, V36, P5822, DOI 10.1093/nar/gkn560; Wray J, 2010, CANCER GENET CYTOGEN, V200, P184, DOI 10.1016/j.cancergencyto.2010.04.011; Wray J, 2009, BLOOD, V114, P1852, DOI 10.1182/blood-2008-08-175760; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	38	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4245	4254		10.1038/onc.2011.586	http://dx.doi.org/10.1038/onc.2011.586			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22231448	Green Accepted			2022-12-28	WOS:000308975800007
J	Harris, LG; Pannell, LK; Singh, S; Samant, RS; Shevde, LA				Harris, L. G.; Pannell, L. K.; Singh, S.; Samant, R. S.; Shevde, L. A.			Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61	ONCOGENE			English	Article						SHH; CYR61; GLI; hedgehog; angiogenesis; metastasis	SONIC HEDGEHOG; ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; TUBE FORMATION; GROWTH-FACTOR; CARCINOMA; PATHWAY; PROGRESSION; EXPRESSION; PROTEINS	The Hedgehog (Hh) pathway is well known for its involvement in angiogenesis and vasculogenesis during ontogeny. The ligand, Sonic Hh (SHH), has an important role in vascular formation during development. However, SHH expression is upregulated on tumor cells and can impact the tumor microenvironment. We have investigated the effects of autocrine as well as paracrine Hh signaling on tumor cells as well as on endothelial cells, respectively. Upon constitutive expression of SHH, breast cancer cells showed aggressive behavior and rapid xenograft growth characterized by highly angiogenic tumors that were spontaneously metastatic. In these cells, SHH caused activation of the Hh transcription factor, GLI1, leading to upregulated expression of the potent pro-angiogenic secreted molecule, CYR61 (cysteine-rich angiogenic inducer 61). Silencing of CYR61 from these SHH-expressing Hh activated cells blunted the malignant behavior of the tumor cells and resulted in reduced tumor vasculature and limited hematogenous metastases. Thus, CYR61 is a critical downstream contributor to the Hh influenced pro-angiogenic tumor microenvironment. We also observed concomitant upregulation of SHH and CYR61 transcripts in tumors from patients with advanced breast cancer, further ratifying the clinical relevance of our findings. In summary, we have defined a novel, VEGF-independent, clinically relevant, pro-angiogenic factor, CYR61, that is a transcriptional target of Hh-GLI signaling. Oncogene (2012) 31, 3370-3380; doi: 10.1038/onc.2011.496; published online 7 November 2011	[Harris, L. G.; Pannell, L. K.; Singh, S.; Samant, R. S.; Shevde, L. A.] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA	University of South Alabama	Shevde, LA (corresponding author), Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, MCI 3018,1660 Springhill Ave, Mobile, AL 36604 USA.	lsamant@usouthal.edu		Samant, Rajeev/0000-0001-5681-4976	NIH [CA138850, CA140472]; Department of Defense (IDEA) [BC061257]; Mayer Mitchell Award; USA-Mitchell Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA138850, R01CA140472] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense (IDEA)(United States Department of Defense); Mayer Mitchell Award; USA-Mitchell Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge support from the NIH (CA138850 to L. A. S. and CA140472 to R. S. S.), Department of Defense (IDEA Award BC061257 to L. A. S.), Mayer Mitchell Award (to L. A. S.) and the USA-Mitchell Cancer Institute. We also would like to thank Dr Laurie Owen, Scientific Director, USAMitchell Cancer Institute for her support of this work and the Department of Pathology and Prof Troy Stevens, Anna Buford and Linn Ayers, Center for Lung Biology, University of South Alabama for generously providing us with endothelial cells.	Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bailey JM, 2009, ONCOGENE, V28, P3513, DOI 10.1038/onc.2009.220; Beachy PA, 2010, GENE DEV, V24, P2001, DOI 10.1101/gad.1951710; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Blagosklonny MV, 2004, CANCER CELL, V5, P13, DOI 10.1016/S1535-6108(03)00336-2; Byrd N, 2004, TRENDS CARDIOVAS MED, V14, P308, DOI 10.1016/j.tcm.2004.09.003; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen CC, 2009, INT J BIOCHEM CELL B, V41, P771, DOI 10.1016/j.biocel.2008.07.025; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Cohen MM, 2010, AM J MED GENET A, V152A, P1875, DOI 10.1002/ajmg.a.32909; Das S, 2011, J BIOL CHEM, V286, P9612, DOI 10.1074/jbc.M110.174920; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Dobroff AS, 2009, J BIOL CHEM, V284, P26194, DOI 10.1074/jbc.M109.019836; Feng P, 2008, INT J BIOCHEM CELL B, V40, P98, DOI 10.1016/j.biocel.2007.06.020; Fox SB, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1796; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Hochman E, 2006, J BIOL CHEM, V281, P33860, DOI 10.1074/jbc.M605905200; Kanda S, 2003, J BIOL CHEM, V278, P8244, DOI 10.1074/jbc.M210635200; Kleer CG, 2007, CELLS TISSUES ORGANS, V185, P95, DOI 10.1159/000101308; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Lu Zhi-hao, 2008, Beijing Da Xue Xue Bao Yi Xue Ban, V40, P480; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mazumdar T, 2011, ONCOTARGET, V2, P638; Mbeunkui F, 2007, J PROTEOME RES, V6, P2993, DOI 10.1021/pr060629m; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Renault MA, 2010, J MOL CELL CARDIOL, V49, P490, DOI 10.1016/j.yjmcc.2010.05.003; Samant RS, 2011, ONCOTARGET, V2, P122; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2; Singh S, 2009, CANCER RES, V69, P411, DOI 10.1158/0008-5472.CAN-08-3378; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Trimmer C, 2010, CANCER RES, V70, P7489, DOI 10.1158/0008-5472.CAN-10-0900; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Vokes SA, 2004, DEVELOPMENT, V131, P4371, DOI 10.1242/dev.01304; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHANG RD, 1991, INVAS METAST, V11, P204; Zhou ZQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-291; Zunich SM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-12	52	91	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3370	3380		10.1038/onc.2011.496	http://dx.doi.org/10.1038/onc.2011.496			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22056874	Green Accepted			2022-12-28	WOS:000306367600006
J	Ganguly, SS; Fiore, LS; Sims, JT; Friend, JW; Srinivasan, D; Thacker, MA; Cibull, ML; Wang, C; Novak, M; Kaetzel, DM; Plattner, R				Ganguly, S. S.; Fiore, L. S.; Sims, J. T.; Friend, J. W.; Srinivasan, D.; Thacker, M. A.; Cibull, M. L.; Wang, C.; Novak, M.; Kaetzel, D. M.; Plattner, R.			c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression	ONCOGENE			English	Article						c-Abl; Arg; melanoma; invasion; STAT3; MMP	TYROSINE KINASE; BREAST-CANCER; MATRIX-METALLOPROTEINASE; CLINICAL-EFFICACY; FAMILY KINASES; GROWTH-FACTOR; IMATINIB; EXPRESSION; INHIBITION; THERAPY	Despite 35 years of clinical trials, there is little improvement in 1-year survival rates for patients with metastatic melanoma, and the disease is essentially untreatable if not cured surgically. The paucity of chemotherapeutic agents that are effective for treating metastatic melanoma indicates a dire need to develop new therapies. Here, we found a previously unrecognized role for c-Abl and Arg in melanoma progression. We demonstrate that the kinase activities of c-Abl and Arg are elevated in primary melanomas (60%), in a subset of benign nevi (33%) and in some human melanoma cell lines. Using siRNA and pharmacological approaches, we show that c-Abl/Arg activation is functionally relevant because it is required for melanoma cell proliferation, survival and invasion. Significantly, we identify the mechanism by which activated c-Abl promotes melanoma invasion by showing that it transcriptionally upregulates matrix metalloproteinase-1 (MMP-1), and using rescue approaches we demonstrate that c-Abl promotes invasion through a STAT3-MMP-1 pathway. Additionally, we show that c-Abl and Arg are not merely redundant, as active Arg drives invasion in a STAT3-independent manner, and upregulates MMP-3 and MT1-MMP, in addition to MMP-1. Most importantly, c-Abl and Arg not only promote in vitro processes important for melanoma progression, but also promote metastasis in vivo, as inhibition of c-Abl/Arg kinase activity with the c-Abl/Arg inhibitor, nilotinib, dramatically inhibits metastasis in a mouse model. Taken together, these data identify c-Abl and Arg as critical, novel, drug targets in metastatic melanoma, and indicate that nilotinib may be useful in preventing metastasis in patients with melanomas harboring active c-Abl and Arg. Oncogene (2012) 31, 1804-1816; doi: 10.1038/onc.2011.361; published online 5 September 2011	[Ganguly, S. S.; Fiore, L. S.; Sims, J. T.; Friend, J. W.; Srinivasan, D.; Thacker, M. A.; Novak, M.; Kaetzel, D. M.; Plattner, R.] Univ Kentucky, Dept Mol & Biomed Pharmacol, Sch Med, Lexington, KY 40536 USA; [Cibull, M. L.] Univ Kentucky, Dept Pathol, Sch Med, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Dept Biostat, Sch Med, Lexington, KY 40536 USA; [Wang, C.] Univ Kentucky, Lucille P Markey Canc Ctr, Sch Med, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Dept Mol & Biomed Pharmacol, Sch Med, 800 Rose St,Combs Res Bldg,Room 209, Lexington, KY 40536 USA.	rplat2@uky.edu			NIH [CA116784, CA83237]; NIH/NCI [1R01CA116784]; NATIONAL CANCER INSTITUTE [R01CA116784, P30CA177558, R01CA083237, R01CA166499] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Plattner's and Dr Kaetzel's work are supported by NIH CA116784 and CA83237, respectively. All of the other authors declare no potential conflict of interest.; We thank Patty Cross, J Anthony Brandon, Holly Bennett and Jennifer Strange for assistance with IHC, IVIS imaging, isolation of GST-STAT3 and cell sorting, respectively; John D'Orazio for primary melanocytes; Meenhard Herlyn for WM melanoma cell lines and for genotyping WM cell lines; Suyan Huang for A375; Fernando deCastro for IHC advice and Paul Manley (Novartis, Switzerland) for STI571 and nilotinib, and advice regarding their use. This work was supported by NIH/NCI grant 1R01CA116784.	Allington TM, 2011, CELLS TISSUES ORGANS, V193, P98, DOI 10.1159/000320163; Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Bachmeier BE, 2005, EXP CELL RES, V305, P83, DOI 10.1016/j.yexcr.2004.12.019; Berwick M, 2009, DERMATOL CLIN, V27, P205, DOI 10.1016/j.det.2008.12.002; Blackburn JS, 2009, ONCOGENE, V28, P4237, DOI 10.1038/onc.2009.272; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Candelaria M, 2005, MED ONCOL, V22, P1, DOI 10.1385/MO:22:1:001; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Deininger MW, 2008, CLIN CANCER RES, V14, P4027, DOI 10.1158/1078-0432.CCR-07-5015; DeMatteo R, 2009, ANN SURG ONCOL, V16, P799, DOI 10.1245/s10434-009-0316-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fanjul-Fernandez M, 2010, BBA-MOL CELL RES, V1803, P3, DOI 10.1016/j.bbamcr.2009.07.004; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furlan A, 2011, CELL DEATH DIFFER; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofmann UB, 2009, CLIN CANCER RES, V15, P324, DOI 10.1158/1078-0432.CCR-08-2243; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Kabbarah O, 2005, CANCER CELL, V8, P439, DOI 10.1016/j.ccr.2005.11.008; Kong YY, 2010, ARCH PATHOL LAB MED, V134, P1740, DOI 10.1043/2009-0418-RAR.1; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; le Coutre P, 2004, CANCER CHEMOTH PHARM, V53, P313, DOI 10.1007/s00280-003-0741-6; Li X, 2010, CELL DEATH DIFFER, V17, P1277, DOI 10.1038/cdd.2010.8; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; Lin Kimberly, 2010, Genes Cancer, V1, P409; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Mayorga ME, 2006, MELANOMA RES, V16, P127, DOI 10.1097/01.cmr.0000215039.30812.9b; Mouawad R, 2010, CRIT REV ONCOL HEMAT, V74, P27, DOI 10.1016/j.critrevonc.2009.08.005; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Ogawa Y, 2008, J DERMATOL SCI, V51, P190, DOI 10.1016/j.jdermsci.2008.03.011; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Raby BN, 2001, INT J CANCER, V93, P644, DOI 10.1002/ijc.1380; Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8; Redondo P, 2004, J INVEST DERMATOL, V123, P1208, DOI 10.1111/j.0022-202X.2004.23496.x; Santos FPS, 2009, LEUKEMIA LYMPHOMA, V50, P16, DOI 10.3109/10428190903383427; Satzger I, 2010, DERMATOLOGY, V220, P77, DOI 10.1159/000265558; Shepherd C, 2010, CURR ONCOL REP, V12, P146, DOI 10.1007/s11912-010-0095-2; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Smalley KSM, 2009, CANCER RES, V69, P3241, DOI 10.1158/0008-5472.CAN-08-4305; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Tsareva SA, 2007, NEOPLASIA, V9, P279, DOI 10.1593/neo.06820; Ugurel S, 2005, BRIT J CANCER, V92, P1398, DOI 10.1038/sj.bjc.6602529; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200	53	50	52	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	14					1804	1816		10.1038/onc.2011.361	http://dx.doi.org/10.1038/onc.2011.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21892207	Green Accepted			2022-12-28	WOS:000302785200006
J	Urbanucci, A; Sahu, B; Seppala, J; Larjo, A; Latonen, LM; Waltering, KK; Tammela, TLJ; Vessella, RL; Lahdesmaki, H; Janne, OA; Visakorpi, T				Urbanucci, A.; Sahu, B.; Seppala, J.; Larjo, A.; Latonen, L. M.; Waltering, K. K.; Tammela, T. L. J.; Vessella, R. L.; Lahdesmaki, H.; Janne, O. A.; Visakorpi, T.			Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer	ONCOGENE			English	Article						prostatic neoplasia; AR; ChIP-seq; FEN1; SKP2; ZWINT	RESPONSE ELEMENT; TRANSCRIPTION; GENE; PROLIFERATION; AMPLIFICATION; ANTIANDROGEN; PROGRESSION; EXPRESSION; CASTRATION; NETWORK	Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of CRPC. We have established two sublines of LNCaP prostate cancer (PC) cell line, one overexpressing AR 2-3-fold and the other 4-5-fold compared with the control cells. We used chromatin immunoprecipitation (ChIP) and deep-sequencing (seq) to identify AR-binding sites (ARBSs). We found that the number of ARBSs and the AR-binding strength were positively associated with the level of AR when cells were stimulated with low concentrations of androgens. In cells overexpressing AR, the chromatin binding of the receptor took place in 100-fold lower concentration of the ligand than in control cells. We confirmed the association of AR level and chromatin binding in two PC xenografts, one containing AR gene amplification with high AR expression, and the other with low expression. By combining the ChIP-seq and expression profiling, we identified AR target genes that are upregulated in PC. Of them, the expression of ZWINT, SKP2 (S-phase kinase-associated protein 2 (p45)) and FEN1 (flap structure-specific endonuclease 1) was demonstrated to be increased in CRPC, while the expression of SNAI2 was decreased in both PC and CRPC. FEN1 protein expression was also associated with poor prognosis in prostatectomy-treated patients. Finally, the knock-down of FEN1 with small interfering RNA inhibited the growth of LNCaP cells. Our data demonstrate that the overexpression of AR sensitizes the receptor binding to chromatin, thus, explaining how AR signaling pathway is reactivated in CRPC cells. Oncogene (2012) 31, 2153-2163; doi:10.1038/onc.2011.401; published online 12 September 2011	[Urbanucci, A.; Latonen, L. M.; Waltering, K. K.; Visakorpi, T.] Univ Tampere, Inst Biomed Technol, FIN-33014 Tampere, Finland; [Urbanucci, A.; Latonen, L. M.; Waltering, K. K.; Tammela, T. L. J.; Visakorpi, T.] Tampere Univ Hosp, Tampere, Finland; [Sahu, B.; Janne, O. A.] Univ Helsinki, Inst Biomed Physiol, Biomedicum Helsinki, Helsinki, Finland; [Seppala, J.; Larjo, A.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Tammela, T. L. J.] Univ Tampere, Dept Urol, FIN-33014 Tampere, Finland; [Vessella, R. L.] Univ Washington, Med Ctr, Dept Urol, NE Pacific, Seattle, WA 98195 USA; [Lahdesmaki, H.] Aalto Univ, Sch Sci & Technol, Dept Informat & Comp Sci, Helsinki, Finland	Tampere University; Tampere University; Tampere University Hospital; University of Helsinki; Tampere University; Tampere University; University of Washington; University of Washington Seattle; Aalto University	Visakorpi, T (corresponding author), Univ Tampere, Inst Biomed Technol, Biokatu 6, FIN-33014 Tampere, Finland.	tapio.visakorpi@uta.fi	Sahu, Biswajyoti/U-6724-2017; Latonen, Leena/C-8787-2016; Urbanucci, Alfonso/S-4450-2019	Sahu, Biswajyoti/0000-0001-6576-5440; Latonen, Leena/0000-0003-4502-2193; Urbanucci, Alfonso/0000-0003-2931-3652; Visakorpi, Tapio/0000-0002-5004-0364	European Union [MEST-CT-2005-020970]; Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; Tampere University Hospital	European Union(European Commission); Academy of Finland(Academy of Finland); Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Tampere University Hospital	We wish to thank Ms Mariitta Vakkuri, Ms Paivi Martikainen and Mr Rolle Rahikainen for the skillful technical assistance. The research leading to these results has received funding from the European Union FP6, CANCURE Programme (contract number: MEST-CT-2005-020970). In addition, grant support has been received from Academy of Finland, Cancer Society of Finland, Reino Lahtikari Foundation, Sigrid Juselius Foundation, and the Medical Research Fund of Tampere University Hospital.	Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Andriole GL, 2010, NEW ENGL J MED, V362, P1192, DOI 10.1056/NEJMoa0908127; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Huggins C, 2002, J UROLOGY, V168, P9, DOI 10.1016/S0022-5347(05)64820-3; ISAACS JT, 1994, VITAM HORM, V49, P433; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kasowski M, 2010, SCIENCE, V328, P232, DOI 10.1126/science.1183621; Keller A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-552; Kokontis JM, 1998, MOL ENDOCRINOL, V12, P941, DOI 10.1210/me.12.7.941; Kops GJPL, 2005, J CELL BIOL, V169, P49, DOI 10.1083/jcb.200411118; Lam JS, 2006, BJU INT, V98, P445, DOI 10.1111/j.1464-410X.2006.06224.x; Leinonen KA, 2010, CLIN CANCER RES, V16, P2845, DOI 10.1158/1078-0432.CCR-09-2505; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Linja MJ, 2001, CANCER RES, V61, P3550; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nguyen PL, 2011, UROL ONCOL-SEMIN ORI, V29, P302, DOI 10.1016/j.urolonc.2009.03.022; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Roudier Martine P, 2004, Cancer Treat Res, V118, P311; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Starr DA, 2000, J CELL SCI, V113, P1939; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Thompson J, 2006, EMBO J, V25, P2757, DOI 10.1038/sj.emboj.7601161; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Urbanucci A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-219; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Waltregny D, 2001, MOL ENDOCRINOL, V15, P765, DOI 10.1210/me.15.5.765; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Xu H, 2011, ONCOGENE, V30, P1072, DOI 10.1038/onc.2010.482; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884; Zinzen RP, 2009, NATURE, V462, P65, DOI 10.1038/nature08531	53	96	100	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	17					2153	2163		10.1038/onc.2011.401	http://dx.doi.org/10.1038/onc.2011.401			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BS	21909140	Bronze			2022-12-28	WOS:000303415900004
J	Chaudhuri, L; Nicholson, AM; Kalen, AL; Goswami, PC				Chaudhuri, L.; Nicholson, A. M.; Kalen, A. L.; Goswami, P. C.			Preferential selection of MnSOD transcripts in proliferating normal and cancer cells	ONCOGENE			English	Article						MnSOD; 3 '-untranslated region; radiation; polyadenylation; quiescence	MANGANESE SUPEROXIDE-DISMUTASE; MESSENGER-RNA DEGRADATION; IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; MALIGNANT PHENOTYPE; 3'-UNTRANSLATED REGION; HUMAN FIBROBLASTS; BINDING; POLYADENYLATION; OVEREXPRESSION	Manganese superoxide dismutase (MnSOD) is a nuclear encoded and mitochondrial matrix-localized redox enzyme that is known to regulate the cellular redox environment. Cellular redox environment changes during transitions between quiescent and proliferative cycles. Human MnSOD has two poly(A) sites resulting in two transcripts: 1.5 and 4.2 kb. The present study investigates if the 3'-untranslated region (UTR) of MnSOD regulates its expression during transitions between quiescent and proliferating cycles, and in response to radiation. A preferential increase in the levels of the 1.5-kb MnSOD transcript was observed in quiescent cells, whereas the abundance of the longer transcript showed a direct correlation with the percentage of S-phase cells. The log-transformed expression ratio of the longer to the shorter transcript was also higher in proliferating normal and cancer cells. Deletion and reporter assays showed a significant decrease in reporter activity in constructs carrying multiple AU-rich sequence that are present in the 3'-UTR of the longer MnSOD transcript. Overexpression of the MnSOD 3'-UTR representing the longer transcript enhanced endogenous MnSOD mRNA levels, which was associated with an increase in MnSOD protein levels and a decrease in the percentage of S-phase cells. Irradiation increases the mRNA levels of the 1.5-kb MnSOD transcript, which was consistent with a significant increase in the reporter activity of the construct carrying the 3'-UTR of the shorter transcript. We conclude that the 3'-UTR of MnSOD regulates MnSOD expression in response to different growth states and radiation. Oncogene (2012) 31, 1207-1216; doi: 10.1038/onc.2011.325; published online 1 August 2011	[Chaudhuri, L.] Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA; [Goswami, P. C.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Div, Med Labs B180, Iowa City, IA 52242 USA	Mayo Clinic; Mayo Clinic Phoenix; University of Iowa	Goswami, PC (corresponding author), Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Div, Med Labs B180, Iowa City, IA 52242 USA.	prabhat-goswami@uiowa.edu	Kalen, Amanda/AAJ-7531-2020	Goswami, Prabhat/0000-0002-5700-2096	NIH [CA111365]; NIEHS [P42 ES 013661]; NATIONAL CANCER INSTITUTE [R01CA111365, P30CA086862] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES013661] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Ehab H Sarsour and Maneesh G Kumar at the Free Radical and Radiation Biology Division, and Amy Dubinsky and Dr Beverly L Davidson at the Department of Internal Medicine, for technical assistance with the UTR cloning and luciferase reporter assay; Drs Ann Simons and Melissa Fath for human oral squamous and lung cancer cells; Mr Gareth Smith with editorial assistance and the staff at the Flow Cytometry and Radiation and Free Radical Research Core Facilities. Funding from NIH CA111365 and NIEHS P42 ES 013661 supported this work.	AKASHI M, 1995, J BIOL CHEM, V270, P15864, DOI 10.1074/jbc.270.26.15864; Chaudhuri L, 2010, ENVIRON INT, V36, P924, DOI 10.1016/j.envint.2010.01.001; Chaudhuri L, 2010, FREE RADICAL BIO MED, V49, P40, DOI 10.1016/j.freeradbiomed.2010.03.012; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chivukula RR, 2008, TRENDS BIOCHEM SCI, V33, P474, DOI 10.1016/j.tibs.2008.06.008; CHURCH SL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P250, DOI 10.1016/0167-4781(90)90213-L; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Clerch LB, 2000, ANN NY ACAD SCI, V899, P103; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Goswami PC, 2000, J BIOL CHEM, V275, P38384, DOI 10.1074/jbc.M005298200; GUO B, 1994, J BIOL CHEM, V269, P24252; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lutz CS, 2008, ACS CHEM BIOL, V3, P609, DOI 10.1021/cb800138w; Martincic K, 1998, P NATL ACAD SCI USA, V95, P11095, DOI 10.1073/pnas.95.19.11095; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mazumder B, 2003, TRENDS BIOCHEM SCI, V28, P91, DOI 10.1016/S0968-0004(03)00002-1; McCord J, 1969, J BIOL CHEM, V244, P6049; Menon SG, 2005, ANTIOXID REDOX SIGN, V7, P711, DOI 10.1089/ars.2005.7.711; Oberley LW, 2001, ANTIOXID REDOX SIGN, V3, P461, DOI 10.1089/15230860152409095; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Sarsour EH, 2005, J BIOL CHEM, V280, P18033, DOI 10.1074/jbc.M501939200; Sarsour EH, 2008, AGING CELL, V7, P405, DOI 10.1111/j.1474-9726.2008.00384.x; Sarsour EH, 2010, MITOCHONDRION, V10, P342, DOI 10.1016/j.mito.2010.02.004; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; STCLAIR DK, 1991, FREE RADICAL RES COM, V12-3, P771; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; Wang YM, 2009, CANCER RES, V69, P4093, DOI 10.1158/0008-5472.CAN-09-0309; Weydert C, 2003, MOL CANCER THER, V2, P361; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	38	16	17	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1207	1216		10.1038/onc.2011.325	http://dx.doi.org/10.1038/onc.2011.325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804600	Green Accepted			2022-12-28	WOS:000301344600001
J	Mao, JH; Wu, D; Kim, IJ; Kang, HC; Wei, G; Climent, J; Kumar, A; Pelorosso, FG; DelRosario, R; Huang, EJ; Balmain, A				Mao, J-H; Wu, D.; Kim, I-J; Kang, H. C.; Wei, G.; Climent, J.; Kumar, A.; Pelorosso, F. G.; DelRosario, R.; Huang, E. J.; Balmain, A.			Hipk2 cooperates with p53 to suppress gamma-ray radiation-induced mouse thymic lymphoma	ONCOGENE			English	Article						Hipk2; p53; radiation; tumorigenesis	INTERACTING PROTEIN KINASE-2; TRANSCRIPTION; TUMORS; GENE	A genome-wide screen for genetic alterations in radiation-induced thymic lymphomas generated from p53+/- and p53-/- mice showed frequent loss of heterozygosity (LOH) on chromosome 6. Fine mapping of these LOH regions revealed three non-overlapping regions, one of which was refined to a 0.2 Mb interval that contained only the gene encoding homeobox-interacting protein kinase 2 (Hipk2). More than 30% of radiation-induced tumors from both p53+/- and p53-/- mice showed heterozygous loss of one Hipk2 allele. Mice carrying a single inactive allele of Hipk2 in the germline were susceptible to induction of tumors by gamma-radiation, but most tumors retained and expressed the wild-type allele, suggesting that Hipk2 is a haploinsufficient tumor suppressor gene for mouse lymphoma development. Heterozygous loss of both Hipk2 and p53 confers strong sensitization to radiation-induced lymphoma. We conclude that Hipk2 is a haploinsufficient lymphoma suppressor gene. Oncogene (2012) 31, 1176-1180; doi:10.1038/onc.2011.306; published online 25 July 2011	[Wu, D.; Kim, I-J; Kang, H. C.; Climent, J.; Kumar, A.; Pelorosso, F. G.; DelRosario, R.; Balmain, A.] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA; [Mao, J-H] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; [Wei, G.; Huang, E. J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Wei, G.; Huang, E. J.] Vet Affairs Med Ctr, Pathol Serv 113B, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Balmain, A (corresponding author), Helen Diller Family Comprehens Canc Ctr, 1450 3rd St, San Francisco, CA 94158 USA.	abalmain@cc.ucsf.edu	Climent, Joan/O-5877-2017; Mao, Jian-Hua/EIZ-8595-2022; Wei, Grace/GPX-0836-2022; Huang, Eric J./AAH-7997-2019	Climent, Joan/0000-0002-8927-6614; Mao, Jian-Hua/0000-0001-9320-6021; Huang, Eric J./0000-0002-5381-3801	NIH/NCI [U01 CA84244R, 01 CA116481]; DOE [DE-FG02-03ER63630]; Office of Biological and Environmental Research of the US Department of Energy [DE-AC02-05CH11231]; Laboratory Directed Research and Development Program (LDRD); UCSF Genome Analysis Core; Barbara Bass Bakar Chair of Cancer Genetics; NATIONAL CANCER INSTITUTE [R01CA116481, U01CA084244] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOE(United States Department of Energy (DOE)); Office of Biological and Environmental Research of the US Department of Energy(United States Department of Energy (DOE)); Laboratory Directed Research and Development Program (LDRD); UCSF Genome Analysis Core; Barbara Bass Bakar Chair of Cancer Genetics; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by NIH/NCI grant U01 CA84244 and the DOE (DE-FG02-03ER63630) to AB, and NIH/NCI grant R01 CA116481, Office of Biological and Environmental Research of the US Department of Energy under Contract No DE-AC02-05CH11231 and Laboratory Directed Research and Development Program (LDRD) to JHM. AB acknowledges support from the UCSF Genome Analysis Core and the Barbara Bass Bakar Chair of Cancer Genetics.	Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dauth I, 2007, CANCER RES, V67, P2274, DOI 10.1158/0008-5472.CAN-06-2884; Deshmukh H, 2008, ONCOGENE, V27, P4745, DOI 10.1038/onc.2008.110; Di Stefano V, 2004, ONCOGENE, V23, P5185, DOI 10.1038/sj.onc.1207656; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kanei-Ishii C, 2004, J BIOL CHEM, V279, P44582, DOI 10.1074/jbc.M407831200; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2007, CANCER CELL, V11, P161, DOI 10.1016/j.ccr.2006.11.025; Mitelman F, 2010, MITELMAN DATABASE CH; Pierantoni GM, 2007, J CLIN INVEST, V117, P693, DOI 10.1172/JCI29852; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Pistritto G, 2007, CELL DEATH DIFFER, V14, P1837, DOI 10.1038/sj.cdd.4402186; Trapasso F, 2009, DNA CELL BIOL, V28, P161, DOI 10.1089/dna.2008.0778; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	17	32	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1176	1180		10.1038/onc.2011.306	http://dx.doi.org/10.1038/onc.2011.306			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21785465	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000300945900010
J	Perna, D; Faga, G; Verrecchia, A; Gorski, MM; Barozzi, I; Narang, V; Khng, J; Lim, KC; Sung, WK; Sanges, R; Stupka, E; Oskarsson, T; Trumpp, A; Wei, CL; Muller, H; Amati, B				Perna, D.; Faga, G.; Verrecchia, A.; Gorski, M. M.; Barozzi, I.; Narang, V.; Khng, J.; Lim, K. C.; Sung, W-K; Sanges, R.; Stupka, E.; Oskarsson, T.; Trumpp, A.; Wei, C-L; Mueller, H.; Amati, B.			Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts	ONCOGENE			English	Article						Myc; chromatin; transcription; serum	EMBRYONIC STEM-CELLS; C-MYC; TRANSCRIPTION FACTOR; IN-VIVO; CHROMATIN-STRUCTURE; CYCLE PROGRESSION; PROTEIN-SYNTHESIS; DNA-REPLICATION; NUCLEAR IMPORT; RNA EXOSOME	The transition from quiescence to proliferation is a key regulatory step that can be induced by serum stimulation in cultured fibroblasts. The transcription factor Myc is directly induced by serum mitogens and drives a secondary gene expression program that remains largely unknown. Using mRNA profiling, we identify close to 300 Myc-dependent serum response (MDSR) genes, which are induced by serum in a Myc-dependent manner in mouse fibroblasts. Mapping of genomic Myc-binding sites by ChIP-seq technology revealed that most MDSR genes were directly targeted by Myc, but represented a minor fraction (5.5%) of all Myc-bound promoters (which were 22.4% of all promoters). Other target loci were either induced by serum in a Myc-independent manner, were not significantly regulated or were negatively regulated. MDSR gene products were involved in a variety of processes, including nucleotide biosynthesis, ribosome biogenesis, DNA replication and RNA control. Of the 29 MDSR genes targeted by RNA interference, three showed a requirement for cell-cycle entry upon serum stimulation and 11 for long-term proliferation and/or survival. Hence, proper coordination of key regulatory and biosynthetic pathways following mitogenic stimulation relies upon the concerted regulation of multiple Myc-dependent genes. Oncogene (2012) 31, 1695-1709; doi:10.1038/onc.2011.359; published online 22 August 2011	[Perna, D.; Faga, G.; Verrecchia, A.; Gorski, M. M.; Barozzi, I.; Mueller, H.; Amati, B.] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Narang, V.; Sung, W-K; Wei, C-L] Genome Inst Singapore, Computat & Math Biol Grp, Singapore, Singapore; [Khng, J.; Lim, K. C.] Genome Inst Singapore, Genome Technol & Biol Grp, Singapore, Singapore; [Sanges, R.; Stupka, E.] Telethon Inst Genet & Med TIGEM, Naples, Italy; [Oskarsson, T.; Trumpp, A.] Ecole Polytech Fed Lausanne, Sch Life Sci, ISREC, CH-1015 Lausanne, Switzerland; [Mueller, H.; Amati, B.] Ist Italiano Tecnol, Ctr Genom Sci IIT SEMM, Milan, Italy	IRCCS European Institute of Oncology (IEO); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Istituto Italiano di Tecnologia - IIT	Amati, B (corresponding author), European Inst Oncol, Dept Expt Oncol, IFOM IEO Campus,Via Adamello 16, I-20139 Milan, Italy.	bruno.amati@ifom-ieo-campus.it	Sanges, Remo/M-9814-2019; Barozzi, Iros/GLQ-8907-2022; Amati, Bruno/AAM-3418-2020; Verrecchia, Alessandro/AAQ-6454-2020; Stupka, Elia/J-6279-2012; Trumpp, Andreas/Z-2141-2019; Oskarsson, Thordur/HBP-9601-2022; Faga, Giovanni/AAB-5540-2021	Sanges, Remo/0000-0002-5047-9713; Barozzi, Iros/0000-0003-0690-3473; Verrecchia, Alessandro/0000-0002-8596-6650; Stupka, Elia/0000-0003-3154-4011; Trumpp, Andreas/0000-0002-6212-3466; Muller, Heiko/0000-0001-9873-3146; Sung, Wing-Kin/0000-0001-7806-7086; Gorski, Marcin M./0000-0002-8276-3866; Oskarsson, Thordur/0000-0002-0983-6969; Narang, Vipin/0000-0001-8669-9964; Amati, Bruno/0000-0002-2958-1799	Agency for Science, Technology and Research (A*STAR) of Singapore; NIH ENCODE; Swiss National Science Foundation; EU; Association for International Cancer Research (AICR); Italian health ministry; Italian Association for Cancer Research (AIRC)	Agency for Science, Technology and Research (A*STAR) of Singapore(Agency for Science Technology & Research (A*STAR)); NIH ENCODE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EU(European Commission); Association for International Cancer Research (AICR); Italian health ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank Gioacchino Natoli for critical discussion; Lucilla Luzi for help with data analysis; Ivan Muradore and Simona Ronzoni for help with imaging; Simone Minardi and Davide Cittaro for help with microarrays; Loris Bernard, Valentina Dall' Olio and Laura Tizzoni for help with real-time PCR; and Atif Shahab and CheeSeng Chan for technical guidance on processing and mapping sequencing data. We also acknowledge the Genome Technology and Biology Group at the Genome Institute of Singapore, in particular the GIS sequencing team, for technical support. Part of this work was supported by grants from the Agency for Science, Technology and Research (A*STAR) of Singapore and NIH ENCODE to C-LW, and from the Swiss National Science Foundation to AT. Work in the Amati lab was supported by grants from the EU-FP7 Program EuroSyStem, the Association for International Cancer Research (AICR), the Italian health ministry and the Italian Association for Cancer Research (AIRC).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blow JJ, 2005, EMBO REP, V6, P1028, DOI 10.1038/sj.embor.7400557; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Bouchard C, 2004, EMBO J, V23, P2830, DOI 10.1038/sj.emboj.7600279; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Corbett AH, 1996, J BIOL CHEM, V271, P18477, DOI 10.1074/jbc.271.31.18477; Cotterman R, 2008, CANCER RES, V68, P9654, DOI 10.1158/0008-5472.CAN-08-1961; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Hirano Y, 2009, GENES CELLS, V14, P155, DOI 10.1111/j.1365-2443.2008.01262.x; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Izumi H, 2001, J CELL SCI, V114, P1533; Kawaji H, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r40; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Klapproth K, 2010, BRIT J HAEMATOL, V149, P484, DOI 10.1111/j.1365-2141.2010.08159.x; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Leung JY, 2008, ONCOGENE, V27, P4172, DOI 10.1038/onc.2008.55; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu QS, 2006, CELL, V127, P1223, DOI 10.1016/j.cell.2006.10.037; Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Masai H, 2005, IUBMB LIFE, V57, P323, DOI 10.1080/15216540500092419; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Quimby BB, 2000, MOL BIOL CELL, V11, P2617, DOI 10.1091/mbc.11.8.2617; Quimby BB, 2000, J BIOL CHEM, V275, P28575, DOI 10.1074/jbc.M005055200; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Schlosser I, 2003, NUCLEIC ACIDS RES, V31, P6148, DOI 10.1093/nar/gkg794; Schmid M, 2008, TRENDS BIOCHEM SCI, V33, P501, DOI 10.1016/j.tibs.2008.07.003; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shen V, 2006, CELL, V127, P1093, DOI 10.1016/j.cell.2006.11.035; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Sridharan R, 2009, CELL, V136, P364, DOI 10.1016/j.cell.2009.01.001; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stewart M, 2007, NAT REV MOL CELL BIO, V8, P195, DOI 10.1038/nrm2114; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tao H, 1999, DNA CELL BIOL, V18, P75, DOI 10.1089/104454999315646; Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Vanacova S, 2007, EMBO REP, V8, P651, DOI 10.1038/sj.embor.7401005; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	82	67	70	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1695	1709		10.1038/onc.2011.359	http://dx.doi.org/10.1038/onc.2011.359			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860422	hybrid, Green Published			2022-12-28	WOS:000302231400008
J	Li, Y; Jaramillo-Lambert, AN; Yang, Y; Williams, R; Lee, NH; Zhu, W				Li, Y.; Jaramillo-Lambert, A. N.; Yang, Y.; Williams, R.; Lee, N. H.; Zhu, W.			And-1 is required for the stability of histone acetyltransferase Gcn5	ONCOGENE			English	Article						Ctf4/And-1; Gcn5; DNA replication; histone acetylation	DNA-POLYMERASE-ALPHA; BINDING PROTEIN; REPLICATION; ACETYLATION; COMPLEX; CTF4; YEAST; DOMAIN; H3; ACTIVATION	Histone acetyltransferases (HATs) have a central role in the modification of chromatin as well as in the pathogenesis of a broad set of diseases including cancers. Gcn5 is the first identified transcription-related HAT that has been implicated in the regulation of diverse cellular functions. However, how Gcn5 proteins are regulated remains largely unknown. Here we show that acidic nucleoplasmic DNA-binding protein (And-1, a high mobility group domain-containing protein) has remarkable capability to regulate the stability of Gcn5 proteins and thereby histone H3 acetylation. We find that And-1 forms a complex with both histone H3 and Gcn5. Downregulation of And-1 results in Gcn5 degradation, leading to the reduction of H3K9 and H3K56 acetylation. And-1 overexpression stabilizes Gcn5 through protein-protein interactions in vivo. Furthermore, And-1 expression is increased in cancer cells in a manner correlating with increased Gcn5 and H3K9Ac and H3K56Ac. Thus, our data reveal not only a functional link between Gcn5 and And-1 that is essential for Gcn5 protein stability and histone H3 acetylation, but also a potential role of And-1 in cancer. Oncogene (2012) 31, 643-652; doi:10.1038/onc.2011.261; published online 4 July 2011	[Li, Y.; Jaramillo-Lambert, A. N.; Yang, Y.; Zhu, W.] George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Williams, R.; Lee, N. H.] George Washington Univ, Sch Med, Dept Pharmacol & Physiol, Washington, DC 20037 USA	George Washington University; George Washington University	Zhu, W (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St NW, Washington, DC 20037 USA.	bcmwxz@gwumc.edu		Jaramillo-Lambert, Aimee/0000-0001-7697-8580	National Institutes of Health [4R00CA136555, CA120316]; NATIONAL CANCER INSTITUTE [R01CA120316, R00CA136555] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Anindya Dutta for And-1 plasmids and antibodies, Ezra Burstein for Gcn5 plasmids, Rakesh Kumar and Jeyanthy Eswaran for reading the manuscript. This work was supported by funding from the National Institutes of Health (4R00CA136555 awarded to WZ; CA120316 awarded to NHL).	Armas-Pineda C, 2007, J EXP CLIN CANC RES, V26, P269; Atanassov BS, 2009, MOL CELL, V35, P352, DOI 10.1016/j.molcel.2009.06.015; Bermudez VP, 2010, J BIOL CHEM, V285, P9493, DOI 10.1074/jbc.M109.093609; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burgess RJ, 2010, CELL CYCLE, V9, P2979, DOI 10.4161/cc.9.15.12498; Burgess RJ, 2010, MOL CELL, V37, P469, DOI 10.1016/j.molcel.2010.01.020; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; Celic I, 2008, GENETICS, V179, P1769, DOI 10.1534/genetics.108.088914; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Espinosa MC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008964; Gambus A, 2009, EMBO J, V28, P2992, DOI 10.1038/emboj.2009.226; Goren A, 2008, GENE DEV, V22, P1319, DOI 10.1101/gad.468308; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Im JS, 2009, P NATL ACAD SCI USA, V106, P15628, DOI 10.1073/pnas.0908039106; Karnani N, 2007, GENOME RES, V17, P865, DOI 10.1101/gr.5427007; Kikuchi H, 2011, BIOCHEM BIOPH RES CO, V405, P657, DOI 10.1016/j.bbrc.2011.01.088; KOUPRINA N, 1992, MOL CELL BIOL, V12, P5736, DOI 10.1128/MCB.12.12.5736; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Lucas I, 2007, EMBO REP, V8, P770, DOI 10.1038/sj.embor.7401026; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Orpinell M, 2010, EMBO J, V29, P2381, DOI 10.1038/emboj.2010.125; Paolinelli R, 2009, NAT STRUCT MOL BIOL, V16, P412, DOI 10.1038/nsmb.1583; Petronczki M, 2004, J CELL SCI, V117, P3547, DOI 10.1242/jcs.01231; Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Tsutsui Y, 2005, CURR GENET, V48, P34, DOI 10.1007/s00294-005-0584-2; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Williams DR, 2002, EUKARYOT CELL, V1, P758, DOI 10.1128/EC.1.5.758-773.2002; Yoshizawa-Sugata N, 2009, J BIOL CHEM, V284, P20718, DOI 10.1074/jbc.M806711200; Zhou J, 2005, CELL CYCLE, V4, P889, DOI 10.4161/cc.4.7.1823; Zhu WG, 2007, GENE DEV, V21, P2288, DOI 10.1101/gad.1585607; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	24	24	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					643	652		10.1038/onc.2011.261	http://dx.doi.org/10.1038/onc.2011.261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725360	Green Accepted			2022-12-28	WOS:000300221800010
J	Udayakumar, D; Zhang, G; Ji, Z; Njauw, CN; Mroz, P; Tsao, H				Udayakumar, D.; Zhang, G.; Ji, Z.; Njauw, C-N; Mroz, P.; Tsao, H.			Epha2 is a critical oncogene in melanoma	ONCOGENE			English	Article						melanoma; EphA2; survival	RECEPTOR TYROSINE KINASE; VASCULOGENIC MIMICRY; PROSTATE-CANCER; CELL-MIGRATION; OVARIAN-CANCER; TUMOR-CELLS; OVEREXPRESSION; EXPRESSION; INVASION; GROWTH	EphA2 is a member of the Eph family of receptor tyrosine kinases and is highly expressed in many aggressive cancer types, including melanoma. We recently showed that EphA2 is also upregulated by ultraviolet radiation and is able to induce apoptosis. These findings suggest that EphA2 may have different, even paradoxical, effects on viability depending on the cellular context and that EphA2 mediates a delicate balance between life and death of the cell. To functionally clarify EphA2's role in melanoma, we analyzed a panel of melanoma cell lines and found that EphA2 levels are elevated in a significant fraction of the samples. Specific depletion of EphA2 in high-expressing melanoma cells using short hairpin RNA led to profound reductions in cellular viability, colony formation and migration in vitro and a dramatic loss of tumorigenic potential in vivo. Stable introduction of EphA2 into low-expressing cell lines enhanced proliferation, colony formation and migration, further supporting its pro-malignant phenotype. Interestingly, transient expression of EphA2 and/or Braf(V600E) in non-transformed melanocytes led to significant and additive apoptosis. These results verify that EphA2 is an important oncogene and potentially a common source of 'addiction' for many melanoma cells. Moreover, acute induction of EphA2 may purge genetically susceptible cells, thereby uncovering a more aggressive population that is in fact dependent on the oncogene. Oncogene (2011) 30, 4921-4929; doi:10.1038/onc.2011.210; published online 13 June 2011	[Udayakumar, D.; Ji, Z.; Mroz, P.; Tsao, H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA; [Udayakumar, D.; Ji, Z.; Njauw, C-N; Mroz, P.; Tsao, H.] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA; [Zhang, G.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Ctr Vasc Biol Res, Boston, MA 02114 USA; [Tsao, H.] Massachusetts Gen Hosp, Melanoma & Pigmented Les Ctr, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital	Tsao, H (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Bartlett 622,48 Blossom St, Boston, MA 02114 USA.	htsao@partners.org	Mroz, Pawel/P-1258-2019	Mroz, Pawel/0000-0003-3838-4743	National Institutes of Health [1R21ES013964]; Dermatology Foundation; American Skin Association; Melanoma Research Alliance; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES013964] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation; American Skin Association; Melanoma Research Alliance; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the National Institutes of Health (1R21ES013964; HT), the Dermatology Foundation (DU), the American Skin Association (HT and DU), the Melanoma Research Alliance (to HT) and the generous philanthropic donors at MGH. We thank Dr Jie Zhao and other members of the Wellman Center Pathology core facility for their help with the tissue sections and confocal analysis. We also thank Dr Michael Hamblin for his support in mice tumor studies.	ALBINI A, 1987, CANCER RES, V47, P3239; ANDRES AC, 1994, ONCOGENE, V9, P1461; Bogan C, 2009, INT J CANCER, V124, P1366, DOI 10.1002/ijc.24083; Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075; Connor RJ, 1998, DEV BIOL, V193, P21, DOI 10.1006/dbio.1997.8786; Cui XD, 2010, INT J CANCER, V126, P940, DOI 10.1002/ijc.24798; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; GANJU P, 1994, ONCOGENE, V9, P1613; Han LQ, 2005, GYNECOL ONCOL, V99, P278, DOI 10.1016/j.ygyno.2005.06.036; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Hess AR, 2006, CANCER BIOL THER, V5, P228, DOI 10.4161/cbt.5.2.2510; Hingorani SR, 2003, CANCER RES, V63, P5198; Kamat AA, 2009, CANCER-AM CANCER SOC, V115, P2684, DOI 10.1002/cncr.24335; Kataoka H, 2004, CANCER SCI, V95, P136, DOI 10.1111/j.1349-7006.2004.tb03194.x; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Liu Y, 2011, J CANCER RES CLIN, V137, P761, DOI 10.1007/s00432-010-0936-2; Lu C, 2008, CANCER BIOL THER, V7, P1098, DOI 10.4161/cbt.7.7.6168; Margaryan NV, 2009, CANCER BIOL THER, V8, P275, DOI 10.4161/cbt.8.3.7485; Menges CW, 2008, ONCOGENE, V27, P2934, DOI 10.1038/sj.onc.1210957; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Moore-Scott BA, 2007, DEV DYNAM, V236, P1997, DOI 10.1002/dvdy.21204; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Parri M, 2009, CANCER RES, V69, P2072, DOI 10.1158/0008-5472.CAN-08-1845; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Straume O, 2002, AM J PATHOL, V160, P1009, DOI 10.1016/S0002-9440(10)64922-X; Sulman EP, 1997, GENOMICS, V40, P371, DOI 10.1006/geno.1996.4569; Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Vaught D, 2009, MOL BIOL CELL, V20, P2572, DOI 10.1091/mbc.E08-04-0378; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372	41	54	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	50					4921	4929		10.1038/onc.2011.210	http://dx.doi.org/10.1038/onc.2011.210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YJ	21666714	Green Accepted			2022-12-28	WOS:000298346500001
J	Floor, S; van Staveren, WCG; Larsimont, D; Dumont, JE; Maenhaut, C				Floor, S.; van Staveren, W. C. G.; Larsimont, D.; Dumont, J. E.; Maenhaut, C.			Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations	ONCOGENE			English	Review						cancer stem cells; epithelial mesenchymal transition metastasis; tumor propagating cell	HIGH ALDEHYDE DEHYDROGENASE; BREAST-CANCER; INITIATING CELLS; GROWTH-FACTOR; PANCREATIC-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTORS; GENOMIC INSTABILITY	Cell populations of solid cancers and their distant models, the cancer cell lines, have been categorized in sub-populations: cancer stem-tumor-propagating cells (CSC-TPC) versus derived cells, epithelial-versus mesenchymal-type cells, dormant versus actively proliferating cells and so on. CSC-TPC are minimally defined by their operational properties: immortality and the ability to regenerate in vivo or in vitro the whole panel of cancer cells. The epithelial-to-mesenchymal transition (EMT), mostly observed in vitro, generates mesenchymal-type from epithelial-type cells. The converse transition is mesenchymal-to-epithelial transition. In vitro work suggests that CSC-TPC and EMT cell phenotypes overlap. An analysis of the properties of these sub-populations, as studied in vitro, shows that indeed these two phenotypes may be linked to some extent. However, the in vivo counterpart of this relation in human tumors has barely been investigated. A model in which among the EMT cells released from the tumor only the most competent CSC-TPC will succeed to metastasize is proposed. It is suggested that in the Darwinian evolution of cancer cells, many phenotypes reflecting the expression of various programs, reversible to irreversible, exclusive, overlapping or linked coexist and compete with each other. Oncogene (2011) 30, 4609-4621; doi:10.1038/onc.2011.184; published online 6 June 2011	[Floor, S.; van Staveren, W. C. G.; Dumont, J. E.; Maenhaut, C.] Univ Brussels, Fac Med, Inst Interdisciplinary Res IRIBHM, B-1070 Brussels, Belgium; [Larsimont, D.] Univ Brussels, Inst Bordet, Fac Med, B-1070 Brussels, Belgium; [Maenhaut, C.] Univ Brussels, Fac Med, WELBIO, B-1070 Brussels, Belgium	Institut Jules Bordet; Universite Libre de Bruxelles; Vrije Universiteit Brussel; WELBIO	Dumont, JE (corresponding author), Univ Brussels, Fac Med, Inst Interdisciplinary Res IRIBHM, Campus Erasme,CP 602,Route Lennik 808, B-1070 Brussels, Belgium.	jedumont@ulb.ac.be						Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Alexander S, 2008, HISTOCHEM CELL BIOL, V130, P1147, DOI 10.1007/s00418-008-0529-1; Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296; Nieto MA, 2009, INT J DEV BIOL, V53, P1541, DOI 10.1387/ijdb.072410mn; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Atsumi N, 2008, BIOCHEM BIOPH RES CO, V373, P36, DOI 10.1016/j.bbrc.2008.05.163; Aulmann S, 2010, HUM PATHOL, V41, P574, DOI 10.1016/j.humpath.2009.08.023; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; BAPTIST M, 1993, J CELL SCI, V105, P69; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bortolomai I, 2010, CELL CYCLE, V9, P1194, DOI 10.4161/cc.9.6.11108; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737; Carmeliet P, 2009, NAT REV CLIN ONCOL, V6, P315, DOI 10.1038/nrclinonc.2009.64; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clement V, 2010, NAT METHODS, V7, P224, DOI [10.1038/nmeth.1430, 10.1038/NMETH.1430]; COCLET J, 1991, MOL CELL ENDOCRINOL, V76, P135, DOI 10.1016/0303-7207(91)90268-W; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Cremers N, 2010, CELL MOL LIFE SCI, V67, P2311, DOI 10.1007/s00018-010-0342-6; Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Daly AC, 2010, J BIOL CHEM, V285, P6489, DOI 10.1074/jbc.M109.043877; Davidson EH, 2010, NATURE, V468, P911, DOI 10.1038/nature09645; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434; Dirks P, 2010, NATURE, V466, P40, DOI 10.1038/466040a; DREMIER S, 1994, ENDOCRINOLOGY, V135, P135, DOI 10.1210/en.135.1.135; Eberth S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-517; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gosselin K, 2009, CANCER RES, V69, P7917, DOI 10.1158/0008-5472.CAN-08-2510; Goswami S, 2004, CANCER RES, V64, P7664, DOI 10.1158/0008-5472.CAN-04-2027; GREENBURG G, 1988, DEVELOPMENT, V102, P605; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gunaratne PH, 2009, CURR STEM CELL RES T, V4, P168, DOI 10.2174/157488809789057400; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harless WW, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-1; He XB, 2009, STEM CELLS, V27, P1487, DOI 10.1002/stem.92; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Horst D, 2009, J PATHOL, V219, P427, DOI 10.1002/path.2597; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Janes KA, 2010, NAT METHODS, V7, P311, DOI [10.1038/nmeth.1442, 10.1038/NMETH.1442]; Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Lander Arthur D., 2009, Journal of Biology (London), V8, P70, DOI 10.1186/jbiol177; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Lehn S, 2010, AM J PATHOL, V177, P2886, DOI 10.2353/ajpath.2010.100303; LEROY A, 1994, INVAS METAST, V14, P177; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Liang Y, 2010, J BIOL CHEM, V285, P4931, DOI 10.1074/jbc.M109.048397; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lingala S, 2010, EXP MOL PATHOL, V89, P27, DOI 10.1016/j.yexmp.2010.05.005; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773; Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013; Maenhaut C, 2010, CARCINOGENESIS, V31, P149, DOI 10.1093/carcin/bgp259; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; Masugi Y, 2010, HUM PATHOL, V41, P1061, DOI 10.1016/j.humpath.2010.01.016; Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639; Merlo LMF, 2010, J CLIN INVEST, V120, P401, DOI 10.1172/JCI42088; Meyer MJ, 2010, CANCER RES, V70, P4624, DOI 10.1158/0008-5472.CAN-09-3619; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mun GI, 2010, AM J PHYSIOL-HEART C, V298, pH2102, DOI 10.1152/ajpheart.00835.2009; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; NEVE P, 1970, Z ZELLFORSCH MIK ANA, V103, P61, DOI 10.1007/BF00335401; Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880; Ohashi S, 2010, CANCER RES, V70, P4174, DOI 10.1158/0008-5472.CAN-09-4614; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Pantel K, 2010, TRENDS MOL MED, V16, P398, DOI 10.1016/j.molmed.2010.07.001; Pera MF, 2010, NATURE, V465, P713, DOI 10.1038/nature09228; Perez-Losada M, 2005, MOL BIOL EVOL, V22, P1887, DOI 10.1093/molbev/msi184; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pusch A, 2010, BBA-MOL CELL RES, V1803, P261, DOI 10.1016/j.bbamcr.2009.12.003; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Refaeli Y, 2009, EMBO REP, V10, P965, DOI 10.1038/embor.2009.184; Reiman JM, 2010, CANCER RES, V70, P3005, DOI 10.1158/0008-5472.CAN-09-4041; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Richardson L, 2006, MECH DEVELOP, V123, P288, DOI 10.1016/j.mod.2006.01.004; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Robson EJD, 2006, DIFFERENTIATION, V74, P254, DOI 10.1111/j.1432-0436.2006.00075.x; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sell S, 2006, CURR GENE THER, V6, P579, DOI 10.2174/156652306778520674; Shackleton M, 2010, SEMIN CANCER BIOL, V20, P85, DOI 10.1016/j.semcancer.2010.04.002; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shervington A, 2009, MOL CELL BIOCHEM, V331, P153, DOI 10.1007/s11010-009-0153-y; Shi Ke-hua, 2010, Zhong Xi Yi Jie He Xue Bao, V8, P785; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Stahlberg A, 2010, METHODS, V50, P282, DOI 10.1016/j.ymeth.2010.01.002; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155; Todaro M, 2010, CANCER RES, V70, P8874, DOI 10.1158/0008-5472.CAN-10-1994; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van Zijl F, 2009, ONCOGENE, V28, P4022, DOI 10.1038/onc.2009.253; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Weinberg R, 2007, BIOL CANC GARLAND SC; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xu XL, 2010, CARCINOGENESIS, V31, P167, DOI 10.1093/carcin/bgp232; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Zalzman M, 2010, NATURE, V464, P858, DOI 10.1038/nature08882	146	146	153	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	46					4609	4621		10.1038/onc.2011.184	http://dx.doi.org/10.1038/onc.2011.184			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	851EV	21643013				2022-12-28	WOS:000297252100001
J	Samanta, S; Sharma, VM; Khan, A; Mercurio, AM				Samanta, S.; Sharma, V. M.; Khan, A.; Mercurio, A. M.			Regulation of IMP3 by EGFR signaling and repression by ER beta: implications for triple-negative breast cancer	ONCOGENE			English	Article						breast cancer; IMP3; ER beta; EGFR	GROWTH-FACTOR RECEPTOR; RNA-BINDING PROTEIN; ESTROGEN-RECEPTOR; MESSENGER-RNA; CELL-PROLIFERATION; EXPRESSION; CARCINOMA; ACTIVATION; KINASE; BIOMARKER	Insulin-like growth factor II (IGF-II) mRNA-binding protein 3 (IMP3) is emerging as a useful indicator of the progression and outcome of several cancers. IMP3 expression is associated with triple-negative breast carcinomas (TNBCs), which are aggressive tumors associated with poor outcome. In this study, we addressed the hypothesis that signaling pathways, which are characteristic of TNBCs, impact the expression of IMP3 and that IMP3 contributes to the function of TNBCs. The data obtained reveal that IMP3 expression is repressed specifically by estrogen receptor beta (ER beta) and its ligand 3 beta A-diol but not by ER alpha. Epidermal growth factor receptor (EGFR) signaling and consequent activation of the mitogen-activated protein kinase pathway induce IMP3 transcription and expression. Interestingly, we discovered that the EGFR promoter contains an imperfect estrogen response element and that ER beta represses EGFR transcription. These data support a mechanism in which ER beta inhibits IMP3 expression indirectly by repressing the EGFR. This mechanism relates to the biology of TNBC, which is characterized by diminished ER beta and increased EGFR expression. We also demonstrate that IMP3 contributes to the migration and invasion of breast carcinoma cells. Given that IMP3 is an mRNA-binding protein, we determined that it binds several key mRNAs that could contribute to migration and invasion, including CD164 (endolyn) and MMP9. Moreover, expression of these mRNAs is repressed by ER beta and enhanced by EGFR signaling, consistent with our proposed mechanism for the regulation of IMP3 expression in breast cancer cells. Our findings show that IMP3 is an effector of EGFR-mediated migration and invasion and they provide the first indication of how this important mRNA-binding protein is regulated in cancer.	[Samanta, S.; Sharma, V. M.; Mercurio, A. M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Khan, A.] UMass Mem Med Ctr, Dept Pathol, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Mercurio, AM (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,Lazare Res Bldg, Worcester, MA 01605 USA.	arthur.mercurio@umassmed.edu			NIH [CA80789, 89209]; NATIONAL CANCER INSTITUTE [R01CA089209, R01CA080789] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NIH Grants CA80789 and 89209 supported this work. We thank Dr Xiofang Yang for her input into this project, and Drs Paul Mak and Hira Lal Goel for their valuable suggestions and technical assistance. We also thank Bryan Pursell for his technical support.	Agrawal A, 2005, ENDOCR-RELAT CANCER, V12, pS135, DOI 10.1677/erc.1.01059; Belotti D, 2003, CANCER RES, V63, P5224; Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305; CASTRO CG, 1993, ARCH GYNECOL OBSTET, V252, P169, DOI 10.1007/BF02426354; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Guerini V, 2005, CANCER RES, V65, P5445, DOI 10.1158/0008-5472.CAN-04-1941; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Havens AM, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-195; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034; Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Li CZ, 2007, MODERN PATHOL, V20, P242, DOI 10.1038/modpathol.3800735; Li DW, 2009, ANN SURG ONCOL, V16, P3499, DOI 10.1245/s10434-009-0648-5; Li S, 2011, HEAD NECK-J SCI SPEC, V33, P368, DOI 10.1002/hed.21457; Li Z, 2011, J BIOL CHEM, V286, P21164, DOI 10.1074/jbc.M110.207571; Liao BS, 2011, J BIOL CHEM, V286, P31145, DOI 10.1074/jbc.M111.263913; Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200; Lu D, 2011, AM J SURG PATHOL, V35, P1638, DOI 10.1097/PAS.0b013e31823272d4; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; Marotti JD, 2010, MODERN PATHOL, V23, P197, DOI 10.1038/modpathol.2009.158; MARTINAZZI M, 1993, J CLIN PATHOL, V46, P1009, DOI 10.1136/jcp.46.11.1009; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; NEWBY JC, 1995, BRIT J CANCER, V71, P1237, DOI 10.1038/bjc.1995.239; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pinton G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014110; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Ryden L, 2010, BREAST CANCER RES TR, V120, P491, DOI 10.1007/s10549-010-0758-6; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Simon R, 2007, HUM PATHOL, V38, P1178, DOI 10.1016/j.humpath.2007.02.001; Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Van Meter TE, 2004, NEURO-ONCOLOGY, V6, P188, DOI 10.1215/S1152851703000486; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Webb Paul, 2003, Nucl Recept, V1, P4, DOI 10.1186/1478-1336-1-4; Xu L, 2010, ONCOGENE, V29, P2616, DOI 10.1038/onc.2010.16; Yantiss RK, 2005, AM J SURG PATHOL, V29, P188, DOI 10.1097/01.pas.0000149688.98333.54; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zeng ZS, 1999, CARCINOGENESIS, V20, P749, DOI 10.1093/carcin/20.5.749; Zhang XT, 2011, ONCOGENE, V30, P770, DOI 10.1038/onc.2010.458; Zheng WX, 2008, AM J SURG PATHOL, V32, P304, DOI 10.1097/PAS.0b013e3181483ff8	52	77	83	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	44					4689	4697		10.1038/onc.2011.620	http://dx.doi.org/10.1038/onc.2011.620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032MW	22266872	Green Accepted			2022-12-28	WOS:000310724400004
J	Jalava, SE; Urbanucci, A; Latonen, L; Waltering, KK; Sahu, B; Janne, OA; Seppala, J; Lahdesmaki, H; Tammela, TLJ; Visakorpi, T				Jalava, S. E.; Urbanucci, A.; Latonen, L.; Waltering, K. K.; Sahu, B.; Janne, O. A.; Seppala, J.; Lahdesmaki, H.; Tammela, T. L. J.; Visakorpi, T.			Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer	ONCOGENE			English	Article						neoplasia; prostatic; miR-32; BTG2; hormone refractory; androgen independent	MICRORNA EXPRESSION; RECEPTOR GENE; MESSENGER-RNAS; PROTEIN; CELLS; AMPLIFICATION; PROGNOSIS; MIR-148A; REGIONS; BINDING	The androgen receptor (AR) signaling pathway is involved in the emergence of castration-resistant prostate cancer (CRPC). Here, we identified several androgen-regulated microRNAs (miRNAs) that may contribute to the development of CRPC. Seven miRNAs, miR-21, miR-32, miR-99a, miR-99b, miR-148a, miR-221 and miR-590-5p, were found to be differentially expressed in CRPC compared with benign prostate hyperplasia (BPH) according to microarray analyses. Significant growth advantage for LNCaP cells transfected with pre-miR-32 and pre-miR-148a was found. miR-32 was demonstrated to reduce apoptosis, whereas miR-148a enhanced proliferation. Androgen regulation of miR-32 and miR-148a was confirmed by androgen stimulation of the LNCaP cells followed by expression analyses. The AR-binding sites in proximity of these miRNAs were demonstrated with chromatin immunoprecipitation (ChIP). To identify target genes for the miRNAs, mRNA microarray analyses were performed with LNCaP cells transfected with pre-miR-32 and pre-miR-148a. Expression of BTG2 and PIK3IP1 was reduced in the cells transfected with pre-miR-32 and pre-miR-148a, respectively. Also, the protein expression was reduced according to western blot analysis. BTG2 and PIK3IP1 were confirmed to be targets by 3'UTR-luciferase assays. Finally, immunostainings showed a statistically significant (P<0.0001) reduction of BTG2 protein in CRPCs compared with untreated prostate cancer (PC). The lack of BTG2 staining was also associated (P<0.01) with a short progression-free time in patients who underwent prostatectomy. In conclusion, androgen-regulated miR-32 is overexpressed in CRPC, leading to reduced expression of BTG2. Thus, miR-32 is a potential marker for aggressive disease and is a putative drug target in PC. Oncogene (2012) 31, 4460-4471; doi: 10.1038/onc.2011.624; published online 23 January 2012	[Jalava, S. E.; Urbanucci, A.; Latonen, L.; Waltering, K. K.; Visakorpi, T.] Tampere Univ, Inst Biomed Technol, FIN-33014 Tampere, Finland; [Sahu, B.; Janne, O. A.] Univ Helsinki, Inst Biomed Physiol, Helsinki, Finland; [Seppala, J.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Lahdesmaki, H.] Aalto Univ, Sch Sci, Dept Informat & Comp Sci, Helsinki, Finland; [Tammela, T. L. J.] Univ Tampere, Dept Urol, FIN-33101 Tampere, Finland; [Tammela, T. L. J.] Tampere Univ Hosp, Tampere, Finland	Tampere University; University of Helsinki; Tampere University; Aalto University; Tampere University; Tampere University; Tampere University Hospital	Visakorpi, T (corresponding author), Tampere Univ, Inst Biomed Technol, FIN-33014 Tampere, Finland.	tapio.visakorpi@uta.fi	Urbanucci, Alfonso/S-4450-2019; Latonen, Leena/C-8787-2016; Sahu, Biswajyoti/U-6724-2017; Jackson, Benjamin L/C-4297-2012	Urbanucci, Alfonso/0000-0003-2931-3652; Latonen, Leena/0000-0003-4502-2193; Sahu, Biswajyoti/0000-0001-6576-5440; Visakorpi, Tapio/0000-0002-5004-0364	European Community [HEALTH-F2-2007-201438]; Academy of Finland; Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation; Medical Research Fund of Tampere University Hospital	European Community(European Commission); Academy of Finland(Academy of Finland); Cancer Society of Finland; Reino Lahtikari Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Medical Research Fund of Tampere University Hospital	We thank Ms Mariitta Vakkuri, Ms Paivi Martikainen and Mr Rolle Rahikainen for skillful technical assistance. The research leading to these results was funded by the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. HEALTH-F2-2007-201438. In addition, grant support has been received from the Academy of Finland, the Cancer Society of Finland, the Reino Lahtikari Foundation, the Sigrid Juselius Foundation and the Medical Research Fund of Tampere University Hospital.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Di Leva G, 2010, TRENDS MOL MED, V16, P257, DOI 10.1016/j.molmed.2010.04.001; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hong JW, 2005, J BIOL CHEM, V280, P21256, DOI 10.1074/jbc.M500318200; Hu XD, 2011, BIOCHEM BIOPH RES CO, V404, P903, DOI 10.1016/j.bbrc.2010.12.064; Jalava SE, 2009, INT J CANCER, V124, P95, DOI 10.1002/ijc.23916; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Leinonen KA, 2010, CLIN CANCER RES, V16, P2845, DOI 10.1158/1078-0432.CCR-09-2505; Linja MJ, 2001, CANCER RES, V61, P3550; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078-0432.CCR-10-2815; Mollerstrom E, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-296; Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Saramaki OR, 2008, CLIN CANCER RES, V14, P3395, DOI 10.1158/1078-0432.CCR-07-2051; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Spahn M, 2010, INT J CANCER, V127, P394, DOI 10.1002/ijc.24715; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thompson J, 2006, EMBO J, V25, P2757, DOI 10.1038/sj.emboj.7601161; Tomlins SA, 2009, EUR UROL, V56, P275, DOI 10.1016/j.eururo.2009.04.036; Urbanucci A, 2012, ONCOGENE, V31, P2153, DOI 10.1038/onc.2011.401; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu ZQ, 2007, BIOCHEM BIOPH RES CO, V358, P66, DOI 10.1016/j.bbrc.2007.04.096	47	151	165	3	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4460	4471		10.1038/onc.2011.624	http://dx.doi.org/10.1038/onc.2011.624			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266859				2022-12-28	WOS:000309704500004
J	Spizzo, R; Almeida, MI; Colombatti, A; Calin, GA				Spizzo, R.; Almeida, M. I.; Colombatti, A.; Calin, G. A.			Long non-coding RNAs and cancer: a new frontier of translational research?	ONCOGENE			English	Review						long non-coding RNAs; cancer; online databases; function	TUMOR-SUPPRESSOR GENE; NATURAL ANTISENSE TRANSCRIPTS; CARTILAGE-HAIR HYPOPLASIA; GNAS1 T393C POLYMORPHISM; PROSTATE-SPECIFIC GENE; PROTEIN-CODING RNA; IN-VIVO; DNA METHYLATION; EVOLUTIONARY CONSERVATION; ULTRACONSERVED ELEMENTS	Tiling array and novel sequencing technologies have made available the transcription profile of the entire human genome. However, the extent of transcription and the function of genetic elements that occur outside of protein-coding genes, particularly those involved in disease, are still a matter of debate. In this review, we focus on long non-coding RNAs (lncRNAs) that are involved in cancer. We define lncRNAs and present a cancer-oriented list of lncRNAs, list some tools (for example, public databases) that classify lncRNAs or that scan genome spans of interest to find whether known lncRNAs reside there, and describe some of the functions of lncRNAs and the possible genetic mechanisms that underlie lncRNA expression changes in cancer, as well as current and potential future applications of lncRNA research in the treatment of cancer.	[Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 1950, Houston, TX 77030 USA; [Spizzo, R.; Colombatti, A.] IRCSS Natl Canc Inst, Ctr Riferimento Oncol, Aviano, PN, Italy; [Almeida, M. I.] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal	University of Texas System; UTMD Anderson Cancer Center; IRCCS Aviano (CRO); Universidade do Minho	Calin, GA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 1950, 1901 East Rd, Houston, TX 77030 USA.	gcalin@mdanderson.org	Calin, George/E-9390-2011; Spizzo, Riccardo/V-1057-2019; Almeida, Maria Ines/AAP-2376-2021; Almeida, Maria Ines/N-3196-2013; Almeida, Maria Ines/AAP-3249-2021	Spizzo, Riccardo/0000-0001-7772-0960; Almeida, Maria Ines/0000-0003-2072-8587; Almeida, Maria Ines/0000-0003-2072-8587; Calin, George/0000-0002-7427-0578; colombatti, alfonso/0000-0002-3676-2379; Calin, George/0000-0001-6704-5615	TALENTS Programme; FCT (Fundacao para a Ciencia e Tecnologia), Portugal; University of Texas MD Anderson Cancer Center Research Trust; Chronic Lymphocytic Leukemia Global Research Foundation; NIH/NCI [CA135444]; Department of Defense Breast Cancer Idea Award; Breast Cancer, Ovarian Cancer, Brain Cancer, Multiple Myeloma and Leukemia Specialized Programs of Research Excellence (SPORE) grants from the National Institutes of Health; NATIONAL CANCER INSTITUTE [P50CA100632, R01CA135444] Funding Source: NIH RePORTER	TALENTS Programme; FCT (Fundacao para a Ciencia e Tecnologia), Portugal(Portuguese Foundation for Science and Technology); University of Texas MD Anderson Cancer Center Research Trust; Chronic Lymphocytic Leukemia Global Research Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense Breast Cancer Idea Award(United States Department of Defense); Breast Cancer, Ovarian Cancer, Brain Cancer, Multiple Myeloma and Leukemia Specialized Programs of Research Excellence (SPORE) grants from the National Institutes of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	RS is supported as a fellow of the TALENTS Programme (7th R&D Framework Programme, Specific Programme: PEOPLE-Marie Curie Actions-COFUND). MIA is supported as a PhD fellow of the FCT (Fundacao para a Ciencia e Tecnologia), Portugal. GAC is supported as a fellow by The University of Texas MD Anderson Cancer Center Research Trust, as a research scholar by The University of Texas System Regents, and by the Chronic Lymphocytic Leukemia Global Research Foundation. Work in GAC's laboratory is supported in part by the NIH/NCI (CA135444); a Department of Defense Breast Cancer Idea Award; Developmental Research Awards from the Breast Cancer, Ovarian Cancer, Brain Cancer, Multiple Myeloma and Leukemia Specialized Programs of Research Excellence (SPORE) grants from the National Institutes of Health; a 2009 Seena Magowitz - Pancreatic Cancer Action Network AACR Pilot Grant; the Laura and John Arnold Foundation and the RGK Foundation.	Agrelo R, 2010, EMBO MOL MED, V2, P6, DOI 10.1002/emmm.200900053; Alakus H, 2009, PHARMACOGENOMICS J, V9, P202, DOI 10.1038/tpj.2009.5; Amaral PP, 2011, NUCLEIC ACIDS RES, V39, pD146, DOI 10.1093/nar/gkq1138; Andre ND, 2008, BLOOD CELL MOL DIS, V40, P227, DOI 10.1016/j.bcmd.2007.08.005; Askarian-Amiri ME, 2011, RNA, V17, P878, DOI 10.1261/rna.2528811; Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; BEDFORD M, 1995, DNA CELL BIOL, V14, P295, DOI 10.1089/dna.1995.14.295; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Benetatos L, 2011, INT J CANCER, V129, P773, DOI 10.1002/ijc.26052; Berteaux N, 2008, MOL CELL BIOL, V28, P6731, DOI 10.1128/MCB.02103-07; Blin-Wakkach C, 2001, P NATL ACAD SCI USA, V98, P7336, DOI 10.1073/pnas.131497098; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Braconi C, 2011, P NATL ACAD SCI USA, V108, P786, DOI 10.1073/pnas.1011098108; Buck AH, 2010, RNA, V16, P307, DOI 10.1261/rna.1819210; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Calin GA, 2007, CANCER CELL, V12, P215, DOI 10.1016/j.ccr.2007.07.027; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Castelnuovo M, 2010, FASEB J, V24, P4033, DOI 10.1096/fj.10-157032; Cayre A, 2003, BREAST CANCER RES, V5, pR223, DOI 10.1186/bcr652; Cazalla D, 2010, SCIENCE, V328, P1563, DOI 10.1126/science.1187197; Chan AS, 2002, ONCOGENE, V21, P3029, DOI 10.1038/sj.onc.1205460; Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674; Chen LL, 2009, MOL CELL, V35, P467, DOI 10.1016/j.molcel.2009.06.027; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Chetcuti A, 2011, PEDIATR BLOOD CANCER, V57, P950, DOI 10.1002/pbc.23003; Chu YJ, 2010, NUCLEIC ACIDS RES, V38, P7736, DOI 10.1093/nar/gkq648; Clark MB, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000625; Colley SM, 2009, CRIT REV BIOCHEM MOL, V44, P25, DOI [10.1080/10409230802661719 , 10.1080/10409230802661719]; Cordaux R, 2009, NAT REV GENET, V10, P691, DOI 10.1038/nrg2640; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Davison EJ, 2005, GENE CHROMOSOME CANC, V44, P384, DOI 10.1002/gcc.20252; Day JR, 2011, CANCER LETT, V301, P1, DOI 10.1016/j.canlet.2010.10.019; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Dinger ME, 2009, NUCLEIC ACIDS RES, V37, pD122, DOI 10.1093/nar/gkn617; Dinger ME, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000176; Drewell RA, 2002, DEVELOPMENT, V129, P1205; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Fiegl H, 2008, INT J CANCER, V123, P725, DOI 10.1002/ijc.23563; Foulds Charles E, 2010, Mol Endocrinol, V24, P1090, DOI 10.1210/me.2009-0427; Franco-Zorrilla JM, 2007, NAT GENET, V39, P1033, DOI 10.1038/ng2079; Frey UH, 2010, EUR J MED RES, V15, P422, DOI 10.1186/2047-783X-15-10-422; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gardner PP, 2009, NUCLEIC ACIDS RES, V37, pD136, DOI 10.1093/nar/gkn766; Gibb EA, 2011, ORAL ONCOL; Ginger MR, 2006, P NATL ACAD SCI USA, V103, P5781, DOI 10.1073/pnas.0600745103; Gopinath SCB, 2005, NUCLEIC ACIDS RES, V33, P4874, DOI 10.1093/nar/gki809; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hancock AL, 2007, HUM MOL GENET, V16, P343, DOI 10.1093/hmg/ddl478; Hanson S, 2003, MOL MICROBIOL, V49, P1627, DOI 10.1046/j.1365-2958.2003.03656.x; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; He HL, 2009, CANCER RES, V69, P625, DOI 10.1158/0008-5472.CAN-08-1071; Hermann T, 2003, BIOPOLYMERS, V70, P4, DOI 10.1002/bip.10410; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39; Iacoangeli A, 2004, CARCINOGENESIS, V25, P2125, DOI 10.1093/carcin/bgh228; Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020; Jacquot C, 2004, INT J ONCOL, V25, P519; Jeon Y, 2011, CELL, V146, P119, DOI 10.1016/j.cell.2011.06.026; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kanduri C, 2011, SEMIN CELL DEV BIOL, V22, P343, DOI 10.1016/j.semcdb.2011.02.020; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Kawasaki H, 2004, NATURE, V431, P211, DOI 10.1038/nature02889; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kim YS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-576; Kin T, 2007, NUCLEIC ACIDS RES, V35, pD145, DOI 10.1093/nar/gkl837; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Klein U, 2010, CANCER CELL, V17, P28, DOI 10.1016/j.ccr.2009.11.019; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Korneev SA, 2008, RNA, V14, P2030, DOI 10.1261/rna.1084308; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar MS, 2011, BLOOD, V118, P4666, DOI 10.1182/blood-2010-12-324715; Lanz RB, 2003, MOL CELL BIOL, V23, P7163, DOI 10.1128/MCB.23.20.7163-7176.2003; Laverty HG, 2009, CYTOKINE GROWTH F R, V20, P305, DOI 10.1016/j.cytogfr.2009.07.002; Lee GL, 2011, NAT REV UROL, V8, P123, DOI 10.1038/nrurol.2011.10; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Leveille N, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1519; Li J, 1997, GENE, V184, P169, DOI 10.1016/S0378-1119(96)00591-4; Li J, 1997, AM J PATHOL, V150, P1297; Li KG, 2010, BLOOD, V115, P133, DOI 10.1182/blood-2009-09-242180; Li L, 2009, P NATL ACAD SCI USA, V106, P12956, DOI 10.1073/pnas.0906005106; Li T, 2000, GENOMICS, V69, P295, DOI 10.1006/geno.2000.6337; Liu AY, 1997, GENOMICS, V39, P171, DOI 10.1006/geno.1996.4463; Liu CN, 2005, NUCLEIC ACIDS RES, V33, pD112, DOI 10.1093/nar/gki041; Lujambio A, 2010, ONCOGENE, V29, P6390, DOI 10.1038/onc.2010.361; Madamanchi NR, 2002, BBA-GENE STRUCT EXPR, V1576, P237, DOI 10.1016/S0167-4781(02)00308-1; Maida Y, 2009, NATURE, V461, P230, DOI 10.1038/nature08283; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; Malleter M, 2010, INT J MOL MED, V25, P897, DOI 10.3892/ijmm_00000420; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Martianov I, 2007, NATURE, V445, P666, DOI 10.1038/nature05519; Martick M, 2008, NATURE, V454, P899, DOI 10.1038/nature07117; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Matouk IJ, 2009, EUR J GASTROEN HEPAT, V21, P688, DOI 10.1097/MEG.0b013e328306a3a2; Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Mestdagh P, 2010, ONCOGENE, V29, P3583, DOI 10.1038/onc.2010.106; Mishra A, 2009, NEUROBIOL DIS, V36, P26, DOI 10.1016/j.nbd.2009.06.010; Mondal T, 2010, GENOME RES, V20, P899, DOI 10.1101/gr.103473.109; Monti L, 2009, INT J ONCOL, V34, P1099, DOI 10.3892/ijo_00000237; Morris KV, 2010, CELL CYCLE, V9, P2544, DOI 10.4161/cc.9.13.12145; Morris KV, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000258; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nakayama T, 2007, WORLD J GASTROENTERO, V13, P4473; Nelles L, 2003, GENOMICS, V82, P460, DOI 10.1016/S0888-7543(03)00169-1; Ng LJ, 2009, NUCLEIC ACIDS RES, V37, P1152, DOI 10.1093/nar/gkn1030; Noonan FC, 2003, GENOMICS, V81, P58, DOI 10.1016/S0888-7543(02)00023-X; Numata K, 2011, NUCLEIC ACIDS RES, V39, P2649, DOI 10.1093/nar/gkq1201; Okamoto J, 2010, ONCOGENE, V29, P5969, DOI 10.1038/onc.2010.330; Okubo Y, 2002, CLIN EXP METASTAS, V19, P503, DOI 10.1023/A:1020346211686; Oliva J, 2009, EXP MOL PATHOL, V87, P12, DOI 10.1016/j.yexmp.2009.03.006; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Pang KC, 2007, NUCLEIC ACIDS RES, V35, pD178, DOI 10.1093/nar/gkl926; Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026; Pasic I, 2010, CANCER RES, V70, P160, DOI 10.1158/0008-5472.CAN-09-1902; Perez DS, 2008, HUM MOL GENET, V17, P642, DOI 10.1093/hmg/ddm336; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Potter SS, 1998, MAMM GENOME, V9, P799, DOI 10.1007/s003359900870; POTTS JD, 1992, DEV DYNAM, V193, P340, DOI 10.1002/aja.1001930407; Preker P, 2008, SCIENCE, V322, P1851, DOI 10.1126/science.1164096; Pushechnikov A, 2009, J AM CHEM SOC, V131, P9767, DOI 10.1021/ja9020149; Rees KA, 2007, INT J ONCOL, V31, P893; Reisman D, 1996, GENOMICS, V38, P364, DOI 10.1006/geno.1996.0639; Revet I, 2008, EXP CELL RES, V314, P707, DOI 10.1016/j.yexcr.2007.12.008; Rice KL, 2007, J CLIN INVEST, V117, P865, DOI 10.1172/JCI31861; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Rintala-Maki Nina D, 2009, Gene, V445, P7, DOI 10.1016/j.gene.2009.06.009; Rivera MN, 2009, P NATL ACAD SCI USA, V106, P8338, DOI 10.1073/pnas.0811349106; Rossignol F, 2002, GENE, V299, P135, DOI 10.1016/S0378-1119(02)01049-1; Scaruffi P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-441; Schwartz JC, 2008, NAT STRUCT MOL BIOL, V15, P842, DOI 10.1038/nsmb.1444; Shamovsky Ilya, 2006, Sci STKE, V2006, ppe40, DOI 10.1126/stke.3552006pe40; Shen H, 2011, BREAST CANCER RES TR, V128, P855, DOI 10.1007/s10549-011-1395-4; Silva JM, 2010, GENOMICS, V95, P355, DOI 10.1016/j.ygeno.2010.02.009; Sliwinski T, 2010, CANCER EPIDEMIOL, V34, P652, DOI 10.1016/j.canep.2010.06.003; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sonkoly E, 2005, J BIOL CHEM, V280, P24159, DOI 10.1074/jbc.M501704200; Spigoni G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008658; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Sunami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018884; Szegedi K, 2010, EXP DERMATOL, V19, P269, DOI 10.1111/j.1600-0625.2010.01066.x; Taft RJ, 2007, BIOESSAYS, V29, P288, DOI 10.1002/bies.20544; Tanaka K, 2001, ONCOLOGY-BASEL, V60, P268, DOI 10.1159/000055328; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; Taskinen M, 2008, AM J MED GENET A, V146A, P2370, DOI 10.1002/ajmg.a.32478; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tochitani S, 2008, BIOCHEM BIOPH RES CO, V372, P691, DOI 10.1016/j.bbrc.2008.05.127; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; van Bakel H, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001102; van Bakel H, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000371; van Bakel Harm, 2009, Briefings in Functional Genomics & Proteomics, V8, P424, DOI 10.1093/bfgp/elp037; Wang F, 2008, FEBS LETT, V582, P1919, DOI 10.1016/j.febslet.2008.05.012; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wang XS, 2006, CLIN CANCER RES, V12, P4851, DOI 10.1158/1078-0432.CCR-06-0134; Washietl S, 2011, RNA, V17, P578, DOI 10.1261/rna.2536111; Weakley SM, 2011, WORLD J SURG, V35, P1751, DOI 10.1007/s00268-010-0951-0; Werstuck G, 1998, SCIENCE, V282, P296, DOI 10.1126/science.282.5387.296; Williams GT, 2011, BIOCHEM SOC T, V39, P482, DOI 10.1042/BST0390482; Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901; Wilusz JE, 2008, CELL, V135, P919, DOI 10.1016/j.cell.2008.10.012; Wojcik SE, 2010, CARCINOGENESIS, V31, P208, DOI 10.1093/carcin/bgp209; Yan MD, 2005, HUM MOL GENET, V14, P1465, DOI 10.1093/hmg/ddi156; Yang RX, 2008, CARCINOGENESIS, V29, P351, DOI 10.1093/carcin/bgm290; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Yochum GS, 2007, J BIOL CHEM, V282, P871, DOI 10.1074/jbc.M609391200; Yoon A, 2011, NUCLEIC ACIDS RES, V39, P8078, DOI 10.1093/nar/gkr492; Yoshimizu T, 2008, P NATL ACAD SCI USA, V105, P12417, DOI 10.1073/pnas.0801540105; Yotova IY, 2008, GENOMICS, V92, P464, DOI 10.1016/j.ygeno.2008.08.004; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang XQ, 2009, BLOOD, V113, P2526, DOI 10.1182/blood-2008-06-162164; Zhang X, 2010, ENDOCRINOLOGY, V151, P939, DOI 10.1210/en.2009-0657; Zhang Y, 2010, RNA, V16, P1889, DOI 10.1261/rna.2226910	187	840	910	3	220	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4577	4587		10.1038/onc.2011.621	http://dx.doi.org/10.1038/onc.2011.621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22266873	Green Accepted, Green Published			2022-12-28	WOS:000310528200001
J	Tessema, M; Yingling, CM; Thomas, CL; Klinge, DM; Bernauer, AM; Liu, Y; Dacic, S; Siegfried, JM; Dahlberg, SE; Schiller, JH; Belinsky, SA				Tessema, M.; Yingling, C. M.; Thomas, C. L.; Klinge, D. M.; Bernauer, A. M.; Liu, Y.; Dacic, S.; Siegfried, J. M.; Dahlberg, S. E.; Schiller, J. H.; Belinsky, S. A.			SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15	ONCOGENE			English	Article						NSCLC; camptothecin; SULF-2; topotecan	ORAL TOPOTECAN; PHASE-II; PROMOTER METHYLATION; ANTITUMOR-ACTIVITY; EXPRESSION; GROWTH; EGFR; RESISTANCE; GENES; ADENOCARCINOMAS	The heparan sulfate 6-O-endosulfatase (SULF2) promotes growth and metastasis of solid tumors. We recently identified that cytosine methylation of the SULF2 promoter is associated with better survival of resected lung adenocarcinoma patients, and now also demonstrates a marginal improvement in survival of advanced non-small cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio = 0.63, P = 0.07). Subsequent studies focused on investigating the effect of methylation on SULF2 expression and its genome-wide impact. The genes and pathways modulated by epigenetic inactivation of SULF2 and the effects on sensitivity to chemotherapy were characterized in vitro and in vivo. Silencing SULF2 through small interfering RNA or methylation primarily increased expression of interferon-inducible genes including ISG15, a marker for increased sensitivity to topoisomerase-1 inhibitors such as camptothecin (CPT). NSCLC cell lines with methylated SULF2 (SULF2M) express 60-fold higher ISG15 compared with SULF2 unmethylated (SULF2U) NSCLC cell lines and normal human bronchial epithelial cells. In vitro, SULF2M and high ISG15 (ISG15H)-expressing NSCLC cell lines were 134-fold more sensitive to CPT than SULF2U and low ISG15 (ISG15L)-expressing cell lines. Topotecan, a soluble analog of CPT and FDA-approved anticancer drug, dramatically arrested the growth of SULF2M-ISG15H, but not SULF2U-ISG15L lung tumors in nude mice (P<0.002). Similarly, high ISG15 expression that is comparable to the topotecan (TPT)-sensitive NSCLC cell lines was found in tumors from 25% of NSCLC patients compared with normal lung, indicating a potential to identify and target the most sensitive NSCLC subpopulation for personalized TPT therapy. Oncogene (2012) 31, 4107-4116; doi: 10.1038/onc.2011.577; published online 12 December 2011	[Tessema, M.; Yingling, C. M.; Thomas, C. L.; Klinge, D. M.; Bernauer, A. M.; Liu, Y.; Belinsky, S. A.] LRRI, Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA; [Dacic, S.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Siegfried, J. M.] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; [Dahlberg, S. E.] Dana Farber Canc Inst, Dept Biostat & Comput Biol, Boston, MA 02115 USA; [Schiller, J. H.] Univ Texas SW, Dept Internal Med, Dallas, TX USA	Lovelace Respiratory Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Belinsky, SA (corresponding author), LRRI, Lovelace Resp Res Inst, Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	sbelinsk@LRRI.org	Dahlberg, Suzanne/L-2622-2019	Dahlberg, Suzanne/0000-0001-5139-831X	NIH [R01 ES008801, CA089551, P50 CA090440]; NATIONAL CANCER INSTITUTE [U24CA114737, R01CA089551, P50CA090440, U10CA023318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008801] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by NIH grants R01 ES008801 and CA089551 to SAB, and P50 CA090440 to JMS.	Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Bishop JR, 2007, NATURE, V446, P1030, DOI 10.1038/nature05817; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2008, MOL CANCER THER, V7, P1430, DOI 10.1158/1535-7163.MCT-07-2345; Duan ZF, 2004, MOL CANCER THER, V3, P833; Gonzalez EE, 2011, INVEST NEW DRUG, V29, P1459, DOI 10.1007/s10637-010-9442-2; Helfrich BA, 2006, CLIN CANCER RES, V12, P7117, DOI 10.1158/1078-0432.CCR-06-0760; Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553; Jones S, 2008, CLIN LUNG CANCER, V9, P154, DOI 10.3816/CLC.2008.n.023; Kalikaki A, 2008, BRIT J CANCER, V99, P923, DOI 10.1038/sj.bjc.6604629; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2010, HEPATOLOGY, V52, P1680, DOI 10.1002/hep.23848; Lemjabbar-Alaoui H, 2010, ONCOGENE, V29, P635, DOI 10.1038/onc.2009.365; Lin CP, 2008, J BIOL CHEM, V283, P21074, DOI 10.1074/jbc.M803493200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; McGuire WP, 2000, J CLIN ONCOL, V18, P1062, DOI 10.1200/JCO.2000.18.5.1062; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Monk BJ, 2009, J CLIN ONCOL, V27, P4649, DOI 10.1200/JCO.2009.21.8909; Morimoto-Tomita M, 2005, NEOPLASIA, V7, P1001, DOI 10.1593/neo.05496; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; O'Brien M, 2007, ONCOLOGIST, V12, P1194, DOI 10.1634/theoncologist.12-10-1194; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Ramlau R, 2006, J CLIN ONCOL, V24, P2800, DOI 10.1200/JCO.2005.03.6491; Sugaya N, 2008, J BIOL CHEM, V283, P10366, DOI 10.1074/jbc.M705948200; Tessema M, 2010, ONCOGENE, V29, P5159, DOI 10.1038/onc.2010.255; Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325; Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114; Uchimura Kenji, 2006, BMC Biochem, V7, P2, DOI 10.1186/1471-2091-7-2; Weitz JJ, 2000, LUNG CANCER-J IASLC, V28, P157, DOI 10.1016/S0169-5002(99)00128-2; White SC, 2000, CLIN CANCER RES, V6, P868	34	37	40	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4107	4116		10.1038/onc.2011.577	http://dx.doi.org/10.1038/onc.2011.577			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158045	Green Accepted			2022-12-28	WOS:000308688900003
J	Villagrasa, P; Diaz, VM; Vinas-Castells, R; Peiro, S; Del Valle-Perez, B; Dave, N; Rodriguez-Asiain, A; Casal, JI; Lizcano, JM; Dunach, M; de Herreros, AG				Villagrasa, P.; Diaz, V. M.; Vinas-Castells, R.; Peiro, S.; Del Valle-Perez, B.; Dave, N.; Rodriguez-Asiain, A.; Casal, J. I.; Lizcano, J. M.; Dunach, M.; Garcia de Herreros, A.			Akt2 interacts with Snail1 in the E-cadherin promoter	ONCOGENE			English	Article						Snail1; EMT; Akt; E-cadherin	PROTEIN-KINASE-B; EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; NF-KAPPA-B; COLORECTAL-CANCER; HISTONE H3; GENE-EXPRESSION; DISTINCT ROLES; UP-REGULATION; ACTIVATION	Snail1 is a transcriptional factor essential for triggering epithelial-to-mesenchymal transition. Moreover, Snail1 promotes resistance to apoptosis, an effect associated to PTEN gene repression and Akt stimulation. In this article we demonstrate that Snail1 activates Akt at an additional level, as it directly binds to and activates this protein kinase. The interaction is observed in the nucleus and increases the intrinsic Akt activity. We determined that Akt2 is the isoform interacting with Snail1, an association that requires the pleckstrin homology domain in Akt2 and the C-terminal half in Snail1. Snail1 enhances the binding of Akt2 to the E-cadherin (CDH1) promoter and Akt2 interference prevents Snail1 repression of CDH1 gene. We also show that Snail1 binding increases Akt2 intrinsic activity on histone H3 and have identified Thr45 as a residue modified on this protein. Phosphorylation of Thr45 in histone H3 is sensitive to Snail1 and Akt2 cellular levels; moreover, Snail1 upregulates the binding of phosphoThr45 histone H3 to the CDH1 promoter. These results uncover an unexpected role of Akt2 in transcriptional control and point out to phosphorylation of Thr45 in histone H3 as a new epigenetic mark related to Snail1 and Akt2 action. Oncogene (2012) 31, 4022-4033; doi:10.1038/onc.2011.562; published online 12 December 2011	[Villagrasa, P.; Del Valle-Perez, B.; Dunach, M.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Med, Unitat Biofis CEB, E-08193 Bellaterra, Spain; [Villagrasa, P.; Diaz, V. M.; Vinas-Castells, R.; Peiro, S.; Dave, N.; Garcia de Herreros, A.] IMIM Hosp Mar, Programa Recerca Canc, Barcelona, Spain; [Diaz, V. M.; Garcia de Herreros, A.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Rodriguez-Asiain, A.; Lizcano, J. M.] Univ Autonoma Barcelona, Fac Med, Inst Neurociencia, Bellaterra, Spain; [Rodriguez-Asiain, A.; Lizcano, J. M.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Med, Bellaterra, Spain; [Casal, J. I.] Ctr Invest Biol CSIC, Madrid, Spain	Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Autonomous University of Barcelona; Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Dunach, M (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Med, Unitat Biofis CEB, E-08193 Bellaterra, Spain.	mireia.dunach@uab.cat; agarcia@imim.es	Díaz, Víctor Manuel/F-5013-2016; Viñas-Castells, Rosa/J-7722-2017; Casal, Ignacio/M-2312-2014; de Herreros, A Garcia/H-3104-2014; Lizcano, Jose M/E-6080-2010; Dunach, Mireia/E-3604-2015; lizcano, jose m/AAK-3577-2020	Díaz, Víctor Manuel/0000-0001-8561-7576; Viñas-Castells, Rosa/0000-0003-0610-4495; Casal, Ignacio/0000-0003-1085-2840; de Herreros, A Garcia/0000-0001-5270-0808; Lizcano, Jose M/0000-0002-3154-5383; Dunach, Mireia/0000-0001-9844-5603; lizcano, jose m/0000-0002-3154-5383; Villagrasa-Gonzalez, Patricia/0000-0002-8662-3641; Peiro, Sandra/0000-0001-9519-3877	Ministerio de Ciencia e Innovacion [BFU2006-03203, BFU2009-07578, SAF2006-00339, SAF2010-16089]; Fundacio La Marato de TV3; Instituto Carlos III-Fondos FEDER (RTICCC) [C03710, RD06/0020/0040]; Generalitat de Catalunya [2009SGR867]; predoctoral fellowship from the Ministerio de Ciencia y Tecnologia; predoctoral fellowship from the Instituto Carlos III	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacio La Marato de TV3; Instituto Carlos III-Fondos FEDER (RTICCC); Generalitat de Catalunya(Generalitat de Catalunya); predoctoral fellowship from the Ministerio de Ciencia y Tecnologia; predoctoral fellowship from the Instituto Carlos III	We are grateful to Neus Ontiveros for technical help; Dr David Casagolda for assistance with confocal microscopy; and Drs Lionel Larue and Alberto Munoz for reagents. This study was supported by grants awarded by the Ministerio de Ciencia e Innovacion (BFU2006-03203 and BFU2009-07578 to MD and SAF2006-00339 and SAF2010-16089 to AGH) and Fundacio La Marato de TV3 (to AGH). The partial support from the Instituto Carlos III-Fondos FEDER (RTICCC, C03710, RD06/0020/0040) and the Generalitat de Catalunya (2009SGR867) is also appreciated. PV and RV-C were supported by predoctoral fellowships from the Ministerio de Ciencia y Tecnologia and Instituto Carlos III, respectively.	AHMED NN, 1993, ONCOGENE, V8, P1957; Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arboleda MJ, 2003, CANCER RES, V63, P196; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cho HJ, 2007, BIOCHEM BIOPH RES CO, V353, P337, DOI 10.1016/j.bbrc.2006.12.035; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Gao HD, 2007, MOL CELL BIOCHEM, V305, P35, DOI 10.1007/s11010-007-9525-3; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Grille SJ, 2003, CANCER RES, V63, P2172; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Herranz N, 2008, MOL CELL BIOL, V28, P3198; Hurd PJ, 2009, J BIOL CHEM, V284, P16575, DOI 10.1074/jbc.M109.005421; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Peiro S, 2006, NUCLEIC ACIDS RES, V34, P2077, DOI 10.1093/nar/gkl141; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Raurell I, 2006, J BIOL CHEM, V281, P1401, DOI 10.1074/jbc.M508153200; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	50	23	24	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					4022	4033		10.1038/onc.2011.562	http://dx.doi.org/10.1038/onc.2011.562			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158034				2022-12-28	WOS:000308688800003
J	Shah, PP; Fong, MY; Kakar, SS				Shah, P. P.; Fong, M. Y.; Kakar, S. S.			PTTG induces EMT through integrin alpha(V)beta(3)-focal adhesion kinase signaling in lung cancer cells	ONCOGENE			English	Article						PTTG; securin; lung cancer	TUMOR-TRANSFORMING GENE; EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASE-2 MMP-2; GROWTH-FACTOR-I; OVARIAN-CANCER; BREAST-CANCER; ALPHA-V-BETA-3 INTEGRIN; EXPRESSION; PROGRESSION; METASTASIS	Pituitary tumor transforming gene (PTTG) is a well-studied oncogene for its role in tumorigenesis and serves as a marker of malignancy in several cancer types including lung. In the present study, we defined the role of PTTG in actin cytoskeleton remodeling, cell migration and induction of epithelial mesenchymal transition (EMT) through the regulation of integrin alpha(V)beta(3)-FAK (focal adhesion kinase) signaling pathway. Overexpression of PTTG through an adenovirus vector resulted in a significant increase in the expression of integrins alpha(V) and beta(3), a process that was reversed with the downregulation of PTTG expression through the use of an adenovirus expressing PTTG-specific small interfering RNA (siRNA). Western blot analysis of cells infected with adenovirus PTTG cDNA resulted in increased FAK and enhanced expression of adhesion complex molecules paxillin, metavincullin, and talin. Furthermore, downstream signaling genes Rac1, RhoA, Cdc42 and DOCK180 showed upregulation upon PTTG overexpression. This process was dependent on integrin alpha(V), as blockage by antagonist echistatin (RGD peptide) or alpha(V)-specific siRNA resulted in a decrease in FAK and subsequent adhesion molecules. Actin cytoskeleton disruption was detected as a result of integrin-FAK signaling by PTTG as well as enhanced cell motility. Taken together, our results suggest for the first time an important role of PTTG in regulation of integrins alpha(V) and beta(3) and adhesion-complex proteins leading to induction of EMT. Oncogene (2012) 31, 3124-3135; doi:10.1038/onc.2011.488; published online 14 November 2011	[Fong, M. Y.; Kakar, S. S.] Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40202 USA; [Shah, P. P.; Kakar, S. S.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Kakar, SS (corresponding author), Univ Louisville, Dept Physiol & Biophys, 505 S Hancock St,CTRB 322, Louisville, KY 40202 USA.	sskaka01@louisville.edu			NCI [CA 124630]; NATIONAL CANCER INSTITUTE [R01CA124630] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Stanley D'Souza for his critical input. The work was supported by a grant from NCI CA 124630 (SSK).	Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911-007-9044-6; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Becam IE, 2005, NAT CELL BIOL, V7, P510, DOI 10.1038/ncb1253; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Blanco D, 2004, LAB INVEST, V84, P999, DOI 10.1038/labinvest.3700129; Chamaon K, 2005, BIOCHEM BIOPH RES CO, V331, P86, DOI 10.1016/j.bbrc.2005.03.124; Chen XY, 2005, NEOPLASIA, V7, P271, DOI 10.1593/neo.04538; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Deng BQ, 2010, MOL CELL BIOCHEM, V340, P21, DOI 10.1007/s11010-010-0396-7; El-Naggar SM, 2007, INT J ONCOL, V31, P137; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Firrincieli D, 2010, GASTROEN CLIN BIOL, V34, P523, DOI 10.1016/j.gcb.2010.04.017; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; Guillou H, 2008, EXP CELL RES, V314, P478, DOI 10.1016/j.yexcr.2007.10.026; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Heaney AP, 1999, BEST PRACT RES CL EN, V13, P367, DOI 10.1053/beem.1999.0028; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Honda S, 2003, ANTICANCER RES, V23, P3775; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Huveneers S, 2008, J BIOL CHEM, V283, P13243, DOI 10.1074/jbc.M800927200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jarzynka NJ, 2007, CANCER RES, V67, P7203, DOI 10.1158/0008-5472.CAN-07-0473; Jung CR, 2006, HEPATOLOGY, V43, P1042, DOI 10.1002/hep.21137; Kakar SS, 2006, INT J ONCOL, V29, P387; Kakar SS, 1999, CYTOGENET CELL GENET, V84, P211, DOI 10.1159/000015261; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Lee IA, 1999, BIOCHEM MOL BIOL INT, V47, P891; Liang HS, 2010, INT J BIOL MARKER, V25, P38, DOI 10.1177/172460081002500106; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Malik MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-61; Martin KH, 2002, CELL MOTIL CYTOSKEL, V51, P76, DOI 10.1002/cm.10018; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mercado-Pimentel ME, 2007, CELLS TISSUES ORGANS, V185, P146, DOI 10.1159/000101315; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Ning SC, 2010, CANCER RES, V70, P7591, DOI 10.1158/0008-5472.CAN-10-1639; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; Panguluri SK, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-577; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Ross RS, 2004, CARDIOVASC RES, V63, P381, DOI 10.1016/j.cardiores.2004.04.027; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P99; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Taneyhill LA, 2007, DEVELOPMENT, V134, P1481, DOI 10.1242/dev.02834; Tang Ming-hua, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P1712; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tsai SJ, 2005, J CLIN ENDOCR METAB, V90, P3715, DOI 10.1210/jc.2004-2303; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; Wang H, 2010, TUMOR BIOL, V31, P59, DOI 10.1007/s13277-009-0009-9; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zheng DQ, 1999, CANCER RES, V59, P1655; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; ZUK A, 1994, DEV DYNAM, V201, P378, DOI 10.1002/aja.1002010409	82	57	59	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	26					3124	3135		10.1038/onc.2011.488	http://dx.doi.org/10.1038/onc.2011.488			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22081074	Green Accepted			2022-12-28	WOS:000305934400002
J	Wang, C; Youle, RJ				Wang, C.; Youle, R. J.			Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak	ONCOGENE			English	Article						HCT116; Bax; Bak; DKO; BH3-only; apoptosis	BH3 MIMETIC ABT-737; BCL-2 HOMOLOG BAX; MITOCHONDRIAL PATHWAY; MEDIATED APOPTOSIS; BH3-ONLY PROTEINS; TRAIL; DEATH; RESISTANCE; NBK/BIK; GENE	The intrinsic mitochondrial apoptotic pathway acts through two core pro-apoptotic proteins Bax (Bcl2-associated X protein) and Bak (Bcl2-antagonist/killer 1). Although Bax and Bak seem to have redundant roles in apoptosis, accumulating evidence also suggests that they might not be interchangeable under certain conditions, at least in some human cell lines. Here we report the generation of Bak knockout as well as BaxBak double knockout HCT116 human colon carcinoma cells. We show that Bak is dispensable for apoptosis induced by a variety of stimuli including ABT-737 but not for fluorouracil-induced apoptosis. In addition, Bax deficiency only provides partial protection against camptothecin and cisplatin-induced apoptosis and no protection against killing by Puma or ABT-737 plus Noxa overexpression. Moreover, Bak is activated normally in response to many chemotherapeutic drugs in the presence of Bax, but remains kept in check by Mcl-1 in the absence of Bax. Our data suggest that Bax and Bak are functionally redundant, but they are counteracted by distinct anti-apoptotic Bcl-2 family proteins in different species. Oncogene (2012) 31, 3177-3189; doi:10.1038/onc.2011.497; published online 7 November 2011	[Youle, R. J.] Natl Inst Neurol Disorders & Stroke, Biochem Sect, Surg Neurol Branch, NIH,SNB,NINDS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), Natl Inst Neurol Disorders & Stroke, Biochem Sect, Surg Neurol Branch, NIH,SNB,NINDS, Bldg 35,Room 2C917,35 Lincoln Dr, Bethesda, MD 20892 USA.	youler@ninds.nih.gov	Wang, Chunxin/B-9312-2016	Wang, Chunxin/0000-0001-6015-6806	National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859] Funding Source: NIH RePORTER	National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Bert Vogelstein for Bax KO HCT116 cells, Fred Bunz for pSEPT vector and advice on gene targeting, Jean-Claude Martinou for comments on the manuscript, NINDS DNA sequencing facility, NINDS imaging facility and NINDS FACS facility. This study is supported in part by the Intramural Research Program of the National Institutes of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH).	Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cleland MM, 2011, CELL DEATH DIFFER, V18, P235, DOI 10.1038/cdd.2010.89; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Dunn SR, 2006, J MOL EVOL, V63, P95, DOI 10.1007/s00239-005-0236-7; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040; Gillissen B, 2010, J CELL BIOL, V188, P851, DOI 10.1083/jcb.200912070; Jiang M, 2009, AM J PHYSIOL-RENAL, V296, pF983, DOI 10.1152/ajprenal.90579.2008; Kagawa S, 2001, CANCER RES, V61, P3330; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kratz E, 2006, CELL DEATH DIFFER, V13, P1631, DOI 10.1038/sj.cdd.4402016; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lee EF, 2008, J CELL BIOL, V180, P341, DOI 10.1083/jcb.200708096; Lindenboim L, 2005, CELL DEATH DIFFER, V12, P713, DOI 10.1038/sj.cdd.4401638; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773; Otera H, 2010, J CELL BIOL, V191, P1141, DOI 10.1083/jcb.201007152; Shimazu T, 2007, GENE DEV, V21, P929, DOI 10.1101/gad.1522007; Theodorakis P, 2002, CANCER RES, V62, P3373; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zmasek CM, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r226; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	35	88	89	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3177	3189		10.1038/onc.2011.497	http://dx.doi.org/10.1038/onc.2011.497			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22056880	Green Accepted			2022-12-28	WOS:000305934400006
J	Hsu, T				Hsu, T.			Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms	ONCOGENE			English	Review						VHL; HIF; model organisms	HYPOXIA-INDUCIBLE FACTOR; VHL GENE; CONDITIONAL INACTIVATION; VASCULAR TUMORS; HIF-ALPHA; PROTEIN; DROSOPHILA; OXYGEN; PVHL; MUTATION	The von Hippel-Lindau tumor suppressor gene (VHL) has attracted intensive interest not only because its mutations predispose carriers to devastating tumors, but also because it is involved in oxygen sensing under physiological conditions. VHL loss-of-function mutations result in organ-specific tumors, such as hemangioblastoma of the central nervous system and renal cell carcinoma, both untreatable with conventional chemotherapies. The VHL protein is best known as an E3 ubiquitin ligase that targets hypoxia-inducible factor-alpha (HIF-alpha), but many diverse, non-canonical cellular functions have also been assigned to VHL, mainly based on studies in cell culture systems. As such, although the HIF-dependent role of VHL is critical, the full spectrum of pathophysiological functions of VHL is still unresolved. Such understanding requires careful cross-referencing with physiologically relevant experimental models. Studies in model systems, such as Caenorhabditis elegans, Drosophila, zebrafish and mouse have provided critical in vivo confirmation of the VHL-HIF pathway, and verification of potentially important cellular functions including microtubule stabilization and epithelial morphogenesis. More recently, animal models have also suggested systemic roles of VHL in hematopoiesis, metabolic homeostasis and inflammation. In this review, the studies performed in model organisms will be summarized and placed in context with existing clinical and in vitro data. Oncogene (2012) 31, 2247-2257; doi:10.1038/onc.2011.442; published online 26 September 2011	Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University	Hsu, T (corresponding author), Boston Univ, Sch Med, Dept Med, 650 Albany St,Rm 440, Boston, MA 02118 USA.	tienh@bu.edu		Hsu, Tien/0000-0003-2308-4297	National Cancer Institute (USA) [RO1CA109860]; NATIONAL CANCER INSTITUTE [R01CA109860] Funding Source: NIH RePORTER	National Cancer Institute (USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Cancer Institute (USA) grant (RO1CA109860).	Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Akis N, 2004, KIDNEY INT, V65, P2223, DOI 10.1111/j.1523-1755.2004.00634.x; Alexander A, 2011, FEBS LETT, V585, P952, DOI 10.1016/j.febslet.2011.03.010; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Aso T, 2000, BIOCHEM BIOPH RES CO, V276, P355, DOI 10.1006/bbrc.2000.3451; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bartolini F, 2006, J CELL SCI, V119, P4155, DOI 10.1242/jcs.03227; Behr M, 2007, NAT CELL BIOL, V9, P847, DOI 10.1038/ncb1611; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Biju MP, 2004, MOL CELL BIOL, V24, P9038, DOI 10.1128/MCB.24.20.9038-9047.2004; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; BRAUCH H, 1995, HUM GENET, V95, P551, DOI 10.1007/BF00223868; Brukamp K, 2007, AM J PHYSIOL-RENAL, V293, pF1397, DOI 10.1152/ajprenal.00133.2007; Bushuev VI, 2006, HAEMATOLOGICA, V91, P744; Centanin L, 2008, DEV CELL, V14, P547, DOI 10.1016/j.devcel.2008.01.020; Champion KJ, 2008, CANCER RES, V68, P4649, DOI 10.1158/0008-5472.CAN-07-6003; Cho D, 2007, CLIN CANCER RES, V13, p758S, DOI 10.1158/1078-0432.CCR-06-1986; Clark PE, 2009, KIDNEY INT, V76, P939, DOI 10.1038/ki.2009.296; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Dammai V, 2003, GENE DEV, V17, P2812, DOI 10.1101/gad.1096903; Danilin S, 2009, CARCINOGENESIS, V30, P387, DOI 10.1093/carcin/bgn275; Datta K, 2005, ONCOGENE, V24, P7850, DOI 10.1038/sj.onc.1208912; Doronkin S, 2010, ONCOGENE, V29, P1123, DOI 10.1038/onc.2009.407; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Duchi S, 2010, DEVELOPMENT, V137, P1493, DOI 10.1242/dev.042804; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181; Feijoo-Cuaresma M, 2008, J BIOL CHEM, V283, P24982, DOI 10.1074/jbc.M709390200; Frew IJ, 2008, EMBO J, V27, P1747, DOI 10.1038/emboj.2008.96; Frew IJ, 2008, MOL CELL BIOL, V28, P4536, DOI 10.1128/MCB.02132-07; Frew IJ, 2007, CURR OPIN CELL BIOL, V19, P685, DOI 10.1016/j.ceb.2007.10.001; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; GAO JZ, 1995, CANCER RES, V55, P743; Ghabrial A, 2003, ANNU REV CELL DEV BI, V19, P623, DOI 10.1146/annurev.cellbio.19.031403.160043; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; Gordeuk VR, 2004, BLOOD, V103, P3924, DOI 10.1182/blood-2003-07-2535; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guo Y, 2009, ONCOGENE, V28, P1864, DOI 10.1038/onc.2009.35; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Harten SK, 2009, MOL BIOL CELL, V20, P1089, DOI 10.1091/mbc.E08-06-0566; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hickey MM, 2010, J CLIN INVEST, V120, P827, DOI 10.1172/JCI36362; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Hong SB, 2006, LAB INVEST, V86, P664, DOI 10.1038/labinvest.3700431; Hsouna A, 2010, MOL CELL BIOL, V30, P3779, DOI 10.1128/MCB.01578-09; Hsu T, 2006, J BIOL CHEM, V281, P12069, DOI 10.1074/jbc.M511621200; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Kaelin WG, 2005, COLD SH Q B, V70, P159, DOI 10.1101/sqb.2005.70.001; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; KESSLER PM, 1995, MOL MED, V1, P457, DOI 10.1007/BF03401583; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kimura K, 2008, AM J PHYSIOL-RENAL, V295, pF1023, DOI 10.1152/ajprenal.90209.2008; Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006; Kurban G, 2008, ONCOGENE, V27, P1004, DOI 10.1038/sj.onc.1210709; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Ma WB, 2003, CANCER RES, V63, P5320; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; McDonald JA, 2003, DEVELOPMENT, V130, P3469, DOI 10.1242/dev.00574; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Montell DJ, 2003, NAT REV MOL CELL BIO, V4, P13, DOI 10.1038/nrm1006; Mortimer NT, 2009, DEV BIOL, V329, P294, DOI 10.1016/j.ydbio.2009.03.001; Muller RU, 2009, J AM SOC NEPHROL, V20, P2513, DOI 10.1681/ASN.2009050497; Nallamothu G, 2008, MOL CELL BIOL, V28, P1964, DOI 10.1128/MCB.01743-07; Nallamothu G, 2009, MOL CELL BIOCHEM, V329, P35, DOI 10.1007/s11010-009-0112-7; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Park DM, 2007, PLOS MED, V4, P333, DOI 10.1371/journal.pmed.0040060; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pfander D, 2004, DEVELOPMENT, V131, P2497, DOI 10.1242/dev.01138; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Rorth P, 2002, TRENDS CELL BIOL, V12, P325, DOI 10.1016/S0962-8924(02)02311-5; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Shen C, 2005, J BIOL CHEM, V280, P20580, DOI 10.1074/jbc.M501894200; Shen HCJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004897; Smith TG, 2006, PLOS MED, V3, P1178, DOI 10.1371/journal.pmed.0030290; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stenmark KR, 2006, CIRC RES, V99, P675, DOI 10.1161/01.RES.0000243584.45145.3f; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020; Tang N, 2006, MOL CELL BIOL, V26, P2519, DOI 10.1128/MCB.26.7.2519-2530.2006; Thoma CR, 2007, NAT CELL BIOL, V9, P588, DOI 10.1038/ncb1579; Thoma CR, 2009, NAT CELL BIOL, V11, P994, DOI 10.1038/ncb1912; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tsarouhas V, 2007, DEV CELL, V13, P214, DOI 10.1016/j.devcel.2007.06.008; Uv A, 2003, TRENDS CELL BIOL, V13, P301, DOI 10.1016/S0962-8924(03)00083-7; van der Velden YU, 2011, P NATL ACAD SCI USA, V108, P4358, DOI 10.1073/pnas.1010210108; van Rooijen E, 2010, DIS MODEL MECH, V3, P343, DOI 10.1242/dmm.004036; van Rooijen E, 2009, BLOOD, V113, P6449, DOI 10.1182/blood-2008-07-167890; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; Wang Y, 2009, NAT MED, V15, P319, DOI 10.1038/nm.1922; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Woodward ER, 2000, GENOMICS, V65, P253, DOI 10.1006/geno.2000.6144; Woolworth JA, 2009, MOL CELL BIOL, V29, P4679, DOI 10.1128/MCB.00297-09; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yaqoob N, 2010, COMP BIOCHEM PHYS A, V156, P475, DOI 10.1016/j.cbpa.2010.03.033; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zehetner J, 2008, GENE DEV, V22, P3135, DOI 10.1101/gad.496908; ZLOTOGORA J, 1994, AM J MED GENET, V49, P10, DOI 10.1002/ajmg.1320490104	113	32	36	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2247	2257		10.1038/onc.2011.442	http://dx.doi.org/10.1038/onc.2011.442			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21996733	Green Accepted			2022-12-28	WOS:000303610800001
J	Stiehl, DP; Bordoli, MR; Abreu-Rodriguez, I; Wollenick, K; Schraml, P; Gradin, K; Poellinger, L; Kristiansen, G; Wenger, RH				Stiehl, D. P.; Bordoli, M. R.; Abreu-Rodriguez, I.; Wollenick, K.; Schraml, P.; Gradin, K.; Poellinger, L.; Kristiansen, G.; Wenger, R. H.			Non-canonical HIF-2 alpha function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop	ONCOGENE			English	Article						hypoxic expression profiles; luminal breast cancer; growth factors; HIF target genes; EGF signaling	HYPOXIA-INDUCIBLE FACTOR-2-ALPHA; TRANSCRIPTIONAL REGULATION; FACTOR (HIF)-1-ALPHA; GENE-EXPRESSION; TARGET GENES; DNA-BINDING; IN-VIVO; HIF-1-ALPHA; CARCINOMA; TUMORIGENESIS	Tumor progression is intrinsically tied to the clonal selection of tumor cells with acquired phenotypes allowing to cope with a hostile microenvironment. Hypoxia-inducible factors (HIFs) master the transcriptional response to local tissue hypoxia, a hallmark of solid tumors. Here, we report significantly longer patient survival in breast cancer with high levels of HIF-2 alpha. Amphiregulin (AREG) and WNT1-inducible signaling pathway protein-2 (WISP2) expression was strongly HIF-2 alpha-dependent and their promoters were particularly responsive to HIF-2 alpha. The endogenous AREG promoter recruited HIF-2 alpha in the absence of a classical HIF-DNA interaction motif, revealing a novel mechanism of gene regulation. Loss of AREG expression in HIF-2 alpha-depleted cells was accompanied by reduced activation of epidermal growth factor (EGF) receptor family members. Apparently opposing results from patient and in vitro data point to an HIF-2 alpha-dependent auto-stimulatory tumor phenotype that, while promoting EGF signaling in cellular models, increased the survival of diagnosed and treated human patients. Our findings suggest a model where HIF-2 alpha-mediated autocrine growth signaling in breast cancer sustains a state of cellular self-sufficiency, thereby masking unfavorable microenvironmental growth conditions, limiting adverse selection and improving therapy efficacy. Importantly, HIF-2 alpha/AREG/WISP2-expressing tumors were associated with luminal tumor differentiation, indicative of a better response to classical treatments. Shifting the HIF-1/2 alpha balance toward an HIF-2-dominated phenotype could thus offer a novel approach in breast cancer therapy. Oncogene (2012) 31, 2283-2297; doi:10.1038/onc.2011.417; published online 19 September 2011	[Stiehl, D. P.; Bordoli, M. R.; Abreu-Rodriguez, I.; Wollenick, K.; Wenger, R. H.] Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; [Stiehl, D. P.; Bordoli, M. R.; Abreu-Rodriguez, I.; Wollenick, K.; Wenger, R. H.] Univ Zurich, Zurich Ctr Human Physiol ZIHP, CH-8057 Zurich, Switzerland; [Schraml, P.] Univ Zurich Hosp, Dept Surg Pathol, CH-8091 Zurich, Switzerland; [Gradin, K.; Poellinger, L.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden; [Poellinger, L.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore; [Kristiansen, G.] Univ Hosp Bonn, Inst Pathol, Bonn, Germany	University of Zurich; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); University of Zurich; University Zurich Hospital; Karolinska Institutet; National University of Singapore; University of Bonn	Stiehl, DP (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	daniel.stiehl@uzh.ch	Wenger, Roland H./B-7953-2009; Stiehl, Daniel/A-3622-2008	Wenger, Roland H./0000-0001-7592-4839; Stiehl, Daniel/0000-0002-0076-4874; Bordoli, Mattia/0000-0001-6917-8753	Swiss National Science Foundation [31003A_129962/1]; Swedish Cancer Society; European Union, Metoxia; COST Action [TD0901 HypoxiaNet]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swedish Cancer Society(Swedish Cancer Society); European Union, Metoxia; COST Action(European Cooperation in Science and Technology (COST))	We thank M Sabbah, SB Lee, S Pastorekova, C Pugh and PJ Ratcliffe for providing materials and primer information. This work was supported by the Swiss National Science Foundation grant 31003A_129962/1 (to RHW and DPS), the Swedish Cancer Society and European Union, Metoxia (to LP), and the COST Action TD0901 HypoxiaNet.	Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Banerjee S, 2008, CANCER RES, V68, P7606, DOI 10.1158/0008-5472.CAN-08-1461; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bordoli MR, 2011, ONCOGENE, V30, P548, DOI 10.1038/onc.2010.433; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Franovic A, 2009, P NATL ACAD SCI USA, V106, P21306, DOI 10.1073/pnas.0906432106; Fritah A, 2008, MOL CELL BIOL, V28, P1114, DOI 10.1128/MCB.01335-07; Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922; Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008-5472.CAN-08-3658; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Helczynska K, 2008, CANCER RES, V68, P9212, DOI 10.1158/0008-5472.CAN-08-1135; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kim HS, 2007, J BIOL CHEM, V282, P16278, DOI 10.1074/jbc.M700215200; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lehmann S, 2009, P NATL ACAD SCI USA, V106, P14004, DOI 10.1073/pnas.0901194106; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Loeb DM, 2001, CANCER RES, V61, P921; Mazumdar J, 2010, P NATL ACAD SCI USA, V107, P14182, DOI 10.1073/pnas.1001296107; Minamishima YA, 2009, MOL CELL BIOL, V29, P5729, DOI 10.1128/MCB.00331-09; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; Patel SA, 2008, CELL DEATH DIFFER, V15, P628, DOI 10.1038/cdd.2008.17; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Saito T, 2010, NAT MED, V16, P678, DOI 10.1038/nm.2146; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sowter HM, 2003, CANCER RES, V63, P6130; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Wang V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009641; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wykoff CC, 2000, CANCER RES, V60, P7075; Yamashita T, 2008, J BIOL CHEM, V283, P18926, DOI 10.1074/jbc.M709133200; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153; Yu P, 2007, J BIOL CHEM, V282, P35035, DOI 10.1074/jbc.M707557200	52	55	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	18					2283	2297		10.1038/onc.2011.417	http://dx.doi.org/10.1038/onc.2011.417			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21927022				2022-12-28	WOS:000303610800004
J	Papagiannakopoulos, T; Friedmann-Morvinski, D; Neveu, P; Dugas, JC; Gill, RM; Huillard, E; Liu, C; Zong, H; Rowitch, DH; Barres, BA; Verma, IM; Kosik, KS				Papagiannakopoulos, T.; Friedmann-Morvinski, D.; Neveu, P.; Dugas, J. C.; Gill, R. M.; Huillard, E.; Liu, C.; Zong, H.; Rowitch, D. H.; Barres, B. A.; Verma, I. M.; Kosik, K. S.			Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases	ONCOGENE			English	Article						microRNA; glioma stem cells; miR-128; EGFR; PDGFR alpha	GROWTH-FACTOR RECEPTOR; STEM-CELL; IN-VIVO; MICRORNAS; BRAIN; EGFR; MODULATION; MECHANISMS; RENEWAL; SET	MicroRNAs (miRNAs) carry out post-transcriptional control of a multitude of cellular processes. Aberrant expression of miRNA can lead to diseases, including cancer. Gliomas are aggressive brain tumors that are thought to arise from transformed glioma-initiating neural stem cells (giNSCs). With the use of giNSCs and human glioblastoma cells, we investigated the function of miRNAs in gliomas. We identified pro-neuronal miR-128 as a candidate glioma tumor suppressor miRNA. Decreased expression of miR-128 correlates with aggressive human glioma subtypes. With a combination of molecular, cellular and in vivo approaches, we characterize miR-128's tumor suppressive role. miR-128 represses giNSC growth by enhancing neuronal differentiation. miR-128 represses growth and mediates differentiation by targeting oncogenic receptor tyrosine kinases (RTKs) epithelial growth factor receptor and platelet-derived growth factor receptor-alpha. Using an autochthonous glioma mouse model, we demonstrated that miR-128 repressed gliomagenesis. We identified miR-128 as a glioma tumor suppressor that targets RTK signaling to repress giNSC self-renewal and enhance differentiation. Oncogene (2012) 31, 1884-1895; doi:10.1038/onc.2011.380; published online 29 August 2011	[Papagiannakopoulos, T.; Gill, R. M.; Kosik, K. S.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Papagiannakopoulos, T.; Neveu, P.; Gill, R. M.; Kosik, K. S.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; [Friedmann-Morvinski, D.; Verma, I. M.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; [Neveu, P.] Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA; [Dugas, J. C.; Barres, B. A.] Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; [Huillard, E.; Rowitch, D. H.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Huillard, E.; Rowitch, D. H.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA USA; [Liu, C.; Zong, H.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; [Rowitch, D. H.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA; [Rowitch, D. H.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Salk Institute; University of California System; University of California Santa Barbara; Stanford University; University of California System; University of California San Francisco; University of Oregon; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kosik, KS (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Room 6139A, Santa Barbara, CA 93106 USA.	kosik@lifesci.ucsb.edu	Neveu, Pierre/C-1170-2009; Liu, Chong/J-4826-2014	Liu, Chong/0000-0001-6578-5919; Friedmann-Morvinski, Dinorah/0000-0002-6394-9876; Neveu, Pierre/0000-0003-4939-3418; Rowitch, David/0000-0002-0079-0060	WM Keck Foundation; Miriam and Sheldon Adelson Medical Foundation; National Science Foundation [PHY05-51164]; Myelin Repair Foundation; National Multiple Sclerosis Society; NIH [R55-CA136495, R01-CA136495]; The Pew Charitable Trusts; NATIONAL CANCER INSTITUTE [R01CA136495, R55CA136495] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053670] Funding Source: NIH RePORTER	WM Keck Foundation(W.M. Keck Foundation); Miriam and Sheldon Adelson Medical Foundation; National Science Foundation(National Science Foundation (NSF)); Myelin Repair Foundation; National Multiple Sclerosis Society(National Multiple Sclerosis Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Pew Charitable Trusts; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Israel Hernandez, Diego Piedrahita and Yngo Garcia for providing assistance with animal experiments, and Na Xu, Min Jeong Kye and Cecilia Conaco for scientific conversations and suggestions. Judith Czerny assisted in constructing target 3'-UTR constructs. Support for the project was from the WM Keck Foundation (KSK), the Miriam and Sheldon Adelson Medical Foundation (KSK), the National Science Foundation under grant No. PHY05-51164 (PN), the Myelin Repair Foundation (JCD and BAB), and the National Multiple Sclerosis Society (JCD and BAB). HZ work is supported by NIH grants (R55-CA136495, R01-CA136495). HZ is a Pew Scholar in Biomedical Sciences, supported by The Pew Charitable Trusts. DHR is an HHMI investigator.	Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Krichevsky AM, 2006, STEM CELLS, V24, P857, DOI 10.1634/stemcells.2005-0441; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Liu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000804; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Mukasa A, 2010, P NATL ACAD SCI USA, V107, P2616, DOI 10.1073/pnas.0914356107; Neveu P, 2010, CELL STEM CELL, V7, P671, DOI 10.1016/j.stem.2010.11.012; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; Wuchty S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014681; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740; Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109-008-0403-6; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	38	133	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1884	1895		10.1038/onc.2011.380	http://dx.doi.org/10.1038/onc.2011.380			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874051	Green Accepted			2022-12-28	WOS:000302809900002
J	Oneyama, C; Morii, E; Okuzaki, D; Takahashi, Y; Ikeda, J; Wakabayashi, N; Akamatsu, H; Tsujimoto, M; Nishida, T; Aozasa, K; Okada, M				Oneyama, C.; Morii, E.; Okuzaki, D.; Takahashi, Y.; Ikeda, J.; Wakabayashi, N.; Akamatsu, H.; Tsujimoto, M.; Nishida, T.; Aozasa, K.; Okada, M.			MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression	ONCOGENE			English	Article						c-Src; miRNA; ILK; tumor progression	CANCER-CELLS; C-SRC; THERAPEUTIC TARGET; DOWN-REGULATION; FAMILY KINASES; PROTEIN-KINASE; BREAST-CANCER; ILK; GROWTH; EXPRESSION	The tyrosine kinase c-Src is upregulated in various human cancers; however, the molecular mechanisms underlying c-Src-mediated tumor progression remain unclear. Here we show that downregulation of microRNA (miR)-542-3p is tightly associated with tumor progression via c-Src-related oncogenic pathways. In c-Src-transformed fibroblasts and human cancer cells that overexpress c-Src, miR-542-3p is substantially downregulated, and the ectopic expression of miR-542-3p suppresses tumor growth. We identified the integrin-linked kinase (ILK) as a conserved target of miR-542-3p. ILK upregulation promotes cell adhesion and invasion by activating the integrin-focal adhesion kinase (FAK)/c-Src pathway, and can also contribute to tumor growth via the AKT and glycogen synthase kinase 3 beta pathways. MiR-542-3p expression is downregulated by the activation of c-Src-related signaling molecules, including epidermal growth factor receptor, K-Ras and Ras/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase. In human colon cancer tissues, downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression. Oncogene (2012) 31, 1623-1635; doi:10.1038/onc.2011.367; published online 22 August 2011	[Oneyama, C.; Takahashi, Y.; Wakabayashi, N.; Okada, M.] Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 5650871, Japan; [Morii, E.; Ikeda, J.; Aozasa, K.] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; [Okuzaki, D.] Osaka Univ, Microbial Dis Res Inst, DNA Chip Dev Ctr Infect Dis, Suita, Osaka 5650871, Japan; [Akamatsu, H.; Tsujimoto, M.; Nishida, T.] Osaka Police Hosp, Osaka, Japan	Osaka University; Osaka University; Osaka University; Osaka Police Hospital	Oneyama, C (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	coneyama@biken.osaka-u.ac.jp	Okuzaki, Daisuke/AAN-5641-2020	Okuzaki, Daisuke/0000-0002-4552-783X	Ministry of Education, Culture, Sports, Science and Technology of Japan; Osaka University; Grants-in-Aid for Scientific Research [22689009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Osaka University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs A Imamoto, T Akagi and M Yutsudo for their generous gifts of reagents. This work was supported by a Grant-in-aid for Young Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan and The Exciting Leading-Edge Research Project at Osaka University.	Abboud ER, 2007, INT J ONCOL, V30, P113; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Cabodi S, 2010, ADV EXP MED BIOL, V674, P43; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hehlgans S, 2007, BBA-REV CANCER, V1775, P163, DOI 10.1016/j.bbcan.2006.09.001; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kim M, 2008, MOL CANCER RES, V6, P222, DOI 10.1158/1541-7786.MCR-07-0142; Kim YB, 2008, J BIOL CHEM, V283, P10089, DOI 10.1074/jbc.M708300200; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oneyama C, 2011, ONCOGENE, V30, P3489, DOI 10.1038/onc.2011.63; Oneyama C, 2008, GENES CELLS, V13, P1, DOI 10.1111/j.1365-2443.2007.01145.x; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Pontier SM, 2010, ONCOGENE, V29, P3374, DOI 10.1038/onc.2010.86; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Toloubeydokhti T, 2008, REPROD SCI, V15, P993, DOI 10.1177/1933719108324132; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Yang L, 2010, ONCOGENE, V29, P516, DOI 10.1038/onc.2009.370; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025	43	59	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1623	1635		10.1038/onc.2011.367	http://dx.doi.org/10.1038/onc.2011.367			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21860426				2022-12-28	WOS:000302231400002
J	Streicher, KL; Zhu, W; Lehmann, KP; Georgantas, RW; Morehouse, CA; Brohawn, P; Carrasco, RA; Xiao, Z; Tice, DA; Higgs, BW; Richman, L; Jallal, B; Ranade, K; Yao, Y				Streicher, K. L.; Zhu, W.; Lehmann, K. P.; Georgantas, R. W.; Morehouse, C. A.; Brohawn, P.; Carrasco, R. A.; Xiao, Z.; Tice, D. A.; Higgs, B. W.; Richman, L.; Jallal, B.; Ranade, K.; Yao, Y.			A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth	ONCOGENE			English	Article						miRNA cluster; melanoma; melanocyte transformation	MICRORNA CLUSTER; SOFT AGAR; EXPRESSION; CANCER; EVOLUTION; CELLS; GENE; OVEREXPRESSION; PROGRESSION; PROFILES	Malignant melanoma is the most aggressive form of skin cancer and its incidence has doubled in the last two decades. It represents only 4% of skin cancer cases per year, but causes as many as 74% of skin cancer deaths. Early detection of malignant melanoma is associated with survival rates of up to 90%, but later detection (stage III to stage IV) is associated with survival rates of only 10%. Dysregulation of microRNA (miRNA) expression has been linked to tumor development and progression by functioning either as a tumor suppressor, an oncogene or a metastasis regulator in multiple cancer types. To understand the role of miRNA in the pathogenesis of malignant melanoma and identify biomarkers of metastasis, miRNA expression profiles in skin punches from 33 metastatic melanoma patients and 14 normal healthy donors were compared. We identified a cluster of 14 miRNAs on the X chromosome, termed the miR-506-514 cluster, which was consistently overexpressed in nearly all melanomas tested (30-60 fold, P < 0.001), regardless of mutations in N-ras or B-raf. Inhibition of the expression of this cluster as a whole, or one of its sub-clusters (Sub-cluster A) consisting of six mature miRNAs, led to significant inhibition of cell growth, induction of apoptosis, decreased invasiveness and decreased colony formation in soft agar across multiple melanoma cell lines. Sub-cluster A of the miR-506-514 cluster was critical for maintaining the cancer phenotype, but the overexpression of the full cluster was necessary for melanocyte transformation. Our results provide new insights into the functional role of this miRNA cluster in melanoma, and suggest new approaches to treat or diagnose this disease. Oncogene (2012) 31, 1558-1570; doi:10.1038/onc.2011.345; published online 22 August 2011	[Streicher, K. L.; Zhu, W.; Lehmann, K. P.; Georgantas, R. W.; Morehouse, C. A.; Brohawn, P.; Higgs, B. W.; Richman, L.; Jallal, B.; Ranade, K.; Yao, Y.] MedImmune LLC, Dept Translat Sci, Gaithersburg, MD USA; [Carrasco, R. A.; Xiao, Z.; Tice, D. A.] MedImmune LLC, Dept Oncol, Gaithersburg, MD USA	AstraZeneca; Medimmune; AstraZeneca; Medimmune	Streicher, KL (corresponding author), Medimmune Inc, 1 MedImmune Way, Gaithersburg, MD 20878 USA.	StreicherK@MedImmune.com; YaoY@MedImmune.com	Xie, Huangming/B-2260-2012	Higgs, Brandon/0000-0002-2951-0245				Ambros Victor, 2004, Methods Mol Biol, V265, P131; Bandarchi B, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/583748; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Hausler SFM, 2010, BRIT J CANCER, V103, P693, DOI 10.1038/sj.bjc.6605833; Hartman ZC, 2011, CANCER RES, V71, P4380, DOI 10.1158/0008-5472.CAN-11-0308; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Kuphal S, 2006, ONCOGENE, V25, P5027, DOI 10.1038/sj.onc.1209508; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Leidinger P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-262; Li JJ, 2010, MOL BIOL EVOL, V27, P671, DOI 10.1093/molbev/msp284; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; MONTESANO R, 1977, J NATL CANCER I, V59, P1651, DOI 10.1093/jnci/59.6.1651; Mueller DW, 2009, BRIT J CANCER, V101, P551, DOI 10.1038/sj.bjc.6605204; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Nakamura JL, 2008, CANCER RES, V68, P6516, DOI 10.1158/0008-5472.CAN-07-6188; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Osawa M, 2008, J INVEST DERMATOL, V128, P2571, DOI 10.1038/jid.2008.289; Palmieri G, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-86; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; RHIM JS, 1983, CANCER DETECT PREV, V6, P381; Rigel DS, 2010, CA-CANCER J CLIN, V60, P301, DOI 10.3322/caac.20074; SCHOLZ CC, 1990, EUR J CANCER, V26, P901, DOI 10.1016/0277-5379(90)90196-Z; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Segura MF, 2010, CLIN CANCER RES, V16, P1577, DOI 10.1158/1078-0432.CCR-09-2721; Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709; Syed M, 2008, CLIN EXP METASTAS, V25, P787, DOI 10.1007/s10585-008-9192-0; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; Zhang R, 2007, GENOME RES, V17, P612, DOI 10.1101/gr.6146507; ZIRVI KA, 1983, INT J CANCER, V32, P45, DOI 10.1002/ijc.2910320108	39	115	127	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1558	1570		10.1038/onc.2011.345	http://dx.doi.org/10.1038/onc.2011.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860416				2022-12-28	WOS:000302132000008
J	Stoddart, A; Tennant, TR; Fernald, AA; Anastasi, J; Brodsky, FM; Le Beau, MM				Stoddart, A.; Tennant, T. R.; Fernald, A. A.; Anastasi, J.; Brodsky, F. M.; Le Beau, M. M.			The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice	ONCOGENE			English	Article						AML; MPD; endocytosis; DOT1L; H3K79 methylation; oligomerization	ACUTE LYMPHOBLASTIC-LEUKEMIA; MLL FUSION PARTNER; TRANSGENIC MICE; CALM/AF10 FUSION; ASSEMBLY PROTEIN; CELL-LINE; T-ALL; GENE; CALM; AF10	The PICALM(CALM) gene, whose product is involved in clathrin-mediated endocytosis, has been identified in two recurring chromosomal translocations, involving either MLL or MLLT10 (AF10). We developed a mouse model of CALM-AF10(+) leukemia to examine the hypothesis that disruption of endocytosis contributes to leukemogenesis. Exclusion of the C-terminal portion of CALM from the fusion protein, which is required for optimal binding to clathrin, resulted in the development of a myeloproliferative disease, whereas inclusion of this domain led to the development of acute myeloid leukemia and changes in gene expression of several cancer-related genes, notably Pim1 and Crebbp. Nonetheless, the development of leukemia could not be attributed directly to interference with endocytosis or consequential changes in proliferation and signaling. In leukemia cells, full-length CALM-AF10 localized to the nucleus with no consistent effect on growth factor endocyctosis, and suppressed histone H3 lysine 79 methylation regardless of the presence of clathrin. Using fluorescence resonance energy transfer analysis, we show that CALM-AF10 has a propensity to homo-oligomerize, raising the possibility that the function of endocytic proteins involved in chimeric fusions may be to provide dimerization properties, a recognized mechanism for unleashing oncogenic properties of chimeric transcription factors, rather than disrupting the internalization of growth factor receptors. Oncogene (2012) 31, 494-506; doi: 10.1038/onc.2011.251; published online 27 June 2011	[Stoddart, A.; Tennant, T. R.; Fernald, A. A.; Le Beau, M. M.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Anastasi, J.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Brodsky, F. M.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	University of Chicago; University of Chicago; University of California System; University of California San Francisco	Stoddart, A (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 900 E,57th St,KCBD 7th Floor, Chicago, IL 60637 USA.	astoddar@bsd.uchicago.edu		Brodsky, Frances/0000-0002-1334-9258	Leukemia and Lymphoma Society [7015]; Special Fellow Award; Cancer Research Foundation; Lauri Strauss Leukemia Foundation; NIH [GM038093]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Special Fellow Award; Cancer Research Foundation; Lauri Strauss Leukemia Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Vytas Bindokas and the University of Chicago Comprehensive Cancer Center Integrated Microscopy, and Flow Cytometry Facilities for their assistance. We also thank Scott Kogan for advice on classifying myeloid malignancies and Elizabeth Davis for technical assistance and members of the Le Beau laboratory for helpful discussions. This work was supported by a Special Fellow Award and SCOR (7015) from the Leukemia and Lymphoma Society, and grants from the Cancer Research Foundation, Lauri Strauss Leukemia Foundation and NIH (GM038093).	Archangelo LF, 2006, ONCOGENE, V25, P4099, DOI 10.1038/sj.onc.1209438; Asnafi V, 2003, BLOOD, V102, P1000, DOI 10.1182/blood-2002-09-2913; BERNARD OA, 1994, ONCOGENE, V9, P1039; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Bradley SV, 2007, CANCER RES, V67, P8923, DOI 10.1158/0008-5472.CAN-07-2153; Broudy VC, 1999, BLOOD, V94, P1979; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chikatsu N, 2003, MODERN PATHOL, V16, P828, DOI 10.1097/01.MP.0000081729.40230.1F; Cho H, 2007, J CELL BIOL, V178, P245, DOI 10.1083/jcb.200604114; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Forissier S, 2007, BIOL CELL, V99, P563, DOI 10.1042/BC20060131; Fu JF, 2003, GENE CHROMOSOME CANC, V37, P214, DOI 10.1002/gcc.10204; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kung AL, 2000, GENE DEV, V14, P272; Lanzetti L, 2008, TRAFFIC, V9, P2011, DOI 10.1111/j.1600-0854.2008.00816.x; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; LEMMON SK, 1990, GENETICS, V124, P27; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Lin YH, 2009, BLOOD, V114, P651, DOI 10.1182/blood-2009-03-209395; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Meyerholz A, 2005, TRAFFIC, V6, P1225, DOI 10.1111/j.1600-0854.2005.00355.x; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Wechsler DS, 2003, GENE CHROMOSOME CANC, V36, P26, DOI 10.1002/gcc.10136	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					494	506		10.1038/onc.2011.251	http://dx.doi.org/10.1038/onc.2011.251			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706055	Green Accepted, Green Submitted			2022-12-28	WOS:000300219300008
J	Lo, PK; Kanojia, D; Liu, X; Singh, UP; Berger, FG; Wang, Q; Chen, H				Lo, P-K; Kanojia, D.; Liu, X.; Singh, U. P.; Berger, F. G.; Wang, Q.; Chen, H.			CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGF beta signaling	ONCOGENE			English	Article						tumor-initiating cells; Her2/neu; mammary tumor; CD49f; CD61; ESA	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; STEM-CELLS; II RECEPTOR; EXPRESSION; MOUSE; GLAND; TUMORIGENESIS; POPULATION; TGF-BETA-1	Human epidermal growth factor receptor 2 (HER2)/Neu is overexpressed in 20-30% of breast cancers and associated with aggressive phenotypes and poor prognosis. For deciphering the role of HER2/Neu in breast cancer, mouse mammary tumor virus (MMTV)-Her2/neu transgenic mice that develop mammary tumors resembling human HER2-subtype breast cancer have been established. Several recent studies have revealed that HER2/Neu is overexpressed in and regulates self renewal of breast tumor-initiating cells (TICs). However, in the MMTV-Her2/neu transgenic mouse model, the identity of TICs remains elusive, despite previous studies showing supportive evidence for existence of TICs in Her2/neu-induced mammary tumors. Through systematic screening and characterization, we identified that surface markers CD49f, CD61 and ESA were aberrantly overexpressed in Her2-overexpressing mammary tumor cells. Analysis of these markers and CD24 detected anomalous expansion of the luminal progenitor population in preneoplastic mammary glands of Her2/neu transgenic mice, indicating that aberrant luminal progenitors originated in Her2-induced mammary tumors. The combined markers, CD49f and CD61, further delineated the CD49f(high)CD61(high)-sorted fraction as a TIC-enriched population, which displayed increased tumorsphere formation ability, enhanced tumorigenicity both in vitro and in vivo and drug resistance to pacitaxel and doxorubicin. Moreover, the TIC-enriched population manifested increased transforming growth factor-beta (TGF beta) signaling and exhibited gene expression signatures of stemness, TGF beta signaling and epithelial-to-mesenchymal transition. Our findings that self-renewal and clonogenicity of TICs were suppressed by pharmacologically inhibiting the TGF beta signaling further indicate that the TGF beta pathway is vital for maintenance of the TIC population. Finally, we showed that the integrin-beta 3 (CD61) signaling pathway was required for sustaining active TGF beta signaling and self-renewal of TICs. We for the first time developed a technique to highly enrich TICs from mammary tumors of Her2/neu transgenic mice, unraveled their properties and identified the cooperative integrin-beta 3-TGF beta signaling axis as a potential therapeutic target for HER2-induced TICs. Oncogene (2012) 31, 2614-2626; doi:10.1038/onc.2011.439; published online 26 September 2011	[Lo, P-K; Kanojia, D.; Berger, F. G.; Chen, H.] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; [Lo, P-K; Kanojia, D.; Berger, F. G.; Wang, Q.; Chen, H.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA; [Liu, X.] Univ S Carolina, Dept Math, Columbia, SC 29208 USA; [Singh, U. P.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29208 USA; [Wang, Q.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chen, H (corresponding author), Univ S Carolina, Dept Biol Sci, 715 Sumter St,PSC621, Columbia, SC 29208 USA.	hchen@biol.sc.edu	Kanojia, Deepak/G-5120-2014; chen, hexin/F-1714-2011	Kanojia, Deepak/0000-0003-4295-4972; Wang, Qian/0000-0002-2149-384X; Singh, Udai/0000-0002-7048-4325	Elsa U Pardee Cancer Foundation [B94AFFAA]; American Cancer Society [RSG-10-067-01-TBE]; NIH [3P20RR017698-08]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017698] Funding Source: NIH RePORTER	Elsa U Pardee Cancer Foundation; American Cancer Society(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Marai M Pena, Celestia Davis, Sara Johnson and Andrea Daamen for experimental assistance. This work was supported by the Elsa U Pardee Cancer Foundation grant (B94AFFAA), the American Cancer Society Research Award (RSG-10-067-01-TBE) to HC and NIH grant (3P20RR017698-08) to HC and QW.	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952; Chen HX, 2010, PROTEOMICS, V10, P3800, DOI 10.1002/pmic.201000297; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gu Y.B., 2011, J BIOTECH RES, V3, P7; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanker L, 2010, BREAST CANCER RES TR, V122, P765, DOI 10.1007/s10549-009-0608-6; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; Ishikawa Toshihisa, 2009, J Exp Ther Oncol, V8, P5; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kveiborg M., 2001, Journal of Endocrinology, V169, P549, DOI 10.1677/joe.0.1690549; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Magnifico A, 2009, CLIN CANCER RES, V15, P2010, DOI 10.1158/1078-0432.CCR-08-1327; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Margadant C, 2010, EMBO REP, V11, P97, DOI 10.1038/embor.2009.276; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Scaffidi AK, 2004, J BIOL CHEM, V279, P37726, DOI 10.1074/jbc.M403010200; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Yang C, 2007, EXP CELL RES, V313, P1240, DOI 10.1016/j.yexcr.2007.01.011	38	149	155	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2614	2626		10.1038/onc.2011.439	http://dx.doi.org/10.1038/onc.2011.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21996747	Green Accepted			2022-12-28	WOS:000304523500002
J	Yang, D; Tao, J; Li, L; Kedei, N; Toth, ZE; Czap, A; Velasquez, JF; Mihova, D; Michalowski, AM; Yuspa, SH; Blumberg, PM				Yang, D.; Tao, J.; Li, L.; Kedei, N.; Toth, Z. E.; Czap, A.; Velasquez, J. F.; Mihova, D.; Michalowski, A. M.; Yuspa, S. H.; Blumberg, P. M.			RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma	ONCOGENE			English	Article						Ras activator; Akt; HGF; melanoma; cell transformation; guanine nucleotide exchange factor	POLYMERASE-CHAIN-REACTION; PHORBOL ESTERS; KINASE ACTIVATION; B-RAF; FUNCTIONAL-ANALYSIS; CELL PROLIFERATION; COLORECTAL TUMORS; REGULATED KINASE; BRAF MUTATIONS; PHOSPHORYLATION	RasGRP3, an activator for H-Ras, R-Ras and Ras-associated protein-1/2, has emerged as an important mediator of signaling downstream from receptor coupled phosphoinositide turnover in B and T cells. Here, we report that RasGRP3 showed a high level of expression in multiple human melanoma cell lines as well as in a subset of human melanoma tissue samples. Suppression of endogenous RasGRP3 expression in these melanoma cell lines reduced Ras-GTP formation as well as c-Met expression and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth factor (EGF) stimulation. RasGRP3 suppression also inhibited cell proliferation and reduced both colony formation in soft agar and xenograft tumor growth in immunodeficient mice, demonstrating the importance of RasGRP3 for the transformed phenotype of the melanoma cells. Reciprocally, overexpression of RasGRP3 in human primary melanocytes altered cellular morphology, markedly enhanced cell proliferation and rendered the cells tumorigenic in a mouse xenograft model. Suppression of RasGRP3 expression in these cells inhibited downstream RasGRP3 responses and suppressed cell growth, confirming the functional role of RasGRP3 in the altered behavior of these cells. The identification of the role of RasGRP3 in melanoma highlights its importance, as a Ras activator, in the phosphoinositide signaling pathway in human melanoma and provides a new potential therapeutic target. Oncogene (2011) 30, 4590-4600; doi: 10.1038/onc.2011.166; published online 23 May 2011	[Yang, D.; Tao, J.; Li, L.; Kedei, N.; Czap, A.; Velasquez, J. F.; Mihova, D.; Michalowski, A. M.; Yuspa, S. H.; Blumberg, P. M.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Toth, Z. E.] Semmelweis Univ, Dept Anat Histol & Embryol, Neuromorphol & Neuroendocrine Res Lab, Budapest, Hungary; [Toth, Z. E.] Hungarian Acad Sci, Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Semmelweis University; Hungarian Academy of Sciences	Blumberg, PM (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, Room 4048,Bldg 37,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov	Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091	NIH, Center for Cancer Research, National Cancer Institute [Z1A BC 005270]; ETT [495/09]; Bolyai fellowship; NATIONAL CANCER INSTITUTE [ZIABC004504, ZIABC005445, ZIABC005270, Z01BC005270] Funding Source: NIH RePORTER	NIH, Center for Cancer Research, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ETT; Bolyai fellowship(Hungarian Academy of Sciences); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported in part by the intramural program of the NIH, Center for Cancer Research, National Cancer Institute (project number Z1A BC 005270) and in part by grant ETT 495/09. ZE Toth is supported by the Bolyai fellowship. We thank Glenn Merlino for helpful comments.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Aiba Y, 2004, P NATL ACAD SCI USA, V101, P16612, DOI 10.1073/pnas.0407468101; BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bauer J, 2006, DERMATOL THER, V19, P40, DOI 10.1111/j.1529-8019.2005.00055.x; Brodie C, 2004, MOL PHARMACOL, V66, P76, DOI 10.1124/mol.66.1.76; Coughlin JJ, 2005, J IMMUNOL, V175, P7179, DOI 10.4049/jimmunol.175.11.7179; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716; Furge KA, 2001, P NATL ACAD SCI USA, V98, P10722, DOI 10.1073/pnas.191067898; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Gawecka JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011269; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Haluska Frank G, 2006, Curr Oncol Rep, V8, P400, DOI 10.1007/s11912-006-0065-x; Hingorani SR, 2003, CANCER RES, V63, P5198; Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6; Huang HP, 2008, J AGR FOOD CHEM, V56, P9286, DOI 10.1021/jf8013102; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Lorenzo PS, 2000, MOL PHARMACOL, V57, P840; Lorenzo PS, 2001, CANCER RES, V61, P943; Oh-Hora M, 2003, J EXP MED, V198, P1841, DOI 10.1084/jem.20031547; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; Pu YM, 2005, J BIOL CHEM, V280, P27329, DOI 10.1074/jbc.M414132200; Roberts DM, 2004, MOL CELL BIOL, V24, P10515, DOI 10.1128/MCB.24.24.10515-10528.2004; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Satyamoorthy K, 2003, CANCER RES, V63, P756; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Stone JC, 2006, BIOCHEM SOC T, V34, P858, DOI 10.1042/BST0340858; Stope MB, 2004, MOL CELL BIOL, V24, P4664, DOI 10.1128/MCB.24.11.4664-4676.2004; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutlovic D, 2005, CROAT MED J, V46, P556; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Teixeira C, 2003, BLOOD, V102, P1414, DOI 10.1182/blood-2002-11-3621; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; van Elsas A, 1995, Recent Results Cancer Res, V139, P57; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yang DZ, 2010, CANCER RES, V70, P7905, DOI 10.1158/0008-5472.CAN-09-4729; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zheng Y, 2005, BLOOD, V105, P3648, DOI 10.1182/blood-2004-10-3916	54	40	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4590	4600		10.1038/onc.2011.166	http://dx.doi.org/10.1038/onc.2011.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	22139084	Green Accepted			2022-12-28	WOS:000296890700006
